PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Davis, JJ				Davis, Jeremy J.			Further Consideration of Advanced Clinical Solutions Word Choice: Comparison to the Recognition Memory Test-Words and Classification Accuracy in a Clinical Sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Word Choice; Performance validity; Recognition Memory Test.	TRAUMATIC BRAIN-INJURY; MONOSYLLABIC WORDS; TEST-PERFORMANCE; RESPONSE BIAS; HEAD-INJURY; NEUROPSYCHOLOGY; CONCRETENESS; REPLICATION; IMPAIRMENT; DEFICITS	Word Choice (WC), a test in the Advanced Clinical Solutions package for Wechsler measures, was examined in two studies. The first study compared WC to the Recognition Memory Test-Words (RMT-W) in a clinical sample (N = 46). WC scores were significantly higher than RMT-W scores overall and in sample subsets grouped by separate validity indicators. In item-level analyses, WC items demonstrated lower frequency, greater imageability, and higher concreteness than RMT-W items. The second study explored WC classification accuracy in a different clinical sample grouped by separate validity indicators into Pass (n = 54), Fail-1 (n = 17), and Fail-2 (n = 8) groups. WC scores were significantly higher in the Pass group (M = 49.1, SD = 1.9) than in the Fail-1 (M = 46.0, SD = 5.3) and Fail-2 (M = 44.1, SD = 4.8) groups. WC demonstrated area under the curve of .81 in classifying Pass and Fail-2 participants. Using the test manual cutoff associated with a 10% false positive rate, sensitivity was 38% and specificity was 96% in Pass and Fail-2 groups with 24% of Fail-1 participants scoring below cutoff. WC may be optimally used in combination with other measures given observed sensitivity.	Univ Utah, Sch Med, Div Phys Med & Rehabil, Salt Lake City, UT 84132 USA		Davis, JJ (corresponding author), Univ Utah, Sch Med, Div Phys Med & Rehabil, 30 North 1900 East,1R55, Salt Lake City, UT 84132 USA.	jeremy.davis@hsc.utah.edu					Aggleton JP, 2011, LEARN MEMORY, V18, P384, DOI 10.1101/lm.1884611; Bashem JR, 2014, CLIN NEUROPSYCHOL, V28, P851, DOI 10.1080/13854046.2014.927927; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; CONDER R, 1992, COMPUTERIZED ASSESSM; Cortese MJ, 2010, MEMORY, V18, P595, DOI 10.1080/09658211.2010.493892; Cortese MJ, 2004, BEHAV RES METH INS C, V36, P384, DOI 10.3758/BF03195585; DAVIES M., 1990, CORPUS CONT AM ENGLI; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Delis D.C., 2000, CALIFORNIA VERBAL LE; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; GILHOOLY KJ, 1980, BEHAV RES METH INSTR, V12, P395, DOI 10.3758/BF03201693; GLANZER M, 1993, PSYCHOL REV, V100, P546, DOI 10.1037/0033-295X.100.3.546; GLANZER M, 1990, J EXP PSYCHOL LEARN, V16, P5, DOI 10.1037/0278-7393.16.1.5; Green P., 2003, MANUAL WORD MEMORY T; Green P., 2004, MANUAL MED SYMPTOM V; Green P.J.E., 2008, MANUAL NONVERBAL MED; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hemmer P, 2013, J EXP PSYCHOL LEARN, V39, P1947, DOI 10.1037/a0033744; Holdnack J. A., 2009, ADV CLIN SOLUTIONS W; Hosmer D.W., 2000, APPL LOGISTIC REGRES, P375, DOI [10.1002/0471722146, DOI 10.1002/0471722146]; Iverson GL, 1998, BRAIN INJURY, V12, P275, DOI 10.1080/026990598122575; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kaufmann P, 2012, FORENSIC NEUROPSYCHO, P70; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kuera H., 1967, COMPUTATIONAL ANAL P; LARRABEE GJ, 2007, ASSESSMENT MALINGERE, P3; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Malmberg KJ, 2008, COGNITIVE PSYCHOL, V57, P335, DOI 10.1016/j.cogpsych.2008.02.004; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; PAIVIO A, 1968, J EXP PSYCHOL, V76, P1, DOI 10.1037/h0025327; Pearson, 2009, WORD CHOIC STIM BOOK; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ross SR, 2006, J CLIN EXP NEUROPSYC, V28, P111, DOI 10.1080/13803390590929270; Salazar X.F., 2007, ASSESSMENT FEIGNED C, P405; Schock J, 2012, BEHAV RES METHODS, V44, P374, DOI 10.3758/s13428-011-0162-0; Schutte C, 2012, MILD TRAUMATIC BRAIN, P159; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Strong EK, 1913, PSYCHOL REV, V20, P339, DOI 10.1037/h0072087; Strong EK, 1912, PSYCHOL REV, V19, P447, DOI 10.1037/h0069812; Suhr J.A., 2007, ASSESSMENT MALINGERE, P131; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Thorndike E. L., 1944, TEACHERS WORD BOOK 3; Toglia MP., 1978, HDB SEMANTIC WORD NO; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Warrington E, 1984, RECOGNITION MEMORY T, V1; WILSON M, 1988, BEHAV RES METH INSTR, V20, P6, DOI 10.3758/BF03202594	56	30	30	1	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2014	28	8					1278	1294		10.1080/13854046.2014.975844			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AY0KY	WOS:000347286600006	25372961				2022-02-06	
J	Mayer, AR; Bedrick, EJ; Ling, JM; Toulouse, T; Dodd, A				Mayer, Andrew R.; Bedrick, Edward J.; Ling, Josef M.; Toulouse, Trent; Dodd, Andrew			Methods for Identifying Subject-Specific Abnormalities in Neuroimaging Data	HUMAN BRAIN MAPPING			English	Article						mild traumatic brain injury; diffusion tensor imaging; neuroimaging; subject-specific abnormalities	TRAUMATIC BRAIN-INJURY; WHITE-MATTER ABNORMALITIES; MULTIPLE-SCLEROSIS; ANISOTROPY; SCHIZOPHRENIA; INFERENCE; MAPS	Algorithms that are capable of capturing subject-specific abnormalities (SSA) in neuroimaging data have long been an area of focus for diverse neuropsychiatric conditions such as multiple sclerosis, schizophrenia, and traumatic brain injury. Several algorithms have been proposed that define SSA in patients (i.e., comparison group) relative to image intensity levels derived from healthy controls (HC) (i.e., reference group) based on extreme values. However, the assumptions underlying these approaches have not always been fully validated, and may be dependent on the statistical distributions of the transformed data. The current study evaluated variations of two commonly used techniques (pothole method and standardization with an independent reference group) for identifying SSA using simulated data (derived from normal, t and chi-square distributions) and fractional anisotropy maps derived from 50 HC. Results indicated substantial group-wise bias in the estimation of extreme data points using the pothole method, with the degree of bias being inversely related to sample size. Statistical theory was utilized to develop a distribution-corrected z-score (DisCo-Z) threshold, with additional simulations demonstrating elimination of the bias and a more consistent estimation of extremes based on expected distributional properties. Data from previously published studies examining SSA in mild traumatic brain injury were then re-analyzed using the DisCo-Z method, with results confirming the evidence of group-wise bias. We conclude that the benefits of identifying SSA in neuropsychiatric research are substantial, but that proposed SSA approaches require careful implementation under the different distributional properties that characterize neuroimaging data. Hum Brain Mapp 35:5457-5470, 2014. (c) 2014 Wiley Periodicals, Inc.	[Mayer, Andrew R.; Ling, Josef M.; Toulouse, Trent; Dodd, Andrew] Mind Res Network, Lovelace Biomed & Environm Res Inst, Albuquerque, NM 87106 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Bedrick, Edward J.] Univ Colorado, Dept Biostat & Informat, Aurora, CO USA		Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org					Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Bulmer, 1979, PRINCIPLES STAT; Cook RD, 1982, RESIDUALS INFLUENCE; Cox R, 2006, EFFICIENT ROBUST NON; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Davis KL, 2003, ARCH GEN PSYCHIAT, V60, P443, DOI 10.1001/archpsyc.60.5.443; Ding ZH, 2005, MAGN RESON MED, V53, P485, DOI 10.1002/mrm.20339; Ehrlich S, 2013, SCHIZOPHR B, V40, P665; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Ge YL, 2005, ANN NY ACAD SCI, V1064, P202, DOI 10.1196/annals.1340.039; Geisser S, 1993, PREDICTIVE INTERFERE; Hayasaka S, 2004, NEUROIMAGE, V22, P676, DOI 10.1016/j.neuroimage.2004.01.041; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; Monnig MA, 2013, ADDICT BIOL, V18, P581, DOI 10.1111/j.1369-1600.2012.00441.x; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Patel SA, 2007, J MAGN RESON IMAGING, V26, P552, DOI 10.1002/jmri.21076; POLINE JB, 1993, J CEREBR BLOOD F MET, V13, P425, DOI 10.1038/jcbfm.1993.57; Saad ZS, 2009, NEUROIMAGE, V44, P839, DOI 10.1016/j.neuroimage.2008.09.037; Scheel M, 2013, BRAIN STRUCT FUNCT, V218, P151, DOI 10.1007/s00429-012-0389-2; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Viviani R, 2007, HUM BRAIN MAPP, V28, P1075, DOI 10.1002/hbm.20332; Watts R, 2014, RADIOLOGY; White T, 2013, SCHIZOPHRENIA BULL, V39, P1077, DOI 10.1093/schbul/sbs106; White T, 2009, PSYCHIAT RES-NEUROIM, V174, P110, DOI 10.1016/j.pscychresns.2009.04.014	37	30	30	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	NOV	2014	35	11					5457	5470		10.1002/hbm.22563			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AS3KK	WOS:000344176100010	24931496	Green Published			2022-02-06	
J	Stratton, KJ; Clark, SL; Hawn, SE; Amstadter, AB; Cifu, DX; Walker, WC				Stratton, Kelcey J.; Clark, Shaunna L.; Hawn, Sage E.; Amstadter, Ananda B.; Cifu, David X.; Walker, William C.			Longitudinal Interactions of Pain and Posttraumatic Stress Disorder Symptoms in US Military Service Members Following Blast Exposure	JOURNAL OF PAIN			English	Article						Chronic pain; stress disorders; posttraumatic; military personnel; blast injuries; longitudinal studies	TRAUMATIC BRAIN-INJURY; PREVALENCE; VETERANS; COMORBIDITY; AFGHANISTAN; IRAQ; DEPRESSION; PTSD; RESILIENCE; GENDER	Military personnel returning from conflicts in Iraq and Afghanistan often endorse pain and posttraumatic stress disorder (PTSD) symptoms, either separately or concurrently. Associations between pain and PTSD symptoms may be further complicated by blast exposure from explosive munitions. Although many studies have reported on the prevalence and disability associated with polytraumatic injuries following combat, less is known about symptom maintenance over time. Accordingly, this study examined longitudinal interactive models of co-occurring pain and PTSD symptoms in a sample of 209 military personnel (mean age = 27.4 years, standard deviation = 7.6) who experienced combat-related blast exposure. Autoregressive cross-lagged analysis examined longitudinal associations between self-reported pain and PTSD symptoms over a 1-year period. The best-fitting covariate model indicated that pain and PTSD were significantly associated with one another across all assessment periods, chi(2) (3) = 3.66, P =.30, Tucker-Lewis index =.98, comparative fit index = 1.00, root mean squared error of approximation =.03. PTSD symptoms had a particularly strong influence on subsequent pain symptoms. The relationship between pain and PTSD symptoms is related to older age, race, and traumatic brain injury characteristics. Results further the understanding of complex injuries among military personnel and highlight the need for comprehensive assessment and rehabilitation efforts addressing the interdependence of pain and co-occurring mental health conditions. Perspective: This longitudinal study demonstrates that pain and PTSD symptoms strongly influence one another and interact across time. These findings have the potential to inform the integrative assessment and treatment of military personnel with polytrauma injuries and who are at risk for persistent deployment-related disorders. (C) Published by Elsevier Inc. on behalf of the American Pain Society	[Stratton, Kelcey J.; Cifu, David X.; Walker, William C.] Hunter Holmes McGuire VA Med Ctr, Richmond, VA 23249 USA; [Stratton, Kelcey J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Cifu, David X.; Walker, William C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Stratton, Kelcey J.; Hawn, Sage E.; Amstadter, Ananda B.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA; [Clark, Shaunna L.] Virginia Commonwealth Univ, Sch Pharm, Ctr Biomarker Res & Personalized Med, Richmond, VA USA		Stratton, KJ (corresponding author), Hunter Holmes McGuire VA Med Ctr, 1201 Broad Rock Blvd 116-B, Richmond, VA 23249 USA.	Kelcey.Stratton@va.gov		Cifu, David/0000-0003-1600-9387	Office of Academic AffiliationsUS Department of Veterans Affairs; Advanced Fellowship Program in Mental Illness Research and Treatment; Department of Veterans Affairs, United States GovernmentUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; U.S. Army Medical Research and Material Command, Congressionally Directed Medical Research Program [W191ZSQ8118N6200001]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K01AA021266, K02AA023239, R01AA020179] Funding Source: NIH RePORTER	Writing of this manuscript was supported in part by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs, United States Government (K.J.S.), the Defense and Veterans Brain Injury Center, and by a grant by the U.S. Army Medical Research and Material Command, Congressionally Directed Medical Research Program (grant no. W191ZSQ8118N6200001; W.C.W.).	ANDERSSON HI, 1993, CLIN J PAIN, V9, P174, DOI 10.1097/00002508-199309000-00004; [Anonymous], 2012, NAT CTR PTSD US PTSD; Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; Curran PJ, 2001, DECADE BEHAV, P107, DOI 10.1037/10409-004; Gatchel RJ, 2004, AM PSYCHOL, V59, P795, DOI 10.1037/0003-066X.59.8.795; Gibson CA, 2012, J REHABIL RES DEV, V49, P753, DOI 10.1682/JRRD.2011.09.0158; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Green CR, 2003, PAIN MED, V4, P277, DOI 10.1046/j.1526-4637.2003.03034.x; Gureje O, 2001, PAIN, V92, P195, DOI 10.1016/S0304-3959(00)00483-8; Hardt J, 2008, PAIN MED, V9, P803, DOI 10.1111/j.1526-4637.2008.00425.x; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Huska J.A., 1993, P 9 ANN M INT SOC TR; Jenewein J, 2009, J TRAUMA STRESS, V22, P540, DOI 10.1002/jts.20453; Keogh E, 2006, EUR J PAIN, V10, P413, DOI 10.1016/j.ejpain.2005.05.007; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koenen KC, 2003, J CONSULT CLIN PSYCH, V71, P980, DOI 10.1037/0022-006X.71.6.980; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Moeller-Bertram T, 2014, PSYCHOSOMATICS, V55, P172, DOI 10.1016/j.psym.2013.01.011; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; Outcalt SD, 2013, PAIN MED; Palyo SA, 2005, PAIN, V117, P121, DOI 10.1016/j.pain.2005.05.028; Perilla JL, 2002, J SOC CLIN PSYCHOL, V21, P20, DOI 10.1521/jscp.21.1.20.22404; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Pietrzak RH, 2011, J ANXIETY DISORD, V25, P456, DOI 10.1016/j.janxdis.2010.11.010; Rahim-Williams FB, 2007, PAIN, V129, P177, DOI 10.1016/j.pain.2006.12.016; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; RESNICK HS, 1993, J CONSULT CLIN PSYCH, V61, P984, DOI 10.1037/0022-006X.61.6.984; RICHARDS JS, 1980, PAIN, V8, P355, DOI 10.1016/0304-3959(80)90079-2; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Shipherd JC, 2007, J REHABIL RES DEV, V44, P153, DOI 10.1682/JRRD.2006.06.0065; Sledjeski EM, 2008, J BEHAV MED, V31, P341, DOI 10.1007/s10865-008-9158-3; Sterling M, 2005, PAIN, V114, P141, DOI 10.1016/j.pain.2004.12.005; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Ullrich PM, 2013, REHABIL PSYCHOL, V58, P158, DOI 10.1037/a0032047; Villano CL, 2007, J REHABIL RES DEV, V44, P167, DOI 10.1682/JRRD.2006.05.0052; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0	45	30	30	0	14	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	OCT	2014	15	10					1023	1032		10.1016/j.jpain.2014.07.002			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AQ2XQ	WOS:000342653700006	25038401	Green Accepted			2022-02-06	
J	Zhang, ZY; Zhang, LX; Dong, XQ; Yu, WH; Du, Q; Yang, DB; Shen, YF; Wang, H; Zhu, Q; Che, ZH; Liu, QJ; Jiang, L; Du, YF				Zhang, Zu-Yong; Zhang, Li-Xin; Dong, Xiao-Qiao; Yu, Wen-Hua; Du, Quan; Yang, Ding-Bo; Shen, Yong-Feng; Wang, Hao; Zhu, Qiang; Che, Zhi-Hao; Liu, Qun-Jie; Jiang, Li; Du, Yuan-Feng			Comparison of the performances of copeptin and multiple biomarkers in long-term prognosis of severe traumatic brain injury	PEPTIDES			English	Article						Traumatic brain injury; Prognosis; Copeptin; Biomarkers	S100B PROTEIN; SERUM; OPPORTUNITIES; VASOPRESSIN; MORTALITY; MARKERS; UTILITY; DISEASE; FUTURE; DAMAGE	Enhanced blood levels of copeptin correlate with poor clinical outcomes after acute critical illness. This study aimed to compare the prognostic performances of plasma concentrations of copeptin and other biomarkers like myelin basic protein, glial fibrillary astrocyte protein, S100B, neuron-specific enolase, phosphorylated axonal neurofilament subunit H, Tau and ubiquitin carboxyl-terminal hydrolase L1 in severe traumatic brain injury. We recruited 102 healthy controls and 102 acute patients with severe traumatic brain injury. Plasma concentrations of these biomarkers were determined using enzyme-linked immunosorbent assay. Their prognostic predictive performances of 6-month mortality and unfavorable outcome ( Glasgow Outcome Scale score of 1-3) were compared. Plasma concentrations of these biomarkers were statistically significantly higher in all patients than in healthy controls, in non-survivors than in survivors and in patients with unfavorable outcome than with favorable outcome. Areas under receiver operating characteristic curves of plasma concentrations of these biomarkers were similar to those of Glasgow Coma Scale score for prognostic prediction. Except plasma copeptin concentration, other biomarkers concentrations in plasma did not statistically significantly improve prognostic predictive value of Glasgow Coma Scale score. Copeptin levels may be a useful tool to predict long-term clinical outcomes after severe traumatic brain injury and have a potential to assist clinicians. (C) 2014 Elsevier Inc. All rights reserved.	[Zhang, Zu-Yong; Dong, Xiao-Qiao; Yu, Wen-Hua; Du, Quan; Yang, Ding-Bo; Shen, Yong-Feng; Wang, Hao; Zhu, Qiang; Che, Zhi-Hao; Liu, Qun-Jie; Jiang, Li; Du, Yuan-Feng] Nanjing Med Univ, Affiliated Hangzhou Hosp, Hangzhou Peoples Hosp 1, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China; [Zhang, Li-Xin] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China		Dong, XQ (corresponding author), Nanjing Med Univ, Affiliated Hangzhou Hosp, Hangzhou Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.	dxqhyy@163.com			Zhejiang Province Medical and Health [2012KYB148]	This study was supported by a grant from Zhejiang Province Medical and Health Project (No. 2012KYB148).	Anand T, 2012, J SURG RES, V178, P321, DOI 10.1016/j.jss.2012.02.062; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; De Marchis GM, 2013, NEUROLOGY, V80, P1278, DOI 10.1212/WNL.0b013e3182887944; DeFazio MV, 2014, WORLD NEUROSURG, V81, P151, DOI 10.1016/j.wneu.2013.01.015; Dong XQ, 2011, J TRAUMA, V71, P1194, DOI 10.1097/TA.0b013e31821283f2; Fenske W, 2012, J CLIN ENDOCR METAB, V97, P3426, DOI 10.1210/jc.2012-1981; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Freynhofer MK, 2012, WIEN MED WOCHENSCHR, V162, P489, DOI 10.1007/s10354-012-0148-2; Giannopoulos G, 2013, CURR TOP MED CHEM, V13, P231, DOI 10.2174/15680266113139990088; JENNETT B, 1975, LANCET, V1, P480; Kleindienst A, 2010, ACTA NEUROCHIR SUPPL, V106, P221, DOI 10.1007/978-3-211-98811-4_41; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Lin C, 2013, PEPTIDES, V42, P43, DOI 10.1016/j.peptides.2013.01.015; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Russell JA, 2009, CRIT CARE MED, V37, P749, DOI 10.1097/CCM.0b013e318194d117; Staub D, 2009, CLIN CHIM ACTA, V399, P69, DOI 10.1016/j.cca.2008.09.016; Stocchetti N, 2014, LANCET NEUROL, V13, P14, DOI 10.1016/S1474-4422(13)70280-1; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Yalta K, 2013, INT J CARDIOL, V167, P1750, DOI 10.1016/j.ijcard.2012.12.039; Yu GF, 2012, PEPTIDES, V33, P164, DOI 10.1016/j.peptides.2011.11.017; Yu WH, 2014, CLIN CHIM ACTA, V433, P174, DOI 10.1016/j.cca.2014.03.014	24	30	34	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0196-9781	1873-5169		PEPTIDES	Peptides	OCT	2014	60						13	17		10.1016/j.peptides.2014.07.016			5	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	AP8YI	WOS:000342364900003	25076464				2022-02-06	
J	Dela Pena, I; Sanberg, PR; Acosta, S; Tajiri, N; Lin, SZ; Borlongan, CV				Dela Pena, I.; Sanberg, P. R.; Acosta, S.; Tajiri, N.; Lin, S-Z; Borlongan, C. V.			Stem cells and G-CSF for treating neuroinflammation in traumatic brain injury: aging as a comorbidity factor	JOURNAL OF NEUROSURGICAL SCIENCES			English	Article						Brain injuries; Stem cells; Aging	COLONY-STIMULATING FACTOR; RANDOMIZED CONTROLLED-TRIAL; MYOCARDIAL-INFARCTION; FUNCTIONAL RECOVERY; EXPERIMENTAL STROKE; CEREBRAL-ISCHEMIA; MOTOR FUNCTION; BLOOD-CELLS; AGED RATS; REPAIR	Traumatic brain injury (TBI), often called the signature wound of Iraq and Afghanistan wars, is characterized by a progressive histopathology and long-lasting behavioral deficits. Treatment options for TBI are limited and patients are usually relegated to rehabilitation therapy and a handful of experimental treatments. Stem cell-based therapies offer alternative treatment regimens for TBI, and have been intended to target the delayed therapeutic window post-TBI, in order to promote "neuroregeneration," in lieu of "neuroprotection" which can be accomplished during acute TBI phase. However, these interventions may require adjunctive pharmacological treatments especially when aging is considered as a comorbidity factor for post-TBI health outcomes. Here, we put forward the concept that a combination therapy of human umbilical cord blood cell (hUCB) and granulocyte-colony stimulating factor (G-CSF) attenuates neuroinflammation in TBI, in view of the safety and efficacy profiles of hUCB and G-CSF, their respective mechanisms of action, and efficacy of hUCB+G-CSF combination therapy in TBI animal models. Further investigations on the neuroinflammatory pathway as a key pathological hallmark in acute and chronic TBI and also as a major therapeutic target of hUCB+G-CSF are warranted in order to optimize the translation of this combination therapy in the clinic.	[Dela Pena, I.; Sanberg, P. R.; Acosta, S.; Tajiri, N.; Borlongan, C. V.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL USA; [Lin, S-Z] China Med Univ & Hosp, Ctr Neuropsychiat, Taichung, Taiwan		Borlongan, CV (corresponding author), 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Lin, Shinn-Zong/AAX-2379-2020; Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782	Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; University of South Florida Signature Interdisciplinary Program in Neuroscience funds; University of South Florida; Veterans Administration Reintegration Funds; University of South Florida Neuroscience Collaborative Program; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS071956-01A1]; James and Esther King Biomedical Research Foundation [1KG01-33966]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	This study was funded by the Department of Defense W81XWH-11-1-0634, the University of South Florida Signature Interdisciplinary Program in Neuroscience funds, the University of South Florida and Veterans Administration Reintegration Funds, and the University of South Florida Neuroscience Collaborative Program. P. R. Sanberg and C. V. Borlongan have patents and patent applications on stem cell therapy and serve as founder and consultant, respectively, of Saneron CCEL Therapeutics, Inc. C. V. Borlongan is funded by the National Institutes of Health 1R01NS071956-01A1, and James and Esther King Biomedical Research Foundation 1KG01-33966. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta S. A., 2013, J STEM CELL RES T S4, V1, pS004; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Boltze J, 2012, CELL TRANSPLANT, V21, P723, DOI 10.3727/096368911X586783; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Brasure M, 2013, ARCH PHYS MED REHAB, V94, P1398, DOI 10.1016/j.apmr.2012.12.019; Chen SJ, 2010, STEM CELLS DEV, V19, P1757, DOI 10.1089/scd.2009.0452; Copeland N, 2009, CLIN MED, V9, P342, DOI 10.7861/clinmedicine.9-4-342; Dietel B, 2012, EXP NEUROL, V237, P379, DOI 10.1016/j.expneurol.2012.06.019; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Faul M, 2010, TRAUMATIC BRAIN INJU; Garbuzova-Davis S, 2006, PROG BRAIN RES, V157, P207, DOI 10.1016/S0079-6123(06)57014-1; Giustini Alessandro, 2013, Handb Clin Neurol, V110, P401, DOI 10.1016/B978-0-444-52901-5.00034-4; Hartung T, 1998, Curr Opin Hematol, V5, P221, DOI 10.1097/00062752-199805000-00013; Hawkins BE, 2013, BRAIN RES, V1496, P28, DOI 10.1016/j.brainres.2012.12.027; Henning RJ, 2008, STEM CELLS DEV, V17, P1207, DOI 10.1089/scd.2008.0023; Herranz AS, 2010, CURR STEM CELL RES T, V5, P17, DOI 10.2174/157488810790442822; Huang HY, 2012, CELL TRANSPLANT, V21, pS3, DOI 10.3727/096368912X633725; Ilic D, 2012, BRIT MED BULL, V102, P43, DOI 10.1093/bmb/lds008; Iskander A, 2013, STEM CELL TRANSL MED, V2, P703, DOI 10.5966/sctm.2013-0066; Kadota R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050391; Kaneko Y, 2012, CELL MED, V4, P55, DOI 10.3727/215517912X639306; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee EJ, 2012, MOL THER, V20, P155, DOI 10.1038/mt.2011.202; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Li T, 2014, MOL CELL BIOCHEM, V387, P91, DOI 10.1007/s11010-013-1874-5; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Liu YP, 2009, ACTA NEUROPATHOL, V117, P469, DOI 10.1007/s00401-009-0516-1; Lu J, 2012, BRAIN INJURY, V26, P1523, DOI 10.3109/02699052.2012.722257; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A., 2003, NEUROSURGERY, V53, P702; Morita Y, 2007, NEUROSCI RES, V58, P356, DOI 10.1016/j.neures.2007.04.006; Mueller BK, 2009, BRIT J PHARMACOL, V157, P675, DOI 10.1111/j.1476-5381.2009.00220.x; Newman MB, 2003, NEUROTOX RES, V5, P355, DOI 10.1007/BF03033155; Newman MB, 2005, STEM CELLS DEV, V14, P29, DOI 10.1089/scd.2005.14.29; Ou YL, 2010, BRAIN RES, V1366, P217, DOI 10.1016/j.brainres.2010.09.098; Pimentel-Coelho PM, 2012, PEDIATR RES, V71, P464, DOI 10.1038/pr.2011.59; Rasouli J, 2011, Einstein J Biol Med, V27, P74; Rolan Terry, 2013, J Spec Oper Med, V13, P45; Sakowitz OW, 2006, ACTA NEUROCHIR SUPPL, V96, P139; Sanberg PR, 2012, PROG BRAIN RES, V201, P99, DOI 10.1016/B978-0-444-59544-7.00006-8; Sanberg PR, 2012, BRIT MED BULL, V101, P163, DOI 10.1093/bmb/lds001; Sanberg PR, 2005, ANN NY ACAD SCI, V1049, P67, DOI 10.1196/annals.1334.008; Sanchez-Ramos J, 2009, NEUROSCIENCE, V163, P55, DOI 10.1016/j.neuroscience.2009.05.071; Sandoe J, 2013, NAT NEUROSCI, V16, P780, DOI 10.1038/nn.3425; Schabitz WR, 2003, STROKE, V34, P745, DOI 10.1161/01.STR.0000057814.70180.17; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Sehara Y, 2007, J NEUROSCI RES, V85, P2167, DOI 10.1002/jnr.21341; Shahaduzzaman M, 2013, AGE, V35, P2071, DOI 10.1007/s11357-012-9496-5; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Solaroglu I, 2009, NEUROL RES, V31, P167, DOI 10.1179/174313209X393582; Stachura DL, 2013, BLOOD, V122, P3918, DOI 10.1182/blood-2012-12-475392; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toth ZE, 2008, BLOOD, V111, P5544, DOI 10.1182/blood-2007-10-119073; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Verina T, 2013, PEDIATR NEUROL, V48, P346, DOI 10.1016/j.pediatrneurol.2012.10.010; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Wong D, 2013, BRAIN INJURY, V27, P1377, DOI 10.3109/02699052.2013.823662; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yang M, 2003, CELL MOL NEUROBIOL, V23, P851, DOI 10.1023/A:1025017423102; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Zhao Li R, 2013, Recent Pat CNS Drug Discov, V8, P2	71	30	31	0	10	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0390-5616	1827-1855		J NEUROSURG SCI	J. Neurosurg. Sci.	SEP	2014	58	3					145	149					5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AR1XH	WOS:000343377400002	24844175				2022-02-06	
J	Krasny-Pacini, A; Limond, J; Evans, J; Hiebel, J; Bendjelida, K; Chevignard, M				Krasny-Pacini, Agata; Limond, Jenny; Evans, Jonathan; Hiebel, Jean; Bendjelida, Karim; Chevignard, Mathilde			Context-Sensitive Goal Management Training for Everyday Executive Dysfunction in Children After Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						child; daily life activities; ecological; executive functions; Goal Management Training; intervention; prospective memory; traumatic/acquired brain injury	BEHAVIOR RATING INVENTORY; PROSPECTIVE MEMORY; COGNITIVE REHABILITATION; ECOLOGICAL ASSESSMENT; YOUNG-CHILDREN; FRONTAL-LOBE; FUNCTION DEFICITS; PEDIATRIC TBI; TEST SCORE; OUTCOMES	Objectives: To assess the effectiveness of a metacognitive training intervention, based on an adapted Goal Management Training and Ylvisaker's principles, on 3 activity domains of executive functions: (1) prospective memory (PM) performance in ecological setting, (2) complex cooking task management, and (3) daily executive functioning (EF) at home and at school. Participants: Five children aged 8 to 14 years, who were 3 to 11 years post-severe traumatic brain injury, experiencing severe EF difficulties in daily life. Design: Single-case experimental design and assessment of EF twice prior to intervention, postintervention, and 3 and 6 months postintervention. Progress was monitored by a weekly ecological PM score. The effect on EF was assessed using the Children's Cooking Task. Transfer to the child's natural context was assessed by parental and teacher questionnaires and Goal Attainment Scaling. Results: All children improved both on the measure of PM and on questionnaires of daily EF. Two children improved on the Children's Cooking Task but returned to their preintervention level in a novel cooking task at follow-up. Participation of school personnel and parents in the program was low. Conclusions: It is feasible but challenging to use Goal Management Training in children with traumatic brain injury. Further research is needed in relation to how to promote generalization and how to increase the involvement of the child's "everyday people" in the intervention.	[Krasny-Pacini, Agata; Hiebel, Jean] Inst Univ Readaptat Clemenceau Strasbourg, F-67082 Strasbourg, France; [Krasny-Pacini, Agata; Hiebel, Jean] Hautepierre Univ Hosp, Dept Paediat Surg, Strasbourg, France; [Chevignard, Mathilde] Hop St Maurice, Rehabil Dept Children Acquired Brain Injury, St Maurice, France; [Limond, Jenny; Evans, Jonathan] Univ Glasgow, Inst Hlth & Wellbeing, Gartnavel Royal Hosp, Glasgow, Lanark, Scotland; [Krasny-Pacini, Agata; Chevignard, Mathilde] Univ Paris 06, Pitie Salpetriere Hosp, ER UPMC 6, Paris, France; [Bendjelida, Karim] Hop Hasenrain, EMOI TC 68, Mulhouse, France		Krasny-Pacini, A (corresponding author), Inst Univ Readaptat Clemenceau Strasbourg, 45 Bd Clemenceau, F-67082 Strasbourg, France.	agata.krasny@ugecam-alsace.fr			"SOFMER"(French Society of Physical and Rehabilitation Medicine); "SFERHE" (French Research Society against Children's handicap); "Fondation Gueules Cassees"	This study was supported by scholarships from the "SOFMER"(French Society of Physical and Rehabilitation Medicine), the "SFERHE" (French Research Society against Children's handicap), and the "Fondation Gueules Cassees."	Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 2001, Pediatr Rehabil, V4, P119, DOI 10.1080/13638490110091347; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bjorklund D. F., 2011, CHILDRENS THINKING C; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Burgess P.W., 2005, EFFECTIVENESS REHABI, P211, DOI DOI 10.1093/ACPROF:OSO/9780198526544.001.0001; Burgess PW, 2011, NEUROPSYCHOLOGIA, V49, P2246, DOI 10.1016/j.neuropsychologia.2011.02.014; Butler RW, 2008, J CONSULT CLIN PSYCH, V76, P367, DOI 10.1037/0022-006X.76.3.367; Catroppa C, 2009, DEV NEUROREHABIL, V12, P361, DOI 10.3109/17518420903087335; Chan DYK, 2011, DISABIL REHABIL, V33, P2023, DOI 10.3109/09638288.2011.556207; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chevignard MP, 2012, BRAIN INJURY, V26, P1033, DOI 10.3109/02699052.2012.666366; Chevignard MP, 2010, BRAIN IMPAIR, V11, P125, DOI 10.1375/brim.11.2.125; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 2013, STAT POWER ANAL BEHA; Cohen MJ, 2001, ECHELLE MEMOIRE ENFA; Cole WR, 2009, DEV DISABIL RES REV, V15, P159, DOI 10.1002/ddrr.58; Corbett C, 2009, THESIS U CAPE TOWN S; Crawford JR, 2002, NEUROPSYCHOLOGIA, V40, P1196, DOI 10.1016/S0028-3932(01)00224-X; Crawford JR, 1998, CLIN NEUROPSYCHOL, V12, P482, DOI 10.1076/clin.12.4.482.7241; Denckla M B, 1994, FRAMES REFERENCE ASS, P117; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Emslie H., 2003, BEHAV ASSESSMENT DYS; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Feeney TJ, 2010, J HEAD TRAUMA REHAB, V25, P416, DOI 10.1097/HTR.0b013e3181fbc0a2; Feeney TJ, 2003, J HEAD TRAUMA REHAB, V18, P33, DOI 10.1097/00001199-200301000-00006; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fish J, 2010, NEUROPSYCHOL REHABIL, V20, P161, DOI 10.1080/09602010903126029; Ford RM, 2012, J EXP CHILD PSYCHOL, V111, P468, DOI 10.1016/j.jecp.2011.10.006; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Gioia GA IP, 2000, BEHAV RATING INVENTO; Graham JE, 2012, ARCH PHYS MED REHAB, V93, pS111, DOI 10.1016/j.apmr.2011.12.017; Jansen LMC, 2003, DEV MED CHILD NEUROL, V45, P58, DOI 10.1017/S0012162203000112; Kerns KA, 2000, J INT NEUROPSYCH SOC, V6, P62, DOI 10.1017/S1355617700611074; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Krasny-Pacini A., 2013, Annals of Physical and Rehabilitation Medicine, V56, P212, DOI 10.1016/j.rehab.2013.02.002; Krasny-Pacini A, GOAL MANAGEMENT TRAI; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Lewis MW, 2011, NEUROPSYCHOL REHABIL, V21, P145, DOI 10.1080/09602011.2010.543867; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; Mackinlay RJ, 2009, J EXP CHILD PSYCHOL, V102, P251, DOI 10.1016/j.jecp.2008.08.006; Mahy CEV, 2011, COGNITIVE DEV, V26, P269, DOI 10.1016/j.cogdev.2011.06.002; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; McCauley SR, 2011, J CLIN EXP NEUROPSYC, V33, P639, DOI 10.1080/13803395.2010.547844; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Missiuna C, 2010, PHYS OCCUP THER PEDI, V30, P205, DOI 10.3109/01942631003761554; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Parker RI, 2009, BEHAV THER, V40, P357, DOI 10.1016/j.beth.2008.10.006; Perdices M, 2009, NEUROPSYCHOL REHABIL, V19, P904, DOI 10.1080/09602010903040691; Philips L., 1997, METHODOLOGY FRONTAL, P200; Rabbitt P., METHODOLOGY FRONTAL; Ross KA, 2011, DEV MED CHILD NEUROL, V53, P692, DOI 10.1111/j.1469-8749.2011.03976.x; Rous R, 2012, 9 INT BRAIN INJ C MA; Schlosser RW, 2004, J COMMUN DISORD, V37, P217, DOI 10.1016/j.jcomdis.2003.09.003; Selznick L, 2000, BEHAV INTERVENT, V15, P243, DOI 10.1002/1099-078X(200007/09)15:3<243::AID-BIN59>3.3.CO;2-T; Servant V, 2009, EVALUATION; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Tamm L, 2012, J ATTENTION DISORD; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2011, PEDIATRICS, V128, pE947, DOI 10.1542/peds.2010-3721; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Walker AJ, 2005, BRAIN INJURY, V19, P1237, DOI 10.1080/02699050500309411; Ward H, 2004, BRAIN INJURY, V18, P471, DOI 10.1080/02699050310001646107; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; Wechsler D., 2005, WISC 4 ECHELLE INTEL; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU	82	30	30	0	43	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2014	29	5					E49	E64		10.1097/HTR.0000000000000015			16	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AP2GW	WOS:000341891700005	24495918	Green Submitted			2022-02-06	
J	McLean, RL; Harrison, AJ; Zimak, E; Joseph, RM; Morrow, EM				McLean, Rebecca L.; Harrison, Ashley Johnson; Zimak, Eric; Joseph, Robert M.; Morrow, Eric M.			Executive Function in Probands With Autism With Average IQ and Their Unaffected First-Degree Relatives	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						autism spectrum disorder; executive functioning; adaptive functioning; IQ; pedigree	TRAUMATIC BRAIN-INJURY; SPECTRUM DISORDERS; COGNITIVE PHENOTYPE; CHILDREN; INDIVIDUALS; PARENTS; IMPAIRMENTS; DYSFUNCTION; CHILDHOOD; PROFILES	Objective: This study aimed to characterize executive function (EF) in pedigrees of children with autism spectrum disorder (ASD) and average IQ. The authors examined the hypothesis that deficits in EF relate to lower levels of adaptive functioning, and they assessed evidence for a cognitive extended phenotype in unaffected relatives in a large, well-characterized sample. Method: Proband EF was assessed by parent-report questionnaires (Behavior Rating Inventory of Executive Functioning [BRIEF], n = 109) and child neuropsychological tests (Delis-Kaplan Executive Functioning System [D-KEFS], n = 35). EF also was examined in parents (D-KEFS, n = 335) and unaffected siblings (BRIEF, n = 114; D-KEFS, n = 57). Adaptive functioning was assessed by the Vineland Adaptive Behavior Scales-II (n = 155). All data were obtained from the Autism Consortium Clinical Genetics Database. Results: Individuals with ASD showed important EF weaknesses. Multiple regression analyses showed that parent-reported EF deficits were related to profound decreases in adaptive functioning even after controlling for age, IQ and severity of ASD symptoms. Parent-reported EF also was related to adaptive skills in preschoolers. First-degree unaffected relatives did not demonstrate difficulties with EF compared with normative data. Conclusion: In this study, EF impairments do not appear to relate to broad familial risk factors for ASD but may be associated with factors relevant to the expression of ASD in probands. Results support the benefits of EF assessment as a way to identify potential therapeutic targets that could lead to improved adaptive behavior in children with ASD and average IQ.	[McLean, Rebecca L.; Morrow, Eric M.] Brown Univ, Sch Med, Emma Pendleton Bradley Hosp, Dev Disorders Genet Res Program, Providence, RI 02912 USA; [McLean, Rebecca L.] Mem Hosp Rhode Isl, Neurodev Ctr, Pawtucket, RI USA; [Harrison, Ashley Johnson; Zimak, Eric] Emma Pendleton Bradley Hosp, Dev Disorders Genet Res Program, East Providence, RI USA; [Harrison, Ashley Johnson; Zimak, Eric] Brown Univ, Med Sch, Providence, RI 02912 USA; [Joseph, Robert M.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Joseph, Robert M.; Morrow, Eric M.] Autism Consortium, Boston, MA USA; [Morrow, Eric M.] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA		Morrow, EM (corresponding author), Brown Univ, Mol Med Lab, 70 Ship St, Providence, RI 02912 USA.	eric_morrow@brown.edu	Morrow, Eric/J-2767-2013	Morrow, Eric/0000-0003-3430-3520; Joseph, Robert/0000-0001-6879-0254	Dr. Morrow's Career Award in Medical Science from the Burroughs Wellcome Fund; National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103645 01A1]; Autism Consortium; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1R01MH085143, 1R01MH083565]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH080954, R01MH085143, R01MH083565] Funding Source: NIH RePORTER	This research was supported by Dr. Morrow's Career Award in Medical Science from the Burroughs Wellcome Fund and the National Institutes of Health (NIH) / National Institute of General Medical Sciences (NIGMS) grant P20GM103645 01A1 : Project Award under Neuroscience COBRE Project. The collection of data and biomaterials comes from the Phenotypic and Genetic Factors in Autism Spectrum Disorders Study. Since 2008, this project has been supported by the Autism Consortium and by NIMH grants (1R01MH085143, principal investigator, Louis M. Kunkel, PhD; 1R01MH083565, principal investigator, Christopher Walsh, MD, PhD)	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; BaronCohen S, 1997, J COGNITIVE NEUROSCI, V9, P548, DOI 10.1162/jocn.1997.9.4.548; Bolte S, 2002, CHILD PSYCHIAT HUM D, V33, P165, DOI 10.1023/A:1020734325815; Delis DC., 2001, DELIS KAPLAN EXECUTI; Delorme R, 2007, EUR PSYCHIAT, V22, P32, DOI 10.1016/j.eurpsy.2006.05.002; Duncan AW, 2013, AUTISM; Fein, 2011, NEUROPSYCHOLOGY AUTI, P281; Fein, 2011, NEUROPSYCHOLOGY AUTI, P185; Gilotty L, 2002, CHILD NEUROPSYCHOL, V8, P241, DOI 10.1076/chin.8.4.241.13504; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA., 1996, BEHAV RATING INVENTO; Gotham K, 2009, J AUTISM DEV DISORD, V39, P693, DOI 10.1007/s10803-008-0674-3; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Hughes C, 1999, J CHILD PSYCHOL PSYC, V40, P705, DOI 10.1017/S0021963099004023; Hughes C, 1997, PSYCHOL MED, V27, P209, DOI 10.1017/S0033291796004308; Ikuta T, 2014, PSYCHIAT RES-NEUROIM, V221, P63, DOI 10.1016/j.pscychresns.2013.08.002; Isquith PK, 2005, MENT RETARD DEV D R, V11, P209, DOI 10.1002/mrdd.20075; Kanne SM, 2011, J AUTISM DEV DISORD, V41, P1007, DOI 10.1007/s10803-010-1126-4; Kenworthy L, 2014, J CHILD PSYCHOL PSYC, V55, P374, DOI 10.1111/jcpp.12161; Kenworthy L, 2009, CHILD NEUROPSYCHOL, V15, P425, DOI 10.1080/09297040802646983; Kenworthy LE, 2005, DEV NEUROPSYCHOL, V28, P809, DOI 10.1207/s15326942dn2803_4; Klin A, 2007, J AUTISM DEV DISORD, V37, P748, DOI 10.1007/s10803-006-0229-4; Latzman RD, 2010, ASSESSMENT, V17, P172, DOI 10.1177/1073191109356254; Le Couteur A, 2003, AUTISM DIAGNOSTIC IN; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Lord C, 1999, AUTISM DIAGNOSTIC OB; Losh M, 2009, ARCH GEN PSYCHIAT, V66, P518, DOI 10.1001/archgenpsychiatry.2009.34; MacAllister WS, 2012, CHILD NEUROPSYCHOL, V18, P404, DOI 10.1080/09297049.2011.613812; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Payne JM, 2011, CHILD NEUROPSYCHOL, V17, P313, DOI 10.1080/09297049.2010.542746; Pellicano E, 2012, AUTISM RES TREAT, V2012, P146; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Risi S, 2006, J AM ACAD CHILD PSY, V45, P1094, DOI 10.1097/01.chi.0000227880.42780.0e; Rosenthal M, 2013, NEUROPSYCHOLOGY, V27, P13, DOI 10.1037/a0031299; Rozga A., 2011, NEUROPSYCHOLOGY AUTI, P97; Sayers N, 2011, J INTELL DISABIL RES, V55, P699, DOI 10.1111/j.1365-2788.2010.01370.x; Semrud-Clikeman M, 2010, J AUTISM DEV DISORD, V40, P1017, DOI 10.1007/s10803-010-0951-9; Smithson PE, 2013, J AUTISM DEV DISORD, V43, P1967, DOI 10.1007/s10803-012-1747-x; Sparrow S.S., 2005, VINELAND ADAPTIVE BE; Sumiyoshi C, 2011, NEUROSCI RES, V69, P252, DOI 10.1016/j.neures.2010.11.007; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHSLER ABBREVIATED; Wecshler D, 2002, WECHSLER PRESCHOOL P; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wong D, 2006, GENES BRAIN BEHAV, V5, P561, DOI 10.1111/j.1601-183X.2005.00199.x	46	30	30	2	33	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	SEP	2014	53	9					1001	1009		10.1016/j.jaac.2014.05.019			9	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	AO3HW	WOS:000341221300010	25151423	Green Accepted			2022-02-06	
J	Tanriverdi, F; Dokmetas, HS; Kebapci, N; Kilicli, F; Atmaca, H; Yarman, S; Ertorer, ME; Erturk, E; Bayram, F; Tugrul, A; Culha, C; Cakir, M; Mert, M; Aydin, H; Taskale, M; Ersoz, N; Canturk, Z; Anaforoglu, I; Ozkaya, M; Oruk, G; Hekimsoy, Z; Kelestimur, F; Erbas, T				Tanriverdi, F.; Dokmetas, H. S.; Kebapci, N.; Kilicli, F.; Atmaca, H.; Yarman, S.; Ertorer, M. E.; Erturk, E.; Bayram, F.; Tugrul, A.; Culha, C.; Cakir, M.; Mert, M.; Aydin, H.; Taskale, M.; Ersoz, N.; Canturk, Z.; Anaforoglu, I.; Ozkaya, M.; Oruk, G.; Hekimsoy, Z.; Kelestimur, F.; Erbas, T.			Etiology of hypopituitarism in tertiary care institutions in Turkish population: analysis of 773 patients from pituitary study group database	ENDOCRINE			English	Article						Hypopituitarism; Pituitary; Sheehan's syndrome; Pituitary tumors	TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; GROWTH-HORMONE DEFICIENCY; REPLACEMENT THERAPY; SHEEHANS-SYNDROME; PREMATURE MORTALITY; GH REPLACEMENT; ACUTE-PHASE; HIGH-RISK; DYSFUNCTION	Hypopituitarism in adult life is commonly acquired and the main causes are known as pituitary tumors and/or their treatments. Since there are new insights into the etiology of hypopituitarism and presence of differences in various populations, more studies regarding causes of hypopituitarism are needed to be done in different ethnic groups with sufficient number of patients. Therefore, we performed a multi-center database study in Turkish population investigating the etiology of hypopituitarism in 773 patients in tertiary care institutions. The study was designed and coordinated by the Pituitary Study Group of SEMT (The Society of Endocrinology and Metabolism of Turkey). Nineteen tertiary reference centers (14 university hospitals and 5 training hospitals) from the different regions of Turkey participated in the study. It is a cross-sectional database study, and the data were recorded for 18 months. We mainly classified the causes of hypopituitarism as pituitary tumors (due to direct effects of the pituitary tumors and/or their treatments), extra-pituitary tumors and non-tumoral causes. Mean age of 773 patients (49.8 % male, 50.2 % female) was 43.9 +/- 16.1 years (range 16-84 years). The most common etiology of pituitary dysfunction was due to non-tumoral causes (49.2 %) among all patients. However, when we analyze the causes according to gender, the most common etiology in males was pituitary tumors, but the most common etiology in females was non-tumoral causes. According to the subgroup analysis of the causes of hypopituitarism in all patients, the most common four causes of hypopituitarism which have frequencies over 10 % were as follows: nonsecretory pituitary adenomas, Sheehan's syndrome, lactotroph adenomas and idiopathic. With regard to the type of hormonal deficiencies; FSH/LH deficiency was the most common hormonal deficit (84.9 % of the patients). In 33.8 % of the patients, 4 anterior pituitary hormone deficiencies (FSH/LH, ACTH, TSH, and GH) were present. Among all patients, the most frequent cause of hypopituitarism was non-secretory pituitary adenomas. However, in female patients, present study clearly demonstrates that Sheehan's syndromeis still one of the most important causes of hypopituitarism in Turkish population. Further, population-based prospective studies need to be done to understand the prevalence and incidence of the causes of hypopituitarism in different countries.	[Tanriverdi, F.; Bayram, F.; Kelestimur, F.] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Dokmetas, H. S.; Kilicli, F.] Cumhuriyet Univ, Sch Med, Dept Endocrinol, Sivas, Turkey; [Kebapci, N.] Osmangazi Univ, Fac Med, Dept Endocrinol, Eskisehir, Turkey; [Atmaca, H.] Karaelmas Univ, Dept Endocrinol, Zonguldak, Turkey; [Yarman, S.] Istanbul Univ, Fac Med, Dept Endocrinol, Istanbul, Turkey; [Ertorer, M. E.] Baskent Univ, Fac Med, Div Endocrinol, Adana, Turkey; [Erturk, E.] Uludag Univ, Sch Med, Dept Endocrinol, Bursa, Turkey; [Tugrul, A.] Trakya Univ, Fac Med, Endocrinol Sect, Edirne, Turkey; [Culha, C.] Ankara Res & Training Hosp, Dept Endocrinol, Ankara, Turkey; [Cakir, M.] Selcuk Univ, Meram Sch Med, Div Endocrinol, Konya, Turkey; [Mert, M.] Okmeydani Training & Res Hosp, Dept Endocrinol, Istanbul, Turkey; [Aydin, H.] Yeditepe Univ, Sch Med, Dept Endocrinol, Istanbul, Turkey; [Taskale, M.] Dr Sadi Konuk Res Hosp, Dept Endocrinol, Istanbul, Turkey; [Ersoz, N.; Erbas, T.] Hacettepe Univ, Sch Med, Dept Endocrinol, Ankara, Turkey; [Canturk, Z.] Kocaeli Univ, Sch Med, Dept Endocrinol, Izmit, Kocaeli, Turkey; [Anaforoglu, I.] Trabzon Numune Educ & Res Hosp, Dept Endocrinol, Trabzon, Turkey; [Ozkaya, M.] Maras Sutcuimam Sch Med, Dept Endocrinol, Kahramanmaras, Turkey; [Oruk, G.] Ataturk Training & Res Hosp, Dept Endocrinol, Izmir, Turkey; [Hekimsoy, Z.] Celal Bayar Univ, Fac Med, Dept Internal Med, Div Endocrinol & Metab, Manisa, Turkey		Tanriverdi, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fatihtan@erciyes.edu.tr	kelestimur, f/ABE-9873-2021; ERTORER, MELEK EDA/ABI-3705-2020; Oruk, Gonca/AAJ-7303-2020; Erbas, Tomris/AAF-7765-2019; Erturk, Erdinc/AAJ-6536-2021; ANAFOROGLU, INAN/AAG-8413-2021; Yarman, Sema/AAS-7526-2020	ERTORER, MELEK EDA/0000-0001-7357-8709; ANAFOROGLU, INAN/0000-0001-8990-3713; 			Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; ARAFAH B M, 1986, Journal of Clinical Endocrinology and Metabolism, V62, P1173; Bates AS, 1996, J CLIN ENDOCR METAB, V81, P1169, DOI 10.1210/jc.81.3.1169; Benvenga S, 2004, AM J MED, V116, P767, DOI 10.1016/j.amjmed.2003.12.038; Bondanelli M, 2010, J CLIN ENDOCR METAB, V95, P4660, DOI 10.1210/jc.2010-0611; De Marinis L, 2006, J ENDOCRINOL INVEST, V29, P516, DOI 10.1007/BF03344141; Elumir-Mamba L.A.S., 2010, PHILIPP J INTERN MED, V48, P23; Fernandez-Rodriguez E, 2013, CLIN ENDOCRINOL, V78, P278, DOI 10.1111/j.1365-2265.2012.04516.x; Kelestimur F, 2005, EUR J ENDOCRINOL, V152, P581, DOI 10.1530/eje.1.01881; Kelestimur Fahrettin, 2003, Pituitary, V6, P181, DOI 10.1023/B:PITU.0000023425.20854.8e; Kurtulmus N, 2006, AGING CLIN EXP RES, V18, P536; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Regal M, 2001, CLIN ENDOCRINOL, V55, P735, DOI 10.1046/j.1365-2265.2001.01406.x; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; SHEEHAN H L, 1965, J Obstet Gynaecol Br Commonw, V72, P103; SONKSEN PH, 1990, HORM RES, V33, P45, DOI 10.1159/000181583; Stochholm K, 2007, EUR J ENDOCRINOL, V157, P9, DOI 10.1530/EJE-07-0013; Stochholm K, 2008, EUR J ENDOCRINOL, V158, P447, DOI 10.1530/EJE-07-0523; Tanriverdi F, 2005, GROWTH HORM IGF RES, V15, P231, DOI 10.1016/j.ghir.2005.03.005; Tanriverdi F, 2012, PITUITARY, V15, P579, DOI 10.1007/s11102-011-0371-7; Tanriverdi F, 2011, J ENDOCRINOL INVEST, V34, P541, DOI 10.3275/7805; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V67, P931, DOI 10.1111/j.1365-2265.2007.02989.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; TOOGOOD AA, 1995, CLIN ENDOCRINOL, V43, P97, DOI 10.1111/j.1365-2265.1995.tb01898.x; Tsiakalos A, 2010, J CLIN ENDOCR METAB, V95, P3277, DOI 10.1210/jc.2010-0144; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306	34	30	31	1	19	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1355-008X	1559-0100		ENDOCRINE	Endocrine	SEP	2014	47	1					198	205		10.1007/s12020-013-0127-4			8	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	AS2CS	WOS:000344087600025	24366641				2022-02-06	
J	Adembri, C; Selmi, V; Vitali, L; Tani, A; Margheri, M; Loriga, B; Carlucci, M; Nosi, D; Formigli, L; De Gaudio, AR				Adembri, Chiara; Selmi, Valentina; Vitali, Luca; Tani, Alessia; Margheri, Martina; Loriga, Beatrice; Carlucci, Martina; Nosi, Daniele; Formigli, Lucia; De Gaudio, Angelo Raffaele			Minocycline But Not Tigecycline Is Neuroprotective and Reduces the Neuroinflammatory Response Induced by the Superimposition of Sepsis Upon Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						cecal ligation and puncture; controlled cortical impact; experimental model; minocycline; sepsis; tigecycline; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; FOCAL CEREBRAL-ISCHEMIA; MICROGLIAL ACTIVATION; COGNITIVE FUNCTION; WATER-MAZE; MICE; RAT; INFLAMMATION; MODEL; TETRACYCLINES	Objective: The development of sepsis in patients with traumatic brain injury increases mortality, exacerbates morphological and functional cerebral damage, and causes persistent neuroinflammation, including microglial activation. The administration of antibiotics possessing both antimicrobial and immunomodulatory activity might attenuate both sepsis and posttraumatic cerebral inflammation. We compared the potential therapeutic efficacy of two tetracyclines, minocycline and the newer generation tigecycline, on functional neurobehavioral impairment and regional histopathological damage in an experimental model of combined traumatic brain injury and sepsis. Design: Prospective, experimental animal study. Setting: University Research Laboratory. Subjects: Adult male Sprague-Dawley rats. Interventions: Controlled cortical impact was used to induce traumatic brain injury and cecal ligation and puncture for sepsis. Immediately following injury, animals were treated with minocycline (45 mg/kg intraperitoneal), tigecycline (7.5 mg/kg intraperitoneal), or saline every 12 hours for 3 days. Measurements and Main Results: The development of sepsis and cerebral inflammatory response were evaluated, respectively, by 1) growth of peritoneal microorganisms and clinical variables and 2) tumor necrosis factor-a expression in the perilesional cortex. To assess posttraumatic outcome, vestibulomotor and cognitive function were evaluated at different time points for 14 days post injury whereupon animals were killed and cerebral tissue analyzed for lesion volume, regional hippocampal (CA1/CA3) cell death, and microglial activation in the perilesional cortex, lesion core zone, and choroid plexus. Treatment with both antibiotics reduced microorganism growth, body weight loss, and mortality but had no effect on vestibulomotor or cognitive function. Minocycline alone attenuated postinjury cortical lesion volume, hippocampal CA3 neuronal cell loss, tumor necrosis factor-a expression, and the extent of microglial activation and infiltration. Conclusions: The significantly heightened mortality caused by the superimposition of sepsis upon traumatic brain injury can be reduced by administration of both antibiotics but only minocycline can decrease the extent of cell death in selectively cortical and hippocampal brain regions, via, in part, a reduction in cerebral inflammation.	[Adembri, Chiara] Univ Florence, Dept Hlth Sci, Sect Anesthesiol & Intens Care, Florence, Italy; Univ Florence, Dept Expt & Clin Med, Florence, Italy		Adembri, C (corresponding author), Univ Florence, Dept Hlth Sci, Sect Anesthesiol & Intens Care, Florence, Italy.	chiara.adembri@unifi.it			Cassa Risparmio Firenze, Firenze; Ministero della Ricerca, Italy; Ministero della Ricerca [20087SM5HM_003]	Dr. Adembri received grant support from Cassa Risparmio Firenze, Firenze; served as board member for Merck Sharp & Dohme (MSD); and received support for article research from Ministero della Ricerca, Italy. Drs. Selmi, Vitali, Tani, Margheri, Loriga, Carlucci, Nosi, and Formigli received support for article research from Ministero della Ricerca, Italy. Dr. De Gaudio served as board member for MSD and received support for article research from Ministero della Ricerca (#20087SM5HM_003). His institution received grant support from Ministero della ricerca.	Adembri C, 2011, CRIT CARE, V15, DOI 10.1186/cc10559; Aid S, 2010, NEUROSCI LETT, V478, P113, DOI 10.1016/j.neulet.2010.04.076; Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Buras JA, 2005, NAT REV DRUG DISCOV, V4, P854, DOI 10.1038/nrd1854; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cai Zhi-You, 2008, Neurosci Bull, V24, P305, DOI 10.1007/s12264-008-0324-y; Chen XH, 2011, J NEUROIMMUNOL, V235, P1, DOI 10.1016/j.jneuroim.2011.04.006; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Czlonkowska A, 2011, J NEUROIMMUNOL, V231, P78, DOI 10.1016/j.jneuroim.2010.09.020; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Graeber MB, 2011, FEBS LETT, V585, P3798, DOI 10.1016/j.febslet.2011.08.033; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Huang DR, 2005, FASEB J, V19, P761, DOI 10.1096/fj.04-3104com; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kieburtz K, 2008, CLIN NEUROPHARMACOL, V31, P141, DOI 10.1097/WNF.0b013e3181342f32; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lin SZ, 2001, NEUROSCI LETT, V315, P61, DOI 10.1016/S0304-3940(01)02324-2; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murata Y, 2008, STROKE, V39, P3372, DOI 10.1161/STROKEAHA.108.514026; Murphy TM, 2000, ANTIMICROB AGENTS CH, V44, P3022, DOI 10.1128/AAC.44.11.3022-3027.2000; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Nimmo Alan J, 2009, Recent Pat CNS Drug Discov, V4, P86; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Patel K, 1998, BRIT DENT J, V185, P560, DOI 10.1038/sj.bdj.4809867; Peeling James, 2006, J Stroke Cerebrovasc Dis, V15, P101, DOI 10.1016/j.jstrokecerebrovasdis.2006.03.001; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Schutt AC, 2009, ANN PHARMACOTHER, V43, P2108, DOI 10.1345/aph.1M324; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Seputiene V, 2010, MEDICINA-LITHUANIA, V46, P240, DOI 10.3390/medicina46040033; Shlaes DM, 2006, CURR OPIN INVEST DR, V7, P167; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Venturi L, 2009, J NEUROTRAUM, V26, P1547, DOI [10.1089/neu.2008.0723, 10.1089/neu.2008-0723]; Wafaisade A, 2011, CRIT CARE MED, V39, P621, DOI 10.1097/CCM.0b013e318206d3df; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zheng WW, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-40; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	53	30	30	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2014	42	8					E570	E582		10.1097/CCM.0000000000000414			13	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AL7QV	WOS:000339330700003	24810523				2022-02-06	
J	Bonfield, CM; Naran, S; Adetayo, OA; Pollack, IF; Losee, JE				Bonfield, Christopher M.; Naran, Sanjay; Adetayo, Oluwaseun A.; Pollack, Ian F.; Losee, Joseph E.			Pediatric skull fractures: the need for surgical intervention, characteristics, complications, and outcomes	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						pediatric; skull fracture; head injury; trauma; surgical intervention	MANAGEMENT; CHILDREN; INJURIES; INFANTS; TRAUMA	Object. Head trauma is a common cause of morbidity and mortality in the pediatric population and often results in a skull fracture. Pediatric skull fractures are distinct from adult fractures. Pediatric fractures have a greater capacity to remodel, but the pediatric brain and craniofacial skeleton are still developing. Although pediatric head trauma has been extensively studied, there is sparse literature regarding skull fractures. The authors' aim was to investigate the characteristics, injuries, complications, and outcomes of the patients in whom surgical intervention was needed for skull fractures. Methods. The authors performed a retrospective review of patients presenting to the emergency department of a pediatric Level I trauma center between 2000 and 2005 with skull fractures. Patient demographics, mechanism of injury, associated injuries, fracture bone involvement, surgical intervention, complications, and outcomes were analyzed. Groups treated nonoperatively, for skull fracture repair, and for traumatic brain injury were compared. Results. A total of 897 patients with a skull fracture were analyzed. Most patients (n = 772, 86.1%) were treated nonoperatively (Non-Op group). Fifty-eight patients (6.5%) underwent repair of the fracture (Repair group) and 67 (7.5%) required intervention for treatment of traumatic brain injury (TBI group). The Non-Op group was significantly younger, and the TBI group had a lower initial Glasgow Coma Scale (GCS) score. A fall (51.2%) was the most common mechanism of injury in the Non-Op group, whereas a motor vehicle crash (23.9%) and being hit in the head with an object (48.2%) were most prevalent in the TBI and Repair groups, respectively. Associated injuries were seen in all 3 groups, with brain injury (hematoma) being the most common. Frontal bone fracture was seen most in the Repair and TBI groups, and the parietal bone was the most frequent bone fractured in the Non-Op group. Patients in the TBI group were much more likely to have 2 or 3 skull bones fractured. In the Repair group, 36.2% had a complication (38.0% intervention related and 62.0% trauma related), but no patient had a worsening of their neurological status. In the TBI group, 48.7% of the patients suffered a complication, the vast majority (90.6%) of which were related to the trauma. Conclusions. The majority of pediatric skull fractures can be managed conservatively. Of those requiring surgical intervention, fewer than half of the surgeries are performed solely for skull fracture repair only. Patients hit in the head with an object or involved in a motor vehicle crash are more likely to need surgical intervention either to repair the skull fracture or for TBI management, respectively. Frontal bone fractures are more likely to necessitate repair, and those patients treated for TBI have a greater incidence of 2 or 3 bones involved in the fracture. Complications occurred but most were related to underlying trauma, not the surgery. No patients who underwent intervention for repair of their skull fracture only had a worsening of their neurological status.	[Bonfield, Christopher M.; Pollack, Ian F.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Naran, Sanjay; Adetayo, Oluwaseun A.; Losee, Joseph E.] Univ Pittsburgh, Dept Plast Surg, Pittsburgh, PA 15260 USA		Bonfield, CM (corresponding author), 200 Lothrop St,Ste B400, Pittsburgh, PA 15213 USA.	bonfieldcm@upmc.edu					BRAAKMAN R, 1972, J NEUROL NEUROSUR PS, V35, P395, DOI 10.1136/jnnp.35.3.395; Erlichman DB, 2010, PEDIATR RADIOL, V40, P1375, DOI 10.1007/s00247-010-1555-4; Ersahin Y, 1996, CHILD NERV SYST, V12, P323, DOI 10.1007/BF00301021; Haug RH, 2000, ORAL SURG ORAL MED O, V90, P126, DOI 10.1067/moe.2000.107974; Hung KL, 2005, J NEUROSURG, V103, P69, DOI 10.3171/ped.2005.103.1.0069; JENNETT B, 1974, J NEUROSURG, V41, P208, DOI 10.3171/jns.1974.41.2.0208; MANN KS, 1986, CHILD NERV SYST, V2, P258; National Center for Injury Prevention and Control of the Centers for Disease Control and Prevention, 2000, TRAUM BRAIN INJ US A; NELSON EL, 1984, NEUROSURGERY, V15, P318, DOI 10.1227/00006123-198409000-00005; Saadat S, 2011, ULUS TRAVMA ACIL CER, V17, P149, DOI 10.5505/tjtes.2011.26043; Sanford RA, 2010, J NEUROSURG-PEDIATR, V5, P213, DOI 10.3171/2009.9.PEDS09180; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shane SA, 1997, PEDIATR EMERG CARE, V13, P198, DOI 10.1097/00006565-199706000-00006; Singh DJ, 2004, CLIN PLAST SURG, V31, P499, DOI 10.1016/j.cps.2004.03.012; STEINBOK P, 1987, J NEUROSURG, V66, P506, DOI 10.3171/jns.1987.66.4.0506; VANDENHEEVER CM, 1989, J NEUROSURG, V71, P186, DOI 10.3171/jns.1989.71.2.0186	16	30	32	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2014	14	2					205	211		10.3171/2014.5.PEDS13414			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	AL9PJ	WOS:000339472900017	24905840				2022-02-06	
J	Mutch, WAC; Ellis, MJ; Graham, MR; Wourms, V; Raban, R; Fisher, JA; Mikulis, D; Leiter, J; Ryner, L				Mutch, W. Alan C.; Ellis, Michael J.; Graham, M. Ruth; Wourms, Vincent; Raban, Roshan; Fisher, Joseph A.; Mikulis, David; Leiter, Jeffrey; Ryner, Lawrence			Brain MRI CO2 Stress Testing: A Pilot Study in Patients with Concussion	PLOS ONE			English	Article							CEREBROVASCULAR RESPONSE; WHITE-MATTER; SPORTS; RECOVERY; KNOWLEDGE; INJURY	Background: There is a real need for quantifiable neuro-imaging biomarkers in concussion. Here we outline a brain BOLD-MRI CO2 stress test to assess the condition. Methods: This study was approved by the REB at the University of Manitoba. A group of volunteers without prior concussion were compared to post-concussion syndrome (PCS) patients - both symptomatic and recovered asymptomatic. Five 3-minute periods of BOLD imaging at 3.0 T were studied - baseline 1 (BL1- at basal CO2 tension), hypocapnia (CO2 decreased similar to 5 mmHg), BL2, hypercapnia (CO2 increased similar to 10 mmHg) and BL3. Data were processed using statistical parametric mapping (SPM) for 1st level analysis to compare each subject's response to the CO2 stress at the p = 0.001 level. A 2nd level analysis compared each PCS patient's response to the mean response of the control subjects at the p = 0.05 level. Results: We report on 5 control subjects, 8 symptomatic and 4 asymptomatic PCS patients. Both increased and decreased response to CO2 was seen in all PCS patients in the 2nd level analysis. The responses were quantified as reactive voxel counts: whole brain voxel counts (2.0 +/- 1.6%, p = 0.012 for symptomatic patients for CO2 response < controls and 3.0 +/- 5.1%, p = 0.139 for CO2 response > controls: 0.49 +/- 0.31%, p = 0.053 for asymptomatic patients for CO2 response < controls and 4.4 +/- 6.8%, p = 0.281 for CO2 response > controls). Conclusions: Quantifiable alterations in regional cerebrovascular responsiveness are present in concussion patients during provocative CO2 challenge and BOLD MRI and not in healthy controls. Future longitudinal studies must aim to clarify the relationship between CO2 responsiveness and individual patient symptoms and outcomes.	[Mutch, W. Alan C.; Graham, M. Ruth; Wourms, Vincent; Raban, Roshan] Univ Manitoba, Hlth Sci Ctr, Dept Anesthesia & Perioperat Med, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Dept Surg, Hlth Sci Ctr, Neurosurg Sect, Winnipeg, MB R3T 2N2, Canada; [Fisher, Joseph A.] Univ Toronto, Toronto Gen Hosp, Dept Anesthesia & Pain Management, Toronto, ON M5G 1L7, Canada; [Mikulis, David] Univ Toronto, Toronto Western Hosp, Dept Radiol, Sect Neuroimaging, Toronto, ON M5T 2S8, Canada; [Leiter, Jeffrey] Univ Manitoba, Dept Surg, Pan Am Clin, Winnipeg, MB R3T 2N2, Canada; [Ryner, Lawrence] Univ Manitoba, Dept Phys & Astron, Winnipeg, MB, Canada		Mutch, WAC (corresponding author), Univ Manitoba, Hlth Sci Ctr, Dept Anesthesia & Perioperat Med, Winnipeg, MB, Canada.	wacmutch@shaw.ca	Mikulis, David J/H-5167-2019	Mutch, W. Alan/0000-0001-7174-7839; Mikulis, David/0000-0003-3956-0892	Anesthesia Oversight Committee	Anesthesia Oversight Committee. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Ashburner J, 2012, NEUROIMAGE, V62, P791, DOI 10.1016/j.neuroimage.2011.10.025; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Burke MJ, 2012, CAN J NEUROL SCI, V39, P763, DOI 10.1017/S0317167100015584; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Fierstra J, 2013, J PHYSIOL-LONDON, V591, P5809, DOI 10.1113/jphysiol.2013.259150; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; He BJ, 2009, TRENDS COGN SCI, V13, P302, DOI 10.1016/j.tics.2009.04.004; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kiebel SJ, 2004, NEUROIMAGE, V22, P503, DOI 10.1016/j.neuroimage.2004.02.013; Kim SG, 2012, J CEREBR BLOOD F MET, V32, P1188, DOI 10.1038/jcbfm.2012.23; Kitzbichler MG, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000314; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Langlois JA, 2008, J HEAD TRAUMA REHAB, V21, P375; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mardimae A, 2012, PFLUG ARCH EUR J PHY, V464, P345, DOI 10.1007/s00424-012-1148-1; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Mutch WAC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057881; Mutch WAC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047443; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Prisman E, 2008, J MAGN RESON IMAGING, V27, P185, DOI 10.1002/jmri.21102; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Raichle ME, 2009, J NEUROSCI, V29, P12729, DOI 10.1523/JNEUROSCI.4366-09.2009; Regan RE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070751; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Sobczyk O, 2014, NEUROIMAGE, V92, P56, DOI 10.1016/j.neuroimage.2014.01.051; Tormenti M, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12282; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005	38	30	30	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2014	9	7							e102181	10.1371/journal.pone.0102181			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AL8VR	WOS:000339418300039	25032707	Green Published, gold, Green Submitted			2022-02-06	
J	Andelic, N; Ye, JJ; Tornas, S; Roe, C; Lu, J; Bautz-Holter, E; Moger, T; Sigurdardottir, S; Schanke, AK; Aas, E				Andelic, Nada; Ye, Jiajia; Tornas, Sveinung; Roe, Cecilie; Lu, Juan; Bautz-Holter, Erik; Moger, Tron; Sigurdardottir, Solrun; Schanke, Anne-Kristine; Aas, Eline			Cost-Effectiveness Analysis of an Early-Initiated, Continuous Chain of Rehabilitation after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; outcome measures; rehabilitation; traumatic brain injury	SEVERE HEAD-INJURY; POPULATION; DIFFERENCE; OUTCOMES; IMPROVE; EUROPE; TRIAL; SCALE; COMA	The aim of this study is to estimate the long-term cost-effectiveness of two different rehabilitation trajectories after severe traumatic brain injury (sTBI). A decision tree model compared hospitalization costs, health effects, and incremental cost-effectiveness ratios (ICER) of a continuous chain versus a broken chain of rehabilitation. The expected costs were estimated by the reimbursement system using diagnosis-related group and based on point estimates of the Disability Rating Scale (DRS); the health effects were measured by means of area under the curve (AUC). The incremental health benefit was estimated as the difference in the AUCs between the chains. Lower values on the DRS scale indicate better health; thus, smaller AUCs were preferred. The modeled population was a cohort of 59 patients with sTBI (30 in continuous chain; 29 in broken chain) with 6-weeks, 1-year, and 5-year post-injury follow-ups. Regarding the DRS estimates, 5-year AUCs were 19.40 (continuous chain) and 23.46 (broken chain). Across 5 years, the continuous chain of rehabilitation had lower costs and better health effects. By replacing the broken chain with the continuous chain, NOK 37.000 could be saved and 4.06 DRS points gained. By means of probabilistic sensitivity analysis, the majority of ICER estimates (67% of the Monte Carlo simulations) indicated that a continuous chain of rehabilitation was less costly and more effective. These findings indicate that the trajectory of continuous rehabilitation represents a dominant strategy in that it reduces costs and improves outcomes after sTBI under reasonable assumptions.	[Andelic, Nada; Sigurdardottir, Solrun] Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, N-0318 Oslo, Norway; [Andelic, Nada; Roe, Cecilie; Bautz-Holter, Erik] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Ye, Jiajia; Moger, Tron; Aas, Eline] Univ Oslo, Dept Hlth Management & Hlth Econ, Inst Hlth & Soc, N-0318 Oslo, Norway; [Tornas, Sveinung; Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp Trust, Nesoddtangen, Norway; [Roe, Cecilie] Univ Oslo, Inst Clin Med, N-0318 Oslo, Norway; [Lu, Juan] Virginia Commonwealth Univ, Dept Family Med & Populat Hlth, Div Epidemiol, Richmond, VA USA		Andelic, N (corresponding author), Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, PB 1130 Blindern, N-0318 Oslo, Norway.	nandelic@online.no		Andelic, Nada/0000-0002-3719-4406; Lu, Juan/0000-0002-5389-7603	Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services); Faculty of Medicine, University of Oslo; Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo	This study was funded by the Institute of Health and Society, CHARM (Research Centre for Habilitation and Rehabilitation Models and Services), the Faculty of Medicine, University of Oslo, and the Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo.	Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Drummond M., 2005, METHODS EC EVALUATIO; Drummond MF, 2005, MED DECIS MAKING, V25, P520, DOI 10.1177/0272989X05280561; Fenwick E, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-52; Frost RB, 2013, NEUROEPIDEMIOLOGY, V40, P154, DOI 10.1159/000343275; Greenwood RJ, 2004, BRIT J NEUROSURG, V18, P462, DOI 10.1080/02688690400012327; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Ho KM, 2011, J TRAUMA, V71, P1637, DOI 10.1097/TA.0b013e31823a08f1; Kompanje EJO, 2007, SCI ENG ETHICS, V13, P371, DOI 10.1007/s11948-007-9027-4; Lu J, 2013, J NEUROTRAUM, V30, P1925, DOI 10.1089/neu.2013.2891; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mishra V, 2001, TRANSPLANT INT, V14, P361, DOI 10.1111/j.1432-2277.2001.tb00074.x; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Price MJ, 2011, VALUE HEALTH, V14, P205, DOI 10.1016/j.jval.2010.08.001; Ramsey S, 2005, VALUE HEALTH, V8, P521, DOI 10.1111/j.1524-4733.2005.00045.x; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Ricker J H, 1998, Appl Neuropsychol, V5, P184, DOI 10.1207/s15324826an0504_3; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; TEASDALE G, 1974, LANCET, V2, P81; Turner-Stokes L, 2004, CLIN MED, V4, P61, DOI 10.7861/clinmedicine.4-1-61; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1016/S0079-6123(09)17707-5; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Whitmore RG, 2012, J NEUROSURG, V116, P1106, DOI 10.3171/2012.1.JNS11962; Zhu XL, 2007, BRAIN INJURY, V21, P681, DOI 10.1080/02699050701468941	31	30	30	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2014	31	14					1313	1320		10.1089/neu.2013.3292			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AN4CA	WOS:000340534000008	24720788				2022-02-06	
J	Lang, GE; Stewart, PS; Vella, D; Waters, SL; Goriely, A				Lang, Georgina E.; Stewart, Peter S.; Vella, Dominic; Waters, Sarah L.; Goriely, Alain			Is the Donnan effect sufficient to explain swelling in brain tissue slices?	JOURNAL OF THE ROYAL SOCIETY INTERFACE			English	Article						Donnan effect; triphasic model; brain mechanics; tissue swelling	MECHANICAL-PROPERTIES; MIXTURE THEORY; MODEL; COMPRESSION; CARTILAGE	Brain tissue swelling is a dangerous consequence of traumatic injury and is associated with raised intracranial pressure and restricted blood flow. We consider the mechanical effects that drive swelling of brain tissue slices in an ionic solution bath, motivated by recent experimental results that showed that the volume change of tissue slices depends on the ionic concentration of the bathing solution. This result was attributed to the presence of large charged molecules that induce ion concentration gradients to ensure electroneutrality (the Donnan effect), leading to osmotic pressures and water accumulation. We use a mathematical triphasic model for soft tissue to characterize the underlying processes that could lead to the volume changes observed experimentally. We suggest that swelling is caused by an osmotic pressure increase driven by both non-permeating solutes released by necrotic cells, in addition to the Donnan effect. Both effects are necessary to explain the dependence of the tissue slice volume on the ionic bath concentration that was observed experimentally.	[Lang, Georgina E.; Stewart, Peter S.; Vella, Dominic; Waters, Sarah L.; Goriely, Alain] Univ Oxford, Inst Math, Oxford OX1 3LB, England; [Stewart, Peter S.] Univ Glasgow, Sch Math & Stat, Glasgow, Lanark, Scotland		Goriely, A (corresponding author), Univ Oxford, Inst Math, 24-29 St Giles, Oxford OX1 3LB, England.	goriely@maths.ox.ac.uk	Vella, Dominic/A-9070-2008; Goriely, Alain/E-3277-2012	Vella, Dominic/0000-0003-1341-8863; Goriely, Alain/0000-0002-6436-8483; Waters, Sarah/0000-0001-5285-0523; Stewart, Peter/0000-0002-0971-8057			Ateshian GA, 2006, J BIOMECH, V39, P464, DOI 10.1016/j.jbiomech.2004.12.013; Atkins P.W., 2006, ATKINSPHYSICAL CHEM; Bilston LE, 2011, BIOL MED PHYS BIOMED, P69, DOI 10.1007/978-1-4419-9997-9_4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Cowin SC, 2009, TISSUE MECH; Donnan FG, 1924, CHEM REV, V1, P73, DOI 10.1021/cr60001a003; Elkin BS, 2011, J NEUROTRAUM, V28, P2277, DOI 10.1089/neu.2010.1603; Elkin BS, 2010, PHILOS T R SOC A, V368, P585, DOI 10.1098/rsta.2009.0223; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Frijns AJH, 1997, INT J ENG SCI, V35, P1419, DOI 10.1016/S0020-7225(97)00047-5; Fritz JS., 2012, INT J NUMER ANAL M B, V3, P82; FUNG YC, 1984, AM ZOOL, V24, P13, DOI 10.1093/icb/24.1.13; Garcia JJ, 2010, LAT AM APPL RES, V40, P295; Gentili C, 2009, CURR PHARM DESIGN, V15, P1334, DOI 10.2174/138161209787846739; Holzapfel GA, 2000, J ELASTICITY, V61, P1, DOI 10.1023/A:1010835316564; Huyghe JM, 1997, INT J ENG SCI, V35, P793, DOI 10.1016/S0020-7225(96)00119-X; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; LAI WM, 1991, J BIOMECH ENG-T ASME, V113, P245, DOI 10.1115/1.2894880; LEAF A, 1959, ANN NY ACAD SCI, V72, P396, DOI 10.1111/j.1749-6632.1959.tb44168.x; Levine DN, 1999, B MATH BIOL, V61, P875, DOI 10.1006/bulm.1999.0116; Lu XL, 2008, MED SCI SPORT EXER, V40, P193, DOI 10.1249/mss.0b013e31815cb1fc; Marmarou A., 2007, NEUROSURG FOCUS, V22, P1; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; NAGASHIMA T, 1990, Neurologia Medico-Chirurgica, V30, P1, DOI 10.2176/nmc.30.1; NICHOLSON C, 2002, J CEREB BLOOD FLOW M, V22, P80, DOI DOI 10.1097/00004647-200201000-00010; OGDEN RW, 1997, NONLINEAR ELASIC DEF; PAPPIUS HM, 1956, CAN J BIOCHEM PHYS, V34, P1007; Rashid B, 2013, J BIOMECH, V46, P1276, DOI 10.1016/j.jbiomech.2013.02.014; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; RASLAN A, 2007, NEUROSURG FOCUS, V220, P1; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Smillie A, 2005, J FLUID MECH, V539, P417, DOI 10.1017/S0022112005005707; Sun DN, 1999, INT J NUMER METH ENG, V45, P1375, DOI 10.1002/(SICI)1097-0207(19990810)45:10<1375::AID-NME635>3.0.CO;2-7; Taylor Z, 2004, J BIOMECH, V37, P1263, DOI 10.1016/j.jbiomech.2003.11.027; THIEX R, 2007, NEUROSURG FOCUS, V220, P1, DOI DOI 10.3171/FOC.2007.22.5.7); Walberer M, 2008, J NEUROSURG, V109, P287, DOI 10.3171/JNS/2008/109/8/0287; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	30	30	0	22	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1742-5689	1742-5662		J R SOC INTERFACE	J. R. Soc. Interface	JUL 6	2014	11	96							20140123	10.1098/rsif.2014.0123			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AH5HN	WOS:000336159200009	24759543	Green Published, Bronze			2022-02-06	
J	Mierzwa, AJ; Sullivan, GM; Beer, LA; Ahn, S; Armstrong, RC				Mierzwa, Amanda J.; Sullivan, Genevieve M.; Beer, Laurel A.; Ahn, Sohyun; Armstrong, Regina C.			Comparison of Cortical and White Matter Traumatic Brain Injury Models Reveals Differential Effects in the Subventricular Zone and Divergent Sonic Hedgehog Signaling Pathways in Neuroblasts and Oligodendrocyte Progenitors	ASN NEURO			English	Article						neuroblast; oligodendrocyte progenitor; sonic hedgehog; stem cell; subventricular zone; traumatic brain injury	NEURAL STEM-CELL; IMPACT INJURY; ADULT BRAIN; MICE; MOUSE; PROLIFERATION; DEMYELINATION; MAINTENANCE; POPULATIONS; ASTROCYTES	The regenerative capacity of the central nervous system must be optimized to promote repair following traumatic brain injury (TBI) and may differ with the site and form of damage. Sonic hedgehog (Shh) maintains neural stem cells and promotes oligodendrogenesis. We examined whether Shh signaling contributes to neuroblast (doublecortin) or oligodendrocyte progenitor (neural/glial antigen 2 [NG2]) responses in two distinct TBI models. Shh-responsive cells were heritably labeled in vivo using Gli1-CreER (T2); R26-YFP bitransgenic mice with tamoxifen administration on Days 2 and 3 post-TBI. Injury to the cerebral cortex was produced with mild controlled cortical impact. Yellow fluorescent protein (YFP) cells decreased in cortical lesions. Total YFP cells increased in the subventricular zone (SVZ), indicating Shh pathway activation in SVZ cells, including doublecortin-labeled neuroblasts. The alternate TBI model produced traumatic axonal injury in the corpus callosum. YFP cells decreased within the SVZ and were rarely double labeled as NG2 progenitors. NG2 progenitors increased in the cortex, with a similar pattern in the corpus callosum. To further test the potential of NG2 progenitors to respond through Shh signaling, Smoothened agonist was microinjected into the corpus callosum to activate Shh signaling. YFP cells and NG2 progenitors increased in the SVZ but were not double labeled. This result indicates that either direct Smoothened activation in NG2 progenitors does not signal through Gli1 or that Smoothened agonist acts indirectly to increase NG2 progenitors. Therefore, in all conditions, neuroblasts exhibited differential Shh pathway utilization compared with oligodendrocyte progenitors. Notably, cortical versus white matter damage from TBI produced opposite responses of Shh-activated cells within the SVZ.	[Mierzwa, Amanda J.; Sullivan, Genevieve M.; Beer, Laurel A.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Mierzwa, Amanda J.; Sullivan, Genevieve M.; Beer, Laurel A.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Sullivan, Genevieve M.; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Program Mol & Cell Biol, Bethesda, MD 20814 USA; [Ahn, Sohyun] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA		Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	regina.armstrong@usuhs.edu	Sullivan, Genevieve/AAK-7415-2021	Sullivan, Genevieve/0000-0002-3561-223X	National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG4675]; Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM)	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Multiple Sclerosis Society (RG4675) and the Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM).	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Ahn S, 2004, CELL, V118, P505, DOI 10.1016/j.cell.2004.07.023; Alvarez JI, 2011, SCIENCE, V334, P1727, DOI 10.1126/science.1206936; Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Badea TC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007859; Balordi F, 2007, J NEUROSCI, V27, P5936, DOI 10.1523/JNEUROSCI.1040-07.2007; Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Ferent J, 2013, J NEUROSCI, V33, P1759, DOI 10.1523/JNEUROSCI.3334-12.2013; Garcia ADR, 2010, J NEUROSCI, V30, P13597, DOI 10.1523/JNEUROSCI.0830-10.2010; Hughes EG, 2013, NAT NEUROSCI, V16, P668, DOI 10.1038/nn.3390; Ihrie RA, 2011, NEURON, V71, P250, DOI 10.1016/j.neuron.2011.05.018; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Ming XT, 2013, J NEUROSCI, V33, P12528, DOI 10.1523/JNEUROSCI.0536-13.2013; Palma V, 2005, DEVELOPMENT, V132, P335, DOI 10.1242/dev.01567; Petrova R, 2013, J NEUROSCI, V33, P17490, DOI 10.1523/JNEUROSCI.2042-13.2013; Radomski KL, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-142; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sirko S, 2013, CELL STEM CELL, V12, P426, DOI 10.1016/j.stem.2013.01.019; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Wang Y, 2008, ANN NEUROL, V64, P417, DOI 10.1002/ana.21457; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Yi X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070306	30	30	30	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro	JUL-SEP	2014	6	5							1759091414551782	10.1177/1759091414551782			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AR7IP	WOS:000343753200001	25290062	gold, Green Published			2022-02-06	
J	Vaughn, MG; Salas-Wright, CP; Delisi, M; Perron, B				Vaughn, Michael G.; Salas-Wright, Christopher P.; Delisi, Matt; Perron, Brian			Correlates of traumatic brain injury among juvenile offenders: A multi-site study	CRIMINAL BEHAVIOUR AND MENTAL HEALTH			English	Article							LIFE-COURSE-PERSISTENT; SELF-CONTROL; CRIME; PREVALENCE; HYPERACTIVITY; DELINQUENCY; GOTTFREDSON; INVENTORY; PATHWAYS; VIOLENCE	Background There is some evidence that antisocial individuals, including young delinquents, are significantly more likely than people in the general population to incur a traumatic brain injury (TBI). Extant studies are hampered by methodological limitations, such as small sample sizes, lack of control for confounding effects, and use of single sites and may lack representativeness. Hypothesis The hypothesis for this study is that young offenders with a history of TBI will not only be at higher risk of impulsivity and negative emotionality than their non-injured peers but also that those with TBI will have had more previous victimisation experiences. Methods Data from two sites (Philadelphia, PA and Phoenix, AZ) in a substantial longitudinal, prospective study - the Pathways to Desistance Study - were used to compare young people (average age 16 years) who reported TBI with those who did not. Independent variables were behavioural, criminogenic and psychosocial measures. Results Male youths were about twice as likely as young females to report TBI. Such injury was associated with higher impulsivity and negative emotion ratings, even after allowing for potentially confounding factors, including sex. In addition, TBI was independently associated with self-reported experience of victimisation. Conclusions/implications This extends the generalisability of earlier suggestions of a relationship between TBI and offending, and various factors thought likely to mediate the relationship. The implications are, thus, that it is likely to be of practical value to screen young people who get into the criminal justice system for a history of TBI, and thus to allow for more specific tailoring of interventions to reduce the range of associated problems, including likely reoffending. Copyright (C) 2014 John Wiley & Sons, Ltd.	[Vaughn, Michael G.] St Louis Univ, Sch Social Work, St Louis, MO 63103 USA; [Salas-Wright, Christopher P.] Univ Texas Austin, Austin, TX 78712 USA; [Delisi, Matt] Iowa State Univ, Ames, IA USA; [Perron, Brian] Univ Michigan, Ann Arbor, MI 48109 USA		Vaughn, MG (corresponding author), St Louis Univ, Sch Social Work, 3550 Lindell BLVD, St Louis, MO 63103 USA.	mvaughn9@slu.edu	Vaughn, Michael/W-2694-2019; DeLisi, Matt/U-9128-2019; Salas-Wright, Christopher/K-5463-2014	DeLisi, Matt/0000-0001-5964-5848; 			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Armstrong TA, 2012, J CRIM JUST, V40, P31, DOI 10.1016/j.jcrimjus.2011.11.001; Bandura A, 1996, J PERS SOC PSYCHOL, V71, P364, DOI 10.1037/0022-3514.71.2.364; Barnes JC, 2010, J CRIM JUST, V38, P1176, DOI 10.1016/j.jcrimjus.2010.09.006; Carswell K, 2004, J ADOLESCENCE, V27, P415, DOI 10.1016/j.adolescence.2004.04.003; Chung HL, 2007, CRIM JUSTICE BEHAV, V34, P1402, DOI 10.1177/0093854807307170; Cohen J., 1988, STAT POWER BEHAV SCI; Cox J, 2013, J CRIM JUST, V41, P125, DOI 10.1016/j.jcrimjus.2012.12.001; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; de Ridder DTD, 2012, PERS SOC PSYCHOL REV, V16, P76, DOI 10.1177/1088868311418749; Defoe IN, 2013, J CRIM JUST, V41, P100, DOI 10.1016/j.jcrimjus.2012.12.002; DeLisi M, 2008, INT J OFFENDER THER, V52, P520, DOI 10.1177/0306624X07308553; DeLisi M, 2011, J CRIM JUST, V39, P103, DOI 10.1016/j.jcrimjus.2011.02.012; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Farrer TJ, 2013, CHILD NEUROPSYCHOL, V19, P225, DOI 10.1080/09297049.2011.647901; Farrington DP, 2009, AGGRESSIVE BEHAV, V35, P150, DOI 10.1002/ab.20296; Faul M, 2010, TRAUMATIC BRAIN INJU; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Forth A. E., 2003, HARE PSYCHOPATHY CHE; Frost RB, 2013, NEUROEPIDEMIOLOGY, V40, P154, DOI 10.1159/000343275; Golden CJ, 1978, STROOP COLOR WORD TE; Gottfredson M. R., 1990, GEN THEORY CRIME; Jennings WG, 2012, J CRIM JUST, V40, P472, DOI 10.1016/j.jcrimjus.2012.07.001; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lichtenstein P, 2012, NEW ENGL J MED, V367, P2006, DOI 10.1056/NEJMoa1203241; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Moffitt TE, 2002, DEV PSYCHOPATHOL, V14, P179, DOI 10.1017/S0954579402001104; Moffitt TE, 2003, CAUSES OF CONDUCT DISORDER AND JUVENILE DELINQUENCY, P49; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Mulvey EP, 2012, VICTIMS OFFENDERS, V7, P407, DOI 10.1080/15564886.2012.713903; Patrick CJ, 2012, DEV PSYCHOPATHOL, V24, P1047, DOI 10.1017/S0954579412000533; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Pratt TC, 2000, CRIMINOLOGY, V38, P931, DOI 10.1111/j.1745-9125.2000.tb00911.x; Raine A, 2005, J ABNORM PSYCHOL, V114, P38, DOI 10.1037/0021-843X.114.1.38; Reynolds C.R., 1985, REVISED CHILDRENS MA; Rocque M, 2012, J CRIM JUST, V40, P306, DOI 10.1016/j.jcrimjus.2012.05.003; Schubert CA, 2004, YOUTH VIOLENCE JUV J, V2, P37; Selner-O'Hagan MB, 1998, J CHILD PSYCHOL PSYC, V39, P215, DOI 10.1017/S002196309700187X; Shaw DS, 2012, DEV PSYCHOPATHOL, V24, P871, DOI 10.1017/S0954579412000429; Shiroma EJ, 2012, J HEAD TRAUMA REHAB, V27, pE1, DOI 10.1097/HTR.0b013e3182571c14; StataCorp, 2011, STAT STAT SOFTW REL; Thornberry T.P., 2003, GANGS DELINQUENCY DE; Vaughn MG, 2011, J CRIM JUST, V39, P212, DOI 10.1016/j.jcrimjus.2011.02.003; Vaughn MG, 2011, J CRIM JUST, V39, P75, DOI 10.1016/j.jcrimjus.2010.12.001; Vaughn MG, 2009, ADDICT BEHAV, V34, P112, DOI 10.1016/j.addbeh.2008.08.011; Walters GD, 2013, J CRIM JUST, V41, P135, DOI 10.1016/j.jcrimjus.2012.12.004; WEINBERGER DA, 1990, J PERS, V58, P381, DOI 10.1111/j.1467-6494.1990.tb00235.x; Welsh BC, 2012, J CRIM JUST, V40, P128, DOI 10.1016/j.jcrimjus.2012.01.008; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; World Health Organization, 2008, ICD 10 INT STAT CLAS	51	30	30	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0957-9664	1471-2857		CRIM BEHAV MENT HEAL	Crim. Behav. Ment. Health	JUL	2014	24	3					188	203		10.1002/cbm.1900			16	Criminology & Penology; Psychiatry	Social Science Citation Index (SSCI)	Criminology & Penology; Psychiatry	AL5GE	WOS:000339160800005	24425682	Green Published			2022-02-06	
J	Corser-Jensen, CE; Goodell, DJ; Freund, RK; Serbedzija, P; Murphy, RC; Farias, SE; Dell'Acqua, ML; Frey, LC; Serkova, N; Heidenreich, KA				Corser-Jensen, Chelsea E.; Goodell, Dayton J.; Freund, Ronald K.; Serbedzija, Predrag; Murphy, Robert C.; Farias, Santiago E.; Dell'Acqua, Mark L.; Frey, Lauren C.; Serkova, Natalie; Heidenreich, Kim A.			Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neuroinflammation; Leukotrienes; FLAP inhibitor; Hippocampus; Long-term potentiation; Memory and learning; Blood-brain barrier; Edema	FOCAL CEREBRAL-ISCHEMIA; TRANSCELLULAR BIOSYNTHESIS; RECEPTOR-1 ANTAGONIST; ASTHMATIC SUBJECTS; EDEMA FORMATION; GERBIL BRAIN; EXPRESSION; PRANLUKAST; INHIBITORS; PERMEABILITY	Neuroinflammation is a component of secondary injury following traumatic brain injury (TBI) that can persist beyond the acute phase. Leukotrienes are potent, pro-inflammatory lipid mediators generated from membrane phospholipids. In the absence of injury, leukotrienes are undetectable in the brain, but after trauma they are rapidly synthesized by a transcellular event involving infiltrating neutrophils and endogenous brain cells. Here, we investigate the efficacy of MK-886, an inhibitor of 5-lipoxygenase activating protein (FLAP), in blocking leukotriene synthesis, secondary brain damage, synaptic dysfunction, and cognitive impairments after TBI. Male Sprague Dawley rats (9-11 weeks) received either MK-886 or vehicle after they were subjected to unilateral moderate fluid percussion injury (FPI) to assess the potential clinical use of FLAP inhibitors for TBI. MK-886 was also administered before FPI to determine the preventative potential of FLAP inhibitors. MK-886 given before or after injury significantly blocked the production of leukotrienes, measured by reverse-phase liquid chromatography coupled to tandem mass spectrometry (RP LC-MS/MS), and brain edema, measured by T2-weighted magnetic resonance imaging (MRI). MK-886 significantly attenuated blood-brain barrier disruption in the CA1 hippocampal region and deficits in long-term potentiation (LTP) at CA1 hippocampal synapses. The prevention of FPI-induced synaptic dysfunction by MK-886 was accompanied by fewer deficits in post-injury spatial learning and memory performance in the radial arm water maze (RAWM). These results indicate that leukotrienes contribute significantly to secondary brain injury and subsequent cognitive deficits. FLAP inhibitors represent a novel anti-inflammatory approach for treating human TBI that is feasible for both intervention and prevention of brain injury and neurologic deficits. (C) 2014 Elsevier Inc. All rights reserved.	[Corser-Jensen, Chelsea E.; Goodell, Dayton J.; Murphy, Robert C.; Farias, Santiago E.; Dell'Acqua, Mark L.; Heidenreich, Kim A.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA; [Corser-Jensen, Chelsea E.; Goodell, Dayton J.; Freund, Ronald K.; Serbedzija, Predrag; Murphy, Robert C.; Farias, Santiago E.; Dell'Acqua, Mark L.; Heidenreich, Kim A.] Univ Colorado, Dept Pharmacol, Aurora, CO 80045 USA; [Frey, Lauren C.] Univ Colorado, Dept Neurol, Aurora, CO 80045 USA; [Serkova, Natalie] Univ Colorado, Dept Anesthesiol, Aurora, CO 80045 USA		Heidenreich, KA (corresponding author), Univ Colorado, Anschutz Med Campus,12800 E 19th Ave, Aurora, CO 80045 USA.	kim.heidenreich@ucdenver.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD041697, R01NS040710, GM069338, R21NS079435]; Colorado Brain Injury Program; UC Denver Center for Neuroscience Translational Research Award; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD041697] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM069338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS079435] Funding Source: NIH RePORTER	This study was supported by NIH grants 5T32HD041697 (C.E.C. and D.J.G.), R01NS040710 (M.L.D.), GM069338 (R.C.M.), and R21NS079435 (K.A.H.), the Colorado Brain Injury Program (K.A.H.), and the UC Denver Center for Neuroscience Translational Research Award (K.A.H.). Contents are the authors' sole responsibility and do not necessarily represent official NIH views.	Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Biber N, 2009, BRAIN INJURY, V23, P577, DOI 10.1080/02699050902926317; Boyce JA, 2007, IMMUNOL REV, V217, P168, DOI 10.1111/j.1600-065X.2007.00512.x; Campbell JN, 2012, J NEUROTRAUM, V29, P218, DOI 10.1089/neu.2011.1762; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Chu LS, 2006, ACTA PHARMACOL SIN, V27, P282, DOI 10.1111/j.1745-7254.2006.00290.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Dahlen B, 1997, THORAX, V52, P342, DOI 10.1136/thx.52.4.342; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; DIAMANT Z, 1995, J ALLERGY CLIN IMMUN, V95, P42, DOI 10.1016/S0091-6749(95)70151-6; Ding Q, 2007, ACTA PHARMACOL SIN, V28, P945, DOI 10.1111/j.1745-7254.2007.00576.x; Evans JF, 2008, TRENDS PHARMACOL SCI, V29, P72, DOI 10.1016/j.tips.2007.11.006; Fang SH, 2006, NEUROSCIENCE, V140, P969, DOI 10.1016/j.neuroscience.2006.02.051; Farias S, 2009, J NEUROTRAUM, V26, P1977, DOI 10.1089/neu.2009.0877; Farias SE, 2007, J NEUROCHEM, V103, P1310, DOI 10.1111/j.1471-4159.2007.04830.x; Faul M, 2010, TRAUMATIC BRAIN INJU; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Folkerts MM, 2007, J NEUROTRAUM, V24, P638, DOI 10.1089/neu.2006.0188; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Hartig W, 2013, BRAIN RES, V1498, P69, DOI 10.1016/j.brainres.2012.12.022; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kenne E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-17; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; Kochanek PM, 2009, J NEUROTRAUM, V26, P813, DOI 10.1089/neu.2008.0893; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LOBERG EM, 1991, ACTA NEUROPATHOL, V81, P479, DOI 10.1007/BF00310126; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MINAMISAWA H, 1988, STROKE, V19, P372, DOI 10.1161/01.STR.19.3.372; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; Qian XD, 2006, EUR J PHARMACOL, V549, P35, DOI 10.1016/j.ejphar.2006.07.056; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Voigt C, 2012, NEUROPATH APPL NEURO, V38, P354, DOI 10.1111/j.1365-2990.2011.01211.x; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; Yu GL, 2005, BRAIN RES, V1053, P116, DOI 10.1016/j.brainres.2005.06.046; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088	51	30	31	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2014	256						7	16		10.1016/j.expneurol.2014.03.008			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI1VZ	WOS:000336644600002	24681156	Green Accepted			2022-02-06	
J	He, BR; Xie, ST; Wu, MM; Hao, DJ; Yang, H				He, Bao-Rong; Xie, Song-Tao; Wu, Ming-Mei; Hao, Ding-Jun; Yang, Hao			Phagocytic Removal of Neuronal Debris by Olfactory Ensheathing Cells Enhances Neuronal Survival and Neurite Outgrowth via p38MAPK Activity	MOLECULAR NEUROBIOLOGY			English	Article						Olfactory ensheathing cells; Phagocytosis; Neuron; Survival; p38MAPK	SPINAL-CORD-INJURY; IN-VITRO; SCHWANN-CELLS; WALLERIAN DEGENERATION; AXONAL REGENERATION; NEUROTROPHIC FACTOR; NERVOUS-SYSTEM; NOGO RECEPTOR; RAT-BRAIN; GLIA	Compelling evidence from animal models and clinical studies suggest that transplantation of olfactory ensheathing cells (OECs), specialized glia in the olfactory system, combined with specific training may be therapeutically useful in the central nervous system (CNS) injuries and neurodegenerative diseases. The unique function of OECs could mainly attribute to both production of cell adhesion molecules and secretion of growth factors in OECs, which support neuron survival and neurite outgrowth. However, little is known about whether engulfment of neuronal degenerative debris by OECs also equally contributes to neuronal survival and neurite outgrowth. Furthermore, the molecular mechanisms responsible for neuronal degenerative corpses' removal remain elusive. Here, we used an in vitro model of primary culture of spinal cord neurons to investigate the effect of engulfment of degenerative neuron debris by OECs on neuronal survival and neurite outgrowth and the possible molecular mechanisms. Our results showed that OECs can engulf an amount of degenerated neuron debris, and this phagocytosis can make a substantial contribution to neuron growth, as demonstrated by increased number of neurons with longer neurite length and richer neurite branches when compared with the combination of neuron debris and OEC conditioned medium (OECCM). Moreover, p38 mitogen-activated protein kinase (p38MAPK) signaling pathway may mediate the OEC engulfment of debris because the p38MAPK-specific inhibitor, SB203580, can abrogate all the positive effects of OECs, including clearance of degenerated neuron debris and generation of bioactive molecules, indicating that p38MAPK is required for the process of phagocytosis of the neuron debris. In addition, the OEC phagocytic activity had no influence on its generation of bioactive molecules. Therefore, these findings provide new insight into further investigations on the OEC role in the repair of traumatic CNS injury and neurodegenerative diseases.	[He, Bao-Rong] Xi An Jiao Tong Univ, Coll Med, Hong Hui Hosp, Dept Spine Surg, Xian 710054, Shaanxi, Peoples R China; [Xie, Song-Tao] Fourth Mil Med Univ, Dept Burns & Cutaneous Surg, Xijing Hosp, Xian 710032, Peoples R China; [Wu, Ming-Mei] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China; [Hao, Ding-Jun] Xi An Jiao Tong Univ, Coll Med, Hong Hui Hosp, Dept Orthopaed, Xian 710054, Shaanxi, Peoples R China; [Yang, Hao] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Clin Stem Cell Res Ctr, Shanghai 200217, Peoples R China		Hao, DJ (corresponding author), Xi An Jiao Tong Univ, Coll Med, Hong Hui Hosp, Dept Orthopaed, Xian 710054, Shaanxi, Peoples R China.	haodingjun@163.com; yanghao.71_99@yahoo.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371411, 81071486, 81171137, 81372056]	This work was supported by the Natural Science Foundation of China (grant nos. 81371411, 81071486, 81171137, and 81372056).	Aldskogius H, 2001, MICROSC RES TECHNIQ, V54, P40, DOI 10.1002/jemt.1119; Bhat NR, 1998, J NEUROSCI, V18, P1633; Buss A, 2005, BRAIN, V128, P356, DOI 10.1093/brain/awh355; Cao L, 2004, BRAIN, V127, P535, DOI 10.1093/brain/awh072; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chiu SC, 2009, J MOL MED, V87, P1179, DOI 10.1007/s00109-009-0528-2; Chung RS, 2004, CELL MOL LIFE SCI, V61, P1238, DOI 10.1007/s00018-004-4026-y; David S, 2008, TRENDS NEUROSCI, V31, P221, DOI 10.1016/j.tins.2008.02.002; Franssen EHP, 2007, BRAIN RES REV, V56, P236, DOI 10.1016/j.brainresrev.2007.07.013; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; Gudino-Cabrera G, 2000, GLIA, V30, P49, DOI 10.1002/(SICI)1098-1136(200003)30:1<49::AID-GLIA6>3.0.CO;2-M; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harris JA, 2009, GLIA, V57, P1848, DOI 10.1002/glia.20899; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Huizinga R, 2012, GLIA, V60, P422, DOI 10.1002/glia.22276; Inatani M, 2001, INVEST OPHTH VIS SCI, V42, P1930; Kafitz KW, 1999, GLIA, V25, P99, DOI 10.1002/(SICI)1098-1136(19990115)25:2<99::AID-GLIA1>3.0.CO;2-V; Kocsis JD, 2009, NEUROSCI LETT, V456, P137, DOI 10.1016/j.neulet.2008.08.093; Lakatos A, 2000, GLIA, V32, P214, DOI 10.1002/1098-1136(200012)32:3<214::AID-GLIA20>3.0.CO;2-7; Lankford KL, 2008, GLIA, V56, P1664, DOI 10.1002/glia.20718; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Leung JYK, 2008, CELL MOL LIFE SCI, V65, P2732, DOI 10.1007/s00018-008-8184-1; Li Y, 2005, GLIA, V52, P245, DOI 10.1002/glia.20241; Li YB, 1998, NEUROSCI RES, V32, P137, DOI 10.1016/S0168-0102(98)00077-7; Liu Y, 2010, MOL VIS, V16, P2903; Lopez-Vales R, 2006, NEUROBIOL DIS, V21, P57, DOI 10.1016/j.nbd.2005.06.011; Ma YH, 2010, CELL TRANSPLANT, V19, P167, DOI 10.3727/096368910X492634; MIRAGALL F, 1989, DEV BIOL, V135, P272, DOI 10.1016/0012-1606(89)90179-6; Mitchell PJ, 2007, J NEUROSCI METH, V164, P350, DOI 10.1016/j.jneumeth.2007.04.021; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nacher J, 1999, HISTOL HISTOPATHOL, V14, P89, DOI 10.14670/HH-14.89; Navarro X, 1999, ANN NEUROL, V45, P207, DOI 10.1002/1531-8249(199902)45:2<207::AID-ANA11>3.0.CO;2-K; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Noda M, 2011, J BIOL CHEM, V286, P2308, DOI 10.1074/jbc.M110.169839; Pastrana E, 2007, NEUROCHEM INT, V50, P491, DOI 10.1016/j.neuint.2006.10.004; Pastrana E, 2006, J NEUROSCI, V26, P5347, DOI 10.1523/JNEUROSCI.1111-06.2006; Pellitteri R, 2007, NEUROSCI LETT, V417, P24, DOI 10.1016/j.neulet.2007.02.065; Raisman G, 2007, NAT REV NEUROSCI, V8, P312, DOI 10.1038/nrn2099; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, BRAIN RES BULL, V46, P175, DOI 10.1016/S0361-9230(97)00463-2; RAMONCUETO A, 1995, GLIA, V14, P163, DOI 10.1002/glia.440140302; Ruitenberg MJ, 2005, BRAIN, V128, P839, DOI 10.1093/brain/awh424; Su ZD, 2010, PROG NEUROBIOL, V92, P517, DOI 10.1016/j.pneurobio.2010.08.008; Tanaka T, 2009, J BIOL CHEM, V284, P21626, DOI 10.1074/jbc.M109.005603; Tsuda M, 2004, GLIA, V45, P89, DOI 10.1002/glia.10308; Vincent AJ, 2007, GLIA, V55, P905, DOI 10.1002/glia.20512; Vincent AJ, 2005, J NEUROCYTOL, V34, P65, DOI 10.1007/s11068-005-5048-6; Vincent AJ, 2005, GLIA, V51, P132, DOI 10.1002/glia.20195; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Williams SK, 2004, J COMP NEUROL, V470, P50, DOI 10.1002/cne.11045; Woodhall E, 2001, MOL BRAIN RES, V88, P203, DOI 10.1016/S0169-328X(01)00044-4; Yang H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y; Yang H, 2011, NEUROCHEM INT, V59, P1010, DOI 10.1016/j.neuint.2011.08.021; Yang H, 2009, CELL MOL NEUROBIOL, V29, P455, DOI 10.1007/s10571-008-9337-3; Yang Hao, 2003, Shi Yan Sheng Wu Xue Bao, V36, P5	55	30	33	2	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUN	2014	49	3					1501	1512		10.1007/s12035-013-8588-2			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AG8KE	WOS:000335666500028	24258406				2022-02-06	
J	Brisson, CD; Hsieh, YT; Kim, D; Jin, AY; Andrew, RD				Brisson, C. Devin; Hsieh, Yi-Ting; Kim, Danielle; Jin, Albert Y.; Andrew, R. David			Brainstem Neurons Survive the Identical Ischemic Stress That Kills Higher Neurons: Insight to the Persistent Vegetative State	PLOS ONE			English	Article							DORSAL-ROOT GANGLIA; SPREADING DEPRESSION; ANOXIC DEPOLARIZATION; LOCUS-COERULEUS; CARDIAC-ARREST; RAT; NUCLEUS; HYPOXIA; GLUTAMATE; DAMAGE	Global ischemia caused by heart attack, pulmonary failure, near-drowning or traumatic brain injury often damages the higher brain but not the brainstem, leading to a 'persistent vegetative state' where the patient is awake but not aware. Approximately 30,000 U. S. patients are held captive in this condition but not a single research study has addressed how the lower brain is preferentially protected in these people. In the higher brain, ischemia elicits a profound anoxic depolarization (AD) causing neuronal dysfunction and vasoconstriction within minutes. Might brainstem nuclei generate less damaging AD and so be more resilient? Here we compared resistance to acute injury induced from simulated ischemia by 'higher' hippocampal and striatal neurons versus brainstem neurons in live slices from rat and mouse. Light transmittance (LT) imaging in response to 10 minutes of oxygen/glucose deprivation (OGD) revealed immediate and acutely damaging AD propagating through gray matter of neocortex, hippocampus, striatum, thalamus and cerebellar cortex. In adjacent brainstem nuclei, OGD-evoked AD caused little tissue injury. Whole-cell patch recordings from hippocampal and striatal neurons under OGD revealed sudden membrane potential loss that did not recover. In contrast brainstem neurons from locus ceruleus and mesencephalic nucleus as well as from sensory and motor nuclei only slowly depolarized and then repolarized post-OGD. Two-photon microscopy confirmed non-recoverable swelling and dendritic beading of hippocampal neurons during OGD, while mesencephalic neurons in midbrain appeared uninjured. All of the above responses were mimicked by bath exposure to 100 mu M ouabain which inhibits the Na+/K+ pump or to 1-10 nM palytoxin which converts the pump into an open cationic channel. Therefore during ischemia the Na+/K+ pump of higher neurons fails quickly and extensively compared to naturally resilient hypothalamic and brainstem neurons. The selective survival of lower brain regions that maintain vital functions will support the persistent vegetative state.	[Brisson, C. Devin; Hsieh, Yi-Ting; Kim, Danielle; Jin, Albert Y.; Andrew, R. David] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada		Andrew, RD (corresponding author), Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada.	andrewd@queensu.ca			Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada [T- 4478]; Faculty of Health Sciences, Queen's University	This work was supported by the Heart and Stroke Foundation of Canada (grant T- 4478) and the Faculty of Health Sciences, Queen's University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Anderson TR, 2005, J NEUROPHYSIOL, V93, P963, DOI 10.1152/jn.00654.2004; Andrew R. D., 2013, Society for Neuroscience Abstract Viewer and Itinerary Planner, V43; Andrew R. D., 2012, Society for Neuroscience Abstract Viewer and Itinerary Planner, V42; Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Andrew RD, 2011, VAS 2011 11 INT C NE, P311; Artigas P, 2004, J GEN PHYSIOL, V123, P357, DOI 10.1085/jgp.200308964; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; Bargiotas P, 2011, P NATL ACAD SCI USA, V108, P20772, DOI 10.1073/pnas.1018262108; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Blanco G, 2005, SEMIN NEPHROL, V25, P292, DOI 10.1016/j.semnephrol.2005.03.004; Brisson CD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079589; Brisson CD, 2012, J NEUROPHYSIOL, V108, P419, DOI 10.1152/jn.00090.2012; BURCHIEL KJ, 1984, EXP NEUROL, V85, P257, DOI 10.1016/0014-4886(84)90139-0; BURES J, 1981, J NEUROBIOL, V12, P211, DOI 10.1002/neu.480120303; Centonze D, 2001, PROG NEUROBIOL, V63, P687, DOI 10.1016/S0301-0082(00)00037-X; COWAN AI, 1992, J PHYSIOL-LONDON, V455, P89, DOI 10.1113/jphysiol.1992.sp019292; CZEH G, 1992, NEUROREPORT, V3, P197, DOI 10.1097/00001756-199202000-00019; de Oliveira RB, 2011, BRAIN RES, V1425, P27, DOI 10.1016/j.brainres.2011.09.053; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dobretsov M, 2005, FRONT BIOSCI-LANDMRK, V10, P2373, DOI 10.2741/1704; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Falini A, 1998, AM J NEURORADIOL, V19, P648; Farkas E, 2010, NEUROIMAGE, V51, P734, DOI 10.1016/j.neuroimage.2010.02.055; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Funke F, 2009, J NEUROPHYSIOL, V101, P2395, DOI 10.1152/jn.91260.2008; Gadsby DC, 2009, PHILOS T R SOC B, V364, P229, DOI 10.1098/rstb.2008.0243; Gao H, 2009, BRAIN RES, V1291, P40, DOI 10.1016/j.brainres.2009.07.024; Gottron MA, 2009, CONTEMP NEUROSCI, P129, DOI 10.1007/978-1-60761-280-3_8; Hamann M, 2005, BRAIN, V128, P2408, DOI 10.1093/brain/awh619; Hawrylycz MJ, 2012, NATURE, V489, P391, DOI 10.1038/nature11405; HENDERSON G, 1982, EXP BRAIN RES, V45, P29; Higuchi T, 1997, MAGNET RESON MED, V37, P851, DOI 10.1002/mrm.1910370608; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Joshi I, 2001, J NEUROPHYSIOL, V85, P414, DOI 10.1152/jn.2001.85.1.414; Kaminogo M, 1998, NEUROL RES, V20, P343, DOI 10.1080/01616412.1998.11740529; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Karunasinghe RN, 2013, BRAIN RES, V1527, P209, DOI 10.1016/j.brainres.2013.06.016; KAWAI K, 1992, J CEREBR BLOOD F MET, V12, P238, DOI 10.1038/jcbfm.1992.34; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Koroleva VI, 2000, ZH VYSSH NERV DEYAT+, V50, P612; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Longstreth WT, 2008, NEUROLOGY GEN MED, P163; Luigetti M, 2012, ACTA NEUROL BELG, V112, P105, DOI 10.1007/s13760-012-0007-3; Madry C, 2010, BRAIN, V133, P3755, DOI 10.1093/brain/awq284; Martin RL, 1999, J PHYSIOL-LONDON, V519, P131, DOI 10.1111/j.1469-7793.1999.0131o.x; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Moriguchi S, 2002, EXP BRAIN RES, V144, P238, DOI 10.1007/s00221-002-1039-3; Muller M, 1998, BRAIN RES, V812, P1, DOI 10.1016/S0006-8993(98)00812-9; Muller M, 2000, J NEUROPHYSIOL, V84, P1869, DOI 10.1152/jn.2000.84.4.1869; Murphy TH, 2008, J NEUROSCI, V28, P1756, DOI 10.1523/JNEUROSCI.5128-07.2008; Obeidat AS, 2000, J CEREBR BLOOD F MET, V20, P412, DOI 10.1097/00004647-200002000-00024; PATON JFR, 1993, BRAIN RES, V604, P112, DOI 10.1016/0006-8993(93)90358-T; Richter F, 2012, J CEREBR BLOOD F MET, V32, P1535, DOI 10.1038/jcbfm.2012.40; Risher WC, 2009, GLIA, V57, P207, DOI 10.1002/glia.20747; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rossini GP, 2011, TOXICON, V57, P429, DOI 10.1016/j.toxicon.2010.09.011; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Senatorov VV, 1997, J PHYSIOL-LONDON, V502, P387, DOI 10.1111/j.1469-7793.1997.387bk.x; SIEBER FE, 1995, STROKE, V26, P2091, DOI 10.1161/01.STR.26.11.2091; Tanaka E, 1999, J NEUROPHYSIOL, V81, P1872, DOI 10.1152/jn.1999.81.4.1872; Tanaka E, 1997, J NEUROPHYSIOL, V78, P891, DOI 10.1152/jn.1997.78.2.891; Thompson RJ, 2006, SCIENCE, V312, P924, DOI 10.1126/science.1126241; URBAN L, 1990, BRAIN RES, V520, P36, DOI 10.1016/0006-8993(90)91689-E; UTZSCHNEIDER DA, 1991, BRAIN RES, V551, P136, DOI 10.1016/0006-8993(91)90924-K; Vincent A, 1999, NEUROSCIENCE, V93, P293, DOI 10.1016/S0306-4522(99)00109-8; White SH, 2012, J NEUROPHYSIOL, V107, P2083, DOI 10.1152/jn.00701.2011; WYTRZES LM, 1989, ARCH NEUROL-CHICAGO, V46, P93, DOI 10.1001/archneur.1989.00520370095028; Yang JJ, 1997, LIFE SCI, V61, P1763, DOI 10.1016/S0024-3205(97)00800-X; Yokomizo Y, 2005, NEUROSCI RES, V51, P463, DOI 10.1016/j.neures.2004.12.016; Yoshida S, 1998, NEUROSCI RES, V30, P227, DOI 10.1016/S0168-0102(98)00003-0; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466; Zhang B, 2012, J PHYSIOL-LONDON, V590, P753, DOI 10.1113/jphysiol.2011.221051	75	30	31	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2014	9	5							e96585	10.1371/journal.pone.0096585			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AJ9KS	WOS:000338029800090	24802253	gold, Green Published, Green Submitted			2022-02-06	
J	Delaney, JS; Al-Kashmiri, A; Correa, JA				Delaney, J. Scott; Al-Kashmiri, Ammar; Correa, Jose A.			Mechanisms of Injury for Concussions in University Football, Ice Hockey, and Soccer	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussions; mechanisms; ice hockey; soccer; football	HEAD-INJURIES; PLAYERS; IMPACTS; ACCELERATION; STATEMENT; SPORT	Objective:To examine the mechanisms of injury for concussions in university football, ice hockey, and soccer.Design:Prospective cohort deign.Setting:McGill University Sport Medicine Clinic.Participants:Male and female athletes participating in varsity football, ice hockey, and soccer.Main Outcome Measures:Athletes were followed prospectively over a 10-year period to determine the mechanisms of injury for concussions and whether contact with certain areas of the body or individual variables predisposed to longer recovery from concussions. For soccer, data were collected on whether concussions occurred while attempting to head the ball.Results:There were 226 concussions in 170 athletes over the study period. The side/temporal area of the head or helmet was the most common area to be struck resulting in concussion in all 3 sports. Contact from another player's head or helmet was the most probable mechanism in football and soccer. In hockey, concussion impacts were more likely to occur from contact with another body part or object rather than another head/helmet. Differences in mechanisms of injuries were found between males and females in soccer and ice hockey. Athletes with multiple concussions took longer to return to play with each subsequent concussion. Half of the concussions in soccer were related to attempting to head the soccer ball.Conclusions:The side of the head or helmet was the most common area to be struck resulting in concussion in all 3 sports. In ice hockey and soccer, there are differences in the mechanisms of injury for males and females within the same sport.	[Delaney, J. Scott] McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; [Delaney, J. Scott] McGill Univ, Dept Emergency Med, Ctr Hlth, Montreal, PQ, Canada; [Al-Kashmiri, Ammar] Khoula Hosp, Emergency Dept, Muscat, Oman; [Correa, Jose A.] McGill Univ, Dept Math & Stat, Montreal, PQ, Canada		Delaney, JS (corresponding author), McGill Sport Med Clin, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada.	j.delaney@mcgill.ca	Al-Kashmiri, Ammar/AAG-4008-2020				Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hodgson VR, 1983, P 27 STAPP CAR CRASH, P225; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; NFL, 2010, NEW NFL RUL DES LIM; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	25	30	30	4	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2014	24	3					233	237		10.1097/JSM.0000000000000017			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	AG4KS	WOS:000335389100007	24284949				2022-02-06	
J	Gill, J; Lee, H; Barr, T; Baxter, T; Heinzelmann, M; Rak, H; Mysliwiec, V				Gill, Jessica; Lee, Hyunhwa; Barr, Taura; Baxter, Tristin; Heinzelmann, Morgan; Rak, Hannah; Mysliwiec, Vincent			Lower health related quality of life in US military personnel is associated with service-related disorders and inflammation	PSYCHIATRY RESEARCH			English	Article						IL-6; Post-traumatic stress disorder; Depression; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SELF-RATED HEALTH; CARDIOVASCULAR EVENTS; PTSD; DEPRESSION; MORTALITY; RISK; BIOMARKERS; SYMPTOMS	Military personnel who have combat exposures are at increased risk for the service-related disorders of post-traumatic stress disorder (PTSD), depression, sleep disturbances and decreased health related quality of life (HRQOL). Those with a traumatic brain injury (TBI) are at even greater risk. Inflammation is associated with these disorders and may underlie the risk for health declines. We evaluated 110 recently deployed, military personnel presenting with sleep disturbances for service-related disorders (TBI, PTSD, and depression) as well as HRQOL. ANOVA models were used to examine differences among military personnel with two or more service-related disorders (high comorbid group), or one or no disorders (low comorbid group). Logistic regression models were used to determine associations among interleukin-6 (IL-6) to HRQOL and service-related disorders. Approximately one-third of the sample had two or more service-related disorders. HRQOL was lower and IL-6 concentrations were higher in military personnel with PTSD or depression, with the most profound differences in those with more service-related disorders, regardless of sleep disorder. Having symptoms of depression and PTSD resulted in a 3.5-fold risk to be in the lower quartile of HRQOL and the highest quartile of IL-6. In a linear regression model, 41% of the relationship between HRQOL and IL-6 concentrations was mediated by PTSD and depression. Military personnel with PTSD and depression are at high risk for lower HRQOL, and higher IL-6 concentrations. Comprehensive treatment is required to address co-occurring service-related disorders in military personnel to promote health and well-being. (C) 2014 Published by Elsevier Ireland Ltd.	[Gill, Jessica; Lee, Hyunhwa; Heinzelmann, Morgan; Rak, Hannah] NINR, NIH, Bethesda, MD 20892 USA; [Barr, Taura] W Virginia Univ, Morgantown, WV 26506 USA; [Baxter, Tristin; Mysliwiec, Vincent] Madigan Army Med Ctr, Tacoma, WA 98431 USA		Gill, J (corresponding author), NINR, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.	gillj@mail.nih.gov	Gill, Gill M/Q-2020-2017	Heinzelmann, Morgan/0000-0002-4399-6229; Lee, Hyunhwa/0000-0002-5625-3141	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [60855]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000027] Funding Source: NIH RePORTER	This study was funded, in part, by the Center for Neuroscience and Regenerative Medicine (Grant 60855). The opinions and assertions in this manuscript are those of the authors and do not necessarily represent those of the Department of the Army, Department of Defense, U.S. Government, or the Center for Neuroscience and Regenerative Medicine.	Agaku Israel, 2012, Morbidity and Mortality Weekly Report, V61, P889; American Congress of Rehabilitation Medicine, DEF MILD TRAUM BRAIN; Andersen K, 2008, HORM METAB RES, V40, P635, DOI 10.1055/s-0028-1083810; Aversa LH, 2013, QUAL LIFE RES, V22, P1381, DOI 10.1007/s11136-012-0280-x; Bhasin MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062817; Boscarino JA, 2006, MED CARE, V44, P454, DOI 10.1097/01.mlr.0000207435.10138.36; Boscarino JA, 2008, PSYCHOSOM MED, V70, P668, DOI 10.1097/PSY.0b013e31817bccaf; Boscarino JA, 2012, PREV MED, V54, P363, DOI 10.1016/j.ypmed.2012.01.001; Boscarino JA, 2010, PSYCHOSOM MED, V72, P481, DOI 10.1097/PSY.0b013e3181d9a80c; Boyko EJ, 2010, DIABETES CARE, V33, P1771, DOI 10.2337/dc10-0296; Britt TW, 2007, MIL MED, V172, P157, DOI 10.7205/MILMED.172.2.157; Celik T, 2013, BLOOD PRESSURE, V22, P94, DOI 10.3109/08037051.2012.716580; Edwards R.D., 2010, NATL BUREAU EC RES W, DOI [10.3386/w16163, DOI 10.3386/w16163]; FERRER CF, 1995, AVIAT SPACE ENVIR MD, V66, P571; Fisher H., 2010, CRS REP C; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Gill J, 2010, BIOL PSYCHIAT, V68, P999, DOI 10.1016/j.biopsych.2010.07.033; Gill JM, 2013, J PSYCHOSOM RES, V74, P301, DOI 10.1016/j.jpsychores.2012.10.013; Gokce N, 2002, CIRCULATION, V105, P1567, DOI 10.1161/01.CIR.0000012543.55874.47; Heltemes KJ, 2012, INJURY, V43, P1990, DOI 10.1016/j.injury.2011.07.021; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobs M., 2009, EUR J CLIN INVEST, V41, P167; Krueger C, 2011, J VIRAL HEPATITIS, V18, pE284, DOI 10.1111/j.1365-2893.2010.01408.x; Leger D, 2012, SLEEP MED, V13, P43, DOI 10.1016/j.sleep.2011.03.020; Lopresti AL, 2014, PROG NEURO-PSYCHOPH, V48, P102, DOI 10.1016/j.pnpbp.2013.09.017; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; MacKenzie EJ, 2002, QUAL LIFE RES, V11, P797, DOI 10.1023/A:1020820017658; Maes M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-66; Maes M, 2012, PROG NEURO-PSYCHOPH, V36, P169, DOI 10.1016/j.pnpbp.2011.09.006; Miller NL, 2010, SLEEP, V33, P1623, DOI 10.1093/sleep/33.12.1623; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Paulus EJ, 2013, J TRAUMA STRESS, V26, P169, DOI 10.1002/jts.21785; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Phillips AC, 2009, PSYCHOSOM MED, V71, P395, DOI 10.1097/PSY.0b013e31819e6706; Pittman JOE, 2012, QUAL LIFE RES, V21, P99, DOI 10.1007/s11136-011-9918-3; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Scherrer JF, 2010, AM HEART J, V159, P772, DOI 10.1016/j.ahj.2010.02.033; Schnabel RB, 2013, ARTERIOSCL THROM VAS, V33, P1728, DOI 10.1161/ATVBAHA.112.301174; Singh-Manoux A, 2007, PSYCHOSOM MED, V69, P138, DOI 10.1097/PSY.0b013e318030483a; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; van Zuiden M, 2013, BRAIN BEHAV IMMUN, V30, P12, DOI 10.1016/j.bbi.2012.08.015; van Zuiden M, 2012, PSYCHONEUROENDOCRINO, V37, P1822, DOI 10.1016/j.psyneuen.2012.03.018; Wagner JS, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-199; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Xu J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-330; Xue Y, 2012, AM J CARDIOL, V109, P1215, DOI 10.1016/j.amjcard.2011.11.063; Zen AL, 2012, HEALTH PSYCHOL, V31, P194, DOI 10.1037/a0025989	53	30	30	0	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-1781			PSYCHIAT RES	Psychiatry Res.	APR 30	2014	216	1					116	122		10.1016/j.psychres.2014.01.046			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AE6XL	WOS:000334141200018	24559851				2022-02-06	
J	Hart, T; Benn, EKT; Bagiella, E; Arenth, P; Dikmen, S; Hesdorffer, DC; Novack, TA; Ricker, JH; Zafonte, R				Hart, Tessa; Benn, Emma K. T.; Bagiella, Emilia; Arenth, Patricia; Dikmen, Sureyya; Hesdorffer, Dale C.; Novack, Thomas A.; Ricker, Joseph H.; Zafonte, Ross			Early Trajectory of Psychiatric Symptoms after Traumatic Brain Injury: Relationship to Patient and Injury Characteristics	JOURNAL OF NEUROTRAUMA			English	Article						longitudinal studies; neurobehavioral signs and symptoms; psychological outcome; traumatic brain injury	MINOR DEPRESSION; HEALTH OUTCOMES; DISORDERS; PSYCHOPATHOLOGY; FREQUENCY; PATTERNS; VALIDITY; 1-YEAR; RATES	Psychiatric disturbance is common and disabling after traumatic brain injury (TBI). Few studies have investigated the trajectory of psychiatric symptoms in the first 6 months postinjury, when monitoring and early treatment might prevent persistent difficulties. The aim of this study was to examine the trajectory of psychiatric symptoms 1-6 months post-TBI, the patient/injury characteristics associated with changes, and characteristics predictive of persisting symptoms. A secondary analysis was performed on data from a clinical trial with three data collection points. Across eight centers, 872 participants with complicated mild to severe TBI were administered the Brief Symptom Inventory (BSI) at 30, 90, and 180 days postinjury. Mixed-effects models were used to assess longitudinal changes in the BSI Global Severity Index (GSI). Multi-variate logistic regression was used to assess predictors of clinically significant GSI elevations persisting to 6 months post-TBI. In general, GSI scores improved over time. Women improved faster than men; race/ethnicity was also significantly associated with rate of change, with Hispanics showing the most and African Americans the least improvement. Clinically significant psychiatric symptoms (caseness) occurred in 42% of the sample at 6 months, and more than one type of symptom was common. Significant predictors of caseness included African American race, age from 30 to 60 years, longer post-traumatic amnesia (PTA) duration, pre-TBI unemployment, and pre-TBI risky alcohol use. Findings indicate that psychiatric symptoms are common in the first 6 months post-TBI and frequently extend beyond the depression and anxiety symptoms that may be most commonly screened. Patients with longer PTA and preinjury alcohol misuse may need more intensive monitoring for symptom persistence.	[Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Benn, Emma K. T.; Bagiella, Emilia] Icahn Sch Med Mt Sinai, Dept Hlth Evidence & Policy, New York, NY USA; [Benn, Emma K. T.; Bagiella, Emilia] Icahn Sch Med Mt Sinai, Ctr Biostat, New York, NY USA; [Arenth, Patricia; Ricker, Joseph H.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Hesdorffer, Dale C.] Columbia Univ, GH Sergievsky Ctr, New York, NY USA; [Novack, Thomas A.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu		Ricker, Joseph/0000-0003-3415-991X; Benn, Emma/0000-0001-7051-5841	NIH (National Institute of Child Health and Human Development/National Center for Medical Rehabilitation Research)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01 HD042738]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042738] Funding Source: NIH RePORTER	This work was funded by Cooperative Agreement #U01 HD042738 from the NIH (National Institute of Child Health and Human Development/National Center for Medical Rehabilitation Research).	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown S, 2004, ELECTRON WORLD, V110, P54; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Eisen SV, 2011, J BEHAV HEALTH SER R, V38, P170, DOI 10.1007/s11414-010-9216-9; Gallo LC, 2009, J PERS, V77, P1707, DOI 10.1111/j.1467-6494.2009.00598.x; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hart T, 2012, J HEAD TRAUMA REHAB, V27, P113, DOI 10.1097/HTR.0b013e31820e686c; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Long JD, 2007, PSYCHOL ASSESSMENT, V19, P298, DOI 10.1037/1040-3590.19.3.298; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Morales LS, 2002, J HEALTH CARE POOR U, V13, P477, DOI 10.1177/104920802237532; National Comorbidity Survey (NCS) and NCS Replication, 2005, NAT COM SURV; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	38	30	30	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					610	617		10.1089/neu.2013.3041			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000002	24237113	Green Published			2022-02-06	
J	Rowe, RK; Harrison, JL; O'Hara, BF; Lifshitz, J				Rowe, Rachel K.; Harrison, Jordan L.; O'Hara, Bruce F.; Lifshitz, Jonathan			Recovery of Neurological Function Despite Immediate Sleep Disruption Following Diffuse Brain Injury in the Mouse: Clinical Relevance to Medically Untreated Concussion	SLEEP			English	Article						Behavior; concussion; diffuse; mild; mouse; sleep; sleep disruption; TBI	CONTROLLED CORTICAL IMPACT; TRAUMATIC AXONAL INJURY; COGNITIVE DEFICITS; BEHAVIORAL DEFICITS; HEAD-INJURY; MICE; DEPRIVATION; RATS; NEURONS; MODEL	Study Objective: We investigated the relationship between immediate disruption of posttraumatic sleep and functional outcome in the diffuse brain-injured mouse. Design: Adult male C57BL/6 mice were subjected to moderate midline fluid percussion injury (n = 65; 1.4 atm; 6-10 min righting reflex time) or sham injury (n = 44). Cohorts received either intentional sleep disruption (minimally stressful gentle handling) or no sleep disruption for 6 h following injury. Following disruption, serum corticosterone levels (enzyme-linked immunosorbent assay) and posttraumatic sleep (noninvasive piezoelectric sleep cages) were measured. For 1-7 days postinjury, sensorimotor outcome was assessed by Rotarod and a modified Neurological Severity Score (NSS). Cognitive function was measured using Novel Object Recognition (NOR) and Morris water maze (MWM) in the first week postinjury. Setting: Neurotrauma research laboratory. Measurements and Results: Disrupting posttraumatic sleep for 6 h did not affect serum corticosterone levels or functional outcome. In the hour following the first dark onset, sleep-disrupted mice exhibited a significant increase in sleep; however, this increase was not sustained and there was no rebound of lost sleep. Regardless of sleep disruption, mice showed a time-dependent improvement in Rotarod performance, with braininjured mice having significantly shorter latencies on day 7 compared to sham. Further, brain-injured mice, regardless of sleep disruption, had significantly higher NSS scores postinjury compared with sham. Cognitive behavioral testing showed no group differences among any treatment group measured by MWM and NOR. Conclusion: Short-duration disruption of posttraumatic sleep did not affect functional outcome, measured by motor and cognitive performance. These data raise uncertainty about posttraumatic sleep as a mechanism of recovery from diffuse brain injury.	[Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Rowe, Rachel K.; Harrison, Jordan L.; Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Harrison, Jordan L.; Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Program Neurosci, Phoenix, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, Lexington, KY USA; [O'Hara, Bruce F.] Univ Kentucky, Coll Med, Dept Biol, Coll Arts & Sci, Lexington, KY USA; [Rowe, Rachel K.; O'Hara, Bruce F.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY USA		Lifshitz, J (corresponding author), Phoenix Childrens Hosp, Translat Neurotrauma Res Program, Barrow Neurol Inst, Phoenix, AZ 85016 USA.	jlifshitz@email.arizona.edu		Rowe, Rachel/0000-0002-9034-3159	National Institute of Neurological DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Stroke of the National Institutes of Health [R01NS065052, R01NS065052- S, R21NS072611]; KSCHIRT; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072611, R01NS065052] Funding Source: NIH RePORTER	This article is dedicated to the memory of Thomas V. Getchell, PhD, Professor of Physiology, University of Kentucky College of Medicine. Dr. Getchell served as a scientific mentor in the art of grant writing, professionalism and leadership. The authors wish to thank Amanda Lisembee for her technical contribution to the corticosterone assays. Thank you to Jennifer Pleasant-Brelsfoard and Dr. Kathryn Saatman for training on behavioral techniques used in these studies. We would also like to thank the members of the laboratory for their help with sleep disruption. Research reported in this publication was supported, in part, by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number R01NS065052, R01NS065052- S, R21NS072611, and KSCHIRT 10-5A. These data were recognized by the National Neurotrauma Society as a top abstract at the 31st Annual Symposium, Nashville, TN.	Silva LFA, 2013, J NEUROTRAUM, V30, P1278, DOI 10.1089/neu.2012.2577; ASIKAINEN M, 1995, NEUROSCI LETT, V198, P21, DOI 10.1016/0304-3940(95)11953-T; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Boone DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046204; Cam E, 2013, EXP NEUROL, V247, P673, DOI 10.1016/j.expneurol.2013.03.003; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chokroverty S, 2010, INDIAN J MED RES, V131, P126; COHEN HB, 1965, SCIENCE, V150, P1318, DOI 10.1126/science.150.3701.1318; Cohen S, 2009, ARCH INTERN MED, V169, P62, DOI 10.1001/archinternmed.2008.505; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Donohue KD, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-14; Ennaceur A, 1997, BEHAV BRAIN RES, V88, P181, DOI 10.1016/S0166-4328(97)02297-3; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gao B, 2010, SLEEP, V33, P879, DOI 10.1093/sleep/33.7.879; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Hagewoud R, 2010, J SLEEP RES, V19, P280, DOI 10.1111/j.1365-2869.2009.00799.x; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Krueger JM, 2007, SLEEP MED CLIN, V2, P161, DOI 10.1016/j.jsmc.2007.03.003; Krueger JM, 2008, CURR PHARM DESIGN, V14, P3408, DOI 10.2174/138161208786549281; KRUEGER JM, 1995, INT ARCH ALLERGY IMM, V106, P97, DOI 10.1159/000236827; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lay CC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011270; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Machado RB, 2004, BRAIN RES, V1004, P45, DOI 10.1016/j.brainres.2004.01.019; Martinez-Vargas M, 2012, NEUROSCI LETT, V529, P118, DOI 10.1016/j.neulet.2012.09.037; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McShane BB, 2010, J NEUROSCI METH, V193, P321, DOI 10.1016/j.jneumeth.2010.08.024; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; OHARA BF, 1993, SLEEP, V16, P1; Patti CL, 2010, SLEEP, V33, P1669, DOI 10.1093/sleep/33.12.1669; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Riechers RG, 2013, J REHABIL RES DEV, V50, P455, DOI 10.1682/JRRD.2012.04.0061; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Schoch KM, 2012, EXP NEUROL, V236, P371, DOI 10.1016/j.expneurol.2012.04.022; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Sheth BR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003190; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Walker MP, 2005, NEUROSCIENCE, V133, P911, DOI 10.1016/j.neuroscience.2005.04.007; Walsh CM, 2011, LEARN MEMORY, V18, P422, DOI 10.1101/lm.2099011; Yang SR, 2012, SLEEP, V35, P849, DOI 10.5665/sleep.1888; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yang XJ, 2012, INT J MOL SCI, V13, P9447, DOI 10.3390/ijms13089447; Zhang F, 2010, MOLECULES, V15, P5246, DOI 10.3390/molecules15085246; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	74	30	31	1	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	APR 1	2014	37	4					743	752		10.5665/sleep.3582			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AE0RF	WOS:000333673100014	24899763	Bronze, Green Published			2022-02-06	
J	Skidmore, ER; Dawson, DR; Whyte, EM; Butters, MA; Dew, MA; Grattan, ES; Becker, JT; Holm, MB				Skidmore, Elizabeth R.; Dawson, Deirdre R.; Whyte, Ellen M.; Butters, Meryl A.; Dew, Mary Amanda; Grattan, Emily S.; Becker, James T.; Holm, Margo B.			Developing complex interventions: lessons learned from a pilot study examining strategy training in acute stroke rehabilitation	CLINICAL REHABILITATION			English	Article						stroke; strategy training; Rehabilitation interventions; cognitive impairment	TRAUMATIC BRAIN-INJURY; EXECUTIVE DYSFUNCTION; COGNITIVE IMPAIRMENT; DEVELOPMENTAL-APPROACH; INTERVIEW; APHASIA; ADULTS; TRIAL; PARTICIPATION; DETERMINANTS	Objective: To examine the feasibility of a strategy training clinical trial in a small group of adults with stroke-related cognitive impairments in inpatient rehabilitation, and to explore the impact of strategy training on disability. Design: Non-randomized two-group intervention pilot study. Setting: Two inpatient rehabilitation units within an academic health centre. Participants: Individuals with a primary diagnosis of acute stroke, who were admitted to inpatient rehabilitation and demonstrated cognitive impairments were included. Individuals with severe aphasia; dementia; major depressive disorder, bipolar, or psychotic disorder; recent drug or alcohol abuse; and anticipated length of stay less than five days were excluded. Intervention: Participants received strategy training or an attention control session in addition to usual rehabilitation care. Sessions in both groups were 30-40 minutes daily, five days per week, for the duration of inpatient rehabilitation. Main outcome measures: We assessed feasibility through participants' recruitment and retention; research intervention session number and duration; participants' comprehension and engagement; intervention fidelity; and participants' satisfaction. We assessed disability at study admission, inpatient rehabilitation discharge, 3 and 6 months using the Functional Independence Measure. Results: Participants in both groups (5 per group) received the assigned intervention (>92% planned sessions; >94% fidelity) and completed follow-up testing. Strategy training participants in this small sample demonstrated significantly less disability at six months (M (SE) = 117 (3)) than attention control participants (M(SE) = 96 (14); t(8) = 7.87, P = 0.02). Conclusions: It is feasible and acceptable to administer both intervention protocols as an adjunct to acute inpatient rehabilitation, and strategy training shows promise for reducing disability.	[Skidmore, Elizabeth R.; Grattan, Emily S.; Holm, Margo B.] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, Pittsburgh, PA 15260 USA; [Skidmore, Elizabeth R.; Grattan, Emily S.] Univ Pittsburgh, Med Ctr, Inst Rehabil, Pittsburgh, PA 15260 USA; [Skidmore, Elizabeth R.; Whyte, Ellen M.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Dawson, Deirdre R.] Rotman Res Inst Baycrest, Toronto, ON, Canada; [Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Dawson, Deirdre R.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Whyte, Ellen M.; Butters, Meryl A.; Dew, Mary Amanda; Becker, James T.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Whyte, Ellen M.; Butters, Meryl A.; Dew, Mary Amanda] Western Psychiat Inst & Clin, Adv Ctr Intervent & Serv Res Late Life Mood Disor, Pittsburgh, PA USA		Skidmore, ER (corresponding author), Univ Pittsburgh, Dept Occupat Therapy, 5012 Forbes Tower, Pittsburgh, PA 15260 USA.	skidmore@pitt.edu	Dawson, Deirdre R/I-8882-2014; Butters, Meryl/AAR-2863-2021	Dawson, Deirdre R/0000-0001-7517-6121; Becker, James/0000-0003-4425-4726	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12 HD055931]; University of Pittsburgh Medical Center Rehabilitation Institute; University of Pittsburgh Office of Research Health Sciences; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD055931] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (K12 HD055931), the University of Pittsburgh Medical Center Rehabilitation Institute and the University of Pittsburgh Office of Research Health Sciences.	Attkisson C.C., 1994, USE PSYCHOL TESTING, P402; Berthier ML, 2005, DRUG AGING, V22, P163, DOI 10.2165/00002512-200522020-00006; Blanton S, 2006, PHYS THER, V86, P1520, DOI 10.2522/ptj.20060091; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Butters MA, 2004, ARCH GEN PSYCHIAT, V61, P587, DOI 10.1001/archpsyc.61.6.587; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; Dickey L, 2010, ARCH PHYS MED REHAB, V91, P196, DOI 10.1016/j.apmr.2009.09.020; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; Hart T, 2012, ARCH PHYS MED REHAB, V93, pS117, DOI 10.1016/j.apmr.2011.11.039; Heruti RJ, 2002, ARCH PHYS MED REHAB, V83, P742, DOI 10.1053/apmr.2002.32739; Hildebrand MW, 2012, AM J PHYS MED REHAB, V91, P715, DOI 10.1097/PHM.0b013e31824ad462; Holm MB, 2000, AM J OCCUP THER, V54, P575, DOI 10.5014/ajot.54.6.575; Kaplan E., 2001, ASSESSMENT APHASIA R; Kwakkel G, 1996, AGE AGEING, V25, P479, DOI 10.1093/ageing/25.6.479; Larson EB, 2010, ARCH PHYS MED REHAB, V91, P389, DOI 10.1016/j.apmr.2009.11.015; Lenze EJ, 2004, ARCH PHYS MED REHAB, V85, P380, DOI 10.1016/j.apmr.2003.06.001; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lubinsky T, 2009, J INT NEUROPSYCH SOC, V15, P704, DOI 10.1017/S1355617709990270; Mandich, 2004, ENABLING OCCUPATION; McColl M. A., 2006, RES CANADIAN OCCUPAT; Meichenbaum, 1977, COGNITIVE BEHAV MODI; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Patel M, 2003, CLIN REHABIL, V17, P158, DOI 10.1191/0269215503cr596oa; PEDERSEN PM, 1995, ANN NEUROL, V38, P659, DOI 10.1002/ana.410380416; Perepletchikova F, 2005, CLIN PSYCHOL-SCI PR, V12, P365, DOI 10.1093/clipsy/bpi045; Petticrew, 2008, DEV EVALUATING COMPL; Pollock N, 1998, CANADIAN OCCUPATIONA; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; ROYALL DR, 1992, J AM GERIATR SOC, V40, P1221, DOI 10.1111/j.1532-5415.1992.tb03646.x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Skidmore ER, 2011, NEUROPSYCHOL REHABIL, V21, P208, DOI 10.1080/09602011.2011.552559; Skidmore ER, 2010, ARCH PHYS MED REHAB, V91, P203, DOI 10.1016/j.apmr.2009.10.026; Skidmore ER, PEDIAT BLOO IN PRESS; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Wales C.E., 1986, EDUC LEADERSHIP, V43, P203; Whyte J, 2007, AM J PHYS MED REHAB, V86, P835, DOI 10.1097/PHM.0b013e3181570b74; Whyte J, 2012, ARCH PHYS MED REHAB, V93, pS101, DOI 10.1016/j.apmr.2011.11.040; Whyte J, 2009, ARCH PHYS MED REHAB, V90, pS3, DOI 10.1016/j.apmr.2009.07.008	42	30	31	1	34	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	APR	2014	28	4					378	387		10.1177/0269215513502799			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	AC0OZ	WOS:000332195900009	24113727	Green Accepted			2022-02-06	
J	Mahdy, HM; Mohamed, MR; Emam, MA; Karim, AM; Abdel-Naim, A; Khalifa, AE				Mahdy, Heba M.; Mohamed, Mohamed R.; Emam, Manal A.; Karim, Amr M.; Abdel-Naim, Ashraf; Khalifa, Amani E.			The anti-apoptotic and anti-inflammatory properties of puerarin attenuate 3-nitropropionic-acid induced neurotoxicity in rats	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article						Huntington's disease; puerarin; 3-nitropropionic acid; apoptosis; neuroinflammation; Nissl staining; ATP	FACTOR-KAPPA-B; TRAUMATIC BRAIN-INJURY; COMPLEX-II INHIBITION; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; STRIATAL DEGENERATION; PC12 CELLS; ACID MODEL; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE MECHANISMS	Puerarin (Pur), an isoflavonoid extracted from the dried roots of Pueraria lobata, has been reported to be useful in the treatment of various diseases. This study was designed to evaluate the anti-apoptotic and anti-inflammatory activities of Pur against 3-nitropropionic acid (3-NP) induced neurotoxicity. For 5 consecutive days, male Wistar rats were given Pur (200 mg/kg body mass) 30 min before treatment with 20 mg/kg body mass of 3-NP. The striata, hippocampi, and cortices of the 3-NP treated group showed apoptotic damage, inflammation, and energy deficit as well as histopathological lesions. The 3-NP-induced alteration in apoptotic biomarkers (caspase-3 activity/level, cytosolic cytochrome c, Bax/Bcl-2 levels) were significantly ameliorated by Pur treatment. Moreover, Pur pretreatment blocked 3-NP-induced inflammatory biomarkers (NF-kappa B, TNF-alpha, and iNOS) and prevented the energy deficit (ATP reduction). Nissl staining further confirmed Pur's neuroprotective effect. These results indicate that Pur may be a useful preventive approach to various neurodegenerative diseases with underlying apoptosis and neuroinflammation.	[Mahdy, Heba M.; Abdel-Naim, Ashraf; Khalifa, Amani E.] Ain Shams Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo, Egypt; [Mohamed, Mohamed R.; Emam, Manal A.; Karim, Amr M.] Ain Shams Univ, Dept Biochem, Fac Sci, Cairo, Egypt		Mahdy, HM (corresponding author), Ain Shams Univ, Fac Pharm, Dept Pharmacol & Toxicol, Monazamet Al Wehdah Al Efrikeya St, Cairo, Egypt.	hebamahdy111@yahoo.com	Mohamed, Mohamed Ragaa/V-9143-2019; Abdel-Naim, Ashraf B/J-3199-2012	Mohamed, Mohamed Ragaa/0000-0002-9269-3128; Abdel-Naim, Ashraf B/0000-0002-0400-9075; Khalifa, Amani/0000-0002-1627-7800; Asem, Manal/0000-0002-6463-0656	Faculty of Pharmacy, Ain Shams University, Cairo, EgyptAin Shams University; Faculty of Science, Ain Shams University, Cairo, EgyptAin Shams University	The Faculty of Pharmacy and Faculty of Science, Ain Shams University, Cairo, Egypt, supported this research.	Ahuja M, 2008, TOXICOL MECH METHOD, V18, P335, DOI 10.1080/15376510701563738; Antonawich FJ, 2002, BRAIN RES BULL, V57, P647, DOI 10.1016/S0361-9230(01)00761-4; Bancroft JD, 1996, THEORY PRACTICE HIST, V4th; Bantubungi K, 2007, Rev Med Brux, V28, P413; BEAL MF, 1993, J NEUROSCI, V13, P4181; Bhateja DK, 2012, EUR J PHARMACOL, V674, P33, DOI 10.1016/j.ejphar.2011.10.029; Bortolatto CF, 2013, NEUROTOX RES, V23, P214, DOI 10.1007/s12640-012-9336-5; Campbell A, 2004, ANN NY ACAD SCI, V1035, P117, DOI 10.1196/annals.1332.008; Canudas AM, 2003, EXP NEUROL, V180, P123, DOI 10.1016/S0014-4886(02)00029-8; CHAN ASC, 2006, Patent No. 2006042454; Chang Y, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-9; Chen Chiung-Mei, 2011, Chang Gung Med J, V34, P135; Cheng YF, 2009, NEUROSCI RES, V63, P52, DOI 10.1016/j.neures.2008.10.009; Cheng Yuefa, 2011, Zhongguo Zhong Yao Za Zhi, V36, P1222; Cuello AC., 1993, IMMUNOHISTOCHEMISTRY; Duran-Vilaregut J, 2011, NEUROTOXICOLOGY, V32, P734, DOI 10.1016/j.neuro.2011.07.009; Eidelberg D, 2011, J CLIN INVEST, V121, P484, DOI 10.1172/JCI45646; Ferreira IL, 2010, EXP NEUROL, V222, P243, DOI 10.1016/j.expneurol.2010.01.002; Gao L, 2009, NEUROL RES, V31, P402, DOI 10.1179/174313209X444017; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Gil JM, 2008, EUR J NEUROSCI, V27, P2803, DOI 10.1111/j.1460-9568.2008.06310.x; Hickey MA, 2003, PROG NEURO-PSYCHOPH, V27, P255, DOI 10.1016/S0278-5846(03)00021-6; Hu WZ, 2011, PHARMACOL REP, V63, P781, DOI 10.1016/S1734-1140(11)70590-4; Hu WZ, 2010, PHARMACOLOGY, V85, P27, DOI 10.1159/000264938; Jin SE, 2012, ARCH PHARM RES, V35, P823, DOI 10.1007/s12272-012-0508-x; Johri A, 2012, BBA-MOL BASIS DIS, V1822, P664, DOI 10.1016/j.bbadis.2011.11.014; Khan HA, 2003, J BIOSCIENCES, V28, P379, DOI 10.1007/BF02705114; Kumar P, 2011, BRIT J PHARMACOL, V164, P644, DOI 10.1111/j.1476-5381.2011.01418.x; Kumar P, 2010, BEHAV BRAIN RES, V206, P38, DOI 10.1016/j.bbr.2009.08.028; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; Lee ST, 2008, BRAIN RES, V1194, P130, DOI 10.1016/j.brainres.2007.11.058; Lee ST, 2008, J NEUROCHEM, V104, P1190, DOI 10.1111/j.1471-4159.2007.05044.x; Li JM, 2010, EUR J PHARMACOL, V649, P195, DOI 10.1016/j.ejphar.2010.09.045; Li Y, 2006, DRUG DEV IND PHARM, V32, P413, DOI 10.1080/03639040600559123; Lim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024620; Liot G, 2009, CELL DEATH DIFFER, V16, P899, DOI 10.1038/cdd.2009.22; Liu XJ, 2010, PHARMAZIE, V65, P127, DOI 10.1691/ph.2010.9734; LU J, 2004, CHIN J MOD APPL PHAR, V4; Mandavilli BS, 2005, MOL BRAIN RES, V133, P215, DOI 10.1016/j.molbrainres.2004.10.033; Mandy HM, 2011, NEUROCHEM INT, V59, P770, DOI 10.1016/j.neuint.2011.07.012; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Mealer RG, 2013, J NEUROSCI, V33, P4206, DOI 10.1523/JNEUROSCI.3730-12.2013; Menze ET, 2012, NEUROTOXICOLOGY, V33, P1265, DOI 10.1016/j.neuro.2012.07.007; Milakovic T, 2005, J BIOL CHEM, V280, P30773, DOI 10.1074/jbc.M504749200; Mrak RE, 2005, J ALZHEIMERS DIS, V8, P369; Napolitano M, 2008, NEUROSCI LETT, V434, P241, DOI 10.1016/j.neulet.2007.09.056; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Pan HP, 2008, YAKUGAKU ZASSHI, V128, P1689, DOI 10.1248/yakushi.128.1689; Park JE, 2008, NEUROSCI LETT, V448, P143, DOI 10.1016/j.neulet.2008.10.020; Pedraza-Chaverri J, 2009, EXP TOXICOL PATHOL, V61, P491, DOI 10.1016/j.etp.2008.11.002; Prasad K, 2012, J MED SYST, V36, P2621, DOI 10.1007/s10916-011-9737-7; PUNEET K, 2007, J CELL TISSUE RES, V7, P853; Ramos-Vara JA, 2005, VET PATHOL, V42, P405, DOI 10.1354/vp.42-4-405; Rangan GK, 2007, NEPHROLOGY, V12, P553, DOI 10.1111/j.1440-1797.2007.00855.x; Rego AC, 2003, NEUROCHEM RES, V28, P1563, DOI 10.1023/A:1025682611389; Rosenstock TR, 2004, J NEUROCHEM, V88, P1220, DOI 10.1046/j.1471-4159.2003.02250.x; Ross CA, 2009, PARKINSONISM RELAT D, V15, pS135, DOI 10.1016/S1353-8020(09)70800-4; Sugino T, 1999, NEUROSCI LETT, V275, P145, DOI 10.1016/S0304-3940(99)00763-6; Tadros MG, 2005, PHARMACOL BIOCHEM BE, V82, P574, DOI 10.1016/j.pbb.2005.10.018; Tian F, 2013, NEUROSCI LETT, V543, P64, DOI 10.1016/j.neulet.2013.03.039; Tobinick EL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-2; Tunez I, 2009, REV NEUROLOGIA, V48, P430, DOI 10.33588/rn.4808.2008678; Tunez I, 2010, MOLECULES, V15, P878, DOI 10.3390/molecules15020878; Turner C, 2010, J BIOENERG BIOMEMBR, V42, P193, DOI 10.1007/s10863-010-9290-y; VALOR LM, 2013, NEUROPHARMACOLOGY, DOI DOI 10.1016/J.NEUR0PHARM.2013.10.025.PMID:24184315; Vis JC, 2001, NEUROPATH APPL NEURO, V27, P68, DOI 10.1046/j.0305-1846.2001.00305.x; Wang JW, 2014, J SURG RES, V186, P328, DOI 10.1016/j.jss.2013.08.027; Wu HQ, 2012, NEURAL REGEN RES, V7, P421, DOI 10.3969/j.issn.1673-5374.2012.06.003; Xiao Li-zhong, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P790; Xing GH, 2011, BRAIN RES BULL, V85, P212, DOI 10.1016/j.brainresbull.2011.03.024; Xu CS, 2012, BRAIN RES BULL, V87, P37, DOI 10.1016/j.brainresbull.2011.10.007; Yan B, 2006, BIOMED CHROMATOGR, V20, P180, DOI 10.1002/bmc.549; Yang JH, 2013, BIOMETALS, V26, P43, DOI 10.1007/s10534-012-9593-z; Yang XJ, 2010, BASIC CLIN PHARMACOL, V107, P637, DOI 10.1111/j.1742-7843.2010.00548.x; Yu WL, 2004, FOOD CHEM, V86, P525, DOI 10.1016/j.foodchem.2003.09.005; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang HY, 2008, CELL BIOL INT, V32, P1230, DOI 10.1016/j.cellbi.2008.07.006; Zhang HY, 2011, EXP GERONTOL, V46, P30, DOI 10.1016/j.exger.2010.09.013; Zhang Z, 2013, J CLIN PHARMACOL, V53, P787, DOI 10.1002/jcph.96; Zhao LX, 2013, BIOL PHARM BULL, V36, P1263, DOI 10.1248/bpb.b12-00769; Zhou J, 2010, J ETHNOPHARMACOL, V132, P150, DOI 10.1016/j.jep.2010.08.005; Zhu GQ, 2010, PLANTA MED, V76, P1820, DOI 10.1055/s-0030-1249976	82	30	36	0	20	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-4212	1205-7541		CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	MAR	2014	92	3					252	258		10.1139/cjpp-2013-0398			7	Pharmacology & Pharmacy; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Physiology	AC6JM	WOS:000332628500010	24593790				2022-02-06	
J	Myer, GD; Smith, D; Foss, KDB; Dicesare, CA; Kiefer, AW; Kushner, AM; Thomas, SM; Sucharew, H; Khoury, JC				Myer, Gregory D.; Smith, David; Foss, Kim D. Barber; Dicesare, Christopher A.; Kiefer, Adam W.; Kushner, Adam M.; Thomas, Staci M.; Sucharew, Heidi; Khoury, Jane C.			Rates of Concussion Are Lower in National Football League Games Played at Higher Altitudes	JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY			English	Article						concussion-mitigation strategies; injury prevention; mild traumatic brain injury; professional football	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; CAVITATION; PRESSURE	STUDY DESIGN: Retrospective epidemiologic investigation. OBJECTIVE: To investigate the relationship between altitude and concussion rate in the National Football League (NFL). Because of the physiologic responses that occur during acclimatization to altitude, it was hypothesized that games played on fields at a higher altitude would have reduced concussion rates compared to games played on. fields at a lower altitude. BACKGROUND: Recent research indicates that the elevation above sea level at which football games are played may be associated with the likelihood of a concussion in high school football athletes. METHODS: Data on incident concussions and athlete exposures for the first 16 weeks of the NFL 2012 and 2013 regular seasons were obtained from publicly available web-based sources and used to calculate competition concussion rates for each NFL stadium. Concussion rates were analyzed in relation to game elevation. RESULTS: During the first 16 weeks of the 2012 and 2013 NFL regular seasons, 300 concussions, involving 284 players, were reported (64.3 primary cases per 10 000 game exposures). The odds of a concussion were 30% lower when playing at a higher elevation (equal to or greater than 644 ft [196.3 m] above sea level) compared to a lower elevation (odds ratio = 0.70; 95% confidence interval: 0.53, 0.94). A multivariable generalized linear model controlling for season, week, and clustering of team at home and away confirmed these results, showing that the odds of at least 1 concussion were reduced by 32% in games played at higher elevation. CONCLUSION: The results of this epidemiological investigation indicate that increased altitude was associated with a reduction in the odds of a sport-related concussion in NFL athletes. The reported relationship of concussion incidence and field elevation should be further investigated, and, if verified, further work will be needed to understand why that relationship exists.	[Myer, Gregory D.; Smith, David; Foss, Kim D. Barber; Dicesare, Christopher A.; Kiefer, Adam W.; Kushner, Adam M.; Thomas, Staci M.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Myer, Gregory D.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Human Performance Lab, Cincinnati, OH 45229 USA; [Myer, Gregory D.; Kiefer, Adam W.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Myer, Gregory D.] Univ Cincinnati, Coll Med, Dept Orthopaed Surg, Cincinnati, OH USA; [Myer, Gregory D.] Ohio State Univ, Wexner Med Ctr, OSU Sports Med, Sports Hlth & Performance Inst, Columbus, OH 43210 USA; [Myer, Gregory D.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Kiefer, Adam W.] Univ Cincinnati, Dept Psychol, Ctr Cognit Act & Percept, Cincinnati, OH 45221 USA; [Sucharew, Heidi; Khoury, Jane C.] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Khoury, Jane C.] Cincinnati Childrens Hosp Med Ctr, Div Endocrinol, Cincinnati, OH 45229 USA		Myer, GD (corresponding author), Cincinnati Childrens Hosp, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA.	greg.myer@chmcc.org	Kiefer, Adam/F-1756-2018; Sucharew, Heidi/M-4338-2015; DiCesare, Christopher/AAA-3327-2021; DiCesare, Christopher/ABH-9573-2020; Khoury, Jane/O-2068-2015; Myer, Gregory/H-6572-2016	DiCesare, Christopher/0000-0002-6576-4904; Myer, Gregory/0000-0002-9983-8422			Associated Press, GOODELL ISSUES MEMO; Associated Press, CONCUSSIONS REPORTED; Associated Press, RESULTS OF CONCUSSIO; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brooks MA, 2013, AMERICAN ACADEMY OF; CHURCH CC, 1989, J ACOUST SOC AM, V86, P215, DOI 10.1121/1.398328; Courtney M, SHEEP COLLISIONS THE; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; de Lench B, HIGH SCHOOL FOOTBALL; Fainaru S, INSIDE THE NUMBERS C; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Hackett PH, 1998, JAMA-J AM MED ASSOC, V280, P1920, DOI 10.1001/jama.280.22.1920; Kraemer W., 1989, PEDIATR EXERC SCI, V1, P336, DOI [10.1123/pes.1.4.336, DOI 10.1123/PES.1.4.336]; Kurosawa Y, 2009, IEEE ENG MED BIO, P7224, DOI 10.1109/IEMBS.2009.5335260; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; LOFGREN J, 1973, ACTA NEUROL SCAND, V49, P575; Moiseyev NN, 1968, DYNAMIC STABILITY OF; National Football League, NFL ANNOUNCES NEW SI; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Smith DW, 2013, ORTHOP J SPORTS MED, V1, DOI 10.1177/2325967113511588; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith MD, NFL OFFICIATING VIDE; Sporting News, SN CONCUSSION REPORT; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Volin B, 2013, BOSTON GLOBE; Ward T, 2012, FDA ISSUES WARNING L; Wilson MH, 2008, NEUROSURGERY, V63, P970, DOI 10.1227/01.NEU.0000327885.15132.CA; Wilson MH, 2013, ANN NEUROL, V73, P381, DOI 10.1002/ana.23796; Wilson MH, 2011, J CEREBR BLOOD F MET, V31, P2019, DOI 10.1038/jcbfm.2011.81; Wilson MH, 2008, J ACOUST SOC AM, V63, P974; Zhong P, 1997, J ACOUST SOC AM, V101, P2940, DOI 10.1121/1.418522; Zhong P, 1998, J ACOUST SOC AM, V104, P3126, DOI 10.1121/1.423905	36	30	30	1	20	J O S P T,	ALEXANDRIA	1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA	0190-6011			J ORTHOP SPORT PHYS	J. Orthop. Sports Phys. Ther.	MAR	2014	44	3					164	172		10.2519/jospt.2014.5298			9	Orthopedics; Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation; Sport Sciences	AD3LC	WOS:000333139600005	24471872	Bronze			2022-02-06	
J	Reznik, JE; Biros, E; Marshall, R; Jelbart, M; Milanese, S; Gordon, S; Galea, MP				Reznik, J. E.; Biros, E.; Marshall, R.; Jelbart, M.; Milanese, S.; Gordon, S.; Galea, M. P.			Prevalence and risk-factors of neurogenic heterotopic ossification in traumatic spinal cord and traumatic brain injured patients admitted to specialised units in Australia	JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS			English	Article						Brain Injury; Spinal Cord Injury; Traumatic; Neurogenic Heterotopic Ossification	PATHOPHYSIOLOGY	Objectives: To identify the prevalence and risk factors in the development of Neurogenic Heterotopic Ossification (NHO) in traumatic brain and spinal cord injured patients admitted to specialised units. Methods: An audit protocol was used to gather all clinically relevant data, in specific patient groups, relating to the prevalence of NHO, and was statistically analysed to identify traumatic brain injury (TBI) and traumatic spinal cord injury (TSCI) patients at high risk of developing NHO. Results: 262 TBI and 151 TSCI patients were identified. NHO was diagnosed in 10 and 16 patients with TBI and TSCI, respectively; 18 clinically relevant characteristics were analysed for association with NHO in these patient groups. The only common variables associated with NHO in both neurological conditions were deep vein thrombosis and/or pulmonary emboli (DVT/PE). Conclusions: The prevalence of NHO in TBI patients is less than one-third of that found in TSCI patients, similar to 4% and 11%, respectively. This study also suggests that the risk factors associated with NHO in TBI patients are distinct from those identified as risk factors in TSCI patients.	[Reznik, J. E.; Milanese, S.; Gordon, S.; Galea, M. P.] James Cook Univ, Townsville, Qld 4811, Australia; [Biros, E.] Queensland Res Ctr Peripheral Vasc Dis, Townsville, Qld 4811, Australia; [Marshall, R.] Royal Adelaide Hosp, Hampstead Rehabil Ctr, Amputee & Spinal Injury Rehabil Serv, Adelaide, SA 5000, Australia; [Jelbart, M.] Hampstead Rehabil Ctr, Brain Injury Rehabil Serv, Adelaide, SA, Australia; [Milanese, S.] Univ S Australia, Adelaide, SA 5001, Australia; [Galea, M. P.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne, Vic 3010, Australia		Reznik, JE (corresponding author), James Cook Univ, POB 165, Townsville, Qld 4811, Australia.	jackie.reznik@jcu.edu.au	Milanese, Steve/F-3898-2013; Galea, Mary/F-4242-2010	Milanese, Steve/0000-0002-6470-3296; Galea, Mary/0000-0003-0045-7978; Gordon, Susan/0000-0002-4760-1212; Reznik, Jacqueline/0000-0002-7324-9531			Beilby J, 2008, NZ J PHYSIOTHERAPY, V36, P7; BRADLEIGH LH, 1992, ARCH PHYS MED REHAB, V73, P293; Chalidis B, 2007, J NEUROTRAUM, V24, P1675, DOI 10.1089/neu.2007.0342; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; Citak M, 2012, SPINE, V37, P1953, DOI 10.1097/BRS.0b013e31825ee81b; Coelho CVC, 2009, ARQ NEURO-PSIQUIAT, V67, P382, DOI 10.1590/S0004-282X2009000300002; DAMANSKI M, 1961, J BONE JOINT SURG BR, V43, P286, DOI 10.1302/0301-620X.43B2.286; Dejerine, 1919, REV NEUROL-FRANCE, V35, P399; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Geschickter CF, 1938, J BONE JOINT SURG, V20, P661; Goldman J, 1980, Physiotherapy, V66, P219; Hitzig SL, 2008, AM J PHYS MED REHAB, V87, P545, DOI 10.1097/PHM.0b013e31817c16d6; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Lyder CH, 2003, JAMA-J AM MED ASSOC, V289, P223, DOI 10.1001/jama.289.2.223; Martinelli I, 2010, CRIT CARE MED, V38, pS3, DOI 10.1097/CCM.0b013e3181c9cbd9; Mavrogenis AF, 2011, ORTHOPEDICS, V34, DOI 10.3928/01477447-20110124-08; McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256-005-0958-z; Reznik JE, 2013, PHYS THER REV, V18, P300, DOI 10.1179/1743288X13Y.0000000084; Reznik JE, 2013, BRAIN INJURY, V27, P242, DOI 10.3109/02699052.2012.729293; Roberts P., 1968, J BONE JOINT SURG BR, V50, P70; Sakellariou VI, 2012, J MUSCULOSKEL NEURON, V12, P230; Seipel R, 2012, SKELETAL RADIOL, V41, P61, DOI 10.1007/s00256-011-1115-5; Silver J R, 1969, Paraplegia, V7, P220; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Teasell RW, 2010, SPINAL CORD, V48, P512, DOI 10.1038/sc.2009.175; van Kampen PJ, 2011, J HEAD TRAUMA REHAB, V26, P384, DOI 10.1097/HTR.0b013e3181f78a59; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549	29	30	35	1	4	JMNI	NAFPLION	7 SPILIADOU SQ, NAFPLION, 21 100, GREECE	1108-7161			J MUSCULOSKEL NEURON	J. Musculoskelet. Neuronal Interact.	MAR	2014	14	1					19	28					10	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	AF2YV	WOS:000334579300003	24583537				2022-02-06	
J	Hughes, RH; Silva, VA; Ahmed, I; Shreiber, DI; Morrison, B				Hughes, Rebecca H.; Silva, Victoria A.; Ahmed, Ijaz; Shreiber, David I.; Morrison, Barclay, III			Neuroprotection by genipin against reactive oxygen and reactive nitrogen species-mediated injury in organotypic hippocampal slice cultures	BRAIN RESEARCH			English	Article						Genipin; Brain injury; Neuroprotection; Organotypic hippocampal slice culture; Reactive oxygen species	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; SIGNALING PATHWAY; GRIESS REACTION; ANTIOXIDANT; GENIPOSIDE; METABOLISM; DAMAGE; DYSFUNCTION; PREVENTION	Genipin, the multipotent ingredient in Gardenia jasmenoides fruit extract (GFE), may be an effective candidate for treatment following stroke or traumatic brain injury (TBI). Secondary injury includes damage mediated by reactive oxygen species (ROS) and reactive nitrogen species (RNS), which can alter the biological function of key cellular structures and eventually lead to cell death. In this work, we studied the neuroprotective potential of genipin against damage stemming from ROS and RNS production in organotypic hippocampal slice cultures (OHSC), as well as its potential as a direct free radical scavenger. A 50 mu M dose of genipin provided significant protection against tert-butyl hydroperoxide (tBHP), a damaging organic peroxide. This dosage of genipin significantly reduced cell death at 48 h compared to vehicle control (0.1% DMSO) when administered 0, 1, 6, and 24 h after addition of tBHP. Similarly, genipin significantly reduced cell death at 48 h when administered 0, 1, 2, and 6 h after addition of rotenone, which generates reactive oxygen species via a more physiologically relevant mechanism. Furthermore, genipin significantly reduced both cell death and nitrite levels at 24 h caused by S-nitroso-N-acetylpenicillamine (SNAP), a direct nitric oxide (NO) donor, and successfully quenched 1,1-Diphenyl-2-picryl-hydrazyl (DPPH), a stable free radical, suggesting that genipin may act as a direct free radical scavenger. Our encouraging findings suggest that genipin should be tested in animal models of CNS injury with a significant component of ROS- and RNS-mediated damage, such as TBI and stroke, to assess its in vivo efficacy. (C) 2013 Elsevier B.V. All rights reserved.	[Hughes, Rebecca H.; Silva, Victoria A.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA; [Ahmed, Ijaz; Shreiber, David I.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA		Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC 8904,1210 Amsterdam Ave, New York, NY 10027 USA.	bm2119@columbia.edu	Shreiber, David/ABE-8254-2021; Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Shreiber, David/0000-0001-8248-419X	New Jersey Commission on Brain Injury Research [10-3215-BIR-E-0]	This research was supported by the New Jersey Commission on Brain Injury Research, Award #10-3215-BIR-E-0.	AKAO T, 1994, BIOL PHARM BULL, V17, P1573; Alia M, 2005, J BIOCHEM MOL TOXIC, V19, P119, DOI 10.1002/jbt.20061; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Dorman HJD, 2011, FOOD CHEM, V129, P1612, DOI 10.1016/j.foodchem.2011.06.017; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Granger DL, 1996, METHOD ENZYMOL, V268, P142; Guangpinx X., 2003, NEUROTOX RES, V5, P529; Guevara I, 1998, CLIN CHIM ACTA, V274, P177, DOI 10.1016/S0009-8981(98)00060-6; Hou YC, 2008, FOOD CHEM TOXICOL, V46, P2764, DOI 10.1016/j.fct.2008.04.033; Jeon WK, 2011, ARCH BIOCHEM BIOPHYS, V512, P119, DOI 10.1016/j.abb.2011.05.016; Jin J, 2004, BIOMACROMOLECULES, V5, P162, DOI 10.1021/bm034286m; Koo HJ, 2006, J ETHNOPHARMACOL, V103, P496, DOI 10.1016/j.jep.2005.08.011; Koo HJ, 2004, EUR J PHARMACOL, V495, P201, DOI 10.1016/j.ejphar.2004.05.031; Lee JH, 2009, FOOD CHEM TOXICOL, V47, P1127, DOI 10.1016/j.fct.2009.01.037; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Morrison B, 2002, BRIT J PHARMACOL, V137, P1255, DOI 10.1038/sj.bjp.0704986; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Ohkubo T, 2004, J HEALTH SCI, V50, P193, DOI 10.1248/jhs.50.193; Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272; Qiu WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041391; Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010; Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Suzuki Y, 2001, PLANTA MED, V67, P807, DOI 10.1055/s-2001-18842; Tseng TY, 2004, ANAL CHIM ACTA, V517, P47, DOI 10.1016/j.aca.2004.04.040; Valgimigli L, 2009, ENVIRON MOL MUTAGEN, V50, P222, DOI 10.1002/em.20468; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wang GF, 2009, ACTA PHARMACOL SIN, V30, P589, DOI 10.1038/aps.2009.31; Yamazaki M, 2001, BIOL PHARM BULL, V24, P1454, DOI 10.1248/bpb.24.1454; Yamazaki M, 2008, EUR J PHARMACOL, V581, P255, DOI 10.1016/j.ejphar.2007.12.001; Yen GC, 2002, FOOD CHEM, V79, P307, DOI 10.1016/S0308-8146(02)00145-0; Yen GC, 1997, J AGR FOOD CHEM, V45, P30, DOI 10.1021/jf9603994; Yuan Y, 2007, CARBOHYD POLYM, V68, P561, DOI 10.1016/j.carbpol.2006.10.023; Zhang CY, 2006, CELL METAB, V3, P417, DOI 10.1016/j.cmet.2006.04.010	38	30	32	4	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 16	2014	1543						308	314		10.1016/j.brainres.2013.11.020			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	300VE	WOS:000330491300034	24275198				2022-02-06	
J	Morishita, S; Oku, H; Horie, T; Tonari, M; Kida, T; Okubo, A; Sugiyama, T; Takai, S; Hara, H; Ikeda, T				Morishita, Seita; Oku, Hidehiro; Horie, Taeko; Tonari, Masahiro; Kida, Teruyo; Okubo, Akiko; Sugiyama, Tetsuya; Takai, Shinji; Hara, Hideaki; Ikeda, Tsunehiko			Systemic Simvastatin Rescues Retinal Ganglion Cells from Optic Nerve Injury Possibly through Suppression of Astroglial NF-kappa B Activation	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; MONOCYTE CHEMOATTRACTANT PROTEIN-1; TRAUMATIC BRAIN-INJURY; RAT RETINA; REACTIVE ASTROCYTES; MULTIPLE-SCLEROSIS; ADULT-RATS; IN-VIVO; EXPRESSION; NEURONS	Neuroinflammation is involved in the death of retinal ganglion cells (RGCs) after optic nerve injury. The purpose of this study was to determine whether systemic simvastatin can suppress neuroinflammation in the optic nerve and rescue RGCs after the optic nerve is crushed. Simvastatin or its vehicle was given through an osmotic minipump beginning one week prior to the crushing. Immunohistochemistry and real-time PCR were used to determine the degree of neuroinflammation on day 3 after the crushing. The density of RGCs was determined in Tuj-1 stained retinal flat mounts on day 7. The effect of simvastain on the TNF-alpha-induced NF-kappa B activation was determined in cultured optic nerve astrocytes. On day 3, CD68-positive cells, most likely microglia/macrophages, were accumulated at the crushed site. Phosphorylated NF-kB was detected in some astrocytes at the border of the lesion where the immunoreactivity to MCP-1 was intensified. There was an increase in the mRNA levels of the CD68 (11.4-fold), MCP-1 (22.6-fold), ET-1 (2.3-fold), GFAP (1.6-fold), TNF-alpha (7.0-fold), and iNOS (14.8-fold) genes on day 3. Systemic simvastatin significantly reduced these changes. The mean +/- SD number of RGCs was 1816.3 +/- 232.6/mm(2) (n = 6) in the sham controls which was significantly reduced to 831.4 +/- 202.5/mm(2) (n = 9) on day 7 after the optic nerve was crushed. This reduction was significantly suppressed to 1169.2 +/- 201.3/mm(2) (P = 0.01, Scheffe; n = 9) after systemic simvastatin. Simvastatin (1.0 mu M) significantly reduced the TNF-a-induced NF-kB activation in cultured optic nerve astrocytes. We conclude that systemic simvastatin can reduce the death of RGCs induced by crushing the optic nerve possibly by suppressing astroglial NF-kappa B activation.	[Morishita, Seita; Oku, Hidehiro; Horie, Taeko; Tonari, Masahiro; Kida, Teruyo; Okubo, Akiko; Sugiyama, Tetsuya; Ikeda, Tsunehiko] Osaka Med Coll, Dept Ophthalmol, Osaka, Japan; [Takai, Shinji] Osaka Med Coll, Dept Pharmacol, Osaka, Japan; [Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Gifu, Japan		Oku, H (corresponding author), Osaka Med Coll, Dept Ophthalmol, Osaka, Japan.	hidehirooku@aol.com	Oku, Hidehiro/AAD-5029-2019	Oku, Hidehiro/0000-0003-4359-4219	Japanese Ministry of Education Grant [225919739]; Osaka Community Foundation grant	This study was supported by Japanese Ministry of Education Grant 225919739 (HO) and Osaka Community Foundation grant ( HO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019; Brambilla R, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-213; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Dvoriantchikova G, 2009, EUR J NEUROSCI, V30, P175, DOI 10.1111/j.1460-9568.2009.06814.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Ghosh A, 2009, J NEUROSCI, V29, P13543, DOI 10.1523/JNEUROSCI.4144-09.2009; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Kawaji T, 2007, CURR EYE RES, V32, P991, DOI 10.1080/02713680701649603; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kitaoka Y, 2006, INVEST OPHTH VIS SCI, V47, P1448, DOI 10.1167/iovs.05-0299; Ko ML, 2011, EXP EYE RES, V93, P580, DOI 10.1016/j.exer.2011.07.003; Krempler K, 2011, INVEST OPHTH VIS SCI, V52, P2606, DOI 10.1167/iovs.10-6005; Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003; Kurimoto T, 2006, NEUROREPORT, V17, P1525, DOI 10.1097/01.wnr.0000234749.80936.54; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Nakazawa T, 2007, J NEUROCHEM, V100, P1018, DOI 10.1111/j.1471-4159.2006.04274.x; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Panagis L, 2005, EUR J NEUROSCI, V21, P2305, DOI 10.1111/j.1460-9568.2005.04046.x; Pazman C, 2000, DEVELOPMENT, V127, P1715; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Rattan R, 2003, FREE RADICAL BIO MED, V35, P1037, DOI 10.1016/S0891-5849(03)00459-3; ROSENMAN SJ, 1995, J IMMUNOL, V154, P1888; Saha RN, 2006, ANTIOXID REDOX SIGN, V8, P929, DOI 10.1089/ars.2006.8.929; Schmeer C, 2008, INVEST OPHTH VIS SCI, V49, P4971, DOI 10.1167/iovs.07-1597; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; SNOW RL, 1995, EXP NEUROL, V134, P13, DOI 10.1006/exnr.1995.1032; Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; Tonari M, 2012, INVEST OPHTH VIS SCI, V53, P3490, DOI 10.1167/iovs.11-9415; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; WINKLER BS, 1972, VISION RES, V12, P1183, DOI 10.1016/0042-6989(72)90106-X; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859	39	30	34	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 2	2014	9	1							e84387	10.1371/journal.pone.0084387			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	286ID	WOS:000329460100054	24392131	Green Published, Green Submitted, gold			2022-02-06	
J	Wisdom, NM; Pastorek, NJ; Miller, BI; Booth, JE; Romesser, JM; Linck, JF; Sim, AH				Wisdom, Nick M.; Pastorek, Nicholas J.; Miller, Brian I.; Booth, Jane E.; Romesser, Jennifer M.; Linck, John F.; Sim, Anita H.			CE PTSD and Cognitive Functioning: Importance of Including Performance Validity Testing	CLINICAL NEUROPSYCHOLOGIST			English	Article						Symptom validity testing; Performance validity testing; Post-traumatic stress disorder; PTSD; Effort; Malingering	POSTTRAUMATIC-STRESS-DISORDER; GULF-WAR VETERANS; FAKE BAD SCALE; COMBAT VETERANS; HIPPOCAMPAL VOLUME; COMPENSATION-SEEKING; BRAIN-INJURY; PSYCHOMETRIC PROPERTIES; VIETNAM VETERANS; REPORT SYMPTOMS	Many studies have observed an association between post-traumatic stress disorder (PTSD) and cognitive deficits across several domains including memory, attention, and executive functioning. The inclusion of response bias measures in these studies, however, remains largely unaddressed. The purpose of this study was to identify possible cognitive impairments correlated with PTSD in returning OEF/OIF/OND veterans after excluding individuals failing a well-validated performance validity test. Participants included 126 men and 8 women with a history of mild traumatic brain injury (TBI) referred for a comprehensive neuropsychological evaluation as part of a consortium of five Veterans Affairs hospitals. The PTSD CheckList (PCL) and Word Memory Test (WMT) were used to establish symptoms of PTSD and invalid performance, respectively. Groups were categorized as follows: Control (PCL < 50, pass WMT), PTSD-pass (PCL 50, pass WMT), and PTSD-fail (PCL 50, fail WMT). As hypothesized, failure on the WMT was associated with significantly poorer performance on almost all cognitive tests administered; however, no significant differences were detected between individuals with and without PTSD symptoms after separating out veterans failing the WMT. These findings highlight the importance of assessing respondent validity in future research examining cognitive functioning in psychiatric illness and warrant further consideration of prior studies reporting PTSD-associated cognitive deficits.	[Wisdom, Nick M.; Pastorek, Nicholas J.; Miller, Brian I.; Booth, Jane E.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Wisdom, Nick M.; Miller, Brian I.; Booth, Jane E.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Romesser, Jennifer M.] Mental Hlth, George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA; [Linck, John F.] Mental & Behav Hlth, Oklahoma City Vet Affairs Med Ctr, Oklahoma City, OK USA; [Sim, Anita H.] Mirmeapolis Vet Affairs Hlth Care Syst, Dept Phys Med & Rehabil, Mirmeapolis, MN USA		Pastorek, NJ (corresponding author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd RCL 117, Houston, TX 77030 USA.	nicholas.pastorek@va.gov		Pastorek, Nicholas/0000-0002-9290-380X	Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs [B6812C]	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; B6812C (PI- Levin HS) VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks; Minnesota Veterans Medical Research & Education Foundation. No pharmaceutical or corporate funding was used in the preparation of this manuscript or collection of data.	American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boone K.B., 2007, ASSESSMENT FEIGNED C; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Brandt J, 2007, CLIN NEUROPSYCHOL, V21, P553, DOI 10.1080/13854040600770800; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Burges C, 2001, BRIT J CLIN PSYCHOL, V40, P209, DOI 10.1348/014466501163544; BURSTEIN A, 1985, J CLIN PSYCHIAT, V46, P374; Bush S. S., 2012, NEUROPSYCHOLOGICAL P, P27; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Bustamante V, 2001, J TRAUMA STRESS, V14, P791, DOI 10.1023/A:1013050423901; Butcher J. N., 2001, MMPI 2 MAN ADM SCORI; Carroll MF, 2003, PSYCHIAT ANN, V33, P732, DOI 10.3928/0048-5713-20031101-09; Centers for Disease Control and Prevention, 2003, MILD TRAUM BRAIN INJ; Danckwerts A, 2003, NEUROPSYCHOL REV, V13, P221, DOI 10.1023/B:NERV.0000009485.76839.b7; Delis D.C., 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Demakis GJ, 2011, PSYCHOL INJ LAW, V4, P24, DOI 10.1007/s12207-011-9099-y; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Department of Defense Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Frueh BC, 2013, PSYCHIAT SERV, V64, P1, DOI 10.1176/appi.ps.640101; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 1996, J TRAUMA STRESS, V9, P427, DOI 10.1007/BF02103656; Frueh BC, 1997, J PERS ASSESS, V68, P369, DOI 10.1207/s15327752jpa6802_8; Frueh BC, 2005, BRIT J PSYCHIAT, V186, P467, DOI 10.1192/bjp.186.6.467; Frueh BC, 2003, PSYCHIATR SERV, V54, P84, DOI 10.1176/appi.ps.54.1.84; Gavin H., 1843, BEING PRIZ ESS CLASS, P1835; Gil T., 1990, J TRAUMA STRESS, V3, P29, DOI DOI 10.1002/JTS.2490030104; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Golden CJ., 2002, STROOP COLOR WORD TE; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2007, ASSESSMENT FEIGNED C, P50; Green P., 2003, WORD MEMORY TEST WIN; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Guilmette T.J., 2013, MILD TRAUMATIC BRAIN, P31; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Gurvits TV, 2002, PSYCHIAT RES, V112, P263, DOI 10.1016/S0165-1781(02)00234-2; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; Howe LLS, 2012, DETECTION OF MALINGERING DURING HEAD INJURY LITIGATION, SECOND EDITION, P301, DOI 10.1007/978-1-4614-0442-2_11; Jenkins MA, 2000, CLIN NEUROPSYCHOL, V14, P7, DOI 10.1076/1385-4046(200002)14:1;1-8;FT007; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Johnsen GE, 2008, J ANXIETY DISORD, V22, P464, DOI 10.1016/j.janxdis.2007.04.007; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Kulka RA, 1990, TRAUMA VIETNAM WAR G; Larrabee G. J., 2007, ASSESSMENT MALINGERI; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; Llewellyn L. J., 1919, PENSIONS PRINCIPLES; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mol MEM, 2006, INT J GERIATR PSYCH, V21, P432, DOI 10.1002/gps.1487; Morel K. R., 2010, DIFFERENTIAL DIAGNOS; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Office of Inspector General Department of Veterans Affairs, 2010, C APR 1 2010 SEP 30, V64; Office of the Inspector General Department of Veterans Affairs, 2005, REV STAT VAR VA DIS; Peterson DI, 1998, NEUROLOGIST, V4, P131, DOI 10.1097/00127893-199805000-00004; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Reckess G. Z., 2012, NEUROPSYCHOLOGICAL P, P161; Reitan R, 1985, HALSTEAD REITAN NEUR; Richardson JD, 2006, J CLIN PSYCHIAT, V67, P1240, DOI 10.4088/JCP.v67n0810; Roca V, 2001, AM J PSYCHIAT, V158, P1738, DOI 10.1176/appi.ajp.158.10.1738-a; Rosen G, 2003, COMMENTARY, V115, P17; Rosen GM, 2006, J ANXIETY DISORD, V20, P530, DOI 10.1016/j.janxdis.2005.03.004; Silver JM, 2012, J NEUROL NEUROSUR PS, V83, P836, DOI 10.1136/jnnp-2011-302078; SLOVENKO R, 1994, PSYCHIAT CLIN N AM, V17, P439; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Stone D. C., 2007, ASSESSMENT FEIGNED C, P3; Sullivan K, 2003, J PSYCHOPATHOL BEHAV, V25, P95, DOI 10.1023/A:1023342915425; Tanielian T., 2008, INVISIBLE WOUNDS WAR; U. S. Government Accountability Office, 2008, VA HEALTHC MIL TRAUM; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Weathers F.W., 1993, ANN CONV INT SOC TRA; Wechsler D., 2008, WIAS 4 ADM SCORING M; Whitley, 1998, STOLEN VALOR VIETNAM; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME; Wisdom NM, 2012, ARCH CLIN NEUROPSYCH, V27, P208, DOI 10.1093/arclin/acr107; Yehuda R, 2000, J CLIN PSYCHIAT, V61, P14; Yehuda R, 2005, J CLIN EXP NEUROPSYC, V27, P504, DOI 10.1080/138033990520223; Young JC, 2011, ARCH CLIN NEUROPSYCH, V26, P194, DOI 10.1093/arclin/acr015	111	30	30	1	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2014	28	1					128	145		10.1080/13854046.2013.863977			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AA0AF	WOS:000330756800009	24354897				2022-02-06	
J	Bertisch, H; Rath, J; Long, C; Ashman, T; Rashid, T				Bertisch, Hilary; Rath, Joseph; Long, Coralynn; Ashman, Teresa; Rashid, Tayyab			Positive psychology in rehabilitation medicine: A brief report	NEUROREHABILITATION			English	Article						Rehabilitation; brain injury; positive psychology; resilience; function; positive psychotherapy inventory	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; SPINAL-CORD-INJURY; SELF-EFFICACY; COGNITIVE REHABILITATION; EXECUTIVE DYSFUNCTION; DEPRESSIVE SYMPTOMS; THE-LITERATURE; RATING-SCALE; HEAD-INJURY	BACKGROUND: The field of positive psychology has grown exponentially within the last decade. To date, however, there have been few empirical initiatives to clarify the constructs within positive psychology as they relate to rehabilitation medicine. Character strengths, and in particular resilience, following neurological trauma are clinically observable within rehabilitation settings, and greater knowledge of the way in which these factors relate to treatment variables may allow for enhanced treatment conceptualization and planning. OBJECTIVE: The goal of this study was to explore the relationships between positive psychology constructs (character strengths, resilience, and positive mood) and rehabilitation-related variables (perceptions of functional ability post-injury and beliefs about treatment) within a baseline data set, a six-month follow-up data set, and longitudinally across time points. METHODS: Pearson correlations and supplementary multiple regression analyses were conducted within and across these time points from a starting sample of thirty-nine individuals with acquired brain injury (ABI) in an outpatient rehabilitation program. RESULTS: Positive psychology constructs were related to rehabilitation-related variables within the baseline data set, within the follow-up data set, and longitudinally between baseline positive psychology variables and follow-up rehabilitation-related data. CONCLUSIONS: These preliminary findings support relationships between character strengths, resilience, and positive mood states with perceptions of functional ability and expectations of treatment, respectively, which are primary factors in treatment success and quality of life outcomes in rehabilitation medicine settings. The results suggest the need for more research in this area, with an ultimate goal of incorporating positive psychology constructs into rehabilitation conceptualization and treatment planning.	[Bertisch, Hilary; Rath, Joseph; Long, Coralynn] NYU, Langone Med Ctr, Ctr Ambulatory Care, Rusk Inst Rehabil Med, New York, NY 10016 USA; [Ashman, Teresa] Shepherd Ctr, Nw Atlanta, GA USA; [Rashid, Tayyab] Univ Toronto, Scarborough Student Ctr, Hlth & Wellness Ctr, Toronto, ON, Canada		Bertisch, H (corresponding author), NYU, Langone Med Ctr, Ctr Ambulatory Care, Rusk Inst Rehabil Med, 240 East 38th St,17th Floor, New York, NY 10016 USA.	Hilary.bertisch@nyumc.org	Rath, Joseph F./C-4823-2008	Rath, Joseph F./0000-0003-2933-6299			Arruda JE, 1999, ARCH PHYS MED REHAB, V80, P676, DOI 10.1016/S0003-9993(99)90171-5; Azar B., 2011, APA MONITOR, V42, P32; Bados A, 2007, J CLIN PSYCHOL, V63, P585, DOI 10.1002/jclp.20368; Ben-Yishay Y., 2011, HDB HOLISTIC NEUROPS, P7; Bertisch H., REHABILITATION PSYCH; Bertisch H, 2011, J SPEC GROUP WORK, V36, P264, DOI 10.1080/01933922.2011.613901; Bonanno GA, 2012, REHABIL PSYCHOL, V57, P236, DOI 10.1037/a0029256; Breier JI, 1998, ARCH NEUROL-CHICAGO, V55, P660, DOI 10.1001/archneur.55.5.660; Catalano D, 2011, REHABIL PSYCHOL, V56, P200, DOI 10.1037/a0024571; Chan IWS, 2006, PSYCHOL HEALTH, V21, P335, DOI 10.1080/14768320500215137; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Driver S, 2009, BRAIN INJURY, V23, P203, DOI 10.1080/02699050802695574; Dunn D.S., 2009, OXFORD HDB POSITIVE, P650, DOI [DOI 10.1093/OXFORDHB/9780195187243.013.0062, 10.1093/oxfordhb/9780195187243.013.0062]; Dunn DS, 2005, REHABIL PSYCHOL, V50, P305, DOI 10.1037/0090-5550.50.3.305; Edlund MJ, 2002, AM J PSYCHIAT, V159, P845, DOI 10.1176/appi.ajp.159.5.845; Eilander HJ, 2009, NEUROPSYCHOL REHABIL, V19, P1, DOI 10.1080/09602010701694822; Evans JJ, 2011, BRAIN IMPAIR, V12, P117, DOI 10.1375/brim.12.2.117; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Guney S, 2011, PROCD SOC BEHV, V29, DOI 10.1016/j.sbspro.2011.11.209; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hampton NZ, 2000, REHABIL COUNS BULL, V43, P66; Hart T, 2009, NEUROPSYCHOLOGY, V23, P729, DOI 10.1037/a0016153; Heppner PP, 2001, J COUNS PSYCHOL, V48, P330, DOI 10.1037/0022-0167.48.3.330; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hudak AM, 2012, J HEAD TRAUMA REHAB, V27, P87, DOI 10.1097/HTR.0b013e3182114efd; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kortte KB, 2012, REHABIL PSYCHOL, V57, P248, DOI 10.1037/a0029004; Langenbahn DM, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P167; Lester P. B., 2013, PSYCHOTHERAPEUTIC IN; Lorr M., 2003, PROFILE MOOD STATES; Lucas SE, 2005, AUSTR OCCUPATIONAL T, V52, P160, DOI DOI 10.1111/J.1440-1630.2005.00485.X; Magee WL, 2002, J MUSIC THER, V39, P20, DOI 10.1093/jmt/39.1.20; Majani Giuseppina, 2011, G Ital Med Lav Ergon, V33, pA64; Malec J. F., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; May Institute for Neurorehabilitation, 2013, ENR DEM STUD TEACH R; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Memorial Hermann Rehabilitation and Research, 2013, PROGR SPEC; Mitchell AJ, 2005, LANCET NEUROL, V4, P556, DOI 10.1016/S1474-4422(05)70166-6; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Perlman LM, 2010, PROF PSYCHOL-RES PR, V41, P120, DOI 10.1037/a0018800; Peterson C., 2004, CHARACTER STRENGTHS; Pierini D, 2010, REHABIL NURS, V35, P167, DOI 10.1002/j.2048-7940.2010.tb00043.x; Prigatano GP, 2009, CURR OPIN NEUROL, V22, P606, DOI 10.1097/WCO.0b013e328332a1e7; Prigatano GP, 2003, ARCH CLIN NEUROPSYCH, V18, P811, DOI 10.1016/S0887-6177(02)00205-6; Quale AJ, 2010, REHABIL PSYCHOL, V55, P12, DOI 10.1037/a0018415; Ramanathan DM, 2011, BRAIN INJURY, V25, P328, DOI 10.3109/02699052.2011.554336; Rashid T., 2008, POSITIVE PSYCHOL EXP; Rashid T, 2008, THERAPISTS GUIDE POS; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; Robinson-Smith G, 2000, ARCH PHYS MED REHAB, V81, P460, DOI 10.1053/mr.2000.3863; Robottom BJ, 2012, PARKINSONISM RELAT D, V18, P174, DOI 10.1016/j.parkreldis.2011.09.021; Russo SJ, 2012, NAT NEUROSCI, V15, P1475, DOI 10.1038/nn.3234; Schutz LE, 2007, BRAIN INJURY, V21, P545, DOI 10.1080/02699050701426923; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seligman MEP, 2006, AM PSYCHOL, V61, P774, DOI 10.1037/0003-066X.61.8.774; Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Seligman MEP, 2000, AM PSYCHOL, V55, P5, DOI 10.1037/0003-066X.55.1.5; Sharf, 2008, DISS ABSTR INT B, V68, P6336; SHERR RL, 1992, NEUROPSYCHOLOGY, V6, P417, DOI DOI 10.1037/0894-4105.6.4.417; Shin JC, 2012, ANN REHABIL MED-ARM, V36, P119, DOI 10.5535/arm.2012.36.1.119; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; Tallman B, 2010, REHABIL PSYCHOL, V55, P204, DOI 10.1037/a0019541; Toien K, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-22; Tonks J, 2011, BRAIN INJURY, V25, P870, DOI 10.3109/02699052.2011.581641; Tsai M, 2014, CLIN PSYCHOL PSYCHOT, V21, P97, DOI 10.1002/cpp.1831; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Vogel DL, 2005, J COUNS PSYCHOL, V52, P459, DOI 10.1037/0022-0167.52.4.459; Wells TS, 2011, INT REV PSYCHIATR, V23, P144, DOI 10.3109/09540261.2011.558833; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; White B, 2010, REHABIL PSYCHOL, V55, P23, DOI 10.1037/a0018451; Wijesuriya N., 2011, PSYCHOL RES, V5, P369; Wilson BA, 2005, J INT NEUROPSYCH SOC, V11, P488, DOI 10.1017/S1355617705050599	85	30	30	4	34	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2014	34	3					573	585		10.3233/NRE-141059			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AJ7YQ	WOS:000337918400018	24448878				2022-02-06	
J	Miller, NR; Yasen, AL; Maynard, LF; Chou, LS; Howell, DR; Christie, AD				Miller, Nick R.; Yasen, Alia L.; Maynard, Logan F.; Chou, Li-Shan; Howell, David R.; Christie, Anita D.			Acute and longitudinal changes in motor cortex function following mild traumatic brain injury	BRAIN INJURY			English	Article						Evoked potentials; mild traumatic brain injury; neurobehavioural	TRANSCRANIAL MAGNETIC STIMULATION; COGNITIVE IMPAIRMENT; CEREBRAL CONCUSSION; SPORTS CONCUSSION; HEAD-INJURY; LONG-TERM; INHIBITION; RECOVERY; ATTENTION; DEFICITS	Primary objective: To evaluate excitability and inhibition of the motor cortex acutely and longitudinally following mild traumatic brain injury (mTBI). Research design: A longitudinal paired case-control design was used to examine cortical excitability and inhibition in 15 adults who had sustained an mTBI (mean age = 20.8 +/- 1.2 years) and 15 matched control participants (mean age = 21.1 +/- 1.3 years). Methods and procedures: Participants visited the lab within 72 hours of injury and again at 1, 2, 4 and 8 weeks post-injury. During each visit, transcranial magnetic stimulation was used to examine resting motor threshold (RMT), motor evoked potential peak-to-peak amplitude (MEPamp) and cortical silent period (CSP) duration of the first dorsal interosseous muscle. Main outcomes and results: There were no differences between groups in RMT (p = 0.10) or MEPamp (p = 0.22) at 72 hours post-injury or across the 2-month testing period (p >= 0.68), indicating similar cortical excitability. However, the CSP duration was higher in individuals with mTBI, indicating greater intra-cortical inhibition compared with the control group at 72 hours post-injury (p = 0.03) and throughout the 2 months of recovery (p = 0.009). Conclusions: mTBI appeared to have little effect on cortical excitability, but an acute and long-lasting effect on intra-cortical inhibition.	[Miller, Nick R.; Yasen, Alia L.; Maynard, Logan F.; Chou, Li-Shan; Howell, David R.; Christie, Anita D.] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA		Christie, AD (corresponding author), 1240 Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA.	adc1@uoregon.edu		Howell, David/0000-0002-2955-0191			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Ding MC, 2011, J NEUROSCI, V31, P14085, DOI 10.1523/JNEUROSCI.3572-11.2011; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Orth M, 2004, CLIN NEUROPHYSIOL, V115, P1076, DOI 10.1016/j.clinph.2003.12.025; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Rossi S, 2011, CLIN NEUROPHYSIOL, V122, P1686, DOI 10.1016/j.clinph.2010.12.037; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; Vink R, 1990, Magnes Res, V3, P163; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006	40	30	30	1	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	10					1270	1276		10.3109/02699052.2014.915987			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AN2ZZ	WOS:000340455900006	24841536				2022-02-06	
J	Harty, S; O'Connell, RG; Hester, R; Robertson, IH				Harty, Siobhan; O'Connell, Redmond G.; Hester, Robert; Robertson, Ian H.			Older Adults Have Diminished Awareness of Errors in the Laboratory and Daily Life	PSYCHOLOGY AND AGING			English	Article						cognitive aging; self-awareness; error awareness; prefrontal cortex; sustained attention	TRAUMATIC BRAIN-INJURY; SELF-AWARENESS; ALZHEIMERS-DISEASE; SUSTAINED ATTENTION; MEMORY PERFORMANCE; IMPAIRED AWARENESS; EXECUTIVE FUNCTION; CINGULATE CORTEX; OWN INCOMPETENCE; AGE-DIFFERENCES	Poor recognition of the degree or scope of one's own cognitive deficits is a common feature of many neurological conditions, including diseases of aging, but little is known about the impact the natural aging process has on this aspect of self-awareness (SA). Here, a group of 45 healthy older adults and a comparison group of 45 young adults completed a multidomain assessment of SA. Awareness of daily functioning was evaluated based on discrepancies between self-and informant ratings on questionnaire measures of attentional control, memory functioning, and socioemotional functioning. Online error awareness was also assessed using a variant of the Go/No-Go Error Awareness Task (EAT) in which participants are required to signal commission errors via a separate manual response. Whereas younger participants tended to underestimate their attentional control and memory functioning relative to informant reports, older adults significantly overestimated their abilities. The older adults also exhibited substantially poorer online error awareness compared with young adults, despite the fact that the two groups were matched for overall accuracy. Levels of online error awareness were significantly correlated with discrepancy scores for daily attentional and memory functioning, and with performance of a sustained attention task. These novel findings suggest that an important aspect of the neuropsychology of healthy aging has hitherto been overlooked.	[Harty, Siobhan; O'Connell, Redmond G.; Robertson, Ian H.] Univ Dublin Trinity Coll, Trinity Coll, Inst Neurosci, Dublin 2, Ireland; [Harty, Siobhan; O'Connell, Redmond G.; Robertson, Ian H.] Univ Dublin Trinity Coll, Sch Psychol, Dublin 2, Ireland; [Hester, Robert] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic, Australia		Harty, S (corresponding author), Univ Dublin Trinity Coll, Trinity Coll, Inst Neurosci, Lloyd Bldg, Dublin 2, Ireland.	sharty@tcd.ie	Hester, Robert/F-2097-2011	Hester, Robert/0000-0003-0982-8026; Harty, Siobhan/0000-0001-7560-9185; O'Connell, Redmond/0000-0001-6949-2793; Robertson, Ian H/0000-0001-8637-561X			Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Balota, 2000, OXFORD HDB MEMORY, P395; Band GPH, 2000, BIOL PSYCHOL, V51, P201, DOI 10.1016/S0301-0511(99)00038-1; Bramham J, 2009, J NEUROPSYCHOL, V3, P125, DOI 10.1348/174866408X293994; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BRUCE PR, 1982, J GERONTOL, V37, P354, DOI 10.1093/geronj/37.3.354; Burke DM, 2004, CURR DIR PSYCHOL SCI, V13, P21, DOI 10.1111/j.0963-7214.2004.01301006.x; Clare L, 2002, NEUROPSYCHOL REHABIL, V12, P341, DOI 10.1080/09602010244000129; Clare L, 2011, DEMENT GERIATR COGN, V31, P317, DOI 10.1159/000327356; Clare L, 2010, AGING NEUROPSYCHOL C, V17, P462, DOI 10.1080/13825580903581558; David AS, 2012, PHILOS T R SOC B, V367, P1379, DOI 10.1098/rstb.2012.0002; DAVID AS, 1992, BRIT J HOSP MED, V48, P652; Endrass T, 2005, J PSYCHOPHYSIOL, V19, P275, DOI 10.1027/0269-8803.19.4.275; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Falkenstein M., 1990, PSYCHOPHYSIOLOGICAL, V1, P192; Fleming JM, 1996, BRAIN INJURY, V10, P1; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gold BT, 2010, NEUROBIOL AGING, V31, P512, DOI 10.1016/j.neurobiolaging.2008.04.005; Grady C, 2012, NAT REV NEUROSCI, V13, P491, DOI 10.1038/nrn3256; Graham DP, 2005, COGNITIVE BRAIN RES, V25, P144, DOI 10.1016/j.cogbrainres.2005.05.001; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R, 2009, NEUROPSYCHOPHARMACOL, V34, P2450, DOI 10.1038/npp.2009.67; Hodges B, 2001, ACAD MED, V76, pS87, DOI 10.1097/00001888-200110001-00029; Hoerold D, 2008, EXP BRAIN RES, V186, P509, DOI 10.1007/s00221-008-1341-9; Hoerold D, 2013, NEUROPSYCHOLOGIA, V51, P385, DOI 10.1016/j.neuropsychologia.2012.11.019; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Jenkinson PM, 2009, CONSCIOUS COGN, V18, P458, DOI 10.1016/j.concog.2008.12.005; Krueger J, 2002, J PERS SOC PSYCHOL, V82, P180, DOI 10.1037//0022-3514.82.2.180; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Larson GE, 1997, BRIT J PSYCHOL, V88, P29, DOI 10.1111/j.2044-8295.1997.tb02618.x; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Leuthold H, 1999, CLIN NEUROPHYSIOL, V110, P342, DOI 10.1016/S1388-2457(98)00058-3; LOVELACE EA, 1985, J GERONTOL, V40, P192, DOI 10.1093/geronj/40.2.192; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Mathalon DH, 2003, NEUROBIOL AGING, V24, P675, DOI 10.1016/S0197-4580(02)00154-9; Mathewson KJ, 2005, BIOL PSYCHOL, V70, P88, DOI 10.1016/j.biopsycho.2004.12.005; Mavroveli S, 2009, BRIT J EDUC PSYCHOL, V79, P259, DOI 10.1348/000709908X368848; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; McAvinue LP, 2012, ATTEN PERCEPT PSYCHO, V74, P1570, DOI 10.3758/s13414-012-0352-6; MCEVOY JP, 1989, J NERV MENT DIS, V177, P43, DOI 10.1097/00005053-198901000-00007; MCGLYNN SM, 1991, J COGNITIVE NEUROSCI, V3, P183, DOI 10.1162/jocn.1991.3.2.183; Murphy PR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00065; Nelson H.E., 1982, NATL ADULT READING T; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, NEUROPSYCHOLOGIA, V47, P1149, DOI 10.1016/j.neuropsychologia.2009.01.011; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Pia L, 2004, CORTEX, V40, P367, DOI 10.1016/S0010-9452(08)70131-X; Prigatano G., 2010, STUDY ANOSOGNOSIA, P321; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rabbitt P, 2002, Q J EXP PSYCHOL-A, V55, P1081, DOI 10.1080/02724980244000080; RABBITT P, 1990, ERGONOMICS, V33, P1291, DOI 10.1080/00140139008925333; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rosen HJ, 2010, NEUROIMAGE, V49, P3358, DOI 10.1016/j.neuroimage.2009.11.041; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Seltzer B, 1997, GERONTOLOGIST, V37, P20, DOI 10.1093/geront/37.1.20; Shalgi S, 2007, EXP BRAIN RES, V182, P119, DOI 10.1007/s00221-007-1054-5; STARKSTEIN SE, 1995, ARCH NEUROL-CHICAGO, V52, P415, DOI 10.1001/archneur.1995.00540280105024; Starratt C., 1997, HDB NEUROPSYCHOLOGY, P15; Suchy Y, 2011, J CLIN EXP NEUROPSYC, V33, P92, DOI 10.1080/13803395.2010.493148; TIPPER SP, 1987, PERS INDIV DIFFER, V8, P667, DOI 10.1016/0191-8869(87)90064-X; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; Wall Sarah E, 2011, Clin Child Psychol Psychiatry, V16, P301, DOI 10.1177/1359104511401187; Wallace JC, 2003, J BUS PSYCHOL, V17, P503, DOI 10.1023/A:1023452218225; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; Wang HX, 2012, BBA-MOL BASIS DIS, V1822, P482, DOI 10.1016/j.bbadis.2011.09.002; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Young Mark S, 2011, J Aging Res, V2011, P918782, DOI 10.4061/2011/918782; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	78	30	30	0	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0882-7974	1939-1498		PSYCHOL AGING	Psychol. Aging	DEC	2013	28	4					1032	1041		10.1037/a0033567			10	Gerontology; Psychology, Developmental	Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Psychology	280QT	WOS:000329046600015	24364407	Green Submitted			2022-02-06	
J	Yu, DT; Li, MF; Ni, B; Kong, JM; Zhang, ZF				Yu, Datang; Li, Mingfang; Ni, Bing; Kong, Jiming; Zhang, Zhengfeng			Induction of Neuronal Mitophagy in Acute Spinal Cord Injury in Rats	NEUROTOXICITY RESEARCH			English	Article						Spinal cord injury; Mitophagy; BNIP3; NIX; p53	TRAUMATIC BRAIN-INJURY; CELL-DEATH; UP-REGULATION; MITOCHONDRIAL AUTOPHAGY; BNIP3 EXPRESSION; MAMMALIAN-CELLS; HYPOXIA; P53; RAPAMYCIN; ACTIVATION	Autophagy and up-regulation of autophagy-associated proteins microtubule-associated protein 1 light chain 3 (LC3) and Beclin-1 have been shown to occur in spinal cord injury (SCI). Bcl-2/E1B-19 K-interacting protein 3 (BNIP3) and Nip-like protein X (NIX, also known as BNIP3L) are mitochondrial BH3-only proteins that are implicated in mitophagy. In this study, we show that mitophagy is activated in the injured neurons, and hypoxia-inducible proteins BNIP3, NIX, and p53 are upregulated after SCI. Numerous autophagosomes containing damaged mitochondria (mitophagosomes) were found in the injured neurons 24 h after SCI in rats by transmission electron microscopy; mitophagy, therefore, had occurred. Hypoxia-inducible proteins BNIP3, NIX, and p53 were upregulated in spinal cord neurons in both a rat model of SCI and cultured primary spinal neurons exposed to hypoxia. BNIP3 and NIX were transcriptionally regulated mainly by hypoxia-inducible factor-1 alpha as well as p53 in cultured spinal cord neurons. This study provides direct morphological and biochemical evidence for mitophagy in the damaged neural tissue after SCI.	[Yu, Datang; Zhang, Zhengfeng] Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing 400037, Peoples R China; [Li, Mingfang] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing 400038, Peoples R China; [Ni, Bing] Third Mil Med Univ, Inst Immunol, Chongqing 400038, Peoples R China; [Kong, Jiming] Univ Manitoba, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada		Zhang, ZF (corresponding author), Third Mil Med Univ, Xinqiao Hosp, Dept Orthoped, Chongqing 400037, Peoples R China.	kongj@cc.umanitoba.ca; zhangz3@126.com		Ni, Bing/0000-0002-4297-5346; Kong, Jiming/0000-0002-2859-9831	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81070980]; CIHRCanadian Institutes of Health Research (CIHR); Canadian Stroke Network	This study was supported by Grants from the National Natural Science Foundation of China (81070980 to Z. Z.), CIHR and Canadian Stroke Network. We would like to thank Zhongfen Tao for technical assistance of electron microscope.	Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Burton TR, 2009, CELL DEATH DIFFER, V16, P515, DOI 10.1038/cdd.2008.185; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Chen HC, 2012, INTEGR SER INFORM SY, V30, P203, DOI 10.1007/978-1-4614-1557-2_11; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Grossman SD, 1999, J NEUROSCI, V19, P5711, DOI 10.1523/JNEUROSCI.19-14-05711.1999; Jian BX, 2011, MOL MED, V17, P542, DOI 10.2119/molmed.2010.00195; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; Novak I, 2011, AUTOPHAGY, V7, P301, DOI 10.4161/auto.7.3.14509; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Quinsay MN, 2010, AUTOPHAGY, V6, P855, DOI 10.4161/auto.6.7.13005; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Rikka S, 2011, CELL DEATH DIFFER, V18, P721, DOI 10.1038/cdd.2010.146; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sarkar S, 2009, CELL DEATH DIFFER, V16, P46, DOI 10.1038/cdd.2008.110; Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104; Sekiguchi A, 2012, J NEUROTRAUM, V29, P946, DOI 10.1089/neu.2011.1919; Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Webster KA, 2005, J MOL CELL CARDIOL, V38, P35, DOI 10.1016/j.yjmcc.2004.11.007; Yan J, 2006, BIOCHEM BIOPH RES CO, V346, P501, DOI 10.1016/j.bbrc.2006.05.160; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang SR, 2007, BRAIN RES, V1138, P221, DOI 10.1016/j.brainres.2006.12.086; Zhang XD, 2009, AUTOPHAGY, V5, P339, DOI 10.4161/auto.5.3.8174; Zhang ZF, 2007, STROKE, V38, P1606, DOI 10.1161/STROKEAHA.106.475129; Zhang ZF, 2011, FEBS J, V278, P134, DOI 10.1111/j.1742-4658.2010.07939.x	47	30	38	4	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	NOV	2013	24	4					512	522		10.1007/s12640-013-9397-0			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	268CJ	WOS:000328145300006	23637053				2022-02-06	
J	Bedi, SS; Walker, PA; Shah, SK; Jimenez, F; Thomas, CP; Smith, P; Hetz, RA; Xue, HS; Pati, S; Dash, PK; Cox, CS				Bedi, Supinder S.; Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Thomas, Chelsea P.; Smith, Philippa; Hetz, Robert A.; Xue, Hasen; Pati, Shibani; Dash, Pramod K.; Cox, Charles S., Jr.			Autologous bone marrow mononuclear cells therapy attenuates activated microglial/macrophage response and improves spatial learning after traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Behavior (rodent); blood-brain barrier; brain trauma; microglia; rats	MOUSE SPINAL-CORD; TIME-COURSE; MICROGLIA; RATS; INFLAMMATION; EXPRESSION	BACKGROUND: Autologous bone marrow-derived mononuclear cells (AMNCs) have shown therapeutic promise for central nervous system insults such as stroke and traumatic brain injury (TBI). We hypothesized that intravenous injection of AMNC provides neuroprotection, which leads to cognitive improvement after TBI. METHODS: A controlled cortical impact (CCI) rodent TBI model was used to examine blood-brain barrier (BBB) permeability, neuronal and glial apoptosis, as well as cognitive behavior. Two groups of rats underwent CCI with AMNC treatment (CCI-autologous) or without AMNC treatment (CCI-alone), consisting of 2 million AMNC per kilogram body weight harvested from the tibia and intravenously injected 72 hours after injury. CCI-alone animals underwent sham harvests and received vehicle injections. RESULTS: Ninety-six hours after injury, AMNC significantly reduced the BBB permeability in injured animals, and there was an increase in apoptosis of proinflammatory activated microglia in the ipsilateral hippocampus. At 4 weeks after injury, we observed significant improvement in probe testing of CCI-Autologous group in comparison to CCI-Alone in the Morris Water Maze paradigm. CONCLUSION: Our data demonstrate that the intravenous injection of AMNC after TBI leads to neuroprotection by preserving early BBB integrity, increasing activated microglial apoptosis and improving cognitive function. (Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Bedi, Supinder S.; Walker, Peter A.; Shah, Shinil K.; Jimenez, Fernando; Thomas, Chelsea P.; Smith, Philippa; Hetz, Robert A.; Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Walker, Peter A.; Shah, Shinil K.; Hetz, Robert A.; Xue, Hasen; Cox, Charles S., Jr.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Shah, Shinil K.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Pati, Shibani] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA; [Pati, Shibani] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA		Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.s.cox@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	Brown Foundation, Inc.; Children's Memorial Hermann Hospital Foundation;  [NIH T32 GM 08 79201];  [M01 RR 02558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This study was supported by grants NIH T32 GM 08 79201, and M01 RR 02558; Brown Foundation, Inc., Children's Memorial Hermann Hospital Foundation.	Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Pineau I, 2010, BRAIN BEHAV IMMUN, V24, P540, DOI 10.1016/j.bbi.2009.11.007; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Savitz SI, 2011, ANN NEUROL, V70, P59, DOI 10.1002/ana.22458; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Terry AV, 2009, SPATIAL NAVIGATION W; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker Peter A, 2011, World J Stem Cells, V3, P9, DOI 10.4252/wjsc.v3.i2.9	29	30	31	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2013	75	3					410	416		10.1097/TA.0b013e31829617c6			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	300GZ	WOS:000330453700009	23928737	Green Accepted			2022-02-06	
J	Ponsford, JL; Spitz, G; Cromarty, F; Gifford, D; Attwood, D				Ponsford, Jennie L.; Spitz, Gershon; Cromarty, Fiona; Gifford, David; Attwood, David			Costs of Care after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						costs; long-term care; hospital; medical; paramedical; TBI	CHARGES; OUTCOMES; LENGTH; STAY	Traumatic brain injuries (TBI) impose a significant burden on the health care system. The aim of the current study was to explore variation in costs in a group of rehabilitation patients in Victoria, Australia, following complicated mild-to-severe TBI treated under the accident compensation system administered by the Transport Accident Commission. Study participants included 1237 individuals with mild-to-severe TBI recruited consecutively from a TBI rehabilitation program. Long-term care, hospital, medical, and paramedical costs were obtained 10 years post-injury and their association with demographic and injury-related variables were examined. Significant variability in costs was evident. Long-term care costs were highest, followed by hospital, paramedical, and medical costs. Duration of post-traumatic amnesia (PTA) was a strong predictor of all costs, and stronger than Glasgow Coma Score (GCS). Longer acute hospital stay was related to higher costs. In addition to PTA duration and GCS, other factors associated with higher long-term costs were having an abnormal CT scan and epilepsy early after injury. Higher hospital and medical costs were associated with these factors, but also with other physical injuries, lower education, pre-injury unemployment, living outside the city, speaking English at home, and, in the case of medical costs, older age and having had pre-injury psychiatric treatment. Higher paramedical costs were associated with most of these variables, but also with being employed prior to injury and being female. In line with the multifaceted nature of TBI, the current findings suggest that both injury-related and demographic factors determine costs following injury.	[Ponsford, Jennie L.; Spitz, Gershon] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie L.; Spitz, Gershon] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Cromarty, Fiona; Gifford, David; Attwood, David] Transport Accid Commiss, Geelong, Vic, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia.	Jennie.Ponsford@monash.edu	Spitz, Gershon/H-7755-2014; Young, Richard A/F-6495-2012	Spitz, Gershon/0000-0002-7810-1480; Young, Richard A/0000-0001-8855-8647	Transport Accident Commission (TAC), through Institute for Safety, Compensation, and Recovery Research (ISCRR)	This project is funded by the Transport Accident Commission (TAC), through the Institute for Safety, Compensation, and Recovery Research (ISCRR).	Access Economics , 2009, EC COST SPIN CORD IN; AIHW, 2007, DIS AUSTR ACQ BRAIN; Berg Jenny, 2004, Eur J Health Econ, V5 Suppl 1, pS84, DOI 10.1007/s10198-005-0293-2; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Helps Y, 2008, INJURY RES STAT SERI, V45; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Homaifar BY, 2009, J REHABIL RES DEV, V46, P1003, DOI 10.1682/JRRD.2008.12.0166; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Mayer NH, 2003, ARCH PHYS MED REHAB, V84, P242, DOI 10.1053/apmr.2003.50101; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Morris S, 2008, ANAESTHESIA, V63, P499, DOI 10.1111/j.1365-2044.2007.05432.x; Ponsford J., 2012, TRAUMATIC BRAIN INJU, V2nd Edition; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prang KH, 2012, BRAIN INJURY, V26, P441	19	30	31	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1498	1505		10.1089/neu.2012.2843			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800005	23570260				2022-02-06	
J	Son, S; Yoo, CJ; Lee, SG; Kim, EY; Park, CW; Kim, WK				Son, Seong; Yoo, Chan Jong; Lee, Sang Gu; Kim, Eun Young; Park, Chan Woo; Kim, Woo Kyung			Natural Course of Initially Non-Operated Cases of Acute Subdural Hematoma : The Risk Factors of Hematoma Progression	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						Acute subdural hematoma; Chronic subdural hematoma; X-ray computed tomography	TRAUMATIC SUBARACHNOID HEMORRHAGE; EXTERNAL HYDROCEPHALUS; RAPID RESOLUTION; BRAIN-INJURY; HEAD TRAUMA; HYGROMA; MANAGEMENT; PATHOGENESIS; ADULTS; FATE	Objective : The objectives of the present study were to characterize the natural course of initially non-operated traumatic acute subdural hematoma (ASDH) and to identify the risk factors of hematoma progression. Methods : Retrospective analysis was performed using sequential computed tomography (CT) images maintained in a prospective observational database containing 177 ASDH cases treated from 2005 to 2011. Patients were allocated to four groups as followings; 136 (76.8%) patients to the spontaneous resolution group, 12 (6.8%) who underwent operation between 4 hours and 7 days to the rapid worsening group (RWG), 24 (13.6%) who experienced an increase of hematoma and that underwent operation between 7 and 28 days to the subacute worsening group (SWG), and 5 (2.8%) who developed delayed aggravation requiring surgery from one month after onset to the delayed worsening group (DWG). Groups were compared with respect to various factors. Results : No significant intergroup difference was found with respect to age, mechanism of injury, or initial Glasgow Coma Scale. The presence of combined cerebral contusion or subarachnoid hemorrhage was found to be a significant prognostic factor. Regarding CT findings, mixed density was common in the RWG and the SWG. Mid line shifting, hematoma thickness, and numbers of CT slices containing hematoma were significant prognostic factors of the RWG and the SWG. Brain atrophy was more severe in the SWG and the DWG. Conclusion : A large proportion of initially non-operated ASDHs worsen in the acute or subacute phase. Patients with risk factors should be monitored carefully for progression by repeat CT imaging.	[Son, Seong; Yoo, Chan Jong; Lee, Sang Gu; Kim, Eun Young; Park, Chan Woo; Kim, Woo Kyung] Gachon Univ, Gil Med Ctr, Dept Neurosurg, Inchon 405760, South Korea		Yoo, CJ (corresponding author), Gachon Univ, Gil Med Ctr, Dept Neurosurg, 1198 Guwol Dong, Inchon 405760, South Korea.	nschan@gilhospital.com					AOKI N, 1990, ACTA NEUROCHIR, V103, P76, DOI 10.1007/BF01420196; BULLOCK MR, 2006, NEUROSURGERY S, V58; Cardoso ER, 1996, J NEUROSURG, V85, P1143, DOI 10.3171/jns.1996.85.6.1143; Chang EF, 2007, NEUROSURGERY, V61, P222, DOI [10.1227/01.NEU.0000197101.68538.E6, 10.1227/01.neu.0000279217.45881.69]; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; Feliciano CE, P R HLTH SCI J, V27, p[220, 200]; Gean AD, 1994, IMAGING HEAD TRAUMA; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Izumihara A, 1997, NEUROL SURG TOKYO, V25, P307; Kawamata T, 1995, SURG NEUROL, V44, P438, DOI 10.1016/0090-3019(95)00249-9; Kim H, 1999, J KOREAN NEUROSURG S, V28, P1636; Lee CH, 2009, J KOREAN MED SCI, V24, P1224, DOI 10.3346/jkms.2009.24.6.1224; Lee KS, 2000, J KOREAN MED SCI, V15, P560, DOI 10.3346/jkms.2000.15.5.560; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Lee KS, 2011, J KOREAN NEUROSURG S, V50, P512, DOI 10.3340/jkns.2011.50.6.512; Marion DW, 2006, NEUROSURGERY, V58, P655; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; Matsuyama T, 1997, SURG NEUROL, V48, P193, DOI 10.1016/S0090-3019(96)00484-3; Matsuyama T, 1997, SURG NEUROL, V47, P423, DOI 10.1016/S0090-3019(96)00398-9; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Okumura Y, 1998, NEUROL SURG TOKYO, V26, P691; Park SH, 2011, CLIN NEUROL NEUROSUR, V113, P272, DOI 10.1016/j.clineuro.2010.11.014; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Servadei F, 2002, ACT NEUR S, V81, P81; Soltys SG, 2007, NEUROSURGERY, V61, P235; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STJOHN JN, 1981, NEUROSURGERY, V9, P621, DOI 10.1227/00006123-198112000-00002; Wu Ming-can, 2004, Chin J Traumatol, V7, P96; Yang AIL, 2012, BRAIN INJURY, V26, P1731, DOI 10.3109/02699052.2012.698364; Zanini MA, 2008, J TRAUMA, V64, P705, DOI 10.1097/TA.0b013e3180485cfc; Zwienenberg-Lee M, 2011, YOUMANS NEUROLOGICAL, P3335; [No title captured]	34	30	34	0	8	KOREAN NEUROSURGICAL SOC	SEOUL	#402 POSCO # OFFICE BUILDING 151 SUNHWA-DONG, JUNG-GU, SEOUL, 100-130, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	SEP	2013	54	3					211	219		10.3340/jkns.2013.54.3.211			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	241YZ	WOS:000326205900009	24278650	Green Submitted, gold, Green Published			2022-02-06	
J	Cross, DJ; Anzai, Y; Petrie, EC; Martin, N; Richards, TL; Maravilla, KR; Peskind, ER; Minoshima, S				Cross, Donna J.; Anzai, Yoshimi; Petrie, Eric C.; Martin, Nathalie; Richards, Todd L.; Maravilla, Kenneth R.; Peskind, Elaine R.; Minoshima, Satoshi			Loss of Olfactory Tract Integrity Affects Cortical Metabolism in the Brain and Olfactory Regions in Aging and Mild Cognitive Impairment	JOURNAL OF NUCLEAR MEDICINE			English	Article						olfactory tract; Alzheimer's disease; fiber tract integrity; glucose metabolism; F-18-FDG PET; DTI	TRAUMATIC AXONAL INJURY; ALZHEIMERS-DISEASE; TAU PATHOLOGY; IN-VIVO; DYSFUNCTION; MRI; EPSILON-4; BULB; PET	Olfactory dysfunction is an early feature of Alzheimer disease. This study used multimodal imaging of PET and F-18-FDG combined with diffusion tensor imaging (DTI) to investigate the association of fiber tract integrity in the olfactory tract with cortical glucose metabolism in subjects with mild cognitive impairment (MCI) and normal controls. We hypothesized that MCI subjects would show loss of olfactory tract integrity and may have altered associations with glucose metabolism. Methods: Subjects diagnosed with amnestic MCI (n = 12) and normal controls (n = 23) received standard brain F-18-FDG PET and DTI with 32 gradient directions on a 3-T MR imaging scanner. Fractional anisotropy (FA) maps were generated. Voxelwise correlation analysis of olfactory tract FA values with F-18-FDG PET images was performed. Results: Integrated analysis over all subjects indicated a positive correlation between white matter integrity in the olfactory tract and metabolic activity in olfactory processing structures, including the rostral prefrontal cortex, dorsomedial thalamus, hypothalamus, orbitofrontal cortex, and uncus, and in the superior temporal gyrus, insula, and anterior cingulate cortex. Subjects with MCI, compared with normal controls, showed differential associations of olfactory tract integrity with medial temporal lobe and posterior cortical structures. Conclusion: These findings indicate that impairment of axonal integrity or neuronal loss may be linked to functional metabolic changes and that disease-specific neurodegeneration may affect this relationship. Multimodal imaging using F-18-FDG PET and DTI may provide better insights into aging and neurodegenerative processes.	[Cross, Donna J.; Anzai, Yoshimi; Petrie, Eric C.; Martin, Nathalie; Richards, Todd L.; Maravilla, Kenneth R.; Minoshima, Satoshi] Univ Washington, Dept Radiol, Seattle, WA 98195 USA; [Petrie, Eric C.; Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Petrie, Eric C.; Peskind, Elaine R.] MIRECC, VA Puget Sound, Seattle, WA USA		Cross, DJ (corresponding author), Univ Washington, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA.	dcross@uw.edu	Anzai, Yoshimi/AAK-8428-2021	Anzai, Yoshimi/0000-0003-2988-7445; Petrie, Eric/0000-0003-1188-6321; Minoshima, Satoshi/0000-0002-0043-3047; Cross, Donna/0000-0003-1918-2214	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS045254]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136]; VA Puget Sound Mental Illness Research, Education and Clinical Center (MIRECC); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005136] Funding Source: NIH RePORTER	The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This study was supported by NIH R01 NS045254, NIA grant P50AG005136, and the VA Puget Sound Mental Illness Research, Education and Clinical Center (MIRECC). No other potential conflict of interest relevant to this article was reported.	Albers MW, 2006, CURR NEUROL NEUROSCI, V6, P379, DOI 10.1007/s11910-996-0018-7; Attems J, 2006, CLIN NEUROPATHOL, V25, P265; Bahar-Fuchs A, 2010, J ALZHEIMERS DIS, V22, P1081, DOI 10.3233/JAD-2010-100696; Bohnen NI, 2012, J NUCL MED, V53, P59, DOI 10.2967/jnumed.111.096578; Chen TF, 2009, PSYCHIAT RES-NEUROIM, V173, P15, DOI 10.1016/j.pscychresns.2008.09.002; Christen-Zaech S, 2003, CAN J NEUROL SCI, V30, P20, DOI 10.1017/S0317167100002389; Cross DJ, 2008, NEUROIMAGE, V39, P915, DOI 10.1016/j.neuroimage.2007.08.036; Duda JE, 2010, J NEUROL SCI, V289, P49, DOI 10.1016/j.jns.2009.08.042; HYMAN BT, 1991, ANN NY ACAD SCI, V640, P14; Kandel E.R., 1991, PRINCIPLES NEURAL SC, V3rd ed.; Kovacs T, 2004, AGEING RES REV, V3, P215, DOI 10.1016/j.arr.2003.10.003; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; Minoshima S, 1999, ANN NY ACAD SCI, V893, P350, DOI 10.1111/j.1749-6632.1999.tb07852.x; MINOSHIMA S, 1994, LANCET, V344, P895, DOI 10.1016/S0140-6736(94)92871-1; Minoshima S, 1998, QUANTITATIVE FUNCTIONAL BRAIN IMAGING WITH POSITRON EMISSION TOMOGRAPHY, P133, DOI 10.1016/B978-012161340-2/50020-2; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Minoshima S, 2008, EUR J NUCL MED MOL I, V35, pS89, DOI 10.1007/s00259-007-0707-8; Mosconi L, 2007, EXP GERONTOL, V42, P129, DOI 10.1016/j.exger.2006.05.016; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Ross GW, 2006, MOVEMENT DISORD, V21, P2062, DOI 10.1002/mds.21076; Scherfler C, 2006, BRAIN, V129, P538, DOI 10.1093/brain/awh674; Talairach J., 1988, COPLANAR STEREOTAXIC; Thomann PA, 2009, J ALZHEIMERS DIS, V17, P213, DOI 10.3233/JAD-2009-1036; Tsuboi Y, 2003, NEUROPATH APPL NEURO, V29, P503, DOI 10.1046/j.1365-2990.2003.00453.x; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1; Worsley K.J., 1996, QUANTIFICATION BRAIN, P327; Zhang Y, 2007, NEUROLOGY, V68, P13, DOI 10.1212/01.wnl.0000250326.77323.01	31	30	31	0	6	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	AUG	2013	54	8					1278	1284		10.2967/jnumed.112.116558			7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	195HH	WOS:000322692400035	23804325	Bronze, Green Accepted			2022-02-06	
J	Garringer, JA; Niyonkuru, C; McCullough, EH; Loucks, T; Dixon, CE; Conley, YP; Berga, S; Wagner, AK				Garringer, Julie A.; Niyonkuru, Christian; McCullough, Emily H.; Loucks, Tammy; Dixon, C. Edward; Conley, Yvette P.; Berga, Sarah; Wagner, Amy K.			Impact of Aromatase Genetic Variation on Hormone Levels and Global Outcome after Severe TBI	JOURNAL OF NEUROTRAUMA			English	Article						aromatase; estradiol; genetics CYP19A1; testosterone; traumatic brain injury	SERUM ESTROGEN-LEVELS; TESTOSTERONE INCREASES; GENDER-DIFFERENCES; BRAIN-INJURY; LESION SIZE; SEX; CYP19; POLYMORPHISMS; ORGANIZATION; ASSOCIATION	Although experimental traumatic brain injury (TBI) studies support estradiol as a neuroprotectant and potent stimulator of neuroplasticity, clinical studies suggest a negative association between endogenous estradiol profiles and mortality/poor outcomes. However, no studies have evaluated associations with cerebral spinal fluid (CSF) hormone profiles and aromatase gene (cytochrome P450 [CYP] 19A1) variability on clinical TBI outcomes. We evaluated 110 adults with severe TBI. Average and daily estradiol, testosterone, and estradiol/testosterone ratios (E2:T) were measured using CSF and serum samples and compared to healthy controls. Eighteen tagging and four functional single-nucleotide polymorphisms (SNPs) for CYP19A1 were genotyped and compared to hormones, acute mortality, and Glasgow Outcome Scale (GOS) scores 6 months post-TBI. TBI subjects had lower CSF estradiol over time versus controls. CSF testosterone was initially high, but declined over time. E2/T ratios were initially low, compared to controls, but rose over time. Higher mean E2/T ratio in bivariate analysis was associated with lower mortality (p = 0.019) and better GOS-6 scores (p = 0.030). rs2470152 influenced CSF E2/T ratio and also serumand CSF testosterone (p <= 0.05 all comparisons). Multiple-risk SNPs rs2470152, rs4646, and rs2470144 were associated with worse GOS-6 scores (p <= 0.05, all comparisons), and those with > 1 risk SNP variant had a higher risk for poor outcome, compared with those with <= 1 risk variant. TBI results in low CSF estradiol and dynamic CSF testosterone and E2/T ratio. In contrast to clinical serum hormone studies, higher CSF E2/T ratio was associated with better outcome. Further, genetic variation in CYP19A1 influences both hormone dynamics and outcome post-TBI.	[Garringer, Julie A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; [Niyonkuru, Christian; McCullough, Emily H.; Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [McCullough, Emily H.; Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15213 USA; [Loucks, Tammy] Emory Univ, Dept Gynecol & Obstet, Atlanta, GA 30322 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Berga, Sarah] Wake Forest Univ, Dept Obstet & Gynecol, Winston Salem, NC 27109 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Loucks, Tammy/N-8223-2019	Loucks, Tammy/0000-0001-7651-7602; Conley, Yvette/0000-0002-1784-6067	Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR323155]; Department of DefenseUnited States Department of Defense [W81XWH-071-0701]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318, R01NR008424, R01 HD048162]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR008424] Funding Source: NIH RePORTER	The authors thank Sandra Deslouches for her technical support and the Brain Trauma Research Center for some elements of data collection. This work was supported by the Centers for Disease Control and Prevention (R49 CCR323155), the Department of Defense (W81XWH-071-0701), and the National Institutes of Health (5P01NS030318, R01NR008424, and R01 HD048162).	Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Azcoitia I, 2011, NEUROSCIENCE, V191, P139, DOI 10.1016/j.neuroscience.2011.02.012; Balthazart J, 2006, ENDOCRINOLOGY, V147, P359, DOI 10.1210/en.2005-0845; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bulun SE, 2004, SEMIN REPROD MED, V22, P5; Cheng J, 2007, J CEREBR BLOOD F MET, V27, P1553, DOI 10.1038/sj.jcbfm.9600457; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Colomer R, 2008, CLIN CANCER RES, V14, P811, DOI 10.1158/1078-0432.CCR-07-1923; Dossett LA, 2008, J TRAUMA, V64, P580, DOI 10.1097/TA.0b013e31816543dd; Eriksson AL, 2009, J CLIN ENDOCR METAB, V94, P1033, DOI 10.1210/jc.2008-1283; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Garcia-Casado Z, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-36; Gibson CL, 2006, J CEREBR BLOOD F MET, V26, P1103, DOI 10.1038/sj.jcbfm.9600270; Guo Y, 2006, HUM MOL GENET, V15, P2401, DOI 10.1093/hmg/ddl155; Haiman CA, 2007, CANCER RES, V67, P1893, DOI 10.1158/0008-5472.CAN-06-4123; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Herson PS, 2009, SEMIN REPROD MED, V27, P229, DOI 10.1055/s-0029-1216276; HOBBS CJ, 1992, J STEROID BIOCHEM, V42, P629, DOI 10.1016/0960-0760(92)90455-R; Hojo Y, 2008, MOL CELL ENDOCRINOL, V290, P31, DOI 10.1016/j.mce.2008.04.017; HONDA S, 1994, BIOCHEM BIOPH RES CO, V198, P1153, DOI 10.1006/bbrc.1994.1163; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2010, CLIN CHIM ACTA, V411, P53, DOI 10.1016/j.cca.2009.09.039; Koudu Y, 2012, BIOCHEM GENET, V50, P389, DOI 10.1007/s10528-011-9483-z; MacLusky NJ, 2006, NEUROSCIENCE, V138, P957, DOI 10.1016/j.neuroscience.2005.12.054; May AK, 2008, CRIT CARE MED, V36, P62, DOI 10.1097/01.CCM.0000292015.16171.6D; McCullough LD, 2003, J NEUROSCI, V23, P8701; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Pennypacker KR, 2000, ACTA NEUROBIOL EXP, V60, P515; Prange-Kiel J, 2006, NEUROSCIENCE, V138, P765, DOI 10.1016/j.neuroscience.2005.05.061; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Sebastian S, 2001, J CLIN ENDOCR METAB, V86, P4600, DOI 10.1210/jc.86.10.4600; Simpson ER, 2004, SEMIN REPROD MED, V22, P11; Sofi M, 2003, BREAST CANCER RES TR, V79, P399, DOI 10.1023/A:1024038632570; Sowers MR, 2006, AM J MED, V119, P1, DOI 10.1016/j.amjmed.2006.07.005; Spratt DI, 2006, AM J PHYSIOL-ENDOC M, V291, pE631, DOI 10.1152/ajpendo.00467.2005; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xu WH, 2007, AM J EPIDEMIOL, V166, P1420, DOI 10.1093/aje/kwm242; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zwain IH, 1999, ENDOCRINOLOGY, V140, P3843, DOI 10.1210/en.140.8.3843	48	30	30	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2013	30	16					1415	1425		10.1089/neu.2012.2565			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	199JB	WOS:000322989500005	23540392	Green Submitted, Green Published			2022-02-06	
J	Theadom, A; Mahon, S; Barker-Collo, S; McPherson, K; Rush, E; Vandal, AC; Feigin, VL				Theadom, A.; Mahon, S.; Barker-Collo, S.; McPherson, K.; Rush, E.; Vandal, A. C.; Feigin, V. L.			Enzogenol for cognitive functioning in traumatic brain injury: a pilot placebo-controlled RCT	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						brain injury; neurological disorders; randomized clinical trial; rehabilitation; trauma	INTRACEREBRAL INFLAMMATORY RESPONSE; HEAD-INJURY; DIETARY SUPPLEMENTATION; FLAVONOID EXTRACT; OXIDATIVE STRESS; HOSPITAL ANXIETY; BARK EXTRACT; VITAMIN-C; PINE BARK; MILD	Background and purpose: Enzogenol, a flavonoid-rich extract from Pinus radiata bark with antioxidant and anti-inflammatory properties has been shown to improve working memory in healthy adults. In traumatic brain injury (TBI), oxidation and inflammation have been linked to poorer cognitive outcomes. Hence, this phase II, randomized controlled trial investigated safety, compliance and efficacy of Enzogenol for improving cognitive functioning in people following mild TBI. Methods: Sixty adults, who sustained a mild TBI, 3-12 months prior to recruitment, and who were experiencing persistent cognitive difficulties [Cognitive Failures Questionnaire (CFQ) score > 38], were randomized to receive Enzogenol (1000 mg/day) or matching placebo for 6 weeks. Subsequently, all participants received Enzogenol for a further 6 weeks, followed by placebo for 4 weeks. Compliance, side-effects, cognitive failures, working and episodic memory, post-concussive symptoms and mood were assessed at baseline, 6, 12 and 16 weeks. Simultaneous estimation of treatment effect and breakpoint was effected, with confidence intervals (CIs) obtained through a treatment-placebo balance-preserving bootstrap procedure. Results: Enzogenol was found to be safe and well tolerated. Trend and breakpoint analyses showed a significant reduction in cognitive failures after 6 weeks [mean CFQ score, 95% CI, Enzogenol versus placebo -6.9 (-10.8 to -4.1)]. Improvements in the frequency of self-reported cognitive failures were estimated to continue until week 11 before stabilizing. Other outcome measures showed some positive trends but no significant treatment effects. Conclusions: Enzogenol supplementation is safe and well tolerated in people after mild TBI, and may improve cognitive functioning in this patient population. This study provides Class IIB evidence that Enzogenol is well tolerated and may reduce self-perceived cognitive failures in patients 3-12 months post-mild TBI.	[Theadom, A.; Mahon, S.; Feigin, V. L.] AUT Univ, Sch Rehabil & Occupat Studies, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Theadom, A.; McPherson, K.] AUT Univ, Sch Rehabil & Occupat Studies, Person Ctr Res Ctr, Auckland, New Zealand; [Barker-Collo, S.] Univ Auckland, Dept Psychol, Auckland, New Zealand; [Rush, E.] AUT Univ, Ctr Phys Act & Nutr, Auckland, New Zealand; [Vandal, A. C.] AUT Univ, Fac Hlth & Environm Sci, Auckland, New Zealand; [Vandal, A. C.] Ctr Clin Res & Effect Practice, Auckland, New Zealand		Feigin, VL (corresponding author), AUT Univ, Natl Inst Stroke & Appl Neurosci, Fac Hlth & Environm Studies, Sch Rehabil & Occupat Studies,Sch Publ Hlth & Psy, AUT North Shore Campus,AA254,90 Akoranga Dr,North, Auckland 1142, New Zealand.	valery.feigin@aut.ac.nz	Rush, Elaine/AAQ-9992-2021; Feigin, Valery/AAF-2313-2019	Rush, Elaine/0000-0001-7713-6203; Theadom, Alice/0000-0003-0351-6216; Feigin, Valery L./0000-0002-6372-1740; McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882	ENZO Nutraceuticals; ABI Rehabilitation Management Ltd; University of Auckland; AUT University	The authors would like to acknowledge the financial support of ENZO Nutraceuticals and thank them for their assistance in providing the capsules for the study. The study was partially funded by ENZO Nutraceuticals who manufacture the Enzogenol supplement. The study was designed and conducted independently by the research team, and the funder did not influence the design of the study or analysis of its findings. The authors would also like to thank the participants for their time and interest in taking part in this study, and the service providers (ABI Rehabilitation Management and Integrated Partners in Health) for their support with patient recruitment and discussion around the implications of the study findings. The lead author (A.T.) was co-funded by ABI Rehabilitation Management Ltd, and the co-author (K.M.) is the Laura Fergusson Trust Chair. S.B.-C. was funded by the University of Auckland; E.R., A.C.V. and V.L.F. were funded by the AUT University.	Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Bejot Y, 2008, J NEUROL NEUROSUR PS, V79, P1344, DOI 10.1136/jnnp.2008.150318; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy JD, 2004, J REHABIL MED, V36, P15, DOI 10.1080/16501960410023688; Chayasirisobhon S, 2006, HEADACHE, V46, P788, DOI 10.1111/j.1526-4610.2006.00454.x; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Delis DC, 1987, CALIFORNIA VERBAL LE; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Frevel MAE, 2012, FOOD CHEM TOXICOL, V50, P4316, DOI 10.1016/j.fct.2012.08.051; Gallop R. J., 2011, J DATA SCI, V9, P221; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gilworth G, 2008, J REHABIL MED, V40, P334, DOI 10.2340/16501977-0169; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Janssen I, 2000, J APPL PHYSIOL, V89, P465, DOI 10.1152/jappl.2000.89.2.465; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Pinheiro, 2011, NLME LINEAR NONLINEA, P1, DOI DOI 10.1371/J0URNAL.P0NE.0018860; Pipingas A, 2008, PHYTOTHER RES, V22, P1168, DOI 10.1002/ptr.2388; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; R Development Core Team, 2011, R LANG ENV STAT COMP; Rigg JL, 2005, J HEAD TRAUMA REHAB, V20, P389, DOI 10.1097/00001199-200507000-00010; Savige GS, 1997, CURRENT THERAPEUTICS, P57; Senthilmohan ST, 2003, NUTR RES, V23, P1199, DOI 10.1016/S0271-5317(03)00127-1; Shand B, 2003, PHYTOTHER RES, V17, P490, DOI 10.1002/ptr.1181; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Spencer JPE, 2010, P NUTR SOC, V69, P244, DOI 10.1017/S0029665110000054; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wallace JC, 2002, J GEN PSYCHOL, V129, P238, DOI 10.1080/00221300209602098; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wechsler D., 2008, WECHSLER ADULT INTEL; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wood JE, 2002, FOOD CHEM, V77, P155, DOI 10.1016/S0308-8146(01)00329-6; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Young JM, 2006, FREE RADICAL RES, V40, P85, DOI 10.1080/10715760500329788; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	45	30	30	3	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	AUG	2013	20	8					1135	1144		10.1111/ene.12099			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	176UM	WOS:000321331100010	23384428				2022-02-06	
J	Andersson, D; Wilhelmsson, U; Nilsson, M; Kubista, M; Stahlberg, A; Pekna, M; Pekny, M				Andersson, Daniel; Wilhelmsson, Ulrika; Nilsson, Michael; Kubista, Mikael; Stahlberg, Anders; Pekna, Marcela; Pekny, Milos			Plasticity Response in the Contralesional Hemisphere after Subtle Neurotrauma: Gene Expression Profiling after Partial Deafferentation of the Hippocampus	PLOS ONE			English	Article							FIBRILLARY ACIDIC PROTEIN; SYNAPSE FORMATION; MICE DEFICIENT; THROMBOSPONDIN-4; RAT; TRANSCRIPTOME; ASTROCYTES; ABSENCE; STROKE; MODEL	Neurotrauma or focal brain ischemia are known to trigger molecular and structural responses in the uninjured hemisphere. These responses may have implications for tissue repair processes as well as for the recovery of function. To determine whether the plasticity response in the uninjured hemisphere occurs even after a subtle trauma, we subjected mice to a partial unilateral deafferentation of the hippocampus induced by stereotactically performed entorhinal cortex lesion (ECL). The expression of selected genes was assessed by quantitative real-time PCR in the hippocampal tissue at the injured side and the contralesional side at day 4 and 14 after injury. We observed that expression of genes coding for synaptotagmin 1, ezrin, thrombospondin 4, and C1q proteins, that have all been implicated in the synapse formation, re-arrangement and plasticity, were upregulated both in the injured and the contralesional hippocampus, implying a plasticity response in the uninjured hemisphere. Several of the genes, the expression of which was altered in response to ECL, are known to be expressed in astrocytes. To test whether astrocyte activation plays a role in the observed plasticity response to ECL, we took advantage of mice deficient in two intermediate filament (nanofilament) proteins glial fibrillary acidic protein (GFAP) and vimentin (GFAP(-/-) Vim(-/-)) and exhibiting attenuated astrocyte activation and reactive gliosis. The absence of GFAP and vimentin reduced the ECL-induced upregulation of thrombospondin 4, indicating that this response to ECL depends on astrocyte activation and reactive gliosis. We conclude that even a very limited focal neurotrauma triggers a distinct response at the contralesional side, which at least to some extent depends on astrocyte activation.	[Andersson, Daniel; Wilhelmsson, Ulrika; Nilsson, Michael; Stahlberg, Anders; Pekna, Marcela; Pekny, Milos] Univ Gothenburg, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden; [Nilsson, Michael] Hunter Med Res Inst, Newcastle, NSW, Australia; [Kubista, Mikael] Acad Sci Czech Republ, Inst Biotechnol, Prague, Czech Republic; [Kubista, Mikael] TATAA Bioctr, Gothenburg, Sweden; [Stahlberg, Anders] Univ Gothenburg, Dept Pathol, Inst Biomed, Sahlgrenska Acad, Gothenburg, Sweden		Pekny, M (corresponding author), Univ Gothenburg, Ctr Brain Repair & Rehabil, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol,Sahlgrenska Acad, Gothenburg, Sweden.	milos.pekny@neuro.gu.se	NILSSON, MICHAEL/ABE-7821-2020; Kubista, Mikael/A-5689-2008; Pekna, Marcela/AAM-3261-2021; Pekna, Marcela/AAM-3249-2021	NILSSON, MICHAEL/0000-0002-8826-1621; Kubista, Mikael/0000-0002-2940-352X; Pekna, Marcela/0000-0003-2734-8237; Pekna, Marcela/0000-0003-2734-8237; Wilhelmsson, Ulrika/0000-0003-3227-2687; Stahlberg, Anders/0000-0003-4243-0191; Andersson, Daniel/0000-0002-4564-6652	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [11548]; AFA Insurance; ALF Goteborg [11392]; Sten A. Olsson Foundation for Research and Culture; VINNOVA Health ProgramVinnova; Swedish Stroke Foundation; Swedish Society of Medicine; Free Mason Foundation; Wilhelm and Martina Lundgren Foundations; NanoNet COST ActionEuropean Cooperation in Science and Technology (COST) [279017]	This work was supported by the Swedish Medical Research Council (project 11548), AFA Insurance, ALF Goteborg (project 11392), Sten A. Olsson Foundation for Research and Culture, VINNOVA Health Program, the Swedish Stroke Foundation, the Swedish Society of Medicine, the Free Mason Foundation, Wilhelm and Martina Lundgren Foundations, NanoNet COST Action (BM1002), the EU FP 7 Program EduGlia (237956) and the EU FP 7 Program TargetBraIn (279017). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; ARBER S, 1995, J CELL BIOL, V131, P1083, DOI 10.1083/jcb.131.4.1083; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Berg A, 2012, EXP NEUROL, V237, P8, DOI 10.1016/j.expneurol.2012.06.008; Buga AM, 2008, J CELL MOL MED, V12, P2731, DOI 10.1111/j.1582-4934.2008.00252.x; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Deller T, 2007, PROG BRAIN RES, V163, P501, DOI 10.1016/S0079-6123(07)63027-1; Dunkle ET, 2007, EXP EYE RES, V84, P707, DOI 10.1016/j.exer.2006.12.014; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Eroglu C, 2009, CELL, V139, P380, DOI 10.1016/j.cell.2009.09.025; Gardzinski P, 2007, J PHYSIOL-LONDON, V581, P75, DOI 10.1113/jphysiol.2006.127472; Hernandez MR, 2002, GLIA, V38, P45, DOI 10.1002/glia.10051; Hori M, 2012, DIS MODEL MECH, V5, P270, DOI 10.1242/dmm.008276; Kim DS, 2012, J NEUROSCI, V32, P8977, DOI 10.1523/JNEUROSCI.6494-11.2012; Kim MW, 2005, BRAIN RES, V1052, P16, DOI 10.1016/j.brainres.2005.05.070; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Lavialle M, 2011, P NATL ACAD SCI USA, V108, P12915, DOI 10.1073/pnas.1100957108; Li SL, 2010, NAT NEUROSCI, V13, P1496, DOI 10.1038/nn.2674; Lu YB, 2011, FASEB J, V25, P624, DOI 10.1096/fj.10-163790; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; Nakazawa T, 2007, INVEST OPHTH VIS SCI, V48, P2760, DOI 10.1167/iovs.06-1398; Parpura V, 2012, J NEUROCHEM, V121, P4, DOI 10.1111/j.1471-4159.2012.07664.x; Pekna M, 2012, STROKE, V43, P2819, DOI 10.1161/STROKEAHA.112.654228; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Pekny M., 2013, CYTOSKELETON IMAGING, P299, DOI DOI 10.1007/978-1-62703-266-7_13; PFENNINGER KH, 1991, MOL NEUROBIOL, V5, P143, DOI 10.1007/BF02935543; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stahlberg A, 2005, EXPERT REV MOL DIAGN, V5, P221, DOI 10.1586/14737159.5.2.221; Stahlberg A, 2004, CLIN CHEM, V50, P1678, DOI 10.1373/clinchem.2004.035469; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Turner DA, 1998, PROG NEUROBIOL, V55, P537, DOI 10.1016/S0301-0082(98)00019-7; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012	37	30	30	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 25	2013	8	7							e70699	10.1371/journal.pone.0070699			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	191SQ	WOS:000322433300112	23936241	gold, Green Published			2022-02-06	
J	Silva, LFA; Hoffmann, MS; Gerbatin, RD; Fiorin, FD; Dobrachinski, F; Mota, BC; Wouters, ATB; Pavarini, SP; Soares, FAA; Fighera, MR; Royes, LFF				Almeida Silva, Luiz Fernando; Hoffmann, Mauricio Scopel; Gerbatin, Rogerio da Rosa; Fiorin, Fernando da Silva; Dobrachinski, Fernando; Mota, Bibiana Castagna; Barth Wouters, Angelica Terezinha; Pavarini, Saulo Petinatti; Antunes Soares, Felix Alexandre; Fighera, Michele Rechia; Freire Royes, Luiz Fernando			Treadmill Exercise Protects Against Pentylenetetrazol-Induced Seizures and Oxidative Stress after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						EEG; epilepsy; oxidative stress; post-traumatic seizure	VOLUNTARY EXERCISE; NA+,K+-ATPASE ACTIVITY; KINDLING DEVELOPMENT; CORTICAL CONTUSION; ADAPTIVE RESPONSES; LIPID-PEROXIDATION; CEREBRAL-CORTEX; TIME-COURSE; RAT-BRAIN; EPILEPSY	Traumatic brain injury (TBI) is a major cause of acquired epilepsy, and significant resources are required to develop a better understanding of the pathologic mechanism as targets for potential therapies. Thus, we decided to investigate whether physical exercise after fluid percussion injury (FPI) protects from oxidative and neurochemical alterations as well as from behavioral electroencephalographic (EEG) seizures induced by subeffective convulsive doses of pentylenetetrazol (PTZ; 35 mg/kg). Behavioral and EEG recordings revealed that treadmill physical training increased latency to first clonic and tonic-clonic seizures, attenuated the duration of generalized seizures, and protected against the increase of PTZ-induced Racine scale 5 weeks after neuronal injury. EEG recordings also revealed that physical exercise prevented PTZ-induced amplitude increase in TBI animals. Neurochemical analysis showed that exercise training increased glutathione/oxidized glutathione ratio and glutathione levels per se. Exercise training was also effective against alterations in the redox status, herein characterized by lipid peroxidation (thiobarbituric acid reactive substances), protein carbonyl increase, as well as the inhibition of superoxide dismutase and Na+, K+-ATPase activities after FPI. On the other hand, histologic analysis with hematoxylin and eosin revealed that FPI induced moderate neuronal damage in cerebral cortex 4 weeks after injury and that physical exercise did not protect against neuronal injury. These data suggest that the ability of physical exercise to reduce FPI-induced seizures is not related to its protection against neuronal damage; however, the effective protection of selected targets, such as Na+/K+-ATPase elicited by physical exercise, may represent a new line of treatment for post-traumatic seizure susceptibility.	[Almeida Silva, Luiz Fernando; Fiorin, Fernando da Silva; Dobrachinski, Fernando; Antunes Soares, Felix Alexandre; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Dept Quim, Programa Posgrad Ciencias Biol Bioqim Toxicol, BR-97105900 Santa Maria, RS, Brazil; [Hoffmann, Mauricio Scopel; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Ctr Ciencias Saude, Programa Posgrad Frmacol, BR-97105900 Santa Maria, RS, Brazil; [Gerbatin, Rogerio da Rosa; Fiorin, Fernando da Silva; Fighera, Michele Rechia; Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Lab Bioquim Exerci, Ctr Educ Fis & Desportos, Programa Posgrad Educ Fis, BR-97105900 Santa Maria, RS, Brazil; [Barth Wouters, Angelica Terezinha; Pavarini, Saulo Petinatti] Univ Fed Rio Grande do Sul, Setor Patol Vet, Fac Vet, Porto Alegre, RS, Brazil		Royes, LFF (corresponding author), Univ Fed Santa Maria, Dept Metodos & Cnicas Desport, Ctr Educ Fis & Desportos, Ave Roraima 1000, BR-97105900 Santa Maria, RS, Brazil.	nandoroyes@yahoo.com.br	Soares, Felix AA/K-7611-2012; Hoffmann, Mauricio/AAM-9899-2020; Soares, Felix/AAE-6251-2020; Fighera, Michele R/J-9576-2014; da Silva Fiorin, Fernando/AAQ-9472-2021; Dobrachinski, Fernando/C-4316-2014; royes, luiz/T-3581-2019	Soares, Felix AA/0000-0002-6453-7902; Hoffmann, Mauricio/0000-0003-4232-3169; Soares, Felix/0000-0002-6453-7902; da Silva Fiorin, Fernando/0000-0002-6517-7160; Dobrachinski, Fernando/0000-0002-3948-1273; royes, luiz/0000-0003-4045-4827; Almeida Silva, Luiz Fernando/0000-0002-7621-4836; Fighera, Michele/0000-0002-3111-7530	FAPERGS/CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [Pronem: 11/2082-4]	The authors thank Dr. Guilherme Bresciani, Dr. Leandro Rodrigo Ribeiro, Iuri Domingues Della-Pace, and Guilherme Busanello for sharing their expertise and knowledge to contribute to this study. This work was supported by FAPERGS/CNPq (grants: Pronem: 11/2082-4).	Silva LFA, 2011, J NEUROL SCI, V308, P35, DOI 10.1016/j.jns.2011.06.030; Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Archer T, 2012, NEUROTOX RES, V21, P418, DOI 10.1007/s12640-011-9297-0; Arida RM, 2007, PHYSIOL BEHAV, V90, P629, DOI 10.1016/j.physbeh.2006.11.016; Arida RM, 1999, EPILEPSY RES, V34, P99, DOI 10.1016/S0920-1211(98)00092-8; Arida RM, 1998, EPILEPSY RES, V30, P127, DOI 10.1016/S0920-1211(97)00102-2; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bao YH, 2011, J NEUROTRAUM, V28, P35, DOI 10.1089/neu.2010.1383; Boveris A, 2008, FREE RADICAL BIO MED, V44, P224, DOI 10.1016/j.freeradbiomed.2007.08.015; Clausen F, 2012, J NEUROTRAUM, V29, P766, DOI 10.1089/neu.2011.1754; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; DISHMAN RK, 1988, PHYSIOL BEHAV, V43, P541, DOI 10.1016/0031-9384(88)90206-5; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Frantseva MV, 2000, NEUROSCIENCE, V97, P431, DOI 10.1016/S0306-4522(00)00041-5; Gluck MR, 2000, EPILEPSY RES, V39, P63, DOI 10.1016/S0920-1211(99)00111-4; GOLDSTEIN LH, 1990, BRIT J CLIN PSYCHOL, V29, P257, DOI 10.1111/j.2044-8260.1990.tb00884.x; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach G.S., 2011, AM ACAD PHYS MED REH, V3, P564; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Gupta A, 2003, BRAIN INJURY, V17, P161, DOI 10.1080/0269905021000010195; Gupta YK, 2003, PHARMACOL BIOCHEM BE, V74, P579, DOI 10.1016/S0091-3057(02)01044-4; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Jensen FE, 2009, J PEDIATR NEUROL, V7, P5, DOI 10.3233/JPN-2009-0270; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; Lima FD, 2009, BRAIN RES, V1279, P147, DOI 10.1016/j.brainres.2009.04.052; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; McColl CD, 2003, NEUROPHARMACOLOGY, V44, P234, DOI 10.1016/S0028-3908(02)00369-6; MISRA HP, 1972, J BIOL CHEM, V247, P6960; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MS, 2004, NEUROSCIENCE, V128, P721, DOI 10.1016/j.neuroscience.2004.07.012; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Packer L, 2007, FREE RADICAL RES, V41, P951, DOI 10.1080/10715760701490975; Patsoukis N, 2004, EPILEPSY RES, V62, P65, DOI 10.1016/j.eplepsyres.2004.08.005; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Rauca C, 1999, BRAIN RES, V847, P347, DOI 10.1016/S0006-8993(99)02084-3; RIOS C, 1991, NEUROCHEM RES, V16, P1139, DOI 10.1007/BF00966592; Sachdev S, 2008, FREE RADICAL BIO MED, V44, P215, DOI 10.1016/j.freeradbiomed.2007.07.019; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Setkowicz Z, 2006, EPILEPSY RES, V71, P142, DOI 10.1016/j.eplepsyres.2006.06.002; Soustiel JF, 2008, NEUROPATH APPL NEURO, V34, P412, DOI 10.1111/j.1365-2990.2007.00906.x; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; WILLMORE LJ, 1980, NEUROSURGERY, V7, P142, DOI 10.1227/00006123-198008000-00005; Wyse ATS, 2000, NEUROREPORT, V11, P2331, DOI 10.1097/00001756-200007140-00052; YAN LJ, 1995, ANAL BIOCHEM, V228, P349, DOI 10.1006/abio.1995.1362	59	30	30	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1278	1287		10.1089/neu.2012.2577			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100008	23530735	Green Published			2022-02-06	
J	O'Connell, KM; Littleton-Kearney, MT				O'Connell, Karen M.; Littleton-Kearney, Marguerite T.			The Role of Free Radicals in Traumatic Brain Injury	BIOLOGICAL RESEARCH FOR NURSING			English	Article						free radicals; traumatic brain injury; secondary injury; superoxide; nitric oxide; peroxynitrite	NITRIC-OXIDE SYNTHASE; SEVERE HEAD-INJURY; CORTICAL IMPACT INJURY; CEREBRAL-BLOOD-FLOW; OXIDATIVE STRESS; COLD INJURY; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; GLUTAMATE TRANSPORTERS; ENERGY-METABOLISM	Traumatic brain injury (TBI) is a significant cause of death and disability in both the civilian and the military populations. The primary impact causes initial tissue damage, which initiates biochemical cascades, known as secondary injury, that expand the damage. Free radicals are implicated as major contributors to the secondary injury. Our review of recent rodent and human research reveals the prominent role of the free radicals superoxide anion, nitric oxide, and peroxynitrite in secondary brain injury. Much of our current knowledge is based on rodent studies, and the authors identified a gap in the translation of findings from rodent to human TBI. Rodent models are an effective method for elucidating specific mechanisms of free radical-induced injury at the cellular level in a well-controlled environment. However, human TBI does not occur in a vacuum, and variables controlled in the laboratory may affect the injury progression. Additionally, multiple experimental TBI models are accepted in rodent research, and no one model fully reproduces the heterogeneous injury seen in humans. Free radical levels are measured indirectly in human studies based on assumptions from the findings from rodent studies that use direct free radical measurements. Further study in humans should be directed toward large samples to validate the findings in rodent studies. Data obtained from these studies may lead to more targeted treatment to interrupt the secondary injury cascades.	[O'Connell, Karen M.; Littleton-Kearney, Marguerite T.] Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, Bethesda, MD 20814 USA		O'Connell, KM (corresponding author), Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	karen.oconnell17@gmail.com					Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brzezinska AK, 2000, AM J PHYSIOL-HEART C, V278, pH1883, DOI 10.1152/ajpheart.2000.278.6.H1883; Camacho A, 2006, ARCH MED RES, V37, P11, DOI 10.1016/j.arcmed.2005.05.014; Carpenter KLH, 2008, ACTA NEUROCHIR SUPPL, V102, P207, DOI 10.1007/978-3-211-85578-2_41; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Centers for Disease Control, 2010, MAN PEOPL HAV TBI; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Defense and Veterans Brain Injury Center, 2011, DOD WORLDW NUMB TRAU; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DeWitt DS, 2001, J CEREBR BLOOD F MET, V21, P253, DOI 10.1097/00004647-200103000-00009; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Erdincler P, 2002, ACTA NEUROCHIR, V144, P195, DOI 10.1007/s007010200024; Faraci FM, 2006, J APPL PHYSIOL, V100, P739, DOI 10.1152/japplphysiol.01044.2005; Faul M, 2010, TRAUMATIC BRAIN INJU; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Grzeschik SM, 2003, J NEUROTRAUM, V20, P571, DOI 10.1089/089771503767168492; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hlatky R, 2003, J CEREBR BLOOD F MET, V23, P582, DOI 10.1097/01.WCB.0000059586.71206.F3; Hlatky R, 2002, ACT NEUR S, V81, P347; Hlatky R, 2002, ACT NEUR S, V81, P331; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huttemann M, 2008, NEUROSCIENCE, V151, P148, DOI 10.1016/j.neuroscience.2007.09.029; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; National Institute of Neurological Disorders and Stroke, 2002, TRAUM BRAIN INJ HOP; Nayak Chandrika D, 2007, Indian J Med Sci, V61, P381; Ono K, 2010, NEUROSCI LETT, V473, P146, DOI 10.1016/j.neulet.2010.02.041; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Park CO, 2001, YONSEI MED J, V42, P518, DOI 10.3349/ymj.2001.42.5.518; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Safari M, 2009, Pak J Biol Sci, V12, P1156; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tuzgen S, 2003, NEUROL RES, V25, P31, DOI 10.1179/016164103101201085; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Uzan M, 2001, SURG NEUROL, V56, P350, DOI 10.1016/S0090-3019(01)00633-4; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Ziaja M, 2007, J NEUROTRAUM, V24, P1845, DOI 10.1089/neu.2007.0303	66	30	31	1	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1099-8004	1552-4175		BIOL RES NURS	Biol. Res. Nurs.	JUL	2013	15	3					253	263		10.1177/1099800411431823			11	Nursing	Science Citation Index Expanded (SCI-EXPANDED)	Nursing	158BP	WOS:000319943800001	22345426				2022-02-06	
J	Wu, JF; Raver, C; Piao, CS; Keller, A; Faden, AI				Wu, Junfang; Raver, Charles; Piao, Chunshu; Keller, Asaf; Faden, Alan I.			Cell Cycle Activation Contributes to Increased Neuronal Activity in the Posterior Thalamic Nucleus and Associated Chronic Hyperesthesia after Rat Spinal Cord Contusion	NEUROTHERAPEUTICS			English	Article						Cell cycle activation; Posterior thalamic nucleus; Neuronal hyperexcitability; Pain; Hyperalgesia; Inflammation	PRIMARY SOMATOSENSORY CORTEX; CENTRAL NEUROPATHIC PAIN; INFLAMMATORY RESPONSE; LIMITS NEUROINFLAMMATION; REMOTE ACTIVATION; DEPENDENT KINASES; SCAR FORMATION; VPL NEURONS; HUMAN BRAIN; INJURY	Spinal cord injury (SCI) causes not only sensorimotor and cognitive deficits, but frequently also severe chronic pain that is difficult to treat (SCI pain). We previously showed that hyperesthesia, as well as spontaneous pain induced by electrolytic lesions in the rat spinothalamic tract, is associated with increased spontaneous and sensory-evoked activity in the posterior thalamic nucleus (PO). We have also demonstrated that rodent impact SCI increases cell cycle activation (CCA) in the injury region and that post-traumatic treatment with cyclin dependent kinase inhibitors reduces lesion volume and motor dysfunction. Here we examined whether CCA contributes to neuronal hyperexcitability of PO and hyperpathia after rat contusion SCI, as well as to microglial and astroglial activation (gliopathy) that has been implicated in delayed SCI pain. Trauma caused enhanced pain sensitivity, which developed weeks after injury and was correlated with increased PO neuronal activity. Increased CCA was found at the thoracic spinal lesion site, the lumbar dorsal horn, and the PO. Increased microglial activation and cysteine-cysteine chemokine ligand 21 expression was also observed in the PO after SCI. In vitro, neurons co-cultured with activated microglia showed up-regulation of cyclin D1 and cysteine-cysteine chemokine ligand 21 expression. In vivo, post-injury treatment with a selective cyclin dependent kinase inhibitor (CR8) significantly reduced cell cycle protein induction, microglial activation, and neuronal activity in the PO nucleus, as well as limiting chronic SCI-induced hyperpathia. These results suggest a mechanistic role for CCA in the development of SCI pain, through effects mediated in part by the PO nucleus. Moreover, cell cycle modulation may provide an effective therapeutic strategy to improve reduce both hyperpathia and motor dysfunction after SCI.	[Wu, Junfang; Piao, Chunshu; Faden, Alan I.] Univ Maryland, Sch Med, Natl Study Ctr Trauma & EMS, Dept Anesthesiol, Baltimore, MD 21201 USA; [Wu, Junfang; Piao, Chunshu; Faden, Alan I.] Univ Maryland, Sch Med, Natl Study Ctr Trauma & EMS, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Raver, Charles; Keller, Asaf] Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; [Keller, Asaf; Faden, Alan I.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA		Wu, JF (corresponding author), Univ Maryland, Sch Med, Natl Study Ctr Trauma & EMS, Dept Anesthesiol, Bressler Res Bldg,655 W Baltimore St,Room 6-009, Baltimore, MD 21201 USA.	jwu@anes.umm.edu		Raver, Charles/0000-0003-3042-3234; Keller, Asaf/0000-0001-8727-663X; Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS054221, R01 NS066965]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054221, R01NS066965] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health Grants R01 NS054221 (AIF) and R01 NS066965 (AK). We thank Michael Dinizo, Kelsey Guanciale, Rainier Cabatbat, Katherine Cardiff, Marie Hanscom, Angela Pan, and Aicha Moutanni for expert technical support.	Abramson CE, 2008, SPINAL CORD, V46, P320, DOI 10.1038/sj.sc.3102136; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Baastrup C, 2008, CNS DRUGS, V22, P455, DOI 10.2165/00023210-200822060-00002; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bureau I, 2006, PLOS BIOL, V4, P2361, DOI 10.1371/journal.pbio.0040382; Bushnell MC, 1999, P NATL ACAD SCI USA, V96, P7705, DOI 10.1073/pnas.96.14.7705; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; Coghill RC, 1999, J NEUROPHYSIOL, V82, P1934, DOI 10.1152/jn.1999.82.4.1934; Crown ED, 2006, EXP NEUROL, V199, P397, DOI 10.1016/j.expneurol.2006.01.003; de Jong EK, 2005, J NEUROSCI, V25, P7548, DOI 10.1523/JNEUROSCI.1019-05.2005; Defrin R, 2002, SPINAL CORD, V40, P96, DOI 10.1038/sj.sc.3101245; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; FABRI M, 1991, BRAIN RES, V538, P351, DOI 10.1016/0006-8993(91)90455-5; Falci S, 2002, J NEUROSURG, V97, P193, DOI 10.3171/spi.2002.97.2.0193; Friedberg MH, 1999, J NEUROPHYSIOL, V81, P2243, DOI 10.1152/jn.1999.81.5.2243; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gerke MB, 2003, NEUROSCIENCE, V117, P715, DOI 10.1016/S0306-4522(02)00961-2; Greenspan JD, 2004, PAIN, V109, P357, DOI 10.1016/S0304-3959(04)00068-5; Gwak YS, 2012, EXP NEUROL, V234, P362, DOI 10.1016/j.expneurol.2011.10.010; Gwak YS, 2010, J PHYSIOL SCI, V60, P59, DOI 10.1007/s12576-009-0066-2; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Hains BC, 2005, BRAIN, V128, P2359, DOI 10.1093/brain/awh623; Hains BC, 2006, J NEUROPHYSIOL, V95, P3343, DOI 10.1152/jn.01009.2005; Hall BJ, 2010, J PAIN, V11, P864, DOI 10.1016/j.jpain.2009.12.008; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; Hubscher CH, 2006, EXP NEUROL, V197, P177, DOI 10.1016/j.expneurol.2005.09.007; Hubscher CH, 2010, NEUROSCI LETT, V477, P153, DOI 10.1016/j.neulet.2010.04.053; Hulsebosch CE, 2008, EXP NEUROL, V214, P6, DOI 10.1016/j.expneurol.2008.07.016; Hulsebosch CE, 2009, BRAIN RES REV, V60, P202, DOI 10.1016/j.brainresrev.2008.12.010; Ji RR, 2006, NEURON GLIA BIOL, V2, P259, DOI 10.1017/S1740925X07000403; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; KORALEK KA, 1988, BRAIN RES, V463, P346, DOI 10.1016/0006-8993(88)90408-8; Lee HJ, 2013, J NEUROSCI RES, V91, P196, DOI 10.1002/jnr.23151; LENZ FA, 1989, BRAIN RES, V496, P357, DOI 10.1016/0006-8993(89)91088-3; Liu DZ, 2010, NEUROBIOL DIS, V37, P549, DOI 10.1016/j.nbd.2009.11.013; LU SM, 1993, SOMATOSENS MOT RES, V10, P1, DOI 10.3109/08990229309028819; Masri R, 2012, ADV EXP MED BIOL, V760, P74; Masri R, 2009, J NEUROPHYSIOL, V102, P181, DOI 10.1152/jn.00152.2009; Moulton EA, 2005, J NEUROPHYSIOL, V93, P2183, DOI 10.1152/jn.01025.2004; NOTHIAS F, 1988, BRAIN RES, V447, P169, DOI 10.1016/0006-8993(88)90980-8; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Persu C, 2009, J Med Life, V2, P296; POGGIO GF, 1960, B JOHNS HOPKINS HOSP, V106, P266; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Quiton RL, 2010, J NEUROPHYSIOL, V104, P1717, DOI 10.1152/jn.00161.2010; Rintala DH, 2005, J REHABIL RES DEV, V42, P573, DOI 10.1682/JRRD.2005.02.0033; Sceniak MP, 2006, J NEUROPHYSIOL, V95, P3865, DOI 10.1152/jn.01196.2005; Schmitt AB, 2000, ACTA NEUROPATHOL, V100, P528, DOI 10.1007/s004010000221; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stormer S, 1997, SPINAL CORD, V35, P446, DOI 10.1038/sj.sc.3100411; TASKER RR, 1992, J NEUROSURG, V77, P373, DOI 10.3171/jns.1992.77.3.0373; TASKER RR, 1991, J NEUROSURG, V75, P168; Tator C H, 1999, Neurosurg Focus, V6, pe8; Tian DS, 2007, BRAIN RES, V1154, P206, DOI 10.1016/j.brainres.2007.04.005; Trageser JC, 2006, J NEUROPHYSIOL, V96, P1456, DOI 10.1152/jn.00423.2006; Tsuda M, 2011, BRAIN, V134, P1127, DOI 10.1093/brain/awr025; Vierck CJ, 2000, PAIN, V89, P1, DOI 10.1016/S0304-3959(00)00463-2; Wang CH, 2005, ACTA PHARMACOL SIN, V26, P46, DOI 10.1111/j.1745-7254.2005.00007.x; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Wang GX, 2008, J NEUROSCI, V28, P11959, DOI 10.1523/JNEUROSCI.3296-08.2008; Waxman SG, 2006, TRENDS NEUROSCI, V29, P207, DOI 10.1016/j.tins.2006.02.003; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Whitt JL, 2013, J NEUROSCI, V33, P3915, DOI 10.1523/JNEUROSCI.2639-12.2013; Widerstrom-Noga EG, 2007, ARCH PHYS MED REHAB, V88, P1628, DOI 10.1016/j.apmr.2007.09.013; Wu JF, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-169; Wu JF, 2012, CELL CYCLE, V11, P1782, DOI 10.4161/cc.20153; Wu JF, 2011, NEUROTHERAPEUTICS, V8, P221, DOI 10.1007/s13311-011-0028-2; Wu JF, 2010, GLIA, V58, P315, DOI 10.1002/glia.20925; Wu JY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044027, 10.1371/journal.pone.0046393]; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yang YR, 2007, PAIN, V127, P109, DOI 10.1016/j.pain.2006.08.008; Yezierski R P, 2000, Prog Brain Res, V129, P429; Yezierski RP, 2009, J REHABIL RES DEV, V46, P95, DOI 10.1682/JRRD.2008.06.0074; Zhang XJ, 2005, J NEUROPHYSIOL, V93, P2552, DOI 10.1152/jn.01237.2004; Zhao P, 2007, J NEUROSCI, V27, P8893, DOI 10.1523/JNEUROSCI.2209-07.2007	87	30	34	0	5	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JUL	2013	10	3					520	538		10.1007/s13311-013-0198-1			19	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	180CF	WOS:000321569800015	23775067	Green Published			2022-02-06	
J	Cervelli, M; Bellavia, G; D'Amelio, M; Cavallucci, V; Moreno, S; Berger, J; Nardacci, R; Marcoli, M; Maura, G; Piacentini, M; Amendola, R; Cecconi, F; Mariottini, P				Cervelli, Manuela; Bellavia, Gabriella; D'Amelio, Marcello; Cavallucci, Virve; Moreno, Sandra; Berger, Joachim; Nardacci, Roberta; Marcoli, Manuela; Maura, Guido; Piacentini, Mauro; Amendola, Roberto; Cecconi, Francesco; Mariottini, Paolo			A New Transgenic Mouse Model for Studying the Neurotoxicity of Spermine Oxidase Dosage in the Response to Excitotoxic Injury	PLOS ONE			English	Article							D-ASPARTATE RECEPTOR; ORNITHINE-DECARBOXYLASE ACTIVITY; POLYAMINE RECOGNITION SITE; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; KAINIC ACID; RAT-BRAIN; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; HUNTINGTONS-DISEASE; CELLULAR FUNCTIONS	Spermine oxidase is a FAD-containing enzyme involved in polyamines catabolism, selectively oxidizing spermine to produce H2O2, spermidine, and 3-aminopropanal. Spermine oxidase is highly expressed in the mouse brain and plays a key role in regulating the levels of spermine, which is involved in protein synthesis, cell division and cell growth. Spermine is normally released by neurons at synaptic sites where it exerts a neuromodulatory function, by specifically interacting with different types of ion channels, and with ionotropic glutamate receptors. In order to get an insight into the neurobiological roles of spermine oxidase and spermine, we have deregulated spermine oxidase gene expression producing and characterizing the transgenic mouse model JoSMOrec, conditionally overexpressing the enzyme in the neocortex. We have investigated the effects of spermine oxidase overexpression in the mouse neocortex by transcript accumulation, immunohistochemical analysis, enzymatic assays and polyamine content in young and aged animals. Transgenic JoSMOrec mice showed in the neocortex a higher H2O2 production in respect to Wild-Type controls, indicating an increase of oxidative stress due to SMO overexpression. Moreover, the response of transgenic mice to excitotoxic brain injury, induced by kainic acid injection, was evaluated by analysing the behavioural phenotype, the immunodistribution of neural cell populations, and the ultrastructural features of neocortical neurons. Spermine oxidase overexpression and the consequently altered polyamine levels in the neocortex affects the cytoarchitecture in the adult and aging brain, as well as after neurotoxic insult. It resulted that the transgenic JoSMOrec mouse line is more sensitive to KA than Wild-Type mice, indicating an important role of spermine oxidase during excitotoxicity. These results provide novel evidences of the complex and critical functions carried out by spermine oxidase and spermine in the mammalian brain.	[Cervelli, Manuela; Bellavia, Gabriella; Moreno, Sandra; Mariottini, Paolo] Univ Roma Tre, Dipartimento Biol, Rome, Italy; [D'Amelio, Marcello; Cavallucci, Virve; Cecconi, Francesco] Fdn Santa Lucia, IRCCS, Lab Mol Neuroembryol, Rome, Italy; [Berger, Joachim] Monash Univ, Fac Med Nursing & Hlth Sci, Clayton, Vic, Australia; [Nardacci, Roberta; Piacentini, Mauro] IRCCS L Spallanzani, Ist Nazl Malattie Infett, Rome, Italy; [Marcoli, Manuela; Maura, Guido] Univ Genoa, Ctr Eccellenza Ric Biomed CEBR, Sez Farmacol & Tossicol, Dipartimento Farm, Genoa, Italy; [Amendola, Roberto] Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Ctr Ric Casaccia 2, Sez Tossicol & Sci Biomed BAS BIOTECMED, Rome, Italy		Cervelli, M (corresponding author), Univ Roma Tre, Dipartimento Biol, Rome, Italy.	cervelli@uniroma3.it	Nardacci, Roberta/K-6555-2016; Piacentini, Mauro/I-2411-2016; Cervelli, Manuela/ABC-6913-2020; Amendola, Roberto/AAM-2034-2020; Berger, Joachim/N-2979-2019; OLIVERIO, MARCO/F-2229-2010; Cecconi, Francesco/K-3969-2016; Moreno, Sandra/D-4254-2014	Nardacci, Roberta/0000-0002-9209-1207; Piacentini, Mauro/0000-0003-2919-1296; Cervelli, Manuela/0000-0001-8535-8279; Berger, Joachim/0000-0002-7859-545X; OLIVERIO, MARCO/0000-0002-0316-4364; Cecconi, Francesco/0000-0002-5614-4359; D'Amelio, Marcello/0000-0001-6526-1832; Cavallucci, Virve/0000-0003-3082-6359; moreno, sandra/0000-0002-1079-3222; Bellavia, Gabriella/0000-0003-0431-0180	Universita Roma Tre	The financial support utilized for this work was mainly from the Universita Roma Tre, the year budget was below 10,000 Euro. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	ALHONEN L, 1995, INT J CANCER, V63, P402, DOI 10.1002/ijc.2910630317; Amendola R, 2009, CURR CANCER DRUG TAR, V9, P118, DOI 10.2174/156800909787580935; Benkovic SA, 2004, BRAIN RES, V1024, P59, DOI 10.1016/j.brainres.2004.07.021; Casero RA, 2009, BIOCHEM J, V421, P323, DOI 10.1042/BJ20090598; Cervelli M, 2004, EUR J BIOCHEM, V271, P760, DOI 10.1111/j.1432-1033.2004.03979.x; Cervelli M, 2012, AMINO ACIDS, V42, P441, DOI 10.1007/s00726-011-1014-z; Cervelli M, 2009, INT J BIOCHEM CELL B, V41, P934, DOI 10.1016/j.biocel.2008.09.009; COYLE JT, 1987, CIBA F SYMP, V126, P186; DEVERA N, 1991, J NEUROCHEM, V57, P1; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doctrow S R, 1997, Adv Pharmacol, V38, P247; FAGE D, 1992, J NEUROCHEM, V58, P2170, DOI 10.1111/j.1471-4159.1992.tb10960.x; Fiori LM, 2011, INT J NEUROPSYCHOPH, V14, P595, DOI 10.1017/S1461145710001574; Fiori LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015146; Fleidervish IA, 2008, P NATL ACAD SCI USA, V105, P18994, DOI 10.1073/pnas.0803464105; HALONEN T, 1993, EUR J NEUROSCI, V5, P1233, DOI 10.1111/j.1460-9568.1993.tb00978.x; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; HOGAN B, 1983, NATURE, V306, P313, DOI 10.1038/306313a0; Iannicola C, 2000, J NEUROCHEM, V75, P830, DOI 10.1046/j.1471-4159.2000.0750830.x; Iarashi K, 2010, INT J BIOCHEM CELL B, V42, P39, DOI 10.1016/j.biocel.2009.07.009; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Janne J, 2005, J CELL MOL MED, V9, P865, DOI 10.1111/j.1582-4934.2005.tb00385.x; Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x; Kaasinen K, 2000, EUR J NEUROSCI, V12, P540, DOI 10.1046/j.1460-9568.2000.00940.x; Kaasinen SK, 2003, EXP NEUROL, V183, P645, DOI 10.1016/S0014-4886(03)00186-9; Kaasinen SK, 2004, PHARM BIOCH BEHAV, V78, P3545; Kauppinen RA, 1995, PROG NEUROBIOL, V47, P545, DOI 10.1016/0301-0082(95)00037-2; Liu W, 2001, J NEUROCHEM, V79, P976, DOI 10.1046/j.1471-4159.2001.00650.x; LUKKARAINEN J, 1995, EUR J NEUROSCI, V7, P1840, DOI 10.1111/j.1460-9568.1995.tb00704.x; Lukkarinen J, 1997, STROKE, V28, P639, DOI 10.1161/01.STR.28.3.639; Lukkarinen JA, 1999, BRAIN RES, V826, P325, DOI 10.1016/S0006-8993(99)01327-X; Lukkarinen JA, 1998, EUR J NEUROSCI, V10, P2046, DOI 10.1046/j.1460-9568.1998.00216.x; MARTINEZ E, 1991, LIFE SCI, V48, P77, DOI 10.1016/0024-3205(91)90427-D; Mastroberardino P, 2002, CELL DEATH DIFFER, V9, P873, DOI 10.1038/sj.cdd.4401093; Masuko T, 2003, J NEUROCHEM, V84, P610, DOI 10.1046/j.1471-4159.2003.01558.x; MATES JM, 1992, AGENTS ACTIONS, V36, P17, DOI 10.1007/BF01991222; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Mony L, 2011, EMBO J, V30, P3134, DOI 10.1038/emboj.2011.203; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NAJM I, 1992, DEV BRAIN RES, V69, P11, DOI 10.1016/0165-3806(92)90117-F; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PASCHEN W, 1991, BRAIN RES, V566, P354, DOI 10.1016/0006-8993(91)91726-H; PASCHEN W, 1992, MOL CHEM NEUROPATHOL, V16, P241, DOI 10.1007/BF03159973; PASCHEN W, 1990, J CEREBR BLOOD F MET, V10, P236, DOI 10.1038/jcbfm.1990.40; Pledgie A, 2005, J BIOL CHEM, V280, P39843, DOI 10.1074/jbc.M508177200; Rea G, 2004, IUBMB LIFE, V56, P167, DOI 10.1080/15216540410001673996; Schauwecker PE, 2003, MOL BRAIN RES, V112, P70, DOI 10.1016/S0169-328X(03)00048-2; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Traynelis SF, 2010, PHARMACOL REV, V62, P405, DOI 10.1124/pr.109.002451; van den Bout CJ, 2002, MECH DEVELOP, V110, P179, DOI 10.1016/S0925-4773(01)00597-4; Wang Q, 2005, MOL NEUROBIOL, V31, P3, DOI 10.1385/MN:31:1-3:003; Wang YL, 2005, BIOCHEM J, V386, P543, DOI 10.1042/BJ20041084; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289; WILLIAMS K, 1989, MOL PHARMACOL, V36, P575; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; Yang DS, 2008, AM J PATHOL, V173, P665, DOI 10.2353/ajpath.2008.071176; Yoshida M, 2010, BIOCHEM BIOPH RES CO, V391, P1234, DOI 10.1016/j.bbrc.2009.12.049; Zahedi K, 2010, J NEUROTRAUM, V27, P515, DOI 10.1089/neu.2009.1097; Zhang XM, 2011, CURR NEUROPHARMACOL, V9, P388, DOI 10.2174/157015911795596540; Zhu XY, 2001, BRAIN RES, V922, P293, DOI 10.1016/S0006-8993(01)03159-6	60	30	30	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2013	8	6							e64810	10.1371/journal.pone.0064810			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190ST	WOS:000322361200005	23840306	Green Published, gold			2022-02-06	
J	Jimenez, N; Ebel, BE; Wang, J; Koepsell, TD; Jaffe, KM; Dorsch, A; Durbin, D; Vavilala, MS; Temkin, N; Rivara, FP				Jimenez, Nathalia; Ebel, Beth E.; Wang, Jin; Koepsell, Thomas D.; Jaffe, Kenneth M.; Dorsch, Andrea; Durbin, Dennis; Vavilala, Monica S.; Temkin, Nancy; Rivara, Frederick P.			Disparities in Disability After Traumatic Brain Injury Among Hispanic Children and Adolescents	PEDIATRICS			English	Article						disability; disparities; Hispanic children; traumatic brain injury	QUALITY-OF-LIFE; ETHNIC DISPARITIES; RELIABILITY; OUTCOMES; VALIDITY; REHABILITATION; PEDSQL(TM)-4.0; INVENTORY; LANGUAGE	OBJECTIVE: To compare the extent of disability in multiple areas of functioning after mild, moderate, and severe traumatic brain injury (TBI) between Hispanic and non-Hispanic white (NHW) children. METHODS: This was a prospective cohort study of children aged <18 years treated for a TBI between March 1, 2007, and September 30, 2008. Hispanic (n = 74) and NHW (n = 457) children were included in the study. Outcome measures were disability in health-related quality of life, adaptive skills, and participation in activities 3, 12, 24, and 36 months after injury compared with preinjury functioning. We compared change in outcome scores between Hispanic and NHW children at each follow-up time. All analyses were adjusted for age, gender, severity and intent of injury, insurance, family function at baseline, parental education, and income. RESULTS: The health-related quality of life for all children was lower at all follow-up times compared with baseline. Although NHW children showed some improvement during the first 3 years after injury, Hispanic children remained significantly impaired. Significant differences were also observed in the domains of communication and self-care abilities after TBI. Differences between groups in scores for participation in activities were also present but were only significant 3 months after injury. CONCLUSIONS: Hispanic children with TBI report larger and long-term reductions in their quality of life, participation in activities, communication, and self-care abilities compared with NHW children. The reasons for these differences need to be better understood and interventions implemented to improve the outcomes of these children.	[Jimenez, Nathalia; Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Jimenez, Nathalia] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Ebel, Beth E.; Koepsell, Thomas D.; Jaffe, Kenneth M.; Durbin, Dennis; Rivara, Frederick P.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Ebel, Beth E.; Koepsell, Thomas D.; Rivara, Frederick P.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Ebel, Beth E.; Wang, Jin; Jaffe, Kenneth M.; Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Jaffe, Kenneth M.] Univ Washington, Ctr Clin & Epidemiol Res, Seattle, WA 98195 USA; [Jaffe, Kenneth M.; Temkin, Nancy] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA 19104 USA; [Durbin, Dennis] Univ Penn, Philadelphia, PA 19104 USA		Jimenez, N (corresponding author), Dept Anesthesiol & Pain Med, Box 9824,4800 Sand Point Way NE, Seattle, WA 98105 USA.	jimenez@seattlechildrens.org	Durbin, Dennis/AAD-7829-2022	Ebel, Beth/0000-0001-9310-8325; Jimenez, Nathalia/0000-0002-6785-8330	Department of Health and Human Services [1T32GM086270-01]; National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK 082325]; National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD078453] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK082325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM086270] Funding Source: NIH RePORTER	This work was supported by the Department of Health and Human Services (1T32GM086270-01 to Dr Jimenez; Principal Investigator: Debra Schwinn), the National Institute of Diabetes and Digestive and Kidney Diseases (DK 082325 to Dr Jimenez; Principal Investigator: Dedra Buchwald), and National Center for Injury Prevention and Control, Centers for Disease Control and Prevention grant R49 CE 001021. Funded by the National Institutes of Health (NIH).	[Anonymous], 2009, STAT PORTR HISP US; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bedell G., CHILD ADOLESCENT PAR; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Flores G, 2006, PEDIATRICS, V118, pE730, DOI 10.1542/peds.2005-2599; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Harrison PL, TECHNICAL REPORT; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Marr A., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2007, J TRAUMA, V63, pS122, DOI 10.1097/TA.0b013e31815accdf; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Mosnaim GS, 2007, J ALLERGY CLIN IMMUN, V120, P1160, DOI 10.1016/j.jaci.2007.08.040; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Newman DA, 2010, EUR J PSYCHOL ASSESS, V26, P194, DOI 10.1027/1015-5759/a000026; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Robertson Charlene M. T., 2001, Pediatr Crit Care Med, V2, P145, DOI 10.1097/00130478-200104000-00009; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Stevens GD, 2010, J IMMIGR MINOR HEALT, V12, P273, DOI 10.1007/s10903-008-9185-8; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Vitullo MW, 2002, J HEALTH CARE POOR U, V13, P504, DOI 10.1177/104920802237533; WASSERMAN RC, 1992, PEDIATRICS, V89, P834	34	30	30	0	13	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2013	131	6					E1850	E1856		10.1542/peds.2012-3354			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	197HH	WOS:000322840200019	23650302	Green Published			2022-02-06	
J	Kolias, AG; Scotton, WJ; Belli, A; King, AT; Brennan, PM; Bulters, DO; Eljamel, MS; Wilson, MH; Papadopoulos, MC; Mendelow, AD; Menon, DK; Hutchinson, PJ				Kolias, A. G.; Scotton, W. J.; Belli, A.; King, A. T.; Brennan, P. M.; Bulters, D. O.; Eljamel, M. S.; Wilson, M. H.; Papadopoulos, M. C.; Mendelow, A. D.; Menon, D. K.; Hutchinson, P. J.		UK Neurosurgical Res Network; RESCUE-ASDH Collaborative Grp	Surgical management of acute subdural haematomas: current practice patterns in the United Kingdom and the Republic of Ireland	BRITISH JOURNAL OF NEUROSURGERY			English	Article						craniotomy; decompressive craniectomy; intracranial pressure; randomised trial; traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; HINGE CRANIOTOMY; BRAIN-INJURY; MORTALITY	Introduction. Uncertainty remains as to the role of decompressive craniectomy (DC) for primary evacuation of acute subdural haematomas (ASDH). In 2011, a collaborative group was formed in the UK with the aim of answering the following question: "What is the clinical- and cost-effectiveness of decompressive craniectomy, in comparison with craniotomy for adult patients undergoing primary evacuation of an ASDH?" The proposed RESCUE-ASDH trial (Randomised Evaluation of Surgery with Craniectomy for patients Undergoing Evacuation of Acute Subdural Haematoma) is a multicentre, pragmatic, parallel group randomised trial of DC versus craniotomy for adult head-injured patients with an ASDH. In this study, we used an online questionnaire to assess the current practice patterns in the management of ASDH in the UK and the Republic of Ireland, and to gauge neurosurgical opinion regarding the proposed RESCUE-ASDH trial. Materials and methods. A questionnaire survey of full members of the Society of British Neurological Surgeons and members of the British Neurosurgical Trainees Association was undertaken between the beginning of May and the end of July 2012. Results. The online questionnaire was answered by 95 neurosurgeons representing 31 of the 32 neurosurgical units managing adult head-injured patients in the UK and the Republic of Ireland. Forty-five percent of the respondents use primary DC in at least 25% of patients with ASDH. In addition, of the 22 neurosurgical units with at least two Consultant respondents, only three units (14%) showed intradepartmental agreement regarding the proportion of their patients receiving a primary DC for ASDH. Conclusion. The survey results demonstrate that there is significant uncertainty as to the optimal surgical technique for primary evacuation of ASDH. The fact that the majority of the respondents are willing to become collaborators in the planned RESCUE-ASDH trial highlights the relevance of this important subject to the neurosurgical community in the UK and Ireland.	[Kolias, A. G.; Scotton, W. J.; Hutchinson, P. J.] Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Kolias, A. G.; Scotton, W. J.; Menon, D. K.; Hutchinson, P. J.] Univ Cambridge, Cambridge, England; [Belli, A.] Queen Elizabeth Hosp, NIHR Ctr Surg Reconstruct & Microbiol, Birmingham B15 2TH, W Midlands, England; [Belli, A.] Univ Birmingham, Birmingham, W Midlands, England; [King, A. T.] Salford Royal Hosp, Div Neurosurg, Manchester, Lancs, England; [King, A. T.] Univ Manchester, Manchester, Lancs, England; [Brennan, P. M.] Western Gen Hosp, Dept Clin Neurosci, Div Neurosurg, Edinburgh EH4 2XU, Midlothian, Scotland; [Brennan, P. M.] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Bulters, D. O.] Southampton Univ Hosp, Div Neurosurg, Southampton, Hants, England; [Bulters, D. O.] Univ Southampton, Southampton, Hants, England; [Eljamel, M. S.] Ninewells Hosp, Div Neurosurg, Dundee DD1 9SY, Scotland; [Eljamel, M. S.] Univ Dundee, Dundee, Scotland; [Wilson, M. H.] St Marys Hosp, Div Neurosurg, London, England; [Wilson, M. H.] Univ London Imperial Coll Sci Technol & Med, London, England; [Papadopoulos, M. C.] Univ London St Georges Hosp, Div Neurosurg, London, England; [Papadopoulos, M. C.] St Georges Univ London, London, England; [Mendelow, A. D.] Royal Victoria Infirm, Div Neurosurg, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Mendelow, A. D.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Menon, D. K.] Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 0QQ, England		Kolias, AG (corresponding author), Addenbrookes Hosp, Div Neurosurg, Box 167,Level 3,A Block, Cambridge CB2 0QQ, England.	angeloskolias@gmail.com	Belli, Antonio/I-3799-2015; Bulters, Diederik/ABH-3573-2020; Mendelow, Alexander/AAW-2878-2021; King, Andrew/AAR-1656-2020	Belli, Antonio/0000-0002-3211-9933; Bulters, Diederik/0000-0001-9884-9050; Corteen, Elizabeth/0000-0002-3069-9655; Scotton, William/0000-0003-0607-3190; King, Andrew/0000-0002-6546-7248; Eljamel, Muftah Salem (Sam)/0000-0002-1491-0094; Wilson, Mark/0000-0002-2346-4911; Kolias, Angelos/0000-0003-3992-0587; Papadopoulos, Marios/0000-0001-9174-4176	Academic Foundation Programme (Neurosciences), Cambridge Academic Training Office, School of Clinical Medicine, University of Cambridge; Royal College of Surgeons of England Research Fellowship; Freemasons; Rosetrees TrustRosetrees Trust; NIHR Academic Clinical Fellowship; Raymond and Beverly Sackler Studentship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, ACF-2011-14-003] Funding Source: researchfish	WJS is supported by an Academic Foundation Programme (Neurosciences), Cambridge Academic Training Office, School of Clinical Medicine, University of Cambridge. AGK is supported by a Royal College of Surgeons of England Research Fellowship (funded by the Freemasons and the Rosetrees Trust), an NIHR Academic Clinical Fellowship and a Raymond and Beverly Sackler Studentship. DKM is an NIHR Senior Investigator. PJH is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship and the NIHR Cambridge Biomedical Research Centre.	[Anonymous], 2007, HEAD INJ TRIAG ASS I; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Kenning TJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0960; Kolias AG, 2012, ACTA NEUROCHIR, V154, P1563, DOI 10.1007/s00701-012-1349-6; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; Marion DW, 2006, NEUROSURGERY, V58, P655; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	11	30	30	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2013	27	3					330	333		10.3109/02688697.2013.779365			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	136HR	WOS:000318353500008	23530712				2022-02-06	
J	Yonutas, HM; Sullivan, PG				Yonutas, Heather M.; Sullivan, Patrick G.			Targeting PPAR Isoforms Following CNS Injury	CURRENT DRUG TARGETS			English	Article						Mitochondria; mitoNEET; traumatic brain injury; spinal cord injury; excitotoxicity; neuroinflammation	TRAUMATIC BRAIN-INJURY; ACTIVATED-RECEPTOR-ALPHA; SPINAL-CORD-INJURY; GAMMA AGONIST ROSIGLITAZONE; MITOCHONDRIAL PERMEABILITY TRANSITION; OXIDATIVE DAMAGE; PROTEIN MITONEET; ADULT RATS; PROLIFERATOR; MECHANISMS	A major focus has developed for the discovery of proregenerative and neuroprotective therapeutic agents to help the millions of Americans who receive a CNS injury annually. Tribulations have been encountered along the way due to the complicated set of pathways that are initiated post-injury. To target this complicated multifaceted signaling cascade, the most promising therapeutics target multiple pathways involved in the secondary injury cascade, such as neuroinflammation, the generation of ROS and mitochondrial dysfunction. Compelling experimental data demonstrates that mitochondrial dysfunction is a pivotal link in the neuropathological sequelae of brain injury. A group of PPAR agonists, specifically rosiglitazone and pioglitazone, have shown an extreme amount of promise in the realm of drug discovery for CNS injury due to their ability to increase functional recovery and decrease lesion volumes following injury. The therapeutic effects of these PPAR agonists are thought to be a direct result of PPAR activity however new data is arising that shows some of the effects may be independent of PPAR activity, targeting a novel mitochondrial protein called mitoNEET. In this review, a thorough evaluation of the role of PPAR and mitoNEET in rosiglitazone and pioglitazone mediated neuroprotection will be completed in order to shed light on the mechanism of a new possible therapeutic intervention for CNS injury.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Sullivan, PG (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Chandler Coll Med, 475 BBSRB,741 South Limestone St, Lexington, KY 40536 USA.	patsullivan@uky.edu					Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso E, 2013, BBA-MOL BASIS DIS, V1832, P1241, DOI 10.1016/j.bbadis.2013.03.006; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Benani A, 2004, NEUROSCI LETT, V369, P59, DOI 10.1016/j.neulet.2004.07.056; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Bhateja DK, 2012, EUR J PHARMACOL, V674, P33, DOI 10.1016/j.ejphar.2011.10.029; Bieganski RM, 2011, J MOL GRAPH MODEL, V29, P965, DOI 10.1016/j.jmgm.2011.04.001; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Bright JJ, 2008, PPAR RES, V2008, DOI 10.1155/2008/658520; Brightt JJ, 2008, EXPERT OPIN THER TAR, V12, P1565, DOI [10.1517/14728220802515400, 10.1517/14728220802515400 ]; Cabrera JA, 2012, TRANSL RES, V159, P383, DOI 10.1016/j.trsl.2011.11.001; Cabrero A., 2002, Current Drug Targets - Inflammation and Allergy, V1, P243, DOI 10.2174/1568010023344616; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Colca JR, 2004, AM J PHYSIOL-ENDOC M, V286, pE252, DOI 10.1152/ajpendo.00424.2003; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; Crisafulli C, 2009, J PHARMACOL EXP THER, V331, P796, DOI 10.1124/jpet.109.156646; Crisafulli C, 2009, SHOCK, V32, P62, DOI 10.1097/SHK.0b013e31818bbad6; Cuzzocrea S, 2008, MOL PHARMACOL, V73, P323, DOI 10.1124/mol.107.041475; Cuzzocrea S, 2006, J LEUKOCYTE BIOL, V79, P999, DOI 10.1189/jlb.0605341; Deplanque D, 2003, J NEUROSCI, V23, P6264; Desvergne B, 2004, MOL ENDOCRINOL, V18, P1321, DOI 10.1210/me.2004-0088; Divakaruni AS, 2013, P NATL ACAD SCI USA, V110, P5422, DOI 10.1073/pnas.1303360110; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Erickson MA, 2012, NEUROIMMUNOMODULAT, V19, P121, DOI 10.1159/000330247; Esposito E, 2012, SPINE, V37, pE73, DOI 10.1097/BRS.0b013e3182276d88; Esposito E, 2011, EXPERT OPIN THER TAR, V15, P943, DOI 10.1517/14728222.2011.581231; Frazier-Wood AC, 2012, PHARMACOGENOMICS J; Gao W, 2013, MOL MED REP, V7, P862, DOI 10.3892/mmr.2013.1282; Geldenhuys WJ, 2011, BIOORG MED CHEM LETT, V21, P5498, DOI 10.1016/j.bmcl.2011.06.111; Glaser J, 2004, J NEUROSCI RES, V77, P701, DOI 10.1002/jnr.20204; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Guan YF, 2002, DRUG NEWS PERSPECT, V15, P147, DOI 10.1358/dnp.2002.15.3.840011; Halestrap AP, 2006, BIOCHEM SOC T, V34, P232, DOI 10.1042/BST0340232; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hall MG, 2008, PPAR RES, V2008, DOI 10.1155/2008/780452; Heun R, 2012, INT J MOL EPIDEMIOL, V3, P39; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Martin HL, 2012, EXP NEUROL, V235, P528, DOI 10.1016/j.expneurol.2012.02.017; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Meng B, 2011, J INT MED RES, V39, P805, DOI 10.1177/147323001103900313; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Morales-Garcia JA, 2011, GLIA, V59, P293, DOI 10.1002/glia.21101; Moreno S, 2004, NEUROSCIENCE, V123, P131, DOI 10.1016/j.neuroscience.2003.08.064; Muia C, 2006, SHOCK, V25, P17, DOI 10.1097/01.shk.0000186930.95227.4f; Nadra K, 2006, MOL CELL BIOL, V26, P3266, DOI 10.1128/MCB.26.8.3266-3281.2006; Neher MD, 2012, PPAR RES, V2012, DOI 10.1155/2012/728461; Pajoohesh-Ganji A, 2011, NEUROTHERAPEUTICS, V8, P195, DOI 10.1007/s13311-011-0036-2; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Paterniti I, 2010, J PHARMACOL EXP THER, V333, P465, DOI 10.1124/jpet.110.165605; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Roth AD, 2003, J NEUROSCI RES, V72, P425, DOI 10.1002/jnr.10596; SAKAKI S, 1986, STROKE, V17, P196, DOI 10.1161/01.STR.17.2.196; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schnegg CI, 2013, FREE RADICAL BIO MED, V61, P1, DOI 10.1016/j.freeradbiomed.2013.03.002; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sood HS, 2003, AM J PHYSIOL-LUNG C, V284, pL333, DOI 10.1152/ajplung.00183.2002; Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Tan NS, 2007, MOL CELL BIOL, V27, P7161, DOI 10.1128/MCB.00436-07; Tate CC, 2007, EXP NEUROL, V207, P13, DOI 10.1016/j.expneurol.2007.05.008; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Tian XY, 2012, DIABETES, V61, P3285, DOI 10.2337/db12-0117; Tyagi S, 2011, J ADV PHARM TECHNOL, V2, P236, DOI 10.4103/2231-4040.90879; Varanyuwatana P, 2012, MITOCHONDRION, V12, P120, DOI 10.1016/j.mito.2011.04.006; White AT, 2010, J NEUROCHEM, V115, P845, DOI 10.1111/j.1471-4159.2010.06999.x; Wilson JL, 2012, PPAR RES, V2012, DOI 10.1155/2012/645969; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang Q, 2011, NEUROSCIENCES, V16, P46; Zhang Q, 2010, NEUROL RES, V32, P852, DOI 10.1179/016164110X12556180206112	90	30	31	0	22	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-4501			CURR DRUG TARGETS	Curr. Drug Targets	JUN	2013	14	7					733	742		10.2174/1389450111314070003			10	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	150IQ	WOS:000319384200003	23627890				2022-02-06	
J	Coelho, C; Le, Ke; Mozeiko, J; Hamilton, M; Tyler, E; Krueger, F; Grafman, J				Coelho, Carl; Le, Karen; Mozeiko, Jennifer; Hamilton, Mark; Tyler, Elizabeth; Krueger, Frank; Grafman, Jordan			Characterizing Discourse Deficits Following Penetrating Head Injury: A Preliminary Model	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						traumatic brain injury; language disorders; memory; executive functions; pragmatics	TRAUMATIC BRAIN-INJURY; NARRATIVE DISCOURSE; EXECUTIVE FUNCTIONS; MEASURING GOODNESS; STORY NARRATIVES; ELICITATION TASK; WORKING-MEMORY; LANGUAGE; ABILITIES; CHILDREN	Purpose: Discourse analyses have demonstrated utility for delineating subtle communication deficits following closed head injuries (CHIs). The present investigation examined the discourse performance of a large group of individuals with penetrating head injury (PHI). Performance was also compared across 6 subgroups of PHI based on lesion locale. A preliminary model of discourse production following PHI was proposed and tested. Method: Story narratives were elicited from 2 groups of participants, 167 with PHI and 46 non brain-injured (NBI). Micro- and macrostructural components of each story were analyzed. Measures of memory, executive functions, and intelligence were also administered. All measures were compared across groups and PHI subgroups. The proposed model of discourse production was tested with a structural equation modeling procedure. Results: No differences for the discourse measures were noted across the six PHI subgroups. Three measures distinguished the PHI and NBI groups: narrative length, story grammar, and completeness. The proposed model of discourse production had an adequate-to-good fit with the cognitive and discourse data. Conclusion: In spite of differing mechanisms of injury, the PHI group's discourse performance was consistent with what has been reported for individuals with CHI. The model tested represents a preliminary step toward understanding discourse production following traumatic brain injury.	[Coelho, Carl; Le, Karen; Mozeiko, Jennifer; Hamilton, Mark; Tyler, Elizabeth] Univ Connecticut, Storrs, CT 06269 USA; [Krueger, Frank] George Mason Univ, Fairfax, VA 22030 USA; [Grafman, Jordan] Rehabil Inst Chicago, Chicago, IL USA		Coelho, C (corresponding author), Univ Connecticut, Storrs, CT 06269 USA.	coelho@uconn.edu		Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F31DC012748] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F31 DC012748] Funding Source: Medline		Barrett J., 1998, OLD MCDONALD HAD APA, V2nd; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Brookshire R. H., 1993, DISCOURSE COMPREHENS; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; Clark LA, 1995, PSYCHOL ASSESSMENT, V7, P309, DOI 10.1037/1040-3590.7.3.309; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho C, 2012, NEUROPSYCHOLOGIA, V50, P3564, DOI 10.1016/j.neuropsychologia.2012.09.005; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Cohen J., 2013, STAT POWER ANAL BEHA; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Delis DC., 2001, DELIS KAPLAN EXECUTI; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dimitrov M, 1999, NEUROPSYCHOLOGY, V13, P135, DOI 10.1037/0894-4105.13.1.135; Duff MC, 2012, SEMIN SPEECH LANG, V33, P44, DOI 10.1055/s-0031-1301162; Ferstl EC, 2008, HUM BRAIN MAPP, V29, P581, DOI 10.1002/hbm.20422; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gernsbacher M.A, 1990, LANGUAGE COMPREHENSI; Gernsbacher Morton Ann, 1999, Discourse Stud, V1, P355, DOI 10.1177/1461445699001003004; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; HUNT KW, 1970, MONOGR SOC RES CHILD, V35, P1; Kaplan E, 1983, BOSTON NAMING TEST; Kenny D. A., 2012, STRUCTURAL EQUATION; Kline R.B., 2011, PRINCIPLES PRACTICE, V3rd; Le K, 2012, AM J SPEECH-LANG PAT, V21, pS115, DOI 10.1044/1058-0360(2012/11-0114); Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; Le K, 2011, J SPEECH LANG HEAR R, V54, P118, DOI 10.1044/1092-4388(2010/09-0022); LILES BZ, 1995, J SPEECH HEAR RES, V38, P415, DOI 10.1044/jshr.3802.415; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Liles BZ, 1998, ANAL DISCOURSE COMMU, P65; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Miyake A, 2012, CURR DIR PSYCHOL SCI, V21, P8, DOI 10.1177/0963721411429458; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; MOHR JP, 1980, NEUROLOGY, V30, P1273, DOI 10.1212/WNL.30.12.1273; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; Mullen, 2008, ELECT J BUSINESS RES, V6, P53, DOI DOI 10.21427/D7CF7R; PLAG JA, 1967, PERS PSYCHOL, V20, P323, DOI 10.1111/j.1744-6570.1967.tb01527.x; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SCHWARTZCOWLEY R, 1989, TOP LANG DISORD, V9, P1, DOI 10.1097/00011363-198903000-00003; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Stein N. L., 1979, NEW DIRECTIONS DISCO, P53; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; U. S. Department of Defense, 1984, TEST MAN ARM SERV VO; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Wechsler D., 1997, WECHSLER INTELLIGENC; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wertheimer JC, 2008, ARCH PHYS MED REHAB, V89, P1983, DOI 10.1016/j.apmr.2008.04.010; Ylioja S, 2010, CLIN NEUROPSYCHOL, V24, P1097, DOI 10.1080/13854046.2010.516021; Ylvisaker M., 2008, LANGUAGE INTERVENTIO, P879; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951; Zafonte RD, 1997, BRAIN INJURY, V11, P403	59	30	31	0	8	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY 1	2013	22	2					S438	S448		10.1044/1058-0360(2013/12-0076)			11	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	156LD	WOS:000319822600017	23695915	Green Accepted			2022-02-06	
J	Hylin, MJ; Orsi, SA; Rozas, NS; Hill, JL; Zhao, J; Redell, JB; Moore, AN; Dash, PK				Hylin, Michael J.; Orsi, Sara A.; Rozas, Natalia S.; Hill, Julia L.; Zhao, Jing; Redell, John B.; Moore, Anthony N.; Dash, Pramod K.			Repeated Mild Closed Head Injury Impairs Short-Term Visuospatial Memory and Complex Learning	JOURNAL OF NEUROTRAUMA			English	Article						active place avoidance; axonal injury; context discrimination; neuroinflammation	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; FLUID PERCUSSION INJURY; ACTIVE PLACE AVOIDANCE; DORSAL HIPPOCAMPUS; COGNITIVE IMPAIRMENT; HISTOLOGICAL-CHANGES; PATTERN SEPARATION; FOOTBALL PLAYERS; MOUSE MODEL	Concussive force can cause neurocognitive and neurobehavioral dysfunction by inducing functional, electrophysiological, and/or ultrastructural changes within the brain. Although concussion-triggered symptoms typically subside within days to weeks in most people, in 15%-20% of the cases, symptomology can continue beyond this time point. Problems with memory, attention, processing speed, and cognitive flexibility (e.g., problem solving, conflict resolution) are some of the prominent post-concussive cognitive symptoms. Repeated concussions (with loss or altered consciousness), which are common to many contact sports, can exacerbate these symptoms. The pathophysiology of repeated concussions is not well understood, nor is an effective treatment available. In order to facilitate drug discovery to treat post-concussive symptoms (PCSs), there is a need to determine if animal models of repeated mild closed head injury (mCHI) can mimic the neurocognitive and histopathological consequences of repeated concussions. To this end, we employed a controlled cortical impact (CCI) device to deliver a mCHI directly to the skull of mice daily for 4 days, and examined the ensuing neurological and neurocognitive functions using beam balance, foot-fault, an abbreviated Morris water maze test, context discrimination, and active place avoidance tasks. Repeated mCHI exacerbated vestibulomotor, motor, short-term memory and conflict learning impairments as compared to a single mCHI. Learning and memory impairments were still observed in repeated mCHI mice when tested 3 months post-injury. Repeated mCHI also reduced cerebral perfusion, prolonged the inflammatory response, and in some animals, caused hippocampal neuronal loss. Our results show that repeated mCHI can reproduce some of the deficits seen after repeated concussions in humans and may be suitable for drug discovery studies and translational research.	[Hylin, Michael J.; Orsi, Sara A.; Rozas, Natalia S.; Hill, Julia L.; Zhao, Jing; Redell, John B.; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Med Sch Houston, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Dash, Pramod K.] Univ Texas Med Sch Houston, Vivian L Smith Dept Neurosurg, Houston, TX 77225 USA		Dash, PK (corresponding author), Univ Texas Med Sch Houston, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019	Dash, Pramod/0000-0001-6746-1002; Hill, Julia/0000-0003-4744-0532; Rozas, Natalia/0000-0003-0848-0478	Institute for Rehabilitation and Research/Mission Connect; Vivian L. Smith Foundation; Gilson-Longenbaugh Foundation	This work was supported by The Institute for Rehabilitation and Research/Mission Connect; The Vivian L. Smith Foundation and the Gilson-Longenbaugh Foundation.	Aoyama N, 2008, BRAIN RES, V1230, P310, DOI 10.1016/j.brainres.2008.07.006; Baki SGA, 2009, BRAIN RES, V1280, P98, DOI 10.1016/j.brainres.2009.05.034; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Blum S, 1999, J NEUROSCI, V19, P3535; Burghardt NS, 2012, HIPPOCAMPUS, V22, P1795, DOI 10.1002/hipo.22013; Chen ZY, 2012, J NEUROTRAUM, V29, P268, DOI 10.1089/neu.2011.2057; Cimadevilla JM, 2000, NEUROSCI LETT, V285, P53, DOI 10.1016/S0304-3940(00)01019-3; Cimadevilla JM, 2001, P NATL ACAD SCI USA, V98, P3531, DOI 10.1073/pnas.051628398; Cimadevilla JM, 2001, BRAIN RES BULL, V54, P559, DOI 10.1016/S0361-9230(01)00448-8; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; d'Hemecourt P, 2011, CLIN SPORTS MED, V30, pviii; d'Hemecourt P, 2011, CLIN SPORT MED, V30, P63, DOI 10.1016/j.csm.2010.08.008; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Faul M, 2010, TRAUMATIC BRAIN INJU; Frankland PW, 1998, BEHAV NEUROSCI, V112, P863, DOI 10.1037/0735-7044.112.4.863; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	51	30	30	0	37	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		716	726		10.1089/neu.2012.2717			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600004	23489238				2022-02-06	
J	Laxe, S; Zasler, N; Selb, M; Tate, R; Tormos, JM; Bernabeu, M				Laxe, Sara; Zasler, Nathan; Selb, Melissa; Tate, Robyn; Tormos, Jose M.; Bernabeu, Montserrat			Development of the International Classification of Functioning, Disability and Health core sets for traumatic brain injury: An International consensus process	BRAIN INJURY			English	Article						Traumatic brain injury; ICF; ICF core sets; functioning and disability; consensus conference	QUALITY-OF-LIFE; CONCEPTUAL DESCRIPTION; UNIFYING MODEL; ICF; TBI	Background: In a patient-oriented healthcare system, the integration of the functional status of the patient from the perspective of different professionals is understandable by the use of the International Classification of Functioning, Disability and Health. Objective: A formal decision-making and consensus process is presented to develop the first version of the International Classification on Functioning, Disability and Health (ICF) Core Sets for Traumatic Brain Injury. Method: A panel with the results from preparatory studies that included a literature review, a qualitative study, empirical data collection and an expert survey, was presented. A consensus conference was held in Barcelona, March 2010 and 23 professionals attended representing nine countries. Results: The preparatory studies identified 183 eligible categories. After the voting process, 139 constituted the Comprehensive Core Sets for TBI and 23 the Brief Core Sets for TBI. Conclusions: The consensus conference led to the integration of evidence and expert opinion based on the ICF. The adoption of the ICF Core Sets for TBI provides a basic international standard for the multidisciplinary assessment of a TBI patient's functioning.	[Laxe, Sara; Bernabeu, Montserrat] Univ Autonoma Barcelona, Brain Injury Unit, Inst Guttmann, Badalona 08916, Spain; [Zasler, Nathan] Concuss Care Ctr Virginia Ltd, Richmond, VA USA; [Zasler, Nathan] Tree Life Serv Inc, Richmond, VA USA; [Selb, Melissa] Guido A Zaech Inst GZI, Swiss Parapleg Res, ICF Res Branch Cooperat World Hlth Org Family Int, DIMDI, Nottwil, Switzerland; [Tate, Robyn] Univ Sydney, Sydney Med Sch, Northern Clin Sch, Rehabil Studies Unit, Ryde, NSW, Australia; [Tormos, Jose M.] Univ Autonoma Barcelona, Res Dept, Inst Guttmann, Badalona 08916, Spain		Laxe, S (corresponding author), Univ Autonoma Barcelona, Brain Injury Unit, Inst Guttmann, Cami Can Ruti Sn, Badalona 08916, Spain.	slaxe@guttmann.com		Tormos Munoz, Jose Maria/0000-0002-8764-2289			Alachini B, 2010, EUR J PHYS REHAB MED, V46, P27; Alguren B, 2012, NEUROREHAB NEURAL RE, V26, P266, DOI 10.1177/1545968311414204; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Brage S, 2008, DISABIL REHABIL, V30, P1392, DOI 10.1080/09638280701642950; Cerniauskaite M, 2011, DISABIL REHABIL, V33, P281, DOI 10.3109/09638288.2010.529235; Cieza A, 2004, J REHABIL MED, V36, P9, DOI 10.1080/16501960410015353; Cieza A, 2010, SPINAL CORD, V48, P305, DOI 10.1038/sc.2009.183; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Ewert T, 2005, DISABIL REHABIL, V27, P367, DOI 10.1080/09638280400014014; Fleming J, 2011, BRAIN INJURY, V25, P806, DOI 10.3109/02699052.2011.585508; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Geyh S, 2004, J REHABIL MED, V36, P135, DOI 10.1080/16501960410016776; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Koskinen S, 2011, COMPARISON OF SUBJEC; Koskinen S, 2007, J REHABIL MED, V39, P467, DOI 10.2340/16501977-0077; Labi MLC, 2003, BRAIN INJURY, V17, P265, DOI 10.1080/0269905021000038410; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laxe S, 2012, CLIN NEUROLOGY NEURO; Laxe S, 2011, NEUROREHABILITATION, V29, P99, DOI 10.3233/NRE-2011-0683; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Pistarini C, 2011, DISABIL REHABIL, V33, P2333, DOI 10.3109/09638288.2011.570414; Rauch A, 2008, EUR J PHYS REHAB MED, V44, P329; Salter K, 2011, BRAIN INJURY, V25, P1147, DOI 10.3109/02699052.2011.613088; Stucki G, 2008, EUR J PHYS REHAB MED, V44, P315; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; Stucki G, 2007, J REHABIL MED, V39, P279, DOI 10.2340/16501977-0041; Stucki G, 2007, J REHABIL MED, V39, P286, DOI 10.2340/16501977-0044; Sveen U, 2012, PROBLEMS IN FUNCTION; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	32	30	32	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					379	387		10.3109/02699052.2012.750757			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300001	23472615				2022-02-06	
J	Leonardi, M; Sattin, D; Raggi, A				Leonardi, Matilde; Sattin, Davide; Raggi, Alberto		Italian Natl Consortium Functionin	An Italian population study on 600 persons in vegetative state and minimally conscious state	BRAIN INJURY			English	Article						Vegetative state; minimally conscious state; anatomical therapeutic chemical classification system; pain; children	TRAUMATIC BRAIN-INJURY; PLACEBO-CONTROLLED TRIAL; LIFE EXPECTANCY; CLINICAL CHARACTERISTICS; RECOVERY; CHILDREN; OUTCOMES; COMA; REHABILITATION; PREVALENCE	Objective: To describes socio-demographic and clinical features of adults and children in vegetative state (VS) and minimally conscious state (MCS). Design: Observational cross-sectional study. Methods: Demographic, aetiological and clinical data were collected, together with patients' management procedures. Mann-Whitney U-test was used for continuous variables and chi-squared test for categorical variables. Results: Six hundred patients (69.7% in VS; 6% children) were enrolled. No difference regarding age at enrolment, age at acute event and disease duration was observed between VS and MCS. Disease duration was superior to 10 years for 3.3% of the whole sample and 64.3-77% of cases had a non-traumatic aetiology. Mean number of drugs per adult patient was four and decreased consistently with increased disease duration. Discussion: Patients with VS and MCS were similar for age at acute event and at enrolment, both over 50 years, as well as for the frequency of non-traumatic aetiology. Disease duration was similar for both conditions and 2.6% of VS and 4.8% of MCS patients survived for more than 10 years. Finally care and treatment needs are similar and not related to diagnosis.	[Leonardi, Matilde; Sattin, Davide; Raggi, Alberto; Italian Natl Consortium Functionin] Neurol Inst C Besta IRCCS Fdn, Neurol Publ Hlth & Disabil Unit, I-20133 Milan, Italy		Leonardi, M (corresponding author), Neurol Inst C Besta IRCCS Fdn, Neurol Publ Hlth & Disabil Unit, Via Celoria 11, I-20133 Milan, Italy.	leonardi@istituto-besta.it	Raggi, Alberto/K-5787-2016; Sattin, Davide/K-5963-2016; leonardi, matilde/J-9997-2018	Raggi, Alberto/0000-0002-7433-7779; Sattin, Davide/0000-0001-7736-4337; leonardi, matilde/0000-0003-0552-8923	Italian Centre for Disease Control and Prevention (Centro Nazionale per la Prevenzione ed il Controllo delle Malattie - 2009), Ministry of Health, Italy	The authors report no conflicts of interest. The study was supported by a Grant of the Italian Centre for Disease Control and Prevention (Centro Nazionale per la Prevenzione ed il Controllo delle Malattie - 2009), Ministry of Health, Italy.	[Anonymous], 2003, Clin Med (Lond), V3, P249; Ashford S, 2000, Physiother Res Int, V5, P202, DOI 10.1002/pri.199; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Ashwal S, 2005, NEUROPSYCHOL REHABIL, V15, P190, DOI 10.1080/09602010443000281; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Avesani R, 2006, BRAIN INJURY, V20, P333, DOI 10.1080/02699050500487605; Beaumont JG, 2005, NEUROPSYCHOL REHABIL, V15, P184, DOI 10.1080/09602010443000489; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Demertzi A, 2009, PROG BRAIN RES, V177, P329, DOI 10.1016/S0079-6123(09)17722-1; Di Carlo A, 2003, CEREBROVASC DIS, V16, P141, DOI 10.1159/000070594; DUBROJA I, 1995, J NEUROL NEUROSUR PS, V58, P465, DOI 10.1136/jnnp.58.4.465; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Fantini MP, 2010, BRAIN INJURY, V24, P620, DOI 10.3109/02699051003652831; Fins JJ, 2007, ARCH NEUROL-CHICAGO, V64, P1400, DOI 10.1001/archneur.64.10.1400; Georgiopoulos M, 2010, STEREOT FUNCT NEUROS, V88, P199, DOI 10.1159/000314354; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2005, PROG BRAIN RES, V150, P381, DOI 10.1016/S0079-6123(05)50027-X; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; International Organization for Standardization, 2002, TECHN AIDS PERS DIS; Jennett B, 2002, J NEUROL NEUROSUR PS, V73, P355, DOI 10.1136/jnnp.73.4.355; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kassubek J, 2003, J NEUROL SCI, V212, P85, DOI 10.1016/S0022-510X(03)00106-0; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2009, PROG BRAIN RES, V177, pXIII, DOI 10.1016/S0079-6123(09)17736-1; Leong B, 2002, BRAIN INJURY, V16, P169, DOI 10.1080/02699050110103292; Leong B, 2002, BRAIN INJURY, V16, P217, DOI 10.1080/02699050110103283; Lin LC, 2008, J CLIN NURS, V17, P861, DOI 10.1111/j.1365-2702.2006.01883.x; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Machado C, 2011, CAN J NEUROL SCI, V38, P341, DOI 10.1017/S0317167100011562; McMahon MA, 2009, AM J PHYS MED REHAB, V88, P525, DOI 10.1097/PHM.0b013e3181a5ade3; Ministry of Health of Italy, 2009, REP TECHN SCI COMM V; MULLER U, 1994, PROG NEURO-PSYCHOPH, V18, P1103, DOI 10.1016/0278-5846(94)90114-7; Ng YS, 2005, NEUROREHABILITATION, V20, P97; O'Neil-Pirozzi TM, 2003, BRAIN INJURY, V17, P389, DOI 10.1080/0269905031000070251; Oliveira L, 2011, BRAIN INJURY, V25, P315, DOI 10.3109/02699052.2011.556103; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Pistoia F, 2010, CNS DRUGS, V24, P625, DOI 10.2165/11535940-000000000-00000; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; Sacco S, 2011, BRAIN INJURY, V25, P488, DOI 10.3109/02699052.2011.558043; Saout V., 2010, Annals of Physical and Rehabilitation Medicine, V53, P96, DOI 10.1016/j.rehab.2010.01.002; Schnakers C, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.124099; Schnakers C, 2012, AAPS J, V14, P437, DOI 10.1208/s12248-012-9346-5; Schnakers C, 2000, CURRENT OPINION NEUR, V20, P620; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Singh R, 2008, BRAIN INJURY, V22, P103, DOI 10.1080/02699050701829704; Snyman N, 2010, NEUROPEDIATRICS, V41, P223, DOI 10.1055/s-0030-1269893; Stepan C, 2004, EUR J NEUROL, V11, P461, DOI 10.1111/j.1468-1331.2004.00817.x; Stocchetti N, 2010, MINERVA ANESTESIOL, V76, P1052; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; TRESCH DD, 1991, ARCH INTERN MED, V151, P930, DOI 10.1001/archinte.151.5.930; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Weeks DL, 2011, ARCH PHYS MED REHAB, V92, P683, DOI 10.1016/j.apmr.2010.12.026; *WHO, 2002, INT CLASS DIS 9 REV; WHO Collaborating Centre for Drug Statistics Methodology, 2012, AN THER CHEM ATC CLA; Wilson FC, 2002, NEUROREHABILITATION, V17, P231; Wittenberg GF, 2009, DEV MED CHILD NEUROL, V51, P130, DOI 10.1111/j.1469-8749.2009.03425.x	68	30	32	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2013	27	4					473	484		10.3109/02699052.2012.750758			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	117LG	WOS:000316954300012	23472633				2022-02-06	
J	Nordstrom, A; Edin, BB; Lindstrom, S; Nordstrom, P				Nordstrom, Anna; Edin, Benoni B.; Lindstroem, Sara; Nordstrom, Peter			Cognitive function and other risk factors for mild traumatic brain injury in young men: nationwide cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COLLABORATING-CENTER; TWINS DISCORDANT; TASK-FORCE; INTELLIGENCE; VALIDATION	Objective To investigate cognitive function and other risk factors for mild traumatic brain injury in young men. Design Nationwide prospective cohort study. Setting Sweden. Participants 305 885 men conscripted for military service from 1989 to 1994. Main outcome measure mild traumatic brain injuries in relation to cognitive function and other potential risk factors assessed at conscription and follow-up. Results Men with one mild traumatic brain injury within two years before (n=1988) or after cognitive testing (n=2214) had about 5.5% lower overall cognitive function scores than did men with no mild traumatic brain injury during follow up (P<0.001 for both). Moreover, men with at least two mild traumatic brain injuries after cognitive testing (n=795) had 15% lower overall cognitive function scores compared with those with no such injury (P<0.001). Independent strong risk factors (P<1x10(-10)) for at least one mild traumatic brain injury after cognitive testing (n=12 494 events) included low overall cognitive function, a previous mild traumatic brain injury, hospital admission for intoxications, and low education and socioeconomic status. In a sub-cohort of twin pairs in which one twin had a mild traumatic brain injury before cognitive testing (n=63), both twins had lower logical performance and technical performance compared with men in the total cohort with no mild traumatic brain injury (P<0.05 for all). Conclusion Low cognitive function, intoxications, and factors related to low socioeconomic status were strong independent risk factors for mild traumatic brain injuries in men. The low cognitive function in twin pairs discordant for mild traumatic brain injury suggests a genetic component to the low cognitive function associated with such injuries. The study included only men, so inferences to women should be made with caution.	[Nordstrom, Anna; Nordstrom, Peter] Umea Univ, Dept Community Med & Rehabil, SE-90187 Umea, Sweden; [Edin, Benoni B.] Umea Univ, Physiol Sect, Dept Integrat Med Biol, SE-90187 Umea, Sweden; [Lindstroem, Sara] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA		Nordstrom, A (corresponding author), Umea Univ, Dept Community Med & Rehabil, SE-90187 Umea, Sweden.	anna.nordstrom@idrott.umu.se	Edin, Benoni B/AAI-3964-2020; Edin, Benoni/D-1057-2009; Nordstrom, Anna/O-2504-2018; Nordstrom, Anna/F-2238-2010	Edin, Benoni B/0000-0001-9010-5612; Edin, Benoni/0000-0001-9010-5612; Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Anna/0000-0003-3534-456X; Nordstrom, Peter/0000-0003-2924-508X	Swedish Research CouncilSwedish Research CouncilEuropean Commission	The study was funded by the Swedish Research Council. The researchers conducted this study totally independently of the funding body.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andersen L. B., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P143; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; Ashman TA, 2006, MT SINAI J MED, V73, P999; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brinch CN, 2012, P NATL ACAD SCI USA, V109, P425, DOI 10.1073/pnas.1106077109; CARLSTEDT B, 1993, SCAND J PSYCHOL, V34, P353, DOI 10.1111/j.1467-9450.1993.tb01131.x; Carlstedt B, 2005, SCAND J PSYCHOL, V46, P31, DOI 10.1111/j.1467-9450.2005.00432.x; Carlstedt B., 2000, COGNITIVE ABILITIES; Davies G, 2011, MOL PSYCHIATR, V16, P996, DOI 10.1038/mp.2011.85; Deary IJ, 2007, INTELLIGENCE, V35, P13, DOI 10.1016/j.intell.2006.02.001; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Heckman JJ, 2006, SCIENCE, V312, P1900, DOI 10.1126/science.1128898; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Murray C. J., 1996, GLOBAL HLTH STAT COM; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; National Institute of Neurological Disorders and Stroke, 2002, NIH PUBL, V02-158; Nordstrom A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001151; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	28	30	30	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 13	2013	346								f723	10.1136/bmj.f723			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	108VQ	WOS:000316324700012	23482939	hybrid, Green Submitted			2022-02-06	
J	Di Pietro, V; Amorini, AM; Tavazzi, B; Hovda, DA; Signoretti, S; Giza, CC; Lazzarino, G; Vagnozzi, R; Lazzarino, G; Belli, A				Di Pietro, Valentina; Amorini, Angela M.; Tavazzi, Barbara; Hovda, David A.; Signoretti, Stefano; Giza, Christopher C.; Lazzarino, Giacomo; Vagnozzi, Roberto; Lazzarino, Giuseppe; Belli, Antonio			Potentially neuroprotective gene modulation in an in vitro model of mild traumatic brain injury	MOLECULAR AND CELLULAR BIOCHEMISTRY			English	Article						Mild traumatic brain injury; Gene expression; Mitochondrial dysfunction; Hypometabolism; Hibernation; Neuroprotection	LOW-FLOW ISCHEMIA; MITOCHONDRIAL DYSFUNCTION; TEMPORAL WINDOW; ENERGY-METABOLISM; OXIDATIVE STRESS; NO-FLOW; HIBERNATION; DAMAGE; VULNERABILITY; DEPRESSION	In this study, we investigated the hypothesis that mild traumatic brain injury (mTBI) triggers a controlled gene program as an adaptive response finalized to neuroprotection, similar to that found in hibernators and in ischemic preconditioning. A stretch injury device was used to produce an equi-biaxial strain field in rat organotypic hippocampal slice cultures at a specified Lagrangian strain of 10 % and a constant strain rate of 20 s(-1). After 24 h from injury, propidium iodide staining, HPLC analysis of metabolites and microarray analysis of cDNA were performed to evaluate cell viability, cell energy state and gene expression, respectively. Compared to control cultures, 10 % stretch injured cultures showed no change in viability, but demonstrated a hypometabolic state (decreased ATP, ATP/ADP, and nicotinic coenzymes) and a peculiar pattern of gene modulation. The latter was characterized by downregulation of genes encoding for proteins of complexes I, III, and IV of the mitochondrial electron transport chain and of ATP synthase; downregulation of transcriptional and translational genes; downregulation and upregulation of genes controlling the synthesis of glutamate and GABA receptors, upregulation of calmodulin and calmodulin-binding proteins; proper modulation of genes encoding for proapoptotic and antiapoptotic proteins. These results support the hypothesis that, following mTBI, a hibernation-type response is activated in non-hibernating species. Unlike in hibernators and ischemic preconditioning, this adaptive gene programme, aimed at achieving maximal neuroprotection, is not triggered by decrease in oxygen availability. It seems rather activated to avoid increase in oxidative/nitrosative stress and apoptosis during a transient period of mitochondrial malfunctioning.	[Di Pietro, Valentina; Belli, Antonio] Univ Birmingham, Neuropharmacol & Neurobiol Sect, Sch Clin & Expt Med, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Di Pietro, Valentina] Univ Southampton, Sch Med, Div Clin Neurosci, Southampton, Hants, England; [Amorini, Angela M.; Tavazzi, Barbara; Lazzarino, Giacomo] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr, Dept Neurosurg,Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Signoretti, Stefano] San Camillo Hosp, Div Neurosurg, Dept Neurosci Head & Neck Surg, Rome, Italy; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Injury Res Ctr,Mattel Childrens Hosp, Div Pediat Neurol,Dept Neurosurg, Los Angeles, CA 90095 USA; [Vagnozzi, Roberto] Univ Roma Tor Vergata, Div Neurotraumatol & Neuroradiol, Dept Biomed & Prevent, Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Div Biochem & Mol Biol, Dept Biol Geol & Environm Sci, Viale A Doria 6, I-95125 Catania, Italy		Lazzarino, G (corresponding author), Univ Catania, Div Biochem & Mol Biol, Dept Biol Geol & Environm Sci, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@unict.it	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; Belli, Antonio/I-3799-2015; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; Belli, Antonio/0000-0002-3211-9933; Di Pietro, Valentina/0000-0001-9430-4723; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279; Lazzarino, Giacomo/0000-0003-1639-0966	Wessex Medical Research Centre; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD004612] Funding Source: NIH RePORTER	We wish to thank the Wessex Medical Research Centre for funding this study and for their support to our research. We also wish to thank Ms. Kathryn Rasco for her technical assistance in the manuscript preparation.	Arun P, 2010, J NEUROTRAUM, V27, P293, DOI 10.1089/neu.2009.0994; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Blackstone E, 2005, SCIENCE, V308, P518, DOI 10.1126/science.1108581; BOCHAROVA LS, 1992, COMP BIOCHEM PHYS B, V101, P189, DOI 10.1016/0305-0491(92)90177-S; Boczek T, 2012, MOL CELL BIOCHEM, V360, P89, DOI 10.1007/s11010-011-1047-3; Buck PW, 2011, HEALTH SOC WORK, V36, P299, DOI 10.1093/hsw/36.4.299; Budinger GRS, 1998, J BIOL CHEM, V273, P3320, DOI 10.1074/jbc.273.6.3320; Chen JP, 2008, COMP BIOCHEM PHYS B, V149, P388, DOI 10.1016/j.cbpb.2007.10.011; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Depre C, 2007, HEART FAIL REV, V12, P307, DOI 10.1007/s10741-007-9040-3; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Dickinson BC, 2011, NAT CHEM BIOL, V7, P504, DOI [10.1038/NCHEMBIO.607, 10.1038/nchembio.607]; Domeniconi M, 2005, J NEUROL SCI, V233, P43, DOI 10.1016/j.jns.2005.03.023; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; Ferrari R, 1996, CIRCULATION, V94, P2587, DOI 10.1161/01.CIR.94.10.2587; Frerichs KU, 1998, P NATL ACAD SCI USA, V95, P14511, DOI 10.1073/pnas.95.24.14511; Giza CC, 2002, J NEUROTRAUM, V19, P387, DOI 10.1089/08977150252932352; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hardeland R, 2009, MOLECULES, V14, P5054, DOI 10.3390/molecules14125054; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Jay G W, 1996, J Insur Med, V27, P262; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kim DY, 2001, MOL CELL NEUROSCI, V17, P1025, DOI 10.1006/mcne.2001.0988; Kim GS, 2012, J CEREBR BLOOD F MET, V32, P720, DOI 10.1038/jcbfm.2011.176; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; Levy RJ, 2007, SHOCK, V28, P24, DOI 10.1097/01.shk.0000235089.30550.2d; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MacDonald JA, 1999, BIOCHEM BIOPH RES CO, V254, P424, DOI 10.1006/bbrc.1998.9960; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Nystul TG, 2004, P NATL ACAD SCI USA, V101, P9133, DOI 10.1073/pnas.0403312101; Ranaivo HR, 2011, J NEUROTRAUM, V28, P1757, DOI 10.1089/neu.2011.1799; Ross AP, 2006, J CEREBR BLOOD F MET, V26, P1148, DOI 10.1038/sj.jcbfm.9600271; SCHULZ R, 1995, CIRC RES, V76, P942, DOI 10.1161/01.RES.76.6.942; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singh BK, 2011, MOL CELL BIOCHEM, V357, P373, DOI 10.1007/s11010-011-0908-0; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Soustiel JF, 2010, NEUROTHERAPEUTICS, V7, P13, DOI 10.1016/j.nurt.2009.11.001; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Storey KB, 2004, BIOL REV, V79, P207, DOI 10.1017/S1464793103006195; STOREY KB, 1990, SCI AM, V263, P92, DOI 10.1038/scientificamerican1290-92; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; TEASDALE G, 1974, LANCET, V2, P81; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Van Damme K, 2003, BRAIN RES, V960, P1, DOI 10.1016/S0006-8993(02)03672-7; Vroom MB, 1996, J CARDIOTHOR VASC AN, V10, P789, DOI 10.1016/S1053-0770(96)80209-6; WANG LCH, 1988, CRYOBIOLOGY, V25, P355, DOI 10.1016/0011-2240(88)90043-0; Wang SQ, 2002, J EXP BIOL, V205, P2957; Williams DR, 2005, PHYSIOL GENOMICS, V24, P13, DOI 10.1152/physiolgenomics.00301.2004; Zhao HWW, 2006, J NEUROSCI RES, V84, P291, DOI 10.1002/jnr.20893; Zhou F, 2001, AM J PATHOL, V158, P2145, DOI 10.1016/S0002-9440(10)64686-X	63	30	30	0	28	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-8177	1573-4919		MOL CELL BIOCHEM	Mol. Cell. Biochem.	MAR	2013	375	1-2					185	198		10.1007/s11010-012-1541-2			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	077MR	WOS:000314032300020	23242602				2022-02-06	
J	Iverson, KM; Pogoda, TK; Gradus, JL; Street, AE				Iverson, Katherine M.; Pogoda, Terri K.; Gradus, Jaimie L.; Street, Amy E.			Deployment-Related Traumatic Brain Injury Among Operation Enduring Freedom/Operation Iraqi Freedom Veterans: Associations with Mental and Physical Health by Gender	JOURNAL OF WOMENS HEALTH			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; PSYCHIATRIC DIAGNOSES; RESILIENCE INVENTORY; SERVICE MEMBERS; WAR VETERANS; COMBAT; MILITARY; AFGHANISTAN; CONCUSSION	Background: Traumatic brain injury (TBI) research among Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) veterans has focused primarily on men. We examine associations between probable deployment-related TBI and postdeployment mental and physical health symptoms separately by gender. To identify unique associations of probable TBI with health symptoms, analyses were also conducted separately for veterans with and without probable posttraumatic stress disorder (PTSD). Methods: A mail survey, including self-report measures of probable deployment-related TBI and mental and physical health symptoms, was completed by 2348 OEF/OIF veterans (51% female), sampled randomly within gender from a national roster. We conducted logistic regressions stratified by gender and probable PTSD status to evaluate associations between probable TBI and health symptoms. Results: Of the respondents, 10.7% of women and 19.7% of men screened positive for probable deployment-related TBI. Probable TBI was significantly associated with increased risk of mental and physical health symptoms for both genders, even after adjusting for potential confounders. Odds ratios for the associations of probable TBI with health symptoms ranged between 2.63 and 9.20 for women and between 1.94 and 7.44 for men. Among veterans with probable PTSD, symptomatic anxiety and symptomatic physical health remained associated with probable TBI. Among veterans without probable PTSD, TBI remained strongly associated with all health symptoms for women and symptomatic anxiety and physical health for men, suggesting an association between TBI and some health symptoms independent of PTSD. Conclusions: Strong associations between probable TBI and health symptoms for women and men confirm the importance of screening for TBI and treatment of associated health symptoms for all OEF/OIF veterans.	[Iverson, Katherine M.; Gradus, Jaimie L.; Street, Amy E.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA; [Iverson, Katherine M.; Gradus, Jaimie L.; Street, Amy E.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Gradus, Jaimie L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA		Iverson, KM (corresponding author), VA Boston Healthcare Syst, 150 S Huntington Ave 116B-3, Boston, MA 02130 USA.	katherine.iverson@va.gov	; Pogoda, Terri/F-6243-2012	Street, Amy/0000-0003-4554-9075; Pogoda, Terri/0000-0003-1397-8780; Gradus, Jaimie/0000-0003-1459-5327	National Center for PTSD, Mental Health Services, Department of Veterans Affairs; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development (HSRD) ServicesUS Department of Veterans Affairs [CDA 10-029]	This research was supported by the National Center for PTSD, Mental Health Services, Department of Veterans Affairs. The funding agency was not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript. Additionally, the research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development (HSR&D) Services as part of Dr. Katherine Iverson's HSR&D Career Development Award (CDA 10-029). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.	ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carlson KF, 2010, J HEAD TRAUMA REHAB, V26, P103; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs, 2009, VA DOD CLIN PRACT GU; Dillman D.A., 2007, MAIL INTERNET SURVEY, V2; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Hendricks AM, 2013, BRAIN INJURY, V27, P125, DOI 10.3109/02699052.2012.729284; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King D. W., 2003, MANUAL DEPLOYMENT RI; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Mattocks KM, 2012, SOC SCI MED, V74, P537, DOI 10.1016/j.socscimed.2011.10.039; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2012, PTSD MILD TRAUMATIC, P199; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Smith B, 2007, AM J EPIDEMIOL, V166, P1345, DOI 10.1093/aje/kwm212; Street AE, J GEN INTER IN PRESS; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T., 2008, INVISIBLE WOUNDS WAR; U.S. General Accounting Office, 2008, GAO08276; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers F., 1993, INT SOC TRAUM STRESS; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	51	30	30	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	MAR	2013	22	3					267	275		10.1089/jwh.2012.3755			9	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	105IU	WOS:000316061700134	23421581				2022-02-06	
J	Wang, XY; Tang, SS; Hu, M; Long, Y; Li, YQ; Liao, MX; Ji, H; Hong, H				Wang, Xiao Yun; Tang, Su Su; Hu, Mei; Long, Yan; Li, Yong Qi; Liao, Ming Xing; Ji, Hui; Hong, Hao			Leukotriene D4 induces amyloid-beta generation via CysLT(1)R-mediated NF-kappa B pathways in primary neurons	NEUROCHEMISTRY INTERNATIONAL			English	Article						LTD4; CysLT(1)R; NF-kappa B; BACE1; A beta	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; CYSTEINYL-LEUKOTRIENES; ASTROCYTE PROLIFERATION; MOUSE MODEL; SECRETASE; RECEPTORS; PROTEIN; BACE1; 5-LIPOXYGENASE	Although the pathogenesis of sporadic Alzheimer's disease (AD) is not clearly understood, neuroinflammation has been known to play a role in the pathogenesis of AD. To investigate a functional link between the neuroinflammation and AD, the effect of leukotriene D4 (LTD4), an inflammatory lipid mediator, was studied on amyloid-beta generation in vitro. Application of LTD4 to cell monolayers at concentrations up to 40 nM LTD4 caused increases in the A beta releases. Concentrations >= 40 nM LTD4 decreased neuronal viability. Application of 20 nM LTD4 caused a significant increase in A beta generation, as assessed by ELISA or Western blotting, without significant cytotoxicity. At this concentration, exposure of neurons to LTD4 for 24 h produced maximal effect in the A beta generation, and significant increases in the expressions of cysteinyl leukotriene 1 receptor (CysLT(1)R) and activity of beta- or gamma-secretase with complete abrogation by the selective CysLT(1)R antagonist pranlukast. Exposure of neurons to LTD4 for 1 h showed activation of NF-kappa B pathway, by assessing the levels of p65 or phospho-p65 in the nucleus, and either CysLT(1)R antagonist pranlukast or NF-kappa B inhibitor PDTC prevented the nuclear translocation of p65 and the consequent phosphorylation. PDTC also inhibited LTD4-induced elevations of beta- or gamma-secretase activity and All generation in vitro. Overall, our data show for the first time that LTD4 causes A beta production by enhancement of beta- or gamma-secretase resulting from activation of CysLT(1)R-mediated NF-kappa B signaling pathway. These findings provide a novel pathologic link between neuroinflammation and AD. (C) 2013 Elsevier Ltd. All rights reserved.	[Wang, Xiao Yun; Tang, Su Su; Hu, Mei; Long, Yan; Li, Yong Qi; Liao, Ming Xing; Ji, Hui; Hong, Hao] China Pharmaceut Univ, Dept Pharmacol, Lab Diabet & Brain Dis, Nanjing 210009, Jiangsu, Peoples R China		Hong, H (corresponding author), China Pharmaceut Univ, Dept Pharmacol, Nanjing 210009, Jiangsu, Peoples R China.	haohongchina@hotmail.com			college graduate research and innovation projects; Jiangsu Province, China	This work was supported by the college graduate research and innovation projects funded by Jiangsu Province, China.	Ait-Ghezala G, 2007, EUR J NEUROSCI, V25, P1685, DOI 10.1111/j.1460-9568.2007.05424.x; Back M, 2011, PHARMACOL REV, V63, P539, DOI 10.1124/pr.110.004184; Bisgaard H, 2001, ALLERGY, V56, P7, DOI 10.1034/j.1398-9995.56.s66.2.x; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Buggia-Prevot V, 2008, J BIOL CHEM, V283, P10037, DOI 10.1074/jbc.M706579200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capra V, 2004, PHARMACOL RES, V50, P1, DOI 10.1016/j.phrs.2003.12.012; Chami L, 2012, J BIOL CHEM, V287, P24573, DOI 10.1074/jbc.M111.333054; Chinnici CM, 2007, NEUROBIOL AGING, V28, P1457, DOI 10.1016/j.neurobiolaging.2006.06.007; Cho HJ, 2009, FASEB J, V23, P2639, DOI 10.1096/fj.08-126383; Choi DY, 2012, NEUROCHEM INT, V60, P68, DOI 10.1016/j.neuint.2011.11.005; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Ding Q, 2007, ACTA PHARMACOL SIN, V28, P945, DOI 10.1111/j.1745-7254.2007.00576.x; Firuzi O, 2008, FASEB J, V22, P1169, DOI 10.1096/fj.07-9131.com; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Guglielmotto M., 2010, NEUROBIOL AGING, V196, pe13; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Huang XJ, 2008, GLIA, V56, P27, DOI 10.1002/glia.20588; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ikonomovic MD, 2008, J HISTOCHEM CYTOCHEM, V56, P1065, DOI 10.1369/jhc.2008.951855; Jiang LY, 2012, CNS NEUROSCI THER, V18, P659, DOI 10.1111/j.1755-5949.2012.00341.x; Kawano T, 2003, J ALLERGY CLIN IMMUN, V112, P369, DOI 10.1067/mai.2003.1636; Lammers CH, 1996, J NEUROCHEM, V66, P147; Lee J.W., 2008, J NEUROINFLAMM, V29, P5; Lynch KR, 1999, NATURE, V399, P789; Morris AAM, 1998, LANCET, V352, P1487, DOI 10.1016/S0140-6736(05)60322-4; ORNING L, 1980, J BIOL CHEM, V255, P8023; Palop JJ, 2010, NAT NEUROSCI, V13, P812, DOI 10.1038/nn.2583; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Sala A, 2001, BIOCHEM BIOPH RES CO, V283, P1003, DOI 10.1006/bbrc.2001.4865; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Singh RK, 2010, PHARMACOLOGY, V85, P336, DOI 10.1159/000312669; Suzuki S, 2008, PHARMACOLOGY, V81, P221, DOI 10.1159/000112866; Thompson C, 2006, AM J RESP CELL MOL, V35, P697, DOI 10.1165/rcmb.2005-0407OC; Townsend KP, 2005, FASEB J, V19, P1592, DOI 10.1096/fj.04-3620rev; Uz T, 1998, FASEB J, V12, P439, DOI 10.1096/fasebj.12.6.439; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; Walch L, 2000, AM J RESP CRIT CARE, V161, pS107, DOI 10.1164/ajrccm.161.supplement_1.ltta-21; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Zhang J, 2006, ACTA PHARMACOL SIN, V27, P1553, DOI 10.1111/j.1745-7254.2006.00458.x; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088	45	30	34	1	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	FEB	2013	62	3					340	347		10.1016/j.neuint.2013.01.002			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	105BX	WOS:000316041700016	23318673				2022-02-06	
J	Dijkers, M; Brandstater, M; Horn, S; Ryser, D; Barrett, R				Dijkers, Marcel; Brandstater, Murray; Horn, Susan; Ryser, David; Barrett, Ryan			Inpatient rehabilitation for traumatic brain injury: The influence of age on treatments and outcomes	NEUROREHABILITATION			English	Article						Traumatic brain injuries; severity; rehabilitation; aging; hospitalization; mortality; activities of daily living; therapies	OLDER-ADULTS; GALVESTON ORIENTATION; SEVERITY; INTENSITY; ILLNESS; LENGTH	BACKGROUND: Elderly persons with traumatic brain injury (TBI) are increasingly admitted to inpatient rehabilitation, but we have limited knowledge of their characteristics, the treatments they receive, and their short-term and medium-term outcomes. This study explored these issues by means of comparisons between age groups. METHODS: Data on 1419 patients admitted to 9 inpatient rehabilitation facilities for initial rehabilitation after TBI were collected by means of (1) abstraction from medical records; (2) point-of care forms completed by therapists after each treatment session; and (3) interviews at 3 months and 9 months after discharge, conducted with the patient or a proxy. RESULTS: Elderly persons (65 or older) had a lower brain injury severity, and a shorter length of stay (LOS) in acute care. During rehabilitation, they received fewer hours of therapy, due to a shorter LOS and fewer hours of treatment per day, especially from psychology and therapeutic recreation. They regained less functional ability during and after inpatient rehabilitation, and had a very high mortality rate. CONCLUSIONS: Elderly people can be rehabilitated successfully, and discharged back to the community. The treatment therapists deliver, and issues surrounding high mortality need further research.	[Dijkers, Marcel] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Brandstater, Murray] Loma Linda Univ, Dept Phys Med & Rehabil, Loma Linda, CA 92350 USA; [Horn, Susan; Barrett, Ryan] Inst Clin Outcomes Res, Salt Lake City, UT USA; [Ryser, David] Intermt Med Ctr, Murray, UT USA		Dijkers, M (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.	marcel.dijkers@mssm.edu		Dijkers, Marcel/0000-0002-8362-5596	National Institute on Child Health and Human developmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R01HD050439-03]; National Institute on Disability and Rehabilitation Research [H133A080023]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD050439] Funding Source: NIH RePORTER	This research was supported by grant 5R01HD050439-03 from the National Institute on Child Health and Human development to the Institute for Clinical Outcomes Research and grant H133A080023 from the National Institute on Disability and Rehabilitation Research to Ohio State University.	AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; Corrigan J. D., 2011, THE JOURNAL OF HEAD, V27, P391; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Dijkers M, 2008, BRAIN INJURY PROFESS, V5, P14; Faul M, 2010, TRAUMATIC BRAIN INJU; Felicetti T, 2008, J HEAD TRAUMA REHAB, V23, P137, DOI 10.1097/01.HTR.0000319929.84590.40; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Goldstein F. C., 2005, REHABILITATION TRAUM, P235; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Hartholt KA, 2011, J NEUROTRAUM, V28, P739, DOI 10.1089/neu.2010.1488; Heinemann Allen W, 1994, Top Stroke Rehabil, V1, P1; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Hirshson C. I., 2012, NEUROREHABILITATION; Horn S. D., 2012, ARCHIVES OF PHYSICAL, V93; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; Horn SD, 2010, MED CARE, V48, pS17, DOI 10.1097/MLR.0b013e3181d57473; Lawes D, 2002, INJURY, V33, P349, DOI 10.1016/S0020-1383(02)00075-X; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007	31	30	30	1	12	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	2					233	252		10.3233/NRE-130841			20	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	115ZT	WOS:000316851900005	23535785				2022-02-06	
J	Matsuoka, Y; Nishi, D; Noguchi, H; Kim, Y; Hashimoto, K				Matsuoka, Yutaka; Nishi, Daisuke; Noguchi, Hiroko; Kim, Yoshiharu; Hashimoto, Kenji			Longitudinal Changes in Serum Brain-Derived Neurotrophic Factor in Accident Survivors with Posttraumatic Stress Disorder	NEUROPSYCHOBIOLOGY			English	Article						Brain-derived neurotrophic factor; Posttraumatic stress disorder; Accident survivors	LONG-TERM POTENTIATION; SOCIAL DEFEAT; BDNF; DEPRESSION; INJURY; SCALE; ANTIDEPRESSANTS; EXPRESSION; CLINICIAN; DISTRESS	Background: This prospective cohort study investigated the serum levels of brain-derived neurotrophic factor (BDNF), which mediates synaptic plasticity crucial for fear memory extinction, in patients severely injured in motor vehicle accidents (MVAs). Method: A nested, case-controlled study was conducted with 103 MVA survivors: 8 medication-naive patients who met the criteria for full diagnosis of posttraumatic stress disorder (PTSD) at 6 months after MVA, 10 medication-naive patients with partial PTSD and 85 patients with no PTSD. PTSD was evaluated by the Clinician-Administered PTSD Scale (CAPS). Serum BDNF levels were measured shortly after the MVA (baseline) and at 6-month follow-up. Results: Posttrauma serum BDNF levels differed between the 3 groups after controlling for age and sex (F = 3.41, p = 0.04), with unexpectedly higher serum BDNF levels seen in the full-PTSD group compared with the no-PTSD group. Additional analysis of patients with serum samples taken at baseline and at 6 months revealed the full-PTSD group had significantly higher serum BDNF levels over the 6 months than the no-PTSD group after controlling for age and sex (F = 6.44, p < 0.01). A positive correlation was seen between changes in serum BDNF levels over 6 months and the CAPS score at 6 months (r = 0.26, p = 0.014). Conclusions: The findings of this study, the first to report longitudinal serum BDNF levels in MVA survivors, suggest that elevated serum BDNF levels could be a biomarker of PTSD after a traumatic event. Copyright (c) 2013 S. Karger AG, Basel	[Matsuoka, Yutaka; Noguchi, Hiroko] Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Kodaira, Tokyo 1878551, Japan; [Matsuoka, Yutaka; Nishi, Daisuke; Kim, Yoshiharu] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Tokyo, Japan; [Matsuoka, Yutaka; Nishi, Daisuke] Natl Disaster Med Ctr, Dept Psychiat, Tokyo, Japan; [Matsuoka, Yutaka; Nishi, Daisuke; Noguchi, Hiroko; Kim, Yoshiharu; Hashimoto, Kenji] Japan Sci & Technol Agcy, CREST, Tokyo, Japan; [Hashimoto, Kenji] Chiba Univ, Div Clin Neurosci, Ctr Forens Mental Hlth, Chiba, Japan		Matsuoka, Y (corresponding author), Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878551, Japan.	yutaka@ncnp.go.jp	Nishi, Daisuke/AAH-7211-2019; Matsuoka, Yutaka/N-1588-2019; Hashimoto, Kenji/I-5800-2015	Nishi, Daisuke/0000-0001-9349-3294; Matsuoka, Yutaka/0000-0002-8690-8129; Hashimoto, Kenji/0000-0002-8892-0439	Japanese Ministry of Health, Labor and WelfareMinistry of Health, Labour and Welfare, Japan [16190501, 19230701, 2030701]; Intramural Research grant for neurological and psychiatric disorders from NCNP [24-4]; CREST, Japan Science and Technology AgencyJapan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST); Ministry of Health, Labor and Welfare of JapanMinistry of Health, Labour and Welfare, Japan; Takeda Pharmaceutical Company LtdTakeda Pharmaceutical Company Ltd; Suntory Wellness Ltd; Eli Lilly Japan KKEli Lilly; Otsuka Pharmaceutical Co., Ltd.Otsuka Pharmaceutical; Toray Industries, Inc.Toray Industries, Inc.; Foundation for Total Health PromotionFoundation for Total Health Promotion; Qol Co., Ltd; NTT DoCoMo, Inc.; Japan Science and Technology AgencyJapan Science & Technology Agency (JST); CRESTCore Research for Evolutional Science and Technology (CREST); GlaxoSmithKline, JapanGlaxoSmithKline; DHA & EPA Association	We especially thank Mss. Akutsu and Kamoshida for clinical data management and Ms. T. Ishima for technical assistance with BDNF measurements. This work was supported by grants from the Japanese Ministry of Health, Labor and Welfare (Research on Psychiatric and Neurological Disease and Mental Health: 16190501, 19230701 and 2030701), an Intramural Research grant (24-4) for neurological and psychiatric disorders from NCNP and CREST, Japan Science and Technology Agency.; Y.M. received research support from the Japan Science and Technology Agency, CREST, and the Ministry of Health, Labor and Welfare of Japan, an Intramural Research grant for neurological and psychiatric disorders from NCNP and lecture fees from Takeda Pharmaceutical Company Ltd, Suntory Wellness Ltd, Eli Lilly Japan KK and Otsuka Pharmaceutical Co., Ltd. D.N. received research support from Toray Industries, Inc. and the Foundation for Total Health Promotion and lecture fees from Qol Co., Ltd, the DHA & EPA Association and NTT DoCoMo, Inc.. Y.K. received research support from the Japanese Ministry of Health, Labour and Welfare, Japan Science and Technology Agency and CREST and received a grant from GlaxoSmithKline, Japan. He has been a speaker for GlaxoSmithKline, Pfizer, Meiji Seika Pharma, Yoshitomi Pharmaceutical and Meiji Yasuda Insurance Co.. The other two authors reported no biomedical financial interests or potential conflicts of interest.	Asukai N, 2002, J NERV MENT DIS, V190, P175, DOI 10.1097/00005053-200203000-00006; Asukai N., 2003, JAP J TRAUM STRESS, V1, P47; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Berger W, 2010, PROG NEURO-PSYCHOPH, V34, P1279, DOI 10.1016/j.pnpbp.2010.07.008; Berger W, 2009, PROG NEURO-PSYCHOPH, V33, P169, DOI 10.1016/j.pnpbp.2008.12.004; Berton O, 2006, SCIENCE, V311, P864, DOI 10.1126/science.1120972; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Chen LY, 2010, J NEUROSCI, V30, P15097, DOI 10.1523/JNEUROSCI.3549-10.2010; Dell'Osso L, 2009, PROG NEURO-PSYCHOPH, V33, P899, DOI 10.1016/j.pnpbp.2009.04.018; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Eisch AJ, 2003, BIOL PSYCHIAT, V54, P994, DOI 10.1016/j.biopsych.2003.08.003; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Hauck S, 2010, PROG NEURO-PSYCHOPH, V34, P459, DOI 10.1016/j.pnpbp.2010.01.010; Hauck S, 2009, REV BRAS PSIQUIATR, V31, P48, DOI 10.1590/S1516-44462009000100012; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Krishnan V, 2007, CELL, V131, P391, DOI 10.1016/j.cell.2007.09.018; Kugaya A, 1998, JPN J CLIN ONCOL, V28, P333, DOI 10.1093/jjco/28.5.333; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Matsuoka Y, 2009, SOC PSYCH PSYCH EPID, V44, P341; Matsuoka Y, 2011, PSYCHOTHER PSYCHOSOM, V80, P310, DOI 10.1159/000322980; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Peters J, 2010, SCIENCE, V328, P1288, DOI 10.1126/science.1186909; Ressler KJ, 2007, NAT NEUROSCI, V10, P1116, DOI 10.1038/nn1944; Saruta J, 2010, STRESS, V13, P53, DOI 10.3109/10253890902875167; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Shimizu E, 2003, BIOL PSYCHIAT, V54, P70, DOI 10.1016/S0006-3223(03)00181-1; Takei S, 2011, J PSYCHIATR RES, V45, P460, DOI 10.1016/j.jpsychires.2010.08.009; Weiss Daniel S., 1997, P399; Yamadori A., 1985, SHINKEISHINRIGAKU, V1, P82; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	34	30	30	0	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0302-282X			NEUROPSYCHOBIOLOGY	Neuropsychobiology		2013	68	1					44	50		10.1159/000350950			7	Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	178YE	WOS:000321482500005	23774996				2022-02-06	
J	Sveen, U; Ostensjo, S; Laxe, S; Soberg, HL				Sveen, Unni; Ostensjo, Sigrid; Laxe, Sara; Soberg, Helene L.			Problems in functioning after a mild traumatic brain injury within the ICF framework: the patient perspective using focus groups	DISABILITY AND REHABILITATION			English	Article						Functioning; ICF; patient perspective; traumatic brain injury	QUALITY-OF-LIFE; POST-CONCUSSION SYMPTOMS; INTERNATIONAL CLASSIFICATION; HEALTH ICF; RHEUMATOID-ARTHRITIS; CORE SETS; DISABILITY; SEVERITY; RECOVERY; OUTCOMES	Purpose: To describe problems in body functions, activities, and participation and the influence of environmental factors as experienced after mild traumatic brain injury (TBI), using the ICF framework. To compare our findings with the Brief and Comprehensive ICF Core Sets for TBI. Methods: Six focus-group interviews were performed with 17 participants (nine women, eight men, age ranged from 22 to 55 years) within the context of an outpatient rehabilitation programme for patients with mild TBI. The interviews were transcribed verbatim and analysed using the ICF. Results: One-hundred and eight second-level categories derived from the interview text, showing a large diversity of TBI-related problems in functioning. Problems in cognitive and emotional functions, energy and drive, and in carrying out daily routine and work, were frequently reported. All ICF categories reported with high-to-moderate frequencies were present in the Brief ICF Core Set and 84% in the Comprehensive ICF Core Set. The reported environmental factors mainly concerned aspects of health and social security systems, social network and attitudes towards the injured person. Conclusions: This study confirms the diversity of problems and the environmental factors that have an impact on post-injury functioning of patients with mild TBI.	[Sveen, Unni; Soberg, Helene L.] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0424 Oslo, Norway; [Sveen, Unni; Ostensjo, Sigrid; Soberg, Helene L.] Oslo & Akershus Univ Coll Appl Sci, Fac Hlth Sci, Oslo, Norway; [Laxe, Sara] Univ Autonoma Barcelona, Guttmann Inst Hosp Neurorehabil, Badalona, Spain		Sveen, U (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, POB 4950 Nydalen, N-0424 Oslo, Norway.	unni.sveen@uus.no			Norwegian Ministry of Health and Care Services	The study is part of a "Return to work" project initiated by the Norwegian Directorate of Health and the Norwegian Ministry of Labour and funded by the Norwegian Ministry of Health and Care Services.	Agan J, 2008, WORK, V31, P259; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; [Anonymous], 2010, ICF CORE SETS TBI; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Broomhall LGJ, 2009, J NERV MENT DIS, V197, P178, DOI 10.1097/NMD.0b013e318199fe7f; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Coenen M, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1956; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Koskinen S, 2007, J REHABIL MED, V39, P467, DOI 10.2340/16501977-0077; Koskinen S, 2011, DISABIL REHABIL, V33, P2464, DOI 10.3109/09638288.2011.574776; Kvale S, 1999, KVALITATIVE FORSKNIN; Lane-Brown AT, 2009, NEUROPSYCHOL REHABIL, V19, P481, DOI 10.1080/09602010902949207; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laxe S, 2011, NEUROREHABILITATION, V29, P99, DOI 10.3233/NRE-2011-0683; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Okochi Jiro, 2005, Health Qual Life Outcomes, V3, P46, DOI 10.1186/1477-7525-3-46; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Petchprapai Nutthita, 2007, J Neurosci Nurs, V39, P260; Pistarini C, 2011, DISABIL REHABIL, V33, P2333, DOI 10.3109/09638288.2011.570414; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ptyushkin P, 2010, BRAIN INJURY, V24, P1519, DOI 10.3109/02699052.2010.523054; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Soberg HL, 2008, DISABIL REHABIL, V30, P98, DOI 10.1080/09638280701216862; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stucki G, 2008, EUR J PHYS REHAB MED, V44, P315; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Uhlig T, 2007, ANN RHEUM DIS, V66, P1078, DOI 10.1136/ard.2006.058693; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; World Health Organization, 2007, INT CLASS FUNCT DIS	48	30	31	0	18	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2013	35	9					749	757		10.3109/09638288.2012.707741			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	118XK	WOS:000317060100007	22897238				2022-02-06	
J	Zhao, W; Ho, L; Varghese, M; Yemul, S; Dams-O'Connor, K; Gordon, W; Knable, L; Freire, D; Haroutunian, V; Pasinetti, GM				Zhao, Wei; Ho, Lap; Varghese, Merina; Yemul, Shrishailam; Dams-O'Connor, Kristen; Gordon, Wayne; Knable, Lindsay; Freire, Daniel; Haroutunian, Vahram; Pasinetti, Giulio Maria			Decreased Level of Olfactory Receptors in Blood Cells Following Traumatic Brain Injury and Potential Association with Tauopathy	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Biomarker; olfactory receptor; peripheral blood mononuclear cell; tauopathy; traumatic brain injury	ALZHEIMERS-DISEASE; MOUSE MODEL; IN-VITRO; EXPRESSION; PROTEIN; TAU; MEMORY; DISCOVERY; DEFICITS; RISK	Traumatic brain injury (TBI) is a leading cause of death and disability among children and young adults in the United States. In this study, we explored whether changes in the gene expression profile of peripheral blood mononuclear cells (PBMC) may provide a clinically assessable "window" into the brain, reflecting molecular alterations following TBI that might contribute to the onset and progression of TBI clinical complications. We identified three olfactory receptor (OR) TBI biomarkers that are aberrantly down-regulated in PBMC specimens from TBI subjects. Down-regulation of these OR biomarkers in PBMC was correlated with the severity of brain injury and TBI-specific symptoms. A two-biomarker panel comprised of OR11H1 and OR4M1 provided the best criterion for segregating the TBI and control cases with 90% accuracy, 83.3% sensitivity, and 100% specificity. We found that the OR biomarkers are ectopically expressed in multiple brain regions, including the entorhinal-hippocampus system known to play an important role in memory formation and consolidation. Activation of OR4M1 led to attenuation of abnormal tau phosphorylation, possibly through JNK signaling pathway. Our results suggested that addition of the two-OR biomarker model to current diagnostic criteria may lead to improved TBI detection for clinical trials, and decreased expression of OR TBI biomarkers might be associated with TBI-induced tauopathy. Future studies exploring the physiological relevance of OR TBI biomarkers in the normal brain and in the brain following TBI will provide a better understanding of the biological mechanisms underlying TBI and insights into novel therapeutic targets for TBI.	[Zhao, Wei; Ho, Lap; Varghese, Merina; Yemul, Shrishailam; Knable, Lindsay; Freire, Daniel; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Dams-O'Connor, Kristen; Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil, New York, NY 10029 USA; [Haroutunian, Vahram; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Yemul, Shrishailam; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA		Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA.	Giulio.Pasinetti@mssm.edu	Zhao, Wei/A-2206-2010; Varghese, Merina/H-5472-2019	Varghese, Merina/0000-0002-1517-3903; Pasinetti, Giulio/0000-0002-1524-5196; Zhao, Wei/0000-0002-3449-2395	National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029887]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138, P01AG002219] Funding Source: NIH RePORTER	This study was supported in part by discretionary funding to GMP and in part from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) (UL1RR029887).	Alberini CM, 2009, PHYSIOL REV, V89, P121, DOI 10.1152/physrev.00017.2008; [Anonymous], 2009, ALL HUM CORT STUD; Archer T, 2012, ACTA NEUROL SCAND, V125, P293, DOI 10.1111/j.1600-0404.2011.01638.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERG L, 1988, PSYCHOPHARMACOL BULL, V24, P637; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; DeMaria S, 2010, J CELL BIOL, V191, P443, DOI 10.1083/jcb.201008163; Derdikman D, 2010, TRENDS COGN SCI, V14, P561, DOI 10.1016/j.tics.2010.09.004; Eichenbaum H, 2008, HIPPOCAMPUS, V18, P1314, DOI 10.1002/hipo.20500; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Feldmesser E, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-121; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gardiner E, 2012, MOL PSYCHIATR, V17, P827, DOI 10.1038/mp.2011.78; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; Haroutunian V, 1999, ARCH NEUROL-CHICAGO, V56, P713, DOI 10.1001/archneur.56.6.713; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lovell M, 2012, NEUROPSYCHIATRY TRAU; Maes OC, 2009, J GERONTOL A-BIOL, V64, P636, DOI 10.1093/gerona/glp045; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Qu CS, 2010, J NEUROTRAUM, V27, P1625, DOI 10.1089/neu.2010.1359; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Sjogren M, 2001, J NEUROL NEUROSUR PS, V70, P624, DOI 10.1136/jnnp.70.5.624; Speciale L, 2007, NEUROBIOL AGING, V28, P1163, DOI 10.1016/j.neurobiolaging.2006.05.020; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; van Heerden Johan H, 2009, BMC Res Notes, V2, P195, DOI 10.1186/1756-0500-2-195; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wang J, 2007, J CLIN INVEST, V117, P3393, DOI 10.1172/JCI31547; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Zhao W, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-51	50	30	31	0	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2013	34	2					417	429		10.3233/JAD-121894			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	095MF	WOS:000315337900008	23241557	Green Accepted			2022-02-06	
J	Jackman, RP; Utter, GH; Muench, MO; Heitman, JW; Munz, MM; Jackman, RW; Biswas, HH; Rivers, RM; Tobler, LH; Busch, MP; Norris, PJ				Jackman, Rachael P.; Utter, Garth H.; Muench, Marcus O.; Heitman, John W.; Munz, Matthew M.; Jackman, Robert W.; Biswas, Hope H.; Rivers, Ryan M.; Tobler, Leslie H.; Busch, Michael P.; Norris, Philip J.			Distinct roles of trauma and transfusion in induction of immune modulation after injury	TRANSFUSION			English	Article							MULTIPLE ORGAN FAILURE; TUMOR-NECROSIS-FACTOR; SOLUBLE ICAM-1 CORRELATE; BLOOD-TRANSFUSION; HEMORRHAGIC-SHOCK; TISSUE TRAUMA; MAJOR INJURY; BLUNT TRAUMA; BRAIN-INJURY; T-HELPER-2-TYPE LYMPHOKINES	BACKGROUND: Trauma and transfusion can both alter immunity, and while transfusions are common among traumatically injured patients, few studies have examined their combined effects on immunity. STUDY DESIGN AND METHODS: We tracked the plasma levels of 41 immunomodulatory proteins in 56 trauma patients from time of injury up to 1 year later. In addition, a murine model was developed to distinguish between the effects of transfusion and underlying injury and blood loss. RESULTS: Thirty-one of the proteins had a significant change over time after traumatic injury, with a mixed early response that was predominantly anti-inflammatory followed by a later increase in proteins involved in wound healing and homeostasis. Results from the murine model revealed similar cytokine responses to humans. In mice, trauma and hemorrhage caused early perturbations in a number of the pro- and anti-inflammatory mediators measured, and transfusion blunted early elevations in interleukin (IL)-6, IL-10, matrix metalloproteinase-9, and interferon-?. Transfusion caused or exacerbated changes in monocyte chemotactic protein-1, IL-1a, IL-5, IL-15, and soluble E-selectin. Finally, trauma and hemorrhage alone increased CXCL1 and IL-13. CONCLUSIONS: This work provides a detailed characterization of the major shift in the immunologic environment in response to trauma and transfusion and clarifies which immune mediators are affected by trauma and hemorrhage and which by transfusion.	[Jackman, Rachael P.] Blood Syst Res Inst, San Francisco, CA 94118 USA; Univ Calif Davis, Dept Surg, Davis, CA 95616 USA; Univ Calif Davis, Dept Polit Sci, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA		Jackman, RP (corresponding author), Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.	rjackman@bloodsystems.org	Jackman, Rachael P/AAH-8398-2020; Muench, Marcus O./C-5025-2009	Jackman, Rachael P/0000-0001-8591-7819; Muench, Marcus O./0000-0001-8946-6605; Utter, Garth/0000-0001-7747-3429	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 HL-083388-01A1]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL083388] Funding Source: NIH RePORTER	This work was supported by NIH RO1 HL-083388-01A1.	ABRAHAM E, 1989, J IMMUNOL, V142, P899; ABRAHAM E, 1986, CRIT CARE MED, V14, P81, DOI 10.1097/00003246-198602000-00001; Asadullah K, 1999, ARCH DERMATOL, V135, P187, DOI 10.1001/archderm.135.2.187; Baker CC, 1998, J TRAUMA, V44, P1045; Biffl WL, 1996, ANN SURG, V224, P647, DOI 10.1097/00000658-199611000-00009; BJORNSON AB, 1978, ANN SURG, V188, P102, DOI 10.1097/00000658-197807000-00017; BURROWS L, 1982, LANCET, V2, P662; Caron A, 2005, EXP CELL RES, V310, P105, DOI 10.1016/j.yexcr.2005.07.004; Choudhry MA, 2007, INJURY, V38, P1382, DOI 10.1016/j.injury.2007.09.027; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; CONE JB, 1994, J TRAUMA, V37, P109; De AK, 2000, CLIN IMMUNOL, V96, P52, DOI 10.1006/clim.2000.4879; de Vries DK, 2009, AM J TRANSPLANT, V9, P1574, DOI 10.1111/j.1600-6143.2009.02675.x; Detmar M, 1997, J INVEST DERMATOL, V108, P263, DOI 10.1111/1523-1747.ep12286453; DIPIRO JT, 1995, ARCH SURG-CHICAGO, V130, P1159; DIPIRO JT, 1992, ANN SURG, V215, P460, DOI 10.1097/00000658-199205000-00008; DiPiro JT, 1995, ARCH SURG-CHICAGO, V130, P1162; ENDO S, 1994, CRIT CARE MED, V22, P949, DOI 10.1097/00003246-199406000-00012; FAIST E, 1993, J TRAUMA, V34, P846, DOI 10.1097/00005373-199306000-00016; FAIST E, 1986, ARCH SURG-CHICAGO, V121, P1000; Ferguson KL, 1997, ACAD EMERG MED, V4, P1035, DOI 10.1111/j.1553-2712.1997.tb03676.x; FOEX BA, 1993, INJURY, V24, P373, DOI 10.1016/0020-1383(93)90098-Q; GARDLUND B, 1995, J INFECT DIS, V172, P296, DOI 10.1093/infdis/172.1.296; Giannoudis PV, 2003, INJURY, V34, P397, DOI 10.1016/S0020-1383(02)00416-3; Giannoudis PV, 2000, INTENS CARE MED, V26, P1076, DOI 10.1007/s001340051320; GIANOTTI L, 1992, TRANSFUSION, V32, P312, DOI 10.1046/j.1537-2995.1992.32492263443.x; Golde WT, 2005, LAB ANIMAL, V34, P39, DOI 10.1038/laban1005-39; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Hess JR, 2005, CRIT CARE, V9, pS10, DOI 10.1186/cc3780; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; Hsieh CH, 2008, J IMMUNOL, V181, P2806, DOI 10.4049/jimmunol.181.4.2806; Jackman RP, 2011, CLIN VACCINE IMMUNOL, V18, P318, DOI 10.1128/CVI.00465-10; Kang SC, 2004, CYTOKINE, V26, P223, DOI 10.1016/j.cyto.2004.03.005; Kavathia N, 2009, AGING-US, V1, P652, DOI 10.18632/aging.100069; Kawasaki T, 2006, J IMMUNOL, V177, P4514, DOI 10.4049/jimmunol.177.7.4514; KEANE RM, 1983, SURG GYNECOL OBSTET, V156, P163; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Kobbe P, 2008, SHOCK, V30, P43, DOI [10.1097/SHK.0b013e31815d190b, 10.1097/SHK.0b013e318d190b]; KUKIELKA GL, 1994, ANN NY ACAD SCI, V723, P258, DOI 10.1111/j.1749-6632.1994.tb36732.x; Kuyvenhoven JP, 2004, THROMB HAEMOSTASIS, V91, P506, DOI 10.1160/TH03-05-0272; LAW MM, 1994, J TRAUMA, V37, P100, DOI 10.1097/00005373-199407000-00017; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Li LX, 2010, ANN NY ACAD SCI, V1203, P151, DOI 10.1111/j.1749-6632.2010.05555.x; LIVINGSTON DH, 1988, ARCH SURG-CHICAGO, V123, P1309; Lyons A, 1997, ANN SURG, V226, P450, DOI 10.1097/00000658-199710000-00006; MacConmara MP, 2006, ANN SURG, V244, P514, DOI 10.1097/01.sla.0000239031.06906.1f; Mack VE, 1996, ARCH SURG-CHICAGO, V131, P1303; Mannick JA, 2001, J AM COLL SURGEONS, V193, P237, DOI 10.1016/S1072-7515(01)01011-0; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; Miller SJ, 2007, AM J PHYSIOL-HEART C, V293, pH2634, DOI 10.1152/ajpheart.00397.2007; Mimasaka S, 2007, INJURY, V38, P1047, DOI 10.1016/j.injury.2007.02.045; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Moore FA, 1996, J TRAUMA, V40, P510; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Murphy TJ, 2005, J IMMUNOL, V174, P2957, DOI 10.4049/jimmunol.174.5.2957; Napolitano LA, 2005, JAIDS-J ACQ IMM DEF, V40, P581, DOI 10.1097/01.qai.0000187442.53708.b4; Ni Choileain N, 2006, J IMMUNOL, V176, P225; Nuki G, 2002, ARTHRITIS RHEUM, V46, P2838, DOI 10.1002/art.10578; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; OKUNO K, 1994, AM J SURG, V168, P340, DOI 10.1016/S0002-9610(05)80161-8; OMAHONY JB, 1984, J TRAUMA, V24, P869, DOI 10.1097/00005373-198410000-00001; OPELZ G, 1973, TRANSPLANT P, V5, P253; OSULLIVAN ST, 1995, ANN SURG, V222, P482; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Paunel-Gorgulu A, 2011, CRIT CARE, V15, DOI 10.1186/cc9965; Perl M, 2003, SHOCK, V19, P299, DOI 10.1097/00024382-200304000-00001; PINCEMAIL J, 1991, J IMMUNOL METHODS, V137, P181, DOI 10.1016/0022-1759(91)90023-9; Pirenne J, 2005, TRANSPLANTATION, V79, pS25, DOI 10.1097/01.TP.0000153295.51565.F1; Proczka RM, 2006, J PHYSIOL PHARMACOL, V57, P305; Crespo ART, 2007, BRAIN INJURY, V21, P441, DOI 10.1080/02699050701311125; Puyana JC, 1998, J TRAUMA, V44, P1037, DOI 10.1097/00005373-199806000-00017; RABINOVICI R, 1993, J TRAUMA, V35, P698, DOI 10.1097/00005373-199311000-00008; Richter V, 2003, GERONTOLOGY, V49, P293, DOI 10.1159/000071710; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; SALVATIERRA O, 1980, ANN SURG, V192, P543, DOI 10.1097/00000658-198010000-00012; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; Seekamp A, 1998, J TRAUMA, V44, P874, DOI 10.1097/00005373-199805000-00022; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sherry RM, 1996, J TRAUMA, V40, P613, DOI 10.1097/00005373-199604000-00016; Shurin GV, 2007, CYTOKINE, V39, P123, DOI 10.1016/j.cyto.2007.06.006; SINGAL DP, 1982, HUM IMMUNOL, V4, P93, DOI 10.1016/0198-8859(82)90010-6; STEPHAN RN, 1987, ARCH SURG-CHICAGO, V122, P62; STYLIANOS S, 1991, J TRAUMA, V31, P1063, DOI 10.1097/00005373-199131080-00003; Sullivan DJ, 1998, J SURG RES, V75, P54, DOI 10.1006/jsre.1997.5254; SZABO G, 1991, J CLIN IMMUNOL, V11, P326, DOI 10.1007/BF00918798; Trunkey DD, 2000, CLIN ORTHOP RELAT R, P36; Ulrich D, 2003, PLAST RECONSTR SURG, V111, P1423, DOI 10.1097/01.PRS.0000049450.95669.07; US Department of Health and Human Services, 2011, 2009 NAT BLOOD COLL; Utter GH, 2007, VOX SANG, V93, P188, DOI 10.1111/j.1423-0410.2007.00954.x; Wichmann MW, 1998, CRIT CARE MED, V26, P1372, DOI 10.1097/00003246-199808000-00024; Wichmann MW, 2000, INTENS CARE MED, V26, P167, DOI 10.1007/s001340050041; Wick M, 2000, ARCH SURG-CHICAGO, V135, P1309, DOI 10.1001/archsurg.135.11.1309; Winslow Glenn A., 1996, Journal of Burn Care and Rehabilitation, V17, P117, DOI 10.1097/00004630-199603000-00005; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Yokoyama Y, 2002, IMMUNOL RES, V26, P63, DOI 10.1385/IR:26:1-3:063; Zou Y, 2003, FASEB J, V17, P320, DOI 10.1096/fj.03-0849fje	97	30	31	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	DEC	2012	52	12					2533	2550		10.1111/j.1537-2995.2012.03618.x			18	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	056BI	WOS:000312461500007	22452342	Green Accepted			2022-02-06	
J	Pandya, NK; Edmonds, EW				Pandya, Nirav K.; Edmonds, Eric W.			Immediate Intramedullary Flexible Nailing of Open Pediatric Tibial Shaft Fractures	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						tibia fracture; open fracture; flexible nailing; immediate; infection; healing; trauma; pediatric	CHILDREN; INFECTION; NONUNION	Background: Flexible nailing has become the preferred implant for pediatric patients with tibial shaft fractures that require operative fixation. Immediate definitive fracture fixation with flexible nails in patients with high-energy, open fractures has not been examined. The purpose of our study was to determine if immediate flexible nailing of open pediatric tibial shaft fractures is safe and efficacious from a bone healing, wound, and infectious standpoint. Methods: A retrospective review of 26 tibial shaft fractures consecutively treated with flexible nailing at our institution from 2003 to 2010 was performed. Age, mechanism of injury, associated injuries, presence of compartment syndrome, antibiotic administration, systemic insults, time to union, as well as bone healing (nonunion, delayed union, malunion, leg length discrepancy, growth arrest), wound, and infectious complications were collected. Comparisons were made between patients with open fractures and those with closed fractures. Results: We identified 14 patients with open fractures and a control group of 12 patients with closed injuries who underwent flexible nailing. Patients with open fractures were more likely to have polytraumatic injuries (71.0% vs. 25.0%, P = 0.04). There was no difference (P = 1.0) in the rates of compartment syndrome (open = 14.0%, closed = 17.0%) between the 2 groups. Systemic complications (pulmonary compromise and increased intracranial pressure) were noted in 2 patients who underwent immediate nailing of their open fractures; both of whom had closed head injuries. There was no difference (P = 1.0) in the rates of wound/infectious complications between the open (7.0%) and closed (4.0%) fractures groups, with no cases of wound breakdown or osteomyelitis. There was an increased rate (P = 0.02) of bone healing complications in the open fracture group (21.0% vs. 4.0%); all in patients with Gustilo type 2 or 3 injuries. All patients achieved radiographic union at final follow-up. Conclusions: Immediate flexible nailing of open pediatric tibial shaft fractures can be safely performed with minimal risk of wound or infectious complications. Clinicians should understand that prolonged bone healing (particularly in Gustilo type 2 or 3 injuries) should be expected in patients who undergo immediate flexible nailing of their open fractures. Open tibial shaft fractures are high-energy injuries, and should be seen as surrogate markers of polytrauma in the pediatric population. The risk of compartment syndrome is high regardless of whether a patient has a closed or open tibia fracture, and caution should be used in performing flexible nailing in patients who may have closed head injury due to a risk of systemic complications. Level of Evidence: Level III, therapeutic study, retrospective cohort.	[Edmonds, Eric W.] Rady Childrens Hosp San Diego, Dept Pediat Orthopaed Surg, San Diego, CA 92123 USA; [Pandya, Nirav K.] Univ Calif San Francisco, Dept Pediat Orthopaed, Childrens Hosp & Res Ctr Oakland, Oakland, CA USA		Edmonds, EW (corresponding author), Rady Childrens Hosp San Diego, Dept Pediat Orthopaed Surg, 3030 Childrens Way,Suite 410, San Diego, CA 92123 USA.	ewedmonds@rchsd.org					Arslan H, 2002, ARCH ORTHOP TRAUM SU, V122, P494, DOI 10.1007/s00402-002-0439-y; Baldwin KD, 2009, J CHILD ORTHOP, V3, P199, DOI 10.1007/s11832-009-0169-6; Bartlett CS, 1997, J ORTHOP TRAUMA, V11, P357, DOI 10.1097/00005131-199707000-00010; BUCKLEY SL, 1990, J BONE JOINT SURG AM, V72A, P1462, DOI 10.2106/00004623-199072100-00006; Galano GJ, 2005, J PEDIATR ORTHOPED, V25, P39; Gopal S, 2000, J BONE JOINT SURG BR, V82B, P959, DOI 10.1302/0301-620X.82B7.10482; Gordon JE, 2007, J PEDIATR ORTHOPED, V27, P442, DOI 10.1097/01.bpb.0000271333.66019.5c; Grimard G, 1996, CLIN ORTHOP RELAT R, P62; GUSTILO RB, 1984, J TRAUMA, V24, P742, DOI 10.1097/00005373-198408000-00009; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HOPE PG, 1992, J BONE JOINT SURG BR, V74, P546, DOI 10.1302/0301-620X.74B4.1624514; Kakar S, 2007, J ORTHOP TRAUMA, V21, P153, DOI 10.1097/BOT.0b013e3180336923; Kubiak EN, 2005, J BONE JOINT SURG AM, V87A, P1761, DOI 10.2106/JBJS.C.01616; Lascombes P, 2006, J PEDIATR ORTHOPED, V26, P827, DOI 10.1097/01.bpo.0000235397.64783.d6; LIGIER JN, 1988, J BONE JOINT SURG BR, V70, P74, DOI 10.1302/0301-620X.70B1.3339064; Liow RYL, 2002, J PEDIATR ORTHOPED, V22, P754, DOI 10.1097/00004694-200211000-00012; Mashru RP, 2005, J AM ACAD ORTHOP SUR, V13, P345, DOI 10.5435/00124635-200509000-00008; Myers SH, 2007, J PEDIATR ORTHOPED, V27, P537, DOI 10.1097/01.bpb.0000279033.04892.25; O'Brien T, 2004, J PEDIATR ORTHOPED, V24, P601, DOI 10.1097/01241398-200411000-00001; Sankar WN, 2007, J CHILD ORTHOP, V1, P281, DOI 10.1007/s11832-007-0056-y; SHANNAK AO, 1988, J PEDIATR ORTHOPED, V8, P306, DOI 10.1097/01241398-198805000-00010; Skaggs DL, 2005, J BONE JOINT SURG AM, V87A, P8, DOI 10.2106/JBJS.C.01561; Srivastava AK, 2008, J PEDIATR ORTHOPED, V28, P152, DOI 10.1097/BPO.0b013e318165210d; Vallamshetla VRP, 2006, J BONE JOINT SURG BR, V88B, P536, DOI 10.1302/0301-620X.88B4.17363; van Oldenrijk J, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-91	25	30	31	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-6798	1539-2570		J PEDIATR ORTHOPED	J. Pediatr. Orthop.	DEC	2012	32	8					770	776		10.1097/BPO.0b013e318270468b			7	Orthopedics; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Pediatrics	037MI	WOS:000311109000010	23147618				2022-02-06	
J	Prang, KH; Ruseckaite, R; Collie, A				Prang, Khic-Houy; Ruseckaite, Rasa; Collie, Alex			Healthcare and disability service utilization in the 5-year period following transport-related traumatic brain injury	BRAIN INJURY			English	Article						Compensation; brain injury; health service use; disability	MEDICAL-CARE; OUTCOMES; REHABILITATION; TBI; COSTS	Primary objective: To describe the type, intensity and direct cost of healthcare and disability services used following transport-related traumatic brain injury (TBI). Methods and procedures: Using the transport accident compensation regulator database, claims records were examined of 423 cases of adult (18-65 years of age) transport-related TBI occurring between 1 January 1995 and 31 December 2004. Claimants were stratified by TBI severity using the Glasgow Coma Scale (GCS) score. Service utilization and costs were examined by TBI severity in the 5-year period post-injury. Main outcomes and results: Claimants accessed a total of 409 740 services. Claimants with severe TBI accessed more medical (median 333 per claimant) and paramedical services (median 436 per claimant) than claimants with mild and moderate TBI. Almost 60% of claimants with severe TBI accessed attendant care services compared to 39% and 45% of claimants with moderate and mild TBI, respectively. Average total costs of services were highest among claimants with severe TBI (AUD $324 515 per claimant). Conclusions: Healthcare service utilization and the economic burden of TBI are substantial. Injury compensation data provides a unique opportunity to explore patterns of healthcare usage post-injury, which is important for the planning and management of resources.	[Prang, Khic-Houy; Ruseckaite, Rasa; Collie, Alex] Monash Univ, Inst Safety Compensat & Recovery Res, Melbourne, Vic 3004, Australia; [Prang, Khic-Houy; Ruseckaite, Rasa; Collie, Alex] Monash Univ, Injury Res Inst, Melbourne, Vic 3004, Australia; [Collie, Alex] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia		Collie, A (corresponding author), Monash Univ, Inst Safety Compensat & Recovery Res, Melbourne, Vic 3004, Australia.	alex.collie@monash.edu	Ruseckaite, Rasa/H-4060-2014	Collie, Alex/0000-0003-2617-9339; Ruseckaite, Rasa/0000-0002-9078-2696	Transport Accident Commission (TAC); WorkSafe Victoria	The authors report no conflicts of interest. Funding for this project and authors' involvement in this study was provided by a research grant from the Transport Accident Commission (TAC) and WorkSafe Victoria.	Access Economics , 2009, EC COST SPIN CORD IN; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Australian Government. Department of Human Services, 2011, MED; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brown JH, 2007, HEALTHCARE POLICY, V2, P121; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Clay Fiona J, 2006, Aust Health Rev, V30, P252; Foster M, 2000, BRAIN INJURY, V14, P1035; Gabbe BJ, 2011, INJURY, V42, P985, DOI 10.1016/j.injury.2011.06.003; Harrison J, 2008, INJURY RES STAT SERI, V45; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Hoofien D, 2001, BRAIN INJURY, V15, P189; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Lippert-Gruener M, 2007, BRAIN INJURY, V21, P1001, DOI 10.1080/02699050701468933; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; O'Callaghan AM, 2010, INT J SPEECH-LANG PA, V12, P107, DOI 10.3109/17549500903431774; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ottenbacher KJ, 2007, ARCH PHYS MED REHAB, V88, P1513, DOI 10.1016/j.apmr.2007.06.761; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ruseckaite R, 2011, INJURY; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; Victorian Injury Surveillance Unit, 2011, TRAUM BRAIN INJ HOSP; Willemse-van Son AHP, 2009, J REHABIL MED, V41, P59, DOI 10.2340/16501977-0294; Wrona RM, 2010, DISABIL REHABIL, V32, P650, DOI 10.3109/09638280903186327	28	30	32	0	14	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1611	1620		10.3109/02699052.2012.698790			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700007	22738249				2022-02-06	
J	Leon-Carrion, J; Leon-Dominguez, U; Pollonini, L; Wu, MH; Frye, RE; Dominguez-Morales, MR; Zouridakis, G				Leon-Carrion, Jose; Leon-Dominguez, Umberto; Pollonini, Luca; Wu, Meng-Hung; Frye, Richard E.; Rosario Dominguez-Morales, Maria; Zouridakis, George			Synchronization between the anterior and posterior cortex determines consciousness level in patients with traumatic brain injury (TBI)	BRAIN RESEARCH			English	Article						Severe neurocognitive disorder; QEEG; Functional cortical connectivity; Minimal conscious state; Consciousness	PREFRONTAL CORTEX; CONNECTIVITY; NETWORK; STATE; EEG; TOOLBOX	Survivors of traumatic brain injury (TB!) often suffer disorders of consciousness as a result of a breakdown in cortical connectivity. However, little is known about the neural discharges and cortical areas working in synchrony to generate consciousness in these patients. In this study, we analyzed cortical connectivity in patients with severe neurocognitive disorder (SND) and in the minimally conscious state (MCS). We found two synchronized networks subserving consciousness; one retrolandic (cognitive network) and the other frontal (executive control network). The synchrony between these networks is severely disrupted in patients in the MCS as compared to those with better levels of consciousness and a preserved state of alertness (SND). The executive control network could facilitate the synchronization and coherence of large populations of distant cortical neurons using high frequency oscillations on a precise temporal scale. Consciousness is altered or disappears after losing synchrony and coherence. We suggest that the synchrony between anterior and retrolandic regions is essential to awareness, and that a functioning frontal lobe is a surrogate marker for preserved consciousness. This article is part of a Special Issue entitled: Brain Integration. (c) 2012 Elsevier B.V. All rights reserved.	[Leon-Carrion, Jose] Univ Seville, Human Neuropsychol Lab, Dept Expt Psychol, Seville 41018, Spain; [Leon-Carrion, Jose; Leon-Dominguez, Umberto; Rosario Dominguez-Morales, Maria] Ctr Brain Injury Rehabil CRECER, Seville, Spain; [Wu, Meng-Hung; Frye, Richard E.] Univ Texas Hlth Sci Ctr, Houston, TX USA; [Pollonini, Luca; Wu, Meng-Hung; Zouridakis, George] Univ Houston, Biomed Imaging Lab, Houston, TX 77004 USA		Leon-Carrion, J (corresponding author), Univ Seville, Human Neuropsychol Lab, Dept Expt Psychol, C Camilo Jose Cela S-N, Seville 41018, Spain.	leoncarrion@us.es	Zouridakis, George/R-8876-2019; Frye, Richard/AAB-5543-2020; Pollonini, Luca/J-9274-2014	Zouridakis, George/0000-0002-7770-9857; Pollonini, Luca/0000-0003-2955-6355; Leon-Dominguez, Umberto/0000-0001-5170-2553	Center for Brain Injury Rehabilitation [(CRECER)]; Spanish Ministry of Science and InnovationSpanish Government [PSI-2008-04218/PSIC]; Fundacion CajaSol de Sevilla, Spain; Fundacion Plenum, Sevilla, Spain	Funding for this study was made possible through grants from the Center for Brain Injury Rehabilitation [(CRECER) (www.neurocrecer.es)], the Spanish Ministry of Science and Innovation (PSI-2008-04218/PSIC), the Fundacion CajaSol de Sevilla, Spain, and the Fundacion Plenum, Sevilla, Spain.	Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Baars B.J., 1989, COGNITIVE THEORY CON; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bendat J., 2010, RANDOM DATA ANAL MEA; Berger H, 1938, ARCH PSYCHIAT NERVEN, V108, P407, DOI 10.1007/BF01824101; Box G. E. P., 2008, TIME SERIES ANAL FOR; Brovelli A, 2004, P NATL ACAD SCI USA, V101, P9849, DOI 10.1073/pnas.0308538101; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cavanna AE, 2007, CNS SPECTRUMS, V12, P545, DOI 10.1017/S1092852900021295; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Cui J, 2008, NEURAL NETWORKS, V21, P1094, DOI 10.1016/j.neunet.2008.05.007; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Fallani FD, 2010, INT J BIFURCAT CHAOS, V20, P905, DOI 10.1142/S0218127410026198; Frye R.E., 2007, CHANGES CORTICAL CON; Frye RE, 2007, ELE COM ENG, P375; Fuster JM, 2008, PREFRONTAL CORTEX, 4TH EDITION, P1; Gaillard R, 2009, PLOS BIOL, V7, P472, DOI 10.1371/journal.pbio.1000061; Giacino J.T., 2009, MINIMALLY CONSCIOUS; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GoldmanRakic PS, 1995, ANN NY ACAD SCI, V769, P71, DOI 10.1111/j.1749-6632.1995.tb38132.x; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Hagen C., 1972, LEVELS COGNITIVE FUN; Hal KM, 1997, J REHABILITATION OUT, V1, P63; Iriarte J, 2003, J CLIN NEUROPHYSIOL, V20, P249, DOI 10.1097/00004691-200307000-00004; John ER, 2005, PROG BRAIN RES, V150, P143, DOI 10.1016/S0079-6123(05)50011-6; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kopell N., 2002, P NATL ACAD SCI USA, V97, P1867; Lau HC, 2006, P NATL ACAD SCI USA, V103, P18763, DOI 10.1073/pnas.0607716103; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Leon-Carrion J, 2002, NEUROREHABILITATION, V17, P115; Leon-Carrion J, 2006, BRAIN INJURY, V20, P857, DOI 10.1080/02699050600832304; LHERMITTE F, 1983, BRAIN, V106, P237, DOI 10.1093/brain/106.2.237; Lisman J, 2005, HIPPOCAMPUS, V15, P913, DOI 10.1002/hipo.20121; Luria A. R., 1966, HUMAN BRAIN PSYCHOL; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Marshall L., J NEUROSURG, V75, pS14; Passingham R.E., 1993, FRONTAL LOBES VOLUNT; Pollonini L, 2010, BRAIN TOPOGR, V23, P221, DOI 10.1007/s10548-010-0139-9; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Seth AK, 2005, NETWORK-COMP NEURAL, V16, P35, DOI 10.1080/09548980500238756; Seth AK, 2007, NEURAL COMPUT, V19, P910, DOI 10.1162/neco.2007.19.4.910; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Sporns O, 2002, BEHAV BRAIN RES, V135, P69, DOI 10.1016/S0166-4328(02)00157-2; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; Ward LM, 2011, CONSCIOUS COGN, V20, P464, DOI 10.1016/j.concog.2011.01.007; Weiskrantz, 1999, CONSCIOUSNESS LOST F; Wilson CRE, 2010, TRENDS NEUROSCI, V33, P533, DOI 10.1016/j.tins.2010.08.001	53	30	34	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 2	2012	1476				SI		22	30		10.1016/j.brainres.2012.03.055			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	035JV	WOS:000310943600003	22534483				2022-02-06	
J	Pauli, C; Thais, MED; Claudino, LS; Bicalho, MAH; Bastos, AC; Guarnieri, R; Nunes, JC; Lin, K; Linhares, MN; Walz, R				Pauli, Carla; de Oliveira Thais, Maria Emilia; Claudino, Lucia Sukys; Horta Bicalho, Maria Alice; Bastos, Alexandre Cunha; Guarnieri, Ricardo; Nunes, Jean Costa; Lin, Katia; Linhares, Marcelo Neves; Walz, Roger			Predictors of quality of life in patients with refractory mesial temporal lobe epilepsy	EPILEPSY & BEHAVIOR			English	Article						Health-related quality of life; QOLIE-31; Mesial temporal lobe epilepsy; Psychiatric disorders	TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; ILAE COMMISSION; DEPRESSION; INVENTORY; SYMPTOMS; HEADACHE; SEIZURES; PROPOSAL; SURGERY	Purpose: The identification of variables associated with health-related quality of life (HRQoL) in patients with mesial temporal lobe epilepsy related to hippocampal sclerosis (MTLE-HS) would improve surgical decision-making and post-operatory follow-up in this group of patients. Methods: We analyzed the independent association between the Quality of Life in Epilepsy Inventory-31 (QOLIE-31) of 81 consecutive patients with refractory MTLE-HS. The clinical, demographic, radiological and electrophysiological variables were analyzed by multiple linear regression analysis. Key findings: Approximately 36% (adjusted R-2 = 0.36; R coefficient = 0.66) of the QOLIE-31 overall score variance was explained by the history of initial precipitant injury, family history of epilepsy, disease duration, age of epilepsy onset, seizure frequency and presence of psychiatric axis-II diagnosis. The variance of QOLIE-31 sub-scales was: seizure worry = 7%; overall QOL = 11%; emotional well-being = 32%; energy/fatigue = 38%; cognitive function = 13%; medication effects = 7%; social function = 13% (R coefficient between 0.30 and 0.65). Significance: The pre-surgical variables studied had relatively low prediction capacity for the overall QOLIE-31 score and its sub-scales in this set of Brazilian patients with refractory MTLE-HS. (C) 2012 Elsevier Inc. All rights reserved.	[Lin, Katia; Walz, Roger] Univ Fed Santa Catarina, Dept Clin Med, HU, BR-88040970 Florianopolis, SC, Brazil; [Linhares, Marcelo Neves] Univ Fed Santa Catarina, Dept Cirurgia, HU, BR-88040970 Florianopolis, SC, Brazil; [Claudino, Lucia Sukys; Lin, Katia] Univ Fed Santa Catarina, Serv Neurol, HU, BR-88040970 Florianopolis, SC, Brazil; [Nunes, Jean Costa] Univ Fed Santa Catarina, Serv Patol, HU, BR-88040970 Florianopolis, SC, Brazil; [Pauli, Carla; Claudino, Lucia Sukys; Horta Bicalho, Maria Alice; Guarnieri, Ricardo; Nunes, Jean Costa; Lin, Katia; Linhares, Marcelo Neves; Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas CeNAp, HU, BR-88040970 Florianopolis, SC, Brazil; [Pauli, Carla; de Oliveira Thais, Maria Emilia; Claudino, Lucia Sukys; Horta Bicalho, Maria Alice; Bastos, Alexandre Cunha; Guarnieri, Ricardo; Linhares, Marcelo Neves; Walz, Roger] HGCR, Ctr Epilepsia Santa Catarina CEPESC, Florianopolis, SC, Brazil		Walz, R (corresponding author), Univ Fed Santa Catarina, Dept Clin Med, HU, 3 Andar, BR-88040970 Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Lin, Katia/G-4891-2012; Neurociencia, Inct/I-1011-2013; Walz, Roger/K-9096-2013	Lin, Katia/0000-0002-5401-7524; Walz, Roger/0000-0002-9875-6687; SUKYS CLAUDINO, LUCIA/0000-0002-4735-2703	PRPe/FUNPESQUISA-UFSC; FAPESC/CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); PPSUS-FAPESC [2.456/2011-2]	This work was supported by the PRPe/FUNPESQUISA-UFSC, PRONEX program of the FAPESC/CNPq (NENASC Project) and the PPSUS-FAPESC (Project 2.456/2011-2).	Alexandre V, 2011, EPILEPTIC DISORD, V13, P56, DOI 10.1684/epd.2011.0411; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Araujo D, 2006, EPILEPSIA, V47, P1354, DOI 10.1111/j.1528-1167.2006.00605.x; Cramer JA, 2003, EPILEPSY BEHAV, V4, P515, DOI 10.1016/j.yebeh.2003.07.009; DEVINSKY O, 1995, EPILEPSIA, V36, P1089, DOI 10.1111/j.1528-1157.1995.tb00467.x; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dickens C, 2011, J CARDIOPULM REHABIL, V31, P105, DOI 10.1097/HCR.0b013e318207d32b; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; First M.B., 1996, STRUCTURED CLIN INTE; Guarnieri R, 2005, PSYCHIAT RES-NEUROIM, V138, P75, DOI 10.1016/j.pscychresns.2004.10.003; Guarnieri R, 2009, EPILEPSY BEHAV, V14, P529, DOI 10.1016/j.yebeh.2009.01.002; da Silva TI, 2007, EPILEPSY BEHAV, V10, P234, DOI 10.1016/j.yebeh.2006.08.022; Jacobson AM, 1997, QUAL LIFE RES, V6, P11; Jehi L, 2011, EPILEPSY BEHAV, V22, P723, DOI 10.1016/j.yebeh.2011.08.039; Johnson EK, 2004, EPILEPSIA, V45, P544, DOI 10.1111/j.0013-9580.2004.47003.x; Karaivazoglou K, 2010, ANN HEPATOL, V9, P419, DOI 10.1016/S1665-2681(19)31618-7; Krishnamoorthy ES, 2007, EPILEPSY BEHAV, V10, P349, DOI 10.1016/j.yebeh.2006.10.002; Kwan P, 2010, EPILEPSIA, V51, P1069, DOI 10.1111/j.1528-1167.2009.02397.x; Luoni C, 2011, EPILEPSIA, V52, P2181, DOI 10.1111/j.1528-1167.2011.03325.x; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Nunes JC, 2011, SEIZURE-EUR J EPILEP, V20, P480, DOI 10.1016/j.seizure.2011.02.014; Nunes JC, 2011, J NEUROL SCI, V306, P20, DOI 10.1016/j.jns.2011.04.006; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Perucca E, 2011, LANCET NEUROL, V10, P446, DOI 10.1016/S1474-4422(11)70047-3; Soh SE, 2011, PARKINSONISM RELAT D, V17, P1, DOI 10.1016/j.parkreldis.2010.08.012; Tavares M, 1996, ENTREVISTA CLIN ESTR; Taylor RS, 2011, EPILEPSIA, V52, P2168, DOI 10.1111/j.1528-1167.2011.03213.x; Terra-Bustamante VC, 2005, J NEUROL NEUROSUR PS, V76, P1080, DOI 10.1136/jnnp.2004.048934; Velasco TR, 2011, NEUROSURGERY, V68, P431, DOI 10.1227/NEU.0b013e318201c293; Vickrey BG, 1993, QUALITY LIFE EPILEPS, P9; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501	31	30	31	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	OCT	2012	25	2					208	213		10.1016/j.yebeh.2012.06.037			6	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	028WZ	WOS:000310457100016	23032134	Bronze			2022-02-06	
J	Albert-Weissenberger, C; Stetter, C; Meuth, SG; Gobel, K; Bader, M; Siren, AL; Kleinschnitz, C				Albert-Weissenberger, Christiane; Stetter, Christian; Meuth, Sven G.; Goebel, Kerstin; Bader, Michael; Siren, Anna-Leena; Kleinschnitz, Christoph			Blocking of bradykinin receptor B1 protects from focal closed head injury in mice by reducing axonal damage and astroglia activation	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						astrocytes; beta-APP; closed head injury; kinin receptors; R-715; TNF-alpha	TRAUMATIC BRAIN-INJURY; B-2 RECEPTORS; RAT-BRAIN; ANTAGONIST ANATIBANT; KININ RECEPTORS; EDEMA FORMATION; MURINE MODEL; EXPRESSION; INHIBITION; ASTROCYTES	The two bradykinin receptors B1R and B2R are central components of the kallikrein-kinin system with different expression kinetics and binding characteristics. Activation of these receptors by kinins triggers inflammatory responses in the target organ and in most situations enhances tissue damage. We could recently show that blocking of B1R, but not B2R, protects from cortical cryolesion by reducing inflammation and edema formation. In the present study, we investigated the role of B1R and B2R in a closed head model of focal traumatic brain injury (TBI; weight drop). Increased expression of B1R in the injured hemispheres of wild-type mice was restricted to the later stages after brain trauma, i.e. day 7 (P<0.05), whereas no significant induction could be observed for the B2R (P > 0.05). Mice lacking the B1R, but not the B2R, showed less functional deficits on day 3 (P<0.001) and day 7 (P<0.001) compared with controls. Pharmacological blocking of B1R in wildtype mice had similar effects. Reduced axonal injury and astroglia activation could be identified as underlying mechanisms, while inhibition of B1R had only little influence on the local inflammatory response in this model. Inhibition of B1R may become a novel strategy to counteract trauma-induced neurodegeneration. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1747-1756; doi:10.1038/jcbfm.2012.62; published online 9 May 2012	[Albert-Weissenberger, Christiane; Kleinschnitz, Christoph] Univ Clin Wurzburg, Dept Neurol, Wurzburg, Germany; [Stetter, Christian; Siren, Anna-Leena] Univ Clin Wurzburg, Dept Neurosurg, Wurzburg, Germany; [Meuth, Sven G.; Goebel, Kerstin] Univ Munster, Inst Physiol Neuropathophysiol, Munster, Germany; [Meuth, Sven G.] Univ Munster, Dept Neurol Inflammatory Disorders Nervous Syst &, Munster, Germany; [Bader, Michael] Max Delbruck Ctr Mol Med, Berlin, Germany		Kleinschnitz, C (corresponding author), Univ Wurzburg, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	Siren.A@nch.uni-wuerzburg.de; christoph.kleinschnitz@uni-wuerzburg.de	Siren, Anna-Leena/AAE-1374-2019	Siren, Anna-Leena/0000-0002-2217-0081; Kleinschnitz, Christoph/0000-0002-1650-8875; Bader, Michael/0000-0003-4780-4164	Deutsche Forschungsgemeinschaft (DFG), Bonn, GermanyGerman Research Foundation (DFG) [SFB 688 (TP A13)]; Wilhelm-Sander-Stiftung, Munich, Germany	This work was supported by the Deutsche Forschungsgemeinschaft (DFG), SFB 688 (TP A13), Bonn, Germany and the Wilhelm-Sander-Stiftung, Munich, Germany.	Albert-WeiSSenberger Christiane, 2012, Exp Transl Stroke Med, V4, P1, DOI 10.1186/2040-7378-4-1; Austinat M, 2009, STROKE, V40, P285, DOI 10.1161/STROKEAHA.108.526673; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; CAMARGO ACM, 1973, BIOCHEMISTRY-US, V12, P1838, DOI 10.1021/bi00733a028; CHOLEWINSKI AJ, 1991, J NEUROCHEM, V57, P1456, DOI 10.1111/j.1471-4159.1991.tb08314.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Frugier T, 2012, J NEUROPATH EXP NEUR, V71, P242, DOI 10.1097/NEN.0b013e3182496149; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GIMPL G, 1992, NEUROSCI LETT, V144, P139, DOI 10.1016/0304-3940(92)90735-P; Gobeil F, 1996, HYPERTENSION, V28, P833, DOI 10.1161/01.HYP.28.5.833; Gobel K, 2011, J AUTOIMMUN, V36, P106, DOI 10.1016/j.jaut.2010.11.004; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; Groger M, 2005, J CEREBR BLOOD F MET, V25, P978, DOI 10.1038/sj.jcbfm.9600096; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Hsieh HL, 2004, CELL SIGNAL, V16, P1163, DOI 10.1016/j.cellsig.2004.03.021; KARIYA K, 1985, J NEUROCHEM, V44, P1892, DOI 10.1111/j.1471-4159.1985.tb07185.x; Ker K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006686.pub2; KIZUKI K, 1994, BRAZ J MED BIOL RES, V27, P1891; Kleinschnitz C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000479; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522; Marmarou A, 2005, J NEUROTRAUM, V22, P1444, DOI 10.1089/neu.2005.22.1444; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; Raslan F, 2010, J CEREBR BLOOD F MET, V30, P1477, DOI 10.1038/jcbfm.2010.28; Lemos MTR, 2010, NEUROPEPTIDES, V44, P163, DOI 10.1016/j.npep.2009.12.006; Rodi D, 2005, CURR PHARM DESIGN, V11, P1313, DOI 10.2174/1381612053507422; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Shakur H, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-109; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; Zhang L, 2000, NEUROREPORT, V11, P409, DOI 10.1097/00001756-200002070-00037; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	41	30	31	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2012	32	9					1747	1756		10.1038/jcbfm.2012.62			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	000MR	WOS:000308390900009	22569191	Green Published			2022-02-06	
J	Sanchez-Porras, R; Santos, E; Czosnyka, M; Zheng, Z; Unterberg, AW; Sakowitz, OW				Sanchez-Porras, Renan; Santos, Edgar; Czosnyka, Marek; Zheng, Zelong; Unterberg, Andreas W.; Sakowitz, Oliver W.			'Long' pressure reactivity index (L-PRx) as a measure of autoregulation correlates with outcome in traumatic brain injury patients	ACTA NEUROCHIRURGICA			English	Article						Cerebral autoregulation; Low-frequency pressure reactivity index; Microdialysis; Neuromonitoring; Outcome; Pressure reactivity index; Traumatic brain injury	CEREBRAL VASOMOTOR REACTIVITY; CEREBROVASCULAR AUTOREGULATION; PERFUSION-PRESSURE; MICRODIALYSIS; CHEMISTRY	Cerebral autoregulation and, consequently, cerebrovascular pressure reactivity, can be disturbed after traumatic brain injury (TBI). Continuous monitoring of autoregulation has shown its clinical importance as an independent predictor of neurological outcome. The cerebral pressure reactivity index (PRx) reflects that changes in seconds of cerebrovascular reactivity have prognostic significance. Using an alternative algorithm similar to PRx, we investigate whether the utilization of lower-frequency changes of the order of minutes of mean arterial blood pressure (MAP) and intracranial pressure (ICP) could have a prognostic value in TBI patients. Head-injured patients requiring continued advanced multimodal monitoring, including hemodynamic, ICP and microdialysis (MD) monitoring, were analyzed retrospectively. A low-frequency sample pressure reactivity index (L-PRx) was calculated, using 20-min averages of MAP and ICP data as a linear Pearson's correlation. The mean values per patient were correlated to outcome at 6 months after injury. Differences of monitoring parameters between non-survivors and survivors were compared. A total of 29 patients (mean age 37.2 years, 26 males) suffering from TBI were monitored for a mean of 109.6 h (16-236 h, SD +/- 60.4). Mean L-PRx was found to be of 0.1 (-0.2 to 0.6, SD +/- 0.20), six patients presented impaired (> 0.2) values. The averaged L-PRx correlated significantly with ICP (r = 0.467, p = 0.011) and 6-month outcome (r = -0.556, p = 0.002). Significant statistical differences were found in L-PRx, cerebral perfusion pressure (CPP), lactate, and lactate-pyruvate ratio when comparing patients who died (n = 5) and patients who survived. L-PRx correlates with the 6-month outcome in TBI patients. Very slow changes of MAP and ICP may contain important autoregulation information. L-PRx may be an alternative algorithm for the estimation of cerebral autoregulation and clinical prognosis.	[Sanchez-Porras, Renan] Heidelberg Univ, Dept Neurosurg, D-69120 Heidelberg, Germany; [Sanchez-Porras, Renan; Santos, Edgar; Zheng, Zelong; Unterberg, Andreas W.; Sakowitz, Oliver W.] Univ Heidelberg Hosp, Dept Neurosurg, Heidelberg, Germany; [Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Neurosurg Unit, Dept Clin Neurosci, Cambridge CB2 2QQ, England		Sanchez-Porras, R (corresponding author), Heidelberg Univ, Dept Neurosurg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	Renan.Sanchez-Porras@med.uni-heidelberg.de	Santos, Edgar/AAV-2506-2021	Santos, Edgar/0000-0002-8976-5549; Sanchez-Porras, Renan/0000-0002-9084-8114; Sakowitz, Oliver/0000-0003-3248-6335	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390, G0600986] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G0600986, G9439390] Funding Source: UKRI		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chan MTV, 2005, ACT NEUR S, V95, P113; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Hejcl A, 2011, Cent Eur Neurosurg, V72, P1, DOI 10.1055/s-0031-1275745; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Low D, 2009, J NEUROTRAUM, V26, P1177, DOI [10.1089/neu.2008.0841, 10.1089/neu.2008-0841]; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Santos E, 2012, ACTA NEUROCHIRURGI S, P363; Santos E, 2011, ACTA NEUROCHIR, V153, P2189, DOI 10.1007/s00701-011-1148-5; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; Timofeev I, 2011, J NEUROTRAUM, V28, P849, DOI 10.1089/neu.2010.1656; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; White H, 2008, ANESTH ANALG, V107, P979, DOI 10.1213/ane.0b013e31817e7b1a; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	24	30	30	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2012	154	9					1575	1581		10.1007/s00701-012-1423-0			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	994UF	WOS:000307957500006	22743796				2022-02-06	
J	Davis, LC; Sherer, M; Sander, AM; Bogner, JA; Corrigan, JD; Dijkers, MP; Hanks, RA; Bergquist, TF; Seel, RT				Davis, Lynne C.; Sherer, Mark; Sander, Angelle M.; Bogner, Jennifer A.; Corrigan, John D.; Dijkers, Marcel P.; Hanks, Robin A.; Bergquist, Thomas F.; Seel, Ronald T.			Preinjury Predictors of Life Satisfaction at 1 Year After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Outcome assessment (health care); Personal satisfaction; Quality of life; Rehabilitation; Treatment outcome	QUALITY-OF-LIFE; 1ST 5 YEARS; SOCIAL COMMUNICATION-SKILLS; IMPAIRED SELF-AWARENESS; REHABILITATION OUTCOMES; SPINAL-CORD; NEIGHBORHOOD CHARACTERISTICS; SUBSTANCE-ABUSE; DEPRESSION; DISABILITY	Davis LC, Sherer M, Sander AM, Bogner JA, Corrigan JD, Dijkers MP, Hanks RA, Bergquist TF, Seel RT. Preinjury predictors of life satisfaction at 1 year after traumatic brain injury. Arch Phys Med Rehabil 2012;93:1324-30. Objective: To investigate the predictive value of preinjury factors for satisfaction with life (SWL) at 1-year posttraumatic brain injury (TBI). Design: Secondary analysis of prospective, longitudinal registry using data collected during inpatient rehabilitation and at 1-year post-TBI. Setting: Fifteen specialized brain injury units providing acute rehabilitation care as part of the Traumatic Brain Injury Model Systems (TBIMS) program. Participants: Community-dwelling persons (N = 444) with moderate to severe TBI aged 16 to 64 years enrolled in the TBIMS program between October 2007 and October 2008 with 1-year follow-up data. Interventions: Not applicable. Main Outcome Measure: Satisfaction With Life Scale (SWLS). Results: Hierarchical stepwise linear regression revealed that injury-related and demographic variables did not contribute significantly to the explained variance in SWLS scores. In contrast, the preinjury functioning (education, productivity/employment) and preinjury condition (psychiatric and substance use problems, severe sensory dysfunction, learning problems, prior TBI) blocks each contributed significantly to the explained variance in SWLS scores. Preinjury functioning accounted for 2.9% of the variance and preinjury conditions for 3.8%. Conclusions: Although their contributions are small, preinjury functioning and preinjury conditions are important to consider in the prediction of SWL post-TBI. Educational level and history of psychiatric and other premorbid difficulties are particularly important for clinicians to consider when implementing or developing interventions for persons with moderate to severe TBI.	[Davis, Lynne C.; Sherer, Mark; Sander, Angelle M.] TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77019 USA; [Sander, Angelle M.] Harris Cty Hosp Dist, Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA; [Bogner, Jennifer A.; Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Hanks, Robin A.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Rochester, MN USA; [Seel, Ronald T.] Crawford Res Inst, Shepherd Ctr, Atlanta, GA USA		Davis, LC (corresponding author), TIRR Mem Hermann, Brain Injury Res Ctr, 2323 S Shepherd,Ste 907, Houston, TX 77019 USA.	lynne.davis@memorialhermann.org; lynne.davis@memorialhermann.org	Bogner, Jennifer/E-2773-2011; Corrigan, John D./E-2921-2011; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [HI33A080044, HI33B090023, HI33A070029, HI33A070033]	Supported by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. HI33A080044, HI33B090023, HI33A070029, and HI33A070033).	Arango-Lasprilla JC, 2008, BRAIN INJURY, V22, P565, DOI 10.1080/02699050802172004; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Argyle M., 1999, WELL BEING FDN HEDON, P353, DOI DOI 10.7758/9781610443258.22; Barclay-Goddard R, 2011, ARCH PHYS MED REHAB, V92, P1762, DOI 10.1016/j.apmr.2011.06.013; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2011, J HEAD TRAUMA REHABI; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Corrigan JD, 2012, ARCH PHYS MED REHAB, V93, P1350, DOI 10.1016/j.apmr.2012.04.028; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Diener E, 2006, AM PSYCHOL, V61, P305, DOI 10.1037/0003-066X.61.4.305; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Harker WF, 2002, INT J REHABIL RES, V25, P93, DOI 10.1097/00004356-200206000-00003; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; Jacobsson LJ, 2011, NEUROPSYCHOL REHABIL, V21, P383, DOI 10.1080/09602011.2011.566711; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Johnson CL, 2010, REHABIL PSYCHOL, V55, P180, DOI 10.1037/a0019480; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Myers DG, 2000, AM PSYCHOL, V55, P56, DOI 10.1037/0003-066X.55.1.56; Pavot W, 2009, SOC INDIC RES SER, V39, P101, DOI 10.1007/978-90-481-2354-4_5; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; Saban KL, 2011, J WOMENS HEALTH, V20, P179, DOI 10.1089/jwh.2010.2334; Schwarz N., 1999, WELL BEING FDN HEDON, P213, DOI DOI 10.1037/0003-066X.61.4.305; Schwarz N., 1999, WELL BEING FDN HEDON, P302; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; *UN DAT SYST MED R, 1997, GUID UN DAT SET MED; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Waldron-Perrine B, 2011, REHABIL PSYCHOL, V56, P107, DOI 10.1037/a0023552; Warren L, 1996, J REHABIL RES DEV, V33, P404; Willer B., 1993, BRAIN INJURY REHABIL, P355; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540	62	30	30	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1324	1330		10.1016/j.apmr.2012.02.036			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700005	22840830				2022-02-06	
J	Schoch, KM; Evans, HN; Brelsfoard, JM; Madathil, SK; Takano, J; Saido, TC; Saatman, KE				Schoch, Kathleen M.; Evans, Heather N.; Brelsfoard, Jennifer M.; Madathil, Sindhu K.; Takano, Jiro; Saido, Takaomi C.; Saatman, Kathryn E.			Calpastatin overexpression limits calpain-mediated proteolysis and behavioral deficits following traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Cognition; Controlled cortical impact; Neuroprotection; Spectrin; Transgenic	CONTROLLED CORTICAL IMPACT; LONG-TERM POTENTIATION; SPINAL-CORD-INJURY; INHIBITOR MDL-28170; ALPHA-SPECTRIN; NEURONAL DEGENERATION; MOLECULAR-MECHANISMS; COGNITIVE DEFICITS; CEREBRAL-ISCHEMIA; AXONAL INJURY	Traumatic brain injury (TBI) results in abrupt, initial cell damage leading to delayed neuronal death. The calcium-activated proteases, calpains, are known to contribute to this secondary neurodegenerative cascade. Although the specific inhibitor of calpains, calpastatin, is present within neurons, normal levels of calpastatin are unable to fully prevent the damaging proteolytic activity of calpains after injury. In this study, increased calpastatin expression was achieved using transgenic mice that overexpress the human calpastatin (hCAST) construct under control of a calcium-calmodulin-dependent kinase II alpha promoter. Naive hCAST transgenic mice exhibited enhanced neuronal calpastatin expression and significantly reduced protease activity. Acute calpain-mediated spectrin proteolysis in the cortex and hippocampus induced by controlled cortical impact brain injury was significantly attenuated in calpastatin overexpressing mice. Aspects of posttraumatic motor and cognitive behavioral deficits were also lessened in hCAST transgenic mice compared to their wildtype littermates. However, volumetric analyses of neocortical contusion revealed no histological neuroprotection at either acute or long-term time points. Partial hippocampal neuroprotection observed at a moderate injury severity was lost after severe TBI. This study underscores the effectiveness of calpastatin overexpression in reducing calpain-mediated proteolysis and behavioral impairment after TB!, supporting the therapeutic potential for calpain inhibition. In addition, the reduction in spectrin proteolysis without accompanied neocortical neuroprotection suggests the involvement of other factors that are critical for neuronal survival after contusion brain injury. (C) 2012 Elsevier Inc. All rights reserved.	[Schoch, Kathleen M.; Evans, Heather N.; Brelsfoard, Jennifer M.; Madathil, Sindhu K.; Saatman, Kathryn E.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, Lexington, KY 40536 USA; [Schoch, Kathleen M.; Evans, Heather N.; Brelsfoard, Jennifer M.; Madathil, Sindhu K.; Saatman, Kathryn E.] Univ Kentucky, Dept Physiol, Coll Med, Lexington, KY 40536 USA; [Takano, Jiro; Saido, Takaomi C.] RIKEN Brain Sci Inst RIKEN BSI, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan		Saatman, KE (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr SCoBIRC, B473 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.	kmscho6@uky.edu; evansh1@nku.edu; jmplea2@uky.edu; Sindhu.KM@uky.edu; jtakano@brain.riken.jp; saido@brain.riken.jp; k.saatman@uky.edu	Madathil, Sindhu K/E-9407-2012; Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [F31 NS071804, P01 NS058484, P30 NS051220]; KSCHIRT [6-12]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS071804, P30NS051220, P01NS058484] Funding Source: NIH RePORTER	This work was funded by NIH F31 NS071804 (KMS), NIH P01 NS058484, P30 NS051220 and KSCHIRT 6-12 (KES).	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Aikman J, 2006, DEV NEUROSCI-BASEL, V28, P457, DOI 10.1159/000094171; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; Bertaina-Anglade V., 2006, Journal of Pharmacological and Toxicological Methods, V54, P99, DOI 10.1016/j.vascn.2006.04.001; Bevers MB, 2010, EXP NEUROL, V224, P170, DOI 10.1016/j.expneurol.2010.03.007; Bevers MB, 2009, J NEUROCHEM, V108, P1237, DOI 10.1111/j.1471-4159.2008.05860.x; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Chidlow G, 2009, EXP EYE RES, V88, P426, DOI 10.1016/j.exer.2008.10.015; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Couto LA, 2004, J NEUROSCI RES, V77, P410, DOI 10.1002/jnr.20170; CRAWFORD C, 1993, BIOCHEM J, V296, P135, DOI 10.1042/bj2960135; Croall DE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-218; DELCERRO S, 1990, BRAIN RES, V530, P91; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DENNY JB, 1990, BRAIN RES, V534, P317, DOI 10.1016/0006-8993(90)90148-5; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farkas B, 2004, BRAIN RES, V1024, P150, DOI 10.1016/j.brainres.2004.07.059; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Grammer M, 2005, NEUROBIOL LEARN MEM, V84, P222, DOI 10.1016/j.nlm.2005.07.007; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hanna RA, 2008, NATURE, V456, P409, DOI 10.1038/nature07451; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Hassen GW, 2008, BRAIN RES, V1236, P206, DOI 10.1016/j.brainres.2008.07.124; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Institute of Laboratory Animal Resources (U.S.), 2011, NIH PUBL; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koumura A, 2008, NEUROSCIENCE, V157, P309, DOI 10.1016/j.neuroscience.2008.09.007; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Mellgren RL, 2009, BBA-MOL CELL RES, V1793, P1886, DOI 10.1016/j.bbamcr.2009.09.013; Moldoveanu T, 2008, NATURE, V456, P404, DOI 10.1038/nature07353; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MULLER D, 1995, SYNAPSE, V19, P37, DOI 10.1002/syn.890190106; Nakajima R, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-7; Naseer MI, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-20; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; Oshitari T, 2008, BRIT J OPHTHALMOL, V92, P552, DOI 10.1136/bjo.2007.132308; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Parr T, 2004, ARCH BIOCHEM BIOPHYS, V427, P8, DOI 10.1016/j.abb.2004.04.001; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Rao MV, 2008, J NEUROSCI, V28, P12241, DOI 10.1523/JNEUROSCI.4119-08.2008; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Serrano GE, 2011, J NEUROSCI, V31, P14850, DOI 10.1523/JNEUROSCI.3922-11.2011; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sorimachi H, 2011, P JPN ACAD B-PHYS, V87, P287, DOI 10.2183/pjab.87.287; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; SUZUKI T, 1992, BIOCHEM BIOPH RES CO, V189, P1515, DOI 10.1016/0006-291X(92)90247-I; Takano J, 1999, BIOCHEM BIOPH RES CO, V260, P339, DOI 10.1006/bbrc.1999.0903; Takano J, 2000, J BIOCHEM, V128, P83, DOI 10.1093/oxfordjournals.jbchem.a022733; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thompson SN, 2010, J NEUROTRAUM, V27, P2233, DOI 10.1089/neu.2010.1474; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yu CG, 2008, J NEUROTRAUM, V25, P833, DOI 10.1089/neu.2007.0490; Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4	81	30	31	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2012	236	2					371	382		10.1016/j.expneurol.2012.04.022			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	976YI	WOS:000306622900019	22572592	Green Accepted			2022-02-06	
J	Yang, Z; Yeo, RA; Pena, A; Ling, JM; Klimaj, S; Campbell, R; Doezema, D; Mayer, AR				Yang, Zhen; Yeo, Ronald A.; Pena, Amanda; Ling, Josef M.; Klimaj, Stefan; Campbell, Richard; Doezema, David; Mayer, Andrew R.			An fMRI Study of Auditory Orienting and Inhibition of Return in Pediatric Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						auditory orienting; bottom-up; functional magnetic resonance imaging; pediatric; traumatic brain injury	EVENT-RELATED FMRI; WORKING-MEMORY; HEAD-INJURY; ATTENTIONAL SKILLS; FUNCTIONAL MRI; EARLY-CHILDHOOD; POSTCONCUSSIVE SYMPTOMS; NEUROCOGNITIVE OUTCOMES; VISUOSPATIAL ATTENTION; VISUAL-ATTENTION	Studies in adult mild traumatic brain injury (mTBI) have shown that two key measures of attention, spatial reorienting and inhibition of return (IOR), are impaired during the first few weeks of injury. However, it is currently unknown whether similar deficits exist following pediatric mTBI. The current study used functional magnetic resonance imaging (fMRI) to investigate the effects of semi-acute mTBI (<3 weeks post-injury) on auditory orienting in 14 pediatric mTBI patients (age 13.50 +/- 1.83 years; education: 6.86 +/- 1.88 years), and 14 healthy controls (age 13.29 +/- 2.09 years; education: 7.21 +/- 2.08 years), matched for age and years of education. The results indicated that patients with mTBI showed subtle (i.e., moderate effect sizes) but non-significant deficits on formal neuropsychological testing and during IOR. In contrast, functional imaging results indicated that patients with mTBI demonstrated significantly decreased activation within the bilateral posterior cingulate gyrus, thalamus, basal ganglia, midbrain nuclei, and cerebellum. The spatial topography of hypoactivation was very similar to our previous study in adults, suggesting that subcortical structures may be particularly affected by the initial biomechanical forces in mTBI. Current results also suggest that fMRI may be a more sensitive tool for identifying semi-acute effects of mTBI than the procedures currently used in clinical practice, such as neuropsychological testing and structural scans. fMRI findings could potentially serve as a biomarker for measuring the subtle injury caused by mTBI, and documenting the course of recovery.	[Yang, Zhen; Yeo, Ronald A.; Pena, Amanda; Ling, Josef M.; Klimaj, Stefan; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM 87106 USA; [Yang, Zhen; Yeo, Ronald A.; Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Campbell, Richard] Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; [Doezema, David] Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Lovelace Biomed & Environm Res Inst, Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	He, Hongbo/H-1815-2013; He, Robert/L-9441-2013; Klimaj, Stefan/AAV-4060-2020		Graduate Dean's Dissertation Fellowship; University of New Mexico; Benjamin Franklin Haught Scholarship; Department of Psychology, University of New Mexico; Mind Research Network [DOE Grant] [DE-FG02-99ER62764]	The first author was supported by The Graduate Dean's Dissertation Fellowship sponsored by the University of New Mexico and The Benjamin Franklin Haught Scholarship sponsored by the Department of Psychology, University of New Mexico. This research was supported by grants from The Mind Research Network [DOE Grant No. DE-FG02-99ER62764] to A.R.M. Special thanks to Diana South, George Malloy, Cathy Smith, Terri Teshiba, Flannery Merideth, and Jim Youngblood for assistance with data collection and/or data entry, to Jesse Rael, M.D. for review of anatomical images, and to Vince Clark and John Phillips for serving on the dissertation committee.	Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Allen DN, 2010, ARCH CLIN NEUROPSYCH, V25, P618, DOI 10.1093/arclin/acq051; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Arrington CM, 2000, J COGNITIVE NEUROSCI, V12, P106, DOI 10.1162/089892900563975; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Babikian T, 2010, DEV NEUROSCI-BASEL, V32, P431, DOI 10.1159/000320667; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belin P, 2002, NEUROPSYCHOLOGIA, V40, P1956, DOI 10.1016/S0028-3932(02)00062-3; Brodeur DA, 1997, CAN J EXP PSYCHOL, V51, P20, DOI 10.1037/1196-1961.51.1.20; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2011, BRAIN INJURY, V25, P858, DOI 10.3109/02699052.2011.589794; Cazalis Fabienne, 2011, Front Neurol, V1, P158, DOI 10.3389/fneur.2010.00158; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Clements-Stephens AM, 2009, NEUROSCI LETT, V449, P155, DOI 10.1016/j.neulet.2008.10.094; Corbetta M, 2011, ANNU REV NEUROSCI, V34, P569, DOI 10.1146/annurev-neuro-061010-113731; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Dennis M, 2005, NEUROPSYCHOLOGIA, V43, P976, DOI 10.1016/j.neuropsychologia.2004.08.012; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Faul M, 2010, TRAUMATIC BRAIN INJU; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Ginstfeldt T, 2010, BRAIN INJURY, V24, P1123, DOI 10.3109/02699052.2010.506853; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; Goldberg MC, 2001, DEVELOPMENTAL SCI, V4, P209, DOI 10.1111/1467-7687.00166; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hamilton NA, 2010, SEMIN PEDIATR SURG, V19, P271, DOI 10.1053/j.sempedsurg.2010.06.005; Harris NS, 1999, COGNITIVE BRAIN RES, V8, P61, DOI 10.1016/S0926-6410(99)00006-3; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Karunanayaka PR, 2007, NEUROREHABILITATION, V22, P355; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Kramer ME, 2008, J INT NEUROPSYCH SOC, V14, P424, DOI 10.1017/S1355617708080545; Kramer ME, 2009, J PEDIATR REHAB MED, V2, P255, DOI 10.3233/PRM-2009-0091; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Lepsien J, 2002, J COGNITIVE NEUROSCI, V14, P127, DOI 10.1162/089892902317236795; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mayer AR, 2007, J COGNITIVE NEUROSCI, V19, P455, DOI 10.1162/jocn.2007.19.3.455; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; Mayer AR, 2004, NEUROIMAGE, V23, P534, DOI 10.1016/j.neuroimage.2004.06.027; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; McKinlay A, 2009, J HEAD TRAUMA REHAB, V24, P221, DOI 10.1097/HTR.0b013e3181a40590; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Posner M.I., 2007, ED HUMAN BRAIN, P62; Ravizza SM, 2001, J COGNITIVE NEUROSCI, V13, P285, DOI 10.1162/08989290151137340; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS, V2; Rueda MR, 2004, NEUROPSYCHOLOGIA, V42, P1029, DOI 10.1016/j.neuropsychologia.2003.12.012; Salmi J, 2007, BRAIN STRUCT FUNCT, V212, P181, DOI 10.1007/s00429-007-0152-2; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SCALEA TM, 2005, NEUROTRAUMA EVIDENCE, P3; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Sowell ER, 2002, DEV MED CHILD NEUROL, V44, P4, DOI 10.1017/S0012162201001591; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Talairach J., 1988, COPLANAR STEREOTAXIC; Talavage TM, 2010, J NEUROTRAUMA; Thiel CM, 2004, NEUROIMAGE, V21, P318, DOI 10.1016/j.neuroimage.2003.08.044; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P181, DOI 10.1017/S1355617710001414; Tomasi D, 2008, NEUROSCIENCE, V151, P1006, DOI 10.1016/j.neuroscience.2007.08.040; Waszak F, 2010, DEV PSYCHOL, V46, P337, DOI 10.1037/a0018541; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zatorre RJ, 2002, NAT NEUROSCI, V5, P905, DOI 10.1038/nn904; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	94	30	30	0	16	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2124	2136		10.1089/neu.2012.2395			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900002	22533632	Green Published			2022-02-06	
J	Seo, JW; Kim, JH; Kim, JH; Seo, M; Han, HS; Park, J; Suk, K				Seo, Jung-Wan; Kim, Jong-Heon; Kim, Jae-Hong; Seo, Minchul; Han, Hyung Soo; Park, Jaechan; Suk, Kyoungho			Time-dependent effects of hypothermia on microglial activation and migration	JOURNAL OF NEUROINFLAMMATION			English	Article						Hypothermia; Microglia; Cell migration; Neuroinflammation; Neuroprotection	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; MESSENGER-RNA STABILITY; MILD HYPOTHERMIA; GENE-EXPRESSION; POSTISCHEMIC HYPOTHERMIA; INFLAMMATORY RESPONSE; MODERATE HYPOTHERMIA; CELL-DEATH	Background: Therapeutic hypothermia is one of the neuroprotective strategies that improve neurological outcomes after brain damage in ischemic stroke and traumatic brain injury. Microglial cells become activated following brain injury and play an important role in neuroinflammation and subsequent brain damage. The aim of this study was to determine the time-dependent effects of hypothermia on microglial cell activation and migration, which are accompanied by neuroinflammation. Methods: Microglial cells in culture were subjected to mild (33 degrees C) or moderate (29 degrees C) hypothermic conditions before, during, or after lipopolysaccharide (LPS) or hypoxic stimulation, and the production of nitric oxide (NO), proinflammatory cytokines, reactive oxygen species, and neurotoxicity was evaluated. Effects of hypothermia on microglial migration were also determined in in vitro as well as in vivo settings. Results: Early-, co-, and delayed-hypothermic treatments inhibited microglial production of inflammatory mediators to varying degrees: early treatment was the most efficient, and delayed treatment showed time-dependent effects. Delayed hypothermia also suppressed the mRNA levels of proinflammatory cytokines and iNOS, and attenuated microglial neurotoxicity in microglia-neuron co- cultures. Furthermore, delayed hypothermia reduced microglial migration in the Boyden chamber assay and wound healing assay. In a stab injury model, delayed local hypothermia reduced migration of microglia toward the injury site in the rat brain. Conclusion: Taken together, our results indicate that delayed hypothermia is sufficient to attenuate microglial activation and migration, and provide the basis of determining the optimal time window for therapeutic hypothermia. Delayed hypothermia may be neuroprotective by inhibiting microglia-mediated neuroinflammation, indicating the therapeutic potential of post-injury hypothermia for patients with brain damages exhibiting some of the inflammatory components.	[Seo, Jung-Wan; Kim, Jong-Heon; Kim, Jae-Hong; Seo, Minchul; Suk, Kyoungho] Kyungpook Natl Univ, Sch Med, CMRI, Brain Sci & Engn Inst,Dept Pharmacol, Taegu 700422, South Korea; [Han, Hyung Soo] Kyungpook Natl Univ, Sch Med, Dept Physiol, Brain Sci & Engn Inst, Taegu 700422, South Korea; [Park, Jaechan] Kyungpook Natl Univ, Sch Med, Dept Neurosurg, Brain Sci & Engn Inst, Taegu 700422, South Korea		Suk, K (corresponding author), Kyungpook Natl Univ, Sch Med, CMRI, Brain Sci & Engn Inst,Dept Pharmacol, 101 Dong In, Taegu 700422, South Korea.	ksuk@knu.ac.kr		Park, Jaechan/0000-0001-7572-3260	Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea [A100870]; National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST) of Korean governmentMinistry of Education, Science and Technology, Republic of Korea [20110028240]	This work was supported by a grant from the Korea Healthcare technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A100870), and by the National Research Foundation (NRF) grants funded by the Ministry of Education, Science and Technology (MEST) of Korean government (20110028240).	Al-Fageeh MB, 2009, RNA, V15, P1164, DOI 10.1261/rna.1179109; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Askalan R, 2011, DEV NEUROSCI-BASEL, V33, P320, DOI 10.1159/000329924; BAKER CJ, 1992, J NEUROSURG, V77, P438, DOI 10.3171/jns.1992.77.3.0438; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bassi R, 2008, J NEURO-ONCOL, V87, P23, DOI 10.1007/s11060-007-9488-y; Batchelor PE, 2008, J NEUROTRAUM, V25, P1217, DOI 10.1089/neu.2007.0308; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Carey HV, 2003, PHYSIOL REV, V83, P1153, DOI 10.1152/physrev.00008.2003; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chang RCC, 2000, BRAIN RES, V853, P236, DOI 10.1016/S0006-8993(99)02255-6; Clark A, 2000, ARTHRITIS RES, V2, P172, DOI 10.1186/ar83; Clark DL, 2007, J CEREBR BLOOD F MET, V27, P115, DOI 10.1038/sj.jcbfm.9600327; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; David HN, 2009, J CEREBR BLOOD F MET, V29, P1159, DOI 10.1038/jcbfm.2009.40; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Diestel A, 2010, EUR J NEUROSCI, V31, P779, DOI 10.1111/j.1460-9568.2010.07128.x; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gibbons H, 2003, MOL BRAIN RES, V110, P63, DOI 10.1016/S0169-328X(02)00585-5; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Gundersen Y, 2001, ACTA ANAESTH SCAND, V45, P994, DOI 10.1034/j.1399-6576.2001.450812.x; Hagiwara S, 2007, INFLAMM RES, V56, P297, DOI 10.1007/s00011-007-6161-z; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; Hinojosa AE, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-77; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Hollams EM, 2002, NEUROCHEM RES, V27, P957, DOI 10.1023/A:1020992418511; KADER A, 1992, NEUROSURGERY, V31, P1056, DOI 10.1227/00006123-199212000-00011; Karabiyikoglu M, 2003, J NEUROSURG, V98, P1271, DOI 10.3171/jns.2003.98.6.1271; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; Lee M, 2011, BRAIN RES, V1400, P99, DOI 10.1016/j.brainres.2011.05.021; Lee S, 2012, J BIOL CHEM, V287, P9414, DOI 10.1074/jbc.M111.330662; Lee S, 2011, J BIOL CHEM, V286, P43855, DOI 10.1074/jbc.M111.299248; Lee S, 2009, J NEUROSCI, V29, P234, DOI 10.1523/JNEUROSCI.5273-08.2009; Lee S, 2007, BIOCHEM PHARMACOL, V74, P723, DOI 10.1016/j.bcp.2007.06.016; Lelekov-Boissard T, 2009, PHILOS T R SOC A, V367, P4699, DOI 10.1098/rsta.2009.0184; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Maekawa S, 2002, CRIT CARE MED, V30, P2700, DOI 10.1097/00003246-200212000-00014; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsui T, NEUROCRIT C IN PRESS; Matsui T, 2008, J NEUROTRAUM, V25, P709, DOI 10.1089/neu.2007.0482; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGeer EG, 2003, PROG NEURO-PSYCHOPH, V27, P741, DOI 10.1016/S0278-5846(03)00124-6; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MOYER DJ, 1992, STROKE, V23, P1812, DOI 10.1161/01.STR.23.12.1812; Nagel S, 2012, NEUROSCIENCE, V208, P109, DOI 10.1016/j.neuroscience.2012.01.048; Ock J, 2007, J NEUROSCI RES, V85, P1989, DOI 10.1002/jnr.21322; Ock J, 2010, BRIT J PHARMACOL, V159, P1646, DOI 10.1111/j.1476-5381.2010.00659.x; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Salman H, 2000, ACTA PHYSIOL SCAND, V168, P431; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Seko Y, 2006, AUTOIMMUN REV, V5, P299, DOI 10.1016/j.autrev.2005.10.013; Shpargel Karl B, 2008, Cleve Clin J Med, V75 Suppl 2, pS77; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Tang XN, 2010, AGEING RES REV, V9, P61, DOI 10.1016/j.arr.2009.10.002; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tymianski M, 1998, J CEREBR BLOOD F MET, V18, P848, DOI 10.1097/00004647-199808000-00005; Wolff B, 2009, INT J CARDIOL, V133, P223, DOI 10.1016/j.ijcard.2007.12.039; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; Yanamoto H, 1996, BRAIN RES, V718, P207, DOI 10.1016/0006-8993(96)00122-9; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yuan HB, 2004, ANESTHESIOLOGY, V100, P331, DOI 10.1097/00000542-200402000-00023; Yunoki M, 2003, EXP NEUROL, V181, P291, DOI 10.1016/S0014-4886(03)00056-6; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	79	30	35	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 9	2012	9								164	10.1186/1742-2094-9-164			22	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	021IQ	WOS:000309878900001	22776061	gold, Green Published			2022-02-06	
J	Bivona, U; D'Ippolito, M; Giustini, M; Vignally, P; Longo, E; Taggi, F; Formisano, R				Bivona, Umberto; D'Ippolito, Mariagrazia; Giustini, Marco; Vignally, Pascal; Longo, Eloise; Taggi, Franco; Formisano, Rita			Return to Driving After Severe Traumatic Brain Injury: Increased Risk of Traffic Accidents and Personal Responsibility	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; return to driving; risk factors; severe traumatic brain injury; traffic safety	PRACTICAL SCALE; DAMAGE	Objective: To determine the frequency of road traffic accidents among individuals who start or resume driving after severe traumatic brain injury (TBI) and to investigate their responsibility for these accidents. Design: Observational/retrospective study. Participants: Sixty adults with severe TBI and their caregivers. Measures: Return to Driving Questionnaire and Glasgow Outcome Scale. Results: Thirty of the 60 participants started to drive or resumed driving after TBI. Nineteen (63%) of them were involved in traffic accidents, with personal responsibility in 26 of 36 after return to driving. Participants caused a significantly higher number of accidents after TBI than before. Conclusions: The ability to drive is frequently compromised after severe TBI. Specific rehabilitation of this complex activity should be a main goal of social reintegration programs in this population.	[Bivona, Umberto; D'Ippolito, Mariagrazia; Formisano, Rita] IRCCS Fdn Santa Lucia, Rome, Italy; [Giustini, Marco; Vignally, Pascal; Longo, Eloise; Taggi, Franco] Ist Super Sanita, Environm & Trauma Unit, I-00161 Rome, Italy		Bivona, U (corresponding author), IRCCS Fdn Santa Lucia, Rome, Italy.	u.bivona@hsantalucia.it	D'Ippolito, Mariagrazia/K-4010-2016; Giustini, Marco/Q-3166-2017	D'Ippolito, Mariagrazia/0000-0001-7818-7352; Giustini, Marco/0000-0003-2691-1956			AVOLIO BJ, 1985, HUM FACTORS, V27, P577, DOI 10.1177/001872088502700506; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Ciurli P, 2010, J INT NEUROPSYCH SOC, V29, P1; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JENNETT B, 1975, LANCET, V1, P480; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Novack TA, 2010, BRAIN INJURY, V24, P464, DOI 10.3109/02699051003601713; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2007, PSYCHOSOMATICS, V48, P217, DOI 10.1176/appi.psy.48.3.217; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; STELMACH GE, 1992, HUM FACTORS, V34, P53, DOI 10.1177/001872089203400107; Stuss D, 2002, FRONTAL LOBES; TEASDALE G, 1974, LANCET, V2, P81	19	30	31	1	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					210	215		10.1097/HTR.0b013e31822178a9			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500009	21829135				2022-02-06	
J	Byom, LJ; Turkstra, L				Byom, Lindsey J.; Turkstra, Lyn			Effects of social cognitive demand on Theory of Mind in conversations of adults with traumatic brain injury	INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS			English	Article						communication; brain injury; social cognition; language; mentalizing; discourse	HEAD-INJURY; EMOTION RECOGNITION; NARRATIVE DISCOURSE; ELICITATION TASK; SELF; ADOLESCENTS; LANGUAGE; DEFICITS; GENDER; SKILLS	Background: A requisite skill for successful conversation is the ability to adjust one's language according to contextual factors. Aims: This study examined one aspect of language use in context-the use of mental-state terms, i.e. words that communicate thoughts, beliefs or feelings-in conversations between adult males with and without traumatic brain injury (TBI) and familiar partners. Methods & Procedures: Participants were five males in the chronic stage of recovery following severe TBI and five male peers matched for age, conversing with friends. Conversational context was manipulated using conversation starters that were designed to induce differing levels of self-disclosure or intimacy, with the expectation that mental-state term use would increase when participants talked about more intimate topics. Outcomes & Results: Participants in both groups used more mental-state terms in more intimate conversations; however, adults with TBI did not increase their mental-state term use to the same extent as matched peers. Adults with TBI also used a significantly different pattern of mental-state term types across intimacy levels as compared with peers. Conclusions & Implications: These quantitative and qualitative differences may contribute to social conversation problems of adults with TBI.	[Byom, Lindsey J.; Turkstra, Lyn] Univ Wisconsin, Madison, WI 53706 USA		Byom, LJ (corresponding author), Univ Wisconsin, 1975Willow Dr, Madison, WI 53706 USA.	ljfrederixon@wisc.edu	Byom, Lindsey/AAC-5095-2019; Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921; Byom, Lindsey/0000-0002-2457-1735	Wisconsin Alumni Research Foundation; Walker Foundation; NIDCDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32DC005359]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32DC005359] Funding Source: NIH RePORTER	This work was supported in part by funds from the Wisconsin Alumni Research Foundation and the Walker Foundation, as well as from a training fellowship to the first author from the University of Wisconsin-Madison Department of Communicative Disorders Interdisciplinary training grant NIDCD T32DC005359. The authors acknowledge Sara Brehm's assistance with data collection; and thank Laura Mork, Jacqueline Johnson and Danielle Schneider for their assistance with data analysis. The authors report no conflict of interest associated with this work. Declaration of Interest: The authors report no conflict of interest and only the authors are responsible for the content and writing of this paper.	Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Adrian JE, 2005, J CHILD LANG, V32, P673, DOI 10.1017/S0305000905006963; Bach LJ, 2006, BRAIN COGNITION, V60, P196; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bosacki SL, 2000, J EDUC PSYCHOL, V92, P709, DOI 10.1037//0022-0663.92.4.709; BRETHERTON I, 1982, DEV PSYCHOL, V18, P906, DOI 10.1037/0012-1649.18.6.906; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Charlton RA, 2009, PSYCHOL AGING, V24, P338, DOI 10.1037/a0015225; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; Frith CD, 1999, SCIENCE, V286, P1692, DOI 10.1126/science.286.5445.1692; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Heatherton TF, 2000, J PERS SOC PSYCHOL, V78, P725, DOI 10.1037/0022-3514.78.4.725; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Kaufman A.S., 2004, K BIT2 KAUFMAN BRIEF, V2nd; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; MACCOBY EE, 1988, DEV PSYCHOL, V24, P755, DOI 10.1037/0012-1649.24.6.755; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Miller CA, 2006, AM J SPEECH-LANG PAT, V15, P142, DOI 10.1044/1058-0360(2006/014); MILLER JF, 1994, SALT GUIDE STANDARD; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Peterson CC, 2006, BRIT J DEV PSYCHOL, V24, P151, DOI 10.1348/026151005X60022; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Samson D, 2007, NEUROPSYCHOLOGIA, V45, P2561, DOI 10.1016/j.neuropsychologia.2007.03.013; Scott CM, 2000, J SPEECH LANG HEAR R, V43, P324, DOI 10.1044/jslhr.4302.324; Sedikides C, 1998, J PERS SOC PSYCHOL, V74, P378, DOI 10.1037/0022-3514.74.2.378; Sedikides C., 1999, REPRESENTATIVE RES S, V23, P1; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Stronach ST, 2008, APHASIOLOGY, V22, P1054, DOI 10.1080/02687030701632187; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Thorndike E.L., 1920, HARPERS MAG, V140, P227, DOI DOI 10.1234/12345678; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Vohs KD, 2004, SOC COGNITION, V22, P168, DOI 10.1521/soco.22.1.168.30983; Walker S, 2005, J GENET PSYCHOL, V166, P297, DOI 10.3200/GNTP.166.3.297-312; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	62	30	30	0	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1368-2822	1460-6984		INT J LANG COMM DIS	Int. J. Lang. Commun. Disord.	MAY-JUN	2012	47	3					310	321		10.1111/j.1460-6984.2011.00102.x			12	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	927WT	WOS:000302941900007	22512516	Green Accepted			2022-02-06	
J	Coats, B; Eucker, SA; Sullivan, S; Margulies, SS				Coats, Brittany; Eucker, Stephanie A.; Sullivan, Sarah; Margulies, Susan S.			Finite element model predictions of intracranial hemorrhage from non-impact, rapid head rotations in the piglet	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Subdural hemorrhage; Traumatic brain injury; Falls; Brain-skull displacement; Pediatric; Finite element	BRAIN-TISSUE; CHILDREN FALL; INJURIES; BIOMECHANICS; BEHAVIOR; IMPACT	Clinicians are charged with the significant task of distinguishing between accidental and inflicted head trauma. Oftentimes this distinction is straightforward, but many times probabilities of injuries from accidental scenarios are unknown making the differential diagnosis difficult. For example, it is unknown whether intracranial hemorrhage (IH) can occur at a location other than a focal contact site following a low height fall. To create a foundation for predicting regional IH in infants, we sought to identify the biomechanical response and injury threshold best able to predict IH in 3-5 day old piglets. First, finite element (FE) model simulations of in situ animal studies were performed to ascertain the optimal representation of the pia-arachnoid complex, cerebrospinal fluid and cortical vasculature (PCC) for predicting brain strain and brain/skull displacement. Second, rapid head rotations resulting in various degrees of IH were simulated (n = 24) to determine the biomechanical predictor and injury threshold most closely correlated with IH. FE models representing the PCC with either spring connectors or solid elements between the brain and skull resulted in peak brain strain and brain/skull displacement similar to measured values in situ. However, when predicting IH, the spring connector representation of the PCC had the best predictive capability for IH with a sensitivity of 80% and a specificity of 85% when >= 1% of all spring connectors had at least a peak strain of 0.31 mm/mm. These findings and reported methodology will be used in the development of a human infant FE model to simulate real-world falls and identify injury thresholds for predicting IH in infants. (C) 2012 ISDN. Published by Elsevier Ltd. All rights reserved.	[Coats, Brittany] Univ Utah, Dept Mech Engn, Salt Lake City, UT 84112 USA; [Eucker, Stephanie A.] Univ Virginia, Dept Emergency Med, Charlottesville, VA 22908 USA; [Sullivan, Sarah; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Coats, B (corresponding author), Univ Utah, Dept Mech Engn, 50 S Cent Campus Dr, Salt Lake City, UT 84112 USA.	brittany.coats@utah.edu	Eucker, Stephanie/AAL-1828-2021; Coats, Brittany/A-4523-2009	Eucker, Stephanie/0000-0001-9986-5773; 	CDC-NCIPCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01-CE001445]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS39679, T32-NS043126-07]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679, T32NS043126] Funding Source: NIH RePORTER	The authors would like to thank Erica Hummel and Jill Ralston for their technical assistance with the IHP scoring. This study was made possible by the generous support of the CDC-NCIPC R01-CE001445, NIH-NINDS R01-NS39679, and NIH-NINDS T32-NS043126-07.	Arbogast K., 1997, P 41 STAPP CAR CRASH; Bertocci GE, 2004, INJURY, V35, P417, DOI 10.1016/S0020-1383(03)00062-7; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Bloomfield IG, 1998, PEDIATR NEUROSURG, V28, P246, DOI 10.1159/000028659; Brands D., 1999, P 43 STAPP CAR CRASH; BYLSKI DI, 1986, J BIOMECH, V19, P19, DOI 10.1016/0021-9290(86)90105-3; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Coats B., 2008, PEDIATRICS, V2, P1; Couper Z, 2008, BIOMECH MODEL MECHAN, V7, P105, DOI 10.1007/s10237-007-0079-9; Delye Hans, 2006, Stapp Car Crash J, V50, P625; Depreitere B, 2006, J NEUROSURG, V104, P950, DOI 10.3171/jns.2006.104.6.950; Eucker S., 2009, EFFECT HEAD ROTATION; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Haney SB, 2010, PEDIATR EMERG CARE, V26, P914, DOI 10.1097/PEC.0b013e3181fe9139; Hennrikus WL, 2003, CLIN ORTHOP RELAT R, P148, DOI 10.1097/01.blo.0000043059.62337.97; Ibrahim NG, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000956; KUIJPERS AHWM, 1995, J NEUROTRAUM, V12, P715, DOI 10.1089/neu.1995.12.715; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Macgregor D M, 2000, Inj Prev, V6, P291, DOI 10.1136/ip.6.4.291; Meaney D.F., 1991, BIOMECHANICS ACUTE S; Meyers MA., 1994, DYNAMIC BEHAV MAT, V2nd ed.; MILLER RT, 1999, 43 STAPP CAR CRASH C; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; MUSEMECHE CA, 1991, J TRAUMA, V31, P1347, DOI 10.1097/00005373-199110000-00004; Nicolle S, 2005, BIORHEOLOGY, V42, P209; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; ROOT I, 1992, AM J FOREN MED PATH, V13, P85, DOI 10.1097/00000433-199203000-00017; Roth S, 2008, COMPUT METH PROG BIO, V90, P262, DOI 10.1016/j.cmpb.2008.01.007; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Sawyer JR, 2000, J PEDIATR ORTHOPED, V20, P197, DOI 10.1097/00004694-200003000-00013; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; SMITH MD, 1975, J TRAUMA, V15, P987, DOI 10.1097/00005373-197511000-00008; Stemper BD, 2007, ANN BIOMED ENG, V35, P285, DOI 10.1007/s10439-006-9229-y; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; Wang MY, 2001, J PEDIATR SURG, V36, P1528, DOI 10.1053/jpsu.2001.27037; Yamada H., 1970, STRENGTH BIOL MAT; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Yan W., 2011, COMPUTER METHODS BIO	44	30	31	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		191	200		10.1016/j.ijdevneu.2011.12.009			10	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800004	22239917	Green Accepted, Green Published			2022-02-06	
J	Kelley, AM; Athy, JR; Cho, TH; Erickson, B; King, M; Cruz, P				Kelley, Amanda M.; Athy, Jeremy R.; Cho, Timothy H.; Erickson, Bradley; King, Melody; Cruz, Pedro			Risk propensity and health risk behaviors in U.S. army soldiers with and without psychological disturbances across the deployment cycle	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Risk propensity; Combat deployment; Health risk behaviors	POSTTRAUMATIC-STRESS-DISORDER; VENTROMEDIAL PREFRONTAL CORTEX; BECK DEPRESSION INVENTORY; TRAUMATIC BRAIN-INJURY; PSYCHOMETRIC PROPERTIES; MILITARY PERSONNEL; PERSONALITY; COMBAT; AFGHANISTAN; IRAQ	Anecdotal and preliminary evidence suggests that Soldiers returning from a combat deployment engage in an increased number of health risk behaviors. Three potential factors driving this change were examined in this study; posttraumatic stress disorder (PTSD), concussion and traumatic brain injury (TBI), and perceived invincibility. We studied members of a combat arms brigade one month prior to a deployment to Iraq and approximately one month after their return (N = 319). Participants anonymously completed surveys characterizing attitudes about risk, risk propensity, invincibility, engagement in health risk behaviors, and personality. Using standardized screening instruments, participants were categorized with respect to PTSD and probable TBI. Results suggest that Soldiers engage in more alcohol use and reckless driving behaviors post-deployment. These changes were exaggerated in those who screened positive for PTSD. Perception of one's invincibility and survival skills increased post-deployment thus suggesting that participants felt less susceptible to adverse consequences and more adept at surviving dangerous situations. This study provides documentation of the pattern of health behavior in Soldiers engaged in the deployment cycle. Our findings suggest increases in the number of risks Soldiers' engage in post-deployment are not limited to those with PTSD symptomtotology. This study has implications for not only adjustment to life post-deployment at the individual level but also operational readiness. Published by Elsevier Ltd.	[Kelley, Amanda M.; Athy, Jeremy R.; Cho, Timothy H.; Erickson, Bradley; King, Melody; Cruz, Pedro] USA, Aeromed Res Lab, Ft Rucker, AL 36362 USA		Kelley, AM (corresponding author), USA, Aeromed Res Lab, Bldg 6901,Farrel Rd,POB 620577, Ft Rucker, AL 36362 USA.	amanda.m.kelley@us.army.mil			Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [633002.800C5, 622787.869P1]	This project was funded by the Medical Research and Material Command under program element numbers 633002.800C5 and 622787.869P1. The funding source had no further role in study and statistical design, data collection, analysis, interpretation of findings, or writing of the report.	Bechara A, 2001, NEUROPSYCHOLOGIA, V39, P376, DOI 10.1016/S0028-3932(00)00136-6; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bell N S, 2001, Inj Prev, V7, P4, DOI 10.1136/ip.7.1.4; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Byrnes JP, 2005, DEV JUDGMENT DECISIO; Centers for Disease Control and Prevention, 2009, YOUTH BEH RISK SURV; Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348; Hewitt P. L., 1993, PSYCHOL ASSESSMENT, V5, P408, DOI DOI 10.1037/1040-3590.5.4.408; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Killgore WDS, 2006, MIL MED, V171, P233, DOI 10.7205/MILMED.171.3.233; Killgore WDS, 2008, J PSYCHIATR RES, V42, P58; Killgore WDS, 2010, MIL MED, V175, P499, DOI 10.7205/MILMED-D-09-00240; King D. W., 2003, MANUAL DEPLOYMENT RI; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lejuez CW, 2002, J EXP PSYCHOL-APPL, V8, P75, DOI 10.1037//1076-898X.8.2.75; MCCRAE RR, 1994, CURR DIR PSYCHOL SCI, V3, P173, DOI 10.1111/1467-8721.ep10770693; MOLINA ME, 2007, WORLD J BIOL PSYCHIA, V13, P1; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; O'Jile JR, 2004, APPL NEUROPSYCHOL, V11, P107, DOI 10.1207/s15324826an1102_7; PARKER D, 1995, ERGONOMICS, V38, P1036, DOI 10.1080/00140139508925170; Roberts BW, 2008, CURR DIR PSYCHOL SCI, V17, P31, DOI 10.1111/j.1467-8721.2008.00543.x; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sharkansky EJ, 2000, J ABNORM PSYCHOL, V109, P188, DOI 10.1037/0021-843X.109.2.188; Sicard B, 2001, MIL MED, V166, P871, DOI 10.1093/milmed/166.10.871; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Thomsen CJ, 2011, J PSYCHIATR RES, V45, P1321, DOI 10.1016/j.jpsychires.2011.04.003; ZUCKERMAN M, 1993, J PERS SOC PSYCHOL, V65, P757, DOI 10.1037/0022-3514.65.4.757; Zuckerman M, 2000, J PERS, V68, P999, DOI 10.1111/1467-6494.00124	36	30	30	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956			J PSYCHIATR RES	J. Psychiatr. Res.	MAY	2012	46	5					582	589		10.1016/j.jpsychires.2012.01.017			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	939VF	WOS:000303846500003	22305118	Green Submitted			2022-02-06	
J	Mossberg, KA; Fortini, E				Mossberg, Kurt A.; Fortini, Elizabeth			Responsiveness and Validity of the Six-Minute Walk Test in Individuals With Traumatic Brain Injury	PHYSICAL THERAPY			English	Article							MAXIMAL OXYGEN-CONSUMPTION; ADVANCED HEART-FAILURE; AEROBIC CAPACITY; CARDIORESPIRATORY FITNESS; ENERGY-EXPENDITURE; SUBACUTE STROKE; EXERCISE; RELIABILITY; CHILDREN; DISEASE	Background. A simple test of aerobic fitness for patients with traumatic brain injury (TBI) that is valid, reliable, and responsive to change is needed to provide clinicians a functional measure of cardiorespiratory capacity. Objective. The purpose of this study was to examine the validity and responsiveness to change of the Six-Minute Walk Test (6MWT) in individuals with TBI. Design. A cohort, pretest-posttest, comparison study was conducted. Methods. Twenty-one patients performed the 6MWT upon admission to and prior to discharge from a postacute rehabilitation facility. Heart rate and distance traveled were recorded. A physiologic cost index (PCI) (beats per meter) was calculated based on steady-state heart rate. At discharge, all participants were able to perform a graded treadmill exercise test to exhaustion during which peak oxygen consumption (Vo(2)) was measured. Results. Between admission and discharge, mean total distance increased from 342.6 m (SD=127.0) to 408.9 m (SD=124.2), and work increased from 27,185 kg.m (SD=10,528) to 34,114 kg.m (SD=12,057). The effect size indexes were 1.10 and 1.12 for distance and work, respectively. Correlations (r) between the discharge peak Vo(2) and the discharge 6MWT distance, PCI, and work were.58, -.61, and .47, respectively. Limitations. Stratification by gait speed may have improved responsiveness, especially for the slow ambulators. Conclusions. All measures correlated well with peak Vo(2), establishing an acceptable level of criterion-related (concurrent) validity. The addition of heart rate and calculating the PCI was only slightly better at predicting peak Vo(2), albeit nonsignificant, than a simple measure of total distance. The 6MWT provides a good estimate of peak aerobic capacity, and some measures are more responsive to change than others in patients recovering from TBI.	[Mossberg, Kurt A.] Univ Texas Med Branch, Dept Phys Therapy SHP, Galveston, TX 77555 USA; [Fortini, Elizabeth] Transit Learning Ctr, Dept Phys Therapy, Galveston, TX USA		Mossberg, KA (corresponding author), Univ Texas Med Branch, Dept Phys Therapy SHP, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Moody Foundation	This work was supported by the National Institute of Child Health and Human Development and the Moody Foundation.	BALKE B, 1959, U S Armed Forces Med J, V10, P675; BERG K, 1971, AM J CLIN NUTR, V24, P1438; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; CAHALIN L, 1995, CHEST, V108, P452, DOI 10.1378/chest.108.2.452; Cahalin LP, 1996, CHEST, V110, P325, DOI 10.1378/chest.110.2.325; Carter R, 2003, CHEST, V123, P1408, DOI 10.1378/chest.123.5.1408; Centers for Disease Control and Prevention, 2017, INJ PREV CONTR TRAUM; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COOPER KH, 1968, J AMER MED ASSOC, V203, P201, DOI 10.1001/jama.203.3.201; Demers C, 2001, AM HEART J, V142, P698, DOI 10.1067/mhj.2001.118468; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; Eaton T, 2005, AM J RESP CRIT CARE, V171, P1150, DOI 10.1164/rccm.200405-578OC; Eng JJ, 2004, ARCH PHYS MED REHAB, V85, P113, DOI 10.1016/S0003-9993(03)00436-2; Eng JJ, 2002, STROKE, V33, P756, DOI 10.1161/hs0302.104195; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HERMANSE.L, 1969, J APPL PHYSIOL, V26, P31, DOI 10.1152/jappl.1969.26.1.31; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; Kelly JO, 2003, ARCH PHYS MED REHAB, V84, P1780, DOI 10.1016/S0003-9993(03)00376-9; Latham NK, 2008, ARCH PHYS MED REHAB, V89, P2146, DOI 10.1016/j.apmr.2008.04.016; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; Lucas C, 1999, AM HEART J, V138, P618, DOI 10.1016/S0002-8703(99)70174-2; MacGregor J, 1981, Physiotherapy, V67, P30; MCGAVIN CR, 1976, BMJ-BRIT MED J, V1, P822, DOI 10.1136/bmj.1.6013.822; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; MOSSBERG KA, 1990, ARCH PHYS MED REHAB, V71, P490; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2003, AM J PHYS MED REHAB, V82, P385, DOI 10.1097/01.PHM.0000052589.96202.BE; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; MOSSBERG KA, 2003, BRAIN INJURY, V17, P266; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; NENE AV, 1990, ARCH PHYS MED REHAB, V71, P116; Nixon PA, 1996, J PEDIATR-US, V129, P362, DOI 10.1016/S0022-3476(96)70067-7; O'Keeffe ST, 1998, HEART, V80, P377, DOI 10.1136/hrt.80.4.377; Oudiz RJ, 2006, AM J CARDIOL, V97, P123, DOI 10.1016/j.amjcard.2005.07.129; Price LG, 1988, ARTHRIT CARE RES, V1, P33; Solway S, 2001, CHEST, V119, P256, DOI 10.1378/chest.119.1.256; STALLARD J, 1978, J MED ENG TECHNOL, V2, P22, DOI 10.3109/03091907809161744; Tang A, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-23; Thompson W R, 2010, ACSMS GUIDELINES EXE; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; Zugck C, 2000, EUR HEART J, V21, P540, DOI 10.1053/euhj.1999.1861	41	30	31	0	17	AMER PHYSICAL THERAPY ASSOC	ALEXANDRIA	1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA	0031-9023			PHYS THER	Phys. Ther.	MAY	2012	92	5					726	733		10.2522/ptj.20110157			8	Orthopedics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation	933PD	WOS:000303373400009	22282772	Bronze, Green Published			2022-02-06	
J	Shin, SS; Verstynen, T; Pathak, S; Jarbo, K; Hricik, AJ; Maserati, M; Beers, SR; Puccio, AM; Boada, FE; Okonkwo, DO; Schneider, W				Shin, Samuel S.; Verstynen, Timothy; Pathak, Sudhir; Jarbo, Kevin; Hricik, Allison J.; Maserati, Megan; Beers, Sue R.; Puccio, Ava M.; Boada, Fernando E.; Okonkwo, David O.; Schneider, Walter			High-definition fiber tracking for assessment of neurological deficit in a case of traumatic brain injury: finding, visualizing, and interpreting small sites of damage	JOURNAL OF NEUROSURGERY			English	Article						axonal injury; diffusion tensor imaging; traumatic brain injury; high-definition fiber tracking	DIFFUSE AXONAL INJURY	For patients with traumatic brain injury (TBI), current clinical imaging methods generally do not provide highly detailed information about the location of axonal injury, severity of injury, or expected recovery. In a case of severe TB!, the authors applied a novel high-definition fiber tracking (HDFT) to directly visualize and quantify the degree of axonal fiber damage and predict functional deficits due to traumatic axonal injury and loss of cortical projections. This 32-year-old man sustained a severe TBI. Computed tomography and MRI revealed an area of hemorrhage in the basal ganglia with mass effect, but no specific information on the location of axonal injury could be obtained from these studies. Examinations of the patient at Week 3 and Week 8 after TBI revealed motor weaknesses of the left extremities. Four months postinjury, 257-direction diffusion spectrum imaging and HDFT analysis was performed to evaluate the degree of axonal damage in the motor pathway and quantify asymmetries in the left and right axonal pathways. High-definition fiber tracking was used to follow corticospinal and corona radiata pathways from the cortical surface to the midbrain and quantify projections from motor areas. Axonal damage was then localized by assessing the number of descending fibers at the level of the cortex, internal capsule, and midbrain. The motor deficit apparent in the clinical examinations correlated with the axonal losses visualized using HDFT. Fiber loss estimates at 4 months postinjury accurately predicted the nature of the motor deficits (severe, focal left-hand weakness) when other standard clinical imaging modalities did not. A repeat scan at 10 months postinjury, when edema and hemorrhage had receded, replicated the fiber loss. Using HDFT, the authors accurately identified the presence and location of damage to the underlying white matter in this patient with TBI. Detailed information of injury provided by this novel technique holds future potential for precise neuroimaging assessment of TBI. (http://thejns.org/doi/abs/10.3171/2012.1.JNS111282)	[Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, UPMC Presbyterian, Pittsburgh, PA 15213 USA; [Boada, Fernando E.; Schneider, Walter] Univ Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15213 USA; [Beers, Sue R.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA; [Verstynen, Timothy; Pathak, Sudhir; Jarbo, Kevin; Schneider, Walter] Univ Pittsburgh, Ctr Learning Res & Dev, Pittsburgh, PA 15213 USA		Okonkwo, DO (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, UPMC Presbyterian, Suite B-400,200 Lothrop St, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu		Jarbo, Kevin/0000-0002-6356-0916	Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [D09PC75271]	Funding for this study was provided through a Defense Advanced Research Projects Agency (DARPA) contract (D09PC75271). The views, opinions, and/or findings contained in this paper are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of DARPA or the United States Department of Defense. The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Fernandez-Miranda JC, 2010, J NEUROSURG, V113, P990, DOI 10.3171/2009.10.JNS09933; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Jbabdi S, 2011, BRAIN CONNECT, V1, P169, DOI 10.1089/brain.2011.0033; Lee SK, 2005, RADIOGRAPHICS, V25, P53, DOI 10.1148/rg.251045085; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Verstynen T, 2011, J NEUROPHYSIOL, V105, P336, DOI 10.1152/jn.00698.2010; Yamada K, 2003, RADIOLOGY, V227, P295, DOI 10.1148/radiol.2271020313; Yokoyama K, 2008, AM J NEURORADIOL, V29, P1159, DOI 10.3174/ajnr.A1001	18	30	30	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1062	1069		10.3171/2012.1.JNS111282			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800022	22381003				2022-02-06	
J	Wilson, AG; Crystal, JD				Wilson, A. George; Crystal, Jonathon D.			Prospective memory in the rat	ANIMAL COGNITION			English	Article						Prospective memory; Prospection; Comparative cognition; Animal model; Rat	MENTAL TIME-TRAVEL; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; WESTERN SCRUB-JAYS; ALZHEIMERS-DISEASE; TASK INTERFERENCE; RADIAL MAZE; FUTURE; ANIMALS; PERFORMANCE	The content of prospective memory is comprised of representations of an action to perform in the future. When people form prospective memories, they temporarily put the memory representation in an inactive state while engaging in other activities, and then activate the representation in the future. Ultimately, successful activation of the memory representation yields an action at an appropriate, but temporally distant, time. A hallmark of prospective memory is that activation of the memory representation has a deleterious effect on current ongoing activity. Recent evidence suggests that scrub jays and non-human primates, but not other species, are capable of future planning. We hypothesized that prospective memory produces a selective deficit in performance at the time when rats access a memory representation but not when the memory representation is inactive. Rats were trained in a temporal bisection task (90 min/day). Immediately after the bisection task, half of the rats received an 8-g meal (meal group) and the other rats received no additional food (no-meal group). Sensitivity to time in the bisection task was reduced as the 90-min interval elapsed for the meal group but not for the no-meal group. This time-based prospective-memory effect was not based on response competition, an attentional limit, anticipatory contrast, or fatigue. Our results suggest that rats form prospective memories, which produces a negative side effect on ongoing activity.	[Wilson, A. George; Crystal, Jonathon D.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA; [Wilson, A. George; Crystal, Jonathon D.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA		Crystal, JD (corresponding author), Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA.	jcrystal@indiana.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080052]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080052] Funding Source: NIH RePORTER	This work was supported by National Institute of Mental Health grant R01MH080052 to JDC. We thank our colleague, the late Rich Marsh-scholar of prospective memory-for encouraging this work. We thank four anonymous reviewers for constructive criticism.	Aberle I, 2010, DEV PSYCHOL, V46, P1444, DOI 10.1037/a0020718; Atance CM, 2001, TRENDS COGN SCI, V5, P533, DOI 10.1016/S1364-6613(00)01804-0; Blanco-Campal A, 2009, J INT NEUROPSYCH SOC, V15, P154, DOI 10.1017/S1355617708090127; Church R.M., 1978, COGNITIVE PROCESS, P277; CHURCH RM, 1977, J EXP PSYCHOL ANIM B, V3, P216, DOI 10.1037/0097-7403.3.3.216; Clayton NS, 2003, NAT REV NEUROSCI, V4, P685, DOI 10.1038/nrn1180; Cohen J., 2013, STAT POWER ANAL BEHA; COOK RG, 1985, J EXP PSYCHOL ANIM B, V11, P453, DOI 10.1037/0097-7403.11.3.453; Correia SPC, 2007, CURR BIOL, V17, P856, DOI 10.1016/j.cub.2007.03.063; Craik FI., 1986, HUMAN MEMORY COGNITI, V5, P409; Crystal JD, 2003, BEHAV BRAIN RES, V144, P57, DOI 10.1016/S0166-4328(03)00062-7; Crystal JD, 2007, BEHAV PROCESS, V74, P152, DOI 10.1016/j.beproc.2006.10.008; Crystal JD, 2009, BEHAV PROCESS, V80, P269, DOI 10.1016/j.beproc.2008.09.009; d'Ydewalle G, 2001, AM J PSYCHOL, V114, P411, DOI 10.2307/1423688; Driscoll I, 2005, NEUROPSYCHOLOGY, V19, P28, DOI 10.1037/0894-4105.19.1.28; Einstein, 2007, PROSPECTIVE MEMORY O; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Flaherty C. F, 1996, INCENTIVE RELATIVITY; FLAHERTY CF, 1982, ANIM LEARN BEHAV, V10, P177, DOI 10.3758/BF03212267; Foster ER, 2009, NEUROPSYCHOLOGY, V23, P347, DOI 10.1037/a0014692; Gallistel CR, 2009, PSYCHOL REV, V116, P439, DOI 10.1037/a0015251; Gallistel C.R., 1990, ORG LEARNING; GIBBON J, 1984, ANN NY ACAD SCI, V423, P52, DOI 10.1111/j.1749-6632.1984.tb23417.x; Gipson CD, 2008, LEARN MOTIV, V39, P285, DOI 10.1016/j.lmot.2008.04.002; Harris J. E., 1984, EVERYDAY MEMORY ACTI, P71; Henry JD, 2004, PSYCHOL AGING, V19, P27, DOI 10.1037/0882-7974.19.1.27; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Hicks JL, 2005, J MEM LANG, V53, P430, DOI 10.1016/j.jml.2005.04.001; Jones S, 2006, NEUROPSYCHOLOGY, V20, P144, DOI 10.1037/0894-4105.20.2.144; Kliegel M, 2001, MEMORY, V9, P1, DOI 10.1080/09658210042000003; Marsh RL, 2006, MEM COGNITION, V34, P1037, DOI 10.3758/BF03193250; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; McCauley SR, 2009, NEUROPSYCHOLOGY, V23, P201, DOI 10.1037/a0014192; MECK WH, 1983, J EXP PSYCHOL ANIM B, V9, P171, DOI 10.1037/0097-7403.9.2.171; Metcalfe J., 2005, MISSING LINK COGNITI, P4, DOI DOI 10.1093/ACPROF:OSO/9780195161564.003.0001; Mulcahy NJ, 2006, SCIENCE, V312, P1038, DOI 10.1126/science.1125456; Naqshbandi M, 2006, J COMP PSYCHOL, V120, P345, DOI 10.1037/0735-7036.120.4.345; Osvath M, 2008, ANIM COGN, V11, P661, DOI 10.1007/s10071-008-0157-0; Osvath M, 2009, CURR BIOL, V19, pR190, DOI 10.1016/j.cub.2009.01.010; Raby CR, 2007, NATURE, V445, P919, DOI 10.1038/nature05575; Raby CR, 2009, BEHAV PROCESS, V80, P314, DOI 10.1016/j.beproc.2008.12.005; Raskin SA, 2011, NEUROPSYCHOLOGY, V25, P201, DOI 10.1037/a0020999; Roberts WA, 2002, PSYCHOL BULL, V128, P473, DOI 10.1037//0033-2909.128.3.473; Roberts WA, 2009, TRENDS COGN SCI, V13, P271, DOI 10.1016/j.tics.2009.03.003; Russell J, 2010, COGNITION, V114, P56, DOI 10.1016/j.cognition.2009.08.013; Schmitter-Edgecombe M, 2009, NEUROPSYCHOLOGY, V23, P168, DOI 10.1037/a0014186; Sheskin D, 2004, HDB PARAMETRIC NONPA; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Smith RE, 2007, J EXP PSYCHOL LEARN, V33, P734, DOI 10.1037/0278-7393.33.4.734; Suddendorf T, 2005, LEARN MOTIV, V36, P110, DOI 10.1016/j.lmot.2005.02.010; Suddendorf T, 2003, TRENDS COGN SCI, V7, P391, DOI 10.1016/S1364-6613(03)00187-6; Suddendorf T, 1997, GENET SOC GEN PSYCH, V123, P133; Suddendorf T, 2007, BEHAV BRAIN SCI, V30, P299, DOI 10.1017/S0140525X07001975; Troyer AK, 2007, J INT NEUROPSYCH SOC, V13, P365, DOI 10.1017/S1355617707070452; Tulving E., 2001, AGE FRONTAL LOBES, P311; Zentall TR, 2006, BEHAV PROCESS, V72, P173, DOI 10.1016/j.beproc.2006.01.009; Zentall TR, 2005, LEARN MOTIV, V36, P208, DOI 10.1016/j.lmot.2005.03.001	57	30	30	2	26	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1435-9448	1435-9456		ANIM COGN	Anim. Cogn.	MAY	2012	15	3					349	358		10.1007/s10071-011-0459-5			10	Behavioral Sciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Zoology	926ED	WOS:000302813200006	21922257	Green Accepted			2022-02-06	
J	Cervellin, G; Benatti, M; Carbucicchio, A; Mattei, L; Cerasti, D; Aloe, R; Lippi, G				Cervellin, Gianfranco; Benatti, Mario; Carbucicchio, Andrea; Mattei, Loris; Cerasti, Davide; Aloe, Rosalia; Lippi, Giuseppe			Serum levels of protein S100B predict intracranial lesions in mild head injury	CLINICAL BIOCHEMISTRY			English	Article						S100B; Computed tomography; Brain injury; Head trauma	TRAUMATIC BRAIN-INJURY; COMPUTED-TOMOGRAPHY; GUIDELINES; RULE; DIAGNOSIS; MARKER; ADULTS; SCAN	Objectives: This study was aimed to assess whether serum S100B levels at emergency department admission can be used to omit unnecessary computed tomography (CT) in patients with minor head injury (MHI). Design and methods: Sixty consecutive patients with recent MHI were included in this study. Serum S100B measurement and CT scanning were performed in all patients within 3 h from head injury. Results: A positive CT scan was present in 20 out of 60 subjects. Significantly higher values of protein S100B were found in CT positive than in CT negative patients (1.35 versus 0.48 mu g/L; p<0.001). The area under the ROC curve for protein S100B was highly significant (AUC 0.80; p<0.001) and a S100B cut-off value of 0.38 mu g/L displayed 100% sensitivity and 58% specificity. Conclusions: Serum S100-B levels might allow to omit unnecessary CT in patients with pure MHI, thus reducing radiation exposure and saving healthcare resources. (C) 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.	[Aloe, Rosalia; Lippi, Giuseppe] Univ Parma, Azienda Osped, Dipartimento Patol, UO Diagnost Ematochim, I-43126 Parma, Italy; [Aloe, Rosalia; Lippi, Giuseppe] Univ Parma, Azienda Osped, Med Lab, UO Diagnost Ematochim, I-43126 Parma, Italy; [Cerasti, Davide] Univ Parma, Azienda Osped, Dipartimento Neurosci, UO Neuroradiol, I-43126 Parma, Italy; [Cervellin, Gianfranco; Benatti, Mario; Carbucicchio, Andrea; Mattei, Loris] Univ Parma, Azienda Osped, Dipartimento Emergenza Urgenza, UO Pronto Soccorso Med Urgenza, I-43126 Parma, Italy		Lippi, G (corresponding author), Univ Parma, Azienda Osped, Dipartimento Patol, UO Diagnost Ematochim, Via Gramsci 14, I-43126 Parma, Italy.	glippi@ao.pr.it	Lippi, Giuseppe/X-7198-2018	Lippi, Giuseppe/0000-0001-9523-9054			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Dummer R, 2010, ANN ONCOL, V21, pv194, DOI 10.1093/annonc/mdq188; Goncalves CA, 2008, CLIN BIOCHEM, V41, P755, DOI 10.1016/j.clinbiochem.2008.04.003; Gonzalez-Quevedo A, 2011, CLIN BIOCHEM, V44, P154, DOI 10.1016/j.clinbiochem.2010.11.006; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; Hatpio R, 2004, CLIN BIOCHEM, V37, P512, DOI 10.1016/j.clinbiochem.2004.05.012; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, ACTA NEUROL SCAND, V93, P207; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Lippi G, 2011, CLIN BIOCHEM, V44, P567, DOI 10.1016/j.clinbiochem.2011.03.133; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; SNOEY ER, 1994, ANN EMERG MED, V23, P1127, DOI 10.1016/S0196-0644(94)70115-6; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tsoporis JN, 2011, AMINO ACIDS, V41, P843, DOI 10.1007/s00726-010-0527-1; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117; Zongo D, 2011, ANN EMERG MED   0922	30	30	35	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	APR	2012	45	6					408	411		10.1016/j.clinbiochem.2012.01.006			4	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	916OA	WOS:000302111900007	22285378				2022-02-06	
J	Larson, MJ; South, M; Clayson, PE; Clawson, A				Larson, Michael J.; South, Mikle; Clayson, Peter E.; Clawson, Ann			Cognitive control and conflict adaptation in youth with high-functioning autism	JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY			English	Article						N2; event-related potential; autism; conflict adaptation; cognitive control	DEVELOPMENTAL LANGUAGE DISORDER; ERROR-RELATED NEGATIVITY; TRAUMATIC BRAIN-INJURY; SPECTRUM DISORDERS; ANTERIOR CINGULATE; STROOP TASK; ERP; CHILDREN; DEFICITS; ADJUSTMENTS	Background: Youth diagnosed with autism spectrum disorders (ASD) often show deficits in cognitive control processes, potentially contributing to characteristic difficulties monitoring and regulating behavior. Modification of performance following conflict can be measured by examining conflict adaptation, the adjustment of cognitive resources based on previous-trial conflict. The electrophysiological correlates of these processes can be measured using the N2, a stimulus-locked component of the event-related potential (ERP). Methods: High-density ERPs and behavioral data [ i. e. response times (RTs) and error rates] were acquired while 28 youth with ASD and 36 typically developing controls completed a modified Eriksen flanker task. Results: Behaviorally, groups showed similar conflict adaptation effects; youth with ASD showed larger RT slowing on switch trials. For electrophysiology, controls demonstrated larger N2 amplitudes for incongruent (high-conflict) trials following congruent (low-conflict) trials than for incongruent trials following incongruent trials. Importantly, youth with ASD showed no such differences in N2 amplitude based on previous-trial conflict. Conclusions: Lack of electrophysiological conflict adaptation effects in youth with ASD indicates irregular neural processing associated with conflict adaptation. Individuals with ASD show declines in level of conflict evaluation and adaptation. Future research is necessary to accurately characterize and understand the behavioral implications of these cognitive control deficits relative to diagnostic severity, anxiety, and personality.	[Larson, Michael J.; South, Mikle; Clayson, Peter E.; Clawson, Ann] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Larson, Michael J.; South, Mikle] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA		Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, 244 TLRB, Provo, UT 84602 USA.	michael_larson@byu.edu	South, Mikle/H-4978-2013; Larson, Michael J/C-8543-2012; Clayson, Peter/AAC-9207-2019; Clayson, Peter E/F-5438-2011; Clayson, Peter/AAC-4028-2022	South, Mikle/0000-0003-0152-1257; Larson, Michael J/0000-0002-8199-8065; Clayson, Peter/0000-0003-4437-6598; Clayson, Peter E/0000-0003-4437-6598; Clawson, Ann/0000-0002-8669-0086	Brigham Young University College of Family, Home, and Social Sciences; Brigham Young University	We gratefully acknowledge the assistance of Annahir Cariello, Oliver Johnston, Jaime Ballard, Adrian Rockwell, Ryan Hunsaker, Sarah Van Tassell, Kyle Jamison, and Tiffani Newton. This study was supported by funds from the Brigham Young University College of Family, Home, and Social Sciences and a Brigham Young University Mentored Environment Grant.	Agam Y, 2010, NEUROIMAGE, V52, P336, DOI 10.1016/j.neuroimage.2010.04.010; Barnea-Goraly N, 2010, ARCH GEN PSYCHIAT, V67, P1052, DOI 10.1001/archgenpsychiatry.2010.123; Belmonte MK, 2004, J NEUROSCI, V24, P9228, DOI 10.1523/JNEUROSCI.3340-04.2004; Birmaher B, 1999, J AM ACAD CHILD PSY, V38, P1230, DOI 10.1097/00004583-199910000-00011; Bogte H, 2007, NEUROPSYCHOLOGIA, V45, P1707, DOI 10.1016/j.neuropsychologia.2006.12.020; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Clayson PE, 2011, PSYCHOPHYSIOLOGY, V48, P1621, DOI 10.1111/j.1469-8986.2011.01265.x; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; COURCHESNE E, 1989, J AUTISM DEV DISORD, V19, P1, DOI 10.1007/BF02212714; Courchesne E, 2001, NEUROLOGY, V57, P245, DOI 10.1212/WNL.57.2.245; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dien J, 2010, BRAIN RES, V1355, P126, DOI 10.1016/j.brainres.2010.07.099; Dien J, 2010, J NEUROSCI METH, V187, P138, DOI 10.1016/j.jneumeth.2009.12.009; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Ferri R, 2003, CLIN NEUROPHYSIOL, V114, P1671, DOI 10.1016/S1388-2457(03)00153-6; Griebling J, 2010, J CHILD NEUROL, V25, P856, DOI 10.1177/0883073809351313; Haznedar MM, 2000, AM J PSYCHIAT, V157, P1994, DOI 10.1176/appi.ajp.157.12.1994; Henderson H, 2006, BRAIN COGNITION, V61, P96, DOI 10.1016/j.bandc.2005.12.009; Henderson HA, 2010, DEV NEUROPSYCHOL, V35, P177, DOI 10.1080/87565640903526538; Herbert MR, 2004, ANN NEUROL, V55, P530, DOI 10.1002/ana.20032; Junghofer M, 1999, CLIN NEUROPHYSIOL, V110, P1149, DOI 10.1016/S1388-2457(99)00044-9; Just MA, 2007, CEREB CORTEX, V17, P951, DOI 10.1093/cercor/bhl006; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Ladouceur CD, 2010, DEV NEUROPSYCHOL, V35, P194, DOI 10.1080/87565640903526553; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROPSYCHOLOGIA, V47, P663, DOI 10.1016/j.neuropsychologia.2008.11.013; Levitt JG, 2003, BIOL PSYCHIAT, V54, P1355, DOI 10.1016/S0006-3223(03)00688-7; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; Mayr U, 2003, NAT NEUROSCI, V6, P450, DOI 10.1038/nn1051; Nieuwenhuis S, 2006, MEM COGNITION, V34, P1260, DOI 10.3758/BF03193270; Ozonoff S., 2007, NEW DEV AUTISM FUTUR, P185; Salmond CH, 2007, CORTEX, V43, P686, DOI 10.1016/S0010-9452(08)70498-2; Solomon M, 2008, INT J DEV NEUROSCI, V26, P239, DOI 10.1016/j.ijdevneu.2007.11.001; Solomon M, 2009, NEUROPSYCHOLOGIA, V47, P2515, DOI 10.1016/j.neuropsychologia.2009.04.019; South M, 2010, BIOL PSYCHOL, V85, P242, DOI 10.1016/j.biopsycho.2010.07.009; Thakkar KN, 2008, BRAIN, V131, P2464, DOI 10.1093/brain/awn099; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Vlamings PHJM, 2008, EUR J NEUROSCI, V28, P399, DOI 10.1111/j.1460-9568.2008.06336.x; Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x	41	30	32	2	36	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0021-9630			J CHILD PSYCHOL PSYC	J. Child Psychol. Psychiatry	APR	2012	53	4					440	448		10.1111/j.1469-7610.2011.02498.x			9	Psychology, Developmental; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	895LT	WOS:000300498400013	22176206				2022-02-06	
J	Robertson, CS; Cherian, L; Shah, M; Garcia, R; Navarro, JC; Grill, RJ; Hand, CC; Tian, TS; Hannay, HJ				Robertson, Claudia S.; Cherian, Leela; Shah, Mahek; Garcia, Robert; Navarro, Jovany Cruz; Grill, Raymond J.; Hand, Carla Cerami; Tian, Tian Siva; Hannay, H. Julia			Neuroprotection with an Erythropoietin Mimetic Peptide (pHBSP) in a Model of Mild Traumatic Brain Injury Complicated by Hemorrhagic Shock	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; head trauma; ischemia; secondary insult; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; CONTROLLED CORTICAL IMPACT; CRITICALLY-ILL PATIENTS; TISSUE-PLASMINOGEN ACTIVATOR; FOCAL CEREBRAL-ISCHEMIA; CARBAMYLATED ERYTHROPOIETIN; ENHANCES NEUROGENESIS; NEURONAL APOPTOSIS; BLOOD-FLOW; IN-VITRO	Pyroglutamate helix B surface peptide (pHBSP) is an 11 amino acid peptide, designed to interact with a novel cell surface receptor, composed of the classical erythropoietin (EPO) receptor disulfide linked to the beta common receptor. pHBSP has the cytoprotective effects of EPO without stimulating erythropoiesis. Effects on early cerebral hemodynamics and neurological outcome at 2 weeks post-injury were compared in a rat model of mild cortical impact injury (3m/sec, 2.5 mm deformation) followed by 50 min of hemorrhagic hypotension (MAP 40 mm Hg for 50 min). Rats were randomly assigned to receive 5000 U/kg of EPO, 30 mu g/kg of pHBSP, or an inactive substance every 12 h for 3 days, starting at the end of resuscitation from the hemorrhagic hypotension, which was 110 min post-injury. Both treatments reduced contusion volume at 2 weeks post-injury, from 20.8 +/- 2.8 mm(3) in the control groups to 7.7 +/- 2.0 mm(3) in the EPO-treated group and 5.9 +/- 1.5 mm(3) in the pHBSP-treated group (p = 0.001). Both agents improved recovery of cerebral blood flow in the injured brain following resuscitation, and resulted in more rapid recovery of performance on beam balancing and beam walking tests. These studies suggest that pHBSP has neuroprotective effects similar to EPO in this model of combined brain injury and hypotension. pHBSP may be more useful in the clinical situation because there is less risk of thrombotic adverse effects.	[Robertson, Claudia S.; Cherian, Leela; Shah, Mahek; Garcia, Robert; Navarro, Jovany Cruz] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX USA; [Hand, Carla Cerami] Univ N Carolina, Dept Epidemiol, Gillisngs Sch Global Publ Hlth, Chapel Hill, NC USA; [Tian, Tian Siva] Univ Houston, Dept Psychol, Houston, TX USA		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.edu		Hannay, H. Julia/0000-0001-7023-912X; Cerami, Carla/0000-0002-7634-0955	U.S. ArmyUnited States Department of Defense [W81XWH-08-2-0132, W81XWH-08-2-0150]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS077964] Funding Source: NIH RePORTER	This work was funded by U.S. Army Award numbers W81XWH-08-2-0132 (C.S.R.) and W81XWH-08-2-0150 (R.J.G.). Araim Pharmaceuticals, Ossining, NY, USA supplied the pHBSP for the study.	Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Ahmet I, 2011, MOL MED, V17, P194, DOI 10.2119/molmed.2010.00235; Brines M, 2008, J INTERN MED, V264, P405, DOI 10.1111/j.1365-2796.2008.02024.x; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Dicato M, 2008, ONCOLOGIST, V13, P11, DOI 10.1634/theoncologist.13-S3-11; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Elliott S, 1997, BLOOD, V89, P493, DOI 10.1182/blood.V89.2.493; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2001, J Neurosurg Sci, V45, P7; Jia LF, 2010, STROKE, V41, P2071, DOI 10.1161/STROKEAHA.110.586198; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Mann C, 2008, EXP NEUROL, V211, P34, DOI 10.1016/j.expneurol.2007.12.013; Marti HH, 2000, NEWS PHYSIOL SCI, V15, P225; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Napolitano LM, 2008, J TRAUMA, V65, P285, DOI 10.1097/TA.0b013e31817f2c6e; Pinzon A, 2008, EXP NEUROL, V213, P129, DOI 10.1016/j.expneurol.2008.05.018; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Springborg JB, 2002, BRIT J PHARMACOL, V135, P823, DOI 10.1038/sj.bjp.0704521; Ueba H, 2010, P NATL ACAD SCI USA, V107, P14357, DOI 10.1073/pnas.1003019107; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Zarychanski R, 2007, CAN MED ASSOC J, V177, P725, DOI 10.1503/cmaj.071055; Zechariah A, 2010, STROKE, V41, P1008, DOI 10.1161/STROKEAHA.109.574418	44	30	32	1	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1156	1166		10.1089/neu.2011.1827			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100016	21545288	Green Published			2022-02-06	
J	Ahmed, AI; Shtaya, AB; Zaben, MJ; Owens, EV; Kiecker, C; Gray, WP				Ahmed, Aminul I.; Shtaya, Anan B.; Zaben, Malik J.; Owens, Emma V.; Kiecker, Clemens; Gray, William P.			Endogenous GFAP-Positive Neural Stem/Progenitor Cells in the Postnatal Mouse Cortex Are Activated following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral cortex; organotypic slices; stem cells; TBI	HIPPOCAMPAL SLICE CULTURES; CENTRAL-NERVOUS-SYSTEM; SONIC-HEDGEHOG; STEM-CELLS; CEREBRAL-CORTEX; ADULT MICE; PROGENITOR CELLS; DENTATE GYRUS; NEURONAL PRECURSORS; COGNITIVE FUNCTION	Interest in promoting regeneration of the injured nervous system has recently turned toward the use of endogenous stem cells. Elucidating cues involved in driving these precursor cells out of quiescence following injury, and the signals that drive them toward neuronal and glial lineages, will help to harness these cells for repair. Using a biomechanically validated in vitro organotypic stretch injury model, cortico-hippocampal slices from postnatal mice were cultured and a stretch injury equivalent to a severe traumatic brain injury (TBI) applied. In uninjured cortex, proliferative potential under in vitro conditions is virtually absent in older slices (equivalent postnatal day 15 compared to 8). However, following a severe stretch injury, this potential is restored in injured outer cortex. Using slices from mice expressing a fluorescent reporter on the human glial fibrillary acidic protein (GFAP) promoter, we show that GFAP + cells account for the majority of proliferating neurospheres formed, and that these cells are likely to arise from the cortical parenchyma and not from the subventricular zone. Moreover, we provide evidence for a correlation between upregulation of sonic hedgehog signaling, a pathway known to regulate stem cell proliferation, and this restoration of regenerative potential following TBI. Our results indicate that a source of quiescent endogenous stem cells residing in the cortex and subcortical tissue proliferate in vitro following TBI. Moreover, these proliferating cells are multipotent and are derived mostly from GFAP-expressing cells. This raises the possibility of using this endogenous source of stem cells for repair following TBI.	[Gray, William P.] Univ Southampton, Fac Med, Dept Clin Neurosci, Southampton SO16 6YD, Hants, England; [Ahmed, Aminul I.; Shtaya, Anan B.; Zaben, Malik J.; Gray, William P.] Southampton Univ Hosp NHS Trust, Wessex Neurol Ctr, Southampton, Hants, England; [Kiecker, Clemens] Kings Coll London, MRC Ctr Dev Neurobiol, London WC2R 2LS, England		Gray, WP (corresponding author), Univ Southampton, Fac Med, Dept Clin Neurosci, LD70,Level D,S Acad Block,Tremona Rd, Southampton SO16 6YD, Hants, England.	W.P.Gray@soton.ac.uk	Kiecker, Clemens/C-7170-2009; Shtaya, Anan/AAX-2494-2020	Shtaya, Anan/0000-0001-7459-8437; Zaben, Malik/0000-0002-7446-4532; Gray, William/0000-0001-7595-8887; Ahmed, Aminul/0000-0001-6670-0438	Wessex Medical Research; Wessex Neurological Centre Trust; Royal College of Surgeons of England; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0300356]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0801418B] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0300356] Funding Source: UKRI	This study was supported by the Wessex Medical Research (A. I. A), the Wessex Neurological Centre Trust (A. I. A), the Royal College of Surgeons of England (A. I. A), and the Medical Research Council (strategic grant G0300356 to W. P. G). We thank Professor Frank Kirchhoff (Gottingen) and Alexei Verkhratsky (Manchester) for supply of the GFAP-GFP transgenic mice, and David Johnston (Biomedical Imaging Unit, University of Southampton) for help with image analysis.	Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Bendel O, 2005, J CEREBR BLOOD F MET, V25, P1586, DOI 10.1038/sj.jcbfm.9600153; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; Burns KA, 2009, GLIA, V57, P1115, DOI 10.1002/glia.20835; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; Chapman SC, 2002, DEV BIOL, V245, P187, DOI 10.1006/dbio.2002.0641; Chechneva O, 2005, NEUROSCIENCE, V136, P343, DOI 10.1016/j.neuroscience.2005.07.058; Chen JH, 2004, P NATL ACAD SCI USA, V101, P16357, DOI 10.1073/pnas.0406795101; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coles-Takabe BLK, 2008, STEM CELLS, V26, P2938, DOI 10.1634/stemcells.2008-0558; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Dimou L, 2008, J NEUROSCI, V28, P10434, DOI 10.1523/JNEUROSCI.2831-08.2008; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Garcia ADR, 2010, J NEUROSCI, V30, P13597, DOI 10.1523/JNEUROSCI.0830-10.2010; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Han YG, 2008, NAT NEUROSCI, V11, P277, DOI 10.1038/nn2059; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Jhaveri DJ, 2010, J NEUROSCI, V30, P2795, DOI 10.1523/JNEUROSCI.3780-09.2010; Jiao J, 2008, STEM CELLS, V26, P1221, DOI 10.1634/stemcells.2007-0513; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koketsu D, 2003, J NEUROSCI, V23, P937; Kondziolka D, 2005, J NEUROSURG, V103, P38, DOI 10.3171/jns.2005.103.1.0038; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Krystkowiak P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000166; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nolte C, 2001, GLIA, V33, P72; Ohira K, 2010, NAT NEUROSCI, V13, P173, DOI 10.1038/nn.2473; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Palmer TD, 1999, J NEUROSCI, V19, P8487; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Raineteau O, 2004, MOL CELL NEUROSCI, V26, P241, DOI 10.1016/j.mcn.2004.01.003; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Richardson RM, 2006, ACTA NEUROCHIR, V148, P773, DOI 10.1007/s00701-006-0778-5; Rivers LE, 2008, NAT NEUROSCI, V11, P1392, DOI 10.1038/nn.2220; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; RUIZ IAA, 2002, NAT REV NEUROSCI, V3, P24, DOI DOI 10.1038/NRN704; Salman H, 2004, J NEUROTRAUM, V21, P283, DOI 10.1089/089771504322972077; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Seidenfaden R, 2006, MOL CELL NEUROSCI, V32, P187, DOI 10.1016/j.mcn.2006.04.003; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Soares HD, 1995, J NEUROSCI, V15, P8223; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Wang L, 2007, J BIOL CHEM, V282, P32462, DOI 10.1074/jbc.M706880200; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zaben M, 2009, STEM CELLS, V27, P2539, DOI 10.1002/stem.184	75	30	32	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					828	842		10.1089/neu.2011.1923			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900011	21895532	Green Published			2022-02-06	
J	Berger, RP; Beers, SR; Papa, L; Bell, M				Berger, Rachel P.; Beers, Sue R.; Papa, Linda; Bell, Michael			Common Data Elements for Pediatric Traumatic Brain Injury: Recommendations from the Biospecimens and Biomarkers Workgroup	JOURNAL OF NEUROTRAUMA			English	Article						best practices; biomarkers; common data elements; pediatrics; standardization; traumatic brain injury	URINARY S100B PROTEIN; SERUM; INFANTS	Biospecimens represent a critically important resource in pediatric brain injury research. Data from these specimens can be used to identify and classify injury, understand the molecular mechanisms underlying different types of brain injury, and ultimately identify therapeutic targets to tailor treatments for individual patient needs. To realize the full potential of biospecimens in pediatric traumatic brain injury (TBI), standardization and adoption of best practice guidelines are needed to ensure the quality and consistency of specimens. Multiple groups, including the National Cancer Institute (NCI), the International Society for Biological and Environmental Repositories (ISBER), and the Organisation for Economic Co-operation and Development (OECD), have previously published best practice guidelines for biospecimen resources. Recommendations have also been provided by the Biospecimens and Biomarkers Workgroup of the interagency TBI Common Data Elements (CDE) initiative. The recommendations from all of these sources, however, focus exclusively on adult biospecimen collection. There are no published pediatric-specific biospecimen collection guidelines. An additional workgroup was formed to specifically address this gap. The aim of the Pediatric TBI CDE Biospecimens and Biomarkers Workgroup was to provide recommendations for best practice guidelines to standardize the quality and accessibility of biospecimens for pediatric brain injury research in general, and for pediatric TBI research in particular. Consensus recommendations were developed by review of previously published adult-specific recommendations, including the recommendations of the original TBI Common Data Elements Biospecimens and Biomarkers Workgroup, and by participation in the interagency workshop "Common Data Elements for TBI Research: Pediatric Considerations," held in Houston, Texas in March of 2010. These recommendations represent expert opinion on this subject. The authors of this article were members of the Biospecimens Workgroup. We hope that with adoption of these best practices, future investigators will be able to obtain biospecimens in a consistent way that meets the needs of pediatric patients, and helps to accelerate acquisition of pediatric-specific biomarker data.	[Berger, Rachel P.; Bell, Michael] Univ Pittsburgh, Safar Ctr Resuscitat Res, Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA 15224 USA; [Beers, Sue R.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15224 USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Beers, Sue R.] Univ Pittsburgh, Inst Review Board, Pittsburgh, PA 15224 USA		Berger, RP (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Childrens Hosp Pittsburgh UPMC, 4427 Penn Ave, Pittsburgh, PA 15224 USA.	rachel.berger@chp.edu			National Institutes of Health-National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); U.S. Department of Education/National Institute on Disability and Rehabilitation ResearchUS Department of Education; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	This project was jointly supported by the National Institutes of Health-National Institute of Neurological Disorders and Stroke, and the U.S. Department of Education/National Institute on Disability and Rehabilitation Research.	Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; [Anonymous], 2007, NIH PUB; Berger R, 2009, PEDIATR CRIT CARE ME, V10, P260, DOI 10.1097/PCC.0b013e31819a376d; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Donato R, 2007, CURR MOL MED, V7, P711, DOI 10.2174/156652407783220688; Eiseman E., 2003, CASE STUDIES EXISTIN; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gazzolo D, 2003, ARCH PEDIAT ADOL MED, V157, P1163, DOI 10.1001/archpedi.157.12.1163; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Goncalves C.A., 2010, CARDIOVASC PSYCHIAT, V2010, DOI [DOI 10.1155/2010/790431, 10.1155/2010/790431]; Holtkamp K, 2008, J NEURAL TRANSM, V115, P937, DOI 10.1007/s00702-008-0041-8; International Society for Biological and Environmental Repositories, 2005, CHIN TAIW UN DET, P5; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Miller A., 2011, J NEUROTRAU IN PRESS; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Netto CBO, 2006, ARCH MED RES, V37, P683, DOI 10.1016/j.arcmed.2005.11.005; Ost M, 2008, ACTA ANAESTH SCAND, V52, P1364, DOI 10.1111/j.1399-6576.2008.01675.x; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Portela LVC, 2002, CLIN CHEM, V48, P950; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034	22	30	30	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					672	677		10.1089/neu.2011.1861			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500006	22106839	Green Published			2022-02-06	
J	Gasco, V; Prodam, F; Pagano, L; Grottoli, S; Belcastro, S; Marzullo, P; Beccuti, G; Ghigo, E; Aimaretti, G				Gasco, Valentina; Prodam, Flavia; Pagano, Loredana; Grottoli, Silvia; Belcastro, Sara; Marzullo, Paolo; Beccuti, Guglielmo; Ghigo, Ezio; Aimaretti, Gianluca			Hypopituitarism following brain injury: when does it occur and how best to test?	PITUITARY			English	Article						Brain Injuries; Hypopituitarism; Diagnosis	ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY DYSFUNCTION; LONG-TERM; NEUROENDOCRINE DYSFUNCTION; HIGH-RISK; PREVALENCE; LESIONS; TBI; DEFICIENCY; SURVIVORS	Aim of this review is to highlight how and when Traumatic Brain Injury (TBI) as well as Subarachnoid Haemorrhage (SAH) and primary Brain Tumours (pBT) of the Central Nervous System (CNS) can induce hypopituitarism, an under-diagnosed clinical problem. Moreover, this review aims to clarify, on the basis of the recent evidences, how these patients have to be tested for pituitary-function. Both retrospective and prospective studies recommended that patients with more severe form of Brain Injuries (BI) and in particular, those with fractures of the base of the skull or early diabetes insipidus, have to be closely monitored for signs and symptoms of endocrine dysfunction. Further studies will be crucial to raise awareness and remind physicians on the prevalence of hypopituitarism in patients with BI and to elucidate any incremental benefits these patients may receive from hormone replacement.	[Gasco, Valentina; Grottoli, Silvia; Beccuti, Guglielmo; Ghigo, Ezio] Univ Turin, Dept Internal Med, Div Endocrinol & Metab, I-10126 Turin, Italy; [Prodam, Flavia; Pagano, Loredana; Belcastro, Sara; Marzullo, Paolo; Aimaretti, Gianluca] Univ Eastern Piedmont Amedeo Avogadro, Dept Clin & Expt Med, Div Endocrinol, Novara, Italy; [Marzullo, Paolo] San Giuseppe Hosp, Oggebbio, Verbania, Italy		Gasco, V (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab, Cso Dogliotti 14, I-10126 Turin, Italy.	valentina.gasco@unito.it	Marzullo, Paolo/K-6371-2016; Pagano, Loredana/AAK-9139-2020; Beccuti, Guglielmo/AAI-5452-2021; Prodam, Flavia/B-8844-2013	Marzullo, Paolo/0000-0003-3215-5747; Beccuti, Guglielmo/0000-0003-3163-2361; Prodam, Flavia/0000-0001-9660-5335			Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2007, NAT CLIN PRACT ENDOC, V3, P318, DOI 10.1038/ncpendmet0460; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2006, J CLIN ENDOCR METAB, V91, P3928, DOI 10.1210/jc.2006-1040; Brandt L, 2004, ACTA NEUROL SCAND, V109, P91, DOI 10.1046/j.0001-6314.2003.00189.x; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Ceballos R, 1966, Ala J Med Sci, V3, P185; CROMPTON MR, 1963, BRAIN, V86, P301, DOI 10.1093/brain/86.2.301; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1959, LANCET, V2, P927; Dimopoulou I, 2004, STROKE, V35, P2884, DOI 10.1161/01.STR.0000147716.45571.45; EDWARDS OM, 1986, MEDICINE, V65, P281; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hellawell DJ, 2001, DISABIL REHABIL, V23, P300, DOI 10.1080/769979114; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schneider HJ, 2006, EUR J ENDOCRINOL, V155, P559, DOI 10.1530/eje.1.02272; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, ACTA NEUROCHIR, V148, P449, DOI 10.1007/s00701-005-0724-y; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476	38	30	34	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X			PITUITARY	Pituitary	MAR	2012	15	1					20	24		10.1007/s11102-010-0235-6			5	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	904IG	WOS:000301187500003	20526744				2022-02-06	
J	Ji, J; Tyurina, YY; Tang, MK; Feng, WH; Stolz, DB; Clark, RSB; Meaney, DF; Kochanek, PM; Kagan, VE; Bayir, H				Ji, Jing; Tyurina, Yulia Y.; Tang, Minke; Feng, Weihong; Stolz, Donna B.; Clark, Robert S. B.; Meaney, David F.; Kochanek, Patrick M.; Kagan, Valerian E.; Bayir, Huelya			Mitochondrial Injury after Mechanical Stretch of Cortical Neurons in vitro: Biomarkers of Apoptosis and Selective Peroxidation of Anionic Phospholipids	JOURNAL OF NEUROTRAUMA			English	Article						cardiolipin; in vitro traumatic brain injury; mitochondria; oxidative lipidomics; oxidative stress	TRAUMATIC BRAIN-INJURY; DEPENDENT PROTEIN-KINASE; CYTOCHROME-C RELEASE; INDUCED CELL-DEATH; OXIDATIVE LIPIDOMICS; ER STRESS; CARDIOLIPIN; MODEL; ACTIVATION; DAMAGE	Mechanical injury of neurites accompanied by rupture of mitochondrial membranes may lead to immediate nonspecific release and spreading of pro-apoptotic factors and activation of proteases, that is, execution of apoptotic program. In the current work, we studied the time course of the major biomarkers of apoptosis as they are induced by exposure of rat cortical neurons to mechanical stretch. By using transmission electron microscopy, we found that mitochondria in the neurites were damaged early (1 h) after mechanical stretch injury whereas somal mitochondria were significantly more resistant and demonstrated structural damage and degenerative mitochondrial changes at a later time point after stretch (12 h). We also report that the stretch injury caused immediate activation of reactive oxygen species production followed by selective oxidation of a mitochondria-specific phospholipid, cardiolipin, whose individual peroxidized molecular species have been identified and quantified by electrospray ionization mass spectrometry analysis. Most abundant neuronal phospholipids - phosphatidylcholine, phophatidylethanolamine - did not undergo oxidative modification. Simultaneously, a small-scale release of cytochrome c was observed. Notably, caspase activation and phosphatidylserine externalization - two irreversible apoptotic events designating a point of no return - are substantially delayed and do not occur until 6-12 h after the initial impact. The early onset of reactive oxygen species production and cytochrome c release may be relevant to direct stretch-induced damage to mitochondria. The delayed emergence of apoptotic neuronal death after the immediate mechanical damage to mitochondria suggests a possible window of opportunity for targeted therapies.	[Ji, Jing; Tyurina, Yulia Y.; Feng, Weihong; Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA USA; [Ji, Jing; Tyurina, Yulia Y.; Feng, Weihong; Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Tang, Minke; Clark, Robert S. B.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Tang, Minke; Clark, Robert S. B.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Stolz, Donna B.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA; [Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Tyurina, YY (corresponding author), Bridgeside Point, 100 Technol Dr,Suite 350, Pittsburgh, PA 15219 USA.	yyt1@pitt.edu; bayihx@ccm.upmc.edu	Ji, J/O-2816-2013; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885; Meaney, David/0000-0002-0954-4122; Tyurina, Yulia/0000-0003-0287-2091	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL70755, U19AI068021, NS061817]; Defense Advanced Research Projects Agency Preventing Violent Explosive Neurologic Trauma (DARPA PREVENT) [N66001-10-C-2124]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817] Funding Source: NIH RePORTER	This work was ssupported by grants from the National Institute of Health (HL70755, U19AI068021, NS061817) and by the Defense Advanced Research Projects Agency Preventing Violent Explosive Neurologic Trauma (DARPA PREVENT) blast program N66001-10-C-2124. The views, opinions, and/or findings contained in this article should not be interpreted as representing the official views or policies, either expressed or implied, of DARPA or the Department of Defense.	Ainslie KM, 2008, ACS NANO, V2, P1076, DOI 10.1021/nn800071k; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bayir H, 2009, J BIOL CHEM, V284, P15951, DOI 10.1074/jbc.M900418200; Borisenko GG, 2008, BIOCHEMISTRY-US, V47, P13699, DOI 10.1021/bi801507s; BOTTCHER CSF, 1961, ANAL CHIM ACTA, V1061, P203; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007; Cardaci S, 2008, MOL PHARMACOL, V74, P1234, DOI 10.1124/mol.108.048975; Chauvier D, 2007, CELL DEATH DIFFER, V14, P387, DOI 10.1038/sj.cdd.4402044; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Dai DF, 2011, J AM COLL CARDIOL, V58, P73, DOI 10.1016/j.jacc.2010.12.044; Dietz GPH, 2007, BRAIN RES, V1164, P136, DOI 10.1016/j.brainres.2007.06.025; Fadeel B, 2003, CELL MOL LIFE SCI, V60, P2575, DOI 10.1007/s00018-003-3145-1; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gartlon J, 2006, TOXICOL IN VITRO, V20, P1569, DOI 10.1016/j.tiv.2006.07.009; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gil-Ad I, 2001, CELL MOL NEUROBIOL, V21, P705, DOI 10.1023/A:1015152021192; Iverson SL, 2004, ARCH BIOCHEM BIOPHYS, V423, P37, DOI 10.1016/j.abb.2003.12.002; Ji J., 2010, J NEUROTRAUM, V5, pA; Jiang JF, 2004, LIPIDS, V39, P1133, DOI 10.1007/s11745-004-1340-1; Jiang JF, 2008, INT J RADIAT ONCOL, V70, P816, DOI 10.1016/j.ijrobp.2007.10.047; Kagan VE, 2009, MOL NUTR FOOD RES, V53, P104, DOI 10.1002/mnfr.200700402; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kagan VE, 2003, AM J PHYSIOL-LUNG C, V285, pL1, DOI 10.1152/ajplung.00365.2002; Kapralov AA, 2007, BIOCHEMISTRY-US, V46, P14232, DOI 10.1021/bi701237b; Kiebish MA, 2008, J NEUROCHEM, V106, P299, DOI 10.1111/j.1471-4159.2008.05383.x; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuznetsov AV, 2009, INT J BIOCHEM CELL B, V41, P1928, DOI 10.1016/j.biocel.2009.03.007; Lahiry L, 2008, APOPTOSIS, V13, P771, DOI 10.1007/s10495-008-0213-x; LAI JCK, 1977, J NEUROCHEM, V28, P625, DOI 10.1111/j.1471-4159.1977.tb10434.x; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Macias CA, 2007, ANN SURG, V245, P305, DOI 10.1097/01.sla.0000236626.57752.8e; Mironov SL, 2009, INT J BIOCHEM CELL B, V41, P2005, DOI 10.1016/j.biocel.2009.04.009; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P1, DOI 10.1016/j.proghi.2008.10.002; Petrosillo G, 2006, FEBS LETT, V580, P6311, DOI 10.1016/j.febslet.2006.10.036; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Pop C, 2008, METHOD ENZYMOL, V446, P351, DOI 10.1016/S0076-6879(08)01621-2; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Schlame M, 2008, J LIPID RES, V49, P1607, DOI 10.1194/jlr.R700018-JLR200; Schwartz J.C., 2005, P 53 AM SOC MASS SPE; Shimazawa M, 2007, INVEST OPHTH VIS SCI, V48, P3729, DOI 10.1167/iovs.06-1122; Shimazawa M, 2006, NEUROSCI LETT, V409, P192, DOI 10.1016/j.neulet.2006.09.074; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Sparvero LJ, 2010, J NEUROCHEM, V115, P1322, DOI 10.1111/j.1471-4159.2010.07055.x; Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Suzuki M, 2005, J NEUROSCI RES, V80, P549, DOI 10.1002/jnr.20461; Tyurin VA, 2008, J NEUROCHEM, V107, P1614, DOI 10.1111/j.1471-4159.2008.05728.x; Tyurina YY, 2006, MOL PHARMACOL, V70, P706, DOI 10.1124/mol.106.022731; Tyurina YY, 2004, BIOCHEM BIOPH RES CO, V324, P1059, DOI 10.1016/j.bbrc.2004.09.102; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yang LH, 2000, NEUROSCI LETT, V295, P97, DOI 10.1016/S0304-3940(00)01597-4; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zielonka J, 2010, FREE RADICAL BIO MED, V48, P983, DOI 10.1016/j.freeradbiomed.2010.01.028	75	30	32	0	18	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	5					776	788		10.1089/neu.2010.1602			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	907TZ	WOS:000301442900008	21895519	Green Published			2022-02-06	
J	Zumsteg, JM; Ennis, SK; Jaffe, KM; Mangione-Smith, R; MacKenzie, EJ; Rivara, FP				Zumsteg, Jennifer M.; Ennis, Stephanie K.; Jaffe, Kenneth M.; Mangione-Smith, Rita; MacKenzie, Ellen J.; Rivara, Frederick P.		Natl Expert Panel Dev Pediat Rehab	Quality of Care Indicators for the Structure and Organization of Inpatient Rehabilitation Care of Children With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Outcome and process assessment (health care); Pediatrics; Quality of health care; Rehabilitation	POSTACUTE REHABILITATION; UNITED-STATES; OUTCOMES; MORTALITY; VOLUME; CENTERS; POLICY	Zumsteg JM, Ennis SK, Jaffe KM, MangioneSmith R, MacKenzie EJ, Rivara FP, and the National Expert Panel for the Development of Pediatric Rehabilitation Quality of Care Indicators. Quality of care indicators for the structure and organization of inpatient rehabilitation care of children with traumatic brain injury. Arch Phys Med Rehabil 2012;93:386-93. Objectives: To develop evidence-based and expert-driven quality indicators for measuring variations in the structure and organization of acute inpatient rehabilitation for children after traumatic brain injury (TBI) and to survey centers across the United States to determine the degree of variation in care. Design: Quality indicators were developed using the RAND/UCLA modified Delphi method. Adherence to these indicators was determined from a survey of rehabilitation facilities. Setting: Inpatient rehabilitation units in the United States. Participants: A sample of rehabilitation programs identified using data from the National Association of Children's Hospitals and Related Institutions, Uniform Data System for Medical Rehabilitation, and the Commission on Accreditation of Rehabilitation Facilities yielded 74 inpatient units treating children with TBI. Survey respondents comprised 31 pediatric and 28 all age units. Interventions: Not applicable. Main Outcome Measures: Variations in structure and organization of care among institutions providing acute inpatient rehabilitation for children with TBI. Results: Twelve indicators were developed. Pediatric inpatient rehabilitation units and units with higher volumes of children with TBI were more likely to have: a census of at least 1 child admitted with a TBI for at least 90% of the time; adequate specialized equipment; a classroom; a pediatric sub-specialty trained medical director; and more than 75% of therapists with pediatric training. Conclusions: There were clinically and statistically significant variations in the structure and organization of acute pediatric rehabilitation based on the pediatric focus of the unit and volume of children with TBI.	[Ennis, Stephanie K.; Jaffe, Kenneth M.; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Zumsteg, Jennifer M.; Ennis, Stephanie K.; Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Mangione-Smith, Rita; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Mangione-Smith, Rita; Rivara, Frederick P.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Baltimore, MD USA		Rivara, FP (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu		Zumsteg, Jennifer/0000-0002-0678-0103; Gaebler-Spira, Deborah/0000-0001-6827-4241; Krach, Linda/0000-0002-0993-8199	Eunice Kennedy Shriver National Institute of Child Health & Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD059049-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD059049] Funding Source: NIH RePORTER	Supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development (grant no. R21 HD059049-01A1).	Aiken LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI 10.1001/jama.288.16.1987; Aiken LH, 2010, HEALTH SERV RES, V45, P904, DOI 10.1111/j.1475-6773.2010.01114.x; [Anonymous], 2011, EM MED SERV TRAUM SY; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROOK RH, 1994, METHODOLOGICAL PERSP; Carney N, 1999, Evid Rep Technol Assess (Summ), P1; Clohan DB, 2007, ARCH PHYS MED REHAB, V88, P1535, DOI 10.1016/j.apmr.2007.07.022; Committee for the Accreditation of Rehabilitation Facilities (CARF), 2009, MED REH STAND MAN; Cortes CG, 2008, J PEDIATR REHAB MED, V1, P51; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Donabedian A, 1980, EXPLORATIONS QUALITY; Duncan PW, 2007, ARCH PHYS MED REHAB, V88, P1482, DOI 10.1016/j.apmr.2007.08.118; Faul M, 2010, TRAUMATIC BRAIN INJU; Fitch K, 2006, RAND UCLA APPROPRIAT; FRENCH K, 1981, INT J NURS STUD, V18, P7, DOI 10.1016/0020-7489(81)90004-3; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hoenig H, 2002, MED CARE, V40, P1036, DOI 10.1097/00005650-200211000-00005; Hoenig H, 2001, HEALTH SERV RES, V35, P1293; Jaffe KM, 2008, J TRAUMA, V64, P819, DOI 10.1097/TA.0b013e318165f177; Jha AK, 2008, NEW ENGL J MED, V359, P1921, DOI 10.1056/NEJMsa0804116; Kane RL, 2007, MED CARE, V45, P1195, DOI 10.1097/MLR.0b013e3181468ca3; Kravitz RL, 1997, HEALTH POLICY, V42, P135, DOI 10.1016/S0168-8510(97)00064-X; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2008, J BONE JOINT SURG AM, V90A, P101, DOI 10.2106/JBJS.F.01225; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Odetola FO, 2010, ARCH PEDIAT ADOL MED, V164, P277, DOI 10.1001/archpediatrics.2009.285; Orr RA, 2009, PEDIATRICS, V124, P40, DOI 10.1542/peds.2008-0515; Petrosyan M, 2009, J TRAUMA, V67, pS114, DOI 10.1097/TA.0b013e3181ad3251; PHILIPS B, OXFORD CTR EVIDENCE; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; Reuben DB, 2002, MED CARE, V40, P416, DOI 10.1097/00005650-200205000-00007; Shekelle PG, 1998, INT J TECHNOL ASSESS, V14, P707, DOI 10.1017/S0266462300012022; Sitzia J, 1998, INT J QUAL HEALTH C, V10, P311, DOI 10.1093/intqhc/10.4.311; The ERABI Research Group, EV BAS REV MOD SEV A; TURNERSTOKES L, 2003, REHABILITATION FOLLO; Wesson D, 2001, J TRAUMA, V51, P832; Whyte J, 2009, NEUROPSYCHOL REHABIL, V19, P807, DOI 10.1080/09602010903031146	41	30	30	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2012	93	3					386	393		10.1016/j.apmr.2011.08.018			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	902GW	WOS:000301027600002	22280893	Green Accepted			2022-02-06	
J	Rodger, J; Drummond, ES; Hellstrom, M; Robertson, D; Harvey, AR				Rodger, Jennifer; Drummond, Eleanor S.; Hellstroem, Mats; Robertson, Donald; Harvey, Alan R.			Long-Term Gene Therapy Causes Transgene-Specific Changes in the Morphology of Regenerating Retinal Ganglion Cells	PLOS ONE			English	Article							PERIPHERAL-NERVE GRAFTS; LEBERS CONGENITAL AMAUROSIS; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH; DENDRITIC GROWTH; PROTEASE NEXIN-1; ADULT CATS; SYMPATHETIC NEURONS; HIPPOCAMPAL-NEURONS; AXONAL REGENERATION	Recombinant adeno-associated viral (rAAV) vectors can be used to introduce neurotrophic genes into injured CNS neurons, promoting survival and axonal regeneration. Gene therapy holds much promise for the treatment of neurotrauma and neurodegenerative diseases; however, neurotrophic factors are known to alter dendritic architecture, and thus we set out to determine whether such transgenes also change the morphology of transduced neurons. We compared changes in dendritic morphology of regenerating adult rat retinal ganglion cells (RGCs) after long-term transduction with rAAV2 encoding: (i) green fluorescent protein (GFP), or (ii) bi-cistronic vectors encoding GFP and ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF) or growth-associated protein-43 (GAP43). To enhance regeneration, rats received an autologous peripheral nerve graft onto the cut optic nerve of each rAAV2 injected eye. After 5-8 months, RGCs with regenerated axons were retrogradely labeled with fluorogold (FG). Live retinal wholemounts were prepared and GFP positive (transduced) or GFP negative (non-transduced) RGCs injected iontophoretically with 2% lucifer yellow. Dendritic morphology was analyzed using Neurolucida software. Significant changes in dendritic architecture were found, in both transduced and non-transduced populations. Multivariate analysis revealed that transgenic BDNF increased dendritic field area whereas GAP43 increased dendritic complexity. CNTF decreased complexity but only in a subset of RGCs. Sholl analysis showed changes in dendritic branching in rAAV2-BDNF-GFP and rAAV2-CNTF-GFP groups and the proportion of FG positive RGCs with aberrant morphology tripled in these groups compared to controls. RGCs in all transgene groups displayed abnormal stratification. Thus in addition to promoting cell survival and axonal regeneration, vector-mediated expression of neurotrophic factors has measurable, gene-specific effects on the morphology of injured adult neurons. Such changes will likely alter the functional properties of neurons and may need to be considered when designing vector-based protocols for the treatment of neurotrauma and neurodegeneration.	[Rodger, Jennifer] Univ Western Australia, Sch Anim Biol, Perth, WA 6009, Australia; [Drummond, Eleanor S.; Hellstroem, Mats; Harvey, Alan R.] Univ Western Australia, Sch Anat & Human Biol, Perth, WA 6009, Australia; [Robertson, Donald] Univ Western Australia, Discipline Physiol, Sch Biomed & Biomol Sci, Perth, WA 6009, Australia		Rodger, J (corresponding author), Univ Western Australia, Sch Anim Biol, Perth, WA 6009, Australia.	alan.harvey@uwa.edu.au	Harvey, Alan R/A-4911-2008; Drummond, Eleanor/AAB-9731-2021; Rodger, Jennifer/H-5735-2014	Rodger, Jennifer/0000-0003-3413-4229; Drummond, Eleanor/0000-0002-5466-4609; , Alan/0000-0002-2590-831X	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; WA Neurotrauma Research Program; Raine Foundation of Western Australia; International Postgraduate Student Scholarship	The research was supported by the National Health and Medical Research Council (NHMRC) and the WA Neurotrauma Research Program. JR was funded by the Raine Foundation of Western Australia and a Senior Research Fellowship from NHMRC. MH was funded by an International Postgraduate Student Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; Bjorklund T, 2010, MOVEMENT DISORD, V25, pS161, DOI 10.1002/mds.22785; BRAY GM, 1987, J EXP BIOL, V132, P5; Chacon PJ, 2010, MOL CELL NEUROSCI, V43, P384, DOI 10.1016/j.mcn.2010.01.005; Chiwitt C, 2011, RESTOR NEUROL NEUROS, V29, P127, DOI 10.3233/RNN-2011-0586; CHOI BH, 1995, NEUROBIOL AGING, V16, P557, DOI 10.1016/0197-4580(95)00060-R; Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086; Cohen-Cory S, 2004, INT J DEV BIOL, V48, P947, DOI 10.1387/ijdb.041883sc; Cui Q, 2000, NEUROREPORT, V11, P3999, DOI 10.1097/00001756-200012180-00019; D Kuipers S, 2006, CURR OPIN DRUG DISC, V9, P580; de Winter W, 2001, NATURE, V409, P710, DOI 10.1038/35055547; Deplano S, 2004, DEV NEUROSCI-BASEL, V26, P396, DOI 10.1159/000082282; Deplano S, 1999, J COMP NEUROL, V405, P262, DOI 10.1002/(SICI)1096-9861(19990308)405:2<262::AID-CNE9>3.0.CO;2-4; DIAZNIDO J, 1991, J CELL SCI, V98, P409; Dijkhuizen PA, 2005, PROG BRAIN RES, V147, P17, DOI 10.1016/S0079-6123(04)47002-2; DREHER B, 1985, BRAIN BEHAV EVOLUT, V26, P10, DOI 10.1159/000118764; Du JL, 2004, NATURE, V429, P878, DOI 10.1038/nature02618; Eberling JL, 2008, NEUROLOGY, V70, P1980, DOI 10.1212/01.wnl.0000312381.29287.ff; FAMIGLIETTI EV, 1976, SCIENCE, V194, P193, DOI 10.1126/science.959847; Frey D, 2000, J CELL BIOL, V149, P1443, DOI 10.1083/jcb.149.7.1443; FUKUDA Y, 1977, BRAIN RES, V119, P327, DOI 10.1016/0006-8993(77)90314-6; Fukuda Y, 1998, VISION RES, V38, P1545, DOI 10.1016/S0042-6989(98)00005-4; Gauthier-Campbell C, 2004, MOL BIOL CELL, V15, P2205, DOI 10.1091/mbc.E03-07-0493; Germain F, 2003, EUR J NEUROSCI, V18, P1103, DOI 10.1046/j.1460-9568.2003.02842.x; Guo X, 1999, J NEUROSCI, V19, P2113; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Hellstrom M, 2011, MOL CELL NEUROSCI, V46, P507, DOI 10.1016/j.mcn.2010.12.003; Hellstrom M, 2011, J NEUROTRAUM, V28, P2475, DOI 10.1089/neu.2011.1928; Hellstrom M, 2011, CURR GENE THER, V11, P116, DOI 10.2174/156652311794940746; Horch HW, 2004, REV NEUROSCIENCE, V15, P117; Horch HW, 2002, NAT NEUROSCI, V5, P1177, DOI 10.1038/nn927; Huberman AD, 2008, NEURON, V59, P425, DOI 10.1016/j.neuron.2008.07.018; Huxlin KR, 1997, J COMP NEUROL, V385, P309; Kells AP, 2008, GENE THER, V15, P966, DOI 10.1038/gt.2008.23; Klein RL, 1999, BRAIN RES, V832, P136, DOI 10.1016/S0006-8993(99)01482-1; Klein RL, 1999, NEUROSCIENCE, V90, P815, DOI 10.1016/S0306-4522(98)00537-5; Kong JH, 2005, J COMP NEUROL, V489, P293, DOI 10.1002/cne.20631; Kwon M, 2011, J NEUROSCI, V31, P9735, DOI 10.1523/JNEUROSCI.6785-10.2011; Lagriffoul A, 1996, J BIOL CHEM, V271, P31508, DOI 10.1074/jbc.271.49.31508; LAU KC, 1991, RESTOR NEUROL NEUROS, V3, P235, DOI 10.3233/RNN-1991-3502; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252; Lin B, 2004, NEURON, V43, P475, DOI 10.1016/j.neuron.2004.08.002; Luikart BW, 2008, J NEUROSCI, V28, P7006, DOI 10.1523/JNEUROSCI.0195-08.2008; Mandel RJ, 2010, CURR OPIN MOL THER, V12, P240; Marks WJ, 2008, LANCET NEUROL, V7, P400, DOI 10.1016/S1474-4422(08)70065-6; MARTIN PR, 1986, EXP BRAIN RES, V62, P77; Meins M, 2001, J NEUROSCI, V21, P8830, DOI 10.1523/JNEUROSCI.21-22-08830.2001; Miller FD, 2003, CURR OPIN NEUROBIOL, V13, P391, DOI 10.1016/s0959-4388(03)00072-2; Milosevic NT, 2009, J THEOR BIOL, V259, P142, DOI 10.1016/j.jtbi.2009.03.011; Miyoshi T, 1999, EXP BRAIN RES, V124, P383, DOI 10.1007/s002210050635; Mizuguchi H, 2000, MOL THER, V1, P376, DOI 10.1006/mthe.2000.0050; Niclou SP, 1998, EUR J NEUROSCI, V10, P1590, DOI 10.1046/j.1460-9568.1998.00183.x; Park KK, 2009, MOL CELL NEUROSCI, V41, P313, DOI 10.1016/j.mcn.2009.04.002; Parrish JZ, 2007, ANNU REV NEUROSCI, V30, P399, DOI 10.1146/annurev.neuro.29.051605.112907; PERRY VH, 1979, PROC R SOC SER B-BIO, V204, P363, DOI 10.1098/rspb.1979.0033; Quan MZ, 1999, INVEST OPHTH VIS SCI, V40, P2360; Ramaswamy S, 2009, NEUROBIOL DIS, V34, P40, DOI 10.1016/j.nbd.2008.12.005; REINHARD E, 1994, J NEUROSCI RES, V37, P256, DOI 10.1002/jnr.490370211; Richardson RM, 2011, MOL THER, V19, P1048, DOI 10.1038/mt.2011.11; Robinson GA, 2004, VISION RES, V44, P2667, DOI 10.1016/j.visres.2004.06.010; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Sapieha PS, 2003, MOL CELL NEUROSCI, V24, P656, DOI 10.1016/S1044-7431(03)00228-8; Schmeer C, 2002, EUR J NEUROSCI, V15, P637, DOI 10.1046/j.1460-9568.2002.01893.x; SHOLL DA, 1953, J ANAT, V87, P387; Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Sommerfeld MT, 2000, J BIOL CHEM, V275, P8982, DOI 10.1074/jbc.275.12.8982; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; Sun WZ, 2002, VISUAL NEUROSCI, V19, P483, DOI 10.1017/S0952523802194107; THANOS S, 1995, J NEUROSCI, V15, P1057, DOI 10.1523/jneurosci.15-02-01057.1995; THANOS S, 1988, CELL TISSUE RES, V254, P599; Tolwani RJ, 2002, NEUROSCIENCE, V114, P795, DOI 10.1016/S0306-4522(02)00301-9; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; WASSLE H, 1988, TRENDS NEUROSCI, V11, P87, DOI 10.1016/0166-2236(88)90147-6; WATANABE M, 1993, J NEUROSCI, V13, P2105; Weber AJ, 2008, INVEST OPHTH VIS SCI, V49, P2456, DOI 10.1167/iovs.07-1325; Wu K, 2003, HUM GENE THER, V14, P1463, DOI 10.1089/104303403769211673; Yacoubian TA, 2000, NAT NEUROSCI, V3, P342, DOI 10.1038/73911; Yang Y, 2009, J GENE MED, V11, P899, DOI 10.1002/jgm.1377; Yata T, 2007, NEUROSCIENCE, V148, P53, DOI 10.1016/j.neuroscience.2007.05.042; Zagrebelsky M, 2005, J NEUROSCI, V25, P9989, DOI 10.1523/JNEUROSCI.2492-05.2005; ZURN AD, 1988, DEV NEUROSCI-BASEL, V10, P17, DOI 10.1159/000111951	87	30	30	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2012	7	2							e31061	10.1371/journal.pone.0031061			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924ZP	WOS:000302730100037	22347429	gold, Green Published, Green Submitted			2022-02-06	
J	Callcut, RA; Hanseman, DJ; Solan, PD; Kadon, KS; Ingalls, NK; Fortuna, GR; Tsuei, BJ; Robinson, BRH				Callcut, Rachael A.; Hanseman, Dennis J.; Solan, Patrick D.; Kadon, Kurt S.; Ingalls, Nichole K.; Fortuna, Gerald R.; Tsuei, Betty J.; Robinson, Bryce R. H.			Early treatment of blunt cerebrovascular injury with concomitant hemorrhagic neurologic injury is safe and effective	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 14-17, 2011	Chicago, IL	Amer Assoc Surg Trauma		Blunt cerebrovascular injury; traumatic brain injury; carotid injury; vertebral injury	VENOUS THROMBOEMBOLISM; PROPHYLAXIS; MANAGEMENT; ANTICOAGULATION; ASSOCIATION; DIAGNOSIS	BACKGROUND: Early pharmacologic treatment for blunt cerebrovascular injury (BCVI) is often withheld when concomitant traumatic brain injury or cervical spinal cord injury occurs. This study examines the safety and efficacy of early treatment for patients with both BCVI and traumatic neurologic injury (TNI). METHODS: Ten-year retrospective review of patients with BCVI and a TNI was performed. Stroke outcomes for those treated with pharmacologic therapy for their BCVI were compared with those not treated. In addition, the likelihood of worsening of TNI was determined for those exposed to pharmacologic therapy compared with those not exposed. Multivariate logistic regression techniques were used to analyze adjusted odds ratio for stroke risk. RESULTS: Seventy-seven patients were identified with BCVI + TNI. Strokes occurred in 27% patients with 3 of 21 (14%) strokes present at arrival. There were no differences in baseline characteristics between groups. Stroke rate was higher in the untreated group compared with treated (57% vs. 4%, p < 0.0001). On multivariate regression, treatment status was the most significant stroke predictor (adjusted odds ratio 4.4, 3.0-6.5, p < 0.0001, c-stat 0.93). There was no difference in risk of hemorrhagic deterioration of traumatic brain injury based on pharmacologic exposure versus no exposure (5% vs. 6%, p = 0.6). Likewise, no patient with spinal cord injury worsened as a result of pharmacologic exposure. Of the potentially preventable strokes, 24% (4 of 17) resulted in a stroke-related death and all four deaths occurred in the untreated group. CONCLUSION: The benefit of early treatment for BCVI markedly outweighs the risk of treatment for patients suffering concomitant BCVI and hemorrhagic neurologic injury. (J Trauma. 2012; 72: 338-346. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Callcut, Rachael A.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA; [Hanseman, Dennis J.; Solan, Patrick D.; Kadon, Kurt S.; Ingalls, Nichole K.; Fortuna, Gerald R.; Tsuei, Betty J.; Robinson, Bryce R. H.] Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA		Callcut, RA (corresponding author), 300 Pasteur Dr,S-067B, Stanford, CA 94305 USA.	rcallcut@stanford.edu	Callcut, Rachael/ABE-1484-2021				Barnes Bryan, 2004, Neurosurg Focus, V17, pE5; Berne JD, 2010, J VASC SURG, V51, P57, DOI 10.1016/j.jvs.2009.08.071; Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Bromberg WJ, 2011, J TRAUMA, V70, P1063; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Cothren C. Clay, 2005, Clinics, V60, P489, DOI 10.1590/S1807-59322005000600011; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; DiCocco JM, 2011, J AM COLL SURGEONS, V212, P549, DOI 10.1016/j.jamcollsurg.2010.12.035; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; Emmett KP, 2011, J TRAUMA, V70, P1058, DOI 10.1097/TA.0b013e318213f849; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; Flint L, 2011, J AM COLL SURGEONS, V212, P557; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P609, DOI 10.1001/archsurg.139.6.609; Mayberry JC, 2004, ARCH SURG-CHICAGO, V139, P612; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Romualdi E, 2009, THROMB HAEMOSTASIS, V101, P290, DOI 10.1160/TH08-07-0474; Scales DC, 2009, J CRIT CARE, V24, P176, DOI 10.1016/j.jcrc.2009.03.010; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Thumbikat P, 2002, SPINAL CORD, V40, P416, DOI 10.1038/sj.sc.3101325; Tominaga GT, 2002, ARCH SURG-CHICAGO, V137, P701; Vermes E, 2005, ASAIO J, V51, P485, DOI 10.1097/01.mat.0000169141.01817.e0; Wei CW, 2010, CAN J NEUROL SCI, V37, P574, DOI 10.1017/S0317167100010726	29	30	31	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2012	72	2					338	345		10.1097/TA.0b013e318243d978			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	898ZN	WOS:000300781000022	22327975				2022-02-06	
J	Joosse, P; Saltzherr, TP; van Lieshout, WAM; van Exter, P; Ponsen, KJ; Vandertop, WP; Goslings, JC				Joosse, Pieter; Saltzherr, Teun-Peter; van Lieshout, Willem A. M.; van Exter, Pieternel; Ponsen, Kees-Jan; Vandertop, W. Peter; Goslings, J. Carel		TraumaNet AMC Collaborating Hosp	Impact of secondary transfer on patients with severe traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Brain injury; Gclasgow Outcome Scale; Glasgow Coma Scale; In-hospital mortality; Patient transfer	EARLY DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; CHILDREN; SURGERY	BACKGROUND: Within a trauma network in the Netherlands, neurosurgical facilities are usually limited to Level I hospitals. Initial transport to a district hospital of patients who are later found to require neurosurgical intervention may cause delay. The purpose of this study was to assess the influence on outcome and time intervals of secondary transfer in trauma patients requiring emergency neurosurgical intervention. METHODS: In a 3-year period, all patients who sustained a severe traumatic brain injury and underwent a neurosurgical intervention within 6 hours after admission to a Level I trauma center were included. Patients were classified into two groups: direct presentation to the Level I trauma center (TC) group or requiring secondary transport after having been diagnosed for neurosurgical intervention in other hospitals (transfer group). RESULTS: Eighty patients were included for analyses. Twenty-four patients in the transfer group had a better Glasgow Coma Scale on-scene but a higher 30-day mortality compared with patients who were primarily presented to the Level I trauma center (33% vs. 27%; p = 0.553). In the transfer group, time to operation was 304 minutes compared with 151 minutes in the TC group (p < 0.001). Most delay occurred during the initial trauma evaluation and the interval between the first computed tomography and the transfer ambulance departure at the referring hospital. CONCLUSION: Patients requiring an emergency neurosurgical intervention appear to have a clinically relevant worse outcome after secondary transfer to a neurosurgical service. Therefore, patient care can probably be improved by better triage on-scene and standardized procedures in case of a secondary transfer. (J Trauma. 2012; 72: 487-490. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Joosse, Pieter; Saltzherr, Teun-Peter; van Lieshout, Willem A. M.; Goslings, J. Carel] Acad Med Ctr, Dept Surg, Trauma Unit, NL-1100 DD Amsterdam, Netherlands; [van Exter, Pieternel] Reg Ambulance Serv, Amsterdam, Netherlands; [Ponsen, Kees-Jan] Med Ctr Alkmaar, Dept Surg, Alkmaar, Netherlands; [Vandertop, W. Peter] Neurosurg Ctr, Amsterdam, Netherlands		Joosse, P (corresponding author), Acad Med Ctr, Dept Surg, Trauma Unit, Meibergdreef 9,POB 22660, NL-1100 DD Amsterdam, Netherlands.	p.joosse@amc.nl	Vandertop, William P./K-9288-2018	Vandertop, William/0000-0001-5417-0265			Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; *AM COLL SURG COMM, 2006, RES OPT CAR INJ PAT; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Eberle BM, 2010, INJURY, V41, P894, DOI 10.1016/j.injury.2010.02.023; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hedges JR, 2009, J EMERG MED, V37, P115, DOI 10.1016/j.jemermed.2008.07.001; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Joosse P, 2009, J CLIN NEUROSCI, V16, P925, DOI 10.1016/j.jocn.2008.06.014; Lee EJ, 1998, J TRAUMA, V45, P946, DOI 10.1097/00005373-199811000-00017; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Splavski B, 1998, SURG NEUROL, V50, P194, DOI 10.1016/S0090-3019(98)00047-0; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563, DOI 10.1089/neu.2000.17.563; The Brain TraumaFoundation, 2000, J NEUROTRAUM, V17, P583, DOI [10.1089/neu.2000.17.583, DOI 10.1089/NEU.2000.17.583]	22	30	31	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2012	72	2					487	490		10.1097/TA.0b013e318226ed59			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	898ZN	WOS:000300781000048	22327988				2022-02-06	
J	Campbell, JN; Low, B; Kurz, JE; Patel, SS; Young, MT; Churn, SB				Campbell, John N.; Low, Brian; Kurz, Jonathan E.; Patel, Sagar S.; Young, Matt T.; Churn, Severn B.			Mechanisms of Dendritic Spine Remodeling in a Rat Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						calcineurin; cofilin; excitatory post-synaptic protein PSD-95; lateral fluid percussion injury; spine-associated Rap guanosine triphosphatase activating protein	MAXIMAL CALCINEURIN ACTIVITY; LATERAL FLUID PERCUSSION; SUBCELLULAR-DISTRIBUTION; SIGNIFICANT INCREASE; HIPPOCAMPAL-NEURONS; PILOCARPINE MODEL; SYNAPTIC PROTEINS; OXIDATIVE STRESS; PHOSPHORYLATION; ASTROCYTES	Traumatic brain injury (TBI), a leading cause of death and disability in the United States, causes potentially preventable damage in part through the dysregulation of neural calcium levels. Calcium dysregulation could affect the activity of the calcium-sensitive phosphatase calcineurin (CaN), with serious implications for neural function. The present study used both an in vitro enzymatic assay and Western blot analyses to characterize the effects of lateral fluid percussion injury on CaN activity and CaN-dependent signaling in the rat forebrain. TBI resulted in an acute alteration of CaN phosphatase activity and long-lasting alterations of its downstream effector, cofilin, an actin-depolymerizing protein. These changes occurred bilaterally in the neocortex and hippocampus, appeared to persist for hours after injury, and coincided with synapse degeneration, as suggested by a loss of the excitatory post-synaptic protein PSD-95. Interestingly, the effect of TBI on cofilin in some brain regions was blocked by a single bolus of the CaN inhibitor FK506, given 1 h post-TBI. Overall, these findings suggest a loss of synapse stability in both hemispheres of the laterally-injured brain, and offer evidence for region-specific, CaN-dependent mechanisms.	[Campbell, John N.; Churn, Severn B.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Low, Brian; Churn, Severn B.] Virginia Commonwealth Univ, Dept Physiol & Biophys, Richmond, VA 23298 USA; [Kurz, Jonathan E.; Patel, Sagar S.; Young, Matt T.; Churn, Severn B.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA; [Churn, Severn B.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA		Churn, SB (corresponding author), Virginia Commonwealth Univ, Dept Anat, POB 980599, Richmond, VA 23298 USA.	schurn@vcu.edu		Kurz, Jonathan/0000-0002-2259-4263	Commonwealth Neurotrauma Initiative [07-302E]; Alzheimer's and Related Diseases Research Award Fund [11-1]	The authors are grateful to Drs. Bob Hamm and Tom Reeves for use of the fluid percussion injury device, and to Drs. Hamm and Leroy Thacker for guidance with statistics. The authors would also like to acknowledge David Register for his technical assistance with these studies. This work was supported by Commonwealth Neurotrauma Initiative grant 07-302E (to S.B.C.), and an Alzheimer's and Related Diseases Research Award Fund, award number 11-1 (to S.B.C.).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bales JW, 2010, BRAIN RES, V1358, P211, DOI 10.1016/j.brainres.2010.08.029; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell J.N., 2011, J NEUROTRAUMA   0425; Campbell JN, 2009, DENDRITIC SPINES: BIOCHEMISTRY, MODELING AND PROPERTIES, P45; CHURN SB, 1992, J NEUROCHEM, V59, P1221, DOI 10.1111/j.1471-4159.1992.tb08431.x; D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M, 2010, TRAUMATIC BRAIN INJU; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Groth RD, 2003, BIOCHEM BIOPH RES CO, V311, P1159, DOI 10.1016/j.bbrc.2003.09.002; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Kato H, 2000, MOL BRAIN RES, V84, P58, DOI 10.1016/S0169-328X(00)00210-2; KAY JE, 1989, CELL IMMUNOL, V124, P175, DOI 10.1016/0008-8749(89)90121-4; Kurz JE, 2005, BRAIN RES, V1048, P153, DOI 10.1016/j.brainres.2005.04.062; Kurz JE, 2005, J NEUROTRAUM, V22, P476, DOI 10.1089/neu.2005.22.476; Kurz JE, 2003, NEUROBIOL DIS, V14, P483, DOI 10.1016/j.nbd.2003.08.018; Kurz JE, 2001, J NEUROCHEM, V78, P304, DOI 10.1046/j.1471-4159.2001.00426.x; Kurz JE, 2008, EPILEPSIA, V49, P1696, DOI 10.1111/j.1528-1167.2008.01616.x; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Morishita W, 2005, NAT NEUROSCI, V8, P1043, DOI 10.1038/nn1506; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Pak DTS, 2003, SCIENCE, V302, P1368, DOI 10.1126/science.1082475; PALLEN CJ, 1985, ARCH BIOCHEM BIOPHYS, V237, P281, DOI 10.1016/0003-9861(85)90279-6; Park KS, 2006, SCIENCE, V313, P976, DOI 10.1126/science.1124254; Romero-Calvo I, 2010, ANAL BIOCHEM, V401, P318, DOI 10.1016/j.ab.2010.02.036; Seeburg DP, 2008, J NEUROSCI, V28, P6583, DOI 10.1523/JNEUROSCI.1853-08.2008; Seeburg DP, 2008, NEURON, V58, P571, DOI 10.1016/j.neuron.2008.03.021; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Szydlowska K, 2006, J NEUROCHEM, V99, P965, DOI 10.1111/j.1471-4159.2006.04136.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang Y, 2005, J BIOL CHEM, V280, P12683, DOI 10.1074/jbc.M411494200; Wu HY, 2010, J NEUROSCI, V30, P2636, DOI 10.1523/JNEUROSCI.4456-09.2010; Wu LX, 2007, BRAIN RES, V1168, P38, DOI 10.1016/j.brainres.2007.06.082; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011	46	30	31	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					218	234		10.1089/neu.2011.1762			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300003	21838518	Green Published			2022-02-06	
J	Sakurai, A; Atkins, CM; Alonso, OF; Bramlett, HM; Dietrich, WD				Sakurai, Atsushi; Atkins, Coleen M.; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton			Mild Hyperthermia Worsens the Neuropathological Damage Associated with Mild Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						concussion; dentate hilus; fluid-percussion brain injury; hyperthermia; temperature; traumatic brain injury	FLUID-PERCUSSION INJURY; CENTRAL-NERVOUS-SYSTEM; DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; INTRAVASCULAR COAGULATION; TEMPERATURE; HYPOTHERMIA; COAGULOPATHY; EXERCISE; MODEL	The effects of slight variations in brain temperature on the pathophysiological consequences of acute brain injury have been extensively described in models of moderate and severe traumatic brain injury (TBI). In contrast, limited information is available regarding the potential consequences of temperature elevations on outcome following mild TBI (mTBI) or concussions. One potential confounding variable with mTBI is the presence of elevated body temperature that occurs in the civilian or military populations due to hot environments combined with exercise or other forms of physical exertion. We therefore determined the histopathological effects of pre- and post-traumatic hyperthermia (39 degrees C) on mTBI. Adult male Sprague-Dawley rats were divided into 3 groups: pre/post-traumatic hyperthermia, post-traumatic hyperthermia alone for 2 h, and normothermia (37 degrees C). The pre/post-hyperthermia group was treated with hyperthermia starting 15 min before mild parasagittal fluid-percussion brain injury (1.4-1.6 atm), with the temperature elevation extending for 2h after trauma. At 72h after mTBI, the rats were perfusion-fixed for quantitative histopathological evaluation. Contusion areas and volumes were significantly larger in the pre/post-hyperthermia treatment group compared to the post-hyperthermia and normothermic groups. In addition, pre/post-traumatic hyperthermia caused the most severe loss of NeuN-positive cells in the dentate hilus compared to normothermia. These neuropathological results demonstrate that relatively mild elevations in temperature associated with pen-traumatic events may affect the long-term functional consequences of mTBI. Because individuals exhibiting mildly elevated core temperatures may be pre-disposed to aggravated brain damage after mTBI or concussion, precautions should be introduced to target this important physiological variable.	Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Lois Pope LIFE Ctr, Miami Project Cure Paralysis, 1095 NW 14th Terrace R-48, Miami, FL 33136 USA.	ddietrich@miami.edu		Atkins, Coleen/0000-0003-4718-7493	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 042133, R01 NS 056072, P50 NS 030291]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, R01NS056072, P50NS030291] Funding Source: NIH RePORTER	The authors wish to thank Jeremy Lytle for editorial assistance and David Sequeira and Yuan Kang for technical support. This study was supported in part by NIH grants R01 NS 042133, R01 NS 056072, and P50 NS 030291.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALMASHHADANI SA, 1994, BLOOD COAGUL FIBRIN, V5, P731, DOI 10.1097/00001721-199410000-00009; Atkins C.M., 2010, EUR J NEUROSCI, V28, P35; Avignone E, 2005, EUR J NEUROSCI, V22, P3077, DOI 10.1111/j.1460-9568.2005.04497.x; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bouchama A, 2005, J APPL PHYSIOL, V98, P697, DOI 10.1152/japplphysiol.00461.2004; Bouchama A, 1996, THROMB HAEMOSTASIS, V76, P909; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CABANAC M, 1975, ANNU REV PHYSIOL, V37, P415, DOI 10.1146/annurev.ph.37.030175.002215; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; CARLSSON C, 1976, J NEUROCHEM, V26, P1001, DOI 10.1111/j.1471-4159.1976.tb06484.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; Chinevere TD, 2008, EUR J APPL PHYSIOL, V103, P307, DOI 10.1007/s00421-008-0707-9; CHOPP M, 1988, STROKE, V19, P1521, DOI 10.1161/01.STR.19.12.1521; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dematte JE, 1998, ANN INTERN MED, V129, P173, DOI 10.7326/0003-4819-129-3-199808010-00001; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; Goosey-Tolfrey V, 2008, J APPL PHYSIOL, V105, P37, DOI 10.1152/japplphysiol.01084.2007; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HAYWARD JN, 1968, AM J PHYSIOL, V215, P389, DOI 10.1152/ajplegacy.1968.215.2.389; Hermstad Erik, 2010, J Emerg Trauma Shock, V3, P66, DOI 10.4103/0974-2700.58660; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KATSUMURA H, 1995, ACTA NEUROCHIR, V135, P62, DOI 10.1007/BF02307416; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer A.R., 2011, HUM BRAIN M IN PRESS; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Nybo L, 2002, J APPL PHYSIOL, V93, P58, DOI 10.1152/japplphysiol.00049.2002; Ohmoto Y, 1996, INT J HYPERTHER, V12, P321, DOI 10.3109/02656739609022521; Ozgunen KT, 2010, SCAND J MED SCI SPOR, V20, P140, DOI 10.1111/j.1600-0838.2010.01219.x; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Rasmussen P, 2010, ACTA PHYSIOL, V199, P63, DOI 10.1111/j.1748-1716.2010.02084.x; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Sinclair HL, 2010, CRIT CARE, V14, DOI 10.1186/cc8220; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; Sukstanskii AL, 2006, P NATL ACAD SCI USA, V103, P12144, DOI 10.1073/pnas.0604376103; Sun YR, 2011, BRIT J NEUROSURG, V25, P363, DOI 10.3109/02688697.2011.552650; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; TAKAGI K, 1994, AM J PHYSIOL-HEART C, V267, pH1770, DOI 10.1152/ajpheart.1994.267.5.H1770; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561	77	30	33	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					313	321		10.1089/neu.2011.2152			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300010	22026555	Green Published			2022-02-06	
J	Bashir, S; Vernet, M; Yoo, WK; Mizrahi, I; Theoret, H; Pascual-Leone, A				Bashir, Shahid; Vernet, Marine; Yoo, Woo-Kyoung; Mizrahi, Ilan; Theoret, Hugo; Pascual-Leone, Alvaro			Changes in cortical plasticity after mild traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Theta burst stimulation; motor cortex; excitability; EEG	HUMAN MOTOR CORTEX; STIMULATION; INHIBITION; CONCUSSION; SPORTS	Purpose: Even after a mild traumatic brain injury (TBI) symptoms may be long lasting and never resolve completely. The neurophysiologic substrate for such lasting deficits remains unclear. There is a lack of objective measures of early brain abnormalities following mild TBI, which could shed light on the genesis of these lasting impairments. Methods: Here we report findings in a previously healthy man tested 2 and 6 weeks after a well-documented concussion. Findings were compared with 12 control subjects. All subjects underwent brain magnetic resonance imaging (MRI) and diffusion-tensor imaging (DTI). Testing included neuropsychological evaluation and physiological assessment with TMS and EEG, excitatory/inhibitory balance and brain plasticity. Results: While the MRI, DTI and neuropsychological evaluations showed no abnormalities, neurophysiologic tests revealed subclinical abnormalities in our patient: (1) Significantly higher intracortical facilitation than the control group at both time points; (2) Intracortical inhibition presumably mediated by GABA(B) receptors was absent at week 2, but returned to normal value at week 6; (3) Abnormal mechanisms of plasticity at week 2, that normalize at week 6. Conclusions: These findings demonstrate a transient alteration of brain cortical physiology following concussion independent of anatomical findings and neuropsychological function. This case study suggests that TMS measures may serve as sensitive biomarkers of physiologic brain abnormalities after concussion.	[Bashir, Shahid; Vernet, Marine; Yoo, Woo-Kyoung; Mizrahi, Ilan; Pascual-Leone, Alvaro] Harvard Univ, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Dept Neurol,Med Sch, Boston, MA 02215 USA; [Bashir, Shahid] King Saud Univ, Fac Med, Dept Physiol, Autism Res & Treatment Ctr, Riyadh, Saudi Arabia; [Bashir, Shahid] King Saud Univ, Fac Med, Dept Physiol, AL Amodi Autism Res Chair, Riyadh, Saudi Arabia; [Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Pascual-Leone, Alvaro] Univ Autonoma Barcelona, Inst Guttmann, E-08193 Barcelona, Spain		Pascual-Leone, A (corresponding author), Harvard Univ, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, Dept Neurol,Med Sch, 330 Brookline Ave, Boston, MA 02215 USA.	apleone@bidmc.harvard.edu	Yoo, Woo-Kyoung/B-6356-2013; Pascual-Leone, Alvaro/AAC-5101-2019; Bashir, Shahid/E-7212-2014; Bashir, Shahid/N-3031-2019	Yoo, Woo-Kyoung/0000-0002-1273-0647; Pascual-Leone, Alvaro/0000-0001-8975-0382; Bashir, Shahid/0000-0001-6286-6895; Theoret, Hugo/0000-0002-7458-8797; Vernet, Marine/0000-0001-7331-3567	CIMIT; National Center for Research Resources: Harvard Clinical and Translational Science CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR025758]; Fyssen Foundation (France); National Research Foundation of KoreaNational Research Foundation of Korea; Korean Government MESTMinistry of Education, Science and Technology, Republic of KoreaKorean Government [NRF-013-2010-1-E00018]; Doris Duke Charitable FoundationDoris Duke Charitable Foundation (DDCF); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758, KL2RR025757] Funding Source: NIH RePORTER	This work was supported in part by grants from CIMIT (Dr. Pascual-Leone), the National Center for Research Resources: Harvard Clinical and Translational Science Center (UL1 RR025758). Dr. Pascual-Leone serves on the scientific advisory boards for Nexstim, Neuronix, Starlab Neuroscience, Allied Mind, Neosync, and Novavision, and holds intellectual property on the real-time integration of transcranial magnetic stimulation (TMS) with electroencephalography (EEG) and magnetic resonance imaging (MRI). Dr. Vernet was supported by the Fyssen Foundation (France). Dr. Yoo was supported by a National Research Foundation of Korea grant funded by the Korean Government MEST, Basic Research Promotion Fund (NRF-013-2010-1-E00018). Mr. Mizrahi was supported by the Doris Duke Charitable Foundation. The authors thank Andrea Vatulas, Cara Burzynski and Ann Connor for their administrative support.	De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Huang YZ, 2008, CEREB CORTEX, V18, P563, DOI 10.1093/cercor/bhm087; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Landi D, 2010, RESTOR NEUROL NEUROS, V28, P349, DOI 10.3233/RNN-2010-0538; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Pascual-Leone A, 2011, BRAIN TOPOGR, V24, P302, DOI 10.1007/s10548-011-0196-8; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini P M, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P171; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734	19	30	30	0	26	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2012	30	4					277	282		10.3233/RNN-2012-110207			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	973OA	WOS:000306368300001	22596356	Green Accepted			2022-02-06	
J	Garcia-Altes, A; Perez, K; Novoa, A; Suelves, JM; Bernabeu, M; Vidal, J; Arrufat, V; Santamarina-Rubio, E; Ferrando, J; Cogollos, M; Cantera, CM; Luque, JCG				Garcia-Altes, Anna; Perez, Katherine; Novoa, Ana; Suelves, Josep M.; Bernabeu, Montserrat; Vidal, Joan; Arrufat, Vita; Santamarina-Rubio, Elena; Ferrando, Josep; Cogollos, Mar; Martin Cantera, Carlos; Gonzalez Luque, Juan Carlos		Working Grp Study Injuries Spanish	Spinal Cord Injury and Traumatic Brain Injury: A Cost-of-Illness Study	NEUROEPIDEMIOLOGY			English	Article						Brain injuries; Traffic accidents; Cost of illness	EPIDEMIOLOGY	Background: Among traumatic injuries, spinal cord injuries (SCI) and traumatic brain injuries (TBI) are of major importance because of their epidemiological and economic impact on society. The overall objective of this study was to estimate the economic cost associated with people with SCI and TBI in Spain in 2007. Methods: A cost-of-illness analysis was performed, considering the perspective of society, using a 1-year time horizon. Medical costs, adaptation costs, material costs, administrative costs, and costs of police, firefighters and roadside assistance, productivity losses due to institutionalization and sick leave, as well as an estimate of productivity losses of carers, and productivity losses due to death were included. Results:The economic cost associated with people with SCI is between EUR 92,087,080.97 and 212,496,196.41 (USD 131 million and 302 million) according to the injury mechanism, and between EUR 1,079,223,688.66Brain injuries Traffic accidents Cost of illness and 3,833,752,692.78 (USD 1,536 million and 5,458 million) for people with TBI. Conclusions:There is an urgent need to develop effective interventions known to prevent SCI and TBI, and to evaluate their effectiveness and efficiency. Copyright (c) 2012 S. Karger AG, Basel	[Garcia-Altes, Anna] Agencia Informacio Avaluacio & Qualitat Salut, ES-08005 Barcelona, Spain; [Perez, Katherine; Novoa, Ana; Santamarina-Rubio, Elena] Agencia Salut Publ Barcelona, CIBER Epidemiol & Salud Publ CIBERESP, Inst Invest Biomed IIB St Pau, Barcelona, Spain; [Suelves, Josep M.] Agencia Salut Publ Catalunya, Barcelona, Spain; [Ferrando, Josep] Univ Autonoma Barcelona, CIBER Epidemiol & Salud Publ CIBERESP, E-08193 Barcelona, Spain; [Martin Cantera, Carlos] Univ Autonoma Barcelona, Dept Med, Unitat Suport Recerca Barcelona, IDIAP Jordi Gol,CAP Passeig St Joan,ICS, E-08193 Barcelona, Spain; [Bernabeu, Montserrat; Vidal, Joan] Inst Guttmann Neurorehabil Hosp, Badalona, Spain; [Arrufat, Vita] Ctr Salut Publ Area 02, Negociat Programes Promocio Salut, Castellon de La Plana, Spain; [Cogollos, Mar] AESLEME, Pozuelo Alarcon, Madrid, Spain; [Gonzalez Luque, Juan Carlos] Observ Nacl Seguridad Vial, Direcc Gen Traf, Madrid, Spain		Garcia-Altes, A (corresponding author), Agencia Informacio Avaluacio & Qualitat Salut, Roc Boronat 81-95,2On Pis, ES-08005 Barcelona, Spain.	agarciaaltes@aatrm.catsalut.cat	Martin Cantera, Carlos/D-2693-2011; Joan, Vidal/AAR-5232-2021; GONZALEZ-LUQUE, JUAN CARLOS/AAY-5164-2021; Suelves, Josep M/F-9080-2011	Martin Cantera, Carlos/0000-0003-0656-8126; GONZALEZ-LUQUE, JUAN CARLOS/0000-0002-4044-8403; Suelves, Josep M/0000-0002-7716-6944; Gonzalez-Luque, Juan Carlos/0000-0001-8081-0377; Perez, Katherine/0000-0001-5892-2807	Direccion General de Salud Publica, Ministerio de Sanidad, Politica Social e Igualdad	This study was developed by the working group for the study of injuries of the Spanish Society of Epidemiology. Thanks also to Ma Antonia Astorga (MSPS), Marivi Librada (MSPS), Pilar Zori (DGT), Rogelio Cozar (MSPS), Ma Angeles Gogorcena (MSPS), and Araceli Diaz (SAS). This study was partially funded by the Direccion General de Salud Publica, Ministerio de Sanidad, Politica Social e Igualdad.	Abellan JM, 2011, VALOR MONETARIO VIDA; Asociacion ICEA, 2008, INV COOP ENT AS FOND; Azeldegui BF, 2002, MED INTENSIVA, V26, P491; Barcelo C., 2010, 2 C DAN CER ADQ COM; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bastida JL, 2004, J TRAUMA, V56, P883, DOI 10.1097/01.TA.0000069207.43004.A5; Berkowitz M., 1998, SPINAL CORD INJURY A; Blincoe L. J., 2002, 809446 DOT HS NAT HI; Chiu WT, 2010, ASIA-PAC J PUBLIC HE, V22, P9, DOI 10.1177/1010539509355470; French DD, 2007, J SPINAL CORD MED, V30, P477, DOI 10.1080/10790268.2007.11754581; Hensher DA, 2006, TRANSPORT REV, V26, P521, DOI 10.1080/01441640600602369; INE, ENC AN COST LAB 2007; INE, 1961, NIV CAL COND VID IND; Institut Guttmann, 2011, SIN DISC ALG XIFR ES; Instituto de Estudios de Automocion, 2002, SECT TRANSP ESP EV H; Laboratorio de medidas potenciadoras de la autonomia, 2009, LAB MED POT AUT SAT; Llado A, 2007, COSTE ACCIDENTES TRA; MacLeod JBA, 2007, AM J SURG, V193, P195, DOI 10.1016/j.amjsurg.2006.09.010; Observatori Social de Barcelona, 2006, OBS SOC BARC GREUG C; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; The National Spinal Cord Injury Statistical Center: Spinal Cord Injury, 2006, SPIN CORD INJ FACTS; UNESPA, 2008, MEM SOC SEG ESP 2007; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328	24	30	32	0	15	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2012	39	2					103	108		10.1159/000338297			6	Public, Environmental & Occupational Health; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Neurosciences & Neurology	005DP	WOS:000308731000005	22846706				2022-02-06	
J	Ho, L; Zhao, W; Dams-O'Connor, K; Tang, CY; Gordon, W; Peskind, ER; Yemul, S; Haroutunian, V; Pasinetti, GM				Ho, Lap; Zhao, Wei; Dams-O'Connor, Kristen; Tang, Cheuk Y.; Gordon, Wayne; Peskind, Elaine R.; Yemul, Shrishailam; Haroutunian, Vahram; Pasinetti, Giulio Maria			Elevated Plasma MCP-1 Concentration Following Traumatic Brain Injury as a Potential "Predisposition" Factor Associated with an Increased Risk for Subsequent Development of Alzheimer's Disease	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; biomarker; long-term clinical TBI phenotypes; mild cognitive impairment; monocyte chemotactic protein-1; plasma; traumatic brain injury	DIFFUSE AXONAL INJURY; MULTIPLE-SCLEROSIS; EXPRESSION; CHEMOKINES; PROTEIN; MECHANISMS; RAT; IDENTIFICATION; LOCALIZATION; INFLAMMATION	We explored whether changes in the expression profile of peripheral blood plasma proteins may provide a clinical, readily accessible "window" into the brain, reflecting molecular alterations following traumatic brain injury (TBI) that might contribute to TBI complications. We recruited fourteen TBI and ten control civilian participants for the study, and also analyzed banked plasma specimens from 20 veterans with TBI and 20 control cases. Using antibody arrays and ELISA assays, we explored differentially-regulated protein species in the plasma of TBI compared to healthy controls from the two independent cohorts. We found three protein biomarker species, monocyte chemotactic protein-1 (MCP-1), insulin-like growth factor-binding protein-3, and epidermal growth factor receptor, that are differentially regulated in plasma specimens of the TBI cases. A three-biomarker panel using all three proteins provides the best potential criterion for separating TBI and control cases. Plasma MCP-1 contents are correlated with the severity of TBI and the index of compromised axonal fiber integrity in the frontal cortex. Based on these findings, we evaluated postmortem brain specimens from 7 mild cognitive impairment (MCI) and 7 neurologically normal cases. We found elevated MCP-1 expression in the frontal cortex of MCI cases that are at high risk for developing Alzheimer's disease. Our findings suggest that additional application of the three-biomarker panel to current diagnostic criteria may lead to improved TBI detection and more sensitive outcome measures for clinical trials. Induction of MCP-1 in response to TBI might be a potential predisposing factor that may increase the risk for development of Alzheimer's disease.	[Ho, Lap; Zhao, Wei; Yemul, Shrishailam; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Dams-O'Connor, Kristen; Gordon, Wayne] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Tang, Cheuk Y.; Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, Bronx, NY USA; [Peskind, Elaine R.] Univ Washington, Sch Med, VA NW Network Mental Illness Res Educ & Clin Ctr, Seattle, WA USA; [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA		Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave,Annenberg Bldg,Room 20-02, New York, NY 10029 USA.	Giulio.Pasinetti@mssm.edu	Zhao, Wei/A-2206-2010	Pasinetti, Giulio/0000-0002-1524-5196	UW Alzheimer's Disease Research Center [P50AG05136]; Pacific Northwest Udall Center [P50NS062684]; ADRC [AG05138, PPG AG02219]; Department of Veterans Affairs Rehabilitation Research and DevelopmentUS Department of Veterans Affairs; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1RR029887]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR029887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS062684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG002219, P50AG005136, P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000521, I01RX001612] Funding Source: NIH RePORTER	This study was supported by UW Alzheimer's Disease Research Center (P50AG05136), Pacific Northwest Udall Center (P50NS062684), the ADRC (AG05138 and PPG AG02219), the Department of Veterans Affairs Rehabilitation Research and Development, and the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) (UL1RR029887).	Alberini CM, 2009, PHYSIOL REV, V89, P121, DOI 10.1152/physrev.00017.2008; [Anonymous], 2008, GULF WAR HLTH, V7; Archer T, 2012, ACTA NEUROL SCAND, V125, P293, DOI 10.1111/j.1600-0404.2011.01638.x; Banisor I, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-7; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chandler S, 1995, NEUROSCI LETT, V201, P223, DOI 10.1016/0304-3940(95)12173-0; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Correa JD, 2011, ARQ NEURO-PSIQUIAT, V69, P455, DOI 10.1590/S0004-282X2011000400009; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.0.CO;2-3; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gardiner E, 2012, MOL PSYCHIATR, V17, P827, DOI 10.1038/mp.2011.78; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Grammas P, 2001, NEUROBIOL AGING, V22, P837, DOI 10.1016/S0197-4580(01)00276-7; Hannay HJ, 2004, NEUROPSYCHOLOGICAL A, P160; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; Hickman SE, 2010, CNS NEUROL DISORD-DR, V9, P168, DOI 10.2174/187152710791011982; Huang Ruo-Pan, 2004, Methods Mol Biol, V264, P215; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Ishizuka K, 1997, PSYCHIAT CLIN NEUROS, V51, P135, DOI 10.1111/j.1440-1819.1997.tb02375.x; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Janelsins MC, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-23; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kim JS, 1996, J NEUROL SCI, V137, P69, DOI 10.1016/0022-510X(95)00338-3; Kim SM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-51; Kooij G, 2011, BRAIN, V134, P555, DOI 10.1093/brain/awq330; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Lee ST, 2009, NEUROLOGY, V72, P1858, DOI 10.1212/WNL.0b013e3181a711f4; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahad DJ, 2003, SEMIN IMMUNOL, V15, P23, DOI 10.1016/S1044-5323(02)00125-2; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Mayeux R, 2011, ALZHEIMERS DEMENT, V7, P15, DOI 10.1016/j.jalz.2010.11.005; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Minami M, 2003, LIFE SCI, V74, P321, DOI 10.1016/j.lfs.2003.09.019; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Olsson A, 2004, J NEUROL, V251, P870, DOI 10.1007/s00415-004-0451-y; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Qu CS, 2010, J NEUROTRAUM, V27, P1625, DOI 10.1089/neu.2010.1359; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ray S, 2007, NAT MED, V13, P1359, DOI 10.1038/nm1653; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Ruan LF, 2009, CURR ALZHEIMER RES, V6, P531, DOI 10.2174/156720509790147070; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Tanriverdi F, 2010, J NEUROTRAUM, V27, P301, DOI 10.1089/neu.2009.1102; Tanuma N, 2006, ACTA NEUROPATHOL, V112, P195, DOI 10.1007/s00401-006-0083-7; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; van Heerden Johan H, 2009, BMC Res Notes, V2, P195, DOI 10.1186/1756-0500-2-195; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Xia MQ, 1999, J NEUROVIROL, V5, P32, DOI 10.3109/13550289909029743; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	72	30	33	0	14	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877			J ALZHEIMERS DIS	J. Alzheimers Dis.		2012	31	2					301	313		10.3233/JAD-2012-120598			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	986WS	WOS:000307377300007	22543850	Green Accepted			2022-02-06	
J	Jovanovski, D; Zakzanis, K; Ruttan, L; Campbell, Z; Erb, S; Nussbaum, D				Jovanovski, Diana; Zakzanis, Konstantine; Ruttan, Lesley; Campbell, Zachariah; Erb, Suzanne; Nussbaum, David			Ecologically Valid Assessment of Executive Dysfunction Using a Novel Virtual Reality Task in Patients with Acquired Brain Injury	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						acquired brain injury; executive function; neuropsychology; stroke; traumatic brain injury; virtual reality	STRATEGY APPLICATION; SIMPLIFIED VERSION; DEFICITS; DAMAGE	The current investigation sought to further establish the psychometric properties and ecological validity of the Multitasking in the City Test (MCT) in a clinical population. Ecological validity was addressed via correlational analyses between performance on this test and a subjective measure of everyday executive functioning (Frontal Systems Behavior Scale; FrSBe). The sample was composed of 13 individuals (11 males) who suffered a stroke or traumatic brain injury. A neuropsychological test battery consisting of the MCT and common executive and nonexecutive measures was administered. The only executive function tests that were significantly related to the FrSBe were the MCT and a semantic fluency test. Compared with a sample of normal participants, the patient group produced better plans but completed fewer tasks on the MCT. Patients made similar types of errors as normals, although some of these errors occurred more frequently in the patient sample. This study demonstrated the ecological validity of the MCT and suggested that patients can be differentiated from healthy individuals by quantitative (i.e., number of errors) rather than qualitative (i.e., type of errors) aspects of performance. Further interpretation of MCT performance and comparison with existing executive function tests is discussed.	[Jovanovski, Diana; Zakzanis, Konstantine] Univ Toronto Scarborough, Dept Psychol, Toronto, ON M1C 1A4, Canada; [Ruttan, Lesley] Toronto Rehabil Inst, Neurorehab Program, Toronto, ON, Canada; [Campbell, Zachariah; Erb, Suzanne; Nussbaum, David] Univ Toronto Scarborough, Dept Psychol, Toronto, ON M1C 1A4, Canada		Zakzanis, K (corresponding author), Univ Toronto Scarborough, Dept Psychol, 1265 Mil Trail, Toronto, ON M1C 1A4, Canada.	diana.jovanovski@utoronto.ca			Sibley & Associates Inc.	The authors wish to acknowledge Sibley & Associates Inc. for their support in the completion of this study and manuscript.	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beck AT, 1993, BECK ANXIETY INVENTO; BENTON A, 1975, NEUROLOGY, V25, P907, DOI 10.1212/WNL.25.10.907; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Dawson DR, 2009, ARCH PHYS MED REHAB, V90, pS41, DOI 10.1016/j.apmr.2009.07.012; Delis D.C., 2000, CALIFORNIA VERBAL LE; Finkelstein E., 2006, INCIDENCE EC BURDEN; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Hamsher K., 1989, MULTILINGUAL APHASIA; Heaton, 2010, NEUROPSYCHOLOGY EVER, P5; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hoerold D, 2008, EXP BRAIN RES, V186, P509, DOI 10.1007/s00221-008-1341-9; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P171, DOI 10.1080/09084282.2011.643955; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Lazar RM, 2007, COGN BEHAV NEUROL, V20, P157, DOI 10.1097/WNN.0b013e31804c703f; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Meyers JE., 1995, REY COMPLEX FIGURE T; National Center for Injury Prevention and Control, 2010, TRAUM BRAIN INJ US E; Pohjasvaara T, 2002, EUR J NEUROL, V9, P269, DOI 10.1046/j.1468-1331.2002.00396.x; *PSYCH CORP, 1997, WAIS 3 WMS 3 TECHN M; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sohlberg M., 2001, COGNITIVE REHABILITA; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Teuber H.-L., 1964, FRONTAL GRANULAR COR; The Psychological Corporation, 2001, WECHSLER TEST ADULT; Tombaugh T.N., 1996, TEST MEMORY MALINGER; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; Zinn S, 2007, ARCH PHYS MED REHAB, V88, P173, DOI 10.1016/j.apmr.2006.11.015; [No title captured]	43	30	31	0	14	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2012	19	3					207	220		10.1080/09084282.2011.643956			14	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	994RU	WOS:000307949900007	23373607				2022-02-06	
J	Ketchum, JM; Getachew, MA; Krch, D; Banos, JH; Kolakowsky-Hayner, SA; Lequerica, A; Jamison, L; Arango-Lasprilla, JC				Ketchum, Jessica M.; Getachew, Mimi Almaz; Krch, Denise; Banos, James H.; Kolakowsky-Hayner, Stephanie A.; Lequerica, Anthony; Jamison, Laura; Arango-Lasprilla, Juan Carlos			Early predictors of employment outcomes 1 year post traumatic brain injury in a population of Hispanic individuals	NEUROREHABILITATION			English	Article						Employment; traumatic brain injury; hispanics	RACIAL-DIFFERENCES; RETURN; WORK; REHABILITATION; STABILITY; MODERATE; HEALTH; TBI	Objective: To determine which demographic, injury, and rehabilitation factors are associated with employment rates in Hispanic individuals 1 year post traumatic brain injury (TBI). Design: Retrospective study. Setting: Longitudinal dataset of the TBI Model Systems National Database. Participants: 418 Hispanic individuals with TBI hospitalized between 1990 and 2009 having year 1 follow-up data (18-55 years and not retired at injury). Main outcome measure: Competitive employment status 1 year post-injury (yes/no). Results: A multiple logistic regression model indicated that pre-injury employment status, pre-injury level of education, etiology, days of posttraumatic amnesia (PTA), associated spinal cord injury, Functional Independence Measure (FIM) motor at rehabilitation discharge, and length of stay in rehabilitation were significant predictors of competitive employment post-injury, controlling for the effects of each other (all p-values <= 0.014). Increases in the odds of not being employed post-injury were associated with not being employed pre-injury, having lower levels of education pre-injury, etiologies due to violence or falls, increased PTA, an associated spinal cord injury, lower FIM motor scores, and greater lengths of stay in rehabilitation. Conclusions: The first year post-TBI is critical for recovery and gainful employment, particularly for Hispanic individuals. Early identification of factors influencing successful gainful employment and expeditious implementation of services to ameliorate these issues are paramount in improving employment outcomes for Hispanic individuals with TBI.	[Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Ctr Rehabil Sci & Engn, Richmond, VA 23298 USA; [Ketchum, Jessica M.; Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Krch, Denise; Lequerica, Anthony] Kessler Fdn Res Ctr, W Orange, NJ USA; [Banos, James H.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA; [Kolakowsky-Hayner, Stephanie A.; Jamison, Laura] Santa Clara Valley Med Ctr, Rehabil Res Ctr, Santa Clara, CA USA; [Krch, Denise; Lequerica, Anthony] UMDNJ New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA		Ketchum, JM (corresponding author), Virginia Commonwealth Univ, Dept Biostat, POB 980032, Richmond, VA 23298 USA.	McKinneyJL@vcu.edu	Ketchum, Jessica/AAE-8200-2020; Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Ketchum, Jessica/0000-0002-5566-3691	National Institute of Disability and Rehabilitation Research (NIDRR), United States Department of Education [H133A070036, H133A07009, H133A080060]; Department of Education, NIDRR [H133P090009]	This work was supported by the National Institute of Disability and Rehabilitation Research (NIDRR), United States Department of Education (Grants: H133A070036, H133A07009, H133A080060).; The contents of this article were developed partially under a grant from the Department of Education, NIDRR grant number H133P090009. However, those contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Arango J. C., 2011, PM R J INJURY UNPUB; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Deutsch PM, 2006, NEUROREHABILITATION, V21, P305; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2010, J VOCAT REHABIL, V33, P65, DOI 10.3233/JVR-2010-0516; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Heckman JJ, 2001, J POLIT ECON, V109, P673, DOI 10.1086/322086; Holtslag H. R., 2001, CLIN REHABIL, V21, P373; Hosmer D. W., 2010, APPL LOGICAL REGRESS; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Ostrosky-Solis F, 1998, ARCH CLIN NEUROPSYCH, V13, P645, DOI 10.1016/S0887-6177(97)00094-2; Parks Jennifer K, 2010, Proc (Bayl Univ Med Cent), V23, P355; Riddell WC, 2011, LABOUR ECON, V18, P453, DOI 10.1016/j.labeco.2011.01.003; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Schwartz SJ, 2010, AM PSYCHOL, V65, P237, DOI 10.1037/a0019330; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Strully K, 2009, SOC SCI MED, V69, P768, DOI 10.1016/j.socscimed.2009.06.025; [United States Department of Labor Bureau of Labor Statistics], EMPL PROJ ED PAYS; US Bureau of Labour Statistics, PERS DIS LAB FORC CH; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wilson KB, 2005, J COUNS DEV, V83, P86, DOI 10.1002/j.1556-6678.2005.tb00583.x; [No title captured]	49	30	30	0	15	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2012	30	1					13	22		10.3233/NRE-2011-0723			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	904ZT	WOS:000301240900003	22349838				2022-02-06	
J	Probst, C; Mirzayan, MJ; Mommsen, P; Zeckey, C; Tegeder, T; Geerken, L; Maegele, M; Samii, A; van Griensven, M				Probst, C.; Mirzayan, M. J.; Mommsen, P.; Zeckey, C.; Tegeder, T.; Geerken, L.; Maegele, M.; Samii, A.; van Griensven, M.			Systemic Inflammatory Effects of Traumatic Brain Injury, Femur Fracture, and Shock: An Experimental Murine Polytrauma Model	MEDIATORS OF INFLAMMATION			English	Article							TUMOR-NECROSIS-FACTOR; PENTOXIFYLLINE IMPROVES SURVIVAL; MULTIPLE ORGAN FAILURE; CLOSED-HEAD-INJURY; FACTOR-ALPHA; RAT-BRAIN; MORTALITY; EXPRESSION; MCP-1; DYSFUNCTION	Objective. Despite broad research in neurotrauma and shock, little is known on systemic inflammatory effects of the clinically most relevant combined polytrauma. Experimental investigation in an animal model may provide relevant insight for therapeutic strategies. We describe the effects of a combined injury with respect to lymphocyte population and cytokine activation. Methods. 45 male C57BL/6J mice (mean weight 27 g) were anesthetized with ketamine/xylazine. Animals were subjected to a weight drop closed traumatic brain injury (WD-TBI), a femoral fracture and hemorrhagic shock (FX-SH). Animals were subdivided into WD-TBI, FX-SH and combined trauma (CO-TX) groups. Subjects were sacrificed at 96 h. Blood was analysed for cytokines and by flow cytometry for lymphocyte populations. Results. Mortality was 8%, 13% and 47% for FX-SH, WD-TBI and CO-TX groups (P < 0.05). TNF alpha (11/13/139 for FX-SH/WD-TBI/CO-TX; P < 0.05), CCL2 (78/96/227; P < 0.05) and IL-6 (16/48/281; P = 0.05) showed significant increases in the CO-TX group. Lymphocyte populations results for FX-SH, WD-TBI and CO-TX were: CD-4 (31/21/22; P = n.s.), CD-8 (7/28/34, P < 0.05), CD-4-CD-8 (11/12/18; P = n.s.), CD-56 (36/7/8; P < 0.05). Conclusion. This study shows that a combination of closed TBI and femur-fracture/shock results in an increase of the humoral inflammation. More attention to combined injury models in inflammation research is indicated.	[Probst, C.; Maegele, M.] Univ Witten Herdecke, Dept Trauma & Orthopaed Surg, Cologne Merheim Med Ctr, Fac Hlth,Sch Med, D-51109 Cologne, Germany; [Mirzayan, M. J.] Hannover Med Sch, Dept Trauma, D-30623 Hannover, Germany; [Mommsen, P.; Zeckey, C.; Tegeder, T.] Hannover Med Sch, Dept Traumatol, D-30623 Hannover, Germany; [Geerken, L.] Nordstadt Hosp Hannover, Dept Anaesthesiol, D-30167 Hannover, Germany; [Samii, A.] Univ Technol Munich, Inst Expt Traumatol, D-81675 Munich, Germany; [van Griensven, M.] Int Neurosci Inst Hannover, Dept Neurosurg, D-30625 Hannover, Germany		Probst, C (corresponding author), Univ Witten Herdecke, Dept Trauma & Orthopaed Surg, Cologne Merheim Med Ctr, Fac Hlth,Sch Med, Ostmerheimer Str 200, D-51109 Cologne, Germany.	probstc@kliniken-koeln.de	Mommsen, Philipp/ABC-3510-2020; van Griensven, Martijn/F-5808-2012	van Griensven, Martijn/0000-0001-5104-9881			Aguilar MM, 1998, J TRAUMA, V45, P14, DOI 10.1097/00005373-199807000-00003; AYALA A, 1990, Cytokine, V2, P170, DOI 10.1016/1043-4666(90)90012-I; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; Berman JW, 1996, J IMMUNOL, V156, P3017; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; COCCIA MT, 1989, CRIT CARE MED, V17, P36, DOI 10.1097/00003246-198901000-00009; Durham RM, 2003, J TRAUMA, V55, P608, DOI 10.1097/01.TA.0000092378.10660.D1; Frink M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/797383; Frink M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-49; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Harkness KA, 2003, J NEUROIMMUNOL, V142, P1, DOI 10.1016/S0165-5728(03)00251-0; Hildebrand F, 2005, INJURY, V36, P544, DOI 10.1016/j.injury.2004.10.017; Jiang J, 1997, Zhonghua Wai Ke Za Zhi, V35, P406; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; LUNDBLAD R, 1995, SHOCK, V3, P210, DOI 10.1097/00024382-199503000-00009; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nast-Kolb D, 2001, J TRAUMA, V51, P835, DOI 10.1097/00005373-200111000-00003; Pape HC, 2008, J ORTHOP RES, V26, P1478, DOI 10.1002/jor.20697; Probst C, 2009, J TRAUMA, V66, P1212, DOI 10.1097/TA.0b013e318197b97c; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SMAIL N, 1995, INTENS CARE MED, V21, P813, DOI 10.1007/BF01700964; Thibeault I, 2001, J COMP NEUROL, V434, P461, DOI 10.1002/cne.1187; Tsukamoto T, 2009, SHOCK, V31, P3, DOI 10.1097/SHK.0b013e31817fdabf; van Griensven M, 2002, EXP TOXICOL PATHOL, V54, P203, DOI 10.1078/0940-2993-00247; van Griensven M, 2003, EUR J TRAUMA, V29, P181, DOI DOI 10.1007/S00068-001-1324-Z	37	30	32	0	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2012	2012								136020	10.1155/2012/136020			7	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	923VB	WOS:000302647100001	22529516	Green Published, Green Submitted, gold			2022-02-06	
J	Riganello, F; Garbarino, S; Sannita, WG				Riganello, Francesco; Garbarino, Sergio; Sannita, Walter G.			Heart Rate Variability, Homeostasis, and Brain Function A Tutorial and Review of Application	JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						heart rate variability; central autonomic network; methods; homeostasis; cognition; emotions; clinical application	RESPIRATORY SINUS ARRHYTHMIA; AUTONOMIC NERVOUS-SYSTEM; MEDIAL PREFRONTAL NETWORKS; POWER SPECTRUM ANALYSIS; POSTTRAUMATIC-STRESS-DISORDER; BAROREFLEX CARDIAC CONTROL; CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE; VAGAL TONE; ANXIETY DISORDERS	Measures of heart rate variability (HRV) are major indices of the sympathovagal balance in cardiovascular research. These measures are thought to reflect complex patterns of brain activation as well and HRV is now emerging as a descriptor thought to provide information on the nervous system organization of homeostatic responses in accordance with the situational requirements. Current models of integration equate HRV to the affective states as parallel outputs of the central autonomic network, with HRV reflecting its organization of affective, physiological, "cognitive,'' and behavioral elements into a homeostatic response. Clinical application is in the study of patients with psychiatric disorders, traumatic brain injury, impaired emotion-specific processing, personality, and communication disorders. HRV responses to highly emotional sensory inputs have been identified in subjects in vegetative state and in healthy or brain injured subjects processing complex sensory stimuli. In this respect, HRV measurements can provide additional information on the brain functional setup in the severely brain damaged and would provide researchers with a suitable approach in the absence of conscious behavior or whenever complex experimental conditions and data collection are impracticable, as it is the case, for example, in intensive care units.	[Garbarino, Sergio; Sannita, Walter G.] Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy; [Riganello, Francesco] S Anna Inst, Crotone, Italy; [Sannita, Walter G.] SUNY Stony Brook, Dept Psychiat, Stony Brook, NY 11794 USA		Sannita, WG (corresponding author), Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy.	wgs@dism.unige.it	Riganello, Francesco/AAC-3976-2020; Riganello, Francesco/N-2615-2014; Garbarino, Sergio/X-5368-2018; Garbarino, Sergio/AAV-4629-2021	Riganello, Francesco/0000-0003-0678-9252; Riganello, Francesco/0000-0003-0678-9252; Garbarino, Sergio/0000-0002-8508-552X; Garbarino, Sergio/0000-0002-8508-552X			AASMAN J, 1987, HUM FACTORS, V29, P161, DOI 10.1177/001872088702900204; Abdullah H, 2009, IEEE ENG MED BIO, P5014, DOI 10.1109/IEMBS.2009.5334607; Abrams DA, 2011, CEREB CORTEX, V21, P1507, DOI 10.1093/cercor/bhq198; Acharya UR, 2006, MED BIOL ENG COMPUT, V44, P1031, DOI 10.1007/s11517-006-0119-0; Adjei P, 2009, EPILEPSY RES, V87, P281, DOI 10.1016/j.eplepsyres.2009.08.011; Agelink MW, 2002, PSYCHIAT RES, V113, P139, DOI 10.1016/S0165-1781(02)00225-1; Ahs F, 2009, NEUROIMAGE, V47, P815, DOI 10.1016/j.neuroimage.2009.05.091; Ahsberg E, 2000, ERGONOMICS, V43, P252, DOI 10.1080/001401300184594; Ako M, 2003, PSYCHIAT CLIN NEUROS, V57, P59, DOI 10.1046/j.1440-1819.2003.01080.x; AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Albert CM, 2005, CIRCULATION, V111, P480, DOI 10.1161/01.CIR.0000153813.64165.5D; Albinet CT, 2010, EUR J APPL PHYSIOL, V109, P617, DOI 10.1007/s00421-010-1393-y; Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; Anders D, 2010, CHRONOBIOL INT, V27, P1609, DOI 10.3109/07420528.2010.504317; Aoki K, 2001, AM J PHYSIOL-REG I, V281, pR591, DOI 10.1152/ajpregu.2001.281.2.R591; Apelbaum H., 2001, DISS ABSTR INT B, V61, P6742; Appelhans BM, 2008, BIOL PSYCHOL, V77, P174, DOI 10.1016/j.biopsycho.2007.10.004; Appelhans BM, 2006, REV GEN PSYCHOL, V10, P229, DOI 10.1037/1089-2680.10.3.229; AstonJones G, 1996, PROG BRAIN RES, V107, P379; Aubert AE, 2003, SPORTS MED, V33, P889, DOI 10.2165/00007256-200333120-00003; Aysin B, 2007, P ANN INT IEEE EMBS, P5047, DOI 10.1109/IEMBS.2007.4353474; Aysin B, 2006, 2006 28TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY, VOLS 1-15, P1726; BACKS RW, 1994, INT J PSYCHOPHYSIOL, V16, P57, DOI 10.1016/0167-8760(94)90042-6; BACKS RW, 1991, P HUM FACT SOC 35, P1495; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Badra LJ, 2001, AM J PHYSIOL-HEART C, V280, pH2674, DOI 10.1152/ajpheart.2001.280.6.H2674; Bar KJ, 2008, PSYCHIAT RES, V157, P255, DOI 10.1016/j.psychres.2007.04.021; Bar KJ, 2006, ALCOHOL CLIN EXP RES, V30, P1592, DOI 10.1111/j.1530-0277.2006.00191.x; Bai XP, 2009, AM J PHYSIOL-HEART C, V297, pH765, DOI 10.1152/ajpheart.01283.2008; BALOGH S, 1993, PSYCHOPHARMACOL BULL, V29, P201; Bandler R, 2000, BRAIN RES BULL, V53, P95, DOI 10.1016/S0361-9230(00)00313-0; BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; Bar KJ, 2005, J PSYCHIATR RES, V39, P519, DOI 10.1016/j.jpsychires.2004.12.007; Barbas H, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-25; Barbieri R, 2002, AM J PHYSIOL-REG I, V283, pR1210, DOI 10.1152/ajpregu.00127.2002; Bartels MN, 2003, CHEST, V124, P863, DOI 10.1378/chest.124.3.863; Bassi A, 2010, EUR NEUROL, V63, P279, DOI 10.1159/000287583; Beauchaine T, 2001, DEV PSYCHOPATHOL, V13, P183, DOI 10.1017/S0954579401002012; Beda A, 2007, PSYCHOPHYSIOLOGY, V44, P767, DOI 10.1111/j.1469-8986.2007.00542.x; Benarroch EE, 2006, NEUROL SCI, V27, pS130, DOI 10.1007/s10072-006-0587-x; Benarroch E.E., 2007, CONTIN LIFELONG LEAR, V13, P13, DOI [10.1212/01.CON.0000299964.20642.9a, DOI 10.1212/01.CON.0000299964.20642.9A]; BENARROCH EE, 1993, MAYO CLIN PROC, V68, P988, DOI 10.1016/S0025-6196(12)62272-1; Bentley M. T., 2003, Medicine & Science in Sports & Exercise, V35, pS254, DOI 10.1097/00005768-200305001-01413; BERNE C, 1992, DIABETOLOGIA, V35, P873, DOI 10.1007/BF00399935; Berntson G.G., 1999, CARD ELECTROPHYSIOL, V3, P279, DOI [10.1023/A:1009920002142, DOI 10.1023/A:1009920002142]; Berntson GG, 2007, BIOL PSYCHOL, V74, P295, DOI 10.1016/j.biopsycho.2006.08.006; BERNTSON GG, 1993, PSYCHOL BULL, V114, P296, DOI 10.1037/0033-2909.114.2.296; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Berntson GG, 1998, BEHAV BRAIN RES, V94, P225, DOI 10.1016/S0166-4328(98)00041-2; Berntson GG, 2004, PSYCHOPHYSIOLOGY, V41, P333, DOI 10.1111/j.1469-8986.2004.00156.x; Berntson GG, 2003, EUR J NEUROSCI, V18, P2103, DOI 10.1046/j.1460-9568.2003.02967.x; BERNTSON GG, 1993, PSYCHOPHYSIOLOGY, V30, P183, DOI 10.1111/j.1469-8986.1993.tb01731.x; BERNTSON GG, 1994, PSYCHOPHYSIOLOGY, V31, P572, DOI 10.1111/j.1469-8986.1994.tb02350.x; Bianchi AM, 2010, METHOD INFORM MED, V49, P479, DOI 10.3414/ME09-02-0037; Bilgin S, 2010, J MED SYST, V34, P155, DOI 10.1007/s10916-008-9227-8; Blom EH, 2010, ACTA PAEDIATR, V99, P604, DOI 10.1111/j.1651-2227.2009.01657.x; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; BOOTSMA M, 1994, AM J PHYSIOL, V266, pH1565, DOI 10.1152/ajpheart.1994.266.4.H1565; Braga ANG, 2002, AM J PHYSIOL-REG I, V282, pR1663, DOI 10.1152/ajpregu.00583.2001; Brennan M, 2001, IEEE T BIO-MED ENG, V48, P1342, DOI 10.1109/10.959330; Britton A, 2008, NEUROEPIDEMIOLOGY, V31, P115, DOI 10.1159/000148257; BROWN HN, 1981, PSYCHOSOMATICS, V22, P907; Buchanan TW, 2010, PSYCHONEUROENDOCRINO, V35, P56, DOI 10.1016/j.psyneuen.2009.09.006; Bylsma LM, 2008, CLIN PSYCHOL REV, V28, P676, DOI 10.1016/j.cpr.2007.10.001; Cadeddu C, 2010, EPILEPSY RES, V92, P145, DOI 10.1016/j.eplepsyres.2010.08.012; Cahill L, 2003, NEUROBIOL LEARN MEM, V79, P194, DOI 10.1016/S1074-7427(02)00036-9; Cain KC, 2007, NEUROGASTROENT MOTIL, V19, P110, DOI 10.1111/j.1365-2982.2006.00877.x; Cameron OG, 2009, NEUROIMAGE, V47, P787, DOI 10.1016/j.neuroimage.2009.05.010; Camm AJ, 1996, CIRCULATION, V93, P1043; Campana LM, 2010, J APPL PHYSIOL, V108, P1668, DOI 10.1152/japplphysiol.00013.2010; Carrasco S, 2001, J MED ENG TECHNOL, V25, P240, DOI 10.1080/03091900110086651; Chambers AS, 2002, PSYCHOPHYSIOLOGY, V39, P861, DOI 10.1111/1469-8986.3960861; Chang CS, 2010, NEUROGASTROENT MOTIL, V22, P546, DOI 10.1111/j.1365-2982.2009.01455.x; Chellakumar PJ, 2005, PHYSIOL MEAS, V26, P979, DOI 10.1088/0967-3334/26/6/008; Chen CL, 2006, SCAND J GASTROENTERO, V41, P1001, DOI 10.1080/00365520600575688; Chen JL, 2006, CLIN ENDOCRINOL, V64, P611, DOI 10.1111/j.1365-2265.2006.02514.x; Chen QH, 2003, NEUROSCIENCE, V118, P797, DOI 10.1016/S0306-4522(03)00033-2; Clark KB, 1999, NAT NEUROSCI, V2, P94, DOI 10.1038/4600; Cohen H, 2003, BIOL PSYCHIAT, V53, P463, DOI 10.1016/S0006-3223(02)01909-1; Cohen H, 1998, BIOL PSYCHIAT, V44, P1054, DOI 10.1016/S0006-3223(97)00475-7; Cohen H, 2000, PSYCHIAT RES, V96, P1, DOI 10.1016/S0165-1781(00)00195-5; Cohen H, 2006, AUTON NEUROSCI-BASIC, V128, P1, DOI 10.1016/j.autneu.2005.06.007; Conte V, 2009, J NEUROSURG ANESTH, V21, P242, DOI 10.1097/ANA.0b013e31819b61df; Cooke WH, 1998, AM J PHYSIOL-HEART C, V274, pH709, DOI 10.1152/ajpheart.1998.274.2.H709; Craig AD, 2004, J COMP NEUROL, V477, P119, DOI 10.1002/cne.20240; Critchley HD, 2005, NEUROIMAGE, V24, P751, DOI 10.1016/j.neuroimage.2004.10.013; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; DALACK GW, 1990, J CLIN PSYCHIAT, V51, P4; Davidson RJ, 2004, PHILOS T R SOC B, V359, P1395, DOI 10.1098/rstb.2004.1510; de Bruyne MC, 1999, AM J EPIDEMIOL, V150, P1282; De Jonge P, 2007, PSYCHOSOM MED, V69, P735, DOI 10.1097/PSY.0b013e31815743ca; de Zambotti M, 2011, J SLEEP RES, V20, P318, DOI 10.1111/j.1365-2869.2010.00871.x; DEBOER RW, 1984, IEEE T BIO-MED ENG, V31, P384, DOI 10.1109/TBME.1984.325351; Dekker JM, 2000, CIRCULATION, V102, P1239, DOI 10.1161/01.CIR.102.11.1239; Dekker JM, 1997, AM J EPIDEMIOL, V145, P899, DOI 10.1093/oxfordjournals.aje.a009049; Dolce G, 2008, J PSYCHOPHYSIOL, V22, P150, DOI 10.1027/0269-8803.22.3.150; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Dringenberg HC, 1997, EXP BRAIN RES, V116, P160, DOI 10.1007/PL00005736; Dringenberg HC, 1998, NEUROSCI BIOBEHAV R, V22, P243, DOI 10.1016/S0149-7634(97)00012-2; Dringenberg HC, 2002, EUR J PHARMACOL, V447, P43, DOI 10.1016/S0014-2999(02)01829-0; Dumont M, 2004, CLIN NEUROPHYSIOL, V115, P2031, DOI 10.1016/j.clinph.2004.04.007; Duschek S, 2009, BIOL PSYCHOL, V81, P110, DOI 10.1016/j.biopsycho.2009.03.003; DWORKIN BR, 1994, P NATL ACAD SCI USA, V91, P6329, DOI 10.1073/pnas.91.14.6329; Earnest CP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002288; Eckberg DL, 2003, J PHYSIOL-LONDON, V548, P339, DOI 10.1113/jphysiol.2002.037192; ECKBERG DL, 1983, J APPL PHYSIOL, V54, P961, DOI 10.1152/jappl.1983.54.4.961; Edwards L, 2002, PSYCHOPHYSIOLOGY, V39, P678, DOI 10.1017/S0048577202011770; Egizio VB, 2008, PSYCHOPHYSIOLOGY, V45, P1046, DOI 10.1111/j.1469-8986.2008.00698.x; Eibe F., 2004, MACHINE LEARNING WEK; Ellis RJ, 2010, MUSIC PERCEPT, V27, P317, DOI 10.1525/MP.2010.27.4.317; Ermis N, 2010, AUTON NEUROSCI-BASIC, V152, P84, DOI 10.1016/j.autneu.2009.08.018; ESLER M, 1993, PHARMACOL TOXICOL, V73, P243, DOI 10.1111/j.1600-0773.1993.tb00579.x; Eustatia-Rutten CFA, 2008, J CLIN ENDOCR METAB, V93, P2835, DOI 10.1210/jc.2008-0080; Faith M, 2001, SCAND J PSYCHOL, V42, P121, DOI 10.1111/1467-9450.00221; Faye PM, 2010, CLIN J PAIN, V26, P777, DOI 10.1097/AJP.0b013e3181ed1058; Field T, 2008, INFANT BEHAV DEV, V31, P361, DOI 10.1016/j.infbeh.2007.12.008; Flouris AD, 2009, J SPORT MED PHYS FIT, V49, P382; Fojt O, 1998, IEEE ENG MED BIOL, V17, P96, DOI 10.1109/51.664037; Fournier GN, 2004, NEUROSCIENCE, V123, P785, DOI 10.1016/j.neuroscience.2003.10.021; Frasure-Smith N, 2008, ARCH GEN PSYCHIAT, V65, P62, DOI 10.1001/archgenpsychiatry.2007.4; Frazier TW, 2004, PSYCHOPHYSIOLOGY, V41, P75, DOI 10.1046/j.1469-8986.2003.00131.x; Friedman BH, 1996, CLIN AUTON RES, V6, P147, DOI 10.1007/BF02281901; Friedman BH, 1998, J PSYCHOSOM RES, V44, P133, DOI 10.1016/S0022-3999(97)00202-X; Friedman BH, 2007, BIOL PSYCHOL, V74, P185, DOI 10.1016/j.biopsycho.2005.08.009; Fujibayashi M, 2009, AM J HUM BIOL, V21, P828, DOI 10.1002/ajhb.20899; Fukusaki C, 2000, CLIN AUTON RES, V10, P123, DOI 10.1007/BF02278016; Fulbright RK, 2001, AM J ROENTGENOL, V177, P1205, DOI 10.2214/ajr.177.5.1771205; FULLER BF, 1992, INT J PSYCHOPHYSIOL, V12, P81, DOI 10.1016/0167-8760(92)90045-D; Galluzzi S, 2009, J GERONTOL A-BIOL, V64, P1312, DOI 10.1093/gerona/glp105; Ge DF, 2002, BIOMED ENG ONLINE, V1, DOI 10.1186/1475-925X-1-5; Gehi A, 2005, ARCH GEN PSYCHIAT, V62, P661, DOI 10.1001/archpsyc.62.6.661; GELSEMA AJ, 1989, J AUTONOM NERV SYST, V27, P91, DOI 10.1016/0165-1838(89)90091-X; Giagkoudaki F, 2010, J SPORT REHABIL, V19, P173, DOI 10.1123/jsr.19.2.173; Gianaros PJ, 2005, PSYCHOSOM MED, V67, P553, DOI 10.1097/01.psy.0000170335.92770.7a; Gianaros PJ, 2004, PSYCHOPHYSIOLOGY, V41, P521, DOI 10.1111/1469-8986.2004.00179.x; Goedhart AD, 2008, PSYCHOPHYSIOLOGY, V45, P1086, DOI 10.1111/j.1469-8986.2008.00710.x; Goldstein David S, 2010, Cleve Clin J Med, V77 Suppl 3, pS34, DOI 10.3949/ccjm.77.s3.06; Gorman Jack M., 2000, American Heart Journal, V140, pS77; Grant CC, 2009, AUTON NEUROSCI-BASIC, V151, P186, DOI 10.1016/j.autneu.2009.08.015; Gray MA, 2009, J NEUROSCI, V29, P1817, DOI 10.1523/JNEUROSCI.3363-08.2009; Grippo AJ, 2002, NEUROSCI BIOBEHAV R, V26, P941, DOI 10.1016/S0149-7634(03)00003-4; Gross JJ., 1998, REV GEN PSYCHOL, V2, P271, DOI [DOI 10.1037/1089-2680.2.3.271, 10.1037/1089-2680.2.3.271]; Grossman P, 2007, BIOL PSYCHOL, V74, P263, DOI 10.1016/j.biopsycho.2005.11.014; Hansen AL, 2004, EUR J APPL PHYSIOL, V93, P263, DOI 10.1007/s00421-004-1208-0; Hansen AL, 2003, INT J PSYCHOPHYSIOL, V48, P263, DOI 10.1016/S0167-8760(03)00073-4; Hansen AL, 2009, ANXIETY STRESS COPIN, V22, P77, DOI 10.1080/10615800802272251; Harnod T, 2009, SEIZURE-EUR J EPILEP, V18, P21, DOI 10.1016/j.seizure.2008.05.013; Harper R M, 1996, Semin Pediatr Neurol, V3, P13, DOI 10.1016/S1071-9091(96)80024-6; Harper RM, 2000, J COMP NEUROL, V417, P195, DOI 10.1002/(SICI)1096-9861(20000207)417:2<195::AID-CNE5>3.0.CO;2-V; Hassert DL, 2004, BEHAV NEUROSCI, V118, P79, DOI 10.1037/0735-7044.118.1.79; HAYANO J, 1991, AM J CARDIOL, V67, P199, DOI 10.1016/0002-9149(91)90445-Q; Henderson LA, 2002, J NEUROPHYSIOL, V88, P3477, DOI 10.1152/jn.00107.2002; Henry B., 2001, NONLINEAR BIOMEDICAL, P1; Holdstock L, 2001, ALCOHOL CLIN EXP RES, V25, P540, DOI 10.1111/j.1530-0277.2001.tb02248.x; HOLTE RC, 1993, MACH LEARN, V11, P63, DOI 10.1023/A:1022631118932; Houtveen JH, 2002, PSYCHOPHYSIOLOGY, V39, P427, DOI 10.1017/S0048577202394022; Hsu DT, 2007, J COMP NEUROL, V504, P89, DOI 10.1002/cne.21440; Hynynen E, 2010, INT J SPORTS MED, V31, P428, DOI 10.1055/s-0030-1249625; Hynynen E, 2011, EUR J APPL PHYSIOL, V111, P733, DOI 10.1007/s00421-010-1698-x; Inagaki H, 2004, EXP ANIM TOKYO, V53, P373, DOI 10.1538/expanim.53.373; Ingjaldsson JT, 2003, BIOL PSYCHIAT, V54, P1427, DOI 10.1016/S0006-3223(02)01926-1; INUI K, 1995, J PHYSIOL-LONDON, V488, P521, DOI 10.1113/jphysiol.1995.sp020987; Janig W, 2006, INTEGRATIVE ACTION OF THE AUTONOMIC NERVOUS SYSTEM: NEUROBIOLOGY OF HOMEOSTASIS, P1; Jansen K, 2010, SEIZURE-EUR J EPILEP, V19, P455, DOI 10.1016/j.seizure.2010.07.008; Jeanne M, 2009, AUTON NEUROSCI-BASIC, V147, P91, DOI 10.1016/j.autneu.2009.01.005; Jehi Lara, 2010, Cleve Clin J Med, V77 Suppl 3, pS51, DOI 10.3949/ccjm.77.s3.09; Jianling S., 2010, CELL BIOCHEM BIOPHYS, V59, P165; Johnsen BH, 2003, J ANXIETY DISORD, V17, P75, DOI 10.1016/S0887-6185(02)00178-0; Jonsson P, 2007, INT J PSYCHOPHYSIOL, V63, P48, DOI 10.1016/j.ijpsycho.2006.08.002; KAMADA T, 1992, PSYCHOSOM MED, V54, P462, DOI 10.1097/00006842-199207000-00008; Kamber, 2006, DATA MINING CONCEPTS; Karasulu L, 2010, LUNG, V188, P315, DOI 10.1007/s00408-010-9237-4; Karthik S, 2009, Indian J Physiol Pharmacol, V53, P243; Katoh K, 2002, ALIMENT PHARM THERAP, V16, P180, DOI 10.1046/j.1365-2036.16.s2.27.x; KATONA PG, 1975, J APPL PHYSIOL, V39, P801, DOI 10.1152/jappl.1975.39.5.801; Katz-Leurer M, 2010, BRAIN INJURY, V24, P110, DOI 10.3109/02699050903508234; KAWACHI I, 1995, AM J CARDIOL, V75, P882, DOI 10.1016/S0002-9149(99)80680-8; Kemp AH, 2010, BIOL PSYCHIAT, V67, P1067, DOI [10.1016/j.biopsych.2009.12.012, 10.1016/j.biopsych.2009.11.019]; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Khaykin Y, 1998, CAN J PSYCHIAT, V43, P183, DOI 10.1177/070674379804300209; Kiecolt-Glaser JK, 2002, J PSYCHOSOM RES, V53, P873, DOI 10.1016/S0022-3999(02)00309-4; Kimmerly DS, 2005, J PHYSIOL-LONDON, V569, P331, DOI 10.1113/jphysiol.2005.091637; King AB, 1999, J COMP NEUROL, V413, P572; King ML, 1997, BRAIN INJURY, V11, P445; Kitzlerova E, 2007, NEUROENDOCRINOL LETT, V28, P832; Kiviniemi AM, 2010, MED SCI SPORT EXER, V42, P1355, DOI 10.1249/MSS.0b013e3181cd5f39; KLEIGER RE, 1991, AM J CARDIOL, V68, P626, DOI 10.1016/0002-9149(91)90355-O; KOIZUMI K, 1981, J AUTONOM NERV SYST, V3, P483, DOI 10.1016/0165-1838(81)90082-5; Kondo H, 2005, J COMP NEUROL, V493, P479, DOI 10.1002/cne.20796; Kondo H, 2003, J COMP NEUROL, V465, P499, DOI 10.1002/cne.10842; Kotchoubey B, 2006, J NEUROL, V253, P1374, DOI 10.1007/s00415-006-0221-0; Krittayaphong R, 1997, PSYCHOSOM MED, V59, P231, DOI 10.1097/00006842-199705000-00004; Kuo TBJ, 2009, EXP NEUROL, V217, P38, DOI 10.1016/j.expneurol.2009.01.012; Kuusela Tom A, 2003, BMC Physiol, V3, P11, DOI 10.1186/1472-6793-3-11; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Lane RD, 2001, BRAIN COGNITION, V47, P97; Lane RD, 2009, NEUROIMAGE, V44, P213, DOI 10.1016/j.neuroimage.2008.07.056; Lanfranchi PA, 2002, AM J PHYSIOL-REG I, V283, pR815, DOI 10.1152/ajpregu.00051.2002; Laureys S, 2006, CURR OPIN NEUROL, V19, P520, DOI 10.1097/WCO.0b013e3280106ba9; Liao DP, 1999, ENVIRON HEALTH PERSP, V107, P521, DOI 10.2307/3434393; Liao DP, 2004, AM J EPIDEMIOL, V159, P768, DOI 10.1093/aje/kwh109; Liao DP, 1997, AM J EPIDEMIOL, V145, P696, DOI 10.1093/aje/145.8.696; Licht Carmilla M M, 2011, Biol Psychiatry, V69, pe3, DOI 10.1016/j.biopsych.2010.06.034; Licht CMM, 2010, BIOL PSYCHIAT, V68, P861, DOI 10.1016/j.biopsych.2010.06.032; Licht CMM, 2009, PSYCHOSOM MED, V71, P508, DOI 10.1097/PSY.0b013e3181a292a6; Lippert-Gruner M, 2006, BRAIN INJURY, V20, P569, DOI 10.1080/02699050600664467; LITVACK DA, 1995, PSYCHOPHYSIOLOGY, V32, P492, DOI 10.1111/j.1469-8986.1995.tb02101.x; Lombardi F, 1996, CARDIOVASC RES, V32, P208, DOI 10.1016/0008-6363(96)00116-2; Lombardi F, 2001, CARDIOVASC RES, V50, P210, DOI 10.1016/S0008-6363(01)00221-8; Lombardi Federico, 2002, Card Electrophysiol Rev, V6, P245, DOI 10.1023/A:1016329008921; Longin E, 2005, EARLY HUM DEV, V81, P663, DOI 10.1016/j.earlhumdev.2005.03.015; Looser RR, 2010, PSYCHOSOM MED, V72, P281, DOI 10.1097/PSY.0b013e3181d35065; Luft CD, 2009, BIOL PSYCHOL, V82, P196, DOI 10.1016/j.biopsycho.2009.07.007; Lunt HC, 2010, J PHYSIOL-LONDON, V588, P3605, DOI 10.1113/jphysiol.2010.193458; Machado C, 2011, CLIN NEUROPHYSIOL, V122, P1059, DOI 10.1016/j.clinph.2010.08.022; Malarvili MB, 2008, IEEE ENG MED BIO, P4756, DOI 10.1109/IEMBS.2008.4650276; Malpas SC, 2002, AM J PHYSIOL-HEART C, V282, pH6, DOI 10.1152/ajpheart.2002.282.1.H6; Martinmaki K, 2008, EUR J APPL PHYSIOL, V102, P353, DOI 10.1007/s00421-007-0594-5; Mashin V., 2000, HUMAN PHYSL, V26, P420, DOI DOI 10.1007/BF02760270; Mativo P, 2010, EPILEPTIC DISORD, V12, P212, DOI 10.1684/epd.2010.0325; May O, 2011, ACTA DIABETOL, V48, P55, DOI 10.1007/s00592-010-0222-4; McCraty R, 2001, BIOL PSYCHOL, V56, P131, DOI 10.1016/S0301-0511(01)00074-6; MCGRADY A, 1994, BIOFEEDBACK SELF-REG, V19, P51, DOI 10.1007/BF01720670; Medford N, 2010, BRAIN STRUCT FUNCT, V214, P535, DOI 10.1007/s00429-010-0265-x; Mendonca GV, 2010, APPL PHYSIOL NUTR ME, V35, P439, DOI 10.1139/H10-028; Monk C, 2001, INT J NEUROPSYCHOPH, V4, P199, DOI 10.1017/S146114570100236X; Montano N, 1998, CIRCULATION, V98, P1394, DOI 10.1161/01.CIR.98.14.1394; Monteiro WD, 2011, EUR J APPL PHYSIOL, V111, P1017, DOI 10.1007/s00421-010-1720-3; Moodithaya Shailaja S, 2009, Indian J Physiol Pharmacol, V53, P227; Mujica-Parodi LR, 2005, NEUROPSYCHOBIOLOGY, V51, P10, DOI 10.1159/000082850; Mulder G., 1986, ENERGETICS HUMAN INF, V31, P175, DOI [10.1007/ 978-94- 009-4448-0_ 12, DOI 10.1007/978-94-009-4448-0_12]; Mulder L. J. M., 2002, HUMAN FACTORS TRANSP, P297; Murakami H, 2007, PERCEPT MOTOR SKILL, V105, P299, DOI 10.2466/PMS.105.5.299-308; Mykletun A, 2007, PSYCHOSOM MED, V69, P323, DOI 10.1097/PSY.0b013e31803cb862; Mylonopoulou M, 2010, NEPHROL DIAL TRANSPL, V25, P3749, DOI 10.1093/ndt/gfq226; Napadow V, 2008, NEUROIMAGE, V42, P169, DOI 10.1016/j.neuroimage.2008.04.238; NEAFSEY EJ, 1990, PROG BRAIN RES, V85, P147; Nickel P, 2003, HUM FACTORS, V45, P575, DOI 10.1518/hfes.45.4.575.27094; Nickel P, 2003, J PSYCHOPHYSIOL, V17, P94; Niskanen JP, 2004, COMPUT METH PROG BIO, V76, P73, DOI 10.1016/j.cmpb.2004.03.004; Nobili L, 1997, VISION RES, V37, P3559, DOI 10.1016/S0042-6989(97)00076-X; O'Connor MF, 2007, NEUROPSYCHOPHARMACOL, V32, P2184, DOI 10.1038/sj.npp.1301342; Ohtake Yuka, 2007, Rinsho Byori, V55, P1075; Okada K, 2009, INT HEART J, V50, P95, DOI 10.1536/ihj.50.95; Owen AM, 2008, NAT REV NEUROSCI, V9, P235, DOI 10.1038/nrn2330; PAGANI M, 1992, TRENDS PHARMACOL SCI, V13, P50, DOI 10.1016/0165-6147(92)90022-X; Pal G. K., 2007, TXB PHYSL, P6; Palatini P, 2004, CLIN EXP HYPERTENS, V26, P637, DOI 10.1081/CEH-200031959; Park Mi-Kyong, 2005, Journal of Physiological Anthropology and Applied Human Science, V24, P601, DOI 10.2114/jpa.24.601; Paton JFR, 2005, BRAIN RES REV, V49, P555, DOI 10.1016/j.brainresrev.2005.02.005; Patra S, 2010, APPL PSYCHOPHYS BIOF, V35, P135, DOI 10.1007/s10484-009-9114-1; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; PENISTON EG, 1986, PSYCHOL REC, V36, P471, DOI 10.1007/BF03394967; Penzel T, 2003, IEEE T BIO-MED ENG, V50, P1143, DOI 10.1109/TBME.2003.817636; Pereira EAC, 2010, EXP NEUROL, V223, P574, DOI 10.1016/j.expneurol.2010.02.004; Perini R, 2003, EUR J APPL PHYSIOL, V90, P317, DOI 10.1007/s00421-003-0953-9; Persson H, 2007, SEIZURE-EUR J EPILEP, V16, P504, DOI 10.1016/j.seizure.2007.03.010; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Philippu A, 2001, DRUG NEWS PERSPECT, V14, P523, DOI 10.1358/dnp.2001.14.9.858409; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Piccirillo G, 1997, INT J CARDIOL, V60, P121, DOI 10.1016/S0167-5273(97)00088-0; Pichon A, 2010, AUTON NEUROSCI-BASIC, V156, P117, DOI 10.1016/j.autneu.2010.03.019; Pieper S, 2010, PSYCHOSOM MED, V72, P570, DOI 10.1097/PSY.0b013e3181dbc0e9; Ponomarenko V. I., 2009, WORLD ACAD SCI ENG T, V56, P581; Porges SW, 2007, BIOL PSYCHOL, V74, P301, DOI 10.1016/j.biopsycho.2006.08.007; Porges SW, 2007, BIOL PSYCHOL, V74, P116, DOI 10.1016/j.biopsycho.2006.06.009; Posner J, 2005, DEV PSYCHOPATHOL, V17, P715, DOI 10.1017/S0954579405050340; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Price JL, 1999, ANN NY ACAD SCI, V877, P383, DOI 10.1111/j.1749-6632.1999.tb09278.x; Pu J, 2010, BIOL PSYCHOL, V84, P531, DOI 10.1016/j.biopsycho.2009.07.006; Pumprla J, 2002, INT J CARDIOL, V84, P1, DOI 10.1016/S0167-5273(02)00057-8; Qingyu, 2001, NONLINEAR BIOMEDICAL, V2, P72; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rasic-Milutinovic ZR, 2010, SAUDI MED J, V31, P650; RECHLIN T, 1994, J AFFECT DISORDERS, V32, P271, DOI 10.1016/0165-0327(94)90091-4; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; RICHTER A, 1990, INT J PSYCHOPHYSIOL, V10, P75, DOI 10.1016/0167-8760(90)90048-I; Rickard N.S., 2004, PSYCHOL MUSIC, V32, P371, DOI [10.1177/0305735604046096, DOI 10.1177/0305735604046096]; Riganello F, 2010, CLIN NEUROPHYSIOL, V121, P2024, DOI 10.1016/j.clinph.2010.05.010; Riganello F, 2008, J PSYCHOPHYSIOL, V22, P166, DOI 10.1027/0269-8803.22.4.166; Riganello F, 2011, CLIN NEUROPHYSIOL, V122, P1061, DOI 10.1016/j.clinph.2010.09.006; Riganello F, 2009, J PSYCHOPHYSIOL, V23, P18, DOI 10.1027/0269-8803.23.1.18; RIMOLDI O, 1990, AM J PHYSIOL, V258, pH967, DOI 10.1152/ajpheart.1990.258.4.H967; Ross DC, 2002, J CLIN PSYCHOPHARM, V22, P414, DOI 10.1097/00004714-200208000-00013; Rottenberg J, 2007, BIOL PSYCHOL, V74, P200, DOI 10.1016/j.biopsycho.2005.08.010; Roumelioti ME, 2010, NEPHROL DIAL TRANSPL, V25, P3733, DOI 10.1093/ndt/gfq234; Roy RA, 2009, J MANIP PHYSIOL THER, V32, P277, DOI 10.1016/j.jmpt.2009.03.003; RUSSELL JA, 1980, J PERS SOC PSYCHOL, V39, P1161, DOI 10.1037/h0077714; Sala Michela, 2009, Ther Adv Cardiovasc Dis, V3, P29, DOI 10.1177/1753944708096282; Santucci AK, 2000, PSYCHOPHYSIOLOGY, V37, pS86; Saper CB, 2002, ANNU REV NEUROSCI, V25, P433, DOI 10.1146/annurev.neuro.25.032502.111311; Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4; SAUL JP, 1990, NEWS PHYSIOL SCI, V5, P32, DOI 10.1152/physiologyonline.1990.5.1.32; Sauvet F, 2009, AVIAT SPACE ENVIR MD, V80, P862, DOI 10.3357/ASEM.2531.2009; Sayar K., 2002, B CLIN PSYCHOPHARMAC, V12, P130; Schneider U, 2010, EARLY HUM DEV, V86, P319, DOI 10.1016/j.earlhumdev.2010.05.018; Scholten MRM, 2006, J PSYCHIAT RES, V40, P638, DOI 10.1016/j.jpsychires.2006.03.005; Schroeder EB, 2005, DIABETES CARE, V28, P668, DOI 10.2337/diacare.28.3.668; Schumann AY, 2010, SLEEP, V33, P943, DOI 10.1093/sleep/33.7.943; Schwerdtfeger A, 2010, PSYCHOPHYSIOLOGY, V47, P786, DOI 10.1111/j.1469-8986.2010.00965.x; Sequeira H, 2000, BRAIN RES BULL, V53, P87, DOI 10.1016/S0361-9230(00)00312-9; Serpiello FR, 2011, EUR J APPL PHYSIOL, V111, P669, DOI 10.1007/s00421-010-1687-0; Servant D, 2009, ENCEPHALE, V35, P423, DOI 10.1016/j.encep.2008.06.016; Sevcencu C, 2010, EPILEPSIA, V51, P725, DOI 10.1111/j.1528-1167.2009.02479.x; Sevoz-Couche C, 2003, J NEUROPHYSIOL, V90, P2521, DOI 10.1152/jn.00275.2003; Shafqat K, 2007, P ANN INT IEEE EMBS, P299; SHIH CD, 1995, AM J PHYSIOL-HEART C, V269, pH46, DOI 10.1152/ajpheart.1995.269.1.H46; Shinba T, 2008, PSYCHIAT CLIN NEUROS, V62, P603, DOI 10.1111/j.1440-1819.2008.01855.x; Siever L., 1994, AM J PSYCHIAT, V142, P1017; SNIDMAN N, 1995, PSYCHOPHYSIOLOGY, V32, P199, DOI 10.1111/j.1469-8986.1995.tb02949.x; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; Song HS, 2003, APPL PSYCHOPHYS BIOF, V28, P13, DOI 10.1023/A:1022312815649; Spiegelhalder K, 2011, J SLEEP RES, V20, P137, DOI 10.1111/j.1365-2869.2010.00863.x; Spyer K, 1990, CENTRAL REGULATION A, P168; Stein PK, 2009, AGE AGEING, V38, P212, DOI 10.1093/ageing/afn292; STEIN PK, 1994, AM HEART J, V127, P1376, DOI 10.1016/0002-8703(94)90059-0; Stephens CL, 2010, BIOL PSYCHOL, V84, P463, DOI 10.1016/j.biopsycho.2010.03.014; STUMPF WE, 1990, EXPERIENTIA, V46, P13, DOI 10.1007/BF01955408; Su SY, 2010, TWIN RES HUM GENET, V13, P1, DOI 10.1375/twin.13.1.1; SUN MK, 1985, AM J PHYSIOL, V249, pR672, DOI 10.1152/ajpregu.1985.249.6.R672; Tak LM, 2010, PSYCHOTHER PSYCHOSOM, V79, P179, DOI 10.1159/000296136; Tak LM, 2009, BIOL PSYCHOL, V82, P101, DOI 10.1016/j.biopsycho.2009.05.002; Takahashi T, 2005, INT J PSYCHOPHYSIOL, V55, P199, DOI 10.1016/j.ijpsycho.2004.07.004; Tarvainen MP, 2002, IEEE T BIO-MED ENG, V49, P172, DOI 10.1109/10.979357; Tattersall AJ, 1995, HUM FACTORS, V37, P682, DOI 10.1518/001872095778995517; Taylor JA, 1998, CIRCULATION, V98, P547, DOI 10.1161/01.CIR.98.6.547; Thayer JF, 2002, SCAND J PSYCHOL, V43, P123, DOI 10.1111/1467-9450.00277; Thayer JF, 2005, PSYCHONEUROENDOCRINO, V30, P1050, DOI 10.1016/j.psyneuen.2005.04.014; Thayer JF, 2000, J AFFECT DISORDERS, V61, P201, DOI 10.1016/S0165-0327(00)00338-4; Thayer JF, 2006, ANN NY ACAD SCI, V1088, P361, DOI 10.1196/annals.1366.014; Thayer JF, 2009, ANN BEHAV MED, V37, P141, DOI 10.1007/s12160-009-9101-z; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; TIBBLIN G, 1975, IRCS (International Research Communications System) Medical Science Library Compendium, V3, P95; TOGASHI H, 1992, J PHARMACOL EXP THER, V262, P343; Treede RD, 1999, PAIN, V79, P105, DOI 10.1016/S0304-3959(98)00184-5; Tsuji H, 1996, CIRCULATION, V94, P2850, DOI 10.1161/01.CIR.94.11.2850; Uijtdehaage SHJ, 2000, CLIN AUTON RES, V10, P107, DOI 10.1007/BF02278013; Urakawa K, 2005, TOHOKU J EXP MED, V206, P213, DOI 10.1620/tjem.206.213; Ursin H, 2004, PSYCHONEUROENDOCRINO, V29, P567, DOI 10.1016/S0306-4530(03)00091-X; Valkonen-Korhonen M, 2003, PSYCHOPHYSIOLOGY, V40, P716, DOI 10.1111/1469-8986.00072; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; van Dixhoorn J, 2005, EUR J CARDIOV PREV R, V12, P193, DOI 10.1097/00149831-200506000-00002; Van Leeuwen P., 2000, HERZSCHRITTMACHERTHE, V11, P127, DOI [10.1007/s003990070031, DOI 10.1007/S003990070031]; van Orshoven NP, 2004, J PHYSIOL-LONDON, V555, P573, DOI 10.1113/jphysiol.2003.056580; Varadhan R, 2009, J GERONTOL A-BIOL, V64, P682, DOI 10.1093/gerona/glp013; Vaschillo EG, 2008, PSYCHOPHYSIOLOGY, V45, P847, DOI 10.1111/j.1469-8986.2008.00673.x; Veltman JA, 1996, BIOL PSYCHOL, V42, P323, DOI 10.1016/0301-0511(95)05165-1; Veltman JA, 1998, ERGONOMICS, V41, P656, DOI 10.1080/001401398186829; Verkuil B, 2009, INT J PSYCHOPHYSIOL, V74, P220, DOI 10.1016/j.ijpsycho.2009.09.003; Vernieri F, 2010, STROKE, V41, P2087, DOI 10.1161/STROKEAHA.110.583088; Villa F, 2008, COMPUTERS IN CARDIOLOGY 2008, VOLS 1 AND 2, P37, DOI 10.1109/CIC.2008.4748971; Virtanen R, 2003, PSYCHOSOM MED, V65, P751, DOI 10.1097/01.PSY.0000088760.65046.CF; Wager TD, 2009, NEUROIMAGE, V47, P821, DOI 10.1016/j.neuroimage.2009.05.043; WALLACE DM, 1992, BRAIN RES BULL, V28, P447, DOI 10.1016/0361-9230(92)90046-Z; Wallin BG, 2007, MUSCLE NERVE, V36, P595, DOI 10.1002/mus.20831; Watkins LL, 1998, PSYCHOSOM MED, V60, P498, DOI 10.1097/00006842-199807000-00018; Watkins LL, 1999, PSYCHOSOM MED, V61, P334, DOI 10.1097/00006842-199905000-00012; Watkins LL, 2002, AM HEART J, V143, P460, DOI 10.1067/mhj.2002.120404; Wheat AL, 2010, APPL PSYCHOPHYS BIOF, V35, P229, DOI 10.1007/s10484-010-9133-y; WIENTJES CJE, 1992, BIOL PSYCHOL, V34, P179, DOI 10.1016/0301-0511(92)90015-M; Wijnen VJM, 2006, CLIN NEUROPHYSIOL, V117, P1794, DOI 10.1016/j.clinph.2006.03.006; WILLIAMS CL, 2001, MEMORY CONSOLIDATION, P141, DOI DOI 10.1037/10413-008; Williamson JB, 2010, AUTON NEUROSCI-BASIC, V156, P60, DOI 10.1016/j.autneu.2010.03.009; Wise V, 2011, INT J PSYCHOPHYSIOL, V79, P155, DOI 10.1016/j.ijpsycho.2010.10.002; Wise V, 2009, INT J PSYCHOPHYSIOL, V74, P34, DOI 10.1016/j.ijpsycho.2009.07.001; Witten I., 2005, DATA MINING PRACTICA, Vsecond; Wong SW, 2007, NEUROIMAGE, V35, P698, DOI 10.1016/j.neuroimage.2006.12.027; Yasui H, 2010, AUTON NEUROSCI-BASIC, V156, P96, DOI 10.1016/j.autneu.2010.03.011; YERAGANI VK, 1991, PSYCHIAT RES, V37, P35, DOI 10.1016/0165-1781(91)90104-W; Yeragani VK, 2002, BIOL PSYCHIAT, V51, P733, DOI 10.1016/S0006-3223(01)01347-6; Yeragani VK, 2001, DEPRESS ANXIETY, V13, P72, DOI 10.1002/da.1019; Yien HW, 1997, CRIT CARE MED, V25, P258, DOI 10.1097/00003246-199702000-00011; ZARDETTOSMITH AM, 1995, BRAIN RES BULL, V38, P253, DOI 10.1016/0361-9230(95)00097-X; Zhang JL, 2011, ARCH GERONTOL GERIAT, V53, P95, DOI 10.1016/j.archger.2010.06.010; Zhong X, 2005, J APPL PHYSIOL, V98, P2024, DOI 10.1152/japplphysiol.00620.2004; Zhuang Z, 2005, INT J NEUROSCI, V115, P315, DOI 10.1080/00207450590520911; Ziegler G, 2009, EUR J NEUROSCI, V30, P2205, DOI 10.1111/j.1460-9568.2009.07008.x	377	30	30	1	68	HOGREFE PUBLISHING CORP	BOSTON	361 NEWBURY ST, 5 FL, BOSTON, MA, UNITED STATES	0269-8803	2151-2124		J PSYCHOPHYSIOL	J. Psychophysiol.		2012	26	4					178	203		10.1027/0269-8803/a000080			26	Psychology, Biological; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	031WY	WOS:000310674500004					2022-02-06	
J	Avraham, Y; Davidi, N; Lassri, V; Vorobiev, L; Kabesa, M; Dayan, M; Chernoguz, D; Berry, E; Leker, RR				Avraham, Y.; Davidi, N.; Lassri, V.; Vorobiev, L.; Kabesa, M.; Dayan, M.; Chernoguz, D.; Berry, E.; Leker, R. R.			Leptin Induces Neuroprotection Neurogenesis and Angiogenesis after Stroke	CURRENT NEUROVASCULAR RESEARCH			English	Article						Angiogenesis; cerebrovascular disease; leptin; neurogenesis; neuroprotection; stroke	ACTIVATED PROTEIN-KINASE; CLOSED-HEAD-INJURY; VEGF EXPRESSION; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; IN-VIVO; RECEPTOR; INCREASES; INHIBITION; ISCHEMIA	Leptin is a potent AMP kinase (AMPK) inhibitor that is central to cell survival. Hence, we explored the effects of leptin on neurogenesis and angiogenesis after stroke. Neural stem cells (NSC) were grown as neurospheres in culture and treated with vehicle or leptin and neurosphere size and terminal differentiation were then determined. We then explored the effects of leptin on endogenous repair mechanisms in vivo. Sabra mice underwent photothrombotic stroke, were given vehicle or leptin and newborn cells were labeled with Bromo-deoxy-Uridine. Functional outcome was studied with the neurological severity score for 90 days post stroke and the brains were then evaluated with immunohistochemistry. In a subset of animals the brains were also evaluated for changes in the expression of leptin receptor and AMPK. In vitro, leptin led to a 2-fold increase in neurosphere size but did not change the differentiation of newborn cells. Following stroke, exogenous leptin led to a 4-fold increase in the number of NSC in the cortex abutting the lesion. There was a 1.5-fold increase in the number of newborn neurons and glia in leptin treated animals. Leptin also significantly increased the number of blood vessels in the peri-lesioned cortex. Leptin treated mice had increased expression of leptin receptor and increased phosphorylated AMPK concentration. Animals treated with leptin also had significantly better functional states. In conclusion, leptin induces neurogenesis and angiogenesis after stroke and leads to increased leptin receptor and pAMPK concentrations. This may explain at least in part the better functional outcome observed in leptin treated animals after stroke.	[Avraham, Y.; Davidi, N.; Vorobiev, L.; Kabesa, M.; Dayan, M.; Berry, E.] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Human Nutr & Metab, IL-91120 Jerusalem, Israel		Avraham, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Neurol, Stroke Serv, POB 12000, IL-91120 Jerusalem, Israel.	yosefa@md.huji.ac.il; leker@hadassah.org.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334	Israel Science FoundationIsrael Science Foundation [1327/07]; Peritz and Chantal Scheinberg Cerebrovascular Research Fund; Sol Irwin Juni Trust	This work was supported in part by a grant from the Israel Science Foundation (Grant No. 1327/07), by the Peritz and Chantal Scheinberg Cerebrovascular Research Fund and by the Sol Irwin Juni Trust Fund.	Abe Y, 2007, AM J PHYSIOL-HEART C, V292, pH2387, DOI 10.1152/ajpheart.00579.2006; Alawi K, 2010, PHARMACOL THERAPEUT, V125, P181, DOI 10.1016/j.pharmthera.2009.10.005; Anagnostoulis S, 2008, CYTOKINE, V42, P353, DOI 10.1016/j.cyto.2008.03.009; Avraham Y, 2010, CURR NEUROVASC RES, V7, P136, DOI 10.2174/156720210791184943; Barouch LA, 2003, CIRCULATION, V108, P754, DOI 10.1161/01.CIR.0000083716.82622.FD; Ben-Hur T, 2007, J NEUROL SCI; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; Dagon Y, 2005, J BIOL CHEM, V280, P42142, DOI 10.1074/jbc.M507607200; Eichenbaum JW, 2002, J PHARMACOL TOXICOL, V47, P67, DOI 10.1016/S1056-8719(02)00215-0; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; Forsberg-Nilsson K, 1998, J NEUROSCI RES, V53, P521, DOI 10.1002/(SICI)1097-4547(19980901)53:5<521::AID-JNR2>3.0.CO;2-B; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Garza JC, 2008, J BIOL CHEM, V283, P18238, DOI 10.1074/jbc.M800053200; Gotts JE, 2005, EXP NEUROL, V194, P139, DOI 10.1016/j.expneurol.2005.02.001; Heida NM, ARTERIOSCLER THROMB, V200-206; Hou N, 2011, CLIN EXP PHARM  0929; Jin KL, 2004, MOL PHARMACOL, V66, P204, DOI 10.1124/mol.66.2.204; Kuramoto N, 2007, NEURON, V53, P233, DOI 10.1016/j.neuron.2006.12.015; Lee JK, 2007, SURG NEUROL, V67, P620, DOI 10.1016/j.surneu.2006.08.077; Leker RR, 2007, STROKE, V38, P153, DOI 10.1161/01.STR.0000252156.65953.a9; Li J, 2007, STROKE, V38, P2992, DOI 10.1161/STROKEAHA.107.490904; Li J, 2010, J CEREBR BLOOD F MET, V30, P480, DOI 10.1038/jcbfm.2009.255; Li XX, 2008, ARTERIOSCL THROM VAS, V28, P1789, DOI 10.1161/ATVBAHA.108.172452; Liapakis IE, 2007, IN VIVO, V21, P797; Matsui H, 2007, LIFE SCI, V80, P672, DOI 10.1016/j.lfs.2006.10.027; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Neurath KM, 2006, GLIA, V53, P733, DOI 10.1002/glia.20326; Ogunshola OO, 2000, DEV BRAIN RES, V119, P139, DOI 10.1016/S0165-3806(99)00125-X; Ouchi N, 2005, CIRC RES, V96, P838, DOI 10.1161/01.RES.0000163633.10240.3b; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; Purdham DM, 2008, AM J PHYSIOL-HEART C, V295, pH441, DOI 10.1152/ajpheart.91537.2007; Ribatti D, 2008, PEPTIDES, V29, P1596, DOI 10.1016/j.peptides.2008.05.011; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Suganami E, 2004, DIABETES, V53, P2443, DOI 10.2337/diabetes.53.9.2443; Tajmir P, 2004, ENDOCRINOLOGY, V145, P1550, DOI 10.1210/en.2003-1128; Talavera-Adame D, 2008, J BIOMED OPT, V13, DOI 10.1117/1.3028010; Toth ZE, 2008, BLOOD, V111, P5544, DOI 10.1182/blood-2007-10-119073	44	30	31	0	12	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2026	1875-5739		CURR NEUROVASC RES	Curr. Neurovasc. Res.	NOV	2011	8	4					313	322		10.2174/156720211798120954			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	883FE	WOS:000299618800006	22023616				2022-02-06	
J	Funck, VR; de Oliveira, CV; Pereira, LM; Rambo, LM; Ribeiro, LR; Royes, LFF; Ferreira, J; Guerra, GP; Furian, AF; Oliveira, MS; Mallmann, CA; de Mello, CF; Oliveira, MS				Funck, Vinicius Rafael; de Oliveira, Clarissa Vasconcelos; Pereira, Leticia Meier; Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Freire Royes, Luiz Fernando; Ferreira, Juliano; Guerra, Gustavo Petri; Furian, Ana Flavia; Oliveira, Mauricio Schneider; Mallmann, Carlos Augusto; de Mello, Carlos Fernando; Oliveira, Mauro Schneider			Differential effects of atorvastatin treatment and withdrawal on pentylenetetrazol-induced seizures	EPILEPSIA			English	Article						Statin; Cholesterol; EEG; Epilepsy; Rat; Blood-brain barrier	BLOOD-BRAIN-BARRIER; HMG-COA REDUCTASE; HIPPOCAMPAL CELL-DEATH; INDUCED EXCITOTOXICITY; OXIDATIVE STRESS; CORTICAL-NEURONS; QUINOLINIC ACID; MICE; STATINS; INHIBITORS	Purpose: Statins are selective inhibitors of 3-hydroxyl-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway for cholesterol biosynthesis. Increasing evidence indicates that statins, particularly atorvastatin, are neuroprotective in several conditions, including stroke, cerebral ischemia, traumatic brain injury, and excitotoxic amino acid exposure. However, only a few studies have investigated whether statins modulate seizure activity. In the current study we investigated whether atorvastatin or simvastatin alters the seizures induced by pentylenetetrazol (PTZ), a classical convulsant. Methods: Adult male Wistar rats were treated with atorvastatin or simvastatin for 7 days (10 mg/kg/day). Seizure activity was induced by PTZ (60 mg/kg, i.p.), and evaluated by behavioral and electrographic methods. Cholesterol levels were determined by a standard spectrophotometric method. Blood-brain barrier (BBB) permeability was assessed by the fluorescein method. Atorvastatin levels in the plasma and cerebral cortex were determined by high-performance liquid chromatography tandem mass spectrometry. Key Findings: We found that oral atorvastatin treatment increased the latency to PTZ-induced generalized seizures. In contrast, when the 7-day atorvastatin treatment was withheld for 1 day (i.e., atorvastatin withdrawal), PTZ-induced seizures were facilitated, as evidenced by a decrease in the latency to clonic and generalized tonic-clonic seizures induced by PTZ. In contrast, simvastatin treatment for 7 days (10 mg/kg/day, p.o.), with or without withdrawal, did not alter PTZ-induced seizures. Interestingly, the effects of atorvastatin treatment and withdrawal were not accompanied by changes in plasma or cerebral cortex cholesterol levels or in the BBB permeability. Atorvastatin levels in the plasma and cerebral cortex after 7 days of treatment were above the half maximal inhibitory concentration for inhibition of HMG-CoA reductase, whereas atorvastatin was not detectable in the plasma or cerebral cortex following a 24 h washout period (atorvastatin withdrawal). Significance: We conclude that atorvastatin treatment and withdrawal have differential effects on pentylenetetrazol-induced seizures, which are not related to changes in plasma or cerebral cortex cholesterol levels or in BBB permeability. Additional studies are necessary to evaluate the molecular mechanisms underlying our findings as well as its clinical implications.	[Oliveira, Mauro Schneider] Univ Fed Pampa, BR-97650000 Itaqui, RS, Brazil; [Funck, Vinicius Rafael; Rambo, Leonardo Magno; Ribeiro, Leandro Rodrigo; Freire Royes, Luiz Fernando; Ferreira, Juliano; Guerra, Gustavo Petri; Oliveira, Mauro Schneider] Univ Fed Santa Maria, Postgrad Program Biol Sci Biochem, BR-97119900 Santa Maria, RS, Brazil; [de Oliveira, Clarissa Vasconcelos; Pereira, Leticia Meier; Freire Royes, Luiz Fernando; Ferreira, Juliano; Furian, Ana Flavia; de Mello, Carlos Fernando; Oliveira, Mauro Schneider] Univ Fed Santa Maria, Postgrad Program Pharmacol, BR-97119900 Santa Maria, RS, Brazil; [Oliveira, Mauricio Schneider; Mallmann, Carlos Augusto] Univ Fed Santa Maria, Postgrad Program Vet Med, BR-97119900 Santa Maria, RS, Brazil		Oliveira, MS (corresponding author), Univ Fed Pampa, Campus Itaqui,Rua Luiz Joaquim de Sa Britto S-N, BR-97650000 Itaqui, RS, Brazil.	oliveira.ms@gmail.com; oliveira.ms@gmail.com	Guerra, Gustavo Petri/AAU-2862-2021; Ferreira, Juliano/A-9803-2013; Rambo, Leonardo/F-8195-2012; Mello, Carlos/C-7188-2013; Funck, Vinicius Rafael/M-6968-2014; Oliveira, Mauro Schneider/G-3437-2012	Guerra, Gustavo Petri/0000-0001-6995-5348; Ferreira, Juliano/0000-0002-9562-0602; Mello, Carlos/0000-0002-1326-1045; Funck, Vinicius Rafael/0000-0002-3569-3711; Oliveira, Mauro Schneider/0000-0002-5381-1208; Mallmann, Carlos/0000-0003-2376-2705; Meier, Leticia/0000-0002-9848-9814; Ribeiro, Leandro/0000-0002-8442-4075; Rambo, Leonardo/0000-0002-4769-3663	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [150905/2009-0, 306469/2009-0, 301552/2007-0]; FapergsFundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [10/0685-8]; PIBIC [507049/2010-1]; CapesCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	This work was supported by CNPq (grants #150905/2009-0, #306469/2009-0 and #301552/2007-0), Fapergs (grant #10/0685-8), PIBIC (grant #507049/2010-1), and Capes.	Bazan NG, 2002, PROG BRAIN RES, V135, P175; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Candrilli SD, 2010, EPILEPSY RES, V91, P260, DOI 10.1016/j.eplepsyres.2010.07.021; ENDO A, 1976, J ANTIBIOT, V29, P841, DOI 10.7164/antibiotics.29.841; ENDO A, 1992, J LIPID RES, V33, P1569; Endo A, 2010, P JPN ACAD B-PHYS, V86, P484, DOI 10.2183/pjab.86.484; Endres M, 2005, J CEREBR BLOOD F MET, V25, P1093, DOI 10.1038/sj.jcbfm.9600116; Ferraro TN, 1999, J NEUROSCI, V19, P6733, DOI 10.1523/JNEUROSCI.19-16-06733.1999; Friedman A, 2011, EPILEPSIA, V52, P33, DOI 10.1111/j.1528-1167.2011.03034.x; Gertz K, 2003, STROKE, V34, P551, DOI 10.1161/01.STR.0000054055.28435.BF; Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564; Heeschen C, 2002, CIRCULATION, V105, P1446, DOI 10.1161/01.CIR.0000012530.68333.C8; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Kahles T, 2007, STROKE, V38, P3000, DOI 10.1161/STROKEAHA.107.489765; Lau YY, 2006, DRUG METAB DISPOS, V34, P1175, DOI 10.1124/dmd.105.009076; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Lee JK, 2008, NEUROSCI LETT, V440, P260, DOI 10.1016/j.neulet.2008.05.112; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; MARCHI N, 2007, CARDIOVASC PSYCHIAT; Marchi N, 2007, EPILEPSIA, V48, P732, DOI 10.1111/j.1528-1167.2007.00988.x; Marchi Nicola, 2011, Cardiovasc Psychiatry Neurol, V2011, P482415, DOI 10.1155/2011/482415; Marchi N, 2010, BRAIN RES, V1353, P176, DOI 10.1016/j.brainres.2010.06.051; McColl CD, 2003, NEUROPHARMACOLOGY, V44, P234, DOI 10.1016/S0028-3908(02)00369-6; Nagotani S, 2005, STROKE, V36, P670, DOI 10.1161/01.STR.0000155732.27333.3c; Oliveira MS, 2008, EPILEPSY RES, V79, P14, DOI 10.1016/j.eplepsyres.2007.12.008; Olsen AL, 2007, ANTIVIR RES, V75, P104, DOI 10.1016/j.antiviral.2006.11.013; Piermartiri TCB, 2009, NEUROTOX RES, V16, P106, DOI 10.1007/s12640-009-9057-6; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Serbanescu I, 2004, J LIPID RES, V45, P2038, DOI 10.1194/jlr.M400097-JLR200; Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003; Taoufiq Z, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-52; Thomas M, 1998, LANCET, V352, P1830, DOI 10.1016/S0140-6736(05)79893-7; Trinder P., 1969, ANN CLIN BIOCHEM, V6, P165; TURPIN JC, 1991, DEV NEUROSCI-BASEL, V13, P304, DOI 10.1159/000112177; van Vliet EA, 2011, EPILEPSIA, V52, P1319, DOI 10.1111/j.1528-1167.2011.03073.x; Vecchione C, 2002, CIRC RES, V91, P173, DOI 10.1161/01.RES.0000028004.76218.B8; Velisek L, 2006, MODELS OF SEIZURES AND EPILEPSY, P127, DOI 10.1016/B978-012088554-1/50013-X; VEZZANI A, 1989, EXP NEUROL, V106, P90, DOI 10.1016/0014-4886(89)90149-0; White HS, 2006, MODELS OF SEIZURES AND EPILEPSY, P539, DOI 10.1016/B978-012088554-1/50046-3; Zacco A, 2003, J NEUROSCI, V23, P11104	43	30	31	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia	NOV	2011	52	11					2094	2104		10.1111/j.1528-1167.2011.03261.x			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	848KE	WOS:000297049700026	21906051	Bronze			2022-02-06	
J	Park, BN; Shim, W; Lee, G; Bang, OY; An, YS; Yoon, JK; Ahn, YH				Park, Bok-Nam; Shim, Wooyoung; Lee, Gwang; Bang, Oh Young; An, Young-Sil; Yoon, Joon-Kee; Ahn, Young Hwan			Early distribution of intravenously injected mesenchymal stem cells in rats with acute brain trauma evaluated by Tc-99m-HMPAO labeling	NUCLEAR MEDICINE AND BIOLOGY			English	Article						Tc-99m-HMPAO; Bone marrow mesenchymal stem cells; Traumatic brain injury; Cell tracking; Gamma camera; Gamma counter	HEMATOPOIETIC PROGENITOR CELLS; IN-VIVO; MYOCARDIAL-INFARCTION; DIFFERENTIATION; TRANSPLANTATION; THERAPIES; MIGRATION; SPECT	Introduction: Stem cell tracking is essential for evaluation of its migration, transplantation and therapeutic response. The aim of this study was to evaluate early distribution of intravenously transplanted rat bone marrow mesenchymal stem cells (BMSCs) in rats with acute cerebral trauma by labeling with Tc-99m-hexamethylpropyleneamine oxime (Tc-99m-HMPAO). Methods: Tc-99m-HMPAO-labeled BMSCs were injected intravenously to trauma rats (n=14) and sham-operated controls (n=13). Gamma camera images were acquired at 4 h after injection, and then organs were removed for gamma counting. Confocal microscope was used to confirm the migration of Tc-99m-BMSCs by co-labeling with PKH26. Cytometric analysis was performed to evaluate apoptotic or necrotic change until the seventh day after labeling. Results: Tc-99m-BMSCs were distributed mostly to lungs, liver and spleen at 4 h, and uptake of these organs was not significantly different between traumatic rats and controls. Meanwhile, the cerebral uptake of Tc-99m-BMSCs was significantly higher in the traumatic rats than in controls (0.40% vs. 0.20%; P=.0002). Additionally, Tc-99m-BMSCs' uptake of traumatic hemisphere was significantly higher than that of contralateral ones (0.27% vs. 0.13%; P=.0001) in traumatic rats. Regardless of radiolabeling, BMSCs migrated to traumatic regions, but not to nontraumatic hemispheres. However, gamma camera failed to demonstrate Tc-99m-BMSCs in traumatic hemispheres. No significant apoptotic or necrotic change was observed until 7 days after radiolabeling. Conclusions: Early distribution of BMSCs in traumatic brain disease could be monitored by Tc-99m-labeling, which does not induce cellular death. However, our data showed that the amount of migrated Tc-99m-BMSCs was not enough to be demonstrated by clinical gamma camera. (C) 2011 Elsevier Inc. All rights reserved.	[Park, Bok-Nam; An, Young-Sil; Yoon, Joon-Kee] Ajou Univ, Sch Med, Dept Nucl Med & Mol Imaging, Suwon 442749, South Korea; [Shim, Wooyoung; Lee, Gwang; Ahn, Young Hwan] Ajou Univ, Sch Med, Inst Neuroregenerat & Stem Cell Res, Suwon 442749, South Korea; [Shim, Wooyoung; Lee, Gwang] Ajou Univ, Dept Mol Sci & Technol, Suwon 442749, South Korea; [Lee, Gwang] Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea; [Bang, Oh Young] Yonsei Univ, Sch Med, Dept Neurol, Seoul 102752, South Korea; [Ahn, Young Hwan] Ajou Univ, Sch Med, Dept Neurosurg, Suwon 442749, South Korea		Yoon, JK (corresponding author), Ajou Univ, Sch Med, Dept Nucl Med & Mol Imaging, Suwon 442749, South Korea.	jkyoon3@gmail.com		An, Young-Sil/0000-0003-0777-6226	Korea Food and Drug Administration, Republic of Korea [KFDA2006-7710[1]]; Department of Medical Sciences, The Graduate School, Ajou University	This work was supported by the Korea Food and Drug Administration, Republic of Korea (KFDA2006-7710[1]), and the 2008 grant from the Department of Medical Sciences, The Graduate School, Ajou University (J.K. Yoon).	Ballas CB, 2002, J CELL BIOCHEM, P20, DOI 10.1002/jcb.10127; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Beeres SLMA, 2007, J AM COLL CARDIOL, V49, P1137, DOI 10.1016/j.jacc.2006.10.072; Bengel FM, 2005, EUR J NUCL MED MOL I, V32, pS404, DOI 10.1007/s00259-005-1898-5; Bindslev L, 2006, EUR J NUCL MED MOL I, V33, P1171, DOI 10.1007/s00259-006-0093-7; Brenner W, 2004, J NUCL MED, V45, P512; Chen Z, 2006, TOXICOL LETT, V163, P109, DOI 10.1016/j.toxlet.2005.10.003; Cho YH, 2006, ACTA NEUROCHIR SUPPL, V99, P125, DOI 10.1007/978-3-211-35205-2_24; Detante O, 2009, CELL TRANSPLANT, V18, P1369, DOI 10.3727/096368909X474230; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Fierro FA, 2004, CLIN EXP METASTAS, V21, P313, DOI 10.1023/B:CLIN.0000046130.79363.33; Frankel MS, 2000, SCIENCE, V287, P1397, DOI 10.1126/science.287.5457.1397; FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83; Hellmann MA, 2006, NEUROSCI LETT, V395, P124, DOI 10.1016/j.neulet.2005.10.097; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Kang WJ, 2006, J NUCL MED, V47, P1295; Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Stodilka RZ, 2006, NUCL MED COMMUN, V27, P807, DOI 10.1097/01.mnm.0000237987.31597.cf; Yoon JK, 2010, NUCL MED BIOL, V37, P381, DOI 10.1016/j.nucmedbio.2009.12.001; Zhu W, 2006, EXP MOL PATHOL, V80, P267, DOI 10.1016/j.yexmp.2005.07.004	24	30	34	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0969-8051			NUCL MED BIOL	Nucl. Med. Biol.	NOV	2011	38	8					1175	1182		10.1016/j.nucmedbio.2011.05.009			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	862DQ	WOS:000298070400013	21831649				2022-02-06	
J	Herkenham, M; Rathore, P; Brown, P; Listwak, SJ				Herkenham, Miles; Rathore, Priyanka; Brown, Pierre; Listwak, Samuel J.			Cautionary notes on the use of NF-kappa B p65 and p50 antibodies for CNS studies	JOURNAL OF NEUROINFLAMMATION			English	Article						NF-kappa?kappa?B; transcription factor; immunohistochemistry; antibody specificity	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; RAT-BRAIN; PROINFLAMMATORY CYTOKINES; TRANSCRIPTIONAL ACTIVITY; TRYPANOSOMA-BRUCEI; DEFICIENT MOUSE; MESSENGER-RNA	Background: The characterization and cellular localization of transcription factors like NF-kappa B requires the use of antibodies for western blots and immunohistochemistry. However, if target protein levels are low and the antibodies not well characterized, false positive data can result. In studies of NF-kappa B activity in the CNS, antibodies detecting NF-kappa B proteins have been used to support the finding that NF-kappa B is constitutively active in neurons, and activity levels are further increased by neurotoxic treatments, glutamate stimulation, or elevated synaptic activity. The specificity of the antibodies used was analyzed in this study. Methods: Selectivity and nonselectivity of commonly used commercial and non-commercial p50 and p65 antibodies were demonstrated in western blot assays conducted in tissues from mutant gene knockout mice lacking the target proteins. Results: A few antibodies for p50 and p65 each mark a single band at the appropriate molecular weight in gels containing proteins from wildtype tissue, and this band is absent in proteins from knockout tissues. Several antibodies mark proteins that are present in knockout tissues, indicating that they are nonspecific. These include antibodies raised against the peptide sequence containing the nuclear localization signals of p65 (MAB3026; Chemicon) and p50 (sc-114; Santa Cruz). Some antibodies that recognize target proteins at the correct molecular weight still fail in western blot analysis because they also mark additional proteins and inconsistently so. We show that the criterion for validation by use of blocking peptides can still fail the test of specificity, as demonstrated for several antibodies raised against p65 phosphorylated at serine 276. Finally, even antibodies that show specificity in western blots produce nonspecific neuronal staining by immunohistochemistry. Conclusions: We note that many of the findings in the literature about neuronal NF-kappa B are based on data garnered with antibodies that are not selective for the NF-kappa B subunit proteins p65 and p50. The data urge caution in interpreting studies of neuronal NF-kappa B activity in the brain.	[Herkenham, Miles; Rathore, Priyanka; Brown, Pierre; Listwak, Samuel J.] NIMH, Funct Neuroanat Sect, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA		Herkenham, M (corresponding author), NIMH, Funct Neuroanat Sect, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA.	herkenh@mail.nih.gov		Herkenham, Miles/0000-0003-2228-4238	National Institute of Mental Health, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH001090] Funding Source: NIH RePORTER	The work was supported by the Intramural Research Program, National Institute of Mental Health, NIH.	Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Acarin L, 1998, NEUROREPORT, V9, P2869, DOI 10.1097/00001756-199808240-00035; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Artis D, 2002, J IMMUNOL, V169, P4481, DOI 10.4049/jimmunol.169.8.4481; Barger SW, 2005, CURR PHARM DESIGN, V11, P985, DOI 10.2174/1381612053381594; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Brochu S, 1999, J NEUROSCI RES, V57, P801, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;801::AID-JNR5&gt;3.0.CO;2-B; Caba E, 2004, ACTA NEUROPATHOL, V108, P173, DOI 10.1007/s00401-004-0876-5; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Cohen H, 2011, NEUROPSYCHOPHARMACOL; De Lorenzi R, 2009, GENESIS, V47, P323, DOI 10.1002/dvg.20468; Denis-Donini S, 2005, DEV BRAIN RES, V154, P81, DOI 10.1016/j.devbrainres.2004.10.010; Dixon EP, 1997, BRAIN RES, V776, P222, DOI 10.1016/S0006-8993(97)01040-8; Duckworth EAM, 2006, BRAIN RES, V1088, P167, DOI 10.1016/j.brainres.2006.02.103; Freudenthal R, 2004, HIPPOCAMPUS, V14, P677, DOI 10.1002/hipo.20020; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GOSLIN K, 1992, CULTURING NERVE CELL, P252; Gu ZZ, 2000, INT J DEV NEUROSCI, V18, P185, DOI 10.1016/S0736-5748(99)00087-8; Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Juttler E, 2007, J NEUROIMMUNOL; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; Ledeboer A, 2005, EUR J NEUROSCI, V22, P1977, DOI 10.1111/j.1460-9568.2005.04379.x; Mao XRR, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-16; Matsuoka Y, 1999, EXP BRAIN RES, V124, P215, DOI 10.1007/s002210050616; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Nadeau S, 1999, J NEUROPATH EXP NEUR, V58, P61, DOI 10.1097/00005072-199901000-00008; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Nadjar A, 2003, J NEUROCHEM, V87, P1024, DOI 10.1046/j.1471-4159.2003.02097.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nurmi A, 2004, STROKE, V35, P987, DOI 10.1161/01.STR.0000120732.45951.26; O'Sullivan NC, 2010, BRAIN RES BULL, V81, P385, DOI 10.1016/j.brainresbull.2009.11.001; Pennypacker KR, 2001, EXP NEUROL, V172, P307, DOI 10.1006/exnr.2001.7817; Pereira DS, 1996, ONCOGENE, V13, P445; PerezOtano I, 1996, GLIA, V16, P306, DOI 10.1002/(SICI)1098-1136(199604)16:4<306::AID-GLIA3>3.0.CO;2-Y; Quan N, 1999, J COMP NEUROL, V414, P114, DOI 10.1002/(SICI)1096-9861(19991108)414:1&lt;114::AID-CNE9&gt;3.0.CO;2-G; Quan N, 1999, J NEUROIMMUNOL, V93, P72, DOI 10.1016/S0165-5728(98)00193-3; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Quan N, 1997, P NATL ACAD SCI USA, V94, P10985, DOI 10.1073/pnas.94.20.10985; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHOLZ WK, 1991, J NEUROSCI, V11, P2422; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Spooren A, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/275892; Stephenson D, 2000, J CEREBR BLOOD F MET, V20, P592, DOI 10.1097/00004647-200003000-00017; Terai K, 1996, BRAIN RES, V739, P343, DOI 10.1016/S0006-8993(96)01073-6; Tounai H, 2007, METAB BRAIN DIS, V22, P89, DOI 10.1007/s11011-006-9040-3; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Voutsinos-Porche B, 2004, NEUROBIOL DIS, V17, P385, DOI 10.1016/j.nbd.2004.07.023; Ward NL, 2000, EUR J NEUROSCI, V12, P1867, DOI 10.1046/j.1460-9568.2000.00070.x; Wellmann H, 2001, J BIOL CHEM, V276, P11821, DOI 10.1074/jbc.M009253200; Won SJ, 1999, NEUROSCIENCE, V94, P83, DOI 10.1016/S0306-4522(99)00196-7; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	63	30	30	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 14	2011	8								141	10.1186/1742-2094-8-141			14	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	843VM	WOS:000296703100001	21999414	Green Published, gold			2022-02-06	
J	Hirsh, AT; Braden, AL; Craggs, JG; Jensen, MP				Hirsh, Adam T.; Braden, Alan L.; Craggs, Jason G.; Jensen, Mark P.			Psychometric Properties of the Community Integration Questionnaire in a Heterogeneous Sample of Adults With Physical Disability	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Disabled persons; Outcome assessment (health care); Psychometrics; Quality of life; Rehabilitation	FORM HEALTH SURVEY; TRAUMATIC BRAIN INJURY; SPINAL-CORD-INJURY; SELF-RATED HEALTH; QUALITY-OF-LIFE; PSYCHOSOCIAL FACTORS; SURVEY SF-36; PARTICIPATION; RELIABILITY; OUTCOMES	Hirsh AT, Braden AL, Craggs JG, Jensen MP. Psychometric properties of the Community Integration Questionnaire in a heterogeneous sample of adults with physical disability. Arch Phys Med Rehabil 2011;92:1602-10. Objective: To investigate the psychometric properties of the Community Integration Questionnaire (CIQ) in a mixed sample of adults with physical disabilities. Design: Cross-sectional, survey study. Setting: Academic and community medical clinics, national registry, and self-referral. Participants: Community-dwelling adults with spinal cord injury (n=146), multiple sclerosis (n=174), limb loss (n=158), or muscular dystrophy (n=273). Interventions: Not applicable. Main Outcome Measures: CIQ, General Health item from the Medical Outcomes Study 36-Item Short-Form Health Survey, and Mental Health Scale from the Medical Outcomes Study 36-Item Short-Form Health Survey. Results: Based on the original scoring procedures, the CIQ Total scale and Home Integration subscale demonstrated acceptable internal consistency; however, reliability indices for the Social Integration and Productive Activities subscales were suboptimal. The exploratory factor analysis yielded a 4-factor solution (accounting for approximately 63% of the variance) that did not replicate the original factor structure of the CIQ. The results of the confirmatory factor analyses indicated that a modified 3-factor solution provided the best fit to the data from our samples. Using a revised scoring system based on these findings, the CIQ demonstrated improved reliability relative to the original scoring and good concurrent validity. Conclusions: The results provide general support for the validity of the CIQ as a measure of participation in adults with physical disabilities. However, our results indicate that some small modifications to the original scoring system are needed to optimize its use in this patient group. Additional research is needed to refine the measurement of participation in these and other populations.	[Hirsh, Adam T.] Indiana Univ Purdue Univ, Dept Psychol, Indianapolis, IN 46202 USA; [Braden, Alan L.; Jensen, Mark P.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; [Craggs, Jason G.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA		Hirsh, AT (corresponding author), Indiana Univ Purdue Univ, Dept Psychol, 402 N Blackford St,LD 124, Indianapolis, IN 46202 USA.	athirsh@iupui.edu		Craggs, Jason/0000-0002-9531-0559	National Institutes of Health, National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Center for Medical Rehabilitation Research [T32 HD007424, PO1 HD33988]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007424, P01HD033988] Funding Source: NIH RePORTER	Supported in part by the National Institutes of Health, National Institute of Child Health and Human Development, and the National Center for Medical Rehabilitation Research (grant nos. T32 HD007424, PO1 HD33988).	Allen K, 1996, JAMA-J AM MED ASSOC, V275, P1001, DOI 10.1001/jama.275.13.1001; Archibald CJ, 1999, AM J RESP CRIT CARE, V160, P523, DOI 10.1164/ajrccm.160.2.9808109; Balkrishnan R, 2001, AM J MANAG CARE, V7, P145; BERWICK DM, 1991, JAMA-J AM MED ASSOC, V266, P841, DOI 10.1001/jama.266.6.841; Beusterien KM, 1996, J GERIATR PSYCH NEUR, V9, P13, DOI 10.1177/089198879600900103; Bollen K. A., 1989, STRUCTURAL EQUATIONS, DOI 10.1002/9781118619179; Bollen K.A., 1993, TESTING STRUCTURAL E, V154; Bullinger M, 1998, J CLIN EPIDEMIOL, V51, P913, DOI 10.1016/S0895-4356(98)00082-1; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Chrispin PS, 1997, ANAESTHESIA, V52, P15, DOI 10.1111/j.1365-2044.1997.015-az014.x; Cohen J., 2013, STAT POWER ANAL BEHA; Coker AL, 2002, AM J PREV MED, V23, P260, DOI 10.1016/S0749-3797(02)00514-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Coulehan JL, 1997, ARCH INTERN MED, V157, P1113, DOI 10.1001/archinte.157.10.1113; Crossley TF, 2002, J HEALTH ECON, V21, P643, DOI 10.1016/S0167-6296(02)00007-3; Dalemans RJ, 2010, ARCH PHYS MED REHAB, V91, P395, DOI 10.1016/j.apmr.2009.10.021; DeSalvo KB, 2005, HEALTH SERV RES, V40, P1234, DOI 10.1111/j.1475-6773.2005.00404.x; Diehr P, 2001, J AM GERIATR SOC, V49, P36, DOI 10.1046/j.1532-5415.2001.49007.x; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers MPJM, 2000, ARCH PHYS MED REHAB, V81, pS63, DOI 10.1053/apmr.2000.20627; Ehde DM, 2006, MULT SCLER J, V12, P629, DOI 10.1177/1352458506071346; Fan VS, 2002, J CLIN EPIDEMIOL, V55, P371, DOI 10.1016/S0895-4356(01)00493-0; FERKETICH S, 1991, RES NURS HEALTH, V14, P165, DOI 10.1002/nur.4770140211; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gontkovsky ST, 2009, NEUROREHABILITATION, V24, P185, DOI 10.3233/NRE-2009-0467; GORDON WA, 1999, REHABILITATION ADULT, P312; Hair JF., 2009, MULTIVARIATE DATA AN, V7; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hirsh AT, 2010, J PAIN, V11, P79, DOI 10.1016/j.jpain.2009.06.004; Johnston Mark, 2002, J Spinal Cord Med, V25, P11; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Kennedy BP, 1998, BRIT MED J, V317, P917; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; McVeigh SA, 2009, J SPINAL CORD MED, V32, P115, DOI 10.1080/10790268.2009.11760762; Miro J, 2009, AM J HOSP PALLIAT ME, V26, P308, DOI 10.1177/1049909109335146; Molton IR, 2009, J REHABIL RES DEV, V46, P31, DOI 10.1682/JRRD.2008.03.0044; Osborne TL, 2007, PAIN, V127, P52, DOI 10.1016/j.pain.2006.07.017; Renwick R, 2003, INT J REHABIL RES, V26, P279, DOI 10.1097/00004356-200312000-00005; Salter KL, 2007, INT J REHABIL RES, V30, P339, DOI 10.1097/MRR.0b013e3282f144b7; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Schafer JL, 1997, ANAL INCOMPLETE MULT; Streiner D.L., 1989, HLTH MEASUREMENT SCA; Tate DG, 2001, REHABIL PSYCHOL, V46, P125, DOI 10.1037/0090-5550.46.2.125; Tate RL, 2010, COMPENDIUM TESTS SCA; Turner-Bowker D, 2002, SF 36 HLTH SURVEY SF; van de Ven L, 2005, DISABIL SOC, V20, P311, DOI 10.1080/09687590500060778; Van der Mei SF, 2007, DISABIL REHABIL, V29, P473, DOI 10.1080/09638280600841257; van der Slot WMA, 2007, DISABIL REHABIL, V29, P179, DOI 10.1080/09638280600747686; Wagner AK, 1998, J CLIN EPIDEMIOL, V51, P925, DOI 10.1016/S0895-4356(98)00083-3; Ware J., 2000, SF 36 HLTH SURVEY MA; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware J.E., 1994, SF 36 PHYS MENTAL SU; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1994, BRAIN INJURY REHABIL, P355; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2007, INT CLASS FUNCT DIS; Yasui NY, 2009, DISABIL REHABIL, V31, P761, DOI 10.1080/09638280802306638	63	30	30	1	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2011	92	10					1602	1610		10.1016/j.apmr.2011.05.004			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	833DE	WOS:000295861200011	21851927	Green Accepted			2022-02-06	
J	Pachalska, M; Lukowicz, M; Kropotov, JD; Herman-Sucharska, I; Talar, J				Pachalska, Maria; Lukowicz, Malgorzata; Kropotov, Juri D.; Herman-Sucharska, Izabela; Talar, Jan			Evaluation of differentiated neurotherapy programs for a patient after severe TBI and long term coma using event-related potentials	MEDICAL SCIENCE MONITOR			English	Article						TBI; executive dysfunctions; behavioral changes; neurotherapy; ERP's	TRAUMATIC BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; FRONTAL BEHAVIORAL INVENTORY; EPIDEMIOLOGY; REHABILITATION; BIOFEEDBACK	Background: This article examines the effectiveness of differentiated rehabilitation programs for a patient with frontal syndrome after severe TBI and long-term coma. We hypothesized that there would be a small response to relative beta training, and a good response to rTMS, applied to regulate the dynamics of brain function. Case Report: M. L-S, age 26, suffered from anosognosia, executive dysfunction, and behavioral changes, after a skiing accident and prolonged coma, rendering him unable to function independently in many situations of everyday life. Only slight progress was made after traditional rehabilitation. The patient took part in 20 sessions of relative beta training (program A) and later in 20 sessions of rTMS (program B); both programs were combined with behavioral training. We used standardized neuropsychological testing, as well as ERPs before the experiment, after the completion of program A, and again after the completion of program B. As hypothesized, patient M. L-S showed small improvements in executive dysfunction and behavioral disorders after the conclusion of program A, and major improvement after program B. Similarly, in physiological changes the patient showed small improvement after relative beta training and a significant improvement of the P300 NOGO component after the rTMS program. Conclusions: The rTMS program produced larger physiological and behavioral changes than did relative beta training. A combination of different neurotherapeutical approaches (such as neurofeedback, rTMS, tDCS) can be suggested for similar severe cases of TBI. ERPs can be used to assess functional brain changes induced by neurotherapeutical programs.	[Pachalska, Maria] Andrzej Frycz Modrzewski Cracow Univ, Chair Neuropsychol, PL-30705 Krakow, Poland; [Pachalska, Maria] Ctr Cognit & Commun, New York, NY USA; [Lukowicz, Malgorzata] Nicolaus Copernicus Univ, Coll Med, Laser Therapy & Physiotherapy Dept, Bydgoszcz, Poland; [Kropotov, Juri D.] Russian Acad Sci, Inst Human Brain, Lab Neurobiol Act Programming, St Petersburg 196140, Russia; [Kropotov, Juri D.] Norwegian Univ Sci & Technol, Inst Psychol, N-7034 Trondheim, Norway; [Herman-Sucharska, Izabela] Jagiellonian Univ, Coll Med, Dept Radiol, Magnet Resonance Lab, Krakow, Poland; [Talar, Jan] Elblag Univ Humanities & Econ, Dept Hlth Sci, Elblag, Poland		Pachalska, M (corresponding author), Andrzej Frycz Modrzewski Cracow Univ, Chair Neuropsychol, Herlinga Grudzinskiego 1 Str, PL-30705 Krakow, Poland.	neuropsychologia23@o2.pl		Malgorzata, Lukowicz/0000-0002-4574-8050			Barry RJ, 2009, INT J PSYCHOPHYSIOL, V71, P124, DOI 10.1016/j.ijpsycho.2008.09.009; Bashir S, 2010, PM&R, V2, pS253, DOI 10.1016/j.pmrj.2010.10.015; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Blair M, 2007, DEMENT GERIATR COGN, V23, P406, DOI 10.1159/000101908; Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Choi JH, 2008, J TRAUMA, V65, P1028, DOI 10.1097/TA.0b013e31815eba9b; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Kertesz A, 1997, CAN J NEUROL SCI, V24, P29, DOI 10.1017/S0317167100021053; Kertesz A, 2000, J INT NEUROPSYCH SOC, V6, P460, DOI 10.1017/S1355617700644041; Kropotov JD, 2005, INT J PSYCHOPHYSIOL, V55, P23, DOI 10.1016/j.ijpsycho.2004.05.011; Kropotov JD, 2009, QUANTITATIVE EEG EVE, P542; Kropotov JD, 2009, ACTA NEUROPSYCHOL, V7, P169; Marvasti Jamshid A, 2011, Conn Med, V75, P133; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; Meinzer M, 2011, APHASIOLOGY, V25, P271, DOI 10.1080/02687038.2010.530672; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Pachalska M, 2002, ORTOPEDIA TRAUMATOLO, V4, P81; Pachalska M., 2008, REHABILITACJA NEUROP; Pachalska M, 2010, MED SCI MONITOR, V16, pCS157; Pape TLB, 2006, J HEAD TRAUMA REHAB, V21, P437, DOI 10.1097/00001199-200609000-00063; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; Pascual-Leone A., 2002, HDB TRANSCRANIAL MAG; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rossi S, 2004, TRENDS COGN SCI, V8, P273, DOI 10.1016/j.tics.2004.04.012; Schoenberger NE, 2001, J HEAD TRAUMA REHAB, V16, P260, DOI 10.1097/00001199-200106000-00005; Slawik H, 2009, J NEUROTRAUM, V26, P1891, DOI 10.1089/neu.2009.0942; Thatcher RW, 2000, CLIN ELECTROENCEPHAL, V31, P38, DOI 10.1177/155005940003100110; Thornton KE, 2009, APPL PSYCHOPHYS BIOF, V34, P59, DOI 10.1007/s10484-009-9075-4; Velikonja D, 2010, J CLIN EXP NEUROPSYC, V32, P610, DOI 10.1080/13803390903401302; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100	34	30	31	0	36	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	OCT	2011	17	10					CS120	CS128		10.12659/MSM.881970			9	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	861QL	WOS:000298034200009	21959618	Green Published, Green Submitted			2022-02-06	
J	Miyake, J; Masatomi, T				Miyake, Junichi; Masatomi, Takashi			Arthroscopic Debridement of the Humeral Capitellum for Osteochondritis Dissecans: Radiographic and Clinical Outcomes	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						Arthroscopic debridement; elbow; humeral capitellum; osteochondritis dissecans	FOLLOW-UP; BASEBALL PLAYERS; ELBOW; CLASSIFICATION; MANAGEMENT; AUTOGRAFT	Purpose Although arthroscopic debridement of the humeral capitellum is an accepted procedure for osteochondritis dissecans, some patients develop radial head enlargement or osteoarthritic lesions after the procedure. The aim of this study was to investigate the radiographic and clinical outcomes of arthroscopic debridement and consider its indications. Methods We retrospectively evaluated 106 patients who had arthroscopic debridement between 1997 and 2007. Surgery was performed after closure of the capitellar physis. We categorized the patients into 4 groups by lesion size and by whether the proximal radial physis was open or closed. The average patient age at surgery was 15 years (range, 12-18 y), and the average follow-up period was 13 months (range, 8-46 mo). Results In patients with large lesions and open proximal radial physes, radiographic and clinical outcomes were poor. Three of 4 patients developed early osteoarthritic lesions of the radiohumeral joint, secondary to radial head enlargement. Radial head resection was required in 2 of 3 patients. Conversely, osteoarthritic lesions did not occur, and we observed noteworthy improvement in elbow pain routinely after the procedure in the other 3 groups. For range of motion, clinically important changes were not observed. Overall, postoperative elbow pain was absent in 89 patients. Mild pain was present in 15 patients and moderate or severe pain in 2 patients. A total of 90 patients returned to sports at pre-injury levels. Time of return to sports varied from 1 month to 5 months (mean, 2.4 mo). Conclusions Arthroscopic debridement of the capitellum can provide excellent short-term results for the treatment of osteochondritis dissecans. However, it is contraindicated in cases with large lesions when the proximal radial physis remains open. (J Hand Surg 2011;36A:1333-1338. Copyright (C) 2011 by the American Society for Surgery of the Hand. All rights reserved.) Type of study/level of evidence Therapeutic IV.	[Miyake, Junichi] Osaka Univ, Dept Orthopaed Surg, Grad Sch Med, Suita, Osaka 5650871, Japan; Yukioka Hosp, Dept Orthopaed Surg, Osaka, Japan		Miyake, J (corresponding author), Osaka Univ, Dept Orthopaed Surg, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	miyake-osk@umin.ac.jp					BAUER M, 1992, CLIN ORTHOP RELAT R, P156; Baumgarten TE, 1998, AM J SPORT MED, V26, P520, DOI 10.1177/03635465980260040801; Brittberg M, 2003, J BONE JOINT SURG AM, V85A, P58, DOI 10.2106/00004623-200300002-00008; Byrd JWT, 2002, AM J SPORT MED, V30, P474, DOI 10.1177/03635465020300040401; Iwasaki N, 2006, AM J SPORT MED, V34, P1233, DOI 10.1177/0363546506286343; Jones KJ, 2010, J PEDIATR ORTHOPED, V30, P8, DOI 10.1097/BPO.0b013e3181c3be83; Mihara K, 2010, J SHOULDER ELB SURG, V19, P31, DOI 10.1016/j.jse.2009.04.007; Mihara K, 2009, AM J SPORT MED, V37, P298, DOI 10.1177/0363546508324970; Miyake J, 2010, J SHOULDER ELB SURG, V19, P958, DOI 10.1016/j.jse.2010.03.002; Oka Y, 2001, J BONE JOINT SURG BR, V83B, P738, DOI 10.1302/0301-620X.83B5.11767; Ruch DS, 1998, ARTHROSCOPY, V14, P797, DOI 10.1016/S0749-8063(98)70013-1; Schoch B, 2010, ARTHROSCOPY, V26, P1469, DOI 10.1016/j.arthro.2010.03.008; Shimada K, 2005, CLIN ORTHOP RELAT R, P140, DOI 10.1097/01.blo.0000160025.14363.f9; Takahara M, 1999, CLIN ORTHOP RELAT R, P108; Takahara M, 2007, J BONE JOINT SURG AM, V89A, P1205, DOI 10.2106/JBJS.F.00622; Toh S, 2002, J BONE JOINT SURG AM, V84A, P593, DOI 10.2106/00004623-200204000-00013; Yamamoto Y, 2006, AM J SPORT MED, V34, P714, DOI 10.1177/0363546505282620	17	30	32	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023			J HAND SURG-AM	J. Hand Surg.-Am. Vol.	AUG	2011	36A	8					1333	1338		10.1016/j.jhsa.2011.05.024			6	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	804QP	WOS:000293669400013	21705155				2022-02-06	
J	Fuller, G; Bouamra, O; Woodford, M; Jenks, T; Patel, H; Coats, TJ; Oakley, P; Mendelow, AD; Pigott, T; Hutchinson, PJ; Lecky, F				Fuller, G.; Bouamra, O.; Woodford, M.; Jenks, T.; Patel, H.; Coats, T. J.; Oakley, P.; Mendelow, A. D.; Pigott, T.; Hutchinson, P. J.; Lecky, F.			Temporal trends in head injury outcomes from 2003 to 2009 in England and Wales	BRITISH JOURNAL OF NEUROSURGERY			English	Article						Critical care; neurosurgery; craniocerebral trauma; cohort studies; patient transfer	TRAUMATIC BRAIN-INJURY; CARE; MORTALITY; GENDER; EPIDEMIOLOGY; IMPROVEMENT; IMPACT	Background: Case fatality rates after blunt head injury (HI) did not improve in England and Wales between 1994 and 2003. The United Kingdom National Institute of Clinical Excellence subsequently published HI management guidelines, including the recommendation that patients with severe head injuries (SHIs) should be treated in specialist neuroscience units (NSU). The aim of this study was to investigate trends in case fatality and location of care since the introduction of national HI clinical guidelines. Methods: We conducted a retrospective cohort study using prospectively recorded data from the Trauma and Audit Research Network (TARN) database for patients presenting with blunt trauma between 2003 and 2009. Temporal trends in log odds of death adjusted for case mix were examined for patients with and without HI. Location of care for patients with SHI was also studied by examining trends in the proportion of patients treated in non-NSUs. Results: Since 2003, there was an average 12% reduction in adjusted log odds of death per annum in patients with HI (n=15,173), with a similar but smaller trend in non-HI trauma mortality (n=48,681). During the study period, the proportion of patients with HI treated entirely in non-NSUs decreased from 31% to 19%, (p < 0.01). Interpretation: The reduction in odds of death following HI since 2003 is consistent with improved management following the introduction of national HI guidelines and increased treatment of SHI in NSUs.	[Fuller, G.; Bouamra, O.; Woodford, M.; Jenks, T.; Lecky, F.] Univ Manchester, Trauma Audit & Res Network, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp,Hlth Sci Res Grp, Salford M6 8HD, Lancs, England; [Patel, H.] Salford Royal Hosp, Dept Neurosurg, Salford M6 8HD, Lancs, England; [Coats, T. J.] Univ Leicester, Leicester Royal Infirm, Dept Accid & Emergency, Emergency Med Acad Grp, Leicester LE1 5WW, Leics, England; [Oakley, P.] N Staffordshire Hosp, Dept Intens Care & Anaesthesia, N Staffordshire NHS Trust Stoke On Trent, Stoke On Trent ST4 7LN, Staffs, England; [Mendelow, A. D.] Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Pigott, T.] Walton Ctr NHS Fdn Trust, Dept Neurosurg, Liverpool L9 7LJ, Merseyside, England; [Hutchinson, P. J.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England		Fuller, G (corresponding author), Univ Manchester, Trauma Audit & Res Network, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp,Hlth Sci Res Grp, Clin Sci Bldg,Eccles Old Rd, Salford M6 8HD, Lancs, England.	gordonwfuller@doctors.net.uk	Coats, Timothy/AAW-1254-2021; Mendelow, Alexander/AAW-2878-2021	Coats, Timothy/0000-0003-2736-2784; bouamra, omar/0000-0002-3155-4634; Fuller, Gordon Ward/0000-0001-8532-3500	Academy of Medical Sciences/Health Foundation; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2008-06-001] Funding Source: researchfish	We declare that we have no conflicts of interest in relation to publication of this paper. PJH is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. TARN is part of the University of Manchester and is self funding through contributions from participating hospitals.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Bouamra O, 2006, J TRAUMA, V61, P701, DOI 10.1097/01.ta.0000197175.91116.10; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; *COMM INJ SCAL ASS, 1990, ABBR INJ SCAL 1990 R; Cooper RJ, 2006, ANN EMERG MED, V47, P19, DOI 10.1016/j.annemergmed.2005.11.030; *DEP HLTH, HLTH PAT INF ADV GRO; DEPARTMENT OF, 2010, GROUP DFDF, P1; Domino KB, 2010, J NEUROSURG ANESTH, V22, P360, DOI 10.1097/ANA.0b013e3181f0db15; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; George RL, 2003, J TRAUMA, V54, P464, DOI 10.1097/01.TA.0000051939.95039.E6; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; Levy MM, 2010, CRIT CARE MED, V38, P367, DOI [10.1007/s00134-009-1738-3, 10.1097/CCM.0b013e3181cb0cdc]; Magnotti LJ, 2008, J AM COLL SURGEONS, V206, P984, DOI 10.1016/j.jamcollsurg.2007.12.038; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; *NAT CONF ENQ PAT, 2007, NCEPOD TRAUM WHO CAR; *NAT I CLIN EXC, 2003, 56 NAT I CLIN EXC NA; *NAT I CLIN EXC, 2003, 4 NAT I CLIN EXC NAT; Nissen Stephen W, 2010, J Pharm Pract, V23, P61, DOI 10.1177/0897190009356555; Office for National Statistics, 2005, MORT STAT CAUS SEX A; PEREL P, 2006, BMC MED INFORM DECIS, V14, P6; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Rubin D.B., 1987, MULTIPLE IMPUTATION; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; SMITH M, 2004, BJ ANAESTHESIA, V93, P754; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Suarez JI, 2006, CRIT CARE MED, V34, pS232, DOI 10.1097/01.CCM.0000231881.29040.25; TWEEDIE IE, 2008, CARE CRITICALLY ILL, V24, P143; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; WESTABY S, 2007, BMJ-BRIT MED J, V335, P795; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7; NEUROCRITICAL CARE C	38	30	30	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2011	25	3					414	421		10.3109/02688697.2011.570882			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	769QR	WOS:000291033800026	21513451				2022-02-06	
J	McClure, J				McClure, John			The Role of Causal Attributions in Public Misconceptions About Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						brain injury; misconceptions; attribution; stigma; rehabilitation	PHYSICAL-DISABILITY; REHABILITATION; DISCRIMINATION; BEHAVIOR; PROFESSIONALS; DEPRESSION; PEOPLE; STIGMA; DAMAGE; TBI	Objective: Social psychological theories such as attribution theory have been applied to conditions such as depression and physical disability, but not to traumatic brain injury (TBI). The goal of this paper is to show that that attribution theory and related concepts help to explain the public's misconceptions about TBI and other challenges faced by clinicians and families of persons with TBI. Results: Research shows that misconceptions about brain injury occur because people misattribute the actions of persons with brain injury. These misattributions reflect two features: (a) the absence of visible markers of the injury, and (b) the tendency to compare persons with TBI with their peers rather than their own preinjury performance. These two processes lead to the opposite pattern to the stigma that occurs with visible disabilities: specifically, a failure among members of the public to recognize that problematic behaviors may result from the injury. This analysis suggests several therapeutic strategies for managing public misconceptions in ways that enhance coping and recovery. Conclusion: Clarifying the attribution processes that underpin misconceptions about brain injury provides a framework for enhancing rehabilitation and addressing these misconceptions effectively.	Victoria Univ Wellington, Sch Psychol, Wellington, New Zealand		McClure, J (corresponding author), Victoria Univ Wellington, Sch Psychol, POB 600, Wellington, New Zealand.	john.mcclure@vuw.ac.nz	McClure, John/O-9060-2015	McClure, John/0000-0002-9261-4995			ALLOY LB, 1999, J COGN PSYCHOTHER, V13, P226; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Berkowitz L., 1978, ADV EXPT SOCIAL PSYC, V11, P249, DOI [10.1016/S0065-2601(08)60009-X, DOI 10.1016/S0065-2601(08)60009-X]; Boysen GA, 2008, J SOC CLIN PSYCHOL, V27, P447, DOI 10.1521/jscp.2008.27.5.447; Buchanan G. M., 1995, EXPLANATORY STYLE; COLLINS JK, 1983, ADOLESCENT BOY AUSTR; Corrigan P, 2003, J HEALTH SOC BEHAV, V44, P162, DOI 10.2307/1519806; Corrigan P, 2004, AM PSYCHOL, V59, P614, DOI 10.1037/0003-066X.59.7.614; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Dunn D. S., 2010, HDB REHABILITATION P, P379; Dunn DS, 2008, REHABIL PSYCHOL, V53, P254, DOI 10.1037/a0012962; Dunn DS, 2005, REHABIL PSYCHOL, V50, P183, DOI 10.1037/0090-5550.50.2.183; Dunn DS, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P565, DOI 10.1037/10361-027; Dunn DS, 1996, REHABIL PSYCHOL, V41, P285, DOI 10.1037/0090-5550.41.4.285; Ernst WJ, 2009, J HEAD TRAUMA REHAB, V24, P213, DOI 10.1097/HTR.0b013e3181a7ecd8; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; FELDMAN DB, 2009, J SOC CLIN PSYCHOL, V26, P137; FINE M, 1988, J SOC ISSUES, V44, P3, DOI 10.1111/j.1540-4560.1988.tb02045.x; FOSTER LA, 2010, EFFECT FAMILIA UNPUB; Gibb BE, 2006, J CLIN CHILD ADOLESC, V35, P264, DOI 10.1207/s15374424jccp3502_10; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; GOUVIER WD, 1991, REHABIL PSYCHOL, V36, P121, DOI 10.1037/0090-5550.36.2.121; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hart H.L.A., 1985, CAUSATION LAW, V2nd; Hastings RP, 1995, J INTELL DISABIL RES, V39, P474, DOI 10.1111/j.1365-2788.1995.tb00567.x; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Heider F., 1958, PSYCHOL INTERPERSONA; HILTON DJ, 1986, PSYCHOL REV, V93, P75, DOI 10.1037/0033-295X.93.1.75; INGLIS M, 2002, NO MEAN FEAT; JONES EE, 1979, AM PSYCHOL, V34, P107, DOI 10.1037/0003-066X.34.2.107; Kapur N, 1997, INJURED BRAINS MED M; Karp DA., 2001, BURDEN SYMPATHY FAMI; Kelley H.H., 1967, NEBRASKA S MOTIVATIO, V15, P192; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; KLECK RE, 1980, J PERS SOC PSYCHOL, V39, P861, DOI 10.1037/0022-3514.39.5.861; KLECK RE, 1983, REHABIL PSYCHOL, V28, P79, DOI 10.1037/h0090997; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Laroi F, 2003, BRAIN INJURY, V17, P175, DOI 10.1080/0269905021000010140; LERNER MJ, 1977, J PERS, V45, P3; LEVIN HS, 1993, HEAD INJURY; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Martz E., 2003, J VOCATIONAL REHABIL, V18, P153; Matthews C., 2000, HDB COMMUNICATION PE; McClure J, 1998, J PERS SOC PSYCHOL, V74, P7, DOI 10.1037/0022-3514.74.1.7; MCCLURE J, 1985, J PERS SOC PSYCHOL, V48, P1534, DOI 10.1037/0022-3514.48.6.1534; MCCLURE J, J HEAD TRAU IN PRESS; McClure J, 2008, BRAIN INJURY, V22, P639, DOI 10.1080/02699050802255585; McClure J, 2006, BRAIN INJURY, V20, P1029, DOI 10.1080/02699050600909870; McClure J, 2009, BRAIN IMPAIR, V10, P180, DOI 10.1375/brim.10.2.180; McGrath JC, 2007, ETHICAL PRACTICE BRA; Moore M.S., 2009, CAUSATION RESPONSIBI; MUKHERJEE D, 2003, WOMEN VISIBLE INVISI, P3; Olkin R, 2003, AM PSYCHOL, V58, P296, DOI 10.1037/0003-066X.58.4.296; OSBORN CL, 1998, MY HEAD DOCTORS STOR; PAULHUS DL, 1991, J PERS SOC PSYCHOL, V60, P307, DOI 10.1037/0022-3514.60.2.307; PHILLIPS J, 2000, EVEREST LIFE BRAIN I; Redpath SJ, 2010, BRAIN INJURY, V24, P802, DOI 10.3109/02699051003709623; Rohmer O, 2009, REHABIL PSYCHOL, V54, P76, DOI 10.1037/a0014445; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; SELIGMAN MEP, 1998, SCI CLIN PSYCHOL ACC; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; SNYDER ML, 1979, J PERS SOC PSYCHOL, V37, P2297, DOI 10.1037/0022-3514.37.12.2297; Sutton RM, 2001, J PERS SOC PSYCHOL, V80, P222, DOI 10.1037/0022-3514.80.2.222; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TAYLOR AJW, 1999, TRAUMATOLOGYE, V5; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; VALLACHER RR, 1987, PSYCHOL REV, V94, P3, DOI 10.1037/0033-295X.94.1.3; WEINER B, 1988, J PERS SOC PSYCHOL, V55, P738, DOI 10.1037/0022-3514.55.5.738; Weiner B., 1995, JUDGMENTS RESPONSIBI; WILLIAMSON G, 1996, PSYCHOL AGING, V4, P502; Williamson GA, 2005, REHABIL PSYCHOL, V50, P215, DOI 10.1037/0090-5550.50.3.215; Wright BA., 1983, PHYS DISABILITY PSYC; Wright BA., 1972, REHABIL PSYCHOL, V19, P38, DOI DOI 10.1037/H0090869; Ylvisaker M., 2000, BRAIN IMPAIR, V1, P12, DOI [DOI 10.1375/BRIM.1.1.12, 10.1375/brim.1.1.12]; [No title captured]	79	30	30	1	7	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2011	56	2					85	93		10.1037/a0023354			9	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	769KL	WOS:000291011800001	21574726				2022-02-06	
J	Staal, JA; Vickers, JC				Staal, Jerome A.; Vickers, James C.			Selective Vulnerability of Non-Myelinated Axons to Stretch Injury in an In Vitro Co-Culture System	JOURNAL OF NEUROTRAUMA			English	Article						axon myelination; diffuse axonal injury; oligodendrocytes; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; SECONDARY AXOTOMY; CALCIUM INFLUX; NEUROFILAMENT COMPACTION; CYTOSKELETAL CHANGES; UNMYELINATED AXONS; CORPUS-CALLOSUM; SODIUM-CHANNELS; MYELINATION	Diffuse axonal injury (DAI) is an evolving axonopathy commonly characterized clinically as widespread damage to the white matter tracts. In recent electrophysiological studies, researchers have proposed that myelinated and unmyelinated axons differ in their vulnerability and functional recovery following DAI. In this study we present for the first time an in vitro stretch-injury approach that utilizes a novel myelinating co-culture system to determine the differential response between myelinated and non-myelinated axon bundles to injury. In implementing this technique we demonstrate that myelinated axon bundles are less vulnerable to stretch injury compared to caliber-matched non-myelinated bundles. Interestingly, moderate axonal strain did not induce demyelination, but instead caused an increase in the proportion of degenerated myelin basic protein over time. Additionally, there were no significant differences in the expression of axonal swellings, which is indicative of disrupted axonal transport. In summary, we present an ideal in vitro model that permits further mechanistic investigations into the role of myelin and oligodendrocyte-neuron interactions in response to DAI.	[Staal, Jerome A.; Vickers, James C.] Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Hobart, Tas 7001, Australia		Staal, JA (corresponding author), Univ Tasmania, Menzies Res Inst, NeuroRepair Grp, Bag 23, Hobart, Tas 7001, Australia.	Jastaal@utas.edu.au	Vickers, James C/J-7464-2014	Vickers, James C/0000-0001-5671-4879	Tasmanian Masonic Medical Research Foundation; University of Tasmania	A. S. is a Masonic Medical Research and Alzheimer's Australia Fellow. This work was supported by the Tasmanian Masonic Medical Research Foundation, and the University of Tasmania.	Armstrong RC, 1998, METHODS, V16, P282, DOI 10.1006/meth.1998.0685; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bauer NG, 2009, GLIA, V57, P1691, DOI 10.1002/glia.20885; Bauer Nina G., 2009, Journal of Biology (London), V8, P78, DOI 10.1186/jbiol169; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Colley BS, 2010, EXP NEUROL, V224, P241, DOI 10.1016/j.expneurol.2010.03.026; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Fields RD, 2008, NEUROSCIENTIST, V14, P540, DOI 10.1177/1073858408320294; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Nave KA, 2010, NATURE, V468, P244, DOI 10.1038/nature09614; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rodriguez M, 2003, BRAIN, V126, P751, DOI 10.1093/brain/awg070; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Staal JA, 2007, DEV NEUROBIOL, V67, P1831, DOI 10.1002/dneu.20552; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Staal JA, 2009, J NEUROTRAUM, V26, P781, DOI 10.1089/neu.2008.0669; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Watkins TA, 2008, NEURON, V60, P555, DOI 10.1016/j.neuron.2008.09.011; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	33	30	30	0	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					841	847		10.1089/neu.2010.1658			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100284	21235329				2022-02-06	
J	Ertmer, C; Kampmeier, T; Rehberg, S; Lange, M				Ertmer, Christian; Kampmeier, Tim; Rehberg, Sebastian; Lange, Matthias			Fluid resuscitation in multiple trauma patients	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						fluid therapy; hemorrhagic shock; permissive hypotension; traumatic brain injury	UNCONTROLLED HEMORRHAGIC-SHOCK; HYPERTONIC SALINE-DEXTRAN; HYDROXYETHYL STARCH 130/0.4; RANDOMIZED CLINICAL-TRIAL; LACTATED RINGERS SOLUTION; 753 CONSECUTIVE DEATHS; SEVERE HEAD-INJURY; ACUTE LUNG INJURY; BRAIN-INJURY; CARDIAC-SURGERY	Purpose of review Fluid resuscitation in trauma patients with hemorrhagic shock is controversially discussed in the literature. The coincidence of brain injury complicates management of these patients. This article summarizes the current knowledge on nonblood component fluid resuscitation and choice of fluids in patients with multiple trauma. Recent findings Whereas current evidence suggests the efficacy of fluid therapy in hemorrhagic shock without active bleeding, experimental and clinical data demonstrate that aggressive volume challenge may be futile or even deleterious in the setting of uncontrolled hemorrhage. Large amounts of isotonic crystalloids may be associated with hypothermia, acidosis and inflammation. In patients with traumatic brain injury hypertonic solutions may positively influence inflammation and intracranial pressure without affecting neurologic outcome or mortality. Summary To date no large-scale clinical studies exist to either support or refute the use of nonblood component fluid resuscitation of hemorrhagic shock in trauma patients. The optimal choice of fluid remains to be determined, but existing evidence suggests avoiding crystalloids in favor of hypertonic solutions. The role of modern, iso-oncotic colloids in the treatment of hemorrhagic shock has not yet been sufficiently defined. In patients with concomitant brain injury, arterial hypotension must be avoided and infusion of hypotonic solutions is obsolete, whereas administration of hypertonic solutions may exert beneficial effects beyond hemodynamic stabilization.	[Ertmer, Christian; Kampmeier, Tim; Rehberg, Sebastian; Lange, Matthias] Univ Munster, Dept Anesthesiol & Intens Care, Munster, Germany		Lange, M (corresponding author), Univ Hosp Muenster, Dept Anesthesiol & Intens Care, D-48129 Munster, Germany.	lange-m@anit.uni-muenster.de	Rehberg, Sebastian/AAD-5191-2019	Kampmeier, Tim/0000-0003-4329-7521			Alam HB, 2009, J TRAUMA, V67, P856, DOI 10.1097/TA.0b013e3181b5ae75; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP A; Attuwaybi B, 2004, J TRAUMA, V56, P749, DOI 10.1097/01.TA.0000119686.33487.65; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Balkamou X, 2010, ANESTHESIOLOGY, V113, P1092, DOI 10.1097/ALN.0b013e3181f56029; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BICKELL WH, 1992, ANN EMERG MED, V21, P1077, DOI 10.1016/S0196-0644(05)80648-1; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; CAREY JS, 1970, SURG GYNECOL OBSTETR, V131, P679; Chen SY, 2009, J TRAUMA, V66, P676, DOI 10.1097/TA.0b013e318173e7da; CHUDNOFSKY CR, 1989, ANN EMERG MED, V18, P122, DOI 10.1016/S0196-0644(89)80099-X; Constable PD, 2003, ANESTH ANALG, V96, P919, DOI 10.1213/01.ANE.0000053256.77500.9D; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Dar DE, 2010, SHOCK, V34, P75, DOI 10.1097/SHK.0b013e3181ce2cbc; Deree J, 2007, J TRAUMA, V62, P104, DOI 10.1097/TA.0b013e31802d96cb; Dubick MA, 2006, SHOCK, V25, P321, DOI 10.1097/01.shk.0000209525.50990.28; Dubniks M, 2007, INTENS CARE MED, V33, P2192, DOI 10.1007/s00134-007-0756-2; Duchesne JC, 2010, J TRAUMA, V69, P976, DOI 10.1097/TA.0b013e3181f2abc9; Dunser MW, 2009, CRIT CARE, V13, DOI 10.1186/cc8167; Ertmer C, 2009, BEST PRACT RES-CLIN, V23, P193, DOI 10.1016/j.bpa.2008.11.001; Flaherty S, 2003, J TRAUMA, V54, P70; GROSS D, 1990, SURG GYNECOL OBSTET, V170, P106; Huet RCGG, 2000, CAN J ANAESTH, V47, P1207; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; KAWESKI SM, 1990, J TRAUMA, V30, P1215, DOI 10.1097/00005373-199010000-00005; Kelman G R, 1969, Int Anesthesiol Clin, V7, P739, DOI 10.1097/00004311-196907040-00003; Kortbeek JB, 2008, J TRAUMA, V64, P1638, DOI 10.1097/TA.0b013e3181744b03; KOWALENKO T, 1992, J TRAUMA, V33, P349, DOI 10.1097/00005373-199209000-00003; KRAUSZ MM, 1992, J TRAUMA, V33, P6, DOI 10.1097/00005373-199207000-00002; Krismer AC, 2005, ANAESTHESIST, V54, P220, DOI 10.1007/s00101-004-0793-y; Kwan I, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002245; Liang L, 2010, J TRAUMA, V68, P655, DOI 10.1097/TA.0b013e3181a8b286; Lier H, 2008, J TRAUMA, V65, P951, DOI 10.1097/TA.0b013e318187e15b; Ljungstrom K G, 1988, Acta Chir Scand Suppl, V543, P26; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Martini WZ, 2009, J TRAUMA, V67, P202, DOI 10.1097/TA.0b013e3181a602a7; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629, DOI 10.1152/ajpheart.1988.255.3.H629; MOSS GS, 1974, NEW ENGL J MED, V290, P724, DOI 10.1056/NEJM197403282901307; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Myburgh J, 2007, NEW ENGL J MED, V357, P874; NAGY KK, 1993, CIRC SHOCK, V40, P289; OWENS TM, 1995, J TRAUMA, V39, P200, DOI 10.1097/00005373-199508000-00004; Payen D, 2008, CRIT CARE, V12, DOI 10.1186/cc6916; Raedler C, 2004, ANESTH ANALG, V98, P1759, DOI 10.1213/01.ANE.0000117150.29361.5A; Regel G, 1997, Acta Anaesthesiol Scand Suppl, V110, P71; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Schortgen F, 2004, INTENS CARE MED, V30, P2222, DOI 10.1007/s00134-004-2415-1; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Sharma RM, 2005, ANESTH ANALG, V101, P833, DOI 10.1213/01.ANE.0000175209.61051.7F; SHATNEY CH, 1983, ARCH SURG-CHICAGO, V118, P804; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; SIMMONS RS, 1987, AM REV RESPIR DIS, V135, P924, DOI 10.1164/arrd.1987.135.4.924; SMITH JP, 1985, J TRAUMA, V25, P65, DOI 10.1097/00005373-198501000-00011; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Stahel PF, 2009, INJURY, V40, pS27, DOI 10.1016/j.injury.2009.10.034; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Sung KC, 2006, ACTA ANAESTH SCAND, V50, P108, DOI 10.1111/j.1399-6576.2005.00881.x; Tieu BH, 2007, WORLD J SURG, V31, P1055, DOI 10.1007/s00268-006-0653-9; Vincenzi R, 2009, AM J SURG, V198, P407, DOI 10.1016/j.amjsurg.2009.01.017; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; WILLIAMS LF, 1968, SURG CLIN N AM, V48, P263; Yeh CC, 2003, ANESTH ANALG, V97, P577, DOI 10.1213/01.ANE.0000070231.16378.A6	69	30	37	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2011	24	2					202	208		10.1097/ACO.0b013e3283445326			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	732AS	WOS:000288154100014	21293262				2022-02-06	
J	Minor, KH; Bournat, JC; Toscano, N; Giger, RJ; Davies, SJA				Minor, Kenneth H.; Bournat, Juan C.; Toscano, Nicole; Giger, Roman J.; Davies, Stephen J. A.			Decorin, erythroblastic leukaemia viral oncogene homologue B4 and signal transducer and activator of transcription 3 regulation of semaphorin 3A in central nervous system scar tissue	BRAIN			English	Article						decorin; scar; semaphorin; ErbB4; STAT3	GROWTH-FACTOR RECEPTOR; COLLAPSIN-1 MESSENGER-RNA; ALPHA-CONVERTING-ENZYME; SPINAL-CORD; ADULT-RAT; PROTEOGLYCANS DECORIN; NUCLEAR-LOCALIZATION; CELL-PROLIFERATION; III COLLAPSIN-1; DOWN-REGULATION	Scar tissue at sites of traumatic injury in the adult central nervous system presents a combined physical and molecular impediment to axon regeneration. Of multiple known central nervous system scar associated axon growth inhibitors, semaphorin 3A has been shown to be strongly expressed by invading leptomeningeal fibroblasts. We have previously demonstrated that infusion of the small leucine-rich proteoglycan decorin results in major suppression of several growth inhibitory chondroitin sulphate proteoglycans and growth of adult sensory axons across acute spinal cord injuries. Furthermore, decorin treatment of leptomeningeal fibroblasts significantly increases their ability to support neurite growth of co-cultured adult dorsal root ganglion neurons. In the present study we show that decorin has the ability to suppress semaphorin 3A expression within adult rat cerebral cortex scar tissue and in primary leptomeningeal fibroblasts in vitro. Infusion of decorin core protein for eight days resulted in a significant reduction of semaphorin 3A messenger RNA expression within injury sites compared with saline-treated control animals. Both in situ hybridization and immunostaining confirmed that semaphorin 3A messenger RNA expression and protein levels are significantly reduced in decorin-treated animals. Similarly, decorin treatment decreased the expression of semaphorin 3A messenger RNA in cultured rat leptomeningeal fibroblasts compared with untreated cells. Mechanistic studies revealed that decorin-mediated suppression of semaphorin 3A critically depends on erythroblastic leukaemia viral oncogene homologue B4 and signal transducer and activator of transcription 3 function. Collectively, our studies show that in addition to suppressing the levels of inhibitory chondroitin sulphate proteoglycans, decorin has the ability to suppress semaphorin 3A in the injured central nervous system. Our findings provide further evidence for the use of decorin as a potential therapy for promoting axonal growth and repair in the injured adult mammalian brain and spinal cord.	[Minor, Kenneth H.; Davies, Stephen J. A.] Univ Colorado Denver, Dept Neurosurg, Aurora, CO 80045 USA; [Bournat, Juan C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Toscano, Nicole; Giger, Roman J.] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48105 USA; [Giger, Roman J.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48105 USA		Davies, SJA (corresponding author), Univ Colorado Denver, Dept Neurosurg, Bldg RC 1 N,Room P18-9100,12800 E 19th Ave, Aurora, CO 80045 USA.	stephen.davies@ucdenver.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [7NS047333]; David Van Wagener Spinal Cord Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS047333, R01NS047333] Funding Source: NIH RePORTER	Supported by NIH 7NS047333, the David Van Wagener Spinal Cord Fund and private donations by the international spinal cord injury community.	Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Arakawa T, 2008, NEPHROL DIAL TRANSPL, V23, P3418, DOI 10.1093/ndt/gfn314; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Beck H, 2002, J NEUROPATH EXP NEUR, V61, P339, DOI 10.1093/jnen/61.4.339; Berthier CC, 2009, DIABETES, V58, P469, DOI 10.2337/db08-1328; Blaskovich MA, 2003, CANCER RES, V63, P1270; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Bouzioukh F, 2006, EUR J NEUROSCI, V23, P2247, DOI 10.1111/j.1460-9568.2006.04783.x; Brandan E, 2006, J BIOL CHEM, V281, P31562, DOI 10.1074/jbc.M602919200; Cabello-Verrugio C, 2007, J BIOL CHEM, V282, P18842, DOI 10.1074/jbc.M700243200; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Davies JE, 2004, EUR J NEUROSCI, V19, P1226, DOI 10.1111/j.1460-9568.2004.03184.x; Davies SJA, 1997, NATURE, V390, P680, DOI 10.1038/37776; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; DE WF, 2002, EXP NEUROL, V175, P61; De Winter F, 2006, MOL CELL NEUROSCI, V32, P102, DOI 10.1016/j.mcn.2006.03.002; Dent EW, 2004, J NEUROSCI, V24, P3002, DOI 10.1523/JNEUROSCI.4963-03.2004; Eastwood SL, 2004, INT REV NEUROBIOL, V59, P47; Eastwood SL, 2003, MOL PSYCHIATR, V8, P148, DOI 10.1038/sj.mp.4001233; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Fenstermaker V, 2004, J NEUROBIOL, V58, P403, DOI 10.1002/neu.10304; Fujita H, 2001, BRAIN RES, V914, P1, DOI 10.1016/S0006-8993(01)02765-2; Fukushima K, 2001, AM J SPORT MED, V29, P394, DOI 10.1177/03635465010290040201; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Giger RJ, 1998, J NEUROSCI RES, V52, P27, DOI 10.1002/(SICI)1097-4547(19980401)52:1<27::AID-JNR4>3.0.CO;2-M; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; Goldoni S, 2009, J CELL BIOL, V185, P743, DOI 10.1083/jcb.200901129; Good PF, 2004, J NEUROCHEM, V91, P716, DOI 10.1111/j.1471-4159.2004.02766.x; Grisanti S, 2005, INVEST OPHTH VIS SCI, V46, P191, DOI 10.1167/iovs.04-0902; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hou ST, 2008, BIOCHEM BIOPH RES CO, V367, P109, DOI 10.1016/j.bbrc.2007.12.103; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505; Kile BT, 2002, TRENDS BIOCHEM SCI, V27, P235, DOI 10.1016/S0968-0004(02)02085-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kolb M, 2001, AM J PHYSIOL-LUNG C, V280, pL1327, DOI 10.1152/ajplung.2001.280.6.L1327; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Krebs DL, 2000, J CELL SCI, V113, P2813; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lim CP, 2006, ONCOGENE, V25, P5416, DOI 10.1038/sj.onc.1209531; Lindholm T, 2004, NEUROREPORT, V15, P649, DOI 10.1097/00001756-200403220-00015; Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Marin O, 2001, SCIENCE, V293, P872, DOI 10.1126/science.1061891; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; Minor K, 2008, NEUROBIOL DIS, V32, P88, DOI 10.1016/j.nbd.2008.06.009; Mire E, 2008, MOL CELL NEUROSCI, V37, P222, DOI 10.1016/j.mcn.2007.09.009; Montolio M, 2009, CHEM BIOL, V16, P691, DOI 10.1016/j.chembiol.2009.05.006; Morita A, 2006, J NEUROSCI, V26, P2971, DOI 10.1523/JNEUROSCI.5453-05.2006; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Niclou SP, 2003, MOL CELL NEUROSCI, V24, P902, DOI 10.1016/S1044-7431(03)00243-4; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Ortiz-Munoz G, 2010, J AM SOC NEPHROL, V21, P763, DOI 10.1681/ASN.2009060625; Pasterkamp RJ, 2009, CURR OPIN NEUROBIOL, V19, P263, DOI 10.1016/j.conb.2009.06.001; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 2001, EUR J NEUROSCI, V13, P457, DOI 10.1046/j.0953-816X.2000.01398.x; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Polleux F, 1998, SCIENCE, V282, P1904, DOI 10.1126/science.282.5395.1904; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; Rakesh K, 2005, BIOCHEM PHARMACOL, V70, P649, DOI 10.1016/j.bcp.2005.04.042; Rewcastle GW, 1998, J MED CHEM, V41, P742, DOI 10.1021/jm970641d; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Sahay A, 2005, J NEUROSCI, V25, P3613, DOI 10.1523/JNEUROSCI.5255-04.2005; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Schaefer L, 2007, AM J PATHOL, V170, P301, DOI 10.2353/ajpath.2007.060497; Seidler DG, 2006, J BIOL CHEM, V281, P26408, DOI 10.1074/jbc.M602853200; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shepherd I, 1996, DEV BIOL, V173, P185, DOI 10.1006/dbio.1996.0016; Shibata N, 2009, NEURODEGENER DIS, V6, P118, DOI 10.1159/000213762; Stichel CC, 1995, BRAIN RES, V704, P263, DOI 10.1016/0006-8993(95)01131-5; Su ZD, 2010, GLIA, V58, P901, DOI 10.1002/glia.20972; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamamaki N, 2001, NEUROREPORT, V12, P775, DOI 10.1097/00001756-200103260-00032; Tamamaki N, 2003, J COMP NEUROL, V455, P238, DOI 10.1002/cne.10476; Thiel KW, 2006, BIOCHEM BIOPH RES CO, V350, P629, DOI 10.1016/j.bbrc.2006.09.095; Tran TS, 2009, NATURE, V462, P1065, DOI 10.1038/nature08628; Wang HJ, 2005, EXP MOL PATHOL, V78, P17, DOI 10.1016/j.yexmp.2004.07.006; Warren CM, 2006, CELL SIGNAL, V18, P923, DOI 10.1016/j.cellsig.2005.12.007; Williams A, 2007, BRAIN, V130, P2554, DOI 10.1093/brain/awm202; Williams G, 2005, J NEUROCHEM, V92, P1180, DOI 10.1111/j.1471-4159.2004.02950.x; Wormald S, 2004, J BIOL CHEM, V279, P821, DOI 10.1074/jbc.R300030200; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yamashita N, 2007, J NEUROSCI, V27, P12546, DOI 10.1523/JNEUROSCI.3463-07.2007; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Zafiropoulos A, 2008, CONNECT TISSUE RES, V49, P244, DOI 10.1080/03008200802147746; Zhou W, 2002, INFLAMM RES, V51, P91, DOI 10.1007/BF02684009	101	30	32	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	APR	2011	134		4				1140	1155		10.1093/brain/awq304			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745KC	WOS:000289163300026	21115466	Bronze, Green Published			2022-02-06	
J	Vrkljan, BH; McGrath, CE; Letts, LJ				Vrkljan, Brenda H.; McGrath, Colleen E.; Letts, Lori J.			Assessment tools for evaluating fitness to drive: A critical appraisal of evidence	CANADIAN JOURNAL OF OCCUPATIONAL THERAPY-REVUE CANADIENNE D ERGOTHERAPIE			English	Article						Automobile driving; Occupational therapy assessment	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE CRASHES; FIELD-OF-VIEW; OLDER-ADULTS; COGNITIVE PREDICTORS; AUTOMOBILE CRASHES; ALZHEIMERS-DISEASE; MEDICAL CONDITIONS; ELDERLY DRIVERS	Background. Many office-based assessment tools are used by occupational therapists to predict fitness to drive. Purpose. To appraise psychometric properties of such tools, specifically predictive validity for on-road performance. Methods. A literature search was conducted to identify assessment tools and studies involving on-road outcomes (behind-the-wheel evaluation, crashes, traffic violations). Using a standardized appraisal process, reviewers rated each tool's psychometric properties, including its predictive validity with on-road performance. Findings. Seventeen measures met the inclusion criteria. Evidence suggests many tools do not have cutoff scores linked with on-road outcomes, although some had stronger evidence than others. Implications. When making a determination regarding driver fitness, clinicians should consider the psychometric properties of the tool as well as existing evidence concerning its utility in predicting on-road performance. Caution is warranted in using any one office-based tool to predict driving fitness; rather, a multifactorial-based assessment approach that includes physical, cognitive, and visual-perceptual components, is recommended.	[Vrkljan, Brenda H.; Letts, Lori J.] McMaster Univ, Occupat Therapy Program, Sch Rehabil Sci, Hamilton, ON L8S 1C7, Canada; [McGrath, Colleen E.] Univ Western Ontario, London, ON, Canada		Vrkljan, BH (corresponding author), McMaster Univ, Occupat Therapy Program, Sch Rehabil Sci, IAHS Bldg,Rm 450,1400 Main St W, Hamilton, ON L8S 1C7, Canada.	vrkljan@mcmaster.ca; lettsl@mcmaster.ca			Canadian Occupational Therapy Foundation (COTF); Auto21-Network of Centres of Excellence	This manuscript was supported in part by the Canadian Occupational Therapy Foundation (COTF) and funding from Auto21-Network of Centres of Excellence provided to the first author.	Akinwuntan AE, 2005, NEUROLOGY, V65, P843, DOI 10.1212/01.wnl.0000171749.71919.fa; Amick MM, 2007, ARCH CLIN NEUROPSYCH, V22, P957, DOI 10.1016/j.acn.2007.07.004; Bajaj JS, 2007, AM J GASTROENTEROL, V102, P1903, DOI 10.1111/j.1572-0241.2007.01424.x; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball KK, 2006, J AM GERIATR SOC, V54, P77, DOI 10.1111/j.1532-5415.2005.00568.x; Bedard M, 2008, TRAFFIC INJ PREV, V9, P336, DOI 10.1080/15389580802117184; Bouillon L, 2006, AM J OCCUP THER, V60, P420, DOI 10.5014/ajot.60.4.420; Canadian Medical Association, 2006, DET MED FITN DRIV GU; *CAOT, 2009, POS STAT DRIV REH; Colarusso R.P., 2003, MOTOR FREE VISUAL PE; Colarusso RP, 1972, MOTOR FREE VISUAL PE; Colarusso RP., 1996, MOTOR FREE VISUAL PE; Dickerson AE, 2007, GERONTOLOGIST, V47, P578, DOI 10.1093/geront/47.5.578; Diegelman Nathan M, 2004, BMC Geriatr, V4, P10, DOI 10.1186/1471-2318-4-10; Diller L, 1974, REHABILITATION MONOG, V50; Dobbs BM, 2008, TRAFFIC INJ PREV, V9, P379, DOI 10.1080/15389580802045823; DOUGLAS A, 2007, GERIATRICS, V26, P13, DOI DOI 10.1080/02703180801963758; *DRIVEABLE ASS CTR, 1998, DRIVEABLE COMP SCREE; Edwards JD, 2008, ACCIDENT ANAL PREV, V40, P1157, DOI 10.1016/j.aap.2007.12.008; Elkin-Frankston S, 2007, ARCH CLIN NEUROPSYCH, V22, P631, DOI 10.1016/j.acn.2007.04.004; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox GK, 1997, J AM GERIATR SOC, V45, P949, DOI 10.1111/j.1532-5415.1997.tb02965.x; Freund B, 2005, J GEN INTERN MED, V20, P240, DOI 10.1111/j.1525-1497.2005.40069.x; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; Grace J, 2005, J INT NEUROPSYCH SOC, V11, P766, DOI 10.1017/S135561770505848; Hoffman L, 2005, PSYCHOL AGING, V20, P610, DOI 10.1037/0882-7974.20.4.610; Hunt LA, 1997, ALZ DIS ASSOC DIS, V11, P13, DOI 10.1097/00002093-199706001-00004; Jang RW, 2007, J GEN INTERN MED, V22, P531, DOI 10.1007/s11606-006-0043-x; Justiss MD, 2006, TOP GERIATR REHABIL, V22, P121; KLAVORA P, 1994, PERCEPT MOTOR SKILL, V79, P448, DOI 10.2466/pms.1994.79.1.448; KLAVORA P, 1995, PERCEPT MOTOR SKILL, V80, P607, DOI 10.2466/pms.1995.80.2.607; Klavora P, 2000, ARCH PHYS MED REHAB, V81, P701, DOI 10.1016/S0003-9993(00)90096-0; Korner-Bitensky N, 2000, AM J PHYS MED REHAB, V79, P253, DOI 10.1097/00002060-200005000-00007; Korner-Bitensky N, 2007, OCCUPATIONAL THERAPY, V9, P10; Korner-Bitensky N, 2005, PHYS OCCUP THER GERI, V23, P123, DOI 10.1300/J148v23n02_08; Korner-Bitensky N, 2006, AM J OCCUP THER, V60, P428, DOI 10.5014/ajot.60.4.428; Korner-Bitensky N, 2009, AUST OCCUP THER J, V56, P200, DOI 10.1111/j.1440-1630.2008.00749.x; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LAW M, 2004, OUTCOME MEASURES REV; LAW M, 1999, ALL OUTCOMES; Law M, 2005, MEASURING OCCUPATION; Law M, 2002, EVIDENCE BASED REHAB, P3; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lloyd S, 2001, Can J Occup Ther, V68, P149; MacGregor JM, 2001, J AM GERIATR SOC, V49, P466, DOI 10.1046/j.1532-5415.2001.49095.x; MAROTTOLI RA, 1994, ANN INTERN MED, V121, P842, DOI 10.7326/0003-4819-121-11-199412010-00003; Marshall S., 2007, SENIOR DRIVER ASSESS; Marshall SC, 2007, TOP STROKE REHABIL, V14, P98, DOI 10.1310/tsr1401-98; Marshall SC, 2008, TRAFFIC INJ PREV, V9, P291, DOI 10.1080/15389580801895244; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McGwin G, 2000, AM J EPIDEMIOL, V152, P424, DOI 10.1093/aje/152.5.424; Molnar FJ, 2007, ACCIDENT ANAL PREV, V39, P1056, DOI 10.1016/j.aap.2007.02.003; Molnar FJ, 2006, J AM GERIATR SOC, V54, P1809, DOI 10.1111/j.1532-5415.2006.00967.x; Myers RS, 2000, PERCEPT MOTOR SKILL, V91, P279, DOI 10.2466/PMS.91.5.279-290; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; ODENHEIMER GL, 1994, J GERONTOL, V49, pM153, DOI 10.1093/geronj/49.4.M153; Oswanski MF, 2007, AM J PHYS MED REHAB, V86, P190, DOI 10.1097/PHM.0b013e31802b7de5; OWSLEY C, 1994, OPTOMETRY VISION SCI, V71, P727, DOI 10.1097/00006324-199412000-00002; Parker D, 2000, ACCIDENT ANAL PREV, V32, P751, DOI 10.1016/S0001-4575(99)00125-6; Rapoport MJ, 2007, CAN MED ASSOC J, V177, P599, DOI 10.1503/cmaj.070342; REASON J, 1990, ERGONOMICS, V33, P1315, DOI 10.1080/00140139008925335; Reimer B, 2005, ACCIDENT ANAL PREV, V37, P996, DOI 10.1016/j.aap.2005.05.002; Reitan R, 1986, TRAIL MAKING TEST MA; Rubin GS, 2007, INVEST OPHTH VIS SCI, V48, P1483, DOI 10.1167/iovs.06-0474; Shulman KI, 2000, INT J GERIATR PSYCH, V15, P548, DOI 10.1002/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U; Soderstrom ST, 2006, SCAND J PSYCHOL, V47, P419, DOI 10.1111/j.1467-9450.2006.00550.x; Staplin L, 2003, J SAFETY RES, V34, P389, DOI 10.1016/j.jsr.2003.09.002; Stav WB, 2008, J SAFETY RES, V39, P1, DOI 10.1016/j.jsr.2007.10.004; Stav WB, 2008, AM J OCCUP THER, V62, P149, DOI 10.5014/ajot.62.2.149; Stephens BW, 2005, PHYS OCCUP THER GERI, V23, P103, DOI 10.1300/J148v23n02_07; Stutts JC, 1998, ACCIDENT ANAL PREV, V30, P337, DOI 10.1016/S0001-4575(97)00108-5; Tant MLM, 2002, NEUROPSYCHOL REHABIL, V12, P419, DOI 10.1080/09602010244000183; *TRANSP CAN, 2001, RS200104TP TRANSP CA; Vernon DD, 2002, ACCIDENT ANAL PREV, V34, P237, DOI 10.1016/S0001-4575(01)00019-7; White T., 1996, COLOR TRAILS TEST PR	77	30	30	1	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0008-4174	1911-9828		CAN J OCCUP THER	Can. J. Occup. Ther.	APR	2011	78	2					80	96		10.2182/cjot.2011.78.2.3			17	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	755UA	WOS:000289961500003	21560912				2022-02-06	
J	Young, JC; Kearns, LA; Roper, BL				Young, J. Christopher; Kearns, Lee A.; Roper, Brad L.			Validation of the MMPI-2 Response Bias Scale and Henry-Heilbronner Index in a U.S. Veteran Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Minnesota Multiphasic Personality Inventory; Response bias; Military veterans; Neuropsychological assessment; Psychometrics	FAKE-BAD-SCALE; PERSONAL-INJURY LITIGANTS; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; VALIDITY SCALES; COMPENSATION SEEKING; DISABILITY; RBS; NEUROPSYCHOLOGY; FBS	The Response Bias Scale (RBS) and the Henry-Heilbronner Index (HHI) are two recently developed Minnesota Multiphasic Personality Inventory-2 (MMPI-2) validity scales empirically derived for the purpose of detecting feigned symptom report. Utilizing a veteran sample, the present study examined the utility of these and other MMPI-2 validity scales in predicting Word Memory Test (WMT) failure and presence of recent, current, or upcoming compensation evaluation. Although a significant predictor of WMT performance, RBS did not show incremental validity over Infrequency scale of the MMPI-2 in prediction of WMT failure and was not significantly associated with membership in the "Compensation-Context" (CC) group. In contrast, HHI best predicted CC group membership, but only trended toward significance in predicting WMT failure. In predicting CC group membership, HHI showed incremental validity above the established MMPI-2 validity scales, but its specificity was low. In the context of current literature on RBS and HHI, results support continued use of RBS and HHI but suggest that these scales may perform differently in samples other than the compensation-seeking samples on which they were developed.	[Young, J. Christopher; Roper, Brad L.] Memphis Vet Affairs Med Ctr, Memphis, TN 38104 USA; [Kearns, Lee A.] Western Washington Med Grp, Everett, WA USA		Young, JC (corresponding author), Memphis Vet Affairs Med Ctr, 1030 Jefferson Ave, Memphis, TN 38104 USA.	john.young5@va.gov; brad.roper@va.gov					Allen L., 1997, CARB 97 MANUAL COMPU; American Psychological Association, 2017, ETH PRINC PSYCH COD; Arbisi P.A, 2004, PSYCHOL SERV, V1, P56, DOI DOI 10.1037/1541-1559.1.1.56; Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; ATKINSON RM, 1982, AM J PSYCHIAT, V139, P1118; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Ben-Porath YS, 2010, PSYCHOL INJ LAW, V3, P77, DOI 10.1007/s12207-009-9049-0; Ben-Porath YS, 2009, PSYCHOL INJ LAW, V2, P62, DOI 10.1007/s12207-009-9037-4; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher JN, 2008, PSYCHOL INJ LAW, V1, P191, DOI 10.1007/s12207-007-9002-z; Butcher JN, 2001, MMPI 2 MANUAL ADM SC; Cohen J., 2013, STAT POWER ANAL BEHA; Frueh BC, 2007, AM J PUBLIC HEALTH, V97, P2143, DOI 10.2105/AJPH.2007.115436; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 1996, J TRAUMA STRESS, V9, P427, DOI 10.1007/BF02103656; Frueh BC, 2003, PSYCHIATR SERV, V54, P84, DOI 10.1176/appi.ps.54.1.84; Gervais RO, 2005, ARCH CLIN NEUROPSYCH, V20, P891; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Green P., 2003, WORD MEMORY TEST WIN; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2008, CLIN NEUROPSYCHOL, V22, P919, DOI 10.1080/13854040701625853; Henry GK, 2006, CLIN NEUROPSYCHOL, V20, P786, DOI 10.1080/13854040500287749; Iverson GL, 2003, HANDBOOK OF FORENSIC NEUROPSYCHOLOGY, P137; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Laffaye C, 2007, MIL MED, V172, P1039, DOI 10.7205/MILMED.172.10.1039; Larrabee G. J., 2008, J INT NEUROPSYCH SOC, V14, P122; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morel K. R., 2010, DIFFERENTIAL DIAGNOS; Morel KR, 2008, CLIN NEUROPSYCHOL, V22, P350, DOI 10.1080/13854040701300531; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2007, J CLIN EXP NEUROPSYC, V29, P67, DOI 10.1080/13803390500488546; SHAW DJ, 1965, J CLIN PSYCHOL, V21, P405, DOI 10.1002/1097-4679(196510)21:4<405::AID-JCLP2270210416>3.0.CO;2-I; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spoont M., 2008, PSYCHOL SERV, V5, P49; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Tombaugh T.N., 1996, TEST MEMORY MALINGER; United States Department of Veterans Affairs, 2009, VET COMP BEN RAT TAB; United States Government Accountability Office, 2010, VET DIS BEN FURTH EV; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Williams CL, 2009, PSYCHOL INJ LAW, V2, P182, DOI 10.1007/s12207-009-9046-3; Wygant DB, 2010, PSYCHOL ASSESSMENT, V22, P745, DOI 10.1037/a0020042	51	30	30	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	APR	2011	26	3					194	204		10.1093/arclin/acr015			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	756WV	WOS:000290046400004	21459900	Bronze, Green Published			2022-02-06	
J	Andersson, EE; Bedics, BK; Falkmer, T				Andersson, Elisabeth Elgmark; Bedics, Beate Karrdahl; Falkmer, Torbjorn			MILD TRAUMATIC BRAIN INJURIES: A 10-YEAR FOLLOW-UP	JOURNAL OF REHABILITATION MEDICINE			English	Article						brain concussion; brain injuries; traumatic; post-concussion symptoms; quality of life; rehabilitation; intervention studies; RCT	CENTER-TASK-FORCE; HEAD-INJURY; HEALTH; ASSOCIATION; DISABILITY; SYMPTOMS; VALIDITY; ADULTS; SF-36	Objective and design: Long-term consequences of mild traumatic brain injuries were investigated based on a 10-year follow-up of patients from a previously-published randomized controlled study of mild traumatic brain injuries. One aim was to describe changes over time after mild traumatic brain injuries in terms of the extent of persisting post-concussion symptoms, life satisfaction, perceived health, activities of daily living, changes in life roles and sick leave. Another aim was to identify differences between the intervention and control groups. Patients: The intervention group comprised 142 persons and the control group 56 persons. Methods: Postal questionnaires with a response rate of 56%. Results: No differences over time were found for the intervention and control groups in terms of post-concussion symptoms. In the intervention group some variables in life satisfaction, perceived health and daily life were decreased. Some roles had changed over the years for both groups. No other differences between the intervention and control groups were found. However, in both groups sick leave decreased. Conclusion: Early individual intervention by a qualified rehabilitation team does not appear to impact on the long-term outcome for persons with symptoms related to mild traumatic brain injuries. The status after approximately 3 weeks is indicative of the status after 10 years.	[Andersson, Elisabeth Elgmark; Falkmer, Torbjorn] Jonkoping Univ, Dept Rehabil, Sch Hlth Sci, SE-55111 Jonkoping, Sweden; [Bedics, Beate Karrdahl] Koping Hosp, Rehabil Unit, Koping, Sweden; [Falkmer, Torbjorn] Curtin Univ, CHIRI, Curtin Hlth Innovat Res Inst, Sch Occupat Therapy & Social Work, Perth, WA, Australia; [Falkmer, Torbjorn] Linkoping Univ, Fac Hlth Sci, S-58183 Linkoping, Sweden; [Falkmer, Torbjorn] La Trobe Univ, Sch Occupat Therapy, Melbourne, Vic, Australia		Andersson, EE (corresponding author), Jonkoping Univ, Dept Rehabil, Sch Hlth Sci, Box 1026, SE-55111 Jonkoping, Sweden.	elisabeth.elgmark@hhj.hj.se			ForeningsSparbankens; Sjuharad Foundation, Boras, Sweden; Axel Linder Foundation, Alingsas, Sweden; Selma Anderssons Foundation; Uppsala University, Sweden	This study was supported by the ForeningsSparbankens, Sjuharad Foundation, Boras, Sweden, the Axel Linder Foundation, Alingsas, Sweden and the Selma Anderssons Foundation, Uppsala University, Sweden. We thank secretaries Margareta Olsson, Marianne Hjalmarsson and Birgitta Hallberg. We are grateful for the support of Sven-Erik Roslin, Head of the physiotherapy department, all at the Rehabilitation Centre, Sodra Alvsborgs Sjukhus, Boras, Sweden and Associate Professor Matthew Molineux at the School of Occupational Therapy and Social Work, Curtin University, Perth, WA, Australia.	Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Andersson EE, 2006, J REHABIL MED, V38, P26, DOI 10.1080/16501970500310564; ANDREN E, 1998, THESIS GOTEBORG U GO; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BRANHOLM IB, 1994, DISABIL REHABIL, V16, P205; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; KARLOWSKI TR, 1975, JAMA-J AM MED ASSOC, V231, P1038, DOI 10.1001/jama.231.10.1038; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Melin R, 2003, J REHABIL MED, V35, P84, DOI 10.1080/16501970306119; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Pocock, 1983, CLIN TRIALS PRACTICA; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; QUELLET MC, 2006, REHABIL PSYCHOL, V5, P140; Sullivan M, 1998, J CLIN EPIDEMIOL, V51, P1105, DOI 10.1016/S0895-4356(98)00102-4; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; The Swedish Council on techonolgy assessment (SBU), 2006, 153 SBU; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	35	30	30	0	8	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAR	2011	43	4					323	329		10.2340/16501977-0666			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	743ID	WOS:000289011000008	21271211	Green Published, gold			2022-02-06	
J	Pardini, M; Krueger, F; Hodgkinson, C; Raymont, V; Ferrier, C; Goldman, D; Strenziok, M; Guida, S; Grafman, J				Pardini, M.; Krueger, F.; Hodgkinson, C.; Raymont, V.; Ferrier, C.; Goldman, D.; Strenziok, M.; Guida, S.; Grafman, J.			Prefrontal cortex lesions and MAO-A modulate aggression in penetrating traumatic brain injury	NEUROLOGY			English	Article							MONOAMINE-OXIDASE-A; BORDERLINE PERSONALITY-DISORDER; POSITRON-EMISSION-TOMOGRAPHY; CHILDHOOD SEXUAL-ABUSE; NEURAL MECHANISMS; HEAD-INJURY; BEHAVIOR; VIOLENCE; GENE; INVENTORY	Objective: This study investigates the interaction between brain lesion location and monoamine oxidase A (MAO-A) in the genesis of aggression in patients with penetrating traumatic brain injury (PTBI). Methods: We enrolled 155 patients with PTBI and 42 controls drawn from the Vietnam Head Injury Study registry. Patients with PTBI were divided according to lesion localization (prefrontal cortex [PFC] vs non-PFC) and were genotyped for the MAO-A polymorphism linked to low and high transcriptional activity. Aggression was assessed with the aggression/agitation subscale of the Neuropsychiatric Inventory (NPI-a). Results: Patients with the highest levels of aggression preferentially presented lesions in PFC territories. A significant interaction between MAO-A transcriptional activity and lesion localization on aggression was revealed. In the control group, carriers of the low-activity allele demonstrated higher aggression than high-activity allele carriers. In the PFC lesion group, no significant differences in aggression were observed between carriers of the 2 MAO-A alleles, whereas in the non-PFC lesion group higher aggression was observed in the high-activity allele than in the low-activity allele carriers. Higher NPI-a scores were linked to more severe childhood psychological traumatic experiences and posttraumatic stress disorder symptomatology in the control and non-PFC lesion groups but not in the PFC lesion group. Conclusions: Lesion location and MAO-A genotype interact in mediating aggression in PTBI. Importantly, PFC integrity is necessary for modulation of aggressive behaviors by genetic susceptibilities and traumatic experiences. Potentially, lesion localization and MAO-A genotype data could be combined to develop risk-stratification algorithms and individualized treatments for aggression in PTBI. Neurology (R) 2011;76:1038-1045	[Pardini, M.; Krueger, F.; Raymont, V.; Strenziok, M.; Grafman, J.] Natl Inst Neurol Disorders & Stroke, Cognit Neurosci Sect, NIH, Bethesda, MD USA; [Pardini, M.; Guida, S.] Univ Genoa, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; [Pardini, M.] Univ Genoa, Magnet Resonance Res Ctr Nervous Syst Dis, Genoa, Italy; [Krueger, F.] George Mason Univ, Dept Mol Neurosci, Fairfax, VA 22030 USA; [Hodgkinson, C.; Ferrier, C.; Goldman, D.] NIAAA, Neurogenet Lab, NIH, Bethesda, MD USA; [Raymont, V.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA		Grafman, J (corresponding author), Kessler Fdn Res Ctr, Brain Injury Res Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jgrafman@kesslerfoundation.org	Majid, Salma/AAT-2616-2020; Goldman, David/F-9772-2010	Majid, Salma/0000-0002-1724-5405; Goldman, David/0000-0002-1724-5405; Grafman, Jordan H./0000-0001-8645-4457; Hodgkinson, Colin/0000-0002-5365-8119	US National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC); National Naval Medical Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Henry M. Jackson Foundation; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000306, ZIAAA000301, Z01AA000306] Funding Source: NIH RePORTER	Supported by the US National Institute of Neurological Disorders and Stroke intramural research program and a project grant from the US Army Medical Research and Material Command administered by the Henry M. Jackson Foundation (Vietnam Head Injury Study Phase III: a 30-year postinjury follow-up study).; The authors thank the Vietnam veterans who participated in this study. Without their long-term commitment to improving the health care of veterans, this study could not have been completed. The authors thank the National Naval Medical Center for their support and provision of their facilities and S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding, and G. Tasick for their help with the testing of participants and organization of this study.; Dr. Pardini and Dr. Krueger report no disclosures. Dr. Hodgkinson receives intramural research support from the NIH. Dr. Raymont and C. Ferrier report no disclosures. Dr. Goldman serves on the editorial boards of Biological Psychiatry and Addictions Biology. Dr. Strenziok and Dr. Guida report no disclosures. Dr. Grafman serves as Co-editor of Cortex and receives research support from the Intramural Research Program NIH/NINDS and the Henry M. Jackson Foundation.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Andersen SL, 2008, J NEUROPSYCH CLIN N, V20, P292, DOI 10.1176/appi.neuropsych.20.3.292; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bremner JD, 2000, DEPRESS ANXIETY, V12, P1, DOI 10.1002/1520-6394(2000)12:1<1::AID-DA1>3.0.CO;2-W; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Ducci F, 2008, MOL PSYCHIATR, V13, P334, DOI 10.1038/sj.mp.4002034; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Kim-Cohen J, 2006, MOL PSYCHIATR, V11, P903, DOI 10.1038/sj.mp.4001851; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Manor I, 2002, MOL PSYCHIATR, V7, P626, DOI 10.1038/sj.mp.4001037; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Meyer-Lindenberg A, 2006, P NATL ACAD SCI USA, V103, P6269, DOI 10.1073/pnas.0511311103; Nelson RJ, 2007, NAT REV NEUROSCI, V8, P536, DOI 10.1038/nrn2174; Ni XQ, 2007, PSYCHIAT GENET, V17, P153, DOI 10.1097/YPG.0b013e328016831c; Passamonti L, 2006, BIOL PSYCHIAT, V59, P334, DOI 10.1016/j.biopsych.2005.07.027; Pietrini P, 2000, AM J PSYCHIAT, V157, P1772, DOI 10.1176/appi.ajp.157.11.1772; Pritchard AL, 2009, INT J GERIATR PSYCH, V24, P1020, DOI 10.1002/gps.2214; RAINE A, 1994, BIOL PSYCHIAT, V36, P365, DOI 10.1016/0006-3223(94)91211-4; Raine A, 1997, BIOL PSYCHIAT, V42, P495, DOI 10.1016/S0006-3223(96)00362-9; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816; Schmahl CG, 2004, BIOL PSYCHIAT, V55, P759, DOI 10.1016/j.biopsych.2003.11.007; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Siever LJ, 2008, AM J PSYCHIAT, V165, P429, DOI 10.1176/appi.ajp.2008.07111774; Strenziok M, 2009, SOC COGN AFFECT 0921; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Vollm BA, 2009, CRIM BEHAV MENT HEAL, V19, P64, DOI 10.1002/cbm.716	32	30	32	0	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR	2011	76	12					1038	1045		10.1212/WNL.0b013e318211c33e			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	741GW	WOS:000288853200007	21422455	Green Published			2022-02-06	
J	Rao, V; Bergey, A; Hill, H; Efron, D; McCann, U				Rao, Vani; Bergey, Alyssa; Hill, Hugh; Efron, David; McCann, Una			Sleep Disturbance After Mild Traumatic Brain Injury: Indicator of Injury?	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							SPECTRAL-ANALYSIS	Mild traumatic brain injury (mTBI) is a complex entity with no known objective diagnostic markers. To test the hypothesis that sleep disturbances in the acute mTBI period can serve as an indicator of brain injury, the authors compared sleep polysomnograms (PSG) and sleep EEG power spectra (PS) data in seven mTBI subjects with seven age- and race-matched healthy-control subjects. The two groups differed significantly on PS measures, suggesting that mTBI can result in a disruption of sleep microarchitecture and, in theory, could be of use as a marker for brain injury. These pilot findings need to be replicated on larger samples. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23: 201-205)	[Rao, Vani] Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Psychiat, Div Neuropsychiat & Geriatr Psychiat, Baltimore, MD 21224 USA; Johns Hopkins Sch Med, Dept Emergency Med, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; Johns Hopkins Sch Med, Dept Psychiat, Anxiety Disorders Program, Baltimore, MD USA		Rao, V (corresponding author), Johns Hopkins Univ, Johns Hopkins Sch Med, Dept Psychiat, Div Neuropsychiat & Geriatr Psychiat, 5300 Alpha Commons Dr,4th Floor,444, Baltimore, MD 21224 USA.	vrao@jhmi.edu			NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 066894, DA16563]; NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002719]; PfizerPfizer; MerckMerck & Company; Elan; Eli LillyEli Lilly; Forest; Jazz PharmaceuticalsJazz Pharmaceuticals; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA016563] Funding Source: NIH RePORTER	This work was supported by K23 MH 066894 from the NIMH (Rao) DA16563 (McCann); and NCRR grant M01RR002719 (Ford). Dr. Rao has a grant from Forest to conduct a clinical trial in post-TBI depression and a grant from Pfizer to conduct a clinical trial in post-stroke anxiety. Dr. McCann served as a speaker for Jazz Pharmaceuticals in 2008 and received $ 14,000 for speaking engagements. She also served as an expert legal witness in an ongoing legal case and has received $ 18,000 for her services. Ms. Bergey is a research assistant on many studies supported by pharmaceutical companies (Merck, Forest, Elan, Pfizer, Eli Lilly).	FEINBERG I, 1979, PSYCHOPHYSIOLOGY, V16, P283, DOI 10.1111/j.1469-8986.1979.tb02991.x; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Iber C., 2007, AASM MANUAL SCORING, P7; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; MURILLORODRI G, 2009, TARGETS, V8, P245; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Valente M, 2002, CLIN NEUROPHYSIOL, V113, P1798, DOI 10.1016/S1388-2457(02)00218-3; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Zhang L, 2008, CHEST, V133, P427, DOI 10.1378/chest.07-1190	11	30	31	2	6	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2011	23	2					201	205		10.1176/jnp.23.2.jnp201			5	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	777VF	WOS:000291652500138	21677251				2022-02-06	
J	Jenrow, KA; Liu, JG; Brown, SL; Kolozsvary, A; Lapanowski, K; Kim, JH				Jenrow, Kenneth A.; Liu, Jianguo; Brown, Stephen L.; Kolozsvary, Andrew; Lapanowski, Karen; Kim, Jae Ho			Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis	JOURNAL OF NEURO-ONCOLOGY			English	Article						Atorvastatin; Ramipril; Radiation; Dentate gyrus; Neurogenesis	ADULT HIPPOCAMPAL NEUROGENESIS; ANGIOTENSIN-CONVERTING ENZYME; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; IONIZING-RADIATION; IRRADIATION; STATINS; CELLS; ACTIVATION; RATS	Whole brain irradiation (WBI) is commonly administered therapeutically and is routinely associated with late delayed radiation injuries, manifesting as severe and irreversible cognitive impairment. Neural progenitors within the subgranular zone (SGZ) of the dentate gyrus are among the most radiosensitive cell types in the adult brain and are known to participate in hippocampal plasticity and normal cognitive function. These progenitors and the specialized SGZ microenvironment required for neuronal differentiation are the source of neurogenic potential in the adult dentate gyrus, and provide a continuous supply of immature neurons which may then migrate into the adjacent granule cell layer to become mature granule cell neurons. The extreme radiosensitivity of these progenitors and the SGZ microenvironment implicate them as potentially significant contributors to radiation-induced cognitive impairment. Previous reports suggest that statin drugs may be neuroprotective and may promote neurogenesis within the SGZ following both traumatic and ischemic brain injury. Here we investigate whether atorvastatin might similarly protect progenitors and/or preserve neurogenic potential within the SGZ when administered following radiation injury. We also investigate whether such mitigating effects might be enhanced by administering atorvastatin in combination with the angiotensin converting enzyme (ACE) inhibitor, ramipril, which has previously been shown to produce subtle mitigating effects in this context. Atorvastatin was administered to adult male Fisher 344 rats beginning 24 h post-WBI at doses of 10 and 15 Gy, and maintained daily until sacrifice at 12 weeks post-WBI. Combined atorvastatin and ramipril (atorvastatin + ramipril) were administered according to the same protocol following WBI doses of 10 Gy. Progenitor proliferation, neuronal differentiation, and microglial activation were assayed immunohistochemically. Our results indicate that chronic administration of atorvastatin is relatively ineffective as a mitigator of radiation injury in this context, whereas atorvastatin + ramipril appear to interact synergistically to potently and selectively mitigate radiation-induced disruption of neurogenic signaling within SGZ microenvironment.	[Jenrow, Kenneth A.; Liu, Jianguo; Brown, Stephen L.; Kolozsvary, Andrew; Lapanowski, Karen; Kim, Jae Ho] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Jenrow, Kenneth A.; Liu, Jianguo; Brown, Stephen L.; Kolozsvary, Andrew; Lapanowski, Karen; Kim, Jae Ho] Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI 48202 USA		Jenrow, KA (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA.	nskje@neuro.hfh.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U19AI067734-010005]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI067734] Funding Source: NIH RePORTER	This study was supported by NIH U19AI067734-010005 (JHK). The authors also wish to acknowledge the contributions of Christina Liccardello, Kelli McDonough, and Jegor Korzyukov for assistance with image acquisition and cell counting.	Abayomi OK, 2002, ACTA ONCOL, V41, P346, DOI 10.1080/028418602760169389; Andres-Mach M, 2008, CELL TISSUE RES, V331, P251, DOI 10.1007/s00441-007-0480-9; Bromet EJ, 2007, HEALTH PHYS, V93, P516, DOI 10.1097/01.HP.0000279635.14108.02; Bruel-Jungerman E, 2006, J NEUROSCI, V26, P5888, DOI 10.1523/JNEUROSCI.0782-06.2006; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cho BP, 2006, GLIA, V53, P92, DOI 10.1002/glia.20265; Conover JC, 2008, CELL TISSUE RES, V331, P211, DOI 10.1007/s00441-007-0503-6; Diomede L, 2001, ARTERIOSCL THROM VAS, V21, P1327, DOI 10.1161/hq0801.094222; Gamache GL, 2005, ARCH CLIN NEUROPSYCH, V20, P81, DOI 10.1016/j.acn.2004.03.005; Haendeler J, 2004, CIRCULATION, V110, P856, DOI 10.1161/01.CIR.0000138743.09012.93; Hattiangady B, 2010, HIPPOCAMPUS, V20, P97, DOI 10.1002/hipo.20594; HAYDONT V, 2007, INT J RADIAT ONCOL, V68, P1417; Hwang SY, 2006, NEUROBIOL DIS, V21, P457, DOI 10.1016/j.nbd.2005.08.006; Jackson EK, 2001, GOODMAN GILMANS PHAR; Jeltsch H, 2001, NEUROBIOL LEARN MEM, V76, P81, DOI 10.1006/nlme.2000.3986; Jenrow KA, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-6; Keles MS, 2009, MOL CELL BIOCHEM, V328, P109, DOI 10.1007/s11010-009-0080-y; KING DS, 2001, PHARMACOTHERAPY, V21, P371; Koulouris S, 2005, AM J CARDIOL, V95, P1386, DOI 10.1016/j.amjcard.2005.01.092; LAROCHE S, 1989, NEUROSCIENCE, V28, P375, DOI 10.1016/0306-4522(89)90184-X; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Pizzi C, 2004, CIRCULATION, V109, P53, DOI 10.1161/01.CIR.0000100722.34034.E4; Radaelli A, 2007, ARTERIOSCL THROM VAS, V27, P2750, DOI 10.1161/ATVBAHA.107.149039; Ramanan S, 2009, INT J RADIAT ONCOL, V75, P870, DOI 10.1016/j.ijrobp.2009.06.059; Robbins ME, 2009, INT J RADIAT ONCOL, V73, P499, DOI 10.1016/j.ijrobp.2008.09.058; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Rola R, 2007, FREE RADICAL BIO MED, V42, P1133, DOI 10.1016/j.freeradbiomed.2007.01.020; Rosi S, 2009, BRAIN, V132, P2464, DOI 10.1093/brain/awp148; Sandmann S, 2006, BLOOD PRESSURE, V15, P116, DOI 10.1080/08037050600586593; SAS Institute Inc, 2004, SAS STAT 9 1 US GUID; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Schelman WR, 1997, MOL BRAIN RES, V48, P197, DOI 10.1016/S0169-328X(97)00093-4; Schindler MK, 2008, INT J RADIAT ONCOL, V70, P826, DOI 10.1016/j.ijrobp.2007.10.054; Shishehbor MH, 2003, CIRCULATION, V108, P426, DOI 10.1161/01.CIR.0000080895.05158.8B; Sparks D L, 2002, J Nutr Health Aging, V6, P324; Sugama S, 2003, NEUROSCIENCE, V116, P925, DOI 10.1016/S0306-4522(02)00572-9; Uberti D, 2001, MOL BRAIN RES, V93, P81, DOI 10.1016/S0169-328X(01)00180-2; Wang J, 2007, INT J RADIAT ONCOL, V68, P1483, DOI 10.1016/j.ijrobp.2007.03.036; Williams JP, 2004, RADIAT RES, V161, P560, DOI 10.1667/RR3168; Yamashima T, 2004, HIPPOCAMPUS, V14, P861, DOI 10.1002/hipo.20001; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759	48	30	31	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	FEB	2011	101	3					449	456		10.1007/s11060-010-0282-x			8	Oncology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Neurosciences & Neurology	709VI	WOS:000286469100010	20617366				2022-02-06	
J	Le, K; Coelho, C; Mozeiko, J; Grafman, J				Le, Karen; Coelho, Carl; Mozeiko, Jennifer; Grafman, Jordan			Measuring Goodness of Story Narratives	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						discourse analysis; content analysis; story grammar; narrative discourse	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; DISCOURSE PRODUCTION; ADULTS; ADOLESCENTS; KNOWLEDGE; CHILDREN; ABILITY; SKILLS; MILD	Purpose: The purpose of this article was to evaluate a new measure of story narrative performance: story completeness. It was hypothesized that by combining organizational (story grammar) and completeness measures, story "goodness" could be quantified. Method: Discourse samples from 46 typically developing adults were compared with those from 24 adults with acquired brain injuries. Story retellings were elicited and analyzed for episode structure (story grammar). Each story was also evaluated for the presence of 5 key components, yielding the story completeness score. Story goodness was quantified by combining the story grammar and completeness measures using a 2-coordinate grid system. A multivariate analysis of variance was performed as well as correlational analyses between the story grammar and story completeness scores. Results: There were significant group differences on both story grammar and story completeness. Moderate correlations were noted between the 2 measures, suggesting that the indices were not entirely measuring the same abilities. Plotting the 2 sets of scores into quadrants discriminated the comparison group and the group with brain injury into 4 distinct categories of story "goodness." Conclusion: The combination of measures provided a more accurate depiction of discourse performance than either measure alone. Results suggest the measure is sensitive, is reliable, and has potential utility for investigating discourse deficits in clinical populations.	[Le, Karen; Coelho, Carl; Mozeiko, Jennifer] Univ Connecticut, Storrs, CT USA; [Grafman, Jordan] NIH, Bethesda, MD 20892 USA		Grafman, J (corresponding author), NINDS, Cognit Neurosci Sect, Bldg 10,7D43,MSC 1440, Bethesda, MD 20892 USA.	grafmanj@ninds.nih.gov		Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002792] Funding Source: NIH RePORTER		Barrett J., 1998, OLD MCDONALD HAD APA, V2nd; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Coelho C. A., 1994, DISCOURSE ANAL APPL, P96; Coelho CA, 2003, APHASIOLOGY, V17, P499, DOI 10.1080/02687030344000111; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FREDERIKSEN CH, 1975, COGNITIVE PSYCHOL, V7, P371, DOI 10.1016/0010-0285(75)90016-X; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Grafman G., 2002, PRINCIPLES FRONTAL L, P292; Grafman J., 1993, J HEAD TRAUMA REHAB, V8, P73, DOI DOI 10.1097/00001199-199303000-00008; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hunt K., 1965, 3 NCTEH; Kaplan E, 1983, BOSTON NAMING TEST; Kaufer D. J, 2007, HUMAN FRONTAL LOBES, P44; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; PLAG JA, 1967, PERS PSYCHOL, V20, P323, DOI 10.1111/j.1744-6570.1967.tb01527.x; Stein N. L., 1979, NEW DIRECTIONS DISCO, P53; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; THORNDYKE PW, 1980, POETICS, V9, P23, DOI 10.1016/0304-422X(80)90011-X; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; U. S. Department of Defense, 1984, TEST MAN ARM SERV VO; Wood JN, 2005, CEREB CORTEX, V15, P1155, DOI 10.1093/cercor/bhh215; [No title captured]	30	30	30	0	5	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	FEB 1	2011	54	1					118	126		10.1044/1092-4388(2010/09-0022)			9	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	714IY	WOS:000286804500015	20719868				2022-02-06	
J	Zohar, O; Lavy, R; Zi, XM; Nelson, TJ; Hongpaisan, J; Pick, CG; Alkon, DL				Zohar, Ofer; Lavy, Rotem; Zi, Xiaomei; Nelson, Thomas J.; Hongpaisan, Jarin; Pick, Chaim G.; Alkon, D. L.			PKC activator therapeutic for mild traumatic brain injury in mice	NEUROBIOLOGY OF DISEASE			English	Article						Mild traumatic brain injury; Therapeutic; Dose dependent; Time frame; Cognitive deficits; Synaptic structures; ADAM10; BACE1	PROTEIN-KINASE-C; AMYLOID PRECURSOR PROTEIN; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; LONG-TERM-MEMORY; COGNITIVE DEFICITS; BRYOSTATIN 1; ANTICANCER DRUGS; HIPPOCAMPAL PKC; TRANSGENIC MICE	Traumatic brain injury (TBI) is a frequent consequence of vehicle, sport and war related injuries. More than 90% of TBI patients suffer mild injury (mTBI). However, the pathologies underlying the disease are poorly understood and treatment modalities are limited. We report here that in mice, the potent PKC activator bryostatin1 protects against mTBI induced learning and memory deficits and reduction in pre-synaptic synaptophysin and post-synaptic spinophylin immunostaining. An effective treatment has to start within the first 8 h after injury, and includes 5x i.p. injections over a period of 14 days. The treatment is dose dependent. Exploring the effects of the repeated bryostatin1 treatment on the processing of the amyloid precursor protein, we found that the treatment induced an increase in the putative alpha-secretase ADAM10 and a reduction in beta-secretase activities. Both these effects could contribute towards a reduction in beta-amyloid production. These results suggest that bryostatin1 protects against mTBI cognitive and synaptic sequela by rescuing synapses, which is possibly mediated by an increase in ADAM10 and a decrease in BACE1 activity. Since bryostatin1 has already been extensively used in clinical trials as an anti-cancer drug, its potential as a remedy for the short- and long-term TBI sequelae is quite promising. (C) 2010 Elsevier Inc. All rights reserved.	[Zohar, Ofer; Lavy, Rotem; Zi, Xiaomei; Nelson, Thomas J.; Hongpaisan, Jarin; Alkon, D. L.] W Virginia Univ, Blanchette Rockefeller Neurosci Inst, Rockville, MD 20850 USA; [Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel		Zohar, O (corresponding author), W Virginia Univ, Blanchette Rockefeller Neurosci Inst, 9601 Med Ctr Dr, Rockville, MD 20850 USA.	zohar@brni-jhu.org					Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; Alkon DL, 2005, P NATL ACAD SCI USA, V102, P16432, DOI 10.1073/pnas.0508001102; Amador ML, 2003, ANN ONCOL, V14, P1607, DOI 10.1093/annonc/mdg443; Asai M, 2003, BIOCHEM BIOPH RES CO, V301, P231, DOI 10.1016/S0006-291X(02)02999-6; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BANK B, 1988, P NATL ACAD SCI USA, V85, P1988, DOI 10.1073/pnas.85.6.1988; BASU A, 1993, PHARMACOL THERAPEUT, V59, P257, DOI 10.1016/0163-7258(93)90070-T; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bird CM, 2008, NAT REV NEUROSCI, V9, P182, DOI 10.1038/nrn2335; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bonini JS, 2007, NEUROSCIENCE, V147, P37, DOI 10.1016/j.neuroscience.2007.04.013; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Craske ML, 2005, J CELL BIOL, V170, P1147, DOI 10.1083/jcb.200503118; Deuss M, 2008, CURR ALZHEIMER RES, V5, P187, DOI 10.2174/156720508783954686; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Etcheberrigaray R, 2004, P NATL ACAD SCI USA, V101, P11141, DOI 10.1073/pnas.0403921101; Farrow B, 2002, J GASTROINTEST CANC, V32, P63, DOI 10.1385/IJGC:32:2-3:63; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Gescher A, 1998, GEN PHARMACOL, V31, P721, DOI 10.1016/S0306-3623(98)00069-X; Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hongpaisan J, 2007, P NATL ACAD SCI USA, V104, P19571, DOI 10.1073/pnas.0709311104; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Karkkainen I, 2000, MOL CELL NEUROSCI, V15, P547, DOI 10.1006/mcne.2000.0848; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kojro E, 2005, SUB CELL BIOCHEM, V38, P105; Kortmansky J, 2003, CANCER INVEST, V21, P924, DOI 10.1081/CNV-120025095; Kuzirian AM, 2006, BIOL BULL-US, V210, P201, DOI 10.2307/4134558; Lan JY, 2001, NAT NEUROSCI, V4, P382, DOI 10.1038/86028; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LEWIN NE, 1991, CANCER COMMUN, V3, P67, DOI 10.3727/095535491820873506; Lorenzo PS, 1997, J BIOL CHEM, V272, P33338, DOI 10.1074/jbc.272.52.33338; Lorenzo PS, 1999, CANCER RES, V59, P6137; Majewski H, 1997, CLIN EXP PHARMACOL P, V24, P619, DOI 10.1111/j.1440-1681.1997.tb02102.x; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Mutter R, 2000, BIOORGAN MED CHEM, V8, P1841, DOI 10.1016/S0968-0896(00)00150-4; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nogues X, 1997, PROG NEURO-PSYCHOPH, V21, P507, DOI 10.1016/S0278-5846(97)00015-8; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; OLDS JL, 1989, SCIENCE, V245, P866, DOI 10.1126/science.2772638; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Paterson I, 2005, SCIENCE, V310, P451, DOI 10.1126/science.1116364; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Postina R, 2008, CURR ALZHEIMER RES, V5, P179, DOI 10.2174/156720508783954668; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Sun MK, 2006, CNS DRUG REV, V12, P1, DOI 10.1111/j.1527-3458.2006.00001.x; Sun MK, 2009, P NATL ACAD SCI USA, V106, P14676, DOI 10.1073/pnas.0907842106; Sun MK, 2005, EUR J PHARMACOL, V512, P43, DOI 10.1016/j.ejphar.2005.02.028; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VanderZee EA, 1997, PROG NEURO-PSYCHOPH, V21, P531, DOI 10.1016/S0278-5846(97)00017-1; Wang DH, 2008, BEHAV PHARMACOL, V19, P245, DOI 10.1097/FBP.0b013e3282feb0d2; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zhang XS, 1996, CANCER RES, V56, P802; Zohar O, 2006, NEUROSCI LETT, V394, P239, DOI 10.1016/j.neulet.2005.10.099; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	78	30	31	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2011	41	2					329	337		10.1016/j.nbd.2010.10.001			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	705QZ	WOS:000286154300011	20951803				2022-02-06	
J	Hong, MS; Feezor, RJ; Lee, WA; Nelson, PR				Hong, Michael S.; Feezor, Robert J.; Lee, W. Anthony; Nelson, Peter R.			The advent of thoracic endovascular aortic repair is associated with broadened treatment eligibility and decreased overall mortality in traumatic thoracic aortic injury	JOURNAL OF VASCULAR SURGERY			English	Article							STENT GRAFT REPAIR; AMERICAN-ASSOCIATION; TRANSECTIONS; SURGERY	Background: Aortic injury is the second leading cause of death in trauma. Thoracic endovascular aortic repair (TEVAR) has recently been applied to traumatic thoracic aortic injuries (TTAIs) as a minimally invasive alternative to open surgery. We sought to determine the impact of TEVAR on national trends in the management of TTAL Methods: We queried the Nationwide Inpatient Sample from the years 2001 to 2007 to select patients diagnosed with TTAI (International Classification of Disease-9 code 901.0). Patients were evaluated based on open surgical repair, TEVAR, or nonoperative management, before and after widespread adoption of TEVAR (2001-2005 and 2006-2007). Outcomes of interest were inpatient mortality, length of stay (LOS), and major complications. Results: An estimated 1180 annual admissions occurred for TTAI in the United States. Comparing the two time periods, there was an increase in TEVAR (P<.001) with a simultaneous decrease in open repair (P<.001) in 2006 to 2007. The overall number of interventions also increased (P<.001). Overall mortality decreased (25.0% vs 19.0%;P<.001), corresponding to improved survival in the nonoperative grouP(28.0% vs 23.2%; P<.001). There was no improvement in open repair mortality rates between the two time periods. Comparing intervention types, the TEVAR group had a higher percentage of patients with brain injury (26.1% vs 20.6%; P=.008), lung injury (25.0% vs 17.7%; P<.001), and hemothorax (32.5% vs 21.7%; P<.001) than the open surgery group. There were no differences in the number of intra-abdominal injuries or major orthopedic fractures. The open surgery group had more respiratory complications (43.9% vs 54.2%; P<.001), whereas TEVAR had a higher stroke rate (1.9% vs 0.7%; P=.021). There were no differences in paraplegia or renal failure. Overall in-hospital mortality was 23.2% (nonoperative group 26.7%, open repair 12.4%, and TEVAR 10.6%). Mortality between open repair and TEVAR groups were not significantly different. LOS was shorter among the TEVAR group vs open (15.7 vs 22.9 days; P<.001). Conclusion: TEVAR has replaced open repair as the primary operative treatment for TTAI and has extended operative treatment to those patients not previously considered candidates for repair. Increased utilization of TEVAR is associated with improved overall mortality. There is no difference in mortality between TEVAR and open repair groups in our study, which likely reflects the multisystem nature of injury and greater preoperative risk in the TEVAR group. (J Vasc Surg 2011;53:36-43.)	[Hong, Michael S.; Feezor, Robert J.; Lee, W. Anthony; Nelson, Peter R.] Univ Florida, Coll Med, Div Vasc Surg & Endovasc Therapy, Dept Surg, Gainesville, FL 32610 USA		Nelson, PR (corresponding author), Univ Florida, Coll Med, Div Vasc Surg & Endovasc Therapy, Dept Surg, POB 100128, Gainesville, FL 32610 USA.	peter.nelson@surgery.ufl.edu	Nelson, Peter R/B-2055-2009	Nelson, Peter R/0000-0003-0398-2962			Arthurs ZM, 2009, J VASC SURG, V49, P988, DOI 10.1016/j.jvs.2008.11.052; Broux C, 2006, INTENS CARE MED, V32, P770, DOI 10.1007/s00134-006-0115-8; Clark DE, 2004, J TRAUMA, V57, P130, DOI 10.1097/01.TA.0000114240.58834.84; Demetriades D, 2008, J TRAUMA, V64, P1415, DOI 10.1097/TA.0b013e3181715e32; Demetriades D, 2008, J TRAUMA, V64, P561, DOI 10.1097/TA.0b013e3181641bb3; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; Feezor RJ, 2009, J AM COLL SURGEONS, V208, P510, DOI 10.1016/j.jamcollsurg.2009.01.012; Hannan EL, 2007, J TRAUMA, V62, P964, DOI 10.1097/01.ta.0000215375.07314.bd; Hemmila MR, 2004, J TRAUMA, V56, P13, DOI 10.1097/01.TA.0000108634.15989.07; Internet Citation: HCUP Databases, 2009, INT CIT HCUP DAT HEA; Mattox KL, 2008, J TRAUMA, V64, P570; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Pate JW, 1997, ANN THORAC SURG, V64, P387; Schulman CI, 2007, J TRAUMA, V62, P664, DOI 10.1097/TA.0b013e318031b58c; Sweeney MS, 1997, ANN THORAC SURG, V64, P384, DOI 10.1016/S0003-4975(97)00561-4; Tang GL, 2008, J VASC SURG, V47, P671, DOI 10.1016/j.jvs.2007.08.031; Verdant A, 2010, J VASC SURG, V51, P294, DOI 10.1016/j.jvs.2009.05.066	17	30	31	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	JAN	2011	53	1					36	43		10.1016/j.jvs.2010.08.009			8	Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Surgery; Cardiovascular System & Cardiology	704WB	WOS:000286085200006	20961728	Bronze			2022-02-06	
J	Jacobsson, LJ; Westerberg, M; Malec, JF; Lexell, J				Jacobsson, L. J.; Westerberg, M.; Malec, J. F.; Lexell, J.			Sense of coherence and disability and the relationship with life satisfaction 6-15 years after traumatic brain injury in northern Sweden	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Long-term outcome; Outcome assessment; Traumatic brain injury; Quality of life; Questionnaires	QUALITY-OF-LIFE; ANTONOVSKYS SENSE; COMMUNITY INTEGRATION; MULTIPLE TRAUMA; HEAD-INJURY; SCALE; HEALTH; INDIVIDUALS; VALIDITY; DEPRESSION	The objective of the study was to assess sense of coherence (SOC) many years after traumatic brain injury (TBI) and explore the relationship between SOC and self-rated life satisfaction (LS) as well as measures of functioning and disability, sex, age at injury, injury severity and time post-injury. Sixty-six individuals (aged 18-65 years) who were 6-15 years post-injury were interviewed. Data on SOC (SOC-13 item scale), measures of functioning and disability (Mayo-Portland Adaptability Inventory, MPAI-4), LS (Satisfaction with Life Scale, SWLS), and sex, age at injury, injury severity and time post-injury were analysed with hierarchical multiple regression analyses. The results showed that SOC in the study group did not differ from the general population and was strongly associated with LS. Regression analyses revealed that emotional factors, social participation, SOC, and time since injury, were more influential than sex, age at injury, and injury severity in explaining LS. It was concluded that SOC in this group of individuals with TBI who were many years post-injury was similar to nondisabled individuals. SOC, together with emotional factors, social participation and injury-related factors, were determinants of LS. These results confirm that LS after TBI is a complex phenomenon dependent on several factors that are important targets for rehabilitation professionals.	[Jacobsson, L. J.] Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden; [Jacobsson, L. J.] Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden; [Westerberg, M.] Lulea Univ Technol, Dept Business Adm & Social Sci, S-95187 Lulea, Sweden; [Malec, J. F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Malec, J. F.] Indiana Univ Sch Med, Indianapolis, IN USA; [Lexell, J.] Skane Univ Hosp, Dept Rehabil Med, Lund, Sweden; [Jacobsson, L. J.; Lexell, J.] Lund Univ, Dept Hlth Sci, Lund, Sweden		Jacobsson, LJ (corresponding author), Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden.	lars_j@glocalnet.net	Westerberg, Mats/C-3300-2012	Westerberg, Mats/0000-0001-5464-9292; Lexell, Jan/0000-0001-5294-3332; Jacobsson, Lars/0000-0002-1127-1178	Norrbacka-Eugenia Foundation; Cancer and Traffic Injury Fund; Norrbotten County Council; Swedish Association of Brain Injured and their Families; Skane county council's research and development foundation	This study was supported by grants from the Norrbacka-Eugenia Foundation, the Cancer and Traffic Injury Fund, Norrbotten County Council, the Swedish Association of Brain Injured and their Families and Skane county council's research and development foundation.	Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Antonovsky A., 1987, UNRAVELING MYSTERY H; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Eriksson M, 2005, J EPIDEMIOL COMMUN H, V59, P460, DOI 10.1136/jech.2003.018085; Eriksson M, 2006, J EPIDEMIOL COMMUN H, V60, P376, DOI 10.1136/jech.2005.041616; Feldt T, 2007, QUAL LIFE RES, V16, P483, DOI 10.1007/s11136-006-9130-z; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hendrikx T, 2008, SCAND J PUBLIC HEALT, V36, P340, DOI 10.1177/1403494808089560; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; JOHNSTONE AJ, 1993, BRAIN INJURY, V7, P501, DOI 10.3109/02699059309008177; Kaiser CF, 1996, J SOC BEHAV PERS, V11, P459; Kallenberg K., 1996, EUROPEAN J PUBLIC HL, V6, P175, DOI [10.1093/eurpub/6.3.175, DOI 10.1093/EURPUB/6.3.175]; Kivimaki M, 2000, SOC SCI MED, V50, P583, DOI 10.1016/S0277-9536(99)00326-3; Klang B, 1996, QUAL LIFE RES, V5, P109, DOI 10.1007/BF00435975; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Langius A, 1993, Scand J Caring Sci, V7, P3; Langius A, 1992, Scand J Caring Sci, V6, P165; Larsson G, 1999, EUR J PERSONALITY, V13, P51, DOI 10.1002/(SICI)1099-0984(199901/02)13:1<51::AID-PER321>3.0.CO;2-P; Lindmark U, 2010, SCAND J PUBLIC HEALT, V38, P1, DOI 10.1177/1403494809351654; Linley PA, 2003, J TRAUMA STRESS, V16, P601, DOI 10.1023/B:JOTS.0000004086.64509.09; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec J., 2005, MAYO PORTLAND ADAPTA; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pallant JF, 2002, PERS INDIV DIFFER, V33, P39, DOI 10.1016/S0191-8869(01)00134-9; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PETRIE K, 1992, BRIT J CLIN PSYCHOL, V31, P293, DOI 10.1111/j.2044-8260.1992.tb00996.x; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Schnyder U, 2000, PSYCHOTHER PSYCHOSOM, V69, P296, DOI 10.1159/000012411; Skarsater I, 2009, ARCH PSYCHIAT NURS, V23, P119, DOI 10.1016/j.apnu.2008.04.007; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Snekkevik H, 2003, CLIN REHABIL, V17, P443, DOI 10.1191/0269215503cr630oa; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; Ying YW, 1997, AM J COMMUN PSYCHOL, V25, P839, DOI 10.1023/A:1022217330005	52	30	31	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	3					383	400	PII 936108151	10.1080/09602011.2011.566711			18	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	761ND	WOS:000290403800005	21480050				2022-02-06	
J	Bowman, SM; Aitken, ME				Bowman, Stephen M.; Aitken, Mary E.			Still Unsafe, Still in Use: Ongoing Epidemic of All-Terrain Vehicle Injury Hospitalizations Among Children	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						All-terrain vehicle; Injury; Hospitalizations; Children; Trends	IMPACT; PREVENTION; PATTERNS; HELMETS	Background: The injury risks to children who ride all-terrain vehicles (ATVs) are well documented and include increased risk of death or hospitalization. We identify pediatric hospitalization trends for ATV injuries, provide national benchmarks, and discuss policy and prevention implications. Methods: We used data (1997-2006) from the kid's inpatient database, the only all-payer inpatient care database for children in the United States. Children and adolescents aged 0 year to 17 years were included. We generate national estimates of hospitalizations. Results: Total pediatric hospitalizations for ATV injuries have increased 150% from an estimated 1,618 in 1997 to 4,039 in 2006. The overall ATV-related injury hospitalization rate increased 139% from 2.3 per 100,000 in 1997 to 5.5 per 100,000 in 2006. Rates increased for both males and females, although the rate for males remained much larger than for females in 2006 (8.1 per 100,000 vs. 2.7 per 100,000, p < 0.001). For all age groups, ATV hospitalizations increased significantly between 1997 and 2006, but this change was most pronounced among those aged 15 years to 17 years. ATV hospitalization rates also increased significantly for patients hospitalized with traumatic brain injuries. Conclusions: ATVs are associated with a significant and increasing number of hospitalizations for children. Reexamination of previous federal policies, including the potential for a new consent decree between the Consumer Product Safety Commission and ATV industry representatives, should be considered to address this alarming trend and to adopt effective strategies to minimize the use by children. Enforceable state-level policy to promote helmet use among ATV riders seems to be critically needed.	[Bowman, Stephen M.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; [Aitken, Mary E.] Univ Arkansas Med Sci, Dept Pediat, Arkansas Childrens Hosp, Little Rock, AR 72205 USA		Bowman, SM (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Injury Res & Policy, Dept Hlth Policy & Management, 624 N Broadway,Room 539, Baltimore, MD 21205 USA.	smbowman@jhsph.edu	Bowman, Stephen/AAF-2154-2019; Aitken, Mary/ABG-6119-2021	Aitken, Mary/0000-0002-8318-9755	Arkansas Biosciences Institute	Supported, in part, by the Arkansas Biosciences Institute, the major research component of the Tobacco Settlement Proceeds Act of 2000.	Aitken ME, 2004, INJURY PREV, V10, P303, DOI 10.1136/ip.2003.004176; American College of Surgeons, 2009, Bull Am Coll Surg, V94, P37; [Anonymous], 2000, PEDIATRICS, V105, P1352; BARRETT M, 2006, 200606 US AG HEALTHC; Bhutta ST, 2004, PEDIATR RADIOL, V34, P130, DOI 10.1007/s00247-003-1085-4; Bowman SM, 2009, INJURY PREV, V15, P3, DOI 10.1136/ip.2008.019372; FELICIANO DV, 1996, TRAUMA, P55; Fonseca AH, 2005, AM SURGEON, V71, P937; Greenberg BS, 2009, PEDIATR RADIOL, V39, P657, DOI 10.1007/s00247-009-1258-x; *HCUP, 2003, KIDS INP DAT KID 200; *J HOPK U, 1997, ICDMAP 90 INJ SEV CO; Jones CS, 2005, J RURAL HEALTH, V21, P70, DOI 10.1111/j.1748-0361.2005.tb00064.x; Kelleher CM, 2005, J PEDIATR SURG, V40, P929, DOI 10.1016/j.jpedsurg.2005.03.007; Killingsworth JB, 2005, PEDIATRICS, V115, pE316, DOI 10.1542/peds.2004-1585; MAYNARD FM, 1988, ANN EMERG MED, V17, P30, DOI 10.1016/S0196-0644(88)80499-2; RODGERS GB, 1990, ACCIDENT ANAL PREV, V22, P47, DOI 10.1016/0001-4575(90)90006-7; Ross RT, 1999, AM SURGEON, V65, P870; Stolz U, 2009, J SAFETY RES, V40, P149, DOI 10.1016/j.jsr.2009.02.005; Streeter RA, 2007, 2007 ANN REPORT ATV; Su W, 2006, J PEDIATR SURG, V41, P931, DOI 10.1016/j.jpedsurg.2006.01.011; *US CONS PROD SAF, 2009, CPSC APPR CONS DECR; Westfall JM, 2001, MED CARE, V39, P459, DOI 10.1097/00005650-200105000-00006; Wu HY, 2007, J UROLOGY, V178, P1672, DOI 10.1016/j.juro.2007.03.160; 2009, ATV CONNECTION MAGAZ	24	30	30	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2010	69	6					1344	1349		10.1097/TA.0b013e3181ea283d			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	695RT	WOS:000285391000016	20962681				2022-02-06	
J	Weiss, H; Agimi, Y; Steiner, C				Weiss, Harold; Agimi, Yll; Steiner, Claudia			Youth Motorcycle-Related Brain Injury by State Helmet Law Type: United States, 2005-2007	PEDIATRICS			English	Article						hospitalizations; hospital discharges; motorcycle; motorcycle helmets; helmet laws; scooters; traffic accidents; non-traffic accidents; adolescents; injury; traumatic brain injury; injury severity	HEAD-INJURIES; HOSPITALIZATIONS; LEGISLATION	BACKGROUND AND OBJECTIVES: Twenty-seven states have youth-specific helmet laws even though such laws have been shown to decrease helmet use and increase youth mortality compared with all-age (universal) laws. Our goal was to quantify the impact of age-specific helmet laws on youth under age 20 hospitalized with traumatic brain injury (TBI). METHODS: Our cross-sectional ecological group analysis compared TBI proportions among US states with different helmet laws. We examined the following null hypothesis: If age-specific helmet laws are as effective as universal laws, there will be no difference in the proportion of hospitalized young motorcycle riders with TBI in the respective states. The data are derived from the 2005 to 2007 State Inpatient Databases of the Healthcare Cost and Utilization Project. We examined data for 17 states with universal laws, 6 states with laws for ages <21, and 12 states with laws for children younger than 18 (9287 motorcycle injury discharges). RESULTS: In states with a <21 law, serious TBI among youth was 38% higher than in universal-law states. Motorcycle riders aged 12 to 17 in 18 helmet-law states had a higher proportion of serious/severe TBI and higher average Abbreviated Injury Scores for head-region injuries than riders from universal-law states. CONCLUSIONS: States with youth-specific laws had an increased risk of TBI that required hospitalization, serious and severe TBI, TBI-related disability, and in-hospital death among the youth they are supposed to protect. The only method known to keep motorcycle-helmet use high among youth is to adopt or maintain universal helmet laws. Pediatrics 2010;126:1149-1155	[Weiss, Harold] Univ Pittsburgh, Ctr Injury Res & Control, Pittsburgh, PA USA; [Agimi, Yll] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; [Agimi, Yll] Assoc Sch Publ Hlth, Washington, DC USA; [Steiner, Claudia] Ctr Delivery Org & Markets Agcy Healthcare Res &, Rockville, MD USA		Weiss, H (corresponding author), POB 56, Dunedin 9054, New Zealand.	hw@injurycontrol.com	AGIMI, YLL/AAL-9337-2021				*AG HEALTHC RES QU, APP A CLIN CLASS SOF; Agency for Healthcare Research and Quality, OV STAT INP DAT SID; *AM MOT ASS, STAT MOT LAWS; Beck LF, 2007, AM J EPIDEMIOL, V166, P212, DOI 10.1093/aje/kwm064; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; BUTLER JA, 2001, CENTRAL NERVOUS SYST; *CDCP, WISQARS INJ MORT REP; CLARK DE, 2008, 9 WORLD C INJ PREV S; Coben JH, 2007, ACCIDENT ANAL PREV, V39, P190, DOI 10.1016/j.aap.2006.06.018; Hagel B, 2006, BMJ-BRIT MED J, V332, P725, DOI 10.1136/bmj.332.7543.725; HEILMAN DR, 1982, ANN EMERG MED, V11, P659, DOI 10.1016/S0196-0644(82)80258-8; Hingson R, 2001, INJURY CONTROL, P157; Houston DJ, 2007, J SAFETY RES, V38, P329, DOI 10.1016/j.jsr.2007.05.002; *INS I HIGHW SAF, Q AS MOT HELM US LAW; Kyrychenko Sergey Y, 2006, Traffic Inj Prev, V7, P55, DOI 10.1080/15389580500377833; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Mertz KJ, 2008, AM J PUBLIC HEALTH, V98, P1464, DOI 10.2105/AJPH.2007.123299; Mullin B, 2000, Inj Prev, V6, P32, DOI 10.1136/ip.6.1.32; *NAT C STAT LEG, STAT TRAFF SAF LEG T; *NAT CTR HLTH STAT, BAR INJ DIAGN MATR F; *NAT TRANSP SAF BO, 2007, SAF REC; National Highway Traffic Safety Administration NHTSA's National Center for Statistics and Analysis, TRAFF SAF FACTS 2007; Robinson DL, 2006, BMJ-BRIT MED J, V332, P722, DOI 10.1136/bmj.332.7543.722-a; Ross H. Laurence, 1982, DETERRING DRINKING D; Scuffham P, 2000, ACCIDENT ANAL PREV, V32, P565, DOI 10.1016/S0001-4575(99)00081-0; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Ulmer R, 2005, 809849 DOT HS NAT HI; *US GEN ACC OFF, 1991, HIGHW SAF MOT HELM L; Weiss H, 2010, PEDIATRICS, V126, P1141, DOI 10.1542/peds.2010-0271; Zambon F, 2006, ACCIDENT ANAL PREV, V38, P1183, DOI 10.1016/j.aap.2006.05.005	31	30	32	0	8	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2010	126	6					1149	1155		10.1542/peds.2010-0902			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	688EF	WOS:000284831900041	21078726	Bronze			2022-02-06	
J	Schober, ME; Block, B; Beachy, JC; Statler, KD; Giza, CC; Lane, RH				Schober, Michelle E.; Block, Benjamin; Beachy, Joanna C.; Statler, Kimberly D.; Giza, Christopher C.; Lane, Robert H.			Early and Sustained Increase in the Expression of Hippocampal IGF-1, But Not EPO, in a Developmental Rodent Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; controlled cortical impact; erythropoietin receptor; insulin-like growth factor-1 receptor; neurocognitive impairment	GROWTH-FACTOR-I; CONTROLLED CORTICAL IMPACT; RAT-BRAIN; GENE-EXPRESSION; IMMATURE RATS; APOPTOTIC NEURODEGENERATION; PROTEIN EXPRESSION; NERVOUS-SYSTEM; MESSENGER-RNA; CELL-DEATH	Pediatric traumatic brain injury (pTBI) is the leading cause of traumatic death and disability in children in the United States. Impaired learning and memory in these young survivors imposes a heavy toll on society. In adult TBI (aTBI) models, cognitive outcome improved after administration of erythropoietin (EPO) or insulin-like growth factor-1 (IGF-1). Little is known about the production of these agents in the hippocampus, a brain region critical for learning and memory, after pTBI. Our objective was to describe hippocampal expression of EPO and IGF-1, together with their receptors (EPOR and IGF-1R, respectively), over time after pTBI in 17-day-old rats. We used the controlled cortical impact (CCI) model and measured hippocampal mRNA levels of EPO, IGF-1, EPOR, IGF-1R, and markers of caspase-dependent apoptosis (bcl2, bax, and p53) at post-injury days (PID) 1, 2, 3, 7, and 14. CCI rats performed poorly on Morris water maze testing of spatial working memory, a hippocampally-based cognitive function. Apoptotic markers were present early and persisted for the duration of the study. EPO in our pTBI model increased much later (PID7) than in aTBI models (12 h), while EPOR and IGF-1 increased at PID1 and PID2, respectively, similar to data from aTBI models. Our data indicate that EPO expression showed a delayed upregulation post-pTBI, while EPOR increased early. We speculate that administration of EPO in the first 1-2 days after pTBI would increase hippocampal neuronal survival and function.	[Schober, Michelle E.; Statler, Kimberly D.] Univ Utah, Sch Med, Div Crit Care, Dept Pediat, Salt Lake City, UT 84158 USA; [Block, Benjamin; Beachy, Joanna C.; Lane, Robert H.] Univ Utah, Sch Med, Div Neonatol, Salt Lake City, UT 84158 USA; [Statler, Kimberly D.] Univ Utah, Inst Brain, Salt Lake City, UT 84158 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Div Pediat Neurol, Los Angeles, CA USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA		Schober, ME (corresponding author), Univ Utah, Sch Med, Div Crit Care, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	michelle.schober@hsc.utah.edu			Primary Children's Medical Center Foundation; Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER	Funding for this study was provided by the Primary Children's Medical Center Foundation and the Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah.	Adelson PD, 1998, ACT NEUR S, V71, P104; Agarwal MK, 2004, CELL CYCLE, V3, P205; Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI 10.1089/neu.2008-0765; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Bayly PV, 2006, BRAIN RES, V1107, P70, DOI 10.1016/j.brainres.2006.05.102; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; BREESE CR, 1994, NEUROSCIENCE, V63, P579, DOI 10.1016/0306-4522(94)90551-7; Cook JL, 1998, BRAIN RES PROTOC, V3, P1, DOI 10.1016/S1385-299X(98)00012-9; Dame C, 2001, BIOL NEONATE, V79, P228; Digicaylioglu M, 2004, P NATL ACAD SCI USA, V101, P9855, DOI 10.1073/pnas.0403172101; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li XS, 1998, MOL BRAIN RES, V57, P92, DOI 10.1016/S0169-328X(98)00075-8; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Ochalski PG, 2010, J NEUROTRAUM, V27, P647, DOI 10.1089/neu.2009.1142; OLCHOVSKY D, 1991, ENDOCRINOLOGY, V128, P923, DOI 10.1210/endo-128-2-923; Papaconstantinou J, 2005, MECH AGEING DEV, V126, P692, DOI 10.1016/j.mad.2005.01.002; Picha ME, 2006, GEN COMP ENDOCR, V147, P196, DOI 10.1016/j.ygcen.2005.12.020; Rao VLR, 2001, BRAIN RES, V911, P96; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; RINK A, 1995, AM J PATHOL, V147, P1575; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Russo VC, 2005, ENDOCR REV, V26, P916, DOI 10.1210/er.2004-0024; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Sanchez PE, 2009, J COMP NEUROL, V514, P403, DOI 10.1002/cne.22020; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Sola A, 2005, PEDIATR RES, V57, p110R, DOI 10.1203/01.PDR.0000159571.50758.39; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stansberg C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-94; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Zhang J, 2007, J NEUROSCI RES, V85, P1618, DOI 10.1002/jnr.21289; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	48	30	30	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					2011	2020		10.1089/neu.2009.1226			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500008	20822461	Green Published			2022-02-06	
J	Ledwith, MB; Bloom, S; Maloney-Wilensky, E; Coyle, B; Polomano, RC; Le Roux, PD				Ledwith, Mary B.; Bloom, Stephanie; Maloney-Wilensky, Eileen; Coyle, Bernadette; Polomano, Rosemary C.; Le Roux, Peter D.			Effect of Body Position on Cerebral Oxygenation and Physiologic Parameters in Patients With Acute Neurological Conditions	JOURNAL OF NEUROSCIENCE NURSING			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; HEALTH-CARE PROFESSIONALS; SPECIAL WRITING GROUP; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; STROKE-COUNCIL; BRAIN-INJURY; MANAGEMENT; GUIDELINES; STATEMENT	How body position influences brain tissue oxygen (PbtO(2)) and intracranial pressure (ICP) in critically ill neurosurgical patients remains poorly defined. In a prospective observational repeated measures study, we examined the effects of 12 different body positions on neurodynamic and hemodynamic outcomes. Thirty-three consecutive patients (mean +/- SD, age = 48.3 +/- 16.6 years; 22 men), admitted after traumatic brain injury, subarachnoid hemorrhage, or craniotomy for tumor, were evaluated in a neurocritical care unit at a level 1 academic trauma center. Patients were eligible if the admission score in the Glasgow Coma Scale was <= 8 and they had a Licox CMP Monitoring System (Integra Neurosciences, Plainsboro, NJ). Patients were exposed to all 12 positions in random order. Changes from baseline to the 15-minute postposition assessment mean change scores showed a downward trend for PbtO(2) for all positions with statistically significant decreases observed for supine head of bed (HOB) elevated 30 degrees and 45 degrees (p < .01) and right and left lateral positioning HOB 30 degrees (p < .05). ICP decreased with supine HOB 45 degrees (p < .01) and knee elevation, HOB 30 degrees and 45 degrees(p < .05), and increased (p < .05) with right and left lateral HOB 15 degrees. Hemodynamic parameters were similar in the various positions. Positioning practices can positively or negatively affect PbtO(2) and ICP and fluctuate with considerable variability among patients. Nurses must consider potential effects of turning, evaluate changes with positioning on the basis of monitoring feedback from multimodality devices, and make independent clinical judgments about optimal positions to maintain or improve cerebral oxygenation.	[Ledwith, Mary B.] Hosp Univ Penn, Neuro Intens Care Unit, Philadelphia, PA 19104 USA; [Maloney-Wilensky, Eileen] Univ Penn, Dept Neurosurg, Midlevel Provider Program, Philadelphia, PA 19104 USA; [Coyle, Bernadette] Hosp Univ Penn, Dept Nursing, Philadelphia, PA 19104 USA; [Polomano, Rosemary C.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA		Ledwith, MB (corresponding author), Hosp Univ Penn, Neuro Intens Care Unit, 3400 Spruce St, Philadelphia, PA 19104 USA.	ledwithm@uphs.upenn.edu			Mary Elisabeth Groff Surgical and Medical Research Trust; Integra Foundation; Integra Neuroscience; University of Pennsylvania	This work was supported, in part, by research grants from the Mary Elisabeth Groff Surgical and Medical Research Trust (PDLR), the Integra Foundation (PDLR), and the Integra Neuroscience (PDLR). The authors thank the Neuro ICU nurses at the University of Pennsylvania for their support; without their help, the study would not have been possible.	Albano C, 2005, CRIT CARE NURS Q, V28, P135, DOI 10.1097/00002727-200504000-00006; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Blissitt PA, 2006, AACN ADV CRIT CARE, V17, P327, DOI 10.1097/01256961-200607000-00012; *BRAIN TRAUM FDN, 2007, FACTS TBI US; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Christie Robert James, 2008, Br J Nurs, V17, P638; Fan Jun-Yu, 2004, J Neurosci Nurs, V36, P278; Griffiths H, 2005, Nurs Stand, V19, P56; HICKEY V, 2003, CLIN PRACTICE NEUROL, P288; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Iacono L A, 2000, J Neurosci Nurs, V32, P54; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Littlejohns L, 2005, AACN ADV CRIT CARE, V16, P501, DOI 10.1097/00044067-200510000-00007; March K, 1990, J Neurosci Nurs, V22, P375; Marklew Anna, 2006, Nurs Crit Care, V11, P16; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Meixensberger J, 1997, NEUROL RES, V19, P249, DOI 10.1080/01616412.1997.11740808; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Nekludov M, 2006, ACTA ANAESTH SCAND, V50, P932, DOI 10.1111/j.1399-6576.2006.01099.x; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; PHILLIPS DL, 2003, AUSTRALASIAN J NEURO, V16, P8; PHILLIPS DL, 2003, AUSTRALASIAN J NEURO, V16, P5; PHILLIPS DL, 2003, AUSTRALASIAN J NEURO, V16, P10; Price Ann M, 2003, Nurs Crit Care, V8, P126, DOI 10.1046/j.1478-5153.2003.00019.x; RAO GSU, 2007, INTERNET J ANESTHESI, V12, P11; Reinprecht A, 2003, CRIT CARE MED, V31, P1831, DOI 10.1097/01.CCM.0000063453.93855.0A; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Stocchetti N, 1998, ACT NEUR S, V71, P162; Sullivan J, 2000, J Neurosci Nurs, V32, P204; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Winkelman C, 2000, Am J Crit Care, V9, P373; Winn HR., 2004, MANAGEMENT CEREBRAL, P303; Wojner Anne W, 2002, Crit Care Nurs Q, V24, P57; Wong F W, 2000, Crit Care Nurse, V20, P18; Yanko J R, 2001, Crit Care Nurs Q, V23, P1	39	30	31	2	29	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	OCT	2010	42	5					280	287		10.1097/JNN.0b013e3181ecafd4			8	Clinical Neurology; Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Nursing	652PC	WOS:000282019200007	20968224				2022-02-06	
J	Walker, PA; Jimenez, F; Gerber, MH; Aroom, KR; Shah, SK; Harting, MT; Gill, BS; Savitz, SI; Cox, CS				Walker, Peter A.; Jimenez, Fernando; Gerber, Michael H.; Aroom, Kevin R.; Shah, Shinil K.; Harting, Matthew T.; Gill, Brijesh S.; Savitz, Sean I.; Cox, Charles S., Jr.			Effect of Needle Diameter and Flow Rate on Rat and Human Mesenchymal Stromal Cell Characterization and Viability	TISSUE ENGINEERING PART C-METHODS			English	Article							TRAUMATIC BRAIN-INJURY	Introduction: Current mesenchymal stromal cell (MSC) delivery methods require infusion/implantation through needles and/or catheters. Little investigation into the effect of delivery via catheter injection has been completed. We hypothesize that injection of rat and human MSCs through various clinically relevant-sized catheters and flow rates will not affect cell viability, characterization, or function. Methods: Both rat and human MSCs were injected through 20-, 25-, and 30-gauge needles, as well through an SL-10 microcatheter at rates of 60, 120, 240, and 500 mL/h. MSC viability and apoptotic fraction was measured. MSCs were characterized 24 h after injection with flow cytometric immunophenotyping, and multilineage differentiation was completed. Results: Catheter diameter or flow rate did not affect rat MSC viability. No clinically significant decrease in human MSC viability was observed immediately after injection; however, a delayed decrease in viability was observed at 24 h. No difference in the surface markers CD11b, CD45, CD29, CD49e, CD73, CD90, CD105, and Stro-1 or the capacity for multilineage differentiation (adipogenesis, osteogenesis, and chondrogenesis) was observed for either rat or human MSCs. Conclusion: The injection of human and rat MSCs through various clinically relevant catheters and flow rates did not have a clinically significant effect on viability immediately after injection, indicating compliance with recently published Food and Drug Administration guidelines (viability >70%). Further, no changes in cell characterization or function were observed via measurement of cell surface markers and the capacity for multilineage differentiation, respectively. These results ensure the biocompatibility of MSCs with commonly used delivery methods.	[Walker, Peter A.; Jimenez, Fernando; Aroom, Kevin R.; Shah, Shinil K.; Harting, Matthew T.; Gill, Brijesh S.; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Walker, Peter A.; Gerber, Michael H.; Shah, Shinil K.; Gill, Brijesh S.; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Savitz, Sean I.] Univ Texas Med Sch Houston, Dept Neurol, Houston, TX 77030 USA		Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Aroom, Kevin/0000-0003-1504-0585; Harting, Matthew/0000-0002-8929-8311	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM 08 79201, M01 RR 02558]; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	Supported by grants from NIH T32 GM 08 79201, M01 RR 02558, Texas Higher Education Coordinating Board, and Children's Memorial Hermann Hospital Foundation.	Britten MB, 2003, CIRCULATION, V108, P2212, DOI 10.1161/01.CIR.0000095788.78169.AF; Bussolati B, 2009, CURR STEM CELL RES T, V4, P2, DOI 10.2174/157488809787169129; *FDA, 2009, GUID FDA REV SPONS C; *FDA, 2009, DRAFT GUID IND SOM C; Fellous TG, 2007, DIABETES-METAB RES, V23, P87, DOI 10.1002/dmrr.692; Harting MT, 2008, CYTOTHERAPY, V10, P243, DOI 10.1080/14653240801950000; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Herrera MB, 2006, STEM CELLS, V24, P2840, DOI 10.1634/stemcells.2006-0114; LEVERETT LB, 1972, BIOPHYS J, V12, P257, DOI 10.1016/S0006-3495(72)86085-5; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Sharp MK, 1998, ANN BIOMED ENG, V26, P788, DOI 10.1114/1.65; SUTERA SP, 1977, CIRC RES, V41, P2, DOI 10.1161/01.RES.41.1.2; Tol M, 2008, CYTOTHERAPY, V10, P98, DOI 10.1080/14653240701762356; Truskey G.A., 2004, TRANSPORT PHENOMENA	16	30	30	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3384			TISSUE ENG PART C-ME	Tissue Eng. Part C-Methods	OCT	2010	16	5					989	997		10.1089/ten.tec.2009.0423			9	Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Engineering; Materials Science	655DN	WOS:000282223800019	20001789	Green Submitted, Green Published			2022-02-06	
J	Hoffmann, U; Dilekoz, E; Kudo, C; Ayata, C				Hoffmann, Ulrike; Dilekoz, Ergin; Kudo, Chiho; Ayata, Cenk			Gabapentin suppresses cortical spreading depression susceptibility	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cortex; electrophysiology; gabapentin; rat; spreading depression	CALCIUM-CHANNEL; BRAIN-INJURY; DEPOLARIZATIONS; DRUG; RATS; NEURONTIN; BLOCKADE; PLASMA	Cortical spreading depression (CSD) is an intense depolarization wave implicated in the pathophysiology of brain injury states and migraine aura. As Ca(v)2.1 channels modulate CSD susceptibility, we tested gabapentin, which inhibits Ca(v)2.1 through high-affinity binding to its alpha(2)delta subunit, on CSD susceptibility in anesthetized rats. Gabapentin, 100 or 200 mg/kg, elevated the electrical threshold for CSD and diminished recurrent CSDs evoked by topical KCl, when administered 1 hour before testing. With its favorable safety and tolerability profile, gabapentin may have a role in suppression of injury depolarizations in stroke, intracranial hemorrhage, and traumatic brain injury. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 1588-1592; doi:10.1038/jcbfm.2010.92; published online 30 June 2010	[Hoffmann, Ulrike; Dilekoz, Ergin; Kudo, Chiho; Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neurovasc Res Lab, Charlestown, MA 02129 USA; [Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Stroke Serv & Neurosci Intens Care Unit,Dept Neur, Charlestown, MA 02129 USA		Ayata, C (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neurovasc Res Lab, 149 13th St,Room 6408, Charlestown, MA 02129 USA.	cayata@partners.org			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061505, NS055104]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [HO 4211/1-1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS055104, R01NS061505] Funding Source: NIH RePORTER	This work was supported by the National Institute of Health (NS061505 and NS055104, Ayata) and Deutsche Forschungsgemeinschaft (HO 4211/1-1, Hoffmann).	Ayata C, 2006, ANN NEUROL, V59, P652, DOI 10.1002/ana.20778; Dooley DJ, 2007, TRENDS PHARMACOL SCI, V28, P75, DOI 10.1016/j.tips.2006.12.006; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hendrich J, 2008, P NATL ACAD SCI USA, V105, P3628, DOI 10.1073/pnas.0708930105; Hunter JC, 1997, EUR J PHARMACOL, V324, P153, DOI 10.1016/S0014-2999(97)00070-8; Kunkler PE, 2004, HIPPOCAMPUS, V14, P356, DOI 10.1002/hipo.10181; RADULOVIC LL, 1995, DRUG METAB DISPOS, V23, P441; Richter F, 2002, NEUROSCI LETT, V334, P123, DOI 10.1016/S0304-3940(02)01120-5; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Shin HK, 2006, J CEREBR BLOOD F MET, V26, P1018, DOI 10.1038/sj.jcbfm.9600252; STEWART BH, 1993, PHARMACEUT RES, V10, P276, DOI 10.1023/A:1018951214146; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; van Hooft JA, 2002, EUR J PHARMACOL, V449, P221, DOI 10.1016/S0014-2999(02)02044-7; WELTY DF, 1993, EPILEPSY RES, V16, P175, DOI 10.1016/0920-1211(93)90078-L; Williams AJ, 2006, J PHARMACOL EXP THER, V318, P947, DOI 10.1124/jpet.106.105999	16	30	31	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2010	30	9					1588	1592		10.1038/jcbfm.2010.92			5	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	646SF	WOS:000281562300005	20588320	Green Published, Bronze			2022-02-06	
J	Bishop, GM; Scheiber, IF; Dringen, R; Robinson, SR				Bishop, Glenda M.; Scheiber, Ivo F.; Dringen, Ralf; Robinson, Stephen R.			Synergistic accumulation of iron and zinc by cultured astrocytes	JOURNAL OF NEURAL TRANSMISSION			English	Article						Zinc; Astrocyte; NTBI; Zip14; DMT1	TRANSPORT PROTEINS; ZNT-1 EXPRESSION; MESSENGER-RNA; INDUCED DEATH; FERROUS IRON; BRAIN; TOXICITY; MECHANISMS; NEURONS; CELLS	Iron and zinc are essential for normal brain function, yet the mechanisms used by astrocytes to scavenge non-transferrin-bound iron (NTBI) and zinc are not well understood. Ischaemic stroke, traumatic brain injury and Alzheimer's disease are associated with perturbations in the metabolism of NTBI and zinc, suggesting that these two metals may collectively contribute to pathology. The present study has investigated the accumulation of NTBI and zinc by rat primary astrocyte cultures. It was found that astrocytes express mRNA for both divalent metal transporter 1 (DMT1) and Zip14, indicating the potential for these transporters to contribute to the accumulation of NTBI and zinc by these cells. Astrocytes were found to accumulate iron from ferric chloride in a time- and dose-dependent manner, and the rate of accumulation was strongly stimulated by co-incubation with zinc acetate. In addition, cultured astrocytes rapidly accumulated zinc from zinc acetate, and this accumulation was stimulated by co-incubation with ferric chloride. Because a synergistic stimulation of iron and zinc accumulation is inconsistent with the known properties of DMT1 and Zip14, the present results suggest that additional mechanisms assist astrocytes to scavenge iron and zinc when they are present together in the extracellular compartment. These mechanisms may be involved in disorders that involve elevations in the extracellular concentrations of these metal ions.	[Bishop, Glenda M.; Dringen, Ralf; Robinson, Stephen R.] Monash Univ, Sch Psychol & Psychiat, Blood Brain Interact Grp, Clayton, Vic 3800, Australia; [Scheiber, Ivo F.; Dringen, Ralf] Univ Bremen, Ctr Biomol Interact Bremen, Fac Biol Chem 2, Bremen, Germany; [Scheiber, Ivo F.; Dringen, Ralf] Univ Bremen, Ctr Environm Res & Sustainable Technol, Bremen, Germany		Bishop, GM (corresponding author), Monash Univ, Sch Psychol & Psychiat, Blood Brain Interact Grp, Wellington Rd, Clayton, Vic 3800, Australia.	glenda.bishop@monash.edu	Robinson, Stephen R/B-7155-2013; Robinson, Stephen R./AAU-3219-2021; Bishop, Glenda M/G-6031-2010	Robinson, Stephen R./0000-0002-0987-0075; Dringen, Ralf/0000-0001-7869-1305; Bishop, Glenda/0000-0002-2736-0415	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [284393]; NeuroSciences Victoria; NHMRCNational Health and Medical Research Council of Australia [334129]; School of Psychology and Psychiatry, Monash UniversityMonash University	GMB was supported by a National Health and Medical Research Council Peter Doherty Fellowship (ID: 284393), and RD was supported by NeuroSciences Victoria for a Senior Research Fellowship. This work was supported by an NHMRC Project Grant (ID: 334129) to SRR and RD and also by the School of Psychology and Psychiatry, Monash University.	ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Attieh ZK, 1999, J BIOL CHEM, V274, P1116, DOI 10.1074/jbc.274.2.1116; Belloni-Olivi L, 2009, J NEUROSCI RES, V87, P3221, DOI 10.1002/jnr.22144; Bishop GM, 2007, FREE RADICAL BIO MED, V42, P1222, DOI 10.1016/j.freeradbiomed.2007.01.022; Bishop GM, 2002, DEV NEUROSCI-BASEL, V24, P184, DOI 10.1159/000065696; Bishop GM, 2001, BRAIN RES, V907, P175, DOI 10.1016/S0006-8993(01)02303-4; Burdo JR, 2003, BIOMETALS, V16, P63, DOI 10.1023/A:1020718718550; Chowanadisai W, 2005, J NUTR, V135, P1002, DOI 10.1093/jn/135.5.1002; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; Crichton RR, 2002, J INORG BIOCHEM, V91, P9, DOI 10.1016/S0162-0134(02)00461-0; Deng ZP, 2009, BIOMETALS, V22, P803, DOI 10.1007/s10534-009-9227-2; Dineley KE, 2000, NEUROBIOL DIS, V7, P310, DOI 10.1006/nbdi.2000.0303; Dringen R, 1998, BRAIN RES PROTOC, V2, P223, DOI 10.1016/S1385-299X(97)00047-0; Dringen R, 2007, NEUROCHEM RES, V32, P1884, DOI 10.1007/s11064-007-9375-0; Erikson KM, 2006, NEUROTOXICOLOGY, V27, P125, DOI 10.1016/j.neuro.2005.07.003; FREDERICKSON CJ, 1988, BRAIN RES, V446, P383, DOI 10.1016/0006-8993(88)90899-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Gaasch JA, 2007, NEUROCHEM RES, V32, P1686, DOI 10.1007/s11064-007-9313-1; Gaasch JA, 2007, NEUROCHEM RES, V32, P1196, DOI 10.1007/s11064-007-9290-4; Gao J, 2008, J BIOL CHEM, V283, P21462, DOI 10.1074/jbc.M803150200; Girijashanker K, 2008, MOL PHARMACOL, V73, P1413, DOI 10.1124/mol.107.043588; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P341; Hoepken HH, 2004, J NEUROCHEM, V88, P1194, DOI 10.1046/j.1471-4159.2003.02236.x; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Jeong SY, 2003, J BIOL CHEM, V278, P27144, DOI 10.1074/jbc.M301988200; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kramer KK, 1996, TOXICOL APPL PHARM, V136, P94, DOI 10.1006/taap.1996.0011; Kress GJ, 2002, J NEUROSCI, V22, P5848; Lin AMY, 2001, FREE RADICAL BIO MED, V30, P225, DOI 10.1016/S0891-5849(00)00464-0; Lipscomb DC, 1998, STROKE, V29, P487, DOI 10.1161/01.STR.29.2.487; Liuzzi JP, 2006, P NATL ACAD SCI USA, V103, P13612, DOI 10.1073/pnas.0606424103; Lovell MA, 2009, J ALZHEIMERS DIS, V16, P471, DOI 10.3233/JAD-2009-0992; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mackenzie B, 2006, PFLUG ARCH EUR J PHY, V451, P544, DOI 10.1007/s00424-005-1494-3; Marciani P, 2004, J MEMBRANE BIOL, V197, P91, DOI 10.1007/s00232-003-0644-9; McCall KA, 2000, J NUTR, V130, p1437S, DOI 10.1093/jn/130.5.1437S; Meguro R, 2008, ARCH HISTOL CYTOL, V71, P205, DOI 10.1679/aohc.71.205; Nolte C, 2004, GLIA, V48, P145, DOI 10.1002/glia.20065; Norgaard-Nielsen K, 2006, HANDB EXP PHARM, V175, P1; Oudit GY, 2006, J MOL MED, V84, P349, DOI 10.1007/s00109-005-0029-x; Riemer J, 2004, ANAL BIOCHEM, V331, P370, DOI 10.1016/j.ab.2004.03.049; Robinson SR, 2001, J NEUROSCI RES, V66, P972, DOI 10.1002/jnr.10057; Sheline CT, 2004, GLIA, V46, P18, DOI 10.1002/glia.10313; Simovich M, 2003, AM J HEMATOL, V74, P32, DOI 10.1002/ajh.10383; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tiffany-Castiglioni E, 2001, NEUROTOXICOLOGY, V22, P577, DOI 10.1016/S0161-813X(01)00050-X; Tulpule K, 2010, J NEUROSCI RES, V88, P563, DOI 10.1002/jnr.22217; Varea E, 2006, GLIA, V54, P304, DOI 10.1002/glia.20382; Wang XS, 2001, J NEUROCYTOL, V30, P353, DOI 10.1023/A:1014464514793; Waring P, 2005, ARCH BIOCHEM BIOPHYS, V434, P33, DOI 10.1016/j.abb.2004.08.001	51	30	31	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	JUL	2010	117	7					809	817		10.1007/s00702-010-0420-9			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	619XT	WOS:000279464300002	20549524				2022-02-06	
J	Pollonini, L; Pophale, S; Situ, N; Wu, MH; Frye, RE; Leon-Carrion, J; Zouridakis, G				Pollonini, Luca; Pophale, Swaroop; Situ, Ning; Wu, Meng-Hung; Frye, Richard E.; Leon-Carrion, Jose; Zouridakis, George			Information Communication Networks in Severe Traumatic Brain Injury	BRAIN TOPOGRAPHY			English	Article; Proceedings Paper	Workshop on Cortical Network Analysis with Neuroelectromagnetic and Hemodynamic Signals	MAY, 2009	Univ Rome Sapienza, Rome, ITALY		Univ Rome Sapienza	Severe neurocognitive disorder; Minimally conscious state; Vegetative state; Granger causality; Functional connectivity analysis		In this study we explored the use of coherence and Granger causality (GC) to separate patients in minimally conscious state (MCS) from patients with severe neurocognitive disorders (SND) that show signs of awareness. We studied 16 patients, 7 MCS and 9 SND with age between 18 and 49 years. Three minutes of ongoing electroencephalographic (EEG) activity was obtained at rest from 19 standard scalp locations, while subjects were alert but kept their eyes closed. GC was formulated in terms of linear autoregressive models that predict the evolution of several EEG time series, each representing the activity of one channel. The entire network of causally connected brain areas can be summarized as a graph of incompletely connected nodes. The 19 channels were grouped into five gross anatomical regions, frontal, left and right temporal, central, and parieto-occipital, while data analysis was performed separately in each of the five classical EEG frequency bands, namely delta, theta, alpha, beta, and gamma. Our results showed that the SND group consistently formed a larger number of connections compared to the MCS group in all frequency bands. Additionally, the number of connections in the delta band (0.1-4 Hz) between the left temporal and parieto-occipital areas was significantly different (P < 0.1%) in the two groups. Furthermore, in the beta band (12-18 Hz), the input to the frontal areas from all other cortical areas was also significantly different (P < 0.1%) in the two groups. Finally, classification of the subjects into distinct groups using as features the number of connections within and between regions in all frequency bands resulted in 100% classification accuracy of all subjects. The results of this study suggest that analysis of brain connectivity networks based on GC can be a highly accurate approach for classifying subjects affected by severe traumatic brain injury.	[Pollonini, Luca; Pophale, Swaroop; Situ, Ning; Wu, Meng-Hung; Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Engn Technol, Houston, TX 77204 USA; [Pollonini, Luca; Pophale, Swaroop; Situ, Ning; Wu, Meng-Hung; Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Comp Sci, Houston, TX 77204 USA; [Pollonini, Luca; Pophale, Swaroop; Situ, Ning; Wu, Meng-Hung; Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Elect & Comp Engn, Houston, TX 77204 USA; [Frye, Richard E.] Univ Texas Hlth Sci Ctr, Dept Pediat, Div Child & Adolescent Neurol, Houston, TX USA; [Frye, Richard E.] Univ Texas Hlth Sci Ctr, Childrens Learning Inst, Houston, TX USA; [Leon-Carrion, Jose] Univ Seville, Human Neuropsychol Lab, Seville, Spain; [Leon-Carrion, Jose] Ctr Brain Injury Rehabil CRECER, Seville, Spain		Zouridakis, G (corresponding author), Univ Houston, Biomed Imaging Lab, Dept Engn Technol, 218 Philip G Hoffman Hall, Houston, TX 77204 USA.	zouridakis@uh.edu	Pollonini, Luca/J-9274-2014; Frye, Richard/AAB-5543-2020; Zouridakis, George/R-8876-2019	Pollonini, Luca/0000-0003-2955-6355; Zouridakis, George/0000-0002-7770-9857			Box G. E. P., 2008, TIME SERIES ANAL FOR; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Cui J, 2008, NEURAL NETWORKS, V21, P1094, DOI 10.1016/j.neunet.2008.05.007; FALLANI FD, J BIFURCAT IN PRESS; Frye R. E., 2007, SOC NEUR M SAN DIEG; FRYE RE, 2009, COMPARISON IN PRESS; FRYE RE, 2007, P WSEAS INT C COMP C; Gonzalez RS, 1977, DIGITAL IMAGE PROCES; GRANGER CWJ, 1969, ECONOMETRICA, V37, P424, DOI 10.2307/1912791; Iriarte J, 2003, J CLIN NEUROPHYSIOL, V20, P249, DOI 10.1097/00004691-200307000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leon-Carrion J, 2008, CLIN NEUROPHYSIOL, V119, P1506, DOI 10.1016/j.clinph.2008.03.030; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; POPHALE S, 2008, THESIS U HOUSTON; Robertson RH, 2008, NEUROPSYCHOL REHABIL, V18, P236, DOI 10.1080/09602010701734438; Seth AK, 2005, NETWORK-COMP NEURAL, V16, P35, DOI 10.1080/09548980500238756; Seth AK, 2007, NEURAL COMPUT, V19, P910, DOI 10.1162/neco.2007.19.4.910; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; TEASDALE G, 1974, LANCET, V2, P81	19	30	30	0	9	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0896-0267	1573-6792		BRAIN TOPOGR	Brain Topogr.	JUN	2010	23	2			SI		221	226		10.1007/s10548-010-0139-9			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	599TI	WOS:000277935900015	20224956				2022-02-06	
J	Cho, Y; Shi, RY; Ivanisevic, A; Ben Borgens, R				Cho, Youngnam; Shi, Riyi; Ivanisevic, Albena; Ben Borgens, Richard			Functional Silica Nanoparticle-Mediated Neuronal Membrane Sealing Following Traumatic Spinal Cord Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						nanoparticles; nanotechnology; spinal cord injury; membrane sealing; PEG	DRUG-DELIVERY SYSTEM; OXIDATIVE STRESS; LIPID-PEROXIDATION; MOLECULAR REPAIR; NERVE MEMBRANES; PC12 CELLS; ACROLEIN; RECOVERY; THERAPY; NANOTECHNOLOGY	The mechanical damage to neurons and their processes induced by spinal cord injury (SCI) causes a progressive cascade of pathophysiological events beginning with the derangement of ionic equilibrium and collapse of membrane permeability. This leads to a cumulative deterioration of neurons, axons, and the tissue architecture of the cord. We have previously shown that the application of the hydrophilic polymer polyethylene glycol (PEG) following spinal cord or brain injury can rapidly restore membrane integrity, reduce oxidative stress, restore impaired axonal conductivity, and mediate functional recovery in rats, guinea pigs, and dogs. However there are limits to both the concentration and the molecular weight of the application that do not permit the broadest recovery across an injured animal population. In this study, PEG-decorated silica nanoparticles (PSiNPs) sealed cells, as shown by the significantly reduced leakage of lactate dehydrogenase from damaged cells compared with uncoated particles or PEG alone. Further in vivo tests showed that PSiNPs also significantly reduced the formation of reactive oxygen species and the process of lipid peroxidation of the membrane. Fabrication of PSiNPs containing embedded dyes also revealed targeting of the particles to damaged, but not undamaged, spinal cord tissues. In an in vivo crush/contusion model of guinea pig SCI, every animal but one injected with PSiNPs recovered conduction through the cord lesion, whereas none of the control animals did. These findings suggest that the use of multifunctional nanoparticles may offer a novel treatment approach for spinal cord injury, traumatic brain injury, and possibly neuro-degenerative disorders. (C) 2009 Wiley-Liss, Inc.	[Ben Borgens, Richard] Purdue Univ, Sch Vet Med, Weldon Sch Biomed Engn, Ctr Paralysis Res, W Lafayette, IN 47907 USA; [Ivanisevic, Albena] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA		Ben Borgens, R (corresponding author), Purdue Univ, Sch Vet Med, Weldon Sch Biomed Engn, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	cpr@purdue.edu			CPR (State of Indiana) [HB 1440]	Contract grant sponsor: General Funds from the CPR (State of Indiana HB 1440); Contract grant sponsor: Mrs. Mari Hulman George.	Barbe C, 2004, ADV MATER, V16, P1959, DOI 10.1002/adma.200400771; Borgens RB, 2000, FASEB J, V14, P27, DOI 10.1096/fasebj.14.1.27; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 2003, RESTORING FUNCTION I; Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014; Brent J, 2001, DRUGS, V61, P979, DOI 10.2165/00003495-200161070-00006; Caravati EM, 2005, CLIN TOXICOL, V43, P327, DOI 10.1080/07313820500184971; CHO Y, 2008, SMALL IN PRESS; Cho Y, 2008, NANOMEDICINE-UK, V3, P507, DOI 10.2217/17435889.3.4.507; Coleman WP, 2000, J SPINAL DISORD, V13, P185, DOI 10.1097/00002517-200006000-00001; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; Donaldson J, 2002, NEUROSURGERY, V50, P147, DOI 10.1097/00006123-200201000-00023; Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088; Emerich DF, 2006, BIOMOL ENG, V23, P171, DOI 10.1016/j.bioeng.2006.05.026; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; Farokhzad OC, 2006, ADV DRUG DELIVER REV, V58, P1456, DOI 10.1016/j.addr.2006.09.011; Gelperina S, 2005, AM J RESP CRIT CARE, V172, P1487, DOI 10.1164/rccm.200504-613PP; GUTTERIDGE JMC, 1994, ANN NY ACAD SCI, V738, P201; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Kaminskas LM, 2004, ORG BIOMOL CHEM, V2, P2578, DOI 10.1039/b408796h; Koo YEL, 2006, ADV DRUG DELIVER REV, V58, P1556, DOI 10.1016/j.addr.2006.09.012; Koob Andrew O, 2008, J Biol Eng, V2, P9, DOI 10.1186/1754-1611-2-9; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; LEE RC, 1994, ANN NY ACAD SCI, V720, P239, DOI 10.1111/j.1749-6632.1994.tb30453.x; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Liu YY, 2007, COLLOID SURFACE B, V58, P180, DOI 10.1016/j.colsurfb.2007.03.005; Liu-Snyder P, 2007, J EXP BIOL, V210, P1455, DOI 10.1242/jeb.02756; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P209, DOI 10.1002/jnr.20863; Liu-Snyder P, 2006, J NEUROSCI RES, V84, P219, DOI 10.1002/jnr.20862; Luo H, 2004, NEUROCHEM INT, V44, P475, DOI 10.1016/j.neuint.2003.09.006; Luo J, 2005, NEUROCHEM INT, V46, P243, DOI 10.1016/j.neuint.2004.09.001; Luo J, 2005, NEUROCHEM INT, V47, P449, DOI 10.1016/j.neuint.2005.07.002; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Mohanraj V. J., 2006, Tropical Journal of Pharmaceutical Research, V5, P561; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; Pathak S, 2006, J NEUROSCI, V26, P1893, DOI 10.1523/JNEUROSCI.3847-05.2006; Santra S, 2001, ANAL CHEM, V73, P4988, DOI 10.1021/ac010406+; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; SHI R, 2000, SOC NEUR ABSTR, V26, P1834; SHI R, 1999, J NEUROTRAUM, V16, P1014; Silva GA, 2006, NAT REV NEUROSCI, V7, P65, DOI 10.1038/nrn1827; Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; Wang L, 2006, ANAL CHEM, V78, P646, DOI 10.1021/ac0693619; Working PK, 1997, ACS SYM SER, V680, P45; Xu YH, 2007, J MAGN MAGN MATER, V311, P131, DOI 10.1016/j.jmmm.2006.11.174; Yan JL, 2007, NANO TODAY, V2, P44, DOI 10.1016/S1748-0132(07)70086-5; Zhao XJ, 2004, ADV MATER, V16, P173, DOI 10.1002/adma.200305622	58	30	31	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAY 15	2010	88	7					1433	1444		10.1002/jnr.22309			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	585VP	WOS:000276858600005	19998478				2022-02-06	
J	Fortune, PM; Shann, F				Fortune, Peter-Marc; Shann, Frank			The motor response to stimulation predicts outcome as well as the full Glasgow Coma Scale in children with severe head injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						brain injuries; Glasgow Coma Scale; Glasgow Outcome Scale; motor activity	EMERGENCY-DEPARTMENT; BRAIN-INJURY; PRACTICAL SCALE; ISCHEMIC COMA; SCORE; TRAUMA; CONSCIOUSNESS; RELIABILITY; TRIAGE; DAMAGE	Objectives: To evaluate how well the full Glasgow Coma Scale and the motor response, which is a subscore of the Glasgow Coma Scale, predict the outcome in children who have sustained a traumatic brain injury. The best scores in the first 24 hrs were used. Design: A retrospective observational study. Setting: A pediatric intensive care unit. Patients: Children admitted between January 1997 and December 1999. Interventions: None. Measurements and Main Results: Recovery with independent function (good outcome), or death, persistent coma, or dependent (bad outcome) at 6 months after the injury. Complete information was available for 130 patients. Both the full Glasgow Coma Scale and the motor response predicted outcome well: the area under the receiver operating characteristic plot was 0.88 (95% confidence interval, 0.82-0.95) for the full score and 0.89 (0.82-0.95) for the motor response. Conclusions: Both the full Glasgow Coma Scale score and the motor response provide a useful indication of long-term outcome, although neither score is sufficiently accurate to be used to limit treatment. The full Glasgow Coma Scale does not have a linear relationship with mortality, and there is poor interobserver agreement. The motor response should be used in children in preference to the full Glasgow Coma Scale; the predictive power is equivalent to the full Glasgow Coma Scale, there is a linear relationship to mortality, and it is easier to collect accurately. (Pediatr Crit Care Med 2010; 11:339-342)	[Fortune, Peter-Marc] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England; [Shann, Frank] Royal Childrens Hosp, Melbourne, Vic, Australia		Fortune, PM (corresponding author), Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England.	peter-marc.fortune@manchester.ac.uk					Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; *AM ASS SURG TRAUM, 2003, PEDIAT CRIT CARE M S, V4, pS1; Bassi S, 1999, BRIT J NEUROSURG, V13, P526; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bullock M Ross, 2002, Neurosurg Focus, V13, pECP1; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1975, LANCET, V1, P480; Kerby JD, 2007, J TRAUMA, V63, P1026, DOI 10.1097/TA.0b013e318157d9e8; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SACCO RL, 1990, ARCH NEUROL-CHICAGO, V47, P1181, DOI 10.1001/archneur.1990.00530110035013; Servadei F, 2006, LANCET, V367, P548, DOI 10.1016/S0140-6736(06)68197-X; TEASDALE G, 1974, LANCET, V2, P81; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019; Zandbergen EGJ, 2001, INTENS CARE MED, V27, P1661, DOI 10.1007/s001340101076	26	30	30	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2010	11	3					339	342		10.1097/PCC.0b013e3181c014ab			4	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	593WO	WOS:000277493200003	19838138				2022-02-06	
J	Doering, P; Stoltenberg, M; Penkowa, M; Rungby, J; Larsen, A; Danscher, G				Doering, Peter; Stoltenberg, Meredin; Penkowa, Milena; Rungby, Jorgen; Larsen, Agnete; Danscher, Gorm			Chemical Blocking of Zinc Ions in CNS Increases Neuronal Damage Following Traumatic Brain Injury (TBI) in Mice	PLOS ONE			English	Article							ENRICHED ZEN TERMINALS; HIPPOCAMPAL-NEURONS; CONTAINING PATHWAYS; MOUSE-BRAIN; CELL-DEATH; IN-VIVO; LOCALIZATION; BOUTONS; TRANSLOCATION; ACCUMULATION	Background: Traumatic brain injury (TBI) is one of the leading causes of disability and death among young people. Although much is already known about secondary brain damage the full range of brain tissue responses to TBI remains to be elucidated. A population of neurons located in cerebral areas associated with higher cognitive functions harbours a vesicular zinc pool co-localized with glutamate. This zinc enriched pool of synaptic vesicles has been hypothesized to take part in the injurious signalling cascade that follows pathological conditions such as seizures, ischemia and traumatic brain injury. Pathological release of excess zinc ions from pre-synaptic vesicles has been suggested to mediate cell damage/death to postsynaptic neurons. Methodology/Principal Findings: In order to substantiate the influence of vesicular zinc ions on TBI, we designed a study in which damage and zinc movements were analysed in several different ways. Twenty-four hours after TBI ZnT3-KO mice (mice without vesicular zinc) were compared to littermate Wild Type (WT) mice (mice with vesicular zinc) with regard to histopathology. Furthermore, in order to evaluate a possible neuro-protective dimension of chemical blocking of vesicular zinc, we treated lesioned mice with either DEDTC or selenite. Our study revealed that chemical blocking of vesicular zinc ions, either by chelation with DEDTC or accumulation in zinc-selenium nanocrystals, worsened the effects on the aftermath of TBI in the WT mice by increasing the number of necrotic and apoptotic cells within the first 24 hours after TBI, when compared to those of chemically untreated WT mice. Conclusion/Significance: ZnT3-KO mice revealed more damage after TBI compared to WT controls. Following treatment with DEDTC or selenium an increase in the number of both dead and apoptotic cells were seen in the controls within the first 24 hours after TBI while the degree of damage in the ZnT3-KO mice remained largely unchanged. Further analyses revealed that the damage development in the two mouse strains was almost identical after either zinc chelation or zinc complexion therapy.	[Doering, Peter; Stoltenberg, Meredin; Larsen, Agnete; Danscher, Gorm] Univ Aarhus, Inst Anat, Aarhus, Denmark; [Penkowa, Milena] Univ Copenhagen, Panum Inst, Fac Hlth Sci, Sect Neuroprotect,Dept Neurosci & Pharmacol, DK-2200 Copenhagen, Denmark; [Rungby, Jorgen] Univ Aarhus, Dept Pharmacol, Aarhus, Denmark		Doering, P (corresponding author), Univ Aarhus, Inst Anat, Aarhus, Denmark.	pdj@neuro.au.dk	Rungby, Jorgen/AAQ-4332-2021	Larsen, Agnete/0000-0001-8765-8443	Augustinus Foundation; Aase and Ejnar Danielsen Foundation; Aarhus University Research Foundation; Beckett Foundation; Danish Medical Association; Lundbeck FoundationLundbeckfonden; Direktor Jacob Madsen og Hustrus Fond	This study was supported by The Augustinus Foundation, The Aase and Ejnar Danielsen Foundation, The Aarhus University Research Foundation, The Beckett Foundation, The Danish Medical Association Research Fund, The Lundbeck Foundation and Direktor Jacob Madsen og Hustrus Fond. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Bitanihirwe BKY, 2009, SYNAPSE, V63, P1029, DOI 10.1002/syn.20683; Brown CE, 2004, J COMP NEUROL, V479, P156, DOI 10.1002/cne.20308; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; Cole TB, 2000, EPILEPSY RES, V39, P153, DOI 10.1016/S0920-1211(99)00121-7; Cote A, 2005, J PHYSIOL-LONDON, V566, P821, DOI 10.1113/jphysiol.2005.089458; DANSCHER G, 1982, HISTOCHEMISTRY, V76, P281, DOI 10.1007/BF00543951; Danscher G, 2005, J HISTOCHEM CYTOCHEM, V53, P141, DOI 10.1369/jhc.4R6460.2005; Danscher G, 2001, NEUROSCIENCE, V105, P941, DOI 10.1016/S0306-4522(01)00243-3; DANSCHER G, 1975, BRAIN RES, V85, P522, DOI 10.1016/0006-8993(75)90825-2; DANSCHER G, 1973, EXP BRAIN RES, V16, P521, DOI 10.1007/BF00234478; DANSCHER G, 1976, THESIS AARHUS U; DANSCHER G, 1984, NEUROBIOLOGY ZINC B, P177; Danscher G, 2006, PROG HISTOCHEM CYTO, V41, P57, DOI 10.1016/j.proghi.2006.06.001; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Doering P, 2007, NEUROSCIENCE, V150, P93, DOI 10.1016/j.neuroscience.2007.09.066; Dominguez MI, 2006, EPILEPSIA, V47, P887, DOI 10.1111/j.1528-1167.2006.00501.x; Frederickson CJ, 2005, J ALZHEIMERS DIS, V8, P155; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; Frederickson CJ, 2004, J NEUROSCI METH, V139, P79, DOI 10.1016/j.jneumeth.2004.04.033; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Hellmich HL, 2008, NEUROSCI LETT, V440, P155, DOI 10.1016/j.neulet.2008.05.068; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; Ismail T, 2008, NEUROSCIENCE, V157, P697, DOI 10.1016/j.neuroscience.2008.09.011; Kitamura Y, 2006, J PHARMACOL SCI, V100, P142, DOI 10.1254/jphs.FP0050805; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Larsen A, 2008, HISTOCHEM CELL BIOL, V130, P681, DOI 10.1007/s00418-008-0448-1; Lee JM, 2002, NEUROSCIENCE, V115, P871, DOI 10.1016/S0306-4522(02)00513-4; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lee JY, 2000, J NEUROSCI, V20; Linkous DH, 2008, J HISTOCHEM CYTOCHEM, V56, P3, DOI 10.1369/jhc.6A7035.2007; Maret W, 2009, BIOMETALS, V22, P149, DOI 10.1007/s10534-008-9186-z; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; Paoletti P, 2009, NEUROSCIENCE, V158, P126, DOI 10.1016/j.neuroscience.2008.01.061; PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9; PerezClausell J, 1996, J CHEM NEUROANAT, V11, P99, DOI 10.1016/0891-0618(96)00131-7; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SLOMIANKA L, 1990, NEUROSCIENCE, V38, P843, DOI 10.1016/0306-4522(90)90076-G; SLOMIANKA L, 1992, NEUROSCIENCE, V48, P325, DOI 10.1016/0306-4522(92)90494-M; Sorensen JC, 1998, BRAIN RES, V812, P265, DOI 10.1016/S0006-8993(98)00943-3; Stoltenberg M, 2007, NEUROSCIENCE, V150, P357, DOI 10.1016/j.neuroscience.2007.09.025; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2001, BRAIN RES, V895, P25, DOI 10.1016/S0006-8993(01)01996-5; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Takeda A, 2000, BRAIN RES REV, V34, P137, DOI 10.1016/S0165-0173(00)00044-8; Takeda A, 2001, BIOMETALS, V14, P343, DOI 10.1023/A:1012982123386; Valente T, 2002, MOL CELL NEUROSCI, V21, P189, DOI 10.1006/mcne.2002.1159; Wang ZY, 2002, NEUROSCI LETT, V321, P37, DOI 10.1016/S0304-3940(01)02560-5; Wang ZY, 2001, BRAIN RES, V921, P165, DOI 10.1016/S0006-8993(01)03114-6; Wei G, 2004, NEUROSCIENCE, V125, P867, DOI 10.1016/j.neuroscience.2004.03.011; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Yeiser EC, 2002, NUTR NEUROSCI, V5, P345, DOI 10.1080/1028415021000033811; Yeiser EC, 1999, NEUROSCI LETT, V277, P75, DOI 10.1016/S0304-3940(99)00825-3	55	30	33	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2010	5	4							e10131	10.1371/journal.pone.0010131			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	580WU	WOS:000276482100027	20396380	gold, Green Published, Green Submitted			2022-02-06	
J	Osuka, S; Matsushita, A; Yamamoto, T; Saotome, K; Isobe, T; Nagatomo, Y; Masumoto, T; Komatsu, Y; Ishikawa, E; Matsumura, A				Osuka, Satoru; Matsushita, Akira; Yamamoto, Tetsuya; Saotome, Kousaku; Isobe, Tomonori; Nagatomo, Yasushi; Masumoto, Tomohiko; Komatsu, Yoji; Ishikawa, Eiichi; Matsumura, Akira			Evaluation of ventriculomegaly using diffusion tensor imaging: correlations with chronic hydrocephalus and atrophy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						diffusion tensor imaging; ventriculomegaly; hydrocephalus; diffusion anisotropy; caudate nucleus	NORMAL-PRESSURE HYDROCEPHALUS; WHITE-MATTER; CSF DYNAMICS; BRAIN; DIAGNOSIS; PATHOLOGY; TISSUES; MRI	Object. Ventriculomegaly is a common imaging finding in many types of conditions. It is difficult to determine whether it is related to true hydrocephalus or to an atrophic process by using only imaging procedures such as MR imaging after traumatic injury, stroke, or infectious disease. Diffusion tensor (DT) imaging can distinguish the compression characteristics of white matter, indicating that increased diffusion anisotropy may be related to white matter compression. In this preliminary study, the authors compared the DT imaging findings of ventriculomegaly with those of chronic hydrocephalus or atrophy to clarify the potential of diffusion anisotropy in the identification of hydrocephalus. Methods. Ten patients with chronic hydrocephalus, 8 patients with atrophy (defined by conventional devices and surgical outcome), and 14 healthy volunteers underwent DT imaging. Images were acquired before and after shunting or once in cases without shunting. The fractional anisotropy (FA) values at many points around the lateral ventricle were evaluated. Results. The FA patterns around the lateral ventricle in the chronic hydrocephalus and atrophy groups were different. Especially in the caudate nucleus. FA was increased in the chronic hydrocephalus group compared with the atrophy group. Furthermore, the FA values returned to normal levels after shunt placement. Conclusions. Assessment of the FA value of the caudate nucleus may be an important, less invasive method for distinguishing true hydrocephalus from ventriculomegaly. Further research in a large number of patients is needed to verify the diagnostic ability of this method. (DOI: 10.3171/2009.7.JNS09550)	[Ishikawa, Eiichi] Univ Tsukuba, Dept Neurosurg, Inst Clin Med, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; [Masumoto, Tomohiko] Univ Tsukuba, Dept Radiol, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan; [Saotome, Kousaku] Tsukuba Med Ctr Hosp, Dept Radiol Technol, Tsukuba, Ibaraki, Japan; [Komatsu, Yoji] Tsukuba Med Ctr Hosp, Dept Neurosurg, Tsukuba, Ibaraki, Japan; [Nagatomo, Yasushi] Katsuta Hosp Mito GammaHouse, Dept Neurosurg, Hitachi, Ibaraki, Japan		Ishikawa, E (corresponding author), Univ Tsukuba, Dept Neurosurg, Inst Clin Med, Grad Sch Comprehens Human Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	e-ishikawa@md.tsukuba.ac.jp	Matsushita, Akira/I-5810-2013; Osuka, Satoru/J-6037-2013	Matsushita, Akira/0000-0003-2335-674X; 	Ministry of Health, Labour and Welfare, JapanMinistry of Health, Labour and Welfare, Japan [20B-9]	This work was supported by the research Grant No. 20B-9 for Nervous and Mental Disorders from the Ministry of Health, Labour and Welfare, Japan.	Assaf Y, 2006, AM J NEURORADIOL, V27, P1717; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Del Bigio MR, 2001, NEUROSURG CLIN N AM, V12, P639, DOI 10.1016/S1042-3680(18)30022-6; DELBIGIO MR, 1988, ACTA NEUROPATHOL, V77, P186, DOI 10.1007/BF00687430; DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666; DeVito EE, 2007, ACTA NEUROL SCAND, V116, P328, DOI 10.1111/j.1600-0404.2007.00906.x; Dixon GR, 2002, MAYO CLIN PROC, V77, P509, DOI 10.4065/77.6.509; FLETCHER JM, 1992, ARCH NEUROL-CHICAGO, V49, P818, DOI 10.1001/archneur.1992.00530320042010; GYLDENSTED C, 1977, NEURORADIOLOGY, V14, P183, DOI 10.1007/BF00496982; Hasan KM, 2009, MAGN RESON IMAGING, V27, P631, DOI 10.1016/j.mri.2008.10.007; Ishikawa M, 2008, NEUROL MED-CHIR, V48, pS1, DOI 10.2176/nmc.48.S1; Kitagaki H, 1998, AM J NEURORADIOL, V19, P1277; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Mataro M, 2007, J NEUROL NEUROSUR PS, V78, P395, DOI 10.1136/jnnp.2006.096164; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; PAGE RB, 1979, ANAT REC, V194, P83, DOI 10.1002/ar.1091940106; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.3.CO;2-A; Pickard JD, 2005, NEUROPSYCHOL REHABIL, V15, P224, DOI 10.1080/09602010443000614; Poca MA, 2002, ACT NEUR S, V81, P7; Schonberg T, 2006, NEUROIMAGE, V30, P1100, DOI 10.1016/j.neuroimage.2005.11.015; Segev Y, 2001, AM J NEURORADIOL, V22, P1674; Sotak CH, 2002, NMR BIOMED, V15, P561, DOI 10.1002/nbm.786; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; TORVIK A, 1977, ACTA NEUROPATHOL, V38, P21, DOI 10.1007/BF00691271; Wieshmann UC, 2000, J NEUROL NEUROSUR PS, V68, P501, DOI 10.1136/jnnp.68.4.501	26	30	30	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2010	112	4					832	839		10.3171/2009.7.JNS09550			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	574ZQ	WOS:000276033200027	19698041				2022-02-06	
J	Thaut, MH				Thaut, Michael H.			NEUROLOGIC MUSIC THERAPY IN COGNITIVE REHABILITATION	MUSIC PERCEPTION			English	Article						neurology; music; cognition; rehabilitation; brain	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEGLECT PATIENTS; IMPLICIT MEMORY; WORKING-MEMORY; TERM-MEMORY; DEMENTIA; RECALL; TEXT; SONG	NEUROLOGIC MUSIC THERAPY LAST CAME INTO research and clinical focus via cognitive rehabilitation. New imaging techniques studying higher cognitive functions in the human brain 'in vivo' and theoretical advancements in music and brain function have facilitated this development. There are shared cognitive and perceptual mechanisms and shared neural systems between musical cognition and parallel nonmusical cognitive functions that provide access for music to affect general nonmusical functions, such as memory, attention, and executive function. The emerging clinical literature shows substantial support for these effects in rehabilitative retraining of the injured brain. Key findings relevant for clinical applications of neurologic music therapy to cognitive rehabilitation are presented and discussed below.	Colorado State Univ, Ctr Biomed Res Mus, Ft Collins, CO 80523 USA		Thaut, MH (corresponding author), Colorado State Univ, Ctr Biomed Res Mus, Ft Collins, CO 80523 USA.	Michael.Thaut@ColoState.EDU					Baur B, 2000, NEUROCASE, V6, P415, DOI 10.1080/13554790008402712; Bhattacharya J, 2001, INT J PSYCHOPHYSIOL, V42, P287, DOI 10.1016/S0167-8760(01)00153-2; Bonnel AM, 2001, PERCEPT PSYCHOPHYS, V63, P1201, DOI 10.3758/BF03194534; BOWER GH, 1981, AM PSYCHOL, V36, P129, DOI 10.1037/0003-066X.36.2.129; Chan AS, 1998, NATURE, V396, P128, DOI 10.1038/24075; CLAUSSEN DW, 1997, CAN J MUSIC THER, V5, P55; Conway CM, 2009, CURR DIR PSYCHOL SCI, V18, P275, DOI 10.1111/j.1467-8721.2009.01651.x; Cowles A, 2003, NEUROCASE, V9, P493, DOI 10.1076/neur.9.6.493.29378; CRYSTAL HA, 1989, J NEUROL NEUROSUR PS, V52, P1415, DOI 10.1136/jnnp.52.12.1415; Cuddy LL, 2005, MED HYPOTHESES, V64, P229, DOI 10.1016/j.mehy.2004.09.005; Deutsch D., 1982, MUSIC MIND BRAIN, P119; Drake C, 2000, COGNITION, V77, P251, DOI 10.1016/S0010-0277(00)00106-2; Foster NA, 2001, EXP AGING RES, V27, P215, DOI 10.1080/036107301300208664; Frassinetti F, 2002, EXP BRAIN RES, V147, P332, DOI 10.1007/s00221-002-1262-y; Frassinetti F, 2002, J COGNITIVE NEUROSCI, V14, P62, DOI 10.1162/089892902317205320; GFELLER KE, 1983, J MUSIC THER, V20, P179, DOI 10.1093/jmt/20.4.179; Glassman RB, 1999, BRAIN RES BULL, V50, P77, DOI 10.1016/S0361-9230(99)00090-8; Grady CL, 2001, BRAIN, V124, P739, DOI 10.1093/brain/124.4.739; Halpern AR, 2000, NEUROPSYCHOLOGY, V14, P391, DOI 10.1037//0894-4105.14.3.391; Haslam C, 2002, NEUROCASE, V8, P453, DOI 10.1093/neucas/8.3.169; Hitch GJ, 1996, Q J EXP PSYCHOL-A, V49, P116, DOI 10.1080/027249896392829; Ho YC, 2003, NEUROPSYCHOLOGY, V17, P439, DOI 10.1037/0894-4105.17.3.439; HOMMEL M, 1990, ARCH NEUROL-CHICAGO, V47, P573, DOI 10.1001/archneur.1990.00530050097018; Irish M, 2006, DEMENT GERIATR COGN, V22, P108, DOI 10.1159/000093487; Jakobson LS, 2003, MUSIC PERCEPT, V20, P307, DOI 10.1525/mp.2003.20.3.307; Janata P, 2002, COGN AFFECT BEHAV NE, V2, P121, DOI 10.3758/CABN.2.2.121; JENSEN US, 2004, P SOC NEUR, P14; JONES MR, 1982, PERCEPT PSYCHOPHYS, V32, P211, DOI 10.3758/BF03206225; JONES MR, 1992, COGNITIVE BASES OF MUSICAL COMMUNICATION, P91, DOI 10.1037/10104-006; JONES MR, 1991, MEM COGNITION, V19, P8, DOI 10.3758/BF03198492; Kilgour AR, 2000, MEM COGNITION, V28, P700, DOI 10.3758/BF03198404; Klein JM, 1996, PERCEPT PSYCHOPHYS, V58, P34, DOI 10.3758/BF03205473; Kleinstauber M., 2006, J COGN REHAB, V24, P4; Large EW, 1999, PSYCHOL REV, V106, P119, DOI 10.1037/0033-295X.106.1.119; Maeller D. H., 1996, THESIS COLORADO STAT; MATZEL LD, 1988, LEARN MOTIV, V19, P317, DOI 10.1016/0023-9690(88)90044-6; Nayak S, 2000, REHABIL PSYCHOL, V45, P274, DOI 10.1037/0090-5550.45.3.274; Rainey DW, 2002, MUSIC PERCEPT, V20, P173, DOI 10.1525/mp.2002.20.2.173; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Robertson IH, 1995, NEUROREPORT, V7, P246, DOI 10.1097/00001756-199512000-00059; ROSENBAUM RS, 2004, P SOC NEUR, P14; Samson S, 2009, ANN NY ACAD SCI, V1169, P245, DOI 10.1111/j.1749-6632.2009.04555.x; Sarnthein J, 1997, NEUROL RES, V19, P107; Sohlberg M. M., 1989, ATTENTION PROCESS TR; Son GR, 2002, J NURS SCHOLARSHIP, V34, P263, DOI 10.1111/j.1547-5069.2002.00263.x; Thaut MH, 2005, ANN NY ACAD SCI, V1060, P243, DOI 10.1196/annals.1360.017; Thaut MH., 2005, RHYTHM MUSIC BRAIN S; Thaut MH, 2009, ANN NY ACAD SCI, V1169, P406, DOI 10.1111/j.1749-6632.2009.04585.x; Vanstone AD, 2010, AGING NEUROPSYCHOL C, V17, P108, DOI 10.1080/13825580903042676; Vanstone AD, 2009, ANN NY ACAD SCI, V1169, P291, DOI 10.1111/j.1749-6632.2009.04763.x; Verwey WB, 2001, ACTA PSYCHOL, V106, P69, DOI 10.1016/S0001-6918(00)00027-5; WALLACE WT, 1994, J EXP PSYCHOL LEARN, V20, P1471, DOI 10.1037/0278-7393.20.6.1471; WOLFE DE, 1993, J MUSIC THER, V30, P100, DOI 10.1093/jmt/30.2.100	53	30	30	3	79	UNIV CALIFORNIA PRESS	BERKELEY	C/O JOURNALS DIVISION, 2000 CENTER ST, STE 303, BERKELEY, CA 94704-1223 USA	0730-7829			MUSIC PERCEPT	Music Percept.	APR	2010	27	4					281	285		10.1525/MP.2010.27.4.281			5	Music; Psychology, Experimental	Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Music; Psychology	581CR	WOS:000276499200005					2022-02-06	
J	Adeleye, A; Shohami, E; Nachman, D; Alexandrovich, A; Trembovler, V; Yaka, R; Shoshan, Y; Dhawan, J; Biegon, A				Adeleye, Amos; Shohami, Esther; Nachman, Dean; Alexandrovich, Alexander; Trembovler, Victoria; Yaka, Rami; Shoshan, Yigal; Dhawan, Jasbeer; Biegon, Anat			D-Cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Glutamate; N-methyl-D-aspartate (NMDA) receptor; Neuroprotection; Head injury	CLOSED-HEAD INJURY; EXCITATORY AMINO-ACIDS; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS; NMDA ANTAGONISTS; ISCHEMIC-STROKE; DYNAMIC CHANGES; MOUSE MODEL; RAT; RECOVERY	It has been long thought that hyperactivation of N-methyl-D-aspartate (NMDA) receptors underlies neurological decline after traumatic brain injury. However, all clinical trials with NMDA receptor antagonists failed. Since NMDA receptors are down-regulated from 4 h to 2 weeks after brain injury, activation at 24 h, rather than inhibition, of these receptors, was previously shown to be beneficial in mice. Here, we tested the therapeutic window, dose regimen and mechanism of action of the NMDA receptor partial agonist D-cycloserine (DCS) in traumatic brain injury. Male mice were subjected to trauma using a weight-drop model, and administered 10 mg/kg (i.p.) DCS or vehicle once (8, 16,24, or 72 h) twice (24 and 48 h) or three times (24, 48 and 72 h). Functional recovery was assessed for up to 60 days, using a Neurological Severity Score that measures neurobehavioral parameters. In all groups in which treatment was begun at 24 or 72 h neurobehavioral function was significantly better than in the vehicle-treated groups. Additional doses, on days 2 and 3 did not further improve recovery. Mice treated at 8 h or 16 h post injury did not differ from the vehicle-treated controls. Co-administration of the NMDA receptor antagonist MK-801 completely blocked the protective effect of DCS given at 24 h. Infarct volume measured by 2,3,5-triphenyltetrazolium chloride staining at 48 h or by cresyl violet at 28 days was not affected by DCS treatment. Since DCS is used clinically for other indications, the present study offers a novel approach for treating human traumatic brain injury with a therapeutic window of at least 24 h. (C) 2009 Elsevier B.V. All rights reserved.	[Adeleye, Amos; Shohami, Esther; Nachman, Dean; Alexandrovich, Alexander; Trembovler, Victoria; Yaka, Rami] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Adeleye, Amos; Nachman, Dean; Shoshan, Yigal] Hebrew Univ Jerusalem, Hadassah Hosp, Dept Neurosurg, IL-91120 Jerusalem, Israel; [Dhawan, Jasbeer; Biegon, Anat] Brookhaven Natl Lab, Dept Med, Upton, NY 11973 USA		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	nachman, Dean/K-2920-2019		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS050285]; IDF; Israel Ministry of Defense; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER	This study was Supported by NIH grant 1R01NS050285 (A. Biegon) and, in part, by a grant from the IDF and the Israel Ministry of Defense (E. Shohami). E. Shohami is the incumbent of the Dr. Leon and Dr. Mina Deutsch Chair in Psychopharmacology at The Hebrew University, and a member of the Brettler Center for Research in Molecular Pharmacology and Therapeutics, The Hebrew University.	Alessandri B, 1996, ACT NEUR S, V67, P6; Andersen JM, 2002, BEHAV BRAIN RES, V129, P211, DOI 10.1016/S0166-4328(01)00318-7; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARTH TM, 1990, STROKE, V21, P153; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Belayev L, 2007, BRAIN RES, V1157, P146, DOI 10.1016/j.brainres.2007.04.077; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BIEGON, 2002, J NEUROCHEM, V82, P1; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; Danysz W, 1998, PHARMACOL REV, V50, P597; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; Duncan EJ, 2004, SCHIZOPHR RES, V71, P239, DOI 10.1016/j.schres.2004.03.013; EMMETT MR, 1991, NEUROPHARMACOLOGY, V30, P1167, DOI 10.1016/0028-3908(91)90161-4; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fisher M, 1998, EUR NEUROL, V40, P65, DOI 10.1159/000007959; Friedman LK, 2001, MOL BRAIN RES, V86, P34, DOI 10.1016/S0169-328X(00)00252-7; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Heifets L B, 1994, Semin Respir Infect, V9, P84; Heresco-Levy U, 2002, INT J NEUROPSYCHOPH, V5, P301, DOI 10.1017/S1461145702003061; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Ji S, 2009, EXP NEUROL, V216, P321, DOI 10.1016/j.expneurol.2008.12.007; Kalia LV, 2008, LANCET NEUROL, V7, P742, DOI 10.1016/S1474-4422(08)70165-0; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LAAKE K, 2002, COCHRANE DB SYST REV; Lees KR, 1997, NEUROLOGY, V49, pS66, DOI 10.1212/WNL.49.5_Suppl_4.S66; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Mark VW, 2008, RESTOR NEUROL NEUROS, V26, P13; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Olga NK, 2006, BEHAV BRAIN RES, V170, P233, DOI 10.1016/j.bbr.2006.02.026; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; ROD MR, 1989, CAN J NEUROL SCI, V16, P340, DOI 10.1017/S031716710002919X; Schneider JS, 2000, BRAIN RES, V860, P190, DOI 10.1016/S0006-8993(00)02036-9; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wolosker H, 2007, MOL NEUROBIOL, V36, P152, DOI 10.1007/s12035-007-0038-6; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com	52	30	33	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 10	2010	629	1-3					25	30		10.1016/j.ejphar.2009.11.066			6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	561UN	WOS:000275004900005	19958766	Green Accepted			2022-02-06	
J	Kreutzer, JS; Marwitz, JH; Godwin, EE; Arango-Lasprilla, JC				Kreutzer, Jeffrey S.; Marwitz, Jennifer H.; Godwin, Emilie E.; Arango-Lasprilla, Juan C.			Practical Approaches to Effective Family Intervention After Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; caregivers; family therapy; intervention	THERAPEUTIC ALLIANCE; REHABILITATION; CAREGIVERS; PREDICTORS; PROGRAM; BURDEN; IMPACT; DAMAGE; TBI	Rehabilitation professionals have become increasingly aware that traumatic brain injury has a long-term adverse impact on family members as well as on survivors. Family members often have a critical supporting role in the recovery process, and researchers have identified a relationship between caregiver well-being and survivor outcome. Drawing from the fields of family therapy, cognitive-behavioral therapy, and individual psychotherapy, this article provides information to help clinicians effectively serve families. First, historically important and widely cited publications are reviewed and their implications for practice are discussed. Recommendations for developing successful therapeutic alliances are provided along with a rationale for their importance. Descriptions of common challenges and issues faced by families are presented along with corresponding therapeutic goals. Intervention principles and strategies, selectively chosen to help family members achieve therapeutic goals, are discussed. The article concludes with a presentation of ideas to help practitioners and systems of care more effectively help family members adjust and live fulfilling lives.	[Kreutzer, Jeffrey S.; Marwitz, Jennifer H.; Godwin, Emilie E.; Arango-Lasprilla, Juan C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurosurg & Psychiat, Richmond, VA 23298 USA		Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, POB 980542, Richmond, VA 23298 USA.	jskreutz@vcu.edu			National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of EducationUS Department of Education [H133A070036]	Supported in part by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grant H133A070036).	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Anderson C. M., 1986, SCHIZOPHRENIA FAMILY; Anderson MI, 2009, BRAIN INJURY, V23, P931, DOI 10.3109/02699050903302336; ANGUS LE, 2003, HDB NARRATIVE PSYCHO; Aragno A, 2008, J AM PSYCHOANAL ASS, V56, P713, DOI 10.1177/0003065108322097; Beck J.S., 1995, COGNITIVE THERAPY BA; Boschen K, 2007, NEUROREHABILITATION, V22, P19; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; Corey, 2008, THEORY PRACTICE COUN; Ducharme JM, 2000, CLIN PSYCHOL REV, V20, P405, DOI 10.1016/S0272-7358(98)00102-0; Duncan B.L., 2004, HEROIC CLIENT REVOLU; Duncan BL, 1996, HDB SOLUTION FOCUSED; Dunst CJ, 2002, FAM RELAT, V51, P221, DOI 10.1111/j.1741-3729.2002.00221.x; Epston, 1990, NARRATIVE MEANS THER; Hubble M., 2006, HEART SOUL CHANGE WH; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; Levack WMM, 2009, BRAIN INJURY, V23, P192, DOI 10.1080/02699050802695582; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Martin DJ, 2000, J CONSULT CLIN PSYCH, V68, P438, DOI 10.1037//0022-006X.68.3.438; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Messer SB, 2002, CLIN PSYCHOL-SCI PR, V9, P21, DOI 10.1093/clipsy/9.1.21; Miller W.R., 2002, MOTIVATIONAL INTERVI; Minuchin S., 1981, FAMILY THERAPY TECHN; Minuchin S., 1993, FAMILY HEALING STRAT; MUIR C, 1990, REHABILITATION ADULT, P433; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Nichols M.P., 2007, FAMILY THERAPY CONCE; Nicki A., 2001, HYPATIA, V16, P80; Panting A, 1972, REHABILITATION, V38, P33; Piercy F., 1996, FAMILY THERAPY SOURC; ROBINSON KM, 1988, ADV NURS SCI, V10, P59, DOI 10.1097/00012272-198801000-00010; Rogers, 1961, BECOMING PERSON; ROGERS CR, 1957, J CONSULT PSYCHOL, V21, P95, DOI 10.1037/0022-006X.60.6.827; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; ROSENTHAL M, 1983, REHABILITATION HEAD, P407; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Weakland J. H., 1992, 1 SESSION BRIEF THER, P306; White M., 2007, MAPS NARRATIVE PRACT, V1st; [No title captured]	47	30	30	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					113	120		10.1097/HTR.0b013e3181cf0712			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000006	20134331				2022-02-06	
J	Pruthi, N; Chandramouli, BA; Kuttappa, TB; Rao, SL; Subbakrishna, DK; Abraham, MP; Mahadevan, A; Shankar, SK				Pruthi, Nupur; Chandramouli, B. A.; Kuttappa, Thelma B.; Rao, Shobini L.; Subbakrishna, D. K.; Abraham, Mariamma Philips; Mahadevan, Anita; Shankar, S. K.			Apolipoprotein E polymorphism and outcome after mild to moderate traumatic brain injury: A study of patient population in India	NEUROLOGY INDIA			English	Article						Apolipoprotein E; Glasgow outcome scale; neurotrauma; neuropsychological test	HEAD-INJURY; APOE GENOTYPE; ASSOCIATION; RECOVERY; ALLELE; EXPRESSION; EPSILON-4	Background: The nature and extent of recovery after traumatic brain injury (TBI) is heterogeneous. Apolipoprotein E (APOE) plays a major role in repair of cell membrane and growth of neurites following injury to cells. Studies done on the western population have shown that the APOE e4 genotype is associated with poor survival following neurotrauma. Aim: To explore the association of APOE polymorphism and outcome following TBI in a patient population from a tertiary care hospital exclusive for neurological diseases in south India. Patients and Methods: Ninety eight patients who sustained mild to moderate TBI (computed tomography (CT) scan brain showing traumatic parenchymal contusions) were the subjects of the study and the study period was from November 2003 to December 2008. APOE polymorphism status was determined by PCR technique using venous blood. Patients were assessed on follow-up with a battery of four neuropsychological tests as well as Glasgow outcome scale. Results: Of the 98 patients, 20 (20%) patients had at least one APOE e4 allele. A follow-up of minimum six months was available for 73 patients. None of the 12 patients who had at least one APOE e4 allele had a poor outcome at six-month follow-up whereas 11(18%) patients without an APOE e4 allele had a poor outcome (Fisher's Exact test, P = 0.192). On the neuropsychological tests, performance of patients with APOE e4 allele did not differ significantly from those without these alleles. Conclusion: This study does not support the current contention that the presence of APOE e4 allele should have a significant negative effect on the outcome after TBI.	[Mahadevan, Anita; Shankar, S. K.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Human Brain Bank, Bangalore 560029, Karnataka, India; [Pruthi, Nupur; Chandramouli, B. A.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India; [Rao, Shobini L.] Natl Inst Mental Hlth & Neurosci, Dept Mental Hlth & Social Psychol, Bangalore 560029, Karnataka, India; [Subbakrishna, D. K.; Abraham, Mariamma Philips] Natl Inst Mental Hlth & Neurosci, Dept Biostat, Bangalore 560029, Karnataka, India; [Kuttappa, Thelma B.] Univ Delhi, Dept Human Genet, New Delhi, India		Shankar, SK (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Human Brain Bank, Bangalore 560029, Karnataka, India.	shankar@nimhans.kar.nic.in					BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gopukumar K, 2004, NIMHANS NEUROPSYCHOL, P6; HALLMAN DM, 1991, AM J HUM GENET, V49, P338; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Mastana SS, 1998, ANN HUM BIOL, V25, P137, DOI 10.1080/03014469800005512; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Singh PP, 2006, ANN HUM BIOL, V33, P279, DOI 10.1080/03014460600594513; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thelma BK, 2001, HUM BIOL, V73, P135, DOI 10.1353/hub.2001.0012	24	30	31	0	7	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0028-3886	1998-4022		NEUROL INDIA	Neurol. India	MAR-APR	2010	58	2					264	269		10.4103/0028-3886.63810			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	611YY	WOS:000278862600018	20508347				2022-02-06	
J	Qian, JC; Herrera, JJ; Narayana, PA				Qian, Junchao; Herrera, Juan J.; Narayana, Ponnada A.			Neuronal and Axonal Degeneration in Experimental Spinal Cord Injury: In Vivo Proton Magnetic Resonance Spectroscopy and Histology	JOURNAL OF NEUROTRAUMA			English	Article						choline; histology; N-acetyl aspartate; proton magnetic resonance spectroscopy; rat; spinal cord injury	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; N-ACETYLASPARTATE; MR SPECTROSCOPY; HISTOPATHOLOGIC CORRELATION; CEREBRAL-ISCHEMIA; METABOLIC-CHANGES; DAMAGE; DYSFUNCTION; ASPARTATE	Longitudinal in vivo proton magnetic resonance spectroscopy (H-1-MRS) and immunohistochemistry were performed to investigate the tissue degeneration in traumatically injured rat spinal cord rostral and caudal to the lesion epicenter. On H-1-MRS significant decreases in N-acetyl aspartate (NAA) and total creatine (Cr) levels in the rostral, epicenter, and caudal segments were observed by 14 days, and levels remained depressed up to 56 days post-injury (PI). In contrast, the total choline (Cho) levels increased significantly in all three segments by 14 days PI, but recovered in the epicenter and caudal, but not the rostral region, at 56 days PI. Immunohistochemistry demonstrated neuronal cell death in the gray matter, and reactive astrocytes and axonal degeneration in the dorsal, lateral, and ventral white-matter columns. These results suggest delayed tissue degeneration in regions both rostrally and caudally from the epicenter in the injured spinal cord tissue. A rostral-caudal asymmetry in tissue recovery was seen both on MRI-observed hyperintense lesion volume and the Cho, but not NAA and Cr, levels at 56 days PI. These studies suggest that dynamic metabolic changes take place in regions away from the epicenter in injured spinal cord.	[Qian, Junchao; Herrera, Juan J.; Narayana, Ponnada A.] Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA		Narayana, PA (corresponding author), Univ Texas Med Sch Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St, Houston, TX 77030 USA.	Ponnada.a.Narayana@uth.tmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045624]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR014804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030821, R01NS045624] Funding Source: NIH RePORTER	This work is supported by NIH grant NS045624 awarded to P.A.N. We thank Tessy Chacko, B.S., for assistance with animal care, and Chirag Patel, M.S.E., for assistance with histology.	Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; ARNOLD DL, 1990, MAGNET RESON MED, V14, P154, DOI 10.1002/mrm.1910140115; ARNOLD DL, 1992, ANN NEUROL, V31, P235, DOI 10.1002/ana.410310302; Balla DZ, 2007, MAGN RESON MATER PHY, V20, P183, DOI 10.1007/s10334-007-0081-3; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Bilgen M, 2001, MAGN RESON MED, V46, P1250, DOI 10.1002/mrm.1325; Bitsch A, 1999, AM J NEURORADIOL, V20, P1619; Blamire AM, 2007, MAGN RESON MED, V58, P880, DOI 10.1002/mrm.21382; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; Cooke FJ, 2004, MAGN RESON MED, V51, P1122, DOI 10.1002/mrm.20084; Demougeot C, 2004, J NEUROCHEM, V90, P776, DOI 10.1111/j.1471-4159.2004.02583.x; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Deng X, 2007, MAGN RESON MED, V57, P620, DOI 10.1002/mrm.21163; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Edden RAE, 2007, J MAGN RESON IMAGING, V26, P1101, DOI 10.1002/jmri.21008; Falconer JC, 1996, J NEUROCHEM, V66, P717; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Ge Y, 2006, AM J NEURORADIOL, V27, P1165; Gomez-Anson B, 2000, NEURORADIOLOGY, V42, P515, DOI 10.1007/s002340000323; Henning A, 2008, MAGN RESON MED, V59, P1250, DOI 10.1002/mrm.21578; Higuchi T, 1996, NEUROSURGERY, V38, P121, DOI 10.1097/00006123-199601000-00030; Holly LT, 2009, J NEUROSURG-SPINE, V10, P194, DOI 10.3171/2008.12.SPINE08367; Kendi ATK, 2004, NEURORADIOLOGY, V46, P764, DOI 10.1007/s00234-004-1231-1; Kim YG, 2004, J SPINAL DISORD TECH, V17, P405, DOI 10.1097/01.bsd.0000124762.36865.9f; Konaka K, 2003, J CEREBR BLOOD F MET, V23, P700, DOI 10.1097/01.WCB.0000071888.63724.56; LARSSON HBW, 1991, MAGN RESON MED, V22, P23, DOI 10.1002/mrm.1910220104; Mader I, 2000, AM J NEURORADIOL, V21, P1220; Malisza KL, 1998, BIOCHEM CELL BIOL, V76, P487, DOI 10.1139/bcb-76-2-3-487; Marliani AF, 2007, MAGN RESON MED, V57, P160, DOI 10.1002/mrm.21113; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Moore Gregory J, 2002, Psychopharmacol Bull, V36, P5; Narayana PA, 2005, J NEUROIMAGING, V15, p46S, DOI 10.1177/1051228405284200; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Narayana PA, 1998, ANN NEUROL, V43, P56, DOI 10.1002/ana.410430112; Pilatus U, 2009, PSYCHIAT RES-NEUROIM, V173, P1, DOI 10.1016/j.pscychresns.2008.07.015; Sager TN, 2000, J CEREBR BLOOD F MET, V20, P780, DOI 10.1097/00004647-200005000-00004; Sajja BR, 2009, NEUROIMAG CLIN N AM, V19, P45, DOI 10.1016/j.nic.2008.08.002; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Silver X, 2001, MAGN RESON MED, V46, P1216, DOI 10.1002/mrm.1319; Simoes RV, 2008, MAGN RESON MATER PHY, V21, P237, DOI 10.1007/s10334-008-0114-6; Tartaglia MC, 2002, J NEUROL, V249, P1382, DOI 10.1007/s00415-002-0846-6; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; van Walderveen MAA, 1999, ANN NEUROL, V46, P79, DOI 10.1002/1531-8249(199907)46:1<79::AID-ANA12>3.0.CO;2-9; VINK R, 1989, ANN NEUROL, V25, P26, DOI 10.1002/ana.410250105; Vroemen M, 2006, AM J NEURORADIOL, V27, P598; WEIRICH SD, 1990, SPINE, V15, P630, DOI 10.1097/00007632-199007000-00004; Zelaya FO, 1996, MAGNET RESON MED, V35, P443, DOI 10.1002/mrm.1910350401	51	30	31	2	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					599	610		10.1089/neu.2009.1145			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100012	20001674	Green Published			2022-02-06	
J	Herrera, JJ; Haywood-Watson, RJL; Grill, RJ				Herrera, Juan J.; Haywood-Watson, Ricky J. L., II; Grill, Raymond J.			Acute and Chronic Deficits in the Urinary Bladder after Spinal Contusion Injury in the Adult Rat	JOURNAL OF NEUROTRAUMA			English	Article						bladder permeability; hematuria; inflammation; recovery; spinal cord injury	TIGHT JUNCTION PROTEIN; BLOOD-BRAIN-BARRIER; CORD-INJURY; EPITHELIAL INJURY; DYSFUNCTION; UROTHELIUM; BIOPSIES; OCCLUDIN; MICE	Traumatic spinal cord injury (SCI) permanently alters bladder function in humans. Hematuria and cystitis occur in both human SCI as well as in rodent models of SCI. Others have reported early SCI-dependent disruption to bladder uroepithelial integrity that results in increased permeability to urine and urine-borne substances. This can result in cystitis, or inflammation of the bladder, an ongoing pathological condition present throughout the chronic phase of SCI in humans. The goals of our study were twofold: (1) to begin to examine the inflammatory and molecular changes that occur within the bladder uroepithelium using a clinically-relevant spinal contusion model of injury, and (2) to assess whether these alterations continue into the chronic phase of SCI. Rats received either moderate SCI or sham surgery. Urine was collected from SCI and sham subjects over 7 days or at 7 months to assess levels of excreted proteins. Inflammation in the bladder wall was assessed via biochemical and immunohistochemical methods. Bladder tight junction proteins, mediators of uroepithelial integrity, were also measured in both the acute and chronic phases of SCI. Urine protein and hemoglobin levels rapidly increase following SCI. An SCI-dependent elevation in numbers of neutrophils within the bladder wall peaked at 48 h. Bladder tight junction proteins demonstrate a rapid but transient decrease as early as 2 h post-SCI. Surprisingly, elevated levels of urine proteins and significant deficits in bladder tight junction proteins could be detected in chronic SCI, suggesting that early pathological changes to the bladder may continue throughout the chronic phase of injury.	[Herrera, Juan J.; Haywood-Watson, Ricky J. L., II; Grill, Raymond J.] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA		Grill, RJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, 6431 Fannin St,Suite 4-110, Houston, TX 77030 USA.	raymond.j.grill@uth.tmc.edu			National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [NINDS NS45462, NINDS RO1 NS049409]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS045462, R01NS049409] Funding Source: NIH RePORTER	The authors would like to acknowledge Bindu Nair for her technical help and assistance in this study. Funding was provided by the National Institutes of Health Postdoctoral Fellowship of the National Institute of Allergy and Infectious Diseases grants NINDS NS45462 and NINDS RO1 NS049409).	Acharya P, 2004, AM J PHYSIOL-RENAL, V287, pF305, DOI 10.1152/ajprenal.00341.2003; Apodaca G, 2003, AM J PHYSIOL-RENAL, V284, pF966, DOI 10.1152/ajprenal.00359.2002; Birder LA, 2006, PROG BRAIN RES, V152, P135, DOI 10.1016/S0079-6123(05)52009-0; Birder LA, 2004, SCAND J UROL NEPHROL, V38, P48, DOI 10.1080/03008880410015165; Birder LA, 2007, NAT CLIN PRACT UROL, V4, P46, DOI 10.1038/ncpuro0672; Brooks TA, 2005, AM J PHYSIOL-HEART C, V289, pH738, DOI 10.1152/ajpheart.01288.2004; Chin AC, 2007, ANNU REV PATHOL-MECH, V2, P111, DOI 10.1146/annurev.pathol.2.010506.091944; Craggs MD, 2006, AUTON NEUROSCI-BASIC, V126, P355, DOI 10.1016/j.autneu.2006.03.010; CROSBY WH, 1956, BLOOD, V11, P380, DOI 10.1182/blood.V11.4.380.380; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Ginzberg HH, 2001, AM J PHYSIOL-GASTR L, V281, pG705, DOI 10.1152/ajpgi.2001.281.3.G705; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Hung EW, 2007, SPINAL CORD, V45, P616, DOI 10.1038/sj.sc.3102004; Janzen J, 1998, NEUROUROL URODYNAM, V17, P525; Janzen J, 2001, SPINAL CORD, V39, P568, DOI 10.1038/sj.sc.3101218; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; Pannek J, 2002, UROLOGY, V59, P240, DOI 10.1016/S0090-4295(01)01495-9; Patrick David M, 2006, BMC Physiol, V6, P2, DOI 10.1186/1472-6793-6-2; Samson Gregory, 2007, Phys Med Rehabil Clin N Am, V18, P255; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schulzke JD, 2005, BBA-BIOMEMBRANES, V1669, P34, DOI 10.1016/j.bbamem.2005.01.008; Tai CF, 2006, RESTOR NEUROL NEUROS, V24, P69; Toosi KK, 2008, ANN BIOMED ENG, V36, P1470, DOI 10.1007/s10439-008-9525-9; Vaidyanathan Subramanian, 2002, BMC Urol, V2, P5, DOI 10.1186/1471-2490-2-5; Vizzard MA, 1999, SOMATOSENS MOT RES, V16, P369, DOI 10.1080/08990229970429; Xu HP, 2005, INVEST OPHTH VIS SCI, V46, P2487, DOI 10.1167/iovs.04-1333; Yu X, 2003, UROLOGY, V62, P755, DOI 10.1016/S0090-4295(03)00486-2	28	30	31	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					423	431		10.1089/neu.2009.0997			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800015	19891526	Green Published			2022-02-06	
J	Grujicic, M; Arakere, G; He, T				Grujicic, M.; Arakere, G.; He, T.			Material-modeling and structural-mechanics aspects of the traumatic brain injury problem	MULTIDISCIPLINE MODELING IN MATERIALS AND STRUCTURES			English	Article						Brain; Injuries; Modeling; Structural analysis		Purpose - This paper aims to conduct a combined Eulerian/Lagrangian fluid/solid transient non-linear dynamics computational analysis of the interaction between a single planar blast wave and a human head in order to assess the extent of intra-cranial shock wave generation and its potential for causing traumatic brain injury. Design/methodology/approach - Two levels of blast peak overpressure were selected, one corresponding to the unprotected lung-injury threshold while the other associated with a 50 percent probability for lung injury caused death. Collision of the head with a stationary/rigid barrier (at an initial collision velocity of 5 m/s) was also analyzed computationally, since blunt-object impact conditions may lead to mild traumatic brain injury (mTBI), i.e. concussion. Findings - A comparison between the two blast and the single blunt-object impact cases with the corresponding head-to-head-collision results showed that, while the von Mises stress-based head-to-head collision mTBI thresholds are not exceeded under blast-loading conditions investigated, the high blast-induced peak-pressure levels within the intra-cranial cavity may lead to mTBI. Practical implications - While concussion is not generally considered as life altering/threatening, the associated temporary loss of situational awareness or consciousness may have devastating consequences in the case of common military tactical and battle-field scenarios. This suggests that the head- protection gear (primarily, the helmet) which are currently designed to withstand blunt-object and ballistic impacts, should be redesigned in order to obtain the necessary level of head protection with respect to blast impact. Originality/value - The paper provides a comprehensive computational investigation of impact on a human skull/brain assembly.	[Grujicic, M.; Arakere, G.; He, T.] Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA		Grujicic, M (corresponding author), Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA.						Altair Engineering, 2010, HYP ALT ENG; [Anonymous], 2007, US DOC; Bake W.E., 1973, EXPLOSIONS AIR; BRAZARIAN J, 2005, BRAIN INJURY, V18, P85; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cooper PW., 1996, EXPLOSIVES ENG; Cuitino A., 1992, ENG COMPUT-GERMANY, V9, P437, DOI DOI 10.1108/EB023876>; Cullis I G, 2001, J R Army Med Corps, V147, P16; Dassault Systems, 2008, US DOC, P8; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; KAMBOUCHEV N, 2007, COMPUT STRUCT, V23, P325; Kelly JP, 1997, NEUROLOGY, V48, P581; Moore DF, 2008, ANN NEUROL, V64, pS30; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Nyein M., 2008, P 26 ARM SCI C ORL F; Saraf H, 2007, J BIOMECH, V40, P1960, DOI 10.1016/j.jbiomech.2006.09.021; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	20	30	30	0	0	EMERALD GROUP PUBLISHING LTD	BINGLEY	HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND	1573-6105	1573-6113		MULTIDISCIP MODEL MA	Multidiscip. Model. Mater. Struct.		2010	6	3					335	363		10.1108/15736101011080097			29	Materials Science, Multidisciplinary; Mechanics	Emerging Sources Citation Index (ESCI)	Materials Science; Mechanics	V1U0S	WOS:000217235300002					2022-02-06	
J	Jaffe, DH; Peleg, K				Jaffe, Dena H.; Peleg, Kobi		Israel Trauma Grp	Terror Explosive Injuries A Comparison of Children, Adolescents, and Adults	ANNALS OF SURGERY			English	Article							PEDIATRIC TRAUMA; HEPATIC-TRAUMA; MANAGEMENT; SEVERITY; OUTCOMES; CARE; PATTERNS; BOMBINGS; GENDER; LIVER	Objective: We sought to characterize injuries and outcomes from terror explosions with specific attention to children (0-10 years) and adolescents (11-15 years) compared to adults (16-45 years). Summary Background Data: Terror explosions target vulnerable populations and result in multidimensional injuries that may vary according to age group. The relative dearth of information regarding terror-related injuries among children inhibits proper preparedness and optimum management during such an event. Methods: A retrospective study was performed using data from the national Israel Trauma Registry (October 2000 to December 2005.). Included were civilians and nonactive military personnel hospitalized as a result of a terror explosion. Results: During the 5.3-year study period, 49 children (0-10 years), 65 adolescents (11-15 years), and 723 adults (16-45 years) were hospitalized from terror explosions. Children were more likely than adults to sustain severe injuries (27% vs. 12%) and traumatic brain injury (35% vs. 20%) and less likely to sustain injuries to their extremities (35% vs. 57%) or open wounds (39% vs. 59%) (P <= 0.05). The adolescent injury profile was similar to that of adults, however, adolescents presented with less internal injuries, more contusions, and superficial wounds to extremities and were more likely to require surgery for mild to moderate wounds. Differences in hospital utilization and outcomes by age groups were observed when data were stratified by injury severity. Conclusions: Compared to adults, children, and adolescents exposed to terror explosions present with different injuries and hospital utilization and outcomes. These results further confirm that preparedness of a pediatric healthcare system is essential for effective management in the event of a future mass casualty incident.	[Jaffe, Dena H.; Peleg, Kobi] Gertner Inst Epidemiol & Hlth Policy Res, Natl Ctr Trauma & Emergency Med Res, IL-52621 Tel Hashomer, Israel; [Peleg, Kobi] Tel Aviv Univ, Sch Publ Hlth, Dept Disaster Med, Tel Aviv, Israel		Jaffe, DH (corresponding author), Gertner Inst Epidemiol & Hlth Policy Res, Natl Ctr Trauma & Emergency Med Res, IL-52621 Tel Hashomer, Israel.	denaj@gertner.health.gov.il			Gertner Institute for Epidemiology and Health Policy Research	Supported by the Gertner Institute for Epidemiology and Health Policy Research.	Aharonson-Daniel L, 2003, PEDIATRICS, V112, pE280, DOI 10.1542/peds.112.4.e280; Almogy G, 2004, ANN SURG, V239, P295, DOI 10.1097/01.sla.0000114014.63423.55; Amir LD, 2005, ANN SURG, V241, P666, DOI 10.1097/01.sla.0000157233.18787.cd; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bauza G, 2008, J TRAUMA, V64, P304, DOI 10.1097/TA.0b013e3181634893; Bilston LE, 2007, SPINE, V32, P2339, DOI 10.1097/BRS.0b013e3181558886; Brandenburg M, 2006, J HOMEL SECUR EMERG, V3, DOI 10.2202/1553-3840.1025; Demetriades D, 2004, J AM COLL SURGEONS, V199, P382, DOI 10.1016/j.jamcollsurg.2004.03.027; Duane TM, 2004, J TRAUMA, V57, P494, DOI 10.1097/01.TA.0000141026.20937.81; Einav S, 2006, ANN SURG, V243, P533, DOI 10.1097/01.sla.0000206417.58432.48; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; Gee AC, 2008, SHOCK, V29, P334, DOI 10.1097/shk.0b013e3181506ee5; Ivarsson B Johan, 2006, Traffic Inj Prev, V7, P290, DOI 10.1080/15389580600652283; Kim H, 2008, J TRAUMA, V65, P1287, DOI 10.1097/TA.0b013e31817196f5; Kluger Y, 2004, J AM COLL SURGEONS, V199, P875, DOI 10.1016/j.jamcollsurg.2004.09.003; Kluger Y, 2003, ISRAEL MED ASSOC J, V5, P235; Markenson D, 2006, PEDIATRICS, V117, pE340, DOI 10.1542/peds.2005-2752; Maxson RT, 2002, CLIN PEDIAT EMERG ME, V3, P256; Mayo Ami, 2006, World J Emerg Surg, V1, P33, DOI 10.1186/1749-7922-1-33; McGuigan R, 2007, J PEDIATR SURG, V42, P207, DOI 10.1016/j.jpedsurg.2006.09.020; Miller K, 1998, J PEDIATR SURG, V33, P1459, DOI 10.1016/S0022-3468(98)90474-2; Mitra B, 2006, ANZ J SURG, V76, P343, DOI 10.1111/j.1445-2197.2006.03723.x; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Newgard CD, 2005, PEDIATRICS, V115, P1579, DOI 10.1542/peds.2004-0555; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Peleg K, 2004, ANN SURG, V239, P311, DOI 10.1097/01.sla.0000114012.84732.be; Phelan HA, 2007, J TRAUMA, V63, P1127, DOI 10.1097/TA.0b013e318154c1b8; Spinella PC, 2008, CRIT CARE MED, V36, pS293, DOI 10.1097/CCM.0b013e31817da99f; Velmahos GC, 2003, ARCH SURG-CHICAGO, V138, P475, DOI 10.1001/archsurg.138.5.475; *WHO, 1986, OPT CAR DIS PEOPL; Willis RB, 2008, PEDIATRICS, V121, P849, DOI 10.1542/peds.2008-0094	33	30	31	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-4932			ANN SURG	Ann. Surg.	JAN	2010	251	1					138	143		10.1097/SLA.0b013e3181b5d7ab			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	538SF	WOS:000273203600021	19838104				2022-02-06	
J	Meyer, M; Deniselle, MCG; Garay, LI; Monachelli, GG; Lima, A; Roig, P; Guennoun, R; Schumacher, M; De Nicola, AF				Meyer, Maria; Gonzalez Deniselle, Maria Claudia; Garay, Laura I.; Monachelli, Gisella Gargiulo; Lima, Analia; Roig, Paulina; Guennoun, Rachida; Schumacher, Michael; De Nicola, Alejandro F.			Stage Dependent Effects of Progesterone on Motoneurons and Glial Cells of Wobbler Mouse Spinal Cord Degeneration	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Wobbler; Progesterone; Glial fibrillary acidic protein; Glutamine synthetase; Neurodegeneration; Neuroprotection	MOTOR-NEURON DISEASE; AMYOTROPHIC-LATERAL-SCLEROSIS; CENTRAL-NERVOUS-SYSTEM; ANTERIOR HORN CELLS; TRAUMATIC BRAIN-INJURY; BINDING-PROTEIN 25-DX; NITRIC-OXIDE; GLUTAMINE-SYNTHETASE; NEUROTROPHIC FACTOR; CHOLINE-ACETYLTRANSFERASE	In the Wobbler mouse, a mutation in the Vps54 gene is accompanied by motoneuron degeneration and astrogliosis in the cervical spinal cord. Previous work has shown that these abnormalities are greatly attenuated by progesterone treatment of clinically afflicted Wobblers. However, whether progesterone is effective at all disease stages has not yet been tested. The present work used genotyped (wr/wr) Wobbler mice at three periods of the disease: early progressive (1-2 months), established (5-8 months) or late stages (12 months) and age-matched wildtype controls (NFR/NFR), half of which were implanted with a progesterone pellet (20 mg) for 18 days. In untreated Wobblers, degenerating vacuolated motoneurons were initially abundant, experienced a slight reduction at the established stage and dramatically diminished during the late period. In motoneurons, the cholinergic marker choline acetyltransferase (ChAT) was reduced at all stages of the Wobbler disease, whereas hyperexpression of the growth-associated protein (GAP43) mRNA preferentially occurred at the early progressive and established stages. Progesterone therapy significantly reduced motoneuron vacuolation, enhanced ChAT immunoreactive perikarya and reduced the hyperexpression of GAP43 during the early progressive and established stages. At all stage periods, untreated Wobblers showed high density of glial fibrillary acidic protein (GFAP)+ astrocytes and decreased number of glutamine synthase (GS) immunostained cells. Progesterone treatment down-regulated GFAP+ astrocytes and up-regulated GS+ cell number. These data reinforced the usefulness of progesterone to improve motoneuron and glial cell abnormalities of Wobbler mice and further showed that therapeutic benefit seems more effective at the early progressive and established periods, rather than on advance stages of spinal cord neurodegeneration.	[Meyer, Maria; Gonzalez Deniselle, Maria Claudia; Garay, Laura I.; Monachelli, Gisella Gargiulo; Lima, Analia; Roig, Paulina; De Nicola, Alejandro F.] Consejo Nacl Invest Cient & Tecn, Lab Bioquim Neuroendocrina, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; [Gonzalez Deniselle, Maria Claudia; Garay, Laura I.; De Nicola, Alejandro F.] Univ Buenos Aires, Fac Med, Dept Human Biochem, Buenos Aires, DF, Argentina; [Guennoun, Rachida; Schumacher, Michael] INSERM, UMR788, Le Kremlin Bicetre, France; [Guennoun, Rachida; Schumacher, Michael] Univ Paris 11, Le Kremlin Bicetre, France		De Nicola, AF (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Bioquim Neuroendocrina, Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300	FONCYTFONCyT [BID 1728 OC AR PICT 2004 5-25610, BID 1728 OC AR PICT 2007-01044]; CONICETConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 112-200801-00542]; University of Buenos AiresUniversity of Buenos Aires [M016, M611]; INSERM/CONICETInstitut National de la Sante et de la Recherche Medicale (Inserm)Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	This work was supported by FONCYT (BID 1728 OC AR PICT 2004 5-25610 and PICT 2007-01044), CONICET (PIP 112-200801-00542), the University of Buenos Aires (M016 and M611) and a cooperative program INSERM/CONICET.	Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Barbeito LH, 2004, BRAIN RES REV, V47, P263, DOI 10.1016/j.brainresrev.2004.05.003; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bigini P, 2001, NEUROREPORT, V12, P1815, DOI 10.1097/00001756-200107030-00011; Bigini P, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-71; Bigini P, 2007, NEUROSCI LETT, V426, P106, DOI 10.1016/j.neulet.2007.08.057; BLONDET B, 1995, NEUROSCI LETT, V183, P179, DOI 10.1016/0304-3940(94)11145-9; Boillee S, 2001, GLIA, V33, P277, DOI 10.1002/1098-1136(20010315)33:4<277::AID-GLIA1026>3.3.CO;2-P; Boillee S, 2003, MOL NEUROBIOL, V28, P65, DOI 10.1385/MN:28:1:65; Boonyaratanakornkit V, 2008, STEROIDS, V73, P922, DOI 10.1016/j.steroids.2008.01.010; Brinton RD, 2008, TRENDS NEUROSCI, V31, P529, DOI 10.1016/j.tins.2008.07.003; Calabrese V, 2007, NAT REV NEUROSCI, V8, P766, DOI 10.1038/nrn2214; CAMMER W, 1990, J NEUROIMMUNOL, V26, P173, DOI 10.1016/0165-5728(90)90088-5; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Clowry GJ, 1996, NEUROSCI LETT, V215, P177, DOI 10.1016/S0304-3940(96)12971-2; Corvino V, 2003, NEUROCHEM RES, V28, P341, DOI 10.1023/A:1022345720852; Cudkowicz ME, 1996, J NEUROL SCI, V139, P10, DOI 10.1016/0022-510X(96)00084-6; Dave KR, 2003, EXP NEUROL, V182, P412, DOI 10.1016/S0014-4886(03)00091-8; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; Deniselle MCG, 2005, EXP NEUROL, V195, P518, DOI 10.1016/j.expneurol.2005.06.015; Deniselle MCG, 2004, BRAIN RES, V1014, P71, DOI 10.1016/j.braines.2004.04.004; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Deniselle MCG, 1999, NEUROCHEM RES, V24, P1535, DOI 10.1023/A:1021199931682; Dennis JS, 2009, NEUROSCIENCE, V158, P745, DOI 10.1016/j.neuroscience.2008.10.030; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Elliott EJ, 1997, BRAIN RES, V755, P221, DOI 10.1016/S0006-8993(97)00100-5; FERRINI M, 1995, LIFE SCI, V57, P2403, DOI 10.1016/0024-3205(95)02236-3; Fumagalli E, 2006, EXP NEUROL, V198, P114, DOI 10.1016/j.expneurol.2005.11.010; Gago N, 2004, J NEUROSCI RES, V78, P770, DOI 10.1002/jnr.20348; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Hantaz-Ambroise D, 2001, DIFFERENTIATION, V69, P100, DOI 10.1046/j.1432-0436.2001.690204.x; Henderson JT, 1996, J NEUROSCI, V16, P7574; Ikeda K, 2000, BRAIN RES, V858, P84, DOI 10.1016/S0006-8993(99)02427-0; Ikemoto A, 1999, ACTA NEUROPATHOL, V98, P367, DOI 10.1007/s004010051096; Ishiyama T, 2004, BRAIN RES, V1019, P226, DOI 10.1016/j.brainres.2004.06.002; Ishiyama T, 2002, BRAIN RES, V944, P195, DOI 10.1016/S0006-8993(02)02881-0; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Julien JP, 2007, NAT NEUROSCI, V10, P535, DOI 10.1038/nn0507-535; KAPFHAMMER JP, 1994, J COMP NEUROL, V340, P194, DOI 10.1002/cne.903400206; Kong JM, 1998, J NEUROSCI, V18, P3241; LAAGE S, 1988, DEV NEUROSCI-BASEL, V10, P190, DOI 10.1159/000111969; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Martin LJ, 2007, J COMP NEUROL, V500, P20, DOI 10.1002/cne.21160; Migheli A, 1999, NAT MED, V5, P966, DOI 10.1038/12381; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MITSUMOTO H, 1987, J NEUROPATH EXP NEUR, V46, P214, DOI 10.1097/00005072-198703000-00008; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Oda Y, 1995, PATHOL INT, V45, P933, DOI 10.1111/j.1440-1827.1995.tb03418.x; Pajovic SB, 2008, PHYSIOL RES, V57, P801, DOI 10.33549/physiolres.931377; PARHAD IM, 1992, ANN NEUROL, V31, P593, DOI 10.1002/ana.410310605; Popper P, 1997, EXP NEUROL, V143, P246, DOI 10.1006/exnr.1996.6364; Rathke-Hartlieb S, 1999, NEUROREPORT, V10, P3411, DOI 10.1097/00001756-199911080-00028; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Santoro B, 2004, NEUROBIOL DIS, V17, P349, DOI 10.1016/j.nbd.2004.07.003; Saravia F, 2007, PSYCHONEUROENDOCRINO, V32, P480, DOI 10.1016/j.psyneuen.2007.02.012; Schmitt-John T, 2005, NAT GENET, V37, P1213, DOI 10.1038/ng1661; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; TANSEY FA, 1991, J NEUROCHEM, V56, P266, DOI 10.1111/j.1471-4159.1991.tb02591.x; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; Tsuzaka K, 2001, MUSCLE NERVE, V24, P474, DOI 10.1002/mus.1029; Vardimon L, 1999, J NEUROBIOL, V40, P513, DOI 10.1002/(SICI)1097-4695(19990915)40:4<513::AID-NEU8>3.0.CO;2-D; Xu GP, 2001, NEUROSCI LETT, V300, P141, DOI 10.1016/S0304-3940(01)01575-0; YUNG KKL, 1992, NEUROSCIENCE, V50, P209, DOI 10.1016/0306-4522(92)90393-G; Zhu Y, 2008, COMP BIOCHEM PHYS C, V148, P381, DOI 10.1016/j.cbpc.2008.05.019; Zoccolella S, 2007, EUR J NEUROL, V14, P262, DOI 10.1111/j.1468-1331.2006.01575.x; Zoing MC, 2006, J CLIN NEUROSCI, V13, P78, DOI 10.1016/j.jocn.2004.04.011	81	30	31	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JAN	2010	30	1					123	135		10.1007/s10571-009-9437-8			13	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	549XI	WOS:000274087400013	19693665				2022-02-06	
J	O'Neill, B; Moran, K; Gillespie, A				O'Neill, Brian; Moran, Kate; Gillespie, Alex			Scaffolding rehabilitation behaviour using a voice-mediated assistive technology for cognition	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Assistive technology for cognition; Executive function; Guide; Complex behaviour; Limb-donning; Activities of daily living	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MEMORY AIDS; PEOPLE; PREDICTORS; INDIVIDUALS; STRATEGIES; DISORDERS; SYSTEM	A variety of cognitive deficits can lead to difficulties performing complex behavioural sequences and thus, disability in the performance of routine and rehabilitation behaviours. Interventions to date involve increasing support or providing behavioural training. Assistive technologies for cognition have the potential to augment cognitive capacity thus enabling the performance of behavioural sequences. Guide is an assistive technology for cognition that scaffolds task performance by providing verbal prompts and responding to verbal feedback. Guide was used to provide verbal support and guidance for eight amputees (mean age 64), with cognitive impairment of vascular origin, putting on their prosthetic limbs. Participants were referred to the research due to problems learning the correct behavioural sequence. The research used repeated trials with random assignment to intervention and baseline conditions. The voice-mediated assistive technology for cognition resulted in a significant reduction of safety critical errors and omitted steps. Discussion focuses upon the relation between voice-mediated cognitive support for memory and executive function, and suggestions are made for future research.	[O'Neill, Brian; Gillespie, Alex] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [O'Neill, Brian] Brain Injury Rehabil Trust, Glasgow, Lanark, Scotland; [Moran, Kate] Ayrshire Cent Hosp, Irvine, Ayr, Scotland		O'Neill, B (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.	brian.oneill@thedtgroup.org			Chief Scientist Office [CZG/2/319]; West of Scotland Mobility and Rehabilitation Centre	The authors would like to acknowledge the financial support of a Chief Scientist Office Research Grant (CZG/2/319). The support of Helen Scott and the therapy staff at the West of Scotland Mobility and Rehabilitation Centre was invaluable.	BACKMAN L, 1992, PSYCHOL BULL, V112, P259, DOI 10.1037/0033-2909.112.2.259; Bakeman R., 1997, OBSERVING INTERACTIO; BALTES PB, 1987, DEV PSYCHOL, V23, P611, DOI 10.1037/0012-1649.23.5.611; Bergman MM, 2002, J HEAD TRAUMA REHAB, V17, P431, DOI 10.1097/00001199-200210000-00005; Berk L.E., 1995, SCAFFOLDING CHILDREN; BURGESS PW, 2000, PSYCHOL RES, V63, P379; Caplan D, 1997, J SPEECH LANG HEAR R, V40, P542, DOI 10.1044/jslhr.4003.542; Carmien S, 2005, CHI 05 EXTENDED ABST, P1252, DOI DOI 10.1145/1056808.1056889; CAVALIER AR, 1993, P REH ENG SCO N AM R, P216; Cole E, 1999, NEUROREHABILITATION, V12, P39; Cornish F, 2009, J HEALTH PSYCHOL, V14, P800, DOI 10.1177/1359105309338974; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; CURRAN C, 2004, DISS ABSTR INT B, V64, P4074; DONAGHEY CL, CLIN REHABI IN PRESS; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Evans JJ, 2003, STUD NEUROPSYCHOL DE, P53; Feyereisen P, 1999, NEUROPSYCHOL REHABIL, V9, P169, DOI 10.1080/713755598; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GILLESPIE A, J THEORY SO IN PRESS; Gitlin LN, 2002, GERONTOLOGIST, V42, P61, DOI 10.1093/geront/42.1.61; Gregor P, 2004, NEUROPSYCHOL REHABIL, V14, P1, DOI 10.1080/09602010343000093; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Inglis E. A., 2003, Universal Access in the Information Society, V2, P226, DOI 10.1007/s10209-003-0057-7; Iverson GL, 1998, INT J GERIATR PSYCH, V13, P661, DOI 10.1002/(SICI)1099-1166(1998100)13:10<661::AID-GPS838>3.0.CO;2-0; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Krabbendam L, 1999, CLIN NEUROPSYCHOL, V13, P370, DOI 10.1076/clin.13.3.370.1739; Lancioni GE, 1999, J INTELL DISABIL RES, V43, P61, DOI 10.1046/j.1365-2788.1999.43120165.x; LANGA KM, 2004, J GEN INTERNAL MED, V16, P770; Langan-Fox J, 2007, AUST PSYCHOL, V42, P39, DOI 10.1080/00050060600827607; LaPlante MP, 2002, HEALTH SERV RES, V37, P397, DOI 10.1111/1475-6773.029; Larner S, 2003, CLIN REHABIL, V17, P493, DOI 10.1191/0269215503cr641oa; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Luria A.R., 1961, ROLE SPEECH REGULATI; Mathuranath PS, 2000, NEUROLOGY, V55, P1613, DOI 10.1212/01.wnl.0000434309.85312.19; Maxwell JP, 2001, Q J EXP PSYCHOL-A, V54, P1049, DOI 10.1080/02724980143000073; Mihailidis A, 2004, NEUROPSYCHOL REHABIL, V14, P135, DOI 10.1080/09602010343000156; O'Neill B, 2008, PSYCHOPROSTHETICS ST; O'Neill B, 2008, J ASSIST TECHNOL, V2, P22, DOI 10.1108/17549450200800015; O'Neill BF, 2009, DISABIL REHABIL, V31, P1083, DOI 10.1080/09638280802509579; Pea RD, 2004, J LEARN SCI, V13, P423, DOI 10.1207/s15327809jls1303_6; Pijnenborg GHM, 2007, REHABIL PSYCHOL, V52, P236, DOI 10.1037/0090-5550.52.2.236; Proot I M, 2000, Clin Nurs Res, V9, P460, DOI 10.1177/10547730022158690; Randolph C., 1998, REPEATABLE BATTERY A; Scherer M.J., 2001, ASSISTIVE TECHNOLOGY; Schoppen T, 2003, ARCH PHYS MED REHAB, V84, P803, DOI 10.1016/S0003-9993(02)04952-3; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; Shepherd A., 2001, HIERARCHICAL TASK AN; Stone CA, 1998, J LEARN DISABIL-US, V31, P344, DOI 10.1177/002221949803100404; Tierney MC, 2007, AM J GERIAT PSYCHIAT, V15, P140, DOI 10.1097/01.JGP.0000230661.32735.c0; Todman J. B., 2001, SINGLE CASE SMALL N; Vygotsky L.S., 1994, VYGOTSKY READER; Wherton JP, 2008, INT J HUM-COMPUT ST, V66, P571, DOI 10.1016/j.ijhcs.2008.03.001; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Winsler A, 2003, CHILD DEV, V74, P659, DOI 10.1111/1467-8624.00561; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; Ylvisaker M., 2003, BRAIN IMPAIR, V4, P1, DOI [DOI 10.1375/brim.4.1.1.27031, https://doi.org/10.1375/brim.4.1.1.27031, DOI 10.1375/BRIM.4.1.1.27031]; Zittoun T, 2007, HUM DEV, V50, P208, DOI 10.1159/000103361	61	30	30	0	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	4					509	527	PII 919471431	10.1080/09602010903519652			19	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	622BT	WOS:000279634300002	20182951	Green Accepted			2022-02-06	
J	Williams, C; Wood, RL				Williams, Claire; Wood, Rodger Ll.			Impairment in the recognition of emotion across different media following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Emotion recognition; Affective valence; Cognitive tests; Media presentation	CLOSED-HEAD INJURY; DIFFUSE AXONAL INJURY; SOCIAL-PERCEPTION; FACIAL EXPRESSIONS; AMYGDALA DAMAGE; FACES; LESIONS; COMMUNICATION; ALEXITHYMIA; VALIDITY	The current study examined emotion recognition following traumatic brain injury (TBI) and examined whether performance differed according to the affective valence and type of media presentation of the stimuli. A total of 64 patients with TBI and matched controls completed the Emotion Evaluation Test (EET) and Ekman 60 Faces Test (E-60-FT). Patients with TBI also completed measures of information processing and verbal ability. Results revealed that the TBI group were significantly impaired compared to controls when recognizing emotion on the EET and E-60-FT. A significant main effect of valence was found in both groups, with poor recognition of negative emotions. However, the difference between the recognition of positive and negative emotions was larger in the TBI group. The TBI group were also more accurate recognizing emotion displayed in audiovisual media (EET) than that displayed in still media (E-60-FT). No significant relationship was obtained between emotion recognition tasks and information-processing speed. A significant positive relationship was found between the E-60-FT and one measure of verbal ability. These findings support models of emotion that specify separate neurological pathways for certain emotions and different media and confirm that patients with TBI are vulnerable to experiencing emotion recognition difficulties.	[Williams, Claire; Wood, Rodger Ll.] Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales		Williams, C (corresponding author), Swansea Univ, Dept Psychol, Sch Human Sci, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	200528@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X	Brain Injury Rehabilitation Trust, UK	Funding for this research was obtained, in part, from the Brain Injury Rehabilitation Trust, UK.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams RB, 2003, SCIENCE, V300, P1536, DOI 10.1126/science.1082244; Adolphs R, 2002, J COGNITIVE NEUROSCI, V14, P1264, DOI 10.1162/089892902760807258; Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; BASSILI JN, 1978, J EXP PSYCHOL HUMAN, V4, P373, DOI 10.1037/0096-1523.4.3.373; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; BOWERS D, 1985, BRAIN COGNITION, V4, P258, DOI 10.1016/0278-2626(85)90020-X; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Cohen J., 2013, STAT POWER ANAL BEHA; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Ekman P., 1976, PICTURES FACIAL AFFE; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; HUMPHREYS GW, 1993, NEUROPSYCHOLOGIA, V31, P173, DOI 10.1016/0028-3932(93)90045-2; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Lane RD, 1996, PSYCHOSOM MED, V58, P203, DOI 10.1097/00006842-199605000-00002; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S., 2002, AWARENESS SOCIAL INF; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; PARRY FM, 1991, J CLIN EXP NEUROPSYC, V13, P545, DOI 10.1080/01688639108401070; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SCHERER KR, 1991, MOTIV EMOTION, V15, P123, DOI 10.1007/BF00995674; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Taylor G. J., 1997, DISORDERS AFFECT REG; TEASDALE G, 1974, LANCET, V2, P81; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518; Young A., 2002, FACIAL EXPRESSIONS E	51	30	30	1	19	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2010	32	2					113	122		10.1080/13803390902806543			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	550YX	WOS:000274172300001	19484648				2022-02-06	
J	Esposito, DP; Walker, JB				Esposito, Domenic P.; Walker, James B.			Contemporary Management of Penetrating Brain Injury	NEUROSURGERY QUARTERLY			English	Article						debridement; penetrating brain injury; surgical management	CIVILIAN GUNSHOT WOUNDS; CEREBRAL-BLOOD-FLOW; CRANIOCEREBRAL INJURIES; INTRACRANIAL-PRESSURE; MISSILE WOUNDS; TRAUMATIC ANEURYSMS; HEAD-INJURY; EXPERIENCE; INFECTIONS; BALLISTICS	Penetrating brain injury includes all traumatic brain injury that is not the result of a blunt mechanism. Concerning these injuries, gunshot wounds are by far the most prevalent. Despite law enforcement efforts, these injuries unfortunately continue to be commonplace in large trauma centers as well as in metropolitan and large community emergency departments. Great efforts have been undertaken to standardize the medical and Surgical management of these patients. The authors review the Guidelines of Penetrating Brain Injury published in 2001 and performed ail updated literature search concerning this topic. There is evidence to suggest based upon current data that aggressive antibiotic prophylaxis and avoidance of aggressive debridement of deep-seated bone and bullet fragments has improved morbidity and mortality over the last 35 years.	[Esposito, Domenic P.; Walker, James B.] Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA		Walker, JB (corresponding author), Univ Mississippi, Med Ctr, Dept Neurosurg, 2500 N State St, Jackson, MS 39216 USA.	jbwalker@neurosurgery.umsmed.edu					Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; Aarabi Bizhan, 2001, Journal of Trauma Injury Infection and Critical Care, V51, pS1; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; AMEEN AA, 1984, INJURY, V16, P88, DOI 10.1016/S0020-1383(84)80004-2; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; ARENDALL REH, 1983, NEUROSURGERY, V13, P377, DOI 10.1227/00006123-198310000-00005; BARACH E, 1986, J TRAUMA, V26, P225, DOI 10.1097/00005373-198603000-00003; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; CAREY ME, 1995, NEUROSURG CLIN N AM, V6, P629; CHAUDHRI KA, 1994, ACTA NEUROCHIR, V126, P120, DOI 10.1007/BF01476420; CROCKARD HA, 1975, J TRAUMA, V15, P339, DOI 10.1097/00005373-197504000-00011; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Gonul E, 1997, NEUROSURG REV, V20, P177, DOI 10.1007/BF01105561; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HELLING TS, 1992, J TRAUMA, V32, P398, DOI 10.1097/00005373-199203000-00019; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; Kordestani RK, 1997, NEUROSURGERY, V41, P351, DOI 10.1097/00006123-199708000-00003; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVY ML, 1999, TRAUMATIC BRAIN INJU, P201; LILLARD PL, 1978, SURG NEUROL, V9, P79; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; MINER ME, 1990, NEUROSURGERY, V26, P20, DOI 10.1227/00006123-199001000-00002; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; MUNSLOW RA, 1946, ANN SURG, V123, P180, DOI 10.1097/00000658-194602000-00002; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; Oliver C, 1997, CLIN RADIOL, V52, P299, DOI 10.1016/S0009-9260(97)80058-X; ORDOG GJ, 1984, ANN EMERG MED, V13, P1113, DOI 10.1016/S0196-0644(84)80336-4; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SARNAIK AP, 1989, J TRAUMA, V29, P1434, DOI 10.1097/00005373-198910000-00023; SHIMURA T, 1997, SHINKEI GEKA, V25, P607; TAHA JM, 1991, NEUROSURGERY, V29, P864, DOI 10.1227/00006123-199112000-00010; TEITELBAUM GP, 1990, RADIOLOGY, V175, P855, DOI 10.1148/radiology.175.3.2343136; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; VRANKOVIC D, 1992, NEUROCHIRURGIA, V35, P150; Whitaker R, 1916, BRIT J SURG, V3, P708; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236	48	30	30	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-6438	1534-4916		NEUROSURG QUART	Neurosurg. Q.	DEC	2009	19	4					249	254		10.1097/WNQ.0b013e3181bd1d53			6	Neurosciences; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	524AK	WOS:000272116000006					2022-02-06	
J	Larson, AN; Stans, AA; Shaughnessy, WJ; Dekutoski, MB; Quinn, MJ; McIntosh, AL				Larson, A. Noelle; Stans, Anthony A.; Shaughnessy, William J.; Dekutoski, Mark B.; Quinn, Michael J.; McIntosh, Amy L.			Motocross Morbidity: Economic Cost and Injury Distribution in Children	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						motocross; motorbike; injury; pediatric; children; dirtbike; trauma	FOOTBALL PLAYERS; CONCUSSION; SPORT	Background: Motocross is a nationally organized sport that is growing in popularity. The distribution and severity of motocross injuries in the pediatric population is not known. We hypothesize a high rate of musculoskeletal injuries requiring hospitalization and/or surgical intervention. Methods: All patients 17 years of age or younger with injuries sustained while using off-road 2-wheeled motorcycles were identified through surgical, diagnostic, and trauma registries at a level 1 regional trauma center. Type, severity, and mechanism of injury were assessed, as well as charges billed for medical care. Both recreational and competitive motocross activities were included. Results: From 2000 to 2007, 299 cases were noted in 249 unique patients. In 141 instances, hospital admission was required, for a total of 412 inpatient days. Twenty patients required ICU admission. Surgery was performed in 91 cases (81 orthopaedic, 6 general, 1 urology, and 4 facial reconstructions). Orthopaedic surgical procedures included treatment of 29 femur fractures, 8 forearm, 6 ankle, 5 tibial shaft, 6 proximal tibia, 5 spine, 6 proximal humerus, 4 hand, 4 foot, 3 elbow fractures, and 5 other. Orthopaedic interventions also included 8 reductions under general anesthesia and 31 conscious sedations. Mean age at injury was 14.1 years (range: 5.4 to 17.9). Ninety-four percent of patients were male and 85% were White. The majority of patients were wearing helmets/safety equipment. One hundred and eighty-four injuries occurred on a track, with 150 during competition. The mean charge billed per injury was $14,947 (range: $105 to $217,780), with a total cost of $4.5 million. Conclusions: Nearly half of motocross patients treated at a regional level 1 trauma center required hospitalization, and nearly one-third required surgery. The vast majority of surgical procedures (89%) were orthopaedic. Despite a high usage rate of helmets and protective gear, severe injuries were still sustained, including femur fracture (29), hemiparesis/spinal cord injury (2), and head injury (43). The majority of injuries occurred during organized race or practice. Families should be counseled with regard to the use of safety equipment and the severity of injuries sustained during competitive motocross activity.	[Larson, A. Noelle; Stans, Anthony A.; Shaughnessy, William J.; Dekutoski, Mark B.; Quinn, Michael J.; McIntosh, Amy L.] Mayo Clin, Rochester, MN 55905 USA		McIntosh, AL (corresponding author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.	mcintosh.amy@mayo.edu	Larson, A. Noelle/AAC-7158-2019; shaughnessy, william/AAJ-4458-2020	McIntosh, Amy/0000-0002-3660-4901; Larson, A. Noelle/0000-0001-6542-6975			*AM MOT ASS, 2008, 2008 RUL GOV PROAM S; Colburn NT, 2003, INJURY, V34, P207, DOI 10.1016/S0020-1383(02)00039-6; Collins CL, 2007, PEDIATRICS, V120, P134, DOI 10.1542/peds.2006-3612; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; *COMM ACC POIS PRE, 1987, PEDIATRICS, V79, P306; FONTIJNE WPJ, 1989, J SPORT MED PHYS FIT, V29, P199; Goldberg LD, 2006, SPORTS MED ARTHROSC, V14, P199, DOI 10.1097/01.jsa.0000212326.23560.09; Killingsworth JB, 2005, PEDIATRICS, V115, pE316, DOI 10.1542/peds.2004-1585; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Pomerantz WJ, 2005, PEDIATRICS, V115, P704, DOI 10.1542/peds.2004-1304; STREETER RA, 2006, 2006 ANN REP ATV REL	13	30	30	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0271-6798	1539-2570		J PEDIATR ORTHOPED	J. Pediatr. Orthop.	DEC	2009	29	8					847	850		10.1097/BPO.0b013e3181c1e2fa			4	Orthopedics; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Pediatrics	526SN	WOS:000272313900003	19934696				2022-02-06	
J	Schuster, KM; Lofthouse, R; Moore, C; Lui, F; Kaplan, LJ; Davis, KA				Schuster, Kevin M.; Lofthouse, Rebecca; Moore, Christopher; Lui, Felix; Kaplan, Lewis J.; Davis, Kimberly A.			Pulseless Electrical Activity, Focused Abdominal Sonography for Trauma, and Cardiac Contractile Activity as Predictors of Survival After Trauma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	39th Annual Meeting of the Western-Trauma-Association	FEB 22-28, 2009	Crested Butte, CO	Western Trauma Assoc		Ultrasound; Echocardiography; Trauma; Pulseless electrical activity	PREHOSPITAL PULSELESS; ULTRASOUND; RESUSCITATION; EMERGENCY	Background: Pulseless electrical activity (PEA) secondary to both blunt and penetrating trauma is associated with minimal survival. The pericardial view of the focused abdominal sonography for trauma (p-FAST) can differentiate between patients with and without organized cardiac activity and may assist in the decision to terminate ongoing resuscitation. Methods: A retrospective review was performed for all patients presenting to a level I trauma center from January 2006 through January/2009 who had PEA on arrival or developed PEA in the emergency department. Additional data abstracted included outcome, the p-FAST findings, and mechanism of injury. Recorded FAST examinations were reviewed by a blinded ultrasound trained physician. Results: During the study period 25 patients presented with PEA and three developed PEA during initial resuscitation. Contractile cardiac activity was present in nine patients with PEA on presentation and immediately after deterioration to PEA in the three patients developing PEA. Four patients had a penetrating mechanism and 24 were blunt. Two pericardial effusions were present on examination, both after blunt trauma. Three patients survived beyond the emergency department (89% early mortality). The survivors had presented in PEA with organized cardiac contractile activity on ultrasound and had tension pneumothorax, tension hemothorax, and hypovolemia treated. Two patients died in the operating room of uncontrolled hemorrhage and one patient died 6 days after admission because of closed head injury. Conclusions: The presence of PEA at any time during initial resuscitation is a grave prognostic indicator. p-FAST is a useful test to identify contractile cardiac activity. p-FAST may identify those patients with potential for survival.	[Schuster, Kevin M.; Moore, Christopher] Yale Univ, Sch Med, Dept Surg, Sect Emergency Med, New Haven, CT 06520 USA; [Lofthouse, Rebecca] Yale New Haven Med Ctr, Ctr Trauma, New Haven, CT 06504 USA		Schuster, KM (corresponding author), Yale Univ, Sch Med, Dept Surg, Sect Emergency Med, 330 Cedar St,BB310, New Haven, CT 06520 USA.	kevin.schuster@yale.edu					*AM COLL SURG, 2008, AM COLL SURG COMM TR; Antonenko DR, 1999, ARCH SURG-CHICAGO, V134, P745; Battistella FD, 1999, ARCH SURG-CHICAGO, V134, P742, DOI 10.1001/archsurg.134.7.742; Blaivas M, 2001, ACAD EMERG MED, V8, P616, DOI 10.1111/j.1553-2712.2001.tb00174.x; Boulanger BR, 2001, J TRAUMA, V51, P320, DOI 10.1097/00005373-200108000-00015; Chang MC, 1998, J TRAUMA, V44, P296; Dyer D, 2008, J TRAUMA, V65, P1209, DOI 10.1097/TA.0b013e3181878052; Falcone R E, 1995, Air Med J, V14, P197, DOI 10.1016/1067-991X(95)90002-0; Falcone RE, 1995, AIR MED J, V14, P204; FRESHMAN SP, 1991, J TRAUMA, V31, P902, DOI 10.1097/00005373-199107000-00004; Martin SK, 2002, J TRAUMA, V53, P876, DOI 10.1097/00005373-200211000-00011; Rozycki GS, 1999, J TRAUMA, V46, P543, DOI 10.1097/00005373-199904000-00002; ROZYCKI GS, 1993, J TRAUMA, V34, P516, DOI 10.1097/00005373-199304000-00008; Salen P, 2001, ACAD EMERG MED, V8, P610, DOI 10.1111/j.1553-2712.2001.tb00172.x; Sisley AC, 1998, J TRAUMA, V44, P291, DOI 10.1097/00005373-199802000-00009; Stratton SJ, 1998, J TRAUMA, V45, P96, DOI 10.1097/00005373-199807000-00021; Su MJ, 2008, TELEMED J E-HEALTH, V14, P816, DOI 10.1089/tmj.2008.0076; Wherrett LJ, 1996, J TRAUMA, V41, P815, DOI 10.1097/00005373-199611000-00008; Wisner DH, 1999, J TRAUMA, V46, P551	19	30	31	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2009	67	6					1154	1157		10.1097/TA.0b013e3181c303e8			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	531IL	WOS:000272658100005	20009660				2022-02-06	
J	Marklund, N; Morales, D; Clausen, F; Hanell, A; Kiwanuka, O; Pitkanen, A; Gimbel, DA; Philipson, O; Lannfelt, L; Hillered, L; Strittmatter, SM; McIntosh, TK				Marklund, N.; Morales, D.; Clausen, F.; Hanell, A.; Kiwanuka, O.; Pitkanen, A.; Gimbel, D. A.; Philipson, O.; Lannfelt, L.; Hillered, L.; Strittmatter, S. M.; McIntosh, T. K.			FUNCTIONAL OUTCOME IS IMPAIRED FOLLOWING TRAUMATIC BRAIN INJURY IN AGING Nogo-A/B-DEFICIENT MICE	NEUROSCIENCE			English	Article						traumatic brain injury; Nogo-A; Nogo-B; Morris water maze; neurological motor deficits	CONTROLLED CORTICAL IMPACT; NEURITE OUTGROWTH INHIBITOR; AMYLOID-BETA; SPINAL-CORD; AXON REGENERATION; COGNITIVE DEFICITS; TRANSGENIC MICE; RECEPTOR; RECOVERY; ADULT	Increasing age is associated with a poor prognosis following traumatic brain injury (TBI). CNS axons may recover poorly following TBI due to expression of myelin-derived inhibitors to axonal outgrowth such as Nogo-A. To study the role of Nogo-A/B in the pathophysiological response of the elderly to TBI, 1-year-old mice deficient in Nogo-A/B (Nogo-A/B homozygous(-/-) mice), Nogo-A/B heterozygous(-/+) mice, and age-matched wild-type (WT) littermate controls were subjected to a controlled cortical impact (CCI) TBI. Sham-injured WT mice (7 months old) and 12 month old naive Nogo-A/B-/- and Nogo-A/B-/+ served as controls. Neurological motor function was evaluated up to 3 weeks, and cognitive function, hemispheric tissue loss, myelin staining and hippocampal beta-amyloid (A beta) immunohistochemistry were evaluated at 4 weeks post-injury. In WT littermates, TBI significantly impaired learning ability at 4 weeks and neurological motor function up to 2 weeks post-injury and caused a significant loss of hemispheric tissue. Following TBI, Nogo-A/B-/- mice showed significantly less recovery from neurological motor and cognitive deficits compared to brain-injured WT mice. Naive Nogo-A/B-/- and Nogo-A/B-/+ mice quickly learned the MWM task in contrast to brain-injured Nogo-A/B-/- mice who failed to learn the MWM task at 4 weeks post-injury. Hemispheric tissue loss and cortical lesion volume were similar among the brain-injured genotypes. Neither TBI nor the absence of NogoA/B caused an increased A beta expression. Myelin staining showed a reduced area and density in the corpus callosum in brain-injured Nogo-A/B-/- animals compared to their littermate controls. These novel and unexpected behavioral results demonstrate that the absence of Nogo-A/B may negatively influence outcome, possibly related to hypomyelination, following TBI in mice and suggest a complex role for this myelin-associated axonal growth inhibitor following TBI. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[Marklund, N.; Clausen, F.; Hanell, A.; Kiwanuka, O.; Hillered, L.] Univ Uppsala Hosp, Dept Neurosurg, SE-75185 Uppsala, Sweden; [Marklund, N.; Morales, D.; McIntosh, T. K.] Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; [Gimbel, D. A.; Strittmatter, S. M.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA; [Marklund, N.; McIntosh, T. K.] Vet Adm Med Ctr, Philadelphia, PA 19104 USA; [Pitkanen, A.] Univ Kuopio, Epilepsy Res Lab, Al Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; [Pitkanen, A.] Univ Kuopio, Dept Neurol, FIN-70211 Kuopio, Finland; [Philipson, O.; Lannfelt, L.] Univ Uppsala Hosp, Dept Publ Hlth & Caring Sci, SE-75185 Uppsala, Sweden		Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, SE-75185 Uppsala, Sweden.	niklas.marklund@neurokir.uu.se	Hanell, Anders/E-4776-2011; Strittmatter, Stephen/F-5739-2011	Hanell, Anders/0000-0001-9369-3886; Kiwanuka, Olivia/0000-0003-3562-5513; Strittmatter, Stephen/0000-0001-8188-3092; Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626; Morales, Diego/0000-0001-6672-9046; Hillered, Lars/0000-0002-2808-9292	NIH NSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS RO1-40978, NS P50-08803, NS RO1-56485, NS RO1-39962]; Swedish MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Uppsala University Hospital; Swedish Brain Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803, R01NS042304, R01NS039962, R01NS056485, R37NS033020] Funding Source: NIH RePORTER	Supported by NIH NS RO1-40978, a Merit Review Grant from the Veterans Administration, NIH NS P50-08803, Swedish MRC, Uppsala University Hospital and the Swedish Brain Foundation. NIH NS RO1-56485 and NS RO1-39962 to S.M.S. We thank Rishi Puri, David LeBold, Carl T. Fulp, Lena Rundstrom and Hilaire J. Thompson for excellent technical support.	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; Cafferty WBJ, 2007, NEURON, V54, P195, DOI 10.1016/j.neuron.2007.04.005; Cafferty WBJ, 2006, J NEUROSCI, V26, P12242, DOI 10.1523/JNEUROSCI.3827-06.2006; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Dimou L, 2006, J NEUROSCI, V26, P5591, DOI 10.1523/JNEUROSCI.1103-06.2006; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fournier AE, 2002, PROG BRAIN RES, V137, P361; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Huber AB, 2002, J NEUROSCI, V22, P3553; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hunt D, 2003, MOL CELL NEUROSCI, V24, P1083, DOI 10.1016/j.mcn.2003.09.002; Hunt D, 2002, J NEUROCYTOL, V31, P93, DOI 10.1023/A:1023941421781; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Li SX, 2003, J NEUROSCI, V23, P4219; Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Lord A, 2006, NEUROBIOL AGING, V27, P67, DOI 10.1016/j.neurobiolaging.2004.12.007; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Marriott MP, 2008, GLIA, V56, P686, DOI 10.1002/glia.20646; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Oertle T, 2003, J NEUROSCI, V23, P5393; Park JH, 2006, J NEUROSCI, V26, P1386, DOI 10.1523/JNEUROSCI.3291-05.2006; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Pernet V, 2008, J NEUROSCI, V28, P7435, DOI 10.1523/JNEUROSCI.0727-08.2008; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Tang BL, 2007, J NEUROCHEM, V100, P314, DOI 10.1111/j.1471-4159.2006.04215.x; Teng FYH, 2005, J NEUROCHEM, V94, P865, DOI 10.1111/j.1471-4159.2005.03238.x; Teng FYH, 2005, J NEUROSCI RES, V79, P273, DOI 10.1002/jnr.20361; The Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, AGE J NEUROTRAUMA, V17, P573; Wang XX, 2006, ANN NEUROL, V60, P540, DOI 10.1002/ana.20953; Wang XX, 2002, J NEUROSCI, V22, P5505; Willi R, 2009, GENES BRAIN BEHAV, V8, P181, DOI 10.1111/j.1601-183X.2008.00460.x; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	65	30	32	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 6	2009	163	2					540	551		10.1016/j.neuroscience.2009.06.042			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	496JR	WOS:000269967800005	19555742	Green Accepted			2022-02-06	
J	Vincenzi, R; Cepeda, LA; Pirani, WM; Sannomyia, P; Rocha-e-Silva, M; Cruz, RJ				Vincenzi, Rodrigo; Cepeda, Lourdes A.; Pirani, William M.; Sannomyia, Paulina; Rocha-e-Silva, Mauricio; Cruz, Ruy J., Jr.			Small volume resuscitation with 3% hypertonic saline solution decrease inflammatory response and attenuates end organ damage after controlled hemorrhagic shock	AMERICAN JOURNAL OF SURGERY			English	Article						Hemorrhagic shock; Hypertonic solution; Inflammation; Cytokines; Trauma; Acute lung injury	LACTATED RINGERS; INTRACRANIAL-PRESSURE; CEREBRAL EDEMA; LUNG INJURY; MODEL; PENTOXIFYLLINE; NACL; INFUSION; TRAUMA; BRAIN	BACKGROUND: Recently, studies have been conducted examining the efficacy of 3% hypertonic saline solution (HS) for the treatment of traumatic brain injury; however, few studies have analyzed the effects of 3% hemorrhagic shock during hemorrhagic shock. The aim of this study was to test the potential immunomodulatory benefits of 3% hemorrhagic shock resuscitation over standard fluid resuscitation. METHODS: Wistar rats were bled to a mean arterial pressure of 35 mm Hg and then randomized into 3 groups: those treated with lactated Ringer's solution (LR; 33 mL/kg, n = 7), 3% HS (10 mL/kg, n = 7), and 7.5% HS (4 mL/kg, n = 7). Half of the extracted blood was reinfused after fluid resuscitation. Animals that did not undergo shock served as controls (n = 5). Four hours after hemorrhagic shock, blood was collected for the evaluation of tumor necrosis factor-a and interleukin-6 by enzyme immunoassay. Lung and intestinal samples were obtained for histopathologic analysis. RESULTS: Animals in the HS groups had significantly higher mean arterial pressure than those in the LR group 1 hour after treatment. Osmolarity and sodium levels were markedly elevated in the HS groups. Tumor necrosis factor-alpha and interleukin-6 levels were similar between the control and HS groups but significantly higher in the LR group (P < .05). The lung injury score was significantly higher in the LR group compared with the 7.5% HS and 3% HS groups (5.7 +/- 0.7, 2.1 +/- 0.4, and 2.7 +/- 0.5, respectively). Intestinal injury was attenuated in the 7.5% HS and 3% HS groups compared with the LR group (2.0 +/- 0.6, 2.3 +/- 0.4, and 5.9 +/- 0.6, respectively). CONCLUSIONS: A small-volume resuscitation strategy modulates the inflammatory response and decreases end-organ damage after HS. Three percent HS provides immunomodulatory and metabolic effects similar to those observed with conventional concentrations of HS. (C) 2009 Elsevier Inc. All rights reserved.	[Cruz, Ruy J., Jr.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA; [Vincenzi, Rodrigo; Sannomyia, Paulina; Rocha-e-Silva, Mauricio] Univ Sao Paulo, Sch Med, InCor, Div Res, Sao Paulo, Brazil; [Cepeda, Lourdes A.; Pirani, William M.] Univ Santo Amaro, Sch Med, Dept Pathol, Sao Paulo, Brazil		Cruz, RJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA.	cruzrj@upmc.edu					Angle N, 1998, J TRAUMA, V45, P7, DOI 10.1097/00005373-199807000-00002; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Chang JX, 2005, WORLD J GASTROENTERO, V11, P5485, DOI 10.3748/wjg.v11.i35.5485; Choileain NN, 2006, ARCH SURG-CHICAGO, V141, P1132, DOI 10.1001/archsurg.141.11.1132; Ciesla DJ, 2000, SHOCK, V14, P265, DOI 10.1097/00024382-200014030-00004; Coimbra R, 1996, J SURG RES, V64, P203, DOI 10.1006/jsre.1996.0329; Cruz RJ, 2006, ANESTH ANALG, V102, P1518, DOI 10.1213/01.ane.0000204255.35494.f2; de Figueiredo LFP, 2005, J INVEST SURG, V18, P257, DOI 10.1080/08941930500248904; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; Kiraly LN, 2006, J TRAUMA, V61, P57, DOI 10.1097/01.ta.0000220373.29743.69; Lee CC, 2005, SHOCK, V24, P177, DOI 10.1097/01.shk.0000171870.42900.15; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629, DOI 10.1152/ajpheart.1988.255.3.H629; Murao Y, 2003, SHOCK, V20, P23, DOI 10.1097/01.shk.0000078832.57685.6c; Pascual JL, 2003, J TRAUMA, V54, P121, DOI 10.1097/00005373-200301000-00015; Pinto FCG, 2006, J TRAUMA, V60, P758, DOI 10.1097/01.ta.0000214581.89316.73; Powers KA, 2003, SURGERY, V134, P312, DOI 10.1067/msy.2003.246; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Rizoli SB, 1998, J IMMUNOL, V161, P6288; Rocha-e-Silva Mauricio, 2005, Clinics, V60, P159, DOI 10.1590/S1807-59322005000200013; Shi HP, 2002, SHOCK, V17, P496, DOI 10.1097/00024382-200206000-00010; Todd SR, 2007, J TRAUMA, V62, P636, DOI 10.1097/TA.0b013e31802ee521; Vaid SU, 2006, CRIT CARE MED, V34, P1185, DOI 10.1097/01.CCM.0000207341.78696.3A; VELASCO IT, 1980, AM J PHYSIOL, V239, pH664, DOI 10.1152/ajpheart.1980.239.5.H664; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; Watters JM, 2006, J TRAUMA, V61, P75, DOI 10.1097/01.ta.0000222723.54559.47; Yada-Langui MM, 2004, EXP BIOL MED, V229, P684, DOI 10.1177/153537020422900713; Yada-Langui MM, 2000, SHOCK, V14, P594, DOI 10.1097/00024382-200014060-00004; Ziai WC, 2007, J NEUROL SCI, V261, P157, DOI 10.1016/j.jns.2007.04.048	30	30	40	0	0	EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC	BRIDGEWATER	685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA	0002-9610	1879-1883		AM J SURG	Am. J. Surg.	SEP	2009	198	3					407	414		10.1016/j.amjsurg.2009.01.017			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	502FK	WOS:000270440800017	19520355				2022-02-06	
J	Baguley, IJ; Heriseanu, RE; Nott, MT; Chapman, J; Sandanam, J				Baguley, Ian J.; Heriseanu, Roxana E.; Nott, Melissa T.; Chapman, Jenny; Sandanam, Joseph			Dysautonomia after Severe Traumatic Brain Injury Evidence of Persisting Overresponsiveness to Afferent Stimuli	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Brain Injuries; Heart Rate; Dysautonomia; Sympathetic Nervous System; Nociception; Sympathetic Overactivity	HEART-RATE-VARIABILITY; AUTONOMIC DYSREFLEXIA; MANAGEMENT; DYSFUNCTION	Objective: To differentiate between dysautonomic and nondysautonomic subjects with acquired brain injury by measuring sympathetic reactivity after a nociceptive clinical procedure and to determine the utility of heart rate variability as an indicator of sympathetic overresponsivity in dysautonomic subjects. Design: This case-controlled study recruited subjects with acquired brain injury (mean, 5 yrs postinjury) attending a hospital-based outpatient clinic, comprising seven dysautonomic subjects with traumatic brain injury, eight nondysautonomic traumatic brain injury subjects, and 11 nondysautonomic subjects with nontraumatic acquired brain injury. Sympathetic reactivity after nociceptive stimuli (limb assessment and botulinum toxin injection for spasticity management) was compared among groups. Results: Sympathetic overactivity in dysautonomic subjects was evident across all physiologic parameters, whereas nondysautonomic subjects demonstrated limited reactivity. Heart rate variability measures of the balance between sympathetic and parasympathetic cardiac control showed a significant elevation in response to nociceptive stimuli, a response not observed in either nondysautonomic group. This sympathetic overactivity showed a normalizing tendency with increasing time postinjury. Conclusions: This study found persistent sympathetic overactivity in response to nociceptive stimuli in dysautonomic subjects (mean, 5 yrs postinjury). This significantly extends the duration over which such sympathetic overactivity has been quantified in this group, contributing to the accumulating empirical evidence that dysautonomic paroxysms result from sympathetic overresponsiveness. Given that sympathetic overactivity has now been observed from day 7 through 5 yrs postinjury, quantitative evaluation of patients for overresponsiveness to stimuli should be added to current diagnostic procedures at all stages of recovery.	[Baguley, Ian J.; Heriseanu, Roxana E.; Nott, Melissa T.] Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; [Baguley, Ian J.] Univ Sydney, Rehabil Studies Unit, Fac Med, Sydney, NSW 2006, Australia; [Chapman, Jenny; Sandanam, Joseph] St Josephs Hosp, Dept Rehabil Med, Auburn, NSW, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.		Baguley, Ian/AAM-5828-2021; Nott, Melissa T/M-6778-2018; Baguley, Ian J/K-6878-2013	Nott, Melissa T/0000-0001-7088-5826; Baguley, Ian J/0000-0001-5650-3705			Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 2008, SEMIN NEUROL, V28, P716, DOI 10.1055/s-0028-1105971; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Camm AJ, 1996, CIRCULATION, V93, P1043; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Diesing TS, 2006, MOVEMENT DISORD, V21, P868, DOI 10.1002/mds.20831; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; GUZZETTI S, 1994, AM J PHYSIOL, V266, pH1112, DOI 10.1152/ajpheart.1994.266.3.H1112; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; HUIKURI HV, 1990, AM J CARDIOL, V65, P391, DOI 10.1016/0002-9149(90)90308-N; LEMKE DM, 2004, J NEUROSCI NURS, V3, P4; Ori Z, 1992, Cardiol Clin, V10, P499; Penfield W, 1954, EPILEPSY FUNCTIONAL, P412; Rabchevsky AG, 2006, PROG BRAIN RES, V152, P265, DOI 10.1016/S0079-6123(05)52017-X; Rabinstein AA, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-a; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; Sacha J, 2005, J ELECTROCARDIOL, V38, P47, DOI 10.1016/j.jelectrocard.2004.09.015; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; Tong CY, 2000, ANESTH ANALG, V91, P1450, DOI 10.1097/00000539-200012000-00028; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Weaver LC, 2001, J NEUROTRAUM, V18, P1107, DOI 10.1089/08977150152693782	32	30	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2009	88	8					615	622		10.1097/PHM.0b013e3181aeab96			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	476VW	WOS:000268475400002	19620826				2022-02-06	
J	Gamino, JF; Chapman, SB; Cook, LG				Gamino, Jacquelyn F.; Chapman, Sandra B.; Cook, Lori G.			Strategic Learning in Youth With Traumatic Brain Injury Evidence for Stall in Higher-Order Cognition	TOPICS IN LANGUAGE DISORDERS			English	Article						adolescence; brain injury; cognitive stall; discourse; executive function/executive control; frontal lobe; gist; neuroplasticity	WORKING-MEMORY; ACADEMIC-ACHIEVEMENT; CHILDREN; DISCOURSE; TEXT	Little is known about strategic learning ability in preteens and adolescents with traumatic brain injury (TBI). Strategic learning is the ability to combine and synthesize details to form abstracted gist-based meanings, a higher-order cognitive skill associated with frontal lobe functions and higher classroom performance. Summarization tasks were used to measure strategic learning ability through the production of abstracted gist-based concepts, and specific probes measured memory for explicit details. Twenty middle school-aged preteens and teenagers who sustained a moderate to severe TBI 1 year postinjury and a control group of 20 typically developing 10- to 15-year-old subjects participated in this study. The results revealed that the youth with moderate to severe TBI were able to recall specific details at a comparable level to the control group. However, the youth with TBI demonstrated significantly lower strategic learning competence, as manifested by a reduced ability to combine details into gist-based ideas. The present findings advance the notion that skills that have not yet developed at the time of brain injury or are in a stage of development may be particularly vulnerable to the long-term and lasting sequelae of TBI in youth, although a longitudinal study is needed to verify this claim.	[Gamino, Jacquelyn F.; Chapman, Sandra B.; Cook, Lori G.] Univ Texas Dallas, Ctr BrainHlth, Sch Behav & Brain Sci, Dallas, TX 75235 USA		Gamino, JF (corresponding author), Univ Texas Dallas, Ctr BrainHlth, Sch Behav & Brain Sci, 2200 W Mockingbird, Dallas, TX 75235 USA.	jgamino@utdallas.edu					Bjorklund DF, 1997, DEV REV, V17, P411, DOI 10.1006/drev.1997.0440; Bor D, 2003, NEURON, V37, P361, DOI 10.1016/S0896-6273(02)01171-6; BRAINERD CJ, 1992, DEV REV, V12, P164, DOI 10.1016/0273-2297(92)90007-O; Brainerd CJ, 1998, DEV PSYCHOL, V34, P342, DOI 10.1037/0012-1649.34.2.342; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; BROWN AL, 1983, J VERB LEARN VERB BE, V22, P1, DOI 10.1016/S0022-5371(83)80002-4; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; CHAPMAN SB, 2007, BRAIN INJ PROF, V3, P10; CHAPMAN SB, 2009, TEST STRATEGIC UNPUB; Cook LG, 2007, CHILDRENS COMPREHENS, P218; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Gabrieli John D E, 2004, Cerebrum, V6, P39; Gamino J. F., 2008, INT NEUR SOC ANN M W; GAMINO JE, 2009, STRATEGIC LEAR UNPUB; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JOHNSON NS, 1983, CHILDRENS LANGUAGE, P314; KINTSCH E, 1990, COGNITION INSTRUCT, V7, P161, DOI 10.1207/s1532690xci0703_1; KINTSCH W, 1994, HDB PSYCHOLINGUISTIC, P00721; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; MALONE LD, 1992, EXCEPT CHILDREN, V58, P270, DOI 10.1177/001440299105800309; Mayer RE, 1996, EDUC PSYCHOL REV, V8, P357, DOI 10.1007/BF01463939; Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024; Reyna VF, 1998, J EXP CHILD PSYCHOL, V71, P194, DOI 10.1006/jecp.1998.2472; STEIN BL, 1992, J READING BEHAV, V24, P217, DOI 10.1080/10862969209547773; TEASDALE G, 1974, LANCET, V2, P81; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; Wechsler D., 2011, WECHSLER ABBREVIATED	31	30	32	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-8294			TOP LANG DISORD	Top. Lang. Disord.	JUL-SEP	2009	29	3					224	235		10.1097/TLD.0b013e3181b531da			12	Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Linguistics; Rehabilitation	488HT	WOS:000269340700004					2022-02-06	
J	Ramati, A; Rubin, LH; Wicklund, A; Pliskin, NH; Ammar, AN; Fink, JW; Bodnar, EN; Lee, RC; Cooper, MA; Kelley, KM				Ramati, Alona; Rubin, Leah H.; Wicklund, Alissa; Pliskin, Neil H.; Ammar, Alia N.; Fink, Joseph W.; Bodnar, Elena N.; Lee, Raphael C.; Cooper, Mary Ann; Kelley, Kathleen M.			Psychiatric morbidity following electrical injury and its effects on cognitive functioning	GENERAL HOSPITAL PSYCHIATRY			English	Article						Electrical injury; Psychopathology; Cognitive	TRAUMATIC BRAIN-INJURY; DISORDERS; THERAPY; ECT	Objective: This study examines the prevalence of psychiatric morbidity in a large sample of electrical injury (EI) patients in three phases of recovery and its effects on cognitive functioning. Methods: Eight-six self-referred El patients received psychiatric and neuropsychological evaluations. Descriptive statistics were conducted to examine the prevalence of psychiatric morbidity. Polytomous logistic regression was used to identify predictors of psychiatric diagnosis. Between-subjects analysis of variances (ANOVA) was conducted to examine the effects of psychiatric morbidity on cognitive functioning. Results: Seventy-eight percent of subjects warranted a psychiatric diagnosis. Long-term patients compared to acute patients were more likely to be diagnosed with two diagnoses than not having any diagnosis (OR= 14.30, 95% CI 1.40-38.71). Patients with two diagnoses performed worse than both patients with a single or no diagnosis on all cognitive outcome measures (P<05). Voltage level, chronic pain and litigation status did not predict psychiatric morbidity. Conclusions: Psychiatric difficulties commonly emerge and persist following EI. EI patients with psychiatric conditions exhibited poorer cognitive performance as compared to EI patients with no post-injury psychiatric difficulties. Health care professionals need to devote careful attention to psychiatric and cognitive status when treating survivors of EI. (C) 2009 Elsevier Inc. All rights reserved.	[Ramati, Alona; Rubin, Leah H.; Wicklund, Alissa; Pliskin, Neil H.; Ammar, Alia N.; Kelley, Kathleen M.] Univ Illinois, Dept Psychiat, Coll Med, Chicago, IL 60612 USA; [Cooper, Mary Ann] Univ Illinois, Dept Emergency Med, Coll Med, Chicago, IL 60612 USA; [Ramati, Alona; Pliskin, Neil H.; Fink, Joseph W.; Bodnar, Elena N.; Lee, Raphael C.; Cooper, Mary Ann; Kelley, Kathleen M.] Chicago Elect Trauma Res Program, Chicago, IL USA; [Fink, Joseph W.] Univ Illinois, Dept Psychiat, Pritzker Sch Med, Chicago, IL 60612 USA; [Bodnar, Elena N.; Lee, Raphael C.] Univ Illinois, Dept Surg, Pritzker Sch Med, Chicago, IL 60612 USA		Pliskin, NH (corresponding author), Univ Illinois, Dept Psychiat, Coll Med, Chicago, IL 60612 USA.	npliskin@uic.edu	Cooper, Mary Ann/AAF-2524-2020	Lee, Raphael C./0000-0002-6628-1867			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Ammar A, 2006, ACTA NEUROPSYCHOL, V4, P119; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Barrash J, 1996, Appl Neuropsychol, V3, P75, DOI 10.1207/s15324826an0302_5; Castaneda AE, 2008, J AFFECT DISORDERS, V106, P1, DOI 10.1016/j.jad.2007.06.006; Cawley JC, 2003, J SAFETY RES, V34, P241, DOI 10.1016/S0022-4375(03)00028-8; Chanpattana W, 2000, BIOL PSYCHIAT, V48, P222, DOI 10.1016/S0006-3223(00)00830-1; Delis D.C., 2000, CALIFORNIA VERBAL LE; Fink M, 2001, J AFFECT DISORDERS, V63, P1, DOI 10.1016/S0165-0327(00)00367-0; GOLDEN CJ, 2002, STROUP COLOR WORD TE; Grossman A. Richard, 1993, Journal of Burn Care and Rehabilitation, V14, P169, DOI 10.1097/00004630-199303000-00008; HOOSHMAND H, 1989, CLIN ELECTROENCEPHAL, V20, P111, DOI 10.1177/155005948902000208; Ishihara K, 1999, JPN J PHARMACOL, V80, P185, DOI 10.1254/jjp.80.185; JARVIS PE, 1984, HALSTED REITAN TEST; JOHANSSON B, 1987, MED HYPOTHESES, V24, P313, DOI 10.1016/0306-9877(87)90208-8; KELLEY KM, 1994, ANN NY ACAD SCI, V720, P213, DOI 10.1111/j.1749-6632.1994.tb30449.x; Kelley KM, 1999, ANN NY ACAD SCI, V888, P356, DOI 10.1111/j.1749-6632.1999.tb07970.x; Kleinbaum DG, 2002, LOGISTIC REGRESSION, P267; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Madianos MG, 2001, PSYCHOTHER PSYCHOSOM, V70, P30, DOI 10.1159/000056222; Mancusi-Ungaro H R Jr, 1986, J Burn Care Rehabil, V7, P521, DOI 10.1097/00004630-198611000-00015; PATTERSON DR, 1993, PSYCHOL BULL, V113, P362, DOI 10.1037/0033-2909.113.2.362; Pliskin NH, 2006, J INT NEUROPSYCH SOC, V12, P17, DOI 10.1017/S1355617706060061; Pliskin NH, 1998, J TRAUMA, V44, P709, DOI 10.1097/00005373-199804000-00027; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; *SAS I INC, 2001, SAS VERS 8 2 WIND; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624	27	30	30	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0163-8343	1873-7714		GEN HOSP PSYCHIAT	Gen. Hosp. Psych.	JUL-AUG	2009	31	4					360	366		10.1016/j.genhosppsych.2009.03.010			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	468DN	WOS:000267794500010	19555797				2022-02-06	
J	Danish, SF; Barone, D; Lega, BC; Stein, SC				Danish, Shabbar F.; Barone, Dean; Lega, Bradley C.; Stein, Sherman C.			Quality of life after hemicraniectomy for traumatic brain injury in adults	NEUROSURGICAL FOCUS			English	Article						traumatic brain injury; hemicraniectomy; outcome	SEVERE HEAD-INJURY; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; DECOMPRESSIVE CRANIECTOMY; CEREBRAL EDEMA; MANAGEMENT; PRESSURE; EXPERIENCE; EXPANSION; THERAPY; ICP	Decompressive hemicraniectomy is well accepted for the surgical treatment of intractable intracranial hypertension in cases in which medical management fails. Although it is performed as a life-saving procedure when death is imminent from intracranial hypertension, little is known about the functional outcomes for these patients on long-term follow-up. In this study, the authors performed a systematic review of the literature to examine neurological outcome after hemicraniectomy. A literature search revealed 29 studies that reported outcomes using GOS scores. The GOS scores were transformed to utility values for quality of life using a conversion method based on decision analysis modeling. Based on the literature, 1422 cases were analyzed. The average 6-month-postoperative mortality rate was 28.2%. The mean QOL value among survivors was 0.592, which corresponds roughly to a GOS score of 4. Although more studies are needed for validation of long-term neurological outcome after hemicraniectomy, the assumption that most patients remain in a vegetative state after this intervention is clearly incorrect. (DOI: 10.3171/2009.3.FOCUS945)	[Danish, Shabbar F.; Barone, Dean] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Neurosurg, New Brunswick, NJ 08901 USA; [Lega, Bradley C.; Stein, Sherman C.] Univ Penn Hlth Syst, Dept Neurosurg, Philadelphia, PA USA		Danish, SF (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Neurosurg, 125 Paterson St,CAB 2100, New Brunswick, NJ 08901 USA.	danishsh@umdnj.edu					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Csokay A, 2001, ACTA NEUROCHIR, V143, P173, DOI 10.1007/s007010170125; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Gold M., 1996, COST EFFECTIVENESS H; Guerra WKW, 1999, INTENS CARE MED, V25, P1327; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; Lee MC, 2003, PEDIATR NEUROSURG, V38, P181, DOI 10.1159/000069096; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Meier U, 2006, ACTA NEUROCHIR SUPPL, V96, P373; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Ogawa M, 1974, Med J Osaka Univ, V25, P73; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Razack N, 1997, J TRAUMA, V43, P840, DOI 10.1097/00005373-199711000-00017; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Salvatore C, 2008, J NEUROSURG, V108, P74, DOI 10.3171/JNS/2008/108/01/0074; Schneider GH, 2002, ACT NEUR S, V81, P77; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Xiong G, 2001, Chin J Traumatol, V4, P126; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	40	30	32	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2009	26	6							E2	10.3171/2009.3.FOCUS945			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	451WK	WOS:000266501400002	19485715	Bronze			2022-02-06	
J	Duchnick, JJ; Letsch, EA; Curtiss, G				Duchnick, Jennifer J.; Letsch, Elizabeth A.; Curtiss, Glenn			Coping Effectiveness Training During Acute Rehabilitation of Spinal Cord Injury/Dysfunction: A Randomized Clinical Trial	REHABILITATION PSYCHOLOGY			English	Article						SCI; group therapy; anxiety; depression; emotional adjustment; randomized clinical trial	TRAUMATIC BRAIN-INJURY; LONGITUDINAL ANALYSIS; DEPRESSION; INTERVENTION; ANXIETY; SCALE; DISABILITY; ADJUSTMENT; STRATEGIES; ACCEPTANCE	Purpose: To compare coping effectiveness training (CET) with supportive group therapy (SGT) for anxiety, depression, and adjustment to injury in an acute spinal cord injury/dysfunction (SCI/D) rehabilitation population. CET was shown to result in decreased anxiety and depression symptoms when compared to historical no-treatment control groups (Kennedy, Duff, Evans, & Beedie, 2003; King & Kennedy, 1999). The present study sought to extend those findings with a comparison of CET to an alternative active therapy condition, SGT. Research Method: Participants (N = 40) entering a hospital-based program were assigned to treatment condition using block randomization. Questionnaire mood measures were completed at program admission, program discharge, and 3-month postdischarge follow-up. Adjustment to disability was assessed at follow-up only. Analyses of variance tested for group differences in anxiety, depression, and adjustment to injury. Results: Both groups reported reductions in mood symptoms with no differences between treatment conditions. However, similar reductions were obtained after fewer sessions of CET. Symptoms of depression increased in both groups following hospital discharge. Conclusions: Clinical and research implications, including innovative interventions during the period after discharge, are discussed.	[Duchnick, Jennifer J.; Letsch, Elizabeth A.; Curtiss, Glenn] James A Haley Vet Affairs Med Ctr, Tampa, FL 33612 USA; [Curtiss, Glenn] Univ S Florida, Dept Psychiat & Behav Sci, Tampa, FL USA		Duchnick, JJ (corresponding author), James A Haley Vet Affairs Med Ctr, Psychol 116B,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Jennifer.Duchnick@va.gov	Curtiss, Glenn/ABB-5566-2020				*AM SPIN INJ ASS I, 2000, INT STAND NEUR CLASS; BECK AT, 1979, COGNITIVE THERAPY DE; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; BOEKAMP JR, 1998, DISS ABSTR INT B, V59, P2412; Botella C, 2004, J CLIN PSYCHOL, V60, P821, DOI 10.1002/jclp.20040; Bowers J E, 1987, Rehabil Nurs, V12, P313; BUCKELEW SP, 1991, PARAPLEGIA, V29, P125, DOI 10.1038/sc.1991.17; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chesney MA, 2003, PSYCHOSOM MED, V65, P1038, DOI 10.1097/01.PSY.0000097344.78697.ED; CIMPERMAN A, 1974, REHABIL PSYCHOL, V21, P44; CRAIG AR, 1994, PARAPLEGIA, V32, P675, DOI 10.1038/sc.1994.109; Craig AR, 1997, ARCH PHYS MED REHAB, V78, P33, DOI 10.1016/S0003-9993(97)90006-X; DEVIVO MJ, 1991, PARAPLEGIA, V29, P620, DOI 10.1038/sc.1991.91; Elliott TR, 2008, BEHAV RES THER, V46, P1220, DOI 10.1016/j.brat.2008.08.004; Elliott TR, 2004, REHABIL PSYCHOL, V49, P134, DOI 10.1037/0090-5550.49.2.134; Elliott TR, 1999, REHABIL PSYCHOL, V44, P315, DOI 10.1037/0090-5550.44.4.315; ELLIOTT TR, 1996, ARCH PHYS MED REHAB, V47, P131; Folkman S., 1991, SOCIAL CONTEXT COPIN, P239; Folkman S., 1984, STRESS; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; FOW NR, 1995, J APPL REHABILITATIO, V26, P30; Groomes DAG, 2007, J REHABIL, V73, P3; HANCOCK K, 1993, AUST NZ J PSYCHIAT, V27, P450, DOI 10.3109/00048679309075802; HANCOCK KM, 1993, PARAPLEGIA, V31, P349, DOI 10.1038/sc.1993.59; HOLAHAN CJ, 1995, HEALTH PSYCHOL, V14, P152, DOI 10.1037/0278-6133.14.2.152; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Kennedy P, 2005, J CLIN PSYCHOL MED S, V12, P93, DOI 10.1007/s10880-005-0917-9; Kennedy P, 2000, BRIT J HEALTH PSYCH, V5, P157, DOI 10.1348/135910700168838; Kennedy P, 2003, BRIT J CLIN PSYCHOL, V42, P41, DOI 10.1348/014466503762842002; KENNEDY P, 2001, COPING EFFECTIVELY S; King C, 1999, BRIT J CLIN PSYCHOL, V38, P5, DOI 10.1348/014466599162629; Kirk RE., 1995, EXPT DESIGN PROCEDUR, V3; KISHI Y, 1994, J NEUROPSYCH CLIN N, V6, P237; KISHI Y, 1995, J NERV MENT DIS, V183, P286, DOI 10.1097/00005053-199505000-00002; LINKOWSKI DC, 1971, REHABIL COUNS BULL, V14, P236; LIPSEY MW, 1993, AM PSYCHOL, V48, P1181, DOI 10.1037/0003-066X.48.12.1181; LIVNEH H, 2000, J APPL REHABILITATIO, V32, P3; MACDONALD MR, 1987, ARCH PHYS MED REHAB, V68, P339; MACLEOD AD, 1988, PARAPLEGIA, V26, P340, DOI 10.1038/sc.1988.48; MCAWEENEY MJ, 1997, SCI PSYCHOSOCIAL PRO, V10, P58; Miller WC, 2008, SPINAL CORD, V46, P287, DOI 10.1038/sj.sc.3102127; PEARSON ES, 1951, BIOMETRIKA, V38, P112, DOI 10.2307/2332321; Pollard C, 2007, BRIT J HEALTH PSYCH, V12, P347, DOI 10.1348/135910707X197046; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RICHARDS JS, 1986, ARCH PHYS MED REHAB, V67, P362; RINTALA DH, 1994, REHABIL PSYCHOL, V39, P15, DOI 10.1037/h0080311; Saravay SM, 1996, AM J PSYCHIAT, V153, P397; Spielberger CD., 1983, STATE TRAIT ANXIETY; Stanley MA, 2005, COGN BEHAV PRACT, V12, P424, DOI 10.1016/S1077-7229(05)80070-7; Verdier-Taillefer MH, 2001, NEUROEPIDEMIOLOGY, V20, P262, DOI 10.1159/000054800; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337	51	30	31	0	12	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2009	54	2					123	132		10.1037/a0015571			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	448HP	WOS:000266254000001	19469601				2022-02-06	
J	Zuberovic, A; Wetterhall, M; Hanrieder, J; Bergquist, J				Zuberovic, Aida; Wetterhall, Magnus; Hanrieder, Joerg; Bergquist, Jonas			CE MALDI-TOF/TOF MS for multiplexed quantification of proteins in human ventricular cerebrospinal fluid	ELECTROPHORESIS			English	Article						CE MALDI-TOF/TOF MS; iTRAQ (TM); Multiplexed quantification; Proteomics; Ventricular cerebrospinal fluid	TRAUMATIC BRAIN-INJURY; CAPILLARY-ELECTROPHORESIS; MASS-SPECTROMETRY; PROTEOMIC ANALYSIS; BIOMARKERS; EXPRESSION; DAMAGE; SERUM; IDENTIFICATION; DISCOVERY	CE, interfaced off-line to MALDI-TOF/TOF MS, was for the first time used to quantitatively monitor the protein content in complex biological and clinical samples with iTRAQ (TM) labeling. The usefulness and advantage of iTRAQ (TM) labeling, in combination, with CE MALDI-TOF/TOF MS is demonstrated on mixtures of protein standards and by a case study on human ventricular cerebrospinal fluid samples collected from a patient with traumatic brain injury during patient recovery. Mixtures of five standard proteins were initially analyzed to optimize the experimental conditions for the CE MALDI-MS and MS/MS analysis. The interactions of proteins and peptides with the capillary inner wall during CE separation were minimized using PolyE-323 modified capillaries. The analysis of the ventricular cerebrospinal fluid samples yielded 43 significantly (p < 0.05 MudPIT scoring) identified proteins that could be quantitatively monitored over time. The identified changes in protein levels for several of these proteins are well in line with the reports from previous studies on protein patterns that could be related to the post-traumatic processes of traumatic brain injury. This study shows that the presented approach, combining isobaric tags with CE MALDI-TOF/TOF MS, is a useful choice for quantitative proteomic analysis.	[Zuberovic, Aida; Wetterhall, Magnus; Hanrieder, Joerg; Bergquist, Jonas] Uppsala Univ, Dept Phys & Analyt Chem Analyt Chem, Uppsala, Sweden		Bergquist, J (corresponding author), Uppsala Univ, Dept Phys & Analyt Chem Analyt Chem, POB 599, Uppsala, Sweden.	Jonas.Bergquist@kemi.uu.se	Bergquist, Jonas/C-5894-2015; Hanrieder, Jorg/E-9706-2011	Bergquist, Jonas/0000-0002-4597-041X	The Swedish Research CouncilSwedish Research Council [621-2005-5379, 342-2004-3944, 629-2002-6821]	The Swedish Research Council (Grant 621-2005-5379, 342-2004-3944 and 629-2002-6821 (J.B.)) is gratefully acknowledged for financial support. Lars Hillered and Per Enblad at the Department of Neurosurgery, Uppsala Academic Hospital, are acknowledged for providing the vCSF sample.	Barr JR, 1996, CLIN CHEM, V42, P1676; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bergstrom SK, 2006, ANALYST, V131, P791, DOI 10.1039/b601660j; Chaerkady R, 2007, PROTEOM CLIN APPL, V1, P1080, DOI 10.1002/prca.200700284; Choe L, 2007, PROTEOMICS, V7, P3651, DOI 10.1002/pmic.200700316; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Dekker LJ, 2006, EXPERT REV PROTEOMIC, V3, P297, DOI 10.1586/14789450.3.3.297; Fenselau C, 2007, J CHROMATOGR B, V855, P14, DOI 10.1016/j.jchromb.2006.10.071; Garza S, 2006, ANAL CHEM, V78, P7309, DOI 10.1021/ac0612269; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Glen A, 2008, J PROTEOME RES, V7, P897, DOI 10.1021/pr070378x; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanrieder J, 2009, J CHROMATOGR A, V1216, P3621, DOI 10.1016/j.chroma.2008.12.026; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Huck CW, 2006, ELECTROPHORESIS, V27, P2063, DOI 10.1002/elps.200600046; Issaq HJ, 2007, ELECTROPHORESIS, V28, P1980, DOI 10.1002/elps.200600834; Issaq HJ, 2001, ELECTROPHORESIS, V22, P3629, DOI 10.1002/1522-2683(200109)22:17<3629::AID-ELPS3629>3.0.CO;2-O; Julka S, 2004, J PROTEOME RES, V3, P350, DOI 10.1021/pr0340734; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kraly J, 2006, ANAL CHEM, V78, P4097, DOI 10.1021/ac060704c; Lau KW, 2007, PROTEOMICS, V7, P2787, DOI 10.1002/pmic.200700127; Neususs C, 2002, ELECTROPHORESIS, V23, P3149, DOI 10.1002/1522-2683(200209)23:18<3149::AID-ELPS3149>3.0.CO;2-8; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Ralhan R, 2008, MOL CELL PROTEOMICS, V7, P1162, DOI 10.1074/mcp.M700500-MCP200; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schiffer E, 2006, PROTEOMICS, V6, P5615, DOI 10.1002/pmic.200600230; Simpson DC, 2005, ELECTROPHORESIS, V26, P1291, DOI 10.1002/elps.200410132; Smith JC, 2007, ANAL CHEM, V79, P4325, DOI 10.1021/ac070741j; Sniehotta M, 2007, ELECTROPHORESIS, V28, P1407, DOI 10.1002/elps.200600581; Ullsten S, 2004, ELECTROPHORESIS, V25, P2090, DOI 10.1002/elps.200305787; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Zuberovic A, 2004, RAPID COMMUN MASS SP, V18, P2946, DOI 10.1002/rcm.1712; Zuberovic A, 2008, EUR J MASS SPECTROM, V14, P249, DOI 10.1255/ejms.929; Zurbig P, 2006, ELECTROPHORESIS, V27, P2111, DOI 10.1002/elps.200500827	40	30	30	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	MAY	2009	30	10			SI		1836	1843		10.1002/elps.200800714			8	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	452FC	WOS:000266524500026	19441030				2022-02-06	
J	MacLellan, CL; Langdon, KD; Churchill, KP; Granter-Button, S; Corbett, D				MacLellan, Crystal L.; Langdon, Kristopher D.; Churchill, Kayla P.; Granter-Button, Shirley; Corbett, Dale			Assessing cognitive function after intracerebral hemorrhage in rats	BEHAVIOURAL BRAIN RESEARCH			English	Article						Hemorrhagic stroke; Cognition; Behavioural testing; Recovery; Spatial memory; Learning; Maze	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; SHORT-TERM-MEMORY; BILATERAL STRIATAL LESIONS; WHITE-MATTER CHANGES; BASAL GANGLIA; ARTERY OCCLUSION; SPATIAL MEMORY; PREFRONTAL CORTEX; OPERANT TEST	Preclinical studies must rigorously assess whether putative therapies improve motor and cognitive function following brain injury. Intracerebral hemorrhage (ICH) causes significant sensory-motor and cognitive deficits in humans. However, no study has evaluated cognition in rodent ICH models. Thus, we used a battery of tests to comprehensively examine whether a striatal ICH causes cognitive impairments in rats. Bacterial collagenase (or sterile saline for SHAM surgery) was injected into the striatum to create an]CH. Two days later, functional deficits were assessed using a neurological deficit scale (NDS), which is most sensitive to ICH injury. Sensory and/or motor deflcits may confound cognitive testing; thus, we waited until these had resolved before testing learning and memory. Testing was conducted 1-7 months after ICH and included spontaneous alternation, elevated plus maze, open-field, Morris water maze, T-maze (win-shift and win-stay paradigms), and the radial arm maze (eight and four arms baited protocols). Significant motor deficits at 2 days completely resolved by 1 month, at which time cognitive testing began. In contrast to persistent cognitive deficits that occur after ICH in humans, we did not detect significant learning or memory deficits after ICH in rats. Our results suggest that these tests will not likely be useful for assessing outcome in experimental ICH studies. In conclusion, animal models that better mimic clinical ICH (both motor and cognitive deficits) must be developed. This may include increasing ICH severity or injuring other functional subdivisions within the striatum that may lead to more profound cognitive deficits. (C) 2008 Elsevier B.V. All rights reserved.	[MacLellan, Crystal L.; Langdon, Kristopher D.; Churchill, Kayla P.; Granter-Button, Shirley; Corbett, Dale] Mem Univ Newfoundland, Fac Med, Div Biomed Sci, St John, NL A1B 3V6, Canada		MacLellan, CL (corresponding author), Mem Univ Newfoundland, Fac Med, Div Biomed Sci, St John, NL A1B 3V6, Canada.	cmaclell@mun.ca	Langdon, Kristopher D/K-4036-2012; Corbett, Dale/D-6625-2011	Langdon, Kristopher D/0000-0002-3717-4712; Corbett, Dale/0000-0003-0217-4576	Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Astra-ZenicaAstraZeneca	This research was supported by a grant (to D.C.) from the Canadian Institutes for Health Research (CIHR). D. Corbett holds a Canada Research Chair in Stroke and Neuroplasticity. C. MacLellan is supported by a CIHR post-doctoral fellowship. K. Langdon received a Focus on Stroke Doctoral award from the Heart and Stroke Foundation of Canada, CIHR, and Astra-Zenica. The authors are grateful to Michael Keough for excellent technical assistance, and to Jared Clarke and Garry Chernenko for helpful comments on earlier drafts of the manuscript.	Andersen MB, 1998, BEHAV BRAIN RES, V91, P15, DOI 10.1016/S0166-4328(97)00103-4; Belayev L, 2007, BRAIN RES, V1157, P146, DOI 10.1016/j.brainres.2007.04.077; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Birrell JM, 2000, J NEUROSCI, V20, P4320; Broderick JP, 1999, STROKE, V30, P905, DOI 10.1161/01.STR.30.4.905; Clarke J, 2007, BRAIN RES, V1145, P204, DOI 10.1016/j.brainres.2007.01.135; Colbourne F, 1998, BRAIN RES, V803, P69, DOI 10.1016/S0006-8993(98)00612-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DOBROSSY MD, 1995, NEUROREPORT, V6, P2049; Dobrossy MD, 1996, BRAIN RES BULL, V41, P159; DUNNETT SB, 1981, BEHAV BRAIN RES, V2, P189, DOI 10.1016/0166-4328(81)90055-3; Dunnett SB, 2005, NEUROSCIENCE, V135, P1055, DOI 10.1016/j.neuroscience.2005.07.033; DUNNETT SB, 1990, CAN J PSYCHOL, V44, P210, DOI 10.1037/h0084240; Dunnett SB, 1999, BEHAV BRAIN RES, V106, P13, DOI 10.1016/S0166-4328(99)00076-5; El Massioui N, 2007, NEUROSCIENCE, V147, P906, DOI 10.1016/j.neuroscience.2007.05.015; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Hardman CD, 2002, J COMP NEUROL, V445, P238, DOI 10.1002/cne.10165; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; HIRAKAWA M, 1994, STROKE, V25, P2471, DOI 10.1161/01.STR.25.12.2471; Hochstenbach J, 1998, CLIN REHABIL, V12, P514, DOI 10.1191/026921598666870672; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Leys D, 1999, EUR NEUROL, V42, P67, DOI 10.1159/000069414; MacLellan CL, 2006, STROKE, V37, P1266, DOI 10.1161/01.STR.0000217268.81963.78; MacLellan CL, 2005, J CEREBR BLOOD F MET, V25, P1020, DOI 10.1038/sj.jcbfm.9600099; MacLellan CL, 2004, J CEREBR BLOOD F MET, V24, P432, DOI 10.1097/00004647-200404000-00008; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2006, BEHAV BRAIN RES, V175, P82, DOI 10.1016/j.bbr.2006.08.001; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nys GMS, 2007, CEREBROVASC DIS, V23, P408, DOI 10.1159/000101464; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P1012, DOI 10.1038/jcbfm.1995.127; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P505, DOI 10.1038/jcbfm.1995.62; OLTON DS, 1976, J EXP PSYCHOL-ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; PACKARD MG, 1990, BEHAV NEURAL BIOL, V53, P39, DOI 10.1016/0163-1047(90)90780-A; Pantoni L, 1997, ANN NY ACAD SCI, V826, P92, DOI 10.1111/j.1749-6632.1997.tb48463.x; Ray KM, 2006, RADIOLOGY, V241, P197, DOI 10.1148/radiol.2411051051; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; RICHMAN C L, 1986, Current Psychological Research and Reviews, V5, P358, DOI 10.1007/BF02686603; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; Sakai N, 1996, BEHAV BRAIN RES, V77, P181, DOI 10.1016/0166-4328(95)00232-4; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Shah AA, 2004, BRAIN RES, V1028, P112, DOI 10.1016/j.brainres.2004.08.061; Su CY, 2007, ARCH CLIN NEUROPSYCH, V22, P465, DOI 10.1016/j.acn.2007.01.025; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; von Euler M, 2006, BEHAV BRAIN RES, V166, P204, DOI 10.1016/j.bbr.2005.07.016; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Wen HM, 2004, STROKE, V35, P1826, DOI 10.1161/01.STR.0000133686.29320.58; Werring DJ, 2004, BRAIN, V127, P2265, DOI 10.1093/brain/awh253; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; Whitehead SN, 2007, STROKE, V38, P3245, DOI 10.1161/STROKEAHA.107.492660; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; Yonemori F, 1999, J CEREBR BLOOD F MET, V19, P483, DOI 10.1097/00004647-199905000-00002; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022	59	30	31	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	MAR 17	2009	198	2					321	328		10.1016/j.bbr.2008.11.004			8	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	420SP	WOS:000264309800008	19041895				2022-02-06	
J	Bevers, MB; Lawrence, E; Maronski, M; Starr, N; Amesquita, M; Neumar, RW				Bevers, Matthew B.; Lawrence, Eric; Maronski, Margaret; Starr, Neasa; Amesquita, Michael; Neumar, Robert W.			Knockdown of m-calpain increases survival of primary hippocampal neurons following NMDA excitotoxicity	JOURNAL OF NEUROCHEMISTRY			English	Article						calpain; neuron; excitotoxicity; RNA interference; NMDA; adeno-associated virus	APOPTOSIS-INDUCING FACTOR; CYCLIN-DEPENDENT KINASE-5; TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; CELL-DEATH; VULNERABLE NEURONS; GLOBAL-ISCHEMIA; AXONAL INJURY; RAT-BRAIN; INHIBITOR	The calpain family of cysteine proteases has a well-established causal role in neuronal cell death following acute brain injury. However, the relative contribution of calpain isoforms to the various forms of injury has not been determined as available calpain inhibitors are not isoform-specific. In this study, we evaluated the relative role of m-calpain and mu-calpain in a primary hippocampal neuron model of NMDA-mediated excitotoxicity. Baseline mRNA expression for the catalytic subunit of m-calpain (capn2 ) was found to be 50-fold higher than for the mu-calpain catalytic subunit (capn1) based on quantitative real-time PCR. Adeno-associated viral vectors designed to deliver short hairpin RNAs targeting capn1 or capn2 resulted in 60% and 90% knockdown of message respectively. Knockdown of capn2 but not capn1 increased neuronal survival after NMDA exposure at 21 days in vitro. Nuclear translocation of calpain substrates apoptosis inducing factor, p35/p25 and collapsin response mediator protein (CRMP) 2-4 was not detected after NMDA exposure in this model. However, nuclear translocation of CRMP-1 was observed and was prevented by capn2 knockdown. These findings provide insight into potential mechanisms of calpain-mediated neurodegeneration and have important implications for the development of isoform-specific calpain inhibitor therapy.	[Bevers, Matthew B.; Lawrence, Eric; Starr, Neasa; Amesquita, Michael; Neumar, Robert W.] Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA; [Maronski, Margaret] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA		Neumar, RW (corresponding author), Univ Penn, Sch Med, Dept Emergency Med, Ground Floor,Ravdin Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	neumarr@uphs.upenn.edu		starr, neasa/0000-0001-5544-7908	National Institutes of HeathUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS039481, P30-DK-047757-14]; American Heart AssociationAmerican Heart Association [0615345U]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK047757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039481] Funding Source: NIH RePORTER	This work was supported by National Institutes of Heath Grant NS039481 (RWN) and American Heart Association Grant 0615345U (MBB). All AAV vectors used in this study were generated by the University of Pennsylvania Vector Core. Vector production was supported by National Institutes of Health Grant P30-DK-047757-14. We would like to thank Dr. Robert Siman for the gift of antibody against calpain-cleaved spectrin, Dr. Virginia Lee for the gift of antibody against MAP2, Dr. Joachim Kappler for the gift of antibodies against CRMP-1, -2, -3, and -4, and Dr. Julie Blendy for the expertise and equipment required for real-time PCR assays.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BEDNARSKI E, 1995, BRAIN RES, V694, P147, DOI 10.1016/0006-8993(95)00851-G; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Cao GD, 2003, J CEREBR BLOOD F MET, V23, P1137, DOI 10.1097/01.WCB.0000087090.01171.E7; Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Cummings DD, 1996, J NEUROSCI, V16, P5312; Dutt P, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-3; Fisher KJ, 1997, NAT MED, V3, P306, DOI 10.1038/nm0397-306; Garcia M, 2005, BIOCHEM BIOPH RES CO, V338, P1241, DOI 10.1016/j.bbrc.2005.10.081; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Grammer M, 2005, NEUROBIOL LEARN MEM, V84, P222, DOI 10.1016/j.nlm.2005.07.007; Herasse M, 1999, MOL CELL BIOL, V19, P4047; Honda S, 2004, J BIOL CHEM, V279, P10615, DOI 10.1074/jbc.M308841200; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Hou ST, 2006, J NEUROSCI, V26, P2241, DOI 10.1523/JNEUROSCI.4485-05.2006; Jiang SX, 2007, EUR J NEUROSCI, V26, P801, DOI 10.1111/j.1460-9568.2007.05715.x; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; Konig N, 2003, J CHEM NEUROANAT, V25, P129, DOI 10.1016/S0891-0618(02)00102-3; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; Li PA, 1998, NEUROSCI LETT, V247, P17, DOI 10.1016/S0304-3940(98)00266-3; Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200; Marcilhac A, 2006, INT J BIOCHEM CELL B, V38, P2128, DOI 10.1016/j.biocel.2006.06.005; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Neumar RW, 1996, J NEUROCHEM, V66, P421; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; O'Hare MJ, 2005, J NEUROSCI, V25, P8954, DOI 10.1523/JNEUROSCI.2899-05.2005; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Saito T, 2007, J NEUROCHEM, V102, P133, DOI 10.1111/j.1471-4159.2007.04540.x; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; TAKANO E, 1999, CALPAIN PHARM TOXICO, P25; Waghray A, 2004, BIOCHEM BIOPH RES CO, V324, P46, DOI 10.1016/j.bbrc.2004.09.012; Wang Y, 2007, J NEUROCHEM, V103, P439, DOI 10.1111/j.1471-4159.2007.04746.x; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xu W, 2007, NEURON, V53, P399, DOI 10.1016/j.neuron.2006.12.020; Yamashima T, 1996, EUR J NEUROSCI, V8, P1932, DOI 10.1111/j.1460-9568.1996.tb01337.x; Yokota M, 1999, BRAIN RES, V819, P8, DOI 10.1016/S0006-8993(98)01334-1; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	57	30	30	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAR	2009	108	5					1237	1250		10.1111/j.1471-4159.2008.05860.x			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	402WW	WOS:000263044800014	19141074	Green Accepted			2022-02-06	
J	Caeyenberghs, K; Wenderoth, N; Smits-Engelsman, BCM; Sunaert, S; Swinnen, SP				Caeyenberghs, K.; Wenderoth, N.; Smits-Engelsman, B. C. M.; Sunaert, S.; Swinnen, S. P.			Neural correlates of motor dysfunction in children with traumatic brain injury: exploration of compensatory recruitment patterns	BRAIN			English	Article						Traumatic brain injury; fMRI; motor control; interlimb coordination; children	PURKINJE-CELL VULNERABILITY; INTERLIMB COORDINATION; RHYTHMIC COORDINATION; FUNCTIONAL-ANATOMY; PHASE-TRANSITIONS; PARIETAL CORTEX; HAND MOVEMENTS; FOOT MOVEMENTS; CEREBELLAR; FMRI	Traumatic brain injury (TBI) is a common form of disability in children. Persistent deficits in motor control have been documented following TBI but there has been less emphasis on changes in functional cerebral activity. In the present study, children with moderate to severe TBI (n 9) and controls (n 17) were scanned while performing cyclical movements with their dominant and non-dominant hand and foot according to the easy isodirectional (same direction) and more difficult non-isodirectional (opposite direction) mode. Even though the children with TBI were shown to be less successful on various items of a clinical motor test battery than the control group, performance on the coordination task during scanning was similar between groups, allowing a meaningful interpretation of their brain activation differences. fMRI analysis revealed that the TBI children showed enhanced activity in medial and anterior parietal areas as well as posterior cerebellum as compared with the control group. Brain activation generally increased during the non-isodirectional as compared with the isodirectional mode and additional regions were involved, consistent with their differential degree of difficulty. However, this effect did not interact with group. Overall, the findings indicate that motor impairment in TBI children is associated with changes in functional cerebral activity, i.e. they exhibit compensatory activation reflecting increased recruitment of neural resources for attentional deployment and somatosensory processing.	[Caeyenberghs, K.; Wenderoth, N.; Smits-Engelsman, B. C. M.; Swinnen, S. P.] Katholieke Univ Leuven, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Dept Biomed Kinesiol,Motor Control Lab, B-3001 Heverlee, Belgium; [Smits-Engelsman, B. C. M.] Univ Profess, Dept Healthcare, Breda, Netherlands; [Sunaert, S.] Katholieke Univ Leuven, Dept Radiol, Univ Hosp, Louvain, Belgium		Swinnen, SP (corresponding author), Katholieke Univ Leuven, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Dept Biomed Kinesiol,Motor Control Lab, Tervuursevest 101, B-3001 Heverlee, Belgium.	stephan.swinnen@faber.kuleuven.be	Sunaert, Stefan/E-8031-2011; Wenderoth, Nicole/D-7262-2015	Sunaert, Stefan/0000-0002-1177-4680; Wenderoth, Nicole/0000-0002-3246-9386; Caeyenberghs, Karen/0000-0001-7009-6843	Research Programme of the Research Foundation-Flanders (FWO)FWO [7.0004.05]; Research Foundation-FlandersFWO; Research Fund K. U. LeuvenKU Leuven [OT/07/073]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [Grant P6/29]	Research Programme of the Research Foundation-Flanders (FWO) (Levenslijn # 7.0004.05); Research Foundation-Flanders (PhD fellowship to C. K.). Research Fund K. U. Leuven (OT/07/073); Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government.	Bartenstein P, 1997, BRAIN, V120, P1553, DOI 10.1093/brain/120.9.1553; Behrmann M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/j.conb.2004.03.012; Blinkenberg M, 1996, J CEREBR BLOOD F MET, V16, P794, DOI 10.1097/00004647-199609000-00004; Burgund ED, 2002, NEUROIMAGE, V17, P184, DOI 10.1006/nimg.2002.1174; CARSON RG, 1995, J MOTOR BEHAV, V27, P211, DOI 10.1080/00222895.1995.9941711; Cavallari P, 2001, EXP BRAIN RES, V141, P398, DOI 10.1007/s00221-001-0898-3; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Ciesielski KT, 2006, NEUROIMAGE, V33, P980, DOI 10.1016/j.neuroimage.2006.07.028; Dassonville P, 1998, NEUROSCI RES, V32, P65, DOI 10.1016/S0168-0102(98)00064-9; Debaere F, 2004, NEUROIMAGE, V21, P1416, DOI 10.1016/j.neuroimage.2003.12.011; Debaere F, 2001, NEUROIMAGE, V14, P947, DOI 10.1006/nimg.2001.0892; Ehrsson HH, 2000, EUR J NEUROSCI, V12, P3385, DOI 10.1046/j.1460-9568.2000.00209.x; Ehrsson HH, 2002, J NEUROSCI, V22, P5074, DOI 10.1523/JNEUROSCI.22-12-05074.2002; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Gut M, 2007, ACTA NEUROBIOL EXP, V67, P43; Heuninckx S, 2005, J NEUROSCI, V25, P6787, DOI 10.1523/JNEUROSCI.1263-05.2005; Heuninckx S, 2008, J NEUROSCI, V28, P91, DOI 10.1523/JNEUROSCI.3300-07.2008; Hikosaka O, 1999, TRENDS NEUROSCI, V22, P464, DOI 10.1016/S0166-2236(99)01439-3; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Ivry R., 1989, J COGNITIVE NEUROSCI, V1, P134; Johnson-Frey SH, 2005, CEREB CORTEX, V15, P681, DOI 10.1093/cercor/bhh169; Kaelin-Lang A, 2008, NEUROREHABILITATION, V23, P89; Kang HC, 2003, NEUROIMAGE, V19, P16, DOI 10.1016/S1053-8119(03)00038-7; KELSO JAS, 1984, AM J PHYSIOL, V246, P1000; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; LEE TD, 1995, J MOTOR BEHAV, V27, P263, DOI 10.1080/00222895.1995.9941716; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; NORRSELL U, 1980, PHYSIOL REV, V60, P327, DOI 10.1152/physrev.1980.60.2.327; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park E, 2007, EXP NEUROL, V204, P49, DOI 10.1016/j.expneurol.2006.09.012; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; Rao SM, 1996, J CEREBR BLOOD F MET, V16, P1250, DOI 10.1097/00004647-199611000-00020; Rascol O, 1997, BRAIN, V120, P103, DOI 10.1093/brain/120.1.103; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; Rizzolatti G, 1997, CURR OPIN NEUROBIOL, V7, P562, DOI 10.1016/S0959-4388(97)80037-2; Rocca MA, 2007, HUM BRAIN MAPP, V28, P218, DOI 10.1002/hbm.20271; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; Sakai K, 2000, J NEUROSCI, V20, P2691; Samuel M, 1997, BRAIN, V120, P963, DOI 10.1093/brain/120.6.963; Serrien DJ, 2007, PROG NEUROBIOL, V82, P95, DOI 10.1016/j.pneurobio.2007.02.003; Serrien DJ, 2003, HUM BRAIN MAPP, V18, P296, DOI 10.1002/hbm.10086; Simon O, 2002, NEURON, V33, P475, DOI 10.1016/S0896-6273(02)00575-5; Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Sugden, 1992, MOVEMENT ASSESSMENT; SWINNEN SP, 1995, EXP BRAIN RES, V105, P439; Swinnen SP, 1997, J COGNITIVE NEUROSCI, V9, P348, DOI 10.1162/jocn.1997.9.3.348; Swinnen SP, 2002, NAT REV NEUROSCI, V3, P350, DOI 10.1038/nrn807; Swinnen SP, 2004, TRENDS COGN SCI, V8, P18, DOI 10.1016/j.tics.2003.10.017; Thomas KM, 2004, J COGNITIVE NEUROSCI, V16, P1339, DOI 10.1162/0898929042304688; Verstynen T, 2005, J NEUROPHYSIOL, V93, P1209, DOI 10.1152/jn.00720.2004; Volman MJM, 2006, CHILD CARE HLTH DEV, V32, P693, DOI 10.1111/j.1365-2214.2006.00679.x; Ward NS, 2006, AGEING RES REV, V5, P239, DOI 10.1016/j.arr.2006.04.003; Ward NS, 2006, ARCH PHYS MED REHAB, V87, pS30, DOI 10.1016/j.apmr.2006.08.334; Ward NS, 2003, BRAIN, V126, P873, DOI 10.1093/brain/awg071; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; Wenderoth N, 2004, NEURO-BEHAVIORAL DETERMINANTS OF INTERLIMB COORDINATION, P187; Wenderoth N, 2005, EUR J NEUROSCI, V22, P235, DOI 10.1111/j.1460-9568.2005.04176.x; Wu T, 2005, BRAIN, V128, P2250, DOI 10.1093/brain/awh569; Wu T, 2005, J PHYSIOL-LONDON, V562, P605, DOI 10.1113/jphysiol.2004.076042; Wu X, 2008, NEUROREPORT, V19, P483, DOI 10.1097/WNR.0b013e3282f6030b; Zemke AC, 2003, STROKE, V34, pE23, DOI 10.1161/01.STR.0000065827.35634.5E	78	30	30	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2009	132		3				684	694		10.1093/brain/awn344			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	428YW	WOS:000264889000013	19153150	Bronze			2022-02-06	
J	Elsworth, C; Dawes, H; Winward, C; Howells, K; Dennis, A; Sackley, C; Wade, D				Elsworth, Charlotte; Dawes, Helen; Winward, Charlotte; Howells, Ken; Dennis, Andrea; Sackley, Catherine; Wade, Derick			Pedometer step counts in individuals with neurological conditions	CLINICAL REHABILITATION			English	Article							ASSESSING PHYSICAL-ACTIVITY; ELECTRONIC PEDOMETERS; ACCURACY; VALIDITY; DISTANCE; WALKING; UTILITY; HEALTH	Objective: To examine the accuracy of measuring step counts using a pedometer in participants with neurological conditions and healthy volunteers in relation to a manual step count tally. Setting: Oxford Centre for Enablement, Nuffield Orthopaedic Centre NHS Trust, Oxford, UK. Subjects: Healthy adults (n = 13, age: mean 29, SD = 12) and adults with neurological conditions (n=20 stroke, n=16 multiple sclerosis, n=5 muscular dystrophy, n=1 spinal cord injury, n = 1 traumatic brain injury; age: mean 54, SD = 13), Main measures Individuals walked for 2 minutes at self-selected walking speeds (SSWS) wearing a pedometer. Healthy individuals were then asked to walk at slow walking speeds (SWS). Step counts were recorded manually and using a pedometer. Results: In healthy individuals there was no difference between manually measured and pedometer counts during walking (P>0.05). In adults with neurological conditions the pedometers undercounted (P=0.003); bias (random error): 27 (111); percentage variability 30% and intraclass correlation coefficient (ICC) 0.66. In neurological adults, from regression analysis the relationship between error and walking speed was cubic, with walking speed accounting for 29% of pedometer error. Healthy individuals showed greater variability and undercounting at SWS bias (random error): 10 (31), percentage variability 8% and ICC 0.73, compared with SSWS bias (random error): -3 (13), percentage variability 3% and ICC 0.84. Conclusions: Pedometers may undercount when used for people with neurological conditions. There may be variability in pedometer accuracy but this was not strongly related to walking speed. The suitability of pedometer use for exercise monitoring should be individually determined.	[Dawes, Helen] Oxford Brookes Univ, Movement Sci Grp, Sch Life Sci, Oxford OX3 0BP, England; [Elsworth, Charlotte; Sackley, Catherine] Univ Birmingham, Birmingham B15 2TT, W Midlands, England; [Dawes, Helen] Univ Oxford, Oxford OX1 2JD, England		Dawes, H (corresponding author), Oxford Brookes Univ, Movement Sci Grp, Sch Life Sci, Oxford OX3 0BP, England.	celsworth@brookes.ac.uk	Winward, Charlie/AAE-6219-2021	, Johnny/0000-0003-4138-2589; sackley, catherine/0000-0002-8580-6622; Wade, Derick/0000-0002-1188-8442; Dawes, Helen/0000-0002-2933-5213	University of Birmingham	Funding for this study was provided by University of Birmingham.	Bassett DR, 1996, MED SCI SPORT EXER, V28, P1071, DOI 10.1097/00005768-199608000-00019; Beets MW, 2005, MED SCI SPORT EXER, V37, P513, DOI 10.1249/01.MSS.0000155395.49960.31; Bravata DM, 2007, JAMA-J AM MED ASSOC, V298, P2296, DOI 10.1001/jama.298.19.2296; Busse ME, 2004, J NEUROL NEUROSUR PS, V75, P884, DOI 10.1136/jnnp.2003.020180; Collen F M, 1991, Int Disabil Stud, V13, P50; Crouter SE, 2003, MED SCI SPORT EXER, V35, P1455, DOI 10.1249/01.MSS.0000078932.61440.A2; Cyarto EV, 2004, MED SCI SPORT EXER, V36, P205, DOI 10.1249/01.MSS.0000113476.62469.98; Le Masurier GC, 2003, RES Q EXERCISE SPORT, V74, P389, DOI 10.1080/02701367.2003.10609109; Macko RF, 2002, MED SCI SPORT EXER, V34, P394, DOI 10.1097/00005768-200203000-00002; Melanson EL, 2004, PREV MED, V39, P361, DOI 10.1016/j.ypmed.2004.01.032; Motl RW, 2005, MULT SCLER, V11, P343, DOI 10.1191/1352458505ms1161oa; Pearson OR, 2004, QJM-INT J MED, V97, P463, DOI 10.1093/qjmed/hch084; Schneider PL, 2004, MED SCI SPORT EXER, V36, P331, DOI 10.1249/01.MSS.0000113486.60548.E9; Speck BJ, 2006, PUBLIC HEALTH NURS, V23, P88, DOI 10.1111/j.0737-1209.2006.230112.x; Tudor-Locke C, 2004, SPORTS MED, V34, P1, DOI 10.2165/00007256-200434010-00001; Tudor-Locke C, 2004, SPORTS MED, V34, P281, DOI 10.2165/00007256-200434050-00001; Tudor-Locke C, 2002, SPORTS MED, V32, P795, DOI 10.2165/00007256-200232120-00004; TUDORLOCKE C, 2002, PRESIDENTS COUNCIL P, V3, P1; Wade D, 1992, MEASUREMENT NEUROLOG	19	30	30	1	10	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	FEB	2009	23	2					171	175		10.1177/0269215508098895			5	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	407VT	WOS:000263393100009	19164404				2022-02-06	
J	Tasaki, O; Shiozaki, T; Hamasaki, T; Kajino, K; Nakae, H; Tanaka, H; Shimazu, T; Sugimoto, H				Tasaki, Osamu; Shiozaki, Tadahiko; Hamasaki, Toshimitsu; Kajino, Kentaro; Nakae, Haruhiko; Tanaka, Hiroshi; Shimazu, Takeshi; Sugimoto, Hisashi			Prognostic Indicators and Outcome Prediction Model for Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	23rd Annual National-Neurotrauma-Society Symposium	NOV 10-11, 2005	Washington, DC	Natl Neurotrauma Soc		Severe traumatic brain injury; Outcome prediction; Multivariate logistic regression; Akaike Information Criterion	VARIABLES; SURVIVAL	Background: Although sonic predictive models for patient outcomes after severe traumatic brain injury have been proposed, a mathematical model with high predictive value has not been established. The purpose of the present study was to analyze the most important indicators of prognosis and to develop the best outcome prediction model. Methods: One hundred eleven consecutive patients with a Glasgow Coma Scale score of <9 were examined and 14 factors were evaluated. Intracranial pressure and cerebral perfusion pressure were recorded at admission to the intensive care unit. The absence of the basal cisterns, presence of extensive subarachnoid hemorrhage, and degree of midline shift were evaluated by means of computed tomography within 24 hours after injury. Multivariate logistic regression analysis was used to identify independent risk factors for a poor prognosis and to develop the best prediction model. Results: The best model included the following variables: age (p < 0.01), light reflex (p = 0.01), extensive subarachnoid hemorrhage (p = 0.01), intracranial pressure (p = 0.04), and midline shift (p = 0.12). Positive predictive value of the model was 97.3%, negative predictive value was 87.1%, and overall predictive value was 94.2%. The area under the receiver operating characteristic curve was 0.977, and the p value for the Hosmer-Lemeshow goodness-of-fit was 0.866. Conclusions: Our predictive model based on age, absence of light reflex, presence of extensive subarachnoid hemorrhage, intracranial pressure, and midline shift was shown to have high predictive value and will be useful for decision making, review of treatment, and family counseling in case of traumatic brain injury.	[Tasaki, Osamu; Shiozaki, Tadahiko; Kajino, Kentaro; Nakae, Haruhiko; Tanaka, Hiroshi; Shimazu, Takeshi; Sugimoto, Hisashi] Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Osaka, Japan; [Hamasaki, Toshimitsu] Osaka Univ, Grad Sch Med, Dept Biomed Stat, Osaka, Japan		Tasaki, O (corresponding author), 2-15 Yamadaoka Suita, Osaka 5650871, Japan.	tasaki@hp-emerg.med.osaka-u.ac.jp	Hamasaki, Toshimitsu/N-3851-2015	Hamasaki, Toshimitsu/0000-0002-4928-1160			AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; *AM COLL SURG COMM, 1999, ADV TRAUM LIF SUPP P; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Efron B., 1993, INTRO BOOTSTRAP; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JENNETT B, 1975, LANCET, V1, P480; Lu J, 2005, ACT NEUR S, V95, P281; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; ROVIAS A, 2004, J NEUROTRAUM, V21, P886; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20	16	30	31	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2009	66	2					304	308		10.1097/TA.0b013e31815d9d3f			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	408NX	WOS:000263442800003	19204501				2022-02-06	
J	Biber, N; Toklu, HZ; Solakoglu, S; Gultomruk, M; Hakan, T; Berkman, Z; Dulger, FG				Biber, Necat; Toklu, Hale Z.; Solakoglu, Seyhun; Gultomruk, Mine; Hakan, Tayfun; Berkman, Zafer; Dulger, F. Gul			Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury	BRAIN INJURY			English	Article						Montelukast; cysteinyl-leukotriene; brain injury; closed head; trauma; blood-brain barrier; oedema; antioxidant; neutrophil	INFLAMMATION; ACTIVATION; PROTECTS	Introduction: Traumatic brain injury is highly associated with the over-production of reactive oxygen species. The aim of this study was to investigate the putative neuroprotective effect of montelukast, a cysteinyl-leukotriene receptor antagonist, in a rat model of traumatic brain injury (TBI). Methods: Sprague Dawley rats were subjected to TBI with a weight-drop device using 300 g-1 m weight-height impact. The groups were: control (saline), montelukast (10 mg kg -1 per day, ip), trauma and trauma + montelukast. Two days post-trauma, neurological examination scores were measured and animals were decapitated and the brain tissues were taken for the histologic and biochemical [malondialdehyde (MDA)an index for lipid peroxidation, reduced glutathione (GSH), myeloperoxidase (MPO)an index for neutrophil infiltration and Na +/K +-ATPase activity] evaluations. Brain oedema and blood-brain barrier (BBB) permeability were also evaluated. Results: The neurological examination scores mildly increased in trauma groups at 48 hours. Although the scores were decreased in the montelukast treated group, they were still significantly higher than the control. The trauma caused a significant increase in brain water content and Evans blue (EB) extravasation. Montelukast treatment reduced BBB permeability. It also decreased lipid peroxidation and MPO activity. Conclusion: The present study suggests that montelukast may have beneficial effects against TBI-induced oxidative stress of the brain.	[Toklu, Hale Z.; Dulger, F. Gul] Marmara Univ, Sch Pharm, Dept Pharmacol, TR-34668 Istanbul, Turkey; [Biber, Necat; Hakan, Tayfun; Berkman, Zafer] Haydarpasa Numune Teaching & Res Hosp, Dept Neurosurg, Istanbul, Turkey; [Solakoglu, Seyhun; Gultomruk, Mine] Istanbul Univ, Istanbul Sch Med, Istanbul, Turkey		Dulger, FG (corresponding author), Marmara Univ, Sch Pharm, Dept Pharmacol, Tibbiye Cad 49, TR-34668 Istanbul, Turkey.	gdulger@marmara.edu.tr	Hakan, Tayfun/P-8626-2015; Toklu, Hale/AAR-2330-2020; solakoglu, seyhun/AAA-4412-2021; Hakan, Tayfun/O-9979-2019; solakoglu, seyhun/AAE-5691-2020	Hakan, Tayfun/0000-0003-1444-7076; Toklu, Hale/0000-0002-9797-3591; solakoglu, seyhun/0000-0002-1389-9639; Hakan, Tayfun/0000-0003-1444-7076; 			Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ayata C, 2002, J CLIN NEUROSCI, V9, P113, DOI 10.1054/jocn.2001.1031; Back M, 2007, THESCIENTIFICWORLDJO, V7, P1422, DOI 10.1100/tsw.2007.187; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Buege J A, 1978, Methods Enzymol, V52, P302; Capra V, 2006, CURR MED CHEM, V13, P3213, DOI 10.2174/092986706778742963; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; Fiske CH, 1925, J BIOL CHEM, V66, P375; Genovese T, 2008, BRIT J PHARMACOL, V153, P568, DOI 10.1038/sj.bjp.0707577; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Huang XJ, 2008, GLIA, V56, P27, DOI 10.1002/glia.20588; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lima FD, 2008, BEHAV BRAIN RES, V193, P306, DOI 10.1016/j.bbr.2008.05.013; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Moos MPW, 2008, FASEB J, V22, P4352, DOI 10.1096/fj.08-113274; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; READING HW, 1980, Q J EXP PHYSIOL CMS, V65, P105, DOI 10.1113/expphysiol.1980.sp002495; Rovati GE, 2007, THESCIENTIFICWORLDJO, V7, P1375, DOI 10.1100/tsw.2007.185; Sala A, 2001, BIOCHEM BIOPH RES CO, V283, P1003, DOI 10.1006/bbrc.2001.4865; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Sener G, 2007, J PHARM PHARMACOL, V59, P837, DOI 10.1211/jpp.59.6.0009; Sener G, 2006, PHARMACOL RES, V54, P65, DOI 10.1016/j.phrs.2006.02.007; Sheng WW, 2006, BIOCHEM BIOPH RES CO, V346, P19, DOI 10.1016/j.bbrc.2006.05.023; Toklu HZ, 2009, J SURG RES, V152, P238, DOI 10.1016/j.jss.2008.03.013; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; Zhang CM, 2008, RARE METAL MAT ENG, V37, P320, DOI 10.1016/S1875-5372(09)60008-4; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088	38	30	30	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					577	584	PII 911809930	10.1080/02699050902926317			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800011	19484631				2022-02-06	
J	Kasturi, BS; Stein, DG				Kasturi, Badrinarayanan S.; Stein, Donald G.			Progesterone decreases cortical and sub-cortical edema in young and aged ovariectomized rats with brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Progesterone; TBI; edema; hypothalamus; anterior pituitary; brain stem	AGING FEMALE RATS; PITUITARY DYSFUNCTION; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; KAPPA-B; STRESS; EXPRESSION; SECRETION; HYPOPITUITARISM; PREVALENCE	Purpose: Traumatic brain injury (TBI)-induced brain edema can be reduced by acute progesterone (PROG) treatment in young adult males and females, and in aged males. To extend these findings we tested these hypotheses: 1. Acute PROG treatment post-TBI will reduce cortical edema in aged females as much as in young adults. 2. TBI will induce edema in sub-cortical structures (SCS): the thalamus (TH), hypothalamus (HT), brain stem (BS) and anterior pituitary (AP). 3. Acute, systemic PROG treatment post-TBI will reduce edema in SCS. Methods: Young adult (n = 42) and aged (n = 40), bilaterally ovariectomized rats were given medial frontal cortical (MFC) contusion injury, treated with PROG (16 mg/kg body weight) or vehicle at 1, 6 and 24 hours post-injury and killed at 6, 24 and 48 hours post-injury. Their brains were removed and the target areas isolated and measured for water content. Results: TBI induced cortical and delayed sub-cortical edema. Acute PROG treatment decreased this edema. At 6 hours post-TBI serum PROG levels were substantially elevated in both young and aged, PROG-treated, groups, but were higher in the latter. Conclusion: Acute PROG treatment post-TBI could prove an effective intervention to prevent or attenuate systemic, post-injury cortical and sub-cortical edema in young and aged females.	[Kasturi, Badrinarayanan S.; Stein, Donald G.] Emory Univ, Sch Med, Brain Res Lab, Dept Emergency Med, Atlanta, GA 30322 USA		Kasturi, BS (corresponding author), Emory Univ, Sch Med, Brain Res Lab, Dept Emergency Med, 1365 B Clifton Rd,NE Suite 5100, Atlanta, GA 30322 USA.	bkastur@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5RO1NS048451]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048451] Funding Source: NIH RePORTER	We gratefully acknowledge the assistance provided by Craig Wirth for part of this study and by Ilana Garza of The Yerkes Biomarker Core Lab Facilities for providing the progesterone assays. We would also like to thank Leslie McCann for her help in the preparation of the manuscript. This study was supported by funding from NIH grant # 5RO1NS048451.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Andersen ML, 2005, J SLEEP RES, V14, P83, DOI 10.1111/j.1365-2869.2004.00428.x; Andersen ML, 2004, BRAZ J MED BIOL RES, V37, P791, DOI 10.1590/S0100-879X2004000600003; Ashley RL, 2006, ENDOCRINOLOGY, V147, P4151, DOI 10.1210/en.2006-0002; Bach-y-Rita P, 2003, BRAIN INJURY, V17, P643, DOI 10.1080/0269905031000107133; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; BOEHM N, 1982, J STEROID BIOCHEM, V16, P339, DOI 10.1016/0022-4731(82)90187-X; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Budec M, 2002, ALCOHOL, V26, P173, DOI 10.1016/S0741-8329(02)00197-0; Cai ZL, 2005, ENDOCRINOLOGY, V146, P5522, DOI 10.1210/en.2005-0759; CHEN G, 2007, J SURG RES; Chen G, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/93431; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dantzer R, 2007, BRAIN BEHAV IMMUN, V21, P153, DOI 10.1016/j.bbi.2006.09.006; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; HUANG HH, 1975, NEUROENDOCRINOLOGY, V17, P289, DOI 10.1159/000122367; KASTURI BS, J NEUROTRAUMA UNPUB; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LU KH, 1979, BIOL REPROD, V21, P193, DOI 10.1095/biolreprod21.1.193; Marieb EN, 2005, HUMAN ANATOMY; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Muller E, 1989, BRAIN MESSENGERS PIT; NEMEROFF CB, 1992, NEUROENDOCRINOLOGY; PERSENGIEV S, 1991, J PINEAL RES, V11, P57, DOI 10.1111/j.1600-079X.1991.tb00456.x; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Romeo RD, 2004, NEUROENDOCRINOLOGY, V80, P387, DOI 10.1159/000084203; Romeo RD, 2005, STRESS, V8, P265, DOI 10.1080/10253890500489320; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SCHAEFFER C, 1987, ACTA ENDOCRINOL-COP, V114, P440, DOI 10.1530/acta.0.1140440; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015	44	30	32	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2009	27	4					265	275		10.3233/RNN-2009-0476			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	492BS	WOS:000269629700002	19738320	Green Accepted			2022-02-06	
J	Lovell, M				Lovell, Mark			The Management of Sports-Related Concussion: Current Status and Future Trends	CLINICS IN SPORTS MEDICINE			English	Article						Concussion; Sports management; Neuropsychology	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; AGREEMENT STATEMENT; RECOVERY; IMPAIRMENT; RETURN; PLAY	This article provides a review of current trends in the management of sports-related concussion. An evidence-based approach to concussion management is presented with a specific focus on return-to-play issues. The use of neuropsychological testing and other diagnostic tools is presented and reviewed.	Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15228 USA		Lovell, M (corresponding author), Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA 15228 USA.	lovellmr@upmc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT, 1989, MILD HEAD INJURY, P257; Bergschneider M, 2003, J NEUROSURG, V86, P241; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; COLVIN A, 2008, AM ORTH SOC SPORTS M; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2000, NEUROLOGIC ATHLETIC; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; PELLMAN EJ, 2004, NEUROSURGERY, V55, P1303; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; Riemann BL, 2000, J ATHL TRAINING, V35, P19; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WOJYTS ED, 1999, AM J SPORTS MED, V27, P676	42	30	31	1	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2009	28	1					95	+		10.1016/j.csm.2008.08.008			18	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	392TD	WOS:000262324200010	19064168				2022-02-06	
J	Nestvold, K; Stavem, K				Nestvold, Knut; Stavem, Knut			Determinants of health-related quality of life 22 years after hospitalization for traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; quality of life; prospective cohort study	CLOSED-HEAD-INJURY; FOLLOW-UP; ADULTS; INDIVIDUALS; QUESTIONNAIRE; POPULATION; VALIDITY	Primary objective: To assess health-related quality of life (HRQoL) and its determinants in a cohort who had sustained a traumatic brain injury 22 years earlier. Research design: Cohort study with a postal follow-up survey. Methods and procedures: Two hundred and fifty-nine individuals with traumatic brain injury responded to the Short Form-36 (SF-36) and General Health Questionnaire-30 (GHQ-30) questionnaires. SF-36 scores were compared with a general population sample (n = 6800). In multiple linear regression analysis determinants of physical and mental component summary scores (PCS, MCS) of SF-36 and the GHQ-30 total score were assessed. Main outcomes and results: Except on the physical functioning scale, SF-36 scores were lower in the traumatic brain injury cohort than in the general population, after adjusting for age, sex and education. In multiple linear regression analysis, reported psychiatric disease and headache 1 day per month were associated with impaired MCS and GHQ-30 total scores. Age, severe headache 3 months after the injury, previous sick leave, lung disease and heart disease were associated with PCS. No injury variable was associated with HRQoL. Conclusions: Headache 3 months after traumatic brain injury and later comorbidity were associated with HRQoL 22 years after traumatic brain injury, but there was no association of HRQoL with injury data.	[Nestvold, Knut] Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway; [Nestvold, Knut; Stavem, Knut] Akershus Univ Hosp, HOKH, Res Ctr, N-1478 Lorenskog, Norway; [Stavem, Knut] Akershus Univ Hosp, Dept Pulm Med, Div Med, N-1478 Lorenskog, Norway; [Stavem, Knut] Univ Oslo, Fac Med, Oslo, Norway		Nestvold, K (corresponding author), Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway.	knut.nestvold@ahus.no			Norwegian Association of Traffic Wounded; Norwegian Foundation for Health and Rehabilitation	Thanks to T. Lundar (TL) for his contribution to the data collection in 1974/1975. The study received financial support from the Norwegian Association of Traffic Wounded and the Norwegian Foundation for Health and Rehabilitation.	Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Grotvedt L, 2005, SCAND J PUBLIC HEALT, V33, P72, DOI 10.1080/14034940410028361; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Loge JH, 1998, SCAND J SOC MED, V26, P250; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; MALT U F, 1989, Tidsskrift for den Norske Laegeforening, V109, P1391; MALT UF, 1989, ACTA PSYCHIAT SCAND, V80, P103, DOI 10.1111/j.1600-0447.1989.tb05260.x; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; Nestvold K, 2007, NEUROEPIDEMIOLOGY, V29, P113, DOI 10.1159/000109825; SYMONDS CP, 1945, BRIT MED BULL, V3, P14, DOI 10.1093/oxfordjournals.bmb.a071858; TEASDALE G, 1974, LANCET, V2, P81; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WILSON JTL, 1993, J NEUROL NEUROSUR PS, V56, P198	22	30	30	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	1					15	21	PII 906993525	10.1080/02699050802530540			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	399FY	WOS:000262787000005	19096968				2022-02-06	
J	Ren, YJ; Zhou, ZY; Cui, FZ				Ren, Yong-Juan; Zhou, Zi-You; Cui, Fu-Zhai			Hyaluronic Acid/Polylysine Hydrogel as a Transfer System for Transplantation of Neural Stem Cells	JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS			English	Article						neural stem cell; tissue engineering; tissue scaffolds; stem cell transplantation; hydrogels; hyaluronic acid hydrogels; polylysine hydrogels; hyaluronic acid/polylysine hydrogels	TRAUMATIC BRAIN-INJURY; REPAIR; REGENERATION; TISSUE	Graft integration and survival are major factors that limit cell therapy for diseases and injury in the central nervous system. Efforts to improve graft survival and integration have focused on the development of biocompatible scaffolds to support neural cells. In this study, rat neural stem cells (NSC), including neurospheres and single cells, were seeded into hyaluronic acid/polylysine hydrogels. Confocal microscopy was used to noninvasively investigate the key cell phonotypes. After culture for 5 days, single NSC had survived and differentiated into neurons and astrocytes, while neurosphere-forming cells had migrated from their original aggregate and maintained the NSC phonotype. These studies, carried out in the absence of serum, identified HA/polylysine hydrogels as potential synthetic cell carriers for transplantation of NSC.	[Ren, Yong-Juan; Zhou, Zi-You; Cui, Fu-Zhai] Tsinghua Univ, Biomat Lab, Dept Mat Sci & Engn, Beijing 100084, Peoples R China		Cui, FZ (corresponding author), Tsinghua Univ, Biomat Lab, Dept Mat Sci & Engn, Beijing 100084, Peoples R China.	Cuifz@mail.tsinghua.edu.cn			National Basic Research Program of ChinaNational Basic Research Program of China [2005CB623905]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [50573044, 30670656]; Laboratory Fund of Tsinghua University	This work was supported by National Basic Research Program of China (No. 2005CB623905), National Natural Science Foundation of China (No. 50573044 and 30670656) and Laboratory Fund of Tsinghua University.	CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Cui FZ, 2003, J BIOACT COMPAT POL, V18, P413, DOI 10.1177/0883911503040470; Geller HM, 2002, EXP NEUROL, V174, P125, DOI 10.1006/exnr.2002.7865; Hung CH, 2006, BIOMATERIALS, V27, P5901, DOI 10.1016/j.biomaterials.2006.08.009; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Schmidt CE, 2003, ANNU REV BIOMED ENG, V5, P293, DOI 10.1146/annurev.bioeng.5.011303.120731; Tatard VM, 2005, BIOMATERIALS, V26, P3727, DOI 10.1016/j.biomaterials.2004.09.042; Tsai RYL, 2000, J NEUROSCI, V20, P3725, DOI 10.1523/JNEUROSCI.20-10-03725.2000; Yin DZ, 2007, J BIOACT COMPAT POL, V22, P143, DOI 10.1177/0883911506076063; Zhang T, 2007, J BIOACT COMPAT POL, V22, P19, DOI 10.1177/0883911506074025	10	30	30	3	48	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0883-9115	1530-8030		J BIOACT COMPAT POL	J. Bioact. Compat. Polym.	JAN	2009	24	1					56	62		10.1177/0883911508099472			7	Biotechnology & Applied Microbiology; Materials Science, Biomaterials; Polymer Science	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Materials Science; Polymer Science	397AV	WOS:000262635100004					2022-02-06	
J	Suskauer, SJ; Slomine, BS; Inscore, AB; Lewelt, AJ; Kirk, J; Salorio, CF				Suskauer, Stacy J.; Slomine, Beth S.; Inscore, Anjeli B.; Lewelt, Aga J.; Kirk, Johnw.; Salorio, Cynthia F.			Injury severity variables as predictors of WeeFIM scores in pediatric TBI: Time to follow commands is best	JOURNAL OF PEDIATRIC REHABILITATION MEDICINE			English	Article						Traumatic brain injury; children; outcome; coma; post-traumatic amnesia	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; GLASGOW COMA SCALE; FUNCTIONAL INDEPENDENCE MEASURE; QUALITY-OF-LIFE; POSTTRAUMATIC AMNESIA; PRACTICAL SCALE; DEVELOPMENTAL-DISABILITIES; CHILDREN; RECOVERY	After pediatric traumatic brain injury (TBI), early prognosis of expected function is important for optimizing care. The power of several common brain injury severity measures for predicting functional outcome in children with TBI was investigated; the severity variables studied were Glasgow Coma Scale (GCS) score, time to follow commands (TFC), duration of post-traumatic amnesia (PTA), and total duration of impaired consciousness (TFC+PTA). Outcome was assessed using the Functional Independence Measure for Children (WeeFIM) at discharge from inpatient rehabilitation (n = 120) and, in a subset of children, at 3 months following discharge. Correlations and multiple linear regression analyses were conducted using GCS, TFC, PTA, and TFC+PTA to predict age-corrected WeeFIM scores. Models in which TFC and PTA duration were entered as separate variables and as a combined variable (TFC+PTA) were all significantly predictive of WeeFIM scores at discharge; however, TFC accounted for the greatest portion of variance in WeeFIM scores. Among children with moderate to severe TBI who received inpatient rehabilitation, TFC was the best predictor of general functional outcome at discharge and follow-up. Our findings highlight the need for careful and consistent assessment of TFC to assist in predicting functional outcomes as early and accurately as possible.	[Suskauer, Stacy J.; Slomine, Beth S.; Salorio, Cynthia F.] Kennedy Krieger Inst, Baltimore, MD USA; [Suskauer, Stacy J.; Salorio, Cynthia F.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Inscore, Anjeli B.] VA Maryland Hlth Care Syst, Baltimore Med Ctr, Baltimore, MD USA; [Lewelt, Aga J.] Univ Utah, Sch Med, Dept Phys Med & Rehabil, Salt Lake City, UT 84112 USA; [Kirk, Johnw.] Childrens Hosp, Dept Phys Med & Rehabil, Denver, CO 80218 USA		Suskauer, SJ (corresponding author), Kennedy Krieger Inst, Pediat Rehabil, 707 North Broadway, Baltimore, MD 21205 USA.	suskauer@kennedykrieger.org			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	This work was supported by the National Institute of Child Health and Human Development, grant number K12HD001097.	Azaula M, 2000, ARCH PHYS MED REHAB, V81, P307, DOI 10.1016/S0003-9993(00)90076-5; Bier JAB, 2005, DEV MED CHILD NEUROL, V47, P609, DOI 10.1017/S0012162205001209; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; BRUCE DA, 1979, CHILD BRAIN, V5, P174; Chung CY, 2006, PEDIATR NEUROL, V34, P379, DOI 10.1016/j.pediatrneurol.2005.10.012; De Guise E, 2005, BRAIN INJURY, V19, P1087, DOI 10.1080/02699050500149882; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Msall ME, 1999, AM J MED GENET, V89, P62, DOI 10.1002/(SICI)1096-8628(19990625)89:2<62::AID-AJMG3>3.0.CO;2-T; MSALL ME, 1994, CLIN PEDIATR, V33, P421, DOI 10.1177/000992289403300708; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Poon WS, 2005, ACT NEUR S, V93, P207; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; RUIJS MBM, 1992, DEV MED CHILD NEUROL, V34, P885; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Seikaly MG, 2005, J PEDIATR ORTHOPED, V25, P786, DOI 10.1097/01.bpo.0000176162.78980.ed; Serghiou MH, 2008, DEV NEUROREHABIL, V11, P39, DOI 10.1080/17518420701520644; Tabachnick B.G., 2001, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91; [No title captured]	54	30	30	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1874-5393	1875-8894		J PEDIATR REHAB MED	J. Pediatr. Rehab. Med.		2009	2	4					297	307		10.3233/PRM-2009-0092			11	Pediatrics	Emerging Sources Citation Index (ESCI)	Pediatrics	GY1ER	WOS:000448267700006	20467579				2022-02-06	
J	Tenovuo, O; Alin, J; Helenius, H				Tenovuo, Olli; Alin, Jouni; Helenius, Hans			A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injuryWhat it showed and taught?	BRAIN INJURY			English	Article						Traumatic brain injury; rivastigmine; randomized controlled trial; placebo-controlled trial; crossover study	SEVERE HEAD-INJURY; COGNITIVE IMPAIRMENT; CHOLINERGIC SYSTEM; BASAL FOREBRAIN; DONEPEZIL; MEMORY; ATTENTION; POLYMORPHISM; DYSFUNCTION; RECOVERY	Primary objective: To evaluate the effectiveness of rivastigmine for chronic sequels of traumatic brain injury (TBI). Research design: Randomized, placebo-controlled, double-blind crossover trial. Methods and procedures: Of 772 outpatients with TBI treated during 1993-2002, all eligible patients were contacted and 102 patients volunteered. They were randomized to receive either rivastigmine (Exelon) or placebo. The study included two periods with titration to the highest tolerated or maximum dose (12 mg rivastigmine daily) and a maintenance period of 8 weeks, separated by a 4-week washout. Computerized neuropsychological testing and standardized clinical interviews were used to assess the outcome. Main outcomes and results: Sixty-nine patients completed the study and 17 withdrew because of adverse effects. In two measures of computerized testing (subtraction test, p = 0.034 and correct answers in the 10-15 minute vigilance test, p = 0.048) rivastigmine was better than placebo. The clinical interviews did not yield significant results. After the study, 45% of patients considered rivastigmine beneficial compared to 20% with placebo. Conclusions: A weak trend favouring rivastigmine for chronic symptoms of TBI was observed. The clinical significance of the results and the problems in conducting drug trials for chronic TBI symptoms are discussed.	[Tenovuo, Olli] Univ Turku, Dept Neurol, FIN-20520 Turku, Finland; [Alin, Jouni; Helenius, Hans] Univ Turku, Dept Biostat, FIN-20520 Turku, Finland		Tenovuo, O (corresponding author), Univ Turku, Dept Neurol, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.	olli.tenovuo@tyks.fi			Novartis FinlandNovartis	This study was supported by Novartis Finland (drugs and funding). The technical assistance of Tuula Tenovuo, Mari Toivola and the Clinical Research Service Turku are warmly acknowledged.	[Anonymous], 2003, J NEUROPSYCH CLIN N, V15, P383, DOI 10.1176/appi.neuropsych.15.3.383; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Bentley P, 2003, NEUROIMAGE, V20, P58, DOI 10.1016/S1053-8119(03)00302-1; Bourgeois JA, 2002, J NEUROPSYCH CLIN N, V14, P463, DOI 10.1176/appi.neuropsych.14.4.463; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Donohoe GG, 1999, CLIN CHEM, V45, P143; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Griffin SL, 2003, J NEUROPSYCH CLIN N, V15, P17, DOI 10.1176/appi.neuropsych.15.1.17; GRIZZLE JE, 1974, BIOMETRICS, V30, P727; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jones, 2003, DESIGN ANAL CROSS OV; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Poole NA, 2008, BRAIN INJURY, V22, P519, DOI 10.1080/02699050802132495; Revonsuo A., 1995, COGNISPEED COMPUTER; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Semba K, 2000, BEHAV BRAIN RES, V115, P117, DOI 10.1016/S0166-4328(00)00254-0; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Silver JM., 1994, NEUROPSYCHIATRY TRAU; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo OS, 2006, CURR DRUG THER, V1, P187, DOI 10.2174/157488506776930932; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Whitlock JA, 1999, J HEAD TRAUMA REHAB, V14, P424, DOI 10.1097/00001199-199908000-00010; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	41	30	30	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					548	558	PII 911808147	10.1080/02699050902926275			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800008	19484628				2022-02-06	
J	Wei, YZ; Wang, L; Clark, JCM; Dass, CR; Choong, PFM				Wei, Yongzhong; Wang, Lei; Clark, Jonathan C. M.; Dass, Crispin R.; Choong, Peter F. M.			Elevated leptin expression in a rat model of fracture and traumatic brain injury	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article							SYMPATHETIC NERVOUS-SYSTEM; BONE METABOLISM; SERUM LEPTIN; HEAD-INJURY; LOCALIZATION; RECEPTORS; INCREASES; MINERALIZATION; INFLAMMATION; RELEASE	A few studies have reported a relationship between leptin induced by brain injury and healing of bone tissue. Our objective was to measure serum and callus leptin expression within the setting of fracture and traumatic brain injury (TBI). Sixty-four male Sprague-Dawley rats were randomised equally into four groups: control, TBI group, fracture group and fracture/TBI group. Rats were sacrificed at 2, 4, 8 and 12 weeks after fracture/TBI. Serum leptin was detected using radioimmunoassay, and callus formation was measured radiologically. Callus leptin was analysed with immunohistochemistry. Serum leptin was significantly increased in the fracture, TBI and combined fracture/TBI groups compared with the control group at 2 weeks (P < 0.05). Serum leptin was significantly higher in the combined fracture/TBI group than in the fracture and TBI groups at 4 and 8 weeks (P < 0.05). The percentage of leptin-positive cells in the callus and callus volume were significantly higher in the fracture/TBI group than in the fracture-only group (P < 0.001). Thus, we demonstrated elevated leptin expression within healing bone, particularly in the first 8 weeks of a rat model combining fracture and TBI. A close association exists between leptin levels and the degree of callus formation in fractures.	[Wei, Yongzhong; Wang, Lei] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Peoples R China; [Clark, Jonathan C. M.; Dass, Crispin R.; Choong, Peter F. M.] Univ Melbourne, Melbourne, Vic 3010, Australia		Wei, YZ (corresponding author), Guangzhou Rd 300, Jiangsu 210029, Peoples R China.	wyz202@hotmail.com	Choong, Peter/F-1109-2014	Choong, Peter/0000-0002-3522-7374	Medical Science and Technology Development of Jiangsu Health Bureau [H200512]	This work was supported by funds from the Medical Science and Technology Development of Jiangsu Health Bureau (H200512), China.	Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Barr VA, 1999, J BIOL CHEM, V274, P21416, DOI 10.1074/jbc.274.30.21416; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Bonnet N, 2007, BONE, V40, P1209, DOI 10.1016/j.bone.2007.01.006; Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013; Faggioni R, 2000, AM J PATHOL, V156, P1781, DOI 10.1016/S0002-9440(10)65049-3; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Jeevanandam M, 1998, JPEN-PARENTER ENTER, V22, P340, DOI 10.1177/0148607198022006340; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; KOLACZYNSKI JW, 1996, DIABETES, V45, P701; Li JL, 2000, J BONE MINER RES, V15, P2042, DOI 10.1359/jbmr.2000.15.10.2042; Li S, 2001, Hua Xi Yi Ke Da Xue Xue Bao, V32, P240; Lin Ji, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P19; Lolmede K, 2003, INT J OBESITY, V27, P1187, DOI 10.1038/sj.ijo.0802407; Mantzoros CS, 1997, J CLIN ENDOCR METAB, V82, P3408, DOI 10.1210/jc.82.10.3408; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Miell JP, 1996, HORM METAB RES, V28, P704, DOI 10.1055/s-2007-979882; PASINETTI GM, 1993, NEUROSCIENCE, V54, P893, DOI 10.1016/0306-4522(93)90583-2; Patel L, 2002, J PEDIATR ENDOCR MET, V15, P963; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; Rayner DV, 2001, J MOL MED, V79, P8, DOI 10.1007/s001090100198; Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426; Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012; Schell H, 2006, BONE, V38, P547, DOI 10.1016/j.bone.2005.09.018; Shahbazian LM, 1999, METABOLISM, V48, P1397, DOI 10.1016/S0026-0495(99)90149-X; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; Thomas T, 2004, CURR OPIN PHARMACOL, V4, P295, DOI 10.1016/j.coph.2004.01.009; Thomas T, 2002, J BONE MINER RES, V17, P1563, DOI 10.1359/jbmr.2002.17.9.1563; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; Utriainen T, 1996, DIABETES, V45, P1364, DOI 10.2337/diabetes.45.10.1364; Wang YH, 2005, ARCH PHYS MED REHAB, V86, P1964, DOI 10.1016/j.apmr.2005.04.017; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009	43	30	36	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	DEC	2008	60	12					1667	1672		10.1211/jpp/60.12.0013			6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	380ON	WOS:000261475100013	19000372				2022-02-06	
J	Burr, RL; Kirkness, CJ; Mitchell, PH				Burr, Robert L.; Kirkness, Catherine J.; Mitchell, Pamela H.			Detrended Fluctuation Analysis of Intracranial Pressure Predicts Outcome Following Traumatic Brain Injury	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						Detrended fluctuation analysis (DFA); intracranial pressure (ICP); monitoring; outcome; traumatic brain injury (TBI)	HEART-RATE-VARIABILITY; APPROXIMATE ENTROPY; SYSTEMS-ANALYSIS; WAVE-FORM; HYPERTENSION; INFORMATION; DYNAMICS; SIGNALS; SCALE; COMA	Detrended fluctuation analysis (DFA) is a recently developed technique suitable for describing scaling behavior of variability in physiological signals. The purpose of this study is to explore applicability of DFA methods to intracranial pressure (ICP) signals recorded in patients with traumatic brain injury (TBI). In addition to establishing the degree of fit of the power-law scaling model of detrended fluctuations of ICP in TBI patients, we also examined the relationship of DFA coefficients (scaling exponent and intercept) to: 1) measures of initial neurological functioning; 2) measures of functional outcome at six month follow-up; and 3) measures of outcome, controlling for patient characteristics, and initial neurological status. In a sample of 147 moderate-to-severely injured TBI patients, we found that a higher DFA scaling exponent is significantly associated with poorer initial neurological functioning, and that lower DFA intercept and higher DFA scaling exponent jointly predict poorer functional outcome at six month follow-up, even after statistical control for covariates reflecting initial neurological condition. DFA describes properties of ICP signal in TBI patients that are associated with both initial neurological condition and outcome at six months postinjury.	[Burr, Robert L.; Kirkness, Catherine J.; Mitchell, Pamela H.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA		Burr, RL (corresponding author), Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA.	bobburr@u.washington.edu; kirkness@u.washington.edu; pmitch@u.washington.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIB R01 NR04501]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004501, R01NR004901] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health under Grant NIB R01 NR04501.	Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Beaumont A, 2002, ACT NEUR S, V81, P193; Chen Z, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041107; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; Czosnyka M, 1998, ACT NEUR S, V71, P74; Echeverria JC, 2004, PHYSIOL MEAS, V25, P763, DOI 10.1088/0967-3334/25/3/015; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Havlin S, 1999, PHYSICA A, V274, P99, DOI 10.1016/S0378-4371(99)00333-7; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Ho KKL, 1997, CIRCULATION, V96, P842; Holm S, 2008, MED ENG PHYS, V30, P164, DOI 10.1016/j.medengphy.2007.03.003; Hornero R, 2005, IEEE T BIO-MED ENG, V52, P1671, DOI 10.1109/TBME.2005.855722; Hu K, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011114; Iyengar N, 1996, AM J PHYSIOL-REG I, V271, pR1078, DOI 10.1152/ajpregu.1996.271.4.R1078; Jospin M, 2007, IEEE T BIO-MED ENG, V54, P840, DOI 10.1109/TBME.2007.893453; Kirkness CJ, 2006, AM J CRIT CARE, V15, P600; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LIN ES, 1991, BRIT J ANAESTH, V66, P476, DOI 10.1093/bja/66.4.476; Moody GB, 2001, IEEE ENG MED BIOL, V20, P70, DOI 10.1109/51.932728; PENG CK, 1994, PHYS REV E, V49, P1685, DOI 10.1103/PhysRevE.49.1685; Peng CK, 2002, ANN BIOMED ENG, V30, P683, DOI 10.1114/1.1481053; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; PENG CK, 1995, PHYSICA A, V221, P180, DOI 10.1016/0378-4371(95)00247-5; Penzel T, 2003, IEEE T BIO-MED ENG, V50, P1143, DOI 10.1109/TBME.2003.817636; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Seely AJE, 2004, CRIT CARE, V8, pR367, DOI 10.1186/cc2948; Tapanainen JM, 2002, AM J CARDIOL, V90, P347, DOI 10.1016/S0002-9149(02)02488-8; TEASDALE G, 1974, LANCET, V2, P81; TEICH MC, 2001, IEEE PRESS SERIES BI, V2, P171; Varela M, 2003, EUR J APPL PHYSIOL, V89, P230, DOI 10.1007/s00421-002-0790-2; Westhout FD, 2008, SURG NEUROL, V70, P70, DOI 10.1016/j.surneu.2007.04.020; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WILSON PS, 2003, PHYS REV E, V68, P31	33	30	31	0	4	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9294	1558-2531		IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	NOV	2008	55	11					2509	2518		10.1109/TBME.2008.2001286			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	371XI	WOS:000260865600003	18990620	Green Accepted			2022-02-06	
J	Anon, J; Remonda, L; Spreng, A; Scheurer, E; Schroth, G; Boesch, C; Thali, M; Dirnhofer, R; Yen, K				Anon, Javier; Remonda, Luca; Spreng, Adrian; Scheurer, Eva; Schroth, Gerhard; Boesch, Chris; Thali, Michael; Dirnhofer, Richard; Yen, Kathrin			Traumatic extra-axial hemorrhage: Correlation of postmortem MSCT, MRI, and forensic-pathological findings	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						traumatic extra-axial hemorrhage; postmortem MSCT; postmortem MRI; forensic neuropathology; correlation	CLOSED-HEAD INJURY; MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; FIELD MR; CT; BRAIN; EXPERIENCE; AUTOPSY	Purpose: To evaluate the diagnostic accuracy of in situ postmortem multislice computed tomography (MSCT) and magnetic resonance imaging (MRI) in the detection of primary traumatic extra-axial hemorrhage. Materials and Methods: Thirty forensic neurotrauma cases and 10 nontraumatic controls who underwent both in situ postmortem cranial MSCT and MR imaging before autopsy were retrospectively reviewed. Both imaging modalities were analyzed in view of their accuracy, sensitivity, and specificity concerning the detection of extra-axial hemorrhage. Statistical significance was calculated using the McNemar test. K values for interobserver agreement were calculated for extra-axial hemorrhage types and to quantify the agreement between both modalities as well as MRI, CT, and forensics, respectively. Results: Analysis of the detection of hemorrhagic localizations showed an accuracy, sensitivity, and specificity of 89%, 82%, and 92% using CT, and 90%, 83%, and 94% using MRI, respectively. MRI was more sensitive than CT in the detection of subarachnoid hemorrhagic localizations (P = 0.001), whereas no significant difference resulted from the detection of epidural and subdural hemorrhagic findings, (P = 0.248 and P = 0.104, respectively). Interobserver agreement for all extra-axial hemorrhage types was substantial (CT kappa = 0,76; MRI kappa = 0.77). The agreement of both modalitites was almost perfect (readers 1 and 2 kappa = 0.88). Conclusion: CT and MRI are of comparable potential as forensic diagnostic tools for traumatic extra-axial hemorrhage. Not only of forensic, but also of clinical interest is the observation that most thin blood layers escape the radiological evaluation.	[Anon, Javier; Remonda, Luca; Spreng, Adrian; Schroth, Gerhard] Univ Bern, Dept Neuroradiol, Inselspital, CH-3010 Bern, Switzerland; [Anon, Javier; Scheurer, Eva; Thali, Michael; Dirnhofer, Richard; Yen, Kathrin] Univ Bern, Inst Forens Med, CH-3010 Bern, Switzerland; [Scheurer, Eva; Boesch, Chris] Univ Bern, Dept Clin Res Magnet Resonance Spect & Methodol, Inselspital, CH-3010 Bern, Switzerland; [Yen, Kathrin] Med Univ Graz, Inst Forens Med, Ctr Clin Theoret Med, Graz, Austria		Remonda, L (corresponding author), Univ Bern, Dept Neuroradiol, Inselspital, Freiburgstr 10, CH-3010 Bern, Switzerland.	luca.remonda@bluewin.ch	Scheurer, Eva/C-6536-2011; Boesch, Chris/F-2577-2010; Scheurer, Eva/AAE-6161-2019	Boesch, Chris/0000-0001-8498-8543; Scheurer, Eva/0000-0002-2742-0422			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Blamire AM, 1999, ACTA RADIOL, V40, P593, DOI 10.3109/02841859909175593; BOYKO OB, 1994, ARCH PATHOL LAB MED, V118, P219; BRADLEY WG, 1984, RADIOLOGY, V152, P695, DOI 10.1148/radiology.152.3.6463251; Brogdon, 1998, FORENSIC RADIOLOGY; BROOKS RA, 1980, J COMPUT ASSIST TOMO, V4, P489, DOI 10.1097/00004728-198008000-00016; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1994, RADIOLOGY, V191, P1; HAN BK, 1990, AM J ROENTGENOL, V154, P361, DOI 10.2214/ajr.154.2.2105031; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; HARRIS LS, 1991, FORENSIC SCI INT, V50, P179, DOI 10.1016/0379-0738(91)90149-D; Hart BL, 1996, AM J FOREN MED PATH, V17, P217, DOI 10.1097/00000433-199609000-00008; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Klufas RA, 1996, AM J ROENTGENOL, V166, P675, DOI 10.2214/ajr.166.3.8623649; KRAULAND W, 1982, INJURIES INTRACRANIA; LANDIS JR, 1977, BIOMETRICS, V33, P174; LANGLOIS JA, 2004, TRAUMATIC BRAIN JURY; Lee Bruce, 2005, NeuroRx, V2, P372; LEE DH, 1995, CAN ASSOC RADIOL J, V46, P174; ORRISON WW, 1991, RADIOLOGY, V181, P121, DOI 10.1148/radiology.181.1.1887020; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; OSBORN AG, 1994, DIAGNOSTIC NEURORADI, P154; OSBORN AG, 1994, DIAGNOSTIC NEURORADI, P199; Patriquin L, 2001, J MAGN RESON IMAGING, V13, P277, DOI 10.1002/1522-2586(200102)13:2<277::AID-JMRI1040>3.0.CO;2-W; ROS PR, 1990, MAGN RESON IMAGING, V8, P303, DOI 10.1016/0730-725X(90)90103-9; SCHELLMANN B, 1978, Z RECHTSMED, V82, P199, DOI 10.1007/BF02092336; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Thali MJ, 2003, J FORENSIC SCI, V48, P386; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	30	30	30	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	OCT	2008	28	4					823	836		10.1002/jmri.21495			14	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	356PY	WOS:000259791300003	18821624	Bronze			2022-02-06	
J	Shuttleworth-Edwards, AB; Noakes, TD; Radloff, SE; Whitefield, VJ; Clark, SB; Roberts, CO; Essack, FB; Zoccola, D; Boulind, MJ; Case, SE; Smith, IP; Mitchell, JLG				Shuttleworth-Edwards, Ann B.; Noakes, Timothy D.; Radloff, Sarah E.; Whitefield, Victoria J.; Clark, Susan B.; Roberts, Craig O.; Essack, Fathima B.; Zoccola, Diana; Boulind, Melissa J.; Case, Stephanie E.; Smith, Ian P.; Mitchell, Julia L. G.			The comparative incidence of reported concussions presenting for follow-up management in South African Rugby Union	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article							INJURIES; STATEMENT; PLAYERS; SCHOOL; SOCCER	Objective: The objective of this study was to compare the seasonal concussion incidence for school, university, club and provincial level Rugby Union players in South Africa. Design: The study presents a retrospective statistical analysis of the number of reported concussions documented annually for groups Of Rugby Union players as a proportion of those who received preseason neurocognitive assessment. Setting: Between 2002 and 2006, concussion management programs using computerized neuropsychological assessment were implemented for clinical and research purposes by psychologists in selected South African institutions involved in Rugby Union from school through to the professional level. Participants: The incidence figures were based on 175 Concussive episodes reported for 165 athletes who were referred for neurocognitive assessment from a Population of 1366 athletes who received preseason baseline testing. Interventions: Concussion management routines varied according to the protocols adopted by the different psychologists and rugby organizations. Main Outcome Measurements: It was expected that the incidence of concussion Would vary significantly due to level of play and different management protocols. Results: There was wide disparity in the manner in which Concussion follow-up was managed by the various organizations. Within broadly comparable cohorts, fighter control was associated with a relatively higher concussion incidence for athletes per rugby playing season, with average institutional figures ranging from 4% to 14% at school level and 3% to 23% at adult level. Conclusions: This analysis suggests that concussion goes unrecognized and therefore incorrectly managed in a number of instances. Recommendations for optimal identification of concussed athletes for follow-up management are presented.	[Shuttleworth-Edwards, Ann B.] Rhodes Univ, Psychol Clin, NSCI, Dept Psychol, ZA-6139 Grahamstown, South Africa; [Noakes, Timothy D.] Univ Cape Town, S African Sports Sci Inst, Dept Human Biol, Newland, South Africa; [Radloff, Sarah E.] Rhodes Univ, Dept Stat, ZA-6139 Grahamstown, South Africa; [Roberts, Craig O.] Natal Rugby Union, Dept Med, Durban, South Africa		Shuttleworth-Edwards, AB (corresponding author), Rhodes Univ, Psychol Clin, NSCI, Dept Psychol, ZA-6139 Grahamstown, South Africa.	a.edwards@ru.ac.za	Noakes, Timothy D./E-7253-2011; Noakes, Tim/AAD-3162-2020	Noakes, Timothy D./0000-0001-7244-2375; Noakes, Tim/0000-0001-7244-2375	Rhodes University Council; National Research Foundation (NRF)	This research was supported by grants from the Rhodes University Council and the National Research Foundation (NRF). Incidence data from neuropsychological theses in progress for three doctoral students (co-authors Clark, Essack and Zoccola) are reported in this article. In each case the focus of these dissertations is the acute and chronic neuropsychological effects of concussion, and not incidence, and therefore this article does not pre-empt the presentation of their doctoral results. The first and fourth authors have a commercial relationship with ImPACT Applications, Inc. (USA) for the development of neurocognitive screening as a component of sports concussion management in South Africa and the UK.	[Anonymous], 2008, PREVALENCE INCIDENCE; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Jakoet I, 1998, S AFR MED J, V88, P45; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; LOVELL MR, TECHNICAL MANUAL PSY; MCCRORY P, 2001, BRIT J SPORT MED, V35, P379; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Micheli L J, 1974, J Sports Med, V2, P93; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; NATHAN M, 1983, S AFR MED J, V64, P132; ROUX CE, 1987, S AFR MED J, V71, P307; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Shuttleworth-Edwards A, 2004, STUD NEUROPSYCHOL DE, P149; Shuttleworth-Edwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P479, DOI 10.1016/j.acn.2008.07.002; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; SHUTTLEWORTHEDW.AB, 2008, J CLIN EXPE IN PRESS; SHUTTLEWORTHEDW.AB, 2007, S AFR J SPORTS MED, V19, P32; SOLOMON GS, 2006, HEADS UP SPORT CONCU; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; WILLS SM, 2001, J INT NEUROPSYCH SOC, V7, P405	32	30	31	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2008	18	5					403	409		10.1097/JSM.0b013e3181895910			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	353SR	WOS:000259589000007	18806547				2022-02-06	
J	Tian, HL; Chen, SW; Xu, T; Hu, J; Rong, BY; Wang, G; Gao, WW; Chen, H				Tian Heng-Li; Chen Shi-Wen; Xu Tao; Hu Jin; Rong Bo-Ying; Wang Gan; Gao Wen-Wei; Chen Hao			Risk factors related to hospital mortality in patients with isolated traumatic acute subdural haematoma: analysis of 308 patients undergone surgery	CHINESE MEDICAL JOURNAL			English	Article						acute subdural haematoma; hospital mortality; risk factors	SEVERE HEAD-INJURY; OUTCOME PREDICTION; PROGNOSTIC-FACTORS; BRAIN-INJURY; MANAGEMENT; AGE	Background Acute subdural haematoma (ASDH) is a common traumatic brain injury with a relatively high mortality rate. However, few studies have examined the factors predicting the outcome of isolated traumatic ASDH. This clinical study examined the hospital mortality and analyzed the risk factors for mortality in patients treated surgically for isolated traumatic ASDH. Methods We collected 308 consecutive patients who underwent neurosurgery for isolated traumatic ASDH between January 1999 and December 2007 and used multivariate Logistic regression analysis to evaluate the influence of 11 clinical variables on hospital mortality. Results The overall hospital mortality was 21.75% (67/308). Age (OR=1.807), preoperative Glasgow Coma Score (OR=0.316), brain herniation (OR=2.181) and the time from trauma to decompression (OR=1.815) were independent predictors of death, while no independent association was observed between hospital mortality and haematoma volume, midline shift, acute brain swelling or brain herniation duration, although these variables were correlated with hospital mortality in univariate analyses. Conclusions This study identified the risk factors for hospital mortality inpatients who underwent surgical treatment for isolated traumatic ASDH. An increased risk of death occurs in patients who are over 50 years of age and have lower preoperative Glasgow Coma Scores, the presence of brain herniation and a long interval between trauma and decompression. The findings should help clinicians determine management criteria and improve survival.	[Tian Heng-Li; Chen Shi-Wen; Xu Tao; Hu Jin; Rong Bo-Ying; Wang Gan; Gao Wen-Wei; Chen Hao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Neurosurg, Shanghai 200233, Peoples R China		Chen, H (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Neurosurg, Shanghai 200233, Peoples R China.	chenhao_316@yahoo.com.cn		Chen, Hao/0000-0002-9943-9237			Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; D'Amato L, 2007, J Neurosurg Sci, V51, P107; Jiang JY, 1998, CHINESE MED J-PEKING, V111, P180; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Leach P, 2007, BRIT J NEUROSURG, V21, P11, DOI 10.1080/02688690701210562; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Marion DW, 2006, NEUROSURGERY, V58, P655; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; PIOTROWSKI WP, 1995, UNFALLCHIRURG, V98, P432; Saito T, 2003, ACTA NEUROCHIR SUPPL, V86, P351; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; VILALTA J, 1989, NEUROLOGIA, V6, P247; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	20	30	30	0	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0366-6999			CHINESE MED J-PEKING	Chin. Med. J.	JUN 20	2008	121	12					1080	1084		10.1097/00029330-200806020-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316IV	WOS:000256943800007	18706221	gold			2022-02-06	
J	Wade, SL; Taylor, HG; Walz, NC; Salisbury, S; Stancin, T; Bernard, LA; Oberjohn, K; Yeates, KO				Wade, Shari L.; Taylor, H. Gerry; Walz, Nicolay Chertkoff; Salisbury, Shelia; Stancin, Terry; Bernard, Lori A.; Oberjohn, Karen; Yeates, Keith Owen			Parent-child interactions during the initial weeks following brain injury in young children	REHABILITATION PSYCHOLOGY			English	Article						early childhood; traumatic brain injury; parent-child interaction; family impact	PREMATURITY STEREOTYPE; MATERNAL DEPRESSION; HEAD-INJURY; OUTCOMES; MOTHERS; TERM; PERCEPTIONS; ADJUSTMENT; FAMILIES; BEHAVIOR	To understand how traumatic brain injury (TBI) affects parent-child interactions acutely following injury. Participants: Young children hospitalized for TBI (n = 80) and orthopedic injuries (OI; n = 113). Method: Raters coded videotaped interactions during free play and structured tasks for parental warmth/responsiveness and negativity and child warmth, behavior regulation, and cooperation. Raters also counted parental directives, critical/restricting statements, and scaffolds. Results: Parents of children with TBI exhibited less warm responsiveness and made more directive statements during a structured task than parents in the OI group. Children with TBI displayed less behavior regulation than children with OI. Parental warm responsiveness was more strongly related to child cooperativeness in the 01 group than in the TBI group. Child behavior also mediated group differences in parental responsiveness and directiveness. TBI accounted for as much variance in parental behaviors as or more than did sociodemographic factors. Conclusion: TBI-related changes in child behavior may negatively influence parent-child interactions and disrupt the reciprocity between parent and child.	[Wade, Shari L.; Bernard, Lori A.; Oberjohn, Karen] Cincinnati Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.; Walz, Nicolay Chertkoff; Salisbury, Shelia] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45221 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; [Stancin, Terry] Case Western Reserve Univ, Dept Pediat, Sch Med, Cleveland, OH 44106 USA; [Walz, Nicolay Chertkoff] Univ Cincinnati, Div Behav Med & Clin Psychol, Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45221 USA; [Salisbury, Shelia] Univ Cincinnati, Div Epidemiol & Biostat, Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45221 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Childrens Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Yeates, Keith Owen] Columbus Childrens Hosp, Dept Pediat, Columbus, OH 43205 USA		Wade, SL (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Phys Med & Rehabil, Dept Pediat, MLC 4009,3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER		Ainsworth M. D. S., 1978, PATTERNS ATTACHMENT, DOI 10.1037/t28248-000; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2000, BRAIN INJURY, V14, P679; Assel M. A., 2003, APPL DEV SCI, V7, P27, DOI [10.1207/s1532480xads0701_3, DOI 10.1207/S1532480XADS0701_3, 10.1207/S1532480XADS0701_3, DOI 10.1207/S1532480XADS0701_]; BAKEMAN R, 1980, CHILD DEV, V51, P437, DOI 10.2307/1129277; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARKLEY RA, 1991, J ABNORM CHILD PSYCH, V19, P149, DOI 10.1007/BF00909976; Chronis AM, 2007, DEV PSYCHOL, V43, P70, DOI 10.1037/0012-1649.43.1.70; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DANFORTH JS, 1991, CLIN PSYCHOL REV, V11, P703, DOI 10.1016/0272-7358(91)90127-G; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; Derogatis LR, 1982, BRIEF SYMPTOM INVENT; DYERHARNISH J, 1995, CHILD DEV, V66, P739; Elgar FJ, 2004, CLIN PSYCHOL REV, V24, P441, DOI 10.1016/j.cpr.2004.02.002; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Floyd F.J., 1997, INT REV RES MENT RET, V20, P47, DOI [10.1016/s0074-7750(08)60175-5, DOI 10.1016/S0074-7750(08)60175-5]; Floyd FJ, 2004, AM J MENT RETARD, V109, P507, DOI 10.1352/0895-8017(2004)109<507:FPWCWH>2.0.CO;2; FLOYD FJ, 1991, CHILD DEV, V62, P1434, DOI 10.2307/1130817; FLOYD FJ, 1992, J PEDIATR PSYCHOL, V17, P607, DOI 10.1093/jpepsy/17.5.607; FLOYD FJ, 1993, AM J MENT RETARD, V97, P673; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Haskett ME, 2007, CHILD CARE HLTH DEV, V33, P67, DOI 10.1111/j.1365-2214.2006.00627.x; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; Holmbeck GN, 2002, J CONSULT CLIN PSYCH, V70, P96, DOI 10.1037//0022-006X.70.1.96; Howe D., 2006, CHILD FAM SOC WORK, V11, P95, DOI [DOI 10.1111/J.1365-2206.2006.00397.X, 10.1111/j.1365-2206.2006.00397.x.]; Johnston C, 2001, CLIN CHILD FAM PSYCH, V4, P183, DOI 10.1023/A:1017592030434; Keogh BK, 2000, AM J MENT RETARD, V105, P32, DOI 10.1352/0895-8017(2000)105<0032:MOCIFC>2.0.CO;2; LANDRY SH, 1990, CHILD DEV, V61, P1605, DOI 10.2307/1130768; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; Landry SH, 2006, DEV PSYCHOL, V42, P627, DOI 10.1037/0012-1649.42.4.627; Landry SH, 1996, MERRILL PALMER QUART, V42, P177; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; Landry SH, 2001, DEV PSYCHOL, V37, P387, DOI 10.1037//0012-1649.37.3.387; Mahoney G, 2004, RES DEV DISABIL, V25, P539, DOI 10.1016/j.ridd.2004.04.001; Mahoney G, 1998, TOP EARLY CHILD SPEC, V18, P5, DOI 10.1177/027112149801800104; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Pipp-Siegel S, 1998, VOLTA REV, V100, P237; QUITTNER AL, 1992, REHABIL PSYCHOL, V37, P275, DOI 10.1037/h0079107; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Seefeldt T., 1997, PSI CHI J UNDERGRADU, V2, P5; Smith KE, 2006, PEDIATRICS, V117, P1608, DOI 10.1542/peds.2005-1284; Smith KE, 2005, J CONSULT CLIN PSYCH, V73, P711, DOI 10.1037/0022-006X.73.4.711; STANCIN T, J DEV BEHAV IN PRESS; STERN M, 1984, DEV PSYCHOL, V20, P360, DOI 10.1037/0012-1649.20.3.360; Stern M, 2000, INF MENTAL HLTH J, V21, P495, DOI 10.1002/1097-0355(200011/12)21:6<495::AID-IMHJ7>3.0.CO;2-F; TANNOCK R, 1988, AM J MENT RETARD, V93, P154; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tronick E. Z., 1997, P54; VAUGHN BE, 1999, HDB ATTACHMENT THEOR, P00198; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Weizman ZO, 2001, DEV PSYCHOL, V37, P265, DOI 10.1037//0012-1649.37.2.265; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31; [No title captured], DOI DOI 10.1002/CD.23219894306	55	30	30	0	10	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2008	53	2					180	190		10.1037/0090-5550.53.2.180			11	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	313AF	WOS:000256712800008	25838616	Green Accepted			2022-02-06	
J	Berne, JD; Reuland, KR; Villarreal, DH; McGovern, TM; Rowe, SA; Norwood, SH				Berne, John D.; Reuland, Kurt R.; Villarreal, David H.; McGovern, Thomas M.; Rowe, Stephen A.; Norwood, Scott H.			Internal carotid artery stenting for blunt carotid artery injuries with an associated pseudoaneurysm	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						carotid artery injury; carotid stent; blunt cerebrovascular injury; pseudoaneurysm	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CEREBROVASCULAR INJURIES; TRAUMATIC PSEUDOANEURYSM; EARLY-DIAGNOSIS; SCREENING-TEST; ENDARTERECTOMY; ANGIOPLASTY; EPISTAXIS; ANEURYSMS; IMPROVES	Background. Blunt carotid artery injuries (BCI) are being recognized and treated with increasing frequency because of improved screening protocols. Recent advances in endovascular techniques using microcoils, angioplasty, and stenting offer a new treatment strategy for those patients with traumatic pseudoaneurysms (PA) (BCI and PA). Experience with these techniques is limited because of the rarity of these injuries. Hypothesis. Early anticoagulation (AC) or antiplatelet (AP) therapy combined with carotid artery stenting is a safe alternative to AC alone for the treatment of grade III carotid artery injuries (BCI and PA). Design: Prospective cohort study. Setting: A rural, community Level I trauma center. Patients and Methods: All patients with a nonocclusive BCI and PA during a 5.5 year period from June 23, 2000 to December 31, 2005 were included in the study. Results. Eleven patients with grade BCI and PA underwent endovascular repair. Nine patients (81%) had associated traumatic intracranial hemorrhage. AC (heparin drip) or AP therapy (clopidogrel or aspirin or both) was initiated in all patients within 48 hours of diagnosis of BCI. Time from admission to AC or AP was 21 +/- 9.5 hours (mean +/- SD). Mortality rate was 18% (2 of 11). One death was attributed to severe brain injury. The other was attributed to a stroke from the carotid injury. No patient had radiologic progression of traumatic intracranial hemorrhage on head computed tomography despite AP or AC. One patient sustained a mild embolic cerebrovascular ischemic event before stenting. No other survivors developed a stroke or any other evidence of cerebral ischemic symptoms. Two recurrent PAs developed during hospitalization and were successfully managed with an additional stent. All survivors were discharged with a good neurologic outcome. Seven patients had follow-up from 6 months to 4 years: one developed asymptomatic 50% sterrosis at 6 months requiring successful angioplasty. All others showed complete healing without stenosis. Conclusions: Carotid artery stenting is safe and effective initial therapy for patients with nonocclusive BCI and PA. Initial intermediate-term follow-up also fails to demonstrate significant morbidity for up to 4 years.	[Berne, John D.; Villarreal, David H.; McGovern, Thomas M.; Rowe, Stephen A.; Norwood, Scott H.] E Texas Med Ctr, Div Trauma Surg, Tyler, TX USA; [Reuland, Kurt R.] E Texas Med Ctr, Div Radiol, Tyler, TX USA		Berne, JD (corresponding author), 1020 E Idel St, Tyler, TX USA.	jberne@aol.com					Berne JD, 2004, J TRAUMA, V57, P11, DOI 10.1097/01.TA.0000135499.70048.C7; Berne JD, 2001, J AM COLL SURGEONS, V192, P314, DOI 10.1016/S1072-7515(01)00772-4; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 2002, ANN SURG, V235, P699, DOI 10.1097/00000658-200205000-00012; Biffl WL, 1998, ANN SURG, V228, P462, DOI 10.1097/00000658-199810000-00003; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Brown MM, 2001, LANCET, V357, P1729; Chen DS, 1998, LARYNGOSCOPE, V108, P326, DOI 10.1097/00005537-199803000-00004; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Coldwell DM, 2000, J TRAUMA, V48, P470, DOI 10.1097/00005373-200003000-00016; Cothren CC, 2005, AM J SURG, V190, P845, DOI 10.1016/j.amsurg.2005.08.007; Cothren CC, 2005, ARCH SURG-CHICAGO, V140, P480, DOI 10.1001/archsurg.140.5.480; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; Duane TM, 2002, J TRAUMA, V52, P149, DOI 10.1097/00005373-200201000-00025; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Eskandari MK, 2004, ARCH SURG-CHICAGO, V139, P734, DOI 10.1001/archsurg.139.7.734; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FABIAN TC, 1990, J TRAUMA, V30, P953, DOI 10.1097/00005373-199008000-00003; Fusonie GE, 2004, ANN VASC SURG, V18, P376, DOI 10.1007/s10016-004-0037-2; Gray WA, 2006, J VASC SURG, V44, P258, DOI 10.1016/j.jvs.2006.03.044; HAN MH, 1994, LARYNGOSCOPE, V104, P370; Kerby JD, 2000, J TRAUMA, V49, P784, DOI 10.1097/00005373-200010000-00036; Maras D, 2006, CARDIOVASC INTER RAD, V29, P958, DOI 10.1007/s00270-005-0367-7; Marotta TR, 1998, NEUROSURGERY, V42, P408, DOI 10.1097/00006123-199802000-00138; Miller PR, 2001, J TRAUMA, V51, P279, DOI 10.1097/00005373-200108000-00009; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Mulloy JP, 1998, RADIOLOGY, V207, P571, DOI 10.1148/radiology.207.3.9609876; Naylor AR, 1998, J VASC SURG, V28, P326, DOI 10.1016/S0741-5214(98)70182-X; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; PALMAZ JC, 1988, RADIOLOGY, V168, P727, DOI 10.1148/radiology.168.3.2970098; PARODI JC, 1995, J VASC SURG, V21, P549, DOI 10.1016/S0741-5214(95)70186-9; Pelz D, 2006, STROKE, V37, P309, DOI 10.1161/01.STR.0000201436.30248.ec; PERRY MO, 1980, ANN SURG, V192, P74, DOI 10.1097/00000658-198007000-00013; Popma JJ, 2004, CHEST, V126, p576S, DOI 10.1378/chest.126.3_suppl.576S; Shames ML, 1999, J TRAUMA, V46, P724, DOI 10.1097/00005373-199904000-00030; Stoeckel D, 2004, EUR RADIOL, V14, P292, DOI 10.1007/s00330-003-2022-5; THOMAS MR, 1993, CATHETER CARDIO DIAG, V30, P169, DOI 10.1002/ccd.1810300219; ul Haq Tanveer, 2004, Australas Radiol, V48, P220; VERNEUIL M, 1872, B ACAD NAT MED PARIS, V1, P46; White RA, 2005, J VASC SURG, V42, P213, DOI 10.1016/j.jvs.2005.04.023; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127; YAMADA S, 1967, J TRAUM, V7, P333, DOI 10.1097/00005373-196705000-00001	44	30	31	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2008	64	2					398	405		10.1097/TA.0b013e31815eb788			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	264KV	WOS:000253287100031	18301205				2022-02-06	
J	Rabin, LA; Borgos, MJ; Saykin, AJ				Rabin, Laura A.; Borgos, Marlana J.; Saykin, Andrew J.			A Survey of Neuropsychologists' Practices and Perspectives Regarding the Assessment of Judgment Ability	APPLIED NEUROPSYCHOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the International-Neuropsychological-Society	FEB 01-04, 2006	Boston, MA	Int Neuropsychol Soc		judgment; judgment tests; neuropsychological assessment; survey	TRAUMATIC BRAIN-INJURY; PROBLEM-SOLVING SKILLS; DECISION-MAKING CAPACITY; TEST USAGE; EXECUTIVE DYSFUNCTION; ALZHEIMERS-DISEASE; OLDER-ADULTS; SCHIZOPHRENIA; AGE; INDIVIDUALS	Judgment is an important aspect of cognitive and real-world functioning that is commonly assessed during neuropsychological evaluations. This study utilized a brief, online survey to examine neuropsychologists' practices and perspectives regarding available judgment instruments. Participants (n=290, 17% response rate) were randomly selected members of the International Neuropsychological Society and the National Academy of Neuropsychology. Respondents rank-ordered the following issues that should be incorporated into assessments of judgment (from most to least important): safety, ability to perform activities of daily living, and problem solving/decision making about medical, financial, social/ethical, and legal matters. A majority of respondents reported that they often or always assessed judgment when evaluating patients with traumatic brain injury (89%), dementia (87%), and psychiatric disorders (70%). Surprisingly, the top-ranked instruments were not tests of judgment per se, and included the WAIS-III Comprehension, Wisconsin Card Sorting Test, and WAIS-III Similarities. Further, 61% of respondents were slightly confident, and only 23% were very confident, in their ability to assess a patient's judgment skills with their current tests. The overwhelming majority (87%) of respondents perceived a need for improved measures. Overall results indicate use of varied techniques by neuropsychologists to evaluate judgment and suggest the need for additional tests of this cognitive domain.	[Rabin, Laura A.] CUNY Brooklyn Coll, Dept Psychol, Brooklyn, NY 11210 USA; [Rabin, Laura A.] CUNY, Grad Ctr, Dept Psychol, Brooklyn, NY 11210 USA; [Rabin, Laura A.; Borgos, Marlana J.; Saykin, Andrew J.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Neuropsychol Program,Dept Psychiat, Hanover, NH 03756 USA; [Saykin, Andrew J.] Indiana Univ, Sch Med, Dept Radiol, Ctr Neuroimaging, Indianapolis, IN 46202 USA		Rabin, LA (corresponding author), CUNY Brooklyn Coll, Dept Psychol, 2900 Bedford Ave, Brooklyn, NY 11210 USA.	lrabin@brooklyn.cuny.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG019771, R01 AG019771-06, R01 AG19771] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771] Funding Source: NIH RePORTER		Allaire JC, 1999, PSYCHOL AGING, V14, P627, DOI 10.1037/0882-7974.14.4.627; Archer RP, 2006, J PERS ASSESS, V87, P84, DOI 10.1207/s15327752jpa8701_07; Artistico D, 2003, PSYCHOL AGING, V18, P68, DOI 10.1037/0882-7974.18.1.68; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; Bearden CE, 2001, BIPOLAR DISORD, V3, P106, DOI 10.1034/j.1399-5618.2001.030302.x; Bertrand RM, 1999, AGING MENT HEALTH, V3, P281, DOI 10.1080/13607869956055; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Cook C, 2000, EDUC PSYCHOL MEAS, V60, P821, DOI 10.1177/00131640021970934; CORNELIUS SW, 1987, PSYCHOL AGING, V2, P144, DOI 10.1037/0882-7974.2.2.144; DENNEY NW, 1989, PSYCHOL AGING, V4, P438, DOI 10.1037/0882-7974.4.4.438; Duke LM, 2000, NEUROPSYCHOL REV, V10, P75, DOI 10.1023/A:1009096603879; FITTEN LJ, 1990, J AM GERIATR SOC, V38, P1097, DOI 10.1111/j.1532-5415.1990.tb01372.x; Flashman Laura A, 2002, Curr Psychiatry Rep, V4, P346, DOI 10.1007/s11920-002-0082-x; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Grisso T., 1998, MACARTHUR COMPETENCE; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Kajanne A, 2003, J ADULT DEV, V10, P173, DOI 10.1023/A:1023414313800; Karlawish J, 2008, NEUROSIGNALS, V16, P91, DOI 10.1159/000109763; Karlawish JHT, 2005, NEUROLOGY, V64, P1514, DOI 10.1212/01.WNL.0000160000.01742.9D; Kim SYH, 2002, AM J GERIAT PSYCHIAT, V10, P151, DOI 10.1176/appi.ajgp.10.2.151; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; LAFLECHE G, 1995, NEUROPSYCHOLOGY, V9, P313, DOI 10.1037/0894-4105.9.3.313; Lai JM, 2007, AM J GERIAT PSYCHIAT, V15, P101, DOI 10.1097/01.JGP.0000239246.10056.2e; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Loeb, 1996, INDEPENDENT LIVING S; LOWENSTEIN DA, 1989, J GERONTOL B-PSYCHOL, V44, P114; Marsiske M., 2006, HDB PSYCHOL AGING, P315, DOI [10.1016/B978-012101264-9/50017-3, DOI 10.1016/B978-012101264-9/50017-3]; Marson D, 1999, Semin Clin Neuropsychiatry, V4, P41; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Medalia A, 2002, SCHIZOPHR RES, V57, P165, DOI 10.1016/S0920-9964(01)00293-6; Medalia A, 2001, SCHIZOPHRENIA BULL, V27, P259, DOI 10.1093/oxfordjournals.schbul.a006872; *NC NEUR GROUP INC, 1988, MAN NEUR COGN STAT E; Rabin LA, 2007, J CLIN EXP NEUROPSYC, V29, P752, DOI 10.1080/13825580601025908; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rempfer MV, 2003, PSYCHIAT RES, V117, P103, DOI 10.1016/S0165-1781(02)00318-9; Revheim N, 2006, SCHIZOPHR RES, V83, P237, DOI 10.1016/j.schres.2005.12.849; Saykin AJ., 2006, P 34 ANN M INT NEUR, P24; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; STERN RA, 2003, NEUROPSYCHOLOGICAL A; Sweet JJ, 2006, CLIN NEUROPSYCHOL, V20, P325, DOI 10.1080/13854040600760488; Temple RO, 2006, ARCH CLIN NEUROPSYCH, V21, P371, DOI 10.1016/j.acn.2006.05.002; Thornton WL, 2007, PSYCHOL AGING, V22, P470, DOI 10.1037/0882-7974.22.3.470; Vellinga A, 2004, INT J GERIATR PSYCH, V19, P645, DOI 10.1002/gps.1139; WECHSLER D, 2003, WISC 4 ADM INTERPRET; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Whitehouse PJ, 2000, CLIN GERONTOLOGIST, V21, P49, DOI DOI 10.1300/J018V21N04_05; Willis S.L., 1993, TEST MANUAL EVERYDAY; Willis SL, 1998, GERONTOLOGIST, V38, P569, DOI 10.1093/geront/38.5.569; WILLIS SL, 1993, PENNSYLVANIA STATE U	55	30	32	0	9	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2008	15	4					264	273	PII 905792272	10.1080/09084280802325090			10	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Psychology	375DQ	WOS:000261094300004	19023743	Green Accepted			2022-02-06	
J	Schaefer, S; Boegershausen, N; Meyer, S; Ivan, D; Schepelmann, K; Kann, PH				Schaefer, S.; Boegershausen, N.; Meyer, S.; Ivan, D.; Schepelmann, K.; Kann, P. H.			Hypothalamic-pituitary insufficiency following infectious diseases of the central nervous system	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; CENTRAL DIABETES-INSIPIDUS; ANEURYSMAL SUBARACHNOID HEMORRHAGE; HYPOPITUITARISM; MENINGOENCEPHALITIS; ENCEPHALITIS; DYSFUNCTION; MENINGITIS; PANHYPOPITUITARISM; COMPLICATION	Objective: Hypothalamic-pituitary insufficiency may have diverse causes. The aim of this study was to determine the incidence of hypothalamic-pituitary insufficiency in patients with previous infectious diseases of the central nervous system (CNS) of different etiologies and mild-to-moderate clinical course. Design: Patient series. Basal and stimulated (insulin tolerance test) pituitary function testing was performed in 19 patients with previous neuroborreliosis. encephalitis, or meningitis following an interval of between 10 and 5 6 months (mean 2 6.1 +/- 13.1 months) after the acute event. Results: Four patients (21%; two males, two females) showed an isolated corticotropic insufficiency (peak cortisol <181.25 mu g/l during the insulin tolerance test). Two patients (11%, males) showed borderline gonadotropic insufficiency (basal testosterone between 2.4 and 3.0 mu g/l). No patient had somatotropic or thyrotropic insufficiency or evidence for diabetes insipidus: all had prolactin concentrations within the reference range. Conclusions: Hypothalamic-pituitary dysfunction and especially isolated corticotropic insufficiency may develop in a relevant proportion of patients after infectious diseases of the CNS.	[Schaefer, S.; Boegershausen, N.; Meyer, S.; Ivan, D.; Kann, P. H.] Philipps Univ Hosp, Div Endocrinol & Diabetol, D-35033 Marburg, Germany; [Schepelmann, K.] Philipps Univ Hosp, Dept Neurol, D-35033 Marburg, Germany		Schaefer, S (corresponding author), Philipps Univ Hosp, Div Endocrinol & Diabetol, Baldingerstr, D-35033 Marburg, Germany.	stscha@med.uni-marburg.de		Bogershausen, Nina/0000-0003-4300-8224			Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BROOKS MH, 1973, AM J MED, V54, P777, DOI 10.1016/0002-9343(73)90065-X; Canton A, 1996, J NEUROL NEUROSUR PS, V61, P325, DOI 10.1136/jnnp.61.3.325; DEXTER RN, 1995, PRINCIPLES PRACTICE; EDWARDS OM, 1986, MEDICINE, V65, P281; Elmlinger MW, 2004, CLIN CHEM LAB MED, V42, P654, DOI 10.1515/CCLM.2004.112; Franco-Paredes C, 2001, ARCH INTERN MED, V161, P1114, DOI 10.1001/archinte.161.8.1114; GREGER NG, 1986, AM J DIS CHILD, V140, P551, DOI 10.1001/archpedi.1986.02140200061028; HAGG E, 1978, ACTA MED SCAND, V203, P231; HASLAM RHA, 1969, AM J DIS CHILD, V118, P903, DOI 10.1001/archpedi.1969.02100040905017; Ickenstein GW, 1999, FORTSCHR NEUROL PSYC, V67, P476, DOI 10.1055/s-2007-994998; JEW K, 1984, NEUROSURGERY, V14, P567, DOI 10.1227/00006123-198405000-00008; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kreitschmann-Andermahr I, 2004, J CLIN ENDOCR METAB, V89, P4986, DOI 10.1210/jc.2004-0146; KUPARI M, 1980, ACTA ENDOCRINOL-COP, V94, P433, DOI 10.1530/acta.0.0940433; Lee YJ, 1995, J PEDIATR ENDOCR MET, V8, P301; LICHTENSTEIN MJ, 1982, J ENDOCRINOL INVEST, V5, P111, DOI 10.1007/BF03350501; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MADHOUN ZT, 1991, AM J MED, V90, P658, DOI 10.1016/S0002-9343(05)80025-7; MENA W, 1993, J PEDIATR-US, V122, P911, DOI 10.1016/S0022-3476(09)90017-8; Nieschlag E, 2005, EUR UROL, V48, P1, DOI 10.1016/j.eururo.2005.04.027; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; SUMMERS VK, 1968, BRIT MED J, V1, P359, DOI 10.1136/bmj.1.5588.359; Torres A M, 2000, Endocr Pract, V6, P26; Vesely DL, 2000, AM J MED SCI, V320, P273, DOI 10.1097/00000441-200010000-00008; Woredekal Y, 1998, J Assoc Acad Minor Phys, V9, P22; 1998, J CLIN ENDOCRINOLOGY, V83, P379	30	30	31	0	5	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	JAN	2008	158	1					3	9		10.1530/EJE-07-0484			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	255SH	WOS:000252677200002	18166811	Bronze			2022-02-06	
J	Burgos, M; Neary, JT; Gonzalez, FA				Burgos, Michelle; Neary, Joseph T.; Gonzalez, Fernando A.			P2Y(2) nucleotide receptors inhibit trauma-induced death of astrocytic cells	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; cell survival; neuroprotection; purinergic receptors	SIGNAL-REGULATED KINASE; ACTIVATED PROTEIN-KINASES; P2 PURINERGIC RECEPTORS; STRETCH-INDUCED INJURY; SPINAL-CORD-INJURY; FIBRILLARY ACIDIC PROTEIN; BRAIN-INJURY; EXTRACELLULAR ATP; IN-VIVO; INDUCED APOPTOSIS	Nucleotides as well as other neurotransmitters are known to be released to the extracellular space upon injury. To determine whether nucleotides acting on P2Y(2) nucleotide receptors promote protective or degenerative events after trauma in astrocytic cells, a well-established model of in vitro brain trauma was applied to 1321N1 cells expressing recombinant P2Y(2) nucleotide receptors (P2Y(2)R-1321N1). Cellular death was examined by measuring DNA fragmentation and caspase activation. Fragmented DNA was observed 48 h post-injury in 1321N1 cells, while P2Y(2) nucleotide receptor expressing cells did not show DNA fragmentation. A laddering pattern of fragmented DNA following injury was observed upon inhibition of P2Y(2) nucleotide receptors with suramin. Time-dependent increases of cleaved caspase-9, a mitochondrial-associated caspase, correlated with injury-induced cellular death. A decreased bax/bcl-2 gene expression ratio was observed in P2Y(2)R-1321N1 cells after traumatic injury, while untransfected 1321N1 cells showed a significant time-dependent increase of the bax/bcl-2 gene expression ratio. Activation of protein kinases was assessed to determine the signaling pathways involved in cell death and survival responses following traumatic injury. In P2Y(2)R-1321N1 and 1321N1 cells p38 phosphorylation was stimulated in a time-dependent manner but the phosphatidylinositol 3-kinase-dependent activation of extracellular signal-regulated kinase 1/2 and protein kinase B (PKB)/Akt was only observed in P2Y(2)R-1321N1 cells after injury. The stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) signaling pathway was not activated by traumatic injury in either astrocytic cell line. Inhibition of p38 kinase signaling pathway by treatment with PD1693, a MKK3/6 inhibitor, abolished the expression of cleaved caspase-9, the increase in the bax/bcl-2 gene expression ratio, as well as the fragmentation of DNA that followed injury of 1321N1 cells. Taken together, our results demonstrate a novel role for P2Y(2) nucleotide receptors and extracellular nucleotides in mediating survival responses to glial cells undergoing cellular death induced by trauma.	Univ Puerto Rico, Dept Chem, San Juan, PR 00931 USA; Univ Puerto Rico, Dept Biochem, San Juan, PR 00936 USA; Univ Miami Miller Sch Med, Vet Adm Med Ctr, Dept Pathol, Res Serv, Miami, FL USA; Univ Miami Miller Sch Med, Vet Adm Med Ctr, Dept Biochem & Mol Biol, Res Serv, Miami, FL USA; Univ Miami Miller Sch Med, Vet Adm Med Ctr, Dept Neurosci Program, Res Serv, Miami, FL USA		Gonzalez, FA (corresponding author), Univ Puerto Rico, Dept Chem, San Juan, PR 00931 USA.	fgonzal@hpcf.upr.edu					ABBRACCHIO MP, 1994, NEUROSCIENCE, V59, P67, DOI 10.1016/0306-4522(94)90099-X; ADMAS JM, 2001, TRENDS BIOCHEM SCI, V26, P61; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Arthur DB, 2005, P NATL ACAD SCI USA, V102, P19138, DOI 10.1073/pnas.0505913102; Arthur DB, 2006, J NEUROSCI, V26, P3798, DOI 10.1523/JNEUROSCI.5338-05.2006; Bambrick L, 2004, NEUROCHEM RES, V29, P601, DOI 10.1023/B:NERE.0000014830.06376.e6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan PH, 2004, NEUROCHEM RES, V29, P1943, DOI 10.1007/s11064-004-6869-x; Cho SG, 2002, J BIOCHEM MOL BIOL, V35, P24, DOI 10.5483/BMBRep.2002.35.1.024; Chorna NE, 2004, J NEUROCHEM, V91, P119, DOI 10.1111/j.1471-4159.2004.02699.x; Copland IB, 2007, J CELL PHYSIOL, V210, P133, DOI 10.1002/jcp.20840; Dai Y, 2004, PAIN, V108, P258, DOI 10.1016/j.pain.2003.12.034; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Chiara G, 2006, J BIOL CHEM, V281, P21353, DOI 10.1074/jbc.M511052200; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; Erb L, 2001, J CELL BIOL, V153, P491, DOI 10.1083/jcb.153.3.491; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Franke H, 2004, NEUROSCIENCE, V127, P431, DOI 10.1016/j.neuroscience.2004.05.003; Franke H, 2001, BRIT J PHARMACOL, V134, P1180, DOI 10.1038/sj.bjp.0704353; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; Harada C, 2006, AM J PATHOL, V168, P261, DOI 10.2353/ajpath.2006.050765; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Hsieh MH, 2005, INT REV CYTOL, V245, P45, DOI 10.1016/S0074-7696(05)45003-2; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Kassa RM, 2007, NEUROBIOL DIS, V25, P121, DOI 10.1016/j.nbd.2006.08.020; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Kikuchi M, 2000, J NEUROSCI, V20, P5037; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim D, 2002, J BIOCHEM MOL BIOL, V35, P106; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Lutz RJ, 2000, BIOCHEM SOC T, V28, P51, DOI 10.1042/bst0280051; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Moon DO, 2006, INT IMMUNOPHARMACOL, V6, P1796, DOI 10.1016/j.intimp.2006.07.027; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Muscella A, 2003, J CELL PHYSIOL, V195, P234, DOI 10.1002/jcp.10242; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Neary J. T., 2001, V151, P305; Neary JT, 2006, J NEUROSCI RES, V84, P515, DOI 10.1002/jnr.20969; Neary JT, 2005, MOL NEUROBIOL, V31, P95, DOI 10.1385/MN:31:1-3:095; Neary JT, 2005, IUBMB LIFE, V57, P711, DOI 10.1080/15216540500319143; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; NEARY JT, 1994, J NEUROCHEM, V63, P490; NEARY JT, 1994, ACTA NEUROPATHOL, V87, P8; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nguyen HT, 2006, NEPHRON EXP NEPHROL, V102, P49, DOI 10.1159/000088401; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Petrin D, 2006, CELL SIGNAL, V18, P479, DOI 10.1016/j.cellsig.2005.05.021; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Rios-Munoz W, 2005, J NEUROCHEM, V93, P1422, DOI 10.1111/j.1471-4159.2005.03129.x; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Santiago-Perez LI, 2001, J CELL PHYSIOL, V187, P196, DOI 10.1002/jcp.1063; Santos-Beneit AM, 2000, J LEUKOCYTE BIOL, V67, P712, DOI 10.1002/jlb.67.5.712; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Sedding DG, 2005, CIRC RES, V96, P635, DOI 10.1161/01.RES.0000160610.61306.0f; Shaw Anthony, 2003, Current Vascular Pharmacology, V1, P41, DOI 10.2174/1570161033386745; Torres JES, 2006, NEUROSCI LETT, V403, P233, DOI 10.1016/j.neulet.2006.04.063; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang XD, 2001, GENE DEV, V15, P2922; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yang LL, 2004, J CELL BIOCHEM, V91, P938, DOI 10.1002/jcb.10774; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zhou YN, 2006, BIOCHEM BIOPH RES CO, V350, P860, DOI 10.1016/j.bbrc.2006.09.103; Zimmermann H, 2006, PFLUG ARCH EUR J PHY, V452, P573, DOI 10.1007/s00424-006-0067-4	84	30	31	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2007	103	5					1785	1800		10.1111/j.1471-4159.2007.04872.x			16	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	231YN	WOS:000250985200009	17868308	Bronze			2022-02-06	
J	Moser, RS				Moser, Rosemarie Scolaro			The growing public health concern of sports concussion: The new psychology practice frontier	PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE			English	Article						concussion; youth; sports; brain; testing	HIGH-SCHOOL	With youth participation in sports at an all-time high, youths have become more vulnerable to the silent epidemic of concussion. Psychologists should become aware of the alarming frequency of mild concussion and the subtle effects of concussion, which often go unnoticed or result in misdiagnosis. This article provides a basic survey of the research and literature on this topic, a simplified knowledge base for understanding updated assessment and management techniques, and a discussion of the important role psychologists can play in educating the public and their patients. Practitioners can become more aware of this developing practice opportunity.	[Moser, Rosemarie Scolaro] RSM Psychol Ctr LLC, Lawrenceville, NJ 08648 USA		Moser, RS (corresponding author), RSM Psychol Ctr LLC, 3131 Princeton Pike,Bldg 5,Suite 110, Lawrenceville, NJ 08648 USA.	r.moser@rcn.com					ALLEN K, 1998, US TODAY        1008, pE1; BARTH JT, 2006, SPORTS NEUROPSYCHOLO, P3; Barth JT, 1989, MILD HEAD INJURY, P257; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benton A., 1978, MULTILINGUAL APHASIA; Bleiberg J., 2006, SPORTS NEUROPSYCHOLO, P263; *BRAIN INJ ASS NEW, 2006, NEWL BRAIN INJ ASS N, P1; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; FERGUSON A, 1999, TIME            0503, P52; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Kaushik T., 2006, SPORTS NEUROPSYCHOLO, P216; Kelly JP, 1997, NEUROLOGY, V48, P581; LAPOINTE J, 1998, NY TIMES        0322, pLSP3; Lovell M. R., 2006, SPORTS NEUROPSYCHOLO, P193; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Lovell MR, 2006, SPORTS NEUROPSYCHOLO, P176; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; MOSER RS, 2005, SPORTS CONCUSSION PR; PEDULLA T, 1998, US TODAY        0812, pC3; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SEEFELDT VDD, 1996, PCPFS RES DIGEST 2, P19; SOLOMON GS, 2006, HEADS UP SPORT CONCU; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WEBBE FM, 2006, SPORTS NEUROPSYCHOLO, P45; WECHSLER D, 1977, WECHSLER ADULT INTEL, V3; 1999, NY TIMES        1228	37	30	30	0	9	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0735-7028	1939-1323		PROF PSYCHOL-RES PR	Prof. Psychol.-Res. Pract.	DEC	2007	38	6					699	704		10.1037/0735-7028.38.6.699			6	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	242VC	WOS:000251753300020					2022-02-06	
J	Farias, SE; Zarini, S; Precht, T; Murphy, RC; Heidenreich, KA				Farias, Santiago E.; Zarini, Simona; Precht, Thomas; Murphy, Robert C.; Heidenreich, Kim A.			Transcellular biosynthesis of cysteinyl leukotrienes in rat neuronal and glial cells	JOURNAL OF NEUROCHEMISTRY			English	Article						glia; leukotrienes; mass spectrometry; neurons; neutrophils; transcellular biosynthesis	POLYMORPHONUCLEAR LEUKOCYTE; ARACHIDONIC-ACID; CEREBRAL-ISCHEMIA; BRAIN-INJURY; METABOLISM; EDEMA; C-4; 5-LIPOXYGENASE; RECEPTOR; RELEASE	Leukotrienes are mediators of inflammation that belong to a family of lipids derived from arachidonic acid by the action of 5-lipoxygenase. Leukotrienes have been detected in the central nervous system in association with different pathological events, but little is known about their biosynthesis or function in the brain. When rat neurons and glial cells in primary culture were stimulated with the calcium ionophore, no significant biosynthesis of leukotrienes was detected using liquid chromatography/mass spectrometry (LC/MS) techniques. However, when exogenous LTA(4) was added to these cultured cells, both neurons and glia were able to synthesize LTC4. Activated neutrophils are known to supply LTA(4) to other cells for transcellular biosynthesis of cysteinyl-leukotrienes. Since neutrophils can infiltrate brain tissue after stroke or traumatic brain injury, we examined whether neutrophils play a similar role in the central nervous system. When peripheral blood neutrophils were co-cultured with rat neurons, glia cells, and then stimulated with calcium ionophore, a robust production of LTC4, LTD4, and LTE4 was observed, revealing that neurons and glia can participate in the transcellular mechanism of leukotriene biosynthesis. The formation of LTC4 through this mechanism may be relevant in the genesis and progression of the inflammatory response as a result of brain injury.	Univ Colorado, Denver & Hlth Sci Ctr, Dept Pharmacol, Aurora, CO USA; VA Med Ctr, Denver, CO USA		Heidenreich, KA (corresponding author), Univ Colorado, Denver & Hlth Sci Ctr, Vet Affairs Res Ctr, Dept Pharmacol, POB 6511,Mail Stop 8303, Aurora, CO 80045 USA.	Kim.Heidenreich@UCHSC.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL025785, R01HL025785] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL025785] Funding Source: Medline		Akopov SE, 1996, STROKE, V27, P1739, DOI 10.1161/01.STR.27.10.1739; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BORGEAT P, 1979, J BIOL CHEM, V254, P7865; Boyce JA, 2005, CHEM IMMUNOL ALLERGY, V87, P59, DOI 10.1159/000087571; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; CARRIER DJ, 1988, PROSTAG LEUKOTR ESS, V34, P27, DOI 10.1016/0952-3278(88)90021-X; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Di Gennaro A, 2004, FASEB J, V18, P842, DOI 10.1096/fj.03-0599fje; Fetissov SO, 2002, NEUROSCIENCE, V115, P891, DOI 10.1016/S0306-4522(02)00411-6; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; Ge QF, 2006, J NEUROCHEM, V97, P992, DOI 10.1111/j.1471-4159.2006.03828.x; Habib GM, 2003, FASEB J, V17, P1313, DOI 10.1096/fj.02-0899fje; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; HASLETT C, 1985, AM J PATHOL, V119, P101; HULTING AL, 1985, P NATL ACAD SCI USA, V82, P3834, DOI 10.1073/pnas.82.11.3834; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; Lam BK, 2003, PROSTAG LEUKOTR ESS, V69, P111, DOI 10.1016/S0952-3278(03)00071-1; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Lieberman MW, 1999, ADV EXP MED BIOL, V469, P301; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; Linseman DA, 2002, J NEUROSCI, V22, P9287; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; Mayatepek E, 2000, J INHERIT METAB DIS, V23, P404, DOI 10.1023/A:1005664204956; McMillan R M, 2001, Paediatr Respir Rev, V2, P238, DOI 10.1053/prrv.2001.0146; MEDINA JF, 1988, BIOCHIM BIOPHYS ACTA, V961, P203, DOI 10.1016/0005-2760(88)90115-4; ORNING L, 1980, J BIOL CHEM, V255, P8023; PALMER MR, 1980, NEUROSCI LETT, V18, P173, DOI 10.1016/0304-3940(80)90322-5; PRZYLIPIAK A, 1990, EXPERIENTIA, V46, P298, DOI 10.1007/BF01951771; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rouzer C A, 1986, Adv Prostaglandin Thromboxane Leukot Res, V16, P3; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; SAADI M, 1990, LIFE SCI, V46, P1857, DOI 10.1016/0024-3205(90)90238-M; Sala A, 1997, J PHYSIOL PHARMACOL, V48, P665; Sala A, 2000, CIRCULATION, V101, P1436, DOI 10.1161/01.CIR.101.12.1436; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Shimada A, 2005, NEUROSCIENCE, V131, P683, DOI 10.1016/j.neuroscience.2004.11.016; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; Winking M, 1998, CEREBROVASC DIS, V8, P318, DOI 10.1159/000015874	44	30	30	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2007	103	4					1310	1318		10.1111/j.1471-4159.2007.04830.x			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	223WH	WOS:000250403500005	17711426	Bronze			2022-02-06	
J	Zhang, S; Zhou, F; Ding, HH; Zhou, XQ; Sun, XL; Hu, G				Zhang, Shu; Zhou, Fang; Ding, Han-Hua; Zhou, Xi-Qiao; Sun, Xiii-Lan; Hu, Gang			ATP-sensitive potassium channel opener iptakalim protects against MPP+-induced astrocytic apoptosis via mitochondria and mitogen-activated protein kinase signal pathways	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; astrocyte; ATP-sensitive potassium channel opener; iptakalim; mitochondria; mitogen-activated protein kinase	JUN NH2-TERMINAL KINASE; TRAUMATIC BRAIN INJURY; CELL-DEATH; IN-VIVO; GLUTATHIONE DEPLETION; DEPENDENT MECHANISM; PARKINSONS-DISEASE; DNA FRAGMENTATION; REGULATED KINASE; OXIDATIVE STRESS	Inhibition of astrocytic apoptosis has been regarded as a novel prospective strategy for treating neurodegenerative disorders such as Parkinson's disease. In the present study, we demonstrated that iptakalim (IPT), an ATP-sensitive potassium channel (K-ATP channel) opener, exerted protective effect on MPP+-induced astrocytic apoptosis, which was reversed by selective mitochondrial KATP channel blocker 5-hydroxydecanoate. Further study revealed that IPT inhibited glutathione (GSH) depletion, mitochondrial membrane potential loss and subsequent release of pro-apoptotic factors (cytochrome c and apoptosis-inducing factor (AIF), and c-Jun NH2-terminal kinase/mitogen-activated protein kinases (MAPK) phosphorylation induced by MPP+. Meanwhile, extracellularsignalregulated kinase (ERK) 1/2 inhibitor PD98059 inhibited the protective effect of IPT on MPP+-induced astrocytic apoptosis. Furthermore, IPT could also activate ERK/MAPK and maintain increased phospho-ERK1/2 level after MPP+ exposure. Taken together, these findings reveal for the first time that IPT protects against MPP+-induced astrocytic apoptosis via inhibition of mitochondria apoptotic pathway and regulating the MAPK signal transduction pathways by opening mitochondrial ATP-sensitive potassium (mitoK(ATP)) channels in astrocytes. And targeting K-ATP channels expressed in astrocytes may provide a novel therapeutic strategy for neurodegenerative disorders.	Nanjing Med Univ, Inst Neurosci, Neuropharmacol Lab, Nanjing 210029, Peoples R China		Hu, G (corresponding author), Nanjing Med Univ, Inst Neurosci, Neuropharmacol Lab, 140 Hanzhong Rd, Nanjing 210029, Peoples R China.	ghu@njmu.edu.cn					Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Anderson CM, 2000, GLIA, V32, P1; Bajgar R, 2001, J BIOL CHEM, V276, P33369, DOI 10.1074/jbc.M103320200; Benjelloun N, 1998, CELL MOL BIOL, V44, P579; Chen YM, 2001, J NEUROCHEM, V77, P1601, DOI 10.1046/j.1471-4159.2001.00374.x; Chiueh C C, 1998, Adv Pharmacol, V42, P796; Cho IH, 2003, J NEUROSCI RES, V74, P736, DOI 10.1002/jnr.10794; CHO Y, 1990, J NEUROCHEM, V55, P2091, DOI 10.1111/j.1471-4159.1990.tb05800.x; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Girolamo LA, 2006, J NEUROSCI RES, V83, P680, DOI 10.1002/jnr.20765; Deutch AY, 2006, NAT MED, V12, P17, DOI 10.1038/nm0106-17; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dunn-Meynell AA, 1998, BRAIN RES, V814, P41, DOI 10.1016/S0006-8993(98)00956-1; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; HAMPRECHT B, 1985, METHOD ENZYMOL, V109, P341; Hansen JB, 2006, CURR MED CHEM, V13, P361, DOI 10.2174/092986706775527947; Henze C, 2005, J NEUROCHEM, V95, P1069, DOI 10.1111/j.1471-4159.2005.03416.x; Hu LF, 2005, J NEUROCHEM, V94, P1570, DOI 10.1111/j.1471-4159.2005.03306.x; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485; Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x; Kobayashi K, 2002, NEUROPATH APPL NEURO, V28, P238, DOI 10.1046/j.1365-2990.2002.00390.x; Kruger N J, 1994, Methods Mol Biol, V32, P9; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liss B, 2005, NAT NEUROSCI, V8, P1742, DOI 10.1038/nn1570; Lotharius J, 2005, J NEUROSCI, V25, P6329, DOI 10.1523/JNEUROSCI.1746-05.2005; Makarov P, 2006, MOL CELL BIOCHEM, V286, P95, DOI 10.1007/s11010-005-9098-y; Mazzanti M, 2001, NEUROSCIENTIST, V7, P396, DOI 10.1177/107385840100700509; McNaught KSP, 2000, BIOCHEM PHARMACOL, V60, P979, DOI 10.1016/S0006-2952(00)00415-9; Nakagawa I, 2005, NEUROSURGERY, V57, P334, DOI 10.1227/01.NEU.0000166681.88736.86; Parrizas M, 1997, J BIOL CHEM, V272, P154; SAGARA J, 1993, J NEUROCHEM, V61, P1672, DOI 10.1111/j.1471-4159.1993.tb09802.x; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Szydlowska K, 2006, J NEUROCHEM, V99, P965, DOI 10.1111/j.1471-4159.2006.04136.x; Tai KK, 2003, J NEUROCHEM, V84, P1193, DOI 10.1046/j.1471-4159.2003.01625.x; Takano T, 2006, NAT NEUROSCI, V9, P260, DOI 10.1038/nn1623; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Thomzig A, 2001, MOL CELL NEUROSCI, V18, P671, DOI 10.1006/mcne.2001.1048; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Tripanichkul W, 2006, BRAIN RES, V1084, P28, DOI 10.1016/j.brainres.2006.02.029; Wang H, 2004, MOL PHARMACOL, V66, P1160, DOI 10.1124/mol.104.003178; Wang H, 2003, DRUG DEVELOP RES, V58, P65, DOI 10.1002/ddr.10132; Wang S, 2006, NEUROPSYCHOPHARMACOL, V31, P933, DOI 10.1038/sj.npp.1300857; Wang S, 2005, NEUROPHARMACOLOGY, V48, P984, DOI 10.1016/j.neuropharm.2005.01.009; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; WU J, 2005, CURRENT NEUROPHARMAC, V3, P1; Wu J, 2006, J PHARMACOL EXP THER, V319, P155, DOI 10.1124/jpet.106.106286; Xie WP, 2005, EUR J PHARMACOL, V511, P81, DOI 10.1016/j.ejphar.2005.01.039; Yang H, 2006, LIFE SCI, V78, P1940, DOI 10.1016/j.lfs.2005.08.001; Yang Y, 2006, INT J NEUROPSYCHOPH, V9, P51, DOI 10.1017/S1461145705005547; Yang Y, 2005, J NEUROSCI RES, V80, P440, DOI 10.1002/jnr.20467; Yang Y, 2004, NEUROSCI LETT, V366, P53, DOI 10.1016/j.neulet.2004.05.009; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zawar C, 1999, J PHYSIOL-LONDON, V514, P327; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhang Yun, 2004, Yaoxue Xuebao, V39, P980; Zhu CL, 2003, J NEUROCHEM, V86, P306, DOI 10.1046/j.1471-4159.2003.01832.x	65	30	32	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2007	103	2					569	579		10.1111/j.1471-4159.2007.04775.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	223PN	WOS:000250384500013	17635669	Bronze			2022-02-06	
J	Vakili, A; Hosseinzadeh, F; Sadogh, T				Vakili, Abedin; Hosseinzadeh, Fezzeh; Sadogh, Toktam			Effect of aminoguanidine on post-ischemic brain edema in transient model of focal cerebral ischemia	BRAIN RESEARCH			English	Article						aminoguanidine; brain edema; BBB permeability; transient focal cerebral ischemic; rat	INFARCT VOLUME; RAT-BRAIN; DIABETIC-NEPHROPATHY; NEUROLOGICAL DEFICIT; ARTERY OCCLUSION; L-ARGININE; DAMAGE; INJURY; MICE; STROKE	Pervious experimental studies have shown that aminoguanidine (AG) is beneficial in the late phase of cerebral ischemia. Recently, it has been reported that AG reduces cerebral edema in traumatic brain injury. However, the effects of AG on post-ischemic cerebral edema and bloodbrain barrier (BBB) permeability are not clear. Under chloral hydrate anesthesia, transient focal cerebral ischemia was induced in rats by 60 min of middle cerebral artery occlusion (MCAO), followed by 23 h of reperfusion. Saline as vehicle or AG at the doses of 75, 150 and 300 mg/kg, i.p., was administered at the beginning or at 1 or 3 h after induction of ischemia. Subsequently, 24 h after MCAO brain edema, BBB permeability and infarct volume were evaluated. Administration of AG (150 mg/kg) at the beginning or at 1 or 3 h after MCAO, significantly reduced cerebral edema (P<0.001), while AG at the doses of 75 and 300 mg/kg had no effect. Moreover, treatment with AG (150 mg/kg) significantly reduces Evans Blue extravasation by 48% into ischemicbrain compared to the saline group (P<0.001). Additionally, AG at the doses of 75 and 150 mg/kg significantly reduces cortical and striatal infarctvolumes (P<0.001), while AG at the dose of 300 mg/kg did not change striatal infarct volumes (P>0.05). Our findings show that AG significantly reduced post-ischemic increase of brain edema with a 3-h therapeutic window in the transient model of focal cerebral ischemia. Moreover, it seems that at least part of the anti-edematous effects of AG is due to decrease of BBB disruption. (c) 2007 Elsevier B.V. All rights reserved.	Semnan Univ Med Sci, Fac Med, Res Ctr Physiol, Lab Cerebrovasc Res, Semnan, Iran; Univ Med Sci, Semnan, Iran		Vakili, A (corresponding author), Semnan Univ Med Sci, Fac Med, Res Ctr Physiol, Lab Cerebrovasc Res, Semnan, Iran.		Vakili, Abedin/G-7934-2017	Vakili, Abedin/0000-0002-4269-9978			Abdel-Rahman E, 2002, EXPERT OPIN INV DRUG, V11, P565, DOI 10.1517/13543784.11.4.565; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; CHAN PH, 1994, BRAIN PATHOL, V4, P59; Cockroft KM, 1996, STROKE, V27, P1393, DOI 10.1161/01.STR.27.8.1393; Danielisova V, 2004, PHYSIOL RES, V53, P533; Ding-Zhou L, 2002, EUR J PHARMACOL, V457, P137, DOI 10.1016/S0014-2999(02)02686-9; Giardino I, 1998, DIABETES, V47, P1114, DOI 10.2337/diabetes.47.7.1114; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HATASHITA S, 1990, STROKE, V21, P581; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Iadecola C, 1995, AM J PHYSIOL, V268, P286; Jones NC, 2004, J NEUROPATH EXP NEUR, V63, P708, DOI 10.1093/jnen/63.7.708; KAZACHKOV M, J PHARM EXP THER; Kondo T, 1997, J NEUROSCI, V17, P4180; KUCUK M, 2002, LIFE SCI, V12, P493; LADECOLA C, 1995, J CEREBR BLOOD FLOW, V15, P378; LASZLO F, 1995, EUR J PHARMACOL, V272, P169, DOI 10.1016/0014-2999(94)00637-M; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Nagayama M, 1998, J CEREBR BLOOD F MET, V18, P1107, DOI 10.1097/00004647-199810000-00007; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356, DOI 10.1152/ajpheart.1992.263.5.H1356; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SLIVKA A, 1995, STROKE, V26, P1061, DOI 10.1161/01.STR.26.6.1061; Sugimoto K, 2002, NEUROSCI LETT, V331, P25, DOI 10.1016/S0304-3940(02)00834-0; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Taguchi T, 2002, INT CONGR SER, V1245, P435, DOI 10.1016/S0531-5131(02)01009-9; Takizawa S, 1999, J CEREBR BLOOD F MET, V19, P667, DOI 10.1097/00004647-199906000-00010; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Vakili Abedin, 2006, Daru, V14, P31; Vakili A, 2007, BRAIN RES, V1144, P186, DOI 10.1016/j.brainres.2007.01.096; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47; Yang GY, 1999, MOL BRAIN RES, V69, P135, DOI 10.1016/S0169-328X(99)00007-8; Yildiz G, 1998, BRIT J PHARMACOL, V124, P905, DOI 10.1038/sj.bjp.0701924; Zhang FY, 1998, BRAIN RES, V802, P104, DOI 10.1016/S0006-8993(98)00557-5; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317; ZHANG XM, 1990, AM J PHYSIOL, V259, pH497, DOI 10.1152/ajpheart.1990.259.2.H497; ZIMMERMAN GA, 1995, P NATL ACAD SCI USA, V92, P3744, DOI 10.1073/pnas.92.9.3744	38	30	31	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 19	2007	1170						97	102		10.1016/j.brainres.2007.07.016			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	219ZN	WOS:000250126800011	17698046				2022-02-06	
J	Lambooij, E; Pilarczyk, M; Bialowas, H; van den Boogaart, JGM; van de Vis, JW				Lambooij, E.; Pilarczyk, M.; Bialowas, H.; van den Boogaart, J. G. M.; van de Vis, J. W.			Electrical and percussive stunning of the common carp (Cyprinus carpio L.): Neurological and behavioural assessment	AQUACULTURAL ENGINEERING			English	Article						common carp; Cyprinus carpio L.; electrical stunning; concussion stunning; EEG; ECG; behaviour	CATFISH CLARIAS-GARIEPINUS; ANGUILLA-ANGUILLA L.; FISH; WELFARE; PAIN; SLAUGHTER	The overall objective of the study was to evaluate electrical and percussive stunning methods under laboratory conditions in common carps. The electrical current needed to induce a general epileptiform insult was assessed in 13 carps. The insult was obtained by delivering a current of 0.24 +/- 0.03 A (163 +/- 1 V; 50 Hz, a.c.) to the head, via scissor-model stunning tongs for approximately 1 s. The duration of the tonic, the clonic and the exhaustion phases were I I 4 s, 5 3 s and 20 14 s on the EEG, respectively. An actual clonic phase was observed in two fish. The total duration of the insult was 31 14 s. The heart rate was 22 +/- 12 beats/min prior to stunning while after stunning, the ECG revealed fibrillation for 18 +/- 7 s and was irregular. The behaviour of 10 individual carp, which were allowed to move freely in water, was recorded following head-only stunning (164 V, 0.23 +/- 0.6 A). The duration of the tonic phase was approximately 10 s and the fish started fin movements after 48 +/- 8 s and resumed swimming after 121 +/- 83 s. A general epileptiform insult could be induced in carps (n = 25) by passing an electrical current through fresh water using 0.14 +/- 0.03 A/dm(2) (113 +/- 17 V; electrode distance 16 cm) for 1 s at a water conductivity of 200 mu S/cm. Twenty three carps were rendered unconscious and insensible during electrical stunning in fresh water, using 0.73 +/- 0.05 A/dm(2) (411 +/- 2 V; electrode distance 16 cm) for 5 s at a water conductivity of 330 mu S/cm, followed by chilling in ice water. As a second stunning procedure, carps were stunned mechanically using a percussion pistol at a maximal velocity of 10.99 +/- 0.88 J. Evidence of unconsciousness and insensibility of the carps was provided by the appearance of theta, delta waves and spikes on the EEG, which were proceeded by no brain activity. However, two carp responded after 0.5 min to administered pain stimuli and one carp after 3 min. It may be concluded from this study that common carp are effectively stunned in fresh water. The application of an electrical current of 0.73 A/dm(2) (26 V/cm, 50 Hz, a.c., 330 mu S/cm) to individual carps in a tank in combination with chilling in ice water is an effective procedure for slaughter. The mechanical method of percussion stunning did not provide assurance of effective stunning as not all carp were unconscious and insensible after its administration. (c) 2007 Elsevier B.V. All rights reserved.	Wageningen UR, Div Anim Husb, Anim Sci Grp, NL-8200 AB Lelystad, Netherlands; Wageningen IMARES BV, NL-1970 AB Ijmuiden, Netherlands; Wageningen UR, Anim Sci Grp, NL-6700 AH Wageningen, Netherlands; Polish Acad Sci, Ins Ichthyobiol & Aquaculture, PL-43520 Chybie, Poland		Lambooij, E (corresponding author), Wageningen UR, Div Anim Husb, Anim Sci Grp, POB 8200, NL-8200 AB Lelystad, Netherlands.	bert.lambooij@wur.nl					Braithwaite VA, 2004, ANIM WELFARE, V13, pS87; Chandroo KP, 2004, APPL ANIM BEHAV SCI, V86, P225, DOI 10.1016/j.applanim.2004.02.004; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; DOWGIALLO A, 2005, J POLISH ARG U, V8; Dubin D., 1999, SNELLE INTERPRETATIE, P69; HEWITT L, 1999, POULTRY MEAT SCI, P422; JOHNSON NL, 1969, DISCRETE DISTRIBUTIO, P59; KESTIN SC, 1995, INT C AQ EUR 95 TRON, P380; KESTIN SC, 1994, PAIN STRESS FISH ROY, P366; Kooi K. A., 1978, FUNDAMENTALS ELECTRO, P125; Lambooij E, 2004, ANIM WELFARE, V13, P71; Lambooij E, 2003, AQUAC RES, V34, P1353, DOI 10.1046/j.1365-2109.2003.00966.x; Lambooij E, 2002, AQUACULTURE, V210, P159, DOI 10.1016/S0044-8486(02)00050-9; Lambooij E, 2002, AQUAC RES, V33, P643, DOI 10.1046/j.1365-2109.2002.00677.x; LAMBOOY E, 1982, MEAT SCI, V6, P15, DOI 10.1016/0309-1740(82)90047-X; LAMBOOY E, 1982, MEAT SCI, V6, P123, DOI 10.1016/0309-1740(82)90022-5; LAMBOOY E, 1981, VET REC, V109, P359, DOI 10.1136/vr.109.16.359; LANBOOIJ E, 2004, ELECT STUNNING ENCY, P1342; Lines J, 2004, AQUACULTURE, V241, P219, DOI 10.1016/j.aquaculture.2004.07.023; Lopes da Silva H. F., 1983, STUNNING ANIMALS SLA, P3; Meek J., 1998, P759; Overmier JB, 1990, NEUROBIOLOGY COMP CO, P204; Robb DHF, 2000, VET REC, V147, P298, DOI 10.1136/vr.147.11.298; Robb DHF, 2002, ANIM WELFARE, V11, P269; Rose JD, 2002, REV FISH SCI, V10, P1, DOI 10.1080/20026491051668; Sneddon LU, 2003, APPL ANIM BEHAV SCI, V83, P153, DOI 10.1016/S0168-1591(03)00113-8; TESCH FW, 1999, AAL, P18; van de Vis H, 2003, AQUAC RES, V34, P211, DOI 10.1046/j.1365-2109.2003.00804.x; Verheijen FJ, 1997, AQUAC RES, V28, P361; WAGENEDER FM, 1967, P 1 INT S GRAZ AUSTR, P95; WIEPKEMA PR, 1997, ANIMAL CONSCIOUSNESS, P93	31	30	31	1	30	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0144-8609	1873-5614		AQUACULT ENG	Aquac. Eng.	SEP	2007	37	2					171	179		10.1016/j.aquaeng.2007.04.004			9	Agricultural Engineering; Fisheries	Science Citation Index Expanded (SCI-EXPANDED)	Agriculture; Fisheries	199HL	WOS:000248686700010					2022-02-06	
J	Titsworth, WL; Onifer, SM; Liu, NK; Xu, XM				Titsworth, W. Lee; Onifer, Stephen M.; Liu, Nal-Kui; Xu, Xiao-Ming			Focal phospholipases A2 group III injections induce cervical white matter injury and functional deficits with delayed recovery concomitant with Schwann cell remyelination	EXPERIMENTAL NEUROLOGY			English	Article						demyelination; schwarm cell; pellet retrieval; dorsolateral funiculus; cervical; spinal cord; phospholipases A(2); secretory phospholipases A(2)	SPINAL-CORD-INJURY; ADULT-RAT; AXONAL REGENERATION; ETHIDIUM-BROMIDE; DORSAL COLUMN; A(2); FORELIMB; DEMYELINATION; DIFFERENTIATION; PERFORMANCE	Phospholipases A(2) (PLA(2)) are group of enzymes that hydrolyze membrane phospholipids at the sn-2 position. PLA2 are present in the brain and spinal cord and are implicated in several neurological disorders. Previously, we showed that PLA2 activity increases following traumatic spinal cord injury and injection of group III secretory PLA(2) (sPLA(2)-III) demyelinates spinal cord axons. Here, we demonstrate that injections of sPLA(2)-III into the cervical dorsolateral funiculus (DLF) resulted in dose-dependent demyelination, loss of oligodendrocytes and astrocytes, as well as axonopathy. Additionally, spared axons within the lesion were remyelinated by Schwann cells between weeks 2 and 3. To assess functional loss and recovery, we employed a modified "Staircase Test" pellet retrieval device and footprint analysis of forelimb function during locomotion. Pellet retrieval assessment sensitively detected the dose dependent lesion and its recovery after sPLA(2)-III injections with greater sensitivity than footprint analysis. We believe that this is the first report of a reaching task being able to discriminate between various grades of cervical white matter damage and varying extents of recovery. Thus, our results indicate that sPLA(2)-III can create white matter pathologies that are remyelinated by Schwann cells 2 to 3 weeks after injury. Additionally, the pellet retrieval test is a sensitive and quantifiable method for assessing the dysfunction and later recovery mediated by sPLA(2)-III injections. (c) 2007 Elsevier Inc. All rights reserved.	Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Xu, XM (corresponding author), Univ Louisville, Sch Med, Kentucky Spinal Cord Injury Res Ctr, Dept Neurol Surg, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	xmxu001@gwise.louisville.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Xu, Xiao-ming/0000-0002-7229-0081	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR15576] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40411, NS36350, F31 NS5657401, NS52290] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052290, R01NS040411, R01NS036350, F31NS056574] Funding Source: NIH RePORTER		BLAKEMORE WF, 1977, J NEUROL SCI, V33, P31, DOI 10.1016/0022-510X(77)90179-4; BLAKEMORE WF, 1978, NEUROPATH APPL NEURO, V4, P47, DOI 10.1111/j.1365-2990.1978.tb00528.x; BLAKEMORE WF, 1982, NEUROPATH APPL NEURO, V8, P365, DOI 10.1111/j.1365-2990.1982.tb00305.x; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BUNGE RP, 1994, CLIN IMPLICATIONS RE; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; DEMEDIUK P, 1989, J NEUROSCI RES, V23, P95, DOI 10.1002/jnr.490230113; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; DUTTA J, 1979, J CHROMATOGR, V173, P379, DOI 10.1016/S0021-9673(00)92307-0; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Huterer SJ, 1995, NEUROCHEM RES, V20, P1335, DOI 10.1007/BF00992509; Jasmin L, 2000, J NEUROSCI, V20, P9215; JEFFERY ND, 1995, J NEUROCYTOL, V24, P775, DOI 10.1007/BF01191213; Kolko M, 2006, J NEUROSCI RES, V83, P874, DOI 10.1002/jnr.20773; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Lucas KK, 2005, BRIT J PHARMACOL, V144, P940, DOI 10.1038/sj.bjp.0706116; McKenna JE, 1999, J NEUROSCI, V19, P1885; McKenna JE, 2000, J COMP NEUROL, V419, P286, DOI 10.1002/(SICI)1096-9861(20000410)419:3<286::AID-CNE2>3.0.CO;2-3; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Molloy GY, 1998, NEUROSCI LETT, V258, P139, DOI 10.1016/S0304-3940(98)00838-6; MONTOYA CP, 1990, PROG BRAIN RES, V82, P459; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; MORELL P, 1984, MYELN; Moses GSD, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-28; MUHL H, 1991, FEBS LETT, V291, P249, DOI 10.1016/0014-5793(91)81295-J; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Onifer SM, 1997, RESTOR NEUROL NEUROS, V11, P211, DOI 10.3233/RNN-1997-11405; OORSCHOT DE, 1994, PROG NEUROBIOL, V44, P233, DOI 10.1016/0301-0082(94)90040-X; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Peilot H, 2000, J BIOL CHEM, V275, P22895, DOI 10.1074/jbc.M002783200; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHRIMSHER GW, 1993, EXP NEUROL, V120, P264, DOI 10.1006/exnr.1993.1060; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; Takami T, 2002, J NEUROSCI, V22, P6670; Talbott JF, 2006, GLIA, V54, P147, DOI 10.1002/glia.20369; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; Touqui Lhousseine, 2001, Current Molecular Medicine (Hilversum), V1, P739, DOI 10.2174/1566524013363258; Woodruff RH, 1999, GLIA, V25, P216, DOI 10.1002/(SICI)1098-1136(19990201)25:3<216::AID-GLIA2>3.0.CO;2-L; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XM, 1999, EUR J NEUROSCI, V11, P1723, DOI 10.1046/j.1460-9568.1999.00591.x; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; Yagami T, 2002, MOL PHARMACOL, V61, P114, DOI 10.1124/mol.61.1.114	49	30	33	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2007	207	1					150	162		10.1016/j.expneurol.2007.06.010			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	210TB	WOS:000249477400016	17678647				2022-02-06	
J	Hamberger, MJ; Palmese, CA; Scarmeas, N; Weintraub, D; Choi, H; Hirsch, LJ				Hamberger, Marla J.; Palmese, Christina A.; Scarmeas, Nikolaos; Weintraub, David; Choi, Hyunmi; Hirsch, Lawrence J.			A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy	EPILEPSIA			English	Article						epilepsy; memory; donepezil; acetylcholine; acetylcholinesterase inhibitor	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; CLINICAL-TRIALS; OPEN-LABEL; DEMENTIA; ADULTS; ACETYLCHOLINE; VOLUNTEERS	Purpose: To determine whether an acetylcholinesterase inhibitor, such as donepezil, would improve memory or other cognitive/psychological functions in epilepsy patients with subjective memory complaints. Methods: Twenty-three epilepsy patients with subjective memory difficulty were randornized to either 3 months of donepezil (10 mg/day) or 3 months of placebo treatment, and then crossed over to the other treatment arm. Patients and physicians were blinded to treatment phase throughout data acquisition. Assessment of memory and other cognitive functions, subjective memory, mood, and self-rated quality of life (QOL) and social functioning was performed at baseline and following completion of both treatment phases. Seizure frequency and severity as well as treatment emergent adverse effects were also monitored. Results: Donepezil treatment was not associated with improvement in memory or other cognitive functions, mood, social functioning or QOL. Comparable increases in self-rated memory functioning relative to baseline were evident during donepezil and placebo phases. Donepezil treatment was not associated with increased seizure frequency or severity. Similar to group results, analysis of change within individual patients as a function of treatment phase also showed neither significant benefit nor detriment associated with donepezil. Conclusion: This study found no benefit on memory or other cognitive/psychological functions in a heterogeneous group of epilepsy patients with subjective memory difficulty. Further investigation would be required to determine whether individual patients, or those with particular epilepsy syndromes, might benefit front donepezil or other acetylcholinesterase inhibitors, or if a higher dosage might he effective.	Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA; Beth Israel Deaconess Med Ctr, Dept Neurol, New York, NY 10003 USA		Hamberger, MJ (corresponding author), Neurol Inst, 710 W 168th St,Box 100, New York, NY 10032 USA.	mh61@columbia.edu	Scarmeas, Nikolaos/AAD-2512-2020; Scarmeas, Nikolaos/AAD-2517-2020	Scarmeas, Nikolaos/0000-0001-6453-8908; Scarmeas, Nikolaos/0000-0001-6453-8908; Hirsch, Lawrence/0000-0002-6333-832X			Albert SM, 1997, NEUROLOGY, V49, P38, DOI 10.1212/WNL.49.1.38; [Anonymous], 2007, PHYS DESK REFERENCE; Barkai E, 1997, MOL NEUROBIOL, V15, P17, DOI 10.1007/BF02740613; Beglinger LJ, 2005, J CLIN PSYCHOPHARM, V25, P159, DOI 10.1097/01.jcp.0000155822.51962.b4; Beglinger LJ, 2004, J PSYCHOPHARMACOL, V18, P102, DOI 10.1177/0269881104040248; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Burt T, 1999, BIOL PSYCHIAT, V45, P959, DOI 10.1016/S0006-3223(98)00320-5; Corcoran R, 1992, SEIZURE SA, V1, P14; Cummings JL, 2000, AM J GERIAT PSYCHIAT, V8, P134, DOI 10.1176/appi.ajgp.8.2.134; Fisher RS, 2001, EPILEPSY BEHAV, V2, P330, DOI 10.1006/ebeh.2001.0221; Golden CJ, 1978, STROOP COLOR WORD TE; Gron G, 2005, PSYCHOPHARMACOLOGY, V182, P170, DOI 10.1007/s00213-005-0043-2; Hermann B, 1995, J CLIN EXP NEUROPSYC, V17, P809, DOI 10.1080/01688639508402430; Hermann B P, 1996, Clin Nurs Pract Epilepsy, V3, P4; HERMANN BP, 1987, ANN NEUROL, P585; JACOBS LW, 1991, P 9 INT ASH US S, V3, P59; Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4; Klove H., 1963, CLIN NEUROPSYCHOLOGY; Krupp LB, 2004, NEUROLOGY, V63, P1579, DOI 10.1212/01.WNL.0000142989.09633.5A; Lorr M., 1971, MANUAL PROFILE MOOD; Lutz MT, 2004, EPILEPSIA, V45, P809, DOI 10.1111/j.0013-9580.2004.54003.x; Martin R, 2005, EPILEPSY BEHAV, V7, P297, DOI 10.1016/j.yebeh.2005.05.003; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; MEADOR KJ, 1993, EPILEPSIA, V34, P153, DOI 10.1111/j.1528-1157.1993.tb02389.x; Mori S, 2006, PSYCHIAT CLIN NEUROS, V60, P190, DOI 10.1111/j.1440-1819.2006.01485.x; Muir JL, 1997, PHARMACOL BIOCHEM BE, V56, P687, DOI 10.1016/S0091-3057(96)00431-5; Passmore AP, 2005, J NEUROL SCI, V229, P141, DOI 10.1016/j.jns.2004.11.017; PERRINE K, 1995, ARCH NEUROL-CHICAGO, V52, P997, DOI 10.1001/archneur.1995.00540340089017; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rupniak NMJ, 1997, PSYCHOPHARMACOLOGY, V131, P406, DOI 10.1007/s002130050310; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; SEIDEL WT, 1991, CLIN NEUROPSYCHOL, V5, P53; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; STAFINIAK P, 1990, NEUROLOGY, V40, P1509, DOI 10.1212/WNL.40.10.1509; TURSKI L, 1986, BRAIN RES, V398, P37, DOI 10.1016/0006-8993(86)91247-3; VICKREY BG, 1993, EPILEPSIA S4, V34, P22; Vickrey BG., 1993, QUALITY LIFE EPILEPS; WOOLF NJ, 1991, PROG NEUROBIOL, V37, P475, DOI 10.1016/0301-0082(91)90006-M; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	41	30	32	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUL	2007	48	7					1283	1291		10.1111/j.1528-1167.2007.01114.x			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	190HF	WOS:000248049200007	17484756	Bronze			2022-02-06	
J	Koskinen, S; Hokkinen, EM; Sarajuuri, J; Alaranta, L; Alaranta, H				Koskinen, Sanna; Hokkinen, Eeva-Maija; Sarajuuri, Jaana; Alaranta, LicPsych; Alaranta, Hannu			Applicability of the icf checklist to traumatically brain-injured patients in post-acute rehabilitation settings	JOURNAL OF REHABILITATION MEDICINE			English	Article						ICF; checklist; traumatic brain injury; rehabilitation; agreement	INTERNATIONAL CLASSIFICATION; NEUROLOGICAL CONDITIONS; HEALTH ICF; CORE SET; DISABILITY; IDENTIFICATION; MEDICINE; FACILITIES; CATEGORIES; SCALE	Objective: To evaluate the applicability of the International Classification of Functioning, Disability and Health (ICF) checklist in post-acute traumatically brain-injured patients in rehabilitation settings. Design: A cross-sectional study based on the written documents of an interdisciplinary rehabilitation team. Subjects: A sample of 55 patients with traumatic brain injury. Methods: Two raters extracted information from the patients' medical documents using the ICF checklist. The most common ICF categories were identified and the agreement between the raters was evaluated. Results;: Of the 123 checklist categories, 30 reached a prevalence of 30% or more in the ratings of both raters, and 18 further categories reached a prevalence of 30% or more in the ratings of either one rater. Seventy-five categories (61%) did not reach the cut-off point and were thus considered irrelevant. Fourteen ICF categories not included in the checklist were also considered important. Extracting the data from pre-existing documents seems to be reliable: in 86% of the most relevant categories the difference between the raters in the qualifier values was at most 1. Conclusion: A checklist is a practical tool in clinical work. However, the current ICF checklist seems not to be adequate in characterizing patients with post-acute traumatic brain injury. Developing an ICF core set for these patients might prove useful.	Kapyla Rehabil Ctr, FI-00251 Helsinki, Finland		Koskinen, S (corresponding author), Kapyla Rehabil Ctr, Synapsia,POB 103, FI-00251 Helsinki, Finland.	sannakos@gmail.com	Sarajuuri, Jaana/AAD-8665-2019	Sarajuuri, Jaana/0000-0002-6432-0295			Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Cieza A, 2004, J REHABIL MED, V36, P9, DOI 10.1080/16501960410015353; Ewert T, 2005, DISABIL REHABIL, V27, P367, DOI 10.1080/09638280400014014; Ewert T, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410015362; FLEISS JL, 1981, STAT METHODS RATES P, P140; Geyh S, 2004, J REHABIL MED, V36, P135, DOI 10.1080/16501960410016776; Grill E, 2005, DISABIL REHABIL, V27, P459, DOI 10.1080/09638280400014063; KOSKINEN S, 2001, 49 FIN SOC SEC HLTH, P179; Lantz CA, 1996, J CLIN EPIDEMIOL, V49, P431, DOI 10.1016/0895-4356(95)00571-4; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 2002, RESTOR NEUROL NEUROS, V20, P103; Reed GM, 2005, REHABIL PSYCHOL, V50, P122, DOI 10.1037/0090-5550.50.2.122; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Stier-Jarmer M, 2005, DISABIL REHABIL, V27, P389, DOI 10.1080/09638280400014022; Stucki G, 2005, AM J PHYS MED REHAB, V84, P733, DOI 10.1097/01.phm.0000179521.70639.83; Stucki G, 2004, J REHABIL MED, V36, P5, DOI 10.1080/16501960410022300; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; Stucki G, 2002, DISABIL REHABIL, V24, P281, DOI 10.1080/09638280110105222; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; Weigl M, 2004, J REHABIL MED, V36, P12, DOI 10.1080/16501960410015443; *WHO, 2004, TOIM TOIM TERV KANS; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2007, INT CLASS FUNCT DIS	27	30	31	0	6	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	JUL	2007	39	6					467	472		10.2340/16501977-0077			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	192TR	WOS:000248226400006	17624481	Green Submitted, gold			2022-02-06	
J	Clough, RW; Neese, SL; Sherill, LK; Tan, AA; Duke, A; Roosevelt, RW; Browning, RA; Smith, DC				Clough, R. W.; Neese, S. L.; Sherill, L. K.; Tan, A. A.; Duke, A.; Roosevelt, R. W.; Browning, R. A.; Smith, D. C.			Cortical edema in moderate fluid percussion brain injury is attenuated by vagus nerve stimulation	NEUROSCIENCE			English	Article						traumatic brain injury; TBI; FPI; VNS; brain swelling; rats	REGIONAL CEREBRAL EDEMA; LOCUS-COERULEUS LESIONS; NOREPINEPHRINE TURNOVER; MOTOR DEFICITS; RECOVERY; CORTEX; RAT; DAMAGE; AMPHETAMINE; WIDESPREAD	Development of cerebral edema (intracellular and/or extracellular water accumulation) following traumatic brain injury contributes to mortality and morbidity that accompanies brain injury. Chronic intermittent vagus nerve stimulation (VNS) initiated at either 2 h or 24 h (VNS: 30 s train of 0.5 mA, 20 Hz, biphasic pulses every 30 min) following traumatic brain injury enhances recovery of motor and cognitive function in rats in the weeks following brain injury; however, the mechanisms of facilitated recovery are unknown. The present study examines the effects of VNS on development of acute cerebral edema following unilateral fluid percussion brain injury (FPI) in rats, concomitant with assessment of their behavioral recovery. Two hours following FPI, VNS was initiated. Behavioral testing, using both beam walk and locomotor placing tasks, was conducted at 1 and 2 days following FPI. Edema was measured 48 h post-FPI by the customary method of region-specific brain weights before and after complete dehydration. Results of this study replicated that VNS initiated at 2 h after FPI: 1) effectively facilitated the recovery of vestibulomotor function at 2 days after FPI assessed by beam walk performance (P<0.01); and 2) tended to improve locomotor placing performance at the same time point (P=0.18). Most interestingly, results of this study showed that development of edema within the cerebral cortex ipsilateral to FPI was significantly attenuated at 48 h in FPI rats receiving VNS compared with non-VNS FPI rats (P<0.04). Finally, a correlation analysis between beam walk performance and cerebral edema following FPI revealed a significant inverse correlation between behavior performance and cerebral edema. Together, these results suggest that VNS facilitation of motor recovery following experimental brain injury in rats is associated with VNS-mediated attenuation of cerebral edema. (c) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.	So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA; So Illinois Univ, Brain & Cognit Sci Program, Dept Psychol, Carbondale, IL 62901 USA; So Illinois Univ, Dept Physiol, Sch Med, Carbondale, IL 62901 USA; So Illinois Univ, Ctr Integrat Res Cognit & Neural ci, Carbondale, IL 62901 USA		Clough, RW (corresponding author), So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA.	rclough@siumed.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41551] Funding Source: Medline		BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baslow MH, 2002, NEUROCHEM INT, V40, P295, DOI 10.1016/S0197-0186(01)00095-X; Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Borges N, 1999, J AUTON PHARMACOL, V19, P209, DOI 10.1046/j.1365-2680.1999.00137.x; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Cheney JA, 2001, J CEREBR BLOOD F MET, V21, P396, DOI 10.1097/00004647-200104000-00008; CLOUGH RW, 2006, J NEUROTRAUM, V22, P1258; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Giorgi FS, 2004, NEUROSCI BIOBEHAV R, V28, P507, DOI 10.1016/j.neubiorev.2004.06.008; Goldstein LB, 1997, RESTOR NEUROL NEUROS, V11, P55, DOI 10.3233/RNN-1997-111206; GRIFFIN MP, 1994, J APPL PHYSIOL, V76, P2760, DOI 10.1152/jappl.1994.76.6.2760; Groves DA, 2005, NEUROSCI BIOBEHAV R, V29, P493, DOI 10.1016/j.neubiorev.2005.01.004; Groves DA, 2005, NEUROSCI LETT, V379, P174, DOI 10.1016/j.neulet.2004.12.055; HARIK SI, 1984, ANN NEUROL, V15, P568, DOI 10.1002/ana.410150609; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; Kroppenstedt SN, 2003, CRIT CARE MED, V31, P2211, DOI 10.1097/01.CCM.0000080482.06856.62; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; LIGHTHALL JW, 1988, J NEUROTRAUM, V5, P617; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MOUFARRIJ NA, 1986, NEUROL RES, V11, P97; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; NATHAN BR, 1999, TXB CLIN NEUROLOGY, P475; Neese SL, 2007, BRAIN RES, V1128, P157, DOI 10.1016/j.brainres.2006.09.073; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; PAXINOS G, 1998, BRAIN RES; Rabinstein AA, 2006, NEUROLOGIST, V12, P59, DOI 10.1097/01.nrl.0000186810.62736.f0; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; ROBERT B, 1992, AGENTS ACTIONS, V37, P268, DOI 10.1007/BF02028119; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Schachter SC, 2002, NEUROLOGY, V59, pS1, DOI 10.1212/WNL.59.6_suppl_4.S1; Schilling L, 1999, ADV EXP MED BIOL, V474, P123; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stover JF, 2002, INTENS CARE MED, V28, P1491, DOI 10.1007/s00134-002-1431-2; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Landeghem FKH, 2003, J NEUROTRAUM, V20, P1327, DOI 10.1089/089771503322686120; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; WOODBURY DM, 1990, EPILEPSIA, V31, pS7, DOI 10.1111/j.1528-1157.1990.tb05852.x	64	30	35	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 29	2007	147	2					286	293		10.1016/j.neuroscience.2007.04.043			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	187NA	WOS:000247853400004	17543463				2022-02-06	
J	Hart, T; O'Neil-Pirozzi, TM; Williams, KD; Rapport, LJ; Hammond, F; Kreutzer, J				Hart, Tessa; O'Neil-Pirozzi, Therese M.; Williams, Kelli D.; Rapport, Lisa J.; Hammond, Flora; Kreutzer, Jefftey			Racial differences in caregiving patterns, caregiver emotional function, and sources of emotional support following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; caregiver function; race differences	QUALITY-OF-LIFE; AFRICAN-AMERICAN; PSYCHOLOGICAL DISTRESS; DEMENTIA CAREGIVERS; SOCIAL SUPPORT; RACE; OUTCOMES; SCALE; REHABILITATION; SATISFACTION	Objective: Compare white and African American caregivers of people with moderate to severe traumatic brain injury (TBI) regarding caregiving patterns, emotional function and life satisfaction, and preferred supports. Design: Prospective, observational study; 1, 2, or 5 years post-TBI. Setting: Six TBI model systems. Participants: Two hundred fifty-six caregivers (195 white and 61 African American). Measures: Brief Symptom Inventory-18, Satisfaction With Life Scale. Results: Races differed as to kinship patterns, with more white caregivers including spouses and more African Americans including "other relatives." African Americans spent significantly more time in direct caregiving, and reported more depression. African American TBI survivors were significantly more disabled than whites, which appeared to account for emotional function differences. Whites were more likely to use professional services for emotional support. Conclusion: Across races, TBI caregiver emotional health is affected by the functional level of the survivor. African American caregivers may be at risk for worse emotional consequences due to worse survivor outcomes, yet may underutilize professional services.	Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA; Spaulding Rehabil Hosp, Boston, MA USA; Northeastern Univ, Boston, MA 02115 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Carolinas Rehabil, Charlotte, NC USA		Hart, T (corresponding author), Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu		Rapport, Lisa/0000-0001-8014-9523			Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Corrigan J.D., 2003, TECHNICAL REPORT PRO; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cox C, 1999, J GERONTOL SOC WORK, V32, P5, DOI 10.1300/J083v32n02_02; COX C, 1993, AM J ALZHEIMERS CARE, V8, P33; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DEROGATIS LR, 2000, BRIEF SYMTPOM INVENT, V18; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dilworth-Anderson P, 2005, J GERONTOL B-PSYCHOL, V60, pS257, DOI 10.1093/geronb/60.5.S257; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Farran CJ, 1997, J AGING HEALTH, V9, P316, DOI 10.1177/089826439700900303; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Haley WE, 2004, AGING MENT HEALTH, V8, P316, DOI 10.1080/13607860410001728998; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hart T, 2003, REHABIL PSYCHOL, V48, P86, DOI 10.1037/0090-5550.48.2.86; HORWITZ AV, 1995, J HEALTH SOC BEHAV, V36, P138, DOI 10.2307/2137221; Knight BG, 1998, AGING MENT HEALTH, V2, P212, DOI 10.1080/13607869856696; Knight BG, 2000, J GERONTOL B-PSYCHOL, V55, pP142, DOI 10.1093/geronb/55.3.P142; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LAWTON MP, 1992, J GERONTOL, V47, pS156, DOI 10.1093/geronj/47.4.S156; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; MILLER B, 1995, J GERONTOL B-PSYCHOL, V50, pS374, DOI 10.1093/geronb/50B.6.S374; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roff LL, 2004, J GERONTOL B-PSYCHOL, V59, pP185, DOI 10.1093/geronb/59.4.P185; Rosenthal M., 1996, J HEAD TRAUMA REHAB, V11, P69; Sander AM, 2007, NEUROREHABILITATION, V22, P1; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sleath B, 2005, J AM GERIATR SOC, V53, P397, DOI 10.1111/j.1532-5415.2005.53155.x; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; *UDS, 1997, GUID UN DAT SET MED; Valentine DP, 1998, FAM SOC-J CONTEMP H, V79, P577, DOI 10.1606/1044-3894.861; Warschausky S, 2001, ARCH PHYS MED REHAB, V82, P329, DOI 10.1053/apmr.2001.21510; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; White TM, 2000, GERONTOLOGIST, V40, P718, DOI 10.1093/geront/40.6.718; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	47	30	30	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2007	22	2					122	131		10.1097/01.HTR.0000265100.37059.44			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	152NU	WOS:000245369500007	17414314				2022-02-06	
J	Abadal-Centellas, JM; Llompart-Pou, JA; Homar-Ramirez, J; Perez-Barcena, J; Rossello-Ferrer, A; Ibanez-Juve, J				Abadal-Centellas, Josep M.; Llompart-Pou, Juan A.; Homar-Ramirez, Javier; Perez-Barcena, Jon; Rossello-Ferrer, Ainhoa; Ibanez-Juve, Jordi			Neurologic outcome of posttraumatic refractory intracranial hypertension treated with external lumbar drainage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; intracranial hypertension; external lumbar drainage	SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; PRESSURE MONITORS; PLACEMENT	Background: Refractory intracranial hypertension (ICH) to second level measures after severe traumatic brain injury (TBI) is associated with mortality up to 84% to 100%. The use of external lumbar drainage (ELD) has been described in these patients. We report our experience with the use of ELD in 17 cases of refractory ICH after severe TBI. Methods: In our Level 3 Intensive Care Unit (ICU) at a university hospital, ICH is treated according to a progressive approach following the Brain Trauma Foundation guidelines. When second level measures fail to control ICH, we use an ELD as a rescue therapy if basal cisterns are discernible. Outcome at ICU discharge and 6 months after injury were analyzed using Glasgow Outcome Scale (GOS). Results: Mean age was 32.5 +/- 13.3 years. ICH was reduced in all patients. ICP before ELD was 30.9 +/- 7.9 mm Hg and after ELD 14.1 +/- 5.9 mm Hg. Four patients (24%) had an ICH rebound after 5 days of ELD placement and died in the ICU. At 6 months after TBI, 13 patients (76%) presented a good outcome (GOS score of 4 and 5). No patient presented pupillary changes or cerebrospinal fluid infection during ELD use. Conclusion: External lumbar drainage is an effective and safe procedure to treat refractory ICH when basal cisterns are discernible. Control of refractory ICH with ELD is associated with an important reduction of mortality and a good functional recovery at 6 months.	Hosp Univ Son Dureta, Serv Med Intens, Palma de Mallorca 07014, Baleares, Spain		Llompart-Pou, JA (corresponding author), Hosp Univ Son Dureta, Serv Med Intens, C Andrea Doria N 55, Palma de Mallorca 07014, Baleares, Spain.	ja_llompart@hotmail.com					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Davis JW, 2004, J TRAUMA, V57, P1173, DOI 10.1097/01.TA.0000151257.79108.FB; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Guyot LL, 1998, ACT NEUR S, V71, P47; Harris CH, 2002, AM SURGEON, V68, P787; JENNETT B, 1975, LANCET, V2, P480; Khan SH, 1998, ACT NEUR S, V71, P50; KOREIN J, 1959, NEUROLOGY, V9, P290, DOI 10.1212/WNL.9.4.290; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARTINEZ E, 1994, LANCET, V344, P1015, DOI 10.1016/S0140-6736(94)91671-3; Munch EC, 2001, CRIT CARE MED, V29, P976; Perez-Barcena J, 2005, NEUROCIRUGIA, V16, P5; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; SENCER W, 1956, J Mt Sinai Hosp N Y, V23, P808; SHAPIRO K, 1980, ANN NEUROL, V7, P508, DOI 10.1002/ana.410070603; Stocchetti N, 2003, ACTA NEUROCHIR, V145, P761, DOI 10.1007/s00701-003-0092-4; Tomosvari Adrienn, 2005, Orvosi Hetilap, V146, P159; Willemse RB, 1998, ACT NEUR S, V71, P37	22	30	34	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2007	62	2					282	286		10.1097/01.ta.0000199422.01949.78			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	137ZY	WOS:000244333300002	17297313				2022-02-06	
J	Itoh, T; Satou, T; Nishida, S; Hashimoto, S; Ito, H				Itoh, Tatsuki; Satou, Takao; Nishida, Shozo; Hashimoto, Shigeo; Ito, Hiroyuki			Cultured rat astrocytes give rise to neural stem cells	NEUROCHEMICAL RESEARCH			English	Article						neural stem cell; differentiation; astrocyte; neurosphere; culture	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ADULT MAMMALIAN BRAIN; SPINAL-CORD; NEURONAL DIFFERENTIATION; PROLIFERATION; PROGENITORS; HIPPOCAMPUS	Previously, we reported the occurrence of neural stem cells (NSCs) around an area of damage after rat traumatic brain injury (TBI); but it was unclear if this was due to blastgenesis in astrocytes, or to NSCs migrating from the subventricular zone (SVZ). In this study, NSCs were isolated and cultured from cultured type I astrocytes taken from newborn rat cortex in which the subventricular zone, and hippocampus had been discarded. All cultured type 1 astrocytes showed glial fibrillary acidic protein (GFAP) immunopositivity. Nestin immunopositive spheres were isolated from type 1 astrocytes and cultured in the presence of bFGF and EGF in the medium. Neurospheres differentiated into Tuj1-, GFAP- and A2B5-positive cells after 4 days of culture without bFGF and EGF. These results indicate that isolated neurospheres from brain cortex astrocytes can differentiate into neurons and glia and might contribute to neurogenesis and neuroplasticity.	Kinki Univ, Sch Med, Dept Pathol, Osaka 589, Japan; Kinki Univ Hosp, Div Hosp Pathol, Sch Med, Osaka, Japan; Kinki Univ, Div Sports Med, Inst Life Sci, Osaka 589, Japan; Kinki Univ, Sch Pharmaceut Sci, Osaka 577, Japan; PL Hosp, Dept Pathol, Osaka, Japan		Itoh, T (corresponding author), Kinki Univ, Sch Med, Dept Pathol, Osaka 589, Japan.	tatsuki@med.kindai.ac.jp		Itoh, Tatsuki/0000-0003-2015-7788			Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bithell A, 2005, CLIN SCI, V108, P13, DOI 10.1042/CS20040276; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021, DOI 10.1523/JNEUROSCI.15-03-02021.1995; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; ITOH T, 2006, IN PRESS NEUROL RES; Jurynec MJ, 2003, MOL CELL NEUROSCI, V23, P69, DOI 10.1016/S1044-7431(03)00019-8; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Morizane A, 2006, J NEUROSCI RES, V83, P1015, DOI 10.1002/jnr.20799; OMALLEY EK, 1992, BRAIN RES, V582, P65, DOI 10.1016/0006-8993(92)90317-3; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Roussa E, 2004, NEUROSCI LETT, V361, P52, DOI 10.1016/j.neulet.2003.12.106; Sergent-Tanguy S, 2006, J NEUROSCI RES, V83, P1515, DOI 10.1002/jnr.20846; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Simpson PB, 1998, J NEUROSCI RES, V52, P468, DOI 10.1002/(SICI)1097-4547(19980515)52:4<468::AID-JNR11>3.0.CO;2-#; WILKIN GP, 1990, TRENDS NEUROSCI, V13, P43, DOI 10.1016/0166-2236(90)90065-I; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xu Y, 2003, J NEUROSCI RES, V74, P533, DOI 10.1002/jnr.10769; Yamamoto S, 2001, EXP NEUROL, V172, P115, DOI 10.1006/exnr.2001.7798; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403; Zhu G, 1999, J NEUROSCI RES, V56, P131, DOI 10.1002/(SICI)1097-4547(19990415)56:2<131::AID-JNR3>3.0.CO;2-I	31	30	32	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	NOV	2006	31	11					1381	1387		10.1007/s11064-006-9186-8			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	110UM	WOS:000242406800010	17053966				2022-02-06	
J	Dinocourt, C; Gallagher, SE; Thompson, SM				Dinocourt, Celine; Gallagher, Sandra E.; Thompson, Scott M.			Injury-induced axonal sprouting in the hippocampus is initiated by activation of trkB receptors	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						brain-derived neurotrophic factor; epilepsy; GAP-43; regeneration; slice culture	TEMPORAL-LOBE EPILEPSY; NEUROTROPHIC FACTOR PROTEIN; FIBER SYNAPTIC REORGANIZATION; EXPERIMENTAL BRAIN TRAUMA; TYROSINE KINASE RECEPTOR; CENTRAL-NERVOUS-SYSTEM; KAINATE-TREATED RATS; CA1 PYRAMIDAL CELLS; MESSENGER-RNA; NEUROPEPTIDE-Y	Penetrating head injuries are often accompanied by the delayed development of post-traumatic epilepsy. Schaffer collateral transection leads to axonal sprouting and hyperexcitability in area CA3 of hippocampal slice cultures. We used this model to test the hypothesis that the injury-induced axonal sprouting results from increased neurotrophin signaling via trkB receptors near the lesion. Using rats and mice, we established that sprouting CA3 pyramidal cell axons are labeled with an antibody to the growth-associated protein GAP-43. We observed two- to threefold increases in the level of brain-derived neurotrophic factor and trkB protein in area CA3 by 24-48 h after Schaffer collateral transection, preceding the onset of axonal sprouting. Finally, we demonstrated that injury-induced axonal sprouting of GAP-43-immunoreactive axons is impaired in hippocampal slice cultures from mice expressing low levels of trkB receptors. We conclude that injury-induced axonal sprouting is initiated by brain-derived neurotrophic factor-trkB signaling and suggest that this process may be critical for the genesis of post-traumatic epilepsy.	Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Program Med & Res Technol, Baltimore, MD 21201 USA		Thompson, SM (corresponding author), Univ Maryland, Sch Med, Dept Physiol, 655 W Baltimore St, Baltimore, MD 21201 USA.	sthom003@umaryland.edu	Thompson, Scott M/K-8921-2015		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065488] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH65488] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40388] Funding Source: Medline		Armitage LL, 1998, BRAIN RES, V781, P37, DOI 10.1016/S0006-8993(97)01218-3; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Bender R, 1998, EXP BRAIN RES, V120, P399, DOI 10.1007/s002210050413; Binder DK, 1999, J NEUROSCI, V19, P4616; Binder DK, 1999, J NEUROSCI, V19, P1424; Cavazos JE, 2004, NEUROSCIENCE, V126, P677, DOI 10.1016/j.neuroscience.2004.04.014; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Chen X, 2005, NEURON, V46, P13, DOI 10.1016/j.neuron.2005.03.009; Conner JM, 1997, J NEUROSCI, V17, P2295; CORSELLIS JAN, 1984, NEUROPATHOLOGY, P921; Danzer SC, 2004, J NEUROSCI, V24, P11346, DOI 10.1523/JNEUROSCI.3846-04.2004; Elmer E, 1998, NEUROSCIENCE, V83, P351, DOI 10.1016/S0306-4522(97)00387-4; Elmer E, 1996, BRAIN RES, V712, P19, DOI 10.1016/0006-8993(95)01424-1; Emery DL, 2000, J COMP NEUROL, V424, P521; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; Gahwiler BH, 1998, CULTURING NERVE CELL, P461; GALL C, 1992, EPILEPSY RES, P171; Gall C M, 1997, Adv Neurol, V72, P9; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; He XP, 2004, NEURON, V43, P31, DOI 10.1016/j.neuron.2004.06.019; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hicks RR, 1998, MOL BRAIN RES, V59, P264, DOI 10.1016/S0169-328X(98)00158-2; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KLEIN R, 1990, DEVELOPMENT, V109, P845; KOKAIA M, 1995, EXP NEUROL, V133, P215, DOI 10.1006/exnr.1995.1024; Koyama R, 2004, J NEUROSCI, V24, P7215, DOI 10.1523/JNEUROSCI.2045-04.2004; Lamballe F, 1991, Princess Takamatsu Symp, V22, P153; Lehmann TN, 2000, EPILEPSIA, V41, pS190, DOI 10.1111/j.1528-1157.2000.tb01580.x; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Longo BM, 1997, NEUROSCI LETT, V226, P163, DOI 10.1016/S0304-3940(97)00267-X; MAJOKOWSKI J, 1990, COMPREHENSIVE EPILEP, P281; MATHERN GW, 1995, J NEUROSURG, V82, P211, DOI 10.3171/jns.1995.82.2.0211; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McKinney RA, 1999, P NATL ACAD SCI USA, V96, P11631, DOI 10.1073/pnas.96.20.11631; MERLIO JP, 1993, NEURON, V10, P151, DOI 10.1016/0896-6273(93)90307-D; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; Mohapel P, 1997, BRAIN RES, V778, P186, DOI 10.1016/S0006-8993(97)01079-2; Murray KD, 2000, J COMP NEUROL, V418, P411, DOI 10.1002/(SICI)1096-9861(20000320)418:4<411::AID-CNE4>3.0.CO;2-F; NADLER JV, 1980, BRAIN RES, V191, P387, DOI 10.1016/0006-8993(80)91289-5; NADLER JV, 1980, BRAIN RES, V182, P1; Perez Y, 1996, EUR J NEUROSCI, V8, P736, DOI 10.1111/j.1460-9568.1996.tb01259.x; Poulsen FR, 2002, BRAIN RES, V950, P103, DOI 10.1016/S0006-8993(02)03009-3; Qiao XX, 2001, J NEUROSCI RES, V64, P268, DOI 10.1002/jnr.1075.abs; REPRESA A, 1989, NEUROSCI LETT, V99, P345, DOI 10.1016/0304-3940(89)90471-0; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Scharfman HE, 2002, EXP NEUROL, V174, P201, DOI 10.1006/exnr.2002.7869; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; SCHWARTZ RS, 2002, REV CARDIOVASC ME S5, V3, P4; Siddiqui AH, 2005, BRAIN RES, V1066, P129, DOI 10.1016/j.brainres.2005.10.066; Smith BN, 2002, J NEUROPHYSIOL, V87, P1655, DOI 10.1152/jn.00581.2001; Sommer W., 1880, ARCH PSYCHIATRIE NER, V10, P631, DOI [10.1007/BF02224538, DOI 10.1007/BF02224538]; STOPPINI L, 1993, NEUROSCIENCE, V57, P985, DOI 10.1016/0306-4522(93)90043-F; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula T, 1998, J COMP NEUROL, V390, P578, DOI 10.1002/(SICI)1096-9861(19980126)390:4<578::AID-CNE9>3.0.CO;2-Y; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Takahashi M, 1999, BRAIN RES, V818, P579, DOI 10.1016/S0006-8993(98)01355-9; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vezzani A, 1999, NEUROSCIENCE, V90, P1445, DOI 10.1016/S0306-4522(98)00553-3; Wyneken U, 2003, EPILEPSIA, V44, P243, DOI 10.1046/j.1528-1157.2003.17602.x; Xu B, 2004, NEUROSCIENCE, V126, P521, DOI 10.1016/j.neuroscience.2004.03.044; Xu BJ, 2000, NEURON, V26, P233, DOI 10.1016/S0896-6273(00)81153-8; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	74	30	35	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	OCT	2006	24	7					1857	1866		10.1111/j.1460-9568.2006.05067.x			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	095YL	WOS:000241344100003	17040478				2022-02-06	
J	Smith, DC; Tan, AA; Duke, A; Neese, SL; Clough, RW; Browning, RA; Jensen, RA				Smith, Douglas C.; Tan, Arlene A.; Duke, Andrea; Neese, Steven L.; Clough, Richard W.; Browning, Ronald A.; Jensen, Robert A.			Recovery of function after vagus nerve stimulation initiated 24 hours after fluid percussion brain injury	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; norepinephrine; recovery of function; traumatic brain injury; vagus nerve stimulation	SENSORIMOTOR CORTEX INJURY; LOCUS-COERULEUS; AMPHETAMINE; MOTOR; RAT; NOREPINEPHRINE; NORADRENALINE; VAGAL; DEFICITS; RELEASE	Recent evidence from our laboratory demonstrated in laboratory rats that stimulation of the vagus nerve (VNS) initiated 2 h after lateral fluid percussion brain injury (FPI) accelerates the rate of recovery on a variety of behavioral and cognitive tests. VNS animals exhibited a level of performance comparable to :that of sham-operated uninjured animals :by the end of a 2-week testing period. The effectiveness of VNS was further evaluated in the present study in which initiation of stimulation was delayed until 24 h post-injury. Rats were subjected to a moderate FPI and tested. on the beam walk, skilled forelimb reaching, locomotor placing, forelimb flexion and Morris water maze tasks for 2 weeks following injury. VNS (30 sec trains of 0:5 mA, 20.0-Hz biphasic pulses) was initiated 24 h post-injury and continued at 30-min intervals for the duration of the study, except for brief periods when the animals were. detached for behavioral assessments. Consistent with our previous findings when stimulation was initiated 2 h post-injury, VNS animals showed significantly faster rates. of recovery compared to controls. By the last day of testing (day 14: post-injury), the FPI-VNS animals were performing significantly better than the FPI-no-VNS animals and were not significantly different from shams in all motor and sensorimotor tasks. Performance in the Morris water maze indicated that the VNS animals acquired the task more rapidly on days 11-13 post-injury. On day 14, the FPI-VNS animals did not differ in the latency to find the platform from sham controls, whereas the injured controls did; however, the FPI-VNS animals and injured controls were not significantly different. Despite the lack of significant histological differences between the FPI groups, VNS, when initiated 24 h following injury, clearly attenuated the ensuing behavioral deficits and enhanced acquisition of the cognitive task. The results are discussed with respect to the norepinephrine hypothesis.	So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA; So Illinois Univ, Dept Psychol, Brain & Cognit Sci Programs, Carbondale, IL USA; So Illinois Univ, Sch Med, Dept Anat, Carbondale, IL 62901 USA; So Illinois Univ, Ctr Intergrat Res Cognit & Neural Sci, Carbondale, IL 62901 USA		Smith, DC (corresponding author), So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA.	dcsmith@siu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41551] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041551] Funding Source: NIH RePORTER		Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Aston-Jones Gary, 1995, P183; ASTONJONES G, 2002, NEUROPSYCHOPHARMACOL, P47; Ben-Menachem E, 2005, EPILEPTIC DISORD, V7, pS22; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; DeGiorgio CM, 2000, EPILEPSIA, V41, P1195, DOI 10.1111/j.1528-1157.2000.tb00325.x; Dose JM, 1997, J NEUROTRAUM, V14, P327, DOI 10.1089/neu.1997.14.327; DunnMeynell AA, 1997, J NEUROTRAUM, V14, P43, DOI 10.1089/neu.1997.14.43; Fai AHC, 2004, CHINESE MED J-PEKING, V117, P58; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; Feeney DM, 1998, RESTORATIVE NEUROLOGY, P35; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; George MS, 2005, BIOL PSYCHIAT, V58, P364, DOI 10.1016/j.biopsych.2005.07.028; Goldstein LB, 2000, NEUROPHARMACOLOGY, V39, P852, DOI 10.1016/S0028-3908(99)00249-X; GOLDSTEIN LB, 1991, RESTOR NEUROL NEUROS, V3, P41, DOI 10.3233/RNN-1991-3105; Goldstein LB, 1998, RESTORATIVE NEUROLOGY, P241; Groves DA, 2005, NEUROSCI LETT, V379, P174, DOI 10.1016/j.neulet.2004.12.055; HALLMAN H, 1984, EUR J PHARMACOL, V103, P269, DOI 10.1016/0014-2999(84)90487-4; Hassert DL, 2004, BEHAV NEUROSCI, V118, P79, DOI 10.1037/0735-7044.118.1.79; HERMANN GE, 1985, J AUTONOM NERV SYST, V13, P1, DOI 10.1016/0165-1838(85)90002-5; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; Krahl S. E., 1994, Society for Neuroscience Abstracts, V20, P1453; Krahl SE, 1998, EPILEPSIA, V39, P709, DOI 10.1111/j.1528-1157.1998.tb01155.x; Krahl SE, 2004, J PSYCHIATR RES, V38, P237, DOI 10.1016/j.jpsychires.2003.11.005; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LHEUREUX R, 1986, J NEUROCHEM, V46, P1794; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NARITOKU DK, 1995, EPILEPSY RES, V22, P53, DOI 10.1016/0920-1211(95)00035-9; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prasad RM, 1995, RESTOR NEUROL NEUROS, V9, P65, DOI 10.3233/RNN-1995-9201; ROOSEVELT RW, IN PRESS BRAIN RES; Rush AJ, 2005, BIOL PSYCHIAT, V58, P355, DOI 10.1016/j.biopsych.2005.05.024; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; TAKIGAWA M, 1977, BRAIN RES, V135, P217, DOI 10.1016/0006-8993(77)91027-7; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	53	30	34	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1549	1560		10.1089/neu.2006.23.1549			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500014	17020489				2022-02-06	
J	Ragnarsson, KT				Ragnarsson, Kristjan T.			Traumatic brain injury research since the 1998 NIH Consensus Conference - Accomplishments and unmet goals	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	2nd Federal Interagency Conference on Traumatic Brain Injury	MAR   10, 2006	Bethesda, MD			caregivers; cognitive impairment; community; epidemiology; integration; psychiatric dysfunction; quality of life; rehabilitation research; traumatic brain injury	SPINAL-CORD-INJURY; REHABILITATION; SCIENCE; STATE	In 1998, an NIH sponsored Consensus Conference on Traumatic Brain Injury (TBI) Rehabilitation identified 30 different areas of needed research. A comprehensive review of recently generated research knowledge in the field of TBI has shown that a large number of Class III and IV evidence studies have been published, but relatively few of the more scientifically rigorous Class I or II studies. A rapid growth of publications on TBI rehabilitation has generated new knowledge in the epidemiology of TBI, the management of TBI and its secondary medical complications, rehabilitation of cognitive impairment, impact of TBI on community integration and quality of life, incidence of psychiatric dysfunction, and how caregivers and family members are affected. However, there is need to replicate many of these studies using more scientifically rigorous methodologies, while other areas of important TBI research remain largely unexplored.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Ragnarsson, KT (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, 1425 Madison Ave,Box 1240, New York, NY 10029 USA.	kristjan.ragnarsson@mssm.edu					Bullock R, 1995, GUIDELINES MANAGEMEN; Esselman PC, 2006, AM J PHYS MED REHAB, V85, P383, DOI 10.1097/01.phm.0000202095.51037.a3; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Johnston MV, 2006, AM J PHYS MED REHAB, V85, P292, DOI 10.1097/01.phm.0000202079.58567.3b; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; LANGLOIS JA, 2004 TRAUMATIC BRAIN; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ragnarsson KT, 2006, AM J PHYS MED REHAB, V85, P289, DOI 10.1097/01.phm.0000202104.22458.aa; Sipski ML, 2006, AM J PHYS MED REHAB, V85, P310, DOI 10.1097/01.phm.0000202105.87011.bf	9	30	30	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2006	21	5					379	387		10.1097/00001199-200609000-00002			9	Clinical Neurology; Rehabilitation	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	084JM	WOS:000240529200002	16983223				2022-02-06	
J	Hartings, JA; Tortella, FC; Rolli, ML				Hartings, Jed A.; Tortella, Frank C.; Rolli, Michael L.			AC electrocorticographic correlates of peri-infarct depolarizations during transient focal ischemia and reperfusion	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						direct current potential; electrocorticography; focal cerebral ischemia; middle cerebral artery occlusion; peri-infarct depolarization; spreading depression	CORTICAL SPREADING DEPRESSION; CEREBRAL-ARTERY OCCLUSION; INTENSIVE-CARE-UNIT; PARTIAL STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; CONTINUOUS EEG; NONCONVULSIVE SEIZURES; QUANTITATIVE EEG; BLOOD-FLOW; INTRACEREBRAL HEMORRHAGE	Several studies have highlighted a delayed secondary pathology developing after reperfusion in animals subjected to prolonged cerebral ischemia, and recently we have shown that peri-infarct depolarizations (PIDs) occur not only during ischemia, but also in this delayed period of infarct maturation. Here we study the electrocorticographic (ECoG) manifestations of PIDs as signatures of developing secondary pathology. DC- and traditional AC-ECoG signals were recorded continuously from epidural, nonpolarizable electrodes during 2 h of middle cerebral artery occlusion (MCAo) and 22 h of reperfusion in freely behaving rats. During MCAo, seizures and PIDs recurred frequently and their incidence was significantly correlated. After reperfusion, seizures and PIDs ceased, and for the next several hours delta wave abnormalities dominated the ECoG with progressively increasing amplitude. After a variable period ( 5 to 15 h), the ECoG amplitude decremented with the onset of a prolonged repetitive series of PIDs. Initial PIDs in this delayed phase produced transient depressions of the high amplitude ECoG signal, but thereafter the ECoG was persistently attenuated, with no transient depressions during subsequent PIDs. The time of onset of postreperfusion PIDs, and hence measures of ECoG attenuation, correlated with 24 h infarct volumes. PIDs could always be detected in baseline shifts of the AC-ECoG signal with a low high-pass cutoff setting. These results suggest that delayed PIDs after reperfusion contribute to a complex secondary pathology involving delayed edema, intracranial hypertension, and hypoperfusion. The manifestation of PIDs in ECoG/electroencephalography recordings may enable continuous real-time monitoring of infarct progression.	Walter Reed Army Inst Res, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA		Hartings, JA (corresponding author), Walter Reed Army Inst Res, Div Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	jed.hartings@na.amedd.army.mil		Hartings, Jed/0000-0001-8583-3471			Afsar N, 2003, SEIZURE-EUR J EPILEP, V12, P23, DOI 10.1016/S1059131102001437; Assal F, 2001, SEIZURE-EUR J EPILEP, V10, P260, DOI 10.1053/seiz.2000.0506; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; Back T, 2000, STROKE, V31, P2901, DOI 10.1161/01.STR.31.12.2901; Borck C, 1999, J NEUROPHYSIOL, V82, P2130, DOI 10.1152/jn.1999.82.5.2130; Cuspineda E, 2003, CLIN ELECTROENCEPHAL, V34, P1; DEAZEREDO FAM, 1992, METAB BRAIN DIS, V7, P101, DOI 10.1007/BF01000149; Donnet A, 1997, EPILEPSIA, V38, P1032, DOI 10.1111/j.1528-1157.1997.tb01487.x; Dreier JP, 2005, NEUROLOGY, V64, P2145, DOI 10.1212/01.WNL.0000176298.63840.99; FABRICIUS M, 2003, J CEREB BLOOD FLOW M, V23, P291; FAUGHT E, 1993, STROKE, V24, P609, DOI 10.1161/01.STR.24.4.609; Finnigan SP, 2004, STROKE, V35, P899, DOI 10.1161/01.STR.0000122622.73916.d2; Garzon E, 2001, NEUROLOGY, V57, P1175, DOI 10.1212/WNL.57.7.1175; Gorji A, 2004, EUR J NEUROSCI, V19, P3371, DOI 10.1111/j.0953-816X.2004.03436.x; GUEDES RCA, 1987, EXP BRAIN RES, V69, P113, DOI 10.1007/BF00247034; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; GYNELL ML, 1995, NMR BIOMED, V8, P206; HABLITZ JJ, 1989, DEV BRAIN RES, V46, P243, DOI 10.1016/0165-3806(89)90288-5; HANDFORTH A, 1994, EPILEPSIA, V35, P876, DOI 10.1111/j.1528-1157.1994.tb02526.x; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Kager H, 2000, J NEUROPHYSIOL, V84, P495, DOI 10.1152/jn.2000.84.1.495; KAGSTROM E, 1983, J CEREBR BLOOD F MET, V3, P170, DOI 10.1038/jcbfm.1983.24; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; Kempski O, 2000, ACT NEUR S, V76, P251; KOROLEVA VI, 1982, PHYSIOL BOHEMOSLOV, V31, P385; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; MATSUMOTO K, 1996, J CEREB BLOOD FLOW M, V16, P271; Murri L, 1998, NEUROPHYSIOL CLIN, V28, P249, DOI 10.1016/S0987-7053(98)80115-9; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; Neumann-Haefelin T, 2000, STROKE, V31, P1965, DOI 10.1161/01.STR.31.8.1965; Ohta K, 2001, STROKE, V32, P535, DOI 10.1161/01.STR.32.2.535; Otori T, 2003, J CEREBR BLOOD F MET, V23, P43, DOI 10.1097/01.WCB.0000035180.38851.38; Pinard E, 2002, STROKE, V33, P606, DOI 10.1161/hs0202.102738; Procaccio F, 2001, Curr Opin Crit Care, V7, P74, DOI 10.1097/00075198-200104000-00004; SIESJO BK, 1985, J CEREBR BLOOD F MET, V5, P47, DOI 10.1038/jcbfm.1985.7; SOMJEN GG, 1984, AN ACAD BRAS CIENC, V56, P495; SRAMKA M, 1978, APPL NEUROPHYSIOL, V40, P48; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; STRONG AJ, 2003, J CEREB BLOOD FLO S1, V23, P300; Taguchi J, 1996, J CEREBR BLOOD F MET, V16, P271, DOI 10.1097/00004647-199603000-00012; Takano K, 1996, ANN NEUROL, V39, P308, DOI 10.1002/ana.410390307; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; TORTELLA FC, 1989, BRAIN RES, V482, P179, DOI 10.1016/0006-8993(89)90558-1; Toyota S, 2003, ACT NEUR S, V86, P153; Toyota S, 2002, STROKE, V33, P1383, DOI 10.1161/01.STR.0000015557.18508.DD; Umegaki M, 2005, J NEUROSCI, V25, P1387, DOI 10.1523/JNEUROSCI.4182-04.2005; van Putten MJAM, 2004, STROKE, V35, P2489, DOI 10.1161/01.STR.0000144649.49861.1d; VANHARREVELD A, 1954, J NEUROPHYSIOL, V17, P505; Vanhatalo S, 2005, CLIN NEUROPHYSIOL, V116, P1, DOI 10.1016/j.clinph.2004.09.015; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Williams AJ, 2003, FUND CLIN PHARMACOL, V17, P581, DOI 10.1046/j.1472-8206.2003.00183.x; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Young GB, 1996, NEUROLOGY, V47, P83	63	30	30	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2006	26	5					696	707		10.1038/sj.jcbfm.9600223			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	038RA	WOS:000237239500011	16177810	Bronze			2022-02-06	
J	Hillman, J; Milos, P; Yu, ZQ; Sjogren, F; Anderson, C; Mellergard, P				Hillman, J; Milos, P; Yu, ZQ; Sjogren, F; Anderson, C; Mellergard, P			Intracerebral microdialysis in neurosurgical intensive care patients utilising catheters with different molecular cut-off (20 and 100 kD)	ACTA NEUROCHIRURGICA			English	Article						cerebral microdialysis; head trauma; intensive care; monitoring; protein; subarachnoidal haemorrhage	HUMAN BRAIN; SUBARACHNOID HEMORRHAGE; CEREBRAL MICRODIALYSIS; BEDSIDE MICRODIALYSIS; METABOLISM	Objective. To compare the properties of a new intracerebral micro-dialysis catheter with a high cut-off membrane (molecular cut-off 100kDalton) with a standard catheter (CMA70, molecular cut-off 20kDalton). Methods. Paired intracerebral microdialysis catheters were inserted in fifteen comatose patients treated in a neurosurgical intensive care unit following subarachnoid haemorrhage or traumatic brain injury. The high-cut-off catheter (D-100) differed from the CMA 70 catheter by the length (20mm) and cut-off properties of the catheter membranes (100kDalton) and the perfusion fluids used (Ringer-Dextran 60). Samples were collected every 4-6 hours, analyzed bedside (for glucose, glutamate, glycerol, lactate, pyruvate and urea) and later in the laboratory (for total protein). Results. Fluid recovery was similar for the two types of catheters, but significantly more protein was recovered by the D-100 catheter. The recovery of glycerol and pyruvate did not differ, while minor differences in recovery of glutamate and glucose were observed. The recovery of lactate was considerably lower in the D-100 catheter (p < 0.01), influencing the lactate/pyruvate-ratio. The patterns of concentration changes over time were consistent for all metabolites, and independent of type of catheter. Conclusion. Microdialysis catheters with high cut-off membranes can be used in routine clinical practice in the NSICU, adding the possibility of macro-molecule sampling from the extracellular space during monitoring.	Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; Linkoping Univ Hosp, Dept Dermatol, S-58185 Linkoping, Sweden		Hillman, J (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	Jan.Hillman@lio.se					BENEVISTE H, 1990, PROG NEUROBIOL, V35, P195; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X	15	30	30	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2006	148	3					319	324		10.1007/s00701-005-0670-8			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	018BL	WOS:000235737700019	16411015				2022-02-06	
J	Schutz, C; Stover, JF; Thompson, HJ; Hoover, RC; Morales, DM; Schouten, JW; McMillan, A; Soltesz, K; Motta, M; Spangler, Z; Neugebauer, E; McIntosh, TK				Schutz, C; Stover, JF; Thompson, HJ; Hoover, RC; Morales, DM; Schouten, JW; McMillan, A; Soltesz, K; Motta, M; Spangler, Z; Neugebauer, E; McIntosh, TK			Acute, transient hemorrhagic hypotension does not aggravate structural damage or neurologic motor deficits but delays the long-term cognitive recovery following mild to moderate traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head injury; secondary brain damage; Morris water maze; hemorrhagic shock; fluid resuscitation	SEVERE HEAD-INJURY; CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; HYPERTONIC FLUID RESUSCITATION; PERCUSSION MODEL; OXYGEN DELIVERY; RAT MODEL; SHOCK; EDEMA; HYPOXIA	Objectives: Posttraumatic hypotension is believed to increase morbidity and mortality in traumatically brain-injured patients. Using a clinically relevant model of combined traumatic brain injury with superimposed hemorrhagic hypotension in rats, the present study evaluated whether a reduction in mean arterial blood pressure aggravates regional brain edema formation, regional cell death, and neurologic motor/cognitive deficits associated with traumatic brain injury. Design: Experimental prospective, randomized study in rodents. Setting: Experimental laboratory at a university hospital. Subjects. One hundred nineteen male Sprague-Dawley rats weighing 350-385 g. Interventions. Experimental traumatic brain injury of mild to moderate severity was induced using the lateral fluid percussion brain injury model in anesthetized rats (n = 89). Following traumatic brain injury, in surviving animals one group of animals was subjected to pressure-controlled hemorrhagic hypotension, maintaining the mean arterial blood pressure at 50-60 mm Hg for 30 mins (n = 47). The animals were subsequently either resuscitated with lactated Ringer's solution (three times shed blood volume, n = 18) or left uncompensated (n = 29). Other groups of animals included those with isolated traumatic brain injury (n = 34), those with isolated hemorrhagic hypotension (n = 8), and sham-injured control animals receiving anesthesia and surgery alone (n = 22). Measurements and Main Results: The withdrawal of 6-7 mL of arterial blood significantly reduced mean arterial blood pressure by 50% without decreasing arterial oxygen saturation or PaO2. Brain injury induced significant cerebral edema (p <.001) in vulnerable brain regions and cortical tissue loss (p <.01) compared with sham-injured animals. Neither regional brain edema formation at 24 hrs postinjury nor the extent of cortical tissue loss assessed at 7 days postinjury was significantly aggravated by superimposed hemorrhagic hypotension. Brain injury-induced neurologic deficits persisted up to 20 wks after injury and were also not aggravated by the hemorrhagic hypotension. Cognitive dysfunction persisted for up to 16 wks postinjury. The superimposition of hemorrhagic hypotension significantly delayed the time course of cognitive recovery. Conclusions. A single, acute hypotensive event lasting 30 mins did not aggravate the short- and long-term structural and motor deficits but delayed the speed of recovery of cognitive function associated with experimental traumatic brain injury.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Cologne, Fac Med, Dept Surg, Biochem & Expt Div, D-5000 Cologne 41, Germany; Univ Washington, Seattle, WA 98195 USA; Policlin Hosp, Dept Anesthesiol & Crit Care Med, Milan, Italy		Schutz, C (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA.		Schuetz, Christian/K-5234-2013	Schuetz, Christian/0000-0002-6828-4543; Morales, Diego/0000-0001-6672-9046	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM034690-19, GM R01-34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS P50-08803, P50 NS008803-31] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32 NR007106-07, T32 NR007106, T32-NR07106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [T32NR007106] Funding Source: NIH RePORTER		Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Bray GA, 1999, DIABETES CARE, V22, P623; BULLOCK R, 1996, J NEUROTRAUM, V14, P639; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Eilig I, 2001, ANESTH ANALG, V92, P669, DOI 10.1213/00000539-200103000-00023; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GOBIET W, 1995, ZBL CHIR, V120, P544; HARTL R, 1995, SHOCK, V3, P274; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hobbs AJ, 2002, TRENDS PHARMACOL SCI, V23, P406, DOI 10.1016/S0165-6147(02)02067-9; Holtzer S, 2001, CRIT CARE MED, V29, P1609, DOI 10.1097/00003246-200108000-00018; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609000-00010; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; LYETH BG, 1987, J NEUROSURG, V67, P110; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; PAXINOS G, 1990, STEREPTACTIC ATLAS R; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Riedel G, 1999, NAT NEUROSCI, V2, P898, DOI 10.1038/13202; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Save E, 2000, HIPPOCAMPUS, V10, P491, DOI 10.1002/1098-1063(2000)10:4<491::AID-HIPO16>3.3.CO;2-S; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WANG P, 1994, AM J PHYSIOL, V266, pR368, DOI 10.1152/ajpregu.1994.266.2.R368; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; Watford M, 2002, J NUTR, V132, P952, DOI 10.1093/jn/132.5.952; WELKERLING H, 1991, ZBL CHIR, V116, P1263; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	51	30	30	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2006	34	2					492	501		10.1097/01.CCM.0000198326.32049.7F			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	008UF	WOS:000235065500029	16424733	Green Accepted			2022-02-06	
J	Thomale, UW; Griebenow, M; Kroppenstedt, SN; Unterberg, AW; Stover, JF				Thomale, UW; Griebenow, M; Kroppenstedt, SN; Unterberg, AW; Stover, JF			The effect of N-acetylcysteine on posttraumatic changes after controlled cortical impact in rats	INTENSIVE CARE MEDICINE			English	Article						brain injury; N-acetylcysteine; controlled cortical impact injury; cerebral perfusion; free radicals; brain edema	TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; BLOOD-FLOW; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; ACETYL-CYSTEINE; NERVE INJURY; KAPPA-B; ANTIOXIDANT	Objective: The antioxidant potential of N-Acetylcysteine (NAC) and its improvement of posttraumatic mitrochondrial dysfunction have been reported. This study investigated the effect of NAC on posttraumatic changes after controlled cortical Impact (CCI) injury. Design and setting: Prospective randomized controlled animal study. Methods: A moderate left focal cortical contusion was induced using CCI. Either NAC (163 mg/kg bw) or physiological saline was administered intraperitoneally immediately and 2 and 4 h after trauma. Blood gases, temperature, mean arterial blood pressure (MABP), and intracranial pressure (ICP) were monitored. Twenty-four hours after trauma brains were removed and either posttraumatic edema was quantified gravimetrically (n=24], or contusion volume was determined morphometrically using slices staining and computerized image analysis (n=24]. Laser Doppler flowmetry was used to assess pericontusional cortical perfusion before trauma, 30 min and 4 and 24 h after trauma (n=14]. Measurements and results: Physiological parameters remained within normal limits. ICP measurements and water content in traumatized hemispheres did not differ between the groups. Relative contusion volume of the left hemisphere was slightly but nonsignificantly diminished in NAC-treated animals (4.7 +/- 0.4% vs. 5.9 +/- 0.5% in controls). In both groups pericontusional perfusion was significantly reduced at 4 h followed by a state of hyperperfusion at 24 h with no differences between the groups. Conclusions: Despite previously reported neuroprotective abilities of NAC, no positive effect on posttraumatic perfusion, brain edema formation, or contusion volume after focal brain injury was observed in this study.	Humboldt Univ, Virchow Med Ctr, Dept Neurosurg, Charite, D-13353 Berlin, Germany; Univ Heidelberg, Dept Neurosurg, Heidelberg, Germany; Univ Zurich Hosp, Dept Surg, Div Surg Intens Care Med, CH-8091 Zurich, Switzerland		Thomale, UW (corresponding author), Humboldt Univ, Virchow Med Ctr, Dept Neurosurg, Charite, Augustenburger Pl 1, D-13353 Berlin, Germany.	uthomale@charite.de		Misch, Martin/0000-0001-5283-5753			Al Moutaery K, 2003, NEUROSURGERY, V53, P704, DOI 10.1227/01.NEU.0000079487.66013.6F; Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Cuzzocrea S, 2000, BRIT J PHARMACOL, V130, P1219, DOI 10.1038/sj.bjp.0703421; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; Hart AM, 2004, NEUROSCIENCE, V125, P91, DOI 10.1016/j.neuroscience.2003.12.040; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; KNUCKEY NW, 1995, STROKE, V26, P305, DOI 10.1161/01.STR.26.2.305; Moinard C, 2005, INTENS CARE MED, V31, P281, DOI 10.1007/s00134-004-2489-9; MUIR JK, 1995, J NEUROTRAUM, V12, P179, DOI 10.1089/neu.1995.12.179; Nomoto Y, 2001, NEUROSURGERY, V48, P158, DOI 10.1097/00006123-200101000-00027; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Schaser KD, 2005, J ORTHOP RES, V23, P231, DOI 10.1016/j.orthres.2004.05.009; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; Silbergleit R, 1999, RESUSCITATION, V40, P181, DOI 10.1016/S0300-9572(99)00027-1; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; Stover JF, 2000, ACTA NEUROCHIR SUPPL, V76, P171; Stover JF, 2000, J NEUROTRAUM, V17, P1171, DOI 10.1089/neu.2000.17.1171; Stroop R, 1998, ACT NEUR S, V71, P303; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; THOMALE UW, ACTA NEUROCHIR S; Unterberg AW, 1997, ACT NEUR S, V70, P106; Wagner R, 1998, PAIN, V77, P173, DOI 10.1016/S0304-3959(98)00091-8; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1002/hep.1840190614; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Yunoki M, 2003, SURG NEUROL, V59, P156, DOI 10.1016/S0090-3019(02)01040-6	39	30	30	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JAN	2006	32	1					149	155		10.1007/s00134-005-2845-4			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	999SN	WOS:000234410900025	16249925				2022-02-06	
J	Earle, SA; Proctor, KG; Patel, MB; Majetschak, M				Earle, SA; Proctor, KG; Patel, MB; Majetschak, M			Ubiquitin reduces fluid shifts after traumatic brain injury	SURGERY			English	Article; Proceedings Paper	66th Annual Meeting of the Society-of-University-Surgeons	FEB 09-12, 2005	Nashville, TN	Soc Univ Surg			EXTRACELLULAR UBIQUITIN; POSSIBLE INVOLVEMENT; CEREBROSPINAL-FLUID; RESUSCITATION; BLOOD; CELLS; PRESSURE; EFFICACY; LACTATE	Background. Ubiquitin has well-described. intracellular properties. Recent data also suggest pleiotropic effects of extracellular ubiquitin, including induction of apoptosis, regulation of immune functions, and therapeutic potential during fluid resuscitation from severe trauma. However, the actions of exogenous ubiquitin after traumatic brain injury (TBI) are unknown. Methods. Series 1: Thirty-five minutes after TBI and hemorrhage, 1.5 mg ubiquitin/kg (n = 5) or albumin (n = 5) intravenous was followed by fluid resuscitation to maintain mean arterial and cerebral perfusion pressure. Series 2: Ubiquitin (n = 5) or vehicle (n = 6) was administered ater TBI only. Ubiquitin was measured with enzyme-linked immunosorbent assay in serum, urine (series 1), and cerebrospinal fluid (series 2) for 300 minutes. Results. Series 1: After intravenous bolus, serum ubiquitin peaked at t = 45 minutes with a half-life of 54 minutes. Recovery in urine was 10 %. With albumin versus ubiquitin, 85 % more resuscitation fluid was required to stabilize systemic and cerebral hemodynamics (P < .05 for t = 150 to 300 minutes), but hematocrit was similar. With albumin there were progressive increases in intracranial pressure, peak inspiratory pressure, and decreases in oxygenation. All were significantly attenuated by ubiquitin (all P < .05 vs albumin). Series 2: Intravenous ubiquitin altered cerebrospinal fluid ubiquitin with an increased time to peak (t = 88 +/- 13 min vs 45 +/- 7min, P < .05) and area under the concentration-tinie curve (82 +/- 22 vs 23 +/- 11 pg/min(1)/mL(-1), P < .05). Conclusions. After TBI, intravenous ubiquitin crossed the blood brain barrier and significantly reduced, third spacing of fluid into the brain and lung during resuscitation.	Univ Miami, Miller Sch Med, Ryder Trauma Ctr,Div Trauma & Surg Crit Care, Dewitt Daughtry Family Dept Surg, Miami, FL 33136 USA		Majetschak, M (corresponding author), Univ Miami, Miller Sch Med, Ryder Trauma Ctr,Div Trauma & Surg Crit Care, Dewitt Daughtry Family Dept Surg, 1800 NW 10th Ave, Miami, FL 33136 USA.	mmajetschak@med.miami.edu	Proctor, Kenneth/AAA-2199-2022; Patel, Mayur/K-2363-2013	Proctor, Kenneth/0000-0003-1326-6628; 			Akarsu E, 2001, NEPHRON, V88, P280, DOI 10.1159/000046005; Akarsu E, 2001, DIABETES CARE, V24, P100, DOI 10.2337/diacare.24.1.100; ASSEMAN C, 1994, J IMMUNOL METHODS, V173, P93, DOI 10.1016/0022-1759(94)90286-0; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Cerovic O, 2003, INTENS CARE MED, V29, P1300, DOI 10.1007/s00134-003-1753-8; Daino H, 2000, BLOOD, V95, P2577; Daino H, 1996, BIOCHEM BIOPH RES CO, V223, P226, DOI 10.1006/bbrc.1996.0875; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Holland KD, 2001, NEUROL CLIN, V19, P313, DOI 10.1016/S0733-8619(05)70021-9; Kieffer AE, 2003, FASEB J, V17, P776, DOI 10.1096/fj.02-0699fje; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Majetschak M, 2004, SURGERY, V135, P536, DOI 10.1016/j.surg.2003.09.006; Majetschak M, 2004, J TRAUMA, V56, P991, DOI 10.1097/01.TA.0000127770.29009.5A; Majetschak M, 2003, BLOOD, V101, P1882, DOI 10.1182/blood-2002-03-0918; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Moomey CB, 1999, CRIT CARE MED, V27, P154, DOI 10.1097/00003246-199901000-00044; Nabika T, 1999, BBA-MOL CELL RES, V1450, P25, DOI 10.1016/S0167-4889(99)00024-5; Ohe Y, 1996, J NEUROCHEM, V67, P964; OKADA M, 1993, CLIN CHIM ACTA, V220, P135, DOI 10.1016/0009-8981(93)90042-3; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; *ROYAL SWED AC SCI, 2004, ADV INF NOB PRIZ CHE; Takada K, 1997, CLIN CHEM, V43, P1188; Takagi M, 1999, ALCOHOL CLIN EXP RES, V23, p76S, DOI 10.1111/j.1530-0277.1999.tb04539.x; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	29	30	33	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	SEP	2005	138	3					431	438		10.1016/j.surg.2005.06.026			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	974XV	WOS:000232625600012	16213895				2022-02-06	
J	Edvardsson, T; Ahlstrom, G				Edvardsson, T; Ahlstrom, G			Illness-related problems and coping among persons with low-grade glioma	PSYCHO-ONCOLOGY			English	Article						brain neoplasms; low-grade glioma; distress; coping; qualitative method	QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVORS; DEFENSE-MECHANISMS; CANCER-PATIENTS; TUMOR PATIENTS; RADIOTHERAPY; ADAPTATION; STRATEGIES; EXPERIENCE	The literature reveals no qualitative study concerning the consequences of low-grade glioma in adults. The aim of the present study was to describe perceived illness-related problems in persons with low-grade glioma and the coping used in everyday living. The study was cross-sectional within a well-defined population. A semi-structured qualitative interview was conducted with each of 39 persons, and the data were subjected to inductive content analysis. There was a wide range of perceived problems, mainly concerning bodily functions, memory, cognition, emotion, communication and perception. Several coping strategies emerged, the most frequent being searching for a solution, which was often related to memory and communication problems. One characteristic of communication was the creation of new words. Other common strategies were refraining from and avoiding and laughing and joking. Caring about self involved prioritising of personal needs. A striving to feel a sense of solidarity within seeking social affinity was coping with a novel content. The study provides vivid narratives about previously unreported phenomena, conveying a deeper understanding. The variety and endurance of problems revealed verifies the need of support from several professionals, including in the form of out-patient post-medical care. Copyright (c) 2005 John Wiley & Sons, Ltd.	Orebro Cty Council, Rehabil Res Ctr, SE-70116 Orebro, Sweden; Univ Orebro, Swedish Inst Disabil Res, S-70130 Orebro, Sweden; Univ Orebro, Dept Caring Sci, S-70130 Orebro, Sweden; Orebro Univ Hosp, Ctr Nursing Sci, Orebro, Sweden		Edvardsson, T (corresponding author), Orebro Cty Council, Rehabil Res Ctr, SE-70116 Orebro, Sweden.	tanja.edvardsson@orebroll.se		Ahlstrom, Gerd/0000-0001-6230-7583			Baxter L. A., 1991, STUDYING INTERPERSON, P239; BOHAN EM, 2002, NEUROSCIENCE NURSING, P269; Bowman KF, 2003, PSYCHO-ONCOLOGY, V12, P226, DOI 10.1002/pon.630; Coyne JC, 2000, AM PSYCHOL, V55, P655, DOI 10.1037//0003-066X.55.6.655; Cramer P, 1998, J PERS, V66, P919, DOI 10.1111/1467-6494.00037; Cramer P, 2000, AM PSYCHOL, V55, P637, DOI 10.1037//0003-066X.55.6.637; Davies E, 2003, DISABIL REHABIL, V25, P259, DOI 10.1080/0963828021000024915; Davies EA, 1998, J ROY COLL PHYS LOND, V32, P406; Downe-Wamboldt B, 1992, Health Care Women Int, V13, P313; DUNKELSCHETTER C, 1992, HEALTH PSYCHOL, V11, P79, DOI 10.1037/0278-6133.11.2.79; Folkman S, 2000, AM PSYCHOL, V55, P647, DOI 10.1037//0003-066X.55.6.647; Folkman S., 1984, STRESS; Gotay CC, 1998, JNCI-J NATL CANCER I, V90, P656, DOI 10.1093/jnci/90.9.656; Herrmann M, 2000, DISABIL REHABIL, V22, P539, DOI 10.1080/096382800416788; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Klein M, 2002, LANCET, V360, P1361, DOI 10.1016/S0140-6736(02)11398-5; LAMPIC C, 1994, ACTA ONCOL, V33, P887, DOI 10.3109/02841869409098451; Lieblich A., 1998, NARRATIVE RES READIN; Lilja A, 1997, PSYCHOPATHOLOGY, V30, P316, DOI 10.1159/000285074; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; Livneh H, 2000, J REHABIL, V66, P40; MAES S, 1996, HDB COPING THEORY RE, P00221; Mathieson CM, 1998, QUAL HEALTH RES, V8, P581, DOI 10.1177/104973239800800502; MCCRAE RR, 1989, J GERONTOL, V44, P161; Meyers Christina A., 1993, Cancer Bulletin (Houston), V45, P362; Osoba D, 1997, QUAL LIFE RES, V6, P103; Pahlson A, 2003, J NEURO-ONCOL, V65, P149, DOI 10.1023/B:NEON.0000003727.09448.dd; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Petticrew M, 2002, BRIT MED J, V325, P1066, DOI 10.1136/bmj.325.7372.1066; Reijneveld JC, 2001, NEUROLOGY, V56, P618, DOI 10.1212/WNL.56.5.618; Richards L., 2002, USING NVIVO QUALITAT; Ritvo P, 1999, PATIENT EDUC COUNS, V38, P161, DOI 10.1016/S0738-3991(99)00063-4; Salander P, 1996, SOC SCI MED, V42, P985, DOI 10.1016/0277-9536(95)00204-9; SALANDER P, 1995, J NEURO-ONCOL, V25, P227, DOI 10.1007/BF01053156; SOMERFIELD M, 1992, SOC SCI MED, V34, P1203, DOI 10.1016/0277-9536(92)90313-F; Sprangers MAG, 1998, QUAL LIFE RES, V7, P291; *STAT SWED, STAT YB SWED 2001, V87, P51; Strang S, 2001, PALLIATIVE MED, V15, P127, DOI 10.1191/026921601670322085; Surma-aho O, 2001, NEUROLOGY, V56, P1285, DOI 10.1212/WNL.56.10.1285; TAPHOORN MJB, 1994, ANN NEUROL, V36, P48, DOI 10.1002/ana.410360111; Tennen H., 1999, COPING PSYCHOL WHAT, P279; van't Spijker A, 1997, PSYCHOSOM MED, V59, P280; Verhoef MJ, 1999, NEUROLOGY, V52, P617, DOI 10.1212/WNL.52.3.617; WATSON M, 1994, J PSYCHOSOC ONCOL, V12, P33, DOI 10.1300/J077V12N03_03; Watson M., 1989, MENTAL ADJUSTMENT CA; WELCHMCCAFFREY D, 1989, ANN INTERN MED, V111, P517, DOI 10.7326/0003-4819-111-6-517	46	30	30	0	6	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	1057-9249			PSYCHO-ONCOL	Psycho-Oncol.	SEP	2005	14	9					728	737		10.1002/pon.898			10	Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology; Psychology; Biomedical Social Sciences	964OU	WOS:000231891200004	15669016				2022-02-06	
J	Enomoto, T; Osugi, T; Satoh, H; McIntosh, TK; Nabeshima, T				Enomoto, T; Osugi, T; Satoh, H; McIntosh, TK; Nabeshima, T			Pre-injury magnesium treatment prevents traumatic brain injury-induced hippocampal ERK activation, neuronal loss, and cognitive dysfunction in the radial-arm maze test	JOURNAL OF NEUROTRAUMA			English	Article						extracellular signal-regulated kinase; hippocampus; magnesium; radial-arm maze; reference memory; traumatic brain injury; working memory	FOCAL CEREBRAL-ISCHEMIA; PROTEIN-KINASE INHIBITION; EXTRACELLULAR LEVELS; GLUTAMATE RELEASE; AMINO-ACIDS; CELL-DEATH; IN-VIVO; RAT; SULFATE; MEMORY	We studied the effect of pre-injury magnesium (Mg2+) treatment on hippocampal extracellular signal-regulated kinase (ERK) activation induced by lateral fluid-percussion (FP) brain injury, and on working and reference memory in the radial-arm maze test in rats subjected to such traumatic brain injury (TBI) (n = 56) or to sham injury (n = 12). In the ipsilateral hippocampus, an increase in the phospho-ERK level was detected at 10 min after injury in rats subjected to FP brain injury of moderate severity (1.9-2.0 atm) as compared to sham-injured controls (p < 0.01), and was maintained for at least 120 min after injury (p < 0.05). In the contralateral hippocampus, the phospho-ERK level was transiently increased at 10 min after injury but fell to nearly its basal level by 30 min. When MgCl2 solution (150 mu mol) was infused intravenously from 20 min to 5 min before injury (n = 4-5), brain injury-induced ERK activation was significantly inhibited in the ipsilateral hippocampus at 60 min but not at 10 min after injury. Mg2+ treatment also significantly prevented injury-induced neuronal loss in the ipsilateral hippocampus (p < 0.05 vs. vehicle-treated, brain-injured controls). At 2 weeks after injury, Mg2+ treatment was found to have significantly prevented injury-induced impairments in working (p < 0.0001 vs. vehicle-treated, brain-injured controls) and reference memory (p < 0.05) in the radial-arm maze test. The present study demonstrates that pretreatment with Mg2+ prevents post-traumatic hippocampal ERK activation and neuronal loss, and cognitive dysfunction in the radial-arm maze test.	Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Dept Pharmacol, Kawanishi, Hyogo 6660193, Japan; Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol, Nagoya, Aichi, Japan; Nagoya Univ, Grad Sch Med, Hosp Pharm, Nagoya, Aichi, Japan; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA		Osugi, T (corresponding author), Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Dept Pharmacol, 1-20-1 Yato, Kawanishi, Hyogo 6660193, Japan.	oosugi@kaw.boehringer-ingelheim.com					Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Baldassa S, 2003, MOL BRAIN RES, V119, P111, DOI 10.1016/j.molbrainres.2003.08.020; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTTON DB, 1993, AM J OBSTET GYNECOL, V168, P974, DOI 10.1016/S0002-9378(12)90855-8; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Davis S, 2000, J NEUROSCI, V20, P4563, DOI 10.1523/JNEUROSCI.20-12-04563.2000; ENOMOTO T, 2005, UNPUB MOL PHARM; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HALLAK M, 1992, AM J OBSTET GYNECOL, V167, P1605, DOI 10.1016/0002-9378(92)91749-Z; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Iida N, 2001, J NEUROSCI, V21, P6459, DOI 10.1523/JNEUROSCI.21-17-06459.2001; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marinov MB, 1996, J NEUROSURG, V85, P117, DOI 10.3171/jns.1996.85.1.0117; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mizuno M, 2003, MOL PSYCHIATR, V8, P217, DOI 10.1038/sj.mp.4001215; Mizuno M, 2002, BEHAV BRAIN RES, V133, P135, DOI 10.1016/S0166-4328(01)00470-3; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Runden E, 1998, J NEUROSCI, V18, P7296; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shohami E, 2003, J CEREBR BLOOD F MET, V23, P728, DOI 10.1097/01.WCB.0000067704.86573.83; SMITH DAS, 1989, BRIT J PHARMACOL, V97, P475, DOI 10.1111/j.1476-5381.1989.tb11975.x; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 2002, EXPERT OPIN INV DRUG, V11, P1375, DOI 10.1517/13543784.11.10.1375; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	49	30	36	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2005	22	7					783	792		10.1089/neu.2005.22.783			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	945VQ	WOS:000230530800006	16004581				2022-02-06	
J	Gurr, B; Coetzer, BR				Gurr, B; Coetzer, BR			The effectiveness of cognitive-behavioural therapy for post-traumatic headaches	BRAIN INJURY			English	Article						head injury; post-concussional symptoms; post-traumatic headaches; cognitive-behavioural therapy	POST-CONCUSSION SYNDROME; QUALITY-OF-LIFE; BRAIN-INJURY; PATHOGENESIS; MANAGEMENT; PAIN	Post-traumatic headache is one of the most common symptoms following mild and moderate head injury. Psychological factors are believed to play a role in the cause, maintenance and relief from chronic post-traumatic headache. This research evaluated the effectiveness of a multi-dimensional cognitive-behavioural approach towards rehabilitation of post-traumatic headaches. The sample included 20 participants with post-traumatic headaches from an original sample of 41. Participants acted as their own controls. Outcome measures consisted of self-rating questionnaires to assess headache severity, intensity, duration, functioning and emotional well-being. Emotional and functional headache characteristics were studied using a multi-dimensional investigation which included relatives' perceptions of the sufferers headaches. The intervention proved effective and beneficial for the 20 therapy participants. It is concluded that cognitive-behavioural therapy provides a useful supplement to the treatment of post-traumatic headache.	Poole Community Clin, Brain Injury Serv, Poole BH15 2NT, Dorset, England		Gurr, B (corresponding author), Poole Community Clin, Brain Injury Serv, Shaftesbury Rd, Poole BH15 2NT, Dorset, England.	birgit.gurr@dorsethc-tr.swest.nhs.uk					Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Andrasik F, 2003, NEUROL SCI, V24, pS80; ANDRASIK F, 1990, NEUROL CLIN, V8, P961, DOI 10.1016/S0733-8619(18)30329-3; BENNETT TL, 1988, COGN REHABIL, P34; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; CAVALLINI A, 1995, HEADACHE, V35, P29, DOI 10.1111/j.1526-4610.1995.hed3501030.x; COETZER BR, 2004, ILLNESS CRISIS LOSS, V12, P171, DOI DOI 10.1177/1054137303262216; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Cramer JA, 2001, HEADACHE, V41, P402, DOI 10.1046/j.1526-4610.2001.111006402.x; DAWN M, 2003, HEADACHE, V43, P117; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FIELDS HF, 1997, HEADACHE, P38; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; GREENBERGER D, 1995, MIND MOOD CHANGE WAY; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; HAM LP, 1994, CEPHALALGIA, V14, P118, DOI 10.1046/j.1468-2982.1994.1402118.x; HAWTON K, 1998, COGNITIVE BEHAV THER; Holroyd KA, 2000, HEADACHE, V40, P3, DOI 10.1046/j.1526-4610.2000.00001.x; HUNT SM, 1980, MEASURING HLTH STATU; JACOBSON GP, 1995, HEADACHE, V35, P534, DOI 10.1111/j.1526-4610.1995.hed3509534.x; JACOBSON GP, 1994, NEUROLOGY, V44, P837, DOI 10.1212/WNL.44.5.837; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; LIPTON RB, 1995, HEADACHE, V35, P447, DOI 10.1111/j.1526-4610.1995.hed3508447.x; Lipton RB, 1999, HEADACHE, V39, pS9, DOI 10.1111/j.1526-4610.1999.00003.x; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MARTIN PR, 1993, PSYCHOL MANAGEMENT C; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McClelland RJ, 1996, J PSYCHOSOM RES, V40, P563, DOI 10.1016/0022-3999(95)00616-8; MELZACK R, 1983, CHALLENGE PAIN; Nicholson K, 2004, J HEAD TRAUMA REHAB, V19, P2, DOI 10.1097/00001199-200401000-00002; OST LG, 1987, BEHAV RES THER, V25, P397, DOI 10.1016/0005-7967(87)90017-9; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; PACKARD RC, 1979, HEADACHE, V19, P370, DOI 10.1111/j.1526-4610.1979.hed1907370.x; PACKARD RC, 1994, J NEUROPSYCH CLIN N, V6, P229; PACKARD RC, 1996, BIOFEEDBACK SELF-REG, V21, P93; PADESKY C, 2004, COGNITIVE THERAPY UN; PARKER RS, 1995, J COGNITIVE REHABILI, V13, P14; Passchier J, 1996, HEADACHE, V36, P556, DOI 10.1046/j.1526-4610.1996.3609556.x; Penzien DB, 2002, APPL PSYCHOPHYS BIOF, V27, P163, DOI 10.1023/A:1016247811416; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Radanov BP, 2001, EUR SPINE J, V10, P403, DOI 10.1007/s005860000227; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Santalucia P, 2000, Med Health R I, V83, P173; Saper JR, 2000, ARCH NEUROL-CHICAGO, V57, P1776, DOI 10.1001/archneur.57.12.1776; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Solomon S, 2001, MED CLIN N AM, V85, P987, DOI 10.1016/S0025-7125(05)70355-2; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; Tatrow K, 2003, HEADACHE, V43, P755, DOI 10.1046/j.1526-4610.2003.03133.x; VONKORFF M, 1994, NEUROLOGY, V44, P40; Warner JS, 1996, NEUROLOGY, V46, P915, DOI 10.1212/WNL.46.4.915; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; YAGAMUCHI M, 1992, HEADACHE, V32, P427; YOUNGJOHN J, 1997, AFTERMATH ROAD ACCID, P98; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	57	30	31	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2005	19	7					481	491		10.1080/02699050400005176			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	933IQ	WOS:000229622500002	16134736				2022-02-06	
J	Hostetler, SG; Hostetler, TL; Smith, GA; Xiang, HY				Hostetler, SG; Hostetler, TL; Smith, GA; Xiang, HY			Characteristics of water skiing-related and wakeboarding-related injuries treated in emergency departments in the United States, 2001-2003	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						water skiing; wakeboarding; athletic injuries; National Electronic Injury Surveillance System (NEISS)	RISK-FACTORS; PREVENTION; ACCIDENT; AVULSION; HAZARDS; DOUCHE; SPILL; TEAR	Background: Water skiing and wakeboarding are popular sports with high potential for injury due to rapid boat acceleration, lack of protective gear, and waterway obstacles. However, trends in water skiing- and wakeboarding-related injuries in the United States have not been described using national data. Hypothesis: The number of injuries, injury diagnoses, and body regions injured vary by sport. Study Design: Descriptive epidemiology study. Methods: Data regarding water skiing- and wakeboarding-related injuries presenting to 98 hospital emergency departments in the United States between January 1, 2001, and December 31, 2003, were extracted from the National Electronic Injury Surveillance System. Data included demographics, injury diagnosis, and body region injured. Results: Data were collected for 517 individuals with water skiing-related injuries and 95 individuals with wakeboarding-related injuries. These injuries represent an estimated 23 460 water skiing- and 4810 wakeboarding-related injuries treated in US emergency departments in 2001 to 2003. Head injuries represented the largest percentage of injuries for wakeboarders (28.8% of all injuries) and the smallest percentage for water skiers (4.3%) (P < .01; relative risk [95% confidence interval], 6.73 [3.89-11.66]). Analysis of injury diagnosis was consistent as wakeboarders had significantly more traumatic brain injuries (12.5% of all injuries) than did water skiers (2.4%) (P < .05; relative risk [95% confidence interval], 5.27 [2.21-12.60]). Strains or sprains were the leading injury diagnoses for water skiing (36.3% of all injuries), and the majority (55.7%) were to the lower extremity. Lacerations were the most common diagnoses for wakeboarders (31.1% of all injuries), and the majority (59.6%) were to the face. Conclusion: The analyses of water skiing- and wakeboarding-related injuries treated in US emergency departments in 2001 to 2003 highlight the differences in injury patterns for these 2 sports. The substantial number of head and facial injuries among wakeboarders underscores the need for research on the potential role of helmets or other protective gear to reduce these common injuries.	Ohio State Univ, Coll Med & Publ Hlth, Ctr Injury Res & Policy, Columbus Childrens Res Inst,Childrens Hosp, Columbus, OH USA; Ohio State Univ, Dept Internal Med Pediat, Med Ctr, Columbus, OH 43210 USA		Xiang, HY (corresponding author), Columbus Childrens Hosp, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	xiangh@pediatrics.ohio-state.edu	Xiang, Huiyun/E-4335-2011				[Anonymous], 2003, STAT ANAL SOFTWARE S; BANERJEE AK, 1985, BRIT J RADIOL, V58, P465, DOI 10.1259/0007-1285-58-689-465; BLASIER RB, 1990, AM J SPORT MED, V18, P435, DOI 10.1177/036354659001800419; BUNDGAARD A, 1984, LANCET, V2, P1157; Carson WG, 2004, AM J SPORT MED, V32, P164, DOI 10.1177/0363546503258910; Chalmers DJ, 2003, SPORTS MED, V33, P745, DOI 10.2165/00007256-200333100-00003; CHANDLER JR, 1972, ARCHIV OTOLARYNGOL, V96, P365; Chia JKK, 2000, PEDIATR NEUROSURG, V32, P291, DOI 10.1159/000028957; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; EDINGTON RF, 1978, CAN MED ASSOC J, V119, P310; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Grace N, 1974, J Sports Med, V2, P212; Greenberg J, 1998, CHEST, V113, P1138, DOI 10.1378/chest.113.4.1138; HUMMEL G, 1982, AM J SPORT MED, V10, P215, DOI 10.1177/036354658201000405; KIZER KW, 1980, ANN EMERG MED, V9, P268, DOI 10.1016/S0196-0644(80)80387-8; KUNTZ WD, 1983, NEW ENGL J MED, V309, P990; LEE RY, 1992, AM J GASTROENTEROL, V87, P662; Maldjian C, 2000, J COMPUT ASSIST TOMO, V24, P594, DOI 10.1097/00004728-200007000-00014; MCCARTHY GF, 1969, MED J AUSTRALIA, V1, P481; MORTON DC, 1970, MED J AUSTRALIA, V1, P1256, DOI 10.5694/j.1326-5377.1970.tb84562.x; Narita Tetsuya, 2004, Journal of Nippon Medical School, V71, P57, DOI 10.1272/jnms.71.57; *NAT CTR INJ PREV, FACTS AD INJ; *NAT EL INJ SURV S, TOOL RES; PATERSON DC, 1971, PRACTITIONER, V206, P655; PERLMAN SE, 1995, PEDIATRICS, V96, P782; RABINOWITCH BL, 1993, CLIN INFECT DIS, V16, P339, DOI 10.1093/clind/16.2.339; Radford A J, 1987, Aust Fam Physician, V16, P1661; ROMANO R L, 1962, Clin Orthop, V23, P140; RUDOFF JC, 1993, ANN EMERG MED, V22, P1072, DOI 10.1016/S0196-0644(05)82758-1; Sallay PI, 1996, AM J SPORT MED, V24, P130, DOI 10.1177/036354659602400202; *SGMA INT, SGMA REP SPORTS PART; STANISAVLJEVIC S, 1978, ORTHOPEDICS, V1, P125; TAIMELA S, 1990, SPORTS MED, V9, P205, DOI 10.2165/00007256-199009040-00002; WALTRIP RL, 2001, SPORTS INJURIES MECH, P804; WEIN P, 1990, AUST NZ J OBSTET GYN, V30, P384, DOI 10.1111/j.1479-828X.1990.tb02038.x; 2003, SOFTWARE SURVEY DESI	36	30	31	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2005	33	7					1065	1070		10.1177/0363546504271748			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	940JR	WOS:000230141300016	15888722				2022-02-06	
J	Siddall, ORM				Siddall, ORM			Use of methylphenidate in traumatic brain injury	ANNALS OF PHARMACOTHERAPY			English	Article						methylphenidate; traumatic brain injury	MANAGEMENT	OBJECTIVE: To review literature regarding the effectiveness of methylphenidate in the management of the cognitive and behavioral changes observed following traumatic brain injury (TBI). DATA SOURCES: A literature search was conducted using the following databases: MEDLINE (1966-June 2004); Cochrane Central Register of Controlled Trials, fourth quarter 2004 (1988-June 2004); and International Pharmaceutical Abstracts (1970-June 2004). Methylphenidate and brain injury were the key search terms used. Limits were set to include clinical trial publications, human subjects, and English language. DATA SYNTHESIS: Ten clinical trials evaluating the efficacy and safety of methylphenidate in pediatric and adult patients with TBI are reviewed. Improvements in different aspects of cognition and behavior were evaluated before, during, and after treatment with methylphenidate. The results demonstrated that methylphenidate is likely to improve memory, attention, concentration, and mental processing, but its effects on behavior have not been determined. CONCLUSIONS: Larger, double-blind, placebo-controlled studies are needed to determine optimal doses, during which phase of recovery to begin treatment, length of treatment, and long-term effects for patients with mild, moderate, and severe TBI.	Xavier Univ, Coll Pharm, New Orleans, LA 70125 USA; Tulane Univ Hosp & Clin, Drug Informat Ctr, New Orleans, LA 70112 USA		Siddall, ORM (corresponding author), Xavier Univ, Coll Pharm, New Orleans, LA 70125 USA.	osiddall@tulane.edu					Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; Arciniegas DB, 2003, INT REV PSYCHIATR, V15, P328, DOI 10.1080/09540260310001606719; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GAULTIERI CT, 1988, BRAIN INJURY, V2, P273; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kajs-Wyllie Marylyn, 2002, J Neurosci Nurs, V34, P303; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; *NIH, 1998, REH PERS TRAUM BRAIN, V16, P1; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	25	30	32	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	JUL-AUG	2005	39	7-8					1309	1313		10.1345/aph.1E637			5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	941QN	WOS:000230229400023	15914519				2022-02-06	
J	Rogatsky, GG; Kamenir, Y; Mayevsky, A				Rogatsky, GG; Kamenir, Y; Mayevsky, A			Effect of hyperbaric oxygenation on intracranial pressure elevation rate in rats during the early phase of severe traumatic brain injury	BRAIN RESEARCH			English	Article						fluid percussion brain injury; HBO2; intracranial pressure	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; FLUID-PERCUSSION INJURY; CARBON-MONOXIDE; BLOOD-FLOW; HYPERTENSION; EDEMA; METABOLISM; EXPERIENCE; MORTALITY	Intracranial pressure (ICP) was monitored to evaluate the therapeutic effect of hyperbaric oxygen (HBO2) treatment following traumatic brain injury (TBI). This subject is controversial. The aim of our study was to determine whether HBO2 treatment has a therapeutic effect on ICP dynamics and survival following severe fluid percussion brain injury (FPBI) in rats. Changes in ICP level were analyzed every 30 min during an 8-h monitoring period following trauma and at the end of experiment (20 h). The control (A) and experimental (B) groups consisted of 7 and 4 rats, respectively. Group B was subjected to 1.5 atmospheres absolute (ATA) 100% oxygen for 60 min beginning 2 h after FPBL No significant differences in ICP were noted between groups A and B before and after HBO2 treatment until 3.5 h after trauma. At 4 h, for the first time, the difference became significant (P = 0.025; n = 11) and remained significant (P < 0.05) for all measurement points until end of monitoring, when mean ICP values reached 37.17 +/- 14.25 and 20.25 +/- 2.63 mm Hg in groups A and B, respectively. Linear approximation models showed different trends (b1 = 3.80 +/- 0.23; r(2) = 0.65, P < 0.001 and b1 = 1.56 +/- 0.25; r(2) = 0.77, P < 0.001) for groups A and B, respectively. Covariance analysis confirmed significant differences between slopes for groups A and B (F = 148.04, P < 0.001; df = 2,177), i.e., a significant difference in mean rate of ICP elevation. By the end of the experiment, 3 out of 7 rats from group A had died, but none from group B. We conclude that the application of HBO2 during the early phase of severe FPBl significantly diminished ICP elevation rate and decreased mortality level. (c) 2005 Elsevier B.V. All rights reserved.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel		Mayevsky, A (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	rogatsg@mail.biu.ac.il; mayevsa@mail.biu.ac.il		Kamenir, Yury/0000-0002-9224-0495			ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Beaumont A, 2002, ACT NEUR S, V81, P217; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Durmaz E, 1999, Br J Nurs, V8, P1067; Hampson NB, 2001, ANN EMERG MED, V38, P36, DOI 10.1067/mem.2001.115532; HAYAKAWA T, 1971, J NEUROL NEUROSUR PS, V34, P580, DOI 10.1136/jnnp.34.5.580; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Manor T, 2003, ADV EXP MED BIOL, V510, P409; Marmarou A, 2003, ACT NEUR S, V86, P7; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MAYEVSKY A, 1992, ADV EXP MED BIOL, V317, P707; MAYEVSKY A, 1995, J APPL PHYSIOL, V78, P1188, DOI 10.1152/jappl.1995.78.3.1188; Mayevsky A, 1999, ACT NEUR S, V75, P63; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1973, EUR NEUROL, V10, P1, DOI 10.1159/000114256; MINK RB, 1995, STROKE, V26, P2307, DOI 10.1161/01.STR.26.12.2307; NIDA TY, 1995, J NEUROTRAUM, V12, P77, DOI 10.1089/neu.1995.12.77; NORUSIS MJ, 1999, SPSS 9 0 GUIDE DATA; Oppel L, 2003, BRAIN INJURY, V17, P225, DOI 10.1080/0269905021000030814; PAPO I, 1980, ACTA NEUROCHIR, V52, P249, DOI 10.1007/BF01402080; Pierson David J, 2002, Respir Care, V47, P249; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rogatsky GG, 2003, J NEUROTRAUM, V20, P1315, DOI 10.1089/089771503322686111; Schaller Bernhard, 2002, Swiss Surg, V8, P123, DOI 10.1024/1023-9332.8.3.123; SUKOFF MH, 1982, NEUROSURGERY, V10, P29, DOI 10.1227/00006123-198201000-00006; van den Brink WA, 1998, ACT NEUR S, V71, P190; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	38	30	43	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 21	2005	1047	2					131	136		10.1016/j.brainres.2005.02.049			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	939MH	WOS:000230076500001	15904900				2022-02-06	
J	Ley, JJ; Vigdorchik, A; Belayev, L; Zhao, WZ; Busto, R; Khoutorova, L; Becker, DA; Ginsberg, MD				Ley, JJ; Vigdorchik, A; Belayev, L; Zhao, WZ; Busto, R; Khoutorova, L; Becker, DA; Ginsberg, MD			Stilbazulenyl nitrone, a second-generation azulenyl nitrone antioxidant, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat: Neurobehavior, histopathology, and pharmacokinetics	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							TRAUMATIC BRAIN INJURY; SPIN-TRAPPING AGENTS; ARTERY OCCLUSION; INTRALUMINAL SUTURE; THERAPEUTIC WINDOW; ACUTE STROKE; NXY-059; TRAPS; RADICALS; PBN	Stilbazulenyl nitrone (STAZN) is a potent lipophilic second-generation azulenyl nitrone antioxidant, which is highly neuroprotective in rodent models of cerebral ischemia and trauma. This study was conducted to establish whether the neuroprotection induced by STAZN persists with chronic survival and to characterize STAZN's pharmacokinetics. Physiologically regulated rats received a 2-h middle cerebral artery occlusion by intraluminal suture and were treated with either STAZN [four 0.6 mg/kg doses i.p. administered at 2 (i.e., onset of recirculation), 4, 24, and 48 h; n = 16] or dimethyl sulfoxide vehicle (n = 11). They received sequential neurobehavioral examinations followed by quantitative neuropathology at 30 days. STAZN improved neurological deficits compared with vehicle controls, beginning within < 2 h of the first dose and persisting throughout a 30-day survival. Large cystic necrotic infarcts were common in vehicle-treated rats but infrequent in STAZN-treated rats, and noninfarcted forebrain tissue was increased on average by 15%. In normal rats administered 5 mg/kg STAZN i.v. in Solutol HS 15/ethanol/saline vehicle, STAZN blood levels exhibited a biexponential decline, with an initial half-life of 28 min and a subsequent slow decay with half-life of similar to 7 h. STAZN tissue levels at 2 to 3 h were, on average, 2.5% of blood levels in forebrain, 56% in myocardium, and 41% in kidney. STAZN was concentrated in liver with initial concentrations averaging 5.2-fold above blood levels and a subsequent linear decline of 40% between 24 and 72 h. These results establish that STAZN confers enduring ischemic neuroprotection, has a long circulating half-life, and penetrates well into brain and other organs - characteristics favoring its potential therapeutic utility.	Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol, Miami, FL 33101 USA; Florida Int Univ, Dept Chem, Miami, FL 33199 USA		Ginsberg, MD (corresponding author), Univ Miami, Sch Med, Cerebral Vasc Dis Res Ctr, Dept Neurol, POB 016960, Miami, FL 33101 USA.	mdginsberg@stroke.med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS046295, P01NS005820] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 P01 NS05820, 1 U01 NS46295] Funding Source: Medline		Becker DA, 2002, J AM CHEM SOC, V124, P4678, DOI 10.1021/ja011507s; Becker DA, 1999, CELL MOL LIFE SCI, V56, P626, DOI 10.1007/s000180050457; Becker DA, 1998, ORG SYN TH, V4, P155; Becker DA, 1996, J AM CHEM SOC, V118, P905, DOI 10.1021/ja952895z; BECKER DA, 1998, J CHEM SOC P2, V6, P1289; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 2002, J NEUROSURG, V96, P1077, DOI 10.3171/jns.2002.96.6.1077; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; BUSTO R, 1998, CEREBROVASC DIS, P287; CARNEVALE NT, 1986, BRAIN RES BULL, V16, P137, DOI 10.1016/0361-9230(86)90022-5; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHEN GM, 1990, FREE RADICAL BIO MED, V9, P93, DOI 10.1016/0891-5849(90)90110-5; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; COON JS, 1991, CANCER RES, V51, P897; Dehouck MP, 2002, BRAIN RES, V955, P229, DOI 10.1016/S0006-8993(02)03469-8; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Fujioka M, 2003, ANN NEUROL, V54, P732, DOI 10.1002/ana.10751; Ginsberg MD, 2003, ANN NEUROL, V54, P330, DOI 10.1002/ana.10659; Hensley K, 1997, INT REV NEUROBIOL, V40, P299; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; Klivenyi P, 1998, EXP NEUROL, V152, P163, DOI 10.1006/exnr.1998.6824; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Lame Mary E, 2004, Drug Metabol Drug Interact, V20, P11; Lees KR, 2003, STROKE, V34, P482, DOI 10.1161/01.STR.0000053032.14223.81; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; Liu KJ, 1999, FREE RADICAL BIO MED, V27, P82, DOI 10.1016/S0891-5849(99)00042-8; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Mojumdar SC, 2004, J ORG CHEM, V69, P2929, DOI 10.1021/jo030390i; Nath KA, 2000, AM J MED, V109, P665, DOI 10.1016/S0002-9343(00)00612-4; Novelli G P, 1986, Free Radic Res Commun, V1, P321, DOI 10.3109/10715768609080971; Reinke LA, 2000, FREE RADICAL BIO MED, V28, P345, DOI 10.1016/S0891-5849(99)00248-8; SCHOENBERG MH, 1993, CRIT CARE MED, V21, P1376, DOI 10.1097/00003246-199309000-00023; Strickley RG, 2004, PHARM RES-DORDR, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23; Strid S, 2002, EUR J CLIN PHARMACOL, V58, P409, DOI 10.1007/s00228-002-0478-x; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; Trudeau-Lame ME, 2003, DRUG METAB DISPOS, V31, P147, DOI 10.1124/dmd.31.2.147; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zhao WZ, 1996, STROKE, V27, P1112, DOI 10.1161/01.STR.27.6.1112	40	30	30	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUN	2005	313	3					1090	1100		10.1124/jpet.105.083386			11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	927OM	WOS:000229203200017	15716383				2022-02-06	
J	Chen, JJ; Tu, YJ; Connolly, EC; Ronnett, GV				Chen, JJ; Tu, YJ; Connolly, EC; Ronnett, GV			Heme oxygenase-2 protects against glutathione depletion-induced neuronal apoptosis mediated by bilirubin and cyclic GMP	CURRENT NEUROVASCULAR RESEARCH			English	Article						heme oxygenase-2; oxidative stress; bilirubin; cyclic GMP; olfaction	OLFACTORY RECEPTOR NEURONS; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; RAT-BRAIN; OXIDATIVE STRESS; CARBON-MONOXIDE; CELL-DEATH; CEREBRAL-ISCHEMIA; BILIVERDIN REDUCTASE; MESSENGER-RNA	Heme oxygenase (HO) enzymes catalyze the breakdown of heme to iron, carbon monoxide (CO), and biliverdin, which is rapidly converted to bilirubin. HO-2 has been implicated in protection against oxidative stress, ischemia, and traumatic brain injury. The neuroprotective effects of HO-2 have been attributed to the generation of bilirubin, which is an important radical scavenger. However, the mechanism by which HO-2 provides protection is unclear. We utilized the olfactory system as a model to define the roles of HO-2 in glutathione depletion-induced oxidative injury, since olfactory receptor neurons (ORNs) express high levels of HO isoforms. We demonstrated that L-buthionine-[S, R]-sulfoximine (BSO), an inhibitor of glutathione biosynthesis, lowered glutathione levels and induced apoptosis of ORNs. Despite the presence of HO-1 in ORNs, HO-2 null animals displayed increased levels of neuronal death after BSO treatment compared to wild type mice. Levels of bilirubin and cGMP were also reduced in HO-2 null mice. Primary cultures of ORNs confirmed that the neuroprotective role of HO-2 was mediated by bilirubin and cGMP. Taken together, these results suggest that HO-2 plays a major role in neuroprotection from oxidative stress, an effect that is mediated by cGMP and bilirubin.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA		Ronnett, GV (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 1006B Preclin Teaching Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	gronnett@jhmi.edu			NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-02979] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-39657] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC002979] Funding Source: NIH RePORTER		Abate C, 1990, Semin Cancer Biol, V1, P19; Arriaga SM, 1999, BBA-GEN SUBJECTS, V1473, P329, DOI 10.1016/S0304-4165(99)00201-9; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; BARGER SW, 1995, J NEUROCHEM, V64, P2087; Belanger S, 1997, BIOL NEONATE, V71, P233; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Borras D, 2000, ACTA NEUROPATHOL, V99, P402, DOI 10.1007/s004010051142; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; CALOF AL, 1989, NEURON, V3, P115, DOI 10.1016/0896-6273(89)90120-7; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen J, 2003, J NEUROCHEM, V85, P1247, DOI 10.1046/j.1471-4159.2003.01776.x; Chen JJ, 2004, DEV BIOL, V269, P165, DOI 10.1016/j.ydbio.2004.01.024; Chen JJ, 1997, NEUROREPORT, V8, P1771, DOI 10.1097/00001756-199705060-00040; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Dore S, 2000, NEUROSCIENCE, V99, P587, DOI 10.1016/S0306-4522(00)00216-5; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; EWING JF, 1993, J NEUROCHEM, V61, P1015, DOI 10.1111/j.1471-4159.1993.tb03615.x; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; FRANDSEN A, 1992, NEUROCHEM RES, V17, P35, DOI 10.1007/BF00966863; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; GARTHWAITE G, 1988, NEUROSCIENCE, V26, P321, DOI 10.1016/0306-4522(88)90148-0; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; GOPINATHAN V, 1994, FEBS LETT, V349, P197, DOI 10.1016/0014-5793(94)00666-0; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Ingi T, 1995, J NEUROSCI, V15, P8214; Knickelbein RG, 1996, AM J PHYSIOL-LUNG C, V270, pL115, DOI 10.1152/ajplung.1996.270.1.L115; KWAK JY, 1991, BIOCHIM BIOPHYS ACTA, V1076, P369, DOI 10.1016/0167-4838(91)90478-I; Le W, 1999, J NEUROSCI RES, V56, P652; LEVY EJ, 1993, P NATL ACAD SCI USA, V90, P9171, DOI 10.1073/pnas.90.19.9171; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; LOLLEY RN, 1977, SCIENCE, V196, P664, DOI 10.1126/science.193183; LUSTIG HS, 1992, BRAIN RES, V577, P343, DOI 10.1016/0006-8993(92)90295-K; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Maines MD, 1996, BRAIN RES, V722, P83, DOI 10.1016/0006-8993(96)00184-9; Margolis FL, 1980, PROTEINS NERVOUS SYS, P59; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; Meisami E, 1998, MICROSC RES TECHNIQ, V43, P476, DOI 10.1002/(SICI)1097-0029(19981215)43:6<476::AID-JEMT2>3.0.CO;2-V; MENCO B, 1992, MICROSC RES TECHNIQ, V22, P215; Mytilineou C, 2002, PARKINSONISM RELAT D, V8, P385, DOI 10.1016/S1353-8020(02)00018-4; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; RATAN RR, 1995, CLIN EXP PHARMACOL P, V22, P309, DOI 10.1111/j.1440-1681.1995.tb02006.x; RIZZARDINI M, 1994, BIOCHEM J, V304, P477, DOI 10.1042/bj3040477; RONNETT GV, 1991, J NEUROSCI, V11, P1243; ROSKAMS AJ, 1994, NEURON, V13, P289; Roskams AJI, 1998, NEUROSCIENCE, V83, P191, DOI 10.1016/S0306-4522(97)00344-8; SANO K, 1985, PEDIATR RES, V19, P587, DOI 10.1203/00006450-198506000-00017; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; SHAN XQ, 1990, PHARMACOL THERAPEUT, V47, P61, DOI 10.1016/0163-7258(90)90045-4; Simpson PJ, 2002, J NEUROSCI, V22, P5536; Simpson PJ, 2003, MOL CELL NEUROSCI, V24, P858, DOI 10.1016/S1044-7431(03)00259-8; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VERHAAGEN J, 1989, J NEUROSCI, V9, P683; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VETVICKA V, 1985, FOLIA MICROBIOL, V30, P373, DOI 10.1007/BF02927593; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; WEILL CL, 1984, NATURE, V308, P452, DOI 10.1038/308452a0; Wenisch S, 2000, HISTOCHEM J, V32, P381, DOI 10.1023/A:1004021832449; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7794; Zhang SY, 1998, BRAIN RES, V801, P101, DOI 10.1016/S0006-8993(98)00564-2; Zufall F, 1997, J NEUROSCI, V17, P2703; [No title captured]	71	30	34	0	3	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2026	1875-5739		CURR NEUROVASC RES	Curr. Neurovasc. Res.	APR	2005	2	2					121	131		10.2174/1567202053586767			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	946ZX	WOS:000230612900004	16181104				2022-02-06	
J	Ferstl, EC; Walther, K; Guthke, T; von Cramon, DY				Ferstl, EC; Walther, K; Guthke, T; von Cramon, DY			Assessment of story comprehension deficits after brain damage	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							RIGHT-HEMISPHERE; DISCOURSE COMPREHENSION; TEXT COMPREHENSION; MAIN IDEAS; INFERENCES; INJURY; MEMORY; ADULTS; DYSFUNCTION; LISTENERS	A story comprehension task was specifically developed for the clinical diagnosis of text comprehension deficits. The performance of 49 healthy control participants on qualitatively different YeslNo questions confirmed that both salience and explicitness of information had an impact on question difficulty. An unselected group of brain damaged patients (n=96) made more errors, particularly on questions about implicit information. The subgroup of patients with left-hemispheric vascular aetiology (n=18) had particular difficulties with stated details, patients with right-hemispheric vascular aetiology (n=12) with implicit main ideas, and patients with traumatic brain injury (n=34) were most impaired on implicit information. Correlations with neuropsychological test scores also confirmed that the questions successfully tapped different subprocesses of comprehension. Performance on implicit main ideas was correlated with tests of executive functions, whereas the performance on the other three question types was correlated with long-term memory and verbal learning. These results suggest that the story comprehension test is a useful diagnostic tool for neuropsychological assessment.	Max Planck Inst Human Cognit & Brain Sci, D-04103 Leipzig, Germany; Univ Leipzig, Day Clin Cognit Neurol, D-7010 Leipzig, Germany		Ferstl, EC (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Stephanstr 1A, D-04103 Leipzig, Germany.	ferstl@cbs.mpg.de					BEEMAN M, 1993, BRAIN LANG, V44, P80, DOI 10.1006/brln.1993.1006; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brookshire R. H., 1993, DISCOURSE COMPREHENS; BROOKSHIRE RH, 1984, BRAIN LANG, V21, P21, DOI 10.1016/0093-934X(84)90033-6; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; Burgess P, 1996, BEHAV ASSESSMENT DYS; CAPLAN D, 1990, BRAIN LANG, V39, P206, DOI 10.1016/0093-934X(90)90012-6; Caplan D., 1992, LANGUAGE STRUCTURE P; CHAPMAN SB, 1995, HDB NEUROLOGICAL SPE, P387; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Delis DC, 1987, CALIFORNIA VERBAL LE; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Ferstl EC, 1999, CONSTRUCTION OF MENTAL REPRESENTATIONS DURING READING, P247; Ferstl EC, 2002, NEUROPSYCHOLOGY, V16, P292, DOI 10.1037//0894-4105.16.3.292; Ferstl EC, 1999, BRAIN LANG, V70, P385, DOI 10.1006/brln.1999.2151; Ferstl EC, 2001, INT ENCY SOCIAL BEHA, V3; GERMANI MJ, 1992, BRAIN LANG, V42, P308, DOI 10.1016/0093-934X(92)90103-L; GRAESSER AC, 1994, PSYCHOL REV, V101, P371, DOI 10.1037/0033-295X.101.3.371; Guthke T., 2001, APHASIE VERWANDTE GE, V15, P29; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HAUT M W, 1990, Brain Injury, V4, P281, DOI 10.3109/02699059009026178; Horn W, 1983, LEISTUNGSPRUFSYSTEM; HOUGH MS, 1990, BRAIN LANG, V38, P253, DOI 10.1016/0093-934X(90)90114-V; HUBER W, 1984, ADV NEUROLOGY, V42; Kaczmarek B. L. J., 1987, FRONTAL LOBES REVISI, P225; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Kintsch W., 1998, COMPREHENSION PARADI; Lehman MT, 2000, APHASIOLOGY, V14, P485, DOI 10.1080/026870300401261; Lehrl S., 1991, MEHRFACHWAHL WORTSCH; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1986, BRAIN LANG, V29, P68, DOI 10.1016/0093-934X(86)90034-9; Murray LL, 1999, AM J SPEECH-LANG PAT, V8, P137, DOI 10.1044/1058-0360.0802.137; Nicholas L.E., 1995, AM J SPEECH LANGUAGE, V4, P69, DOI [DOI 10.1044/1058-0360.0403.69, 10.1044/1058-0360.0403.69]; NICHOLAS LE, 1986, J SPEECH HEAR RES, V29, P462, DOI 10.1044/jshr.2904.462; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; PIERCE RS, 1988, APHASIOLOGY, V2, P577, DOI 10.1080/02687038808248968; PRAGATANO GP, 1986, NEUROPSYCHOLOGICAL R; Ronnberg J, 1996, SCAND J PSYCHOL, V37, P46, DOI 10.1111/j.1467-9450.1996.tb00638.x; Singer M., 1994, HDB PSYCHOLINGUISTIC, P479; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; Van Dijk TA., 1983, STRATEGIES DISCOURSE; WEBSTER JS, 1992, J CLIN EXP NEUROPSYC, V14, P222, DOI 10.1080/01688639208402825; Wechsler D, 1987, MEMORY SCALE REVISED; WEGNER ML, 1984, BRAIN LANG, V21, P37, DOI 10.1016/0093-934X(84)90034-8; Welland RJ, 2002, J SPEECH LANG HEAR R, V45, P1175, DOI 10.1044/1092-4388(2002/095); Zimmermann P., 1992, TESTBATTERIE AUFMERK	50	30	32	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	2005	27	3					367	384		10.1080/13803390490515784			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	913HD	WOS:000228141300007	15969358	Green Submitted			2022-02-06	
J	McCrory, P; Johnston, K; Meeuwisse, W; Aubry, M; Cantu, R; Dvorak, J; Graf-Baumann, T; Kelly, J; Lovell, M; Schamasch, P				McCrory, P; Johnston, K; Meeuwisse, W; Aubry, M; Cantu, R; Dvorak, J; Graf-Baumann, T; Kelly, J; Lovell, M; Schamasch, P		Concussion Sport Grp	Summary and agreement statement of the Second International Conference on Concussion in Sport, Prague 2004	PHYSICIAN AND SPORTSMEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E EPSILON-4; COLLEGE FOOTBALL PLAYERS; AMYLOID BETA-PROTEIN; MINOR HEAD-INJURY; STANDARDIZED ASSESSMENT; MILD CONCUSSION; MANAGEMENT; SEVERITY; SYMPTOMS					pmccrory@bigpond.com	McCrory, Paul/Q-8688-2019				Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu R, 2004, LANCET NEUROL, V3, P437; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; *COL MED SOC SPORT, 1991, GUID MAN CONC SPORTS; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; CREMONAMEYTARD SL, 1993, LIFE CYCLE DEV MATUR, P137; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Gross R, 1997, JAMA-J AM MED ASSOC, V278, P2143, DOI 10.1001/jama.1997.03550240033025; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Katzman R, 1996, NEUROLOGY, V46, P889; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; MCCRORY P, 1996, SMA ACSP ANN SCI C 1, P214; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh TK, 1996, LAB INVEST, V74, P315; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TURNER M, 1998, JOCK CLUB C HEAD INJ, P1; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863	64	30	30	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0091-3847	2326-3660		PHYSICIAN SPORTSMED	Physician Sportsmed.	APR	2005	33	4					29	+		10.3810/psm.2005.04.76			12	Primary Health Care; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Orthopedics; Sport Sciences	913RV	WOS:000228171600005	20086357				2022-02-06	
J	Arataki, S; Tomizawa, K; Moriwaki, A; Nishida, K; Matsushita, M; Ozaki, T; Kunisada, T; Yoshida, A; Inoue, H; Matsui, H				Arataki, S; Tomizawa, K; Moriwaki, A; Nishida, K; Matsushita, M; Ozaki, T; Kunisada, T; Yoshida, A; Inoue, H; Matsui, H			Calpain inhibitors prevent neuronal cell death and ameliorate motor disturbances after compression-induced spinal cord injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; motor neuron; SCI; spinal cord; terminal deoxynucleotidyl transferase-uridine nucleotide end-labeling technique	TRAUMATIC BRAIN-INJURY; FODRIN PROTEOLYSIS; I ACTIVATION; APOPTOSIS; CASPASE-3; DEGRADATION; EXPRESSION; SURVIVAL; PRETREATMENT; RELEASE	Traumatic spinal cord injury (SCI) results in widespread neuronal cell death. Recent studies have suggested that activated calpain mediates neuronal cell death in the central nervous system. We conducted a study to determine whether calpain mediates neuronal cell death in the motor neurons of the spinal cord after SCI, and whether postinjury administration of the calpain inhibitors N-acetyl-Leu-Leu-Met-CHO (ALLM) and calpain inhibitor III (CI III) (MDL28170) reduces the motor disturbances in rats with a model of SCI. Adult male Wistar rats were subjected to SCI by application of a 20-g weight impactor probe to the spinal cord at T12 for 20 min. The rats were divided into three groups according to whether they were injected intravenously with 0.05-2.5 mg/kg ALLM, 10 mg/kg CI III, or 0.1% DMSO as a control every 24 h for I week after SCI. Calpain was activated in the spinal cord at 8 h, 24 h, and 5 days after SCI, and administration of ALLM inhibited its activation. ALLM, as compared to the DMSO vehicle alone, also significantly reduced the number of motor neurons in spinal-cord lesions that were positively labeled at 24 h after SCI with the terminal deoxynucleotidyl transferase-uridine nucleotide end-labeling (TUNEL) technique. Additionally, both the inclined plane test and footprint analysis showed markedly better motor activity after 4 weeks in rats injected with ALLM or CI III than in rats given vehicle only. These results suggest that activation of calpain plays a critical role in the neuronal cell death that follows SCI, and that calpain inhibitors may have benefit in treating the motor disturbances that follow SCI.	Okayama Univ, Grad Sch Med & Dent, Dept Physiol, Okayama, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Sci Funct Recovery & Reconstruct, Okayama, Japan		Tomizawa, K (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Physiol, 2-5-1 Shikata, Okayama, Japan.	tomikt@md.okayama-u.ac.jp	NISHIDA, Keiichiro/B-2014-2011; Tomizawa, Kazuhito/F-2405-2015	Tomizawa, Kazuhito/0000-0002-5663-2627; Nishida, Keiichiro/0000-0003-1260-586X			Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Dong HX, 2003, J NEUROSCI, V23, P8682; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; IIZUKA H, 1986, J NEUROSURG, V65, P92, DOI 10.3171/jns.1986.65.1.0092; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; IWASAKI Y, 1985, BRAIN RES, V347, P124, DOI 10.1016/0006-8993(85)90897-2; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kitagawa K, 1999, J NEUROSCI RES, V55, P643, DOI 10.1002/(SICI)1097-4547(19990301)55:5<643::AID-JNR11>3.0.CO;2-V; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; NICHOLSON DW, 1997, TRENDS BIOCHEM SCI, V22, P229; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Ray SK, 2001, BRAIN RES, V916, P115, DOI 10.1016/S0006-8993(01)02874-8; Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x; Ray SK, 2000, BRAIN RES, V867, P80, DOI 10.1016/S0006-8993(00)02260-5; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; Schaecher KE, 2001, NEUROCHEM RES, V26, P731, DOI 10.1023/A:1010903823668; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Shields DC, 1998, J NEUROSCI RES, V53, P482, DOI 10.1002/(SICI)1097-4547(19980815)53:4<482::AID-JNR10>3.0.CO;2-4; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Taoka Y, 1997, J NEUROSURG, V86, P1007, DOI 10.3171/jns.1997.86.6.1007; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Taoka Y, 1998, J NEUROSCI, V18, P1393; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; Tomizawa K, 2002, J NEUROSCI, V22, P2590, DOI 10.1523/JNEUROSCI.22-07-02590.2002; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wu HY, 2003, NEUROSCI RES, V47, P131, DOI 10.1016/S0168-0102(03)00195-0; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	38	30	35	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2005	22	3					398	406		10.1089/neu.2005.22.398			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	911QM	WOS:000228019500006	15785234	Green Submitted			2022-02-06	
J	Casanueva, FF; Leal, A; Koltowska-Haggstrom, M; Jonsson, P; Goth, MI				Casanueva, FF; Leal, A; Koltowska-Haggstrom, M; Jonsson, P; Goth, MI			Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: A KIMS-based study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; growth hormone deficiency dwarfism; head trauma; rehabilitation	POSTTRAUMATIC HYPOPITUITARISM; HEAD-INJURY; HYPOGONADISM; DYSFUNCTION; LESIONS; COMA	Objectives: To characterize further the clinical manifestations and the efficacy of growth hormone (GH) replacement therapy in patients with adult-onset growth hormone deficiency (GHD) reported in the KIMS (Pfizer's international metabolic database) as caused by traumatic brain injury (TBI) and to compare them with nonirradiated patients whose GHD was due to a nonfunctioning pituitary adenoma (NFPA). Design: Observational study. Setting: Subjects selected from the KIMS database. Participants: Fifty-one patients with GHD resulting from TBI and 688 patients with GHD resulting from NFPA. Both groups were selected from the KIMS and had adult-onset GHD with GH replacement therapy only after KIMS entry and before and after KIMS entry. Interventions: Not applicable. Main Outcome Measures: Age, body mass index, age at disease onset, age at disease diagnosis, age at KIMS entry, final height, GH peak at testing, GH replacement dose, routine biochemical analysis, clinical manifestations of disease, and quality of life measurements. Results: Patients with TBI were significantly younger at study entry and were younger both at pituitary disease onset and at GHD diagnosis, but they showed a significant delay in treatment. When comparing patients not treated with GH before entering in the KIMS, patients with TBI were significantly shorter (167.2 +/- 1.7cm) than those with NFPA (171.6 +/- 0.4cm) in final height. TBI patients had lower GH reserves than NFPA patients, and although the latter group experienced more positive changes, both groups benefited from GH replacement therapy. Conclusions: Patients with GHD due to TBI showed a significant reduction in height and a reduction in pituitary GH reserve and were diagnosed and treated with inappropriate delay. (C) 2005 by American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Santiago de Compostela, Univ Santiago, Complejo Hosp, Santiago De Compostela, Spain; Univ Santiago de Compostela, Sch Med, Dept Med, Endocrine Sect, Santiago De Compostela, Spain; Hosp Virgen Rocio, Div Endocrinol, Seville, Spain; Pharma AB, Outcomes Res, KIMS, KIGS, Stockholm, Sweden; Natl Med Ctr, Dept Med, Budapest, Hungary		Casanueva, FF (corresponding author), POB 563, E-15780 Santiago De Compostela, Spain.	endocrine@usc.es					ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; CASTANER MF, 1981, MED CLIN, V78, P358; Ceballos R, 1966, Ala J Med Sci, V3, P185; Centers for Disease Control and Prevention, 2003, TRAUM BRAIN INJ US R; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; DANIEL PM, 1961, MOD TRENDS ENDOCRINO, V2, P55; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; GUNN IR, 1991, ANN CLIN BIOCHEM, V28, P327, DOI 10.1177/000456329102800402; GUZMAN AL, 1992, ACTA PAEDIATR, V81, P698, DOI 10.1111/j.1651-2227.1992.tb12337.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lieberman SA, 1996, J PEDIATR-US, V128, pS58, DOI 10.1016/S0022-3476(96)70013-6; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCGAULEY GA, 1990, HORM RES, V33, P52, DOI 10.1159/000181584; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; PORTER RJ, 1948, J NEUROL NEUROSUR PS, V11, P258, DOI 10.1136/jnnp.11.4.258; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306; WITTER M, 1957, FORTSCHR NEUROL PSYC, V25, P523	31	30	33	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2005	86	3					463	468		10.1016/j.apmr.2004.05.018			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	904DB	WOS:000227475200017	15759229				2022-02-06	
J	Land, PW; Aizenman, E				Land, PW; Aizenman, E			Zinc accumulation after target loss: an early event in retrograde degeneration of thalamic neurons	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; kainate; lateral geniculate nucleus; rodent; target deprivation	LATERAL GENICULATE-NUCLEUS; NITRIC-OXIDE; CELL-DEATH; TRANSCRIPTION FACTOR; INTRACELLULAR ZINC; CEREBRAL-ISCHEMIA; INDUCED APOPTOSIS; OXIDATIVE STRESS; VISUAL-CORTEX; KAINIC ACID	Accumulation of cytoplasmic zinc is linked with a cascade of events leading to neuronal death. In many in vivo models of zinc-induced cell death, toxic concentrations of synaptically released zinc enter vulnerable neurons via neurotransmitter- or voltage-gated ion channels. In vitro studies demonstrate, in addition, that zinc can be liberated from intracellular stores following oxidative stress and contribute to cell death processes, including apoptosis. Here we describe accumulation of intracellular zinc in an in vivo model of cell death in the absence of presynaptic zinc release. We focused on the lateral geniculate nucleus (LGN) because LGN neurons undergo apoptosis when separated from their target, the primary visual cortex (V1), and the LGN is mostly devoid of zinc-containing presynaptic terminals. Infant and adult rats and adult mice received unilateral ablation of V1, either by aspiration or kainate injection. One to 14 days later, brain sections were stained with selenium autometallography or fluorescently labeled to localize zinc, or stained immunochemically for activated caspase-3. V1 lesions led to zinc accumulation in LGN neurons in infant and adult subjects. Zinc-containing neurons were evident 1-3 days after aspiration lesions, depending on age, but not until 14 days after kainate injection. Zinc accumulation was followed rapidly by immunostaining for activated caspase-3. Our data indicate that like neurotrauma and excitotoxicity, target deprivation leads to accumulation of zinc in apoptotic neurons. Moreover, zinc accumulation in vivo can occur in the absence of presynaptic zinc release. Together these findings suggest that accumulation of intracellular zinc is a ubiquitous component of the cell death cascade in neurons.	Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Ctr Neurosci, Pittsburgh, PA 15261 USA		Land, PW (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA.	pland@pitt.edu	Aizenman, Elias/K-2726-2012	Aizenman, Elias/0000-0001-9610-4194	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043277, R56NS043277] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS043277-10, R01 NS043277-07A2, R01 NS043277, R01 NS043277-03, R56 NS043277, R56 NS043277-06, R01 NS043277-08, R01 NS043277-09, NS43277] Funding Source: Medline		Agarwala S, 1998, J COMP NEUROL, V392, P264; Agarwala S, 1998, J COMP NEUROL, V392, P252, DOI 10.1002/(SICI)1096-9861(19980309)392:2<252::AID-CNE7>3.0.CO;2-1; Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Al-Abdulla NA, 1998, NEUROSCIENCE, V86, P191, DOI 10.1016/S0306-4522(98)00014-1; Al-Abdulla NA, 2002, NEUROSCIENCE, V115, P7, DOI 10.1016/S0306-4522(02)00363-9; Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Burdette SC, 2003, J AM CHEM SOC, V125, P1778, DOI 10.1021/ja0287377; Casanovas-Aguilar C, 1998, J CHEM NEUROANAT, V15, P97, DOI 10.1016/S0891-0618(98)00035-0; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CUNNINGHAM TJ, 1979, J COMP NEUROL, V184, P423, DOI 10.1002/cne.901840213; DANSCHER G, 1982, HISTOCHEMISTRY, V76, P281, DOI 10.1007/BF00543951; DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; DYCK R, 1993, J COMP NEUROL, V329, P53, DOI 10.1002/cne.903290105; EAGLESON KL, 1990, EXP NEUROL, V110, P284, DOI 10.1016/0014-4886(90)90040-Y; EAGLESON KL, 1992, EXP NEUROL, V116, P156, DOI 10.1016/0014-4886(92)90163-K; Estevez AG, 1998, J NEUROSCI, V18, P923; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; Frederickson CJ, 2004, J NEUROSCI METH, V139, P79, DOI 10.1016/j.jneumeth.2004.04.033; Frederickson CJ, 2002, NEUROSCIENCE, V115, P471, DOI 10.1016/S0306-4522(02)00399-8; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GARRETT B, 1992, ANAT EMBRYOL, V186, P487; Hara H, 2004, J NEUROSCI METH, V137, P175, DOI 10.1016/j.jneumeth.2004.02.018; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; JONES KJ, 1986, J NEUROCYTOL, V15, P197, DOI 10.1007/BF01611656; Koh JY, 2001, MOL NEUROBIOL, V24, P99, DOI 10.1385/MN:24:1-3:099; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Land PW, 1999, SOMATOSENS MOT RES, V16, P139; Lashley KS, 1941, J COMP NEUROL, V75, P67, DOI 10.1002/cne.900750105; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lee JY, 2000, J NEUROSCI, V20; LEES GJ, 1989, ACTA NEUROPATHOL, V77, P519, DOI 10.1007/BF00687254; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; Martin LJ, 2001, J COMP NEUROL, V433, P299, DOI 10.1002/cne.1141; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MATTHEWS MA, 1973, J NEUROCYTOL, V2, P265, DOI 10.1007/BF01104030; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; McLaughlin B, 2001, J NEUROSCI, V21, P3303, DOI 10.1523/JNEUROSCI.21-10-03303.2001; Mengual E, 2001, NEUROSCIENCE, V102, P863, DOI 10.1016/S0306-4522(00)00472-3; Pal S, 2004, PFLUG ARCH EUR J PHY, V448, P296, DOI 10.1007/s00424-004-1256-7; Pal S, 2003, J NEUROSCI, V23, P4798; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; Pandey S, 2003, APOPTOSIS, V8, P497, DOI 10.1023/A:1025542424986; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Repici M, 2003, NEUROSCIENCE, V117, P859, DOI 10.1016/S0306-4522(02)00968-5; Riba-Bosch A, 2004, NEUROSCIENCE, V125, P803, DOI 10.1016/j.neuroscience.2004.02.017; SCHWARCZ R, 1977, BRAIN RES, V127, P235, DOI 10.1016/0006-8993(77)90538-8; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; VONGUDDEN B, 1870, ARCH PSYCHIAT NERVEN, V2, P693; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x	59	30	31	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2005	21	3					647	657		10.1111/j.1460-9568.2005.03903.x			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	906OU	WOS:000227652300005	15733083	Green Accepted			2022-02-06	
J	Katz, S; Kravetz, S; Grynbaum, F				Katz, S; Kravetz, S; Grynbaum, F			Wives' coping flexibility, time since husbands' injury and the perceived burden of wives of men with traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; FAMILY; RELATIVES; STRESS; PERSPECTIVE; CHILDREN; ADULTS; IMPACT	Primary objective: To examine the moderating effect of wives' coping flexibility on the relation between time since husband's traumatic brain injury (TBI) and wives' perceived burden and the hypotheses that wives of long duration TBI men and wives with less coping flexibility will express more burden than wives of short duration burden men and wives with more coping flexibility. Research design: Forty-four wives whose husbands had sustained brain injury were interviewed 1 year or more after hospital discharge. Methods and procedures: The Relatives' Burden Questionnaire and Ways of Coping Questionnaire for each of four different problem vignettes were administered to the wives. Main findings and conclusions: No statistically significant effects were found for TBI duration or for wives' coping flexibility, although longer duration TBI wives reported a statistically significant higher level of burden than short duration TBI wives, only if the wives were characterized by low coping flexibility.	Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel		Katz, S (corresponding author), Bar Ilan Univ, Dept Psychol, IL-52900 Ramat Gan, Israel.	katzsh2@mail.biu.ac.il					ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Block JH, 1980, MINNESOTA S CHILD PS, V13, P39; Brislin R.W., 1980, METHODOLOGY-EUR, V2, P389; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; BROWN BW, 1988, FAM RELAT, V37, P12, DOI 10.2307/584423; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; DAY AM, 1988, REHABIL PSYCHOL, V33, P113; DELORTO AE, 2000, BRAIN INJURY FAMILY; FELTON BJ, 1984, SOC SCI MED, V18, P889, DOI 10.1016/0277-9536(84)90158-8; FLEISHMAN JA, 1984, J HEALTH SOC BEHAV, V25, P229, DOI 10.2307/2136671; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Florian V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; FOLKMAN S, 1985, J PERS SOC PSYCHOL, V48, P150, DOI 10.1037/0022-3514.48.1.150; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Haan N., 1977, COPING DEFENDING PRO; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HOOFIEN D, 1993, FUNCTIONING ADULT PE; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KATZ S, 1990, MONOGRAPH WORLD REHA, V45; KIDARDARDASHTI M, 1991, THESIS BAR ILAN U RA; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Krohne HW., 1986, DYNAMICS STRESS PHYS, P207, DOI [10.1007/978-1-4684-5122-1_11, DOI 10.1007/978-1-4684-5122-1_11]; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEARY TF, 1975, INTERPERSONAL DIAGNO; LESTER N, 1994, PSYCHOL HEALTH, V9, P409, DOI 10.1080/08870449408407468; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MARTIN DA, 1988, J LEARN DISABIL, V21, P464, DOI 10.1177/002221948802100803; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; Perlesz A, 1998, INT J REHABIL RES, V21, P339, DOI 10.1097/00004356-199812000-00001; PERLESZ A, 1989, RECOVERY BRAIN INJUR, P180; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; POWER PW, 1985, REHABIL LIT, V46, P78; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SCHWARZ CE, 1990, THESIS HARVARD BOSTO; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vaillant G. E., 1977, ADAPTATION LIFE; VANUNUYAACOBI A, 1986, THESIS BAR ILAN U RA; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; [No title captured], DOI DOI 10.1097/00001199-198812000-00004	49	30	30	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2005	19	1					59	66		10.1080/02699050410001719970			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	875AS	WOS:000225392600006	15762101				2022-02-06	
J	Leone, M; Albanese, J; Viviand, X; Garnier, F; Bourgoin, A; Barrau, K; Martin, C				Leone, M; Albanese, J; Viviand, X; Garnier, F; Bourgoin, A; Barrau, K; Martin, C			The effects of remifentanil on endotracheal suctioning-induced increases in intracranial pressure in head-injured patients	ANESTHESIA AND ANALGESIA			English	Article							CEREBRAL-BLOOD-FLOW; PREVENTING INCREASES; DOSE REMIFENTANIL; PHARMACODYNAMICS; PHARMACOKINETICS; REACTIVITY; ALFENTANIL; FENTANYL	In patients with severe traumatic brain injury, bronchotracheal toilet may be accompanied by deleterious variations in intracranial pressure (ICP). To avoid these effects, IV opioids have been proposed. Twenty mechanically-ventilated patients received 3 ascending IV doses of remifentanil: dose 1 (1 mug/kg bolus, 0.25 mug/kg/min infusion); dose 2 (2 mug/kg bolus, 0.5 mug/kg/min infusion); and dose 3: (4 mug/kg bolus, 1 mug/kg/min infusion). Endotracheal suction was performed 20 min after the beginning of infusion to assess coughing. Heart rate, ICP, mean arterial blood pressure (MAP), cerebral perfusion pressure (CPP), middle cerebral artery mean flow velocity (V-MCA), and bispectral index were monitored throughout the 30-min study period. Twelve, 15, and 19 patients receiving dose 1, 2, and 3, respectively, required vasopressors to maintain CPP >60 mm Hg. Suctioning resulted in coughing in 16,15, and 5 patients receiving dose 1, 2, and 3, respectively. An increase in ICP, without change in VMCA, corresponded to the reduction in MAP consistent with the preservation of autoregulation. Remifentanil used as a continuous infusion in head-injured patients is not an effective drug to block responses to suctioning.	Washington Univ, Sch Med, Dept Anesthesiol & Crit Care Med, St Louis, MO 63110 USA; Marseilles Univ Hosp Syst, Nord Hosp, Intens Care Unit, Marseille, France; Marseilles Univ Hosp Syst, Nord Hosp, Dept Anesthesiol, Marseille, France; Marseilles Univ Hosp Syst, Nord Hosp, Dept Biostat & Epidemiol, Marseille, France; Marseilles Sch Med, Marseille, France		Leone, M (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Box 8054,660 S Euclid Ave, St Louis, MO 63110 USA.	leonem@msnotes.wustl.edu	Albanese, Jacques/AAS-7466-2021; Leone, Marc/P-4835-2016	Leone, Marc/0000-0002-3097-758X; Baumstarck, Karine/0000-0003-3602-6766			Abdallah C, 2002, CAN J ANAESTH, V49, P1070, DOI 10.1007/BF03017905; ARMITAGE P, 2002, STAT METHODS MED RES, P727; DUPONT WD, 2003, STAT MODELING BIOMED, P345; Egan TD, 1996, ANESTHESIOLOGY, V84, P821, DOI 10.1097/00000542-199604000-00009; Gemma M, 2002, J NEUROSURG ANESTH, V14, P50, DOI 10.1097/00008506-200201000-00010; Glass PSA, 1999, ANESTH ANALG, V89, pS7, DOI 10.1097/00000539-199910001-00003; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Guignard B, 2000, ANESTH ANALG, V90, P161, DOI 10.1097/00000539-200001000-00034; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014; JAMES MK, 1992, J PHARMACOL EXP THER, V263, P84; Kerr ME, 1999, CRIT CARE MED, V27, P2776, DOI 10.1097/00003246-199912000-00028; Klimscha W, 2003, ANESTHESIOLOGY, V99, P834, DOI 10.1097/00000542-200310000-00014; Lorenz IH, 2000, BRIT J ANAESTH, V85, P199, DOI 10.1093/bja/85.2.199; Lorenz IH, 2003, BRIT J ANAESTH, V90, P296, DOI 10.1093/bja/aeg055; Minto CF, 1997, ANESTHESIOLOGY, V86, P24, DOI 10.1097/00000542-199701000-00005; Myre K, 2003, ACTA ANAESTH SCAND, V47, P267, DOI 10.1034/j.1399-6576.2003.00073.x; Ostapkovich ND, 1998, ANESTHESIOLOGY, V89, P358, DOI 10.1097/00000542-199808000-00011; Paris A, 1998, ANESTH ANALG, V87, P569, DOI 10.1097/00000539-199809000-00013; Patel SS, 1996, DRUGS, V52, P417, DOI 10.2165/00003495-199652030-00009; RUDY EB, 1991, HEART LUNG, V20, P667; Shinohara K, 2000, CAN J ANAESTH, V47, P361, DOI 10.1007/BF03020954; Tipps LB, 2000, NEUROSURGERY, V46, P596, DOI 10.1097/00006123-200003000-00015; Warner DS, 1996, ANESTH ANALG, V83, P348, DOI 10.1097/00000539-199608000-00025; WHITE PF, 1982, ANESTHESIOLOGY, V57, P242, DOI 10.1097/00000542-198209000-00019; YANO M, 1986, ANESTHESIOLOGY, V64, P651, DOI 10.1097/00000542-198605000-00019	26	30	33	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2004	99	4					1193	1198		10.1213/01.ANE.0000132546.79769.91			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	856IW	WOS:000224039900043	15385374				2022-02-06	
J	Minoyama, O; Tsuchida, H				Minoyama, O; Tsuchida, H			Injuries in professional motor car racing drivers at a racing circuit between 1996 and 2000	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article								Background: Research on injuries in racing drivers is limited. Objective: To gain more information about such injuries. Methods: Injuries recorded during and after races between 1996 and 2000 were investigated using the medical charts from the circuit medical centre at Fuji Speedway, which is one of the biggest circuits in Japan. Races were in either single seat/formula cars or saloon cars. Results: Data were obtained from 39 races in single seat cars (1030 participating cars) and 42 races in saloon cars (1577 cars). Fifty injuries were recorded during the single seat car races, and 62 during the saloon car races (injury rate 1.2 per 1000 competitors per race and 0.9 per 1000 competitors per race respectively). Thirteen injuries were recorded after the race, 12 of them in saloon car racing. Bruises were the major injury in single seat car racing (58%). Lower limb bruising was more common than upper limb bruising. Most of the injuries in saloon car racing (53.2%) were neck sprains. The incidence of concussion was high in both groups compared with other high risk sports. Conclusions: There were some differences in injuries between the two types of car. No serious injuries occurred except for one death. However, the driver's body is subjected to large forces in a crash, hence the high incidence of concussion. The injuries recorded after the race emphasise that motor racing is a demanding sport.	Fuji Toranomon Orthopaed Hosp, Ctr Sports Med, Gotemba, Shizuoka 4120045, Japan		Minoyama, O (corresponding author), Fuji Toranomon Orthopaed Hosp, Ctr Sports Med, 1067-1 Kawashimada, Gotemba, Shizuoka 4120045, Japan.	msportsdr@aol.com					*ASS ADV AUT MED, ABBR INJ SCAL AIS 19; Burton A K, 1983, Br J Sports Med, V17, P150; BURTON AK, 1987, APPL ERGON, V18, P3, DOI 10.1016/0003-6870(87)90064-0; Chapman M A, 1991, Br J Sports Med, V25, P121; Chesser TJS, 1999, INJURY, V30, P293, DOI 10.1016/S0020-1383(99)00086-8; Hunter H C, 1996, J Am Osteopath Assoc, V96, P179; Jareno A, 1987, Br J Sports Med, V21, P48; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Mansfield NJ, 2001, BRIT J SPORT MED, V35, P314, DOI 10.1136/bjsm.35.5.314; Masmejean EH, 1999, BRIT J SPORT MED, V33, P270, DOI 10.1136/bjsm.33.4.270; NAHUM AM, 1993, ACCIDENTAL INJURY BI, P247; Videman T, 2000, CLIN BIOMECH, V15, P83, DOI 10.1016/S0268-0033(99)00047-9; WATKINS S, 1996, LIFE LIMIT TRIUMPH T, P188; YOGANANDAN N, 1989, 33 STAPP CAR CRASH C, P22	14	30	31	2	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	OCT 1	2004	38	5					613	616		10.1136/bjsm.2003.007674			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	856PE	WOS:000224056300020	15388550	Bronze, Green Published			2022-02-06	
J	Chiaretti, A; Antonelli, A; Piastra, M; Genovese, O; Polidori, G; Aloe, L				Chiaretti, A; Antonelli, A; Piastra, M; Genovese, O; Polidori, G; Aloe, L			Expression of neurotrophic factors in cerebrospinal fluid and plasma of children with viral and bacterial meningoencephalitis	ACTA PAEDIATRICA			English	Article						brain-derived neurotrophic factor; child; glial-derived neurotrophic factor; meningoencephalitis; nerve growth factor	NERVE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; TRKB RECEPTOR EXPRESSION; TYROSINE KINASE TRKA; UP-REGULATION; CELLS; PHOSPHORYLATION; INTERLEUKIN-6; MENINGITIS; DEATH	Aim: To evaluate the expression of neurotrophic factors (nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF)) and their association with the clinical-radiological characteristics and outcome of children with viral and bacterial meningoencephalitis (ME). Methods: Prospective observational clinical study performed on 13 children with ME and 12 controls with non-inflammatory obstructive hydrocephalus. Neurotrophic factor levels in the cerebro-spinal fluid (CSF) and plasma were measured using an immunoenzymatic assay. Results: High levels of NGF and BDNF were demonstrated in all patients, while GDNF levels did not undergo significant variations. NGF expression in the CSF was higher in viral ME than in bacterial ME and was correlated with CSF cellularity (particularly mononuclear cells). BDNF expression in the CSF was higher in bacterial ME than in viral ME and was correlated with CSF cellularity and blood platelet count. No relationships were noted between CSF protein or serum C-reactive protein levels and the expression of neurotrophic factors. Regarding clinical and radiological features, elevated NGF/BDNF levels in the CSF correlated with higher incidence of seizures and prolonged comatose state and with specific radiological lesions. No correlation was found between NGF/BDNF levels and final outcome. Conclusions: The variations in neurotrophic factor levels may reflect an endogenous attempt at neuroprotection against biochemical and molecular changes during both viral and bacterial ME. The expression of these factors is likely to play a neuro-immunomodulatory or neurosurvival role in ME infections.	Catholic Univ, Sch Med, Paediat Intens Care Unit, Rome, Italy; CNR, Inst Neurobiol, Rome, Italy		Chiaretti, A (corresponding author), Policlin Gemelli, IT-00168 Rome, Italy.	achiaretti@yahoo.it		GENOVESE, Orazio/0000-0002-1989-1363			Aronica E, 2001, ACTA NEUROPATHOL, V101, P383; Azmitia EC, 2001, BRAIN DEV-JPN, V23, pS1, DOI 10.1016/S0387-7604(01)00368-0; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BRDE YA, 1994, PROG CLIN BIOL RES, V390, P1855; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Kanai M, 2002, TOHOKU J EXP MED, V196, P241, DOI 10.1620/tjem.196.241; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; Kim JY, 2002, EPILEPSIA, V43, P220, DOI 10.1046/j.1528-1157.43.s.5.33.x; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Lappalainen R, 1996, J CHILD NEUROL, V11, P296, DOI 10.1177/088307389601100407; Laurenzi MA, 1998, J LEUKOCYTE BIOL, V64, P228, DOI 10.1002/jlb.64.2.228; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Marz P, 1999, GLIA, V26, P191, DOI 10.1002/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#; Mizuno Y, 2000, J CHILD NEUROL, V15, P19, DOI 10.1177/088307380001500104; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; Qiao LY, 2002, J COMP NEUROL, V454, P200, DOI 10.1002/cne.10447; Qiao LY, 2002, J COMP NEUROL, V449, P217, DOI 10.1002/cne.10283; Santer R, 1996, ACTA PAEDIATR, V85, P902, DOI 10.1111/j.1651-2227.1996.tb14181.x; Seguier-Lipszyc E, 2001, J UROLOGY, V165, P2269, DOI 10.1016/S0022-5347(05)66182-4; Sherwood ER, 2000, CRIT CARE MED, V28, P1221, DOI 10.1097/00003246-200004000-00054; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Suzaki I, 1997, J CHILD NEUROL, V12, P205, DOI 10.1177/088307389701200310; Tokunaga Y, 2002, PEDIATR NEUROL, V27, P102, DOI 10.1016/S0887-8994(02)00387-9	30	30	31	0	2	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0803-5253			ACTA PAEDIATR	Acta Paediatr.	SEP	2004	93	9					1178	1184		10.1080/08035250410031314			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	850OE	WOS:000223621500010	15384880				2022-02-06	
J	Scott, GS; Szabo, C; Hooper, DC				Scott, GS; Szabo, C; Hooper, DC			Poly (ADP-ribse) polymerase activity contributes to peroxynitrite-induced spinal cord neuronal cell death in vitro	JOURNAL OF NEUROTRAUMA			English	Article						neurotoxicity; peroxynitrite; poly(ADP-ribose) polymerase; spinal cord injury	TRAUMATIC BRAIN-INJURY; DNA STRAND BREAKAGE; POLY(ADP-RIBOSE) POLYMERASE; NITRIC-OXIDE; ENERGY DEPLETION; ACTIVATION; INHIBITORS; SYNTHETASE; NICOTINAMIDE; NAD(+)	Peroxynitrite, which has been implicated in secondary neuronal damage resulting from spinal cord injury, is capable of mediating several toxic interactions including inducing DNA strand breaks and activating the nuclear enzyme, poly (ADP-ribose) polymerase (PARP). In the present study we have tested the hypothesis that peroxynitrite-induced cell death in spinal cord injury is due to activation of PARP. Initially we examined whether peroxynitrite exerts toxic effects on primary cultures of spinal cord neurons and then determined whether the spinal cord neuronal cell death triggered by peroxynitrite was associated with PARP activation. Peroxynitrite dose-dependently reduced the viability of spinal cord neurons in vitro. Furthermore, peroxynitrite exposure markedly increased the number of DNA strand breaks in primary spinal cord neurons, resulting in activation of PARP. To identify whether PARP activation plays a direct role in peroxynitrite-induced neurotoxicity we assessed the effects of the PARP inhibitors, nicotinamide, 3-aminobenzamide and 5-iodo-6-amino-1,2 benzopyrone on cell viability in spinal cord neurons exposed to peroxynitrite. The presence of the PARP inhibitors in the cultures not only inhibited peroxynitrite-induced PARP activity in spinal cord neurons but also protected the cells from the deleterious actions of peroxynitrite. Therefore, our results demonstrate that peroxynitrite exerts toxic effects on spinal cord neurons in vitro at least in part through a PARP-dependent pathway.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Barts & London Queen Marys Sch Med & Dent, William Harvey Res Inst, Dept Biochem Pharmacol, London, England; Inotek Pharmaceut Corp, Beverly, MA USA		Hooper, DC (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, 1020 Locust St, Philadelphia, PA 19107 USA.	c_hooper@mail.jci.tju.edu	Szabo, Csaba/D-1882-2013; Szabo, Csaba/ABG-2644-2021	Hooper, Douglas/0000-0002-8578-5104	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS037985] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44 NS 037985] Funding Source: Medline		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bao F, 2002, NEUROSCIENCE, V115, P839, DOI 10.1016/S0306-4522(02)00506-7; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BOLANOS JP, 1994, J NEUROCHEM, V63, P910; BREWER KL, 2003, ACAD EMERG MED, V10, P464; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Chiarugi A, 2002, BRIT J PHARMACOL, V137, P761, DOI 10.1038/sj.bjp.0704934; Colak A, 2003, J NEUROSURG, V98, P275, DOI 10.3171/spi.2003.98.3.0275; Cole KK, 2002, J NEUROCHEM, V82, P19, DOI 10.1046/j.1471-4159.2002.00935.x; Cookson MR, 1998, J NEUROCHEM, V70, P501; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Cosi C, 1996, BRAIN RES, V729, P264, DOI 10.1016/0006-8993(96)00571-9; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; DEMURCIA G, 1986, J BIOL CHEM, V261, P7011; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Keller JN, 1998, REV NEUROSCIENCE, V9, P105; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEDOUX SP, 1988, DIABETES, V37, P1015, DOI 10.2337/diabetes.37.8.1015; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247; Mandir AS, 2000, J NEUROSCI, V20, P8005; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Moroni F, 2001, CELL DEATH DIFFER, V8, P921, DOI 10.1038/sj.cdd.4400884; Nakazawa H, 2000, FREE RADICAL RES, V33, P771, DOI 10.1080/10715760000301291; PFLUEGER E, 1990, J IMMUNOL METHODS, V129, P165, DOI 10.1016/0022-1759(90)90436-Y; RALEY KM, 1990, NEUROSCI LETT, V110, P118, DOI 10.1016/0304-3940(90)90798-E; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2003, GLIA, V41, P105, DOI 10.1002/glia.10137; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Szabo C, 2003, TOXICOL LETT, V140, P105, DOI 10.1016/S0378-4274(02)00507-6; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; SZABO C, 2000, CELL DEATH ROLE PARP; TANUMA SI, 1978, EXP CELL RES, V117, P421, DOI 10.1016/0014-4827(78)90155-6; Toborek M, 1999, J NEUROCHEM, V73, P684, DOI 10.1046/j.1471-4159.1999.0730684.x; UETA K, 1985, ANNU REV BIOCHEM, V54, P73; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WALLIS RA, 1993, NEUROREPORT, V5, P245; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1996, J IMMUNOL, V156, P350	55	30	32	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1255	1263		10.1089/neu.2004.21.1255			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900013	15453994				2022-02-06	
J	Hoane, MR; Lasley, LA; Akstulewicz, SL				Hoane, MR; Lasley, LA; Akstulewicz, SL			Middle age increases tissue vulnerability and impairs sensorimotor and cognitive recovery following traumatic brain injury in the rat	BEHAVIOURAL BRAIN RESEARCH			English	Article						aging; recovery of function; traumatic brain injury; rat; behavior; cognition	FACILITATE RECOVERY; FUNCTIONAL RECOVERY; MAGNESIUM THERAPY; NMDA ANTAGONISTS; CORTEX LESIONS; WATER MAZE; DEFICITS; ATROPHY; MODEL	With increasing age comes an increased risk for sustaining traumatic brain injuries (TBI). However, the effect of age is rarely studied in animal models of TBI. The present study evaluated the effect of increased age on recovery of function following bilateral medial frontal cortex injury. Groups of young (3 months) and middle-aged (14 months) rats received bilateral frontal cortex contusions or sham injuries. The rats were tested on a variety of tests to measure sensorimotor performance (bilateral tactile adhesive removal test), skilled forelimb use (staircase test), and the acquisition of reference and working memory in the Morris water maze. Results indicated that injury produced significant impairments on all behavioral tests compared to sham controls. Middle-aged rats that received cortical contusions were significantly impaired on the bilateral tactile adhesive removal test, acquisition of a reference memory task, and working memory compared to young-injured rats. Histological analysis showed that middle-aged rats developed significantly larger lesion cavities but did not show an increase in the number of glial fibrillary acidic protein (GFAP(+)) cells compared to young-injured rats. Age alone also significantly impaired function on the bilateral adhesive tactile removal test, skilled forelimb use, the acquisition of a reference memory task, and also increased the number of GFAP(+) cells compared to young rats. These results indicate that middle-aged rats respond to brain injury differently than young rats and that age is an important factor to consider in pre-clinical efficacy studies. (C) 2003 Elsevier B.V. All rights reserved.	E Carolina Univ, Dept Psychol, Brain Injury Lab, Greenville, NC 27858 USA; E Carolina Univ, Program Neurosci, Greenville, NC 27858 USA		Hoane, MR (corresponding author), E Carolina Univ, Dept Psychol, Brain Injury Lab, Rawl 217, Greenville, NC 27858 USA.	hoanem@mail.ecu.edu; lasleyl@mail.ecu.edu; akstulewicza@mail.ecu.edu		Hoane, Michael/0000-0001-7779-2657			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Albeck D, 2003, BRAIN RES, V967, P306, DOI 10.1016/S0006-8993(03)02272-8; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; BARTH TM, 1990, STROKE, V21, P153; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Lifshitz J, 2003, J NEUROTRAUM, V20, P139, DOI 10.1089/08977150360547062; Lindner MD, 1997, NEUROBIOL LEARN MEM, V68, P203, DOI 10.1006/nlme.1997.3782; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lindner MD, 1999, BEHAV BRAIN RES, V102, P1, DOI 10.1016/S0166-4328(98)00160-0; Mukherjee SK, 1997, MOL CHEM NEUROPATHOL, V32, P59, DOI 10.1007/BF02815167; Paxinos G, 1997, RAT BRAIN STEREOTAXI; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Sandhu SK, 2002, BIOGERONTOLOGY, V3, P161, DOI 10.1023/A:1015643107449; SCHEFF SW, 2002, J NEUROTRAUM, V19, P1340; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tsay HJ, 2000, J BIOMED SCI, V7, P466; UNTERBERG A, 1994, ACTA NEUROCHIR, P431; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	33	30	31	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	AUG 12	2004	153	1					189	197		10.1016/j.bbr.2003.11.012			9	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	840ST	WOS:000222880600021	15219720				2022-02-06	
J	Robertson, CL; Bucci, CJ; Fiskum, G				Robertson, CL; Bucci, CJ; Fiskum, G			Mitochondrial response to calcium in the developing brain	DEVELOPMENTAL BRAIN RESEARCH			English	Article						cytochrome c; brain mitochondria; development; acidosis	IMMATURE RAT-BRAIN; CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; HYPOXIA-ISCHEMIA; CELL-DEATH; CEREBRAL-ISCHEMIA; LIVER MITOCHONDRIA; FOREBRAIN ISCHEMIA; LACTIC-ACIDOSIS; HEAD TRAUMA	Developmental differences in mitochondrial content and metabolic enzyme activities have been defined, but less is understood about the responses of brain mitochondria to stressful stimuli during development. Cerebral mitochondrial response to high Ca2+ loads after brain injury is a critical determinant of neuronal outcome. Brain mitochondria isolated from 16-18-day-old rats had lower maximal, respiration-dependent Ca2+ uptake capacity than brain mitochondria isolated from adult rats in the presence of ATP at both a pH of 7.0 and 6.5. However, in the absence of ATP, immature brain mitochondria exhibited greater Ca2+ uptake capacity at pH 7.0 and 6.5, indicating a greater resistance of immature brain mitochondria to Ca2+-induced dysfunction under conditions relevant to those that exist during acute ischemic and traumatic brain injury. Acidosis reduced the maximal Ca2+ uptake capacity in both immature and adult brain mitochondria. Cytochrome c was released from both immature and adult brain mitochondria, in response to Ca2+ exposure, but was not affected by cyclosporin A, an inhibitor of the mitochondrial membrane permeability transition. Developmental changes in mitochondrial response to Ca2+ loads may have important implications in the pathobiology of brain injury to the developing brain. (C) 2004 Elsevier B.V. All rights reserved.	Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA		Robertson, CL (corresponding author), Univ Maryland, Sch Med, Dept Pediat, 22 S Greene St,S5D18, Baltimore, MD 21201 USA.	croberts@peds.umaryland.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01 HD16596] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS34152, K08 NS42805] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805, R01NS034152] Funding Source: NIH RePORTER		AKERMAN KEO, 1978, ARCH BIOCHEM BIOPHYS, V189, P256, DOI 10.1016/0003-9861(78)90211-4; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Budd SL, 1996, J NEUROCHEM, V67, P2282; Chinopoulos C, 2003, J BIOL CHEM, V278, P27382, DOI 10.1074/jbc.M303808200; DIENEL G, 1977, BIOCHIM BIOPHYS ACTA, V496, P484, DOI 10.1016/0304-4165(77)90330-0; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gilland E, 1998, J CEREBR BLOOD F MET, V18, P297, DOI 10.1097/00004647-199803000-00008; GREENAWALT JW, 1964, J CELL BIOL, V23, P21, DOI 10.1083/jcb.23.1.21; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HILLERED L, 1984, J CEREBR BLOOD F MET, V4, P430, DOI 10.1038/jcbfm.1984.62; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; HOLTZMAN D, 1975, J NEUROCHEM, V24, P1011, DOI 10.1111/j.1471-4159.1975.tb03670.x; HOLTZMAN D, 1973, BIOL NEONATE, V22, P230; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; Keelan J, 1999, BRAIN RES, V821, P124, DOI 10.1016/S0006-8993(99)01084-7; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Kushnareva YE, 2001, ARCH BIOCHEM BIOPHYS, V386, P251, DOI 10.1006/abbi.2000.2201; Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nagao S, 1996, EXP BRAIN RES, V111, P51; Nakajima W, 2000, J NEUROSCI, V20, P7994; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Polster BM, 2001, J BIOL CHEM, V276, P37887; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P43, DOI 10.1016/S0165-3806(00)00111-5; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; ROSENBERG JM, 1989, ANN EMERG MED, V18, P341, DOI 10.1016/S0196-0644(89)80565-7; ROSENTHAL RE, 1987, J CEREBR BLOOD F MET, V7, P752, DOI 10.1038/jcbfm.1987.130; ROTTENBERG H, 1989, FEBS LETT, V247, P483, DOI 10.1016/0014-5793(89)81396-1; SITKIEWICZ D, 1982, J NEUROCHEM, V39, P1308, DOI 10.1111/j.1471-4159.1982.tb12571.x; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; SUTTON LN, 1995, PEDIATR NEUROSURG, V22, P81, DOI 10.1159/000120881; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VONHANWEHR R, 1986, J NEUROCHEM, V46, P331; Wallin C, 2000, DEV BRAIN RES, V125, P51, DOI 10.1016/S0165-3806(00)00112-7; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; WEINBACH EC, 1967, BIOCHIM BIOPHYS ACTA, V148, P256, DOI 10.1016/0304-4165(67)90301-7; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Yager JY, 1996, BRAIN RES, V712, P230, DOI 10.1016/0006-8993(95)01423-3; YAGER JY, 1991, AM J PHYSIOL, V261, pH1102, DOI 10.1152/ajpheart.1991.261.4.H1102	51	30	30	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-3806			DEV BRAIN RES	Dev. Brain Res.	JUL 19	2004	151	1-2					141	148		10.1016/j.devbrainres.2004.04.007			8	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	841VQ	WOS:000222960200014	15246700				2022-02-06	
J	Jones, NC; Constantin, D; Gibson, CL; Prior, MJW; Morris, PG; Marsden, CA; Murphy, S				Jones, NC; Constantin, D; Gibson, CL; Prior, MJW; Morris, PG; Marsden, CA; Murphy, S			A detrimental role for nitric oxide synthase-2 in the pathology resulting from acute cerebral injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						aseptic cryogenic cerebral injury; behavior; knockout mice; magnetic resonance imaging; NOS-2; trauma	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; CORTICAL IMPACT INJURY; NECROSIS-FACTOR-ALPHA; INOS-DEFICIENT MICE; FOCAL ISCHEMIA; KNOCKOUT MICE; TIME-COURSE; RAT-BRAIN; MEDIATED NEUROTOXICITY	Nitric oxide (NO) synthesized froth the inducible isoform of nitric oxide synthase (NOS-2) has been suggested to play both beneficial and deleterious roles in various neuropathologies. To define the role of nitric oxide in traumatic brain injury, we subjected male mice lacking a functional NOS-2 gene (NOS-2(-/-)) and their wild-type littermates (NOS-2(+/+)) to mild or severe aseptic cryogenic cerebral injury. Expression of NOS-2 mRNA and protein was observed in NOS-2(+/+) animals following injury. Lesion volume (as measured by histology and brain imaging) and neurological outcome (using motor and cognitive behavioral paradigms) were assessed at various times after injury. While magnetic resonance imaging revealed the extent of edema of the 2 genotypes to be similar, histology showed a reduced (32%) lesion volume in severely injured NOS2(-/-) compared with NOS-2(+/+) mice. In addition, NOS-2(-/-) mice showed significant improvements in both contralateral sensorimotor deficits (grid test: p = 0.011) and cognitive function (Morris water maze: p = 0.009) after severe injury compared to their wild-type littermates. This indicates that lesion volume is reduced and neurological recovery is improved after acute traumatic injury in mice lacking a functional NOS-2 gene, and strongly suggests that the post-trauma production of NO from this source contributes to neuropathology.	Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England; Univ Nottingham, Sir Peter Mansfield Magnet Resonance Ctr, Nottingham NG7 2UH, England; Univ Nottingham, Inst Neurosci, Nottingham NG7 2UH, England		Murphy, S (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Cell Signalling, Nottingham NG7 2UH, England.	sean.murphy@nottingham.ac.uk	Jones, Nigel C/K-7773-2012	Jones, Nigel/0000-0002-1080-8439; Gibson, Claire/0000-0002-3358-7341			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Barker JE, 2001, J PATHOL, V194, P109, DOI 10.1002/path.845; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Boer R, 2000, MOL PHARMACOL, V58, P1026, DOI 10.1124/mol.58.5.1026; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cash D, 2001, BRAIN RES, V905, P91, DOI 10.1016/S0006-8993(01)02508-2; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cuzzocrea S, 2002, SHOCK, V18, P169, DOI 10.1097/00024382-200208000-00014; Dal Secco D, 2003, NITRIC OXIDE-BIOL CH, V9, P153, DOI 10.1016/j.niox.2003.11.001; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DE CR, 1995, J CLIN INVEST, V96, P60; Deitch EA, 2002, J GASTROINTEST SURG, V6, P599, DOI 10.1016/S1091-255X(01)00016-6; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gardner CR, 2002, TOXICOL APPL PHARM, V184, P27, DOI 10.1006/taap.2002.9474; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Gorlach C, 2000, PFLUG ARCH EUR J PHY, V440, P309; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Grzybicki D, 1998, ACTA NEUROPATHOL, V95, P98, DOI 10.1007/s004010050770; HAMMOND BL, 1994, WORLD SCI C, V1, P1; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Hesse M, 2000, AM J PATHOL, V157, P945, DOI 10.1016/S0002-9440(10)64607-X; Hickey MJ, 1997, FASEB J, V11, P955, DOI 10.1096/fasebj.11.12.9337148; Hines IN, 2002, MOL CELL BIOCHEM, V234, P229, DOI 10.1023/A:1015952926016; Huang PL, 1999, BRAZ J MED BIOL RES, V32, P1353, DOI 10.1590/S0100-879X1999001100005; Iadecola C, 1997, J NEUROSCI, V17, P9157; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Kamada Kyousuke, 1995, Neurologia Medico-Chirurgica, V35, P1, DOI 10.2176/nmc.35.1; Kashii S, 1996, BRAIN RES, V711, P93, DOI 10.1016/0006-8993(95)01330-X; Kenyon NJ, 2002, AM J PHYSIOL-LUNG C, V282, pL540, DOI 10.1152/ajplung.00297.2001; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Kobayashi H, 2001, AM J RESP CELL MOL, V24, P390, DOI 10.1165/ajrcmb.24.4.4218; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Lecanu L, 1998, BRIT J PHARMACOL, V125, P584, DOI 10.1038/sj.bjp.0702119; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Loihl AK, 1999, J BIOL CHEM, V274, P8844, DOI 10.1074/jbc.274.13.8844; Loihl AK, 1998, PROG BRAIN RES, V118, P253; Loihl AK, 1999, BRAIN RES, V830, P155, DOI 10.1016/S0006-8993(99)01388-8; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; McIntosh TK, 1996, LAB INVEST, V74, P315; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Murphy S, 2000, GLIA, V29, P1, DOI 10.1002/(SICI)1098-1136(20000101)29:1<1::AID-GLIA1>3.0.CO;2-N; Nag S, 2001, LAB INVEST, V81, P41, DOI 10.1038/labinvest.3780210; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Sirsjo A, 2003, J CARDIOVASC PHARM, V41, P897, DOI 10.1097/00005344-200306000-00010; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Trajkovic V, 2001, CURR DRUG METAB, V2, P315, DOI 10.2174/1389200013338405; Virag L, 2003, TOXICOL LETT, V140, P113, DOI 10.1016/S0378-4274(02)00508-8; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Zhao XR, 2003, BRAIN RES, V966, P308, DOI 10.1016/S0006-8993(02)04223-3; Zhu DY, 2003, J NEUROSCI, V23, P223	87	30	36	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2004	63	7					708	720		10.1093/jnen/63.7.708			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	835LM	WOS:000222484700004	15290896	Bronze			2022-02-06	
J	Pelinka, LE; Jafarmadar, M; Redl, H; Bahrami, S				Pelinka, LE; Jafarmadar, M; Redl, H; Bahrami, S			Neuron-specific-enolase is increased in plasma after hemorrhagic shock and after bilateral femur fracture without traumatic brain injury in the rat	SHOCK			English	Article						traumatic brain injury; extracerebral trauma; acidosis; serum markers	SYSTEM-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; CARDIAC-SURGERY; SERUM-LEVELS; PROTEIN; DAMAGE; BLOOD; S100B; RESUSCITATION; PREDICTOR	Neuron-specific enolase (NSE) is an acknowledged marker of traumatic brain injury. Several markers originally considered reliable in the setting of traumatic brain injury have been challenged after having been studied more extensively. The aim of our experimental study was to determine whether NSE is a reliable marker of traumatic brain injury early after trauma. Hemorrhagic shock was achieved by bleeding anesthetized rats to a mean arterial pressure (MAP) of 30-35 mmHg through a femoral catheter until incipient decompensation. MAP was maintained at 30-35 mmHg until 40% of shed blood had been administered as Ringer's solution and was then increased and maintained at 40-45 mmHg for 40 min by further administration of Ringer's solution, mimicking the phase of inadequate preclinical resuscitation. Blood samples were drawn at the end of the 40-min period of inadequate resuscitation. Femur fracture was achieved in anesthetized rats by bilateral application of forceps. Blood samples were drawn 30 and 60 min after fracture. Hemorrhagic shock caused NSE increase versus laboratory controls at the end of inadequate resuscitation (P < 0.01). Bilateral femur fracture caused NSE increase versus laboratory controls 30 min after fracture, which was significant 60 min after fracture (P < 0.01). During femur fracture, MAP remained at a level that is not associated with shock in rats. Our findings show for the first time that NSE increases after hemorrhagic shock as well as after femur fracture without hemorrhagic shock in rats. From a clinical point of view, these findings indicate that NSE cannot be considered a reliable marker of traumatic brain injury early after trauma in cases associated with hemorrhagic shock and/or femur fracture.	Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; AUVA, Res Ctr Workers Compensat Board, A-1200 Vienna, Austria		Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.	lindapel@via.at		Bahrami, Soheyl/0000-0002-4563-6251			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; HULLIN DA, 1980, BIOCHIM BIOPHYS ACTA, V628, P98, DOI 10.1016/0304-4165(80)90355-4; Ishida K, 2003, J CARDIOTHOR VASC AN, V17, P4, DOI 10.1053/jcan.2003.2; ISHIGURO Y, 1982, CLIN CHIM ACTA, V121, P173, DOI 10.1016/0009-8981(82)90056-0; KATO K, 1982, BRAIN RES, V237, P441, DOI 10.1016/0006-8993(82)90455-3; Kleine TO, 2003, BRAIN RES BULL, V61, P265, DOI 10.1016/S0361-9230(03)00090-X; Krumnikl JJ, 2002, ACTA ANAESTH SCAND, V46, P1168, DOI 10.1034/j.1399-6576.2002.460920.x; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MARANGOS PJ, 1980, J NEUROCHEM, V34, P1254, DOI 10.1111/j.1471-4159.1980.tb09967.x; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Novak L, 1999, J TRAUMA, V47, P834, DOI 10.1097/00005373-199911000-00003; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; PELINKA G, 2000, RECONSTR NEUROL NEUR, V16, P282; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SEMBA R, 1982, J NEUROCHEM, V39, P360, DOI 10.1111/j.1471-4159.1982.tb03956.x; Snyder-Ramos SA, 2003, RESTOR NEUROL NEUROS, V21, P123; Szalay L, 2003, SHOCK, V20, P245, DOI 10.1097/00024382-200309000-00008; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	33	30	31	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUL	2004	22	1					88	91		10.1097/01.shk.0000130157.34382.3f			4	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	830UU	WOS:000222150100015	15201708				2022-02-06	
J	Masel, BE				Masel, BE			Rehabilitation and hypopituitarism after traumatic brain injury	GROWTH HORMONE & IGF RESEARCH			English	Article; Proceedings Paper	35th International Symposium on Growth Hormone and Growth Factors in Endocrinology and Metabolism	APR 04-05, 2003	Prague, CZECH REPUBLIC	Pfizer Inc		traumatic brain injury; rehabilitation; hypopituitarism; amnesia; Glasgow coma scale	ADULTS	Traumatic brain injury (TBI) is a leading cause of death and disability in the United States (US). The severity of a TBI is difficult to assess, and therefore, accurate determination of the prognosis is difficult. The symptoms of a TBI involve most major medical systems, and share many similarities with the symptoms of hypopituitarism. Although more than two-thirds of patients with severe head injuries who die have structural abnormalities in the hypothalamus and the pituitary, pituitary function is not routinely assessed after head trauma. Thus, studies have shown that anterior pituitary hormone deficiencies are common following brain injury [Endocrinologist 11 (2001) 275; J. Clin. Endocrinol. Metab. 86 (2001) 2752]. Survivors of brain injury should be screened for such deficiencies so that replacement therapy can be initiated to optimize rehabilitation and outcome. (C) 2004 Elsevier Ltd. All rights reserved.	Transit Learning Ctr Galveston, Galveston, TX 77550 USA		Masel, BE (corresponding author), Transit Learning Ctr Galveston, 1528 PO St, Galveston, TX 77550 USA.	bmasel@tlc-galveston.org					Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; EDWARDS OM, 1986, MEDICINE, V65, P281; Eledrisi M, 2001, ENDOCRINOLOGIST, V11, P275, DOI 10.1097/00019616-200107000-00005; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; Fink M E, 1987, Emerg Med Clin North Am, V5, P783; GARLAND DE, 1978, CLIN ORTHOP RELAT R, P111; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; GUPTA N, 2003, NEUROREVIEW; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; TEASDALE G, 1974, LANCET, V2, P81; 1998, NIH CONSENSUS STATEM, V16, P1	18	30	32	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1096-6374	1532-2238		GROWTH HORM IGF RES	Growth Horm. IGF Res.	JUN	2004	14			A			S108	S113		10.1016/j.ghir.2004.03.024			6	Cell Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Cell Biology; Endocrinology & Metabolism	827CS	WOS:000221876700025	15135790				2022-02-06	
J	Vreugdenhil, HJI; Van Zanten, GA; Brocaar, MP; Mulder, PGH; Weisglas-Kuperus, N				Vreugdenhil, HJI; Van Zanten, GA; Brocaar, MP; Mulder, PGH; Weisglas-Kuperus, N			Prenatal exposure to polychlorinated biphenyls and breastfeeding: opposing effects on auditory P300 latencies in 9-year-old Dutch children	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							EVENT-RELATED POTENTIALS; CLOSED-HEAD-INJURY; ENVIRONMENTAL EXPOSURE; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; BRAIN POTENTIALS; HUMAN-MILK; PCBS; AGE; SCHIZOPHRENIA	Prenatal exposure to polychlorinated biphenyls and breastfeeding: opposing effects on auditory P300 latencies in 9-year-old Dutch children.	Erasmus MC Sophia, Div Neonatol, Dept Paediat, NL-3000 CB Rotterdam, Netherlands; Erasmus MC, Dept Audiol, Rotterdam, Netherlands; Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands; Erasmus MC, Div Neonatol, Dept Paediat, Rotterdam, Netherlands		Weisglas-Kuperus, N (corresponding author), Erasmus MC Sophia, Div Neonatol, Dept Paediat, POB 2060, NL-3000 CB Rotterdam, Netherlands.	n.weisglas@erasmusmc.nl					Blackwood D, 2000, LANCET, V355, P771, DOI 10.1016/S0140-6736(99)00261-5; BLACKWOOD DHR, 1987, PSYCHOL MED, V17, P349, DOI 10.1017/S0033291700024892; Brouwer A, 1999, ENVIRON HEALTH PERSP, V107, P639, DOI 10.2307/3434557; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; BRUDER GE, 1995, PSYCHOPHYSIOLOGY, V32, P373, DOI 10.1111/j.1469-8986.1995.tb01220.x; BRUDER GE, 1992, ANN NY ACAD SCI, V658, P205, DOI 10.1111/j.1749-6632.1992.tb22846.x; Caldwell B, 1984, HOME OBSERVATION ENV; CHEN YJ, 1994, DEV MED CHILD NEUROL, V36, P312, DOI 10.1111/j.1469-8749.1994.tb11851.x; FINLEY WW, 1985, NEUROLOGY, V35, P323, DOI 10.1212/WNL.35.3.323; Ford JM, 1999, BIOL PSYCHIAT, V46, P94, DOI 10.1016/S0006-3223(98)00290-X; Ford JM, 1999, PSYCHOPHYSIOLOGY, V36, P667, DOI 10.1111/1469-8986.3660667; HOLCOMB PJ, 1985, PSYCHOPHYSIOLOGY, V22, P656, DOI 10.1111/j.1469-8986.1985.tb01663.x; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; JACOBSON JL, 1992, DEV PSYCHOL, V28, P297, DOI 10.1037/0012-1649.28.2.297; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; Jeon YW, 2001, PSYCHIAT RES, V104, P61, DOI 10.1016/S0165-1781(01)00297-9; Kaneko WM, 1996, ALCOHOL CLIN EXP RES, V20, P35, DOI 10.1111/j.1530-0277.1996.tb01040.x; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KOOPMANESSEBOOM C, 1994, CHEMOSPHERE, V29, P2327, DOI 10.1016/0045-6535(94)90401-4; KOOPMANESSEBOOM C, 1994, CHEMOSPHERE, V28, P1721, DOI 10.1016/0045-6535(94)90428-6; KoopmanEsseboom C, 1996, PEDIATRICS, V97, P700; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; Mariussen E, 2001, TOXICOLOGY, V159, P11, DOI 10.1016/S0300-483X(00)00374-7; MARTIN LJ, 1988, SCAND AUDIOL, P105; MORROW LA, 1992, ARCH NEUROL-CHICAGO, V49, P315, DOI 10.1001/archneur.1992.00530270135031; Morrow LA, 1996, J NEUROPSYCH CLIN N, V8, P446; Morrow LA, 1998, NEUROPSY NEUROPSY BE, V11, P146; Morse DC, 1996, TOXICOL APPL PHARM, V139, P252, DOI 10.1006/taap.1996.0164; NESHIGE R, 1988, J NEUROL NEUROSUR PS, V51, P1120, DOI 10.1136/jnnp.51.9.1120; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; Patandin S, 1999, J PEDIATR-US, V134, P33, DOI 10.1016/S0022-3476(99)70369-0; Patandin S, 1997, AM J PUBLIC HEALTH, V87, P1711, DOI 10.2105/AJPH.87.10.1711; POLICH J, 1989, BIOMED PHARMACOTHER, V43, P493, DOI 10.1016/0753-3322(89)90110-8; POLICH J, 1991, ELECTROEN CLIN NEURO, P304; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; POLICH J, 1990, INT J PSYCHOPHYSIOL, V9, P237, DOI 10.1016/0167-8760(90)90056-J; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; Rugg M.D., 1995, OX PSYCH S, P27; Sangal RB, 1998, CLIN ELECTROENCEPHAL, V29, P1, DOI 10.1177/155005949802900105; SATTERFIELD JH, 1990, BIOL PSYCHIAT, V28, P879, DOI 10.1016/0006-3223(90)90569-N; SEEGAL RF, 1991, TOXICOLOGY, V66, P145, DOI 10.1016/0300-483X(91)90215-M; SEEGAL RF, 1989, NEUROTOXICOLOGY, V10, P757; SEEGAL RF, 1992, VULNERABLE BRAIN ENV, V2, P169; Steinhauer SR, 1997, BIOL PSYCHIAT, V42, P854, DOI 10.1016/S0006-3223(97)00285-0; STINISSEN J, 1970, DUTCH VERSION WECHSL; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; TAYLOR MJ, 1990, PSYCHOPHYSIOLOGY, V27, P318, DOI 10.1111/j.1469-8986.1990.tb00389.x; Tilson HA, 1998, NEUROTOXICOLOGY, V19, P517; Uauy R, 2001, NUTR REV, V59, pS34; Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1; Van den Berg M, 1998, ENVIRON HEALTH PERSP, V106, P775, DOI 10.1289/ehp.98106775; Vreugdenhil HJI, 2004, NEUROPSYCHOLOGY, V18, P185, DOI 10.1037/0894-4105.18.1.185; Vreugdenhil HJI, 2002, J PEDIATR-US, V140, P48, DOI 10.1067/mpd.2002.119625; Walkowiak J, 2001, LANCET, V358, P1602, DOI 10.1016/S0140-6736(01)06654-5; Weisglas-Kuperus N, 1998, CHEMOSPHERE, V37, P1845, DOI 10.1016/S0045-6535(98)00250-1; Yanai I, 1997, J AFFECT DISORDERS, V46, P263, DOI 10.1016/S0165-0327(97)00100-6	58	30	30	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUN	2004	46	6					398	405		10.1017/S0012162204000647			8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	824OS	WOS:000221696500006	15174531				2022-02-06	
J	Brown, SA; McCauley, SR; Levin, HS; Contant, C; Boake, C				Brown, SA; McCauley, SR; Levin, HS; Contant, C; Boake, C			Perception of health and quality of life in minorities after mild-to-moderate traumatic brain injury	APPLIED NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury; health perception; depression; ethnic minority	HEAD-INJURY; GENERAL HEALTH; SCALES; POPULATIONS; INDIVIDUALS; DEPRESSION; DISABILITY; IMPACT; ADULTS; SCORE	Much has been reported of the influence of age, affective symptoms, and satisfaction on self-ratings of health functioning, but little is known about the extent that race-based perceptions may have on influencing behavior or adjustment after a mild-to-moderate traumatic brain injury (MTBI). We investigated differences in perception of health functioning by race for mental and physical functioning using a global measure of health functioning. MTBI (n = 135) and general trauma (GT, n = 83) patients recruited from an area Level-1 trauma center at 3 months after injury were administered the Medical Outcomes Study: Short Form (SF-36), Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; American Psychiatric Association, 1994), Community Integration Questionnaire, Social Support Questionnaire (SSQ), Center for Epidemiological Studies-Depression, and the Visual Analogue Scale of Depression. A significant interaction for Race x Group (p < .01) was found on the Physical Component Scale (PCS) of the SF-36 In the MTBI group, African Americans reported worse functioning (p < .04) on the PCS scale; they perceived functioning on subscales General Health Perception (p < .02) and Physical Functioning (p < .04) to be more limited. On the SSQ, Hispanic MTBI patients reported having fewer social supports available to them (p < .05), although the race groups were comparable for satisfaction with their support. Rate of depression across groups was comparable, although subjective reporting by minority MTBI patients indicated greater depressed feelings. Differences in perception of health functioning may be related to the unique interaction created between sustaining an MTBI and variations in cultural expression of disability Manifestations of physical difficulties may be better accepted for some cultures than having mental illness.	Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Biobehav Sci, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA		Brown, SA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, Cognit Neurosci Lab, 6560 Fannin,Ste 1144,Box 67, Houston, TX 77030 USA.	sbrown@bcm.tmc.edu			ODCDC CDC HHS [R49-CCR 612707] Funding Source: Medline		AITKEN RCB, 1969, P ROY SOC MED, V62, P989, DOI 10.1177/003591576906201005; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD JH, 1982, ARCH GEN PSYCHIAT, V39, P1195; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Burnett DM, 2000, BRAIN INJURY, V14, P713; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Dana, 1993, MULTICULTURAL ASSESS; Deane M, 1996, BRIT J NEUROSURG, V10, P187; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Freeman HP, 1998, CANCER, V82, P219, DOI 10.1002/(SICI)1097-0142(19980101)82:1<219::AID-CNCR27>3.0.CO;2-4; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Jackson-Triche ME, 2000, J AFFECT DISORDERS, V58, P89, DOI 10.1016/S0165-0327(99)00069-5; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LINN MW, 1980, MED CARE, V18, P282, DOI 10.1097/00005650-198003000-00003; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RASKIN S, 2000, NEUROPSYCHOLOGICAL M, P269; Ren X S, 1996, Ethn Health, V1, P293; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; Shetterly SM, 1996, AM J PUBLIC HEALTH, V86, P1798, DOI 10.2105/AJPH.86.12.1798; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; TEASDALE G, 1974, LANCET, V2, P81; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Williams, 1995, USERS GUIDE STRUCTUR; [No title captured]	38	30	30	0	11	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	0908-4282			APPL NEUROPSYCHOL	Appl. Neuropsychol.		2004	11	1					54	64		10.1207/s15324826an1101_7			11	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	858AR	WOS:000224163000007	15471747				2022-02-06	
J	Tasci, A; Okay, O; Gezici, AR; Ergun, R; Ergungor, F				Tasci, A; Okay, O; Gezici, AR; Ergun, R; Ergungor, F			Prognostic value of interleukin-1 beta levels after acute brain injury	NEUROLOGICAL RESEARCH			English	Article						cytokines; head trauma; inflammation; interleukin-1 beta	RAT-BRAIN; CEREBRAL-ISCHEMIA; TEMPORAL PROFILE; CYTOKINE; EXPRESSION; RELEASE; MENINGITIS; ASTROCYTES; MICROGLIA; ADHESION	Traumatic injury to central nervous system results in the production of inflammatory cytokines via intrinsic mechanisms by neurons, astrocytes and microglia, and extrinsic mechanisms by infiltrating macrophages, lymphocytes and other leukocytes. Interleukin-1 beta is the key mediator of the acute inflammatory host response. While this response is necessary for resolution of the pathologic event, the toxic nature of many of its products can cause significant tissue damage. We analyzed serum interleukin-1 beta levels by enzyme-linked immunosorbent assay in 48 patients with solitary head injury who were transported to our clinic immediately after trauma. We categorized the patients according to their initial Glasgow coma scores in three groups, and compared their serum interleukin-1 beta values both with their Glasgow coma initial and outcome scores. This study helped to provide quantitative data to estimate clinical impressions and prognosis after head injury.	Ankara Numune Hosp, Dept Neurosurg, Ankara, Turkey		Ergun, R (corresponding author), Ozdogukent Sitesi,46,Sokak 15-A-3,B-Block,Keklikp, TR-06450 Ankara, Turkey.	ruchanergun@hotmail.com					BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; Campbell VA, 1998, NEUROBIOL AGING, V19, P575, DOI 10.1016/S0197-4580(98)00097-9; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fassbender K, 1997, J NEUROIMMUNOL, V74, P130, DOI 10.1016/S0165-5728(96)00214-7; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; HARTUNG HP, 1989, BRAIN RES, V489, P113, DOI 10.1016/0006-8993(89)90013-9; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; KATABAMI T, 1992, BIOCHEM BIOPH RES CO, V188, P565, DOI 10.1016/0006-291X(92)91093-6; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Kohno K, 1998, CLIN IMMUNOL IMMUNOP, V86, P11, DOI 10.1006/clin.1997.4475; Murray CA, 1999, GERONTOLOGY, V45, P136, DOI 10.1159/000022076; PHELPS CP, 1995, BRAIN RES, V688, P193, DOI 10.1016/0006-8993(95)00491-8; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROSTWOROWSKI M, 1997, NEUROSCIENCE, V17, P3663; Sairanen TR, 1997, J CEREBR BLOOD F MET, V17, P1107, DOI 10.1097/00004647-199710000-00013; SCHLUTER D, 1995, AM J PATHOL, V146, P999; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; van der Meer JWM, 1998, ANN NY ACAD SCI, V856, P243; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xia LN, 1996, NEUROENDOCRINOLOGY, V63, P79, DOI 10.1159/000126938; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yong VW, 1998, MENT RETARD DEV D R, V4, P193, DOI 10.1002/(SICI)1098-2779(1998)4:3<193::AID-MRDD7>3.0.CO;2-P; Zhang ZG, 1998, BRAIN RES, V784, P210, DOI 10.1016/S0006-8993(97)01317-6	31	30	31	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	DEC	2003	25	8					871	874		10.1179/016164103771953998			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	756LW	WOS:000187467500016	14669533				2022-02-06	
J	Petridou, E; Kedikoglou, S; Andrie, E; Farmakakis, T; Tsiga, A; Angelopoulos, M; Dessypris, N; Trichopoulos, D				Petridou, E; Kedikoglou, S; Andrie, E; Farmakakis, T; Tsiga, A; Angelopoulos, M; Dessypris, N; Trichopoulos, D			Injuries among disabled children: a study from Greece	INJURY PREVENTION			English	Article							DISABILITIES; PREVENTION; PEOPLE	Objective: To compare the differential implications of sociodemographic and situational factors on the risk of injury among disabled and non-disabled children. Design: Data from the Emergency Department Injury Surveillance System (EDISS) were used to compare, in a quasi case-control approach, injured children with or without disability with respect to sociodemographic, event and injury variables, and to estimate adjusted odds ratios for the injury in a disabled rather than a non-disabled child. Setting: Two teaching hospitals in Athens and two district hospitals in the countryside that participate in the EDISS. Patients: In the five year period 1996-2000, 110066 children were recorded with injuries; 251 among them were identified as having a motor/psychomotor or sensory disability before the injury event. Interventions: None. Main outcome measures: Mechanism of injury, type of injury, risk-predisposing socioeconomic and environmental variables, odds ratio for injury occurrence. Results: Falls and brain concussion are proportionally more common among disabled children, whereas upper limb and overexertion injuries are less common among them. Urban environment, migrant status, and cold months are also associated with increased odds for injuries to occur among disabled rather than non-disabled children. The odds ratio for the occurrence of an injury among disabled children increases with increasing age. Conclusions: The results of the study provide the information for the targeting of trials of preventive measure in disabled children at increased risk of severe injuries.	Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA		Petridou, E (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, 75 Mikras Asias Str, GR-11527 Athens, Greece.	epetrid@med.uoa.gr		PETRIDOU, ELENI/0000-0003-3695-3439			ANGLE CR, 1975, PEDIATRICS, V56, P819; Bergeron J W, 1999, Phys Med Rehabil Clin N Am, V10, P213; BRESLOW NE, 1993, IARC SCI PUBLICATION, V32; COPPENS NM, 1986, J PEDIATR PSYCHOL, V11, P189, DOI 10.1093/jpepsy/11.2.189; Dessypris N, 2002, J Cancer Epidemiol Prev, V7, P123; DUNNE RG, 1993, MENT RETARD, V31, P83; Forjuoh SN, 2001, BRIT MED J, V322, P940, DOI 10.1136/bmj.322.7292.940; LELAND NL, 1994, J DEV BEHAV PEDIATR, V15, P402; MELLINGER GD, 1967, J HEALTH SOC BEHAV, V8, P96, DOI 10.2307/2948340; MITCHELL PL, 1996, 6 NAT I DIS REH RES; *NAT I CHILD HLTH, 1993, NIH PUBL, P33; OLLI S, 1985, THEORETICAL EPIDEMIO; PERRIN MJ, 1993, HOME COMMUNITY CARE; RIVARA FP, 1995, J DEV BEHAV PEDIATR, V16, P362; Roberts I, 1995, Inj Prev, V1, P12, DOI 10.1136/ip.1.1.12; Sherrard J, 2001, Inj Prev, V7, P56; Strauss D, 1998, AM J EPIDEMIOL, V147, P855, DOI 10.1093/oxfordjournals.aje.a009539; STRUNK W, 1999, ELEMENTS STYLE, P13; *US DEP HHS, 1990, ICD 9 CM INT CLASS D, V1; *US DEP HHS, 1990, ICD 9 CM INT CLASS D, V2; World Health Organization, 1980, INT CLASS DIS	21	30	31	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	SEP	2003	9	3					226	230		10.1136/ip.9.3.226			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	719QK	WOS:000185214900007	12966010	Green Published, Bronze			2022-02-06	
J	Hiraiwa, M; Liu, J; Lu, AG; Wang, CY; Misasi, R; Yamauchi, T; Hozumi, I; Inuzuka, T; O'Brien, JS				Hiraiwa, M; Liu, J; Lu, AG; Wang, CY; Misasi, R; Yamauchi, T; Hozumi, I; Inuzuka, T; O'Brien, JS			Regulation of gene expression in response to brain injury: Enhanced expression and alternative splicing of rat prosaposin (SGP-1) mRNA in injured brain	JOURNAL OF NEUROTRAUMA			English	Article						alternative splicing; cerebral ischemia; gene regulation; neurotrauma; neurotrophic factor; prosaposin; sphingolipid activator protein	SPHINGOLIPID ACTIVATOR PROTEINS; FOCAL CEREBRAL-ISCHEMIA; NERVOUS-SYSTEM; SCHWANN-CELLS; METACHROMATIC LEUKODYSTROPHY; NEUROTROPHIC FACTOR; STAB WOUNDS; IN-VIVO; DEFICIENCY; MUTATION	Prosaposin, the precursor of saposins or saps, is an injury-repair protein that acts on both neurons and glia. Previous studies identified the prosaposin gene as one of differentially expressed genes following nerve injury. In the present study, we investigated expression of prosaposin mRNA in injured brain utilizing rat models of focal cerebral ischemia and cortical stab wound in order to explore the significance of prosaposin in nerve injury. In ischemic brain, the level of prosaposin mRNA was elevated greater than 400% over controls within 5 days after ischemic insults. Importantly, this induction was accompanied by a 9-base splicing consistent with the alternative Exon-8 splicing of human prosaposin mRNA. In normal brain, two prosaposin mRNA species with and without the 9-base insertion were expressed at a ratio of 85:15; however, this equilibrium reverted to 5:95 following ischemic injury. Similar inductions were observed in stab wound brains. Immunohistochemical staining and in situ hybridization demonstrated an enhanced signal distribution of prosaposin mRNA and injury-induced prosaposin protein around the lesion. The data suggest the expression and processing of prosaposin mRNA may be crucially regulated not only for cerebral homeostasis but also during nerve regenerative and degenerative processes.	Univ Calif San Diego, Sch Med, Dept Neurosci, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Rome, Italy; Gifu Univ, Dept Neurol & Geriatr, Gifu, Japan		Hiraiwa, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Neurosci, Ctr Mol Genet, 9500 Gilman Dr,CMG-115, La Jolla, CA 92093 USA.			Hozumi, Isao/0000-0003-0984-6291			Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; Chambers CB, 1997, MOL BRAIN RES, V48, P115, DOI 10.1016/S0169-328X(97)00089-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; FU Q, 1994, J MOL NEUROSCI, V5, P59, DOI 10.1007/BF02736694; Fujita N, 1998, J NEUROSCI, V18, P1970; Fujita N, 1996, HUM MOL GENET, V5, P711, DOI 10.1093/hmg/5.6.711; GILLEN C, 1995, J NEUROSCI RES, V42, P159, DOI 10.1002/jnr.490420203; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; Henseler M, 1996, J BIOL CHEM, V271, P8416, DOI 10.1074/jbc.271.14.8416; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; Hiraiwa M, 1997, P NATL ACAD SCI USA, V94, P4778, DOI 10.1073/pnas.94.9.4778; Hiraiwa M, 1999, GLIA, V26, P353, DOI 10.1002/(SICI)1098-1136(199906)26:4<353::AID-GLIA9>3.0.CO;2-G; Hiraiwa M, 1997, ARCH BIOCHEM BIOPHYS, V341, P17, DOI 10.1006/abbi.1997.9958; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; HOLTSCHMIDT H, 1991, FEBS LETT, V280, P267, DOI 10.1016/0014-5793(91)80308-P; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Hozumi I, 1999, NEUROSCI LETT, V267, P73, DOI 10.1016/S0304-3940(99)00325-0; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; Igase K, 1999, J CEREBR BLOOD F MET, V19, P298, DOI 10.1097/00004647-199903000-00008; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KONDOH K, 1991, BIOCHEM BIOPH RES CO, V181, P286, DOI 10.1016/S0006-291X(05)81415-9; Kotani Y, 1996, J NEUROCHEM, V66, P2197; Kotani Y, 1996, J NEUROCHEM, V66, P2019; KREDA SM, 1994, DEV NEUROSCI-BASEL, V16, P90, DOI 10.1159/000112093; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; LAMONTAGNE S, 1994, J BIOL CHEM, V269, P20528; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LIU WK, 1993, AM J PATHOL, V142, P387; Lu AG, 2000, NEUROREPORT, V11, P1791, DOI 10.1097/00001756-200006050-00039; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; Madar-Shapiro L, 1999, BIOCHEM J, V337, P433, DOI 10.1042/0264-6021:3370433; Matsuda J, 2001, HUM MOL GENET, V10, P1191, DOI 10.1093/hmg/10.11.1191; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Oya Y, 1998, ACTA NEUROPATHOL, V96, P29, DOI 10.1007/s004010050857; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; RAFI MA, 1990, BIOCHEM BIOPH RES CO, V166, P1017, DOI 10.1016/0006-291X(90)90912-7; RAMSHAW AL, 1992, J CLIN PATHOL, V45, P1015, DOI 10.1136/jcp.45.11.1015; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sandhoff K, 1998, ANN NY ACAD SCI, V845, P139, DOI 10.1111/j.1749-6632.1998.tb09667.x; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; SUN Y, 1994, AM J PATHOL, V145, P1390; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TANIUCHI M, 1988, J NEUROSCI, V8, P664; Vouyiouklis DA, 2000, J NEUROCHEM, V74, P940, DOI 10.1046/j.1471-4159.2000.0740940.x; Wahli W., 1998, BIOCHEMICA, V1, P10; Woodruff RH, 1998, J NEUROCYTOL, V27, P683, DOI 10.1023/A:1006972316697; Yokota N, 2001, STROKE, V32, P168, DOI 10.1161/01.STR.32.1.168; ZHANG XL, 1991, HUM GENET, V87, P211, DOI 10.1007/BF00204185; ZHANG XL, 1990, P NATL ACAD SCI USA, V87, P1426, DOI 10.1073/pnas.87.4.1426	56	30	32	0	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2003	20	8					755	765		10.1089/089771503767869980			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	712BU	WOS:000184777000006	12965054				2022-02-06	
J	Pachet, A; Friesen, S; Winkelaar, D; Gray, S				Pachet, A; Friesen, S; Winkelaar, D; Gray, S			Beneficial behavioural effects of lamotrigine in traumatic brain injury	BRAIN INJURY			English	Article							FUNCTIONAL ASSESSMENT MEASURE; INTERRATER RELIABILITY; VALPROIC ACID; CARBAMAZEPINE; AGITATION; MECHANISM; EPILEPSY; DRUGS	Anti-convulsant medications have been employed to treat behavioural disorders resulting from traumatic brain injury (TBI). However, there is a paucity of literature investigating the use of lamotrigine to treat aggression and agitation in patients with TBI. In a single case study design, the present study examined the effectiveness of lamotrigine to treat aggressive and agitated behaviour in a 40-year-old male who sustained a severe TBI. A substantial decrease in problematic behaviours and a significant improvement in neurobehavioural functioning were observed after lamotrigine treatment. This case study provides some support for the use of lamotrigine to treat aggression and agitation in patients with a TBI. Further research is needed to examine the relationship between lamotrigine and functional outcome after TBI.	Alberta Hosp Ponoka, Alberta Mental Hlth Board, Brain Injury Rehabil Prov Program, Edmonton, AB, Canada		Pachet, A (corresponding author), Columbia Hlth Ctr, Brain Injury Program, 2121 29th St NE, Calgary, AB T1Y 7H8, Canada.						Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Brunbech L, 2002, DRUGS, V62, P593, DOI 10.2165/00003495-200262040-00004; Calabrese JR, 1999, AM J PSYCHIAT, V156, P1019; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; de la Cruz M, 1999, ARCH OTOLARYNGOL, V125, P225, DOI 10.1001/archotol.125.2.225; Devarajan S, 2000, AM J PSYCHIAT, V157, P1178, DOI 10.1176/appi.ajp.157.7.1178; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; ENTERS EK, 1992, BRAIN RES, V576, P271; Goldberg JF, 2001, J CLIN PSYCHIAT, V62, P27; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HORN LJ, 1987, J HEAD TRAUMA REHAB, V2, P18; Jette N, 2002, NEUROLOGY, V59, P275, DOI 10.1212/WNL.59.2.275; JOFFE RT, 1994, ANTICONVULSANTS MOOD; JULIEN RM, 1998, PRIMER DRUG ACTION; LEACH MJ, 1986, EPILEPSIA, V27, P490, DOI 10.1111/j.1528-1157.1986.tb03573.x; LEES G, 1993, BRAIN RES, V612, P190, DOI 10.1016/0006-8993(93)91660-K; Levine J, 2000, J CLIN PSYCHIAT, V61, P680, DOI 10.4088/JCP.v61n0914h; Maltese TM, 1999, AM J PSYCHIAT, V156, P1833; Martin R, 2001, EPILEPSIA, V42, P764, DOI 10.1046/j.1528-1157.2001.33300.x; MARTIN S, 2002, EPILSPSIA, V43, P482; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Meador KJ, 2001, NEUROLOGY, V56, P1177, DOI 10.1212/WNL.56.9.1177; MEYTHALER J, 1999, REHABILITATION PHARM, V10, P275; NEPPE V, 1998, J CLIN PSYCHIAT, V49, P4; OTTENBACHER KJ, 1996, ARCH PHYS MED REHAB, V7, P1226; Post RM, 1987, PSYCHOPHARMACOLOGY 3, P567; PRATT JA, 1984, J NEUROL NEUROSUR PS, V47, P1131, DOI 10.1136/jnnp.47.10.1131; Rhodes LJ, 2000, AM J PSYCHIAT, V157, P2058, DOI 10.1176/appi.ajp.157.12.2058; Ryan J M, 2000, Semin Clin Neuropsychiatry, V5, P238, DOI 10.1053/scnp.2000.9553; SHOWALTER C, 1996, J NEUROPSYCHIATRY CL, V8, P96; Showalter PEC, 2000, BRAIN INJURY, V14, P997; SMALL JG, 1991, ARCH GEN PSYCHIAT, V48, P915; Wroblewski BA, 1997, BRAIN INJURY, V11, P37, DOI 10.1080/026990597123791	34	30	31	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2003	17	8					715	722		10.1080/0269905031000110445			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	691MF	WOS:000183609500009	12850956				2022-02-06	
J	Sarcia, PJ; Scumpia, PO; Moldawer, LL; DeMarco, VG; Skimming, JW				Sarcia, PJ; Scumpia, PO; Moldawer, LL; DeMarco, VG; Skimming, JW			Hypothermia induces interleukin-10 and attenuates injury in the lungs of endotoxemic rats	SHOCK			English	Article						anti-inflammatory; pro-inflammatory; LPS; GRO/CINC-1; IL-1 beta; IL-6; myeloperoxidase; normothermia	NITRIC-OXIDE SYNTHASE; TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; MODERATE HYPOTHERMIA; CARDIOPULMONARY BYPASS; INFLAMMATORY RESPONSE; CYTOKINE PRODUCTION; HEMORRHAGIC-SHOCK; SKELETAL-MUSCLE; IN-VITRO	We recently reported that hypothermia protects against intrapulmonary nitric oxide overproduction and nitric oxide-mediated lung injury in endotoxemic rats. Few studies have been performed to investigate whether hypothermia reduces inflammation by affecting favorable changes in chemokine and pro- and anti-inflammatory cytokine profiles. In this study, we tested the hypothesis that hypothermia decreases concentrations of growth-related oncogene/cytokine-induced neutrophil chemoattractant-1 (GRO/CINC-1), interleukin (IL)-1beta, IL-6, and myeloperoxidase and increases concentration of IL-10 in the lungs endotoxemic rats. Twelve rats were anesthetized and randomized to treatment with either hypothermia (T = 18-24degreesC; n = 6) or normothermia (T = 36-38degreesC, n = 6). Endotoxin (15 mg/kg of Escherichia coli lipopolysaccharide) was administered intravascularly and lung tissue was harvested 150 min later. Three additional rats were sham instrumented and maintained as normothermic but not given endotoxin. Hematoxylin & eosin staining was performed for qualitative inspection of tissues. Quantitative analyses of lung homogenates were performed using enzyme-linked immunosorbent assays for IL-1beta, IL-6, IL-10, and GRO/CINC-1. Myeloperoxidase concentrations were determined using a colorimetric assay. Hypothermia attenuated the induction of intrapulmonary IL-1beta (P < 0.05), IL-6(P < 0.05), GRO/CINC-1 (P < 0.05), and myeloperoxidase (P < 0.05) caused by endotoxin. Inspection of the lungs revealed that hypothermia similarly attenuated histological signs of injury, such as interstitial edema and neutrophil accumulation. Hypothermia increased the intrapulmonary concentration of IL-10 more than 3-fold over that measured in the normothermia (endotoxin-exposed) group (P < 0.05). Hypothermia inhibits neutrophil recruitment in the lungs of endotoxemic rats in part by decreasing proinflammatory cytokine expression. Additionally, hypothermia induces intrapulmonary IL-10 expression. Further studies are needed to investigate whether IL-10 mediates the anti-inflammatory effects of hypothermia.	Univ Missouri, Dept Child Hlth, Columbia, MO 65211 USA; Univ Missouri, Dept Physiol, Columbia, MO 65211 USA; Univ Florida, Dept Pediat, Gainesville, FL USA; Univ Florida, Dept Surg, Gainesville, FL USA		Skimming, JW (corresponding author), Univ Missouri, Dept Child Hlth, 1 Hosp Dr, Columbia, MO 65211 USA.			DeMarco, Vincent/0000-0003-2092-9995	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000082] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5M01 RR000082-390655] Funding Source: Medline		Adams V, 2002, CARDIOVASC RES, V54, P95, DOI 10.1016/S0008-6363(02)00228-6; Ameredes BT, 2001, J LEUKOCYTE BIOL, V70, P730; Angstwurm K, 2000, J CEREBR BLOOD F MET, V20, P834, DOI 10.1097/00004647-200005000-00010; Biagas Katherine V., 1998, Current Opinion in Pediatrics, V10, P271, DOI 10.1097/00008480-199806000-00009; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; COX G, 1996, AM J PHYSIOL, V271, P566; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; de Waal Malefyt R, 1991, J EXP MED, V174, P1209, DOI DOI 10.1084/JEM.174.5.1209; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Gaines GC, 1999, J VASC SURG, V29, P370, DOI 10.1016/S0741-5214(99)70390-3; Gesser B, 1996, J LEUKOCYTE BIOL, V59, P407, DOI 10.1002/jlb.59.3.407; Gui Y, 2000, AM J PHYSIOL-HEART C, V279, pH566, DOI 10.1152/ajpheart.2000.279.2.H566; Gundersen Y, 2001, ACTA ANAESTH SCAND, V45, P994, DOI 10.1034/j.1399-6576.2001.450812.x; Huang CJ, 2002, NITRIC OXIDE-BIOL CH, V6, P79, DOI 10.1006/niox.2001.0402; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; Kabir K, 2002, SHOCK, V17, P300, DOI 10.1097/00024382-200204000-00010; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Lee SL, 2001, J SURG RES, V100, P150, DOI 10.1006/jsre.2001.6230; Lu MY, 2002, INTENS CARE MED, V28, P636, DOI 10.1007/s00134-002-1262-1; Olszyna DP, 2000, J INFECT DIS, V181, P613, DOI 10.1086/315275; Qing M, 2001, SHOCK, V15, P372, DOI 10.1097/00024382-200115050-00007; Schmidt M, 2000, EUR J IMMUNOL, V30, P1769, DOI 10.1002/1521-4141(200006)30:6<1769::AID-IMMU1769>3.0.CO;2-9; Scumpia PO, 2002, AM J PHYSIOL-LUNG C, V283, pL1231, DOI 10.1152/ajplung.00102.2002; STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222; Takasu A, 2000, CRIT CARE MED, V28, P2465, DOI 10.1097/00003246-200007000-00047; Tassani P, 2002, J THORAC CARDIOV SUR, V123, P648, DOI 10.1067/mtc.2002.121285; Thomassen MJ, 1996, CLIN IMMUNOL IMMUNOP, V80, P321, DOI 10.1006/clin.1996.0130; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; vanderPoll T, 1997, J IMMUNOL, V158, P1971; WATANABE K, 1991, EXP MOL PATHOL, V55, P30, DOI 10.1016/0014-4800(91)90016-Q; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407; Whalen MJ, 1997, ACT NEUR S, V70, P260; Wladis A, 2001, SHOCK, V15, P60, DOI 10.1097/00024382-200115010-00010	35	30	31	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	JUL	2003	20	1					41	45		10.1097/01.shk.0000071080.50028.f2			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	693FJ	WOS:000183706100008	12813367				2022-02-06	
J	Turkstra, L; Ciccia, A; Seaton, C				Turkstra, L; Ciccia, A; Seaton, C			Interactive behaviors in adolescent conversation dyads	LANGUAGE SPEECH AND HEARING SERVICES IN SCHOOLS			English	Article						pragmatics; social communication; gaze; adolescent	TRAUMATIC BRAIN-INJURY; LANGUAGE-SKILLS; DISCOURSE; COMMUNICATION; CLINICIAN; COHESION; STUDENTS	Purpose: Verbal and nonverbal conversational behaviors often are the target of intervention for adolescents with social communication disorders. There are, however, few sources of data on the interactive conversational behaviors of typically developing-adolescents that can be used as guidelines when working with clinical populations. The purpose of this study was to collect behavioral data from conversations of adolescents so as to provide comparison data for adolescents with communication disorders. Method: Conversational behaviors were measured in 50 typically developing African American and Caucasian adolescents (24 females, 26 males) from the Midwest United States who engaged in extemporaneous, 3-minute conversations in dyads with peers. The effects of age, race, and sex of the participant were assessed. Results: Behaviors occurring at relatively high frequencies included directing gaze at the partner, particularly during listening; nodding and showing neutral and positive facial expressions; using back-channel responses; and giving contingent responses. Participants rarely showed negative emotions, turned away from each other, asked for clarification, or failed to answer questions. Overall, there were few effects of race and sex of the speaker and greater variability within than between groups. Clinical Implications: The data may serve as a source of information for clinicians serving individuals with communication disorders, with the caveat that the conversations included here represent a subset of typical adolescent interactive conversational behaviors.	Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA		Turkstra, L (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.	ls2@po.cwru.edu	Ciccia, Angela/J-5967-2019; Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921			ASHER SR, 1986, SOCIAL WORK ED, V8, P205; Body R, 1998, BRAIN INJURY, V12, P963, DOI 10.1080/026990598122016; Brice A, 1996, LANG SPEECH HEAR SER, V27, P68, DOI 10.1044/0161-1461.2701.68; BUCHNER A, 1997, GASTERISKPOWER PRIOR; CAPPELLA JN, 1994, HDB INTERPERSONAL CO, P380; CHAMBERS JK, 1995, SOCIOLINGUISTIC THEO; Cherney L. R., 1998, ANAL DISCOURSE COMMU; CHERULNIK PD, 1978, J SOC PSYCHOL, V104, P263, DOI 10.1080/00224545.1978.9924068; CIECIA A, 2002, ADV SPEECH LANGUAGE, V4, P1; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Cohen J., 2013, STAT POWER ANAL BEHA; DAVIS AD, 1991, J COMMUN DISORD, V24, P251, DOI 10.1016/0021-9924(91)90001-Y; DUNCAN S, 1972, J PERS SOC PSYCHOL, V23, P283, DOI 10.1037/h0033031; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; FLAVELL JH, 1968, DEV ROLE TAKING COMM; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Hartley L. L, 1995, COGNITIVE COMMUNICAT; Hendry LB, 2000, J ADOLESCENCE, V23, P705, DOI 10.1006/jado.2000.0354; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Hux K, 1997, J COMMUN DISORD, V30, P133, DOI 10.1016/S0021-9924(96)00060-3; Kamphaus R, 1990, HDB PSYCHOL ED ASSES, P423; KENDON A, 1967, ACTA PSYCHOL, V26, P22, DOI 10.1016/0001-6918(67)90005-4; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; LAFRANCE M, 1976, J PERS SOC PSYCHOL, V33, P547, DOI 10.1037/0022-3514.33.5.547; Lagomarsino J, 1998, PSYCHOL REC, V48, P317, DOI 10.1007/BF03395272; LAPADAT JC, 1991, J LEARN DISABIL-US, V24, P147, DOI 10.1177/002221949102400303; Larson R., 1984, BEING ADOLESCENT CON; Larson RW, 1996, DEV PSYCHOL, V32, P744, DOI 10.1037/0012-1649.32.4.744; LARSON RW, 1983, J MARRIAGE FAM, V45, P739, DOI 10.2307/351787; MARCELLE YM, 1976, THESIS KANSAS STATE; McBride CK, 1997, ADOLESCENCE, V32, P515; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Mundy P, 1997, MENT RETARD DEV D R, V3, P343; Muuss R. E., 1996, THEORIES ADOLESCENCE; Myers P.S., 1999, RIGHT HEMISPHERE DAM; *NOLD CORP, 2000, OBS VERS 3 0; PARENTE R, 1996, J VOCATIONAL REHABIL, V7, P181; Penn C, 1999, BRAIN LANG, V68, P535, DOI 10.1006/brln.1999.2127; PLACE KS, 1991, DISCOURSE PROCESS, V14, P227, DOI 10.1080/01638539109544783; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RAFFAELLI M, 1989, J YOUTH ADOLESCENCE, V18, P567, DOI 10.1007/BF02139074; Readdick CA, 1997, ADOLESCENCE, V32, P313; Sillars A., 1991, STUDYING INTERPERSON, P197; Smith TE, 1997, ADOLESCENCE, V32, P483; Snow PC, 2000, BRAIN INJURY, V14, P397; SPENCE SH, 1981, J APPL BEHAV ANAL, V14, P159, DOI 10.1901/jaba.1981.14-159; *STATA, 1999, STATA STAT SOFTW VER; STEINBERG L, 1999, ADOLESCENCE; STEPHENS J, 1986, J LANG SOC PSYCHOL, V5, P119, DOI DOI 10.1177/0261927X8652003; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; *SYST SOFTW, 1998, SYSTAT VERS 8 0; Turkstra LS, 2001, J COMMUN DISORD, V34, P151, DOI 10.1016/S0021-9924(00)00046-0; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WERTZ RT, 1998, APPROACHES TREATMENT, P11; WIEMANN JM, 1981, HUM COMMUN RES, V7, P302, DOI 10.1111/j.1468-2958.1981.tb00577.x; WINT G, 1965, 3 KILLER MEDIATIONS; [No title captured]	60	30	31	0	7	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	0161-1461	1558-9129		LANG SPEECH HEAR SER	Lang. Speech Hear. Serv. Sch.	APR	2003	34	2					117	127		10.1044/0161-1461(2003/010)			11	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	668AU	WOS:000182268800003	27764492				2022-02-06	
J	Skokan, EG; Junkins, EP; Kadish, H				Skokan, EG; Junkins, EP; Kadish, H			Serious winter sport injuries in children and adolescents requiring hospitalization	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Pediatrics	OCT 19-25, 2001	SAN FRANCISCO, CA	Amer Acad Pediat		skiing; snowboarding; recreational injury; pediatric trauma; helmets; injury prevention	SNOWBOARDING INJURIES; HEAD-INJURIES; SEVERITY; SKIERS; RISK	To describe the epidemiology of serious winter sports-related injuries resulting in hospitalization in children and adolescents, we prospectively collected and analyzed records of all winter sports-related injuries requiring hospitalization at our respective institutions from 1996 to 2000. We identified 101 patients with a mean age of 10.7 years, of whom 68% were male and 32% female. Skiers accounted for 71% and snowboarders 26% of injuries; 3% of injuries were snowmobile-or luge-related. Leading mechanisms of injury were ground level falls (50%), crashes into trees, (18%), and falls from ski lift(13%). Approximately 26% of the patients met criteria for trauma-team activation. Leading diagnoses were head injury (20%), femur fracture (18%), and concussion (11%). Five patients required admission to the intensive care unit. The median injury severity score (ISS) was 7; 8% of patients had an ISS score > 15. Abbreviated Injury Scale-1990 scores of greater than or equal to 3 were noted in 34% of the patients. We conclude that Injuries sustained through participation in winter sports may be severe, especially in the case of injuries involving the head. Injury-prevention strategies should focus on head injuries. Copyright 2003, Elsevier Science (USA). All rights reserved.	Univ Utah, Sch Med, Dept Pediat, Div Pediat Emergency Med, Salt Lake City, UT USA; Intermt Injury Control Res Ctr, Salt Lake City, UT USA		Skokan, EG (corresponding author), Primary Childrens Med Ctr, Div Pediat Emergency Med, 100 Med Dr, Salt Lake City, UT 84113 USA.	eskokan@hsc.utah.edu					*AM MED ASS, HELM RECR SKIING OTH; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1992, INJURY FACT BOOK, P89; Bergstrom KA, 1999, SCAND J MED SCI SPOR, V9, P110; Bonnie R.J., 1999, REDUCING BURDEN INJU; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; Diamond PT, 2001, BRAIN INJURY, V15, P429, DOI 10.1080/02699050010005922; Ferrera PC, 1999, AM J EMERG MED, V17, P575, DOI 10.1016/S0735-6757(99)90199-7; Fukuda O, 2001, AM J SPORT MED, V29, P437, DOI 10.1177/03635465010290040901; Hackam DJ, 1999, J PEDIATR SURG, V34, P65, DOI 10.1016/S0022-3468(99)90230-0; Hagel BE, 1999, CLIN J SPORT MED, V9, P9, DOI 10.1097/00042752-199901000-00003; Hennessey T, 2002, AM J PREV MED, V22, P110, DOI 10.1016/S0749-3797(01)00411-1; Hunter RE, 1999, AM J SPORT MED, V27, P381, DOI 10.1177/03635465990270032101; Josefson D, 1998, BRIT MED J, V316, P172; Levy AS, 2000, SEMIN NEUROL, V20, P233, DOI 10.1055/s-2000-9833; Machold W, 2000, J TRAUMA, V48, P1109, DOI 10.1097/00005373-200006000-00018; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; Muller R, 2000, SPORTVERLETZ SPORTSC, V14, P121, DOI 10.1055/s-2000-8954; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; O'Neill DF, 1999, AM J SPORT MED, V27, P94; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; Shorter NA, 1999, AM J EMERG MED, V17, P261, DOI 10.1016/S0735-6757(99)90121-3; US Consumer Product Safety Commission, 1999, SKIING HELM EV POT R; WARME WJ, 1995, AM J SPORT MED, V23, P597, DOI 10.1177/036354659502300514	25	30	31	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAR	2003	21	2					95	99		10.1053/ajem.2003.50032			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	663VQ	WOS:000182027400002	12671807				2022-02-06	
J	Tate, RL				Tate, RL			Impact of pre-injury factors on outcome after severe traumatic brain injury: Does post-traumatic personality change represent an exacerbation of premorbid traits?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEVERE HEAD-INJURY; SUBSTANCE-ABUSE; REHABILITATION OUTCOMES; PSYCHOSOCIAL ADJUSTMENT; FOLLOW-UP; PREDICTION; IMPAIRMENT; DYSFUNCTION; DISABILITY; COMMUNITY	Although personality change is a frequent and disabling consequence of severe degrees of traumatic brain injury (TBI), little information is available beyond descriptive statements. The present paper presents a brief overview of the literature on the effects of pre-injury variables on post-trauma psychosocial functioning, and makes specific examination of the effect of premorbid personality structure on the post-trauma personality in people with TBI. A close relative of 28 people undergoing rehabilitation after TBI completed the Eysenck Personality Questionnaire-Revised (EPQ-R) and Current Behaviour Scale (CBS) regarding the injured person's personality and character. Data were collected on three occasions: Ratings about premorbid status were taken as soon as feasible after admission, and follow-up ratings regarding current status were made at 6 and 12 months post-trauma. As a group, premorbid ratings indicated an unremarkable profile on the EPQ-R. Significant changes had occurred by 6 months post-trauma, which were sustained at 12 months post-trauma for both the EPQ-R and CBS. Yet none of the specific hypotheses regarding premorbid personality structure on the EPQ-R and post-trauma characterological deficits on the two CBS factors, Loss of Emotional Control (LEC) and Loss of Motivation (LM), was supported: There were no significant differences between subgroups with high or low premorbid levels of Extraversion, Neuroticism, Psychoticism, Addiction and Criminality and post-trauma CBS factors, LEC, and LM. These findings suggest that although personality changes occur as a result of traumatic brain injury, they are largely independent of the premorbid personality structure.	Univ Sydney, Royal Rehabil Ctr Sydney, Dept Med, Rehabil Studies Unit, Ryde, NSW 1680, Australia		Tate, RL (corresponding author), Univ Sydney, Royal Rehabil Ctr Sydney, Dept Med, Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.						ALBERTS MS, 1991, COGNITIVE REHABILITA, P95; Alfano Dennis P, 1990, Clin Neuropsychol, V4, P69, DOI 10.1080/13854049008401498; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bond M. R., 1990, REHABILITATION ADULT, P179; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P746; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Damasio A.R., 1993, CLIN NEUROPSYCHOLOGY, P409; DODWELL D, 1988, PSYCHOL MED, V18, P495, DOI 10.1017/S0033291700008035; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; ELSASS L, 1991, THESIS LA TROBE U AU; Eysenck H.W., 1981, MODEL PERSONALITY; Eysenck HJ., 1991, MANUAL EYSENCK PERSO; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; Fleming J, 1999, BRAIN INJURY, V13, P417; Folkman S., 1984, STRESS; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; GASS CS, 1995, CLIN PERSONALITY ASS, P192; GOLDSTEIN FC, 1989, INTEGRATING THEORY P, P217; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JAMIESON KG, 1966, 13 NAT HLTH MED RES; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KAY T, 1992, REHABILITATION POST, P109; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Lannoo E, 1997, J PSYCHOSOM RES, V43, P505, DOI 10.1016/S0022-3999(97)00152-9; Ley P., 1972, QUANTITATIVE ASPECTS; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1998, ORGANIC PSYCHIAT PSY; LONDON PS, 1967, ANN ROY COLL SURG, V41, P607; Luria A.R., 1973, WORKING BRAIN; Luria AR, 1969, HDB CLINICAL NEUROLO, P725; MACMILLAN M, 1996, BRAIN DAM B, P243; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; SELECKI BR, 1967, MED J AUSTR     0715, P113; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; Tate PS, 1999, BRAIN INJURY, V13, P767; TATE RL, 1987, SCAND J REHABIL MED, V19, P19; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TSUANG MT, 1985, AM J PSYCHIAT, V142, P538; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296; [No title captured]	75	30	30	0	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		43	64		10.1080/09602010244000372			22	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500004	21854327				2022-02-06	
J	Cox, WM; Heinemann, AW; Miranti, SV; Schmidt, M; Klinger, E; Blount, J				Cox, WM; Heinemann, AW; Miranti, SV; Schmidt, M; Klinger, E; Blount, J			Outcomes of systematic motivational counseling for substance use following traumatic brain injury	JOURNAL OF ADDICTIVE DISEASES			English	Article						motivational counseling; substance use; traumatic brain injury	GALVESTON ORIENTATION; EMERGENCY ROOM; AMNESIA TEST; PATTERNS	The effects of Systematic Motivational Counseling (SMC) on adults following traumatic brain injury (TBI) were assessed. The sample comprised 40 participants in the SMC Group who received 12 individual SMC sessions and 54 participants in the Comparison Group who received no motivational or substance-abuse treatment. Both groups received rehabilitation for their brain injuries. The SMC additionally focused on participants' personal goals and concerns in various areas of their lives, and helped them to formulate and execute concrete and realistic plans for resolving their concerns. To assess changes across time in the SMC Group, motivational structure, positive and negative affect, and substance use were measured at baseline, immediately after the intervention (mean of 10.2 months from baseline), and at a follow-up (mean of 9.1 months later). Because the comparison group had no SMC intervention, only two assessments were taken: at baseline and at a follow-up (mean of 12.8 months later). Across time, the SMC Group showed significant improvements in motivational structure and a significant reduction in negative affect and the use of substances of abuse. There were no corresponding changes in the Comparison Group. The results indicate that SMC improves motivational indices and may help to moderate substance use; hence they suggest a potential role for SMC in the rehabilitation of patients with TBI. (C) 2003 by The Haworth Press, Inc. All rights reserved.	Univ Coll N Wales, Sch Psychol, Bangor LL57 2AS, Gwynedd, Wales; Northwestern Univ, Sch Med, Dept Phys Med & Rehabil, Chicago, IL USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; Schwab Rehabil Hosp & Care Network, Chicago, IL USA; Lutheran Gen Hosp, Park Ridge, IL 60068 USA; Univ Minnesota, Morris, MN 56267 USA; Stat Comp & Design Consultants, Kansas City, MO USA		Cox, WM (corresponding author), Univ Coll N Wales, Sch Psychol, Bangor LL57 2AS, Gwynedd, Wales.	m.cox@bangor.ac.uk	Heinemann, Allen W./AAI-2790-2021; Heinemann, Allen W/K-6283-2012	Heinemann, Allen W./0000-0003-2782-7326; Heinemann, Allen W/0000-0003-2782-7326			BLOUNT JP, 1996, ALCOHOL DRUG INVENTO; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Cherpitel CJ, 1998, DRUG ALCOHOL REV, V17, P423, DOI 10.1080/09595239800187261; Cox W.M., 1990, WHY PEOPLE DRINK PAR, P291; Cox WM, 2000, ADDICT RES, V8, P121, DOI 10.3109/16066350009004415; COX WM, 1988, J ABNORM PSYCHOL, V97, P168, DOI 10.1037/0021-843X.97.2.168; COX WM, 1991, MOTIVATIONAL INTERVI, P260; COX WM, IN PRESS J STUDIES A; COX WM, 1996, SYSTEMATIC MNORIVATI; DAMASIO AR, 1994, DESCARTESERROR; HOWARD KI, 1999, COST EFFECTIVENESS P, P143; Keppel G., 1991, DESIGN ANAL RES HDB; Klinger E., 1987, ADV PERSONALITY ASSE, V6, P31; Klinger E, 1995, OXF TEXT CLIN PSY, P267; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Macdonald S, 1999, DRUG ALCOHOL DEPEN, V55, P53, DOI 10.1016/S0376-8716(98)00184-7; MURRAY PK, 1987, REHABIL PSYCHOL, P501; ROSENTHAL M, 1998, REHABILITATION ADULT; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WEHMAN P, 1990, VOCATIONAL REHABILIT; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; [No title captured]	22	30	30	0	5	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	1055-0887			J ADDICT DIS	J. Addict. Dis.		2003	22	1					93	110		10.1300/J069v22n01_07			18	Substance Abuse	Social Science Citation Index (SSCI)	Substance Abuse	659MN	WOS:000181780600007	12661982				2022-02-06	
J	Hart, T; O'Neil-Pirozzi, T; Morita, C				Hart, T; O'Neil-Pirozzi, T; Morita, C			Clinician expectations for portable electronic devices as cognitive-behavioural orthoses in traumatic brain injury rehabilitation	BRAIN INJURY			English	Article							MEMORY AID; PEOPLE	Objective: To ascertain experiences and expectations of clinicians as to uses of portable electronic devices such as hand-held computers as cognitive-behavioural orthoses in TBI rehabilitation. Design: Survey study. Procedures: A survey developed and piloted with the input of clinician focus groups was completed by 81 TBI clinicians from a variety of disciplines and work settings. Results: About half of the respondents reported prior exposure to clients with TBI who had used portable electronic aids. Of 10 key cognitive/behavioural areas, respondents saw most potential for devices in the areas of learning/memory, planning/organization and initiation; less potential was seen for social/interpersonal or behavioural difficulties. However, many respondents also identified learning and memory abilities as essential client characteristics for successful use of portable electronics. Cost was identified as a significant barrier to use of portable devices in rehabilitation. Respondents expressed low confidence overall in their ability to guide clients in use of devices; those who reported personal use were significantly more confident than those who did not. Conclusion: Clinicians believe that new electronic devices have potential for treatment of some cognitive impairments, but clinical experimentation may be limited by costs of technology and low clinician confidence.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980034, H133A70033] Funding Source: Medline		Fuhrer MJ, 2001, AM J PHYS MED REHAB, V80, P528, DOI 10.1097/00002060-200107000-00013; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; KAYE H, 2000, DISABILITY STAT REPO, V13; Kennedy PR, 1998, NEUROREPORT, V9, P1707, DOI 10.1097/00001756-199806010-00007; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; KREUTZER JS, 1992, J HEAD TRAUMA REHAB, V7, P70; Loebl D, 1999, AM J OCCUP THER, V53, P387, DOI 10.5014/ajot.53.4.387; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; SCHERER M, 1996, HUMAN PERSPECTIVE, P99; Scherer MJ, 2002, DISABIL REHABIL, V24, P1, DOI 10.1080/09638280110066262; Vaccaro MJ, 2002, NEUROREHABILITATION, V17, P169; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wright P, 2001, INT J REHABIL RES, V24, P299, DOI 10.1097/00004356-200112000-00006	19	30	30	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	5					401	411		10.1080/0269905021000038438			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	660MQ	WOS:000181837300004	12745712				2022-02-06	
J	Jones, PA; Andrews, PJD; Easton, VJ; Minns, RA				Jones, PA; Andrews, PJD; Easton, VJ; Minns, RA			Traumatic brain injury in childhood: Intensive Care time series data and outcome	BRITISH JOURNAL OF NEUROSURGERY			English	Article						age-specific physiological derangements; cerebral perfusion pressure; children; intracranial pressure; outcome; secondary insults; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; INTRA-CRANICAL PRESSURE; PERFUSION-PRESSURE; SECONDARY INSULTS; YOUNG-CHILDREN; AGE; COMA; MANAGEMENT; SEVERITY	Age-specific norms are necessary to determine potential secondary brain insult after head injury in children. We describe and quantify the secondary physiological derangement recorded in children of different ages following traumatic brain injury, and relate it to outcome at 12 months post-injury. Prospective time-series data (including intracranial pressure, arterial blood pressure, cerebral perfusion pressure, oxygen saturation, temperature and heart rate) downloaded from ICU monitors, were examined to identify abnormal (i.e. outside normal age-specific limits) recordings lasting more than 5 min. Cumulated total duration of derangement was calculated for each parameter and as a percentage of the time that the ICP monitor was in situ. Univariate and multivariate logistic regression modelling was used to evaluate predictors of outcome. Age-specificity allows realistic comparisons of physiological data among children. Duration of age-specific derangement of CPP was found to predict outcome (dead v. alive: p = 0.003 and Glasgow Outcome Score 1-3 v. 4-5, i.e. poor v. independent outcome p = 0.004).	Univ Edinburgh, Dept Child Life & Hlth, Royal Hosp Sick Children, Edinburgh EH9 1UW, Midlothian, Scotland; Western Gen Hosp, Dept Clin & Surg Serv Anaesthet Pain Management &, Edinburgh EH4 2XU, Midlothian, Scotland; ICON Clin Res Ltd, Dublin 18, Ireland		Minns, RA (corresponding author), Univ Edinburgh, Dept Child Life & Hlth, Royal Hosp Sick Children, 20 Sylvan Pl, Edinburgh EH9 1UW, Midlothian, Scotland.	Robert.Minns@ed.ac.uk					Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; *AM ASS AUT MED, 1995, ABBR INJ SCAL 1985 R; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; ANDREWS PJD, 1995, ACTA ANAESTH SCAND, V39, P112, DOI 10.1111/j.1399-6576.1995.tb04287.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; [Anonymous], 1987, PEDIATRICS, V79, P1; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; DONMALL MC, 1985, ACTA PAEDIAT SC S318, V74, P23; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Falkner B, 1996, PEDIATRICS, V98, P649; Hosmer D, 1989, APPL LOGISTIC REGRES; Howells T. P., 1995, Journal of Neurotrauma, V12, P471; HOWELLS TP, 1997, P 10 INT S INTR PRES; HOWELLS TP, 1994, EDINBURGH MONITOR BR; JACKSON S, 1999, BRIT J NEUROSURG, V13, P104; JAMES HE, 1993, NEUROSURG QUART, V3, P272; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kirkpatrick PJ, 1996, J NEUROL NEUROSUR PS, V60, P131, DOI 10.1136/jnnp.60.2.131; Kollevold T, 1976, J Oslo City Hosp, V26, P99; LAM WH, 1999, CARE CRITICALLY 3, V15, P95; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MANN N, 1999, CARE CRITICALLY 3, V2, P143; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MAYER T, 1982, CLIN PEDIATR, V21, P391, DOI 10.1177/000992288202100701; MCLAURIN R L, 1989, Neurosurgical Review, V12, P219, DOI 10.1007/BF01790652; MINNS RA, 1991, PROBLEMS INTRACRANIA, P170; MORONT ML, 1994, PEDIATR CLIN N AM, V41, P1201; Nybo T, 1999, BRAIN INJURY, V13, P759; Ott R, 2000, J TRAUMA, V49, P729, DOI 10.1097/00005373-200010000-00023; PAYNE W, 1998, INTENS CARE WORLD, V15, P45; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PIPER IR, 1991, BR J INTENS CARE, V1, P73; REILLY PL, 1988, CHILD NERV SYST, V4, P30; ROSNER B, 1993, J PEDIATR-US, V123, P871, DOI 10.1016/S0022-3476(05)80382-8; SETTERGREN G, 1980, ACTA PAEDIATR SCAND, V69, P457, DOI 10.1111/j.1651-2227.1980.tb07114.x; SHANN F, 1996, DRUG DOSES; SHAPIRO K, 1993, HEAD INJURY, P427; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Signorini DF, 1997, CRIT CARE MED, V25, P2048, DOI 10.1097/00003246-199712000-00024; SIGNORINI DF, 1997, J NEUROTRAUM, V14, P280; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TEASDALE GM, 2000, 46 SIGN ROY COLL PHY; VANDER AJ, 1975, HUMAN PHYSL MECH BOD, P391; Verger K, 2000, BRAIN INJURY, V14, P495; WELCH K, 1980, J NEUROSURG, V52, P693, DOI 10.3171/jns.1980.52.5.0693; ZIMMERMAN RA, 1981, J NEURORADIOLOGY, V8, P257	63	30	31	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		2003	17	1					29	39		10.1080/0268869031000093708			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	677GE	WOS:000182797900009	12779199				2022-02-06	
J	Wilson, BA; Scott, H; Evans, J; Emslie, H				Wilson, BA; Scott, H; Evans, J; Emslie, H			Preliminary report of a NeuroPage service within a health care system	NEUROREHABILITATION			English	Article						memory; brain injury; rehabilitation; external aids	MEMORY AID; REHABILITATION	NeuroPage, a paging service designed to reduce the everyday memory and/or planning problems of people with neurological deficits, is described. Following several research studies carried out to-evaluate the system, a British local health authority set up a nationwide commercial NeuroPage service. A report on the first 40 clients recruited to the service is provided. The age range was 14-81 years, the majority of clients were men and the most frequent diagnosis was traumatic brain injury although a number of different diagnostic groups were represented. The types of messages sent and the group's satisfaction with NeuroPage are considered. Three brief case studies to illustrate the different ways clients used the system are presented.	Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge CB2 2QQ, England; Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, Cambs, England		Wilson, BA (corresponding author), Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Box 58, Cambridge CB2 2QQ, England.						Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; EVANS JJ, IN PRESS J INT NEURO; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Inglis E, 2002, UNIVERSAL ACCESS AND ASSISTIVE TECHNOLOGY, P171; Robertson IH, 1999, CURR OPIN NEUROL, V12, P703, DOI 10.1097/00019052-199912000-00008; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; WILSON BA, IN PRESS CLIN NEUROP; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161	12	30	32	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2003	18	1					3	8					6	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	688EB	WOS:000183419400002	12719616				2022-02-06	
J	Vela, JM; Yanez, A; Gonzalez, B; Castellano, B				Vela, JM; Yanez, A; Gonzalez, B; Castellano, B			Time course of proliferation and, elimination of microglia/macrophages in different neurodegenerative conditions	JOURNAL OF NEUROTRAUMA			English	Article						cell death; degeneration; inflammation; lesion; microglia; proliferation	CELL NUCLEAR ANTIGEN; DELAYED NEURONAL DEATH; BLOOD-BRAIN-BARRIER; SPINAL-CORD INJURY; MICROGLIAL CELLS; NERVOUS-SYSTEM; FLOW-CYTOMETRY; RAT-BRAIN; PHAGOCYTIC MICROGLIA; DNA FRAGMENTATION	Ablation of the hindlimb area of the sensorimotor cortex produces degeneration in the cortex (invasive traumatic injury) and leads to retrograde and/or anterograde degeneration in the thalamus (non-invasive injury, distal reaction). This provides an useful model to study the proliferation and elimination of microglia/macrophages in different neurodegenerative conditions. Changes in the morphology, distribution and numbers of microglia in the affected cortex and thalamus were analyzed at various time points (12 h to 30 days) after injury. In parallel, proliferation was determined by immunocytochemistry for the proliferating cell nuclear antigen and cell death, by the TUNEL method. Proliferation was an early event in the microglia/macrophage response (from 12 h in the cortex and from 2 days post-lesion in the thalamus) and persisted up to 30 days. The different microglia/macrophage phenotypes proliferated in a specific temporospatial pattern. In the lesioned cortex, early activation and proliferation of intrinsic microglia was accompanied, from the second post-lesion day, by monocyte entrance and proliferation of monocyte-derived cells. In contrast, accumulation of cells in the thalamus resulted from proliferation of intrinsic microglia, without apparent/significant monocytic recruitment. During the subsequent microglia/macrophages removal the majority of the cells in the cortex transformed into ameboid cells devoid of cell processes that progressively accumulated as fully-developed macrophages tissue within the lesion (3-14 days) ultimately migrating out to the meningeal connective tissue (14-30 days). Only some process-bearing cells, remaining in the cortical tissue bordering the lesion, underwent degeneration by 14-21 days post-lesion. In contrast, in the distal. affected thalamic nuclei, microglial cell death occurred by 14-30 days post-lesion. Altogether, this study shows that both the origin and fate of microglia/macrophages depend on the nature of the lesion.	Univ Autonoma Barcelona, Fac Med, Dept Biol Cellular Fisiol & Immunol, Unitat Histol, E-08193 Barcelona, Spain		Castellano, B (corresponding author), Univ Autonoma Barcelona, Fac Med, Dept Biol Cellular Fisiol & Immunol, Unitat Histol, Torre M-5, E-08193 Barcelona, Spain.	Bernardo.Castellano@uab.es	Castellano, Bernardo/G-1428-2010; Gonzalez, Berta/G-6250-2010; Gonzalez, Berta/G-1428-2010	Castellano, Bernardo/0000-0003-1976-971X; Vela, Jose Miguel/0000-0002-6809-1477; Gonzalez, Berta/0000-0002-1860-3980			ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Acarin L, 2001, STROKE, V32, P2394, DOI 10.1161/hs1001.097243; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; ANGELOV DN, 1995, GLIA, V13, P113, DOI 10.1002/glia.440130205; AVANZI GC, 1991, CANCER RES, V51, P1741; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bignami Amico, 1995, P843; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Castano A, 1996, NEUROBIOL AGING, V17, P745; CHAMAK B, 1991, NEUROSCIENCE, V45, P513, DOI 10.1016/0306-4522(91)90267-R; CHAMAK B, 1994, J NEUROSCI RES, V38, P221, DOI 10.1002/jnr.490380213; Del Rio-Hortega P., 1932, CYTOLOGY CELLULAR PA, P481; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Elkabes S, 1996, J NEUROSCI, V16, P2508; Faull RLM, 1985, RAT NERVOUS SYSTEM, V1, P129; GADBOIS DM, 1995, EXP CELL RES, V220, P220, DOI 10.1006/excr.1995.1309; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; Gehrmann Jochen, 1995, P883; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, ADV NEUROL, V59, P315; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GIULIAN D, 1994, NEUROCHEM INT, V25, P227, DOI 10.1016/0197-0186(94)90066-3; GIULIAN D, 1993, STROKE, V24, pI84; Giulian Dana, 1995, P671; Hernandez JMV, 1997, BRAIN RES, V747, P130, DOI 10.1016/S0006-8993(96)01267-X; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; Jones LL, 1997, J NEUROCYTOL, V26, P755, DOI 10.1023/A:1018514415073; Kadota E, 2000, ACT NEUR S, V76, P69; Kalla R, 2001, J COMP NEUROL, V436, P182; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KURKI P, 1988, J IMMUNOL METHODS, V109, P49, DOI 10.1016/0022-1759(88)90441-3; LASSMANN H, 1991, REV NEUROL-FRANCE, V147, P763; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LAWSON LJ, 1995, IMMUNE RESPONSES NER, P27; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; Leskovar A, 2001, CELL TISSUE RES, V304, P311, DOI 10.1007/s004410000325; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; LOHR F, 1995, CELL PROLIFERAT, V28, P93, DOI 10.1111/j.1365-2184.1995.tb00058.x; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MCCORMICK D, 1992, HISTOPATHOLOGY, V21, P591, DOI 10.1111/j.1365-2559.1992.tb00454.x; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MILLIGAN CE, 1991, J COMP NEUROL, V314, P136, DOI 10.1002/cne.903140113; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Nakajima K, 2001, J BIOCHEM-TOKYO, V130, P169, DOI 10.1093/oxfordjournals.jbchem.a002969; NITATORI T, 1995, J NEUROSCI, V15, P1001; Paxinos G, 1985, RAT NERVOUS SYSTEM, VI, P487; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; PERRY VH, 1992, NEUROPATH APPL NEURO, V18, P454, DOI 10.1111/j.1365-2990.1992.tb00811.x; Polazzi E, 2001, GLIA, V36, P271, DOI 10.1002/glia.1115; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RIVADEPATY I, 1994, EXP NEUROL, V128, P77, DOI 10.1006/exnr.1994.1114; Shibata H, 1996, NEUROSCI RES, V26, P83, DOI 10.1016/0168-0102(96)01083-8; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SKOFF RP, 1971, J COMP NEUROL, V141, P133, DOI 10.1002/cne.901410202; Snider BJ, 1999, ANN NY ACAD SCI, V893, P243, DOI 10.1111/j.1749-6632.1999.tb07829.x; Sorensen JC, 1996, EXP BRAIN RES, V112, P203; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Suzuki H, 2001, NEUROSCI LETT, V312, P95, DOI 10.1016/S0304-3940(01)02198-X; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAKAHASHI T, 1993, J NEUROCYTOL, V22, P1096, DOI 10.1007/BF01235751; THOMPSON D, 1992, SIGHT SOUND, V1, P61; VANGROEN T, 1992, J COMP NEUROL, V324, P427, DOI 10.1002/cne.903240310; VELA JM, 1995, J COMP NEUROL, V361, P602, DOI 10.1002/cne.903610405; Vela JM, 1996, BRAIN RES, V712, P134, DOI 10.1016/0006-8993(95)01422-5; Wang Y, 1998, BRAIN RES, V781, P137, DOI 10.1016/S0006-8993(97)01223-7; WISE SP, 1977, J COMP NEUROL, V175, P129, DOI 10.1002/cne.901750202; Yamashita K, 2000, CELL MOL NEUROBIOL, V20, P541, DOI 10.1023/A:1007007710703; Yoshida Kazunari, 1997, Keio Journal of Medicine, V46, P55; Zietlow R, 1999, EUR J NEUROSCI, V11, P1657, DOI 10.1046/j.1460-9568.1999.00583.x; ZILLES K, 1985, RAT NERVOUS SYSTEM, V1, P375; ZIMMER J, 1982, NEUROSCIENCE, V7, P1905, DOI 10.1016/0306-4522(82)90006-9; ZOLZER F, 1994, CELL PROLIFERAT, V27, P685, DOI 10.1111/j.1365-2184.1994.tb01383.x	82	30	31	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1503	1520		10.1089/089771502320914723			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500010	12490014				2022-02-06	
J	Bondanelli, M; Ambrosio, MR; Margutti, A; Boldrini, P; Basaglia, N; Franceschetti, P; Zatelli, MC; Uberti, ECD				Bondanelli, M; Ambrosio, MR; Margutti, A; Boldrini, P; Basaglia, N; Franceschetti, P; Zatelli, MC; Uberti, ECD			Evidence for integrity of the growth hormone/insulin-like growth factor-1 axis in patients with severe head trauma during rehabilitation	METABOLISM-CLINICAL AND EXPERIMENTAL			English	Article							HORMONE-RELEASING-FACTOR; BRAIN-INJURY; HYPOGONADISM; WITHDRAWAL; PROLACTIN; SECRETION; RESPONSES	Severe traumatic head injury has been recognized to be associated with hypothalamo-hypophyseal impairment and subsequent abnormalities in hormone secretion, which can contribute to a prolonged clinical course and to hampered recovery in many head-injured patients. Most of the data on the growth hormone/insulin-like growth factor -1 (GH/IGF-1) axis function have been obtained early after head injury, whereas GH secretory pattern has not been fully elucidated after patients had left the intensive care unit. We examined the activity of the GH/IGF-1 axis in 16 severely closed head-injured (CHI) patients (14 males; age range, 17 to 47 years; body mass index [BMI], 21.4 +/- 0.8 kg/m(2)) during the rehabilitation period at least 1 month after leaving the intensive care unit and in 12 sex-, age-, and weight-matched healthy controls. The severity of trauma was assessed by the Glasgow Coma Scale (GCS) score (8 or less), posttraumatic amnesia (PTA, more than 24 hours), and initial computed tomography (CT) scan. The clinical picture at time of the study was evaluated by the Rancho Los Amigos Scale of Cognitive Functioning (CFS) and the Functional Independence Measure (FIM). In all subjects, we evaluated basal levels of anterior pituitary hormones, IGF-1, insulin-like growth factor-binding protein (IGFBP)-3, and IGFBP-1, as well as the GH responses to intravenous (IV) infusion of growth hormone-releasing hormone (GHRH) alone, GHRH plus arginine (ARG), and the GH release evoked by somatostatin (SRIH) infusion withdrawal, which is related to endogenous GHRH tone. In all subjects, nutritional parameters and nitrogen balance were normal. Basal plasma concentrations of GH, IGF-1, IGFBP-3, and IGFBP-1 did not significantly differ between CHI patients and controls. The GH responses to GHRH and GHRH plus ARG did not significantly differ between CHI patients (GH peak, 10.7 +/- 3.0 mug/L; area under the curve [AUC], 5.9 +/- 1.5 mug/L . min; and GH peak, 34.7 +/- 6.1 mug/L; AUC, 20.25 +/- 3.3 mug/L . min, respectively) and normal subjects (GH peak at 30 minutes, 7.23 +/- 1.35 mug/L; AUC, 4.7 +/- 0.8 mug/L . min; and GH peak at 60 minutes, 41.0 +/- 5.1 mug/L; AUC, 24.3 +/- 1.7 mug/L . min, respectively). SRIH withdrawal resulted in an unequivocal increase in plasma GH concentrations both in CHI patients and in controls, without any significant difference between the 2 groups. A negative correlation was found between the GH response (DeltaGH peak) to SRIH withdrawal and CFS (r = -.615, P <.005). In conclusion, our study indicates that patients receiving rehabilitation after leaving the intensive care unit for severe traumatic head injury have no significant changes of GH secretion with normal central regulation of the GH-IGF-1 axis. Copyright 2002, Elsevier Science (USA). All rights reserved.	Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, I-44100 Ferrara, Italy; Arcispedale St Anna, Dept Rehabil Med, Ferrara, Italy		Uberti, ECD (corresponding author), Univ Ferrara, Endocrinol Sect, Dept Biomed Sci & Adv Therapies, Via Savonarola 9, I-44100 Ferrara, Italy.		Zatelli, Maria Chiara/Y-1160-2019; Zatelli, Maria Chiara/U-2649-2018	Zatelli, Maria Chiara/0000-0001-8408-7796; degli Uberti, Ettore/0000-0002-9441-7223; ambrosio, maria rosaria/0000-0002-7911-9770; Bondanelli, Marta/0000-0001-8071-6559			Baxter RC, 1999, GROWTH HORM IGF RES, V9, P67, DOI 10.1016/S1096-6374(99)80013-6; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Cappa M, 1999, J CLIN ENDOCR METAB, V84, P4426, DOI 10.1210/jc.84.12.4426; Cernak I, 1999, BRAIN INJURY, V13, P1005; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; Della Corte F, 1998, CRIT CARE MED, V26, P1419; Giustina A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/er.19.6.717; GOTTARDIS M, 1990, INTENS CARE MED, V16, P163, DOI 10.1007/BF01724795; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hatton J, 1997, J NEUROSURG, V86, P779, DOI 10.3171/jns.1997.86.5.0779; JACKSON RD, 1989, AM J PHYS MED REHAB, V68, P18, DOI 10.1097/00002060-198902000-00006; JEEVANANDAM M, 1995, METABOLISM, V44, P1205, DOI 10.1016/0026-0495(95)90017-9; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MELARVIE S, 1995, SURGERY, V117, P402, DOI 10.1016/S0039-6060(05)80060-1; MIKI N, 1988, J ENDOCRINOL, V117, P245, DOI 10.1677/joe.0.1170245; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; TEASDALE G, 1974, LANCET, V2, P81; Uberti ECD, 1997, J CLIN ENDOCR METAB, V82, P2885, DOI 10.1210/jc.82.9.2885; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Welbourne TC, 1997, BAILLIERE CLIN ENDOC, V11, P699, DOI 10.1016/S0950-351X(97)80974-3; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011	29	30	34	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0026-0495	1532-8600		METABOLISM	Metab.-Clin. Exp.	OCT	2002	51	10					1363	1369		10.1053/meta.2002.34714			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	603XU	WOS:000178587200023	12370860				2022-02-06	
J	Lynch, B				Lynch, B			Historical review of computer-assisted cognitive retraining	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; cognitive retraining software; computer-assisted cognitive retraining; microcomputers; personal digital assistants	TRAUMATIC BRAIN INJURY; REHABILITATION; MEMORY; REMEDIATION; RETENTION; DEFICITS	Objectives: This article details the introduction and development of the use of microcomputers as adjuncts to traditional cognitive rehabilitation of persons with acquired brain injury. Summary: The initial application of video games as therapeutic recreation in the late 1970s was soon followed in the early 1980s by the use of the first personal computers and available educational software. By the mid-1980s, both the IBM PC and Macintosh platforms were established, along with simplified programming languages that allowed individuals without extensive technical expertise to develop their own software. Several rehabilitation clinicians began to produce and market specially written cognitive retraining software for one or the other platform. Their work was detailed and reviewed, as was recently released software from commercial sources. The latter discussion included the latest developments in the rehabilitation applications of personal digital assistants and related organizing, reminding, and dictation devices. A summary of research on the general and specific efficacy of computer-assisted cognitive retraining illustrated the lingering controversy and skepticism that have been associated with this field since its inception. Conclusions: Computer-assisted cognitive retraining (CACR) can be an effective adjunct to a comprehensive program of cognitive rehabilitation. Training needs to be focused, structured, monitored, and as ecologically relevant as possible for optimum effect. Transfer or training or generalizabitity of skills remains a key issue in the field and should be considered the key criterion in evaluating whether to initiate or continue CACR.			Lynch, B (corresponding author), 133 Arch St,Suite 4, Redwood City, CA 94062 USA.						*AG HLTH CAR POL R, 1998, EV REP TECHN ASS; BENEDICT RHB, 1994, SCHIZOPHRENIA BULL, V20, P537, DOI 10.1093/schbul/20.3.537; BENEDICT RHB, 1989, BRIT J CLIN PSYCHOL, V28, P187, DOI 10.1111/j.2044-8260.1989.tb00832.x; BORTNER M, 1960, J NERV MENT DIS, V130, P49, DOI 10.1097/00005053-196001000-00008; BRACY O, 1998, PSSCOGREHAB ULTIMATE; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chen SHA, 1997, BRAIN INJURY, V11, P197; Chute DL, 1988, NEUROPSYCHOLOGY, V2, P41, DOI 10.1037//0894-4105.2.1.41; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cole E, 1999, NEUROREHABILITATION, V12, P39; COLE E, 1999, SW DISTORSION LEICHT; CRAINE JF, 1981, REHABILITATION BRAIN; DILLER L, 1976, CLINICAL PSYCHOLOGIS, V29, P13; DREW B, 1986, COGNITIVE REHABILITA, V4, P26; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; ENGUM ES, 1989, COGNITIVE REHABILITA, V7, P22; Engum ES, 1990, COGNITIVE REHABILITA, V8, P20; GIANUTSOS R, 1981, COGREHAB 1; Giaquinto S, 1992, Acta Neurol (Napoli), V14, P547; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; GUILMETTE TJ, 1997, POCKET GUIDE BRAIN I; HAGEN C, 1982, COGNITIVE REHABILITA; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; LAMBERT EW, 1990, COGNITIVE REHABILITA, V8, P34; LAMBERT EW, 1992, J COGNITIVE REHABIL, V10, P32; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LYNCH W, 1982, COGNITIVE REHABILITA; LYNCH W, 1992, J HEAD TRAUMA REHAB, V7, P106; Lynch W., 1986, COGNITIVE REHABILITA, V4, P14; LYNCH W, 1986, J HEAD TRAUMA REHAB, V1, P79; LYNCH W, 1983, COGN REHABIL, V1, P119; LYNCH W, 1983, VIDEO GAMES HUMAN DE; LYNCH W, 1984, BEHAV ASSESSMENT REH; LYNCH W, 1987, HDB CONTEMPORARY REH; LYNCH W, 1990, J HEAD TRAUMA REHAB, V5, P78; LYNCH W, 1992, J HEAD TRAUMA REHAB, V7, P36; Lynch WJ, 1998, J HEAD TRAUMA REHAB, V13, P91, DOI 10.1097/00001199-199810000-00011; Matthews E, 1991, GLOBAL BIOGEOCHEM CY, V5, P3, DOI 10.1029/90GB02311; McKitrick Leslie A., 1997, Clinical Gerontologist, V17, P58; MEEDER D, 1982, COGNITIVE REHABILITA; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Ray EC, 1997, ARCH CLIN NEUROPSYCH, V12, P491; SANDFORD J, 1985, CAPTAIN COGNITIVE RE; SBORDONE RJ, 1986, PSYCHOTHERAPY PRIVAT, V4, P51; Sohlberg M, 1993, J HEAD TRAUMA REHAB, V8, P45, DOI DOI 10.1097/00001199-199303000-00006; STEELE RD, 1989, NEUROPSYCHOLOGIA, V27, P409, DOI 10.1016/0028-3932(89)90048-1; Stuss D., 1985, FRONTAL LOBES; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874; Wood R L, 1987, Int Disabil Stud, V9, P149	56	30	40	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2002	17	5					446	457		10.1097/00001199-200210000-00006			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	610DD	WOS:000178944700006	12802254				2022-02-06	
J	Santaniello, JM; Miller, PR; Croce, MA; Bruce, L; Bee, TK; Malhotra, AK; Fabian, TC				Santaniello, JM; Miller, PR; Croce, MA; Bruce, L; Bee, TK; Malhotra, AK; Fabian, TC			Blunt aortic injury with concomitant intra-abdominal solid organ injury: Treatment priorities revisited	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						blunt aortic injury; liver and spleen; nonoperative management; heparin	TRAUMATIC RUPTURE; HEPATIC-TRAUMA; MANAGEMENT; ASSOCIATION; SURGERY; ISTHMUS	Background: Patients with blunt aortic injury (BAI) often have concomitant liver or spleen (L/S) injuries. With increasing use of cardiopulmonary bypass with heparinization in repair of BAI, many advocate operative management of the US injury before aortic repair to eliminate risk of hemorrhage. We evaluated the safety of nonoperative management (NOM) of blunt L/S injuries in patients undergoing acute BAI repair with bypass. Methods: All patients admitted over a 6-year period with BAI were identified from the registry of our Level I trauma center. Patients with isolated L/S injuries without BAI admitted over the same period served as controls. Groups were compared with regard to demographics, injury characteristics, hospital course, and mortality. Results. Eighty-four patients were diagnosed with BAI from 1994 to 2000; 28 (33%) also had blunt abdominal trauma. Three patients with severe brain injury did not undergo BAI repair, and five required laparotomy before BAI repair for other intra-abdominal injuries (two for hemodynamic instability with splenic injury, and three for concomitant bowel injury). Therefore, 20 of 28 (71.4%) BAI patients with grade I or II US injury (Aorta L/S group) underwent planned NOM. All BAIs were repaired using partial bypass with full heparinization. These 20 patients are compared with 894 patients with grade I or II L/S injuries with no BAI (L/S group) over the same time period. There was no difference in the nonoperative failure rate of the Aorta L/S group versus the L/S group (0% vs. 1.7%). Both groups had similar complication rates. The Aorta L/S group was also compared with 56 BAIs without solid organ injury (Aorta group). Although the Aorta L/S group was more severely injured than the Aorta group (Injury Severity Score of 35.3 vs. 26.8, p < 0.0001), transfusion rates (5.7 U of packed red blood cells vs. 8.0 U of packed red blood cells, p = NS), hospital days (17.9 vs. 19.1, p = NS) and mortality (10% vs. 9%, p = NS) were similar. Conclusion: NOM of patients with grade I or II L/S injury who undergo systemic anticoagulation with heparin for repair of BAI is safe and associated with transfusion rates similar to BAI alone. Patients with low-grade liver or spleen injuries do not require laparotomy before BAI repair using partial bypass.	Loyola Univ, Med Ctr, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA; Univ Tennessee, Dept Surg, Memphis, TN 38104 USA; Wake Forest Sch Med, Dept Surg, Winston Salem, NC USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Surg, Richmond, VA 23298 USA		Santaniello, JM (corresponding author), Loyola Univ, Med Ctr, Stritch Sch Med, Dept Surg, 2160 S 1st Ave,Bldg 110,Room 4234, Maywood, IL 60153 USA.	jsantan@lumc.edu					Attar S, 1999, ANN THORAC SURG, V67, P959, DOI 10.1016/S0003-4975(99)00174-5; BORMAN KR, 1982, AM J SURG, V144, P728, DOI 10.1016/0002-9610(82)90559-1; CROCE MA, 1995, ANN SURG, V221, P744, DOI 10.1097/00000658-199506000-00013; Fabian TC, 1998, ANN SURG, V227, P666, DOI 10.1097/00000658-199805000-00007; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; Fisher PJ, 2000, SOUTH MED J, V93, P865; Frick EJ, 1997, J TRAUMA, V43, P844, DOI 10.1097/00005373-199711000-00018; Hunt JP, 1996, J TRAUMA, V40, P547, DOI 10.1097/00005373-199604000-00005; LEE RB, 1992, AM SURGEON, V58, P37; MATTOX KL, 1985, ANN THORAC SURG, V40, P456, DOI 10.1016/S0003-4975(10)60100-2; Morgan PB, 2000, SOUTHERN MED J, V93, P173; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Pate JW, 1999, WORLD J SURG, V23, P59, DOI 10.1007/s002689900565; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; Peitzman AB, 2000, J TRAUMA, V49, P177, DOI 10.1097/00005373-200008000-00002; Pierangeli A, 2000, CARDIOVASC SURG, V8, P280, DOI 10.1016/S0967-2109(00)00015-6; Richardson JD, 2000, ANN SURG, V232, P324, DOI 10.1097/00000658-200009000-00004; Sweeney MS, 1997, ANN THORAC SURG, V64, P384, DOI 10.1016/S0003-4975(97)00561-4; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; Wahl WL, 1999, J TRAUMA, V47, P254, DOI 10.1097/00005373-199908000-00006	20	30	31	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2002	53	3					442	445		10.1097/00005373-200209000-00008			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	599GA	WOS:000178324700010	12352478				2022-02-06	
J	Takaoka, M; Tabuse, H; Kumura, E; Nakajima, S; Tsuzuki, T; Nakamura, K; Okada, A; Sugimoto, H				Takaoka, M; Tabuse, H; Kumura, E; Nakajima, S; Tsuzuki, T; Nakamura, K; Okada, A; Sugimoto, H			Semiquantitative analysis of corpus callosum injury using magnetic resonance imaging indicates clinical severity in patients with diffuse axonal injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; QUANTITATIVE-ANALYSIS; MRI; STEM; MODEL; COMA	Objective: To evaluate the hypothesis that the extent of corpus callosum injury indicates the depth of shearing lesions in the central brain structure and therefore relates to the clinical severity of diffuse axonal injury. Methods: A simple and objective procedure for semiquantitative analysis of magnetic resonance images (MRI)-the maximum signal intensity ratio (MSIR)-was employed prospectively in 21 patients with diffuse axonal injury but without apparent injury to the ventral pons. All were diagnosed using serial combination MRI scans of fluid attenuated inversion recovery (FLAIR) and T2* weighted gradient echo imaging during the initial two weeks after the injury. The signal intensity ratio between the two regions of interest-the corpus callosum and the normal appearing ventral pons-was calculated serially in mid-sagittal and parasagittal FLAIR image sections in each patient. The MSIR during the study period was determined as a semiquantitative index of corpus callosum injury in each patient. The correlations between MSIR and the duration of unconsciousness, Glasgow outcome scale at six months, and the presence of apparent midbrain injury were investigated. Results: The mean (SD) MSIR value was 1.12 (0.18) at 7.4 (3.1) days after the injury (n = 2 1). MSIR correlated strongly with the duration of unconsciousness (n = 19, R-2 = 0.74, p < 0.0001), and was higher in patients with both an unfavourable GOS outcome (p = 0.020) and apparent midbrain injury (p < 0.001). Conclusions: MSIR, which is a simple and objective procedure for semiquantitative analysis of corpus callosum damage in diffuse axonal injury, correlated with clinical severity. A high MSIR value may indicate the presence of concomitant midbrain injury.	Osaka Prefectural Nakakawachi Med Ctr Acute Med, Higashiosaka, Osaka 5780947, Japan; Osaka Univ, Sch Med, Dept Radiol, Osaka 553, Japan; Osaka Univ, Sch Med, Dept Traumatol, Osaka 553, Japan		Takaoka, M (corresponding author), Osaka Prefectural Nakakawachi Med Ctr Acute Med, 3-4-13 Nishiiwata, Higashiosaka, Osaka 5780947, Japan.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Coulthard A, 1999, BRIT J RADIOL, V72, P742, DOI 10.1259/bjr.72.860.10624339; Gean AD, 1994, IMAGING HEAD TRAUMA; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; LAISSY JP, 1993, AM J NEURORADIOL, V14, P145; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Plum F., 1982, DIAGNOSIS STUPOR COM, V3rd; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Tokutomi T, 1997, ACT NEUR S, V70, P80; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	20	30	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2002	73	3					289	293		10.1136/jnnp.73.3.289			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	588LL	WOS:000177702900013	12185160	Bronze, Green Published			2022-02-06	
J	Auman, KM; Kufera, JA; Ballesteros, MF; Smialek, JE; Dischinger, PC				Auman, KM; Kufera, JA; Ballesteros, MF; Smialek, JE; Dischinger, PC			Autopsy study of motorcyclist fatalities: The effect of the 1992 Maryland motorcycle helmet use law	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							HEAD-INJURIES; IMPACT; COSTS; REPEAL; TRAUMA; RIDERS; CRASHES; USAGE; STATE	Objectives. This study sought to determine the impact of Maryland's all-rider motorcycle helmet law (enacted on October 1, 1992) on preventing deaths and traumatic brain injuries among motorcyclists. Methods. Statewide motorcyclist fatalities occurring during seasonally comparable 33-month periods immediately preceding and following enactment of the law were compared. Results. The motorcyclist fatality rate dropped from 10.3 per 10000 registered motorcycles prelaw to 4.5 postlaw despite almost identical numbers of registered motorcycles. Motorcyclists wearing helmets had a lower risk of traumatic brain injury than those not wearing helmets (odds ratio = 0.31, 95% confidence interval = 0.14. 0.68). Conclusions. Maryland's controversial motorcycle helmet law appears to be an effective public health policy and may be responsible for saving many lives.	Univ Maryland, Natl Study Ctr Trauma & EMS, Baltimore, MD 21201 USA; Off Chief Med Examiner, Baltimore, MD USA		Auman, KM (corresponding author), Univ Maryland, Natl Study Ctr Trauma & EMS, 701 W Pratt St,5th Floor, Baltimore, MD 21201 USA.						BACHULIS BL, 1988, AM J SURG, V155, P708, DOI 10.1016/S0002-9610(88)80151-X; CHENIER TC, 1987, ACCIDENT ANAL PREV, V19, P133, DOI 10.1016/0001-4575(87)90032-7; Conrad P, 1996, ACCIDENT ANAL PREV, V28, P193, DOI 10.1016/0001-4575(95)00056-9; Gopalakrishna G, 1998, ANN EMERG MED, V32, P425, DOI 10.1016/S0196-0644(98)70170-2; HEILMAN DR, 1982, ANN EMERG MED, V11, P659, DOI 10.1016/S0196-0644(82)80258-8; JOHNSON RM, 1995, J TRAUMA, V38, P876, DOI 10.1097/00005373-199506000-00008; KELLY P, 1991, ANN EMERG MED, V20, P852, DOI 10.1016/S0196-0644(05)81426-X; KRAUS JF, 1995, AM J PUBLIC HEALTH, V85, P96, DOI 10.2105/AJPH.85.1.96; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LLOYD LE, 1987, TEX MED, V83, P30; LUNA GK, 1981, WESTERN J MED, V135, P89; May C, 1989, J Emerg Nurs, V15, P389; MCSWAIN NE, 1980, SURG GYNECOL OBSTET, V151, P215; MCSWAIN NE, 1990, J TRAUMA, V30, P1189, DOI 10.1097/00005373-199010000-00002; MUELLEMAN RL, 1992, ANN EMERG MED, V21, P266, DOI 10.1016/S0196-0644(05)80886-8; MURDOCK MA, 1991, WESTERN J MED, V155, P370; *NAT HIGHW TRAFF S, 1998, TRAFF SAF FACTS 1998; NELSON D, 1992, ANN EMERG MED, V21, P279, DOI 10.1016/S0196-0644(05)80888-1; OFFNER PJ, 1992, J TRAUMA, V32, P636, DOI 10.1097/00005373-199205000-00016; ORSAY E, 1995, ANN EMERG MED, V26, P455, DOI 10.1016/S0196-0644(95)70114-1; Peek-Asa C, 1999, ACCIDENT ANAL PREV, V31, P229, DOI 10.1016/S0001-4575(98)00071-2; PeekAsa C, 1997, ANN EMERG MED, V29, P630, DOI 10.1016/S0196-0644(97)70252-X; Rowland J, 1996, AM J PUBLIC HEALTH, V86, P41, DOI 10.2105/AJPH.86.1.41; SARKAR S, 1995, J TRAUMA, V38, P242, DOI 10.1097/00005373-199502000-00017; SHANKAR BS, 1992, ACCIDENT ANAL PREV, V24, P385, DOI 10.1016/0001-4575(92)90051-J; Thurman DJ., 1995, GUIDELINES SURVEILLA; TSAI YJ, 1995, AM J EPIDEMIOL, V142, P974, DOI 10.1093/oxfordjournals.aje.a117746; WATSON GS, 1980, AM J PUBLIC HEALTH, V70, P579, DOI 10.2105/AJPH.70.6.579	28	30	31	0	4	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	AUG	2002	92	8					1352	1355		10.2105/AJPH.92.8.1352			4	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	578GV	WOS:000177109800034	12144996	Green Published			2022-02-06	
J	Gaviria, M; Haton, H; Sandillon, F; Privat, A				Gaviria, M; Haton, H; Sandillon, F; Privat, A			A mouse model of acute ischemic spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						C57BL/6 mice; functional outcome; histopathology; immunocytochemistry; photochemical lesion; spinal cord injury; wound healing response	CENTRAL-NERVOUS-SYSTEM; ADULT-RATS; REACTIVE GLIOSIS; GENE-THERAPY; TRAUMA; ANTAGONIST; CONTUSION; SECONDARY; LESION; TRANSPLANTATION	Mice models of spinal cord injury (SCI) should improve our knowledge of the mechanisms of injury and repair of the nervous tissue. They represent a powerful tool for the development of therapeutic strategies in the fields of pharmacological, cellular, and genetic approaches of neurotrauma. We demonstrate here that the photochemical graded ischemic spinal cord injury model, described in rats, can be successfully adapted in mice, in a reliable and reproducible manner. Following the intravenous injection of Rose Bengal, the translucent dorsal surface of the T9 vertebral laminae of C57BL/6 female mice was irradiated with a 560-nm wavelength-light (3-8 min depending on the experimental group). Animals were sacrificed at 1 day or 7 days after injury. Functional tests were performed daily for motor, sensory, autonomic, and reflex responses. Lesion histopathology was assessed for lesion length, percentage of residual white matter, and astrocytic reactivity. Experimental groups demonstrated a functional deficit, which was correlated to the increase of the irradiation time and, therefore, to the severity of the injury. Histopathological and immunocytochemical data were reliable morphological measurements characterizing the degree of injury, which were strongly correlated to the severity of the functional impairment. Despite differences in the mechanism of injury, the wound healing response described in other traumatic SCI mice models was confirmed (no cavitation and, conversely, the formation of a dense connective tissue matrix). In this context, the precise understanding of the mechanisms of healing response after SCI in mice and of neurochemical kinetics appear to be crucial in the development of therapeutic strategies of CNS repair. Thus, the possible use of an increasing collection of transgenic mice offers a new dimension for experimental research in this area. The ischemic photochemical model of SCI in mice represents a relevant model that can play a key role in this new era of neurotrauma research.	Ctr Propara, Lab Neurochirurg Expt, F-34195 Montpellier 5, France; Ctr Propara, Clin Neurophysiol Lab, Montpellier, France; INSERM, U336, Montpellier, France; Fac Med, Lab Physiopathol Malad Neuromusculaires, Montpellier, France		Gaviria, M (corresponding author), Ctr Propara, Lab Neurochirurg Expt, Parc Euromed, F-34195 Montpellier 5, France.	gaviria@univ-montp2.fr	Gaviria, Manuel/AAH-4403-2019	Gaviria, Manuel/0000-0001-6106-6538			Audouy S, 1999, GLIA, V25, P293, DOI 10.1002/(SICI)1098-1136(19990201)25:3<293::AID-GLIA9>3.0.CO;2-G; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; CAMERON T, 1990, EXP NEUROL, V109, P214, DOI 10.1016/0014-4886(90)90076-5; Cauquil-Caubere I, 1999, J NEUROSCI RES, V56, P160, DOI 10.1002/(SICI)1097-4547(19990415)56:2<160::AID-JNR5>3.0.CO;2-C; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; Gaviria M, 2000, BRAIN RES, V874, P200, DOI 10.1016/S0006-8993(00)02581-6; Guth L, 1999, ANN NY ACAD SCI, V890, P366, DOI 10.1111/j.1749-6632.1999.tb08017.x; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Olby NJ, 1996, J NEUROCYTOL, V25, P481, DOI 10.1007/BF02284817; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; Pikov V, 2001, J NEUROSCI, V21, P559, DOI 10.1523/JNEUROSCI.21-02-00559.2001; PRADO R, 1987, J NEUROSURG, V67, P745, DOI 10.3171/jns.1987.67.5.0745; PRIVAT A, 1994, B ACAD NAT MED PARIS, V178, P445; RATABOUL P, 1988, J NEUROSCI RES, V20, P165, DOI 10.1002/jnr.490200204; Ray SK, 1999, ANN NY ACAD SCI, V890, P261, DOI 10.1111/j.1749-6632.1999.tb08001.x; Ribotta MGY, 1998, CURR OPIN NEUROL, V11, P647, DOI 10.1097/00019052-199812000-00007; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; Ribotta MGY, 1997, J NEUROSCI RES, V48, P281; RIDET JL, 1995, J NEUROSCI RES, V42, P287, DOI 10.1002/jnr.490420302; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rosen CJ, 1999, J CLIN DENSITOM, V2, P3, DOI 10.1385/JCD:2:1:3; SAMPATH D, 1995, INT J DEV NEUROSCI, V13, P645, DOI 10.1016/0736-5748(95)00033-D; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P588, DOI 10.1001/archneurpsyc.1954.02320410050004; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; VANREEMPTS J, 1994, HISTOL HISTOPATHOL, V9, P185; WATSON BD, 1986, BRAIN RES, V367, P296, DOI 10.1016/0006-8993(86)91606-9; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1992, J NEUROTRAUM, V9, pS129; Zhang ZY, 1996, J COMP NEUROL, V371, P485	43	30	33	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2002	19	2					205	221		10.1089/08977150252806965			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	526ER	WOS:000174117100003	11893023				2022-02-06	
J	Tolentino, PJ; DeFord, SM; Notterpek, L; Glenn, CC; Pike, BR; Wang, KKW; Hayes, RL				Tolentino, PJ; DeFord, SM; Notterpek, L; Glenn, CC; Pike, BR; Wang, KKW; Hayes, RL			Up-regulation of tissue-type transglutaminase after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						quantitative PCR; transglutaminase; traumatic brain injury	CORTICAL IMPACT INJURY; HUMAN HEAD-INJURY; CROSS-LINKING; ALZHEIMERS-DISEASE; BINDING PROTEIN; RAT-BRAIN; ALPHA-1-ADRENERGIC RECEPTOR; PHOSPHOLIPASE-C; AMYLOID PROTEIN; SPINAL-CORD	Tissue-type transglutaminase (tTG, EC 2.3.2.13) has been implicated in various disease paradigms including neurodegenerative disease. In these studies, tTG induction after traumatic brain injury was studied using a rat cortical impact model. Using western blots, two forms of tTG protein expression were identified - a similar to79-kDa primary form (tTG-L) and a less abundant similar to70-kDa form (tTG-S). Both forms of tTG protein were elevated after injury. In ipsilateral cortex, peak induction of tTG-L protein [561% +/- 80% of control (n = 5)] was observed five days after injury, with expression remaining elevated after two weeks. Peak induction of tTG-S protein [302% +/-81% of control (n = 5)] was observed three days after injury. Lesser tTG protein induction was observed in hippocampus. Northern blot analysis demonstrated two tTG transcripts in the ipsilateral cortex with peak induction of tTG-L mRNA three days after injury. However, tTG-S mRNA was not identified in control samples and only faintly detected in injured tissue. To facilitate analysis of low abundance transcripts in smaller tissue samples, a semiquantitative real-time PCR strategy was used. Semi-quantitative PCR analysis of tTG-L mRNA induction in ipsilateral cortex (peak after three days; 414% +/- 21% of control, n = 3) confirmed tTG-L mRNA induction determined by northern blot (410% of control).	Univ Florida, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Gainesville, FL 32611 USA; Pfizer Inc, Dept Neurosci Therapeut, Ann Arbor, MI USA		Hayes, RL (corresponding author), Univ Florida, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Ctr Traumat Brain Injury Studies, 100 S Newell Dr,Box 100244, Gainesville, FL 32611 USA.			Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS039091] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39091, R01 NS40182] Funding Source: Medline		ANDO M, 1993, BRAIN RES, V604, P64, DOI 10.1016/0006-8993(93)90352-N; Appelt DM, 1996, J HISTOCHEM CYTOCHEM, V44, P1421, DOI 10.1177/44.12.8985134; Appelt DM, 1997, BRAIN RES, V745, P21, DOI 10.1016/S0006-8993(96)01121-3; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DAS T, 1993, J BIOL CHEM, V268, P27398; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; DUDEK SM, 1994, BRAIN RES, V651, P129, DOI 10.1016/0006-8993(94)90688-2; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Feng JF, 1999, BIOCHEMISTRY-US, V38, P2224, DOI 10.1021/bi9823176; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; Fujita K, 1995, NEUROCHEM RES, V20, P1195, DOI 10.1007/BF00995383; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GILAD GM, 1985, J NEUROCHEM, V44, P1385, DOI 10.1111/j.1471-4159.1985.tb08774.x; GILAD GM, 1985, J NEUROCHEM, V45, P1522, DOI 10.1111/j.1471-4159.1985.tb07222.x; Gorza L, 1997, AM J PATHOL, V150, P2087; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; HO GJ, 1994, FEBS LETT, V349, P151, DOI 10.1016/0014-5793(94)00663-6; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; IKURA K, 1993, FEBS LETT, V326, P109, DOI 10.1016/0014-5793(93)81772-R; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; MACCIONI RB, 1986, MOL CELL BIOCHEM, V69, P161; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Melino G, 1998, FEBS LETT, V430, P59, DOI 10.1016/S0014-5793(98)00521-3; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MILLER ML, 1995, J NEUROCHEM, V65, P1760; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; Murthy SNP, 1998, J NEUROCHEM, V71, P2607; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oliverio S, 1997, MOL CELL BIOL, V17, P6040, DOI 10.1128/MCB.17.10.6040; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; PERRY MJM, 1993, INT J DEV NEUROSCI, V11, P325, DOI 10.1016/0736-5748(93)90004-W; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; RINK A, 1995, AM J PATHOL, V147, P1575; Rostworowski M, 1997, J NEUROSCI, V17, P3664; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SELKOE DJ, 1982, P NATL ACAD SCI-BIOL, V79, P6070, DOI 10.1073/pnas.79.19.6070; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TETZLAFF W, 1988, BRAIN RES, V445, P142, DOI 10.1016/0006-8993(88)91083-9; WOODRING JH, 1991, J THORAC IMAG, V6, P1, DOI 10.1097/00005382-199104000-00003; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang W, 1998, ACTA NEUROPATHOL, V96, P395, DOI 10.1007/s004010050910	59	30	30	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	2002	80	4					579	588		10.1046/j.0022-3042.2001.00726.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	522NQ	WOS:000173903800004	11841565				2022-02-06	
J	Comerford, VE; Geffen, GM; May, C; Medland, SE; Geffen, LB				Comerford, VE; Geffen, GM; May, C; Medland, SE; Geffen, LB			A rapid screen of the severity of mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL SEQUELAE; STANDARDIZED ASSESSMENT; CONCUSSION; PLAYERS	This study investigated the sensitivity of information processing, recall and orientation tasks to the presence of mild Traumatic Brain Injury (mTBI). Fifty-six (40 male, 16 female) mTBI patients and 85 (57 male and 28 female) controls with orthopaedic injuries were tested within 24 hr of injury in the Department of Emergency Medicine. mTBI patients answered fewer orientation questions and recalled fewer words in delayed recall than orthopaedic patients. mTBI patients judged fewer sentences in 2 min than orthopaedic controls, and female mTBI patients judged fewer sentences than male mTBI patients. Male mTBI patients correctly recalled fewer words during immediate memory and learning than female mTBI patients and orthopaedic controls. Those mTBI patients with a history of previous head injuries did not perform more poorly than those mTBI patients without previous head injuries. These results indicate that tests of speed of information processing, word learning and orientation questions are sensitive to the acute effects of mTBI.	Univ Queensland, Cognit Psychophysiol Lab, Herston, Qld, Australia; Royal Brisbane Hosp, Dept Emergency Med, Brisbane, Qld 4029, Australia		Comerford, VE (corresponding author), Sch Med, Cognit Psychophysiol Lab, Edith Cavell Bldg,Herston Rd, Brisbane, Qld 4006, Australia.		Medland, Sarah/AAT-7595-2020; Medland, Sarah E/C-7630-2013	Medland, Sarah/0000-0003-1382-380X; Medland, Sarah E/0000-0003-1382-380X			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Baddeley A., 1992, SPEED CAPACITY LANGU; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P10; *CO MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hillier SL, 1997, BRAIN INJURY, V11, P649; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HINTONBAYRE AD, 1997, SPORT HLTH, V15, P4; HINTONBAYRE AD, 2000, THESIS U QUEENSLAND; Kelly JP, 1997, NEUROLOGY, V48, P581; KOLB B, 1996, FUNDAMENTALS HUMAN N; KRAUS JF, 1989, MILD HEAD INJURY, P8; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; National Health and Medical Research Council, 1992, IS THER SAF LEV DAIL; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Pols R G, 1992, Drug Alcohol Rev, V11, P339, DOI 10.1080/09595239200185461; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	27	30	30	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	4					409	419		10.1076/jcen.24.4.409.1044			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	568ZJ	WOS:000176574600001	12187455				2022-02-06	
S	Khaldi, A; Chiueh, CC; Bullock, MR; Woodward, JJ		Chiueh, CC; Hong, JS; Leong, SK		Khaldi, A; Chiueh, CC; Bullock, MR; Woodward, JJ			The significance of nitric oxide production in the brain after injury	NITRIC OXIDE: NOVEL ACTIONS, DELETERIOUS EFFECTS AND CLINICAL POTENTIAL	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	30th Annual Meeting of the Society-for-Neuroscience	NOV 04-09, 2000	NEW ORLEANS, LOUISIANA	Soc Neurosci, Taiwanese Biosci Amer		nitric oxide production; brain injury; NMDA receptor	NMDA-RECEPTOR; CELL-DEATH; NEURONS; NEUROTOXICITY; ACTIVATION; NO; NITROSYLATION; MECHANISMS; CULTURES; DISEASE	Glutamate toxicity has been implicated in many aspects of brain injury including traumatic, ischemic, and hemorrhagic damage. We have used in vitro as well as in vivo methods to measure NO production and to examine the role of NO in glutamate toxicity. In building our recombinant system, we used human kidney embryonic cells, HEK 293, as host for transfection of nNOS and NMDA receptor proteins. Cells cotransfected with NMDA and nNOS were more resistant to glutamate toxicity. This resistance correlated with NO production as measured by citrulline assay. Meanwhile, the production of NO did not significantly change the response of the NMDA receptor as seen by calcium studies. Moreover, in vivo, NO production was directly correlated with brain tissue oxygen tension in subarachnoid hemorrhage patients. These data and others point toward the importance of NO production in the response of brain to injury.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA		Khaldi, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, POB 980631, Richmond, VA 23298 USA.				NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA009986] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA009986] Funding Source: NIH RePORTER		ANEGAWA NJ, 1995, J NEUROCHEM, V64, P2004; BECKMAN JS, 1994, PROG BRAIN RES, V103, P371; Chandler LJ, 1997, MOL PHARMACOL, V51, P733, DOI 10.1124/mol.51.5.733; Chiueh CC, 1999, ANN NY ACAD SCI, V890, P301, DOI 10.1111/j.1749-6632.1999.tb08007.x; CHIUEH CC, 1994, ANN NY ACAD SCI, V738, P279; DAWSON VL, 1993, J NEUROSCI, V13, P2651; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; Fiorucci S, 2001, TRENDS IMMUNOL, V22, P232, DOI 10.1016/S1471-4906(01)01904-4; GARTHWAITE G, 1994, NEUROPHARMACOLOGY, V33, P1431, DOI 10.1016/0028-3908(94)90046-9; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016; HEWETT SJ, 1993, BRAIN RES, V625, P337, DOI 10.1016/0006-8993(93)91078-7; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Khaldi A, 2001, NEUROSURGERY, V49, P33; KHALDI A, 1995, THESIS VIRGINIA COMM; KOH JY, 1986, SCIENCE, V234, P73, DOI 10.1126/science.2875522; LIPTON SA, 1994, PROG BRAIN RES, V103, P359; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Pluta RM, 2001, NEUROSURGERY, V48, P884, DOI 10.1097/00006123-200104000-00039; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0	26	30	30	0	3	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-366-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2002	962						53	59		10.1111/j.1749-6632.2002.tb04055.x			7	Multidisciplinary Sciences; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Pharmacology & Pharmacy	BU76R	WOS:000176952400005	12076962				2022-02-06	
J	Ercan, M; Inci, S; Kilinc, K; Palaoglu, S; Aypar, U				Ercan, M; Inci, S; Kilinc, K; Palaoglu, S; Aypar, U			Nimodipine attenuates lipid peroxidation during the acute phase of head trauma in rats	NEUROSURGICAL REVIEW			English	Article						head trauma; lipid peroxidation; nimodipine; oxygen free radicals	NERVOUS-SYSTEM TRAUMA; ANEURYSMAL SUBARACHNOID HEMORRHAGE; FOCAL CEREBRAL-ISCHEMIA; OXYGEN FREE-RADICALS; BLOOD-FLOW; ANTAGONIST NIMODIPINE; BRAIN PROTECTION; CALCIUM; INJURY; PHARMACOLOGY	Oxygen free radical-mediated lipid peroxidation is one of the major mechanisms of secondary damage in traumatic brain injury. We assessed the effects of nimodipine on lipid peroxidation 1 h after head trauma in rats. Nimodipine (1.5 mug/kg IV bolus injection) was given immediately after head trauma by either the carotid artery or the jugular vein. Placebo treated rats received saline by the same routes. Control rats received head trauma only. Sham-operated rats were the group without head trauma. Malondialdehyde (MDA), which is the end product of lipid peroxidation, was measured as an indicator of oxygen free radical formation in the brain tissue. The mean values for MDA in sham operated rats were 92.4 +/-4.9 nanomoles/gram wet weight (nmol/gww) of brain tissue. In the control group, MDA content of the brain tissue was 120.8 +/-9.4 nmol/gww. In placebo treated rats, the results were similar. In the groups receiving ni modipine via carotid artery or jugular vein, the mean values were 101.1 +/-6.9 and 106.5 +/-6.0 nmol/gww, respectively. These results indicate that nimodipine caused a significant decrease in lipid peroxidation when given in the acute phase of head trauma in rats. This occurred regardless of the route of injection.	Hacettepe Univ, Sch Med, Inst Anesthesiol & Reanimat, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Inst Biochem, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Inst Neurosurg, TR-06100 Ankara, Turkey		Inci, S (corresponding author), Emek Mah,4 Cad,70-8, TR-06510 Ankara, Turkey.						AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAETHMANN A, 1986, EUR NEUROL, V25, P102, DOI 10.1159/000116105; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FADEN AI, 1984, J NEUROSURG, V60, P796, DOI 10.3171/jns.1984.60.4.0796; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GISVOLD SE, 1991, CURR OPIN ANESTHESIO, V4, P229; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL R, 1990, CAN J ANAESTH, V37, P762, DOI 10.1007/BF03006535; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HOLLEY AE, 1993, BRIT MED BULL, V49, P494, DOI 10.1093/oxfordjournals.bmb.a072626; IKEDA Y, 1990, ACT NEUR S, V51, P74; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LANGLEY MS, 1989, DRUGS, V37, P669, DOI 10.2165/00003495-198937050-00004; LEBLANC R, 1991, CURR OPIN NEUROL NEU, V4, P63; MCCALDEN TA, 1984, STROKE, V15, P527, DOI 10.1161/01.STR.15.3.527; MEYER FB, 1986, J NEUROSURG, V64, P617, DOI 10.3171/jns.1986.64.4.0617; PEROUTKA SJ, 1983, J NEUROSURG, V59, P933, DOI 10.3171/jns.1983.59.6.0933; POZZILLI C, 1989, J NEUROL, V236, P199, DOI 10.1007/BF00314499; SCRIABINE A, 1988, ANN NY ACAD SCI, V522, P698; SIESJO BK, 1990, EUR NEUROL, V30, P3, DOI 10.1159/000117184; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SOLOMON RA, 1987, ARCH NEUROL-CHICAGO, V44, P769, DOI 10.1001/archneur.1987.00520190073018; TONI D, 1991, J CARDIOVASC PHARM, V18, pS10, DOI 10.1097/00005344-199106188-00004; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; VANZWIETEN PA, 1993, AM HEART J, V125, P566, DOI 10.1016/0002-8703(93)90204-M	33	30	31	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JUL	2001	24	2-3					127	130		10.1007/PL00012396			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	450LF	WOS:000169743800015	11485234				2022-02-06	
J	Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Li, JH; Zhang, J; Smulson, ME				Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Li, JH; Zhang, J; Smulson, ME			Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy	NUCLEIC ACIDS RESEARCH			English	Article							FOCAL CEREBRAL-ISCHEMIA; ANTISENSE RNA EXPRESSION; DNA-DAMAGE; DEPENDENT TRANSCRIPTION; NICOTINAMIDE TREATMENT; GENE AMPLIFICATION; GENOMIC STABILITY; RIBOSE POLYMERASE; MAMMALIAN-CELLS; MICE RESISTANT	Poly(ADP-ribose) polymerase (PARP) knockout mice are resistant to murine models of human diseases such as cerebral and myocardial ischemia, traumatic brain injury, diabetes, Parkinsonism, endotoxic shock and arthritis, implicating PARP in the pathogenesis of these diseases. Potent selective PARP inhibitors are therefore being evaluated as novel therapeutic agents in the treatment of these diseases. Inhibition or depletion of PARP, however, increases genomic instability in cells exposed to genotoxic agents. We recently demonstrated the presence of a genomically unstable tetraploid population in PARP(-/-)fibroblasts and its loss after stable transfection with PARP cDNA. To elucidate whether the genomic instability is attributable to PARP deficiency or lack of PARP activity, we investigated the effects of PARP inhibition on development of tetraploidy. Immortalized wild-type and PARP(-/-) fibroblasts were exposed for 3 weeks to 20 muM GPI 6150 (1,11b-dihydro-[2H]benzopyrano[4,3,2-de]isoquinolin-3-one), a novel small molecule specific competitive inhibitor of PARP (Ki = 60 nM) and one of the most potent PARP inhibitors to date (1C(50) = 0.15 muM). Although GPI 6150 initially decreased cell growth in wild-type cells, there was no effect on cell growth or viability after 24 h, GPI 6150 inhibited endogenous PARP activity in wild-type cells by similar to 91%, to about the residual levels in PARP(-/-)cells. Flow cytometric analysis of unsynchronized wild-type cells exposed for 3 weeks to GPI 6150 did not induce the development of tetraploidy, suggesting that, aside from its catalytic function, PARP may play other essential roles in the maintenance of genomic stability.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Guildford Pharmaceut Inc, Baltimore, MD 21224 USA		Smulson, ME (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	smulson@bc.georgetown.edu	Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01 CA074175, CA25344, 1PO1 CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA074175, R01CA025344] Funding Source: NIH RePORTER		Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Andreassen PR, 1996, MUTAT RES-FUND MOL M, V372, P181, DOI 10.1016/S0027-5107(96)00138-8; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; BANASIK M, 1994, MOL CELL BIOCHEM, V138, P185, DOI 10.1007/BF00928461; Burkart V, 1999, NAT MED, V5, P314, DOI 10.1038/6535; BURKLE A, 1990, CANCER RES, V50, P5756; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Chatterjee PK, 2000, FASEB J, V14, P641, DOI 10.1096/fasebj.14.5.641; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; di Fagagna FD, 1999, NAT GENET, V23, P76; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FERRO AM, 1983, J BIOL CHEM, V258, P6000; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KUHULE S, 1999, BIOCHEM BIOPH RES CO, V263, P433; Kupper JH, 1996, CANCER RES, V56, P2715; LAPLACA M, 1999, NEUROTRAUMA, V16, P976; Lautar S., 1998, Society for Neuroscience Abstracts, V24, P1226; LIN MH, 1994, ORAL ONCOL, V30B, P252, DOI 10.1016/0964-1955(94)90007-8; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; MANDRUPPOULSEN T, 1993, DIABETES METAB REV, V9, P295, DOI 10.1002/dmr.5610090410; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 1999, P NATL ACAD SCI USA, V96, P2301, DOI 10.1073/pnas.96.5.2301; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MORGAN WF, 1982, MUTAT RES, V104, P361, DOI 10.1016/0165-7992(82)90170-1; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Pieper AA, 1999, P NATL ACAD SCI USA, V96, P3059, DOI 10.1073/pnas.96.6.3059; RAMEL S, 1995, PANCREAS, V11, P213, DOI 10.1097/00006676-199510000-00001; Robinson JK, 1996, CANCER-AM CANCER SOC, V77, P284, DOI 10.1002/(SICI)1097-0142(19960115)77:2<284::AID-CNCR10>3.3.CO;2-A; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Simbulan-Rosenthal CM, 1999, MOL CELL BIOCHEM, V193, P137, DOI 10.1023/A:1006988832729; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; Sun AY, 1998, ACTA PHARMACOL SIN, V19, P104; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; VAGUE P, 1989, DIABETOLOGIA, V32, P316, DOI 10.1007/BF00265549; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; VINDELOV LL, 1983, CYTOMETRY, V3, P332, DOI 10.1002/cyto.990030505; WALDMAN AS, 1991, NUCLEIC ACIDS RES, V19, P5943, DOI 10.1093/nar/19.21.5943; Walles T, 1998, CIRCULATION, V98, P260; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Zhang J., 1999, Acta Physiologica Scandinavica, V167, P90; Zhang J, 2000, BIOCHEM BIOPH RES CO, V278, P590, DOI 10.1006/bbrc.2000.3816; Zingarelli B, 1999, GASTROENTEROLOGY, V116, P335, DOI 10.1016/S0016-5085(99)70130-7; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	69	30	30	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0305-1048	1362-4962		NUCLEIC ACIDS RES	Nucleic Acids Res.	FEB 1	2001	29	3					841	849		10.1093/nar/29.3.841			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398ZL	WOS:000166786300031	11160908	Green Published, Bronze			2022-02-06	
J	Mautes, AEM; Muller, M; Cortbus, F; Schwerdtfeger, K; Maier, B; Holanda, M; Nacimiento, A; Marzi, I; Steudel, WI				Mautes, AEM; Muller, M; Cortbus, F; Schwerdtfeger, K; Maier, B; Holanda, M; Nacimiento, A; Marzi, I; Steudel, WI		HOTBIG	Alterations of norepinephrine levels in plasma and CSF of patients after traumatic brain injury in relation to disruption of the blood-brain barrier	ACTA NEUROCHIRURGICA			English	Article						blood-brain/CSF barrier (BBB); catecholamines; cerebral spinal fluid (CSF); clinical study; traumatic brain injury (TBI)	HEAD-INJURY; PRESSURE; OXIDASE; FLOW; RAT; CATECHOLAMINES; MICROVESSELS; METABOLISM; ADRENALINE; RELEVANCE	Background. In injured brain tissue with a disrupted blood-brain barrier (BBB) catecholamines such as norepinephrine (NE) are known to enhance glucose consumption and cerebral blood flow but may lead to an energy-depletion increasing the risk of ischemia. Therefore it is of great interest whether the exogenous administration of NE used mainly to maintain an adequate cerebral perfusion pressure influences CSF NE levels or not, and whether elevated plasma or CSF levels of NE can influence the actual clinical condition. We addressed this issue by measuring the levels of NE in CSF and plasma and correlating them with the actual clinical condition of the patients. Methods. In 29 patients with severe TBI (<8 points on the Glasgow Coma Scale: GCS) NE levels were analysed by high performance liquid chromatography (HPLC) in paired blood and CSF specimens which were collected from days 1 to 14 after severe TBI (total number of pairs = 121). The integrity of the BBB was evaluated by determining the CSF/serum albumin ratio. The clinical condition of the patients was assessed by GCS. Results. Elevated plasma and CSF NE: levels were observed in 50% of all samples, most consistently in patients treated with NE. NE elevation in CSF was independent of whether or not the BBB remained intact. There was no correlation between GCS and the levels of NE in CSF or plasma either in samples from the treated or the untreated group. Interpretation. Exogenous administration of NE seems to increase NE levels in plasma and CSF. However, in this group of patients with severe TBI there was no clinical evidence that exogenous administration of NE was detrimental to the traumatized patients.	Univ Saarland, Sch Med, Neurosurg Res Lab, Dept Neurosurg, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Dept Trauma Surg, D-66421 Homburg, Germany; Univ Saarland, Sch Med, Dept Neurol, D-66421 Homburg, Germany		Mautes, AEM (corresponding author), Univ Saarland, Sch Med, Neurosurg Res Lab, Dept Neurosurg, Kirrberger Str, D-66421 Homburg, Germany.						BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BUSTO R, 1985, ANN NEUROL, V18, P329, DOI 10.1002/ana.410180310; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; DAHLGREN N, 1980, BRAIN RES, V184, P143, DOI 10.1016/0006-8993(80)90593-4; EISENBERG HM, 1983, INTRACRANIAL PRESSUR, V5, P549; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HARDEBO JE, 1980, ANN NEUROL, V8, P1, DOI 10.1002/ana.410080102; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; JOHANSSON B, 1970, ACTA NEUROPATHOL, V16, P117, DOI 10.1007/BF00687666; LAI FM, 1978, ARCH INT PHARMACOD T, V233, P227; LASBENNES F, 1983, J CEREBR BLOOD F MET, V3, P521, DOI 10.1038/jcbfm.1983.80; LASBENNES F, 1988, BRAIN RES, V454, P205, DOI 10.1016/0006-8993(88)90819-0; Levin BE, 1998, BRAIN RES, V808, P317, DOI 10.1016/S0006-8993(98)00839-7; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483, DOI 10.1152/ajplegacy.1976.231.2.483; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Miller J D, 1972, Prog Brain Res, V35, P411; RAPOPORT S, 1976, BLOOD BRAIN BARRIER, P4386; REIBER H, 1987, CLIN CHIM ACTA, V163, P43; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SEELIG JM, 1986, INTRACRANIAL PRESSUR, V6, P675; Strittmatter M, 1997, HEADACHE, V37, P211, DOI 10.1046/j.1526-4610.1997.3704211.x; VORBRODT AW, 1988, PROG HISTOCHEM CYTOC, V18, P1; WEILMALHERBE H, 1959, SCIENCE, V129, P1226, DOI 10.1126/science.129.3357.1226; WERDAN K, 1992, SCH INT MED, V80, P133; Zwetnow N N, 1970, Acta Physiol Scand Suppl, V339, P1	30	30	31	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2001	143	1					51	58		10.1007/s007010170138			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	402CA	WOS:000166967400022	11345718				2022-02-06	
J	Beschorner, R; Schluesener, HJ; Nguyen, TD; Magdolen, V; Luther, T; Pedal, I; Mattern, R; Meyermann, R; Schwab, JM				Beschorner, R; Schluesener, HJ; Nguyen, TD; Magdolen, V; Luther, T; Pedal, I; Mattern, R; Meyermann, R; Schwab, JM			Lesion-associated accumulation of uPAR/CD87-expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						fibrinolysis; human; ischaemia; tissue remodelling; traumatic brain injury; urokinase-type plasminogen activator receptor	PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; MESSENGER-RNA; MATRIX METALLOPROTEINASES; CLINICAL-TRIALS; BRAIN EDEMA; U937 CELLS; EXPRESSION; MODULATION; SYSTEM	Urokinase-type plasminogen activator receptor (uPAR/CD87) together with its ligand, urokinase-type plasminogen activator (uPA), constitutes a proteolytic system associated with tissue remodelling and leucocyte infiltration. uPAR is a member of the glycosyl phosphatidyl inositol (GPI) anchored protein family. The functional role of uPAR comprises fibrinolysis by conversion of plasminogen to plasmin. In addition, uPAR promotes cell adhesion, migration, proliferation, re-organization of the actin cytoskeleton, and angiogenesis. Furthermore, uPAR is involved in prevention of scar formation and is chemoattractant to macrophages and leucocytes. In order to investigate the pathophysiological role of uPAR following human CNS injury we examined necrotic brain lesions resulting from traumatic brain injury (TBI; n = 28) and focal cerebral infarctions (FCI; n = 17) by immunohistochemistry. Numbers of uPAR(+) cells and uPAR(+) blood vessels were counted. Following brain damage, uPAR(+) cells increased significantly within 12 h, reached a maximum after 3-4 days and remained elevated until later stages. uPAR was expressed by infiltrating granulocytes, activated microglia/macrophages and endothelial cells. Numbers of uPAR(+) vessels increased in parallel subsiding earlier following FCI than post TBI. The restricted, lesion-associated accumulation of uPAR(+) cells in the brain parenchyma and upregulated expression by endothelial cells suggests a crucial role for the influx of inflammatory cells and blood-brain barrier (BBB) disturbance. Through a failure in BBB function, uPAR participates in formation of brain oedema and thus contributes to secondary brain damage. In conclusion, the study defines the localization, kinetic course and cellular source of uPAR as a potential pharmacological target following human TBI and FCI.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Tech Univ Munich, Klinikum Rechts Isar, Dept Gynecol, D-8000 Munich, Germany; Tech Univ Dresden, Inst Pathol, D-8027 Dresden, Germany		Beschorner, R (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	rudi.beschorner@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Schwab, Jan/0000-0001-6784-4919; Beschorner, Rudi/0000-0003-1109-915X			Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.0.CO;2-3; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; Fauser S, 2000, J NEUROIMMUNOL, V111, P234, DOI 10.1016/S0165-5728(00)00368-4; Fujimoto J, 1996, J STEROID BIOCHEM, V59, P1, DOI 10.1016/S0960-0760(96)00084-2; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Higazi AAR, 1996, BIOCHEMISTRY-US, V35, P6884, DOI 10.1021/bi9514774; HOOGERWERF WA, 1994, GENE CHROMOSOME CANC, V9, P88, DOI 10.1002/gcc.2870090203; KALIMO H, 1997, GREENFIELDS NEUROPAT, P315; LAN HY, 1995, J HISTOCHEM CYTOCHEM, V43, P97, DOI 10.1177/43.1.7822770; LAURSEN H, 1993, ACTA NEUROPATHOL, V86, P378, DOI 10.1007/BF00369451; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LUND LR, 1991, J BIOL CHEM, V266, P5177; Luther T, 1997, AM J PATHOL, V150, P1231; MAGDOLEN V, 1995, ELECTROPHORESIS, V16, P813, DOI 10.1002/elps.11501601134; MENZIES SA, 1993, J NEUROSURG, V78, P257, DOI 10.3171/jns.1993.78.2.0257; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Moser KL, 1998, P NATL ACAD SCI USA, V95, P14869, DOI 10.1073/pnas.95.25.14869; Nonaka T, 2000, J RHEUMATOL, V27, P997; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Peiretti F, 1996, BLOOD, V87, P162; Piguet PF, 1999, CIRCULATION, V99, P3315, DOI 10.1161/01.CIR.99.25.3315; PLOUG M, 1992, BLOOD, V79, P1447; Reid E, 2000, AM J HUM GENET, V66, P728, DOI 10.1086/302783; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Reuning U, 1998, INT J ONCOL, V13, P893; Shetty S, 1998, ARCH BIOCHEM BIOPHYS, V356, P265, DOI 10.1006/abbi.1998.0789; Shimazaki C, 1999, BRIT J HAEMATOL, V104, P672, DOI 10.1111/j.1365-2141.1999.01239.x; Speth C, 1998, IMMUNOBIOLOGY, V199, P152, DOI 10.1016/S0171-2985(98)80071-5; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Stratakis CA, 1998, J CLIN ENDOCR METAB, V83, P2972, DOI 10.1210/jc.83.8.2972; TranThang C, 1996, BRIT J CANCER, V74, P846, DOI 10.1038/bjc.1996.447; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Washington RA, 1996, J NEUROSCI RES, V45, P392; YAMAMOTO M, 1994, CANCER RES, V54, P5016; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Yoshida E, 1996, INFLAMMATION, V20, P319, DOI 10.1007/BF01488206	40	30	36	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	DEC	2000	26	6					522	527		10.1046/j.0305-1846.2000.287.x			6	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	384XL	WOS:000165972500005	11123718				2022-02-06	
J	Ishikawa, K; Tanaka, H; Shiozaki, T; Takaoka, M; Ogura, H; Kishi, M; Shimazu, T; Sugimoto, H				Ishikawa, K; Tanaka, H; Shiozaki, T; Takaoka, M; Ogura, H; Kishi, M; Shimazu, T; Sugimoto, H			Characteristics of infection and leukocyte count in severely head-injured patients treated with mild hypothermia	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						hypothermia; head injury; leukopenia; infection; pneumonia	TRAUMATIC BRAIN INJURY; T-CELL FUNCTION; NEUTROPHIL ACCUMULATION; MODERATE HYPOTHERMIA; CHEMI-LUMINESCENCE; THERAPY; RATS; COMPLICATIONS; CONSCIOUSNESS; TEMPERATURE	Objective: This study was designed to characterize the infectious complications and kinetics of leukocyte count in severely head-injured patients treated with mild hypothermia. Patients and Methods: We retrospectively analyzed the incidence and severity of infectious complications as well as daily changes in leukocyte count in 41 severely head-injured patients treated with mild hypothermia (group H), They were retrospectively compared with 25 severely head-injured patients treated with high-dose barbiturates (group B) and to 25 other severely head-injured patients treated with no barbiturates (group N), Results: initial intracranial pressure was significantly higher in group H than in the other groups, No significant differences existed in the incidence of pneumonia or meningitis among the three groups, whereas the incidence of bacteremia was significantly higher in group H than in the other two groups, Pneumonia was significantly more severe in group H than in the other groups, In six patients of group H, pneumonia spread fulminantly to become life threatening. Daily changes in total leukocyte count showed the same pattern, consisting of a peak, a nadir, and a second peak in all groups. Total leukocyte count was, however, significantly lower during the first 2 weeks in group H than in the other two groups. Lymphocyte and neutrophil counts were also lower in group H, Conclusion: Infectious. complications were more severe and leukocyte counts were lower in patients treated with mild hypothermia, who also had the highest initial intracranial pressures, than in patients treated with conventional therapies, Measures against increased susceptibility to infection and leukocyte suppression should be explored.	Osaka Univ, Sch Med, Dept Traumatol, Suita, Osaka 5650871, Japan; Osaka Prefectural Nakakawachi Med Ctr Acute Med, Suita, Osaka, Japan		Tanaka, H (corresponding author), Osaka Univ, Sch Med, Dept Traumatol, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan.						Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BALTAS I, 1994, NEUROSURGERY, V35, P422, DOI 10.1227/00006123-199409000-00009; BIGGAR WD, 1986, J APPL PHYSIOL, V60, P1186, DOI 10.1152/jappl.1986.60.4.1186; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; BULLOCK MR, 1996, J NEUROTRAUM, V13, P638; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Cazzadori A, 1997, RESP MED, V91, P193, DOI 10.1016/S0954-6111(97)90038-X; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Fagerli J, 1996, W V Med J, V92, P265; FREWEN TC, 1982, J PEDIATR-US, V100, P663, DOI 10.1016/S0022-3476(82)80782-8; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; HIRAIDE A, 1995, JPN J SURG METAB NUT, V29, P7; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Ishikawa K, 1998, J TRAUMA, V44, P1047, DOI 10.1097/00005373-199806000-00018; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; KRESS HG, 1989, ACTA ANAESTH SCAND, V33, P122, DOI 10.1111/j.1399-6576.1989.tb02873.x; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SHENAQ SA, 1986, ANN CLIN LAB SCI, V16, P130; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; TEASDALE G, 1974, LANCET, V2, P81; vanEeden SF, 1997, AM J PHYSIOL-HEART C, V272, pH1717; VILLALOBOS TJ, 1955, P SOC EXP BIOL MED, V89, P192; Wenisch C, 1996, ANESTH ANALG, V82, P810, DOI 10.1097/00000539-199604000-00023; Whalen MJ, 1997, ACT NEUR S, V70, P260; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; WHITE IWC, 1983, CAN ANAESTH SOC J, V30, P506, DOI 10.1007/BF03007085	45	30	31	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2000	49	5					912	922		10.1097/00005373-200011000-00020			11	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	372KA	WOS:000165231800020	11086785				2022-02-06	
J	LeBlanc, JM; Hayden, ME; Paulman, RG				LeBlanc, JM; Hayden, ME; Paulman, RG			A comparison of neuropsychological and situational assessment for predicting employability after closed head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adult closed head injury; cognitive neuropsychological assessment; ecological validity functioning; employment; executive functioning; situational assessment; vocational evaluation	TRAUMATIC BRAIN INJURY; EMPLOYMENT STATUS; FOLLOW-UP; IMPAIRMENT; RECOVERY; WORK	The relationships among neuropsychological assessment, situational assessment, and judgments of future employability in 127 survivors of moderate to severe closed head injury were evaluated. Participants received a comprehensive neuropsychological battery and a situational vocational evaluation. Two groups mere created, based on employment recommendation from the situational evaluation. a seven-factor model was found to account for the preponderance of variance within the neuropsychological battery used, and one factor mas predictive of group assignment from situational assessment. However, the present data reinforce the predominance of Endings in the literature that indicate that, in general, no individual neuropspchological test can be used to predict vocational performance in more environmentally relevant environments. Exceptions to this "rule" may occur when comparisons between results of formal neuropsychological tests and situational evaluation are limited to very simple, very circumscribed, and/or very well-defined functions. Thus, situational assessment is seen as a critical adjunct to neuropspchological assessment in making "real-world" predictions, The particular situational assessment used in this study was internally valid, an important finding given the importance of situational assessment in ecologically valid predictions.	Sabine Valley Ctr, Marshall Youth Serv, Marshall, TX 75670 USA; Pate Rehabil, Dallas, TX USA; Univ Texas, SW Med Ctr, Dallas, TX USA		LeBlanc, JM (corresponding author), Sabine Valley Ctr, Marshall Youth Serv, Marshall, TX 75670 USA.						ACKER MB, 1986, CLIN NEUROPSYCHOLOGY; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baum C, 1996, ARCH CLIN NEUROPSYCH, V11, P69, DOI 10.1016/0887-6177(95)00009-7; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BOLLER F, 1966, BRAIN, V89, P815, DOI 10.1093/brain/89.4.815; BRANDT GC, 1992, J CAN HIST ASSOC, V3, P3; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; BRUNSWICK E, 1955, PSYCHOL REV, V67, P193; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Christensen AL, 1979, LURIAS NEUROPSYCHOLO; CRISP R, 1992, J REHABIL, V58, P27; DEFILLIPIS NA, 1987, BOOKLET CATEGORY TES; DEPOY E, 1992, J COGN REHABIL   JAN, P30; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P1; DILLER L, 1970, Archives of Physical Medicine and Rehabilitation, V51, P358; DILLER L, 1991, NEUROBEHAVIORAL RECO; Diller L, 1974, REHABILITATION MONOG, V50; FINUF P, 1995, INJ PREV CONTROL PRO; FORDYCE D, 1994, BRAIN INJURY REHABIL; Fraser R. T., 1991, J HEAD TRAUMA REHAB, V6, P46; Goldstein FC, 1995, CLIN NEUROPSYCHOLOGI; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hamsher K., 1989, MULTILINGUAL APHASIA; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; HART T, 1986, CLIN NEUROPSYCHOLOGY; Heaton RK, 1991, COMPREHENSIVE NORMS; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JOHNSON EW, 1991, AM J PHYS MED REHAB, V70, P1, DOI 10.1097/00002060-199102000-00001; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LEVIN H, 1987, NEUROBEHAVORIAL RECO; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LONG C, 1988, NP STUD NONFOCAL BRA; LORING DW, 1987, J CLIN EXP NEUROPSYC, V9, P340, DOI 10.1080/01688638708405055; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; MAPOU R, 1992, HDB HEAD TRAUMA ACUT; MAPOU R, 1995, CLIN NP ASSESSESSMEN; MATHEWS CG, 1964, INSTRUCTION MANUAL A; MCCUE M, 1992, HDB HEAD TRAUMA ACUT; NEFF W, 1983, REHABILITATION CLIEN; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; ROBERTS R, 1992, HDB HEAD TRAUMA ACUT; SACHS PR, 1993, REHABIL PSYCHOL, V38, P87, DOI 10.1037/h0080294; SBORDONE R, 1992, PSYCHOTHER PRIVATE P, V10, P45; Sbordone RJ, 1996, ECOLOGICAL VALIDITY; SCHENKENBERG T, 1980, NEUROLOGY, V30, P509, DOI 10.1212/WNL.30.5.509; Shallice T., 1991, FRONTAL LOBE FUNCTIO; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; SPECTOR J, 1995, CLIN NEUROPSYCHOLOGI; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stuss D. T., 1994, BRAIN INJURY REHABIL, P212; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TRAHAN D, 1986, CONTINUOUS VISUAL ME; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; VELOZO CA, 1993, AM J OCCUP THER, V47, P203, DOI 10.5014/ajot.47.3.203; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WHEMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66; WHEMAN P, 1990, ARCH PHYS MED REHAB, V71, P1047; [No title captured]	70	30	30	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2000	15	4					1022	1040		10.1097/00001199-200008000-00005			19	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	340DK	WOS:000088517700005	10876173				2022-02-06	
J	DiCarlo, MA; Gfeller, JD; Oliveri, MV				DiCarlo, MA; Gfeller, JD; Oliveri, MV			Effects of coaching on detecting feigned cognitive impairment with the Category Test	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; coaching strategies; category test	NEUROPSYCHOLOGICAL IMPAIRMENT; BELIEVABLE DEFICITS; HEAD-INJURY; INTELLIGENCE; VALIDITY; BATTERY; FAKING	In a replication and extension of previous research (Tenhula & Sweet, 1996), the current study investigated the utility of the Category Test (CT) for detecting feigned cognitive impairment. Ninety-two undergraduate participants were randomly assigned to one of three groups and administered the CT. A Coached Simulator group was instructed to simulate cognitive impairment and was provided lest-taking strategies to avoid detection. An Uncoached Simulator group was simply insmrcred to feign impairment. A control group was instructed to perform optimally. In addition, the CT results of 30 traumatic brain injury (TBI) patients were analyzed. The results largely supported the utility of five CT malingering indicators identified by TenhrLla and Sweet: (a) number of errors on subtests I and II, (6) number of errors errors on subtest VII, (c) total CT errors, (d) number of errors on 19 "easy" items, and (e) number of criteria exceeded. Correct Classification rates of the five indicators for Uncoached Simulators and optimal performance controls ranged from 87% to 98%. Correct Classification rates for the TBI patients ranged from 70% to 100%. In addition, significantly more Coached Simulators were misclassified as nonsimulators on four of the CT malingering indicators, relative to their Uncoached counterparts. A decision rule of > I error on subtests I and II was consistently the most accurate malingering indicator, regardless of degree of coaching or presence of TBI. This indicator correctly classified 76% of all simulators and 100% of the optimal performance controls and TBI patients. Implications of providing persons with test-taking strategies and the utility of these CT malingering indicators for various populations are discussed. (C) 2000 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	St Louis Univ, St Louis, MO 63103 USA; St Johns Mercy Med Ctr, St Louis, MO 63141 USA		DiCarlo, MA (corresponding author), Roger Williams Med Ctr, Dept Psychiat, 825 Chalkstone Blvd, Providence, RI 02908 USA.						BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; Bolter J. F., 1985, ANN M NAT AC NEUR PH; Brandt J., 1985, ANN NY ACAD SCI, V44, P502; CULLUM CM, 1984, INT J CLIN NEUROPSYC, V6, P172; DeFilippis NA, 1979, BOOKLET CATEGORY TES; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; Franzen M.D., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401]; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Gfeller JD, 1998, J CLIN PSYCHOL, V54, P431, DOI 10.1002/(SICI)1097-4679(199806)54:4<431::AID-JCLP5>3.0.CO;2-Q; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; IVERSON GL, 1994, SPECIFICITY CATEGORY; Johnstone B, 1997, PSYCHOL ASSESSMENT, V9, P28, DOI 10.1037/1040-3590.9.1.28; Laatsch L., 1991, PSYCHOL ASSESSMENT J, V3, P701; Lamb D.G., 1994, PSYCHOL ASSESSMENT, V6, P8, DOI [https://doi.org/10.1037/1040-3590.6.1.8, DOI 10.1037/1040-3590.6.1.8]; LeesHaley PR, 1997, ASSESSMENT, V4, P321, DOI 10.1177/107319119700400402; LEZAK MD, 1995, NEUROPSYCHOL ASSESSM; MARTIN RC, 1991, ANN M NAT AC NEUR DA; Miller W., 1992, PHYSICAL MED REHABIL, V6, P547; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; PERRINE K, 1993, J CLIN EXP NEUROPSYC, V15, P461, DOI 10.1080/01688639308402571; Reitan R.M., 1993, HALSTEADREITAN NEURO; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; ROGERS R, 1983, J PSYCHIAT LAW, V11, P443, DOI 10.1177/009318538301100404; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; [No title captured]	36	30	30	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2000	15	5					399	413		10.1016/S0887-6177(99)00031-1			15	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	336XV	WOS:000088329000006	14590216	Bronze			2022-02-06	
J	Jaeger, M; Hertrich, I; Stattrop, U; Schonle, PW; Ackermann, H				Jaeger, M; Hertrich, I; Stattrop, U; Schonle, PW; Ackermann, H			Speech disorders following severe traumatic grain injury: Kinematic analysis of syllable repetitions using electromagnetic articulography	FOLIA PHONIATRICA ET LOGOPAEDICA			English	Article						traumatic brain injury; kinematic analysis; electromagnetic articulography; speech motor deficits; dysarthria; articulation	CLOSED-HEAD-INJURY; BRAIN INJURY; DYSFUNCTION; DYSARTHRIA; MOVEMENTS	Using electromagnetic articulography, the lips, the tip of the tongue, and the tongue dorsum were tracked during repetitions of the syllables [pa], [ta] and [ka] in 10 speakers with dysarthria following severe traumatic brain injury and in 10 age-matched control subjects. When asked to produce the syllable trains as fast as possible, the patient group showed a rather homogeneous pattern of movement abnormalities including prolonged syllable durations and reduced peak velocity/amplitude ratios. Most presumably, limited speed generation gives rise to the impaired ability to increase speech rate. During the habitual speaking condition, reduced velocity/amplitude ratios were restricted to the tongue tip and tongue dorsum. Obviously, the tongue and the lips are differentially affected in dysarthria following severe traumatic brain injury. Copyright (C) 2000 S. Karger AG, Basel.	Univ Konstanz, Lurija Inst Rehabil Sci & Hlth Res, Neurol Rehabil Ctr Schmieder, Allensbach, Germany; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany		Jaeger, M (corresponding author), Kliniken Schmieder, Postfach 240, D-78473 Aliensbach, Germany.		Hertrich, Ingo/T-1154-2018	Hertrich, Ingo/0000-0001-8965-6249			ABBS J, 1985, SPEECH DISORDERS ADU; ACKERMANN H, 1995, FOLIA PHONIATR LOGO, V47, P15, DOI 10.1159/000266338; ACKERMANN H, 1995, J SPEECH HEAR RES, V38, P1252, DOI 10.1044/jshr.3806.1252; Ackermann H, 1997, MOVEMENT DISORD, V12, P1019, DOI 10.1002/mds.870120628; BARLOW SM, 1990, J SPEECH HEAR RES, V33, P660, DOI 10.1044/jshr.3304.660; BLUMBERGER J, 1995, BRAIN INJURY, V9, P797, DOI 10.3109/02699059509008235; BROWN SH, 1990, J NEUROL NEUROSUR PS, V53, P306, DOI 10.1136/jnnp.53.4.306; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; Gennarelli TA, 1993, HEAD INJURY, P137; HERTRICH I, 1997, ACCURACY LIP MOVEMEN, V35, P165; KELSO JAS, 1985, J ACOUST SOC AM, V77, P266, DOI 10.1121/1.392268; KENT RD, 1987, J SPEECH HEAR DISORD, V52, P367, DOI 10.1044/jshd.5204.367; LEFKOWITZ D, 1994, J MED SPEECH-LANG PA, V2, P1; MENNEL HD, 1997, SEVERE HEAD INJURIES, P19; Netsell R, 1992, ASHA SPECIAL INTERES, V2, P1; OSTRY DJ, 1985, J ACOUST SOC AM, V77, P457; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SCHONLE P, 1988, ELEKTROMAGNETISCHE A; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; THEODOROS DG, 1995, BRAIN INJURY, V9, P237, DOI 10.3109/02699059509008196; THEODOROS DG, 1994, BRAIN INJURY, V8, P667, DOI 10.3109/02699059409151021; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; VOGEL M, 1983, FOLIA PHONIATR, V35, P294, DOI 10.1159/000265705; Yorkston K, 1991, COMMUNICATION DISORD, P251; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZYSKI BJ, 1987, J COMMUN DISORD, V20, P367, DOI 10.1016/0021-9924(87)90025-6; [No title captured]	28	30	31	0	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7762			FOLIA PHONIATR LOGO	Folia Phoniatr. Logop.	JUL-AUG	2000	52	4					187	196		10.1159/000021533			10	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	314DW	WOS:000087040700004	10782011				2022-02-06	
J	Li, GL; Farooque, M; Lewen, A; Lennmyr, F; Holtz, A; Olsson, Y				Li, GL; Farooque, M; Lewen, A; Lennmyr, F; Holtz, A; Olsson, Y			MAP2 and neurogranin as markers for dendritic lesions in CNS injury. An immunohistochemical study in the rat	APMIS			English	Article						dendrite; injury; MAP2; neurogranin; rat	MICROTUBULE-ASSOCIATED PROTEIN-2; MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN INJURY; KINASE-C SUBSTRATE; SPINAL-CORD; ISCHEMIC DEGRADATION; SENSITIVE MARKER; LOCALIZATION; PHOSPHORYLATION; RC3	We compared two staining methods for the demonstration of dendrites under normal and pathological conditions of the rat central nervous system. MAP2- and neurogranin immunohistochemistry was applied to samples from normal tissue, spinal cord subjected to graded compression trauma, cerebral cortex following contusion trauma, and brains with focal ischemic lesions induced by occlusion of the middle cerebral artery (MCAO). Normal rats showed MAP2 immunoreactivity in nerve cell bodies and dendrites of brain and spinal cord. However, neurogranin staining was present only in nerve cell bodies and dendrites of the normal brain, and not in the spinal cord. Reduction of MAP2 immunoreactivity was seen in lesions of spinal cords subjected to compression trauma. Neurogranin staining was of no value in this experimental condition since it was not present under normal conditions. The brain contusions showed loss of both MAP2- and neurogranin immunoreactivity at the site of the lesion. MCAO resulted in an extensive loss of MAP2- and neurogranin staining in the ipsilateral hemisphere. In conclusion, our study shows that MAP2 immunostaining is a sensitive method for identifying dendritic lesions of various CNS injuries in the rat. Neurogranin immunostaining is an alternative method for investigations of dendritic pathology in the brain but not in the spinal cord.	Univ Uppsala Hosp, Neuropathol Lab, Dept Genet & Pathol, Res Grp Neuropathol, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosci, Neurosurg Unit, Uppsala, Sweden; Univ Uppsala Hosp, Dept Med, Uppsala, Sweden		Li, GL (corresponding author), Univ Uppsala Hosp, Neuropathol Lab, Dept Genet & Pathol, Res Grp Neuropathol, S-75185 Uppsala, Sweden.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			AlvarezBolado G, 1996, NEUROSCIENCE, V73, P565, DOI 10.1016/0306-4522(96)00061-9; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; CACERES A, 1984, J NEUROSCI, V4, P394; Camilli P.D., 1984, NEUROSCIENCE, V11, P819; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; Emery JA, 1997, J NEUROPATH EXP NEUR, V56, P1276, DOI 10.1097/00005072-199712000-00002; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HOLTZ A, 1989, ACTA UNIVERSITATIS U, V209, P1; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KUWAKI T, 1989, STROKE, V20, P78, DOI 10.1161/01.STR.20.1.78; LENOMYR F, 1998, J NEUROPATHOL EXP NE, V57, P874; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li GL, 1997, FREE RADICAL RES, V27, P187, DOI 10.3109/10715769709097851; LI GL, 1995, RESTOR NEUROL NEUROS, V8, P189, DOI 10.3233/RNN-1995-8404; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MATUS A, 1994, TRENDS NEUROSCI, V17, P19, DOI 10.1016/0166-2236(94)90030-2; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; NeunerJehle M, 1996, BRAIN RES, V733, P149, DOI 10.1016/S0006-8993(96)00786-X; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P460, DOI 10.1111/j.1600-0404.1988.tb03688.x; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Prichard L, 1999, J BIOL CHEM, V274, P7689, DOI 10.1074/jbc.274.12.7689; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1994, MOL BRAIN RES, V27, P323, DOI 10.1016/0169-328X(94)90017-5; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; Yamanouchi H, 1998, ACTA NEUROPATHOL, V95, P466, DOI 10.1007/s004010050826; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	33	30	39	0	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-4641			APMIS	APMIS	FEB	2000	108	2					98	106					9	Immunology; Microbiology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Microbiology; Pathology	292QR	WOS:000085807000002	10737454				2022-02-06	
J	Hutchinson, PJ; Al-Rawi, PG; O'Connell, MT; Gupta, AK; Pickard, JD; Kirkpatrick, PJ				Hutchinson, PJ; Al-Rawi, PG; O'Connell, MT; Gupta, AK; Pickard, JD; Kirkpatrick, PJ			Biochemical changes related to hypoxia during cerebral aneurysm surgery: Combined microdialysis and tissue oxygen monitoring: Case report	NEUROSURGERY			English	Article						brain metabolism; microdialysis; oxygen monitor; subarachnoid hemorrhage	CAROTID ENDARTERECTOMY; INTRACEREBRAL MICRODIALYSIS; SUBSTRATE DELIVERY; SUBARACHNOID HEMORRHAGE; NEUROSURGICAL PATIENTS; TRANSCRANIAL DOPPLER; INITIAL EXPERIENCE; HEAD-INJURY; BRAIN; PH	OBJECTIVE AND IMPORTANCE: The objective of this study was to monitor brain metabolism on-line during aneurysm surgery, by combining the use of a multiparameter (brain tissue oxygen, brain carbon dioxide, pH, and temperature) sensor with microdialysis (extracellular glucose, lactate, pyruvate, and glutamate). The case illustrates the potential value of these techniques by demonstrating the effects of adverse physiological events on brain metabolism and the ability to assist in both intraoperative and postoperative decision-making. CLINICAL PRESENTATION: A 41-year-old woman presented with a World Federation of Neurological Surgeons Grade 1 subarachnoid hemorrhage. Angiography revealed a basilar artery aneurysm that was not amenable to coiling, so the aneurysm was clipped. Before the craniotomy was performed, a multiparameter sensor and a microdialysis catheter were inserted to monitor brain metabolism. INTERVENTION: During the operation, the brain oxygen level decreased, in relation to biochemical changes, including the reduction of extracellular glucose and pyruvate and the elevation of lactate and glutamate. These changes were reversible. However, when the craniotomy was closed, a second decrease in brain oxygen occurred in association with brain swelling, which immediately prompted a postoperative computed tomographic scan. The scan demonstrated acute hydrocephalus, requiring external ventricular drainage. The patient made a full recovery. CONCLUSION: The monitoring techniques influenced clinical decision-making in the treatment of this patient. On-line measurement of brain tissue gases and extracellular chemistry has the potential to assist in the perioperative and postoperative management of patients under going complex cerebrovascular surgery and to establish the effects of intervention on brain homeostasis.	Univ Cambridge, Acad Dept Neurosurg, Cambridge, England; Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge, England; Univ Cambridge, Dept Neuroanaesthesia, Cambridge, England; Univ Cambridge, MRC, Ctr Brain Repair, Cambridge, England		Hutchinson, PJ (corresponding author), Addenbrookes Hosp, Acad Dept Neurosurg, Box 167, Cambridge CB2 2QQ, England.			O'Connell, Mark/0000-0001-6272-8767	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI		ALRAWI PG, 1999, BRIT J NEUROSURG, V13, P225; Bachli H, 1996, NEUROL RES, V18, P370; BENVENISTE H, 1987, J NEUROCHEM, V49, P729, DOI 10.1111/j.1471-4159.1987.tb00954.x; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BENVENISTE H, 1988, J CEREBR BLOOD F MET, V8, P713, DOI 10.1038/jcbfm.1988.118; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Charbel FT, 1997, SURG NEUROL, V48, P414, DOI 10.1016/S0090-3019(96)00473-9; CHIAPPA KH, 1979, STROKE, V10, P381, DOI 10.1161/01.STR.10.4.381; CHO I, 1986, ANN NEUROL, V20, P508, DOI 10.1002/ana.410200411; CLUTTONBROCK TH, 1994, J CLIN MONITOR, V10, P387, DOI 10.1007/BF01618420; Doppenberg EMR, 1997, J NEUROSURG, V87, P809, DOI 10.3171/jns.1997.87.6.0809; Goodman JC, 1996, ACT NEUR S, V67, P37; Hoffman WE, 1997, NEUROSURGERY, V40, P294, DOI 10.1097/00006123-199702000-00012; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; Hutchinson PJ, 1999, NEUROREPORT, V10, pI; HUTCHINSON PJA, 1998, BRIT J NEUROSURG, V12, pP87; Jansen C, 1993, Ann Vasc Surg, V7, P95, DOI 10.1007/BF02042666; Kirkpatrick PJ, 1998, J NEUROSURG, V89, P389, DOI 10.3171/jns.1998.89.3.0389; MCDOWELL HA, 1992, ANN SURG, V215, P514, DOI 10.1097/00000658-199205000-00014; Mendelowitsch A, 1996, ACT NEUR S, V67, P48; NAYLOR AR, 1991, BRIT J SURG, V78, P1264, DOI 10.1002/bjs.1800781038; Nilsson OG, 1996, ACT NEUR S, V67, P45; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Plestis KA, 1997, J VASC SURG, V25, P620, DOI 10.1016/S0741-5214(97)70287-8; Ungerstedt U, 1984, METHODS NEUROSCIENCE, V6, P81; VENKATESH B, 1995, J CARDIOTHOR VASC AN, V9, P412, DOI 10.1016/S1053-0770(05)80096-5; VENKATESH B, 1994, CRIT CARE MED, V22, P588, DOI 10.1097/00003246-199404000-00013; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WHITTLE I R, 1990, British Journal of Neurosurgery, V4, P459, DOI 10.3109/02688699008993792; Whittle IR, 1998, NEUROREPORT, V9, P2821, DOI 10.1097/00001756-199808240-00025; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	34	30	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JAN	2000	46	1					201	205		10.1093/neurosurgery/46.1.201			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	270MT	WOS:000084540200104	10626951				2022-02-06	
J	Nicholson, K				Nicholson, K			Pain, cognition and traumatic brain injury	NEUROREHABILITATION			English	Article							POSITRON-EMISSION-TOMOGRAPHY; MILD HEAD-INJURY; POST-CONCUSSIONAL SYNDROME; POSTTRAUMATIC HEADACHE; POSTCONCUSSION SYMPTOMS; TEST-PERFORMANCE; RISK-FACTORS; MEMORY; MIGRAINE; INFORMATION	There has been considerable controversy concerning the problem of the persisting post-concussive syndrome and whether cognitive or other sequelae might be attributed to the effects of brain injury or other causes. Headache is the predominant problem in virtually all surveys of the post-concussive syndrome. It is suggested that pain and related problems may account for most of the difficulties in those presenting with the persisting post-concussive syndrome or other cases in which mild to moderate brain injury is suspected. A survey of the literature concerning the relationship of pain, cognition and traumatic brain injury indicates that cognitive difficulties are common in acute or chronic pain, with or without any indication of brain injury. However, numerous methodological problems are apparent and there is clearly need for further study. Consideration is given both to psychosocial and neurobiological effects underlying any such relationships.	Toronto Western Hosp, Comprehens Pain Program, Toronto, ON M5T 2S8, Canada		Nicholson, K (corresponding author), Toronto Western Hosp, Comprehens Pain Program, 4BFell-150,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	keith@playfair.utoronto.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Andary MT, 1997, CLIN J PAIN, V13, P244, DOI 10.1097/00002508-199709000-00010; Aziz Q, 1997, GASTROENTEROLOGY, V113, P50, DOI 10.1016/S0016-5085(97)70079-9; Bell BD, 1999, ARCH CLIN NEUROPSYCH, V14, P389, DOI 10.1016/S0887-6177(98)00020-1; BERNARD JF, 1992, J NEUROPHYSIOL, V68, P551; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blume H G, 1990, Beitr Gerichtl Med, V48, P397; Branca B, 1996, HEADACHE, V36, P300, DOI 10.1046/j.1526-4610.1996.3605300.x; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BRUYN GW, 1990, HDB CLIN NEUROLOGY, V13, P421; Burker E, 1989, NEUROPSYCHOLOGY, V3, P61, DOI 10.1037//0894-4105.3.2.61; CHEN ACN, 1993, PAIN, V54, P133, DOI 10.1016/0304-3959(93)90201-Y; Coghill RC, 1999, J NEUROPHYSIOL, V82, P1934, DOI 10.1152/jn.1999.82.4.1934; Crombez G, 1997, PAIN, V70, P149, DOI 10.1016/S0304-3959(96)03304-0; Crombez G, 1996, BEHAV RES THER, V34, P911, DOI 10.1016/S0005-7967(96)00058-7; CROMBEZ G, 1994, BEHAV RES THER, V32, P611, DOI 10.1016/0005-7967(94)90015-9; DANDREA G, 1989, CEPHALALGIA, V9, P25, DOI 10.1046/j.1468-2982.1989.0901025.x; DAVIDSON H, 1991 INT NEUR SOC AN; Denys P, 1996, BRAIN INJURY, V10, P149, DOI 10.1080/026990596124656; DERBYSHIRE SWG, 1994, J NEUROL NEUROSUR PS, V57, P1166, DOI 10.1136/jnnp.57.10.1166; Derbyshire SWG, 1997, PAIN, V73, P431, DOI 10.1016/S0304-3959(97)00138-3; Diener HC, 1997, HEADACHE, V37, P622, DOI 10.1046/j.1526-4610.1997.3710622.x; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIPIERO V, 1991, PAIN, V46, P9, DOI 10.1016/0304-3959(91)90026-T; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; DUFTON BD, 1989, INT J PSYCHIAT MED, V19, P291, DOI 10.2190/JDJK-0795-5BFL-5N6K; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Farrell MJ, 1996, PAIN, V67, P7, DOI 10.1016/0304-3959(96)03041-2; FIORAVANTI M, 1983, CEPHALALGIA, V3, P221, DOI 10.1177/03331024830030S137; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; GRIGSBY J, 1994, ARCH CLIN NEUROPSYCH, V9, P135; HART RP, IN PRESS NEUROREHABI; HEBBEN N, 1981, NEUR ABSTR, V7, P235; HOOKER WD, 1986, ARCH NEUROL-CHICAGO, V43, P709, DOI 10.1001/archneur.1986.00520070065020; Hsieh JC, 1996, PAIN, V64, P303, DOI 10.1016/0304-3959(95)00129-8; HSIEH JC, 1996, INT C FUNCT MAPP HUM; IADAROLA MJ, 1995, PAIN, V63, P55, DOI 10.1016/0304-3959(95)00015-K; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JAMISON RN, 1988, INT J PSYCHIAT MED, V18, P183; Jones AKP, 1996, ANN RHEUM DIS, V55, P411, DOI 10.1136/ard.55.7.411; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; KEWMAN DG, 1989, ARCH PHYSICAL MED RE; KOEHLER SM, 1991, J CLIN EXP NEUROPSYC, V13, P60; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lake AE, 1999, J HEAD TRAUMA REHAB, V14, P70, DOI 10.1097/00001199-199902000-00008; LEIJDEKKERS MLA, 1990, HEADACHE, V30, P352, DOI 10.1111/j.1526-4610.1990.hed3006352.x; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lorenz J, 1997, PSYCHOPHYSIOLOGY, V34, P436, DOI 10.1111/j.1469-8986.1997.tb02387.x; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MAZZUCCHI A, 1988, HEADACHE, V28, P488, DOI 10.1111/j.1526-4610.1988.hed2807488.x; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MIDDELBOE T, 1992, J PERS DISORD, V6, P246, DOI 10.1521/pedi.1992.6.3.246; NICHOLSON K, NEUROREHABILITATION; NICHOLSON K, NEUROREHABILITION; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; PATIL PG, 1995, PHYSIOL BEHAV, V58, P1281, DOI 10.1016/0031-9384(95)02071-3; PEYRON R, 1995, PAIN, V62, P275, DOI 10.1016/0304-3959(94)00211-V; Price DD, 1988, PSYCHOL NEURAL MECH; PUCA F, 1985, MIGRAINE CLIN RES AD, P1; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, MILD HEAD INJURY, P217; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; SELTZER SF, 1991, PAIN, V47, P47, DOI 10.1016/0304-3959(91)90010-U; Sepe C, 1993, Acta Neurol (Napoli), V15, P421; SHAPIRO AP, 1993, SPINE STATE ART REV, V7, P455; Silverman DHS, 1997, GASTROENTEROLOGY, V112, P64, DOI 10.1016/S0016-5085(97)70220-8; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; TSUSHIMA WT, 1993, HEADACHE, V33, P139, DOI 10.1111/j.1526-4610.1993.hed3303139.x; Tsushima WT, 1996, HEADACHE, V36, P613, DOI 10.1046/j.1526-4610.1996.3610613.x; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VERNONWILKINSON R, 1993 NAT AC NEUR ANN; Vogt BA, 1996, EUR J NEUROSCI, V8, P1461, DOI 10.1111/j.1460-9568.1996.tb01608.x; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; ZEITLIN C, 1984, BRIT J CLIN PSYCHOL, V23, P27, DOI 10.1111/j.2044-8260.1984.tb00623.x	89	30	32	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2000	14	2					95	103					9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	338AL	WOS:000088395900005	11455072				2022-02-06	
J	Dirette, DK; Hinojosa, J; Carnevale, GJ				Dirette, DK; Hinojosa, J; Carnevale, GJ			Comparison of remedial and compensatory interventions for adults with acquired brain injuries	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							CLOSED-HEAD-INJURY; MODERATE	Objective: To examine the effects of a compensatory intervention versus a remedial intervention for deficits in visual processing of adults with acquired brain injuries (ABT). Setting: A cognitive rehabilitation program at a large comprehensive rehabilitation hospital in the New York City metropolitan area. Patients: Thirty adults with ABI were matched according to severity of injury, gender, age, and time post-injury, and randomly assigned to the remedial or compensatory group. Interventions: The remedial intervention consisted of four 45-minute sessions (once weekly) of participation in computer tasks without instruction in compensatory strategies. The compensatory intervention consisted of four 45-minute sessions of instruction in the use of three internal compensatory strategies, including verbalization, chunking, and pacing. Main Outcome Measures: Pretest/posttest measures included three functional computer tasks. Weekly measures included a computerized version of the Paced Auditory Serial Addition Task (PASAT) and two computerized matching tasks. Results: Both groups exhibited statistically significant improvement of comparable degree on posttests and weekly measures. Further analysis revealed that 80% of both groups used compensatory strategies, regardless of intervention method. Those who used strategies demonstrated better performance than those who did not. Conclusion: The ability to use internal compensatory strategies may be a significant confound in research examining the effects of the various cognitive rehabilitation intervention methods.	Western Michigan Univ, Occupat Therapy Dept, Kalamazoo, MI 49008 USA; NYU, Dept Occupat Therapy, New York, NY USA; Kessler Inst Rehabil, Dept Psychol & Neuropsychol, E Orange, NJ USA		Dirette, DK (corresponding author), Western Michigan Univ, Occupat Therapy Dept, 1201 Oliver St, Kalamazoo, MI 49008 USA.						AERO R, 1984, BRAIN GAME SOFTWARE; Anderson J. R., 1985, COGNITIVE PSYCHOL IT; ASINOVSKY V, 1992, IQ BUILDER SOFTWARE; CONSTANTINIDOU F, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199508000-00009; Diller L., 1993, AOTA SELF STUDY SERI, P7; GIANUTSOS R, 1987, HIGHER ORDER FUNCTIO; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; Haase B., 1997, ASSESSMENT OCCUPATIO, P333; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; *LOF DEV CORP, 1986, LOT 1 2 3 SOFTW; MALEC J, 1984, COGNITIVE REHABILITA, V2, P18; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MOSEY AC, 1993, AOTA SELF STUDY SERI, P23; NEIMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811; Norusis M.J., 1994, SPSS ADV STAT 6 1; Oberg L, 1998, J HEAD TRAUMA REHAB, V13, P44, DOI 10.1097/00001199-199806000-00005; Parente R., 1989, J HEAD TRAUMA REHAB, V4, P53; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIMEL RW, 1982, NEUROSURGERY, V11, P334; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; *SPSS INC, 1995, SPSS 6 1 ADV VERS WI; STRACHE W, 1987, International Journal of Rehabilitation Research, V10, P141, DOI 10.1097/00004356-198700105-00028; Tabachnick B. G., 1989, USING MULTIVARIATE S; TEHAN G, 1995, MEM COGNITION, V23, P181, DOI 10.3758/BF03197220; Toglia JA., 1993, AOTA SELF STUDY SERI, P1; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505; Wood R L, 1987, Int Disabil Stud, V9, P149; WOOD RL, 1984, CLIN MANAGEMENT MEMO, P148	32	30	31	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					595	601		10.1097/00001199-199912000-00008			7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300007	10671705				2022-02-06	
J	Zhang, C; Raghupathi, R; Saatman, KE; LaPlaca, MC; McIntosh, TK				Zhang, C; Raghupathi, R; Saatman, KE; LaPlaca, MC; McIntosh, TK			Regional and temporal alterations in DNA fragmentation factor (DFF)-like proteins following experimental brain trauma in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						DNA fragmentation; DFF45/DFF40; fluid percussion; immunoblotting; traumatic brain injury	APOPTOTIC CELL-DEATH; CASPASE-ACTIVATED DNASE; DELAYED NEURONAL DEATH; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; GRANULE CELLS; SPINAL-CORD; INJURY; CLEAVAGE; CPP32	DNA fragmentation, an early event in neuronal death following traumatic brain injury, may be triggered by the 40-kDa subunit of DNA fragmentation factor (DFF40). DFF40 is typically bound to the 45-kDa subunit of DFF (DFF45), and activation of DFF40 may occur as a result of caspase-3-mediated cleavage of DFF45 into 30- and 11-kDa fragments. In this study, the intracellular distribution of DFF45 and DFF40 was examined following lateral fluid percussion brain injury of moderate severity (2.4-2.7 arm) in male Sprague-Dawley rats. In the cytosolic fraction (S1) of the injured cortex at 2 and 24 h postinjury, significant decreases in the intensities of DFF45-like proteins at 45- and 32-kDa bands and a concomitant increase in the 11-kDa bands were observed (p < 0.05 vs, uninjured controls). A significant decrease in the intensities of the 32-kDa band in the nuclear (P1) fraction of the injured cortex was observed at 30 min and 2 h postinjury (p < 0.01). Concomitantly, a decrease in DFF40 was observed in the cortical S1 fraction at 2 and 24 h (p < 0.05) and in the P1 fraction at 30 min and 2 h postinjury (p < 0.01). In the hippocampus, DFF45 decreased at 30 min in the P1 and 2 h in the S1 fraction (p < 0.05) and recovered by 24 h postinjury, whereas DFF40 was significantly decreased in the S1 and increased in the P1 fraction at both 2 and 24 h (p < 0.01), which indicated a translocation of DFF40 from cytosol to nucleus. These data are the first to demonstrate that changes in DFF proteins occur after brain trauma and suggest that these changes may play a role in apoptotic cell death via caspase-3-DFF45/DFF40-DNA cleavage observed following traumatic brain injury.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803] Funding Source: NIH RePORTER		Armstrong RC, 1997, J NEUROSCI, V17, P553; Barinaga M, 1998, SCIENCE, V281, P1303, DOI 10.1126/science.281.5381.1303; Barinaga M, 1998, SCIENCE, V281, P1302, DOI 10.1126/science.281.5381.1302; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chen J, 1998, J NEUROSCI, V18, P4914; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; Marks N, 1998, J NEUROSCI RES, V52, P334, DOI 10.1002/(SICI)1097-4547(19980501)52:3<334::AID-JNR9>3.0.CO;2-E; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mitamura S, 1998, BIOCHEM BIOPH RES CO, V243, P480, DOI 10.1006/bbrc.1998.8122; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Namura S, 1998, J NEUROSCI, V18, P3659; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NITATORI T, 1995, J NEUROSCI, V15, P1001; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; PETITO CK, 1995, AM J PATHOL, V146, P1121; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/S0006-8993(96)00222-3; RINK A, 1995, AM J PATHOL, V147, P1575; Sabol SL, 1998, BIOCHEM BIOPH RES CO, V253, P151, DOI 10.1006/bbrc.1998.9770; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Samejima K, 1998, EXP CELL RES, V243, P453, DOI 10.1006/excr.1998.4212; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	54	30	30	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	OCT	1999	73	4					1650	1659		10.1046/j.1471-4159.1999.0731650.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	236TZ	WOS:000082616200037	10501212				2022-02-06	
J	Wada, K; Alonso, OF; Busto, R; Panetta, J; Clemens, JA; Ginsberg, MD; Dietrich, WD				Wada, K; Alonso, OF; Busto, R; Panetta, J; Clemens, JA; Ginsberg, MD; Dietrich, WD			Early treatment with a novel inhibitor of lipid peroxidation (LY341122) improves histopathological outcome after moderate fluid percussion brain injury in rats	NEUROSURGERY			English	Article						fluid percussion brain injury; free radical scavenger; lipid peroxidation inhibitor; LY341122; rat	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; CONJUGATED SUPEROXIDE-DISMUTASE; FREE-RADICAL PRODUCTION; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE SYNTHASE; REPERFUSION INJURY; SUBDURAL-HEMATOMA; NMDA RECEPTORS; GLUTAMATE	OBJECTIVE: Reactive oxygen species are thought to participate in the pathobiology of traumatic brain injury (TBI). This study determined whether treatment with LY341122, a potent inhibitor of lipid peroxidation and an antioxidant, would provide neuroprotection in a rat model of TBI. METHODS: To investigate the efficacy of LY341122 in this parasagittal fluid percussion model (1.8-2.1 atm), the rats received oval administration of LY341122 (100 mg/kg) or vehicle 2 hours before and 4 hours after TBI teach group, n = 7). To investigate the therapeutic window for treatment, rats were treated with LY341122 or vehicle for 20 hours by femoral vein infusion starting at 5 minutes, 30 minutes, or 3 hours after TBI teach group, n = 5). Three days after injury, analysis of contusion volumes and the frequency of damaged cortical neurons was conducted. RESULTS: Oral administration of LY341122 before and after TBI led to a significant reduction in overall contusion volume (3.28 mm(3) +/- 0.75 mm(3) [mean +/- standard error of the mean] versus 1.32 mm(3) +/- 0.33 mm(3); P < 0.05) and also reduced the frequency of damaged cortical neurons (1191.7 +/- 267.1 versus 474.6 +/- 80.2; P < 0.05). In the second experiment, rats treated with LY341122 at 5 minutes or 30 minutes after TBI also demonstrated a significant reduction (P < 0.05) in contusion volume (1.92 mm(3) +/- 0.64 mm(3) or 1.59 mm(3) +/- 0.50 mm(3), respectively) compared with vehicle-treated rats (4.32 mm(3) +/- 1.15 mm(3)). A significant reduction in total cortical necrotic neuron counts was also demonstrated in the 5-minute group (2243.8 +/- 265.3 versus 1457.8 +/- 265.3; P < 0.05). In contrast, histopathological outcome was not significantly improved when treatment was delayed until 3 hours after TBI. CONCLUSION: These data reinforce the hypothesis that lipid peroxidation and reactive oxygen species participate in the acute pathogenesis of TBI. Treatment delayed until 3 hours after TBI did not provide significant histopathological protection.	Univ Miami, Dept Neurol, Miami, FL 33101 USA; Univ Miami, Dept Neurol Surg, Neurotrauma Res Ctr, Miami, FL 33101 USA; Lilly Res Labs, Indianapolis, IN USA		Dietrich, WD (corresponding author), Univ Miami, Dept Neurol Surg & Neurol R48, POB 016960, Miami, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		Aldana P. R., 1998, Society for Neuroscience Abstracts, V24, P1732; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; CLEMENS JA, 1999, J CEREB BLOOD FLO S1, V19, pS183; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DEWITT DS, 1997, J NEUROTRAUM, V14, P219; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIETRICH WD, 1997, J CEREB BLOOD FLO S1, V17, pS25; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; DUCKROW RB, 1986, J NEUROSURG, V54, P607; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HAMMER B, 1993, NEUROREPORT, V5, P72, DOI 10.1097/00001756-199310000-00018; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLEIHUES P, 1974, J NEUROCHEM, V23, P417, DOI 10.1111/j.1471-4159.1974.tb04374.x; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lin SZ, 1996, STROKE, V27, P747, DOI 10.1161/01.STR.27.4.747; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1987, FASEB J, V46, P2402; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; RATAN RR, 1994, J NEUROCHEM, V62, P376; RINK A, 1995, AM J PATHOL, V147, P1575; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WELSH FA, 1984, CEREBRAL ISCHEMIA, P177; WILSON JT, 1995, J TRAUMA, V39, P473; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA K, 1992, STROKE, V23, P865, DOI 10.1161/01.STR.23.6.865; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Zilles K., 1985, CORTEX RAT STEREOTAX	64	30	31	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1999	45	3					601	608		10.1097/00006123-199909000-00031			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	235MT	WOS:000082546000072	10493379				2022-02-06	
J	Blackmer, J; Marshall, SC				Blackmer, J; Marshall, SC			A comparison of traumatic brain injury in the Saskatchewan native North American and non-native North American populations	BRAIN INJURY			English	Article							INDIAN POPULATION; DIABETES-MELLITUS; ALASKA NATIVES; ALCOHOL-ABUSE; PREVALENCE; TRENDS; MORTALITY; QUEBEC	Objective: To compare native North American and non-native North American patients admitted for inpatient rehabilitation following traumatic brain injury in order to identify pertinent differences between the two groups with regards to the initial injury, medical management and allocated resources. Design: A retrospective chart review was performed on all patients admitted to the unit between July 1994 and March 1997 with the diagnosis of traumatic brain injury. Results: Significant differences were found between the two groups in the areas of alcohol and drug involvement with the initial injury (p < 0.0001), geographical location of the injury (p < 0.0001), initial treatment received (p = 0.0102), discharge planning (p < 0.0001), and post-discharge followup (p = 0.0052). Conclusions: The results indicate that native North Americans are more likely to suffer a head injury than non-native North Americans, that alcohol is more likely to be involved, and that native North American patients are less likely to be offered post-discharge resources. Further prospective study to explore these areas is required.	Saskatoon City Hosp, Dept Phys Med & Rehabil, Saskatoon, SK S7K 0M7, Canada; Rehabil Ctr, Ottawa, ON, Canada		Blackmer, J (corresponding author), Saskatoon City Hosp, Dept Phys Med & Rehabil, 701 Queen St, Saskatoon, SK S7K 0M7, Canada.	blackmer@duke.usask.ca					Beauvais F, 1996, AM J PUBLIC HEALTH, V86, P1594, DOI 10.2105/AJPH.86.11.1594; BOYD DL, 1968, ARCH ENVIRON HEALTH, V17, P101, DOI 10.1080/00039896.1968.10665197; BRASSARD P, 1993, CAN MED ASSOC J, V149, P303; CamposOutcalt D, 1997, AM J PUBLIC HEALTH, V87, P282, DOI 10.2105/AJPH.87.2.282; CONWAY GA, 1992, J ACQ IMMUN DEF SYND, V5, P803; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; DELISLE HF, 1993, CAN MED ASSOC J, V148, P41; ERSTAD JL, 1994, IHS PROVIDER, V19, P9; FRASERLEE NJ, 1994, CAN J PUBLIC HEALTH, V85, P197; Gilliland FD, 1995, ALCOHOL CLIN EXP RES, V19, P1572, DOI 10.1111/j.1530-0277.1995.tb01026.x; HISNANICK JJ, 1993, AM J DRUG ALCOHOL AB, V19, P387, DOI 10.3109/00952999309001628; Kraus JF, 1993, HEAD INJURY, P1; Levin HS., 1982, NEUROBEHAVIORAL CONS; MAY PA, 1988, SURG GEN WORKSH DRUN; Oken E, 1995, AM J PREV MED, V11, P375, DOI 10.1016/S0749-3797(18)30416-1; RHOADES ER, 1988, PUBLIC HEALTH REP, V103, P621; Sievers ML, 1996, DIABETES CARE, V19, P107, DOI 10.2337/diacare.19.2.107; Soderstrom CA, 1997, JAMA-J AM MED ASSOC, V277, P1769, DOI 10.1001/jama.277.22.1769; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; *SPSS INC, 1989, SPSS WIND REL 6 1; *STAT CAN, 1997, 1991 CENS POP; Sugarman JR, 1996, PUBLIC HEALTH REP, V111, P321; TEASDALE G, 1974, LANCET, V2, P81; TRACKS JGG, 1973, SOC WORK, V18, P30; *UB FDN ARCH INC, 1993, GUID UN DAT SET MED; Walker RD, 1996, AM INDIAN ALASKA NAT, V7, P1; Wall TL, 1996, ALCOHOL CLIN EXP RES, V20, P1159, DOI 10.1111/j.1530-0277.1996.tb01105.x; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P186; Whyte J, 1993, REHABILITATION MED P, P825; WILLS TE, 1969, PINE RIDGE RES B, V8, P49; YOUNG TK, 1991, PREV MED, V20, P474, DOI 10.1016/0091-7435(91)90045-6	31	30	30	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1999	13	8					627	635					9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200006	10901690				2022-02-06	
J	Webster, G; Daisley, A; Rings, N				Webster, G; Daisley, A; Rings, N			Relationship and family breakdown following acquired brain injury: the role of the rehabilitation team	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RELATIVES; CAREGIVERS; SUPPORT	Although the literature documents the considerable problems acquired brain injury causes for the survivors family and close relationships, and the corresponding significantly inflated rate of separation and divorce, few papers offer practical solutions. The objective of this paper is to respond to this gap in the literature by presenting some of the problems raised for the rehabilitation team when a family separates, and some suggestions for ways in which these problems could be overcome. The literature is reviewed briefly, followed by reflections and suggestions which are based on this review and on clinical experience. The discussion indicates that there are a number of practical dilemmas raised for the rehabilitation team when a family already involved in the rehabilitation process starts to break up. Some specific suggestions for addressing these issues are made; further research is needed to evaluate their effectiveness.	Rivermead Rehabil Ctr, Dept Clin Neuropsychol, Oxford OX1 4XD, England; Warneford Hosp, Isis Educ Ctr, Oxford Reg Training Course Clin Psychol, Oxford, England		Daisley, A (corresponding author), Rivermead Rehabil Ctr, Dept Clin Neuropsychol, Abingdon Rd, Oxford OX1 4XD, England.						Bond M R, 1979, Int Rehabil Med, V1, P155; BRANNEN J, 1982, MARRIAGES TROUBLE; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Frosch S, 1997, BRAIN INJURY, V11, P891; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Jackson A, 1991, COUNS PSYCHOL, V4, P355; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; Martin K M, 1994, J Neurosci Nurs, V26, P134; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; *MED DIS SOC, 1988, WORK PART REP MAN TR; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A, 1972, REHABILITATION, V38, P33; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Stilwell J, 1997, NATL TRAUMATIC BRAIN; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Testani-Dufour L, 1992, J Neurosci Nurs, V24, P317; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1988, NEW DEV CLIN PSYCHOL, V2, P189; TYERMAN A, 1991, COUNSELLING COMMUNIC, P115; WALKER J, 1988, FAMILY THERAPY BRITA, P241; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Woods B, 1997, AGING MENT HEALTH, V1, P11, DOI 10.1080/13607869757335	38	30	30	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1999	13	8					593	603					11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200004	10901688				2022-02-06	
J	Weider, L; Hughes, K; Ciarochi, J; Dunn, E				Weider, L; Hughes, K; Ciarochi, J; Dunn, E			Early versus delayed repair of facial fractures in the multiply injured patient	AMERICAN SURGEON			English	Article							CRANIOFACIAL TRAUMA; INTERNAL-FIXATION; MANAGEMENT; MIDFACE	The management of facial fractures in the polytrauma patient requires the coordination of multiple surgical disciplines to optimize the functional and cosmetic outcome while minimizing overall morbidity and mortality. Although the plastic surgery literature historically advocates the early repair of facial fractures, the risk of general anesthesia in patients with associated injuries sometimes makes early repair unsafe. We compared early operative repair versus delayed operative repair of facial fractures in multitrauma patients. We specifically examined wound infection, overall complication rate, total length of hospital stay, days in the Intensive Care Unit (ICU), and days on the ventilator in the two groups. A 5-year (1991-1996) retrospective study of multitrauma patients with associated facial fractures was undertaken at an urban community hospital. We had a total of 82 patients, who were divided into three groups. Thirty-three patients did not have operative repair of the facial fractures during the initial admission and were followed by the plastic surgery service on an outpatient basis. These patients will not be discussed further. Seven patients underwent early operative repair, which was defined as repair within 48 hours of admission (group I). Forty-two patients had delayed operative repair, defined as repair more than 48 hours after admission (group II). The reasons for delayed repair included: excessive soft tissue swelling (16), intracranial injuries (12), unstable medical condition (8), and coordination of procedures with other services (6). Of the 49 patients who underwent operative repair, 43 were involved in motor vehicle accidents, 3 were injured by a fall from a height, 2 were involved in auto-pedestrian accidents, and 1 was a victim of assault. Forty-eight of the 49 patients were initially admitted to the ICU. Cumulative associated injuries were as follows: closed head injury (38), extremity fracture (21), blunt chest injuries (11), intra-abdominal injuries (5), vertebral column injuries (7), and ocular injuries (2). The average Injury Severity Score for Group I was 17.3 and for Group II, 18.1. In group I, there were no deaths, there were no wound infections, and the complication rate was 14.3 per cent. The average total number of days spent on the ventilator was 3.0, the average total number of days spent in the ICU was 5.0, and the average total hospital stay was 16.0 days. In group II, there were no deaths, the wound infection rate was 5 per cent, and the overall complication rate was 21 per cent. The average total number of days spent on the ventilator was 3.3, the average total number of days spent in the ICU was 5.8, and the average total days in the hospital was 14.8. Our results indicate that in a similar cohort of multitrauma patients, delayed repair did not increase length of ICU stay or hospital stay. The wound infection rate was negligible, and the complication rate was similar in the two groups. We conclude that a delay in repair of facial fractures in the critically ill patient has an acceptably low complication rate and may be advantageous in decreasing operative risk and minimizing cost by coordinating multiple procedures with various surgical subspecialties.	Methodist Hosp, Dept Surg, Dallas, TX 75265 USA		Dunn, E (corresponding author), Methodist Hosp, Dept Surg, POB 655999, Dallas, TX 75265 USA.						BENZIL DL, 1992, NEUROSURGERY, V30, P166, DOI 10.1227/00006123-199202000-00003; BRANDT KE, 1991, J TRAUMA, V31, P15, DOI 10.1097/00005373-199101000-00003; DERDYN C, 1990, PLAST RECONSTR SURG, V86, P238, DOI 10.1097/00006534-199008000-00005; DUFRESNE CR, 1992, CLIN PLAST SURG, V19, P207; Hartel J, 1991, Dtsch Z Mund Kiefer Gesichtschir, V15, P111; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; JETER TS, 1988, ORAL SURG ORAL MED O, V66, P416, DOI 10.1016/0030-4220(88)90257-5; KLOTCH DW, 1987, J TRAUMA, V27, P1136, DOI 10.1097/00005373-198710000-00008; MACIAS JD, 1993, ARCH OTOLARYNGOL, V119, P308; RAVEH J, 1988, J CRANIO MAXILL SURG, V16, P160, DOI 10.1016/S1010-5182(88)80042-8; REHM CG, 1995, J ORAL MAXIL SURG, V53, P522, DOI 10.1016/0278-2391(95)90063-2; THALLER SR, 1990, PLAST RECONSTR SURG, V85, P196, DOI 10.1097/00006534-199002000-00005; THALLER SR, 1992, PLAST RECONSTR SURG, V90, P562, DOI 10.1097/00006534-199210000-00003	13	30	31	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	AUG	1999	65	8					790	793					4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	220MR	WOS:000081670200029	10432093				2022-02-06	
J	Brana, C; Benham, CD; Sundstrom, LE				Brana, C; Benham, CD; Sundstrom, LE			Calpain activation and inhibition in organotypic rat hippocampal slice cultures deprived of oxygen and glucose	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						calpain inhibition; hippocampus; MDL 28170; organotypic cultures; oxygen-glucose deprivation	CYTOSKELETAL PROTEOLYSIS; PROPIDIUM IODIDE; NEURONAL DAMAGE; IN-VITRO; BRAIN; ISCHEMIA; CALCIUM; NMDA; NEUROPROTECTION; CALPASTATIN	It has been suggested that, after ischaemia, activation of proteases such as calpains could be involved in cytoskeletal degradation leading to neuronal cell death. In vivo, calpain inhibitors at high doses have been shown to reduce ischaemic damage and traumatic brain injury, however, the relationship between calpain activation and cell death remains unclear. We have investigated the role of calpain activation in a model of ischaemia based on organotypic hippocampal slice cultures using the appearance of spectrin breakdown products (BDPs) as a measure of calpain I activation. Calpain I activity was detected on Western blot immediately after a 1-h exposure to ischaemia. Up to 4 h post ischaemia, BDPs were found mainly in the CA1 region and appeared before uptake of the vital dye propidium iodide (PI). 24 h after the insult, BDPs were detected extensively in CA1 and CA3 pyramidal cells, all of which was PI-positive. However, there were many more PI-positive cells that did not have BDPs, indicating that the appearance of BDPs does not necessarily accompany ischaemic cell death. Inhibition of BDP formation by the broad-spectrum protease inhibitor leupeptin was not accompanied by any neuroprotective effects. The more specific and more cell-permeant calpain inhibitor MDL 28170 had a clear neuroprotective effect when added after the ischaemic insult. In contrast, when MDL 28170 was present throughout the entire pre- and post-incubation phases, PI labelling actually increased, indicating a toxic effect. These results suggest that calpain activation is not always associated with cell death and that, while inhibition of calpains can be neuroprotective under some conditions, it may not always lead to beneficial outcomes in ischaemia.	Univ Southampton, Southampton Gen Hosp, Dept Clin Neurol Sci, Southampton SO16 6YD, Hants, England; SmithKline Beecham Pharmaceut, Harlow CM19 5AW, Essex, England		Brana, C (corresponding author), Univ Southampton, Southampton Gen Hosp, Dept Clin Neurol Sci, Level F,S Acad Block,Tremona Rd, Southampton SO16 6YD, Hants, England.						BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Faddis BT, 1997, J NEUROSCI, V17, P951; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; GOTO K, 1994, MOL BRAIN RES, V23, P40, DOI 10.1016/0169-328X(94)90209-7; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MACKLIS JD, 1990, J NEUROSCI METH, V31, P43, DOI 10.1016/0165-0270(90)90007-3; MALIK MN, 1981, LIFE SCI, V29, P795, DOI 10.1016/0024-3205(81)90035-7; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; OSWALD K, 1991, SOC NEUR ABSTR, V17, P185; Pringle AK, 1996, NEUROSCI LETT, V211, P203, DOI 10.1016/0304-3940(96)12745-2; Pringle AK, 1997, BRAIN RES, V755, P36, DOI 10.1016/S0006-8993(97)00089-9; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SANDOVAL IV, 1978, EUR J BIOCHEM, V92, P463, DOI 10.1111/j.1432-1033.1978.tb12768.x; SCHLAEPFER WW, 1979, BRAIN RES, V168, P299, DOI 10.1016/0006-8993(79)90171-9; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIMAN R, 1985, BRAIN RES, V347, P399, DOI 10.1016/0006-8993(85)90208-2; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SIMAN R, 1989, J NEUROSCI, V9, P1579; Siman R, 1996, ADV NEUROL, V71, P167; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STRASSER U, 1995, J NEUROSCI METH, V57, P177, DOI 10.1016/0165-0270(94)00147-9; SUNDSTROM LE, 1995, J CEREBRAL BLOOD FLO, V15, pS11; VORNOV JJ, 1994, STROKE, V25, P457, DOI 10.1161/01.STR.25.2.457; VORNOV JJ, 1991, EXP NEUROL, V114, P11, DOI 10.1016/0014-4886(91)90079-R; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WILDE GJC, 1994, NEUROSCI LETT, V180, P223, DOI 10.1016/0304-3940(94)90525-8	35	30	30	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	JUL	1999	11	7					2375	2384		10.1046/j.1460-9568.1999.00653.x			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	211NT	WOS:000081175400019	10383627				2022-02-06	
J	Gibbs, RW				Gibbs, RW			Interpreting what speakers say and implicate	BRAIN AND LANGUAGE			English	Article							BRAIN-DAMAGED PATIENTS; CLOSED-HEAD-INJURY; COMPREHENSION; RELEVANCE; REQUESTS; LANGUAGE; SARCASM; ABILITY; IDIOMS; AUTISM	The traditional view in pragmatic theory is that a distinction exists between what speakers say and what they mean, communicate, or implicate in context. For example, when uttering Jane has three children, a speaker might only say that "Jane has three children but may have more than three," but the speaker implicates that "Jane has exactly three children." Under this view, pragmatics plays only a small role in determining what speakers say and has a primary part in interpreting speaker's intended messages. My aim in this article is to challenge this view. I describe empirical work showing that pragmatics has a fundamental role in determining both what speakers say and implicate. Thus, when a speaker utters Jane has three children, enriched pragmatic information is used to infer that the speaker says "Jane has exactly three children" and that in specific contexts, the speaker can go on to express additional pragmatic meanings, such as ''Jane is married'' or "Jane is very busy because she has three children." I also describe work on the importance of complex pragmatic, metarepresentational reasoning in understanding irony and metaphor. Finally, I briefly discuss the relevance of these new developments in pragmatics for neurolinguistic research. (C) 1999 Academic Press.	Univ Calif Santa Cruz, Dept Psychol, Santa Cruz, CA 95064 USA		Gibbs, RW (corresponding author), Univ Calif Santa Cruz, Dept Psychol, Santa Cruz, CA 95064 USA.		Van Mulken, Margot/J-3567-2012	Van Mulken, Margot/0000-0002-0801-287X			BIHRLE AM, 1986, BRAIN COGNITION, V5, P399, DOI 10.1016/0278-2626(86)90042-4; BLASKO DG, 1993, J EXP PSYCHOL LEARN, V19, P295, DOI 10.1037/0278-7393.19.2.295; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; CACCIARI C, 1988, J MEM LANG, V27, P668, DOI 10.1016/0749-596X(88)90014-9; CARSTON R, 1993, LINGUA, V90, P27, DOI 10.1016/0024-3841(93)90059-6; DASCAL M, 1987, COGNITIVE SCI, V11, P259, DOI 10.1016/S0364-0213(87)80007-1; FRITH U, 1994, COGNITION, V50, P115, DOI 10.1016/0010-0277(94)90024-8; GIBBS R, IN PRESS METAREPRESE; GIBBS R, UNPUB METAREPRESENTA; Gibbs Raymond W., 1994, POETICS MIND FIGURAT; Gibbs RW, 1997, COGNITION, V62, P51, DOI 10.1016/S0010-0277(96)00724-X; GIBBS RW, 1995, PSYCHOL BULL, V118, P133, DOI 10.1037/0033-2909.118.1.133; GIBBS RW, 1986, ACTA PSYCHOL, V62, P41, DOI 10.1016/0001-6918(86)90004-1; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; GIBBS RW, 1993, DISCOURSE PROCESS, V16, P387, DOI 10.1080/01638539309544846; GIBBS RW, 1986, DISCOURSE PROCESS, V9, P17, DOI 10.1080/01638538609544629; Grice H. P., 1975, SYNTAX SEMANTICS, P41; Grice P., 1989, STUDIES WAY WORDS; GROEFSEMA M, 1992, LINGUA, V87, P103, DOI 10.1016/0024-3841(92)90028-H; Happe F., 1994, METAPHOR SYMBOLIC AC, V10, P275; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Katz A.N., 1998, FIGURATIVE LANGUAGE; Kempson R., 1988, MENTAL REPRESENTATIO, P155; LEEKAM SR, 1994, J CHILD PSYCHOL PSYC, V35, P901, DOI 10.1111/j.1469-7610.1994.tb02301.x; Levinson S., 1987, PRAGMATIC PERSPECTIV, P61, DOI [10.1075/pbcs.5.10lev, DOI 10.1075/PBCS.5.10LEV]; Levinson Stephen., 1983, PRAGMATICS; LUCARIELLO J, 1994, J EXP PSYCHOL GEN, V123, P129, DOI 10.1037/0096-3445.123.2.129; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; PAPAFRAGOU A, 1996, LINGUA, V94, P169; PEARCE S, 1995, J INT NEUROPSYCH SOC, V1, P342; Recanati Francois, 1993, DIRECT REFERENCE LAN; Recanati Francois, 1989, MIND LANG, V4, P295, DOI DOI 10.1111/J.1468-0017.1989.TB00258.X; Searle J., 1979, METAPHOR THOUGHT, P92; SEARLE J, 1983, INTENTIONALITY; Searle John R., 1978, ERKENNTNIS, V13, P216, DOI [10.1007/BF00160894, DOI 10.1007/BF00160894]; STEMMER B, 1994, BRAIN LANG, V46, P565, DOI 10.1006/brln.1994.1031; Van Lancker D, 1990, Behav Neurol, V3, P169, DOI 10.3233/BEN-1990-3304; WILSON D, 1993, LINGUA, V90, P1, DOI 10.1016/0024-3841(93)90058-5; Wilson D., 1986, RELEVANCE COMMUNICAT; [No title captured]	43	30	33	2	14	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X			BRAIN LANG	Brain Lang.	JUL	1999	68	3					466	485		10.1006/brln.1999.2123			20	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	226TE	WOS:000082037100006	10441189				2022-02-06	
J	Joseph, S; Masterson, J				Joseph, S; Masterson, J			Posttraumatic stress disorder and traumatic brain injury: Are they mutually exclusive?	JOURNAL OF TRAUMATIC STRESS			English	Article						PTSD; TBI	CLOSED-HEAD-INJURY; FOLLOW-UP; MEMORY; INFORMATION; INDIVIDUALS; ACCIDENTS; VICTIMS; MODEL; SCALE; PTSD	It has been suggested that posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) must be mutually incompatible disorders. However growing empirical evidence has begun to question this. Evidence suggests that although PTSD may be relatively rare among the TBI population, some TBI patients seem to develop PTSD. We suggest two theoretical routes through which PTSD might develop in TBI patients: through nonconscious processes in individuals who are subsequently amnesic, but who were conscious at the time of the traumatic episode and through subsequent appraisal processes in individuals who were unconscious during the traumatic episode.	Univ Essex, Colchester CO4 3SQ, Essex, England		Joseph, S (corresponding author), Univ Essex, Wivenhoe Pk, Colchester CO4 3SQ, Essex, England.			Masterson, Jackie/0000-0003-2869-6612; joseph, stephen/0000-0001-7171-3356			American Psychiatric Association, 1980, DIAGN STAT MAN MENT; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Amick-McMullan A., 1989, J TRAUMATIC STRESS, V2, P21, DOI DOI 10.1002/JTS.2490020104; BLEDIN K, 1994, BRIT J MED PSYCHOL, V67, P125, DOI 10.1111/j.2044-8341.1994.tb01778.x; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; COCKBURN J, 1997, NEUROPSYCHOLOGICAL R, V7, P259; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIXON P, 1993, BRIT J MED PSYCHOL, V66, P193, DOI 10.1111/j.2044-8341.1993.tb01741.x; EVERLY GS, 1989, PERCEPT MOTOR SKILL, V68, P807, DOI 10.2466/pms.1989.68.3.807; FOA EB, 1989, BEHAV THER, V20, P155, DOI 10.1016/S0005-7894(89)80067-X; FOA EB, 1991, J ABNORM PSYCHOL, V100, P156, DOI 10.1037/0021-843X.100.2.156; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; GERSONS BPR, 1992, BRIT J PSYCHIAT, V161, P742, DOI 10.1192/bjp.161.6.742; GILES GM, 1993, BRAIN INJURY REHABIL; GROSS Y, 1996, 2 WORLD C INT SOC TR; HOROWITZ M, 1980, HUMAN STRESS COGNITI, P253; Horowitz M. J., 1976, STRESS RESPONSE SYND; HOROWITZ MJ, 1975, ARCH GEN PSYCHIAT, V32, P1457; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; Janoff-Bulman R., 1992, SHATTERED ASSUMPTION; JOSEPH S, 1995, CLIN PSYCHOL REV, V15, P515, DOI 10.1016/0272-7358(95)00029-O; JOSEPH S, 1997, UNDERSTANDING POST T; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KING NS, 1997, J NEUROL NEUROSUR PS, V144, P989; KLAG E, 1996, P 2 WORLD C INT SOC; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEVIN HS, 1989, MILD MODERATE HEAD I, P153; Levy A., 1996, 2 WORLD C INT SOC TR; LHEMKUHL LD, 1990, HEAD INJURY GLOSSARY; LITZ BT, 1989, CLIN PSYCHOL REV, V9, P243, DOI 10.1016/0272-7358(89)90030-5; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; MCNALLY RJ, 1993, J TRAUMA STRESS, V6, P33; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1992, P BRIT PSYCH SOC ANN; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; PARKER R, 1990, TRAUMATIC BRAIN INJU; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; Putnam S. H., 1994, ADV MED PSYCHOTHERAP, V7, P1; ROSEN GM, 1995, PROF PSYCHOL-RES PR, V26, P82, DOI 10.1037/0735-7028.26.1.82; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SBORDONE RJ, 1991, NEUROPSYCHOLOGY ATTO; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHREIBER S, 1996, 2 WORLD C INT SOC TR; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; TEASDALE G, 1974, LANCET, V2, P81; VARNEY NR, 1987, NEUROPSYCHOLOGY, V1, P79; WAKEFIELD JC, 1992, AM PSYCHOL, V47, P373, DOI 10.1037/0003-066X.47.3.373; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Wood R. L1., 1990, NEUROBEHAVIOURAL SEQ; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	71	30	31	0	0	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0894-9867			J TRAUMA STRESS	J. Trauma Stress	JUL	1999	12	3					437	453		10.1023/A:1024762919372			17	Psychology, Clinical; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Psychiatry	227ZM	WOS:000082110100003	10467554				2022-02-06	
J	Shao, LF; Ciallella, JR; Yan, HQ; Ma, XC; Wolfson, BM; Marion, DW; Dekosky, ST; Dixon, CE				Shao, LF; Ciallella, JR; Yan, HQ; Ma, XC; Wolfson, BM; Marion, DW; Dekosky, ST; Dixon, CE			Differential effects of traumatic brain injury on vesicular acetylcholine transporter and M-2 muscarinic receptor mRNA and protein in rat	JOURNAL OF NEUROTRAUMA			English	Article						cholinergic; cortical impact; M-2; muscarinic; rat; vesicular acetylcholine transporter (VAChT)	CONTROLLED CORTICAL IMPACT; CHOLINE-ACETYLTRANSFERASE ACTIVITY; NEUTROPHIL ACCUMULATION; TEMPORAL CORTEX; HEAD-INJURY; GENE LOCUS; EXPRESSION; HIPPOCAMPAL; DEFICITS; RELEASE	Experimental traumatic brain injury (TBI) produces cholinergic neurotransmission deficits that may contribute to chronic spatial memory deficits. Cholinergic neurotransmission deficits may result from presynaptic alterations in the storage and release of acetylcholine (ACh) or from changes in the receptors for ACh. The vesicular ACh transporter (VAChT) mediates accumulation of ACh into secretory vesicles, and the M-2 muscarinic receptor subtype can modulate cholinergic neurotransmission via a presynaptic inhibitory feedback mechanism. We examined the effects of controlled cortical impact (CCI) injury on hippocampal VAChT and M-2 muscarinic receptor subtype protein and medial septal mRNA levels at 4 weeks following injury. Rats were anesthetized and surgically prepared for CCI injury (4 m/sec, 2.5 to 2.9 mm in depth) and sham surgery. Animals were sacrificed, and coronal sections (35 mu m thick) were cut through the dorsal hippocampus for VAChT and M-2 immunohistochemistry. Semiquantitative measurements of VAChT and M-2 protein in hippocampal homogenates from injured and sham rats were assessed with Western blot analysis. Changes in VAChT and M-2 mRNA levels were evaluated by reverse transcriptase polymerase chain reaction (RT-PCR). At 4 weeks after injury, both immunohistochemical and Western blot methods demonstrated an increase in hippocampal VAChT protein. An increase in VAChT mRNA was also observed. Immunohistochemistry demonstrated a loss of M-2; however, there was no significant change in M-2 mRNA levels in comparison with sham controls. These changes may represent a compensatory response of cholinergic neurons to increase the efficiency of ACh neurotransmission chronically after TBI through differential transcriptional regulation.	Univ Pittsburgh, Med Ctr, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Psychiat & Neurol, Pittsburgh, PA 15260 USA		Dixon, CE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, Brain Trauma Res Ctr, Hill Bldg,Suite 201,3434 5th Ave, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49-CCR310285] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS312296, NIH-NS33150] Funding Source: Medline		Barnes PJ, 1997, LIFE SCI, V60, P1015, DOI 10.1016/S0024-3205(97)00042-8; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; Eiden LE, 1998, J NEUROCHEM, V70, P2227; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gilmor ML, 1996, J NEUROSCI, V16, P2179; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J HEAD TRAUMA REHAB, V7, P16; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONARD BE, 1994, MED PSYCHIATRY, V1, P379; LEVEY AI, 1995, J NEUROSCI, V15, P4077; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POSMANTUR R, 1996, J NEUROPATHOL EXP NE, V55, P65; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; RUBERG M, 1990, NEUROSCIENCE, V35, P327, DOI 10.1016/0306-4522(90)90086-J; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; WEI J, 1994, J NEUROCHEM, V63, P815; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	50	30	31	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1999	16	7					555	566		10.1089/neu.1999.16.555			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	220EN	WOS:000081651700001	10447068				2022-02-06	
J	Riese, H; Hoedemaeker, M; Brouwer, WH; Mulder, LJM; Cremer, R; Veldman, JBP				Riese, H; Hoedemaeker, M; Brouwer, WH; Mulder, LJM; Cremer, R; Veldman, JBP			Mental fatigue after very severe closed head injury: Sustained performance, mental effort, and distress at two levels of workload in a driving simulator	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; DIVIDED ATTENTION; RATE-VARIABILITY	In patients with very severe closed head injury (CHI), returning to work is often problematic. The present study focuses on a persistent complaint of these patients, viz. mental fatigue. To study this, the effect of sustained workload is assessed in a continuous dynamic divided attention task. Three types of measures are employed: performance loss with time-on-task, and subjective reports and cardiovascular measures of mental effort and distress. Eight very severe CHI patients (mean post-traumatic amnesia duration 51 days, mean age 23 years, (SD 6.4) and eight hospital controls (mean age 29 years, (SD 5.9) were tested. No differences were found between the patients and controls in the effects of task load on performance and the amount of mental effort, even in very demanding simulated work conditions. This parallels previous findings in less demanding laboratory tasks of sustained attention. Effects of CHI were found on both subjective and physiological indicators of distress. Compared to the controls, patients showed stronger effects on systolic blood pressure and subjectively experienced load.	Vrije Univ Amsterdam, Dept Biol Psychol, NL-1081 HV Amsterdam, Netherlands; Delft Univ Technol, Delft, Netherlands; Univ Groningen, Groningen, Netherlands; Inst TNO Work & Employment, Hoofddorp, Netherlands			h.riese@psy.vu.nl	Riese, Harriette/E-7234-2012	Riese, Harriette/0000-0003-3661-3151			AASMAN J, 1987, HUM FACTORS, V29, P161, DOI 10.1177/001872088702900204; AASMAN J, 1988, HUMAN MENTAL WORKLOA; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brouwer W, 1996, BRAIN COGNITION, V30, P380; Brouwer W.H., 1985, THESIS U GRONINGEN N; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; HELLINGA P, 1985, HEYMANS B U GRONINGE; KOORN R, 1995, GEDRAG ORG, V8, P318; Luria AR, 1963, RESTORATION FUNCTION; Luteijn F., 1983, HANDLEIDING GRONINGE; MANLY T, 1977, METHODOLOGY FRONTAL, P135; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Meijman TF, 1989, MENTALE BELASTING WE; MINDERHOUD JM, 1984, TRAUMATISCHE HERSENL; MULDER G, 1981, PSYCHOPHYSIOLOGY, V18, P392, DOI 10.1111/j.1469-8986.1981.tb02470.x; MULDER G, 1986, ENERGETICS HUMAN INF; Mulder L. J. M., 1988, COMPUTERS PSYCHOL ME, P30; MULDER LJM, 1988, THESIS U GRONINGEN N; MULER B, 1992, BLOOD PRESSURE HEART, P153; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Penaz J., 1973, 10 INT C MED BIOL EN, P104; PONSFORD JL, 1989, 1 BIANN C INT ASS ST; ROBBE HWJ, 1987, HYPERTENSION, V10, P538, DOI 10.1161/01.HYP.10.5.538; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Schmidt I W, 1996, Appl Neuropsychol, V3, P155, DOI 10.1207/s15324826an0303&4_8; SNIJDERS JT, 1958, OPSTELLING EEN INTEL; THAYER RE, 1978, PSYCHOL REP, V42, P747, DOI 10.2466/pr0.1978.42.3.747; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANROON AM, 1998, THESIS U GRONINGEN N; VANWOLFFELAAR P, 1988, ROAD USER BEHAVIOUR, P302; VANWOLFFELAAR PC, 1991, COMPUTERS PSYCHOL AP; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VELDMAN JBP, 1992, THESIS U GRONINGEN N; VELDMAN JBP, IN PRESS J PSYCHOPHY; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; WESSELING KH, 1993, BLOOD PRESSURE HEART, P56; Wesseling KH, 1982, FUNKT BIOL MED, V1, P245; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Zijlstra FRH, 1985, CONSTRUCTION SUBJECT; [No title captured]; [No title captured]; [No title captured]	46	30	31	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	APR	1999	9	2					189	205		10.1080/713755600			17	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	185ZJ	WOS:000079701300005		Green Submitted			2022-02-06	
J	Lewen, A; Fredriksson, A; Li, GL; Olsson, Y; Hillered, L				Lewen, A; Fredriksson, A; Li, GL; Olsson, Y; Hillered, L			Behavioural and morphological outcome of mild cortical contusion trauma of the rat brain: Influence of NMDA-receptor blockade	ACTA NEUROCHIRURGICA			English	Article						traumatic brain injury; rat; glutamate-receptors; recovery of function	PRECURSOR PROTEIN IMMUNOREACTIVITY; MICROTUBULE-ASSOCIATED PROTEIN-2; CEREBRAL-ISCHEMIA; AMINO-ACIDS; INJURY; MK-801; DEFICITS; GERBILS; IMPACT; HYPERACTIVITY	The authors studied the effect of a mild cortical contusion to the rat brain on behavioural and morphological outcome and the influence of NMDA-receptor blockade (MK-801, 0.5 mg/kg i.v. 30 min prior to trauma). Spontaneous motor activity was assessed 16-18 days post trauma. Saline treated traumatised rats showed a significant (p < 0.01) hyperactive behaviour compared to animals without injury. MK-SOI treated rats performed significantly better than the saline treated animals (p < 0.05). For histopathological evaluation hippocampal hilar neurons were counted, cortical thickness under the impact was measured and microtubule-associated protein 2 (MAP2) immunoreactivity in the dentate hilus was quantified 1, 3 and 21 days post trauma. In traumatised rats scattered loss of nerve cells, oedema and minute haemorrhages were present at the site of the impact one and three days after injury. At day 21 there was a significant reduction of cortical thickness at the site of impact. One day after trauma there was a bilateral, significant loss of neurons and MAP2. immunostaining in the dentate hilus of the hippocampus. MK-801 pretreated rats showed similar morphological changes. The disturbed spontaneous motor behaviour may be caused by hippocampal damage and a reduction of somatosensory cortical neurons. NMDA-receptor blockade improved the outcome assessed by the functional tests but failed to influence the morphological changes, suggesting that this behavioural test is a more sensitive indicator of outcome after mild traumatic brain injury (TBI).	Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Med, Uppsala, Sweden; Univ Uppsala Hosp, Dept Genet, Uppsala, Sweden; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden		Lewen, A (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348			ADAMS FS, 1994, PHYSIOL BEHAV, V55, P947, DOI 10.1016/0031-9384(94)90084-1; AMANO M, 1993, JPN J PHARMACOL, V63, P469, DOI 10.1254/jjp.63.469; ARCHER T, 1986, PSYCHOPHARMACOLOGY, V88, P141, DOI 10.1007/BF00652230; BUCHAN A, 1990, J NEUROSCI, V10, P311; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DIDIER M, 1990, J NEUROSCI RES, V27, P25, DOI 10.1002/jnr.490270105; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feeney D M, 1987, Brain Inj, V1, P27, DOI 10.3109/02699058709034441; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FREDRIKSSON A, 1994, THESIS U UPSALIENSIS; GERHARDT SC, 1988, BEHAV NEUROSCI, V102, P301, DOI 10.1037/0735-7044.102.2.301; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMBLE DP, 1975, HIPPOCAMPUS NEUROPHY, V2, P309; KUROIWA T, 1991, NEUROSCI LETT, V122, P141, DOI 10.1016/0304-3940(91)90842-H; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis CA, 1997, J VASC INTERV RADIOL, V8, P475, DOI 10.1016/S1051-0443(97)70592-X; LIPTON SA, 1994, NEW ENGL J MED, V331, P274; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McCulloch J, 1993, Acta Neurochir Suppl (Wien), V57, P73; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NELLGARD B, 1991, ANESTHESIOLOGY, V75, P279, DOI 10.1097/00000542-199108000-00016; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; ROBINSON RG, 1986, PHARMACOL BIOCHEM BE, V25, P263, DOI 10.1016/0091-3057(86)90264-9; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; VALTYSSON J, 1994, ACTA NEUROCHIR, V129, P58, DOI 10.1007/BF01400874; YANG CR, 1987, NEUROSCIENCE, V23, P1041, DOI 10.1016/0306-4522(87)90179-5	56	30	31	0	4	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1999	141	2					193	202		10.1007/s007010050286			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	174MV	WOS:000079039700034	10189503				2022-02-06	
J	Pieter, W; Zemper, ED				Pieter, W; Zemper, ED			Incidence of reported cerebral concussion in adult taekwondo athletes	JOURNAL OF THE ROYAL SOCIETY OF HEALTH			English	Article						taekwondo; cerebral concussion; injury	CHRONIC BRAIN-DAMAGE; AMATEUR BOXING LEAD; INJURIES; KARATE	The purpose of the present study was to assess the exact conditions under which cerebral concussions occur in full-contact taekwondo competition. Injury data were collected by project staff and tournament medical personnel with simple check-off forms that describe the athlete and nature, site, circumstances and severity of the injury. The Mann-Whitney U test was used to determine the difference in injury rate between men and women. The men (7.04/1,000 athlete-exposures) sustained more cerebral concussions than the women (2.42/1,000 athlete-exposures) (p<0.001). The dominant injury mechanism in both the males and females was receiving a blow (6.46/1,000 athlete-exposures and 2.42/1,000 athlete-exposures for the men and women, respectively).	Univ N London, Sch Hlth & Sports Sci, London N7 8DB, England; Exercise Res Associates Oregon ExRA, Eugene, OR USA		Pieter, W (corresponding author), Univ N London, Sch Hlth & Sports Sci, 166-220 Holloway Rd, London N7 8DB, England.						Birrer R B, 1983, Br J Sports Med, V17, P131; BLIJD C, 1995, 1995 ICHPER SD 38 WO; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; ESTWANIK J J, 1984, Physician and Sportsmedicine, V12, P123; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; Johannsen H V, 1988, Br J Sports Med, V22, P113; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; JORRITSMA LSM, 1987, VEILIGHEID BOKSEN; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; MCCLATCHIE GR, 1980, J TRAUMA, V20, P956; MCLATCHIE GR, 1976, BR J ACC SURG, V8, P132; MCLATCHIE GR, 1994, CLIN PRACTICE SPORTS, P609; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pieter F, 1995, BIOL SPORT, V12, P257; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1996, 199L INT PREOLYMP SC; PIETER W, 1997, SCI COACHING OLYMPIC; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; PIETER W, 1996, EPIDEMIOLOGY SPORTS, P268; PIETER W, 1995, 1995 ICHPER SD 38 WO; PIETER W, 1995, SPORTGEZONDHEIDSZORG; Porter M, 1996, CLIN J SPORT MED, V6, P97, DOI 10.1097/00042752-199604000-00006; Ryan A J, 1983, Phys Sportsmed, V11, P49, DOI 10.1080/00913847.1983.11708702; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; SMITH PK, 1987, BIOMECHANICS, V3, P57; STRICEVIC MV, 1983, AM J SPORT MED, V11, P320, DOI 10.1177/036354658301100507; SYMONDS C, 1962, LANCET, V1, P1; WHITING WC, 1988, AM J SPORT MED, V16, P130, DOI 10.1177/036354658801600207; Zemper E D, 1989, Br J Sports Med, V23, P161; Zemper E. D., 1991, INT C EXP SPORTS MED	37	30	32	0	6	ROYAL SOC OF HEALTH	LONDON	38A ST, GEORGES DR, LONDON SW1V 4BH, ENGLAND	0264-0325			J ROY SOC HEALTH	J. R. Soc. Health	OCT	1998	118	5					272	279		10.1177/146642409811800512			8	Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	230HN	WOS:000082245900012	10076687				2022-02-06	
J	Perry, VH; Bolton, SJ; Anthony, DC; Betmouni, S				Perry, VH; Bolton, SJ; Anthony, DC; Betmouni, S			The contribution of inflammation to acute and chronic neurodegeneration	RESEARCH IN IMMUNOLOGY			English	Article; Proceedings Paper	12th Macrophage Conference	SEP 17-19, 1998	PARIS, FRANCE	Inst Pasteur, European Macrophage Study Grp		CNS; neurodegeneration; Alzheimer's disease; Parkinson's disease; inflammation; review	INDUCED NEURONAL DEGENERATION; TISSUE-PLASMINOGEN ACTIVATOR; TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; MICROGLIAL RESPONSE; ISCHEMIC STROKE; NERVOUS-SYSTEM; RECRUITMENT; SCRAPIE; EXPRESSION		Univ Southampton, Sch Biol Sci, CNS Inflammat Grp, Southampton SO16 7PX, Hants, England		Perry, VH (corresponding author), Univ Southampton, Sch Biol Sci, CNS Inflammat Grp, Bassett Crescent E, Southampton SO16 7PX, Hants, England.		Anthony, Daniel C/F-7765-2010; Perry, V. Hugh/Y-2935-2019	Anthony, Daniel C/0000-0003-1380-6655; Betmouni, Samar/0000-0002-4947-0658; Bolton, Sarah/0000-0002-6098-6903			ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; Anthony DC, 1998, CURR BIOL, V8, pR274, DOI 10.1016/S0960-9822(98)70171-X; Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; BELL MD, 1995, J NEUROCYTOL, V24, P695, DOI 10.1007/BF01179819; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Betmouni S, 1996, NEUROSCIENCE, V74, P1, DOI 10.1016/0306-4522(96)00212-6; BETMOUNI S, 1998, IN PRESS PSYCHOBIOLO; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Breitner JCS, 1996, NEUROBIOL AGING, V17, P789; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; BTMOUNI S, 1998, IN PRESS NEUROPATH A; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CHOI DW, 1992, CEREBROVASC DIS, P187; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clark WM, 1996, CNS DRUGS, V6, P90, DOI 10.2165/00023210-199606020-00002; DEARMOND SJ, 1993, CURR OPIN NEUROL, V6, P872, DOI 10.1097/00019052-199312000-00008; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MCFARLIN DE, 1971, NATURE, V233, P336, DOI 10.1038/233336a0; MCGEER PL, 1992, NEUROLOGY, V42, P447, DOI 10.1212/WNL.42.2.447; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; PRUSINER SG, 1996, SCI AM, V272, P30; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Schnell L, 1997, EUR J NEUROSCI, V9, P1000, DOI 10.1111/j.1460-9568.1997.tb01450.x; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Webster S, 1997, NEUROBIOL AGING, V18, P415, DOI 10.1016/S0197-4580(97)00042-0; WILLIAMS AE, 1994, NEUROPATH APPL NEURO, V20, P47, DOI 10.1111/j.1365-2990.1994.tb00956.x; WILLIAMS AE, 1995, ACTA NEUROPATHOL, V90, P164, DOI 10.1007/BF00294316	34	30	30	0	4	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0923-2494			RES IMMUNOL	Res. Immunol.	SEP-OCT	1998	149	7-8					721	725		10.1016/S0923-2494(99)80046-7			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Immunology	141XG	WOS:000077169100021	9851531				2022-02-06	
J	Stahel, PF; Kossmann, T; Joller, H; Trentz, O; Morganti-Kossmann, MC				Stahel, PF; Kossmann, T; Joller, H; Trentz, O; Morganti-Kossmann, MC			Increased interleukin-12 levels in human cerebrospinal fluid following severe head trauma	NEUROSCIENCE LETTERS			English	Article						cytokines; interleukin-12; traumatic brain injury; blood-brain barrier	CYTOKINE; THERAPY; DISEASE	An overwhelming intracranial inflammatory response occurs as a consequence of severe head trauma, leading to cerebral edema and secondary brain injury. Cytokines are important mediators of post-traumatic cerebral inflammation. In the present study, levels of interleukin-12 (IL-12), a pro-inflammatory cytokine which activates cellular immune response mechanisms, were measured by ELISA in 140 matched serum and ventricular cerebrospinal fluid (CSF) samples from ten patients with severe traumatic brain injury. The mean IL-12 CSF levels were significantly elevated in all patients in the course of 14 days after trauma, compared to CSF samples from 15 control patients. Assessment of the IL-12 CSF/serum ratio and of the blood-brain barrier function, using the CSF/serum albumin ratio, suggest that elevated IL-12 CSF levels might be in part derived from intracerebral cytokine synthesis. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.	Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med, Clin Immunol Sect, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland		Stahel, PF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			Aloisi F, 1997, J IMMUNOL, V159, P1604; Balashov KE, 1997, P NATL ACAD SCI USA, V94, P599, DOI 10.1073/pnas.94.2.599; CLEMONS KV, 1994, ANTIMICROB AGENTS CH, V38, P460, DOI 10.1128/AAC.38.3.460; Constantinescu CS, 1996, ANN NY ACAD SCI, V795, P328, DOI 10.1111/j.1749-6632.1996.tb52684.x; Drulovic J, 1997, J NEUROL SCI, V147, P145, DOI 10.1016/S0022-510X(96)05320-8; Guery JC, 1997, EUR J IMMUNOL, V27, P1632, DOI 10.1002/eji.1830270707; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; KOCHANEK PM, 1997, BRAIN DAMAGE 2 HEMOR, P197; Kornelisse RF, 1997, INFECT IMMUN, V65, P877, DOI 10.1128/IAI.65.3.877-881.1997; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Leonard JP, 1997, CRIT REV IMMUNOL, V17, P545; Mastroianni CM, 1997, CLIN IMMUNOL IMMUNOP, V84, P171, DOI 10.1006/clin.1997.4367; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Park JH, 1996, BIOCHEM BIOPH RES CO, V224, P391, DOI 10.1006/bbrc.1996.1038; Reiss CS, 1996, ANN NY ACAD SCI, V795, P257, DOI 10.1111/j.1749-6632.1996.tb52675.x; Stalder AK, 1997, J IMMUNOL, V159, P1344; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; TRINCHIERI G, 1994, IMMUNOL TODAY, V15, P460, DOI 10.1016/0167-5699(94)90189-9; WINDHAGEN A, 1995, J EXP MED, V182, P1986	20	30	33	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUN 19	1998	249	2-3					123	126		10.1016/S0304-3940(98)00410-8			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZZ591	WOS:000074745500014	9682832				2022-02-06	
J	Roddy, SP; Cohn, SM; Moller, BA; Duncan, CC; Gosche, JR; Seashore, JH; Touloukian, RJ				Roddy, SP; Cohn, SM; Moller, BA; Duncan, CC; Gosche, JR; Seashore, JH; Touloukian, RJ			Minimal head trauma in children revisited: Is routine hospitalization required?	PEDIATRICS			English	Article; Proceedings Paper	56th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 19-21, 1996	HOUSTON, TEXAS	Amer Assoc Surg Trauma		trauma; brain injury; CT scan; pediatric injuries	INJURY; MANAGEMENT; SCANS; SCORE; RISK	Objective. Children with a question of occult head injury are routinely hospitalized despite having both normal central nervous system (CNS) and computed tomographic (CT) scan examinations. We determined the incidence of significant CNS morbidity after occult head injury to determine whether or not hospital admission was necessary in children after minimal head trauma. Methods. We reviewed the records of children admitted to a level I trauma center with a question of closed head injury, an initial Glasgow Coma Scale equal to 15, a normal neurologic exam, and a normal head CT scan. Children with associated injuries requiring admission were excluded. The endpoints were deterioration in CNS exam, new CT findings, and the need for a prolonged hospital stay. Results. Sixty-two patients were studied with a mean age of 7 years (range, 1 month to 15 years), and 65% were male. The primary mechanisms of injury were fall (45%) and vehicular crash (23%). The mean injury severity score was 4 +/- 2. The mean length of stay was 1.2 days (range, 1 to 3 days). Prolonged hospitalization occurred in 9 patients (15%). No child developed significant CNS sequelae warranting hospital admission. Total charges for these hospitalizations were $177 874. Conclusions. Children undergoing emergency department work-up of occult head injury, who have a normal CNS exam and a normal head CT scan, do not seem to be at risk for significant CNS sequelae. These patients can be discharged home with parental supervision and avoid unnecessary and costly hospitalization.	Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA		Cohn, SM (corresponding author), Univ Miami, Sch Med, Dept Surg, Div Trauma & Surg Crit Care, Miami, FL 33101 USA.						BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BRUCE DA, 1980, CLIN PEDIATR, V19, P719, DOI 10.1177/000992288001901101; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DUNCAN CC, 1990, PEDIAT TRAUMA, P222; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; Goldstein B, 1994, Pediatr Rev, V15, P213, DOI 10.1542/pir.15-6-213; HENNES H, 1988, AM J DIS CHILD, V142, P1045, DOI 10.1001/archpedi.1988.02150100039021; KADISH HA, 1995, ANN EMERG MED, V26, P37, DOI 10.1016/S0196-0644(95)70235-0; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; ROS S P, 1989, Pediatric Emergency Care, V5, P216, DOI 10.1097/00006565-198912000-00003; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1990, J PEDIATR SURG, V25, P92, DOI 10.1016/S0022-3468(05)80170-8	17	30	32	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR	1998	101	4					575	577		10.1542/peds.101.4.575			3	Pediatrics	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	ZE903	WOS:000072843200001	9521936				2022-02-06	
J	Stewart-Scott, AM; Douglas, JM				Stewart-Scott, AM; Douglas, JM			Educational outcome for secondary and postsecondary students following traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; PREDICTING RETURN; PROFILE; SCHOOL; WORK	During the 12 month period of January-December 1991, 75 admissions were made to the Head Injury Unit at Bethesda Hospital, Melbourne, Australia. Approximately 26% (20) of these admissions were either secondary or postsecondary students. Thirteen of the 20 students were interviewed by telephone at approximately 3 years postinjury and demographic and medical information were obtained from their medical files. Outcome was documented in three areas: educational, medical and psychosocial status. At 3 years postinjury, 11 subjects (85%) had either completed a course or were still studying. The average lime for students to return to study was approximately 11 months postinjury. The students reported a number of changes including: enrolment in different courses, a reduction in course load to part-time study, altered educational and vocational goals and an increased need to utilize study skill strategies, individual tuition and special consideration. In addition, students reported changes to their relationships with peers and their involvement in extracurricular activities. It is apparent from these results that a number of factors need to be: considered when a student is planning to return to study following TBI and that a range of support services may be required. Future studies are needed to examine the factors which impede or enhance a student's progress following TBI.	La Trobe Univ, Fac Hlth Serv, Sch Human Commun Sci, Bundoora, Vic 3083, Australia; Bethesda Hosp, Speech Pathol Dept, Melbourne, Vic, Australia		Douglas, JM (corresponding author), La Trobe Univ, Fac Hlth Serv, Sch Human Commun Sci, Bundoora, Vic 3083, Australia.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			BATES K, 1993, 2 INT C REC BRAIN IN; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BLOSSER JL, 1989, TOP LANG DISORD, V9, P66; BUETHE C, 1989, J COLL STUDENT DEV, V30, P172; COHEN SB, 1991, J HEAD TRAUMA REHAB, V6, P56; Cook J, 1991, J HEAD TRAUMA REHAB, V6, P64, DOI [10.1097/00001199-199103000-00011, DOI 10.1097/00001199-199103000-00011]; DONDERS J, 1992, ANN M INT NEUR SOC S; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; HALL DE, 1986, COGNITIVE REHABI MAY, P6; HARRINGTON DE, 1990, REHABILITATION ADULT, P476; *HLTH DEP VICT COM, 1991, REP HEAD INJ IMP STU; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kaplan S. P., 1988, J APPLIED REHABILITA, V19, P3; KAPLAN SP, 1993, REHABILITATION COUNS, V36, P152; KINSELLA G, 1995, J INT NEUROPSYCHOLOG, V1, P325; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; LANGE M, 1991, COGNITIVE REHABI JAN, P22; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MIRA MP, 1991, FOCUS EXCEPT CHILD, V23, P1; OCONNOR BA, 1995, AUSTR DISABILITY REV, V1, P31; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Russell N, 1993, LANG SPEECH HEAR SER, V24, P67; SAVAGE R, 1988, COGNITIVE REHABI JUL, P10; Savage RC, 1987, J HEAD TRAUMA REHAB, V2, P1; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006	36	30	31	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1998	12	4					317	331		10.1080/026990598122629			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZF942	WOS:000072948700008	9562914				2022-02-06	
J	Moriarty, LJ; Duerstock, BS; Bajaj, CL; Lin, KN; Borgens, RB				Moriarty, LJ; Duerstock, BS; Bajaj, CL; Lin, KN; Borgens, RB			Two- and three-dimensional computer graphic evaluation of the subacute spinal cord injury	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						macrophage; spinal cord injury; cavitation; 3-D morphometry; neurotrauma; computer graphics	CENTRAL-NERVOUS-SYSTEM; MONONUCLEAR PHAGOCYTES; MACROPHAGES; RAT; INFLAMMATION	We have evaluated three-week-old compression lesions of the rat spinal cord using two-dimensional and three-dimensional morphometry, reconstruction, and visualization techniques. We offer a new computer assisted method to determine the number and density of macrophages within the spinal lesion using the macrophage specific monoclonal label ED1. We also provide quantitative information on pathological cyst formation and cavitation. This technique does not require: (1) subjective identification of the cell type, (2) human interaction with the data during the phase of quantification, and (3) can be applied to any sampling paradigm based on immunocytochemical labeling. Using novel algorithms based on solutions to 'correspondence' and 'branching' problems inherent in cross-sectional histological data, we provide three-dimensional reconstructions and visualizations of the macrophagic lesions and cysts imbedded within it. Our three-dimensional surface reconstructions can be interrogated to determine volumes and surface areas of structures within the data set. Using these methods we have learned that macrophage numbers approach the maximum density possible for such isodiametric cells (similar to 12 mu m diameter) in the central lesion ranging from 4000-7000 cells per mm(2) of lesion. At the time point studied, macrophage numbers would have peaked following the initial insult, and would not be expected to decline for several months. While the density of macrophages is highest in the region of most tissue damage, we show that the central regions of cavitated and cystic spinal parenchyma is not. We discuss how this density of cells may effect the secondary pathological responses of the spinal cord to injury. (C) 1998 Elsevier Science B.V.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Comp Sci, W Lafayette, IN 47907 USA		Borgens, RB (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, Dept Basic Med Sci, 1244 VCPR, W Lafayette, IN 47907 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR509137] Funding Source: Medline		Bajaj C., 1996, P 5 INT IM ROUNDT SA, P169; Bajaj CL, 1996, GRAPH MODEL IM PROC, V58, P524, DOI 10.1006/gmip.1996.0044; BLIGHT A R, 1984, Society for Neuroscience Abstracts, V10, P887; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BLIGHT AR, 1991, J NEUROL SCI, V106, P158, DOI 10.1016/0022-510X(91)90253-4; BLIGHT AR, 1993, ADV NEUROL, V59, P91; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DAVIES P, 1979, J RETICULOENDOTH SOC, V26, P37; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GORDON S, 1995, BIOESSAYS, V17, P977, DOI 10.1002/bies.950171111; KAO CC, 1977, J NEUROSURG, V46, P197, DOI 10.3171/jns.1977.46.2.0197; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PERRY VH, 1992, BIOESSAYS, V14, P401, DOI 10.1002/bies.950140610; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; POLMAN CH, 1986, J NEUROIMMUNOL, V11, P215, DOI 10.1016/0165-5728(86)90005-6; Reier P., 1983, SPINAL CORD RECONSTR, P163; Reier P J, 1988, Adv Neurol, V47, P87; Stocum D. L., 1995, WOUND REPAIR REGENER; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Waibl H., 1973, TOPOGRAPHIE MEDULLA; YOUNG W, 1995, CONT MANAGEMENT SPIN, P27	33	30	31	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	MAR 5	1998	155	2					121	137		10.1016/S0022-510X(97)00203-7			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZD999	WOS:000072746900001	9562256				2022-02-06	
J	Forbes, ML; Clark, RSB; Dixon, CE; Graham, SH; Marion, DW; DeKosky, ST; Schiding, JK; Kochanek, PM				Forbes, ML; Clark, RSB; Dixon, CE; Graham, SH; Marion, DW; DeKosky, ST; Schiding, JK; Kochanek, PM			Augmented neuronal death in CA3 hippocampus following hyperventilation early after controlled cortical impact	JOURNAL OF NEUROSURGERY			English	Article						head injury; hyperventilation; alkalosis; hippocampus; rat	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; PROLONGED HYPERVENTILATION; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; COMATOSE PATIENTS; CELL-DEATH; RATS; HYPOTHERMIA	Minimizing secondary injury after severe traumatic brain injury (TBI) is the primary goal of cerebral resuscitation. For more than two decades, hyperventilation has been one elf the most often used strategies in the management of TBI. Laboratory and clinical studies, however, have verified a post-TBI state of reduced cerebral perfusion that may increase the brain's vulnerability to secondary injury. In addition, it has been suggested in a clinical study that hyperventilation may worsen outcome after TBI. Object. Using the controlled cortical impact model in rats, the authors tested the hypothesis that aggressive hyperventilation applied immediately after TBI would worsen functional outcome, expand the contusion, and promote neuronal death in selectively vulnerable hippocampal neurons. Methods. Twenty-six intubated, mechanically ventilated, isoflurane-anesthetized male Sprague-Dawley rats were subjected to controlled cortical impact (4 m/second, 2.5-mm depth of deformation) and randomized after 10 minutes to either hyperventilation (PaCO2 = 20.3 +/- 0.7 mm Hg) or normal ventilation groups (PaCO2 = 34.9 +/- 0.3 mm Hg) containing 13 rats apiece and were treated for 5 hours. Beam balance and Morris water maze (MWM) performance latencies were measured in eight rats from each group on Days 1 to 5 and 7 to 11, respectively, after controlled cortical impact. The rats were killed at 14 days postinjury, and serial coronal sections of their brains were studied for contusion volume and hippocampal neuron counting (CA1, CA3) by an observer who was blinded to their treatment group. Mortality rates were similar in both groups (two of 13 in the normal ventilation compared with three of 13 in the hyperventilation group, not significant [NS]). There were no differences between the groups in mean arterial blood pressure, brain temperature, and serum glucose concentration. There were no differences between groups in performance latencies for both beam balance and MWM or contusion Volume (27.8 +/- 5.1 mm(3) compared with 27.8 +/- 3.3 mm(3), NS) in the normal ventilation compared with the hyperventilation groups, respectively. In brain sections cut from the center of the contusion, hippocampal neuronal survival in the CA1 region was similar in both groups; however, hyperventilation reduced the number of surviving hippocampal CA3 neurons (29.7 cells/hpf, range 24.2-31.7 in the normal ventilation group compared with 19.9 cells/hpf, range 17-23.7 in the hyperventilation group [25th-75th percentiles]; *p < 0.05, Mann-Whitney rank-sum test). Conclusions. Aggressive hyperventilation early after TBI augments CA3 hippocampal neuronal death; however, it did not impair functional outcome or expand the contusion. These data indicate that CA3 hippocampal neurons are selectively vulnerable to the effects of hyperventilation after TBI. Further studies delineating the mechanisms underlying these effects are needed, because the injudicious application of hyperventilation early after TBI may contribute to secondary neuronal injury.	Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Brain Trauma Res Ctr, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015; Forbes, MD, FAAP, Michael/C-4110-2009	Kochanek, Patrick M/0000-0002-2627-913X; Forbes, MD, FAAP, Michael/0000-0002-2612-5392; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318, NS3198] Funding Source: Medline		ARTRU AA, 1987, J CEREBR BLOOD F MET, V7, P471, DOI 10.1038/jcbfm.1987.90; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock MR, 1996, J NEUROTRAUM, V13, P699; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; CROCKARD HA, 1973, BMJ-BRIT MED J, V4, P634, DOI 10.1136/bmj.4.5893.634; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; GIFFARD RG, 1992, STROKE, V23, P1817, DOI 10.1161/01.STR.23.12.1817; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HURN PD, 1995, J CEREB BLOOD FLO S1, V15, pS201; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KENNEALY JA, 1980, AM REV RESPIR DIS, V122, P407; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MADSEN FF, 1990, ACTA NEUROCHIR, V106, P164, DOI 10.1007/BF01809461; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MEIS G, 1991, J CEREB BLOOD FLOW M, V11, P753; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; MOSER E, 1993, J NEUROSCI, V13, P3916; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OUYANG YB, 1994, BRAIN RES, V646, P65, DOI 10.1016/0006-8993(94)90058-2; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; RINK A, 1995, AM J PATHOL, V147, P1575; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; TAKADERA T, 1992, BRAIN RES, V572, P126, DOI 10.1016/0006-8993(92)90460-Q; VANICKY I, 1992, NEUROSCI LETT, V135, P167, DOI 10.1016/0304-3940(92)90428-A; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087	58	30	30	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1998	88	3					549	556		10.3171/jns.1998.88.3.0549			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	YY305	WOS:000072133800018	9488311				2022-02-06	
J	Engberg, A; Teasdale, TW				Engberg, A; Teasdale, TW			Traumatic brain injury in children in Denmark: A national 15-year study	EUROPEAN JOURNAL OF EPIDEMIOLOGY			English	Article						Denmark; disability pension; epidemiology; mortality; traumatic brain injury	HEAD-INJURY; ADOLESCENTS; CHILDHOOD; DEATH	Demographic trends are reported concerning three types of traumatic brain injury (concussions, cranial fractures, and intracranial contusions/haemorrhages) among children in Denmark of ages up to and including 14 years, for a fifteen pear period from 1979 through 1993. The data were derived from a national computer-based hospitalization register and include 49,594 children, of whom 60% were boys and 89% had suffered a concussion. Virtually all injuries were the result of accidents. A major finding was that there has been a general decline in the incidence of traumatic brain injuries, especially for boys from 5 to 14 years old, suggesting a degree of success in preventive measures, particularly regarding road safety. The incidence of fatal cases of intracranial contusions/haemorrhages approximately halved over the 15 year period. However, as a proportion of all diagnosed cases, mortality from intracranial contusions/haemorrhages remained fairly constant at about 22%, perhaps because there have been no markedly successful innovations in acute care. Among children surviving a intracranial contusions/haemorrhages, rather considerable numbers were found to have been awarded disability pension at ages under 30.	Odense Univ Hosp, Dept Neurol, DK-5000 Odense, Denmark		Teasdale, TW (corresponding author), Univ Copenhagen, Psychol Lab, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	Teasdale@axp.psl.ku.dk					ALS E, 1958, Ugeskr Laeger, V120, P857; ANDERSON DW, 1980, J NEUROSURG, V53, pS1; ARNARSON EO, 1995, ACTA PAEDIATR, V84, P96, DOI 10.1111/j.1651-2227.1995.tb13496.x; BARQUERO AV, 1990, NEUROLOGIA, V5, P155; BERNEY J, 1995, CHILD NERV SYST, V11, P256, DOI 10.1007/BF00301755; Caveness W F, 1979, Adv Neurol, V22, P1; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; ENGBERG A, 1995, ACTA NEUROL SCAND, V92, P5, DOI 10.1111/j.1600-0404.1995.tb01701.x; GUDMUNDSSON KR, 1986, ICELANDIC HLTH REC S, P43; Hansen T B, 1991, Ugeskr Laeger, V153, P2944; JORGENSEN IM, 1995, DAN MED BULL, V42, P285; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacKenzie E J, 1989, Md Med J, V38, P725; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Mikkelsen S S, 1991, Ugeskr Laeger, V153, P3239; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PITT WR, 1994, J PAEDIATR CHILD H, V30, P114, DOI 10.1111/j.1440-1754.1994.tb00593.x; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SHARPLES PM, 1990, BRIT MED J, V301, P1193, DOI 10.1136/bmj.301.6762.1193; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; *SUNDH, 1981, DODS DANM; *SUNDH, 1981, SYG; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	27	30	30	0	3	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0393-2990	1573-7284		EUR J EPIDEMIOL	Eur. J. Epidemiol.	FEB	1998	14	2					165	173		10.1023/A:1007492025190			9	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	ZG292	WOS:000072986400009	9556176				2022-02-06	
J	Rapport, LJ; Farchione, TJ; Coleman, RD; Axelrod, BN				Rapport, LJ; Farchione, TJ; Coleman, RD; Axelrod, BN			Effects of coaching on malingered motor function profiles	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; TESTS; PROSPECTS; DEFICITS; VALIDITY	Measures of motor functioning were evaluated to assess a nonphysiological performance pattern initially revealed in a sample of litigating patients with postconcussive syndrome (grip strength < finger tapping < grooved pegs). The opposite pattern is observed in patients with traumatic brain injury, whose performance follows a gradient of increasing impairment corresponding to the sensory-motor complexity of these tasks. Naive and coached malingerers performed worse on all three motor tests relative to controls (N = 92); however, the presence of nonphysiologic configurations showed poor predictive accuracy among malingerers and controls. Exploratory analyses suggested that IQ may mediate the ability to dissimulate successfully. Although worthy of additional study, the use of pattern analysis in evaluation of malingered motor functioning has not been proven reliable or valid.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Dept Vet Affairs Med Ctr, Psychol Serv, Detroit, MI USA		Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.			Rapport, Lisa/0000-0001-8014-9523			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; CRAWFORD JR, 1989, PERS INDIV DIFFER, V10, P585, DOI 10.1016/0191-8869(89)90043-3; CRAWFORD JR, 1992, DEV CLIN EXPT NEUROP; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Haaland K. Y., 1989, NEUROPSYCHOLOGICAL F, P219; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton RK, 1991, COMPREHENSIVE NORMS; HISCOCK CK, 1994, J PSYCHOPATHOL BEHAV, V16, P95, DOI 10.1007/BF02232721; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MARTIN RC, 1992, FORENSIC REPORTS, V5, P393; MEISNER S, 1988, J PERS ASSESS, V52, P564, DOI 10.1207/s15327752jpa5203_19; MENSCH AJ, 1986, INT J CLIN NEUROPSYC, V8, P59; Reitan R, 1985, HALSTEAD REITAN NEUR; SCHRETLEN DJ, 1990, BEHAV SCI L, V0008, P00075; Spreen O, 1991, COMPENDIUM NEUROPSYC; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P18, DOI 10.1080/13854049008401493; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P64, DOI 10.1080/13854049008401497; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; [No title captured]; [No title captured]	25	30	30	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1998	20	1					89	97		10.1076/jcen.20.1.89.1488			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	ZZ028	WOS:000074688100008	9672822				2022-02-06	
J	Sander, AM; Kreutzer, JS; Fernandez, CC				Sander, AM; Kreutzer, JS; Fernandez, CC			Neurobehavioral functioning, substance abuse, and employment after brain injury: Implications for vocational rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							SEVERE HEAD-INJURY; PREDICTING RETURN; FOLLOW-UP; WORK	Objective: To characterize neurobehavioral and substance abuse problems distinguishing between employed and unemployed persons with brain injury and to propose relevant vocational rehabilitation interventions. Design: A quasi-experimental, fixed effects factorial design was used. T-tests were used to compare employed and unemployed persons regarding neurobehavioral factor scale scares. Chi-square analyses were used to compare alcohol use and rate of mental health treatment for the two groups. Fisher's Exact Test was used to compare drug use for the two groups. Setting: Outpatient rehabilitation clinic at a large urban medical center. Participants: Patients with traumatic brain injury who received acute medical care and inpatient rehabilitation at a level I trauma center. Patients were evaluated an average of 16 months after injury. The employed (33%) and unemployed (67%) groups were similar regarding age and chronicity, but unemployed persons had more severe injuries. Main Outcome Measures: Neurobehavioral Functioning Inventory (NFI), Quantity Frequency Variability Index (QFVI), General Health and History Questionnaire. Results: Unemployed persons reported a greater frequency of difficulties on the NFI Depression, Attention/Memory, Aggression, Communication, and Motor scales. The most common difficulties among unemployed persons related to mood, personality, and slowness. Also, more unemployed persons had received mental health services. A substantially higher proportion of employed persons were classified as moderate or heavy drinkers, whereas there were more abstainers among the unemployed group: A low rate of drug use was reported and differences between groups were not observed. Conclusions: The unique neurobehavioral difficulties of unemployed persons should be carefully considered when developing empirically based preplacement training, job matching, and postplacement interventions. The high rate of alcohol use among employed persons indicates the need for follow-along that emphasizes education and prevention.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, DIV NEUROL SURG, RICHMOND, VA 23298 USA								Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; GREENSPAN AI, 1996, ARCH PHYS MED REHAB, V10, P207; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Mysiw W J, 1989, Brain Inj, V3, P27, DOI 10.3109/02699058909008070; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1984, CLOSED HEAD INJURY P; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SERIO CD, 1993, NEUROREHABILITATION, V4, P53; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	34	30	30	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1997	12	5					28	41		10.1097/00001199-199710000-00004			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	YA515	WOS:A1997YA51500004					2022-02-06	
J	Teasdale, TW; Engberg, A				Teasdale, TW; Engberg, A			Duration of cognitive dysfunction after concussion, and cognitive dysfunction as a risk factor: a population study of young men	BRITISH MEDICAL JOURNAL			English	Article							MINOR HEAD-INJURY; SECULAR TRENDS; INTELLIGENCE; SYMPTOMS; SEQUELAE; RECOVERY	Objectives: To establish how long cognitive dysfunction lasts after concussion, and the extent to which it may be a predisposing risk factor for concussion, by examining the prevalence of cognitive dysfunction among young men who have sustained concussion. Design: Observational study. Setting: Denmark. Subjects: 1220 young men who had been admitted to hospital for concussion between the ages of 16 and 24 (identified in a national register of admissions) and who had also been cognitively tested by the Danish conscription draft board. Main outcome measure: Score on the draft board's cognitive screening test, dichotomised as dysfunctional or non-dysfunctional (20.4% of the general population of Danish men appearing before the draft board had a dysfunctional score). Results: 700 of the 1220 men had been tested after sustaining concussion; 520 had been tested before concussion. Four (50%) of the eight men who were tested less than seven days after the injury had a dysfunctional score. Among groups of the remaining 692 men who were tested at later time points after injury, the rates were only marginally raised (range 21.4% to 26.5%) above the population level. Among men tested before injury, the rate of dysfunctional scores was higher (30.4% (158/520)). Apart from suggesting cognitive dysfunction as a risk factor for concussion, this higher proportion seems to relate to the fact that they were typically injured as young adults, whereas those men who were tested after concussion had more often been injured as adolescents. The relative risk for concussion in the presence of cognitive dysfunction is estimated to be 1.57 (95% confidence interval 1.32 to 1.86). Conclusions: Cognitive dysfunction is not only a short term consequence of concussion but also a predisposing risk factor for concussion, more so for young adults than for adolescents.	ODENSE UNIV HOSP,DEPT NEUROL,DK-5000 ODENSE C,DENMARK		Teasdale, TW (corresponding author), UNIV COPENHAGEN,PSYCHOL LAB,NJALSGADE 88,DK-2300 COPENHAGEN S,DENMARK.						BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Duus B R, 1991, Ugeskr Laeger, V153, P2111; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; GRONWALL D, 1974, LANCET, V2, P605; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1989, MANAGEMENT HEAD INJU; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1989, MILD HEAD INJURY; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MORTENSEN EL, 1989, SCAND J PSYCHOL, V30, P315, DOI 10.1111/j.1467-9450.1989.tb01094.x; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; TEASDALE TW, 1994, SCAND J PSYCHOL, V35, P328, DOI 10.1111/j.1467-9450.1994.tb00957.x; TEASDALE TW, 1987, NATURE, V325, P119, DOI 10.1038/325119a0	19	30	30	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 6	1997	315	7108					569	572					4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	XV717	WOS:A1997XV71700022	9302952				2022-02-06	
J	Manchester, D; Hodgkinson, A; Casey, T				Manchester, D; Hodgkinson, A; Casey, T			Prolonged, severe behavioural disturbance following traumatic brain injury: What can be done?	BRAIN INJURY			English	Article							HEAD-INJURY; REHABILITATION; RELATIVES; SERVICES	At the end of 1994 the New South Wales Department of Health identified the need for a specialized unit for people with a brain injury who exhibited aggressive and violent behaviour at such a level that they could not be cared for in standard rehabilitation programmes and who were not mentally ill as defined by the Mental Health Act. An interim unit based on the principles of neurobehavioural rehabilitation was opened in the grounds of Lidcombe Hospital, and in January 1995 the first patient (SA) was admitted. Following intervention weekly aggression decreased from a peak of 159 incidents to zero after ten months. Other maladaptive behaviours also decreased markedly. Simultaneous attempts to improve adaptive behaviours were successful. At 11 months follow-up in the community, these gains were all noted to have been maintained. This article discusses the need for specialized units dealing with severe behavioural problems following head injury, presents the case of SA for illustrative purposes, and addresses some of the more common criticisms of such environments.	STEPPING HILL HOSP,DEPT PSYCHOL,STOCKPORT,ENGLAND								ANDERSON DW, 1980, J NEUROSURGERY S, V53; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BULLARD H, 1988, MED SCI LAW, V28, P312, DOI 10.1177/002580248802800410; BURGESS PW, 1990, COGNITIVE REHABILITA; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; COLOND JS, 1995, AM J MENT RETARD, V100, P201; DIRMEN S, 1993, BRAIN INJURY, V7, P113; Drinkwater J, 1989, CLIN APPROACHES VIOL, P287; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; EMERSON E, 1987, MENTAL HANDICAP, V15, P166; GASKELL G, 1995, BRIT J CLIN PSYCHOL, V34, P383; GILES GM, 1988, REHABILITATION SEVER; GLOAG D, 1985, BRIT MED J, V290, P913, DOI 10.1136/bmj.290.6472.913; LLOYD LF, 1994, BRAIN INJURY, V8, P529, DOI 10.3109/02699059409151005; LONDON PS, 1967, ANN ROY COLL SURG, V41, P479; MANCHESTER D, 1997, IN PRESS BRAIN INJUR; MANCHESTER D, 1993, BRIT MED J      0717, P384; MAROSSZEKY JE, 1994, BEHAV MANAGEMENT UNI; MARTIN MA, 1991, AUSTR NZ J DEV DISAB, V17, P201; MILLER L, 1990, COGNITIVE REHABI NOV, P14; MURPHY G, 1991, MENT HANDICAP RES, V4, P44; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; SACHDEV PS, 1991, MED J AUSTRALIA, V155, P75, DOI 10.5694/j.1326-5377.1991.tb142129.x; TATE RL, 1987, SCAND J REHABIL MED, V19, P13; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANMINNEN A, 1993, BRIT J DEV DISABIL, V39, P126, DOI 10.1179/bjdd.1993.015; WOOD J, 1989, MENT HANDICAP RES, V2, P3; Wood R. L. L., 1981, APPL CONDITIONING TH; Wood R. L. L., 1984, CLOSED HEAD INJURY P; WOOD RL, 1967, BRIAN INJURY REHABIL; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	32	30	31	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1997	11	8					605	617		10.1080/026990597123296			13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	XL930	WOS:A1997XL93000005	9251868				2022-02-06	
J	Rubin, Y; Cecil, K; Wehrli, S; McIntosh, TK; Lenkinski, RE; Smith, DH				Rubin, Y; Cecil, K; Wehrli, S; McIntosh, TK; Lenkinski, RE; Smith, DH			High-resolution H-1 NMR spectroscopy following experimental brain trauma	JOURNAL OF NEUROTRAUMA			English	Article						acetate; brain injury; fluid percussion; N-acetyl aspartate; nuclear magnetic resonance	ACETYL-L-ASPARTATE; NUCLEAR-MAGNETIC-RESONANCE; H-1-NMR SPECTROSCOPY; N-ACETYLASPARTATE; INJURY; RAT; DISEASE; LACTATE; FLUID; METABOLISM	We investigated acute metabolic changes following parasagittal fluid-percussion brain injury in the rat, using high-resolution H-1 nuclear magnetic resonance (NMR) spectroscopy. Sixty minutes following brain injury or sham (surgery, no injury) treatment, brains were rapidly removed and the injured and control cortices were isolated (n = 5/group). Isolates of brain cortices were then placed in buffer and studied in a 400-MHz spectrometer with measurements taken every 15 min over a 145-min period. At the initial NMR evaluation (immediately following dissection), we observed significantly lower levels of N-acetyl aspartic acid (NAA) in the injured group compared to the sham group. Surprisingly, a reciprocal increase in the concentration of acetate, a major metabolic product of NAA, was not observed at this timepoint. At subsequent timepoints, a progressive loss of NAA was observed in both injured and sham cortices, presumably due to ischemic conditions of the ex vivo samples. However, this progressive loss of NAA was now accompanied by a commensurate accumulation of acetate. These results suggest that (I) a decrease in the concentration of NAA occurs by 1 h following experimental brain trauma, potentially marking traumatic neural injury; (2) the initial absence of an expected reciprocal increase in acetate concentration may signify rapid utilization of acetate following trauma, potentially for reparative processes; and (3) in contrast to trauma alone, post mortem ischemic conditions may induce an increase in acetate concentrations.	UNIV PENN,DEPT NEUROSURG,DIV NEUROSURG,PHILADELPHIA,PA 19104; HOSP UNIV PENN,DEPT RADIOL,PHILADELPHIA,PA 19104; CHILDRENS HOSP,NMR CORE FACIL,PHILADELPHIA,PA 19104				smith, douglas/A-1321-2007; Lenkinski, Robert/F-9045-2014	Lenkinski, Robert/0000-0001-7371-5048; Cecil, Kim/0000-0001-8233-5485	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803, R55NS026818, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		AUSTIN SJ, 1991, MAGNET RESON MED, V19, P439, DOI 10.1002/mrm.1910190235; BENUCK M, 1968, BIOCHIM BIOPHYS ACTA, V152, P611, DOI 10.1016/0005-2760(68)90101-X; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; CHRISTIANSEN P, 1993, MAGN RESON IMAGING, V11, P799, DOI 10.1016/0730-725X(93)90197-L; COHEN Y, 1991, MAGNET RESON MED, V17, P225, DOI 10.1002/mrm.1910170125; DADAMO AF, 1966, J NEUROCHEM, V13, P961, DOI 10.1111/j.1471-4159.1966.tb10292.x; DADAMO AF, 1973, J NEUROCHEM, V20, P1275, DOI 10.1111/j.1471-4159.1973.tb00097.x; DUNLOP DS, 1992, BRAIN RES, V580, P44, DOI 10.1016/0006-8993(92)90925-Y; HUGG JW, 1993, ANN NEUROL, V34, P788, DOI 10.1002/ana.410340606; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAUL M, 1991, J NEUROCHEM, V56, P192; KLUNK WE, 1992, NEUROLOGY, V42, P1578, DOI 10.1212/WNL.42.8.1578; KNIZLEY H, 1967, J BIOL CHEM, V242, P4619; KRIWACKI RW, 1989, PHARMACEUT RES, V6, P531, DOI 10.1023/A:1015941128608; MATALON R, 1995, J PEDIATR-US, V127, P511, DOI 10.1016/S0022-3476(95)70105-2; MATALON R, 1988, AM J MED GENET, V29, P463, DOI 10.1002/ajmg.1320290234; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER BL, 1991, NMR BIOMED, V4, P47, DOI 10.1002/nbm.1940040203; MYERHOFF DJ, 1993, NEUROLOGY, V43, P509; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; PAULUS W, 1990, J NEUROL SCI, V95, P49, DOI 10.1016/0022-510X(90)90116-5; PEDEN CJ, 1993, DEV MED CHILD NEUROL, V35, P502; PETROFF OAC, 1988, J NEUROCHEM, V51, P163, DOI 10.1111/j.1471-4159.1988.tb04850.x; PLAITAKIS A, 1993, BRAIN RES BULL, V30, P381, DOI 10.1016/0361-9230(93)90269-H; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; RICHARDS TL, 1991, AM J ROENTGENOL, V157, P1073, DOI 10.2214/ajr.157.5.1927795; Rothman DL, 1994, NMR PHYSL BIOMEDICIN, P353; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SUTTON LN, 1994, J NEUROSURG, V81, P443, DOI 10.3171/jns.1994.81.3.0443; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, MAGNET RESON MED, V7, P95, DOI 10.1002/mrm.1910070111	33	30	34	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1997	14	7					441	449		10.1089/neu.1997.14.441			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	XP778	WOS:A1997XP77800002	9257662				2022-02-06	
J	Wong, AMK; Lee, MY; Kuo, JK; Tang, FT				Wong, AMK; Lee, MY; Kuo, JK; Tang, FT			The development and clinical evaluation of a standing biofeedback trainer	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						biofeedback; postural symmetry; rehabilitation; standing training	HEMIPLEGIC PATIENTS; POSTURAL STABILITY; BALANCE	A new standing biofeedback training device, which includes a height-adjustable work table, weight-bearing sensors, and a real-time visual and auditory feedback system, has been developed for postural training. Sixty persons with hemiplegia after acute stroke or traumatic brain injury were randomly divided into Group A (experimental) and Group B (control). After a training period of 4 weeks, the percentage of postural in Group A and Group B was reduced from 17.2 +/- 10.8% and 17.0 +/- 10.00% to 3.5 +/- 2.2% and 10.1 +/- 16.4 percent, respectively (p=0.003). There was no significant difference between subjects with right or left hemiplegia. The results indicated that this device had a positive training effect on stance symmetry in hemiplegic subjects.	CHANG GUNG UNIV, DEPT ENGN MECH, TAYUAN, TAIWAN		Wong, AMK (corresponding author), CHANG GUNG MEM HOSP, DEPT REHABIL MED, 199 TUNG HWA N RD, TAIPEI 10591, TAIWAN.		Wong, Alice M. K./ABI-1000-2020	Wong, Alice M. K./0000-0003-3586-1292			BOHANNON RW, 1985, PHYS THER, V65, P1323, DOI 10.1093/ptj/65.9.1323; BROOKS VB, 1983, PHYS THER, V63, P664, DOI 10.1093/ptj/63.5.664; DETTMANN MA, 1987, AM J PHYS MED REHAB, V66, P77; DICKSTEIN R, 1984, PHYS THER, V64, P19, DOI 10.1093/ptj/64.1.19; DIFABIO RP, 1990, PHYS THER, V70, P542, DOI 10.1093/ptj/70.9.542; DIFABIO RP, 1991, ARCH PHYS MED REHAB, V72, P292; GOLDIE PA, 1989, ARCH PHYS MED REHAB, V70, P510; HOCHERMAN S, 1984, ARCH PHYS MED REHAB, V65, P588; KEENAN MA, 1984, CLIN ORTHOP RELAT R, P165; KOTTKE FJ, 1978, ARCH PHYS MED REHAB, V59, P567; Mckay M, 1976, J BIOMECH, V9, P453; SHUMWAYCOOK A, 1988, ARCH PHYS MED REHAB, V69, P395; TWITCHELL TE, 1951, BRAIN, V74, P443, DOI 10.1093/brain/74.4.443; WALL JC, 1986, ARCH PHYS MED REHAB, V67, P550; WINSTEIN CJ, 1989, ARCH PHYS MED REHAB, V70, P755; WU SH, 1990, J OCCUPATIONAL THERA, V8, P1; [No title captured]	17	30	31	0	4	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	JUL	1997	34	3					322	327					6	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	XK919	WOS:A1997XK91900010	9239626				2022-02-06	
J	Naso, WB; Cure, J; Cuddy, BG				Naso, WB; Cure, J; Cuddy, BG			Retropharyngeal pseudomeningocele after atlanto-occipital dislocation: Report of two cases	NEUROSURGERY			English	Article							SPINAL PSEUDOMENINGOCELE	OBJECTIVE AND IMPORTANCE: We report two cases of retropharyngeal pseudomeningocele after atlanto-occipital dislocation. This is rare, with only one other reported case in the literature. CLINICAL PRESENTATION: We report two patients who presented after blunt cervical and head trauma. Plain films revealed that each patient had atlanto-occipital dislocation. Subsequent magnetic resonance imaging revealed the delayed development of retropharyngeal pseudomeningocele. Concomitant hydrocephalus was noted in both patients. INTERVENTION: The surviving patient showed marked neurological improvement and resolution of his pseudomeningocele after ventriculoperitoneal shunting. CONCLUSION: For patients with closed head injuries who develop posttraumatic pseudomeningocele, we recommend cranial computed tomography to assess for the presence of hydrocephalus. In patients with atlanto-occipital dislocation, delayed neurological deterioration warrants magnetic resonance imaging of the craniocervical junction to rule out posttraumatic pseudomeningocele.	MED UNIV S CAROLINA,DEPT NEUROSURG,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT RADIOL,CHARLESTON,SC 29425								COLLALTO PM, 1986, J BONE JOINT SURG AM, V68A, P1106, DOI 10.2106/00004623-198668070-00024; COOK DA, 1989, CLIN ORTHOPAEDICS, V247, P74; HELLE TL, 1981, NEUROSURGERY, V9, P314, DOI 10.1227/00006123-198109000-00018; HOFF JT, 1993, BRAIN SURG COMPLICAT, P108; HOROWITZ SW, 1990, AM J NEURORADIOL, V11, P784; KITCHEN N, 1992, SURG NEUROL, V38, P46, DOI 10.1016/0090-3019(92)90211-5; LOUW JA, 1991, S AFR J SURG, V29, P26; PRASAD VSSV, 1994, PARAPLEGIA, V32, P627, DOI 10.1038/sc.1994.100; SKLAR EML, 1990, AM J NEURORADIOL, V11, P1184; WILLIAMS MJ, 1995, J CLIN ANESTH, V7, P156, DOI 10.1016/0952-8180(94)00031-X	10	30	31	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1997	40	6					1288	1290		10.1097/00006123-199706000-00033			3	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	XC450	WOS:A1997XC45000088	9179904				2022-02-06	
J	Lee, ST; Lui, TN; Wong, CW; Yeh, YS; Tzaan, WC; Chen, TY; Hung, SY; Wu, CT				Lee, ST; Lui, TN; Wong, CW; Yeh, YS; Tzaan, WC; Chen, TY; Hung, SY; Wu, CT			Early seizures after severe closed head injury	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							PROGNOSIS; CONSCIOUSNESS; FEATURES; EPILEPSY; TRAUMA; MILD	Background: We studied the incidence and clinical significance of early post-traumatic seizures after severe closed head injury. Methods: This prospective study is based on clinical observation of 3340 adult patients with severe closed head injuries, each of them having a Glasgow Coma Scale (GCS) 3 to 8 after trauma. Anticonvulsant agents were not given to these patients unless there was evidence of seizure. Results: One hundred and twenty-one patients (3.6%) experienced seizures within 1 week after head injury; 42 of these (1.26% of the series) had seizures within 24 hours after trauma. The incidence of intracerebral parenchymal damage was found to be higher among those patients who developed seizures in the first week (66.1%) than in those who did not (62.7%). However this result did not reach statistical significance, The patients with early seizures had a lower mortality rate (p < 0.01). In patients who survived from the initial injury, the occurrence of early post-traumatic seizures did not appear to influence the neurological recovery at 6 months after injury. Conclusion: Presence of intracerebral parenchymal damage on CT scan after severe closed head injury does not increase the risk of early post-traumatic seizures. With proper treatment, patients presenting with early seizures may have a lower mortality rate. However, the occurrence of early seizures does not influence the neurological recovery in patients who survive the initial severe closed head injury.	CHANG GUNG MEM HOSP,CHANG GUNG MED COLL,TAYUAN 333,TAIWAN		Lee, ST (corresponding author), CHANG GUNG MEM HOSP,DEPT NEUROSURG,5 FU SHING ST,TAYUAN 333,TAIWAN.			Wu, Chieh-Tsai/0000-0002-8419-3764			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOWERS SA, 1980, NEUROSURGERY, V6, P2327; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; CAVENESS WF, 1961, EPILEPSIA, V2, P123; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; DASILVA AM, 1990, ACT NEUR S, V50, P48; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; ELVIDGE AR, 1960, INJURIES BRAIN SPINA, P285; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Guidice M A, 1987, Brain Inj, V1, P61; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; Jennett B, 1979, Acta Neurochir Suppl (Wien), V28, P149; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT B, 1981, MANAGEMENT HEAD INJU, P301; JENNETT B, 1975, EPILEPSY NONMISSILE; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MISES J, 1976, EPILEPSIA, V11, P37; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; TEASDALE G, 1974, LANCET, V2, P81; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	36	30	32	0	2	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	FEB	1997	24	1					40	43		10.1017/S0317167100021077			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WH812	WOS:A1997WH81200007	9043746	Bronze			2022-02-06	
J	vandeMeent, HV; Hamers, FPT; Lankhorst, AJ; Joosten, EAJ; Gispen, WH				vandeMeent, HV; Hamers, FPT; Lankhorst, AJ; Joosten, EAJ; Gispen, WH			Beneficial effects of the melanocortin alpha-melanocyte-stimulating hormone on clinical and neurophysiological recovery after experimental spinal cord injury	NEUROSURGERY			English	Article						evoked potentials; melanocortins; neurological recovery; rat; spinal cord injury	METHYLPREDNISOLONE SODIUM SUCCINATE; BLOOD-FLOW; ACTH(4-9) ANALOG; MOLECULAR-CLONING; NERVE CRUSH; FUNCTIONAL RECOVERY; INDUCED NEUROPATHY; ACTH-(4-9) ANALOG; NUCLEUS ACCUMBENS; DOPAMINE SYSTEMS	OBJECTIVE: Melanocortins, peptides related to melanocyte-stimulating hormone (MSH) and corticotropin (ACTH), exhibit neurotrophic and neuroprotective activity in several established models of peripheral and central nervous system damage. The beneficial effects of melanocortins on functional recovery after experimental brain damage and central demyelinating diseases have prompted us to investigate alpha MSH treatment in a weight drop model of traumatic spinal cord injury in rats. METHODS: In two independent randomized blinded experiments, treatment with either alpha MSH (75 mu g/kg of body weight administered subcutaneously every 48 h for 3 weeks after trauma) or single high-dose (30 mg/kg, 30 min after injury) methylprednisolone was compared with saline treatment in rats subjected to a moderately severe 20-gcm weight drop injury. Spinal cord function was monitored using behavioral, electrophysiological, and histological parameters. RESULTS: In both experiments, alpha MSH significantly improved recovery, as illustrated by Tarlov scores, thoracolumbar height, and amplitude of rubrospinal motor evoked potentials. The magnitude of the alpha MSH effect on motor performance was comparable with the one observed after treatment with methylprednisolone. CONCLUSION: The reproducible neurological and electrophysiological improvement in spinal cord function of animals treated with alpha MSH suggests a new lead in the treatment of traumatic spinal cord injury.	UNIV UTRECHT HOSP, RES LAB NEUROL, UTRECHT, NETHERLANDS; UNIV UTRECHT, RUDOLF MAGNUS INST NEUROSCI, DEPT MED PHARMACOL, UTRECHT, NETHERLANDS								Adan RAH, 1996, MOL BRAIN RES, V36, P37, DOI 10.1016/0169-328X(95)00236-L; Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Anderson DK, 1991, J NEUROTRAUM, V8, P187, DOI 10.1089/neu.1991.8.187; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BEHRMANN DL, 1993, EXP NEUROL, V119, P258, DOI 10.1006/exnr.1993.1028; BIJLSMA WA, 1983, MUSCLE NERVE, V6, P104, DOI 10.1002/mus.880060205; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; COLLINS WF, 1983, PARAPLEGIA, V21, P204, DOI 10.1038/sc.1983.34; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DEKKER AJAM, 1987, PEPTIDES, V8, P1057, DOI 10.1016/0196-9781(87)90136-7; DEKONING P, 1987, EXP NEUROL, V97, P746, DOI 10.1016/0014-4886(87)90132-4; DELABAUME S, 1981, NEUROSCIENCE, V6, P315, DOI 10.1016/0306-4522(81)90125-1; Dohrmann G J, 1976, Surg Neurol, V5, P315; DUCKERS HJ, 1994, BRAIN, V117, P365, DOI 10.1093/brain/117.2.365; DUCKERS HJ, IN PRESS J NEUROSCI; EDWARDS PM, 1984, J NEUROL SCI, V64, P333, DOI 10.1016/0022-510X(84)90181-3; FADEN AI, 1988, BRAIN RES, V463, P63, DOI 10.1016/0006-8993(88)90527-6; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; FERINGA ER, 1976, NEUROLOGY, V26, P839, DOI 10.1212/WNL.26.9.839; FORD RWJ, 1983, J NEUROSURG, V59, P268, DOI 10.3171/jns.1983.59.2.0268; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GISPEN WH, 1994, PROG BRAIN RES, V100, P223; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; HAMERS FPT, 1993, CANCER CHEMOTH PHARM, V32, P162, DOI 10.1007/BF00685621; HAMERS FPT, 1993, EUR J PHARMACOL, V233, P177, DOI 10.1016/0014-2999(93)90367-Q; HANNIGAN JH, 1985, PHARMACOL BIOCHEM BE, V23, P1019, DOI 10.1016/0091-3057(85)90109-1; HOL EM, 1993, NEUROREPORT, V4, P651, DOI 10.1097/00001756-199306000-00012; HOLTZ A, 1989, SURG NEUROL, V31, P350, DOI 10.1016/0090-3019(89)90066-9; HOLTZ A, 1990, ACTA NEUROL SCAND, V82, P68; HUNG TK, 1979, SURG NEUROL, V11, P470; ISAACSON RL, 1983, BEHAV NEURAL BIOL, V39, P52, DOI 10.1016/S0163-1047(83)90620-9; Joosten E. A. J., 1995, Journal of Neurotrauma, V12, P373; KAKULAS BA, 1987, PARAPLEGIA, V25, P212, DOI 10.1038/sc.1987.37; KOENIG G, 1977, J NEUROL NEUROSUR PS, V40, P1203, DOI 10.1136/jnnp.40.12.1203; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NOBLE LJ, 1987, EXP NEUROL, V95, P530, DOI 10.1016/0014-4886(87)90162-2; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NYAKAS C, 1985, BRAIN RES BULL, V15, P257, DOI 10.1016/0361-9230(85)90148-0; PITSIKAS N, 1991, PHARMACOL BIOCHEM BE, V38, P931, DOI 10.1016/0091-3057(91)90267-6; SANDLER AN, 1976, J NEUROSURG, V45, P638, DOI 10.3171/jns.1976.45.6.0638; STRAND FL, 1991, PHYSIOL REV, V71, P1017, DOI 10.1152/physrev.1991.71.4.1017; STRAND FL, 1994, PHARMACOL THERAPEUT, V62, P1, DOI 10.1016/0163-7258(94)90002-7; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P588, DOI 10.1001/archneurpsyc.1954.02320410050004; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; ULENKATE HJLM, 1993, GLIA, V9, P219, DOI 10.1002/glia.440090307; VANDEMEENT H, 1995, EUR J NEUROSCI, V8, P197; VANDEMEENT H, IN PRESS J NEUROTRAU; VANDERHOOP RG, 1990, NEW ENGL J MED, V322, P89, DOI 10.1056/NEJM199001113220204; VANDERNEUT R, 1992, PEPTIDES, V13, P1109, DOI 10.1016/0196-9781(92)90015-U; VANDERZEE CEEM, 1988, EUR J PHARMACOL, V147, P351, DOI 10.1016/0014-2999(88)90168-9; VANREE JM, 1991, EUR NEUROPSYCHOPHARM, V1, P386; VERHAAGEN J, 1986, EXP NEUROL, V92, P451, DOI 10.1016/0014-4886(86)90098-1; VERHAAGEN J, 1987, PEPTIDES, V8, P581, DOI 10.1016/0196-9781(87)90028-3; WOLTERINK G, 1990, BRAIN RES, V507, P115, DOI 10.1016/0006-8993(90)90529-K; WOLTERINK G, 1990, BRAIN RES, V507, P109, DOI 10.1016/0006-8993(90)90528-J; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667	69	30	31	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	1997	40	1					122	130		10.1097/00006123-199701000-00028			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VY973	WOS:A1997VY97300068	8971834				2022-02-06	
J	Chambers, J; Cohen, SS; Hemminger, L; Prell, JA; Nichols, JS				Chambers, J; Cohen, SS; Hemminger, L; Prell, JA; Nichols, JS			Mild traumatic brain injuries in low-risk trauma patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						mild traumatic brain injury; conclusion; screening; blunt trauma; cognitive deficit	MINOR HEAD-INJURY; POSTCONCUSSION SYMPTOMS; SEQUELAE	Background: Moderate or severe traumatic brain injury (TBI) resulting from cranial trauma is usually easily recognizable, Mild TBI (MTBI), however, may escape detection at presentation because of delayed symptoms and the absence of radiographic abnormalities, Despite its subtle or delayed presentation, the spectrum of symptoms often experienced after MTBI, collectively referred to as ''postconcussive syndrome,'' may cause serious psychosocial dysfunction. Methods/Results: To assess the sensitivity of emergency department screening for MTBI, a prospective follow-up study was conducted on a group of patients (N = 129) who had been evaluated at a regional trauma center after blunt trauma, None had symptoms or signs of TBI at presentation, nor any history of direct cranial trauma, All were discharged to home from the emergency department without a diagnosis of TBI, At 1 month after injury, 41 of 129 (32%) patients described an increase in symptoms consistent with MTBI. The most common symptoms were insomnia (62%), headaches (58%), irritability (56%) and fatigue (56%). At 2 months, most symptoms had decreased significantly, and none had increased in severity. Despite improvement in their symptoms over that time period, 11% of those with persistent symptoms remained unable to resume their premorbid daily activities, Conclusions: These data, obtained from a population of patients considered to be at extremely low risk for TBI, indicate that MTBI occurs more often among blunt trauma patients than is commonly appreciated, even in busy trauma centers. Because early recognition of MTBI may expedite referral of these patients for appropriate outpatient follow-up care, thereby avoiding potentially serious social and financial repercussions, emergency department personnel should have a high index of suspicion for MTBI in any patient sustaining blunt systemic trauma. Current measures that screen for MTBI appear to be inadequate; follow-up protocols may prove to be more sensitive screening tools.	UNIV COLORADO,HLTH SCI CTR,INTERMT NEUROSURG & NEUROSCI,DENVER,CO 80204; UNIV COLORADO,HLTH SCI CTR,PROVENANT ST ANTHONY CENT HOSP,DENVER,CO 80204; UNIV COLORADO,HLTH SCI CTR,DIV NEUROSURG,DENVER,CO 80204								ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BOLLOK I, 1983, NEUROPEPTIDES, V3, P263; CARTLIDGE NEF, 1978, INJURY, V10, P73; Colohan A. R. T., 1986, J HEAD TRAUMA REHAB, V1, P13; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; ENDERSON BL, 1991, SURG CLIN N AM, V71, P399; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1974, LANCET, V2, P604; Hinkle J L, 1986, J Neurosci Nurs, V18, P268; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; Jennett B, 1978, Practitioner, V221, P77; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; Mahon D, 1989, J Neurosci Nurs, V21, P382; Maio T, 1980, J Med Soc N J, V77, P637; Mattice C, 1994, J Emerg Nurs, V20, P48; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; *NATL HEAD INJ FDN, 1993, INT HEAD INJ TASK FO; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Veltman R H, 1993, J Neurosci Nurs, V25, P367; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	28	30	32	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1996	41	6					976	980		10.1097/00005373-199612000-00006			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	VY407	WOS:A1996VY40700007	8970549				2022-02-06	
J	Ater, JL; Moore, BD; Francis, DJ; Castillo, R; Slopis, J; Copeland, DR				Ater, JL; Moore, BD; Francis, DJ; Castillo, R; Slopis, J; Copeland, DR			Correlation of medical and neurosurgical events with neuropsychological status in children at diagnosis of astrocytoma: Utilization of a neurological severity score	JOURNAL OF CHILD NEUROLOGY			English	Article							CENTRAL NERVOUS-SYSTEM; BRAIN-TUMOR PATIENTS; CLOSED HEAD-INJURY; CRANIAL IRRADIATION; CHILDHOOD; MEDULLOBLASTOMA; QUALITY; INFANTS; CANCER; CHEMOTHERAPY	Neuropsychological studies of children who have brain tumors have yielded diverse results with respect to identifying factors that contribute to poor intellectual outcome. The purpose of this study was to evaluate the relationship between pre- and perioperative events, tumor-related factors, and the neuropsychological status of children diagnosed with astrocytoma. Events that could potentially be detrimental to neuropsychological outcome were quantified utilizing a new ''neurological severity score.'' The Neurological Severity Score was developed as a research tool to test our hypothesis that ultimate intellectual outcome is a result of cumulative, interactive insults on the central nervous system. This study constitutes a first step in examining the predictive value of the Neurological Severity Score by evaluating its correlation with baseline neuropsychological status. Fifty-nine children who had astrocytoma (36 supratentorial and 23 infratentorial) received complete neurological and neuropsychological evaluations within 3 months of diagnosis. Each child's neurological history and examination results were scored by an independent observer using the Neurological Severity Score. Neuroimages obtained at diagnosis and at the time of neuropsychological testing were evaluated as well. For the group as a whole, memory, attention, and motor abilities were significantly below age-appropriate norms, whereas intelligence, language, and academic skills were preserved. Patterns of deficits were identified and related to tumor site. There were no significant differences in mean neuropsychological domain scores between groups based on gender, pre- versus post-operative status, ethnicity, tumor grade, or abnormalities on magnetic resonance imaging (MRI). The Neurological Severity Score was significantly inversely correlated with visual-spatial skills, memory, attention, performance IQ, and global IQ. Ln conclusion, among all the medical and neurological factors present at diagnosis, the neurological severity score had the highest correlation with neuropsychological scores. This instrument has promise as a research tool in investigations of the psychological effects of cancer and its treatment on children.	UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX		Ater, JL (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PEDIAT,DIV PEDIAT,BOX 87,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Francis, David/0000-0003-3944-3274	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA-33097] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA033097] Funding Source: NIH RePORTER		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Ater Joann L., 1993, Cancer Bulletin (Houston), V45, P351; BARAM TZ, 1987, CANCER, V60, P173, DOI 10.1002/1097-0142(19870715)60:2<173::AID-CNCR2820600209>3.0.CO;2-F; BEERY KE, 1967, DEV TEST VISUAL MOTO; BLEYER WA, 1990, CA-CANCER J CLIN, V40, P355, DOI 10.3322/canjclin.40.6.355; BROOKSHIRE B, 1991, NEUROSURGERY, V17, P887; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; COPELAND DR, 1992, CA-CANCER J CLIN, V42, P283, DOI 10.3322/canjclin.42.5.283; DUNN LM, 1970, PEABODY INDIVIDUAL A; ELLENBERG L, 1987, NEUROSURGERY, V21, P638, DOI 10.1227/00006123-198711000-00006; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; FLETCHER JM, 1988, J CLIN EXP NEUROPSYC, V10, P495, DOI 10.1080/01688638808408255; FLETCHER JM, 1985, J EXP CHILD PSYCHOL, V40, P244, DOI 10.1016/0022-0965(85)90088-8; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; HIRSCH JF, 1989, J NEUROSURG, V70, P568, DOI 10.3171/jns.1989.70.4.0568; HOCHBERG FH, 1980, NEUROLOGY, V30, P172, DOI 10.1212/WNL.30.2.172; Hollingshead A. B., 1957, 2 FACTOR INDEX SOCIA; HOPPEHIRSCH E, 1990, CHILD NERV SYST, V6, P60, DOI 10.1007/BF00307922; KUN LE, 1983, J NEUROSURG, V58, P1, DOI 10.3171/jns.1983.58.1.0001; KUN LE, 1983, AM J CLIN ONCOL-CANC, V6, P651; LEBARON S, 1988, CANCER, V62, P1215, DOI 10.1002/1097-0142(19880915)62:6<1215::AID-CNCR2820620629>3.0.CO;2-C; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MADAMSWAIN A, 1991, CLIN PSYCHOL REV, V1, P267; McCarthy, 1972, MCCARTHY SCALES CHIL; MOORE BD, 1992, J CHILD NEUROL, V7, P281, DOI 10.1177/088307389200700308; MOSTOW EN, 1991, J CLIN ONCOL, V9, P592, DOI 10.1200/JCO.1991.9.4.592; MULHERN RK, 1989, J CLIN ONCOL, V7, P1660, DOI 10.1200/JCO.1989.7.11.1660; MULHERN RK, 1992, MED PEDIATR ONCOL, V20, P181, DOI 10.1002/mpo.2950200302; MULHERN RK, 1988, J CHILD NEUROL, V3, P47, DOI 10.1177/088307388800300111; MULHERN RK, 1985, MED PEDIATR ONCOL, V13, P318, DOI 10.1002/mpo.2950130604; PACKER RJ, 1983, CHILD BRAIN, V10, P393; PACKER RJ, 1987, MED PEDIATR ONCOL, V15, P241, DOI 10.1002/mpo.2950150505; PACKER RJ, 1987, PEDIATR NEUROSCI, V13, P169, DOI 10.1159/000120325; RADCLIFFE J, 1992, ANN NEUROL, V32, P551, DOI 10.1002/ana.410320411; Reitan R, 1969, MANUAL ADM NEUROPSYC; RIS MD, 1994, J CLIN EXP NEUROPSYC, V16, P21, DOI 10.1080/01688639408402615; Sattler, 1986, STANFORDBINET INTELL; SATTLER JM, 1988, ASSESSMENT CHILDRENS; STEHBENS J A, 1991, Neuropsychology Review, V2, P147, DOI 10.1007/BF01109052; SUTTON LN, 1987, PEDIATR NEUROSCI, V13, P98, DOI 10.1159/000120311; Wechsler D., 1974, WECHSLER INTELLIGENC; Wilkinson, 1984, WIDE RANGE ACHIEVEME	44	30	32	0	2	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	NOV	1996	11	6					462	469		10.1177/088307389601100610			8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	VW886	WOS:A1996VW88600009	9120225				2022-02-06	
J	Clifton, GL; Donovan, WH; Dimitrijevic, MM; Allen, SJ; Ku, A; Potts, JR; Moody, FG; Boake, C; Sherwood, AM; Edwards, JV				Clifton, GL; Donovan, WH; Dimitrijevic, MM; Allen, SJ; Ku, A; Potts, JR; Moody, FG; Boake, C; Sherwood, AM; Edwards, JV			Omental transposition in chronic spinal cord injury	SPINAL CORD			English	Article						spinal cord injury; omental transposition; MRI; neurophysiology; neurological examinations; neurological	SOMATOSENSORY EVOKED-POTENTIALS; EXPERIMENTAL CEREBRAL-ISCHEMIA; INTACT OMENTUM; BRAIN; NEOVASCULARIZATION; VASCULARIZATION; TRANSPLANTATION; PREVENTION; INFARCTION; SURFACE	The results of omental transposition in chronic spinal cord injury have been reported in 160 patients operated upon in the United States, Great Britain, China, Japan, India and Mexico, with detailed outcomes reported in few studies. Recovery of function to a greater degree than expected by natural history has been reported. In this series, 15 patients with chronic traumatic spinal cord injury (>1.5 years from injury) underwent transposition of pedicled omentum to the area of spinal cord injury. Of the first series of four patients who were operated upon in 1988, one died, one was lost to follow-up and two were followed with sequential neurological examinations and Magnetic Resonance Imaging (MRI) scans preoperatively, at 1 year post injury and 4 1/2 years post injury. Another 11 patients were operated in 1992 and underwent detailed neurological and neurophysiological examinations and had MRT scans preoperatively and every 4 months for at least 1 year after surgery. All patients completed a detailed self-report form. Of the total of 13 operated patients in both series followed for 1-4 1/2 years, six reported some enhanced function at 1 year and five of these felt the changes justified surgery primarily because of improved truncal control and decreased spasticity. MRI scans showed enlargement of the spinal cord as compared to preoperative scans in seven patients. Increased T2 signal intensity of the spinal cord was found by 1 year after surgery in eight of 13 operated patients. Neurophysiological examinations of 11 patients in the second series agreed with self-reports of increases or decreases in spasticity (r = 0.65, P < 0.03). Somatosensory evoked potentials and motor evoked potentials at 4 month intervals up to 1 year in these patients showed no change after surgery. Neurological testing, using the American Spinal Injury Association (ASIA) and International Medical Society of Paraplegia (IMSOP) international scoring standards, failed to show any significant changes when the I-year post operative examination was compared to the first preoperative examination except for decreased sensory function after surgery which approached statistical significance. When the 11 patients in the second series were compared to eight non-operated matched patients, followed for a similar length of time, no significant differences were found. Complications encountered in the operated patients from both series included one postoperative death from a pulmonary embolus, one postoperative pneumonia, three chronic subcutaneous cerebrospinal fluid (CSF) fistulae requiring wound revision, and one patient who developed biceps and wrist extensor weakness bilaterally requiring graft removal. We conclude that the omental graft remains viable over time and this operation can induce anatomical changes in the spinal cord as judged by MRI. Some patients reported subjective improvement but this was not supported by objective testing. We, therefore, find no justification for further clinical trials of this procedure in patients who have complete or sensory incomplete lesions. Further testing in motor incomplete patients would seem appropriate only with compelling supportive data.			Clifton, GL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,SCH MED,641 FANNIN,SUITE 7149,HOUSTON,TX 77030, USA.			Sherwood, Arthur/0000-0002-0110-4317			ABRAHAM J, 1980, PARAPLEGIA, V25, P44; ABRAHAM J, 1990, OMENTUM, P147; AZZENA GB, 1983, ACTA NEUROCHIR, V68, P63, DOI 10.1007/BF01406203; BERIC A, 1988, MUSCLE NERVE, V11, P621, DOI 10.1002/mus.880110615; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; BLIGHT AR, 1989, J NEUROL SCI, V82, P145; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CARTIER R, 1990, J THORAC CARDIOV SUR, V99, P264; CUCCA GS, 1980, ACTA NEUROCHIR, V51, P253, DOI 10.1007/BF01406752; DELATORRE JC, 1990, ACTA NEUROCHIR, V102, P152, DOI 10.1007/BF01405432; DERIU PL, 1980, NEUROSURGERY, V7, P57, DOI 10.1227/00006123-198007000-00009; DIMITRIJEVIC MM, 1989, PHYS MED REHAB, V3, P64; DIMITRIJEVIC MR, 1992, ELECTROEN CLIN NEURO, V85, P365, DOI 10.1016/0168-5597(92)90049-H; DITUNNO JF, 1992, AM SPINAL INJURY ASS; FRACKOWIAK R, 1987, STROKE, V18, P46; GOLDSMITH HS, 1978, STROKE, V9, P224, DOI 10.1161/01.STR.9.3.224; GOLDSMITH HS, 1979, STROKE, V10, P471, DOI 10.1161/01.STR.10.4.471; GOLDSMITH HS, 1986, SURG GYNECOL OBSTET, V162, P579; GOLDSMITH HS, 1986, PARAPLEGIA, V24, P173, DOI 10.1038/sc.1986.23; GOLDSMITH HS, 1994, NEUROL RES, V16, P159; GOLDSMITH HS, 1975, AM J SURG, V129, P262, DOI 10.1016/0002-9610(75)90236-6; GOLDSMITH HS, 1973, ARCH SURG-CHICAGO, V106, P695; GOLDSMITH HS, 1975, AM J SURG, V130, P317, DOI 10.1016/0002-9610(75)90393-1; Goldsmith HS, 1990, OMENTUM RES CLIN APP, P45; KADABA MP, 1985, J ORTHOPAED RES, V3, P350, DOI 10.1002/jor.1100030312; KAKULAS A, 1988, PARAPLEGIA, V26, P371, DOI 10.1038/sc.1988.57; LIU JF, 1980, J NERV MENT DIS, V6, P321; MACMILLAN M, 1991, SPINE, V16, P176, DOI 10.1097/00007632-199102000-00014; MCINTOSH TK, 1990, OMENTUM RES CLIN APP, P75; MINSHU Z, 1990, OMENTUM, P173; MIYAMOTO S, 1990, OMENTUM, P159; NAGASHIMA C, 1991, Neurological Surgery, V19, P309; NI MS, 1983, CHINESE MED J-PEKING, V96, P787; OSHIO I, 1993, SPINE, V18, P1140; PAU A, 1982, ACTA NEUROCHIR, V66, P159, DOI 10.1007/BF02074502; PAU A, 1982, ACTA NEUROCHIR, V54, P213; PIEPMEIER JM, 1988, J NEUROSURG, V69, P399, DOI 10.3171/jns.1988.69.3.0399; RAFAEL H, 1992, ACTA NEUROCHIR, V114, P145, DOI 10.1007/BF01400604; ROSADINI G, 1990, OMENTUM, P109; SHERWOOD AM, 1981, IEEE T BIO-MED ENG, V28, P481, DOI 10.1109/TBME.1981.324733; SHERWOOD AM, 1992, J NEUROL SCI, V110, P90, DOI 10.1016/0022-510X(92)90014-C; SHERWOOD AM, 1992, 9 INT C ISEK FLOR IT, P95; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SIEK GC, 1990, OMENTUM RES CLIN APP, P83; SONG MF, 1990, CHUNG HUA WAI KO TSA, V28, P342; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; YOUNG W, 1987, FRONTIERS CLIN NEURO, V10, P156; ZHANG C, 1983, CHUNG HUA SHEN CHING, V16, P23; ZHU ZC, 1982, CHUNG HUA WAI KO TSA, V20, P11; ZOU XW, 1985, CHIN J NEUROSURG, V1, P107	50	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	1362-4393			SPINAL CORD	Spinal Cord	APR	1996	34	4					193	203		10.1038/sc.1996.38			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	UR611	WOS:A1996UR61100003	8963963	Bronze			2022-02-06	
J	vanReekum, R; Links, PS; Finlayson, MAJ; Boyle, M; Boiago, I; Ostrander, LA; Moustacalis, E				vanReekum, R; Links, PS; Finlayson, MAJ; Boyle, M; Boiago, I; Ostrander, LA; Moustacalis, E			Repeat neurobehavioral study of borderline personality disorder	JOURNAL OF PSYCHIATRY & NEUROSCIENCE			English	Article						borderline personality disorder; etiology; brain injury; cognition; case-control study	DIAGNOSTIC INTERVIEW; SCHIZOPHRENIA; IMPAIRMENT; DEFICITS; INJURY	Previous research has tentatively identified a large subgroup of patients with borderline personality disorder (BPD) with histories of developmental or acquired brain insults. Similarly, these studies have demonstrated a possible biological correlation between the severity of BPD and the number of previous brain insults. The possibility of frontal system cognitive dysfunction in BPD has been raised. This single-blind, case-control study of BPD showed that 13 of 24 subjects with BPD had suffered a brain insult. Correlations between neurodevelopmental/acquired brain injury score and the diagnostic interview for borderline (DIB) score (r = 0.47), and between frontal system cognitive functioning and DIB score (r = -0.37) were seen. Neurocognitive testing and comparison with a cohort of subjects with traumatic brain injury (TBI) showed a pattern of similar cognitive functioning between the 2 groups, with the only differences on individual tests being in the direction of worse functioning in the group with BPD on 2 tasks. These results support the hypotheses described above. The main limitation reflects the low numbers of subjects.	UNIV TORONTO,DEPT PSYCHIAT,TORONTO,ON,CANADA; WELLESLEY HOSP,TORONTO,ON,CANADA; MCMASTER UNIV,DEPT PSYCHIAT,HAMILTON,ON,CANADA; HAMILTON CIV HOSP,HAMILTON,ON,CANADA; CHEDOKE MCMASTER HOSP,ACQUIRED BRAIN INJURY PROGRAM,HAMILTON,ON,CANADA		vanReekum, R (corresponding author), BAYCREST CTR GERIATR CARE,DEPT PSYCHIAT,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.						AKHTAR S, 1986, J CLIN PSYCHIAT, V47, P196; Albert M., 1980, NEW DIRECTIONS MEMOR, P403; ANDRULONIS PA, 1982, J NERV MENT DIS, V170, P670, DOI 10.1097/00005053-198211000-00006; ANDRULONIS PA, 1984, BRIT J PSYCHIAT, V144, P358, DOI 10.1192/bjp.144.4.358; ANDRULONIS PA, 1980, PSYCHIATRIC CLIN N A, V4, P47; Army Individual Test Battery, 1944, MAN DIR SCOR; BENSON DF, 1975, PSYCHIATRIC ASPECTS; BLISHEN BR, 1976, CAN REV SOC ANTHROP, V13, P71, DOI 10.1111/j.1755-618X.1976.tb00759.x; BURGESS JW, 1991, PSYCHIAT RES, V38, P77, DOI 10.1016/0165-1781(91)90054-S; BURGESS JW, 1992, PSYCHIAT RES, V42, P283, DOI 10.1016/0165-1781(92)90120-R; CORNELIUS JR, 1989, J PERSONALITY DISORD, V3, P19; Cummings J, 1985, CLIN NEUROPSYCHIATRY; DAHL AA, 1985, PSYCHIATR DEV, V2, P109; DREWE EA, 1975, NEUROPSYCHOLOGIA, V13, P421, DOI 10.1016/0028-3932(75)90065-2; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FREEDMAN M, 1986, BEHAV NEUROSCI, V100, P337, DOI 10.1037/0735-7044.100.3.337; GARDNER D, 1987, J NERV MENT DIS, V175, P177, DOI 10.1097/00005053-198703000-00009; GUNDERSON JG, 1981, AM J PSYCHIAT, V138, P896; HAMBLIN KT, 1992, 1992 AM PSYCH ASS AN; Heaton R.K., 1981, WISCONSIN CARD SORTI; LEWINSOHN PM, 1973, UNPUB PSYCHOL ASSESS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LINKS PS, 1988, CAN J PSYCHIAT, V33, P336, DOI 10.1177/070674378803300504; LINKS PS, 1994, IN PRESS J NERV MENT; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria A. R., 1966, HUMAN BRAIN PSYCHOL; MILNER B, 1970, BIOL MEMORY; OLEARY KM, 1991, AM J PSYCHIAT, V148, P106; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SHUE KL, 1992, BRAIN COGNITION, V20, P104, DOI 10.1016/0278-2626(92)90064-S; SOLOFF PH, 1983, COMPR PSYCHIAT, V24, P574, DOI 10.1016/0010-440X(83)90026-3; SPREEN O, 1965, J NERV MENT DIS, V140, P323, DOI 10.1097/00005053-196505000-00002; Stangl, 1989, STRUCTURED INTERVIEW; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TUPPER D, 1987, SOFT NEUROLOGICAL SI; VANREEKUM R, 1993, CAN J PSYCHIAT, V38, pS4; VANREEKUM R, 1993, J PSYCHIATR NEUROSCI, V18, P121; VANREEKUM R, IN PRESS BRAIN INJUR; Wechsler, 1997, WECHSLER ADULT INTEL; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; Wilkinson, 1984, WIDE RANGE ACHIEVEME; ZANARINI MC, 1994, BIOL NEUROBEHAVIORAL; ZIMMEMAN M, 1989, ARCH GEN PSYCHIAT, V42, P682; [No title captured]	46	30	30	0	3	CANADIAN PSYCHIATRIC ASSOC	OTTAWA	SUITE 200, 237 ARGYLE AVE, OTTAWA ON K2P 1B8, CANADA	1180-4882			J PSYCHIATR NEUROSCI	J. Psychiatry Neurosci.	JAN	1996	21	1					13	20					8	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	TP746	WOS:A1996TP74600003	8580113				2022-02-06	
J	Wallis, RA; Panizzon, KL				Wallis, RA; Panizzon, KL			Felbamate neuroprotection against CA1 traumatic neuronal injury	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						traumatic brain injury; felbamate; long-term potentiation; CA1; hippocampus	LONG-TERM POTENTIATION; BRAIN INJURY; HEAD-INJURY; HYPOXIC PROTECTION; HIPPOCAMPAL SLICE; AMINO-ACIDS; RAT; HYPOGLYCEMIA; RECEPTORS; CHILDREN	Traumatic brain injury is a leading cause of disability and death. Since the anticonvulsant felbamate provides hypoxic neuroprotection, we investigated whether felbamate would provide protection against traumatic neuronal injury as well. Traumatic injury to CA1 neurons in hippocampal slices was induced by fluid percussion, and CA1 evoked response was monitored. Pre-treatment with felbamate was strongly protective against neuronal injury, and permitted CA1 antidromic population spike recovery to a mean 94 +/- 1% (S.E.M.) of initial amplitude, compared to unmedicated slices which regained only 15 +/- 6%. The felbamate EC(50) for this protection was 136 mg/l, and significant protection was found at felbamate concentrations similar to those reported in felbamate monotherapy for seizures. Significant protection was also defected when felbamate was initiated 15 min after trauma. Slices given brief post-trauma felbamate treatment could demonstrate long-term potentiation when assessed 8 h after trauma. These studies indicate that felbamate is neuroprotective against CA1 traumatic neuronal injury.	UNIV CALIF LOS ANGELES,DEPT NEUROL,LOS ANGELES,CA 90024		Wallis, RA (corresponding author), SEPULVEDA VAMC,NEURONAL INJURY LAB,16111 PLUMMER ST,SEPULVEDA,CA 91343, USA.						BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; DODSON WE, 1993, EPILEPSIA, V34, pS18, DOI 10.1111/j.1528-1157.1993.tb04590.x; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAUGHT E, 1993, NEUROLOGY, V43, P688, DOI 10.1212/WNL.43.4.688; JENSEN PK, 1993, EPILEPSIA, V34, pS25, DOI 10.1111/j.1528-1157.1993.tb04591.x; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; MCCABE RT, 1993, J PHARMACOL EXP THER, V264, P1248; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NELLGARD B, 1992, EXP BRAIN RES, V92, P259; NIGHTINGALE SL, 1994, JAMA-J AM MED ASSOC, V272, P995, DOI 10.1001/jama.272.13.995; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Olney J, 1978, KAINIC ACID TOOL NEU, P95; PANIZZON KL, 1993, NEUROLOGY, V43, pA312; PAPAGAPIOU MP, 1990, J CEREBR BLOOD F MET, V10, P270, DOI 10.1038/jcbfm.1990.44; SCHURR A, 1984, BRAIN RES, V297, P357, DOI 10.1016/0006-8993(84)90576-6; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P770; TASKER RC, 1992, J NEUROSCI, V12, P4298; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; WAGNER ML, 1990, EPILEPSIA, V31, P642; WALLIS RA, 1992, STROKE, V23, P547, DOI 10.1161/01.STR.23.4.547; WALLIS RA, 1993, NEUROREPORT, V4, P951, DOI 10.1097/00001756-199307000-00029; WALLIS RA, 1994, BRAIN RES, V664, P115, DOI 10.1016/0006-8993(94)91961-5; WASTERLAIN CG, 1992, EUR J PHARMACOL, V212, P275, DOI 10.1016/0014-2999(92)90343-3	26	30	30	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	DEC 29	1995	294	2-3					475	482		10.1016/0014-2999(95)00568-4			8	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	TP560	WOS:A1995TP56000013	8750708				2022-02-06	
J	VAKIL, E; WEISZ, H; JEDWAB, L; GROSWASSER, Z; ABERBUCH, S				VAKIL, E; WEISZ, H; JEDWAB, L; GROSWASSER, Z; ABERBUCH, S			STROOP COLOR-WORD TASKS AS A MEASURE OF SELECTIVE ATTENTION - EFFICIENCY IN CLOSED-HEAD-INJURED PATIENTS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MECHANISMS; SYMPTOMS; DEFICITS	Deficits in attention and concentration are reported to be among the most common symptoms following head injury. Various underlying mechanisms of selective attention such as excitation, inhibition, and habituation have been isolated in recent studies. In the present study 27 control and 25 closed-head-injured (CHI) subjects were compared on four conditions based on the Stroop color-word task (neutral, habituation, Stroop, and negative priming). Cross-comparison of the different tasks enables examination of the various components of selective attention. The hypothesis that the control group's overall reading time would be faster than that of the CHI group was confirmed. Also confirmed was the hypothesis that the overall reading time pattern between task conditions would be neutral < habituation < Stroop < negative priming. The prediction that the CHI patients, due to their impaired inhibitory mechanism, would not show a slower reading time on the negative priming as compared to the Stroop condition, was confirmed as well. The theoretical and diagnostic implications of the results are discussed.	LOEWENSTEIN HOSP & REHABIL CTR,RAANANA,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL		VAKIL, E (corresponding author), BAR ILAN UNIV,DEPT PSYCHOL,IL-52900 RAMAT GAN,ISRAEL.						BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HASHER L, 1988, J EXPT PSYCHOL LEARN, V17, P163; Jennett B, 1981, MANAGEMENT HEAD INJU; LORCH EP, 1986, J EXPT CHILD PSYCHOL, V41, P84; LOWE DG, 1985, MEM COGNITION, V13, P74, DOI 10.3758/BF03198446; MATTSON AJ, 1990, J NERV MENT DIS, V178, P82; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NEILL WT, 1977, J EXP PSYCHOL HUMAN, V3, P444, DOI 10.1037/0096-1523.3.3.444; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Stroop JR, 1935, AM J PSYCHOL, V47, P499, DOI 10.2307/1416349; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TIPPER SP, 1989, J EXP CHILD PSYCHOL, V48, P353, DOI 10.1016/0022-0965(89)90047-7; TIPPER SP, 1985, Q J EXP PSYCHOL-A, V37, P591, DOI 10.1080/14640748508400921; TIPPER SP, 1985, Q J EXP PSYCHOL-A, V37, P571, DOI 10.1080/14640748508400920; Van Zomeren A. H., 1981, REACTION TIME ATTENT; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; [No title captured]	24	30	32	0	2	SWETS ZEITLINGER BV	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1995	17	3					335	342		10.1080/01688639508405127			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	RA265	WOS:A1995RA26500002	7650097				2022-02-06	
J	MAITZ, EA; SACHS, PR				MAITZ, EA; SACHS, PR			TREATING FAMILIES OF INDIVIDUALS WITH TRAUMATIC BRAIN INJURY FROM A FAMILY SYSTEMS PERSPECTIVE	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						AUTHORITY; FAMILY SYSTEMS; POWER; REHABILITATION; TRAUMATIC BRAIN INJURY	ADOLESCENTS	Research and clinical experience continue to demonstrate the impact of a traumatic brain injury on the entire family system and the importance of incorporating the family in the treatment process. Many authors have advocated for family education and support; however, there is less discussion of family therapy for families of individuals with traumatic brain injury. As a result, it has been difficult to apply research findings and clinical impressions to family treatment strategies. This article describes key treatment issues-specifically, power and authority-from a family systems perspective. Treatment recommendations are discussed that incorporate the special needs of families of individuals with traumatic brain injury within a family systems model.			MAITZ, EA (corresponding author), CLIN NEUROPSYCHOL ASSOCIATES,PHILADELPHIA,PA, USA.						BREUNLIN DC, 1992, METAFRAMEWORKS TRANS; BURR W, 1979, CONTEMPORARY THEORIE, V2; CAMPLER P, 1990, COMMUNITY INTEGRATIO; Carter E. A., 1980, FAMILY LIFE CYCLE FR; DEPOMPEI R, 1987, COGN REHABIL; EVANS RL, 1991, ARCH PHYS MED REHAB, V72, P144; FALICOV C, 1988, FAMILY T CONTINUITY; GLICK I, 1987, MARITAL FAMILY THERA; GURMAN AS, 1991, HDB FAMILY THERAPY, V2; Guttman H., 1991, HDB FAMILY THERAPY, VII; HALEY J, 1976, PROBLEM SOLVING THER; Hill R., 1949, FAMILIES STRESS; HOFFMAN L, 1981, F FAMILY THERAPY; KAY T, 1994, NEUROPSYCHIATRY TRAU; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KUBLERROSS E, 1962, DEATH DYING; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LIVINGSTON M, 1958, J HEAD TRAUMA REHABI, V3, P6; MALTZ E, 1991, HEAD INJURY FAMILY M; MARTIN DA, 1988, J LEARN DISABIL, V21, P464, DOI 10.1177/002221948802100803; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCLAUGHLIN AM, 1985, COGNITIVE REHABI JAN, P14; Minuchin S., 1974, FAMILIES FAMILY THER; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; NICHOLS M, 1984, FAMILY THERAPY CONCE; OLSON D, 1988, FAMILY T CONTINUITY; POWER PW, 1985, REHABIL LIT, V46, P78; Rolland JS., 1987, FAMILY SYST MED, V5, P482, DOI DOI 10.1037/H0089735; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; SACHS PR, 1991, TREATING FAMILIES BR; SAUBER SR, 1993, DICT FAMILY PSYCHOL; SLATER EJ, 1987, PSYCHIAT ANN, V17, P786, DOI 10.3928/0048-5713-19871201-08; TELSMANN M, 1982, J MARITAL FAM THER; WILLIAMS J, 1991, HEAD INJURY FAMILY M; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31; ZARSKI JJ, 1987, AM J FAM THER, V15, P62	37	30	30	0	4	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1995	10	2					1	11		10.1097/00001199-199504000-00003			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QR039	WOS:A1995QR03900003					2022-02-06	
J	THEODOROS, DG; MURDOCH, BE; STOKES, P				THEODOROS, DG; MURDOCH, BE; STOKES, P			A PHYSIOLOGICAL ANALYSIS OF ARTICULATORY DYSFUNCTION IN DYSARTHRIC SPEAKERS FOLLOWING SEVERE CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							AMYOTROPHIC LATERAL SCLEROSIS; MOTOR CONTROL; TRAUMATIC DYSARTHRIA; VOWEL DISTORTION; POSITION CONTROL; FORCE; IMPAIRMENTS	A physiological analysis of the lip and tongue function of a group of 18 severely closed-head injured (CHI) subjects was performed using lip and tongue force transduction systems. Lip and tongue strength, endurance and rate of repetitive movements were assessed on four non-speech tasks: maximum strength, sustained maximum strength, repetition of 10 maximum strength compressions, and maximum repetition rate. The values recorded were compared to those achieved by a soup of 18 non-neurologically impaired subjects, matched for age and sex, who served as the controls. The results of the study indicated that the CHI subjects demonstrated a significant impairment of lip and tongue function based on strength, endurance and rate bf repetitive movements, compared to the controls. While lip function was found to be significantly impaired on several measures of strength and endurance, tongue function was noted to be more severely compromised. The CHI subjects were found to exhibit a significantly reduced rate of repetitive movements of the lips and tongue. The results are discussed in relation to the effects of CHI on neuromuscular function and differential subsystem impairment in dysarthria. The clinical implications of these findings are also discussed in relation to the treatment of articulatory disturbances following severe CHI.	UNIV QUEENSLAND,DEPT SPEECH & HEARING,MOTOR SPEECH RES UNIT,BRISBANE,QLD 4072,AUSTRALIA				Murdoch, Bruce E/C-1397-2012; Theodoros, Deborah/F-1362-2010				Abbs J. H., 1983, CLIN DYSARTHRIA, P21; ABBS JH, 1987, NEUROLOGY, V37, P394, DOI 10.1212/WNL.37.3.394; ABBS JH, 1978, UNPUB LIP CLOSING FO; ABBS JH, 1982, SPEECH MOTOR CONTROL, P159; BARLOW SM, 1983, J SPEECH HEAR RES, V26, P616, DOI 10.1044/jshr.2604.616; BARLOW SM, 1986, EXP NEUROL, V94, P699, DOI 10.1016/0014-4886(86)90248-7; BARLOW SM, 1989, RECENT ADVANCES IN CLINICAL DYSARTHRIA, P53; BARLOW SM, 1984, NEUROLOGY, V34, P145, DOI 10.1212/WNL.34.2.145; BARLOW SM, 1990, J SPEECH HEAR RES, V33, P660, DOI 10.1044/jshr.3304.660; BARLOW SM, 1988, ASS RES OT ABSTR, V218; Brown J.R., 1975, MOTOR SPEECH DISORDE; DEPAUL R, 1988, NEUROLOGY, V38, P281, DOI 10.1212/WNL.38.2.281; DWORKIN JP, 1986, J COMMUN DISORD, V19, P115, DOI 10.1016/0021-9924(86)90015-8; DWORKIN JP, 1980, J SPEECH HEAR RES, V23, P828, DOI 10.1044/jshr.2304.828; GRIMBY L, 1981, J PHYSIOL-LONDON, V316, P545, DOI 10.1113/jphysiol.1981.sp013805; HUNKER CJ, 1982, NEUROLOGY NY, V32, P755; LANGMORE SE, 1994, J SPEECH HEAR RES, V37, P28, DOI 10.1044/jshr.3701.28; Marquardt TP, 1990, TRAUMATIC BRAIN INJU, P181; MCCLOSKEY DI, 1983, MOTOR CONTROL MECHAN, P151; MCNEIL MR, 1990, J SPEECH HEAR RES, V33, P255, DOI 10.1044/jshr.3302.255; NETSELL R, 1979, ARCH PHYS MED REHAB, V60, P502; Netsell R., 1985, SPEECH LANGUAGE EVAL, P363; NORUSIS MJ, 1990, SPSS PC PLUS STATIST; PORTNOY RA, 1982, J SPEECH HEAR DISORD, V47, P324, DOI 10.1044/jshd.4703.324; ROBIN DA, 1991, DYSARTHRIA AND APRAXIA OF SPEECH, P173; ROBIN DA, 1992, J SPEECH HEAR RES, V35, P1239, DOI 10.1044/jshr.3506.1239; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; STIERWALT JG, 1994, C MOTOR SPEECH SEDON; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; VOGEL M, 1983, FOLIA PHONIATR, V35, P294, DOI 10.1159/000265705; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P239, DOI 10.1055/s-2008-1064200; ZIEGLER W, 1983, PHONETICA, V40, P63; ZIEGLER W, 1983, PHONETICA, V40, P312, DOI 10.1159/000261698; [No title captured]	34	30	31	0	1	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	APR	1995	9	3					237	254		10.3109/02699059509008196			18	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QR499	WOS:A1995QR49900003	7606237				2022-02-06	
J	MAX, JE; SMITH, WL; LINDGREN, SD; ROBIN, DA; MATTHEIS, P; STIERWALT, J; MORRISEY, M				MAX, JE; SMITH, WL; LINDGREN, SD; ROBIN, DA; MATTHEIS, P; STIERWALT, J; MORRISEY, M			CASE-STUDY - OBSESSIVE-COMPULSIVE DISORDER AFTER SEVERE TRAUMATIC BRAIN INJURY IN AN ADOLESCENT	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						OBSESSIVE-COMPULSIVE DISORDER; TRAUMATIC BRAIN INJURY; CHILDREN AND ADOLESCENTS	HEAD-INJURY; DEPRESSION	The neurological underpinnings of obsessive-compulsive disorder (OCD) are still largely undetermined. We report a prospective case study of a young subject who developed OCD and impulsive aggression after traumatic brain injury. The implications are that frontal and temporal lobe lesions may be sufficient to precipitate OCD in the absence of clear striatal injury and that compulsivity and impulsivity may represent different psychophysiological states.	UNIV IOWA,DEPT RADIOL,IOWA CITY,IA 52242; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242; UNIV IOWA,DEPT SPEECH PATHOL & AUDIOL,IOWA CITY,IA 52242		MAX, JE (corresponding author), UNIV IOWA,DEPT PSYCHIAT,200 HAWKINS DR,1876 JPP,IOWA CITY,IA 52242, USA.		Robin, Donald/F-2109-2010				Adams W., 1990, WIDE RANGE ASSESSMEN; BAXTER LR, 1990, J CLIN PSYCHIAT, V51, P61; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; Benton A.L., 1983, CONTRIBUTIONS NEUROP; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Damasio H., 1989, LESION ANAL NEUROPSY; DONOVAN NJ, 1994, AM J PSYCHIAT, V151, P618; Dunn LM., 1981, PEABODY PICTURE VOCA; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FLAMENT MF, 1988, J AM ACAD CHILD PSY, V27, P764, DOI 10.1097/00004583-198811000-00018; German D.J., 1986, TEST WORD FINDING; Goldstein K, 1952, PSYCHIATR, V15, P245, DOI 10.1080/00332747.1952.11022878; Goodman W. K., 1991, CHILDRENS YALE BROWN; Hamsher K., 1989, MULTILINGUAL APHASIA; HILLBOM E, 1960, ACTA PSYCHIAT NEUROL, V6142, P35; INSEL TR, 1992, ARCH GEN PSYCHIAT, V49, P739; KETTL PA, 1986, BRIT J PSYCHIAT, V149, P315, DOI 10.1192/bjp.149.3.315; KROLL L, 1993, J NERV MENT DIS, V181, P457, DOI 10.1097/00005053-199307000-00011; LINDGREN SD, 1984, PEDIATRIC ASSESSMENT; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; McElroy S. L., 1993, DEPRESSION, V1, P121; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; Michael AJ, 1988, J ANXIETY DISORD, V4, P353, DOI DOI 10.1016/0887-6185(88)90030-8; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; RAUCH SL, 1994, ARCH GEN PSYCHIAT, V51, P62; TEASDALE G, 1974, LANCET, V2, P81; *US DEP HLTH HUM S, 1989, INT HEAD INJ TASK FO; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD	29	30	30	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JAN	1995	34	1					45	49		10.1097/00004583-199501000-00012			5	Psychology, Developmental; Pediatrics; Psychiatry	Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	QD725	WOS:A1995QD72500013	7860455				2022-02-06	
J	CARREL, M; MOESCHLER, O; RAVUSSIN, P; FAVRE, JB; BOULARD, G				CARREL, M; MOESCHLER, O; RAVUSSIN, P; FAVRE, JB; BOULARD, G			AEROMEDICAL PREHOSPITAL NEUROTRAUMA CARE AND SECONDARY SYSTEMIC INSULTS TO THE INJURED BRAIN	ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION			French	Article								Advanced supportive therapy at the site of the accident, associated with direct transfer to a trauma centre increases survival and reduces morbidity rates. Patients with severe head injury, especially those with multiple injuries, often arrive in the emergency department with potentially causes of serious secondary systemic insults to the already injured brain, such as acute anemia (Hematocrit less-than-or-equal-to 30%), hypotension (systolic arterial pressure (Pa(sys)) less-than-or-equal-to 95 mmHg, 12,7 kPa), hypercapnia (Paco2 greater-than-or-equal-to 45 mmHg, 6 kPa) and/or hypoxemia (Pao2 less-than-or-equal-to 65 mmHg, 8,7 kPa). The incidence of such insults and their impact on mortality were studied in a group of 51 consecutive adults suffering from non penetrating severe head injury (Glasgow score less-than-or-equal-to 8, mean age 31 +/- 17 yrs) rescued by a medicalised helicopter. Each patient received medical care on the site of the accident by an anaesthesiologist of a university hospital (UH) complying with an advanced trauma life support protocol including intubation, hyperventilation with FIO2 = 1, restoration of an adequate Pa(sys) and direct transportation to the UH. Mean delay from call to arrival of the rescue team on the site was 15 +/- 5 min. Mean scene time was 32 +/- 10 min in cases not requiring extrication. Nineteen patients (Group I) were admitted without secondary systemic insults to the brain, 13 with isolated head injury, and 6 with multiple injuries, with a low Glasgow Outcome Score (GOS 1-3) of 42 % at 3 months. In 32 patients (Group II), despite advanced supportive measures a the scene of the accident and during transportation, one or more secondary systemic insults to the brain were detected upon arrival at the emergency room, one with isolated head injury, 31 with multiple injuries, with a bad GOS of 72 % at 3 months. We conclude that : 1) advanced trauma life support prevents from secondary systemic insults in the great majority of isolated severe head injured patients, 2) secondary systemic insults to the already injured brain are frequent in patients with multiple injuries and are difficult to avoid despite rapid aeromedical trauma care, 3) secondary systemic insults to the brain have a catastrophic impact on the outcome of severely head injured patients.	CHU VAUDOIS,SERV ANESTHESIOL,CH-1011 LAUSANNE,SWITZERLAND				Moeschler, Olivier/B-1694-2008					0	30	30	0	0	EDITIONS SCIENTIFIQUES ELSEVIER	PARIS CEDEX 15	141 RUE JAVEL, 75747 PARIS CEDEX 15, FRANCE	0750-7658			ANN FR ANESTH	Ann. Fr. Anest. Reanim.		1994	13	3					326	335		10.1016/S0750-7658(94)80041-3			10	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	NX499	WOS:A1994NX49900009	7992940				2022-02-06	
J	DONDERS, J				DONDERS, J			MEMORY FUNCTIONING AFTER TRAUMATIC BRAIN INJURY IN CHILDREN	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; ADOLESCENTS	Immediate and 45-minute delayed recall of a paragraph-length story and of a complex geometric figure were investigated in a sample of 30 children with traumatic brain injury. There was no significant difference between children with mild to moderate injuries and children with severe injuries with regard to general level of verbal recall. However, there was a trend for children with mild to moderate injuries to have better recall of visual information than children with severe injuries. Recall of verbally presented information deteriorated significantly over the 45-minute delay, regardless of injury severity. No such deterioration was found for recall of visually presented information. Clinical and research implications are discussed.			DONDERS, J (corresponding author), MARY FREE BED HOSP,235 WEALTHY SE,GRAND RAPIDS,MI 49503, USA.						BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Denman S.B., 1987, DENMAN NEUROPSYCHOLO; Denman S.B, 1984, DENMAN NEUROPSYCHOLO; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; PARENTE R, 1991, COGNITIVE REHABILITA, P147; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Wechsler D., 1974, WECHSLER INTELLIGENC; WILSON B, 1987, REHABILITATION MEMOR; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	16	30	31	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP-OCT	1993	7	5					431	437		10.3109/02699059309029686			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	MA172	WOS:A1993MA17200006	8401485				2022-02-06	
J	SILVERMAN, IE; GALETTA, SL; GRAY, LG; MOSTER, M; ATLAS, SW; MAURER, AH; ALAVI, A				SILVERMAN, IE; GALETTA, SL; GRAY, LG; MOSTER, M; ATLAS, SW; MAURER, AH; ALAVI, A			SPECT IN PATIENTS WITH CORTICAL VISUAL-LOSS	JOURNAL OF NUCLEAR MEDICINE			English	Article							POSITRON EMISSION TOMOGRAPHY; CEREBRAL METABOLISM; ALZHEIMERS-DISEASE; STATUS EPILEPTICUS; STIMULATION; CORTEX; SYSTEM	Single-photon emission computed tomography (SPECT) with Tc-99m-hexamethyl propyleneamine oxime (HMPAO) was used to investigate changes in cerebral blood flow in seven patients with cortical visual impairment. Traumatic brain injury (TBI) was the cause of cortical damage in two patients, cerebral ischemia in two patients and carbon monoxide (CO) poisoning, status epilepticus and Alzheimer's Disease (AD) each in three separate patients. The SPECT scans of the seven patients were compared to T2-weighted magnetic resonance image (MRI) scans of the brain to determine the correlation between functional and anatomical findings. In six of the seven patients, the qualitative interpretation of the SPECT studies supported the clinical findings (i.e., the visual field defect) by revealing altered regional cerebral blood flow (rCBF) in the appropriate regions of the visual pathway. MR scans in all of the patients, on the other hand, were either normal or disclosed smaller lesions than those detected by SPECT. We conclude that SPECT may reveal altered rCBF in patients with cortical visual impairment of various etiologies, even when MRI studies are normal or nondiagnostic.	TEMPLE UNIV, DEPT NEUROL & NUCL MED, PHILADELPHIA, PA 19122 USA; UNIV PENN, DEPT NEUROL, DIV NEURORADIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT RADIOL, DIV NUCL MED, PHILADELPHIA, PA 19104 USA						EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35HD007217] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T35-HD-07217-11] Funding Source: Medline		Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; ALAVI A, 1991, SEMIN NUCL MED, V21, P58, DOI 10.1016/S0001-2998(05)80079-0; BAUER J, 1989, J NEUROL, V236, P296, DOI 10.1007/BF00314460; BOSLEY TM, 1985, NEUROLOGY, V35, P470, DOI 10.1212/WNL.35.4.470; BRYAN RN, 1991, MAGNETIC RESONANCE I, P411; CELESIA GG, 1991, NEUROLOGY, V41, P862, DOI 10.1212/WNL.41.6.862; FUJIWARA T, 1991, EPILEPSIA, V32, P650, DOI 10.1111/j.1528-1157.1991.tb04704.x; GENTRY LR, 1991, MAGNETIC RESONANCE I, P439; HOLMAN BL, 1992, J NUCL MED, V33, P181; JIBIKI I, 1991, EUR NEUROL, V31, P149, DOI 10.1159/000116665; KIYOSAWA M, 1989, OPHTHALMOLOGY, V96, P1077; KUMAR A, 1991, INT J GERIATR PSYCH, V6, P775, DOI 10.1002/gps.930061104; KUSHNER MJ, 1988, NEUROLOGY, V38, P89, DOI 10.1212/WNL.38.1.89; Kuwabara Y, 1990, Ann Nucl Med, V4, P75; PHELPS ME, 1981, NEUROLOGY, V31, P517, DOI 10.1212/WNL.31.5.517; STECKER MM, 1992, J NUCL MED, V35, P928; WOODS SW, 1991, J NUCL MED, V32, P210	17	30	30	0	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	SEP	1993	34	9					1447	1451					5	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	LU701	WOS:A1993LU70100016	8355062				2022-02-06	
J	BJORNSTIG, U; OSTROM, M; ERIKSSON, A; SONNTAGOSTROM, E				BJORNSTIG, U; OSTROM, M; ERIKSSON, A; SONNTAGOSTROM, E			HEAD AND FACE INJURIES IN BICYCLISTS - WITH SPECIAL REFERENCE TO POSSIBLE EFFECTS OF HELMET USE	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SAFETY HELMETS; ACCIDENTS; CHILDREN; CRASHES; SWEDEN	Fatal and nonfatal head and face injuries to unhelmeted bicyclists were analyzed to assess the injury-reducing potential of bicycle helmet use. Of the fatally injured, 64% (median age, 55 years) had fatal head and face injuries compared with 38% (median age, 18 years) with head and face injuries in the nonfatal injury group. The fatally injured often had multiple impact points, mostly to the occipital and temporal regions. Brain contusions, most often to the frontal and temporal lobes, were the most common cause of fatal injury, followed by subdural hematomas. In the nonfatal injury group abrasions/lacerations were most common type of injury, followed by cerebral concussions/contusions and superficial contusions. If all types of injuries to bicyclists are taken into account a helmet might have had an injury-reducing effect in two of every five fatal cases and in one of every five nonfatal cases. To increase the helmet use among bicyclists, a law, as in Australia, would be an excellent instrument.	REG HOSP UMEA,UMEA,SWEDEN; UMEA UNIV,DEPT FORENS MED,S-90185 UMEA,SWEDEN; UMEA UNIV,UMEA ACCIDENT ANAL GRP,S-90185 UMEA,SWEDEN; UNIV MICHIGAN,TRANSPORTAT RES INST,ANN ARBOR,MI 48109								ALDMAN B, 1978, 3RD P INT IRCOBI C L, P118; [Anonymous], 1990, ABBREVIATED INJURY S; BADER M, 1990, JAMA-J AM MED ASSOC, V263, P1914, DOI 10.1001/jama.263.14.1914; BERGMAN AB, 1990, AM J DIS CHILD, V144, P727, DOI 10.1001/archpedi.1990.02150300127033; BJORNSTIG U, 1984, ACTA CHIR SCAND, V150, P353; BJORNSTIG UL, 1985, ACTA CHIR SCAND, V151, P577; BURG A, 1971, HUM FACTORS, V13, P79, DOI 10.1177/001872087101300110; DIGUISEPPI CG, 1990, AM J DIS CHILD, V144, P83, DOI 10.1001/archpedi.1990.02150250093041; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; EVANS L, 1991, TRAFFIC SAFETY DRIVE, P25; FIFE D, 1983, J TRAUMA, V23, P745, DOI 10.1097/00005373-198308000-00011; GENARELLI TA, 1984, BIOMECHANICS IMPACT, P103; GUICHON DMP, 1975, J TRAUMA, V15, P504, DOI 10.1097/00005373-197506000-00009; HOWLAND J, 1989, AM J DIS CHILD, V143, P741, DOI 10.1001/archpedi.1989.02150180123033; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; LEICESTER P, 1991, GR914REP; LIND MG, 1986, ACTA CHIR SCAND    S, P531; MILLS NJ, 1991, ACCIDENT ANAL PREV, V23, P153, DOI 10.1016/0001-4575(91)90045-7; MORGAN M, 1991, GR919; OMMAYA AK, 1984, BIOMECHANICS IMPACT, P117; OMMAYA AK, 1988, 32ND P ANN M ASS ADV; OSTROM M, IN PRESS INT J EPIDE; RIVARA FP, 1990, JAMA-J AM MED ASSOC, V263, P1915, DOI 10.1001/jama.1990.03440140034017; SANDELS S, 1972, SMA BARN TRAFIKEN; SCIALFA CT, 1987, 31ST P ANN M HUM FAC, P558; SJOGREN H, 1991, ACCIDENT ANAL PREV, V23, P77, DOI 10.1016/0001-4575(91)90037-6; SOSIN DM, 1990, JAMA-J AM MED ASSOC, V264, P2395, DOI 10.1001/jama.264.18.2395; STUTTS JC, 1990, ACCIDENT ANAL PREV, V22, P67, DOI 10.1016/0001-4575(90)90008-9; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1388, DOI 10.2105/AJPH.80.11.1388; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; WASSERMAN RC, 1988, AM J PUBLIC HEALTH, V78, P1220, DOI 10.2105/AJPH.78.9.1220; WESTMAN E, 1983, PEOPLE ROAD OFFICIAL, P11; WILLIAMS M, 1991, ACCIDENT ANAL PREV, V23, P119, DOI 10.1016/0001-4575(91)90043-5; WOOD T, 1988, ACCIDENT ANAL PREV, V20, P177, DOI 10.1016/0001-4575(88)90002-4; WORELL J, 1987, INJURY, V18, P5; 1982, INT STATISTICAL CLAS; 1982, ACCIDENT FACTS, P45; 1990, LIGHTWEIGHT PROTECTI; 1987, MORBIDITY MORTALITY, V32, P269; 1989, BICYCLE I AM BICYCLI; 1985, KONSUMENTVERKETS FOR; 1990, TRAFFIC INJURIES 198; 1984, ANSIZ9041984 AM NAT; 1990, FATAL ACCIDENT REPOR; 1982, LIGHTWEIGHT PROTECTI; 1982, NEISS DATA HIGHLIGHT, V6	47	30	32	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1992	33	6					887	893					7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	KF879	WOS:A1992KF87900016	1474633				2022-02-06	
J	SCHMOKER, JD; SHACKFORD, SR; WALD, SL; PIETROPAOLI, JA				SCHMOKER, JD; SHACKFORD, SR; WALD, SL; PIETROPAOLI, JA			AN ANALYSIS OF THE RELATIONSHIP BETWEEN FLUID AND SODIUM ADMINISTRATION AND INTRACRANIAL-PRESSURE AFTER HEAD-INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	22ND ANNUAL MEETING OF THE WESTERN TRAUMA ASSOC	FEB 29-MAR 07, 1992	STEAMBOAT SPRINGS, CO	W TRAUMA ASSOC			BRAIN; TRAUMA; SYSTEM; CATECHOLAMINES; HYPONATREMIA; MANAGEMENT; EDEMA	Severe head injury is the leading cause of traumatic death. When a severe head injury is combined with hypotension the mortality doubles. The use of asanguineous salt solutions to maintain blood pressure, however, may contribute to cerebral swelling and intracranial hypertension. For this reason, restrictions of fluids (FLD) and sodium (Na) have been advocated. To our knowledge, however, there are no clinical data to support this recommendation. We hypothesized that in adult patients sustaining severe head injuries (Glasgow Coma Scale score less-than-or-equal-to 8) with or without associated injuries: (1) FLD balance and total Na administered during the initial 72 hours of hospital admission are positively and significantly correlated with each other, and (2) total FLD, FLD balance, and total Na administration during the initial 72 hours are significantly and positively correlated with changes in ICP and adverse outcome. We retrospectively studied 40 adult trauma patients with severe head injuries. We found a significant correlation between total Na and FLD balance (R2 = 0.54; p < 0.05). However, we found no significant correlation between total FLD and maximum ICP (R2 = 0.081), ICP score (R2 = 0.01), or outcome (R2 = 0.066), no significant correlation between FLD balance and maximum ICP (R2 = 0.000), ICP score (R2 = 0.000), or outcome (R2 = 0.01), and no significant correlation between total Na and maximum ICP (R2 = 0.000), ICP score (R 2 = 0.001), or outcome (R2 = 0.02). We conclude that Na and FLD administration are not independent determinants of ICP during the initial 72 hours after brain injury.	UNIV VERMONT,COLL MED,DEPT SURG,BURLINGTON,VT 05405; UNIV VERMONT,COLL MED,DIV NEUROSURG,BURLINGTON,VT 05405						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030324] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS30324-01] Funding Source: Medline		[Anonymous], 1990, ABBREVIATED INJURY S; BECKER DP, 1972, INTRACRANIAL PRESSUR, V1, P309; BIRKHAHN RH, 1980, SURGERY, V88, P294; BLAND JE, 1968, NEUROLOGY, V18, P821, DOI 10.1212/WNL.18.8.821; BOUZARTH WF, 1982, LANCET, V1, P1061; BOWERS SA, 1980, NEUROSURGERY, V6, P237; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; FEUSTEL PJ, 1990, J TRAUMA, V30, P1259, DOI 10.1097/00005373-199010000-00011; FOX JL, 1971, J NEUROSURG, V34, P506, DOI 10.3171/jns.1971.34.4.0506; GO KG, 1972, J NEUROL SCI, V16, P209, DOI 10.1016/0022-510X(72)90090-1; Go KG, 1991, CEREBRAL PATHOPHYSIO, P66; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; JENNETT B, 1972, LANCET, V1, P734; KIEN CL, 1978, ANN SURG, V187, P3837; KINNEY VM, 1966, P C ENERGY METABOLIS, P173; MCLAURIN RL, 1960, SURG GYNECOL OBSTET, V110, P282; MEYER WJ, 1983, SURG CLIN N AM, V63, P401; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Parent A D, 1972, J Neurosurg Nurs, V4, P9; REULEN HJ, 1976, BRIT J ANAESTH, V48, P741, DOI 10.1093/bja/48.8.741; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCALEA T, 1991, J TRAUMA, V31, P1720; SCHMOKER J, 1991, Journal of Trauma, V31, P1038, DOI 10.1097/00005373-199107000-00091; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHENKIN HA, 1976, J NEUROSURG, V45, P432, DOI 10.3171/jns.1976.45.4.0432; Shoemaker W C, 1974, Crit Care Med, V2, P317, DOI 10.1097/00003246-197411000-00006; SHOEMAKER WC, 1982, CRIT CARE MED, V10, P398, DOI 10.1097/00003246-198206000-00015; Starling E H, 1896, J Physiol, V19, P312; TEASDALE G, 1974, LANCET, V2, P81; WALD S, 1991, Journal of Trauma, V31, P1041, DOI 10.1097/00005373-199107000-00102; WILMORE DW, 1974, ANN SURG, V180, P653, DOI 10.1097/00000658-197410000-00031; ZHUANG J, 1991, J TRAUMA, V31, P1722; [No title captured]	37	30	32	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1992	33	3					476	481		10.1097/00005373-199209000-00024			6	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	JR171	WOS:A1992JR17100024	1404521				2022-02-06	
J	ROBERTS, WO				ROBERTS, WO			WHO PLAYS - WHO SITS - MANAGING CONCUSSIONS ON THE SIDELINES	PHYSICIAN AND SPORTSMEDICINE			English	Article								Allowing a player to return to competition too soon after a concussion may result in further injury or even death. By carefully evaluating and monitoring an athlete who sustains a concussion, then classifying the concussion by severity, the physician can determine whether the athlete can safely return to play.			ROBERTS, WO (corresponding author), MINNHEALTH PA,WHITE BEAR LAKE,MN, USA.			Roberts, William O/0000-0003-4517-4330				0	30	30	0	1	MCGRAW HILL HEALTHCARE PUBLICATIONS	MINNEAPOLIS	4530 WEST 77TH ST, MINNEAPOLIS, MN 55435-5000	0091-3847			PHYSICIAN SPORTSMED	Physician Sportsmed.	JUN	1992	20	6					66	72					7	Primary Health Care; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Orthopedics; Sport Sciences	HX590	WOS:A1992HX59000011	27438927				2022-02-06	
J	KIRSCHNER, CE; GRANTZ, A; MULLEN, MW				KIRSCHNER, CE; GRANTZ, A; MULLEN, MW			IMPACT ORIGIN OF THE AVAK STRUCTURE, ARCTIC ALASKA, AND GENESIS OF THE BARROW GAS-FIELDS	AAPG BULLETIN-AMERICAN ASSOCIATION OF PETROLEUM GEOLOGISTS			English	Article								Geophysical and subsurface geologic data suggest that the Avak structure. which underlies the Arctic Costal Plain 12 km southeast of Barrow, Alaska, is a hypervelocity meteorite or comet impact structure. The structure is a roughly circular area of uplifted, chaotically deformed Upper Triassic to Lower Cretaceous sedimentary rocks 8 km in diameter that is bounded by a ring of anastomosing, inwardly dipping, listric normal faults 12 km in diameter. A zone of gently outward-dipping sedimentary country rocks forms a discontinuous ring of "rim anticlines" within the peripheral ring of normal faults. Beyond these anticlines, the sedimentary rocks are almost flat-living. Basement consists of strongly deformed ordovician and Silurian argillite. Density and acoustic impedance contrasts between the argillite and the overlying strata produce gravity and seismic-reflection signatures that define a ring of anticlines around the disturbed zone and a structural high surrounded by an annular structural low at its center. In the adjacent Barrow gas fields, the tops of the informally named Neocomian "pebble shale" unit and the gas-producing Lower Jurassic Barrow sand (local usage) lie at average subsea depths of 488 m and 670 m, respectively. In the Avak 1 well, drilled on the central high, the pebble shale and the Barrow sand lie near the surface, documenting more than 500 m of relative uplift at the high. The cores in this well have steep dips (30-90-degrees), mixed breccia with Franklinian argillite clasts 10 and 90 m above basement, quartz grains with shock mosaicism and multiple sets of shock lamellae, oriented concussion fractures in sand-size quartz grains, and shatter cones resembling those found in the peripheral zones of well-documented impact structures. In addition, above-background levels of fractured quartz grains in Barrow sand were found as far as 19 km beyond the rim of the Avak structure. Data concerning the age of the Avak structure are not definitive. If submarine landslide deposits in the upper part of the Aptian and Albian Torok Formation, in the subsurface 200 km to the east, were triggered by the Avak event, then the Avak meteorite struck a submerged marine shelf about 100 +/- 5 Ma. However, the impact features found at Avak (shatter cones, concussion fractures, shock lamellae and shock mosaicism in quartz grains, and widespread cataclasis) characterize, the distal zones of meteorite impact structures. Fused rocks, plastic deformation. and shock-metamorphic minerals found in more proximal zones of impact structures are apparently missing. These observations. and the lack of Avak ejecta in cuttings and cores from the Torok Formation and Nanushuk Group (Albian to middle Cenomanian) in surrounding test wells, indicate that the impact event postdated these beds. In this case, the Avak meteorite Struck a Late Cretaceous or Tertiary marine shelf or coastal plain between the Cenomanian (ca. 95 Ma), and deposition of the basal beds of the overlying late Pliocene and Quaternary Gubik Formation (ca. 3 Ma).	US GEOL SURVEY,MENLO PK,CA 94025		KIRSCHNER, CE (corresponding author), US GEOL SURVEY,POB 154,UNION,WA 98592, USA.						BRUYNZEEL JW, 1982, PETROLEUM EXPLORATIO; CARTER C, 1975, AAPG BULL, V59, P457; CARTER NL, 1965, AM J SCI, V263, P747, DOI 10.2475/ajs.263.9.747; Collins F. R., 1961, US GEOLOGICAL SURVEY, P569; COLLINS FR, 1967, USGS287 OP FIL REP; Dence M.R., 1968, SHOCK METAMORPHISM N, P169; Dietz R.S., 1968, SHOCK METAMORPHISM N, P87; DIETZ RS, 1960, SCIENCE, V131, P1781, DOI 10.1126/science.131.3416.1781; DIETZ RS, 1947, SCIENCE, V105, P42, DOI 10.1126/science.105.2715.42; Eardley A. J., 1951, STRUCTURAL GEOLOGY N; Grantz A., 1990, ARCTIC OCEAN REGION, VL, P257; GUTMAN SI, 1982, GRAVITY MAGNETIC INV; IZETT GA, 1990, 249 GEOL SOC AM SP P; KIEFFER SW, 1971, J GEOPHYS RES, V76, P5449, DOI 10.1029/JB076i023p05449; KIRSCHNER CE, 1988, USGS1399 PROF PAP; KIRSCHNER CE, 1990, AAPG BULL, V74, P696; KIRSCHNER CE, 1983, USGS911 CIRC, P24; KIRSCHNER CE, 1984, GEOLOGICAL SOC AM, P293; LANTZ RJ, 1981, OIL GAS J, V79, P197; MICKEY MB, 1987, ALASKAN N SLOPE GEOL, V1, P397; MILTON DJ, 1972, SCIENCE, V175, P1199, DOI 10.1126/science.175.4027.1199; MOLENAAR CM, 1987, ALASKAN N SLOPE GEOL, V1, P513; MOLENAAR CM, 1981, USGS811084 OP FIL RE; PALMER AR, 1983, DECADE N AM GEOLOGY; ROCKWELL DW, 1981, USGS1408000116474 HU; Stoffler D., 1972, FORTSCHRITTE MINERAL, V49, P50; THURSTON DK, 1991, GEOLOGY, V19, P477, DOI 10.1130/0091-7613(1991)019<0477:SEOEDI>2.3.CO;2; WEIMER P, 1987, ALASKAN N SLOPE GEOL, V1, P481; WILSHIRE HG, 1972, USGS599H PROF PAP; WILSON CW, 1968, TENNESSEE DIV GEOL B, V68; WOOLSON JR, 1962, USGS304A PROF PAP	31	30	30	0	4	AMER ASSOC PETROLEUM GEOLOGIST	TULSA	1444 S BOULDER AVE, PO BOX 979, TULSA, OK 74101	0149-1423			AAPG BULL	AAPG Bull.-Am. Assoc. Petr. Geol.	MAY	1992	76	5					651	679					29	Geosciences, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Geology	HR238	WOS:A1992HR23800005					2022-02-06	
J	CREMONAMETEYARD, SL; CLARK, CR; WRIGHT, MJ; GEFFEN, GM				CREMONAMETEYARD, SL; CLARK, CR; WRIGHT, MJ; GEFFEN, GM			COVERT ORIENTATION OF VISUAL-ATTENTION AFTER CLOSED HEAD-INJURY	NEUROPSYCHOLOGIA			English	Article								The ability to orient visual attention covertly was studied in 11 patients who had suffered a moderate or severe closed head injury (CHI) at least 1 year previously. Their performance was compared to nine matched controls using a cued reaction time (RT) task which measured the RT benefit of valid directional cueing and the RT cost of miscueing. The CHI and control groups did not differ in overall RT. Relative to controls, the CHI group showed normal cost but hardly any benefit, indicating that the normal capacity to pre-align attention with a cued location was impaired.	UNIV QUEENSLAND, DEPT PSYCHOL, COGNIT PSYCHOPHYSIOL LAB, ST LUCIA, QLD 4067, AUSTRALIA				Wright, Margaret J/H-3308-2014; Wright, Margaret Jane/A-4560-2016; clark, christopher richard/B-3525-2012	Wright, Margaret Jane/0000-0001-7133-4970; 			BROOKWS H, 1984, CLOSED HEAD INJURY P; CLARK CR, 1989, NEUROPSYCHOLOGIA, V27, P131, DOI 10.1016/0028-3932(89)90166-8; DFRIVER J, 1989, J EXP PSYCHOL HUMAN, V16, P448; ERIKSEN CW, 1987, PERCEPT PSYCHOPHYS, V42, P299, DOI 10.3758/BF03203082; GAZZANIGA MS, 1962, P NATL ACAD SCI USA, V48, P1765, DOI 10.1073/pnas.48.10.1765; GEFFEN GM, 1991, J CLIN EXP NEUROPSYC, V13, P423; KEPPEL S, 1982, DESIGN ANAL RES HDB; Levin HS., 1982, NEUROBEHAVIORAL CONS; MILLER E, 1969, CORTEX, V6, P132; MOUNTCASTLE VB, 1978, J ROY SOC MED, V71, P14; PETERSEN SE, 1985, J NEUROPHYSIOL, V54, P867, DOI 10.1152/jn.1985.54.4.867; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; Posner MI, 1975, INFORM PROCESSING CO, P55; POSNER MI, 1982, MODES PERCEIVING PRO, V298, P197; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SHUM DHK, 1988, J CLIN EXPT NEUROPSY, V12, P125; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; Vogenthaler D R, 1987, Brain Inj, V1, P113; WRIGHT MJ, 1990, NEUROPSYCHOLOGIA, V28, P151, DOI 10.1016/0028-3932(90)90097-8; [No title captured]	24	30	30	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	FEB	1992	30	2					123	132		10.1016/0028-3932(92)90022-E			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	HG882	WOS:A1992HG88200002	1560891				2022-02-06	
J	WERNER, RA; VANDERZANT, CW				WERNER, RA; VANDERZANT, CW			MULTIMODALITY EVOKED-POTENTIAL TESTING IN ACUTE MILD CLOSED HEAD-INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						EVOKED POTENTIALS; AUDITORY; EVOKED POTENTIALS; SOMATOSENSORY; EVOKED POTENTIALS; VISUAL; HEAD INJURIES	BRAIN-STEM RESPONSES; CONCUSSION; SYMPTOMS; PROGNOSIS	Multimodality evoked potential (MEP) testing, including brainstem auditory, visual, and somatosensory evoked potentials, have been reported to be useful in predicting outcome i in severe closed head injury. Brainstem auditory evoked potentials have been demonstrated to be abnormal in 10% to 40% of acute mild head injury. A prospective study of 18 patients with mild closed head injury was undertaken to determine the usefulness of MEP screening within two weeks of the acute event. Long latency event-related potentials (P300s), in response to auditory stimuli with an oddball paradigm, were included in the screening. The subjects had several symptoms consistent with the postconcussive syndrome at the time of the evoked potential testing. Only one patient had an abnormal evoked potential response (greater than three standard deviations from the mean) from all the testing done. The standard methods of MEP testing were insensitive to quantifying the possible physiologic changes that are associated with memory deficits, lethargy, and emotional irritability after mild closed head injury.	UNIV MICHIGAN,MED CTR,DEPT NEUROL,ANN ARBOR,MI 48109		WERNER, RA (corresponding author), UNIV MICHIGAN,MED CTR,DEPT PHYS MED & REHABIL,BOX 0042,1500 E MED CTR DR,ANN ARBOR,MI 48109, USA.						BENNA P, 1982, ITAL J NEUROL SCI, V3, P281, DOI 10.1007/BF02043575; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CHIAPPA KH, 1982, NEW ENGL J MED, V306, P1140, DOI 10.1056/NEJM198205133061904; DRAKE ME, 1987, CLIN EVOKED POTENTIA, V5, P19; Greenberg R P, 1979, Acta Neurochir Suppl (Wien), V28, P50; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Levin HS., 1982, NEUROBEHAVIORAL CONS; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NEWLON PG, 1985, NEUROL CLIN, V3, P675, DOI 10.1016/S0733-8619(18)31029-6; NORDBY HK, 1984, ACTA NEUROCHIR, V71, P205, DOI 10.1007/BF01401315; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P138, DOI 10.1016/0013-4694(86)90007-6; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P167, DOI 10.1177/155005948101200403; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; RUTH RA, 1982, 1982 AM SPEECH HEAR; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; Schoenhuber R, 1983, J Neurosurg Sci, V27, P157; SCHOENHUBER R, 1985, EVOKED POTENTIALS NE, P237; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; 1984, J CLIN NEUROPHYSL, V1, P3	26	30	31	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1991	72	1					31	34					4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	ET653	WOS:A1991ET65300008	1985621				2022-02-06	
J	BASSETT, SS; SLATER, EJ				BASSETT, SS; SLATER, EJ			NEUROPSYCHOLOGICAL FUNCTION IN ADOLESCENTS SUSTAINING MILD CLOSED HEAD-INJURY	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article									UNIV MARYLAND,COLLEGE PK,MD 20742						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-240510] Funding Source: Medline		BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Benton A., 1976, MULTILINGUAL APHASIA; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; GAILBRAITH S, 1977, SCOTTISH MED J, V22, P129; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kirk RE, 1968, EXPT DESIGN; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENBERRY T L, 1980, Neurochemistry International, V2, P135, DOI 10.1016/0197-0186(80)90020-0; RUTTER M, 1983, DEV NEUROPSYCHIATRY; TEASDALE G, 1974, LANCET, V2, P81; TOTTEN J, 1979, LANCET, V1, P369; *US DEPT WAR, 1944, ARM IND TEST BATT MA; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1974, WECHSLER ADULT INTEL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	26	30	30	0	0	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	APR	1990	15	2					225	236		10.1093/jpepsy/15.2.225			12	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	DJ074	WOS:A1990DJ07400005	2374077				2022-02-06	
J	LEVIN, HS; AMPARO, EG; EISENBERG, HM; MINER, ME; HIGH, WM; EWINGCOBBS, L; FLETCHER, JM; GUINTO, FC				LEVIN, HS; AMPARO, EG; EISENBERG, HM; MINER, ME; HIGH, WM; EWINGCOBBS, L; FLETCHER, JM; GUINTO, FC			MAGNETIC-RESONANCE IMAGING AFTER CLOSED HEAD-INJURY IN CHILDREN	NEUROSURGERY			English	Article									UNIV TEXAS,MED BRANCH,DEPT RADIOL,GALVESTON,TX 77550; UNIV TEXAS,SCH MED,DIV NEUROSURG,HOUSTON,TX 77025; UNIV TEXAS,SCH MED,DEPT PSYCHIAT & BEHAV SCI,HOUSTON,TX 77025; UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX 77004		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,JOHN SEALY HOSP 9-112,DIV NEUROSURG,D-73,GALVESTON,TX 77550, USA.		fletcher, jack/Q-5975-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; Beery KE, 1967, VISUAL MOTOR INTEGRA; Benton A., 1978, MULTILINGUAL APHASIA; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; Dunn LM., 1981, PEABODY PICTURE VOCA; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; JENKINS A, 1986, LANCET, V2, P445; LEVIN HS, 1985, SEMIN NEUROL, V5, P221, DOI 10.1055/s-2008-1041519; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MATTHEWS CG, 1964, INSTRUCTION MANUAL A; TEASDALE G, 1974, LANCET, V2, P81; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011	18	30	30	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	FEB	1989	24	2					223	227		10.1227/00006123-198902000-00011			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	R9584	WOS:A1989R958400011	2918973				2022-02-06	
J	Wiedmann, KD; Wilson, JTL; Wyper, D; Hadley, DM; Teasdale, GM; Brooks, DN				Wiedmann, K. D.; Wilson, J. T. L.; Wyper, D.; Hadley, D. M.; Teasdale, G. M.; Brooks, D. N.			SPECT Cerebral Blood Flow, MR Imaging, and Neuropsychological Findings in Traumatic Head Injury	NEUROPSYCHOLOGY			English	Article						Single-photon emission computed tomography; magnetic resonance imaging; head injury; neuropsychology		Two groups of head injury patients were investigated 5 to 12 months (median 6 months) after injury employing single-photon emission computed tomography (SPECT) cerebral blood flow measurements and neuropsychological examination. The groups differed in primary clinical diagnosis: a group of 16 patients with a diagnosis of diffuse or contusional brain damage and a group of 8 patients with space-occupying lesions. The groups differed significantly on GCS admission score and on PTA, which indicated greater injury severity for the diffuse group. They also differed in neuropsychological test performance. Compared to a control group, the diffuse group showed statistically significant differences on 13 of 24 measures after correction for premorbid differences, whereas the focal group was significantly impaired on only three tests after correction. Regional analysis of SPECT-CBF abnormalities revealed consistent relationships, with impaired test performance for the diffuse group, but relationships were less clear for the focal group. The authors conclude that (1) patterns of CBF abnormalities were different for the focal and diffuse groups; (2) SPECT was able to identify abnormalities not demonstrated on MRI and vice versa; and (3) abnormal regional CBF was related to neuropsychological defects.	[Wiedmann, K. D.; Wilson, J. T. L.] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [Wyper, D.; Hadley, D. M.; Teasdale, G. M.] So Gen Hosp, Inst Neurol Sci, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland; [Wyper, D.; Hadley, D. M.; Teasdale, G. M.] So Gen Hosp, Inst Neurol Sci, Dept Neuroradiol, Glasgow G51 4TF, Lanark, Scotland; [Wyper, D.; Hadley, D. M.; Teasdale, G. M.] So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; [Brooks, D. N.] Univ Glasgow, Dept Psychol Med, Glasgow, Lanark, Scotland		Wiedmann, KD (corresponding author), Univ Edinburgh, Dept Psychol, 7 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland.		Wilson, Lindsay/O-8883-2019; Wilson, Lindsay/A-3659-2009	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328	Medical Research Council of Great BritainUK Research & Innovation (UKRI)Medical Research Council UK (MRC)	This study was supported by the Medical Research Council of Great Britain.	ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ANDERSEN AR, 1988, J CEREBR BLOOD F MET, V8, pS69, DOI 10.1038/jcbfm.1988.35; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; Bullock R., 1989, J CEREBRAL BLOOD S1, V9, pS204; ELL PJ, 1983, LANCET, V1, P1348; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; JENKINS A, 1986, LANCET, V2, P445; Langfitt T W, 1981, Prog Neurol Surg, V10, P14, DOI 10.1159/000384767; McKenna P., 1983, GRADED NAMING TEST; Nelson H, 1981, NATL ADULT READING T; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Rey A, 1941, ARCH PSYCHOL, V28; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wiedmann K. D., 1989, J CLIN EXPT NEUROPSY, V11, P58; Wilson J. T. L., 1990, PATTERNS LESIO UNPUB; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WILSON JTL, 1988, J CLIN EXP NEUROPSYC, V10, P222, DOI 10.1080/01688638808408237	24	30	30	0	0	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology		1989	3	4					267	281		10.1037//0894-4105.3.4.267			15	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	V44JW	WOS:000209746300006					2022-02-06	
J	LEVIN, HS; MADISON, CF; BAILEY, CB; MEYERS, CA; EISENBERG, HM; GUINTO, FC				LEVIN, HS; MADISON, CF; BAILEY, CB; MEYERS, CA; EISENBERG, HM; GUINTO, FC			MUTISM AFTER CLOSED HEAD-INJURY	ARCHIVES OF NEUROLOGY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEURORADIOL,GALVESTON,TX 77550; UNIV TEXAS,SCH MED,DIV NEUROSURG,HOUSTON,TX 77025		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BARAT M, 1981, REV NEUROL, V137, P343; BENSON DR, 1976, APHASIA ALEXIA AGRAP; Benton A. L., 1976, MANUAL MULTILINGUAL; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; BROWN JW, 1975, BRAIN LANG, V2, P18, DOI 10.1016/S0093-934X(75)80051-4; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; DAMASIO AR, 1982, ARCH NEUROL-CHICAGO, V39, P15, DOI 10.1001/archneur.1982.00510130017003; DEMOL J, 1979, ACTA NEUROL BELG, V79, P369; FISHER CM, 1979, ARCH NEUROL-CHICAGO, V36, P65, DOI 10.1001/archneur.1979.00500380035003; Geschwind N., 1974, SELECTED PAPERS LANG; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 1981, MANAGEMENT HEAD INJU; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; MAKI Y, 1980, CHILD BRAIN, V7, P113; NAESER MA, 1982, ARCH NEUROL-CHICAGO, V39, P2, DOI 10.1001/archneur.1982.00510130004002; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; SEGARRA JM, 1970, CEREBROVASCULAR DISE, P3; Spreen O., 1969, NEUROSENSORY CTR COM; TEASDALE G, 1974, LANCET, V2, P81	22	30	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1983	40	10					601	606		10.1001/archneur.1983.04050090037004			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	RJ617	WOS:A1983RJ61700002	6615266				2022-02-06	
J	MANAKA, S; SANO, K				MANAKA, S; SANO, K			THYROTROPIN-RELEASING-HORMONE TARTRATE (TRH-T) SHORTENS CONCUSSION EFFECTS FOLLOWING HEAD IMPACT IN MICE	NEUROSCIENCE LETTERS			English	Article											MANAKA, S (corresponding author), UNIV TOKYO,FAC MED,DEPT NEUROSURG,TOKYO 113,JAPAN.						BREESE GR, 1974, LIFE SCI, V14, P1053, DOI 10.1016/0024-3205(74)90230-6; INANAGA K, 1975, Kurume Medical Journal, V22, P159; KASTIN AJ, 1972, LANCET, V2, P740; KELLER HH, 1974, NATURE, V248, P528, DOI 10.1038/248528a0; MANAKA S, 1977, BRAIN NERV, V29, P1075; MCCAUL JA, 1974, LANCET, V1, P735; MIYAMOTO M, 1977, EUR J PHARMACOL, V44, P143, DOI 10.1016/0014-2999(77)90100-5; PRANGE AJ, 1972, LANCET, V2, P999; PRANGE AJ, 1974, LIFE SCI, V14, P447, DOI 10.1016/0024-3205(74)90359-2; SAJI Y, 1977, Journal of Takeda Research Laboratories, V36, P39; SAJI Y, 1976, BASIC PHARM THERAP, V4, P515; WILSON IC, 1973, LANCET, V2, P43	12	30	30	1	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.		1978	8	3					255	258		10.1016/0304-3940(78)90131-3			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FL615	WOS:A1978FL61500013	19605168				2022-02-06	
J	Sas, AR; Carbajal, KS; Jerome, AD; Menon, R; Yoon, C; Kalinski, AL; Giger, RJ; Segal, BM				Sas, Andrew R.; Carbajal, Kevin S.; Jerome, Andrew D.; Menon, Rajasree; Yoon, Choya; Kalinski, Ashley L.; Giger, Roman J.; Segal, Benjamin M.			A new neutrophil subset promotes CNS neuron survival and axon regeneration	NATURE IMMUNOLOGY			English	Article							CELL-LINE HL-60; BRAIN-INJURY; MACROPHAGES; DIFFERENTIATION; INFLAMMATION; PHENOTYPE; EXPRESSION; PLASTICITY	Segal and colleagues identify a neuroprotective immature-like neutrophil subset that participates in dectin-1-dependent axon repair and regeneration in the central nervous system. Transected axons typically fail to regenerate in the central nervous system (CNS), resulting in chronic neurological disability in individuals with traumatic brain or spinal cord injury, glaucoma and ischemia-reperfusion injury of the eye. Although neuroinflammation is often depicted as detrimental, there is growing evidence that alternatively activated, reparative leukocyte subsets and their products can be deployed to improve neurological outcomes. In the current study, we identify a unique granulocyte subset, with characteristics of an immature neutrophil, that had neuroprotective properties and drove CNS axon regeneration in vivo, in part via secretion of a cocktail of growth factors. This pro-regenerative neutrophil promoted repair in the optic nerve and spinal cord, demonstrating its relevance across CNS compartments and neuronal populations. Our findings could ultimately lead to the development of new immunotherapies that reverse CNS damage and restore lost neurological function across a spectrum of diseases.	[Sas, Andrew R.; Jerome, Andrew D.; Segal, Benjamin M.] Ohio State Univ, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA; [Sas, Andrew R.; Jerome, Andrew D.; Segal, Benjamin M.] Ohio State Univ, Neurosci Res Inst, Columbus, OH 43210 USA; [Sas, Andrew R.; Carbajal, Kevin S.; Segal, Benjamin M.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Menon, Rajasree] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Yoon, Choya; Kalinski, Ashley L.; Giger, Roman J.] Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; [Giger, Roman J.] Univ Michigan, Neurosci Grad Program, Ann Arbor, MI 48109 USA		Segal, BM (corresponding author), Ohio State Univ, Dept Neurol, Wexner Med Ctr, Columbus, OH 43210 USA.; Segal, BM (corresponding author), Ohio State Univ, Neurosci Res Inst, Columbus, OH 43210 USA.; Segal, BM (corresponding author), Univ Michigan, Dept Neurol, Ann Arbor, MI USA.	benjamin.segal@osumc.edu		Kalinski, Ashley/0000-0001-7611-0810; Menon, Rajasree/0000-0001-6280-9639; Segal, Benjamin/0000-0002-0906-6319	National Eye Institute (NEI), National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY029159, R01EY028350, K08EY029362]; Wings of Life Foundation; Dr. Miriam and Sheldon G. Adelson Research Foundation	We thank S. Atkins for technical support. Financial support for this research was provided by the National Eye Institute (NEI), National Institutes of Health (R01EY029159 and R01EY028350 to B.M.S. and R.J.G; K08EY029362 to A.R.S.), the Wings of Life Foundation (C.Y.) and the Dr. Miriam and Sheldon G. Adelson Research Foundation (R.J.G.). B.M.S. holds the Stanley D. and Joan H. Ross chair in neuromodulation at the Ohio State University.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Baldwin KT, 2015, P NATL ACAD SCI USA, V112, P2581, DOI 10.1073/pnas.1423221112; Benowitz LI, 2017, EXP NEUROL, V287, P365, DOI 10.1016/j.expneurol.2015.12.015; Bollaerts I, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9478542; BOSS MA, 1980, BLOOD, V56, P910; Brennan FH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.98254; Chen F, 2014, NAT IMMUNOL, V15, P938, DOI 10.1038/ni.2984; Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173; Cloke T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048939; Dai XM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09544-9; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Giles DA, 2018, J CLIN INVEST, V128, P5322, DOI 10.1172/JCI123708; Giles DA, 2018, ANN NEUROL, V83, P131, DOI 10.1002/ana.25128; Gliem M, 2016, BBA-MOL BASIS DIS, V1862, P329, DOI 10.1016/j.bbadis.2015.11.004; Grifka-Walk HM, 2015, EUR J IMMUNOL, V45, P2780, DOI 10.1002/eji.201545800; Herz J, 2015, STROKE, V46, P2916, DOI 10.1161/STROKEAHA.115.010620; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Hou Y, 2019, INT IMMUNOPHARMACOL, V77, DOI 10.1016/j.intimp.2019.105970; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Liu CY, 2010, J CANCER RES CLIN, V136, P35, DOI 10.1007/s00432-009-0634-0; Lorber B, 2009, J NEUROSCI RES, V87, P2645, DOI 10.1002/jnr.22095; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mistry P, 2019, P NATL ACAD SCI USA, V116, P25222, DOI 10.1073/pnas.1908576116; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; NEWBURGER PE, 1979, J CELL BIOL, V82, P315, DOI 10.1083/jcb.82.2.315; OLSSON I, 1981, EXP CELL RES, V131, P225, DOI 10.1016/0014-4827(81)90422-5; Park J, 2018, SCIENCE, V360, P758, DOI 10.1126/science.aar2131; Rodriguez PC, 2009, CANCER RES, V69, P1553, DOI 10.1158/0008-5472.CAN-08-1921; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Ruschel J, 2015, SCIENCE, V348, P347, DOI 10.1126/science.aaa2958; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Schwartz M, 2010, BRAIN BEHAV IMMUN, V24, P1054, DOI 10.1016/j.bbi.2010.01.010; Segal BM, 2005, J NEUROL SCI, V228, P210, DOI 10.1016/j.jns.2004.10.014; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Shi KB, 2019, LANCET NEUROL, V18, P1058, DOI 10.1016/S1474-4422(19)30078-X; Ssemaganda A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085696; Stoolman JS, 2014, J IMMUNOL, V193, P564, DOI 10.4049/jimmunol.1400825; Tourki B, 2017, FASEB J, V31, P4226, DOI 10.1096/fj.201700109R; Tsuda Y, 2004, IMMUNITY, V21, P215, DOI 10.1016/j.immuni.2004.07.006; von Leden RE, 2019, EXP NEUROL, V317, P144, DOI 10.1016/j.expneurol.2019.03.004; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yoon C, 2013, J BIOL CHEM, V288, P26557, DOI 10.1074/jbc.M113.478552	48	29	29	2	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1529-2908	1529-2916		NAT IMMUNOL	Nat. Immunol.	DEC	2020	21	12					1496	+		10.1038/s41590-020-00813-0		OCT 2020	20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	OT0EL	WOS:000583963700002	33106668	Green Accepted			2022-02-06	
J	Gravesteijn, BY; Nieboer, D; Ercole, A; Lingsma, HF; Nelson, D; van Calster, B; Steyerberg, EW				Gravesteijn, Benjamin Y.; Nieboer, Daan; Ercole, Ari; Lingsma, Hester F.; Nelson, David; van Calster, Ben; Steyerberg, Ewout W.		CENTER-TBI Collaborators	Machine learning algorithms performed no better than regression models for prognostication in traumatic brain injury	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						Machine learning; Prognosis; Traumatic brain injury; Prediction; Data science; Cohort study	BIG DATA; VALIDATION; PROGNOSIS; TUTORIAL; CARE	Objective: We aimed to explore the added value of common machine learning (ML) algorithms for prediction of outcome for moderate and severe traumatic brain injury. Study Design and Setting: We performed logistic regression (LR), lasso regression, and ridge regression with key baseline predictors in the IMPACT-II database (15 studies, n = 11,022). ML algorithms included support vector machines, random forests, gradient boosting machines, and artificial neural networks and were trained using the same predictors. To assess generalizability of predictions, we performed internal, internal-external, and external validation on the recent CENTER-TBI study (patients with Glasgow Coma Scale <13, n = 1,554). Both calibration (calibration slope/intercept) and discrimination (area under the curve) was quantified. Results: In the IMPACT-II database, 3,332/11,022 (30%) died and 5,233(48%) had unfavorable outcome (Glasgow Outcome Scale less than 4). In the CENTER-TBI study, 348/1,554(29%) died and 651(54%) had unfavorable outcome. Discrimination and calibration varied widely between the studies and less so between the studied algorithms. The mean area under the curve was 0.82 for mortality and 0.77 for unfavorable outcomes in the CENTER-TBI study. Conclusion: ML algorithms may not outperform traditional regression approaches in a low-dimensional setting for outcome prediction after moderate or severe traumatic brain injury. Similar to regression-based prediction models, ML algorithms should be rigorously validated to ensure applicability to new populations. (C) 2020 The Authors. Published by Elsevier Inc.	[Gravesteijn, Benjamin Y.; Nieboer, Daan; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Postbus 2040, NL-3000 CA Rotterdam, Netherlands; [Ercole, Ari] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Nelson, David] Karolinska Inst, Dept Physiol & Pharmacol, Sect Perioperat Med & Intens Care, Stockholm, Sweden; [van Calster, Ben] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium; [van Calster, Ben; Steyerberg, Ewout W.] Leiden Univ, Dept Biomed Data Sci, Med Ctr, Leiden, Netherlands		Gravesteijn, BY (corresponding author), Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Postbus 2040, NL-3000 CA Rotterdam, Netherlands.	b.gravesteijn@erasmusmcm.nl	Sahuquillo, Juan/B-3577-2008; Badenes, Rafael/K-6628-2019; Oresic, Matej/K-7673-2016; Posti, Jussi P./Y-2908-2019; Laureys, Steven/AAN-2097-2021; Vande Vyvere, Thijs/AAB-5180-2022; Volovici, Victor/AAZ-8901-2020; Van Calster, Ben/F-9150-2010; Castano-Leon, Ana M/ABF-6322-2020; Ercole, Ari/B-6288-2009; Cooper, D. James/G-7961-2013; Lagares, Alfonso/B-2969-2011; Bartels, R.H.M.A./L-4184-2015; Raj, Rahul/K-7693-2012; Gomez, Pedro/E-2411-2014	Sahuquillo, Juan/0000-0003-0713-5875; Badenes, Rafael/0000-0001-7017-0150; Oresic, Matej/0000-0002-2856-9165; Posti, Jussi P./0000-0002-5925-5193; Laureys, Steven/0000-0002-3096-3807; Vande Vyvere, Thijs/0000-0003-4032-5443; Volovici, Victor/0000-0002-5798-5360; Van Calster, Ben/0000-0003-1613-7450; Castano-Leon, Ana M/0000-0002-7918-5049; Ercole, Ari/0000-0001-8350-8093; Cooper, D. James/0000-0002-5872-9051; Lagares, Alfonso/0000-0003-3996-0554; Rossi, Sandra/0000-0002-9963-8121; Kondziella, Daniel/0000-0001-5562-9808; van der Naalt, Joukje/0000-0001-9873-2418; Zeiler, Frederick/0000-0003-1737-0510; Coles, Jonathan/0000-0003-4013-679X; Gravesteijn, Benjamin/0000-0001-8096-5803; Newcombe, Virginia/0000-0001-6044-9035; Radoi, Andreea/0000-0002-0677-3544; Bartels, R.H.M.A./0000-0002-8638-4660; Gratz, Johannes/0000-0001-8717-0544; Sakowitz, Oliver/0000-0003-3248-6335; Nelson, David/0000-0003-2530-8207; Parizel, Paul M./0000-0002-0221-2854; Raj, Rahul/0000-0003-4243-9591; Palotie, Aarno/0000-0002-2527-5874; Bragge, Peter/0000-0003-0745-5131; Kolias, Angelos/0000-0003-3992-0587; Sanchez-Porras, Renan/0000-0002-9084-8114; Van Essen, Thomas/0000-0003-4657-5283; Pirinen, Matti/0000-0002-1664-1350; Della Corte, Francesco/0000-0003-1736-2318; Gomez, Pedro/0000-0002-4185-5238	European Union 7th Framework program (EC grant) [602150]; Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA)	Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), the OneMind (USA) and the Integra LifeSciences Corporation (USA). The funder had no role in the study design, enrollment, collection of data, writing, or publication decisions.	Afanador NL, 2016, J CHEMOMETR, V30, P232, DOI 10.1002/cem.2790; [Anonymous], 2012, LANCET NEUROL, V11, P651, DOI 10.1016/S1474-4422(12)70166-7; Beam AL, 2018, JAMA-J AM MED ASSOC, V319, P1317, DOI 10.1001/jama.2017.18391; Bisaso KR, 2018, BMC MED INFORM DECIS, V18, DOI 10.1186/s12911-018-0659-x; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555; Buuren, 2018, FLEXIBLE IMPUTATION; Charles D, 2016, ONC DATA BRIEF, V35, P1; Christodoulou E, 2019, J CLIN EPIDEMIOL, V110, P12, DOI 10.1016/j.jclinepi.2019.02.004; Churpek MM, 2016, CRIT CARE MED, V44, P368, DOI 10.1097/CCM.0000000000001571; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1002/bjs.9736, 10.1111/dme.12654, 10.1038/bjc.2014.639, 10.1016/j.jclinepi.2014.11.010, 10.1186/s12916-014-0241-z, 10.1136/bmj.g7594]; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Decruyenaere A, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0206-y; Delahanty RJ, 2018, CRIT CARE MED, V46, pE481, DOI 10.1097/CCM.0000000000003011; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Desautels T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017199; Feng JZ, 2019, J CRIT CARE, V54, P110, DOI 10.1016/j.jcrc.2019.08.010; FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755; Harrell FE Jr, 2017, REGRESSION MODELING; Jain AK, 1996, COMPUTER, V29, P31, DOI 10.1109/2.485891; Klau S, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2344-6; Konig IR, 2007, STAT MED, V26, P5499, DOI 10.1002/sim.3069; Lee HC, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110428; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Liu NT, 2017, SHOCK, V48, P504, DOI 10.1097/SHK.0000000000000898; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Matsuo K, 2018, J NEUROTRAUM, V37, P202; Moons KGM, 2012, HEART, V98, P691, DOI 10.1136/heartjnl-2011-301247; Natekin A, 2013, FRONT NEUROROBOTICS, V7, DOI 10.3389/fnbot.2013.00021; Ngiam KY, 2019, LANCET ONCOL, V20, pE262, DOI 10.1016/S1470-2045(19)30149-4; Poldrack RA, 2014, NAT NEUROSCI, V17, P1510, DOI 10.1038/nn.3818; Probst P, 2019, J MACH LEARN RES, V20; Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1; Rau Cheng-Shyuan, 2018, PLoS One, V13, pe0207192, DOI 10.1371/journal.pone.0207192; Reps JM, 2018, J AM MED INFORM ASSN, V25, P969, DOI 10.1093/jamia/ocy032; Royston P, 2004, STAT MED, V23, P907, DOI 10.1002/sim.1691; Rubin D.B., 2004, MULTIPLE IMPUTATION; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sakr S, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0566-6; Steyerberg E. W., 2009, CLIN PREDICTION MODE, DOI [10.1007/978-0-387-77244-8, 10. 1007/978-0-387-77244-8., DOI 10.1007/978-0-387-77244-8]; Steyerberg EW, 2016, J CLIN EPIDEMIOL, V69, P245, DOI 10.1016/j.jclinepi.2015.04.005; Steyerberg EW, 2014, EUR HEART J, V35, P1925, DOI 10.1093/eurheartj/ehu207; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Thelin EP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002368; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Van Calster B, 2016, J CLIN EPIDEMIOL, V74, P167, DOI 10.1016/j.jclinepi.2015.12.005; van der Ploeg T, 2016, J CLIN EPIDEMIOL, V78, P83, DOI 10.1016/j.jclinepi.2016.03.002; van der Ploeg T, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-137; van Os HJA, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00784	54	29	29	4	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0895-4356	1878-5921		J CLIN EPIDEMIOL	J. Clin. Epidemiol.	JUN	2020	122						95	107		10.1016/j.jclinepi.2020.03.005			13	Health Care Sciences & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services; Public, Environmental & Occupational Health	LV9SZ	WOS:000538788700015	32201256	Green Published, Green Submitted, hybrid			2022-02-06	
J	Lumba-Brown, A; Teramoto, M; Bloom, OJ; Brody, D; Chesnutt, J; Clugston, JR; Collins, M; Gioia, G; Kontos, A; Lal, A; Sills, A; Ghajar, J				Lumba-Brown, Angela; Teramoto, Masaru; Bloom, O. Josh; Brody, David; Chesnutt, James; Clugston, James R.; Collins, Michael; Gioia, Gerard; Kontos, Anthony; Lal, Avtar; Sills, Allen; Ghajar, Jamshid			Concussion Guidelines Step 2: Evidence for Subtype Classification	NEUROSURGERY			English	Article						Concussion; subtype; systematic review; meta-analysis; mild traumatic brain injury; head injury; oculomotor; vestibular; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; SYMPTOMS; SLEEP; METAANALYSIS; RECOVERY; SENSITIVITY; DISORDERS; MIGRAINE	BACKGROUND: Concussion is a heterogeneous mild traumatic brain injury (mTBI) characterized by a variety of symptoms, clinical presentations, and recovery trajectories. By thematically classifying the most common concussive clinical presentations into concussion subtypes (cognitive, ocular-motor, headache/migraine, vestibular, and anxiety/mood) and associated conditions (cervical strain and sleep disturbance), we derive useful definitions amenable to future targeted treatments. OBJECTIVE: To use evidence-based methodology to characterize the 5 concussion subtypes and 2 associated conditions and report their prevalence in acute concussion patients as compared to baseline or controls within 3 d of injury. METHODS: A multidisciplinary expert workgroup was established to define the most common concussion subtypes and their associated conditions and select clinical questions related to prevalence and recovery. A literature search was conducted from January 1, 1990 to November 1, 2017. Two experts abstracted study characteristics and results independently for each article selected for inclusion. A third expert adjudicated disagreements. Separate meta-analyses were conducted to do the following: 1) examine the prevalence of each subtype/associated condition in concussion patients using a proportion, 2) assess subtype/associated conditions in concussion compared to baseline/uninjured controls using a prevalence ratio, and 3) compare the differences in symptom scores between concussion subtypes and uninjured/baseline controls using a standardized mean difference (SMD). RESULTS: The most prevalent concussion subtypes for pediatric and adult populations were headache/migraine (0.52; 95% CI = 0.37, 0.67) and cognitive (0.40; 95% CI = 0.25, 0.55), respectively. In pediatric patients, the prevalence of the vestibular subtype was also high (0.50; 95% CI = 0.40, 0.60). Adult patients were 4.4, 2.9, and 1.7 times more likely to demonstrate cognitive, vestibular, and anxiety/mood subtypes, respectively, as compared with their controls (P < .05). Children and adults with concussion showed significantly more cognitive symptoms than their respective controls (SMD = 0.66 and 0.24; P < .001). Furthermore, ocular-motor in adult patients (SMD = 0.72; P < .001) and vestibular symptoms in both pediatric and adult patients (SMD = 0.18 and 0.36; P < .05) were significantly worse in concussion patients than in controls. CONCLUSION: Five concussion subtypes with varying prevalence within 3 d following injury are commonly seen clinically and identifiable upon systematic literature review. Sleep disturbance, a concussion-associated condition, is also common. There was insufficient information available for analysis of cervical strain. A comprehensive acute concussion assessment defines and characterizes the injury and, therefore, should incorporate evaluations of all 5 subtypes and associated conditions.	[Lumba-Brown, Angela] Stanford Univ, Brain Performance Ctr, Dept Emergency Med, Stanford, CA 94305 USA; [Teramoto, Masaru] Univ Utah, Div Phys Med & Rehabil, Salt Lake City, UT USA; [Bloom, O. Josh] Carolina Sports Concuss Clin, Cary, NC USA; [Brody, David] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; [Chesnutt, James] Oregon Hlth & Sci Univ, Dept Orthoped & Rehabil, Portland, OR 97201 USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Gainesville, FL USA; [Clugston, James R.] Univ Florida, Dept Neurol, Gainesville, FL USA; [Collins, Michael; Kontos, Anthony] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA; [Collins, Michael] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Gioia, Gerard] George Washington Univ, Sch Med, Div Pediat Neuropsychol,Dept Pediat, Safe Concuss Outcome Recovery & Educ Program,Chil, Rockville, MD USA; [Gioia, Gerard] George Washington Univ, Sch Med, Div Pediat Neuropsychol,Dept Psychiat & Behav Sci, Safe Concuss Outcome Recovery & Educ Program,Chil, Rockville, MD USA; [Kontos, Anthony] Univ Pittsburgh, Dept Sports Med & Rehabil, Pittsburgh, PA USA; [Lal, Avtar] Stanford Univ, Concuss & Brain Performance Ctr, Dept Neurosurg, Stanford, CA 94305 USA; [Sills, Allen] Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN USA; [Sills, Allen] Vanderbilt Univ, Med Ctr, Vanderbilt Sports Concuss Ctr, Nashville, TN USA; [Ghajar, Jamshid] Stanford Univ, Brain Performance Ctr, Dept Neurosurg, Stanford, CA 94305 USA		Lumba-Brown, A (corresponding author), 900 Welch Rd 350,MC 5119, Palo Alto, CA 94304 USA.	alumba@stanford.edu		Lumba-Brown, Angela/0000-0002-9102-8791; Clugston, James/0000-0002-2103-1039	US Army Contracting Command, Aberdeen ProvingGround, Natick ContractingDivision [W911 QY-14-C-0086]	This material is based in part upon work supported by (1) the US Army Contracting Command, Aberdeen ProvingGround, Natick ContractingDivision, through a contract awarded to Stanford University (W911 QY-14-C-0086). Any opinions, findings, and conclusions, or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, or Stanford University. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Borenstein M., 2011, INTRO META ANAL, DOI DOI 10.1002/9780470743386; Bradburn MJ, 2016, METAANALYSIS STATA U, P3; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Cheever K, 2016, J ATHL TRAINING, V51, P1037, DOI 10.4085/1062-6050-51.12.15; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; Cohen J, 1988, STAT POWER ANAL BEHA; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2013, BRAIN INJURY, V27, P1589, DOI 10.3109/02699052.2013.823656; Craton N, 2014, CLIN J SPORT MED, V24, P93, DOI 10.1097/JSM.0000000000000023; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; de Dhaem OB, 2017, J HEADACHE PAIN, V18, DOI 10.1186/s10194-017-0767-5; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; DoD Clinical Recommendation, 2014, MAN SLEEP DISTR FOLL; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756; Fu R, 2008, METHODS GUIDE EFFECT; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Harbord RM, 2009, STATA J, V9, P197, DOI 10.1177/1536867X0900900202; Harris RJ, 2016, METAANALYSIS STATA U, P3; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holcomb EM, 2016, J HEAD TRAUMA REHAB, V31, P82, DOI 10.1097/HTR.0000000000000230; Howell DR, 2019, CLIN J SPORT MED, V29, P391, DOI 10.1097/JSM.0000000000000629; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Kontos AP, 2017, J ATHL TRAINING, V52, P256, DOI 10.4085/1062-6050-51.11.05; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; Lim MM, 2018, SLEEP WAKE DISORDERS; Lumba-Brown A, 2018, JAMA PEDIATR, V172, DOI 10.1001/jamapediatrics.2018.2853; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Marshall CM, 2015, PHYSICIAN SPORTSMED, V43, P274, DOI 10.1080/00913847.2015.1064301; Maruta J, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01034; Maruta J, 2017, MIL MED, V182, P120, DOI 10.7205/MILMED-D-16-00093; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; MILLER JJ, 1978, AM STAT, V32, P138, DOI 10.2307/2682942; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535, 10.1371/journal.pmed.1000217, 10.1016/j.ijsu.2010.02.007]; Mucha A, 2018, HAND CLINIC, V158, P135, DOI 10.1016/B978-0-444-63954-7.00014-8; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Nance ML, 2016, BRAIN INJURY, V30, P184, DOI 10.3109/02699052.2015.1075591; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39; Pac-12, 2019, STUD ATHL HLTH WELL; Patsopoulos NA, 2008, INT J EPIDEMIOL, V37, P1148, DOI 10.1093/ije/dyn065; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Rizzoli P, 2018, AM J MED, V131, P17, DOI 10.1016/j.amjmed.2017.09.005; Saltychev M, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-008756; Sandel N, 2017, SPORT EXERC PERFORM, V6, P304, DOI 10.1037/spy0000098; Sandsmark DK, 2017, SLEEP, V40, DOI 10.1093/sleep/zsx044; Sateia MJ, 2014, CHEST, V146, P1387, DOI 10.1378/chest.14-0970; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Seifert T, 2018, HAND CLINIC, V158, P119, DOI 10.1016/B978-0-444-63954-7.00012-4; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1016/j.ijsu.2010.02.007, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; St-Onge MP, 2014, INT J OBESITY, V38, P411, DOI 10.1038/ijo.2013.114; Starkey NJ, 2018, BRAIN INJURY, V32, P617, DOI 10.1080/02699052.2018.1439533; Steichen T., 2000, STATA TECHNICAL B, V61, P8; Stone ME, 2015, J TRAUMA ACUTE CARE, V79, P147, DOI 10.1097/TA.0000000000000679; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sufrinko A, 2018, J HEAD TRAUMA REHAB, V33, P7, DOI 10.1097/HTR.0000000000000315; Sufrinko A, 2015, AM J SPORT MED, V43, P830, DOI 10.1177/0363546514566193; Sussman ES, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15610; Sutton A.J., 2000, METHODS METAANALYSIS; Thomasy HE, 2019, J NEUROTRAUM, V36, P802, DOI 10.1089/neu.2018.5810; Tobias A., 2001, STATA TECHNICAL B, V10; Tobias A, 1999, STATA TECH B, V47, P15; Wickwire EM, 2016, NEUROTHERAPEUTICS, V13, P403, DOI 10.1007/s13311-016-0429-3; Wiener-Vacher SR, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00092; Zaremski JL, 2015, CURR SPORT MED REP, V14, P16, DOI 10.1249/JSR.0000000000000121	81	29	29	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2020	86	1					2	13		10.1093/neuros/nyz332			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	LS6QI	WOS:000536505700004	31432081	hybrid, Green Published			2022-02-06	
J	Xiao, L; Wei, F; Zhou, YH; Anderson, GJ; Frazer, DM; Lim, YC; Liu, TQ; Xiao, Y				Xiao, Lan; Wei, Fei; Zhou, Yinghong; Anderson, Gregory J.; Frazer, David M.; Lim, Yi Chieh; Liu, Tianqing; Xiao, Yin			Dihydrolipoic Acid-Gold Nanoclusters Regulate Microglial Polarization and Have the Potential To Alter Neurogenesis	NANO LETTERS			English	Article						Gold nanoclusters; neuroinflammation; microglial polarization; neuronal regeneration; immunomodulation	NF-KAPPA-B; ALPHA-LIPOIC ACID; NEURONAL NUCLEAR ANTIGEN; CENTRAL-NERVOUS-SYSTEM; AUTOPHAGIC CELL-DEATH; PROTEIN-KINASE-C; IN-VITRO MODEL; OXIDATIVE STRESS; METAL NANOCLUSTERS; NITRIC-OXIDE	Microglia-mediated neuroinflammation is one of the most significant features in a variety of central nervous system (CNS) disorders such as traumatic brain injury, stroke, and many neurodegenerative diseases. Microglia become polarized upon stimulation. The two extremes of the polarization are the neuron-destructive proinflammatory M1-like and the neuron-regenerative M2-like phenotypes. Thus, manipulating microglial polarization toward the M2 phenotype is a promising therapeutic approach for CNS repair and regeneration. It has been reported that nanoparticles are potential tools for regulating microglial polarization. Gold nanoclusters (AuNCs) could penetrate the blood brain barrier and have neuroprotective effects, suggesting the possibility of utilizing AuNCs to regulate microglial polarization and improve neuronal regeneration in CNS. In the current study, AuNCs functionalized with dihydrolipoic acid (DHLA-AuNCs), an antioxidant with demonstrated neuroprotective roles, were prepared, and their effects on polarization of a microglial cell line (BV2) were examined. DHLA-AuNCs effectively suppressed proinflammatory processes in BV2 cells by inducing polarization toward the M2-like phenotype. This was associated with a decrease in reactive oxygen species and reduced NF-kB signaling and an improvement in cell survival coupled with enhanced autophagy and inhibited apoptosis. Conditioned medium from DHLA-AuNC-treated BV2 cells was able to enhance neurogenesis in both the neuronal cell line N2a and in an ex vivo brain slice stroke model. The direct treatment of brain slices with DHLA-AuNCs also ameliorated stroke-related tissue injury and reduced astrocyte activation (astrogliosis). This study suggests that by regulating neuroinflammation to improve neuronal regeneration, DHLA-AuNCs could be a potential therapeutic agent in CNS disorders.	[Xiao, Lan; Wei, Fei; Zhou, Yinghong; Xiao, Yin] Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia; [Zhou, Yinghong; Xiao, Yin] Australia China Ctr Tissue Engn & Regenerat Med, Shanghai, Peoples R China; [Anderson, Gregory J.; Frazer, David M.; Lim, Yi Chieh; Liu, Tianqing] QIMR Berghofer Med Res Inst, 300 Herston Rd, Brisbane, Qld 4006, Australia		Xiao, Y (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia.; Xiao, Y (corresponding author), Australia China Ctr Tissue Engn & Regenerat Med, Shanghai, Peoples R China.; Liu, TQ (corresponding author), QIMR Berghofer Med Res Inst, 300 Herston Rd, Brisbane, Qld 4006, Australia.	michelle.liu@qimrberghofer.edu.au; yin.xiao@qut.edu.au	Zhou, Yinghong/ABE-6575-2021; Frazer, David M/L-3570-2014; Xiao, Yin/AAM-4033-2020; Anderson, Gregory/G-4148-2013	Zhou, Yinghong/0000-0001-9757-7735; Frazer, David M/0000-0003-4098-1379; Xiao, Yin/0000-0003-1785-3491; Lim, Yi Chieh/0000-0003-1261-5419; Anderson, Gregory/0000-0002-8814-5866; Liu, Tianqing/0000-0002-9058-2643; Xiao, Lan/0000-0002-5227-9352	National Health and Medical Research Council (NHMRC) Early Career FellowshipNational Health and Medical Research Council of Australia [1105035]	Dr. Tianqing Liu is supported by the National Health and Medical Research Council (NHMRC) Early Career Fellowship (Grant No. 1112258). Dr. Yinghong Zhou is supported by the National Health and Medical Research Council (NHMRC) Early Career Fellowship (Grant No. 1105035).	Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x; Bae EA, 2006, PLANTA MED, V72, P627, DOI 10.1055/s-2006-931563; Belarbi K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00145; Bhaskar S, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-3; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bookout A. L, 2003, NUCL RECEPT SIGNALIN, V1; Bundscherer A, 2013, ANTICANCER RES, V33, P3201; Bustamante J, 1998, FREE RADICAL BIO MED, V24, P1023, DOI 10.1016/S0891-5849(97)00371-7; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Cakatay U, 2006, MED HYPOTHESES, V66, P110, DOI 10.1016/j.mehy.2005.07.020; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen K, 2008, J CELL BIOL, V181, P1129, DOI 10.1083/jcb.200709049; Chen ZT, 2017, ACS NANO, V11, P4494, DOI 10.1021/acsnano.6b07808; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cho S, 2007, CURR NEUROPHARMACOL, V5, P19, DOI 10.2174/157015907780077105; Cho SG, 2004, NEUROCHEM INT, V45, P117, DOI 10.1016/j.neuint.2003.11.012; Colonna M, 2017, ANNU REV IMMUNOL, V35, P441, DOI 10.1146/annurev-immunol-051116-052358; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; DACHARYPRIGENT J, 1993, BLOOD, V81, P2554; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Fan LW, 2017, NEURAL REGEN RES, V12, P366, DOI 10.4103/1673-5374.202926; Fernandez TD, 2015, BIOMATERIALS, V43, P1, DOI 10.1016/j.biomaterials.2014.11.045; Finley M, 2004, BRAIN RES, V1001, P125, DOI 10.1016/j.brainres.2003.12.009; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gao GB, 2019, BIOMATERIALS, V194, P36, DOI 10.1016/j.biomaterials.2018.12.013; Ghibu S, 2009, J CARDIOVASC PHARM, V54, P391, DOI 10.1097/FJC.0b013e3181be7554; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Gloor SM, 2001, BRAIN RES REV, V36, P258, DOI 10.1016/S0165-0173(01)00102-3; Goraca A, 2011, PHARMACOL REP, V63, P849; GORCZYCA W, 1993, EXP CELL RES, V207, P202, DOI 10.1006/excr.1993.1182; Gosselin D, 2007, BRAIN BEHAV IMMUN, V21, P281, DOI 10.1016/j.bbi.2006.12.004; GREENAMYRE JT, 1994, NEUROSCI LETT, V171, P17, DOI 10.1016/0304-3940(94)90593-2; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Gusel'nikova VV, 2015, ACTA NATURAE, V7, P42, DOI 10.32607/20758251-2015-7-2-42-47; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Hingorani R, 2011, DETECTION APOPTOSIS; Ho YS, 2007, BIOCHEM PHARMACOL, V73, P1786, DOI 10.1016/j.bcp.2006.12.006; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Humpel C, 2015, NEUROSCIENCE, V305, P86, DOI 10.1016/j.neuroscience.2015.07.086; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ishaque A, 1998, J IMMUNOL METHODS, V221, P43, DOI 10.1016/S0022-1759(98)00166-5; JACQUE CM, 1978, J NEUROL SCI, V35, P147, DOI 10.1016/0022-510X(78)90107-7; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; Kamenova Petya, 2006, Hormones (Athens), V5, P251; Kim YJ, 2006, J NEUROSCI RES, V84, P1037, DOI 10.1002/jnr.21011; Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Koenig ML, 2003, NEUROTOX RES, V5, P265, DOI 10.1007/BF03033384; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Kuroda J, 2010, P NATL ACAD SCI USA, V107, P15565, DOI 10.1073/pnas.1002178107; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Leu JG, 2012, NANOMED-NANOTECHNOL, V8, P767, DOI 10.1016/j.nano.2011.08.013; Li JJ, 2014, TRAC-TREND ANAL CHEM, V58, P90, DOI 10.1016/j.trac.2014.02.011; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Maczurek A, 2008, ADV DRUG DELIVER REV, V60, P1463, DOI 10.1016/j.addr.2008.04.015; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mao AJ, 2000, J BIOL CHEM, V275, P34407, DOI 10.1074/jbc.M003917200; Margaritescu O, 2009, ROM J MORPHOL EMBRYO, V50, P327; Minami SS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-22; MINANA MD, 1990, P NATL ACAD SCI USA, V87, P4335, DOI 10.1073/pnas.87.11.4335; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Moini H, 2002, TOXICOL APPL PHARM, V182, P84, DOI 10.1006/taap.2002.9437; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Nair LV, 2017, J MATER CHEM B, V5, P8314, DOI 10.1039/c7tb02247f; Nair LV, 2015, ACS NANO, V9, P5825, DOI 10.1021/acsnano.5b00406; Niemann A, 2001, J HISTOCHEM CYTOCHEM, V49, P177, DOI 10.1177/002215540104900205; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; Papa S, 2013, ACS NANO, V7, P9881, DOI 10.1021/nn4036014; Paradells-Navarro S, 2017, ACS CHEM NEUROSCI, V8, P569, DOI 10.1021/acschemneuro.6b00306; Park J, 2015, NEUROSCI LETT, V584, P191, DOI 10.1016/j.neulet.2014.10.016; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Ponomarev ED, 2007, J NEUROSCI, V27, P10714, DOI 10.1523/JNEUROSCI.1922-07.2007; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Ryu J, 2000, J BIOL CHEM, V275, P29955, DOI 10.1074/jbc.M001220200; Sanchez-Ramos JR, 2001, EXP NEUROL, V171, P109, DOI 10.1006/exnr.2001.7748; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Sato C, 2002, J BIOL CHEM, V277, P45299, DOI 10.1074/jbc.M206046200; Seleverstov O, 2006, NANO LETT, V6, P2826, DOI 10.1021/nl0619711; Shahsavari S, 2016, J NANOMED RES, V3; Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72; Shang L, 2013, ANGEW CHEM INT EDIT, V52, P11154, DOI 10.1002/anie.201306366; Shang L, 2012, NANOSCALE, V4, P4155, DOI 10.1039/c2nr30219e; Shang L, 2011, SMALL, V7, P2614, DOI 10.1002/smll.201100746; Shi JY, 2013, AUTOPHAGY, V9, P1591, DOI 10.4161/auto.26059; Shinto L, 2014, J ALZHEIMERS DIS, V38, P111, DOI 10.3233/JAD-130722; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577; Sirokmany G, 2016, TRENDS PHARMACOL SCI, V37, P318, DOI 10.1016/j.tips.2016.01.006; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Song XR, 2016, ANALYST, V141, P3126, DOI 10.1039/c6an00773b; Stansley B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-115; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Sun Q, 2017, MOL MED, V23, P188, DOI 10.2119/molmed.2017.00077; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Tasca CI, 2015, METHODS MOL BIOL, V1254, P197, DOI 10.1007/978-1-4939-2152-2_15; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Tremblay RG, 2010, J NEUROSCI METH, V186, P60, DOI 10.1016/j.jneumeth.2009.11.004; Vazquez CL, 2009, METHOD ENZYMOL, V452, P85, DOI 10.1016/S0076-6879(08)03606-9; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vidal PM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.466; Wei ZJ, 2015, MOL MED REP, V12, P63, DOI 10.3892/mmr.2015.3395; Wu CT, 2012, BIOMATERIALS, V33, P2076, DOI 10.1016/j.biomaterials.2011.11.042; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Xiao L, 2018, J BONE MINER RES, V33, P1090, DOI 10.1002/jbmr.3396; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XD, 2017, BRAIN BEHAV IMMUN, V64, P162, DOI 10.1016/j.bbi.2017.03.003; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yuan L, 2014, MOL CELL BIOCHEM, V386, P153, DOI 10.1007/s11010-013-1854-9; Zabirnyk O, 2007, AUTOPHAGY, V3, P278, DOI 10.4161/auto.3916; Zhang CL, 2013, J MATER CHEM B, V1, P5045, DOI 10.1039/c3tb20784f; Zhang LB, 2014, NANO TODAY, V9, P132, DOI 10.1016/j.nantod.2014.02.010; Zhao CH, 2007, NEUROBIOL DIS, V26, P36, DOI 10.1016/j.nbd.2006.11.012; Zhao YF, 2016, ACS NANO, V10, P5959, DOI 10.1021/acsnano.6b01326; Zheng YK, 2017, ADV COLLOID INTERFAC, V242, P1, DOI 10.1016/j.cis.2017.02.005; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057; Zhou KR, 2018, STROKE, V49, P175, DOI 10.1161/STROKEAHA.117.018593; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	154	29	29	18	72	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1530-6984	1530-6992		NANO LETT	Nano Lett.	JAN	2020	20	1					478	495		10.1021/acs.nanolett.9b04216			18	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	KC4LO	WOS:000507151600062	31789044				2022-02-06	
J	Winston, CN; Romero, HK; Ellisman, M; Nauss, S; Julovich, DA; Conger, T; Hall, JR; Campana, W; O'Bryant, SE; Nievergelt, CM; Baker, DG; Risbrough, VB; Rissman, RA				Winston, Charisse N.; Romero, Haylie K.; Ellisman, Maya; Nauss, Sophie; Julovich, David A.; Conger, Tori; Hall, James R.; Campana, Wendy; O'Bryant, Sid E.; Nievergelt, Caroline M.; Baker, Dewleen G.; Risbrough, Victoria B.; Rissman, Robert A.			Assessing Neuronal and Astrocyte Derived Exosomes From Individuals With Mild Traumatic Brain Injury for Markers of Neurodegeneration and Cytotoxic Activity	FRONTIERS IN NEUROSCIENCE			English	Article						traumatic brain injury; neuronal exosomes; astrocytes; amyloid; tau	ALZHEIMERS-DISEASE; COLLABORATING CENTER; NEUROFILAMENT LIGHT; SYNAPTIC PROTEINS; AMYLOID-BETA; TASK-FORCE; TAU; BIOMARKERS; DEPLOYMENT; ASSOCIATION	Mild traumatic brain injury (mTBI) disproportionately affects military service members and is very difficult to diagnose. To-date, there is currently no blood-based, diagnostic biomarker for mTBI cases with persistent post concussive symptoms. To examine the potential of neuronally-derived (NDE) and astrocytic-derived (ADE) exosome cargo proteins as biomarkers of chronic mTBI in younger adults, we examined plasma exosomes from a prospective longitudinal study of combat-related risk and resilience, marine resiliency study II (MRSII). After return from a combat-deployment participants were interviewed to assess TBI exposure while on deployment. Plasma exosomes from military service members with mTBI (mean age, 21.7 years, n = 19, avg. days since injury 151), and age-matched, controls (deployed service members who did not endorse a deployment-related TBI or a pre-deployment history of TBI; mean age, 21.95 years, n = 20) were precipitated and enriched against a neuronal adhesion protein, L1-CAM, and an astrocyte marker, glutamine aspartate transporter (GLAST) using magnetic beads to immunocapture the proteins and subsequently selected by fluorescent activated cell sorting (FACS). Extracted protein cargo from NDE and ADE preparations were quantified for protein levels implicated in TBI neuropathology by standard ELISAs and on the ultra-sensitive single molecule assay (Simoa) platform. Plasma NDE and ADE levels of A beta 42 were significantly higher while plasma NDE and ADE levels of the postsynaptic protein, neurogranin (NRGN) were significantly lower in participants endorsing mTBI exposure compared to controls with no TBI history. Plasma NDE and ADE levels of A beta 40, total tau, and neurofilament light (NFL), P-T181-tau, P-S396-tau were either undetectable or not significantly different between the two groups. In an effort to understand the pathogenetic potential of NDE and ADE cargo proteins, neuron-like cultures were treated with NDE and ADE preparations from TBI and non-TBI groups. Lastly, we determined that plasma NDE but not ADE cargo proteins from mTBI samples were found to be toxic to neuron-like recipient cells in vitro. These data support the presence of markers of neurodegeneration in NDEs of mTBI and suggest that these NDEs can be used as tools to identify pathogenic mechanisms of TBI.	[Winston, Charisse N.; Ellisman, Maya; Nauss, Sophie; Rissman, Robert A.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Romero, Haylie K.; Campana, Wendy] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA; [Julovich, David A.; Conger, Tori; Hall, James R.; O'Bryant, Sid E.] Univ North Texas Hlth Sci Ctr, Inst Translat Res, Dept Pharmacol & Neurosci, Ft Worth, TX USA; [Campana, Wendy; Rissman, Robert A.] VA San Diego Healthcare Syst, La Jolla, CA 92161 USA; [Nievergelt, Caroline M.; Baker, Dewleen G.; Risbrough, Victoria B.] Ctr Excellence Stress & Mental Hlth, La Jolla, CA 92161 USA; [Nievergelt, Caroline M.; Baker, Dewleen G.; Risbrough, Victoria B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA		Rissman, RA (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.; Rissman, RA (corresponding author), VA San Diego Healthcare Syst, La Jolla, CA 92161 USA.; Risbrough, VB (corresponding author), Ctr Excellence Stress & Mental Hlth, La Jolla, CA 92161 USA.; Risbrough, VB (corresponding author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.	vrisbrough@ucsd.edu; rrissman@ucsd.edu	Youssef, Nagy A/F-5869-2019	Youssef, Nagy A/0000-0002-1922-9396	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG057459, AG057469, AG051848, AG018440, ADRC P50 AG005131]; VA Merit Awards [BX003040, BX004312, RX002484]; Department of DefenseUnited States Department of Defense [W81XWH1810761, P50 MH096889-06]; VA Center of Excellence for Stress and Mental Health; Flow Cytometry Core at the San Diego Center for AIDS Research [P30 AI036214]; VA San Diego Health Care SystemUS Department of Veterans Affairs; San Diego Veterans Medical Research Foundation; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG018440, R56AG057469] Funding Source: NIH RePORTER	This study was supported by grants AG057459, AG057469, AG051848, AG018440, and ADRC P50 AG005131 from the National Institute on Aging, and VA Merit Awards BX003040 and BX004312 to RR and VA Merit Award BX004312, Department of Defense W81XWH1810761, P50 MH096889-06 to VR, VA Merit Award RX002484 to WC, and the VA Center of Excellence for Stress and Mental Health funding to VR, CN, and DB. This work was performed with the support of the Flow Cytometry Core at the San Diego Center for AIDS Research (P30 AI036214), the VA San Diego Health Care System, and the San Diego Veterans Medical Research Foundation.	Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Baker DG, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110134; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Budnik V, 2016, NAT REV NEUROSCI, V17, P160, DOI 10.1038/nrn.2015.29; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; DeKosky, 1998, Semin Clin Neuropsychiatry, V3, P176; Eme R, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7050046; Fiandaca MS, 2015, ALZHEIMERS DEMENT, V11, P600, DOI 10.1016/j.jalz.2014.06.008; Gill J, 2018, BRAIN INJURY, V32, P1277, DOI 10.1080/02699052.2018.1471738; Glenn DE, 2017, DEPRESS ANXIETY, V34, P723, DOI 10.1002/da.22642; Goetzl EJ, 2019, FASEB J, V33, P5082, DOI 10.1096/fj.201802319R; Goetzl EJ, 2018, ANN NEUROL, V83, P544, DOI 10.1002/ana.25172; Goetzl EJ, 2018, FASEB J, V32, P888, DOI 10.1096/fj.201700731R; Goetzl EJ, 2016, FASEB J, V30, P4141, DOI 10.1096/fj.201600816R; Goetzl EJ, 2016, FASEB J, V30, P3853, DOI 10.1096/fj.201600756R; Goetzl L, 2018, ANN CLIN TRANSL NEUR, V5, P4, DOI 10.1002/acn3.499; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Hamlett ED, 2017, ALZHEIMERS DEMENT, V13, P541, DOI 10.1016/j.jalz.2016.08.012; Helmick K., 2006, DEFENSE VETERANS BRA; Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kawata K, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00239; Kenney Kimbra, 2018, Brain Inj, V32, P1276, DOI 10.1080/02699052.2018.1483530; Kim C, 2015, CELL REP, V13, P771, DOI 10.1016/j.celrep.2015.09.044; Kim HJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97105; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lee RR, 2014, PROG NEUROL SURG, V28, P94, DOI 10.1159/000358768; Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006; Lin YS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35766-w; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; Moore TM, 2017, J PSYCHIATR RES, V95, P121, DOI 10.1016/j.jpsychires.2017.08.013; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ngolab J, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0445-5; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prince C, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080105; Putz U, 2008, J BIOL CHEM, V283, P32621, DOI 10.1074/jbc.M804120200; Rajendran L, 2006, P NATL ACAD SCI USA, V103, P11172, DOI 10.1073/pnas.0603838103; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Reilly P, 2017, NEUROBIOL DIS, V106, P222, DOI 10.1016/j.nbd.2017.06.005; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Salat DH, 2017, BRAIN INJURY, V31, P1204, DOI 10.1080/02699052.2017.1327672; Shahim P, 2018, NEUROLOGY, V90, pE1780, DOI 10.1212/WNL.0000000000005518; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shin SS, 2017, BRAIN IMAGING BEHAV, V11, P591, DOI 10.1007/s11682-017-9684-0; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Vogt D, 2013, J TRAUMA STRESS, V26, P710, DOI 10.1002/jts.21868; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; Wakida NM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196153; Winston CN, 2019, ALZH DEMENT-DADM, V11, P61, DOI 10.1016/j.dadm.2018.11.002; Winston CN, 2018, J ALZHEIMERS DIS, V66, P971, DOI 10.3233/JAD-180302; Winston Charisse N, 2016, Alzheimers Dement (Amst), V3, P63, DOI 10.1016/j.dadm.2016.04.001; Xiong Y, 2018, CHIN J TRAUMATOL, V21, P137, DOI 10.1016/j.cjtee.2018.02.003; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	70	29	30	6	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-453X		FRONT NEUROSCI-SWITZ	Front. Neurosci.	OCT 2	2019	13								1005	10.3389/fnins.2019.01005			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	JO4RN	WOS:000497567100001	31680797	gold, Green Published			2022-02-06	
J	Leddy, JJ; Haider, MN; Hinds, AL; Darling, S; Willer, BS				Leddy, John J.; Haider, Mohammad N.; Hinds, Andrea L.; Darling, Scott; Willer, Barry S.			A Preliminary Study of the Effect of Early Aerobic Exercise Treatment for Sport-Related Concussion in Males	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						exercise treatment; relative rest; concussion; adolescent; symptoms	POSTCONCUSSION SYNDROME; SLEEP QUALITY; HIGH-SCHOOL; RECOVERY; SYMPTOMS; RELIABILITY; REHABILITATION; CHILDREN; BRAIN; PARTICIPATION	Objective: To study the effect of early prescribed aerobic exercise versus relative rest on rate of recovery in male adolescents acutely after sport-related concussion (SRC). Design: Quasi-experimental design. Setting: University sports medicine centers. Participants: Exercise group (EG, n = 24, 15.13 +/- 1.4 years, 4.75 +/- 2.5 days from injury) and rest group (RG, n = 30, 15.33 +/- 1.4 years, 4.50 +/- 2.1 days from injury). Interventions: Exercise group performed a progressive program of at least 20 minutes of daily subthreshold aerobic exercise. Rest group was prescribed relative rest (no structured exercise). Both groups completed daily online symptom reports (Postconcussion Symptom Scale) for 14 days. Main Outcome Measures: Days to recovery after treatment prescription. Recovery was defined as return to baseline symptoms, exercise tolerant, and judged recovered by physician examination. Results: Recovery time from initial visit was significantly shorter in EG (8.29 +/- 3.9 days vs 23.93 +/- 41.7 days, P = 0.048). Mixed-effects linear models showed that all symptom clusters decreased with time and that there was no significant interaction between treatment group and time. No EG participants experienced delayed recovery (>30 days), whereas 13% (4/30) of RG participants experienced delayed recovery. Conclusions: These preliminary data suggest that early subthreshold aerobic exercise prescribed to symptomatic adolescent males within 1 week of SRC hastens recovery and has the potential to prevent delayed recovery.	[Leddy, John J.; Haider, Mohammad N.; Hinds, Andrea L.; Darling, Scott] SUNY Buffalo, UBMD Orthopaed & Sports Med, Buffalo, NY USA; [Haider, Mohammad N.] SUNY Buffalo, Dept Neurosci, Buffalo, NY USA; [Willer, Barry S.] SUNY Buffalo, Dept Psychiat, Buffalo, NY USA		Leddy, JJ (corresponding author), UBMD Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu			The Ralph C. Wilson Foundation; Program for Understanding Childhood Concussion and Stroke; Robert Rich Family Foundation; Buffalo Sabres Foundation; National Football League Charities; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094444] Funding Source: NIH RePORTER	The authors thank The Ralph C. Wilson Foundation, Program for Understanding Childhood Concussion and Stroke, The Robert Rich Family Foundation, The Buffalo Sabres Foundation, the National Football League Charities, and the National Institutes of Health for their financial support.	[Anonymous], 2013, R LANG ENV STAT COMP; ARAI Y, 1989, AM J PHYSIOL, V256, pH132, DOI 10.1152/ajpheart.1989.256.1.H132; Balasundaram AP, 2017, SCAND J MED SCI SPOR, V27, P2002, DOI 10.1111/sms.12844; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Borg G., 1998, BORGS PERCEIVED EXER; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Chrisman SPD, 2017, NEUROREHABILITATION, V40, P493, DOI 10.3233/NRE-161436; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Dimeo F, 2001, BRIT J SPORT MED, V35, P114, DOI 10.1136/bjsm.35.2.114; Echemendia RJ, 2017, BRIT J SPORT MED, V51, P895, DOI 10.1136/bjsports-2016-097466; El-Sheikh M, 2013, J SLEEP RES, V22, P282, DOI 10.1111/jsr.12019; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Griffin EW, 2011, PHYSIOL BEHAV, V104, P934, DOI 10.1016/j.physbeh.2011.06.005; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Guiney H, 2015, NEUROPSYCHOLOGY, V29, P1, DOI 10.1037/neu0000124; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Haider MN, 2017, BR J SPORTS MED; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hinds A, 2016, J NEUROL NEUROPHYSIO, V7, P388, DOI DOI 10.4172/2155-9562.1000388; Hinds Andrea, 2016, Concussion, V1, pCNC15, DOI 10.2217/cnc-2016-0002; Joyce AS, 2015, MED SCI SPORT EXER, V47, P1119, DOI 10.1249/MSS.0000000000000534; Kappus RM, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-015-0046-6; Kline CE, 2013, SLEEP, V36, P1279, DOI 10.5665/sleep.2946; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Leddy J, 2017, J ATHL TRAINING, V52, P299, DOI 10.4085/1062-6050-51.11.08; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2018, CLIN J SPORT MED, V28, P13, DOI 10.1097/JSM.0000000000000431; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P273, DOI 10.1080/87565641.2015.1067706; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Matuszak JM, 2016, SPORTS HEALTH, V8, P260, DOI 10.1177/1941738116641394; McCarty CA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0459; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Merritt VC, 2015, J CLIN EXP NEUROPSYC, V37, P764, DOI 10.1080/13803395.2015.1060950; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; Oliveira NL, 2014, AM HEART J, V167, P753, DOI 10.1016/j.ahj.2014.02.001; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Schwandt M, 2012, J HEAD TRAUMA REHAB, V27, P99, DOI 10.1097/HTR.0b013e31820e6858; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Vega SR, 2006, BRAIN RES, V1121, P59, DOI 10.1016/j.brainres.2006.08.105; Yang PY, 2012, J PHYSIOTHER, V58, P157, DOI 10.1016/S1836-9553(12)70106-6; Youngstedt SD, 2005, CLIN SPORT MED, V24, P355, DOI 10.1016/j.csm.2004.12.003	54	29	30	8	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2019	29	5					353	360		10.1097/JSM.0000000000000663			8	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	KG1HH	WOS:000509692100002	30239422	Green Accepted			2022-02-06	
J	Lee, EB; Kinch, K; Johnson, VE; Trojanowski, JQ; Smith, DH; Stewart, W				Lee, Edward B.; Kinch, Kevin; Johnson, Victoria E.; Trojanowski, John Q.; Smith, Douglas H.; Stewart, William			Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players	ACTA NEUROPATHOLOGICA			English	Article						Chronic traumatic encephalopathy; Traumatic brain injury; Neurodegeneration; Dementia; Alzheimer's disease; Tau	ALZHEIMERS ASSOCIATION GUIDELINES; NEUROPATHOLOGIC ASSESSMENT; NATIONAL INSTITUTE; DISEASE; BRAIN; PATHOLOGY; CRITERIA; CONSEQUENCE; CONSORTIUM; DEPOSITION	Chronic traumatic encephalopathy (CTE) is reported at high prevalence in selected autopsy case series of former contact sports athletes. Nevertheless, the contribution of CTE pathology to clinical presentation and its interaction with co-morbid neurodegenerative pathologies remain unclear. To address these issues, we performed comprehensive neuropathology assessments on the brains of former athletes with dementia and considered these findings together with detailed clinical histories to derive an integrated clinicopathological diagnosis for each case. Consecutive, autopsy-acquired brains from former soccer and rugby players with dementia were assessed for neurodegenerative pathologies using established and preliminary consensus protocols. Thereafter, next of kin interviews were conducted to obtain detailed accounts of the patient's clinical presentation and course of disease to inform a final, integrated clinicopathological diagnosis. Neuropathologic change consistent with CTE (CTE-NC) was confirmed in five of seven former soccer and three of four former rugby players' brains, invariably in combination with mixed, often multiple neurodegenerative pathologies. However, in just three cases was the integrated dementia diagnosis consistent with CTE, the remainder having alternate diagnoses, with the most frequent integrated diagnosis Alzheimer's disease (AD) (four cases; one as mixed AD and vascular dementia). This consecutive autopsy series identifies neuropathologic change consistent with preliminary diagnostic criteria for CTE (CTE-NC) in a high proportion of former soccer and rugby players dying with dementia. However, in the majority, CTE-NC appears as a co-morbidity rather than the primary, dementia causing pathology. As such, we suggest that while CTE-NC might be common in former athletes with dementia, in many cases its clinical significance remains uncertain.	[Lee, Edward B.] Univ Penn, Translat Neuropathol Res Lab, Philadelphia, PA 19104 USA; [Kinch, Kevin; Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland; [Johnson, Victoria E.; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Penn Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Trojanowski, John Q.] Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Inst Aging,Perelman Sch Med, Philadelphia, PA USA; [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland		Stewart, W (corresponding author), Queen Elizabeth Univ Hosp, Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.; Stewart, W (corresponding author), Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland.	william.stewart@glasgow.ac.uk	Lee, Edward/AAU-8436-2021	Stewart, William/0000-0003-2199-2582	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398, R01NS094003, R01NS038104]; Professional Footballers Association; NHS Research Scotland Career Researcher Fellowship; Football Association; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G1100578, G0701018, MR/N004272/1] Funding Source: UKRI; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092398, R01NS094003, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG017586] Funding Source: NIH RePORTER	This work is supported by funding from: the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award numbers R01NS092398, R01NS094003 and R01NS038104; The Football Association and Professional Footballers Association (WS); and an NHS Research Scotland Career Researcher Fellowship (WS).	Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dickson DW, 2002, J NEUROPATH EXP NEUR, V61, P935, DOI 10.1093/jnen/61.11.935; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goldfinger MH, 2018, ACTA NEUROPATHOL, V136, P973, DOI 10.1007/s00401-018-1926-8; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grinberg LT, 2016, J ALZHEIMERS DIS, V54, P169, DOI 10.3233/JAD-160312; Hales C, 2014, NEUROLOGY, V83, P2307, DOI 10.1212/WNL.0000000000001081; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; Hyman BT, 2012, ALZHEIMERS DEMENT, V8, P1, DOI 10.1016/j.jalz.2011.10.007; Jack CR, 2011, ALZHEIMERS DEMENT, V7, P257, DOI 10.1016/j.jalz.2011.03.004; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Josephs KA, 2016, ACTA NEUROPATHOL, V131, P571, DOI 10.1007/s00401-016-1537-1; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Kovacs GG, 2008, DEMENT GERIATR COGN, V26, P343, DOI 10.1159/000161560; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P605, DOI 10.1093/jnen/nlx041; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Lee EB, 2018, ACTA NEUROPATHOL, V135, P643, DOI 10.1007/s00401-018-1827-x; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 2017, NEUROLOGY, V89, P88, DOI 10.1212/WNL.0000000000004058; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Nag S, 2015, ANN NEUROL, V77, P942, DOI 10.1002/ana.24388; OLICHNEY JM, 1995, ARCH NEUROL-CHICAGO, V52, P702, DOI 10.1001/archneur.1995.00540310076019; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Outeiro TF, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0306-8; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Robinson JL, 2018, BRAIN, V141, P2181, DOI 10.1093/brain/awy146; Smith DH, 2019, NAT REV NEUROL, V15, P179, DOI 10.1038/s41582-018-0114-8; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Spires-Jones TL, 2017, ACTA NEUROPATHOL, V134, P187, DOI 10.1007/s00401-017-1709-7; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stewart W, 2016, QJM-INT J MED, V109, P11, DOI 10.1093/qjmed/hcv070; Stewart W, 2019, LANCET NEUROL, V18, P231, DOI 10.1016/S1474-4422(19)30020-1; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Wilson L, 2017, LANCET NEUROL, V16, P813, DOI 10.1016/S1474-4422(17)30279-X; Zanier ER, 2018, BRAIN, V141, P2685, DOI 10.1093/brain/awy193	50	29	29	1	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	SEP	2019	138	3			SI		389	399		10.1007/s00401-019-02030-y			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	IQ2SB	WOS:000480599000004	31152201	Green Published, Green Accepted, hybrid			2022-02-06	
J	Spaite, DW; Bobrow, BJ; Keim, SM; Barnhart, B; Chikani, V; Gaither, JB; Sherrill, D; Denninghoff, KR; Mullins, T; Adelson, PD; Rice, AD; Viscusi, C; Hu, C				Spaite, Daniel W.; Bobrow, Bentley J.; Keim, Samuel M.; Barnhart, Bruce; Chikani, Vatsal; Gaither, Joshua B.; Sherrill, Duane; Denninghoff, Kurt R.; Mullins, Terry; Adelson, P. David; Rice, Amber D.; Viscusi, Chad; Hu, Chengcheng			Association of Statewide Implementation of the Prehospital Traumatic Brain Injury Treatment Guidelines With Patient Survival Following Traumatic Brain Injury The Excellence in Prehospital Injury Care (EPIC) Study	JAMA SURGERY			English	Article							ADVANCED LIFE-SUPPORT; RAPID-SEQUENCE INTUBATION; HOSPITAL CARDIAC-ARREST; GLASGOW COMA SCALE; AMERICAN-HEART-ASSOCIATION; ENDOTRACHEAL INTUBATION; CARDIOPULMONARY-RESUSCITATION; CLINICAL-TRIALS; RECOMMENDED GUIDELINES; EUROPEAN-RESUSCITATION	Importance Traumatic brain injury (TBI) is a massive public health problem. While evidence-based guidelines directing the prehospital treatment of TBI have been promulgated, to our knowledge, no studies have assessed their association with survival. Objective To evaluate the association of implementing the nationally vetted, evidence-based, prehospital treatment guidelines with outcomes in moderate, severe, and critical TBI. Design, Setting, and Participants The Excellence in Prehospital Injury Care (EPIC) Study included more than 130 emergency medical services systems/agencies throughout Arizona. This was a statewide, multisystem, intention-to-treat study using a before/after controlled design with patients with moderate to critically severe TBI (US Centers for Disease Control and Prevention Barell Matrix-Type 1 and/or Abbreviated Injury Scale Head region severity >= 3) transported to trauma centers between January 1, 2007, and June 30, 2015. Data were analyzed between October 25, 2017, and February 22, 2019. Interventions Implementation of the prehospital TBI guidelines emphasizing avoidance/treatment of hypoxia, prevention/correction of hyperventilation, and avoidance/treatment of hypotension. Main Outcomes and Measures Primary: survival to hospital discharge; secondary: survival to hospital admission. Results Of the included patients, the median age was 45 years, 14666 (67.1%) were men, 7181 (32.9%) were women; 16408 (75.1% ) were white, 1400 (6.4%) were Native American, 743 (3.4% ) were Black, 237 (1.1%) were Asian, and 2791 (12.8%) were other race/ethnicity. Of the included patients, 21852 met inclusion criteria for analysis (preimplementation phase [P1]: 15228; postimplementation [P3]: 6624). The primary analysis (P3 vs P1) revealed an adjusted odds ratio (aOR) of 1.06 (95% CI, 0.93-1.21; P = .40) for survival to hospital discharge. The aOR was 1.70 (95% CI, 1.38-2.09; P < .001) for survival to hospital admission. Among the severe injury cohorts (but not moderate or critical), guideline implementation was significantly associated with survival to discharge (Regional Severity Score-Head 3-4: aOR, 2.03; 95% CI, 1.52-2.72; P < .001; Injury Severity Score 16-24: aOR, 1.61; 95% CI, 1.07-2.48; P = .02). This was also true for survival to discharge among the severe, intubated subgroups (Regional Severity Score-Head 3-4: aOR, 3.14; 95% CI, 1.65-5.98; P < .001; Injury Severity Score 16-24: aOR, 3.28; 95% CI, 1.19-11.34; P = .02). Conclusions and Relevance Statewide implementation of the prehospital TBI guidelines was not associated with significant improvement in overall survival to hospital discharge (across the entire, combined moderate to critical injury spectrum). However, adjusted survival doubled among patients with severe TBI and tripled in the severe, intubated cohort. Furthermore, guideline implementation was significantly associated with survival to hospital admission. These findings support the widespread implementation of the prehospital TBI treatment guidelines.	[Spaite, Daniel W.; Bobrow, Bentley J.; Keim, Samuel M.; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Rice, Amber D.; Viscusi, Chad; Hu, Chengcheng] Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ USA; [Spaite, Daniel W.; Bobrow, Bentley J.; Keim, Samuel M.; Gaither, Joshua B.; Denninghoff, Kurt R.; Rice, Amber D.; Viscusi, Chad] Univ Arizona, Dept Emergency Med, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA; [Bobrow, Bentley J.; Chikani, Vatsal; Mullins, Terry] Arizona Dept Hlth Serv, Bur EMS, Phoenix, AZ 85007 USA; [Keim, Samuel M.; Sherrill, Duane; Hu, Chengcheng] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85724 USA; [Adelson, P. David] Univ Arizona, Coll Med, Dept Child Hlth Neurosurg, Barrow Neurol Inst,Phoenix Childrens Hosp, Phoenix, AZ USA		Spaite, DW (corresponding author), Univ Arizona, Dept Emergency Med, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	dan@aemrc.arizona.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS071049]	The EPIC Study is funded by a grant from the National Institutes of Health (1R01NS071049)	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; [Anonymous], 2017, GAMM4 GEN ADDITIVE M; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bell J, 2014, TRAUMATIC BRAIN INJU; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark DE, 2006, INJURY PREV, V12, P111, DOI 10.1136/ip.2005.010058; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Davis DP, 2008, RESUSCITATION, V76, P333, DOI 10.1016/j.resuscitation.2007.08.004; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, NEUROCRIT CARE, V2, P165, DOI 10.1385/NCC:2:2:165; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Denninghoff KR, 2017, PREHOSP EMERG CARE, V21, P539, DOI 10.1080/10903127.2017.1315201; Denninghoff KR, 2008, WEST J EMERG MED, V9, P184; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Feldman A, 2015, ANN EMERG MED, V65, P325, DOI 10.1016/j.annemergmed.2014.07.454; Finkelstein E.A., 2006, INCIDENCE EC BURDEN, DOI [10.1093/acprof:oso/9780195179484.001.0001, DOI 10.1093/ACPROF:OSO/9780195179484.001.0001]; FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.2307/2336755; Ford I, 2016, NEW ENGL J MED, V375, P454, DOI 10.1056/NEJMra1510059; Gaither JB, 2012, ANN EMERG MED, V60, P732, DOI 10.1016/j.annemergmed.2012.06.017; GENTLEMAN D, 1992, INT SURG, V77, P297; Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, P496, DOI 10.1097/PCC.0b013e318259ee85; Kreutzer JS, 2001, BRAIN INJURY, V15, P763, DOI 10.1080/02699050010025786; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2010, J TRAUMA, V69, P1, DOI 10.1097/TA.0b013e3181e03a21; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MAYER TA, 1985, ANN EMERG MED, V14, P1178, DOI 10.1016/S0196-0644(85)81025-8; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Lynnger TM, 2016, J NEUROSURG-PEDIATR, V17, P19, DOI 10.3171/2015.5.PEDS1544; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; R Foundation for Statistical Computing, R LANG ENV STAT COMP; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schuttler J, 1995, ANAESTHESIST, V44, P850, DOI 10.1007/s001010050221; Shutter LA, 2008, ANN EMERG MED, V51, pS37, DOI 10.1016/j.annemergmed.2007.11.013; Spaite DW, 2017, ANN EMERG MED, V70, P522, DOI 10.1016/j.annemergmed.2017.03.027; Spaite DW, 2017, JAMA SURG, V152, P360, DOI 10.1001/jamasurg.2016.4686; Spaite DW, 2017, ANN EMERG MED, V69, P62, DOI 10.1016/j.annemergmed.2016.08.007; Spaite DW, 2014, ANN EMERG MED, V64, P496, DOI 10.1016/j.annemergmed.2014.05.028; Spaite DW, 2014, ACAD EMERG MED, V21, P818, DOI 10.1111/acem.12411; SPAITE DW, 1995, ANN EMERG MED, V26, P146, DOI 10.1016/S0196-0644(95)70144-3; SPAITE DW, 1990, ANN EMERG MED, V19, P1270, DOI 10.1016/S0196-0644(05)82286-3; Spaite DW, 2009, EMERGENCY MED SERVIC; Spaite DW, 1993, PREHOSP DISASTER MED, V8, pS35; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Stiell IG, 2007, NEW ENGL J MED, V356, P2156, DOI 10.1056/NEJMoa060334; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Stiell IG, 1999, ANN EMERG MED, V34, P256, DOI 10.1016/S0196-0644(99)70241-6; Stocchetti N, 2001, Eur J Emerg Med, V8, P215, DOI 10.1097/00063110-200109000-00009; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; US Centers for Disease Control and Prevention, BAR MATR CDC WEBS; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Wang CH, 2014, RESUSCITATION, V85, P1219, DOI 10.1016/j.resuscitation.2014.06.022; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Wood S, 2017, GEN ADDITIVE MODELS, VSecond; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; ZARITSKY A, 1995, RESUSCITATION, V30, P95, DOI 10.1016/0300-9572(95)00884-V; Zornow MH, 2002, CRIT CARE MED, V30, P2774, DOI 10.1097/00003246-200212000-00026	91	29	30	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	JUL	2019	154	7							e191152	10.1001/jamasurg.2019.1152			11	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	IR6AU	WOS:000481522400029	31066879	Green Published			2022-02-06	
J	Ezekiel, L; Collett, J; Mayo, NE; Pang, L; Field, L; Dawes, H				Ezekiel, Leisle; Collett, Johnny; Mayo, Nancy E.; Pang, Lori; Field, Leanne; Dawes, Helen			Factors Associated With Participation in Life Situations for Adults With Stroke: A Systematic Review	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the Royal-College-of-Occupational-Therapists	JUN 20, 2017	Birmingham, ENGLAND	Royal Coll Occupat Therapists		Rehabilitation; Social participation; Stroke	QUALITY-OF-LIFE; SICKNESS IMPACT PROFILE; TRAUMATIC BRAIN-INJURY; SOCIAL-PARTICIPATION; OUTCOME MEASURES; INTERNATIONAL CLASSIFICATION; COMMUNITY REINTEGRATION; PSYCHOMETRIC PROPERTIES; ISCHEMIC-STROKE; YOUNG-ADULTS	Objectives: To identify biopsychosocial factors associated with participation outcomes for adults with stroke and to investigate factors associated with participation at different time points poststroke. Data Sources: Medline, CINAHL, AMED, PyschINFO, and Web of Science were systematically searched using keywords stroke, participation, and outcomes and their synonyms on May 15, 2017. Study Selection: Observational studies reporting on biopsychosocial factors and participation outcomes for community-dwelling adults with stroke were selected. Studies were eligible for inclusion if participation outcomes were measured using indices that mapped to the participation domain of the International Classification of Functioning, Disability and Health (ICF). Intervention studies were excluded. A second reviewer checked all studies against eligibility criteria at each stage. Data Extraction: Data were extracted on any statistically determined association between biopsychosocial factors and participation outcomes. Data Synthesis: The proportion of studies reporting significant associations with variables was classified according to the ICF. The exact binomial test was used to determine the probability that the proportion of studies reporting significant associations was due to chance alone. Qualitative descriptive summaries of each study allowed consideration of interactions between variables and changes in participation over time points. Conclusions: Although depressive symptoms, cognitive functioning, and mobility were found to have the strongest associations with participation, we found that other frequently occurring factors (such as fatigue and environmental factors) were less extensively considered. The diversity of outcome measures encountered within the review highlight the need for a consensus on a core set of outcome measures to evaluate long-term participation in life situations poststroke. (C) 2018 by the American Congress of Rehabilitation Medicine	[Ezekiel, Leisle; Collett, Johnny; Field, Leanne; Dawes, Helen] Oxford Brookes Univ, Oxford Inst Nursing Midwifery & Allied Hlth Res O, Fac Hlth & Life Sci, Gipsy Lane, Oxford OX3 0BP, England; [Mayo, Nancy E.] McGill Univ, Canadian Acad Hlth Sci, Dept Med, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Pang, Lori] Cent London Community Healthcare NHS Trust, London, England		Ezekiel, L (corresponding author), Oxford Brookes Univ, Oxford Inst Nursing Midwifery & Allied Hlth Res O, Fac Hlth & Life Sci, Gipsy Lane, Oxford OX3 0BP, England.	lezekiel@brookes.ac.uk	Ezekiel, Leisle/I-3632-2019	, Johnny/0000-0003-4138-2589; Dawes, Helen/0000-0002-2933-5213	Oxford Brookes University; Elizabeth Casson Trust; National Institute for Health Research, Oxford Biomedical Research CentreNational Institute for Health Research (NIHR); Heath Education England Thames Valley; Health Education England Thames Valley INTALECA program	Leisle Ezekiel was supported by Oxford Brookes University. Helen Dawes was supported by the Elizabeth Casson Trust and National Institute for Health Research, Oxford Biomedical Research Centre. Johnny Collett was supported by Heath Education England Thames Valley and Oxford Brookes University. Leanne Field was supported by Health Education England Thames Valley INTALECA program.	[Anonymous], 2013, US ICF PRACT MAN US; Atler K, 2015, DISABIL REHABIL, V37, P121, DOI 10.3109/09638288.2014.910560; Bartlett DJ, 2006, DISABIL REHABIL, V28, P1169, DOI 10.1080/09638280600551567; Baum C. M., 2001, ACTIVITY CARD SORT; Bejot Y, 2014, J NEUROL NEUROSUR PS, V85, P509, DOI 10.1136/jnnp-2013-306203; Bentsen L, 2014, J STROKE CEREBROVASC, V23, P1944, DOI 10.1016/j.jstrokecerebrovasdis.2014.02.002; Berges IM, 2012, DISABIL REHABIL, V34, P2119, DOI 10.3109/09638288.2012.673684; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Blomer AMV, 2015, ARCH PHYS MED REHAB, V96, P456, DOI 10.1016/j.apmr.2014.09.003; Butler Andrew, 2006, J Neurol Phys Ther, V30, P148; Cardol M, 2001, ARCH PHYS MED REHAB, V82, P210, DOI 10.1053/apmr.2001.18218; Carod-Artal FJ, 2009, J NEUROL SCI, V284, P63, DOI 10.1016/j.jns.2009.04.008; Carter BS, 2000, NEUROSURGERY, V46, P1326, DOI 10.1097/00006123-200006000-00008; Chahal N, 2011, NEUROEPIDEMIOLOGY, V37, P31, DOI 10.1159/000328647; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Clarke PJ, 1999, DISABIL REHABIL, V21, P116, DOI 10.1080/096382899297855; Coole C, 2013, J OCCUP REHABIL, V23, P406, DOI 10.1007/s10926-012-9401-1; Cooper CL, 2015, BRIT J CLIN PSYCHOL, V54, P181, DOI 10.1111/bjc.12068; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Craig P, 2013, INT J NURS STUD, V50, P587, DOI 10.1016/j.ijnurstu.2012.09.010; Crichton SL, 2016, J NEUROL NEUROSUR PS, V87, P1091, DOI 10.1136/jnnp-2016-313361; Dehlendorff C, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001967; Desrosiers J, 2005, J REHABIL MED, V37, P353, DOI 10.1080/16501970510037096; Desrosiers J, 2002, DISABIL REHABIL, V24, P774, DOI 10.1080/09638280210125814; Desrosiers J, 2008, NEUROREHAB NEURAL RE, V22, P288, DOI 10.1177/1545968307307116; Desrosiers J, 2006, TOP STROKE REHABIL, V13, P86, DOI 10.1310/tsr1304-86; Dijkers MP, 2010, ARCH PHYS MED REHAB, V91, pS5, DOI 10.1016/j.apmr.2009.10.036; Duncan F, 2012, J PSYCHOSOM RES, V73, P18, DOI 10.1016/j.jpsychores.2012.04.001; Duncan PW, 1999, STROKE, V30, P2131, DOI 10.1161/01.STR.30.10.2131; Egan M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1872-5; Egan M, 2014, ARCH PHYS MED REHAB, V95, P262, DOI 10.1016/j.apmr.2013.08.013; Eyssen IC, 2011, ARCH PHYS MED REHAB, V92, P983, DOI 10.1016/j.apmr.2011.01.006; Ezekiel L, 2015, PROTOCOL FACTORS ASS; Fallahpour M, 2011, J REHABIL MED, V43, P388, DOI 10.2340/16501977-0789; Gall SL, 2009, CEREBROVASC DIS, V27, P123, DOI 10.1159/000177919; Gottlieb A, 2001, AGING-CLIN EXP RES, V13, P11, DOI 10.1007/BF03351488; Graven C, 2011, DISABIL REHABIL, V33, P1501, DOI 10.3109/09638288.2010.542874; Greenl S., 2008, MODERN EPIDEMIOLOGY, P652; Gum A, 2006, PSYCHOL HEALTH, V21, P319, DOI 10.1080/14768320500422907; HARWOOD RH, 1994, J NEUROL NEUROSUR PS, V57, P825, DOI 10.1136/jnnp.57.7.825; Harwood RH, 1997, DISABIL REHABIL, V19, P205, DOI 10.3109/09638289709166528; Heinemann AW, 2015, ARCH PHYS MED REHAB, V96, P589, DOI 10.1016/j.apmr.2013.11.024; Jansen HE, 2012, J REHABIL MED, V44, P47, DOI 10.2340/16501977-0908; Kessler D, 2012, BRIT J OCCUP THER, V75, P403, DOI 10.4276/030802212X13470263980757; Lakshminarayan K, 2014, STROKE, V45, P2575, DOI 10.1161/STROKEAHA.114.005512; Levasseur M, 2010, SOC SCI MED, V71, P2141, DOI 10.1016/j.socscimed.2010.09.041; Mallinson T, 2010, ARCH PHYS MED REHAB, V91, pS29, DOI 10.1016/j.apmr.2010.04.027; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Mercer VS, 2009, PHYS THER, V89, P1061, DOI 10.2522/ptj.20080368; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535, 10.1371/journal.pmed.1000217, 10.1016/j.ijsu.2010.02.007]; Naess H, 2006, STROKE, V37, P1232, DOI 10.1161/01.STR.0000217652.42273.02; National Heart Lung and Blood Institute, QUAL ASS TOOL OBS CO; NHLBI, BACKGR DEV US STUD Q; Noonan VK, 2009, DISABIL REHABIL, V31, P1883, DOI 10.1080/09638280902846947; Noreau L, 2004, DISABIL REHABIL, V26, P346, DOI 10.1080/09638280410001658649; Northcott S, 2016, CLIN REHABIL, V30, P811, DOI 10.1177/0269215515602136; Obembe AO, 2016, NEUROREHAB NEURAL RE, V30, P384, DOI 10.1177/1545968315597072; Ostir GV, 2006, ARCH PHYS MED REHAB, V87, P1043, DOI 10.1016/j.apmr.2006.04.024; Patel MD, 2006, AGE AGEING, V35, P273, DOI 10.1093/ageing/afj074; Perenboom RJM, 2003, DISABIL REHABIL, V25, P577, DOI 10.1080/0963828031000137081; Poole C, 2006, INT J EPIDEMIOL, V35, P370, DOI 10.1093/ije/dyi248; Popay J., 2006, ESRC METHODS PROGRAM, DOI DOI 10.13140/2.1.1018.4643; Post MWM, 2008, J REHABIL MED, V40, P620, DOI 10.2340/16501977-0223; Post MWM, 2012, DISABIL REHABIL, V34, P478, DOI 10.3109/09638288.2011.608148; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rosenthal R., 2008, ESSENTIALS BEHAV RES; Salinas J, 2016, STROKE, V47, P180, DOI 10.1161/STROKEAHA.115.010898; Salter K, 2005, DISABIL REHABIL, V27, P507, DOI 10.1080/0963828040008552; Salter K., 2013, OUTCOME MEASURES STR; Salter K, 2008, J REHABIL MED, V40, P595, DOI 10.2340/16501977-0238; Schepers VP, 2005, ARCH PHYS MED REHAB, V86, P1472, DOI 10.1016/j.apmr.2004.11.039; SCHULING J, 1993, STROKE, V24, P1173, DOI 10.1161/01.STR.24.8.1173; Singam A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144344; Sivan M, 2011, J REHABIL MED, V43, P181, DOI 10.2340/16501977-0674; Skolarus LE, 2014, STROKE, V45, P224, DOI 10.1161/STROKEAHA.113.002874; Stummer C, 2015, DISABIL REHABIL, V37, P942, DOI 10.3109/09638288.2014.948137; Sturm JW, 2002, STROKE, V33, P2888, DOI 10.1161/01.STR.0000040407.44712.C7; Sturm JW, 2002, STROKE, V33, P762, DOI 10.1161/hs0302.103815; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tse T, 2017, TOP STROKE REHABIL, V24, P405, DOI 10.1080/10749357.2017.1318339; Tse T, 2013, ARCH PHYS MED REHAB, V94, P177, DOI 10.1016/j.apmr.2012.09.002; Valentine J.C., 2009, HDB RES SYNTHESIS ME; Veras M, 2017, J TELEMED TELECARE, V23, P567, DOI 10.1177/1357633X16656235; Verhoeven CLM, 2011, J STROKE CEREBROVASC, V20, P450, DOI 10.1016/j.jstrokecerebrovasdis.2010.02.018; Walsh ME, 2015, DISABIL REHABIL, V37, P1599, DOI 10.3109/09638288.2014.974834; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whiteneck G., 2006, WORKSH DIS AM NEW LO, P50; Whiteneck GG, 2010, ARCH PHYS MED REHAB, V91, pS54, DOI 10.1016/j.apmr.2009.08.154; Wolf TJ, 2012, BRAIN IMPAIR, V13, P16, DOI 10.1017/BrImp.2012.1; Wood JP, 2010, CLIN REHABIL, V24, P1045, DOI 10.1177/0269215510375901; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; Woodman P, 2014, DISABIL REHABIL, V36, P2031, DOI 10.3109/09638288.2014.887796; World Health Organization, 2002, COMM LANG FUNCT DIS; World Health Organization, 2001, INT CLASS FUNCT DIS; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; 2012, TOP STROKE REHABIL, V19, P457, DOI DOI 10.1310/TSR1906-457; 2010, NEUROLOGY, V75, P1597; 2015, ARCH PHYS MED REHAB, V96, P1684, DOI DOI 10.1016/J.APMR.2015.05.005; 2008, STROKE, V39, P148, DOI DOI 10.1161/STROKEAHA.107.491399	100	29	29	1	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2019	100	5					945	955		10.1016/j.apmr.2018.06.017			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	HW3UV	WOS:000466619100019	29981316	Green Submitted			2022-02-06	
J	Alverson, WA; O'Rourke, JJF; Soble, JR				Alverson, W. Alex; O'Rourke, Justin J. F.; Soble, Jason R.			The Word Memory Test genuine memory impairment profile discriminates genuine memory impairment from invalid performance in a mixed clinical sample with cognitive impairment	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance validity; cognitive impairment; neuropsychological assessment; psychometrics; Word Memory Test (WMT)	SYMPTOM VALIDITY TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; TRAUMATIC BRAIN-INJURY; RELIABLE DIGIT SPAN; DEMENTIA PROFILE; HIGH SPECIFICITY; TRIAL 1; SENSITIVITY; ACCURACY; SCORES	Objective: The Word Memory Test (WMT) is a memory-based performance validity test (PVT) with adjusted interpretive criteria (Genuine Memory Impairment Profile; GMIP) proposed for those with cognitive impairment (CI). The GMIP has been criticized for poor discriminability; thus, this study sought to validate the GMIP in a mixed clinical sample. Analyses aimed to demonstrate enhanced detection of invalid neuropsychological test performance while minimizing false positives in a sample including patients with mild CI. Method: Data included 116 Veterans who completed the WMT and four criterion PVTs during clinical evaluation. This sample was 37.1% valid-CI, 33.6% valid-unimpaired, and 29.3% invalid per criterion PVTs. Group differences in WMT performance and diagnostic accuracy were assessed. Results: WMT performance significantly differed between validity groups (Wilk's Lambda = .40, F[6, 109] = 27.62, p < .001, eta(2)(p) = .60) with invalid participants scoring significantly lower across all WMT indices, with larger effect sizes for the effort subtests (eta(2)(p) = .44-.55) than memory subtests (eta(2)(p) = .16-.32). CI also had a significant effect on WMT performance (Wilk's Lambda = .65, F[6, 75] = 6.66, p < .001, eta(2)(p) = .35). Those with CI scored lower across all indices, with larger effect sizes for the memory subtests (eta(2)(p) = .29-.30) relative to effort subtests (eta(2)(p) = .18-.20). Standard WMT pass/fail criteria were sensitive (.97), but had unacceptable specificity (. 66). GMIP sensitivity (.94) and specificity (.91) were robust with a DOR of 171.43. Conclusions: WMT indices were more significantly affected by performance validity than memory. However, with CI, GMIP criteria is essential to improve diagnostic accuracy and reduce false positive errors when identifying invalid performance.	[Alverson, W. Alex; O'Rourke, Justin J. F.; Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Psychiat, Chicago, IL USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Neurol, Chicago, IL USA		Alverson, WA (corresponding author), South Texas Vet Hlth Care Syst, Psychol Serv 116B, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	William.Alverson@VA.gov					Allen MD, 2007, BRAIN INJURY, V21, P1425, DOI 10.1080/02699050701769819; Allen MD, 2011, PSYCHOL INJ LAW, V4, P140, DOI 10.1007/s12207-011-9105-4; APA, 2013, DIAGNOSTIC STAT MANU, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Arnett P., 2013, SECONDARY INFLUENCES; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2010, CLIN NEUROPSYCHOL, V24, P873, DOI 10.1080/13854040903527295; Bain K. M., ASSESSMENT, DOI [10.1177/107319111772517, DOI 10.1177/107319111772517]; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Boone K., 2002, DOT COUNTING TEST; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Eichstaedt KE, 2014, CLIN NEUROPSYCHOL, V28, P941, DOI 10.1080/13854046.2014.942374; Fazio RL, 2015, ARCH CLIN NEUROPSYCH, V30, P293, DOI 10.1093/arclin/acv024; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; GERVAIS RO, 2001, J FORENSIC NEUROPSYC, V2, DOI DOI 10.1300/J151V02N02_01; Green P., 2005, WORD MEMORY TEST WIN; Green P., 2004, MED SYMPTOM VALIDITY; Green P., 2003, WORD MEMORY TEST WIN; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Howe L, 2009, CLIN NEUROPSYCHOL, V23, P329, DOI 10.1080/13854040801945060; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Pearson, 2009, ADV CLIN SOLUTIONS W; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rienstra A, 2013, ARCH CLIN NEUROPSYCH, V28, P463, DOI 10.1093/arclin/act026; Robinson JS, 2018, ARCH CLIN NEUROPSYCH, V33, P238, DOI 10.1093/arclin/acx069; Schroeder RW, 2019, CLIN NEUROPSYCHOL, V33, P466, DOI 10.1080/13854046.2018.1484517; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Webber TA, 2018, CLIN NEUROPSYCHOL, V32, P657, DOI 10.1080/13854046.2017.1415374; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083	48	29	29	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	NOV 17	2019	33	8			SI		1420	1435		10.1080/13854046.2019.1599071		APR 2019	16	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	JH1IM	WOS:000465948000001	31002017				2022-02-06	
J	Rudolfson, N; Dewan, MC; Park, KB; Shrime, MG; Meara, JG; Alkire, BC				Rudolfson, Niclas; Dewan, Michael C.; Park, Kee B.; Shrime, Mark G.; Meara, John G.; Alkire, Blake C.			The economic consequences of neurosurgical disease in low- and middle-income countries	JOURNAL OF NEUROSURGERY			English	Article						global health; cost of illness; surgical procedures; operative; neurosurgical procedures; economics	STATISTICAL LIFE; GLOBAL BURDEN; AIR-POLLUTION; HEALTH; SURGERY; COSTS; HYDROCEPHALUS; MORTALITY; DEATH	OBJECTIVE The objective of this study was to estimate the economic consequences of neurosurgical disease in low-and middle-income countries (LMICs). METHODS The authors estimated gross domestic product (GDP) losses and the broader welfare losses attributable to 5 neurosurgical disease categories in LMICs using two distinct economic models. The value of lost output (VLO) model projects annual GDP losses due to neurosurgical disease during 2015-2030, and is based on the WHO's "Projecting the Economic Cost of Ill-health" tool. The value of lost economic welfare (VLW) model estimates total welfare losses, which is based on the value of a statistical life and includes nonmarket losses such as the inherent value placed on good health, resulting from neurosurgical disease in 2015 alone. RESULTS The VLO model estimates the selected neurosurgical diseases will result in $4.4 trillion (2013 US dollars, purchasing power parity) in GDP losses during 2015-2030 in the 90 included LMICs. Economic losses are projected to disproportionately affect low-and lower-middle-income countries, risking up to a 0.6% and 0.54% loss of GDP, respectively, in 2030. The VLW model evaluated 127 LMICs, and estimates that these countries experienced $3 trillion (2013 US dollars, purchasing power parity) in economic welfare losses in 2015. Regardless of the model used, the majority of the losses can be attributed to stroke and traumatic brain injury. CONCLUSIONS The economic impact of neurosurgical diseases in LMICs is significant. The magnitude of economic losses due to neurosurgical diseases in LMICs provides further motivation beyond already compelling humanitarian reasons for action.	[Rudolfson, Niclas; Dewan, Michael C.; Park, Kee B.; Shrime, Mark G.; Meara, John G.; Alkire, Blake C.] Harvard Med Sch, Dept Global Hlth & Social Med, Program Global Surg & Social Change, Boston, MA 02115 USA; [Rudolfson, Niclas] Lund Univ, Dept Clin Sci Lund, Surg & Publ Hlth, Lund, Sweden; [Dewan, Michael C.; Shrime, Mark G.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN USA; [Alkire, Blake C.] Massachusetts Eye & Ear Infirm, Off Global Surg, Boston, MA 02114 USA; [Shrime, Mark G.; Alkire, Blake C.] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA 02115 USA; [Meara, John G.] Boston Childrens Hosp, Dept Plast & Reconstruct Surg, Boston, MA USA		Rudolfson, N (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	rudolfson@gmail.com	Alkire, Blake/AAY-6463-2020	Rudolfson, Niclas/0000-0002-2393-8494			Abdelgadir J, 2017, WORLD NEUROSURG, V101, P651, DOI 10.1016/j.wneu.2017.02.048; Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Acemoglu D, 2006, 12269 NAT BUR EC RES; Aldy JE, 2008, REV ECON STAT, V90, P573, DOI 10.1162/rest.90.3.573; Alkire B, 2011, WORLD J SURG, V35, P1194, DOI 10.1007/s00268-011-1055-1; Alkire BC, 2015, LANCET GLOB HEALTH, V3, pE316, DOI 10.1016/S2214-109X(15)70115-4; Alkire BC, 2015, LANCET GLOB HEALTH, V3, pS21, DOI 10.1016/S2214-109X(15)70088-4; Alkire BC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034595; Alleyne GA, 2002, HLTH EC GROWTH POVER; [Anonymous], 2015, WORLD HLTH ORG; Bhagava A, 2001, J HEALTH ECON, V20, P423, DOI 10.1016/S0167-6296(01)00073-X; Bhalla K, 2007, RISK ANAL, V27, P125, DOI 10.1111/j.1539-6924.2006.00864.x; Black Peter M, 2007, Clin Neurosurg, V54, P185; Bleakley H, 2007, Q J ECON, V122, P73, DOI 10.1162/qjec.121.1.73; Bloom DE, 2000, SCIENCE, V287, P1207, DOI 10.1126/science.287.5456.1207; Bloom DE, 2004, WORLD DEV, V32, P1, DOI 10.1016/j.worlddev.2003.07.002; Bloom DE, 2014, MANSONS TROPICAL DIS; Bloom DE, 2009, DIS DEV REVISITED; Chao TE, 2014, LANCET GLOB HEALTH, V2, pE334, DOI 10.1016/S2214-109X(14)70213-X; Chisholm D, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c924; CUDDINGTON JT, 1993, WORLD BANK ECON REV, V7, P173, DOI 10.1093/wber/7.2.173; Debas HT, 2015, ESSENTIAL SURG DIS C, V1; Dewan MC, 2019, J NEUROSURG, V130, P1098, DOI 10.3171/2017.10.JNS17347; El-Fiki M, 2010, WORLD NEUROSURG, V73, P254, DOI 10.1016/j.wneu.2010.02.012; Feenstra RC, 2015, AM ECON REV, V105, P3150, DOI 10.1257/aer.20130954; Gallup JL, 2001, AM J TROP MED HYG, V64, P85, DOI 10.4269/ajtmh.2001.64.85; Hammitt JK, 2002, RISK ANAL, V22, P985, DOI 10.1111/1539-6924.00265; Jamison DT, 2014, LANCET, V383, P218; Jane-Llopis E, 2011, GLOBAL EC BURDEN NON; Lorentzen P, 2008, J ECON GROWTH, V13, P81, DOI 10.1007/s10887-008-9029-3; Madheswaran S, 2007, SOC INDIC RES, V84, P83, DOI 10.1007/s11205-006-9076-0; Meara JG, 2015, AM J OBSTET GYNECOL, V213, P338, DOI 10.1016/j.ajog.2015.04.010; Murray CJL, 2013, LANCET, V381, P628; Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; Robinson LA, 2011, J BENEFIT-COST ANAL, V2, DOI [10.2202/2152-2812.1059, 10.2202/2152-2812.1009]; Roman HA, 2012, RISK ANAL, V32, P2133, DOI 10.1111/j.1539-6924.2012.01826.x; Sachs JD, 2001, MACR HLTH INV HLTH E; Shrime MG, 2015, LANCET GLOB HEALTH, V3, pS8, DOI 10.1016/S2214-109X(14)70384-5; Shrime MG, 2015, LANCET GLOB HEALTH, V3, pS38, DOI 10.1016/S2214-109X(15)70085-9; Strauss J, 1998, J ECON LIT, V36, P766; Viscusi WK, 2003, J RISK UNCERTAINTY, V27, P5, DOI 10.1023/A:1025598106257; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Warf BC, 2011, J NEUROSURG-PEDIATR, V8, P509, DOI 10.3171/2011.8.PEDS11163; Warf BC, 2010, WORLD NEUROSURG, V73, P296, DOI 10.1016/j.wneu.2010.02.009; Winkler AS, 2010, WORLD NEUROSURG, V73, P264, DOI 10.1016/j.wneu.2010.03.037; World Health Organization, 2009, WHO GUID ID EC CONS; Yaduma N, 2013, ENVIRON RESOUR ECON, V54, P361, DOI 10.1007/s10640-012-9598-7	48	29	29	0	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2019	130	4					1149	1156		10.3171/2017.12.JNS17281			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	HR1CV	WOS:000462866700011	29775144	Bronze			2022-02-06	
J	Caccese, JB; DeWolf, RM; Kaminski, TW; Broglio, SP; McAllister, TW; McCrea, M; Buckley, TA; Hoy, AM; Hazzard, JB; Kelly, LA; Ortega, JD; Port, N; Putukian, M; Langford, TD; Benjamin, HJ; Clugston, JR; Schmidt, JD; Feigenbaum, LA; Eckner, JT; Mihalik, JP; Miles, JD; Anderson, S; Master, CL; Collins, M; Kontos, AP; Chrisman, SPO; Brooks, A; Jackson, J; McGinty, G; Cameron, K; Susmarski, A; Duma, S; Rowson, S; Miles, CM; Dykhuizen, BH; Lintner, L				Caccese, Jaclyn B.; DeWolf, Ryan M.; Kaminski, Thomas W.; Broglio, Steven P.; McAllister, Thomas W.; McCrea, Michael; Buckley, Thomas A.; Hoy, April Marie (Reed); Hazzard, Joseph B., Jr.; Kelly, Louise A.; Ortega, Justus D.; Port, Nicholas; Putukian, Margot; Langford, T. Dianne; Benjamin, Holly J.; Clugston, James R.; Schmidt, Julianne D.; Feigenbaum, Luis A.; Eckner, James T.; Mihalik, Jason P.; Miles, Jessica Dysart; Anderson, Scott; Master, Christina L.; Collins, Micky; Kontos, Anthony P.; Chrisman, Sara P. O.; Brooks, Alison; Jackson, Jonathan; McGinty, Gerald; Cameron, Kenneth; Susmarski, Adam; Duma, Stefan; Rowson, Steve; Miles, Christopher M.; Dykhuizen, Brian H.; Lintner, Laura		CARE Consortium Investigators	Estimated Age of First Exposure to American Football and Neurocognitive Performance Amongst NCAA Male Student-Athletes: A Cohort Study	SPORTS MEDICINE			English	Article							TEST-RETEST RELIABILITY; HEAD IMPACT EXPOSURE; HIGH-SCHOOL FOOTBALL; POST-CONCUSSION ASSESSMENT; LIFE COGNITIVE IMPAIRMENT; CONSTRUCT-VALIDITY; ONLINE VERSION; HUMAN-BRAIN; COLLEGIATE; SENSITIVITY	Background Repetitive head impacts in young athletes are potentially detrimental to later life (e.g., age 50+ years) neurological function; however, it is unknown what the short-term effects (e.g., age 20 years) are in collegiate student-athletes. Objective The purpose of this study was to determine the effect of the estimated age of first exposure to American tackle football participation on neurocognitive performance and symptom severity scores in collegiate student-athletes. Methods We used a cohort study in which neurocognitive performance was assessed using the Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) test in 4376 male athletes (age 19.3 +/- 1.5 years, mass 96.3 +/- 20.3 kg, height 185.0 +/- 7.4 cm). Athletes were grouped by sport participation [American football (n = 3462) or non-contact (n = 914)] and estimated age of first exposure [< 12 years (n= 3022) or >= 12 years (n = 1354)]. The outcome measures were the four primary cognitive scores and the symptom severity score from ImPACT. We assessed primary outcomes across groups, controlling for age, learning accommodations, and concussion history. Results Neurocognitive performance was not associated with the estimated age of first exposure-by-group interaction. Conclusion Our findings indicate that participation in American tackle football before age 12 years does not result in neurocognitive deficits in college. Therefore, we suggest the following: the consequences of early exposure to repetitive head impacts do not manifest by college, the ImPACT test was not sensitive enough to identify the effects of an earlier estimated age of first exposure, or there is no association between an earlier estimated age of first exposure and neurocognitive functioning. Future longitudinal studies are warranted.	[Caccese, Jaclyn B.; Kaminski, Thomas W.; Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, 349 Tower STAR,100 Discovery Blvd, Newark, DE 19713 USA; [DeWolf, Ryan M.] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA; [Kaminski, Thomas W.; Buckley, Thomas A.] Univ Delaware, Biomech & Movement Sci Interdisciplinary Program, Newark, DE USA; [Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Injury Ctr, Ann Arbor, MI 48109 USA; [McAllister, Thomas W.; Buckley, Thomas A.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg & Neurol, Milwaukee, WI 53226 USA; [Hoy, April Marie (Reed)] Azusa Pacific Univ, Azusa, CA USA; [Hazzard, Joseph B., Jr.] Bloomsburg Univ, Bloomsburg, PA USA; [Kelly, Louise A.] Calif Lutheran Univ, Thousand Oaks, CA USA; [Ortega, Justus D.] Humboldt State Univ, Arcata, CA USA; [Port, Nicholas] Indiana Univ, Bloomington, IN 47405 USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Langford, T. Dianne] Temple Univ, Philadelphia, PA 19122 USA; [Benjamin, Holly J.] Univ Chicago, Chicago, IL 60637 USA; [Clugston, James R.] Univ Florida, Gainesville, FL 32611 USA; [Schmidt, Julianne D.] Univ Georgia, Athens, GA 30602 USA; [Feigenbaum, Luis A.] Univ Miami, Coral Gables, FL 33124 USA; [Clugston, James R.; Eckner, James T.] Univ Michigan, Ann Arbor, MI 48109 USA; [Mihalik, Jason P.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Miles, Jessica Dysart] Univ North Georgia, Dahlonega, GA USA; [Anderson, Scott] Univ Oklahoma, Norman, OK 73019 USA; [Master, Christina L.] Univ Penn, Philadelphia, PA 19104 USA; [Collins, Micky; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Chrisman, Sara P. O.] Univ Washington, Seattle, WA 98195 USA; [Brooks, Alison] Univ Wisconsin, Madison, WI 53706 USA; [Jackson, Jonathan; McGinty, Gerald] US Air Force Acad, Colorado Springs, CO 80840 USA; [Susmarski, Adam] US Naval Acad, Annapolis, MD 21402 USA; [Duma, Stefan; Rowson, Steve] Virginia Tech, Blacksburg, VA USA; [Miles, Christopher M.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Dykhuizen, Brian H.] Wilmington Coll, Wilmington, OH USA; [Lintner, Laura] Winston Salem Univ, Winston Salem, NC USA; [Cameron, Kenneth] US Mil Acad, West Point, NY USA		Caccese, JB (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 349 Tower STAR,100 Discovery Blvd, Newark, DE 19713 USA.	tbuckley@udel.edu	Rowson, Steven/B-1270-2012; Caccese, Jaclyn B./AAH-4571-2020; Buckley, Thomas A/B-7525-2016	Rowson, Steven/0000-0002-3227-0596; Caccese, Jaclyn B./0000-0003-2329-3603; Buckley, Thomas A/0000-0002-0515-0150; Master, Christina/0000-0002-6717-4270; Cameron, Kenneth/0000-0002-6276-4482; Susmarski, Adam/0000-0003-3698-4163; Chrisman, Sara/0000-0001-5373-7223; Ortega, Justus/0000-0002-9931-5605; Clugston, James/0000-0002-2103-1039	Grand Alliance CARE Consortium - National Collegiate Athletic Association; Department of Defence; United States Army Medical Research Acquisition Activity, Ford Detrick, MD, USA; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This publication was made possible, in part, with support from the Grand Alliance CARE Consortium, funded by the National Collegiate Athletic Association and the Department of Defence. The United States Army Medical Research Acquisition Activity, Ford Detrick, MD, USA is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No. W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (Defense Health Program funds).	Allen BJ, 2011, BRAIN INJURY, V25, P179, DOI 10.3109/02699052.2010.541897; Alosco ML, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.197; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Alsalaheen B, 2016, SPORTS MED, V46, P1487, DOI 10.1007/s40279-016-0532-y; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Belanger HG, 2016, J HEAD TRAUMA REHAB, V31, P159, DOI 10.1097/HTR.0000000000000138; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2018, J NEUROTRAUM, V35, P2776, DOI 10.1089/neu.2018.5643; Broglio SP, 2018, SPORTS MED, V48, P1255, DOI 10.1007/s40279-017-0813-0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Caccese JB, 2016, INTERNATIONAL RESEARCH IN SCIENCE AND SOCCER II, P133; Caccese JB, 2016, RES SPORTS MED, V24, P407, DOI 10.1080/15438627.2016.1230549; Caccese JB, 2016, SPORTS MED, V46, P1591, DOI 10.1007/s40279-016-0544-7; Catenaccio E, 2016, RES SPORTS MED, V24, P416, DOI 10.1080/15438627.2016.1234472; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Epstein HT, 1999, BRAIN DEV-JPN, V21, P535, DOI 10.1016/S0387-7604(99)00066-2; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erlanger DM, 2015, BRAIN INJURY, V29, P171, DOI 10.3109/02699052.2014.965211; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Houck Z, 2018, J INT NEUROPSYCH SOC, V24, P1, DOI 10.1017/S1355617717000716; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Janssen PHH, 2017, MAYO CLIN PROC, V92, P66, DOI 10.1016/j.mayocp.2016.09.004; Katz BP, 2018, SPORTS MED, V48, P1971, DOI 10.1007/s40279-018-0875-7; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Kuhn AW, 2017, SPORTS HEALTH, V9, P30, DOI 10.1177/1941738116674006; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lehman EJ, 2016, AM J SPORT MED, V44, P2486, DOI 10.1177/0363546516645093; Lovell M, 2007, IMPACT 2007 6 0 CLIN; Lovell M.R.C.M., 2003, IMMEDIATE POSTCONCUS; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Manley G, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097791; Maroon JC, 2015, NEUROLOGY, V85, P1007, DOI 10.1212/WNL.0000000000001942; Martini DN, 2018, INT J PSYCHOPHYSIOL, V132, P25, DOI 10.1016/j.ijpsycho.2017.09.019; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Nakayama Y, 2014, AM J SPORT MED, V42, P2000, DOI 10.1177/0363546514535901; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schultz V, 2018, J NEUROTRAUM, V35, P278, DOI 10.1089/neu.2017.5145; Shaw P, 2006, NATURE, V440, P676, DOI 10.1038/nature04513; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; Solomon GS, 2016, AM J SPORT MED, V44, P1106, DOI 10.1177/0363546515626164; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stone Arthur A., 1999, SCI SELF REPORT IMPL; Taylor KM, 2018, AM J SPORT MED, V46, P3262, DOI 10.1177/0363546518798801; Trudeau F, 2008, INT J BEHAV NUTR PHY, V5, DOI 10.1186/1479-5868-5-10; Uematsu A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046970; Zeigler DW, 2005, PREV MED, V40, P23, DOI 10.1016/j.ypmed.2004.04.044	69	29	28	3	8	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	MAR	2019	49	3					477	487		10.1007/s40279-019-01069-x			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	HQ6FA	WOS:000462506700010	30747378				2022-02-06	
J	Jak, AJ; Jurick, S; Crocker, LD; Sanderson-Cimino, M; Aupperle, R; Rodgers, CS; Thomas, KR; Boyd, B; Norman, SB; Lang, AJ; Keller, AV; Schiehser, DM; Twamley, EW				Jak, Amy J.; Jurick, Sarah; Crocker, Laura D.; Sanderson-Cimino, Mark; Aupperle, Robin; Rodgers, Carie S.; Thomas, Kelsey R.; Boyd, Briana; Norman, Sonya B.; Lang, Ariel J.; Keller, Amber V.; Schiehser, Dawn M.; Twamley, Elizabeth W.			SMART-CPT for veterans with comorbid post-traumatic stress disorder and history of traumatic brain injury: a randomised controlled trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							COGNITIVE PROCESSING THERAPY; PERSISTENT POSTCONCUSSION SYNDROME; PTSD; AFGHANISTAN; SYMPTOMS; DROPOUT; IRAQ; PERFORMANCE; PREVALENCE; COMPLAINTS	Objective To better concurrently address emotional and neuropsychological symptoms common in veterans with comorbid post-traumatic stress disorder (PTSD) and history of traumatic brain injury (TBI), we integrated components of compensatory cognitive training from the Cognitive Symptom Management and Rehabilitation Therapy (CogSMART) programme into cognitive processing therapy (CPT) for PTSD to create a hybrid treatment, SMART-CPT (CogSMART+CPT). This study compared the efficacy of standard CPT with SMART-CPT for treatment of veterans with comorbid PTSD and history of TBI reporting cognitive symptoms. Methods One hundred veterans with PTSD, a history of mild to moderate TBI and current cognitive complaints were randomised and received individually delivered CPT or SMART-CPT for 12 weeks. Participants underwent psychological, neurobehavioural and neuropsychological assessments at baseline, on completion of treatment and 3 months after treatment. Results Both CPT and SMART-CPT resulted in clinically significant reductions in PTSD and postconcussive symptomatology and improvements in quality of life. SMART-CPT resulted in additional improvements in the neuropsychological domains of attention/working memory, verbal learning/memory and novel problem solving. Conclusion SMART-CPT, a mental health intervention for PTSD, combined with compensatory cognitive training strategies, reduces PTSD and neurobehavioural symptoms and also provides added value by improving cognitive functioning.	[Jak, Amy J.; Thomas, Kelsey R.; Norman, Sonya B.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92161 USA; [Jak, Amy J.; Jurick, Sarah; Crocker, Laura D.; Norman, Sonya B.; Lang, Ariel J.; Schiehser, Dawn M.; Twamley, Elizabeth W.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA USA; [Jak, Amy J.; Crocker, Laura D.; Boyd, Briana; Keller, Amber V.; Schiehser, Dawn M.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Jak, Amy J.; Jurick, Sarah; Sanderson-Cimino, Mark; Thomas, Kelsey R.; Norman, Sonya B.; Lang, Ariel J.; Schiehser, Dawn M.; Twamley, Elizabeth W.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Aupperle, Robin] Univ Tulsa, Laureate Inst Brain Res, Tulsa, OK 74104 USA; [Rodgers, Carie S.] PsychArmor Inst, San Diego, CA USA; [Norman, Sonya B.] Natl Ctr PTSD, White River Jct, VT USA		Jak, AJ (corresponding author), VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92161 USA.	ajak@ucsd.edu	Aupperle, Robin/AAU-8550-2020	Sanderson-Cimino, Mark/0000-0002-5872-3186; Thomas, Kelsey/0000-0003-4277-8876; Keller, Amber/0000-0002-2972-784X	Department of DefenseUnited States Department of Defense [W81XWH-11-1-0641]; VA Interprofessional Polytrauma and TBI Fellowship and Career Development from the VA Rehabilitation Research & Development (RR D) Service [IK2 RX002459]; VA RR D MERIT [1 I01 RX001691]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH108707] Funding Source: NIH RePORTER	Funding was provided by the Department of Defense (award W81XWH-11-1-0641). LDC received salary support during this work from the VA Interprofessional Polytrauma and TBI Fellowship and Career Development (award number IK2 RX002459) from the VA Rehabilitation Research & Development (RR& D) Service. DMS received salary support from VA RR& D MERIT (award 1 I01 RX001691).	Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Boyd B, 2016, COGN BEHAV PRACT, V23, P173, DOI 10.1016/j.cbpra.2015.10.001; Bryant RA, 2012, PTSD TRAUMATIC BRAIN; Bryant RA, 2012, PTSD MILD TRAUMATIC; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cook JM, 2014, PROF PSYCHOL-RES PR, V45, P136, DOI 10.1037/a0036183; Davis JJ, 2013, REHABIL PSYCHOL, V58, P36, DOI 10.1037/a0031525; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Fulton JJ, 2015, J ANXIETY DISORD, V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Galovski TE, 2012, J CONSULT CLIN PSYCH, V80, P968, DOI 10.1037/a0030600; Garcia HA, 2011, PSYCHOL SERV, V8, P1, DOI 10.1037/a0022705; Geuze E, 2009, DEPRESS ANXIETY, V26, P7, DOI 10.1002/da.20476; Goetter EM, 2015, J TRAUMA STRESS, V28, P401, DOI 10.1002/jts.22038; Institute of Medicine, 2014, TREATM POSTTR STRESS; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Jak AJ, 2018, CURR TOP BEHAV NEURO, V38, P93, DOI 10.1007/7854_2016_62; Jak AJ, 2015, CONTEMP CLIN TRIALS, V45, P210, DOI 10.1016/j.cct.2015.10.009; Kehle-Forbes SM, 2016, PSYCHOL TRAUMA-US, V8, P107, DOI 10.1037/tra0000065; Kilmer B, 2011, PSYCHOL TRAUMA-US, V3, P201, DOI 10.1037/a0020592; LaFrance WC, 2014, JAMA PSYCHIAT, V71, P997, DOI 10.1001/jamapsychiatry.2014.817; Lehman A, 1994, TOOLKIT EVALUATING Q; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; McCrea M., 2008, MILD TRAUMATIC BRAIN; O'Neill M.E., 2017, ACM T MATH SOF UNPUB, P1; Pape TLB, 2016, J HEAD TRAUMA REHAB, V31, pE10, DOI 10.1097/HTR.0000000000000220; Schottenbauer MA, 2008, PSYCHIATRY, V71, P134, DOI 10.1521/psyc.2008.71.2.134; Scott JC, 2015, PSYCHOL BULL, V141, P105, DOI 10.1037/a0038039; Singer J, 2003, APPL LONGITUDINAL DA APPL LONGITUDINAL DA, DOI [10.1093/acprof:oso/ 9780195152968.003.0001, DOI 10.1093/ACPROF:OSO/9780195152968.003.0001]; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Storzbach D, 2017, J HEAD TRAUMA REHAB, V32, P16, DOI 10.1097/HTR.0000000000000228; Stroupe KT, 2013, J REHABIL RES DEV, V50, P1047, DOI 10.1682/JRRD.2012.06.0107; Suris A, 2013, J TRAUMA STRESS, V26, P28, DOI 10.1002/jts.21765; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; VA/DoD, 2010, VA DOD CLIN PRACT GU; VA/DoD, 2016, VA DOD CLIN PRACT GU; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Wolf GK, 2018, J HEAD TRAUMA REHAB, V33, pE53, DOI 10.1097/HTR.0000000000000344; Wrocklage KM, 2016, J INT NEUROPSYCH SOC, V22, P399, DOI 10.1017/S1355617716000059; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	46	29	29	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2019	90	3					333	341		10.1136/jnnp-2018-319315			9	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	IC7UC	WOS:000471181900183	30554135				2022-02-06	
J	Wilks, CR; Morland, LA; Dillon, KH; Mackintosh, MA; Blakey, SM; Wagner, HR; Elbogen, EB				Wilks, Chelsey R.; Morland, Leslie A.; Dillon, Kirsten H.; Mackintosh, Margaret-Anne; Blakey, Shannon M.; Wagner, H. Ryan; Elbogen, Eric B.		VA Mid-Atlantic MIRECC Workgrp	Anger, social support, and suicide risk in US military veterans	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Anger; Suicide; Veterans; Social support; PTSD	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; INTERMITTENT EXPLOSIVE DISORDER; CLINICAL-SAMPLE; IDEATION; PREVALENCE; RESILIENCE; DEPRESSION; SYMPTOMS; HEALTH	There have been considerable efforts to understand, predict, and reduce suicide among U.S. military veterans. Studies have shown that posttraumatic stress disorder (PTSD), major depression (MDD), and traumatic brain injury (TBI) increase risk of suicidal behavior in veterans. Limited research has examined anger and social support as factors linked to suicidal ideation, which if demonstrated could lead to new, effective strategies for suicide risk assessment and prevention. Iraq/Afghanistan era veterans (N = 2467) were evaluated in the ongoing Veterans Affairs Mid-Atlantic Mental Illness Research, Education and Clinical Center (MIRECC) multi-site Study of Post-Deployment Mental Health on demographic and psychological variables. Analyses revealed that suicidal ideation in veterans was positively associated with anger and negatively associated with social support. These results remained significant in multivariate logistic regression models controlling for relevant variables including PTSD, MDD, and TBI. Examining interrelationships among these variables, the analyses revealed that the association between PTSD and suicidal ideation was no longer statistically significant once anger was entered in the regression models. Further, it was found that TBI was associated with suicidal ideation in veterans with MDD but not in veterans without MDD. These findings provide preliminary evidence that suicide risk assessment in military veterans should include clinical consideration of the roles of anger and social support in addition to PTSD, MDD, and TBI. Further, the results suggest that suicide prevention may benefit from anger management interventions as well as interventions aimed at bolstering social and family support as treatment adjuncts to lower suicide risk in veterans.	[Wilks, Chelsey R.; Morland, Leslie A.] Vet Affairs Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA; [Morland, Leslie A.] Univ Calif San Diego, Dept Psychiat, 9500 Gilman Dr, La Jolla, CA 92093 USA; [Morland, Leslie A.] Natl Ctr PTSD, Pacific Isl Div, 3375 Koapaka St, Honolulu, HI 96819 USA; [Dillon, Kirsten H.; Wagner, H. Ryan; Elbogen, Eric B.] Vet Affairs Midatlantic Mental Illness Res Educ &, 3022 Croasdaile Dr, Durham, NC 27705 USA; [Dillon, Kirsten H.; Wagner, H. Ryan; Elbogen, Eric B.] Durham Vet Affairs Healthcare Syst, 508 Fulton St, Durham, NC 27705 USA; [Dillon, Kirsten H.; Wagner, H. Ryan; Elbogen, Eric B.] Duke Univ, Sch Med, 2424 Erwin Rd, Durham, NC 27705 USA; [Mackintosh, Margaret-Anne] Vet Affairs Palo Alto Healthcare Syst, Natl Ctr PTSD, Disseminat & Training Div, 334795 Willow Rd, Menlo Pk, CA 94025 USA; [Blakey, Shannon M.] Univ N Carolina, Dept Psychol & Neurosci, Davie Hall,CB 3270, Chapel Hill, NC 27599 USA		Wilks, CR (corresponding author), Vet Affairs Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	chelseywilks@fas.harvard.edu		Blakey, Shannon/0000-0002-9291-3688; Mackintosh, Margaret-Anne/0000-0002-2725-3177	VA Mid-Atlantic Mental Illness Research, Education and Clinical Center	Preparation of this report was supported by the VA Mid-Atlantic Mental Illness Research, Education and Clinical Center.	Addis ME, 2008, CLIN PSYCHOL-SCI PR, V15, P153, DOI 10.1111/j.1468-2850.2008.00125.x; Babor TF, 2001, AUDIT ALCOHOL USE DI; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Bertolote JM., 2002, SUICIDOLOGI, V7, P3, DOI [DOI 10.1186/1477-7525-9-13, 10.5617/suicidologi.2330, DOI 10.5617/SUICIDOLOGI.2330]; Brancu M, 2017, INT J METH PSYCH RES, V26, DOI 10.1002/mpr.1570; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Chu C, 2017, J PERS DISORD, V31, P145, DOI 10.1521/pedi_2016_30_241; Conner KR, 2003, AGGRESS VIOLENT BEH, V8, P413, DOI 10.1016/S1359-1789(02)00067-8; DeBeer BB, 2014, PSYCHIAT RES, V216, P357, DOI 10.1016/j.psychres.2014.02.010; Department of Veterans Affairs, 2017, VA REL VET SUIC STAT; Derogatis L.R., 1994, SYMPTOM CHECKLIST 90, V3rd ed.; Dobscha SK, 2014, J GEN INTERN MED, V29, pS853, DOI 10.1007/s11606-014-3028-1; Doran N., 2018, MILITARY BEHAV HLTH, V6, P215, DOI [10.1080/21635781.2017.1379453, DOI 10.1080/21635781.2017.1379453]; Fanning JR, 2016, COMPR PSYCHIAT, V70, P125, DOI 10.1016/j.comppsych.2016.05.018; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; Hawkins KA, 2014, J PSYCHIATR RES, V50, P59, DOI 10.1016/j.jpsychires.2013.12.005; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Joiner T.E., 2005, WHY PEOPLE DIE SUICI; Kang HK, 2015, ANN EPIDEMIOL, V25, P96, DOI 10.1016/j.annepidem.2014.11.020; Kessler RC, 2006, ARCH GEN PSYCHIAT, V63, P669, DOI 10.1001/archpsyc.63.6.669; Kleiman EM, 2012, CRISIS, V33, P273, DOI 10.1027/0227-5910/a000136; Klonsky ED, 2017, CURR OPIN PSYCHIATR, V30, P15, DOI 10.1097/YCO.0000000000000294; Klonsky ED, 2014, SUICIDE LIFE-THREAT, V44, P1, DOI 10.1111/sltb.12068; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Lemaire CM, 2011, J AFFECT DISORDERS, V130, P231, DOI 10.1016/j.jad.2010.10.021; Miles SR, 2016, J INTERPERS VIOLENCE, V31, P1795, DOI 10.1177/0886260515570746; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Nock MK, 2008, BRIT J PSYCHIAT, V192, P98, DOI 10.1192/bjp.bp.107.040113; Nock MK, 2015, SUICIDE LIFE-THREAT, V45, P588, DOI 10.1111/sltb.12153; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; Nolen-Hoeksema S, 2008, CLIN PSYCHOL-SCI PR, V15, P178, DOI 10.1111/j.1468-2850.2008.00128.x; Reyes VA, 2005, MIL MED, V170, P483, DOI 10.7205/MILMED.170.6.483; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Sher L, 2012, CLEV CLIN J MED, V79, P92, DOI 10.3949/ccjm.79a.11069; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Sippel LM, 2016, PSYCHIAT RES, V243, P421, DOI 10.1016/j.psychres.2016.06.040; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Stanley IH, 2017, J PSYCHIATR RES, V84, P161, DOI 10.1016/j.jpsychires.2016.10.004; Stroebe M, 2005, AM J PSYCHIAT, V162, P2178, DOI 10.1176/appi.ajp.162.11.2178; Teo AR, 2018, J AFFECT DISORDERS, V230, P42, DOI 10.1016/j.jad.2018.01.003; Thompson M., 2006, ENHANCING MENTAL REA; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Youssef NA, 2013, ANN CLIN PSYCHIATRY, V25, P59	48	29	30	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	FEB	2019	109						139	144		10.1016/j.jpsychires.2018.11.026			6	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	HI9FR	WOS:000456761200018	30537566				2022-02-06	
J	Kanser, RJ; Rapport, LJ; Bashem, JR; Hanks, RA				Kanser, Robert J.; Rapport, Lisa J.; Bashem, Jesse R.; Hanks, Robin A.			Detecting malingering in traumatic brain injury: Combining response time with performance validity test accuracy	CLINICAL NEUROPSYCHOLOGIST			English	Article						Traumatic brain injury; malingering; response time; performance validity	RECOGNITION MEMORY TEST; CLINICAL NEUROPSYCHOLOGY; AMERICAN ACADEMY; RETENTION TRIAL; CLASSIFICATION ACCURACY; BELIEFS; SCORES; SPECIFICITY; SENSITIVITY; SIMULATION	Objective: The present study examined the incremental utility of item-level response time (RT) variables on a traditional performance validity test in distinguishing adults with verified TBI from adults coached to feign neurocognitive impairment. Method: Participants were 45 adults with moderate to severe TBI, 45 healthy adults coached to feign neurocognitive impairment (SIM), and 61 healthy adult comparisons providing full effort (HC). All participants completed a computerized version of the Test of Memory Malingering (TOMM-C) in the context of a larger test battery. RT variables examined along with TOMM-C accuracy scores included mean RTs (Trial 1, Trial 2, correct and incorrect trials) and RT variability indices. Results: Several RT indices differed significantly across the groups. In general, SIM produced longer, more variable RTs than HC and TBI. Of the RT indices, average RT for Trial 1 and 2 were the best predictors of group membership; however, classification accuracies were greatly influenced by the groups being compared. Average RT for Trial 1 and 2 showed excellent discrimination of SIM and HC. All RT indices were less successful in discriminating SIM and TBI. Average RT for Trial 1 and 2 added incremental predictive value to TOMM-C accuracy in distinguishing SIM from TBI. Conclusion: Findings contribute to a limited body of research examining the incremental utility of combining RT with traditional PVTs in distinguishing feigned and bona fide TBI. Findings support the hypothesis that combining RT with TOMM-C accuracy can improve its diagnostic accuracy. Future research with other groups of clinical interest is recommended.	[Kanser, Robert J.; Rapport, Lisa J.; Bashem, Jesse R.] Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA; [Hanks, Robin A.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA		Kanser, RJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	robert.kanser@wayne.edu			National Institute on Disability, Independent Living and Rehabilitation ResearchUnited States Department of Health & Human Services [90IFOO92]; Wayne State University Graduate School Thesis and Dissertation grants (Kanser, Bashem)	This research was supported by grants from the National Institute on Disability, Independent Living and Rehabilitation Research [grant number 90IFOO92, Rapport] and Wayne State University Graduate School Thesis and Dissertation grants (Kanser, Bashem).	Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2002, INT J NEUROSCI, V112, P1479, DOI 10.1080/00207450290158377; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; Booksh RL, 2007, ARCH CLIN NEUROPSYCH, V22, P87, DOI 10.1016/j.acn.2006.11.002; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Dandachi-FitzGerald B, 2017, J CLIN EXP NEUROPSYC, V39, P257, DOI 10.1080/13803395.2016.1223278; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Essig SM, 2001, ARCH CLIN NEUROPSYCH, V16, P271, DOI 10.1016/S0887-6177(99)00065-7; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Hosmer D.W., 2000, APPL LOGISTIC REGRES, P375, DOI [10.1002/0471722146, DOI 10.1002/0471722146]; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kanser RJ, 2017, CLIN NEUROPSYCHOL, V31, P644, DOI 10.1080/13854046.2016.1278040; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kireev M, 2013, INT J PSYCHOPHYSIOL, V90, P291, DOI 10.1016/j.ijpsycho.2013.09.005; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Pearson, 2009, WECHSL MEM SCAL; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Reicker LI, 2008, ARCH CLIN NEUROPSYCH, V23, P419, DOI 10.1016/j.acn.2008.02.003; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; Schroeder RW, 2013, ARCH CLIN NEUROPSYCH, V28, P21, DOI 10.1093/arclin/acs094; Schroeder RW, 2016, CLIN NEUROPSYCHOL, V30, P515, DOI 10.1080/13854046.2016.1177118; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Suhr J.A., 2007, ASSESSMENT MALINGERE, P287; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sun DL, 2015, CEREB CORTEX, V25, P927, DOI 10.1093/cercor/bht284; Sweet JJ, 2015, CLIN NEUROPSYCHOL, V29, P1069, DOI 10.1080/13854046.2016.1140228; Tabachnick BG., 2012, USING MULTIVARIATE S; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 2000, MANUAL COMPUTERIZED; Vagnini VL, 2008, J CLIN EXP NEUROPSYC, V30, P766, DOI 10.1080/13803390701754746; van Hooff JC, 2009, INT J PSYCHOPHYSIOL, V73, P246, DOI 10.1016/j.ijpsycho.2009.04.002; Vanderslice-Barr JL, 2011, APPL NEUROPSYCHOL, V18, P34, DOI 10.1080/09084282.2010.523377; Warrington E, 1984, RECOGNITION MEMORY T, V1; Whiteside DM, 2015, J CLIN EXP NEUROPSYC, V37, P220, DOI 10.1080/13803395.2014.1002758; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; Woods DL, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00595	58	29	30	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2019	33	1					90	107		10.1080/13854046.2018.1440006			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	HK9OC	WOS:000458320100006	29469640				2022-02-06	
J	An, KY; Charles, J; Ali, S; Enache, A; Dhuga, J; Erdodi, LA				An, Kelly Y.; Charles, Jordan; Ali, Sami; Enache, Anca; Dhuga, Jasmine; Erdodi, Laszlo A.			Reexamining performance validity cutoffs within the Complex Ideational Material and the Boston Naming Test-Short Form using an experimental malingering paradigm	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Boston Naming Test; Complex Ideational Material; embedded validity indicators; Erdodi Index; experimental malingering; performance validity	TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; RECOGNITION MEMORY TEST; RELIABLE DIGIT SPAN; CARD SORTING TEST; SYMPTOM VALIDITY; RESPONSE BIAS; NEUROCOGNITIVE DYSFUNCTION; INVALID PERFORMANCE	Objective: This study was designed to cross-validate previously published performance validity cutoffs embedded within the Complex Ideational Material (CIM) and the Boston Naming Test-Short Form (BNT-15).Method: Seventy healthy undergraduate students were randomly assigned to either a control condition (n=40) and instructed to perform to the best of their ability or an experimental malingering (n=30) condition and instructed to feign cognitive impairment while avoiding detection. All participants were administered the same battery of neuropsychological tests.Results: Previously published validity cutoffs within the CIM (raw score 9 or T-score 29) and BNT-15 (12) produced good classification accuracy using both experimental malingering and psychometrically defined invalid responding as criterion variable. However, a BNT-15 completion time 85 s produced a better signal detection profile than BNT-15 accuracy scores.Conclusions: Results support the clinical utility of existing cutoffs. Given the relatively high base rate of failure even in the control group (5-15%), and the perfect specificity of CIM 9 and BNT-1511 to noncredible responding, relabeling this range of performance as Abnormal instead of Impaired would better capture the uncertainty in its clinical interpretation.	[An, Kelly Y.; Charles, Jordan; Ali, Sami; Enache, Anca; Dhuga, Jasmine; Erdodi, Laszlo A.] Univ Windsor, Dept Psychol, Windsor, ON, Canada		Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Abeare CA, 2018, JAMA NEUROL, V75, P697, DOI 10.1001/jamaneurol.2018.0031; An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Armistead-Jehle P, 2015, APPL NEUROPSYCH-ADUL, V22, P147, DOI 10.1080/23279095.2014.880842; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Axelrod BN, 2011, APPL NEUROPSYCHOL, V18, P27, DOI 10.1080/09084282.2010.523369; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2014, BRAIN INJURY, V28, P1623, DOI 10.3109/02699052.2014.947627; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Brennan A, 2009, CLIN NEUROPSYCHOL, V23, P314, DOI 10.1080/13854040802054151; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Chafetz MD, 2011, ARCH CLIN NEUROPSYCH, V26, P306, DOI 10.1093/arclin/acr030; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; DenBoer JW, 2007, CLIN NEUROPSYCHOL, V21, P943, DOI 10.1080/13854040601020783; DeRight J, 2015, CLIN NEUROPSYCHOL, V29, P101, DOI 10.1080/13854046.2014.989267; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Dunn TM, 2003, ARCH CLIN NEUROPSYCH, V18, P121, DOI 10.1016/S0887-6177(01)00188-3; Erdodi L. A., 2017, PSYCHOL ASSESSMENT; Erdodi L.A., 2017, PSYCHOL NEUROSCIENCE, V10, P325, DOI [10.1037/pne0000103, DOI 10.1037/PNE0000103, https://doi.org//10.1037/pne0000103, DOI https://doi.org/10.1037/pne0000103]; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2019, APPL NEUROPSYCH-ADUL, V26, P155, DOI 10.1080/23279095.2017.1384925; Erdodi LA, 2018, PSYCHOL ASSESSMENT, V30, P755, DOI 10.1037/pas0000525; Erdodi LA, 2018, PSYCHOL INJ LAW, V11, P1, DOI 10.1007/s12207-017-9309-3; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, PSYCHOL INJ LAW, V10, P96, DOI 10.1007/s12207-017-9282-x; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Green P, 2004, GREENS MED SYMPTOM V; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton R. K., 2004, REVISED COMPREHENSIV; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Jelicic M, 2011, J CLIN PSYCHOL, V67, P850, DOI 10.1002/jclp.20805; Johnson SC, 2012, CLIN NEUROPSYCHOL, V26, P1230, DOI 10.1080/13854046.2012.709886; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kanser RJ, 2019, CLIN NEUROPSYCHOL, V33, P90, DOI 10.1080/13854046.2018.1440006; Kanser RJ, 2017, CLIN NEUROPSYCHOL, V31, P644, DOI 10.1080/13854046.2016.1278040; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2015, AM PSYCHOL, V70, P779, DOI 10.1037/a0039835; Lau L, 2017, CLIN NEUROPSYCHOL, V31, P1412, DOI 10.1080/13854046.2017.1318954; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; MACK WJ, 1992, J GERONTOL, V47, pP154, DOI 10.1093/geronj/47.3.P154; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOL WAIS 4; Persinger V. C., 2017, CLIN NEUROPSYCHOL, P1; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 2008, CLIN ASSESSMENT MALI; Russeler J, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-37; Santos OA, 2014, ARCH CLIN NEUROPSYCH, V29, P609, DOI 10.1093/arclin/acu039; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit GM, 2014, ARCH CLIN NEUROPSYCH, V29, P415, DOI 10.1093/arclin/acu028; Silverberg ND, 2008, CLIN NEUROPSYCHOL, V22, P140, DOI 10.1080/13854040601160597; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Whiteside DM, 2015, J CLIN EXP NEUROPSYC, V37, P220, DOI 10.1080/13803395.2014.1002758; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	97	29	29	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2019	41	1					15	25		10.1080/13803395.2018.1483488			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	HP3MF	WOS:000461580200002	29943654				2022-02-06	
J	Shin, S; Burnett, RT; Kwong, JC; Hystad, P; van Donkelaar, A; Brook, JR; Copes, R; Tu, K; Goldberg, MS; Villeneuve, PJ; Martin, RV; Murray, BJ; Wilton, AS; Kopp, A; Chen, H				Shin, Saeha; Burnett, Richard T.; Kwong, Jeffrey C.; Hystad, Perry; van Donkelaar, Aaron; Brook, Jeffrey R.; Copes, Ray; Tu, Karen; Goldberg, Mark S.; Villeneuve, Paul J.; Martin, Randall V.; Murray, Brian J.; Wilton, Andrew S.; Kopp, Alexander; Chen, Hong			Effects of ambient air pollution on incident Parkinson's disease in Ontario, 2001 to 2013: a population-based cohort study	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						Parkinson's disease; neurodegenerative diseases; air pollution; incidence	FINE PARTICULATE MATTER; LONG-TERM EXPOSURE; TRAUMATIC BRAIN-INJURY; RISK; BURDEN; TRANSMISSION; ASSOCIATION; MORTALITY; MODELS; HEALTH	Background: Despite recent studies linking air pollution to neurodegenerative illness, evidence relating air pollution and Parkinson's disease (PD) remains scarce. We conducted a population-based cohort study in Ontario, Canada, to determine the association between air pollution and incident PD. Methods: Using health administrative databases, we identified all adults aged 55-85 years, free of PD, and who lived in Ontario on 1 April 2001 (similar to 2.2 million). Individuals were followed up until 31 March 2013. We derived long-term average exposures to fine particulate matter (particles <= 2.5 mu m in diameter, or PM2.5), nitrogen dioxide (NO2) and ozone from satellite-based estimates, land-use regression models and optimal interpolation methods, respectively. Using 2-year lags in exposures, we linked these estimates to individuals' annual postal codes from 1994 (7 years before cohort inception). We applied spatial random-effects Cox proportional hazards models, adjusting for individual- and area-level characteristics. We also performed sensitivity analyses, such as considering longer lags in exposures and stratifying by selected characteristics. Results: During the study period, we identified 38 745 newly diagnosed cases of PD. Each interquartile increment (3.8 mu g/m(3)) of PM2.5 was associated with a 4% increase in incident PD (95% confidence interval, 1.01-1.08) after adjusting for various covariates. We also found positive associations for NO2 and ozone [hazard ratios (HRs) ranged from 1.03 to 1.04]. The associations for all exposures were unaltered with various sensitivity analyses except for considering longer lags, which somewhat attenuated the estimates, particularly for NO2 and ozone. Conclusions: Exposure to air pollution, especially PM2.5, was found to be related to incident PD.	[Shin, Saeha; Copes, Ray; Chen, Hong] Publ Hlth Ontario, Dept Environm & Occupat Hlth, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada; [Shin, Saeha; Kwong, Jeffrey C.; Brook, Jeffrey R.; Copes, Ray; Chen, Hong] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Burnett, Richard T.] Hlth Canada, Populat Studies Div, Ottawa, ON, Canada; [Kwong, Jeffrey C.; Wilton, Andrew S.; Kopp, Alexander; Chen, Hong] Inst Clin Evaluat Sci, Primary Care & Populat Hlth Res Program, Toronto, ON, Canada; [Kwong, Jeffrey C.; Tu, Karen] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Kwong, Jeffrey C.; Tu, Karen] Univ Hlth Network, Toronto Western Hosp, Family Hlth Team, Toronto, ON, Canada; [Kwong, Jeffrey C.] Publ Hlth Ontario, Dept Appl Immunizat Res, Toronto, ON, Canada; [Hystad, Perry] Oregon State Univ, Coll Publ Hlth & Human Studies, Corvallis, OR 97331 USA; [van Donkelaar, Aaron] Dalhousie Univ, Dept Phys & Atmospher Sci, Halifax, NS, Canada; [Brook, Jeffrey R.] Environm Canada, Air Qual Res Div, Toronto, ON, Canada; [Goldberg, Mark S.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Goldberg, Mark S.] McGill Univ, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ, Canada; [Villeneuve, Paul J.] Carleton Univ, Dept Hlth Sci, Ottawa, ON, Canada; [Martin, Randall V.] Harvard Smithsonian Ctr Astrophys, Smithsonian Astrophys Observ, 60 Garden St, Cambridge, MA 02138 USA; [Murray, Brian J.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Murray, Brian J.] Sunnybrook Hlth Sci Ctr, Div Neurol, Toronto, ON, Canada		Chen, H (corresponding author), Publ Hlth Ontario, Dept Environm & Occupat Hlth, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.	hong.chen@oahpp.ca	van Donkelaar, Aaron/AAF-8355-2021; Martin, Randall/C-1205-2014	Martin, Randall/0000-0003-2632-8402; Villeneuve, Paul/0000-0001-7786-7997; Tu, Karen/0000-0003-0883-4934	Health Canada [MOA-4500314182]; Public Health Ontario (PHO); Institute for Clinical Evaluative Sciences (ICES) - Ontario Ministry of Health and Long-Term Care (MOHLTC)Ministry of Health and Long-Term Care, Ontario; New Investigator Award from the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Clinician Scientist Award from the Department of Family and Community Medicine, University of Toronto; Department of Family and Community Medicine, University of TorontoUniversity of Toronto	This study was funded by Health Canada (MOA-4500314182). This study was also supported by Public Health Ontario (PHO) and the Institute for Clinical Evaluative Sciences (ICES), which are funded by annual grants from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed in the material are those of the author(s), and not necessarily those of PHO, ICES, MOHLTC or CIHI. J.K. is supported by a New Investigator Award from the Canadian Institutes of Health Research and a Clinician Scientist Award from the Department of Family and Community Medicine, University of Toronto. K.T. is supported by a research scholar award from the Department of Family and Community Medicine, University of Toronto. H.C. is the guarantor who had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.	Becker C, 2010, PARKINSONISM RELAT D, V16, P31, DOI 10.1016/j.parkreldis.2009.06.005; Beelen R, 2014, LANCET, V383, P785, DOI 10.1016/S0140-6736(13)62158-3; Block ML, 2009, TRENDS NEUROSCI, V32, P506, DOI 10.1016/j.tins.2009.05.009; Butt DA, 2014, NEUROEPIDEMIOLOGY, V43, P28, DOI 10.1159/000365590; Calderon-Garciduenas L, 2008, TOXICOL PATHOL, V36, P289, DOI 10.1177/0192623307313011; Calderon-Garciduenas L, 2010, EXP TOXICOL PATHOL, V62, P91, DOI 10.1016/j.etp.2009.02.117; Chen H, 2017, INT J EPIDEMIOL, V46, P405, DOI 10.1093/ije/dyw030; Chen H, 2016, ENVIRON HEALTH PERSP, V124, P1421, DOI 10.1289/EHP185; Chen H, 2013, ENVIRON HEALTH PERSP, V121, P804, DOI 10.1289/ehp.1205958; Chen H, 2013, EPIDEMIOLOGY, V24, P35, DOI 10.1097/EDE.0b013e318276c005; Crouse DL, 2012, ENVIRON HEALTH PERSP, V120, P708, DOI 10.1289/ehp.1104049; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Desplats P, 2009, P NATL ACAD SCI USA, V106, P13010, DOI 10.1073/pnas.0903691106; Driver JA, 2008, DIABETES CARE, V31, P2003, DOI 10.2337/dc08-0688; Finkelstein MM, 2007, ENVIRON RES, V104, P420, DOI 10.1016/j.envres.2007.03.002; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Genc S, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/782462; Huse DM, 2005, MOVEMENT DISORD, V20, P1449, DOI 10.1002/mds.20609; Hystad P, 2011, ENVIRON HEALTH PERSP, V119, P1123, DOI 10.1289/ehp.1002976; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Jellinger KA, 2012, MOVEMENT DISORD, V27, P8, DOI 10.1002/mds.23795; Kirrane EF, 2015, J OCCUP ENVIRON MED, V57, P509, DOI 10.1097/JOM.0000000000000451; Kowal SL, 2013, MOVEMENT DISORD, V28, P311, DOI 10.1002/mds.25292; Kralj B., 2000, ONT MED REV, V67, P33; Lee PC, 2016, ENVIRON INT, V96, P75, DOI 10.1016/j.envint.2016.08.017; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Leibson CL, 2006, MOVEMENT DISORD, V21, P446, DOI 10.1002/mds.20685; Levesque S, 2011, ENVIRON HEALTH PERSP, V119, P1149, DOI 10.1289/ehp.1002986; Li X, 2015, ARCH GERONTOL GERIAT, V61, P510, DOI 10.1016/j.archger.2015.08.004; Liu R, 2016, ENVIRON HEALTH PERSP, V124, P1759, DOI 10.1289/EHP135; Luk KC, 2012, SCIENCE, V338, P949, DOI 10.1126/science.1227157; Ma RJ, 2003, BIOMETRIKA, V90, P157, DOI 10.1093/biomet/90.1.157; Mougenot AL, 2012, NEUROBIOL AGING, V33, P2225, DOI 10.1016/j.neurobiolaging.2011.06.022; Naira PM, 2006, J CHEM NEUROANAT, V31, P114, DOI 10.1016/j.jchemneu.2005.09.006; Palacios N, 2017, REV ENVIRON HEALTH, V32, P303, DOI 10.1515/reveh-2017-0009; Palacios N, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP259; Palacios N, 2014, ENVIRON HEALTH-GLOB, V13, DOI 10.1186/1476-069X-13-80; Palacios N, 2014, ENVIRON HEALTH PERSP, V122, P933, DOI 10.1289/ehp.1307218; Pohar SL, 2009, ARCH GERONTOL GERIAT, V49, P317, DOI 10.1016/j.archger.2008.11.006; Pudykiewicz JA, 1997, TELLUS B, V49, P231, DOI 10.1034/j.1600-0889.49.issue3.1.x; Qiu CX, 2011, HYPERTENSION, V57, P1094, DOI 10.1161/HYPERTENSIONAHA.111.171249; Ritz B, 2016, ENVIRON HEALTH PERSP, V124, P351, DOI 10.1289/ehp.1409313; Robichaud A, 2014, ATMOS CHEM PHYS, V14, P1769, DOI 10.5194/acp-14-1769-2014; Santiago-Lopez D, 2010, TOXICOL LETT, V197, P193, DOI 10.1016/j.toxlet.2010.05.020; Shin HH, 2014, ENVIRON RES, V134, P482, DOI 10.1016/j.envres.2014.05.016; Siderowf A, 2012, MOVEMENT DISORD, V27, P608, DOI 10.1002/mds.24954; van Donkelaar A, 2015, ENVIRON SCI TECHNOL, V49, P10482, DOI 10.1021/acs.est.5b02076; van Donkelaar A, 2015, ENVIRON HEALTH PERSP, V123, P135, DOI 10.1289/ehp.1408646; Veronesi B, 2005, INHAL TOXICOL, V17, P235, DOI 10.1080/08958370590912888; Willis AW, 2010, AM J EPIDEMIOL, V172, P1357, DOI 10.1093/aje/kwq303; Wirdefeldt K, 2011, EUR J EPIDEMIOL, V26, pS1, DOI 10.1007/s10654-011-9581-6; World Health Organization, 2014, NEUR DIS PUBL HLTH C; Yang F, 2015, BRAIN, V138, P269, DOI 10.1093/brain/awu323	55	29	29	2	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	DEC	2018	47	6					2038	2048		10.1093/ije/dyy172			11	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	HI7VN	WOS:000456664500035	30124852				2022-02-06	
J	Carnevale, JA; Segar, DJ; Powers, AY; Shah, M; Doberstein, C; Drapcho, B; Morrison, JF; Williams, JR; Collins, S; Monteiro, K; Asaad, WF				Carnevale, Joseph A.; Segar, David J.; Powers, Andrew Y.; Shah, Meghal; Doberstein, Cody; Drapcho, Benjamin; Morrison, John F.; Williams, John R.; Collins, Scott; Monteiro, Kristina; Asaad, Wael F.			Blossoming contusions: identifying factors contributing to the expansion of traumatic intracerebral hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						intraparenchymal hemorrhage; traumatic brain injury; hemorrhagic progression of contusion; volumetric progression; intracerebral hemorrhage; trauma	BRAIN-INJURY; HEAD-INJURY; FRACTURE FIXATION; RISK-FACTORS; CEREBRAL CONTUSIONS; ETHANOL; PROGRESSION; ANTIPLATELET; AGGREGATION; PREDICTORS	OBJECTIVE Traumatic brain injury (TBI) remains a significant cause of neurological morbidity and mortality. Each year, more than 1.7 million patients present to the emergency department with TBI. The goal of this study was to evaluate the prognosis of traumatic cerebral intraparenchymal hemorrhage (tIPH), to develop subclassifications of these injuries that relate to prognosis, and to provide a more comprehensive assessment of hemorrhagic progression contusion (HPC) by analyzing the rate at which tIPH " blossom" (i.e., expansion), depending on a variety of intrinsic and modifiable factors. METHODS In this retrospective study, 726 patients (age range 0-100 years) were admitted to a level 1 trauma center with tIPH during an 8-year period (2005-2013). Of these patients, 491 underwent both admission and follow-up head CT (HCT) within 72 hours. The change in tIPH volume over time, the expansion rate, was recorded for all 491 patients. Effects of prehospital and in-hospital variables were examined using ordinal response logistic regression analyses. These variables were further examined using multivariate linear regression analysis to accurately predict the extent to which a hemorrhage will progress. RESULTS Of the 491 (67.6%) patients who underwent both admission and follow-up HCT, 368 (74.9%) patients experienced HPC. These hemorrhages expanded on average by 61.6% (4.76 ml) with an average expansion rate of 0.71 ml per hour. On univariate analysis, certain patient characteristics were significantly (p < 0.05) related to HPC, including age (> 60 years), admission Glasgow Coma Scale score, blood alcohol level, international normalized ratio, absolute platelet count, transfusion of platelets, concomitant anticoagulation and antiplatelet medication, the initial tIPH volume on admission HCT, and ventriculostomy. Increased expansion rate was significantly associated with patient disposition to hospice or death (p < 0.001). To determine which factors most accurately predict overall patient disposition, an ordinal-response logistic regression identified systolic blood pressure, Injury Severity Score, admission Glasgow Coma Scale score, follow-up scan volume, transfusion of platelets, and ventriculostomy as predictors of patient discharge disposition following tIPH. A multivariate logistic regression identified several prehospital and in-hospital variables (age, Injury Severity Score, blood alcohol level, initial scan volume, concomitant epidural hematoma, presence of subarachnoid hemorrhage, transfusion of platelets, and ventriculostomy) that predicted the volumetric expansion of tIPH. Among these variables, the admission tIPH volume by HCT proved to be the factor most predictive of HPC. CONCLUSIONS Several factors contribute to the rate at which traumatic cerebral contusions blossom in the acute posttraumatic period. Identifying the intrinsic and modifiable aspects of cerebral contusions can help predict the rate of expansion and highlight potential therapeutic interventions to improve TBI-associated morbidity and mortality.	[Carnevale, Joseph A.; Segar, David J.; Powers, Andrew Y.; Shah, Meghal; Drapcho, Benjamin; Williams, John R.; Monteiro, Kristina; Asaad, Wael F.] Brown Univ, Warren Alpert Med Sch, Dept Neurosurg, Providence, RI 02912 USA; [Segar, David J.] Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; [Morrison, John F.] SUNY Buffalo, Dept Neurosurg, Buffalo, NY USA; [Doberstein, Cody] Haverford Coll, Haverford, PA 19041 USA; [Williams, John R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Collins, Scott] Rhode Isl Hosp, Dept Diagnost Imaging, Providence, RI USA; [Asaad, Wael F.] Rhode Isl Hosp, Norman Prince Neurosci Inst, Providence, RI USA		Carnevale, JA (corresponding author), NewYork Presbyterian Hosp, Weill Cornell Med, Brain & Spine Ctr, New York, NY 10010 USA.	joseph_carnevale@alumni.brown.edu	; Asaad, Wael/I-8485-2012	Collins, Scott/0000-0002-8117-164X; Segar, David/0000-0001-9369-1856; Carnevale, Joseph Anthony/0000-0002-9477-9996; Asaad, Wael/0000-0003-4406-9096			Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Allison RZ, 2017, NEUROCRIT CARE, V26, P80, DOI 10.1007/s12028-016-0303-5; Bullock MR, 2007, GUIDELINES MANAGEMEN; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Carnevale J, 2016, NEUROSURGERY S1, V63, P195; Cepeda S, 2015, J NEUROTRAUM, V32, P1246, DOI 10.1089/neu.2014.3808; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Creutzfeldt CJ, 2009, J STROKE CEREBROVASC, V18, P221, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.007; Ehrlich D, 2014, PLATELETS, V25, P16, DOI 10.3109/09537104.2013.764979; Faul M, 2010, TRAUMATIC BRAIN INJU; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; Flierl MA, 2010, J ORTHOP TRAUMA, V24, P107, DOI 10.1097/BOT.0b013e3181b6bdfc; Folkerson LE, 2015, SURGERY, V158, P655, DOI 10.1016/j.surg.2015.02.029; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Grotz MRW, 2004, INJURY, V35, P1077, DOI 10.1016/j.injury.2004.05.025; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; JAKUBOWSKI JA, 1988, ARTERIOSCLEROSIS, V8, P436, DOI 10.1161/01.ATV.8.4.436; Jamjoom BA, 2012, NEUROSCIENCES, V17, P111; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; Kim H, 2015, J NEUROTRAUM, V32, P950, DOI 10.1089/neu.2014.3697; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Marumo M, 2010, ALCOHOL, V44, P343, DOI 10.1016/j.alcohol.2010.02.002; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; MEHTA P, 1987, THROMB RES, V48, P653, DOI 10.1016/0049-3848(87)90431-2; Mendelow AD, 2015, J NEUROTRAUM, V32, P1312, DOI 10.1089/neu.2014.3644; MIKHAILIDIS DP, 1990, ALCOHOL, V7, P171, DOI 10.1016/0741-8329(90)90080-V; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pape HC, 2009, J AM ACAD ORTHOP SUR, V17, P541, DOI 10.5435/00124635-200909000-00001; Rosado JA, 2006, ARCH BIOCHEM BIOPHYS, V452, P9, DOI 10.1016/j.abb.2006.05.011; Rundhaug NP, 2015, J NEUROSURG, V122, P211, DOI 10.3171/2014.9.JNS14322; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sanus GZ, 2004, NEUROSURG QUART, V14, P97, DOI 10.1097/01.wnq.0000127718.06183.12; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Yuan F, 2012, J NEUROTRAUM, V29, P2137, DOI 10.1089/neu.2011.2233	42	29	31	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2018	129	5					1305	1316		10.3171/2017.7.JNS17988			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HE4XT	WOS:000453373600026	29303442	Bronze			2022-02-06	
J	Garrigan, B; Adlam, ALR; Langdon, PE				Garrigan, Beverley; Adlam, Anna L. R.; Langdon, Peter E.			Moral decision-making and moral development: Toward an integrative framework	DEVELOPMENTAL REVIEW			English	Article						Moral decision-making; Moral development; Moral reasoning; Perspective taking; Social information processing	TRAUMATIC BRAIN-INJURY; INFORMATION-PROCESSING PROBLEMS; WORKING-MEMORY; CHILDRENS CONCEPTIONS; FACIAL EXPRESSIONS; AGGRESSIVE-BEHAVIOR; ATTENTION NETWORKS; AFFECTIVE EMPATHY; SOCIAL COGNITION; RISK-TAKING	How moral decision-making occurs, matures over time and relates to behaviour is complex. To develop a full picture of moral decision-making, moral development and moral behaviour it is necessary to understand: (a) how real-time moral decisions are made (including relevant social and contextual factors), (b) what processes are required to develop to enable mature moral decisions, (c) how these processes develop over time, and (d) how moral decisions relate to behaviour. In this paper, psychological and social neuroscience theories of moral decision-making and development are briefly reviewed, as is the development of relevant component processes. Various component processes and factors are seen as required for moral decision-making and development, yet there is no comprehensive framework incorporating these components into one explanation of how real-time moral decisions are made and mature. In this paper, we integrated these components into a new framework based on social information processing (SIP) theory. Situational factors, and how both cognitive and affective processes guide moral decisions was incorporated into the Social Information Processing-Moral Decision-Making (SIP-MDM) framework, drawing upon theories and findings from developmental psychology and social neuroscience. How this framework goes beyond previous SIP models was outlined, followed by a discussion of how it can explain both real-time moral decisions and moral development. We concluded with how the SIP-MDM framework could be used to guide future research and theory development in this area.	[Garrigan, Beverley] Univ East Anglia, Norwich Med Sch, Dept Clin Psychol, Norwich, Norfolk, England; [Adlam, Anna L. R.] Univ Exeter, Coll Life & Environm Sci, Sch Psychol, Exeter, Devon, England; [Langdon, Peter E.] Hertfordshire Partnership Univ NHS Fdn Trust Norf, Broadland Clin, Exeter, Devon, England		Langdon, PE (corresponding author), Univ Kent, Tizard Ctr, Canterbury CT2 7LR, Kent, England.	P.E.Langdon@kent.ac.uk	Langdon, Peter/B-3212-2008	Langdon, Peter/0000-0002-7745-1825	University of East Anglia; National Institute for Health Research Postdoctoral FellowshipNational Institute for Health Research (NIHR); National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [PDF-2011-04-040, PB-PG-0214-33040] Funding Source: researchfish	Beverley Garrigan is supported by a PhD studentship stipend from the University of East Anglia.; Peter E Langdon is funded by a National Institute for Health Research Postdoctoral Fellowship. This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.	Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Amso D, 2015, NAT REV NEUROSCI, V16, P606, DOI 10.1038/nrn4025; Anderson CA, 2002, ANNU REV PSYCHOL, V53, P27, DOI 10.1146/annurev.psych.53.100901.135231; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Anderson V., 2012, DEV SOCIAL NEUROSCIE, P3; Arsenio WF, 2004, CHILD DEV, V75, P987, DOI 10.1111/j.1467-8624.2004.00720.x; Baird A.A., 2008, MORAL PSYCHOL, P323; Beauchamp MH, 2013, BRAIN INJURY, V27, P896, DOI 10.3109/02699052.2013.775486; Bechara A, 2005, GAME ECON BEHAV, V52, P336, DOI 10.1016/j.geb.2004.06.010; Beddeley AD., 1974, PSYCHOL LEARN MOTIV, V8, P47, DOI [DOI 10.1016/S0079-7421(08)60452-1, 10.1016/S0079-7421(08)60452-1]; Bujoreanu IS, 2008, DEV NEUROPSYCHOL, V33, P584, DOI 10.1080/87565640802254364; Burks VS, 1999, SOC DEV, V8, P220; Calvete E, 2012, J ABNORM CHILD PSYCH, V40, P105, DOI 10.1007/s10802-011-9546-y; CAMPOS JJ, 1989, DEV PSYCHOL, V25, P394, DOI 10.1037/0012-1649.25.3.394; Carlo G, 2010, PERS INDIV DIFFER, V48, P872, DOI 10.1016/j.paid.2010.02.010; Carlo G, 2011, INT J BEHAV DEV, V35, P116, DOI 10.1177/0165025410375921; Carrigan B, 2016, BRAIN COGNITION, V108, P88, DOI 10.1016/j.bandc.2016.07.007; Chiasson V, 2017, CLIN NEUROPSYCHOL, V31, P515, DOI 10.1080/13854046.2016.1268650; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; Cigala A, 2015, EARLY CHILD DEV CARE, V185, P1199, DOI 10.1080/03004430.2014.987272; COLBY A, 1983, MONOGR SOC RES CHILD, V48, P1, DOI 10.2307/1165935; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Crone EA, 2009, DEVELOPMENTAL SCI, V12, P55, DOI 10.1111/j.1467-7687.2008.00743.x; Cushman F, 2013, COGNITION, V127, P6, DOI 10.1016/j.cognition.2012.11.008; Damasio R., 1994, DESCARTES ERROR EMOT; Darki F, 2015, CEREB CORTEX, V25, P1587, DOI 10.1093/cercor/bht352; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; de Sousa A, 2010, NEUROPSYCHOLOGIA, V48, P3585, DOI 10.1016/j.neuropsychologia.2010.08.008; de Wilde A, 2016, J ABNORM CHILD PSYCH, V44, P19, DOI 10.1007/s10802-015-0053-4; Decety J, 2014, TRENDS COGN SCI, V18, P337, DOI 10.1016/j.tics.2014.04.008; DENTON K, 1990, J PERS SOC PSYCHOL, V59, P242, DOI 10.1037/0022-3514.59.2.242; Dodge KA, 2002, PSYCHOL ASSESSMENT, V14, P60, DOI 10.1037//1040-3590.14.1.60; Dooley JJ, 2010, BRAIN IMPAIR, V11, P152, DOI 10.1375/brim.11.2.152; Dosch M, 2010, NEUROIMAGE, V50, P837, DOI 10.1016/j.neuroimage.2009.12.013; Dumontheil I, 2014, DEV COGN NEUROS-NETH, V10, P57, DOI 10.1016/j.dcn.2014.07.009; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Duska R., 1977, MORAL DEV GUIDE PIAG; Eisenberg N, 2000, CHILD DEV, V71, P1367, DOI 10.1111/1467-8624.00233; EISENBERG N, 1995, CHILD DEV, V66, P1179, DOI 10.2307/1131806; Engle RW, 1999, J EXP PSYCHOL GEN, V128, P309, DOI 10.1037/0096-3445.128.3.309; Etkin A, 2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Farrant K, 2015, DEV COGN NEUROS-NETH, V12, P165, DOI 10.1016/j.dcn.2015.02.001; Fiedler S, 2015, CURR OPIN PSYCHOL, V6, P139, DOI 10.1016/j.copsyc.2015.08.008; Fransson N., 2010, OPEN PSYCHOL J, V3, P67, DOI [10.2174/1874350101003010067, DOI 10.2174/1874350101003010067]; Fumagalli M, 2012, BRAIN, V135, P2006, DOI 10.1093/brain/awr334; Garaigordobil M., 2009, INT J PSYCHOL PSYCHO, V9, P217, DOI DOI 10.1037/T28278-000; Gardner M, 2005, DEV PSYCHOL, V41, P625, DOI 10.1037/0012-1649.41.4.625; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gibbs J.C., 1992, MORAL MATURITY MEASU; Gilligan C., 1982, DIFFERENT VOICE PSYC, V326; Gratz KL, 2004, J PSYCHOPATHOL BEHAV, V26, P41, DOI 10.1023/B:JOBA.0000007455.08539.94; Greene J.D., 2009, COGNITIVE NEUROSCIEN, P987; Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Greene JD, 2008, COGNITION, V107, P1144, DOI 10.1016/j.cognition.2007.11.004; Gruhn D, 2008, EMOTION, V8, P753, DOI 10.1037/a0014123; Haidt J, 2001, PSYCHOL REV, V108, P814, DOI 10.1037//0033-295X.108.4.814; Haidt J, 2001, J APPL SOC PSYCHOL, V31, P191, DOI 10.1111/j.1559-1816.2001.tb02489.x; Haidt J., 2008, MORAL PSYCHOL, P181; Hamlin JK, 2010, DEVELOPMENTAL SCI, V13, P923, DOI 10.1111/j.1467-7687.2010.00951.x; Hare TA, 2011, J NEUROSCI, V31, P11077, DOI 10.1523/JNEUROSCI.6383-10.2011; Harenski CL, 2012, DEV COGN NEUROS-NETH, V2, P162, DOI 10.1016/j.dcn.2011.09.002; Hinson JM, 2003, J EXP PSYCHOL LEARN, V29, P298, DOI 10.1037/0278-7393.29.2.298; Hinson JM, 2002, COGN AFFECT BEHAV NE, V2, P341, DOI 10.3758/CABN.2.4.341; HOFFMAN M.L., 2000, EMPATHY MORAL DEV IM; Humphries M. L., 2000, J BLACK PSYCHOL, V26, P51, DOI [10.1177/0095798400026001003, DOI 10.1177/0095798400026001003]; Kagan J., 2008, NEUROSCIENCE MORALIT, V2, P297; Kahneman D., 2012, THINKING FAST SLOW; Killen M, 1999, CHILD DEV, V70, P486, DOI 10.1111/1467-8624.00035; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kohlberg, 1984, ESSAYS MORAL DEV, V2; Kohlberg L., 1981, PHILOS MORAL DEV MOR; Kohlberg L., 1976, MORAL DEV BEHAV THEO, P31; Kohlberg L, 1984, PSYCHOL MORAL DEV NA, V2; Krebs D. L., 2014, HDB MORAL BEHAV DEV, P139; Krebs DL, 2005, PSYCHOL REV, V112, P629, DOI 10.1037/0033-295X.112.3.629; Kurtines, 1984, MORALITY MORAL BEHAV, P24; Lansford JE, 2006, J ABNORM CHILD PSYCH, V34, P715, DOI 10.1007/s10802-006-9057-4; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Lourenco O, 2014, NEW IDEAS PSYCHOL, V32, P1, DOI 10.1016/j.newideapsych.2013.08.001; Lovett BJ, 2007, CLIN PSYCHOL REV, V27, P1, DOI 10.1016/j.cpr.2006.03.003; Nobes G, 2016, COGNITION, V157, P190, DOI 10.1016/j.cognition.2016.08.019; Nobes G, 2009, J EXP CHILD PSYCHOL, V104, P382, DOI 10.1016/j.jecp.2009.08.001; Nucci Larry, 2001, ED MORAL DOMAIN; Oostermeijer S, 2016, PERS INDIV DIFFER, V90, P54, DOI 10.1016/j.paid.2015.10.035; Palmer EJ, 2000, CLIN PSYCHOL PSYCHOT, V7, P303, DOI 10.1002/1099-0879(200010)7:4<303::AID-CPP263>3.0.CO;2-K; Palmer Emma J., 2003, OFFENDING BEHAV MORA; Penton-Voak IS, 2013, PSYCHOL SCI, V24, P688, DOI 10.1177/0956797612459657; Peterson C, 2016, DEV PSYCHOL, V52, P46, DOI 10.1037/a0039833; Piaget Jean, 1932, MORAL JUDGMENT CHILD; Powell NL, 2012, J EXP CHILD PSYCHOL, V113, P186, DOI 10.1016/j.jecp.2012.03.006; Pozuelos JP, 2014, DEV PSYCHOL, V50, P2405, DOI 10.1037/a0037469; Rest J. R., 1999, POST CONVENTIONAL MO; Robinson L, 2012, INT J LAW PSYCHIAT, V35, P57, DOI 10.1016/j.ijlp.2011.11.009; Ross-Sheehy S, 2015, INFANCY, V20, P467, DOI 10.1111/infa.12087; Roth-Hanania R, 2011, INFANT BEHAV DEV, V34, P447, DOI 10.1016/j.infbeh.2011.04.007; Rueda MR, 2005, P NATL ACAD SCI USA, V102, P14931, DOI 10.1073/pnas.0506897102; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Salas CE, 2016, SOC COGN AFFECT NEUR, V11, P1528, DOI 10.1093/scan/nsw075; Scherf KS, 2006, J COGNITIVE NEUROSCI, V18, P1045, DOI 10.1162/jocn.2006.18.7.1045; Sebastian CL, 2012, SOC COGN AFFECT NEUR, V7, P53, DOI 10.1093/scan/nsr023; SELMAN RL, 1976, MORAL DEV BEHAV, P299; SERRANO JM, 1992, DEV PSYCHOBIOL, V25, P411, DOI 10.1002/dev.420250603; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2011, NEUROSCIENTIST, V17, P18, DOI 10.1177/1073858410379268; Morris AS, 2007, SOC DEV, V16, P361, DOI 10.1111/j.1467-9507.2007.00389.x; Smetana JG, 2006, HANDBOOK OF MORAL DEVELOPMENT, P119; SMETANA JG, 1985, DEV PSYCHOL, V21, P18, DOI 10.1037/0012-1649.21.1.18; SNAREY JR, 1985, PSYCHOL BULL, V97, P202, DOI 10.1037/0033-2909.97.2.202; Sodian B, 2007, DEVELOPMENTAL SCI, V10, P199, DOI 10.1111/j.1467-7687.2007.00580.x; Solomon M, 2011, J AUTISM DEV DISORD, V41, P32, DOI 10.1007/s10803-010-1017-8; Somsen RJM, 2007, DEVELOPMENTAL SCI, V10, P664, DOI 10.1111/j.1467-7687.2007.00613.x; SONG MJ, 1987, DEV PSYCHOL, V23, P577, DOI 10.1037/0012-1649.23.4.577; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Steinberg L, 2007, CURR DIR PSYCHOL SCI, V16, P55, DOI 10.1111/j.1467-8721.2007.00475.x; Susac A., 2014, FRONTIERS HUMAN NEUR, V8; Svetlova M, 2010, CHILD DEV, V81, P1814, DOI 10.1111/j.1467-8624.2010.01512.x; Taber-Thomas B. C., 2012, DEV SOCIAL NEUROSCIE, P65; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Thomas LA, 2007, DEVELOPMENTAL SCI, V10, P547, DOI 10.1111/j.1467-7687.2007.00614.x; Thompson R A, 1994, Monogr Soc Res Child Dev, V59, P25, DOI 10.2307/1166137; TISAK MS, 1988, DEV PSYCHOL, V24, P352, DOI 10.1037/0012-1649.24.3.352; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turiel Elliot, 1983, DEV SOCIAL KNOWLEDGE; Van Bavel JJ, 2015, CURR OPIN PSYCHOL, V6, P167, DOI 10.1016/j.copsyc.2015.08.009; Van der Graaff J, 2014, DEV PSYCHOL, V50, P881, DOI 10.1037/a0034325; van Nieuwenhuijzen M, 2011, RES DEV DISABIL, V32, P358, DOI 10.1016/j.ridd.2010.10.012; Vera-Estay E, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00227; Vetter NC, 2013, DEV NEUROPSYCHOL, V38, P114, DOI 10.1080/87565641.2012.733786; Walker LJ, 2002, J MORAL EDUC, V31, P353, DOI 10.1080/0305724022000008160; Wikstr_om P. O., 2012, BREAKING RULES SOCIA; Yeates KO, 2012, DEV SOCIAL NEUROSCIE, P207; Ziv Y, 2011, J EXP CHILD PSYCHOL, V109, P412, DOI 10.1016/j.jecp.2011.02.009	135	29	31	13	46	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0273-2297	1090-2406		DEV REV	Dev. Rev.	SEP	2018	49						80	100		10.1016/j.dr.2018.06.001			21	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	GS8AY	WOS:000443929900006		Green Accepted, hybrid, Green Published			2022-02-06	
J	Hess, ER; Homme, JL; Kharbanda, AB; Tzimenatos, L; Louie, JP; Cohen, DM; Nigrovic, LE; Westphal, JJ; Shah, ND; Inselman, J; Ferrara, MJ; Herrin, J; Montori, VM; Kupperrnann, N				Hess, Erik R.; Homme, James L.; Kharbanda, Anupam B.; Tzimenatos, Leah; Louie, Jeffrey P.; Cohen, Daniel M.; Nigrovic, Lise E.; Westphal, Jessica J.; Shah, Nilay D.; Inselman, Jonathan; Ferrara, Michael J.; Herrin, Jeph; Montori, Victor M.; Kupperrnann, Nathan			Effect of the Head Computed Tomography Choice Decision Aid in Parents of Children With Minor Head Trauma A Cluster Randomized Trial	JAMA NETWORK OPEN			English	Article							PHYSICIAN; NUMERACY; TRUST	IMPORTANCE The Pediatric Emergency Care Applied Research Network prediction rules for minor head trauma identify children at very low, intermediate, and high risk of clinically important traumatic brain injuries (ciTBIs) and recommend no computed tomography (CT) for those at very low risk. However, the prediction rules provide little guidance in the choice of home observation or CT in children at intermediate risk for ciTBI. OBJECTIVE To compare a decision aid with usual care in parents of children at intermediate risk for ciTBI. DESIGN, SETTINGS, AND PARTICIPANTS This cluster randomized trial was conducted in 7 geographically diverse US emergency departments (EDs) from April 1, 2014, to September 30, 2016. Eligible participants were emergency clinicians, children ages 2 to 18 years with minor head trauma at intermediate risk for ciTBI, and their parents. INTERVENTIONS Clinicians were randomly assigned (1:1ratio) to shared decision-making facilitated by the Head CT Choice decision aid or to usual care. MAIN OUTCOMES AND MEASURES The primary outcome, selected by parent stakeholders, was knowledge of their child's risk for ciTBI and the available diagnostic options. Secondary outcomes included decisional conflict, parental involvement in decision-making, the ED CT rate, 7-day health care utilization, and missed ciTBI. RESULTS A total of 172 clinicians caring for 971 children (493 decision aid; 478 usual care) with minor head trauma at intermediate risk for ciTBI were enrolled. The patient mean (SD) age was 6.7 (7.1) years, 575 (59%) were male, and 253 (26%) were of nonwhite race. Parents in the decision aid arm compared with the usual care arm had greater knowledge (mean [SD] questions correct: 6.2 [2.0] vs 5.3 [2.0]; mean difference, 0.9; 95% CI, 0.6-1.3), had less decisional conflict (mean [SD] decisional conflict score, 14.8 [15.5] vs 19.2 [16.6]; mean difference, -4.4; 95% CI, -7.3 to -2.4), and were more involved in CT decision-making (observing patient involvement [OPTION] scores: mean [SD], 25.0 [8.5] vs 13.3 [6.5]; mean difference, 11.7; 95% CI, 9.6-13.9). Although the ED CT rate did not significantly differ (decision aid, 22% vs usual care, 24%; odds ratio, 0.81; 95% CI, 0.51-1.27), the mean number of imaging tests was lower in the decision aid arm 7 days after injury. No child had a missed ciTBI. CONCLUSIONS AND RELEVANCE Use of a decision aid in parents of children at intermediate risk of ciTBI increased parent knowledge, decreased decisional conflict, and increased involvement in decision-making. The intervention did not significantly reduce the ED CT rate but safely decreased health care utilization 7 days after injury.	[Hess, Erik R.] Univ Alabama Birmingham, Dept Emergency Med, 619 19th St S, Birmingham, AL 35249 USA; [Hess, Erik R.; Ferrara, Michael J.] Mayo Clin, Dept Emergency Med, Coll Med, Rochester, MN USA; [Hess, Erik R.; Montori, Victor M.] Mayo Clin, Knowledge & Evaluat Res Unit, Coll Med, Rochester, MN USA; [Homme, James L.] Mayo Clin, Div Pediat Emergency Med, Dept Emergency Med, Rochester, MN USA; [Homme, James L.] Mayo Clin, Dept Pediat, Div Pediat Emergency Med, Rochester, MN USA; [Kharbanda, Anupam B.; Kupperrnann, Nathan] Childrens Hosp & Clin Minnesota, Dept Pediat Emergency Med, Minneapolis, MN USA; [Tzimenatos, Leah] Univ Calif Davis Hlth, Sacramento, CA USA; [Louie, Jeffrey P.] Univ Minnesota, Dept Pediat, Div Emergency Med, Minneapolis, MN 55455 USA; [Cohen, Daniel M.] Nationwide Childrens Hosp, Div Emergency Med, Columbus, OH USA; [Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Shah, Nilay D.] Mayo Clin, Dept Hlth Sci Res, Div Hlth Care Policy & Res, Coll Med, Rochester, MN USA; [Shah, Nilay D.; Inselman, Jonathan] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Healthcare Del, Rochester, MN USA; [Ferrara, Michael J.] Mayo Clin, Dept Surg, Coll Med, Div Trauma Crit Care & Gen Surg, Rochester, MN USA; [Herrin, Jeph] Yale Univ, Sch Med, New Haven, CT USA; [Kupperrnann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA		Hess, ER (corresponding author), Univ Alabama Birmingham, Dept Emergency Med, 619 19th St S, Birmingham, AL 35249 USA.	ehess@uabmc.edu		Kharbanda, Anupam/0000-0001-5231-9855	Patient-Centered Outcomes Research Institute AwardPatient-Centered Outcomes Research Institute - PCORI [12-11-4435]	This study was funded from contract 12-11-4435 through a Patient-Centered Outcomes Research Institute Award.	Atabaki SM, 2016, ACAD EMERG MED, V23, P566, DOI 10.1111/acem.12923; Coyne I, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008970.pub3; Elwyn G, 2005, HEALTH EXPECT, V8, P34, DOI 10.1111/j.1369-7625.2004.00311.x; Fagerlin A, 2007, MED DECIS MAKING, V27, P672, DOI 10.1177/0272989x07304449; Faul M, 2010, TRAUMATIC BRAIN INJU, DOI [10.15620/cdc.55710272989X07304449, DOI 10.15620/CDC.55710272989X07304449]; Hess EP, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6165; Hess EP, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-253; Hess EP, 2012, CIRC-CARDIOVASC QUAL, V5, P251, DOI 10.1161/CIRCOUTCOMES.111.964791; Karanicolas PJ, 2009, J CLIN EPIDEMIOL, V62, P479, DOI 10.1016/j.jclinepi.2008.02.009; Klar, 2000, DESIGN ANAL CLUSTER; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LeBlanc A, 2015, JAMA INTERN MED, V175, P1761, DOI 10.1001/jamainternmed.2015.5214; LeBlanc A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128063; McNaughton C, 2011, ACAD EMERG MED, V18, P1148, DOI 10.1111/j.1553-2712.2011.01210.x; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Moseley KL, 2006, AMBUL PEDIATR, V6, P58, DOI 10.1016/j.ambp.2005.08.001; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Quayle KS, 2014, NEW ENGL J MED, V371, P1945, DOI 10.1056/NEJMc1407902; Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1186/1741-7015-8-18]; Stacey D, 2014, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001431.PUB4; Thom DH, 2002, FAM PRACT, V19, P476, DOI 10.1093/fampra/19.5.476	21	29	30	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	SEP	2018	1	5							e182430	10.1001/jamanetworkopen.2018.2430			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HD6JU	WOS:000452645200010	30646167	Green Published, gold			2022-02-06	
J	Di Pietro, V; Porto, E; Ragusa, M; Barbagallo, C; Davies, D; Forcione, M; Logan, A; Di Pietro, C; Purrello, M; Grey, M; Hammond, D; Sawlani, V; Barbey, AK; Belli, A				Di Pietro, Valentina; Porto, Edoardo; Ragusa, Marco; Barbagallo, Cristina; Davies, David; Forcione, Mario; Logan, Ann; Di Pietro, Cinzia; Purrello, Michele; Grey, Michael; Hammond, Douglas; Sawlani, Vijay; Barbey, Aron K.; Belli, Antonio			Salivary MicroRNAs: Diagnostic Markers of Mild Traumatic Brain Injury in Contact-Sport	FRONTIERS IN MOLECULAR NEUROSCIENCE			English	Article						concussion; mild traumatic brain injury; biomarkers; saliva; microRNA	FIBRILLARY ACIDIC PROTEIN; IN-VITRO MODEL; TEMPORAL WINDOW; INTRACRANIAL LESIONS; BIOMARKERS; SERUM; CONCUSSION; RNA; VULNERABILITY; REGULATORS	Concussion is difficult to diagnose, particularly when symptoms are atypical or late in presenting. An accurate and timely initial assessment is crucial for clinical management. Cerebral spinal fluid (CSF) and blood markers of traumatic brain injury show promising results but their clinical applicability in concussion has significant limitations. In the study, we explored saliva as a new source of biomarkers of concussion. Saliva samples of concussed players were collected after 48-72 h from concussion and analyzed by high-throughput technologies. A discovery group of 10 concussed rugby professional and semiprofessional athletes and 10 non-concussed matched controls was used for the analysis of 92 inflammatory proteins by the Proseek-Multiplex-Inflammation technology. In addition, saliva samples of 6 concussed and 6 non-concussed athletes were used to screen 800 human microRNAs (miRNAs) by the Nanostring Technology. The results were then validated by RT-qPCR in an enlarged cohort (validation group) comprising 22 concussed athletes. Results showed, no significant variations of the 65 inflammatory proteins detected in saliva between groups but 5 microRNAs, miR-27b-3p (p=0.016), let-7i-5p (p=0.001), miR-142-3p (p=0.008), miR-107 (p=0.028), miR-135b-5p (p=0.017) significantly upregulated in concussed athletes. Univariate ROC curve analysis showed that the differentially expressed miRNAs could be considered good classifiers of concussion. Further analyses showed significant correlation between these microRNAs and Reaction Time component of the ImPACT concussion assessment tool. In addition, biocomputation analysis predicted the involvement of these microRNAs in important biological processes that might be related to trauma, such as response to hypoxia, cell death, neurogenesis, axon repair and myelination. Ease of access and non-invasiveness of saliva samples make these biomarkers particularly suitable for concussion assessment.	[Di Pietro, Valentina; Porto, Edoardo; Logan, Ann; Belli, Antonio] Univ Birmingham, Inst Inflammat & Ageing, Neurotrauma & Ophthalmol Res Grp, Birmingham, W Midlands, England; [Di Pietro, Valentina; Porto, Edoardo; Davies, David; Forcione, Mario; Hammond, Douglas; Sawlani, Vijay; Belli, Antonio] Queen Elizabeth Hosp, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England; [Di Pietro, Valentina; Barbey, Aron K.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL USA; [Ragusa, Marco; Barbagallo, Cristina; Di Pietro, Cinzia; Purrello, Michele] Univ Catania, Dept Biomed Sci & Biotechnol, Sect Biol & Genet G Sichel, BioMol Genome & Complex Syst BioMed Unit BMGS, Catania, Italy; [Ragusa, Marco] IRCCS Associaz Oasi Maria SS, Inst Res Mental Retardat & Brain Aging, Troina, Italy; [Grey, Michael] Univ East Anglia, Sch Sport & Exercise, Norwich, Norfolk, England		Di Pietro, V (corresponding author), Univ Birmingham, Inst Inflammat & Ageing, Neurotrauma & Ophthalmol Res Grp, Birmingham, W Midlands, England.; Di Pietro, V (corresponding author), Queen Elizabeth Hosp, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England.; Di Pietro, V (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL USA.	v.dipietro@bham.ac.uk	Belli, Antonio/I-3799-2015; Barbagallo, Cristina/AAA-8871-2022; Ragusa, Marco/D-7691-2010; Barbey, Aron/L-7312-2015; Forcione, Mario/K-2852-2018	Belli, Antonio/0000-0002-3211-9933; Barbagallo, Cristina/0000-0002-6769-4516; Ragusa, Marco/0000-0002-4282-920X; Porto, Edoardo/0000-0002-1442-9137; Barbey, Aron/0000-0002-6092-0912; Forcione, Mario/0000-0002-4045-8011	National Institute for Health Research (NIHR), Midlands Neuroscience Training and Research Fund; British Medical Association; Department Research Plan of University of Catania; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/N019016/1, MR/J011584/1] Funding Source: UKRI	This study was funded by the National Institute for Health Research (NIHR), Midlands Neuroscience Training and Research Fund and by the British Medical Association. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was also funded by 2016/2018 Department Research Plan of University of Catania (2 degrees line of intervention).	Aas JA, 2005, J CLIN MICROBIOL, V43, P5721, DOI 10.1128/JCM.43.11.5721-5732.2005; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Bi YJ, 2009, J CELL PHYSIOL, V218, P467, DOI 10.1002/jcp.21639; Bonne NJ, 2012, GENOME MED, V4, DOI 10.1186/gm383; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Burbelo PD, 2012, ORAL DIS, V18, P121, DOI 10.1111/j.1601-0825.2011.01863.x; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92; Cirnigliaro M, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00250; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Devic I, 2011, BRAIN, V134, DOI 10.1093/brain/awr015; Di Pietro V, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00429; Di Pietro V, 2017, J NEUROTRAUM, V34, P1948, DOI 10.1089/neu.2016.4857; Di Pietro V, 2015, NEUROCHEM RES, V40, P991, DOI 10.1007/s11064-015-1554-9; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gaetz M, 2017, MED HYPOTHESES, V102, P130, DOI 10.1016/j.mehy.2017.03.023; Gauthier BR, 2006, NAT MED, V12, P36, DOI 10.1038/nm0106-36; Guerriero RM, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0545-1; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Hicks SD, 2018, J NEUROTRAUM, V35, P64, DOI 10.1089/neu.2017.5111; Johnson JJ, 2018, JAMA PEDIATR, V172, P65, DOI 10.1001/jamapediatrics.2017.3884; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Li MA, 2012, BIOESSAYS, V34, P670, DOI 10.1002/bies.201200019; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Ludwig N, 2016, NUCLEIC ACIDS RES, V44, P3865, DOI 10.1093/nar/gkw116; Maroon JC, 2014, PROG NEUROL SURG, V28, P1, DOI 10.1159/000358746; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Mitoh Y, 2004, BRAIN RES, V999, P62, DOI 10.1016/j.brainres.2003.11.053; Mitra B, 2017, J CLIN NEUROSCI, V38, P37, DOI 10.1016/j.jocn.2016.12.009; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nylen K, 2006, NEUROSCI LETT, V404, P132, DOI 10.1016/j.neulet.2006.05.029; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Park NJ, 2006, CLIN CHEM, V52, P988, DOI 10.1373/clinchem.2005.063206; Ragusa M, 2017, INT J GENOMICS, V2017, DOI 10.1155/2017/4723193; Ragusa M, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00051; Ragusa M, 2015, CANCER BIOL THER, V16, P1387, DOI 10.1080/15384047.2015.1046021; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shi M, 2011, J ALZHEIMERS DIS, V27, P299, DOI 10.3233/JAD-2011-110731; Szafranskil K, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00087; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vallelunga A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00156; Vos BC, 2018, CLIN J SPORT MED, V28, P91, DOI 10.1097/JSM.0000000000000432; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Yang T, 2016, J NEUROCHEM, V137, P122, DOI 10.1111/jnc.13534; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	60	29	29	2	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5099			FRONT MOL NEUROSCI	Front. Molec. Neurosci.	AUG 20	2018	11								290	10.3389/fnmol.2018.00290			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GQ9XY	WOS:000442156900001	30177873	Green Published, Green Accepted, gold			2022-02-06	
J	Fowler, JH; McQueen, J; Holland, PR; Manso, Y; Marangoni, M; Scott, F; Chisholm, E; Scannevin, RH; Hardingham, GE; Horsburgh, K				Fowler, Jill H.; McQueen, Jamie; Holland, Philip R.; Manso, Yasmina; Marangoni, Martina; Scott, Fiona; Chisholm, Emma; Scannevin, Robert H.; Hardingham, Giles E.; Horsburgh, Karen			Dimethyl fumarate improves white matter function following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory mediators	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Electrophysiology; cerebrovascular disease; inflammation; microglia; white matter	CHRONIC CEREBRAL HYPOPERFUSION; TRAUMATIC BRAIN-INJURY; OLIGODENDROCYTE PROGENITOR CELLS; SMALL-VESSEL DISEASE; RAT-BRAIN; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; CORPUS-CALLOSUM; ACID ESTERS; SPINAL-CORD	The brain's white matter is highly vulnerable to reductions in cerebral blood flow via mechanisms that may involve elevated microgliosis and pro-inflammatory pathways. In the present study, the effects of severe cerebral hypoperfusion were investigated on white matter function and inflammation. Male C57Bl/6J mice underwent bilateral common carotid artery stenosis and white matter function was assessed at seven days with electrophysiology in response to evoked compound action potentials (CAPs) in the corpus callosum. The peak latency of CAPs and axonal refractoriness was increased following hypoperfusion, indicating a marked functional impairment in white matter, which was paralleled by axonal and myelin pathology and increased density and numbers of microglia/macrophages. The functional impairment in peak latency was significantly correlated with increased microglia/macrophages. Dimethyl fumarate (DMF; 100mg/kg), a drug with anti-inflammatory properties, was found to reduce peak latency but not axonal refractoriness. DMF had no effect on hypoperfusion-induced axonal and myelin pathology. The density of microglia/macrophages was significantly increased in vehicle-treated hypoperfused mice, whereas DMF-treated hypoperfused mice had similar levels to that of sham-treated mice. The study suggests that increased microglia/macrophages following cerebral hypoperfusion contributes to the functional impairment in white matter that may be amenable to modulation by DMF.	[Fowler, Jill H.; McQueen, Jamie; Holland, Philip R.; Manso, Yasmina; Marangoni, Martina; Scott, Fiona; Chisholm, Emma; Horsburgh, Karen] Univ Edinburgh, Ctr Neuroregenerat, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland; [McQueen, Jamie; Hardingham, Giles E.] Univ Edinburgh, Ctr Integrat Physiol, Edinburgh, Midlothian, Scotland; [Holland, Philip R.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, London, England; [Manso, Yasmina] Dev Neurobiol & Regenerat Lab, Parc Cient Barcelona, Barcelona, Spain; [Marangoni, Martina] Univ Florence, Dept Hlth Sci, Florence, Italy; [Scannevin, Robert H.] Biogen, Cambridge, MA USA; [Hardingham, Giles E.] Univ Edinburgh, UK Dementia Res Inst, Edinburgh, Midlothian, Scotland; [Horsburgh, Karen] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland		Fowler, JH; Horsburgh, K (corresponding author), Univ Edinburgh, Ctr Neuroregenerat, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	Jill.Fowler@ed.ac.uk; Karen.Horsburgh@ed.ac.uk		McQueen, Jamie/0000-0001-7172-7504; Scannevin, Robert/0000-0002-5749-2785; Marangoni, Martina/0000-0003-0706-6566; Holland, Philip Robert/0000-0003-3345-4853; Fowler, Jill/0000-0003-3204-1221; Hardingham, Giles/0000-0002-7629-5314; Manso Sanz, Yasmina/0000-0002-5788-4180; Horsburgh, Karen/0000-0002-9620-3691	Alzheimer's Society; Alzheimer Research UKAlzheimer's Research UK (ARUK); BiogenBiogen; Wellcome TrustWellcome TrustEuropean Commission; University of Edinburgh Centre for Cognitive Aging and Cognitive Epidemiology (CCACE), part of the Lifelong Health and Wellbeing Initiative [(G0700704/84698]; CCACE PhD studentship; Alzheimer's Society Fellowship [297]; Alzheimer's Research UK Senior Fellowship [ARUK-SRF2013-4]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0902044, UKDRI-4001] Funding Source: UKRI; Alzheimers Research UKAlzheimer&apos;s Research UK (ARUK) [ARUK-SRF2013-4] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [UKDRI-4001, MR/K026992/1, G0902044] Funding Source: researchfish	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Alzheimer's Society, Alzheimer Research UK, Biogen, Wellcome Trust and The University of Edinburgh Centre for Cognitive Aging and Cognitive Epidemiology (CCACE), part of the Lifelong Health and Wellbeing Initiative (G0700704/84698). J.M. was supported by a CCACE PhD studentship, J.H.F. was funded by an Alzheimer's Society Fellowship (Grant 297) and is currently funded by an Alzheimer's Research UK Senior Fellowship (Grant ARUK-SRF2013-4).	Ahuja M, 2016, J NEUROSCI, V36, P6332, DOI 10.1523/JNEUROSCI.0426-16.2016; Al-Jaderi Z, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00278; Baltan S, 2008, J NEUROSCI, V28, P1479, DOI 10.1523/JNEUROSCI.5137-07.2008; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brennan MS, 2016, ANTIOXID REDOX SIGN, V24, P1058, DOI 10.1089/ars.2015.6622; Chen L, 2015, SCI REP-UK, V5, DOI 10.1038/srep14308; Cho H, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0452-z; Cho KO, 2006, J NEUROSCI RES, V83, P285, DOI 10.1002/jnr.20727; Coltman R, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.09.005; Corcoba A., 2015, INT J NEUROPSYCHOPH, V19; Crawford DK, 2009, NEUROSCIENCE, V164, P1407, DOI 10.1016/j.neuroscience.2009.09.069; Crawford DK, 2009, J NEUROSCI METH, V182, P25, DOI 10.1016/j.jneumeth.2009.05.013; de Groot JC, 2002, ANN NEUROL, V52, P335, DOI 10.1002/ana.10294; Ellrichmann G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016172; Fernando MS, 2006, STROKE, V37, P1391, DOI 10.1161/01.STR.0000221308.94473.14; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Goncharenko K, 2014, J NEUROPHYSIOL, V112, P2067, DOI 10.1152/jn.00037.2013; Hamner MA, 2015, J NEUROSCI, V35, P15599, DOI 10.1523/JNEUROSCI.2544-15.2015; Han RR, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0559-x; Holland PR, 2015, J CEREBR BLOOD F MET, V35, P1005, DOI 10.1038/jcbfm.2015.12; Holland PR, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.11.009; Hou X, 2015, NEUROSCIENCE, V297, P118, DOI 10.1016/j.neuroscience.2015.03.033; Iniaghe LO, 2015, NEUROBIOL DIS, V82, P349, DOI 10.1016/j.nbd.2015.07.001; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Jing X, 2015, NEUROSCIENCE, V286, P131, DOI 10.1016/j.neuroscience.2014.11.047; KIM JS, 1995, J NEUROIMMUNOL, V56, P127, DOI 10.1016/0165-5728(94)00138-E; Kunze R, 2015, EXP NEUROL, V266, P99, DOI 10.1016/j.expneurol.2015.02.022; Lambertsen KL, 2004, J NEUROPATH EXP NEUR, V63, P942, DOI 10.1093/jnen/63.9.942; Lastres-Becker I, 2016, ANTIOXID REDOX SIGN, V25, P61, DOI 10.1089/ars.2015.6549; Lee KM, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0652-1; Lin RH, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0733-1; Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386; Liu QH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084802; Liu YZ, 2015, J NEUROSURG, V123, P915, DOI 10.3171/2014.11.JNS132348; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Matute C, 2012, ASN NEURO, V4, P89, DOI 10.1042/AN20110060; McQueen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087227; Michell-Robinson MA, 2016, ANN CLIN TRANSL NEUR, V3, P27, DOI 10.1002/acn3.270; Miki K, 2009, J NEUROSCI RES, V87, P1270, DOI 10.1002/jnr.21925; Miljkovic D, 2015, J IMMUNOL, V194, P2493, DOI 10.4049/jimmunol.1402302; Mirabelli-Badenier M, 2011, THROMB HAEMOSTASIS, V105, P409, DOI 10.1160/TH10-10-0662; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Moharregh-Khiabani D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011769; Moore S, 2013, NEUROSCIENCE, V245, P166, DOI 10.1016/j.neuroscience.2013.04.017; Moore S, 2014, J NEUROSCI RES, V92, P1621, DOI 10.1002/jnr.23440; Morsali D, 2013, BRAIN, V136, P1067, DOI 10.1093/brain/awt041; Murray KN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00018; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Parodi B, 2015, ACTA NEUROPATHOL, V130, P279, DOI 10.1007/s00401-015-1422-3; Patel R, 2013, BRAIN PATHOL, V23, P462, DOI 10.1111/bpa.12029; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Pitarokoili K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143416; Prins ND, 2005, BRAIN, V128, P2034, DOI 10.1093/brain/awh553; Prins ND, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.10; Pryor J, 2006, SPINAL CORD, V44, P653, DOI 10.1038/sj.sc.3101901; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2016, EXP NEUROL, V283, P188, DOI 10.1016/j.expneurol.2016.06.011; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reimer MM, 2011, J NEUROSCI, V31, P18185, DOI 10.1523/JNEUROSCI.4936-11.2011; Ritter J, 2013, J NEUROSCI, V33, P8990, DOI 10.1523/JNEUROSCI.5528-12.2013; Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034; Schilling S, 2006, CLIN EXP IMMUNOL, V145, P101, DOI 10.1111/j.1365-2249.2006.03094.x; Schulze-Topphoff U, 2016, P NATL ACAD SCI USA, V113, P4777, DOI 10.1073/pnas.1603907113; Sun J, 2013, BRAIN RES, V1491, P225, DOI 10.1016/j.brainres.2012.11.006; Takami S, 1997, NEUROSCI LETT, V227, P173, DOI 10.1016/S0304-3940(97)00338-8; Tanaka K, 2003, BRAIN RES, V989, P172, DOI 10.1016/S0006-8993(03)03317-1; Tanaka K, 2001, NEUROREPORT, V12, P2169, DOI 10.1097/00001756-200107200-00025; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; Tsai TH, 2015, J HYPERTENS, V33, P1001, DOI 10.1097/HJH.0000000000000529; Ueno M, 2002, J CEREBR BLOOD F MET, V22, P97, DOI 10.1097/00004647-200201000-00012; Ueno Y, 2015, J CEREBR BLOOD F MET, V35, P382, DOI 10.1038/jcbfm.2014.210; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang JP, 2016, MOL NEUROBIOL, V53, P6057, DOI 10.1007/s12035-015-9512-8; Wang Y, 2016, PROG NEUROBIOL, V141, P45, DOI [10.1016/j.pneurobio.2016.04.00, 10.1016/j.pneurobio.2016.04.005]; Washida K, 2010, STROKE, V41, P1798, DOI 10.1161/STROKEAHA.110.583948; Wiesner D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076670; Wilms H, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-30; Yamagami S, 1999, J LEUKOCYTE BIOL, V65, P744, DOI 10.1002/jlb.65.6.744; Yamazaki Y, 2010, NEUROSCIENTIST, V16, P11, DOI 10.1177/1073858409334425; Yao Y, 2016, TRANSL STROKE RES, V7, P535, DOI 10.1007/s12975-016-0496-0; Yoshizaki K, 2008, EXP NEUROL, V210, P585, DOI 10.1016/j.expneurol.2007.12.005; Yuan BQ, 2017, MOL CELL NEUROSCI, V78, P52, DOI 10.1016/j.mcn.2016.08.003; Zechariah A, 2013, STROKE, V44, P1690, DOI 10.1161/STROKEAHA.111.000240; Zhang JD, 2013, J NEUROSCI RES, V91, P240, DOI 10.1002/jnr.23150; Zhao XR, 2015, STROKE, V46, P1923, DOI 10.1161/STROKEAHA.115.009398	89	29	30	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2018	38	8					1354	1370		10.1177/0271678X17713105			17	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	GP2OQ	WOS:000440674900008	28606007	hybrid, Green Published			2022-02-06	
J	Song, HL; Konan, LM; Cui, JK; Johnson, CE; Langenderfer, M; Grant, D; Ndam, T; Simonyi, A; White, T; Demirci, U; Mott, DR; Schwer, D; Hubler, GK; Cernak, I; DePalma, RG; Gu, ZZ				Song, Hailong; Konan, Landry M.; Cui, Jiankun; Johnson, Catherine E.; Langenderfer, Martin; Grant, DeAna; Ndam, Tina; Simonyi, Agnes; White, Tommi; Demirci, Utkan; Mott, David R.; Schwer, Doug; Hubler, Graham K.; Cernak, Ibolja; DePalma, Ralph G.; Gu, Zezong			Ultrastructural brain abnormalities and associated behavioral changes in mice after low-intensity blast exposure	BEHAVIOURAL BRAIN RESEARCH			English	Article						Blast-induced TBI; Blast wave; Behavior; Neuropathology; Ultrastructural abnormalities	INJURY; MODEL; STRESS; MATTER; WHITE; AXONS	Explosive blast-induced mild traumatic brain injury (mTBI), a "signature wound" of recent military conflicts, commonly affects service members. While past blast injury studies have provided insights into TBI with moderate- to high-intensity explosions, the impact of primary low-intensity blast (LIB)-mediated pathobiology on neurological deficits requires further investigation. Our prior considerations of blast physics predicted ultrastructural injuries at nanoscale levels. Here, we provide quantitative data using a primary LIB injury murine model exposed to open field detonation of 350 g of high-energy explosive C4. We quantified ultrastructural and behavioral changes up to 30 days post blast injury (DPI). The use of an open-field experimental blast generated a primary blast wave with a peak overpressure of 6.76 PSI (46.6 kPa) at a 3-m distance from the center of the explosion, a positive phase duration of approximate 3.0 milliseconds (ms), a maximal impulse of 8.7 PSI x ms and a sharp rising time of 9 x 10(-3) ms, with no apparent impact/acceleration in exposed animals. Neuropathologically, myelinated axonal damage was observed in blast-exposed groups at 7 DPI. Using transmission electron microscopy, we observed and quantified myelin sheath defects and mitochondrial abnormalities at 7 and 30 DPI. Inverse correlations between blast intensities and neurobehavioral outcomes including motor activities, anxiety levels, nesting behavior, spatial learning and memory occurred. These observations uncover unique ultrastructural brain abnormalities and associated behavioral changes due to primary blast injury and provide key insights into its pathogenesis and potential treatment.	[Song, Hailong; Konan, Landry M.; Cui, Jiankun; Ndam, Tina; Gu, Zezong] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65212 USA; [Johnson, Catherine E.; Langenderfer, Martin] Missouri Univ Sci & Technol, Dept Min & Nucl Engn, Rolla, MO 65409 USA; [Grant, DeAna; White, Tommi] Univ Missouri, Electron Microscopy Core Facil, Columbia, MO 65211 USA; [Simonyi, Agnes] Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65212 USA; [Demirci, Utkan] Stanford Univ, Dept Radiol, Sch Med, Dept Elect Engn, Stanford, CA 94305 USA; [Mott, David R.; Schwer, Doug] US Naval Res Lab, Washington, DC 20375 USA; [Hubler, Graham K.] Univ Missouri, Dept Phys & Astron, Sidney Kimmel Inst Nucl Renaissance, Columbia, MO 65211 USA; [Cernak, Ibolja] Univ Alberta, Fac Rehabil Med, Canadian Mil & Vet Clin Rehabil, Edmonton, AB T6G 2G4, Canada; [DePalma, Ralph G.] Off Res & Dev, Dept Vet Affairs, Washington, DC 20420 USA; [Cui, Jiankun; Gu, Zezong] Truman VA Hosp Res Serv, Columbia, MO 65201 USA		Gu, ZZ (corresponding author), Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65212 USA.	guze@health.missouri.edu	Song, Hailong/I-9418-2018; DePalma, Ralph/P-1733-2019	Song, Hailong/0000-0002-4204-6459; Ibolja, Cernak/0000-0003-3214-698X; Konan, Landry/0000-0003-2679-3785	DoD Congressionally Directed Medical Research Programs (CDMRP) for the Peer Reviewed Alzheimer's Research Program Convergence Science Research Award (PRARP-CSRA) [AZ140109]; University of Missouri	The authors thank the technical support of Drs. Shanyan Chen and Zhe Qu for the initial blast studies. This publication was made possible by funding from the DoD Congressionally Directed Medical Research Programs (CDMRP) for the Peer Reviewed Alzheimer's Research Program Convergence Science Research Award (PRARP-CSRA; AZ140109) and the research funds of the University of Missouri (ZG). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the United States government, the DoD, the United States Army or the Department of Veterans Affairs.	Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; [Anonymous], 2017, DVBIC DOD WORLDWIDE; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Beamer M, 2016, EXP NEUROL, V283, P16, DOI 10.1016/j.expneurol.2016.05.025; Bowen I. G., 1968, ESTIMATE MANS TOLERA, P37; Castejon OJ, 2004, BRAIN INJURY, V18, P1107, DOI 10.1080/02699050410001672332; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I., 2015, BRAIN NEUROTRAUMA MO; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2017, BRAIN INJURY, V31, P1168, DOI 10.1080/02699052.2016.1274779; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chandra N., 2015, BRAIN NEUROTRAUMA MO; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CLEMEDSON C, 1961, J APPL PHYSIOL, V16, P426, DOI 10.1152/jappl.1961.16.3.426; Deacon RMJ, 2006, NAT PROTOC, V1, P1117, DOI 10.1038/nprot.2006.170; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DePalma R, 2011, P NATO RTO MP HFM 20, P1; DePalma R. G., 2015, COMBAT TBI HIST EPID; DePalma RG, 2018, BEHAV BRAIN RES, V340, P102, DOI 10.1016/j.bbr.2016.08.036; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Elder GA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00269; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Feng K, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00179; Fievisohn E., 2018, J BIOMECH ENG, V140, DOI [10.1-115/1.4038710, DOI 10.1-115/1.4038710]; Gao J, 2014, EPILEPSY RES, V108, P162, DOI 10.1016/j.eplepsyres.2013.11.016; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; JOHNSON ES, 1981, ACTA NEUROPATHOL, V53, P93, DOI 10.1007/BF00689988; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kucherov Y, 2012, J APPL PHYS, V112, DOI 10.1063/1.4765727; Kucherov Y, 2012, J APPL PHYS, V111, DOI 10.1063/1.3675274; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2017, JAMA NEUROL, V74, P821, DOI 10.1001/jamaneurol.2017.0143; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Ojo JO, 2015, J NEUROPATH EXP NEUR, V74, P1012, DOI 10.1097/NEN.0000000000000247; Perez-Garcia G, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0357-17.2018; Proud W. G., 2016, FUNDAMENTALS BLAST P, P3; Przekwas A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00002; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Song HL, 2018, BEHAV BRAIN RES, V340, P147, DOI 10.1016/j.bbr.2016.08.037; Sosa MAG, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0483-z; Stewart C., 2006, EMERG MED PRACT, V8, P1; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024	58	29	30	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUL 16	2018	347						148	157		10.1016/j.bbr.2018.03.007			10	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	GL2BA	WOS:000436916800018	29526786	Bronze			2022-02-06	
J	Bretzin, AC; Covassin, T; Fox, ME; Petit, KM; Savage, JL; Walker, LF; Gould, D				Bretzin, Abigail C.; Covassin, Tracey; Fox, Meghan E.; Petit, Kyle M.; Savage, Jennifer L.; Walker, Lauren F.; Gould, Daniel			Sex Differences in the Clinical Incidence of Concussions, Missed School Days, and Time Loss in High School Student-Athletes: Part 1	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports-related concussion; sex-comparable sports; clinical incidence; male athletes; female athletes	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; STATES HIGH-SCHOOL; REPORTING BEHAVIORS; EPIDEMIOLOGY; KNOWLEDGE; SYMPTOMS; ACCELERATION; RECOVERY; PLAYERS	Background: Sports-related concussion (SRC) injury rates are well established in collegiate athletics through epidemiological studies using the National Collegiate Athletic Association Injury Surveillance System. However, few studies have examined sex differences, time loss, and missed school days in high school athletes, especially at the state level. Purpose: To identify sex differences in the clinical incidence of SRCs, missed school days, and time loss in high school student-athletes. Study Design: Descriptive epidemiological study. Methods: A total of 193,757 (116,434 male and 77,323 female) student-athletes (10th grade +/- 1.1) participating in Michigan High School Athletic Association (MHSAA)-sponsored athletic activities were recorded in the Head Injury Reporting System. Certified athletic trainers, school athletic administrators, and coaches from MHSAA high schools reported SRC data and overall participation for the 2015-2016 academic year. Total concussive injuries, as well as missed school days and time loss for each concussive injury, were reported. The clinical incidence was calculated by dividing the number of SRCs in a particular category by the number of participants in that category and presented with 95% CIs. Relative risk ratios (RRs) were determined for sex-comparable sports. Results: The overall clinical incidence for all sports was 1.7 per 100 player-seasons (95% CI, 1.6-1.8) and 1.9 (95% CI, 1.8-2.0) for male sports and 1.5 (95% CI, 1.4-1.6) for female sports. Female athletes were at a 1.9 (95% CI, 1.8-2.2) times greater risk for enduring SRCs than male athletes in sex-comparable sports, with a greater risk in baseball/softball (RR, 2.7 [95% CI, 1.9-3.8]), basketball (RR, 2.5 [95% CI, 2.1-2.9]), and soccer (RR, 1.6 [95% CI, 1.4-1.9]). Female student-athletes had significantly longer time loss than male student-athletes (P<.001). The mean number of missed school days did not differ between sexes (P=.70). Conclusion: High school female student-athletes have a higher risk for an SRC in all sex-comparable sports except lacrosse. This may be because of biomechanical differences of the head-neck segment, hormonal differences, and the fact that female athletes are more likely to report symptoms after a suspected SRC.	[Bretzin, Abigail C.; Covassin, Tracey; Fox, Meghan E.; Petit, Kyle M.; Savage, Jennifer L.; Walker, Lauren F.; Gould, Daniel] Michigan State Univ, 308 West Circle Dr,Room 1, E Lansing, MI 48824 USA; [Fox, Meghan E.] Grand Valley State Univ, Allendale, MI 49401 USA		Bretzin, AC (corresponding author), Michigan State Univ, 308 West Circle Dr,Room 1, E Lansing, MI 48824 USA.	bretzina@msu.edu		Bretzin, Abigail/0000-0003-3730-2849	Michigan High School Athletic Association (MHSAA)	This project was supported by the Michigan High School Athletic Association (MHSAA). The content of this report is solely the responsibility of the authors and does not necessarily reflect the views of the MHSAA.	Baker JG, 2016, CLIN PEDIATR, V55, P771, DOI 10.1177/0009922815606417; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bretzin AC, 2017, SPORTS HEALTH, V9, P168, DOI 10.1177/1941738116678615; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenland S., 1998, MODERN EPIDEMIOLOGY, P231; Greenland S, 1998, MODERN EPIDEMIOLOGY, P29; Grubenhoff' JA, 2015, BRAIN INJURY, V29, P1186, DOI 10.3109/02699052.2015.1035325; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Mansell J, 2005, J ATHL TRAINING, V40, P310; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; O'Connor KL, 2017, J ATHL TRAINING, V52, P175, DOI 10.4085/1062-6050-52.1.15; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Stone S, 2017, SPORTS HEALTH, V9, P41, DOI 10.1177/1941738116672184; Swartz EE, 2015, J ATHL TRAINING, V50, P1219, DOI 10.4085/1062-6050-51.1.06; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Wallace J, 2017, J ATHL TRAINING, V52, P682, DOI 10.4085/1062-6050-52.3.06; Wallace J, 2017, J ATHL TRAINING, V52, P228, DOI 10.4085/1062-6050-52.1.07; Wasserman EB, 2016, AM J PUBLIC HEALTH, V106, P1247, DOI 10.2105/AJPH.2016.303154; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257	29	29	28	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2018	46	9					2263	2269		10.1177/0363546518778251			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	GN4BM	WOS:000438958100029	29879362				2022-02-06	
J	Garcia, GGP; Broglio, SP; Lavieri, MS; McCrea, M; McAllister, T				Garcia, Gian-Gabriel P.; Broglio, Steven P.; Lavieri, Mariel S.; McCrea, Michael; McAllister, Thomas		CARE Consortium Investigators	Quantifying the Value of Multidimensional Assessment Models for Acute Concussion: An Analysis of Data from the NCAA-DoD Care Consortium	SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; HIGH-SCHOOL; RECURRENT CONCUSSION; SEX-DIFFERENCES; NEUROCOGNITIVE PERFORMANCE; COGNITIVE IMPAIRMENT; SIDELINE CONCUSSION; PROLONGED RECOVERY; NORMATIVE DATA; LONG-TERM	Background Many concussion assessment methods exist, but few studies quantify the performance of these methods to determine which can best assess acute concussion alone or in combination. Objectives The objectives of this study were to evaluate: (1) selected concussion assessments for acute concussion assessment; (2) the utility of change scores for acute concussion assessment; and (3) concussion assessment capabilities when constrained to limited clinical data or objective clinical measures. Methods The 'acute concussion' group contained assessments from <6 h post-injury (n = 560) and 24-48 h postinjury (n = 733). The 'normal performance' group contained assessments from baseline testing (n = 842) and unrestricted return to play (n = 707) timepoints. Univariate and multivariate logistic regression models were created separately for <6-and 24-to 48-h timepoints. Models were evaluated on sensitivity, specificity, and area under the receiver operating characteristic curve. Results Within the univariate analysis, Sport Concussion Assessment Tool symptom assessments had the highest combination of sensitivity, specificity, and area under the receiver operating characteristic curve, with values up to 0.93, 0.97, and 0.98, respectively. Full models had a sensitivity, specificity, and area under the receiver operating characteristic curve up to 0.94, 0.97, and 0.99, respectively, and outperformed all univariate models, raw score models, and objective models. Objective models were outperformed by all multivariate models and the univariate models containing only Sport Concussion Assessment Tool symptom assessments. Conclusion Results support the use of multidimensional assessment batteries over single instruments and suggest the importance of self-reported symptoms in acute concussion assessment. Balance assessments, however, may not provide additional benefit when symptom and neurocognitive assessments are available. Additionally, change scores provide some clinical utility over raw scores, but the difference may not be clinically meaningful.	[Garcia, Gian-Gabriel P.; Lavieri, Mariel S.] Univ Michigan, Dept Ind & Operat Engn, 1205 Beal Ave, Ann Arbor, MI 48109 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA		Garcia, GGP (corresponding author), Univ Michigan, Dept Ind & Operat Engn, 1205 Beal Ave, Ann Arbor, MI 48109 USA.	garciagg@umich.edu		Chrisman, Sara/0000-0001-5373-7223; Ortega, Justus/0000-0002-9931-5605; Cameron, Kenneth/0000-0002-6276-4482; Garcia, Gian-Gabriel/0000-0001-9315-0195; Master, Christina/0000-0002-6717-4270; Clugston, James/0000-0002-2103-1039	National Science FoundationNational Science Foundation (NSF) [DGE 1256260]; Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense; Office of the Assistant Secretary of Defense for Health Affairs [W81XWH-14-2-0151]; US Army Medical Research Acquisition Activity, Fort Detrick, MD, USA	This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 1256260. This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, in part, by the National Collegiate Athletic Association and the Department of Defense. The US Army Medical Research Acquisition Activity, Fort Detrick, MD, USA is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award No. W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the author(s) and are not necessarily endorsed by the Department of Defense (Defense Health Program funds).	Asken BM, 2016, J ATHL TRAINING, V51, P329, DOI 10.4085/1062-6050-51.5.02; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; BOZDOGAN H, 1987, PSYCHOMETRIKA, V52, P345, DOI 10.1007/BF02294361; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce JM, 2004, NEUROLOGY, V63, P1516; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Echemendia RJ, 2017, BRIT J SPORT MED, V51, DOI DOI 10.1136/BJSPORTS-2017-097506; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2004, JAMA-J AM MED ASSOC, V290, P2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Pepe MS, 2009, STATA J, V9, P1; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, pe000012, DOI DOI 10.1136/BMJSEM-2015-000012; SCAT3, 2013, BRIT J SPORT MED, V47, P259; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Sufrinko A, 2017, J ATHL TRAINING, V52, P676, DOI 10.4085/1062-6050-52.4.01; Sufrinko AM, 2017, AM J SPORT MED, V45, P1187, DOI 10.1177/0363546516685061; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	56	29	29	0	6	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	JUL	2018	48	7					1739	1749		10.1007/s40279-018-0880-x			11	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	GR5HE	WOS:000442657800014	29488165				2022-02-06	
J	Chou, A; Krukowski, K; Morganti, JM; Riparip, LK; Rosi, S				Chou, Austin; Krukowski, Karen; Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna			Persistent Infiltration and Impaired Response of Peripherally-Derived Monocytes after Traumatic Brain Injury in the Aged Brain	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						traumatic brain injury; monocyte; inflammation; ageing; cognition	CONTROLLED CORTICAL IMPACT; ALTERNATIVE ACTIVATION; COGNITIVE FUNCTION; MICROGLIA DERIVE; MICE; MACROPHAGES; CCR2; PLASTICITY; BIOMARKERS; DYNAMICS	Traumatic brain injury (TBI) is a leading cause for neurological disabilities world-wide. TBI occurs most frequently among the elderly population, and elderly TBI survivors suffer from reduced recovery and poorer quality of life. The effect of age on the pathophysiology of TBI is still poorly understood. We previously established that peripherally-derived monocytes (CCR2(+)) infiltrate the injured brain and contribute to chronic TBI-induced cognitive deficits in young animals. Furthermore, age was shown to amplify monocyte infiltration acutely after injury. In the current study, we investigated the impact of age on the subchronic response of peripherally-derived monocytes (CD45(hi); CCR2(+)) and their role in the development of chronic cognitive deficits. In the aged brain, there was a significant increase in the number of peripherally-derived monocytes after injury compared to young, injured animals. The infiltration rate of peripherally-derived monocytes remained elevated subchronically and corresponded with enhanced expression of CCR2 chemotactic ligands. Interestingly, the myeloid cell populations observed in injured aged brains had impaired anti-inflammatory responses compared to those in young animals. Additionally, in the aged animals, there was an expansion of the blood CCR2(+) monocyte population after injury that was not present in the young animals. Importantly, knocking out CCR2 to inhibit infiltration of peripherally-derived monocytes prevented chronic TBI-induced spatial memory deficits in the aged mice. Altogether, these results demonstrate the critical effects of age on the peripherally-derived monocyte response during the progression of TBI pathophysiology.	[Chou, Austin; Krukowski, Karen; Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Chou, Austin; Krukowski, Karen; Morganti, Josh M.; Riparip, Lara-Kirstie; Rosi, Susanna] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Rosi, Susanna] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94158 USA; [Rosi, Susanna] Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94158 USA		Rosi, S (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94158 USA.; Rosi, S (corresponding author), Univ Calif San Francisco, Kavli Inst Fundamental Neurosci, San Francisco, CA 94158 USA.	austin.chou@ucsf.edu; karen.krukowski@ucsf.edu; josh.morganti@uky.edu; lriparip@gmail.com; susanna.rosi@ucsf.edu	Morganti, Josh/AAL-9727-2020	Morganti, Josh/0000-0002-4183-0049; Chou, Austin/0000-0003-4328-5811	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458]; NIH/NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056770]; NRSA post-doctoral fellowship NIA [F32AG054126]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG056770] Funding Source: NIH RePORTER	This work was supported by research grants: NIA R21AG042016 (SR), NIH/NINDS R21NS087458 (SR), NIH/NIA R01AG056770 (SR), NRSA post-doctoral fellowship NIA F32AG054126 (KK).	Agoston DV, 2017, BRAIN INJURY, V31, P1195, DOI 10.1080/02699052.2017.1357836; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; Alliot F, 1999, DEV BRAIN RES, V117, P145, DOI 10.1016/S0165-3806(99)00113-3; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Davies LC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2877; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gliem M, 2016, BBA-MOL BASIS DIS, V1862, P329, DOI 10.1016/j.bbadis.2015.11.004; Gong DP, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-31; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Hazeldine J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00235; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Itoh T, 2013, BRAIN STRUCT FUNCT, V218, P209, DOI 10.1007/s00429-012-0394-5; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee DC, 2013, NEUROBIOL AGING, V34, P1610, DOI 10.1016/j.neurobiolaging.2012.12.014; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Morganti JM, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0547-1; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Prinz M, 2010, J NEUROIMMUNOL, V224, P80, DOI 10.1016/j.jneuroim.2010.05.015; Rosenzweig ES, 2003, PROG NEUROBIOL, V69, P143, DOI 10.1016/S0301-0082(02)00126-0; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001	50	29	29	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	JUN	2018	19	6							1616	10.3390/ijms19061616			15	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	GK8UZ	WOS:000436506600071	29848996	gold, Green Published, Green Submitted			2022-02-06	
J	Jullienne, A; Salehi, A; Affeldt, B; Baghchechi, M; Haddad, E; Avitua, A; Walsworth, M; Enjalric, I; Hamer, M; Bhakta, S; Tang, JP; Zhang, JH; Pearce, WJ; Obenaus, A				Jullienne, Amandine; Salehi, Arjang; Affeldt, Bethann; Baghchechi, Mohsen; Haddad, Elizabeth; Avitua, Angela; Walsworth, Mark; Enjalric, Isabelle; Hamer, Mary; Bhakta, Sonali; Tang, Jiping; Zhang, John H.; Pearce, William J.; Obenaus, Andre			Male and Female Mice Exhibit Divergent Responses of the Cortical Vasculature to Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; heme oxygenase-1; sex difference; vasculature; Wnt/beta-catenin	SEX-DIFFERENCES; INFLAMMATORY RESPONSE; VONWILLEBRAND-FACTOR; GENDER-DIFFERENCES; IMPACT INJURY; HEAD-INJURY; ESTROGEN; NEURODEGENERATION; PROGESTERONE; RECOVERY	We previously reported that traumatic brain injuries (TBI) alter the cerebrovasculature near the injury site in rats, followed by revascularization over a 2-week period. Here, we tested our hypothesis that male and female adult mice have differential cerebrovascular responses following a moderate controlled cortical impact (CCI). Using in vivo magnetic resonance imaging (MRI), a new technique called vessel painting, and immunohistochemistry, we found no differences between males and females in lesion volume, neurodegeneration, blood-brain barrier (BBB) alteration, and microglia activation. However, females exhibited more astrocytic hypertrophy and heme-oxygenase-1 (HO-1) induction at 1 day post-injury (dpi), whereas males presented with increased endothelial activation and expression of beta-catenin, shown to be involved in angiogenesis. At 7dpi, we observed an increase in the number of vessels and an enhancement in vessel complexity in the injured cortex of males compared with females. Cerebrovasculature recovers differently after CCI, suggesting biological sex should be considered when designing new therapeutic agents.	[Jullienne, Amandine; Salehi, Arjang; Affeldt, Bethann; Baghchechi, Mohsen; Haddad, Elizabeth; Avitua, Angela; Walsworth, Mark; Enjalric, Isabelle; Hamer, Mary; Bhakta, Sonali; Obenaus, Andre] Loma Linda Univ, Dept Basic Sci, Loma Linda, CA 92350 USA; [Tang, Jiping; Zhang, John H.; Pearce, William J.] Loma Linda Univ, Dept Physiol & Pharmacol, Loma Linda, CA 92350 USA; [Zhang, John H.] Loma Linda Univ, Dept Anesthesiol, Loma Linda, CA 92350 USA; [Zhang, John H.] Loma Linda Univ, Dept Neurosurg, Loma Linda, CA 92350 USA; [Pearce, William J.] Loma Linda Univ, Ctr Perinatal Biol, Loma Linda, CA 92350 USA; [Obenaus, Andre] Univ Calif Irvine, Dept Pediat, Hewitt Hall,Room 2066, Irvine, CA 92697 USA		Obenaus, A (corresponding author), Univ Calif Irvine, Dept Pediat, Hewitt Hall,Room 2066, Irvine, CA 92697 USA.	obenausa@uci.edu	Bhakta, Sonali/K-6996-2019; Jullienne, Amandine/H-3081-2019	Jullienne, Amandine/0000-0001-9458-055X; Pearce, William/0000-0002-5331-5677; Haddad, Elizabeth/0000-0002-7622-9085	NIH Program Project grant from NINDS [POINS082184]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD083132] Funding Source: NIH RePORTER	We would like to thank Saburi Eliamani for acquiring the MRI data. This study was supported by a NIH Program Project grant from NINDS (POINS082184, Project 3).	Acaz-Fonseca E., 2015, GLIA; Ahnstedt H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062698; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Arias C, 2009, HORM BEHAV, V55, P257, DOI 10.1016/j.yhbeh.2008.10.016; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Bhalla RC, 1997, AM J PHYSIOL-HEART C, V272, pH1996, DOI 10.1152/ajpheart.1997.272.4.H1996; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Caplan HW, 2017, J NEUROSCI RES, V95, P509, DOI 10.1002/jnr.23854; Chenu C, 2017, ARTERIOSCL THROM VAS, V37, P909, DOI 10.1161/ATVBAHA.117.309219; Chisholm NC, 2016, NEUROBIOL DIS, V85, P245, DOI 10.1016/j.nbd.2015.03.028; Cordeau P, 2008, STROKE, V39, P935, DOI 10.1161/STROKEAHA.107.501460; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cosgrove KP, 2007, BIOL PSYCHIAT, V62, P847, DOI 10.1016/j.biopsych.2007.03.001; Covassin T, 2003, J ATHL TRAINING, V38, P238; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Dulak J, 2004, ANTIOXID REDOX SIGN, V6, P858, DOI 10.1089/1523086041797980; Faul M, 2010, TRAUMATIC BRAIN INJU; Ghosh N, 2014, MED IMAGE ANAL, V18, P1059, DOI 10.1016/j.media.2014.05.002; Ghosh N, 2011, J MAGN RESON IMAGING, V33, P772, DOI 10.1002/jmri.22488; Gunther M, 2015, ACTA NEUROCHIR, V157, P649, DOI 10.1007/s00701-014-2331-2; Haast RAM, 2012, J CEREBR BLOOD F MET, V32, P2100, DOI 10.1038/jcbfm.2012.141; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Hirschberg R, 2008, FUTUR NEUROL, V3, P483, DOI 10.2217/14796708.3.4.483; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hughes S, 2014, METHODS MOL BIOL, V1135, P127, DOI 10.1007/978-1-4939-0320-7_12; Immonen R, 2010, J CEREBR BLOOD F MET, V30, P1318, DOI 10.1038/jcbfm.2010.15; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Karperien A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00003; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Krasinski K, 1997, CIRCULATION, V95, P1768; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Mannix R, 2014, J NEUROSURG, V121, P1337, DOI 10.3171/2014.8.JNS14715; McCarthy MM, 2012, J NEUROSCI, V32, P2241, DOI 10.1523/JNEUROSCI.5372-11.2012; Meyer MR, 2006, HYPERTENSION, V47, P1019, DOI 10.1161/01.HYP.0000223064.62762.0b; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; Obenaus A., 2015, ENCY MENTAL HLTH, P329; Obenaus A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00161-4; Ossei-Gerning N, 1998, THROMB HAEMOSTASIS, V79, P736, DOI 10.1055/s-0037-1615055; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Pearce WJ, 2016, AM J PHYSIOL-REG I, V311, pR1093, DOI 10.1152/ajpregu.00240.2016; Perez-Barcena J, 2015, J NEUROL SCI, V353, P38, DOI 10.1016/j.jns.2015.03.044; Randi AM, 2017, J THROMB HAEMOST, V15, P13, DOI 10.1111/jth.13551; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Salehi A, 2018, J CEREBR BLOOD F MET, V38, P274, DOI 10.1177/0271678X17744124; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; SARJI KE, 1975, THROMB RES, V7, P885, DOI 10.1016/0049-3848(75)90092-4; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Scott EL, 2013, BRAIN RES, V1514, P63, DOI 10.1016/j.brainres.2012.12.015; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Shansky RM, 2016, J NEUROSCI, V36, P11817, DOI 10.1523/JNEUROSCI.1390-16.2016; Sharp FR, 2013, TRANSL STROKE RES, V4, P685, DOI 10.1007/s12975-013-0271-4; Sieveking DP, 2010, J EXP MED, V207, P345, DOI 10.1084/jem.20091924; SPORN LA, 1989, J CELL BIOL, V108, P1283, DOI 10.1083/jcb.108.4.1283; Toth B, 2003, ARCH SURG-CHICAGO, V138, P1375, DOI 10.1001/archsurg.138.12.1375; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wang LF, 2016, SCI REP-UK, V6, DOI 10.1038/srep26358; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang QG, 2008, J NEUROSCI, V28, P8430, DOI 10.1523/JNEUROSCI.2752-08.2008; Zhang XM, 2008, NEUROTOXICOLOGY, V29, P406, DOI 10.1016/j.neuro.2008.01.006; Zheng MZ, 2016, ACTA NEUROCHIR SUPPL, V121, P367, DOI 10.1007/978-3-319-18497-5_63; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	79	29	29	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1646	1658		10.1089/neu.2017.5547		MAY 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000431584200001	29648973	Green Submitted, Green Published			2022-02-06	
J	Anuncibay-Soto, B; Perez-Rodriguez, D; Santos-Galdiano, M; Font-Belmonte, E; Ugidos, IF; Gonzalez-Rodriguez, P; Regueiro-Purrinos, M; Fernandez-Lopez, A				Anuncibay-Soto, Berta; Perez-Rodriguez, Diego; Santos-Galdiano, Maria; Font-Belmonte, Enrique; Ugidos, Irene F.; Gonzalez-Rodriguez, Paloma; Regueiro-Purrinos, Marta; Fernandez-Lopez, Arsenio			Salubrinal and robenacoxib treatment after global cerebral ischemia. Exploring the interactions between ER stress and inflammation	BIOCHEMICAL PHARMACOLOGY			English	Article						COX-2 inhibitor; Salubrinal; Blood-brain barrier; Microglia; Inflammation; ER stress	ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B; CYCLOOXYGENASE-2 INHIBITORS; BIDIRECTIONAL REGULATION; ALZHEIMERS-DISEASE; RODENT MODEL; CELL-DEATH	Background Blood reperfusion of the ischemic tissue after stroke promotes increases in the inflammatory response as well as accumulation of unfolded/misfolded proteins in the cell, leading to endoplasmic reticulum (ER) stress. Both Inflammation and ER stress are critical processes in the delayed death of the cells damaged after ischemia. The aim of this study is to check the putative synergic neuroprotective effect by combining anti-inflammatory and anti-ER stress agents after ischemia. Methods: The study was performed on a two-vessel occlusion global cerebral ischemia model. Animals were treated with salubrinal one hour after ischemia and with robenacoxib at 8 h and 32 h after ischemia. Parameters related to the integrity of the blood brain barrier (BBB), such as matrix metalloproteinase 9 and different cell adhesion molecules (CAMs), were analyzed by qPCR at 24 h and 48 h after ischemia. Microglia and cell components of the neurovascular unit, including neurons, endothelial cells and astrocytes, were analyzed by immunofluorescence after 48 h and seven days of reperfusion. Results: Pharmacologic control of ER stress by salubrinal treatment after ischemia, revealed a neuroprotective effect over neurons that reduces the transcription of molecules involved in the impairment of the BBB. Robenacoxib treatment stepped neuronal demise forward, revealing a detrimental effect of this anti-inflammatory agent. Combined treatment with robenacoxib and salubrinal after ischemia prevented neuronal loss and changes in components of the neurovascular unit and microglia observed when animals were treated only with robenacoxib. Conclusion Combined treatment with anti-ER stress and anti-inflammatory agents is able to provide enhanced neuroprotective effects reducing glial activation, which opens new avenues in therapies against stroke.	[Anuncibay-Soto, Berta; Perez-Rodriguez, Diego; Santos-Galdiano, Maria; Font-Belmonte, Enrique; Ugidos, Irene F.; Gonzalez-Rodriguez, Paloma; Fernandez-Lopez, Arsenio] Univ Leon, Inst Biomed, Dept Biol Celular, Leon, Spain; [Regueiro-Purrinos, Marta] Univ Leon, Dept Cirugia Med & Anat Vet, Leon, Spain		Fernandez-Lopez, A (corresponding author), Univ Leon, Area Biol Celular, Inst Biomed, Leon, Spain.	aferl@unileon.es	Rodriguez, Paloma Gonzalez/AAO-4519-2020; Fernandez-Lopez, Arsenio/E-1280-2011	Rodriguez, Paloma Gonzalez/0000-0002-3962-6858; Fernandez-Lopez, Arsenio/0000-0001-5557-2741; Perez Rodriguez, Diego/0000-0003-4903-3914; Santos Galdiano, Maria/0000-0002-9918-8319; Fernandez Ugidos, Irene/0000-0002-3727-0544	MINECOSpanish Government [BIO2013-49006-C2-2-R, RTC-2015-4094-1]; University of Leon [EDU/529/2017]; Junta de Castilla y LeonJunta de Castilla y Leon [EDU/529/2017, EDU/346/2013, EDU/310/2015]; Neural Therapies	This study was supported by MINECO (reference BIO2013-49006-C2-2-R and RTC-2015-4094-1), which also supports Berta Anuncibay-Soto and Maria Santos-Galdiano by fellowships. Enrique Font is supported by the University of Leon (EDU/529/2017). Diego Perez Rodriguez, Paloma Gonzalez-Rodriguez and Irene F Ugidos has a grant from Junta de Castilla y Leon (EDU/346/2013; EDU/310/2015; EDU/529/2017). We also thank Neural Therapies for additional financial support.	Abbott NJ, 2013, J INHERIT METAB DIS, V36, P437, DOI 10.1007/s10545-013-9608-0; Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Aid S, 2011, BIOCHIMIE, V93, P46, DOI 10.1016/j.biochi.2010.09.009; Anuncibay-Soto B, 2016, J NEUROCHEM, V138, P295, DOI 10.1111/jnc.13651; Anuncibay-Soto B, 2014, AGE, V36, DOI 10.1007/s11357-014-9703-7; Barreda-Manso MA, 2017, J CELL PHYSIOL, V232, P1501, DOI 10.1002/jcp.25655; Baron R, 2014, AGING CELL, V13, P584, DOI 10.1111/acel.12210; Berezowski V., 2012, INT J CELL BIOL, V2012, P1; Cai XH, 2014, EXP NEUROL, V257, P148, DOI 10.1016/j.expneurol.2014.04.029; Cairns JA, 2007, CAN J CARDIOL, V23, P125, DOI 10.1016/S0828-282X(07)70732-8; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Candelario-Jalil E, 2008, CURR PHARM DESIGN, V14, P1401, DOI 10.2174/138161208784480216; da Fonseca ACC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00362; Castro CC, 2014, NEUROL RES, V36, P198, DOI 10.1179/1743132813Y.0000000286; Choi SH, 2009, TRENDS PHARMACOL SCI, V30, P174, DOI 10.1016/j.tips.2009.01.002; Chu K, 2004, J CEREBR BLOOD F MET, V24, P926, DOI 10.1097/01.WCB.0000130866.25040.7D; Feng L, 2017, ENVIRON SCI POLLUT R, V24, P11683, DOI 10.1007/s11356-017-8773-3; Fiebich BL, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00260; FitzGerald GA, 2001, CLIN EXP RHEUMATOL, V19, pS31; Hartman RE, 2005, BRAIN RES, V1043, P48, DOI 10.1016/j.brainres.2005.02.030; Hasnain SZ, 2012, IMMUNOL CELL BIOL, V90, P260, DOI 10.1038/icb.2011.112; Huang YC, 2013, ACTA PHARMACOL SIN, V34, P6, DOI 10.1038/aps.2012.178; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; King JN, 2009, J VET PHARMACOL THER, V32, P1, DOI 10.1111/j.1365-2885.2008.00962.x; KIRINO T, 1985, PROG BRAIN RES, V63, P39; Kitamura M, 2009, ANTIOXID REDOX SIGN, V11, P2353, DOI [10.1089/ars.2008.2391, 10.1089/ARS.2008.2391]; KOUDSTAAL PJ, 1993, STROKE, V24, P219, DOI 10.1161/01.STR.24.2.219; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Llorente IL, 2015, NEUROSCIENCE, V292, P118, DOI 10.1016/j.neuroscience.2015.02.040; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Luissint AC, 2012, FLUIDS BARRIERS CNS, V9, DOI 10.1186/2045-8118-9-23; De los Reyes LM, 2014, BIOMEDICA, V34, P366, DOI [10.1590/S0120-41572014000300007, 10.7705/biomedica.v34i3.2191]; Nakajima S, 2013, FREE RADICAL BIO MED, V65, P162, DOI 10.1016/j.freeradbiomed.2013.06.020; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Patrono C, 2016, BRIT J CLIN PHARMACO, V82, P957, DOI 10.1111/bcp.13048; Patrono C, 2016, CURR CARDIOL REP, V18, DOI 10.1007/s11886-016-0702-4; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Rom S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0729-x; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Roumie CL, 2008, STROKE, V39, P2037, DOI 10.1161/STROKEAHA.107.508549; Rubovitch V, 2015, NEUROMOL MED, V17, P58, DOI 10.1007/s12017-015-8340-3; Schwab C, 2008, J ALZHEIMERS DIS, V13, P359; Szekely CA, 2010, CNS NEUROL DISORD-DR, V9, P132, DOI 10.2174/187152710791012026; Taylor S, 2010, METHODS, V50, pS1, DOI 10.1016/j.ymeth.2010.01.005; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; Ugidos IF, 2017, BBA-BIOMEMBRANES, V1859, P1648, DOI 10.1016/j.bbamem.2017.03.009; Vieira M, 2014, NEUROBIOL DIS, V68, P26, DOI 10.1016/j.nbd.2014.04.002; Walker FR, 2014, BRAIN BEHAV IMMUN, V37, P1, DOI 10.1016/j.bbi.2013.12.010; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xin Q, 2014, NEUROCHEM INT, V68, P18, DOI 10.1016/j.neuint.2014.02.001; Yenari MA, 2006, STROKE, V37, P1087, DOI 10.1161/01.STR.0000206281.77178.ac; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yilmaz G, 2010, NEUROMOL MED, V12, P193, DOI 10.1007/s12017-009-8074-1; Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203; Zhu H, 2012, J NEUROCHEM, V120, P574, DOI 10.1111/j.1471-4159.2011.07550.x	62	29	29	1	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	MAY	2018	151						26	37		10.1016/j.bcp.2018.02.029			12	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	GE3FO	WOS:000431099400004	29499167				2022-02-06	
J	Tanqueiro, SR; Ramalho, RM; Rodrigues, TM; Lopes, LV; Sebastiao, AM; Diogenes, MJ				Tanqueiro, Sara R.; Ramalho, Rita M.; Rodrigues, Tiago M.; Lopes, Luisa V.; Sebastiao, Ana M.; Diogenes, Maria J.			Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid beta	FRONTIERS IN PHARMACOLOGY			English	Article						Alzheimer's disease; brain-derived neurotrophic factor; TrkB receptor; extrasynaptic N-methyl-d-aspartate receptors; memantine; long-term potentiation; spine density; synaptic plasticity	LONG-TERM POTENTIATION; TRUNCATED TRKB RECEPTORS; TRAUMATIC BRAIN-INJURY; D-ASPARTATE RECEPTORS; ALZHEIMERS-DISEASE; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; MOUSE MODEL; HIPPOCAMPAL-NEURONS; CULTURED HIPPOCAMPAL	Brain-derived neurotrophic factor (BDNF) plays important functions in cell survival and differentiation, neuronal outgrowth and plasticity. In Alzheimer's disease (AD), BDNF signaling is known to be impaired, partially because amyloid beta (A beta) induces truncation of BDNF main receptor, TrkB-full length (TrkB-FL). We have previously shown that such truncation is mediated by calpains, results in the formation of an intracellular domain (ICD) fragment and causes BDNF loss of function. Since calpains are Ca2+-dependent proteases, we hypothesized that excessive intracellular Ca2+ build-up could be due to dysfunctional N-methyl-d-aspartate receptors (NMDARs) activation. To experimentally address this hypothesis, we investigated whether TrkB-FL truncation by calpains and consequent BDNF loss of function could be prevented by NMDAR blockade. We herein demonstrate that a NMDAR antagonist, memantine, prevented excessive calpain activation and TrkB-FL truncation induced by A beta(25-35). When calpains were inhibited by calpastatin, BDNF was able to increase the dendritic spine density of neurons exposed to A beta(25135). Moreover, NMDAR inhibition by memantine also prevented A beta-driven deleterious impact of BDNF loss of function on structural (spine density) and functional outcomes (synaptic potentiation). Collectively, these findings support NMDAR/Ca2+/calpains mechanistic involvement in A beta-triggered BDNF signaling disruption.	[Tanqueiro, Sara R.; Ramalho, Rita M.; Rodrigues, Tiago M.; Sebastiao, Ana M.; Diogenes, Maria J.] Univ Lisbon, Fac Med, Inst Farmacol & Neurociencias, Lisbon, Portugal; [Tanqueiro, Sara R.; Ramalho, Rita M.; Rodrigues, Tiago M.; Lopes, Luisa V.; Sebastiao, Ana M.; Diogenes, Maria J.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal; [Rodrigues, Tiago M.] Ctr Hosp & Univ Coimbra, Dept Ophthalmol, Coimbra, Portugal		Diogenes, MJ (corresponding author), Univ Lisbon, Fac Med, Inst Farmacol & Neurociencias, Lisbon, Portugal.; Diogenes, MJ (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal.	diogenes@medicina.ulisboa.pt		Tanqueiro, Sara/0000-0002-9151-7149; Lopes, Luisa/0000-0001-8367-3005; Rodrigues, Tiago M./0000-0002-0973-9763; Sebastiao, Ana M/0000-0001-9030-6115	Fundacao para a Ciencia e a TecnologiaPortuguese Foundation for Science and TechnologyEuropean Commission [SFRH/BPD/94474/2013, PD/BD/128091/2016, LISBOA-01-0145-FEDER-007391]; Santa Casa da Misericordia [MB-37-2017]; SynaNet from the European Union's Horizon research and innovation program [692340]; FEDER, through POR Lisboa - Programa Operacional Regional de Lisboa, PORTUGAL [LISBOA-01-0145-FEDER-007391]; Fundacao para a Ciencia e a TecnologiaPortuguese Foundation for Science and TechnologyEuropean Commission	RR was supported by Fundacao para a Ciencia e a Tecnologia (SFRH/BPD/94474/2013). ST was supported by Fundacao para a Ciencia e a Tecnologia (PD/BD/128091/2016). LL is an Investigator FCT. This work was supported by Santa Casa da Misericordia (MB-37-2017) and SynaNet which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 692340. LISBOA-01-0145-FEDER-007391, project cofunded by FEDER, through POR Lisboa 2020 - Programa Operacional Regional de Lisboa, PORTUGAL 2020, and Fundacao para a Ciencia e a Tecnologia.	Albensi BC, 2007, EXP NEUROL, V204, P1, DOI 10.1016/j.expneurol.2006.12.009; Alberdi E, 2010, CELL CALCIUM, V47, P264, DOI 10.1016/j.ceca.2009.12.010; Allen SJ, 1999, BIOCHEM BIOPH RES CO, V264, P648, DOI 10.1006/bbrc.1999.1561; Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Arancio O, 2007, CURR OPIN NEUROBIOL, V17, P325, DOI 10.1016/j.conb.2007.03.013; Arevalo JC, 2006, CELL MOL LIFE SCI, V63, P1523, DOI 10.1007/s00018-006-6010-1; Bi H, 2002, J NEUROL SCI, V200, P11, DOI 10.1016/S0022-510X(02)00087-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Caba E, 2002, J NEUROSCI RES, V67, P787, DOI 10.1002/jnr.10163; Caselli RJ, 2013, J ALZHEIMERS DIS, V33, pS405, DOI 10.3233/JAD-2012-129026; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen QS, 2000, J NEUROSCI RES, V60, P65, DOI 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q; Citri A, 2008, NEUROPSYCHOPHARMACOL, V33, P18, DOI 10.1038/sj.npp.1301559; Connor B, 1997, MOL BRAIN RES, V49, P71, DOI 10.1016/S0169-328X(97)00125-3; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; DELCERRO S, 1994, NEUROSCI LETT, V167, P149, DOI 10.1016/0304-3940(94)91049-9; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Diogenes MJ, 2011, NEUROPSYCHOPHARMACOL, V36, P1823, DOI 10.1038/npp.2011.64; Dorsey SG, 2006, NEURON, V51, P21, DOI 10.1016/j.neuron.2006.06.009; Eide FF, 1996, J NEUROSCI, V16, P3123; Ferreira IL, 2012, CELL CALCIUM, V51, P95, DOI 10.1016/j.ceca.2011.11.008; Ferrer I, 1999, J NEUROPATH EXP NEUR, V58, P729, DOI 10.1097/00005072-199907000-00007; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P229; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Folch J, 2018, J ALZHEIMERS DIS, V62, P1223, DOI 10.3233/JAD-170672; Fontinha BM, 2008, NEUROPHARMACOLOGY, V54, P924, DOI 10.1016/j.neuropharm.2008.01.011; Gilson V, 2015, J ALZHEIMERS DIS, V47, P453, DOI 10.3233/JAD-142529; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gomes JR, 2012, J NEUROSCI, V32, P4610, DOI 10.1523/JNEUROSCI.0374-12.2012; Granic I, 2010, NEUROPHARMACOLOGY, V59, P334, DOI 10.1016/j.neuropharm.2010.07.013; Hanson JE, 2015, NEUROBIOL DIS, V74, P254, DOI 10.1016/j.nbd.2014.11.017; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Holsinger RMD, 2000, MOL BRAIN RES, V76, P347, DOI 10.1016/S0169-328X(00)00023-1; Hunt DL, 2012, CURR OPIN NEUROBIOL, V22, P496, DOI 10.1016/j.conb.2012.01.007; Hynd MR, 2004, J NEUROCHEM, V90, P913, DOI 10.1111/j.1471-4159.2004.02548.x; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Jeronimo-Santos A, 2015, CEREB CORTEX, V25, P3107, DOI 10.1093/cercor/bhu105; Ji YY, 2010, NAT NEUROSCI, V13, P302, DOI 10.1038/nn.2505; Ji YY, 2005, NAT NEUROSCI, V8, P164, DOI 10.1038/nn1381; Kaminsky YG, 2010, EXP NEUROL, V221, P26, DOI 10.1016/j.expneurol.2009.09.005; Kellner Yves, 2014, Front Synaptic Neurosci, V6, P5, DOI 10.3389/fnsyn.2014.00005; Kelly BL, 2007, NEUROSCIENCE, V147, P60, DOI 10.1016/j.neuroscience.2007.03.047; Kelly BL, 2006, J BIOL CHEM, V281, P28079, DOI 10.1074/jbc.M605081200; Kemppainen S, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.11.006; Knobloch M, 2008, MOL NEUROBIOL, V37, P73, DOI 10.1007/s12035-008-8018-z; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1998, NEUROPHARMACOLOGY, V37, P553, DOI 10.1016/S0028-3908(98)00035-5; Koskinen M, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00074; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; Leveille F, 2008, FASEB J, V22, P4258, DOI 10.1096/fj.08-107268; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Li SM, 2011, J NEUROSCI, V31, P6627, DOI 10.1523/JNEUROSCI.0203-11.2011; Lipton SA, 2007, CURR DRUG TARGETS, V8, P621, DOI 10.2174/138945007780618472; Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505; Luscher C, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005710; Martinez-Senac MD, 1999, EUR J BIOCHEM, V265, P744, DOI 10.1046/j.1432-1327.1999.00775.x; McShane R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003154.pub5; Medeiros R, 2012, AM J PATHOL, V181, P616, DOI 10.1016/j.ajpath.2012.04.020; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; Minichiello L, 2002, NEURON, V36, P121, DOI 10.1016/S0896-6273(02)00942-X; Mishizen-Eberz AJ, 2004, NEUROBIOL DIS, V15, P80, DOI 10.1016/j.nbd.2003.09.016; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nguyen KQ, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00037; Nixon RA, 2003, AGEING RES REV, V2, P407, DOI 10.1016/S1568-1637(03)00029-1; Ono Y, 2012, BBA-PROTEINS PROTEOM, V1824, P224, DOI 10.1016/j.bbapap.2011.08.005; Pang PT, 2004, AGEING RES REV, V3, P407, DOI 10.1016/j.arr.2004.07.002; Paoletti P, 2013, NAT REV NEUROSCI, V14, P383, DOI 10.1038/nrn3504; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Parameshwaran K, 2008, EXP NEUROL, V210, P7, DOI 10.1016/j.expneurol.2007.10.008; PARSONS CG, 1993, NEUROPHARMACOLOGY, V32, P1337, DOI 10.1016/0028-3908(93)90029-3; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Parsons MP, 2014, NEURON, V82, P279, DOI 10.1016/j.neuron.2014.03.030; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; Pinho J, 2017, NEUROPHARMACOLOGY, V114, P12, DOI 10.1016/j.neuropharm.2016.11.017; Plotkin JL, 2014, NEURON, V83, P178, DOI 10.1016/j.neuron.2014.05.032; Porritt MJ, 2005, EXP NEUROL, V192, P226, DOI 10.1016/j.expneurol.2004.11.030; Ronicke R, 2011, NEUROBIOL AGING, V32, P2219, DOI 10.1016/j.neurobiolaging.2010.01.011; Rogawski MA, 2003, CNS DRUG REV, V9, P275, DOI 10.1111/j.1527-3458.2003.tb00254.x; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rueda CB, 2016, BBA-BIOENERGETICS, V1857, P1158, DOI 10.1016/j.bbabio.2016.04.003; Schindowski K, 2008, GENES BRAIN BEHAV, V7, P43, DOI 10.1111/j.1601-183X.2007.00378.x; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Shrestha BR, 2006, MOL CELL NEUROSCI, V33, P274, DOI 10.1016/j.mcn.2006.07.011; Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106; Smith JP, 2009, BRAIN RES, V1269, P176, DOI 10.1016/j.brainres.2009.03.007; Song JH, 2015, MOL NEUROBIOL, V52, P1477, DOI 10.1007/s12035-014-8958-4; Spires TL, 2005, J NEUROSCI, V25, P7278, DOI 10.1523/JNEUROSCI.1879-05.2005; Spires-Jones TL, 2007, AM J PATHOL, V171, P1304, DOI 10.2353/ajpath.2007.070055; Talantova M, 2013, P NATL ACAD SCI USA, V110, pE2518, DOI 10.1073/pnas.1306832110; Tartaglia N, 2001, J BIOL CHEM, V276, P37585, DOI 10.1074/jbc.M101683200; Tejeda GS, 2016, J PATHOL, V238, P627, DOI 10.1002/path.4684; Texido L, 2011, CELL CALCIUM, V49, P184, DOI 10.1016/j.ceca.2011.02.001; Toni N, 1999, NATURE, V402, P421, DOI 10.1038/46574; Trinchese F, 2008, J CLIN INVEST, V118, P2796, DOI 10.1172/JCI34254; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vidaurre OG, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.143; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Wang YB, 2013, J NEUROSCI, V33, P18880, DOI 10.1523/JNEUROSCI.3293-13.2013; Wei W, 2010, NAT NEUROSCI, V13, P190, DOI 10.1038/nn.2476; Xia P, 2010, J NEUROSCI, V30, P11246, DOI 10.1523/JNEUROSCI.2488-10.2010; Xu J, 2009, J NEUROSCI, V29, P9330, DOI 10.1523/JNEUROSCI.2212-09.2009; Yan XX, 2012, CURR GERIATR REP, V1, P85, DOI 10.1007/s13670-012-0009-2; Zhou Q, 2013, NEUROPHARMACOLOGY, V74, P69, DOI 10.1016/j.neuropharm.2013.03.030	108	29	30	0	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	APR 11	2018	9								237	10.3389/fphar.2018.00237			14	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	GC2XH	WOS:000429647200001	29695962	Green Published, gold			2022-02-06	
J	Brooks, BL; Silverberg, N; Maxwel, B; Mannix, R; Zafonte, R; Berkner, PD; Iverson, GL				Brooks, Brian L.; Silverberg, Noah; Maxwel, Bruce; Mannix, Rebekah; Zafonte, Ross; Berkner, Paul D.; Iverson, Grant L.			Investigating Effects of Sex Differences and Prior Concussions on Symptom Reporting and Cognition Among Adolescent Soccer Players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						child; adolescent; traumatic brain injury; sports; postconcussion syndrome; cumulative	COLLEGIATE FOOTBALL PLAYERS; MULTIPLE PAST CONCUSSIONS; SPORTS-RELATED CONCUSSION; ICE HOCKEY PLAYERS; HIGH-SCHOOL SOCCER; NEUROCOGNITIVE PERFORMANCE; ELECTROPHYSIOLOGICAL ABNORMALITIES; NEUROPSYCHOLOGICAL PERFORMANCE; FEMALE; HISTORY	Background: There has been increasing concern regarding the possible effect of multiple concussions on the developing brain, especially for adolescent females. Hypothesis/Purpose: The objectives were to determine if there are differences in cognitive functioning, symptom reporting, and/or sex effects from prior concussions. In a very large sample of youth soccer players, it was hypothesized that (1) there would be no differences in cognitive test performance between those with and without prior concussions, (2) baseline preseason symptoms would be better predicted by noninjury factors than concussion history, and (3) males and females with prior concussions would not have differences in cognition or symptoms. Study Design: Cross-sectional study; Level of evidence, 3. Methods: Participants included 9314 youth soccer players (mean = 14.8 years, SD = 1.2) who completed preseason baseline cognitive testing, symptom reporting, and a health/injury history questionnaire from the ImPACT battery (Immediate Post-concussion Assessment and Cognitive Testing). On the basis of injury history, athletes were grouped by number of prior concussions: 0 (boys, n = 4012; girls, n = 3963), 1 (boys, n = 527; girls, n = 457), 2 (boys, n = 130; girls, n = 97), or >= 3 (boys, n = 73; girls, n = 55). The primary measures were the 4 primary cognitive scores and the total symptom ratings from ImPACT. Primary outcomes were assessed across injury groups, controlling for age, sex, learning disability, attention-deficit/hyperactivity disorder (ADHD), treatment for headaches/migraines, substance abuse, and mental health problems. Results: Cognitive test performance was not associated with concussion history but was associated with sex, age, learning disability, ADHD, and prior mental health problems. Greater symptom reporting was more strongly associated with psychiatric problems, older age, learning disability, substance abuse, headaches, being female, and ADHD than with a history of multiple concussions. Boys and girls did not differ on cognitive scores or symptom reporting based on a history of concussion. Conclusion: In this very large sample of youth soccer players with prior concussion, there was no evidence of negative effects on cognition, very weak evidence of negative effects on symptom reporting, and no evidence of sex 3 concussion differences in cognition or symptom reporting.	[Brooks, Brian L.; Silverberg, Noah; Maxwel, Bruce; Mannix, Rebekah; Zafonte, Ross; Berkner, Paul D.; Iverson, Grant L.] Colby Coll, Waterville, ME 04901 USA; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Univ Calgary, Dept Pediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Dept Psychol, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp Res Inst, Calgary, AB, Canada; [Silverberg, Noah] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah] Vancouver Coastal Hlth Res Inst, Rehabil Res Program, Vancouver, BC, Canada; [Silverberg, Noah] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Maxwel, Bruce] Colby Coll, Dept Comp Sci, Waterville, ME 04901 USA; [Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, Brain Injury Ctr, Boston, MA USA; [Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Massachusetts Gen Hosp,Brigham & Womens Hosp, Boston, MA USA; [Zafonte, Ross] Home Base, Boston, MA USA; [Berkner, Paul D.] Colby Coll, Hlth Serv, Waterville, ME 04901 USA; [Berkner, Paul D.] Colby Coll, Dept Biol, Waterville, ME 04901 USA; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Home Base,MassGen Hosp Children Sport Concuss Pro, Boston, MA USA		Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@ahs.ca	Mannix, Rebekah/AAD-8702-2020	Iverson, Grant/0000-0001-7348-9570	Canadian Institutes of Health Research Embedded Clinician Researcher Salary Award; Vancouver Coastal Health Research Institute; Harvard Integrated Program to Protect and Improve the Health of NFLPA members	Goldfarb Center for Public Policy and Civic Engagement / Colby College and the Bill and Joan Alfond Foundation. B.L.B. acknowledges salary support from the Canadian Institutes of Health Research Embedded Clinician Researcher Salary Award; is a principal investigator, coinvestigator, or collaborator on several grants relating to the study of mild traumatic brain injury (TBI) and concussion among youth; and receives royalties for the sales of the Pediatric Forensic Neuropsychology textbook (Oxford University Press) and pediatric neuropsychological tests: Child and Adolescent Memory Profile, Memory Validity Profile, and Multidimensional Everyday Memory Ratings for Youth (all PAR Inc). He has received in-kind support (free test credits) from a computerized cognitive test publisher (CNS Vital Signs). N.S. receives salary support from the Vancouver Coastal Health Research Institute; and has received clinical consulting fees from professional sport organizations, workers' compensation boards, and insurance agencies. R. Z. serves on the Scientific Advisory Board of Myomo, Oxeia Pharma, and ElMInda. G.L.I. has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to mild TBI and sport-related concussion at meetings, scientific conferences, and symposiums; has a clinical practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including athletes); has received honorariums for serving on research panels that provide scientific peer review of programs; is a coinvestigator, collaborator, or consultant on grants relating to mild TBI funded by several organizations; has received research support from test-publishing companies in the past, including ImPACT Applications Systems; has received support from the Harvard Integrated Program to Protect and Improve the Health of NFLPA members; and acknowledges unrestricted philanthropic support from the Mooney-Reed Charitable Foundation and ImPACT Applications, Inc.	[Anonymous], 2010, IBM SPSS STAT WIND V; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Black AM, 2017, CLIN J SPORT MED, V27, P52, DOI 10.1097/JSM.0000000000000308; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Brooks BL, 2016, AM J SPORT MED, V44, P3243, DOI 10.1177/0363546516655095; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2016, J ATHL TRAINING, V51, P189, DOI 10.4085/1062-6050-51.3.05; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Federation Internationale de Football Association, 2007, FED RES DIV COUNTR P, P11; Fedor A, 2013, OBESITY FACTS, V6, P185, DOI 10.1159/000351138; Forbes CR, 2016, APPL NEUROPSYCH-CHIL, V5, P14, DOI 10.1080/21622965.2014.933108; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; ImPACT Applications Inc., 2011, TECHN MAN ONL IMPACT; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Iverson GL, 2014, APPL NEUROPSYCH-ADUL, V21, P36, DOI 10.1080/09084282.2012.721149; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/316575; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kriz PK, 2016, J PEDIATR-US, V171, P234, DOI 10.1016/j.jpeds.2015.12.006; Kriz PK, 2016, J PEDIAT, V171, pe1; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Mannix R, 2014, ANN CLIN TRANSL NEUR, V1, P433, DOI 10.1002/acn3.70; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJ, 1998, J CLIN EXP NEUROPSYC, V23, P770; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Mckay CD, 2014, J ORTHOP SPORT PHYS, V44, P329, DOI 10.2519/jospt.2014.5053; Miller M, 2016, J PEDIAT NEUROPSYCHO, V2, P99; Moore DR, 2016, INT J PSYCHOPHYSIOL, V99, P85, DOI 10.1016/j.ijpsycho.2015.11.010; Moore RD, 2017, INT J PSYCHOPHYSIOL, V112, P22, DOI 10.1016/j.ijpsycho.2016.11.011; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Sandel NK, 2017, AM J SPORT MED, V45, P937, DOI 10.1177/0363546516677246; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tsushima WT, 2016, APPL NEUROPSYCH-CHIL, V5, P9, DOI 10.1080/21622965.2014.902762; Tsushima WT, 2013, APPL NEUROPSYCH-CHIL, V2, P13, DOI 10.1080/09084282.2011.643967; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wunderle K, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000006; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	62	29	29	1	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2018	46	4					961	968		10.1177/0363546517749588			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	GC0IU	WOS:000429461800029	29323926				2022-02-06	
J	Buckley, TA; Munkasy, BA; Clouse, BP				Buckley, Thomas A.; Munkasy, Barry A.; Clouse, Brandy P.			Sensitivity and Specificity of the Modified Balance Error Scoring System in Concussed Collegiate Student Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; efficacy; postural control; diagnostic accuracy; mild traumatic brain injury	MANAGEMENT PRACTICE PATTERNS; TRAUMATIC BRAIN-INJURY; TRAINERS	Objective: To assess the efficacy of the modified Balance En-or Scoring System (mBESS) compared with the Balance Error Scoring System (BESS) in an acutely concussed population. Design: Prospective observational study. Setting: University athletic training room. Patients: Thirty-five collegiate student-athletes (18 Female, 18.9 +/- 0.8 year old, height: 1.71 +/- 0.12 m, weight: 76.3 +/- 24.1 kg) with diagnosed concussions and baseline BESS/mBESS tests. Interventions: All participants completed the BESS and mBESS on the day after the concussion (acute) and were retested daily until their BESS score achieved baseline value (recovery). Main Outcome Measures: The number of errors committed during the BESS and mBESS at each time point were recorded. The sensitivity and specificity of the BESS and mBESS compared with the baseline test was calculated for acute and recovery as well as the mBESS compared with the BESS. Results: At acute, the sensitivity of the BESS and mBESS were 60.0% and 71.4%, respectively. Relative to mBESS baseline, 60% of participants were misclassified at either acute or recovery. Conclusions: The mBESS had higher sensitivity at acute and identified lingering deficits at BESS recovery. Use of the mBESS is likely to produce different results than the BESS; however, the clinical implications of this warrant further investigation.	[Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA; [Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA; [Munkasy, Barry A.] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA USA; [Clouse, Brandy P.] Georgia Southern Univ, Dept Intercollegiate Athlet, Statesboro, GA USA		Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA.	TBuckley@UDel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R15NS070744-01A1]	This project was funded, in part, by an NIH/NINDS grant (1R15NS070744-01A1). All authors of this article were primary investigators on the grant. The funding agency had no role in the development of the manuscript, the interpretation of the results, or the decision where to submit the manuscript.	Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf	11	29	29	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2018	28	2					174	176		10.1097/JSM.0000000000000426			3	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	GP1HC	WOS:000440564900014	28454123				2022-02-06	
J	Jenkins, PO; De Simoni, S; Bourke, NJ; Fleminger, J; Scott, G; Towey, DJ; Svensson, W; Khan, S; Patel, M; Greenwood, R; Cole, JH; Sharp, DJ				Jenkins, Peter O.; De Simoni, Sara; Bourke, Niall J.; Fleminger, Jessica; Scott, Gregory; Towey, David J.; Svensson, William; Khan, Sameer; Patel, Maneesh; Greenwood, Richard; Cole, James H.; Sharp, David J.			Dopaminergic abnormalities following traumatic brain injury	BRAIN			English	Article						traumatic brain injury; dopamine; cognitive impairment; SPECT imaging; ioflupane	CONTROLLED CORTICAL IMPACT; NAIVE PARKINSONS-DISEASE; DIFFUSE AXONAL INJURY; COGNITIVE IMPAIRMENT; HEAD-INJURY; TRANSPORTER EXPRESSION; PREFRONTAL CORTEX; RAT STRIATUM; SCALE; PET	Traumatic brain injury can reduce striatal dopamine levels. The cause of this is uncertain, but is likely to be related to damage to the nigrostriatal system. We investigated the pattern of striatal dopamine abnormalities using 123 I-Ioflupane single-photon emission computed tomography (SPECT) scans and their relationship to nigrostriatal damage and clinical features. We studied 42 moderate- severe traumatic brain injury patients with cognitive impairments but no motor parkinsonism signs and 20 healthy controls. 123 I-Ioflupane scanning was used to assess dopamine transporter levels. Clinical scan reports were compared to quantitative dopamine transporter results. Advanced MRI methods were used to assess the nigrostriatal system, including the area through which the nigrostriatal projections pass as defined from high-resolution Human Connectome data. Detailed clinical and neuropsychological assessments were performed. Around 20% of our moderate-severe patients had clear evidence of reduced specific binding ratios for the dopamine transporter in the striatum measured using 123 I-Ioflupane SPECT. The caudate was affected more consistently than other striatal regions. Dopamine transporter abnormalities were associated with reduced substantia nigra volume. In addition, diffusion MRI provided evidence of damage to the regions through which the nigrostriatal tract passes, particularly the area traversed by dopaminergic projections to the caudate. Only a small percentage of patients had evidence of macroscopic lesions in the striatum and there was no relationship between presence of lesions and dopamine transporter specific binding ratio abnormalities. There was also no relationship between reduced volume in the striatal subregions and reduced dopamine transporter specific binding ratios. Patients with low caudate dopamine transporter specific binding ratios show impaired processing speed and executive dysfunction compared to patients with normal levels. Taken together, our results suggest that the dopaminergic system is affected by a moderate-severe traumatic brain injury in a significant proportion of patients, even in the absence of clinical motor parkinsonism. Reduced dopamine transporter levels are most commonly seen in the caudate and this is likely to reflect the pattern of nigrostriatal tract damage produced by axonal injury and associated midbrain damage.	[Jenkins, Peter O.; De Simoni, Sara; Bourke, Niall J.; Fleminger, Jessica; Scott, Gregory; Cole, James H.; Sharp, David J.] Imperial Coll London, Hammersmith Hosp, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London, England; [Towey, David J.; Svensson, William; Khan, Sameer] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Dept Nucl Med, London, England; [Patel, Maneesh] Imperial Coll Healthcare NHS Trust, Charing Cross Hosp, Imaging Dept, London, England; [Greenwood, Richard] UCL, Inst Neurol, Div Clin Neurol, London, England		Sharp, DJ (corresponding author), Imperial Coll London, Dept Med, Div Brain Sci, C3NL, Du Cane Rd, London W12 0NN, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013; Cole, James H/I-5197-2019; Towey, David/I-6571-2016	Cole, James H/0000-0003-1908-5588; Scott, Gregory/0000-0001-8063-5871; Fleminger, Jessica/0000-0002-5744-5137; Towey, David/0000-0002-6209-3826	National Institute of Health Research Professorship [NIHR-RP-011-048]; Guarantors of Brain Clinical Fellowship; National Institute for Health Research (NIHR) Imperial Biomedical Research Centre; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	D.J.S. is funded by a National Institute of Health Research Professorship (NIHR-RP-011-048). P.O.J. is funded by Guarantors of Brain Clinical Fellowship. The research was also supported by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Backman L, 1997, BRAIN, V120, P2207, DOI 10.1093/brain/120.12.2207; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Benamer HTS, 2003, MOVEMENT DISORD, V18, P977, DOI 10.1002/mds.10482; Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006; Cheng HC, 2010, ANN NEUROL, V67, P715, DOI 10.1002/ana.21995; Cools R, 2002, BRAIN, V125, P584, DOI 10.1093/brain/awf052; DIVAC I, 1967, J COMP PHYSIOL PSYCH, V63, P184, DOI 10.1037/h0024348; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Ekman U, 2012, LANCET NEUROL, V11, P679, DOI 10.1016/S1474-4422(12)70138-2; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goetz CG, 2007, MOVEMENT DISORD, V22, P41, DOI 10.1002/mds.21198; Gulley JM, 2003, EUR J PHARMACOL, V479, P139, DOI 10.1016/j.ejphar.2003.08.064; Guttman M, 1997, NEUROLOGY, V48, P1578, DOI 10.1212/WNL.48.6.1578; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kehagia AA, 2010, LANCET NEUROL, V9, P1200, DOI 10.1016/S1474-4422(10)70212-X; Keuken MC, 2014, NEUROIMAGE, V94, P40, DOI 10.1016/j.neuroimage.2014.03.032; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Krauss JK, 2002, NEUROSURGERY, V50, P927, DOI 10.1097/00006123-200205000-00003; LEE KA, 1991, PSYCHIAT RES, V36, P291, DOI 10.1016/0165-1781(91)90027-M; Ma Y, 2002, SYNAPSE, V45, P125, DOI 10.1002/syn.10090; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Marek KL, 1996, NEUROLOGY, V46, P231, DOI 10.1212/WNL.46.1.231; Marie RM, 1999, NEUROSCI LETT, V260, P77, DOI 10.1016/S0304-3940(98)00928-8; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; Mattay VS, 2002, ANN NEUROL, V51, P156, DOI 10.1002/ana.10078; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Mozley LH, 2001, AM J PSYCHIAT, V158, P1492, DOI 10.1176/appi.ajp.158.9.1492; Muller U, 2000, J NEURAL TRANSM, V107, P303, DOI 10.1007/s007020050025; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Racette BA, 2006, NEUROTOXICOLOGY, V27, P357, DOI 10.1016/j.neuro.2005.11.005; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sockeel P, 2006, J NEUROL NEUROSUR PS, V77, P579, DOI 10.1136/jnnp.2005.075929; Staal JA, 2011, J NEUROTRAUM, V28, P841, DOI 10.1089/neu.2010.1658; Tournier JD, 2012, INT J IMAG SYST TECH, V22, P53, DOI 10.1002/ima.22005; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wenning GK, 1998, MOVEMENT DISORD, V13, P438, DOI 10.1002/mds.870130311; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson MS, 2005, J NEUROSCI RES, V80, P85, DOI 10.1002/jnr.20419; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	53	29	29	2	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR	2018	141		3				797	810		10.1093/brain/awx357			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FY4RP	WOS:000426813600024	29360949	Green Submitted, Bronze			2022-02-06	
J	Kataria, H; Alizadeh, A; Shahriary, GM; Rizi, SS; Henrie, R; Santhosh, KT; Thliveris, JA; Karimi-Abdolrezaee, S				Kataria, Hardeep; Alizadeh, Arsalan; Shahriary, Ghazaleh M.; Rizi, Shekoofeh Saboktakin; Henrie, Ryan; Santhosh, Kallivalappil T.; Thliveris, James A.; Karimi-Abdolrezaee, Soheila			Neuregulin-1 promotes remyelination and fosters a pro-regenerative inflammatory response in focal demyelinating lesions of the spinal cord	GLIA			English	Article						IL-10; lysolecithin demyelination; neuregulin-1; neural precursor cells; oligodendrogenesis; remyelination	CHONDROITIN SULFATE PROTEOGLYCANS; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM/PROGENITOR CELLS; SCHWANN-CELL; OLIGODENDROCYTE DIFFERENTIATION; FUNCTIONAL RECOVERY; PRECURSOR CELLS; TERMINAL DIFFERENTIATION; NEUROLOGICAL RECOVERY; NEUROTROPHIC FACTOR	Oligodendroglial cell death and demyelination are hallmarks of neurotrauma and multiple sclerosis that cause axonal damage and functional impairments. Remyelination remains a challenge as the ability of endogenous precursor cells for oligodendrocyte replacement is hindered in the unfavorable milieu of demyelinating conditions. Here, in a rat model of lysolecithin lysophosphatidyl-choline (LPC)-induced focal demyelination, we report that Neuregulin-1 (Nrg-1), an important factor for oligodendrocytes and myelination, is dysregulated in demyelinating lesions and its bio-availability can promote oligodendrogenesis and remyelination. We delivered recombinant human Nrg-11 (rhNrg-11) intraspinally in the vicinity of LPC demyelinating lesion in a sustained manner using poly lactic-co-glycolic acid microcarriers. Availability of Nrg-1 promoted generation and maturation of new oligodendrocytes, and accelerated endogenous remyelination by both oligodendrocyte and Schwann cell populations in demyelinating foci. Importantly, Nrg-1 enhanced myelin thickness in newly remyelinated spinal cord axons. Our complementary in vitro studies also provided direct evidence that Nrg-1 significantly promotes maturation of new oligodendrocytes and facilitates their transition to a myelinating phenotype. Nrg-1 therapy remarkably attenuated the upregulated expression chondroitin sulfate proteoglycans (CSPGs) specific glycosaminoglycans in the extracellular matrix of demyelinating foci and promoted interleukin-10 (IL-10) production by immune cells. CSPGs and IL-10 are known to negatively and positively regulate remyelination, respectively. We found that Nrg-1 effects are mediated through ErbB2 and ErbB4 receptor activation. Our work provides novel evidence that dysregulated levels of Nrg-1 in demyelinating lesions of the spinal cord pose a challenge to endogenous remyelination, and appear to be an underlying cause of myelin thinning in newly remyelinated axons.	[Kataria, Hardeep; Alizadeh, Arsalan; Shahriary, Ghazaleh M.; Rizi, Shekoofeh Saboktakin; Henrie, Ryan; Santhosh, Kallivalappil T.; Karimi-Abdolrezaee, Soheila] Univ Manitoba, Rady Fac Hlth Sci, Spinal Cord Res Ctr, Dept Physiol & Pathophysiol,Regenerat Med Program, Winnipeg, MB, Canada; [Thliveris, James A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada		Karimi-Abdolrezaee, S (corresponding author), Univ Manitoba, Fac Med, Dept Physiol & Pathophysiol, Regenerat Med Program, 629 Basic Med Sci Bldg,745 Bannatyne Ave, Winnipeg, MB R3E 0J9, Canada.	Soheila.Karimi@umanitoba.ca	Kataria, Hardeep/AAI-8411-2020	Karimi-Abdolrezaee, Soheila/0000-0002-0683-2663	Canadian Institutes of Health Research, CIHRCanadian Institutes of Health Research (CIHR) [MOP 133721]; Multiple Sclerosis Society of Canada, CHRIM [EGID-2936]; Research Manitoba; Rick Hansen Institute; U of M GETS Program, Max Rady College of Medicine, University of Manitoba	Canadian Institutes of Health Research, CIHR, Grant Number: MOP 133721; Multiple Sclerosis Society of Canada (EGID-2936), CHRIM; Research Manitoba; Rick Hansen Institute; U of M GETS Program, Max Rady College of Medicine, University of Manitoba	Alizadeh A, 2017, GLIA, V65, P1152, DOI 10.1002/glia.23150; Alizadeh A, 2016, J PHYSIOL-LONDON, V594, P3539, DOI 10.1113/JP270895; Alizadeh A, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00035; Almad A, 2011, NEUROTHERAPEUTICS, V8, P262, DOI 10.1007/s13311-011-0033-5; BARRES BA, 1993, DEVELOPMENT, V118, P283; Bartus K, 2016, BRAIN, V139, P1394, DOI 10.1093/brain/aww039; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Birchmeier C, 2008, GLIA, V56, P1491, DOI 10.1002/glia.20753; Blakemore WF, 2008, CURR TOP MICROBIOL, V318, P193; BLAKEMORE WF, 1976, NEUROPATH APPL NEURO, V2, P21, DOI 10.1111/j.1365-2990.1976.tb00559.x; BLIGHT AR, 1989, J NEUROL SCI, V91, P15, DOI 10.1016/0022-510X(89)90073-7; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brinkmann BG, 2008, NEURON, V59, P581, DOI 10.1016/j.neuron.2008.06.028; Bunge R P, 1993, Curr Opin Neurobiol, V3, P805, DOI 10.1016/0959-4388(93)90157-T; Butzkueven H, 2002, NAT MED, V8, P613, DOI 10.1038/nm0602-613; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Canoll PD, 1996, NEURON, V17, P229, DOI 10.1016/S0896-6273(00)80155-5; Colello RJ, 1997, MOL NEUROBIOL, V15, P83, DOI 10.1007/BF02740617; Crespo D, 2007, EXP NEUROL, V206, P159, DOI 10.1016/j.expneurol.2007.05.001; Denney L, 2012, J IMMUNOL, V189, P551, DOI 10.4049/jimmunol.1103608; Du YZ, 2006, J NEUROSCI RES, V84, P1692, DOI 10.1002/jnr.21080; Duncan ID, 1997, J ANAT, V190, P35, DOI 10.1046/j.1469-7580.1997.19010035.x; Dyck SM, 2015, STEM CELLS, V33, P2550, DOI 10.1002/stem.1979; Elion E. A., 2006, CURRENT PROTOCOLS IN, V35; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Fancy SPJ, 2009, GENE DEV, V23, P1571, DOI 10.1101/gad.1806309; FELTS PA, 1992, BRAIN RES, V574, P178, DOI 10.1016/0006-8993(92)90815-Q; Felts PA, 1996, NEUROSCIENCE, V75, P643, DOI 10.1016/0306-4522(96)00282-5; Fernandez PA, 2000, NEURON, V28, P81, DOI 10.1016/S0896-6273(00)00087-8; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; Franklin RJM, 2012, NAT REV NEUROL, V8, P624, DOI 10.1038/nrneurol.2012.200; Fricker FR, 2011, FUTUR NEUROL, V6, P809, DOI 10.2217/FNL.11.45; Gauthier MK, 2013, EUR J NEUROSCI, V38, P2693, DOI 10.1111/ejn.12268; Gilson JM, 2002, NEUROREPORT, V13, P1205, DOI 10.1097/00001756-200207020-00027; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Hammond TR, 2014, NEURON, V81, P588, DOI 10.1016/j.neuron.2013.11.015; Hartung HP, 2011, LANCET NEUROL, V10, P293, DOI 10.1016/S1474-4422(11)70043-6; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Irvine KA, 2008, BRAIN, V131, P1464, DOI 10.1093/brain/awn080; JEFFERY ND, 1995, J NEUROCYTOL, V24, P775, DOI 10.1007/BF01191213; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Karimi-Abdolrezaee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037589; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Kim JY, 2003, J NEUROSCI, V23, P5561; Kotter MR, 2006, J NEUROSCI, V26, P328, DOI 10.1523/JNEUROSCI.2615-05.2006; Lau LW, 2012, ANN NEUROL, V72, P419, DOI 10.1002/ana.23599; Li Q, 2009, J MOL NEUROSCI, V37, P67, DOI 10.1007/s12031-008-9121-3; Li YG, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0283-y; Lobo-Silva D, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0763-8; Lourenco T, 2016, SCI REP-UK, V6, DOI 10.1038/srep21563; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mason JL, 2000, J NEUROSCI, V20, P5703, DOI 10.1523/JNEUROSCI.20-15-05703.2000; Mason JL, 2004, AM J PATHOL, V164, P1673, DOI 10.1016/S0002-9440(10)63726-1; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Mei L, 2014, NEURON, V83, P27, DOI 10.1016/j.neuron.2014.06.007; Mencel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070338; Mi S, 2007, NAT MED, V13, P1228, DOI 10.1038/nm1664; Mikita J, 2011, MULT SCLER J, V17, P2, DOI 10.1177/1352458510379243; Miron VE, 2014, J NEUROCHEM, V130, P165, DOI 10.1111/jnc.12705; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; Mothe AJ, 2008, EXP NEUROL, V213, P176, DOI 10.1016/j.expneurol.2008.05.024; Nait-Oumesmar B, 1999, EUR J NEUROSCI, V11, P4357, DOI 10.1046/j.1460-9568.1999.00873.x; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Nave KA, 2014, ANNU REV CELL DEV BI, V30, P503, DOI 10.1146/annurev-cellbio-100913-013101; Ohori Y, 2006, J NEUROSCI, V26, P11948, DOI 10.1523/JNEUROSCI.3127-06.2006; Oluich LJ, 2012, J NEUROSCI, V32, P8317, DOI 10.1523/JNEUROSCI.1053-12.2012; Park SK, 2001, J CELL BIOL, V154, P1245, DOI 10.1083/jcb.200104025; Pedraza CE, 2014, ASN NEURO, V6, DOI 10.1177/1759091414538134; Pendleton JC, 2013, EXP NEUROL, V247, P113, DOI 10.1016/j.expneurol.2013.04.003; Perlin JR, 2011, DEVELOPMENT, V138, P4639, DOI 10.1242/dev.068072; Powers BE, 2013, P NATL ACAD SCI USA, V110, P4075, DOI 10.1073/pnas.1210293110; Roy K, 2007, P NATL ACAD SCI USA, V104, P8131, DOI 10.1073/pnas.0702157104; Ruffini F, 2004, AM J PATHOL, V164, P1519, DOI 10.1016/S0002-9440(10)63709-1; Santhosh KT, 2017, J CONTROL RELEASE, V261, P147, DOI 10.1016/j.jconrel.2017.06.030; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Simmons LJ, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0703-7; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Sussman CR, 2005, J NEUROSCI, V25, P5757, DOI 10.1523/JNEUROSCI.4748-04.2005; Sussman CR, 2000, J NEUROSCI RES, V59, P413, DOI 10.1002/(SICI)1097-4547(20000201)59:3<413::AID-JNR16>3.0.CO;2-G; Syed YA, 2011, J NEUROSCI, V31, P3719, DOI 10.1523/JNEUROSCI.4930-10.2011; Taveggia C, 2008, GLIA, V56, P284, DOI 10.1002/glia.20612; Taveggia C, 2010, NAT REV NEUROL, V6, P276, DOI 10.1038/nrneurol.2010.37; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Van't Veer A, 2009, J NEUROSCI RES, V87, P69, DOI 10.1002/jnr.21841; Vartanian T, 1999, P NATL ACAD SCI USA, V96, P731, DOI 10.1073/pnas.96.2.731; Wang Z, 2007, GLIA, V55, P537, DOI 10.1002/glia.20480; Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031; Xu ZF, 2006, J CEREBR BLOOD F MET, V26, P527, DOI 10.1038/sj.jcbfm.9600212; YANG J, 2009, THE JOURNAL OF CLINI, V119, P3678, DOI DOI 10.1172/JCI37914; Zawadzka M, 2010, CELL STEM CELL, V6, P578, DOI 10.1016/j.stem.2010.04.002; Zhang SX, 2011, HISTOL HISTOPATHOL, V26, P45, DOI 10.14670/HH-26.45; Zhao C, 2015, J NEUROSCI, V35, P11482, DOI 10.1523/JNEUROSCI.3655-14.2015	94	29	31	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	2018	66	3					538	561		10.1002/glia.23264			24	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FS6MX	WOS:000419912600006	29148104				2022-02-06	
J	Kochanek, PM; Bramlett, HM; Dixon, CE; Dietrich, WD; Mondello, S; Wang, KKW; Hayes, RL; Lafrenaye, A; Povlishock, JT; Tortella, FC; Poloyac, SM; Empey, P; Shear, DA				Kochanek, Patrick M.; Bramlett, Helen M.; Dixon, C. Edward; Dietrich, W. Dalton; Mondello, Stefania; Wang, Kevin K. W.; Hayes, Ronald L.; Lafrenaye, Audrey; Povlishock, John T.; Tortella, Frank C.; Poloyac, Samuel M.; Empey, Philip; Shear, Deborah A.			Operation Brain Trauma Therapy: 2016 Update	MILITARY MEDICINE			English	Article; Proceedings Paper	Military Health System Research Symposium (MHSRS)	2016	FL				CONTROLLED CORTICAL IMPACT; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; CLINICAL-TRIALS; DOUBLE-BLIND; HEAD-INJURY; NF-H; ERYTHROPOIETIN; AMANTADINE; LEVETIRACETAM	Operation brain trauma therapy (OBTT) is a multi-center, pre-clinical drug and biomarker screening consortium for traumatic brain injury (TBI). Therapies are screened across three rat models (parasagittal fluid percussion injury, controlled cortical impact [CCI], and penetrating ballistic-like brain injury). Operation brain trauma therapy seeks to define therapies that show efficacy across models that should have the best chance in randomized clinical trials (RCTs) and/or to define model-dependent therapeutic effects, including TBI protein biomarker responses, to guide precision medicine-based clinical trials in targeted pathologies. The results of the first five therapies tested by OBTT (nicotinamide, erythropoietin, cyclosporine [CsA], simvastatin, and levetiracetam) were published in the Journal of Neurotrauma. Operation brain trauma therapy now describes preliminary results on four additional therapies (glibenclamide, kollidon-VA64, AER-271, and amantadine). To date, levetiracetam was beneficial on cognitive outcome, histology, and/or biomarkers in two models. The second most successful drug, glibenclamide, improved motor function and histology in CCI. Other therapies showed model-dependent effects (amantadine and CsA). Critically, glial fibrillary acidic protein levels predicted treatment effects. Operation brain trauma therapy suggests that levetiracetam merits additional pre-clinical and clinical evaluation and that glibenclamide and amantadine merit testing in specific TBI phenotypes. Operation brain trauma therapy has established that rigorous, multi-center consortia could revolutionize TBI therapy and biomarker development.	[Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Dept Neurol Surg, Miller Sch Med, 1095 NW 14th Terrace, Miami, FL 33136 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurol Surg, Safar Ctr Resuscitat Res, 4401 Penn Ave, Pittsburgh, PA 15224 USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Via Consolare Valeria 1, I-98125 Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Program Neuroprote & Biomarkers Res, POB 100256, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Program Neuroprote & Biomarkers Res, POB 100256, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Chem, Program Neuroprote & Biomarkers Res, POB 100256, Gainesville, FL 32611 USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Ctr Neuroprote & Biomarkers Res, 13400 Progress Blvd, Alachua, FL 32615 USA; [Lafrenaye, Audrey; Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, 1101 East Marshall St, Richmond, VA 23298 USA; [Tortella, Frank C.] Walter Reed Army Inst Res, Dept Army, 503 Robert Grant Ave, Silver Spring, MD 20910 USA; [Poloyac, Samuel M.; Empey, Philip] Univ Pittsburgh, Dept Pharm & Therapeut, Ctr Clin Pharmaceut Sci, 3501 Terrace St, Pittsburgh, PA 15261 USA; [Empey, Philip] Univ Pittsburgh, Clin Translat Sci Inst, 3501 Terrace St, Pittsburgh, PA 15261 USA; [Shear, Deborah A.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect & Neurorestorat Branch, 503 Robert Grant Ave, Silver Spring, MD 20910 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, 4401 Penn Ave, Pittsburgh, PA 15224 USA.		Mondello, Stefania/A-1813-2012; Empey, Philip/L-9604-2019	Mondello, Stefania/0000-0002-8587-3614; Empey, Philip/0000-0001-7474-2339; Wang, Kevin/0000-0002-9343-6473	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0623, WH81XWH-14-2-0018]	Supported by Department of Defense grants W81XWH-10-1-0623 and WH81XWH-14-2-0018.	Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Begley CG, 2015, CIRC RES, V116, P116, DOI 10.1161/CIRCRESAHA.114.303819; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; Bramlett HM, 2016, J NEUROTRAUM, V33, P538, DOI 10.1089/neu.2015.4116; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; Carney N, 2016, NEUROSURGERY, DOI [DOI 10.1227/NEU.0000000000001432, 10.1227/NEU.0000000000001432, 10.1227/neu.0000000000001432]; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Dixon CE, 2016, J NEUROTRAUM, V33, P553, DOI 10.1089/neu.2015.4122; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Hayakawa K, 2012, SPINAL CORD, V50, P493, DOI 10.1038/sc.2011.184; Hayden E. C., 2011, NATURE NEWS; Jha Ruchira M, 2017, Crit Care Med, V45, pe255, DOI 10.1097/CCM.0000000000002079; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Kochanek PM, 2015, CRIT CARE MED, V43, P1544, DOI 10.1097/CCM.0000000000001041; Kochanek PM, 2013, LANCET NEUROL, V12, P1132, DOI 10.1016/S1474-4422(13)70245-X; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Martinez-Morillo E, 2015, CLIN CHEM LAB MED, V53, P1575, DOI 10.1515/cclm-2014-0908; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Neselius S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099870; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Oliver JM, 2016, J NEUROTRAUM, V33, P1784, DOI 10.1089/neu.2015.4295; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00073; Sheth KN, 2016, LANCET NEUROL, V15, P1160, DOI 10.1016/S1474-4422(16)30196-X; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Wallisch J, 2016, J NEUROTRAUM, V33, pA61; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Weisbrod AB, 2012, J TRAUMA ACUTE CARE, V73, P1525, DOI 10.1097/TA.0b013e318270e179; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zurek J, 2011, BRAIN INJURY, V25, P221, DOI 10.3109/02699052.2010.541895	46	29	30	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	MAR-APR	2018	183			S			303	312		10.1093/milmed/usx184			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	GC0JM	WOS:000429463600043	29635589	Bronze			2022-02-06	
J	Hood, KN; Zhao, J; Redell, JB; Hylin, MJ; Harris, B; Perez, A; Moore, AN; Dash, PK				Hood, Kimberly N.; Zhao, Jing; Redell, John B.; Hylin, Michael J.; Harris, Brynn; Perez, Alec; Moore, Anthony N.; Dash, Pramod K.			Endoplasmic Reticulum Stress Contributes to the Loss of Newborn Hippocampal Neurons after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						context fear discrimination; dendritic shortening; loss of hippocampal newborn neurons; memory impairment; traumatic brain injury	UNFOLDED PROTEIN RESPONSE; DENTATE GYRUS; PATTERN SEPARATION; ADULT NEUROGENESIS; GENE-EXPRESSION; CYTOCHROME-C; ER STRESS; CELL LOSS; DEATH; MEMORY	Adult hippocampal neurogenesis has been shown to be required for certain types of cognitive function. For example, studies have shown that these neurons are critical for pattern separation, the ability to store similar experiences as distinct memories. Although traumatic brain injury (TBI) has been shown to cause the loss of newborn hippocampal neurons, the signaling pathway(s) that triggers their death is unknown. Endoplasmic reticulum (ER) stress activates the PERK-eIF2 alpha pathway that acts to restore ER function and improve cell survival. However, unresolved/intense ER stress activates C/EBP homologous protein (CHOP), leading to cell death. We show that TBI causes the death of hippocampal newborn neurons via CHOP. Using CHOP KO mice, we show that loss of CHOP markedly reduces newborn neuron loss after TBI. Injured CHOP mice performed significantly better in a context fear discrimination task compared with injured wild-type mice. In contrast, the PERK inhibitor GSK2606414 exacerbated doublecortin cell loss and worsened contextual discrimination. Administration of guanabenz (which reduces ER stress) to injured male rats reduced the loss of newborn neurons and improved one-trial contextual fear memory. Interestingly, we also found that the surviving newborn neurons in brain-injured animals had dendritic loss, which was not observed in injured CHOPKO mice or in animals treated with guanabenz. These results indicate that ER stress plays a key role in the death of newborn neurons after TBI. Further, these findings indicate that ER stress can alter dendritic arbors, suggesting a role for ER stress in neuroplasticity and dendritic pathologies.	[Hood, Kimberly N.; Zhao, Jing; Redell, John B.; Hylin, Michael J.; Harris, Brynn; Perez, Alec; Moore, Anthony N.; Dash, Pramod K.] Univ Texas Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX 77225 USA; [Hylin, Michael J.] Southern Illinois Univ, Dept Psychol, Life Sci 2 6502, Carbondale, IL 62901 USA		Dash, PK (corresponding author), Univ Texas Houston, Med Sch, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019	Dash, Pramod/0000-0001-6746-1002	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS090935, NS088298, NS087149]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088298, R01NS090935, R01NS087149] Funding Source: NIH RePORTER	This work was supported by NIH Grants NS090935, NS088298 and NS087149 to P.K.D. We thank Jacilyn MacGowan for maintaining the animal colonies and genotyping, and Dr. Mark Maynard for critical reading of the paper.	Ambrogini P, 2004, BRAIN RES, V1017, P21, DOI 10.1016/j.brainres.2004.05.039; Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Crespillo-Casado A, 2017, ELIFE, V6, DOI 10.7554/eLife.26109; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash PK, 2000, NEUROREPORT, V11, P2811, DOI 10.1097/00001756-200008210-00040; Dash PK, 2015, J NEUROTRAUM, V32, P1608, DOI 10.1089/neu.2014.3772; Denny CA, 2012, HIPPOCAMPUS, V22, P1188, DOI 10.1002/hipo.20964; Drew MR, 2010, BEHAV NEUROSCI, V124, P446, DOI 10.1037/a0020081; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI [10.1089/neu.2008.0744, 10.1089/neu.2008-0744]; Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189; HALL ED, 1993, RES P ARNMD, V71, P81; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harris LK, 2001, J NEUROTRAUM, V18, P993, DOI 10.1089/08977150152693692; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; Hotamisligil GS, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a006072; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kheirbek MA, 2012, NAT NEUROSCI, V15, P1613, DOI 10.1038/nn.3262; Kheirbek MA, 2012, J NEUROSCI, V32, P8696, DOI 10.1523/JNEUROSCI.1692-12.2012; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Liu CL, 2012, J GERIATR CARDIOL, V9, P258, DOI 10.3724/SP.J.1263.2012.02292; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; McClelland JL, 1996, HIPPOCAMPUS, V6, P654; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Niibori Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2261; Opendak M, 2015, TRENDS COGN SCI, V19, P151, DOI 10.1016/j.tics.2015.01.001; Osier N, 2016, METHODS MOL BIOL, V1462, P177, DOI 10.1007/978-1-4939-3816-2_11; Pandya Jignesh D, 2013, Front Neuroenergetics, V5, P10, DOI 10.3389/fnene.2013.00010; Plumpe T, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-77; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sun D, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00095; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Tsaytler P, 2011, SCIENCE, V332, P91, DOI 10.1126/science.1201396; Van Der Vlies D, 2003, ANTIOXID REDOX SIGN, V5, P381, DOI 10.1089/152308603768295113; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wek RC, 2007, ANTIOXID REDOX SIGN, V9, P2357, DOI 10.1089/ars.2007.1764; Yassa MA, 2011, TRENDS NEUROSCI, V34, P515, DOI 10.1016/j.tins.2011.06.006; YU CCW, 1992, HISTOCHEM J, V24, P121, DOI 10.1007/BF01047461; Zhao YH, 2016, STEM CELLS, V34, P1263, DOI 10.1002/stem.2310; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	64	29	30	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 28	2018	38	9					2372	2384		10.1523/JNEUROSCI.1756-17.2018			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FX8PM	WOS:000426357200019	29386258	Bronze, Green Published			2022-02-06	
J	Gao, TL; Chen, Z; Chen, H; Yuan, H; Wang, YN; Peng, X; Wei, C; Yang, JX; Xu, CQ				Gao, Tielei; Chen, Zhe; Chen, He; Yuan, Hui; Wang, Yuena; Peng, Xue; Wei, Can; Yang, Jinxia; Xu, Changqing			Inhibition of HMGB1 mediates neuroprotection of traumatic brain injury by modulating the microglia/macrophage polarization	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						Glycyrrhizin; HMGB1; Microglia/macrophage; M1/M2 phenotype; Traumatic brain injury	MACROPHAGE PHENOTYPE; THERAPEUTIC TARGET; GLYCYRRHIZIN; ACTIVATION; INFLAMMATION; EXPRESSION; PROTEIN; REPAIR; CELLS; M1	Microglia/Macrophages have a double-edged role in secondary brain damage after traumatic brain injury (TBI) depending on polarization toward proinflammatory M1 or anti-inflammatory M2 phenotypes. Recently, high-mobility group box 1 (HMGB1) was found to influence the polarization of macrophages. In this study, glycyrrhizin (GL), an inhibitor of HMGB1, was used to investigate whether the inhibition of HMGB1 could modulate microglia/macrophage polarization after TBI. The results showed that treatment with GL improved the neurological function recovery, reduced the lesion volume, and inhibited the release and expression of HMGB1 after TBI. In addition, the administration of GL suppressed M1 phenotype activation and promoted M2 phenotype activation of microglia/macrophages. In conclusion, the results suggested that GL attenuated TBI by inhibiting M1 phenotype while inducing M2 phenotype activation of microglia/macrophages, at least partly through inhibiting HMGB1. Also, targeting HMGB1 to modulate the microglia/macrophage polarization should be one potential therapeutic approach for TBI. (C) 2018 Elsevier Inc. All rights reserved.	[Gao, Tielei; Wei, Can; Yang, Jinxia; Xu, Changqing] Harbin Med Univ, Dept Pathophysiol, 157 Bao Jian Rd, Harbin 150081, Heilongjiang, Peoples R China; [Gao, Tielei; Chen, He; Peng, Xue] Harbin Med Univ, Dept Forens Med, 157 Bao Jian Rd, Harbin 150081, Heilongjiang, Peoples R China; [Chen, Zhe] Gen Hosp, Heilongjiang Land Reclamat Bur, Dept Infect Dis, 235 Ha Shuang Rd, Harbin 150088, Heilongjiang, Peoples R China; [Yuan, Hui] Mudanjiang Med Univ, Dept Med Funct Expt, 3 Tong Xiang Rd, Mudanjiang 157011, Peoples R China; [Wang, Yuena] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, 247 Bao Jian Rd, Harbin 150086, Heilongjiang, Peoples R China		Xu, CQ (corresponding author), Harbin Med Univ, Dept Pathophysiol, 157 Bao Jian Rd, Harbin 150081, Heilongjiang, Peoples R China.	gaotielei8866@126.com; chenzhe810207@sina.com; chenhe_2008@aliyun.com; yuanhui007@163.com; 1004644171@qq.com; flysnow990119@126.com; Canwei528@163.com; Yangjinzia1981@163.com; xucq45@126.com	Wei, Can/AAN-7658-2020	Wei, Can/0000-0003-4291-7653	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81270311]	This research is supported by the National Natural Science Foundation of China (No.81270311).	Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bu W, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00449; Das A, 2015, AM J PATHOL, V185, P2596, DOI 10.1016/j.ajpath.2015.06.001; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Gu XJ, 2014, CHIN J TRAUMATOL, V17, P1, DOI 10.3760/cma.j.issn.1008-1275.2014.01.001; Honda H, 2012, J LEUKOCYTE BIOL, V91, P967, DOI 10.1189/jlb.0112038; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Karuppagounder V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152922; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Kopitar-Jerala N, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00458; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Mills CD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00212; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Schaper F, 2016, RHEUMATOLOGY, V55, P2260, DOI 10.1093/rheumatology/kew324; Su ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21884; Tian SJ, 2015, AM J PHYSIOL-RENAL, V308, pF69, DOI 10.1152/ajprenal.00484.2014; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Ugrinova I, 2017, ADV PROTEIN CHEM STR, V107, P37, DOI 10.1016/bs.apcsb.2016.10.001; Wang XN, 2015, INT J CLIN EXP MED, V8, P20675; Wu CX, 2015, SHOCK, V43, P412, DOI 10.1097/SHK.0000000000000309; Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662; Yuan A, 2015, SCI REP-UK, V5, DOI 10.1038/srep14273; ZHAO F, 2017, BIOMED RES INT, V2017, DOI DOI 10.1155/2017/9719647; Zhao Y, 2017, BIOCHEM BIOPH RES CO, V494, P42, DOI 10.1016/j.bbrc.2017.10.088; Zhu LN, 2015, INT REV IMMUNOL, V34, P82, DOI 10.3109/08830185.2014.969421	29	29	31	5	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	FEB 26	2018	497	1					430	436		10.1016/j.bbrc.2018.02.102			7	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	GB5CI	WOS:000429079600064	29448108				2022-02-06	
J	Pati, S; Peng, ZL; Wataha, K; Miyazawa, B; Potter, DR; Kozar, RA				Pati, Shibani; Peng, Zhanglong; Wataha, Katherine; Miyazawa, Byron; Potter, Daniel R.; Kozar, Rosemary A.			Lyophilized plasma attenuates vascular permeability, inflammation and lung injury in hemorrhagic shock	PLOS ONE			English	Article							FRESH-FROZEN PLASMA; TRAUMATIC BRAIN-INJURY; ENDOTHELIAL GLYCOCALYX DEGRADATION; DAMAGE CONTROL RESUSCITATION; SPRAY-DRIED PLASMA; LEUKOCYTE ADHESION; SYNDECAN 1; MODEL; SURVIVAL; COAGULOPATHY	In severe trauma and hemorrhage the early and empiric use of fresh frozen plasma (FFP) is associated with decreased morbidity and mortality. However, utilization of FFP comes with the significant burden of shipping and storage of frozen blood products. Dried or lyophilized plasma (LP) can be stored at room temperature, transported easily, reconstituted rapidly with ready availability in remote and austere environments. We have previously demonstrated that FFP mitigates the endothelial injury that ensues after hemorrhagic shock (HS). In the current study, we sought to determine whether LP has similar properties to FFP in its ability to modulate endothelial dysfunction in vitro and in vivo. Single donor LP was compared to single donor FFP using the following measures of endothelial cell (EC) function in vitro: permeability and transendothelial monolayer resistance; adherens junction preservation; and leukocyte-EC adhesion. In vivo, using a model of murine HS, LP and FFP were compared in measures of HS-induced pulmonary vascular inflammation and edema. Both in vitro and in vivo in all measures of EC function, LP demonstrated similar effects to FFP. Both FFP and LP similarly reduced EC permeability, increased transendothelial resistance, decreased leukocyte-EC binding and persevered adherens junctions. In vivo, LP and FFP both comparably reduced pulmonary injury, inflammation and vascular leak. Both FFP and LP have similar potent protective effects on the vascular endothelium in vitro and in lung function in vivo following hemorrhagic shock. These data support the further development of LP as an effective plasma product for human use after trauma and hemorrhagic shock.	[Pati, Shibani; Wataha, Katherine; Miyazawa, Byron; Potter, Daniel R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Peng, Zhanglong] Univ Texas Hlth Sci Ctr Houston, Dept Anesthesia, Houston, TX 77030 USA; [Kozar, Rosemary A.] Univ Maryland, Sch Med, Shock Trauma Ctr, Baltimore, MD 21201 USA		Pati, S (corresponding author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.	shibani.pati@ucsf.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1GM107482]; Department of DefenseUnited States Department of Defense [W81XWH-11-2-006]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM107482] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health RO1GM107482 (to RAK) and the Department of Defense W81XWH-11-2-006 (to SP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was supported by the National Institutes of Health RO1GM107482 and the Department of Defense W81XWH-11-2-006. There are no conflicts of interest reported.	[Anonymous], 2017, SHOCK, P1; [Anonymous], 2009, SAFETY AUTOLOGOUS LY; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Chappell D, 2010, SHOCK, V34, P133, DOI 10.1097/SHK.0b013e3181cdc363; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; GIAEVER I, 1986, IEEE T BIO-MED ENG, V33, P242, DOI 10.1109/TBME.1986.325896; Hart ML, 2005, J IMMUNOL, V174, P6373, DOI 10.4049/jimmunol.174.10.6373; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Holcomb JB, 2013, JAMA SURG; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Imam AM, 2013, J TRAUMA ACUTE CARE, V75, P976, DOI 10.1097/TA.0b013e31829e2186; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jenkins DH, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000140; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2011, BIOMED CENTRAL, V15, pR272; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kozar RA, 2015, J TRAUMA ACUTE CARE, V78, pS83, DOI 10.1097/TA.0000000000000631; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Lee TH, 2013, TRANSFUSION, V53, p72S, DOI 10.1111/trf.12039; Letourneau PA, 2011, J TISSUE SCI ENG S3; Lipowsky HH, 2012, ANN BIOMED ENG, V40, P840, DOI 10.1007/s10439-011-0427-x; Matijevic N, 2011, J TRAUMA, V70, P71, DOI 10.1097/TA.0b013e318207abec; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Pati S, 2016, J TRAUMA ACUTE CARE, V80, P576, DOI 10.1097/TA.0000000000000961; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peng ZL, 2016, J TRAUMA ACUTE CARE, V81, pS171, DOI 10.1097/TA.0000000000001221; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Peng ZL, 2012, SHOCK, V38, P57, DOI 10.1097/SHK.0b013e31825a188a; Potter DR, 2015, J TRAUMA ACUTE CARE, V78, pS7, DOI 10.1097/TA.0000000000000630; Pusateri AE, 2016, TRANSFUSION, V56, pS128, DOI 10.1111/trf.13580; Query C, 2010, REPORTING SYSTEM WIS; Rahbar E, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0481-5; Sillesen M, 2013, SURGERY, V154, P197, DOI 10.1016/j.surg.2013.04.002; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Spoerke N, 2009, ARCH SURG-CHICAGO, V144, P829, DOI 10.1001/archsurg.2009.154; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Van PY, 2011, J TRAUMA, V71, P20, DOI 10.1097/TA.0b013e3182214f44; Wataha K, 2013, TRANSFUSION, V53, p80S, DOI 10.1111/trf.12040	41	29	29	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2018	13	2							e0192363	10.1371/journal.pone.0192363			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU7VI	WOS:000424060400039	29394283	Green Published, Green Submitted, gold			2022-02-06	
J	Mutch, WAC; Ellis, MJ; Ryner, LN; McDonald, PJ; Morissette, MP; Pries, P; Essig, M; Mikulis, DJ; Duffin, J; Fisher, JA				Mutch, W. Alan C.; Ellis, Michael J.; Ryner, Lawrence N.; McDonald, Patrick J.; Morissette, Marc P.; Pries, Philip; Essig, Marco; Mikulis, David J.; Duffin, James; Fisher, Joseph A.			Patient-Specific Alterations in CO2 Cerebrovascular Responsiveness in Acute and Sub-Acute Sports-Related Concussion	FRONTIERS IN NEUROLOGY			English	Article						sports-related concussion; adolescent; magnetic resonance imaging; blood oxygen level dependent imaging; cerebrovascular reactivity	PROSPECTIVE MOTION CORRECTION; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW ALTERATIONS; RECOVERY-TIME; REACTIVITY MEASURES; CLINICAL RECOVERY; CARBON-DIOXIDE; HIGH-SCHOOL; BOLD MRI; MANAGEMENT	Background: Preliminary studies suggest that sports-related concussion (SRC) is associated with alterations in cerebral blood flow (CBF) regulation. Here, we use advanced magnetic resonance imaging (MRI) techniques to measure CBF and cerebrovascular responsiveness (CVR) in individual SRC patients and healthy control subjects. Methods: 15 SRC patients (mean age = 16.3, range 14-20 years) and 27 healthy control subjects (mean age = 17.6, range 13-21 years) underwent anatomical MRI, pseudo-continuous arterial spin labeling (pCASL) MRI and model-based prospective end-tidal targeting (MPET) of CO2 during blood oxygenation level-dependent (BOLD) MRI. Group differences in global mean resting CBF were examined. Voxel-by-voxel group and individual differences in regional CVR were examined using statistical parametric mapping (SPM). Leave-one-out receiver operating characteristic curve analysis was used to evaluate the utility of brain MRI CO2 stress testing biomarkers to correctly discriminate between SRC patients and healthy control subjects. Results: All studies were tolerated with no complications. Traumatic structural findings were identified in one SRC patient. No significant group differences in global mean resting CBF were observed. There were no significant differences in the CO2 stimulus and O-2 targeting during BOLD MRI. Significant group and patient-specific differences in CVR were observed with SRC patients demonstrating a predominant pattern of increased CVR. Leave-one-out ROC analysis for voxels demonstrating a significant increase in CVR was found to reliably discriminate between SRC patients and healthy control subjects (AUC of 0.879, p = 0.0001). The optimal cutoff for increased CVR declarative for SRC was 1,899 voxels resulting in a sensitivity of 0.867 and a specificity of 0.778 for this specific ROC analysis. There was no correlation between abnormal voxel counts and Postconcussion Symptom Scale scores among SRC patients. Conclusion: Acute and subacute SRCs are associated with alterations in CVR that can be reliably detected by brain MRI CO2 stress testing in individual patients.	[Mutch, W. Alan C.] Univ Manitoba, Dept Anesthesia & Perioperat Med, Winnipeg, MB, Canada; [Mutch, W. Alan C.; Ellis, Michael J.; Ryner, Lawrence N.; McDonald, Patrick J.; Essig, Marco] Univ Manitoba, Winnipeg, MB, Canada; [Mutch, W. Alan C.; Ellis, Michael J.; Ryner, Lawrence N.; McDonald, Patrick J.; Essig, Marco] Univ Manitoba, Canada North Concuss Network, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Dept Surg & Pediat & Child Hlth, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Sect Neurosurg, Winnipeg, MB, Canada; [Ellis, Michael J.; Essig, Marco] Univ Manitoba, Pan Am Concuss Program, Winnipeg, MB, Canada; [Ellis, Michael J.] Univ Manitoba, Childrens Hosp, Res Inst Manitoba, Winnipeg, MB, Canada; [Ryner, Lawrence N.; Essig, Marco] Univ Manitoba, Dept Radiol Diagnost Imaging, Winnipeg, MB, Canada; [McDonald, Patrick J.] Univ British Columbia, BC Childrens Hosp, Div Neurosurg, Natl Core Neuroeth, Vancouver, BC, Canada; [Morissette, Marc P.] Pan Am Clin Fdn, Winnipeg, MB, Canada; [Pries, Philip] Univ Manitoba, Max Rady Coll Med, Winnipeg, MB, Canada; [Mikulis, David J.] Univ Toronto, Dept Med Imaging, Toronto, ON, Canada; [Mikulis, David J.; Duffin, James; Fisher, Joseph A.] Univ Toronto, Toronto, ON, Canada; [Mikulis, David J.; Duffin, James; Fisher, Joseph A.] Univ Hlth Network, Cerebrovasc React Res Grp, Toronto, ON, Canada; [Duffin, James] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Duffin, James; Fisher, Joseph A.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada		Mutch, WAC (corresponding author), Univ Manitoba, Dept Anesthesia & Perioperat Med, Winnipeg, MB, Canada.; Mutch, WAC (corresponding author), Univ Manitoba, Winnipeg, MB, Canada.; Mutch, WAC (corresponding author), Univ Manitoba, Canada North Concuss Network, Winnipeg, MB, Canada.	wacmutch@shaw.ca	Mikulis, David J/H-5167-2019	Morissette, Marc/0000-0002-5342-8938; essig, marco/0000-0002-7964-2297; Mikulis, David/0000-0003-3956-0892	Health Sciences Center Foundation; Manitoba Health Research Council; University of Manitoba Department of Surgery, Winnipeg, MB, Canada	All phases of this study were supported by grants from the Health Sciences Center Foundation, the Manitoba Health Research Council and the University of Manitoba Department of Surgery, Winnipeg, MB, Canada.	Bhogal AA, 2015, NEUROIMAGE, V114, P239, DOI 10.1016/j.neuroimage.2015.04.014; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Davis GA, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097415; Duffin J, 2015, NEUROIMAGE, V114, P207, DOI 10.1016/j.neuroimage.2015.04.029; Ellis MJ, 2017, CAN J NEUROL SCI, V44, P24, DOI 10.1017/cjn.2016.312; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00136; Ellis MJ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00061; Fierstra J, 2013, J PHYSIOL-LONDON, V591, P5809, DOI 10.1113/jphysiol.2013.259150; Fisher JA, 2017, HUM BRAIN MAPP, V38, P3415, DOI 10.1002/hbm.23598; Giza CC, 2001, J ATHL TRAINING, V36, P228; HOSKINS PR, 1990, CLIN PHYS PHYSIOL M, V11, P1, DOI 10.1088/0143-0815/11/1/001; Ito S, 2008, J PHYSIOL-LONDON, V586, P3675, DOI 10.1113/jphysiol.2008.154716; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Leung J, 2016, J MAGN RESON IMAGING, V43, P1191, DOI 10.1002/jmri.25063; Losoi H, 2015, J NEUROTRAUM, V32, P942, DOI 10.1089/neu.2014.3799; Mark CI, 2010, MAGN RESON MED, V64, P749, DOI 10.1002/mrm.22405; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097447; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Militana AR, 2016, BRAIN IMAGING BEHAV, V10, P559, DOI 10.1007/s11682-015-9407-3; Mutch WAC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00107; Mutch WAC, 2016, J NEUROSURG, V125, P648, DOI 10.3171/2015.6.JNS15972; Mutch WAC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047443; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Prisman E, 2008, J MAGN RESON IMAGING, V27, P185, DOI 10.1002/jmri.21102; Sobczyk O, 2016, AM J NEURORADIOL, V37, P818, DOI 10.3174/ajnr.A4679; Sobczyk O, 2015, J CEREBR BLOOD F MET, V35, P213, DOI 10.1038/jcbfm.2014.184; Spano VR, 2013, RADIOLOGY, V266, P592, DOI 10.1148/radiol.12112795; Stock M, 2006, MED PHYS, V33, P2868, DOI 10.1118/1.2219775; Tanenbaum AB, 2015, J CEREBR BLOOD F MET, V35, P1697, DOI 10.1038/jcbfm.2015.124; Thomas BP, 2013, NEUROIMAGE, V83, P505, DOI 10.1016/j.neuroimage.2013.07.005; Turner BO, 2015, BRAIN IMAGING BEHAV, V9, P115, DOI 10.1007/s11682-014-9351-7; Wang Y, 2016, J NEUROTRAUM, V33, P1227, DOI 10.1089/neu.2015.4072; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zaitsev M, 2017, NEUROIMAGE, V154, P33, DOI 10.1016/j.neuroimage.2016.11.014; Zun ZH, 2014, MAGN RESON MED, V72, P1049, DOI 10.1002/mrm.25024	45	29	29	2	9	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 24	2018	9								23	10.3389/fneur.2018.00023			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FT5KH	WOS:000423191900001	29416525	gold, Green Published			2022-02-06	
J	Aucott, H; Lundberg, J; Salo, H; Klevenvall, L; Damberg, P; Ottosson, L; Andersson, U; Holmin, S; Harris, HE				Aucott, Hannah; Lundberg, Johan; Salo, Henna; Klevenvall, Lena; Damberg, Peter; Ottosson, Lars; Andersson, Ulf; Holmin, Staffan; Harris, Helena Erlandsson			Neuroinflammation in Response to Intracerebral Injections of Different HMGB1 Redox Isoforms	JOURNAL OF INNATE IMMUNITY			English	Article						HMGB1; Brain; Redox; Neuroinflammation; Blood-brain barrier	ISCHEMIC BRAIN-DAMAGE; GROUP BOX-1 HMGB1; PROINFLAMMATORY CYTOKINE; NLRP3 INFLAMMASOME; NERVOUS-SYSTEM; DANGER SIGNALS; ALARMIN HMGB1; RECEPTOR 4; MOBILITY; INJURY	Background: Neuroinflammation triggered by infection or trauma is the cause of central nervous system dysfunction. High-mobility group box 1 protein (HMGB1), released from stressed and dying brain cells, is a potent neuroinflammatory mediator. The proinflammatory functions of HMGB1 are tightly regulated by post-translational redox modifications, and we here investigated detailed neuroinflammatory responses induced by the individual redox isoforms. Methods: Male Dark Agouti rats received a stereotactic injection of saline, lipopolysaccharide, disulfide HMGB1, or fully reduced HMGB1, and were accessed for blood-brain barrier modifications using magnetic resonance imaging (MRI) and inflammatory responses by immunohistochemistry. Results and Conclusions: Significant blood-brain barrier disruption appeared 24 h after injection of lipopolysaccharide, disulfide HMGB1, or fully reduced HMGB1 compared to controls, as assessed in post-gadolinium T1-weighted MRI images and confirmed by increased uptake of FITC-conjugated dextran. Immunohistochemistry revealed that both HMGB1 isoforms also induced a local production of IL-1 beta. Additionally, disulfide HMGB1 increased major histocompatibility complex class II expression and apoptosis. Together, the results demonstrate that extracellular, cerebral HMGB1 causes significant blood-brain barrier disruption in a redox-independent manner and activates several components of neuroinflammation. Blocking HMGB1 might potentially improve clinical outcome in conditions such as stroke and traumatic brain injury. (C) 2018 The Author(s) Published by S. Karger AG, Basel	[Aucott, Hannah; Salo, Henna; Harris, Helena Erlandsson] Karolinska Inst, Ctr Mol Med, Dept Med Solna, Rheumatol Unit, Stockholm, Sweden; [Lundberg, Johan; Damberg, Peter; Holmin, Staffan] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Lundberg, Johan; Holmin, Staffan] Karolinska Univ Hosp, Dept Neuroradiol, Stockholm, Sweden; [Klevenvall, Lena; Ottosson, Lars; Andersson, Ulf] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden		Aucott, H (corresponding author), Karolinska Inst Solna, Karolinska Hosp, Ctr Mol Med L8 04, Rheumatol Unit,Dept Med, SE-17176 Stockholm, Sweden.	hannah.aucott@ki.se	Andersson, Ulf/ABD-5162-2021	Andersson, Ulf/0000-0003-0316-3860; Holmin, Staffan/0000-0002-1628-1615	Soderberg Foundation; Swedish Heart and Lung AssociationSwedish Heart-Lung Foundation; Linne Center CERIC; Stockholm County Council (SLL)Stockholm County Council; Karolinska InstitutetKarolinska Institutet	The authors would like to thank the staff at the Department of Comparative Medicine, Karolinska Institutet, in particular Kicki Edwardsson, for technique assistance. This work was supported by grants from the Soderberg Foundation, the Swedish Heart and Lung Association, The Linne Center CERIC, Karolinska Institutet, and Stockholm County Council (SLL).	Agalave NM, 2014, PAIN, V155, P1802, DOI 10.1016/j.pain.2014.06.007; Agnello D, 2002, CYTOKINE, V18, P231, DOI 10.1006/cyto.2002.0890; Balosso S, 2014, ANTIOXID REDOX SIGN, V21, P1726, DOI 10.1089/ars.2013.5349; Boutin H, 2001, J NEUROSCI, V21, P5528, DOI 10.1523/JNEUROSCI.21-15-05528.2001; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; Frank MG, 2016, BRAIN BEHAV IMMUN, V55, P215, DOI 10.1016/j.bbi.2015.10.009; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Gelderblom M, 2015, AGEING RES REV, V24, P77, DOI 10.1016/j.arr.2015.07.004; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Hreggvidsdottir HS, 2009, J LEUKOCYTE BIOL, V86, P655, DOI 10.1189/jlb.0908548; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Lian YJ, 2017, BRAIN BEHAV IMMUN, V59, P322, DOI 10.1016/j.bbi.2016.09.017; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; O'Connor KA, 2003, CYTOKINE, V24, P254, DOI 10.1016/j.cyto.2003.08.001; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6; Sasaki T, 2016, EXP NEUROL, V275, P220, DOI 10.1016/j.expneurol.2015.11.003; Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739; Singh V, 2016, ANTIOXID REDOX SIGN, V24, P635, DOI 10.1089/ars.2015.6397; Tang YT, 2016, ANTIOXID REDOX SIGN, V24, P620, DOI 10.1089/ars.2015.6409; Terrando N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00441; Thundyil J, 2015, AGEING RES REV, V24, P17, DOI 10.1016/j.arr.2014.11.003; Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037; Venereau E, 2012, J EXP MED, V209, P1519, DOI 10.1084/jem.20120189; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Weber MD, 2015, J NEUROSCI, V35, P316, DOI 10.1523/JNEUROSCI.3561-14.2015; Yamasoba D, 2016, J PHARMACOL SCI, V130, P139, DOI 10.1016/j.jphs.2016.01.005; Yang H, 2012, MOL MED, V18, P250, DOI 10.2119/molmed.2011.00389; Yang HA, 2010, P NATL ACAD SCI USA, V107, P11942, DOI 10.1073/pnas.1003893107; Yang QW, 2011, J CEREBR BLOOD F MET, V31, P593, DOI 10.1038/jcbfm.2010.129; Zandarashvili L, 2013, J BIOL CHEM, V288, P11621, DOI 10.1074/jbc.M113.449942; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087915	40	29	29	5	17	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1662-811X	1662-8128		J INNATE IMMUN	J. Innate Immun.		2018	10	3					215	227		10.1159/000487056			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	GK2KR	WOS:000435959200007	29478057	gold, Green Published			2022-02-06	
J	Erdodi, LA; Pelletier, CL; Roth, RM				Erdodi, Laszlo A.; Pelletier, Chantalle L.; Roth, Robert M.			Elevations on select Conners' CPT-II scales indicate noncredible responding in adults with traumatic brain injury	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Conners' CPT-II; embedded validity indicators; performance validity testing; traumatic brain injury	RECOGNITION MEMORY TEST; PERFORMANCE TEST-II; CLOSED-HEAD-INJURY; OFFICIAL POSITION; SYMPTOM VALIDITY; BIAS; CUTOFFS; SCORES; TIME; RECOMMENDATIONS	Elevations on certain Conners' CPT-II scales are known to be associated with invalid responding. However, scales and cutoffs vary across studies. In addition, the methodology behind developing performance validity tests (PVTs) has been challenged for mistaking true impairment for noncredible presentation. Using ability-based tests as a PVT makes clinicians especially vulnerable to this criticism. The present study examined the ability of CPT-II to dissociate effort from impairment in 47 adults clinically referred for neuropsychological assessment. CPT-II scales previously identified as PVTs (Omissions, Commissions, Hit Reaction Time SE, Variability, and Perseverations) produced classification accuracies hovering around .50 sensitivity at .90 specificity. The subsample that failed these PVTs performed within normal range on other tests of working memory, processing speed, visual attention, and executive function. Results suggest that the select CPT-II based PVTs are sensitive to invalid responding, and are associated with depression and anxiety, but are unrelated to cognitive functioning.	[Erdodi, Laszlo A.] Univ Windsor, Neuropsychol Track, Dept Psychol, Windsor, ON, Canada; [Erdodi, Laszlo A.; Pelletier, Chantalle L.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA		Erdodi, LA (corresponding author), 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Conners, 2004, CONNERS CONTINUOUS P; Conners K.C., 2014, CONNERS CONTINUOUS P; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Erdodi LA, 2017, APPL NEUROPSYCH-CHIL, V6, P355, DOI 10.1080/21622965.2016.1198908; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2013, BEHAV SCI LAW, V31, P686, DOI 10.1002/bsl.2087; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOL WAIS 4; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439	38	29	29	0	3	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2018	25	1					19	28		10.1080/23279095.2016.1232262			10	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	FY7NF	WOS:000427048500004	27662418				2022-02-06	
J	Fernandes, FAO; Tchepel, D; de Sousa, RJA; Ptak, M				Fernandes, Fabio A. O.; Tchepel, Dmitri; Alves de Sousa, Ricardo J.; Ptak, Mariusz			Development and validation of a new finite element human head model: Yet another head model (YEAHM)	ENGINEERING COMPUTATIONS			English	Article						Finite element analysis; Biomechanics; Brain modelling; Finite element head model; Head trauma	TRAUMATIC BRAIN-INJURY; MECHANICAL-PROPERTIES; IN-VIVO; TISSUE; STRAIN; DEFORMATION; COMPRESSION; PREDICTORS; BEHAVIOR; DESIGN	Purpose Currently, there are some finite element head models developed by research groups all around the world. Nevertheless, the majority are not geometrically accurate. One of the problems is the brain geometry, which usually resembles a sphere. This may raise problems when reconstructing any event that involves brain kinematics, such as accidents, affecting the correct evaluation of resulting injuries. Thus, the purpose of this study is to develop a new finite element head model more accurate than the existing ones. Design/methodology/approach In this work, a new and geometrically detailed finite element brain model is proposed. Special attention was given to sulci and gyri modelling, making this model more geometrically accurate than currently available ones. In addition, these brain features are important to predict specific injuries such as brain contusions, which usually involve the crowns of gyri. Findings The model was validated against experimental data from impact tests on cadavers, comparing the intracranial pressure at frontal, parietal, occipital and posterior fossa regions. Originality/value As this model is validated, it can be now used in accident reconstruction and injury evaluation and even as a design tool for protective head gear.	[Fernandes, Fabio A. O.; Tchepel, Dmitri; Alves de Sousa, Ricardo J.] Univ Aveiro, Dept Mech Engn, Ctr Mech Technol & Automat, TEMA, Aveiro, Portugal; [Ptak, Mariusz] Wroclaw Univ Technol, Dept Mech Engn, Wroclaw, Poland		Fernandes, FAO (corresponding author), Univ Aveiro, Dept Mech Engn, Ctr Mech Technol & Automat, TEMA, Aveiro, Portugal.	fabiofernandes@ua.pt; dmitritchepel@ua.pt; rsousa@ua.pt; mariusz.ptak@pwr.edu.pl	de Sousa, Ricardo Alves/E-4405-2010; Ptak, Mariusz/B-1493-2013; Fernandes, Fabio A.O./H-2680-2012	de Sousa, Ricardo Alves/0000-0002-5848-6424; Ptak, Mariusz/0000-0001-8081-8336; Fernandes, Fabio A.O./0000-0001-9751-8807	Portuguese Foundation for Science and Technology (FCT)Portuguese Foundation for Science and Technology [SFRH/BD/91292/2012]	The authors are grateful to the Portuguese Foundation for Science and Technology (FCT), which financially supported this work, through the scholarship SFRH/BD/91292/2012. The authors also acknowledge Dr Alfredo Calheiros from the Hospital Geral de Santo Antonio, Porto, for providing the medical images and Professors Paula Martins, Silvia Francesco (University of Aveiro) and Teresa Magalhaes (University of Porto) for the fruitful discussions.	ABAQUS, 2010, 6 10 DOC; [Anonymous], 2003, OS US MAN; [Anonymous], 2012, MESHM MAN; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Bilston LE, 2011, BIOL MED PHYS BIOMED, P69, DOI 10.1007/978-1-4419-9997-9_4; Brands DWA, 2004, J BIOMECH, V37, P127, DOI 10.1016/S0021-9290(03)00243-4; Cheng S, 2007, J BIOMECH, V40, P117, DOI 10.1016/j.jbiomech.2005.11.004; Chinn B., 2009, TECHNICAL RESPONSE U; Cignoni P., 2008, ERCIM NEWS, V73, P45, DOI DOI 10.2312/L0CALCHAPTEREVENTS/ITALCHAP/ITALIANCHAPC0NF2008/129-136; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Cotton RT, 2015, COMPUTER METHODS BIO, V19, P1; Deck C., 2009, P 7 EUR LS DYNA C; deSouzaNeto EA, 1996, INT J SOLIDS STRUCT, V33, P3277, DOI 10.1016/0020-7683(95)00259-6; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Fernandes FAO, 2017, PROCEDIA MANUF, V13, P227, DOI 10.1016/j.promfg.2017.09.055; Fernandes FAO, 2017, PROCEDIA MANUF, V13, P219, DOI 10.1016/j.promfg.2017.09.052; Fernandes FAO, 2015, MATER DESIGN, V82, P335, DOI 10.1016/j.matdes.2015.06.004; Fernandes FAO, 2013, ACCIDENT ANAL PREV, V56, P1, DOI 10.1016/j.aap.2013.03.011; Fernandes F. A. O., 2013, P IRCOBI C GOTH, P431; Fernandes FAO, 2015, P I MECH ENG H, V229, P592, DOI 10.1177/0954411915592906; Fernandes FAO, 2013, STRUCT ENG MECH, V48, P661, DOI 10.12989/sem.2013.48.5.661; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Gilchrist MD, 2003, KEY ENG MATER, V245-2, P417, DOI 10.4028/www.scientific.net/KEM.245-246.417; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P112; HARDY CH, 1973, J APPL MECH-T ASME, V40, P838, DOI 10.1115/1.3423172; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hosey R. R., 1982, FINITE ELEMENTS BIOM, P379; Joldes GR, 2009, COMMUN NUMER METH EN, V25, P827, DOI 10.1002/cnm.1185; KHALIL TB, 1977, J BIOMECH, V10, P119, DOI 10.1016/0021-9290(77)90075-6; KHALIL TB, 1982, P 26 STAPP CAR CRASH, P87; Kleiven S., 2002, THESIS; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Lin DC, 2009, BIOMECH MODEL MECHAN, V8, P345, DOI 10.1007/s10237-008-0139-9; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Meaney D.F., 1990, INT C BIOM IMP; Miller K, 2011, BIOL MED PHYS BIOMED, P111, DOI 10.1007/978-1-4419-9997-9_6; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; Miller R.T., 1998, STAPP CAR CRASH J, P155; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Nahum A., 1977, 21 STAPP CAR CRASH C, DOI DOI 10.4271/770922; Nahum A.M., 1976, 20 STAPP CAR CRASH C, P2638; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ogden R.W., 1997, NONLINEAR ELASTIC DE; OGDEN RW, 1972, PROC R SOC LON SER-A, V326, P565, DOI 10.1098/rspa.1972.0026; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Ptak M, 2017, INT J IMPACT ENG, V106, P238, DOI 10.1016/j.ijimpeng.2017.04.014; Ptak M., 2017, LECT NOTES MECH ENG; Rashid B., 2012, P ASME 2012 INT MECH, P9; Rashid B, 2012, J MECH BEHAV BIOMED, V14, P113, DOI 10.1016/j.jmbbm.2012.04.005; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Ruan J, 2001, Stapp Car Crash J, V45, P395; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Sauren A. A. H. J., 1993, P INT IRCOBI C BIOM, P241; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tamura A, 2007, J BIOMECH SCI ENG, V2, P115, DOI [10.1299/jbse.2.115, DOI 10.1299/JBSE.2.115]; Tchepel D., 2016, REFERENCE MODULE MAT; Tchepel D., 2016, WHAT ARE FORENSIC SC, P3542; Tchepel D, 2016, BRAIN INJURY, V30, P516; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Tse K.M., 2014, AM J ENG TECHNOL SOC, V1, P28; van Dommelen JAW, 2011, STUD MECHANOBIOL TIS, V3, P41, DOI 10.1007/8415_2010_16; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Wismans, 1997, P 41 STAPP CAR CRASH, V41, P315, DOI DOI 10.4271/973338; Yang J, 2011, COMPUTATIONAL BIOMEC; Yang KH, 2011, BIOL MED PHYS BIOMED, P91, DOI 10.1007/978-1-4419-9997-9_5; Zhang JY, 2011, J BIOMECH, V44, P391, DOI 10.1016/j.jbiomech.2010.10.024; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; 2011, BIOMECHANICS BRAIN, P1	81	29	29	2	9	EMERALD GROUP PUBLISHING LTD	BINGLEY	HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND	0264-4401	1758-7077		ENG COMPUTATION	Eng. Comput.		2018	35	1					477	496		10.1108/EC-09-2016-0321			20	Computer Science, Interdisciplinary Applications; Engineering, Multidisciplinary; Mathematics, Interdisciplinary Applications; Mechanics	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Mathematics; Mechanics	GA2QM	WOS:000428168600025					2022-02-06	
J	Holzmacher, JL; Reynolds, C; Patel, M; Maluso, P; Holland, S; Gamsky, N; Moore, H; Acquista, E; Carrick, M; Amdur, R; Hancock, H; Metzler, M; Dunn, J; Sarani, B				Holzmacher, Jeremy L.; Reynolds, Cassandra; Patel, Mayur; Maluso, Patrick; Holland, Seth; Gamsky, Nathaniel; Moore, Henry; Acquista, Elizabeth; Carrick, Matthew; Amdur, Richard; Hancock, Heather; Metzler, Michael; Dunn, Julie; Sarani, Babak			Platelet transfusion does not improve outcomes in patients with brain injury on antiplatelet therapy	BRAIN INJURY			English	Article						Traumatic brain injury; brain injury; closed head injury	TRAUMATIC INTRACRANIAL HEMORRHAGE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; EMERGENCY-DEPARTMENT; PREINJURY WARFARIN; CLOPIDOGREL USE; AGENTS; MORTALITY; IMPACT; RISK	Introduction: Platelet dysfunction following traumatic brain injury (TBI) is associated with worse outcomes. The efficacy of platelet transfusion to reverse antiplatelet medication (APM) remains unknown. Thrombelastography platelet mapping (TEG-PM) assesses platelet function. We hypothesize that platelet transfusion can reverse the effects of APM but does not improve outcomes following TBI.Methods: An observational study at six US trauma centres was performed. Adult patients on APM with CT evident TBI after blunt injury were enrolled. Demographics, brain CT and TEG-PM results before/after platelet transfusion, length of stay (LOS), and injury severity score (ISS) were abstracted.Results: Sixty six patients were enrolled (89% aspirin, 50% clopidogrel, 23% dual APM) with 23 patients undergoing platelet transfusion. Transfused patients had significantly higher ISS and admission CT scores. Platelet transfusion significantly reduced platelet inhibition due to aspirin (76.030.2% to 52.7 +/- 31.5%, p<0.01), but had a non-significant impact on clopidogrel-associated inhibition (p=0.07). Platelet transfusion was associated with longer length of stay (7.8vs. 3.5days, p<0.01), but there were no differences in mortality.Conclusion: Platelet transfusion significantly decreases platelet inhibition due to aspirin but is not associated with change in outcomes in patients on APM following TBI.	[Holzmacher, Jeremy L.; Maluso, Patrick; Gamsky, Nathaniel; Amdur, Richard; Sarani, Babak] George Washington Univ, Dept Surg, Ctr Trauma & Crit Care, Washington, DC USA; [Reynolds, Cassandra] East Carolina Univ, Dept Surg, Brody Sch Med, Greenville, NC USA; [Patel, Mayur] Vanderbilt Univ, Dept Surg,Surg Serv,Gen Surg Sect, Div Trauma Emergency Gen Surg & Surg Crit Care,Me, Sect Surg Sci,Vanderbilt Brain Inst,Vanderbilt Ct, Nashville, TN 37240 USA; [Patel, Mayur] Vanderbilt Univ, Med Ctr,Dept Neurosurg,Gen Surg Sect, Div Trauma Emergency Gen Surg & Surg Crit Care,Su, Sect Surg Sci,Vanderbilt Brain Inst,Vanderbilt Ct, Nashville, TN 37240 USA; [Patel, Mayur] Vanderbilt Univ, Med Ctr,Dept Hearing & Speech Sci,Gen Surg Sect, Div Trauma Emergency Gen Surg & Surg Crit Care,Su, Sect Surg Sci,Vanderbilt Brain Inst,Vanderbilt Ct, Nashville, TN 37240 USA; [Patel, Mayur] US Dept Vet Affairs, Med Ctr, Tennessee Valley Healthcare Syst, Nashville, TN USA; [Holland, Seth; Hancock, Heather] San Antonio Mil Med Ctr, Dept Surg, Ft Sam Houston, TX USA; [Moore, Henry] Carle Fdn Hosp, Dept Surg, Urbana, IL USA; [Acquista, Elizabeth] Univ North Carolina Chapel Hill, Dept Surg, Chapel Hill, NC USA; [Carrick, Matthew] Med Ctr Plano, Dept Surg, Plano, TX USA; [Metzler, Michael; Dunn, Julie] Med Ctr Rockies, Dept Surg, Loveland, CO USA		Sarani, B (corresponding author), George Washington Univ, Dept Surg, 2150 Penn Ave NW,Suite 6B, Washington, DC 20037 USA.	bsarani@mfa.gwu.edu	Amdur, Richard L/AAE-5345-2019		NCATSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445]; Vanderbilt Faculty Research Scholars Program; National Institutes of Health NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111]; NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002243, UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484] Funding Source: NIH RePORTER	Funding was provided by NCATS UL1TR000445 for REDCap (all authors), Vanderbilt Faculty Research Scholars Program (mbp); National Institutes of Health NHLBI R01HL111111 (mbp) and NIGMS R01GM120484(mbp).	Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Bonville DJ, 2011, SURGERY, V150, P861, DOI 10.1016/j.surg.2011.07.070; Briggs A, 2015, J SURG RES, V193, P802, DOI 10.1016/j.jss.2014.08.016; Downey DM, 2009, AM SURGEON, V75, P1100; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Ives C, 2012, J AM COLL SURGEONS, V215, P496, DOI 10.1016/j.jamcollsurg.2012.06.005; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Major J, 2009, EMERG MED J, V26, P871, DOI 10.1136/emj.2008.068643; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Narum S, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0094-1; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Peck KA, 2011, J TRAUMA, V71, P1600, DOI 10.1097/TA.0b013e31823b9ce1; Sirajuddin S, 2016, J TRAUMA ACUTE CARE, V81, P328, DOI 10.1097/TA.0000000000001057; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e	24	29	29	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2018	32	3					325	330		10.1080/02699052.2018.1425804			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FU3PV	WOS:000423764700006	29341793	Green Accepted			2022-02-06	
J	Kumar, RG; Juengst, SB; Wang, ZS; Dams-O'Connor, K; Dikmen, SS; O'Neil-Pirozzi, TM; Dahdah, MN; Hammond, FM; Felix, ER; Arenth, PM; Wagner, AK				Kumar, Raj G.; Juengst, Shannon B.; Wang, Zhensheng; Dams-O'Connor, Kristen; Dikmen, Sureyya S.; O'Neil-Pirozzi, Therese M.; Dahdah, Marie N.; Hammond, Flora M.; Felix, Elizabeth R.; Arenth, Patricia M.; Wagner, Amy K.			Epidemiology of Comorbid Conditions Among Adults 50 Years and Older With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aging; brain injuries; comorbidity; epidemiology	SYSTEMS NATIONAL DATABASE; SUBSTANCE USE DISORDERS; MODEL SYSTEMS; INPATIENT REHABILITATION; UNITED-STATES; OUTCOMES; HEALTH; CARE; AGE; REPRESENTATIVENESS	Objectives: Aging individuals with traumatic brain injury (TBI) experience multiple comorbidities that can affect recovery from injury. The objective of this study was to describe the most commonly co-occurring comorbid conditions among adults 50 years and older with TBI. Setting: Level I Trauma centers. Participants: Adults 50 years and older with moderate/severe TBI enrolled in the TBI-Model Systems (TBI-MS) from 2007 to 2014 (n = 2134). Design: A TBI-MS prospective cohort study. Main Measures: International Classification of Disease-9th Revision codes collapsed into 45 comorbidity categories. Comorbidity prevalence estimates and trend analyses were conducted by age strata (50-54, 55-64, 65-74, 75-84, = 85 years). A dimension reduction method, Treelet Transform, classified clusters of comorbidities that tended to co-occur. Results: The 3 most commonly occurring comorbid categories were hypertensive disease (52.6/100 persons), other diseases of the respiratory system (51.8/100 persons), and fluid component imbalances (43.7/100 persons). Treelet Transform classified 3 clusters of comorbid codes, broadly classified as (1) acute medical diseases/infections, (2) chronic conditions, and (3) substance abuse disorders. Conclusion: This study provides valuable insight into comorbid conditions that co-occur among adults 50 years and older with TBI and provides a foundation for future studies to explore how specific comorbidities affect TBI recovery.	[Kumar, Raj G.; Juengst, Shannon B.; Wang, Zhensheng; Arenth, Patricia M.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA; [Kumar, Raj G.; Wang, Zhensheng] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Commun Sci & Disorders, Boston, MA 02115 USA; [O'Neil-Pirozzi, Therese M.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [Dahdah, Marie N.] Baylor Scott & White Hlth Med Ctr, Plano, TX USA; [Dahdah, Marie N.] Baylor Inst Rehabil, Dallas, TX USA; [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA; [Felix, Elizabeth R.] Univ Miami, Dept Phys Med & Rehabil, Miami, FL USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Juengst, Shannon B/AAC-5891-2019; Felix, Elizabeth/AAD-6356-2021	Juengst, Shannon B/0000-0003-4709-545X; Felix, Elizabeth/0000-0002-6239-715X	NIDILRRUnited States Department of Health & Human Services [90DP0041, 90DP0045, 90DP0046, 90DP0038-03-00]; NIH/NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1 K01 HD07465101A1]	The authors acknowledge NIDILRR Grant 90DP0041 (R.G.K., A.K.W., S.B.J., P.M.A., Z.W.) (University of Pittsburgh); NIDILRR Grant 90DP0045 (M.D.); NIDILRR Grant 90DP0046 (E.R.F.) (University of Miami); NIDILRR 90DP0038-03-00, NIH/NICHD 1 K01 HD07465101A1 (K.D-O) (Icahn School of Medicine at Mount Sinai). Kristen Dams-O'Connor, PhD, serves as a consultant to the Brain Injury Association of America and Craig Hospital and provides clinical expert testimony in forensic cases. Marie Dahdah, PhD, receives some project from the Ginger Murchison Foundation.	Beard JR, 2015, LANCET, V385, P658, DOI 10.1016/S0140-6736(14)61461-6; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; Cappellini MD, 2015, SEMIN HEMATOL, V52, P261, DOI 10.1053/j.seminhematol.2015.07.006; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; CDC, PERC DISTR TBI REL H; Center for Disease Control and Prevention, 2013, STAT AG HLTH AM 2013; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Corrigan JD, 2012, J HEAD TRAUMA REHAB, V27, P391, DOI 10.1097/HTR.0b013e3182238cdd; Crownover J, 2012, CURR GERIATR REP, V1, P149, DOI 10.1007/s13670-012-0021-6; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P122, DOI 10.1097/HTR.0000000000000012; Cuthbert JP, 2012, J HEAD TRAUMA REHAB, V27, pE15, DOI 10.1097/HTR.0b013e31826da983; Dams-O'Connor K, 2016, J AM GERIATR SOC, V64, P844, DOI 10.1111/jgs.14014; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2001, DOI 10.1089/neu.2013.3047; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Failla MD, 2014, NEUROREHAB NEURAL RE; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Fulop T, 2016, REV INVEST CLIN, V68, P84; Golub A, 2013, SUBST USE MISUSE, V48, P811, DOI 10.3109/10826084.2013.796988; Gorst-Rasmussen A, 2011, TT TREELET TRANSFORM; Gorst-Rasmussen A, 2011, AM J EPIDEMIOL, V173, P1097, DOI 10.1093/aje/kwr060; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Hamirudin AH, 2016, ARCH GERONTOL GERIAT, V62, P9, DOI 10.1016/j.archger.2015.09.007; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2015, J NEUROTRAUM, V32, P1893, DOI 10.1089/neu.2014.3353; Hsiao KY, 2015, INJURY, V46, P859, DOI 10.1016/j.injury.2014.11.025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Karpur A, 2013, GUIDE TRAUMATIC BRAI; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Kesinger MR, 2016, ARCH PHYS MED REHABI; Kumar RG, 2015, BRAIN BEHAV IMMUN; Lecours A, 2012, J HEAD TRAUMA REHAB, V27, P379, DOI 10.1097/HTR.0b013e31823b2385; Nacionales DC, 2015, J IMMUNOL, V195, P2396, DOI 10.4049/jimmunol.1500984; Olson-Madden JH, 2012, J HEAD TRAUMA REHAB, V27, P370, DOI 10.1097/HTR.0b013e318268d496; Ortman JM, 2014, AGING NATION OLDER P, V1140, P1; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; SAVITEER SM, 1988, AM J MED, V84, P661, DOI 10.1016/0002-9343(88)90101-5; Schutte C, 2010, INT J NEUROSCI, V120, P551, DOI 10.3109/00207454.2010.494789; Smith SM, 2012, BMJ, V345; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2012, J NEUROTRAUM, V29, P1864, DOI 10.1089/neu.2011.2284; Thompson HJ, 2012, RES GERONTOL NURS, V5, P17, DOI 10.3928/19404921-20111206-02; Tuglus C, 2008, ANN APPL STAT, V2, P489, DOI 10.1214/08-AOAS137F; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; [No title captured]	55	29	30	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2018	33	1					15	24		10.1097/HTR.0000000000000273			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	GB0QS	WOS:000428752300010	28060201				2022-02-06	
J	Sufrinko, A; McAllister-Deitrick, J; Elbin, RJ; Collins, MW; Kontos, AP				Sufrinko, Alicia; McAllister-Deitrick, Jamie; Elbin, R. J.; Collins, Michael W.; Kontos, Anthony P.			Family History of Migraine Associated With Posttraumatic Migraine Symptoms Following Sport-Related Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion recovery; migraine history; neurocognitive testing; ocular motor; sport-related concussion; vestibular	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; RISK; EPIDEMIOLOGY; PREVALENCE; HEADACHE; CHILDREN; RECOVERY; ADOLESCENTS; SPECIFICITY	Objective: To determine whether family history of migraine increased the likelihood of posttraumatic migraine (PTM) symptom presentation in adolescents following concussion, and examine the influence of family history of migraine and PTM on postinjury outcomes. Setting: Outpatient concussion clinic. Participants: A total of 153 patients with concussion (103 males and 50 females) aged 15.72 +/- 1.48 years (range 12-18 years). Design: Cross-sectional, observational study of patients presenting for initial evaluation 4.72 +/- 3.05 days (range 1-14) postinjury. Main Measures: Computerized neurocognitive testing, symptom report, and vestibular/oculomotor screening. Results: Patients with a family history of migraine were 2.6 times (odds ratio = 2.60, confidence interval = 1.35-5.02, P = .003) more likely to present with PTM compared with patients without a family history. Results of multivariate analyses of covariance, controlling for concussion history, revealed significant main effects for PTM on (1) Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT)/Post-Concussion Symptom Scale (PCSS) (F = 15.43, P < .001) and (2) Vestibular/OcularMotor Screening (VOMS) (F = 8.52, P < .001). There was no main effect for family history of migraine on ImPACT/PCSS (P = .22) and VOMS (P = .83) or interaction between family history of migraine and PTM on ImPACT/PCSS (P = .84) and VOMS (P = .52). Conclusion: Family history of migraine is associated with PTM symptoms following sport-related concussion, suggesting a genetic predisposition for migraine may serve as a catalyst or trigger for onset of PTM. However, only presence of PTM, rather than family history ofmigraine, was related to worse neurocognitive and vestibular/oculomotor outcomes.	[Sufrinko, Alicia; McAllister-Deitrick, Jamie; Collins, Michael W.; Kontos, Anthony P.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Off Sport Concuss Res, Fayetteville, AR 72701 USA		Sufrinko, A (corresponding author), Univ Pittsburgh, Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15221 USA.	sufrinkoam@upmc.edu			National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	This research was supported in part by a grant to the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) to Dr Kontos.	Abu-Arafeh I, 2010, DEV MED CHILD NEUROL, V52, P1088, DOI 10.1111/j.1469-8749.2010.03793.x; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Bisdorff A, 2014, CURR OPIN NEUROL, V27, P105, DOI 10.1097/WCO.0000000000000061; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Covassin T., 2014, ATHL TRAIN SPORT HLT, DOI [10.3928/19425864-20140916-01, DOI 10.3928/19425864-20140916-01]; Dieterich M, 1999, J NEUROL, V246, P883, DOI 10.1007/s004150050478; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Elbin R, 2015, PERSPECT NEUROPHYSIO, V25, P4, DOI DOI 10.1044/NNSLD25.1.4; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Gasparini CF, 2013, CURR GENOMICS, V14, P300, DOI 10.2174/13892029113149990007; Genizi J, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0625-x; Genizi J, 2013, J HEADACHE PAIN, V14, P1, DOI 10.1186/1129-2377-14-54; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Heyer GL, 2016, CEPHALALGIA, V36, P309, DOI 10.1177/0333102415590240; Immediate Post-Concussion Assessment Testing (ImPACT&REG;) Test, 2011, IMPACT APPL TECHN MA; Kontos AP, 2016, BRAIN IMAGING BEHAV, V10, P594, DOI 10.1007/s11682-015-9412-6; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lempert T, 2012, J VESTIBUL RES-EQUIL, V22, P167, DOI 10.3233/VES-2012-0453; Lipton RB, 2005, AM J MED, V118, p3S, DOI 10.1016/j.amjmed.2005.01.014; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lu SR, 2000, CEPHALALGIA, V20, P479, DOI 10.1046/j.1468-2982.2000.00076.x; McCrory P, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.014860; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Merikangas KR, 2013, HEADACHE, V53, P230, DOI 10.1111/head.12038; Mihalik JP, 2013, AM J SPORT MED, V41, P1490, DOI 10.1177/0363546513487982; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Pastor Patricia N, 2008, Vital Health Stat 10, P1; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; RUSSELL MB, 1995, BRIT MED J, V311, P541, DOI 10.1136/bmj.311.7004.541; Sandel N, 2014, ARCH CLIN NEUROPSYCH, V29, P584; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Singer AB, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0533-5; Singman Eric L, 2014, Am Orthopt J, V64, P112, DOI 10.3368/aoj.64.1.112; Stewart WF, 2008, CEPHALALGIA, V28, P1170, DOI 10.1111/j.1468-2982.2008.01666.x; Stewart WF, 1997, ANN NEUROL, V41, P166, DOI 10.1002/ana.410410207; Wober-Bingol C, 2013, CURR PAIN HEADACHE R, V17, P341, DOI 10.1007/s11916-013-0341-z	48	29	30	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2018	33	1					7	14		10.1097/HTR.0000000000000315			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	GB0QS	WOS:000428752300009	28520665	Green Accepted			2022-02-06	
J	Zhang, DD; Xiao, YN; Lv, PY; Teng, ZJ; Dong, YH; Qi, QQ; Liu, ZJ				Zhang, Dandan; Xiao, Yining; Lv, Peiyuan; Teng, Zhenjie; Dong, Yanhong; Qi, Qianqian; Liu, Zhijuan			Edaravone attenuates oxidative stress induced by chronic cerebral hypoperfusion injury: role of ERK/Nrf2/HO-1 signaling pathway	NEUROLOGICAL RESEARCH			English	Article						Chronic cerebral hypoperfusion; vascular dementia; edaravone; oxidative stress; cognitive damage; nuclear factor erythroid 2-related factor 2	VASCULAR COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; INTRACEREBROVENTRICULAR STREPTOZOTOCIN; RAT HIPPOCAMPUS; MICE; EXPRESSION; MODEL; NRF2; NEUROPROTECTION; DEMENTIA	Objectives: The potential protective effects and mechanisms of edaravone have not been well elucidated in vascular dementia (VaD) induced by chronic cerebral hypoperfusion (CCH). The aim of this study was to investigate whether edaravone could improve cognitive damage in rats induced by CCH, and whether the effects of edaravone were associated with ERK/Nrf2/HO-1 signaling pathway. Methods: CCH was induced by bilateral common carotid arteries occlusion (BCCAO). Sprague-Dawley (SD) rats were randomly divided into four groups: sham (sham-operated) group, vehicle (BCCAO + normal saline) group, edaravone3.0 group and edaravone6.0 group. The edaravone3.0 and edaravone6.0 group rats were provided 3.0 mg/kg and 6.0 mg/kg of edaravone, respectively, intraperitoneal (i.p.) injection twice daily following the first day after BCCAO. In this experiment, the spatial learning and memory were assessed using the Morris water maze. The malondialdehyde (MDA) contents and superoxide dismutase (SOD) activities in the hippocampus were measured biochemically. And, the levels of total ERK1/2 (t-ERK1/2), Phospho-ERK1/2 (p-ERK1/2), total Nrf2 (t-Nrf2), nuclear Nrf2 (n-Nrf2), and HO-1 were assessed by western blot. Results: The results showed that the treatment with edaravone significantly improved CCH-induced cognitive damage, and boosted endogenous antioxidants SOD activity and HO-1 level, decreased MDA contents in the hippocampus by activating Nrf2 signaling pathway which was related to ERK1/2. We also found that the neuronal morphology of the hippocampal CA1 area significantly improved and the number of Nrf2 positive cells markedly increased in the edaravone treatment groups. Conclusion: Our results demonstrated a neuroprotective effect of edaravone on hippocampus against oxidative stress and cognitive deficit induced by CCH. The mechanism may be related to the enhancement of antioxidant defense system by activating ERK/Nrf2/HO-1 signaling pathway.	[Zhang, Dandan; Lv, Peiyuan; Teng, Zhenjie] Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China; [Zhang, Dandan; Xiao, Yining; Lv, Peiyuan; Teng, Zhenjie; Dong, Yanhong; Qi, Qianqian; Liu, Zhijuan] Hebei Gen Hosp, Dept Neurol, Shijiazhuang, Hebei, Peoples R China		Lv, PY (corresponding author), Hebei Med Univ, Shijiazhuang, Hebei, Peoples R China.; Lv, PY (corresponding author), Hebei Gen Hosp, Dept Neurol, Shijiazhuang, Hebei, Peoples R China.	peiyuanlu@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81241037]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [H2013307046]; Provincial Major Medical Scientific Research Projects [zd2013005]	This work was financially supported by the National Natural Science Foundation of China, [grant number 81241037], Natural Science Foundation of China, [grant number H2013307046] and Provincial Major Medical Scientific Research Projects, [grant number zd2013005].	Bhardwaj M, 2016, EUR J PHARMACOL, V772, P43, DOI 10.1016/j.ejphar.2015.12.037; Bordeleau M, 2016, ONCOTARGET, V7, P11864, DOI 10.18632/oncotarget.7689; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Czerska M, 2015, MED PR, V66, P393, DOI 10.13075/mp.5893.00137; Du SQ, 2017, MOL NEUROBIOL, V54, P3670, DOI 10.1007/s12035-016-9915-1; Fan MY, 2015, BEHAV BRAIN RES, V291, P399, DOI 10.1016/j.bbr.2015.05.047; Godman CA, 2010, CELL STRESS CHAPERON, V15, P431, DOI 10.1007/s12192-009-0159-0; Huang TT, 2012, SEMIN CELL DEV BIOL, V23, P738, DOI 10.1016/j.semcdb.2012.04.003; Ihara M, 2014, METHODS MOL BIOL, V1135, P95, DOI 10.1007/978-1-4939-0320-7_8; Jangra A, 2016, EUR J PHARMACOL, V791, P51, DOI 10.1016/j.ejphar.2016.08.003; Jiao L, 2011, NEUROSCIENCE, V182, P177, DOI 10.1016/j.neuroscience.2011.01.017; Jing Z, 2015, J CEREBR BLOOD F MET, V35, P1249, DOI 10.1038/jcbfm.2015.55; Jiwa NS, 2010, J NEUROCHEM, V115, P814, DOI 10.1111/j.1471-4159.2010.06958.x; Kaur C, 2008, CURR MED CHEM, V15, P3068, DOI 10.2174/092986708786848640; Kikuchi K, 2009, BIOCHEM BIOPH RES CO, V390, P1121, DOI 10.1016/j.bbrc.2009.09.015; Kovac S, 2015, BBA-GEN SUBJECTS, V1850, P794, DOI 10.1016/j.bbagen.2014.11.021; Lapchak PA, 2010, EXPERT OPIN PHARMACO, V11, P1753, DOI 10.1517/14656566.2010.493558; Lee BJ, 2010, BRAIN RES, V1307, P22, DOI 10.1016/j.brainres.2009.10.026; Lee KM, 2013, BMC COMPLEM ALTERN M, V13, P246; Li WJ, 2013, NEUROBIOL DIS, V59, P18, DOI 10.1016/j.nbd.2013.06.014; Liu H, 2012, INT J NEUROSCI, V122, P494, DOI 10.3109/00207454.2012.686543; Liu TH, 2016, FOOD FUNCT, V7, P3444, DOI 10.1039/c6fo00223d; Lu XY, 2015, CELL MOL NEUROBIOL, V35, P713, DOI 10.1007/s10571-015-0167-9; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Nie CJ, 2016, NEUROSCI LETT, V615, P9, DOI 10.1016/j.neulet.2015.11.019; Ozacmak VH, 2009, J PINEAL RES, V47, P156, DOI 10.1111/j.1600-079X.2009.00695.x; Perez-Gonzalez A, 2012, J PHYS CHEM B, V116, P1180, DOI 10.1021/jp209930y; Rong LX, 2015, BEHAV BRAIN FUNCT, V11, DOI 10.1186/s12993-014-0050-8; Saxena AK, 2015, APPL TRANSL GENOM, V5, P30, DOI 10.1016/j.atg.2015.05.004; Ueno Y, 2009, NEUROSCIENCE, V162, P317, DOI 10.1016/j.neuroscience.2009.04.065; Wang C, 2016, CLIN NEUROPHYSIOL, V127, P324, DOI 10.1016/j.clinph.2015.04.063; Wang DY, 2015, J ALZHEIMERS DIS, V43, P519, DOI 10.3233/JAD-140567; Wang GB, 2013, NEUROSCI LETT, V543, P72, DOI 10.1016/j.neulet.2013.02.067; Wang PQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153708; Wang RM, 2013, HIPPOCAMPUS, V23, P634, DOI 10.1002/hipo.22126; Watanabe T, 2008, CARDIOVASC THER, V26, P101, DOI 10.1111/j.1527-3466.2008.00041.x; Yang Y, 2014, INT J NEUROSCI, V124, P577, DOI 10.3109/00207454.2013.863196; Yoshida H, 2011, NEUROSCI RES, V69, P291, DOI 10.1016/j.neures.2010.12.016; Zhou SS, 2013, NEUROTOXICOLOGY, V38, P136, DOI 10.1016/j.neuro.2013.07.007	41	29	33	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.		2018	40	1					1	10		10.1080/01616412.2017.1376457			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GA2CC	WOS:000428123300001	29125058				2022-02-06	
J	Berkner, J; Meehan, WP; Master, CL; Howell, DR				Berkner, Justin; Meehan, William P., III; Master, Christina L.; Howell, David R.			Gait and Quiet-Stance Performance Among Adolescents After Concussion-Symptom Resolution	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; dual-task gait; symptom recovery	TRAUMATIC BRAIN-INJURY; DUAL-TASK GAIT; EXTREMITY MUSCULOSKELETAL INJURY; SPORTS-RELATED CONCUSSION; ERROR SCORING SYSTEM; NEUROCOGNITIVE PERFORMANCE; POSTURAL STABILITY; BALANCE CONTROL; COGNITIVE TASK; YOUNG-ADULTS	Context: Concussions affect a large number of US athletes each year. Returning an athlete to activity once self-reported symptoms have resolved can be problematic if unrecognized neurocognitive and balance deficits persist. Pairing cognitive and motor tasks or cognitive and quiet-stance tasks may allow clinicians to detect and monitor these changes postconcussion. Objective: To prospectively examine adolescent athletes' gait and quiet-stance performance while concurrently completing a cognitive task acutely after concussion and after symptom resolution. Design: Case-control study. Setting: Sport concussion clinic. Patients or Other Participants: Thirty-seven athletes (age = 16.2 +/- 3.1 years; 54% female) were diagnosed with a concussion, and their performance was compared with that of a group of 44 uninjured control participants (age = 15.0 +/- 2.0 years; 57% female). Intervention: Participants diagnosed with a concussion completed a symptom inventory and single-and dual-task gait and quiet-stance evaluations within 21 days of injury and then again after symptom resolution. Gait and postural-control measurements were quantified using an inertial sensor system and analyzed using multivariate analyses of covariance. Main Outcome Measure(s): Post-Concussion Symptom Scale, single-task and dual-task gait measures, quiet-stance measures, and cognitive task performance. Results: At the initial postinjury examination, single-task gait stride length (1.16 +/- 0.14 versus 1.25 +/- 0.13 m, P = .003) and dual-task gait stride length (1.02 +/- 0.13 m versus 1.10 +/- 0.13 m, P = .011) for the concussion group compared with the control group, respectively, were shorter. After symptom resolution, no single-task gait differences were found, but the concussion group demonstrated slower gait velocity (0.78 +/- 0.15 m/s versus 0.92 +/- 0.14 m/ s, P = .005), lower cadence (92.5 +/- 12.2 steps/min versus 99.3 +/- 7.8 steps/min, P= .001), and a shorter stride length (0.99 +/- 0.15 m versus 1.10 +/- 0.13 m, P = .003) during dual-task gait than the control group. No between-groups differences were detected during quiet stance at either time point. Conclusions: Acutely after concussion, single-task and dual-task stride-length alterations were present among youth athletes compared with a control group. Although single-task gait alterations were not detected after symptom resolution, dual-task gait differences persisted, suggesting that dual-task gait alterations may persist longer after concussion than single-task gait or objective quiet-stance alterations. Dual-task gait assessments may, therefore, be a useful component in monitoring concussion recovery after symptom resolution.	[Berkner, Justin] Univ New England, Biddeford, ME USA; [Meehan, William P., III; Howell, David R.] Boston Childrens Hosp, Micheli Ctr Sports Injury Prevent, Div Sports Med, Waltham, MA USA; [Master, Christina L.] Univ Penn, Childrens Hosp Philadelphia, Sports Med & Performance Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA; [Howell, David R.] Univ Colorado, Childrens Hosp Colorado, Ctr Sports Med, Sch Med,Dept Orthoped, 13123 East 16th Ave B060, Aurora, CO 80045 USA		Howell, DR (corresponding author), Univ Colorado, Childrens Hosp Colorado, Ctr Sports Med, Sch Med,Dept Orthoped, 13123 East 16th Ave B060, Aurora, CO 80045 USA.	David.Howell@childrenscolorado.org		Master, Christina/0000-0002-6717-4270			Broglio SP, 2007, J ATHL TRAINING, V42, P504; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2016, GAIT POSTURE, V49, P176, DOI 10.1016/j.gaitpost.2016.07.008; Howell DR, 2016, PHYSICIAN SPORTSMED, V44, P304, DOI 10.1080/00913847.2016.1197763; Howell DR, 2016, ACTA PAEDIATR, V105, pE426, DOI 10.1111/apa.13486; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mancini M, 2016, GAIT POSTURE, V43, P125, DOI 10.1016/j.gaitpost.2015.08.015; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170	29	29	29	0	24	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	DEC	2017	52	12					1089	1095		10.4085/1062-6050-52.11.23			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FR9BQ	WOS:000419368900001	29154694	Bronze, Green Published			2022-02-06	
J	Black, AM; Hagel, BE; Palacios-Derflingher, L; Schneider, KJ; Emery, CA				Black, Amanda M.; Hagel, Brent E.; Palacios-Derflingher, Luz; Schneider, Kathryn J.; Emery, Carolyn A.			The risk of injury associated with body checking among Pee Wee ice hockey players: an evaluation of Hockey Canada's national body checking policy change	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							4TH INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; NOVEMBER 2012; SPORT HELD; CONCUSSION; ZURICH; EPIDEMIOLOGY; REDUCTION	Background In 2013, Hockey Canada introduced an evidence-informed policy change delaying the earliest age of introduction to body checking in ice hockey until Bantam (ages 13-14) nationwide. Objective To determine if the risk of injury, including concussions, changes for Pee Wee (11-12 years) ice hockey players in the season following a national policy change disallowing body checking. Methods In a historical cohort study, Pee Wee players were recruited from teams in all divisions of play in 2011-2012 prior to the rule change and in 2013-2014 following the change. Baseline information, injury and exposure data for both cohorts were collected using validated injury surveillance. Results Pee Wee players were recruited from 59 teams in Calgary, Alberta (n=883) in 2011-2012 and from 73 teams in 2013-2014 (n=618). There were 163 game-related injuries (incidence rate (IR)=4.37/1000 game-hours) and 104 concussions (IR=2.79/1000 game-hours) in Alberta prior to the rule change, and 48 injuries (IR=2.16/1000 game-hours) and 25 concussions (IR=1.12/1000 game-hours) after the rule change. Based on multivariable Poisson regression with exposure hours as an offset, the adjusted incidence rate ratio associated with the national policy change disallowing body checking was 0.50 for all game-related injuries (95% CI 0.33 to 0.75) and 0.36 for concussion specifically (95% CI 0.22 to 0.58). Conclusions Introduction of the 2013 national body checking policy change disallowing body checking in Pee Wee resulted in a 50% relative reduction in injury rate and a 64% reduction in concussion rate in 11-year-old and 12-year-old hockey players in Alberta.	[Black, Amanda M.; Hagel, Brent E.; Palacios-Derflingher, Luz; Schneider, Kathryn J.; Emery, Carolyn A.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Black, Amanda M.; Schneider, Kathryn J.; Emery, Carolyn A.] Univ Calgary, Hotchkiss Brain Inst, Cumming Sch Med, Calgary, AB, Canada; [Black, Amanda M.; Hagel, Brent E.; Schneider, Kathryn J.; Emery, Carolyn A.] Univ Calgary, Cumming Sch Med, Res Inst, Alberta Childrens Hosp, Calgary, AB, Canada; [Hagel, Brent E.; Emery, Carolyn A.] Univ Calgary, OBrien Inst Publ Hlth, Cumming Sch Med, Calgary, AB, Canada; [Hagel, Brent E.; Palacios-Derflingher, Luz; Emery, Carolyn A.] Univ Calgary, Cumming Sch Med, Community Hlth Sci, Calgary, AB, Canada; [Hagel, Brent E.; Emery, Carolyn A.] Univ Calgary, Cumming Sch Med, Dept Pediat, Calgary, AB, Canada		Black, AM (corresponding author), Fac Kinesiol, Sport Injury Res Prevent Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	ablack@ucalgary.ca	Black, Amanda/O-7675-2017; Emery, Carolyn/AAI-2761-2020; Hagel, Brent/AAK-3319-2020	Black, Amanda/0000-0001-5668-9706; Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute; Alberta Innovates Health Solutions; Hotchkiss Brain Institute Dr T Chen Fong Doctoral Scholarship in Neuroscience; Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation; International Olympic Committee; Alberta Innovates [201201160] Funding Source: researchfish	This study was funded by the Canadian Institutes of Health Research (CIHR), Alberta Children's Hospital Research Institute and a grant from Alberta Innovates Health Solutions. AMB is supported by the Hotchkiss Brain Institute Dr T Chen Fong Doctoral Scholarship in Neuroscience. CAE is supported by an Alberta Children's Hospital Foundation Chair in Pediatric Rehabilitation. The University of Calgary Sport Injury Prevention Research Centre is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee. The role of the sponsors and funding bodies was to provide financial support for this research and the translation of the findings to all community partners.	Annual Report 2015-2016, 2016, ANN REP 2015 2016; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Black AM, 2016, BRIT J SPORT MED, V50, P55, DOI 10.1136/bjsports-2015-095103; Brenner JS, 2014, PEDIATRICS, V133, P1151, DOI 10.1542/peds.2014-0692; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Emery CA, 2010, INJURY PREV, V16, P113, DOI 10.1136/ip.2009.022764; Emery CA, 2009, CLIN J SPORT MED, V19, P207, DOI 10.1097/JSM.0b013e31819d658e; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Hockey Canada, 2012, ANN REP 2012; Hockey Canada, 2013, ANN REP 2013; Hockey Canada, 2015, 2014 15 ANN REP; Hockey Canada, 2014, REF CAS BOOK RUL COM; International Ice Hockey Federation, 2013, NEWS ARCH; Juhn MS, 2002, CLIN J SPORT MED, V12, P46, DOI 10.1097/00042752-200201000-00014; Krolikowski MP, 2017, AM J SPORT MED, V45, P468, DOI 10.1177/0363546516669701; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Matic GT, 2015, PHYSICIAN SPORTSMED, V43, P119, DOI 10.1080/00913847.2015.1035210; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckay CD, 2014, CAN J PUBLIC HEALTH, V105, pE445, DOI 10.17269/cjph.105.4653; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Richmond SA, 2014, BRIT J SPORT MED, V48, P941, DOI 10.1136/bjsports-2012-091921; Royston P, 2011, J STAT SOFTW, V45, P1, DOI 10.18637/jss.v045.i04; Slutzky CB, 2009, PSYCHOL SPORT EXERC, V10, P381, DOI 10.1016/j.psychsport.2008.09.006; Stata Corporation, 2015, STAT STAT SOFTW REL STAT STAT SOFTW REL; USA Hockey, 2015, MEMB STAT; Zullig KJ, 2011, APPL RES QUAL LIFE, V6, P277, DOI 10.1007/s11482-010-9129-z	30	29	29	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2017	51	24					1767	+		10.1136/bjsports-2016-097392			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FN6SI	WOS:000416145900013	28279963				2022-02-06	
J	Meier, TB; Nelson, LD; Huber, DL; Bazarian, JJ; Hayes, RL; McCrea, MA				Meier, Timothy B.; Nelson, Lindsay D.; Huber, Daniel L.; Bazarian, Jeffrey J.; Hayes, Ronald L.; McCrea, Michael A.			Prospective Assessment of Acute Blood Markers of Brain Injury in Sport-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						GFAP; mild traumatic brain injury; S100B; UCH-L1	FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; HEAD COMPUTED-TOMOGRAPHY; TRAUMATIC INTRACRANIAL LESIONS; FOOTBALL PLAYERS; NEUROSURGICAL INTERVENTION; SERUM BIOMARKERS; MILD; S100B; CHILDREN	There is a pressing need to identify objective biomarkers for the assessment of sport-related concussion (SRC) to reduce the reliance on clinical judgment for the management of these injuries. The goal of the current study was to prospectively establish the acute effects of SRC on serum levels of S100 calcium-binding protein beta (S100B), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1). Collegiate and high school football players were enrolled and provided blood at pre-season. Injured athletes participated in follow-up visits at similar to 6 and 24-48 h following documented SRC (n = 32). Uninjured football players participated in similar follow-up visits and served as controls (n = 29). The median time between injury and blood collection was 2 h (6 h visit) and 22.5 h (24-48 h visit) in concussed athletes. Concussed athletes had significantly elevated UCH-L1 levels at the 6 h visit relative to pre-season levels (Z = 2.22, p = 0.03) and levels in control athletes (Z = 3.02, p = 0.003). Concussed athletes also had elevated S100B at 6 h relative to pre-season (Z = 2.07, p = 0.04) and controls (Z = 2.75, p = 0.006). Both markers showed fair discrimination between concussed and control athletes (UCH-L1 area under receiver operating characteristic curve [AUC] [95% CI] = 0.74 [0.61-0.88], S100B AUC=0.72 [0.58-0.87]). Percent-change of UCH-L1 and S100B at 6 h relative to pre-season also showed fair discrimination (AUC = 0.79 [0.66-0.92] and AUC=0.77 [0.64-0.90]). GFAP levels did not differ between groups or in concussed athletes relative to pre-season. This study provides prospective evidence of significant increases in serum levels of UCH-L1 and S100B during the early acute period following SRC, and lays the foundation for future studies examining the clinical potential for blood-based biomarkers in the early detection of concussion.	[Meier, Timothy B.; Nelson, Lindsay D.; Huber, Daniel L.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Meier, Timothy B.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Labs, Alachua, FL USA		Meier, TB (corresponding author), Med Coll Wisconsin, Neurosci Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	tmeier@mcw.edu		Huber, Daniel/0000-0003-2079-0647	Defense Health Program under the Department of Defense Broad Agency Announcement for Extramural Medical Research [W81XWH-14-10561]; National Center for Advancing Translational Sciences, National Institutes of Health (NIH) [8UL1TR000055, 1UL1-RR031973 (-01)]	This work was supported by the Defense Health Program under the Department of Defense Broad Agency Announcement for Extramural Medical Research through Award No. W81XWH-14-10561. This project was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through Grant Number 8UL1TR000055 and 1UL1-RR031973 (-01). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Dr. Meier had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Asadollahi S, 2016, BRAIN INJURY, V30, P172, DOI 10.3109/02699052.2015.1091504; Barth JT, 2002, ENCY HUMAN BRAIN, P81; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Bouvier D, 2017, SPORTS MED, V47, P781, DOI 10.1007/s40279-016-0579-9; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Graham MR, 2015, INT J IMMUNOPATH PH, V28, P539, DOI 10.1177/0394632015577045; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Holdnack H.A., 2001, WECHSLER TEST ADULT; Kiechle K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084977; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kulbe JR, 2016, EXP NEUROL, V275, P334, DOI 10.1016/j.expneurol.2015.05.004; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Papa L, 2015, ACAD EMERG MED, V22, P1274, DOI 10.1111/acem.12795; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Posti JP, 2017, J NEUROTRAUM, V34, P1427, DOI 10.1089/neu.2016.4442; Posti JP, 2016, NEUROSURGERY, V79, P456, DOI 10.1227/NEU.0000000000001226; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Qu BX, 2016, J NEUROTRAUM, V33, pA19; Schulte S, 2014, J ATHL TRAINING, V49, P830, DOI 10.4085/1062-6050-49.3.33; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	40	29	29	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2017	34	22					3134	3142		10.1089/neu.2017.5046			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	FL9GC	WOS:000414560000009	28699381	Green Published			2022-02-06	
J	Nelson, LD; Ranson, J; Ferguson, AR; Giacino, J; Okonkwo, DO; Valadka, AB; Manley, GT; McCrea, MA				Nelson, Lindsay D.; Ranson, Jana; Ferguson, Adam R.; Giacino, Joseph; Okonkwo, David O.; Valadka, Alex B.; Manley, Geoffrey T.; McCrea, Michael A.		TRACK-TBI Investigators	Validating Multi-Dimensional Outcome Assessment Using the Traumatic Brain Injury Common Data Elements: An Analysis of the TRACK-TBI Pilot Study Sample	JOURNAL OF NEUROTRAUMA			English	Article						common data elements; Glasgow Outcome Scale; neuropsychological; outcome assessment; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; SEVERE HEAD-INJURY; POST-CONCUSSION SYMPTOMS; FUNCTIONAL STATUS EXAMINATION; VERBAL-LEARNING TEST; PTSD CHECKLIST; CLINICAL-TRIALS; PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; STRUCTURED INTERVIEWS	The Glasgow Outcome Scale-Extended (GOSE) is often the primary outcome measure in clinical trials for traumatic brain injury (TBI). Although the GOSE's capture of global functional outcome has several strengths, concerns have been raised about its limited ability to identify mild disability and failure to capture the full scope of problems patients exhibit after TBI. This analysis examined the convergence of disability ratings across a multi-dimensional set of outcome domains in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot Study. The study collected measures recommended by the TBI Common Data Elements (CDE) Workgroup. Patients presenting to three emergency departments with a TBI of any severity enrolled in TRACK-TBI prospectively after injury; outcome measures were collected at 3 and 6 months post-injury. Analyses examined frequency of impairment and overlap between impairment status across the CDE outcome domains of Global Level of Functioning (GOSE), Neuropsychological (cognitive) Impairment, Psychological Status, TBI Symptoms, and Quality of Life. GOSE score correlated in the expected direction with other outcomes (mean [M] Spearman's rho = 0.21 and 0.49 with neurocognitive and self-report outcomes, respectively). The subsample in the Upper Good Recovery (GOSE 8) category appeared quite healthy across most other outcomes, although 19.0% had impaired executive functioning (Trail Making Test Part B). A significant minority of participants in the Lower Good Recovery subgroup (GOSE 7) met criteria for impairment across numerous other outcome measures. The findings highlight the multi-dimensional nature of TBI recovery and the limitations of applying only a single outcome measure.	[Nelson, Lindsay D.; Ranson, Jana; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA; [Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci Brain & Spinal Injury Ctr BAS, San Francisco, CA USA; [Ferguson, Adam R.] San Francisco VA Med Ctr, San Francisco, CA USA; [Giacino, Joseph] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, Zuckerberg San Francisco Gen Hosp, San Francisco, CA USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Trauma Ctr, San Francisco, CA 94143 USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA		Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.; Nelson, LD (corresponding author), Med Coll Wisconsin, Dept Neurol, 8701 West Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu	Yue, John K/P-1348-2015; Ranson, Jana/H-9899-2019; Giacino, Joseph/AAF-1952-2021	Yue, John K/0000-0001-9694-7722; Giacino, Joseph/0000-0002-7916-9698; Ranson, PhD, Jana/0000-0003-0967-192X; Ferguson, Adam/0000-0001-7102-1608	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC2 NS0694909, RC2 NS069409-02S1, R03 NS100691-01]; Department of DefenseUnited States Department of Defense [USAMRAAW81XWH-13-1-0441]	This work was supported by the National Institutes of Health (grant nos. RC2 NS0694909 [to G.T.M.], RC2 NS069409-02S1 [to G.T.M.], and R03 NS100691-01 [to L.D.N.]) and the Department of Defense (USAMRAAW81XWH-13-1-0441; to G.T.M.); Registry: ClinicalTrials.gov Identifier NCT01565551. We thank Anna Klotz for her assistance in processing the neurocognitive outcome data. Editorial support was provided by Amy J. Markowitz, JD.	Agresti A., 2013, CATEGORICAL DATA ANA, V3; Agresti A., 2010, ANAL ORDINAL CATEGOR, V2nd; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; [Anonymous], 2016, IBM SPSS STAT WIND C; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; BRANT R, 1990, BIOMETRICS, V46, P1171, DOI 10.2307/2532457; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Centers for Disease and Control, 2016, TRAUM BRAIN INJ CONC; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Clegg F., 1998, SIMPLE STAT COURSE B; Clogg C.C., 1994, STAT MODELS ORDINAL; Cohen J., 2003, APPL MULTIPLE CORREL, V3rd; Cohen L., 2011, RES METHODS ED, V3rd ed.; Cook JM, 2005, J TRAUMA STRESS, V18, P371, DOI 10.1002/jts.20038; Derogatis LR., 2001, BSI 18 BRIEF SYMPTOM; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Donders J, 2006, PSYCHOL ASSESSMENT, V18, P458, DOI 10.1037/1040-3590.18.4.458; Drane DL, 2002, NEUROPSY NEUROPSY BE, V15, P39; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Heaton RK, 1991, COMPREHENSIVE NORMS; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hellawell DJ, 1997, INT J REHABIL RES, V20, P345, DOI 10.1097/00004356-199712000-00001; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; ISOAHO R, 1995, SCAND J PRIM HEALTH, V13, P122, DOI 10.3109/02813439508996748; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JUDGE TA, 1993, ORGAN BEHAV HUM DEC, V56, P388, DOI 10.1006/obhd.1993.1061; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kohler R., 2011, COGNITIVE REHABILITA; Lang AJ, 2005, BEHAV RES THER, V43, P585, DOI 10.1016/j.brat.2004.04.005; Lang AJ, 2003, J TRAUMA STRESS, V16, P257, DOI 10.1023/A:1023796007788; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LONDON P S, 1967, Annals of the Royal College of Surgeons of England, V41, P460; Lu J, 2008, J NEUROTRAUM, V25, P641, DOI 10.1089/neu.2007.0510; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Manley G. T., 2017, J NEUROTRAUMA ADV ON, DOI [10.1089/neur.2016.4729, DOI 10.1089/NEUR.2016.4729]; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Manne SL, 1998, J PEDIATR PSYCHOL, V23, P357, DOI 10.1093/jpepsy/23.6.357; Marmarou A., 2001, AM BRAIN INJURY CONS; McCrea M, 2015, BRAIN INJURY, V29, P276, DOI 10.3109/02699052.2014.965216; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; McMillan TM, 2013, J NEUROTRAUM, V30, P970, DOI 10.1089/neu.2012.2703; McMillan T, 2016, NAT REV NEUROL, V12, P477, DOI 10.1038/nrneurol.2016.89; Mellick D., 2000, CRAIG HANDICAP ASSES; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Center for PTSD, 2012, US PTSD CHECKL PCL; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; O'Connell A.A., 2006, LOGISTIC REGRESSION; O'Connell AA, 2011, J MOD APPL STAT METH, V10, P139, DOI 10.22237/jmasm/1304223240; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Retzlaff PJ, 1992, PSYCHOL ASSESSMENT, V4, P92, DOI [10.1037/1040-3590.4.1.92, DOI 10.1037/1040-3590.4.1.92]; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; Scott Long J., 1997, REGRESSION MODELS CA, V7; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherman JJ, 2005, J OROFAC PAIN, V19, P309; Silberstein Morry, 2002, Neurosurg Focus, V13, pecp2, DOI 10.3171/foc.2002.13.1.6; Smead V. S., 1991, ANN CONV AM ASS APPL; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; van der Naalt J, 2000, BRAIN INJURY, V14, P781; Walker EA, 2002, GEN HOSP PSYCHIAT, V24, P375, DOI 10.1016/S0163-8343(02)00203-7; Weathers F. W., 1994, PTSD CHECKLIST CIVIL; Weathers F.W., 2013, PTSD CHECKLIST DSM 5; Wechsler D., 2008, WAIS IV MANUAL; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Widows MR, 2000, PSYCHOSOM MED, V62, P873, DOI 10.1097/00006842-200011000-00018; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P413, DOI 10.1016/j.acn.2006.06.002; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	112	29	29	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2017	34	22					3158	3172		10.1089/neu.2017.5139			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	FL9GC	WOS:000414560000012	28595478	Green Published			2022-02-06	
J	Feng, Y; Cui, CM; Liu, X; Wu, Q; Hu, FG; Zhang, HF; Ma, ZZ; Wang, LQ				Feng, Yan; Cui, Changmeng; Liu, Xin; Wu, Qiang; Hu, Fuguang; Zhang, Haofeng; Ma, Zhizhao; Wang, Liqun			Protective Role of Apocynin via Suppression of Neuronal Autophagy and TLR4/NF-kappa B Signaling Pathway in a Rat Model of Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Apocynin; Traumatic brain injury; Autophagy; Toll-like receptor 4; Nuclear factor-kappa B	NADPH OXIDASE INHIBITOR; ACTIVATION; RESPONSES; DEFICITS; EDEMA; DEATH	Neuronal autophagy and inflammatory responses are important in the pathogenesis of traumatic brain injury (TBI), and toll-like receptor 4 (TLR4) may play an important role in the related molecular cascade. The present study investigated the protective effect of apocynin, an inhibitor of NADPH oxidase, in a TBI rat model and further examined neuronal autophagy and the TLR4-mediated pathway. Adult male Sprague-Dawley rats were subjected to controlled cortical impact injury and intraperitoneally injected with apocynin (50 mg/kg) immediately after the trauma. In addition to motor and behavioral studies, brain water content and histology analyses were performed. Expression of autophagy-related proteins as well as TLR4/NF-kappa B signaling and inflammatory mediators was analyzed. The apocynin treatment significantly attenuated TBI-induced motor and behavioral impairment, brain edema and neuronal damage in rats. Immunohistochemical and Western blot analyses revealed that apocynin treatment significantly reduced the expression of NOX2, LC3 and Beclin1 in the hippocampus at 12-48 h after injury. Double immunolabeling demonstrated that apocynin decreased the co-localization of LC3 or TLR4-positive cells with hippocampal neurons at 24 h following TBI. In addition, CD11b (microglial marker) and GFAP (astrocyte marker)-immunopositive cells were also clearly decreased in hippocampal tissues. Meanwhile, protein levels of TLR4, NF-kappa B p65, TNF-alpha and IL-1 beta were found to be significantly downregulated by Western blot analysis. In conclusion, our findings indicate that the protective effects of apocynin may be related to modulation of neuronal autophagy and the TLR4/NF-kappa B signaling pathway.	[Feng, Yan; Liu, Xin; Wu, Qiang; Hu, Fuguang; Zhang, Haofeng; Ma, Zhizhao; Wang, Liqun] Hebei Med Univ, Hosp 2, Dept Neurosurg, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China; [Cui, Changmeng] Jining Med Univ, Affiliated Hosp, Dept Neurosurg, Jining, Shandong, Peoples R China		Wang, LQ (corresponding author), Hebei Med Univ, Hosp 2, Dept Neurosurg, 215 Heping West Rd, Shijiazhuang 050000, Hebei, Peoples R China.	lqwangdr@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2014105079]	This work was supported by the Natural Science Foundation of Hebei Province (Grant No. H2014105079).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ano Y, 2010, NEUROSCI LETT, V469, P39, DOI 10.1016/j.neulet.2009.11.040; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Carty M, 2011, BIOCHEM PHARMACOL, V81, P825, DOI 10.1016/j.bcp.2011.01.003; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Georgiou AP, 2013, BRIT J ANAESTH, V110, P357, DOI 10.1093/bja/aes500; Haar CV, 2012, RESTOR NEUROL NEUROS, V30, P291, DOI 10.3233/RNN-2012-110196; Hayashi T, 2005, DIABETES OBES METAB, V7, P334, DOI 10.1111/j.1463-1326.2004.00393.x; Hoffmann O, 2007, J IMMUNOL, V178, P6476, DOI 10.4049/jimmunol.178.10.6476; Huang J, 2009, AUTOPHAGY, V5, P887, DOI 10.4161/auto.9125; Jackman KA, 2009, BRIT J PHARMACOL, V156, P680, DOI 10.1111/j.1476-5381.2008.00073.x; Jinnouchi Y, 2007, BRAIN RES, V1167, P92, DOI 10.1016/j.brainres.2007.04.088; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Lu Q, 2015, REDOX BIOL, V6, P516, DOI 10.1016/j.redox.2015.06.016; Lu XY, 2014, NEUROCHEM INT, V69, P14, DOI 10.1016/j.neuint.2014.02.006; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo T, 2013, ANESTHESIOLOGY, V119, P1370, DOI 10.1097/ALN.0000000000000020; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Teng RJ, 2012, AM J PHYSIOL-LUNG C, V302, P1651, DOI 10.1152/ajplung.00177.2011; Tu XK, 2010, NEUROCHEM RES, V35, P1147, DOI 10.1007/s11064-010-0167-6; Uysal A, 2015, PERFUSION-UK, V30, P472, DOI 10.1177/0267659114559260; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59	39	29	29	0	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	NOV	2017	42	11					3296	3309		10.1007/s11064-017-2372-z			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	FK4IR	WOS:000413457000026	28786047				2022-02-06	
J	Montgomery, S; Hiyoshi, A; Burkill, S; Alfredsson, L; Bahmanyar, S; Olsson, T				Montgomery, Scott; Hiyoshi, Ayako; Burkill, Sarah; Alfredsson, Lars; Bahmanyar, Shahram; Olsson, Tomas			Concussion in adolescence and risk of multiple sclerosis	ANNALS OF NEUROLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; T-CELL; METAANALYSIS; ASSOCIATION; POPULATION; RESPONSES; MEN	ObjectiveTo assess whether concussion in childhood or adolescence is associated with subsequent multiple sclerosis (MS) risk. Previous research suggests an association, but methodological limitations included retrospective data collection and small study populations. MethodsThe national Swedish Patient Register (hospital diagnoses) and MS Register were used to identify all MS diagnoses up to 2012 among people born since 1964, when the Patient Register was established. The 7,292 patients with MS were matched individually with 10 people without MS by sex, year of birth, age/vital status at MS diagnosis, and region of residence (county), resulting in a study population of 80,212. Diagnoses of concussion and control diagnoses of broken limb bones were identified using the Patient Register from birth to age 10 years or from age 11 to 20 years. Conditional logistic regression was used to examine associations with MS. ResultsConcussion in adolescence was associated with a raised risk of MS, producing adjusted odds ratios (95% confidence intervals) of 1.22 (1.05-1.42, p=0.008) and 2.33 (1.35-4.04, p=0.002) for 1 diagnosis of concussion and >1 diagnosis of concussion, respectively, compared with none. No notable association with MS was observed for concussion in childhood, or broken limb bones in childhood and adolescence. InterpretationHead trauma in adolescence, particularly if repeated, is associated with a raised risk of future MS, possibly due to initiation of an autoimmune process in the central nervous system. This further emphasizes the importance of protecting young people from head injuries. Ann Neurol 2017;82:554-561	[Montgomery, Scott; Hiyoshi, Ayako] Orebro Univ, Sch Med Sci, Clin Epidemiol & Biostat, Campus USO, Orebro, Sweden; [Montgomery, Scott; Burkill, Sarah; Bahmanyar, Shahram] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Solna, Sweden; [Montgomery, Scott] UCL, Dept Epidemiol & Publ Hlth, London, England; [Burkill, Sarah; Bahmanyar, Shahram] Karolinska Inst, Dept Med, Ctr Pharmacoepidemiol, Solna, Sweden; [Alfredsson, Lars] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Alfredsson, Lars] Stockholm Cty Council, Ctr Occupat & Environm Med, Stockholm, Sweden; [Olsson, Tomas] Karolinska Inst, Dept Clin Neurosci, Ctr Mol Med, Stockholm, Sweden		Montgomery, S (corresponding author), Orebro Univ, Sch Med Sci, Clin Epidemiol & Biostat, Campus USO, Orebro, Sweden.	scott.montgomery@oru.se	Alfredsson, Lars/AAC-9007-2019; Montgomery, Scott/AAN-2546-2020	Alfredsson, Lars/0000-0003-1688-6697; Montgomery, Scott/0000-0001-6328-5494; Hiyoshi, Ayako/0000-0002-2088-0530; Olsson, Tomas/0000-0002-2938-1877; Bahmanyar, Shahram/0000-0002-9205-6540	F. Hoffmann-La RocheHoffmann-La Roche; Novartis Pharma	Funding to obtain and analyze the data was provided by research grants from F. Hoffmann-La Roche and Novartis Pharma.	Ascherio A, 2010, J NEUROIMMUNE PHARM, V5, P271, DOI 10.1007/s11481-010-9201-3; Bahmanyar S, 2009, NEUROLOGY, V72, P1170, DOI 10.1212/01.wnl.0000345366.10455.62; Bjornevik K, 2016, MULT SCLER J, V22, P104, DOI 10.1177/1352458515579444; BOBOWICK AR, 1978, NEUROLOGY, V28, P978, DOI 10.1212/WNL.28.10.978; DisBattista AP, 2016, PLOS ONE, V11; Dokuchaeva NN, 2006, ZH NEVROL PSIKHIATR, P4; Goncharova ZA, 2009, ZH NEVROL PSIKHIATR, V109, P10; Gunnarsson M, 2015, EUR J NEUROL, V22, P1131, DOI 10.1111/ene.12718; Gusev E, 1996, ACTA NEUROL SCAND, V94, P386, DOI 10.1111/j.1600-0404.1996.tb00050.x; Hedstrom AK, 2012, MULT SCLER J, V18, P1334, DOI 10.1177/1352458512436596; Hedstrom AK, 2014, NEUROLOGY, V82, P865, DOI 10.1212/WNL.0000000000000203; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Koch-Henriksen N, 1989, Acta Neurol Scand Suppl, V124, P1; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Lin CW, 2015, J NEUROTRAUM, V32, P655, DOI 10.1089/neu.2014.3723; Lin WS, 2006, BRAIN, V129, P1306, DOI 10.1093/brain/awl044; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; Lunny CA, 2014, J NEUROL SCI, V336, P13, DOI 10.1016/j.jns.2013.08.011; National Board of Health and Welfare, PAT REG; Niedziela N, 2014, INT J NEUROSCI, V124, P322, DOI 10.3109/00207454.2013.840618; OLSSON T, 1993, J NEUROL SCI, V117, P130, DOI 10.1016/0022-510X(93)90165-U; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; VARTANIAN T, 1995, MOL MED, V1, P732, DOI 10.1007/BF03401888; WANG WZ, 1992, CLIN EXP IMMUNOL, V88, P157; Warren SA, 2013, CAN J NEUROL SCI, V40, P168, DOI 10.1017/S0317167100013688; Yang L, 2017, METAB BRAIN DIS, V32, P1395, DOI 10.1007/s11011-017-9991-6; Zaadstra BM, 2008, MULT SCLER J, V14, P307, DOI 10.1177/1352458507084265; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	31	29	29	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	OCT	2017	82	4					554	561		10.1002/ana.25036			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FK6AB	WOS:000413584000009	28869671				2022-02-06	
J	Spaite, DW; Hu, CC; Bobrow, BJ; Chikani, V; Barnhart, B; Gaither, JB; Denninghoff, KR; Adelson, PD; Keim, SM; Viscusi, C; Mullins, T; Rice, AD; Sherrill, D				Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Adelson, P. David; Keim, Samuel M.; Viscusi, Chad; Mullins, Terry; Rice, Amber D.; Sherrill, Duane			Association of Out-of-Hospital Hypotension Depth and Duration With Traumatic Brain Injury Mortality	ANNALS OF EMERGENCY MEDICINE			English	Article							SEVERE HEAD-INJURY; BLOOD-PRESSURE; PROGNOSTIC VALUE; HYPOXIA; INSULTS; SEVERITY; RESUSCITATION; MANAGEMENT; HYPOXEMIA; CHILDREN	Study objective: Out-of-hospital hypotension has been associated with increased mortality in traumatic brain injury. The association of traumatic brain injury mortality with the depth or duration of out-of-hospital hypotension is unknown. We evaluated the relationship between the depth and duration of out-of-hospital hypotension and mortality in major traumatic brain injury. Methods: We evaluated adults and older children with moderate or severe traumatic brain injury in the preimplementation cohort of Arizona's statewide Excellence in Prehospital Injury Care study. We used logistic regression to determine the association between the depth-duration dose of hypotension (depth of systolic blood pressure <90 mm Hg integrated over duration [minutes] of hypotension) and odds of inhospital death, controlling for significant confounders. Results: There were 7,521 traumatic brain injury cases included (70.6% male patients; median age 40 years [interquartile range 24 to 58]). Mortality was 7.8% (95% confidence interval [CI] 7.2% to 8.5%) among the 6,982 patients without hypotension (systolic blood pressure >= 90 mm Hg) and 33.4% (95% CI 29.4% to 37.6%) among the 539 hypotensive patients(systolic blood pressure <90 mm Hg). Mortality was higher with increased hypotension dose: 0.01 to 14.99 mm Hg-minutes 16.3%; 15 to 49.99 mm Hg-minutes 28.1%; 50 to 141.99 mm Hg-minutes 38.8%; and greater than or equal to 142 mm Hg-minutes 50.4%. Log(2) (the logarithm in base 2) of hypotension dose was associated with traumatic brain injury mortality (adjusted odds ratio 1.19 [95% CI 1.14 to 1.25] per 2-fold increase of dose). Conclusion: In this study, the depth and duration of out-of-hospital hypotension were associated with increased traumatic brain injury mortality. Assessments linking out-of-hospital blood pressure with traumatic brain injury outcomes should consider both depth and duration of hypotension.	[Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Keim, Samuel M.; Viscusi, Chad; Rice, Amber D.] Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ 85004 USA; [Adelson, P. David] Univ Arizona, Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Adelson, P. David] Univ Arizona, Coll Med, Dept Child Hlth Neurosurg, Phoenix, AZ USA; [Spaite, Daniel W.; Bobrow, Bentley J.; Gaither, Joshua B.; Denninghoff, Kurt R.; Keim, Samuel M.; Viscusi, Chad; Rice, Amber D.] Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ USA; [Hu, Chengcheng; Sherrill, Duane] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA; [Bobrow, Bentley J.; Chikani, Vatsal; Mullins, Terry] Arizona Dept Hlth Serv, Bur EMS & Trauma Syst, Phoenix, AZ 85007 USA		Spaite, DW (corresponding author), Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ 85004 USA.; Spaite, DW (corresponding author), Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ USA.	dan@aemrc.arizona.edu	Adelson, David/W-2083-2019	Chikani, Vatsal/0000-0003-0904-7887	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist. Research reported in this publication was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award R01NS071049. The University of Arizona receives funding from the NIH supporting the Excellence in Prehospital Injury Care study. This includes support for the following authors: Drs. Spaite, Bobrow, Gaither, Denninghoff, Adelson, Viscusi, and Sherrill and Mssrs. Chikani and Barnhart.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bobrow BJ, 2013, ANN EMERG MED, V62, P47, DOI 10.1016/j.annemergmed.2012.12.020; Brenner M, 2012, J TRAUMA ACUTE CARE, V72, P1135, DOI 10.1097/TA.0b013e31824af90b; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chesnut RM, 2000, J NEUROTRAUM, V17, P199; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Franschman G, 2011, J TRAUMA, V71, P826, DOI 10.1097/TA.0b013e31820cebf0; GENTLEMAN D, 1992, INT SURG, V77, P297; Haddad Samir, 2005, Middle East Journal of Anesthesiology, V18, P45; Hannan EL, 2005, J TRAUMA, V58, P244, DOI 10.1097/01.TA.0000141995.44721.44; HILL DA, 1993, AUST NZ J SURG, V63, P604, DOI 10.1111/j.1445-2197.1993.tb00466.x; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JEFFREYS RV, 1981, LANCET, V2, P459; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MAYER TA, 1985, ANN EMERG MED, V14, P1178, DOI 10.1016/S0196-0644(85)81025-8; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Newgard CD, 2013, J AM COLL SURGEONS, V216, P147, DOI 10.1016/j.jamcollsurg.2012.08.017; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pencina MJ, 2011, STAT MED, V30, P11, DOI 10.1002/sim.4085; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; R Core Team, 2018, R LANGUAGE ENV STAT; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SEELIG JM, 1986, INTRACRANIAL PRESSUR, P675; Shutter LA, 2008, ANN EMERG MED, V51, pS37, DOI 10.1016/j.annemergmed.2007.11.013; Spaite DW, 2017, JAMA SURG, V152, P360, DOI 10.1001/jamasurg.2016.4686; Spaite DW, 2017, ANN EMERG MED, V69, P62, DOI 10.1016/j.annemergmed.2016.08.007; Spaite DW, 2014, ACAD EMERG MED, V21, P818, DOI 10.1111/acem.12411; Spaite DW, 1993, PREHOSP DISASTER MED, V8, pS35; Stassen W, 2014, SAMJ S AFR MED J, V104, P424, DOI [10.7196/SAMJ.7494, 10.7196/samj.7494]; Stewart KE, 2011, INJURY, V42, P934, DOI 10.1016/j.injury.2010.05.033; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Wood S.N., 2017, GEN ADDITIVE MODELS, DOI [10.1201/978131537027, DOI 10.1201/9781315370279]; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x; YEH KC, 1978, J PHARMACOKINET BIOP, V6, P79, DOI 10.1007/BF01066064	54	29	29	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	OCT	2017	70	4					522	530		10.1016/j.annemergmed.2017.03.027			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	FJ7VM	WOS:000412967800014	28559036	Green Accepted			2022-02-06	
J	Cheng, YJ; Wei, YX; Yang, WL; Song, YY; Shang, HB; Cai, Y; Wu, ZB; Zhao, WG				Cheng, Yijun; Wei, Yongxu; Yang, Wenlei; Song, Yaying; Shang, Hanbing; Cai, Yu; Wu, Zhebao; Zhao, Weiguo			Cordycepin confers neuroprotection in mice models of intracerebral hemorrhage via suppressing NLRP3 inflammasome activation	METABOLIC BRAIN DISEASE			English	Article						Intracerebral hemorrhage; Neuroinflammation; NLRP3 inflammasome; Cordycepin; Neuronal death; HMGB1	ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; FOCAL ISCHEMIA; CELL-DEATH; RAT MODEL; EXPRESSION; MILITARIS; PROTECTS; 3-DEOXYADENOSINE; PATHOGENESIS	Neuroinflammation has been recognized as a major contributor to brain injury caused by intracerebral hemorrhage (ICH). Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome acts as an important mediator of inflammatory response in various inflammation-related diseases including hemorrhagic insults. Cordycepin has recently been shown to possess anti-inflammatory effect; however, its role and the possible underlying mechanisms in ICH remain unclear. This study was designed to investigate the neuroprotective effect of cordycepin in mice models of ICH and to elucidate the underlying molecular mechanisms. ICH was induced in male ICR mice by injecting autologous blood infusion stereotactically. Cordycepin was then given intraperitoneally (i.p.) at 30 min after ICH induction. The results demonstrated that NLRP3 inflammasome was activated and exacerbated the inflammatory progression after ICH. Cordycepin treatment significantly alleviated neurological deficits, brain edema, and perihematomal tissue damage following ICH. These changes were accompanied by downregulated NLRP3 inflammasome components expression and a reduction of production and release of inflammasome substrates interleukin-1beta (IL-1 beta) and interleukin-18 (IL-18). Furthermore, cordycepin ameliorated neuronal death in the perihematomal regions, accompanied by a large reduction in the expression of high-mobility group protein B 1 (HMGB1) post-ICH. In conclusion, this study provides in vivo evidence that cordycepin confers neuroprotective effect in the models of ICH, possibly through the suppression of NLRP3 inflammasome activation.	[Cheng, Yijun; Wei, Yongxu; Yang, Wenlei; Shang, Hanbing; Wu, Zhebao; Zhao, Weiguo] Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Neurosurg, Sch Med, Shanghai 200025, Peoples R China; [Song, Yaying] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Neurol, Shanghai 200025, Peoples R China; [Cai, Yu] Shanghai Jiao Tong Univ, Sch Med, North Rui Jin Hosp, Dept Neurosurg, Shanghai 201800, Peoples R China		Wu, ZB; Zhao, WG (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Neurosurg, Sch Med, Shanghai 200025, Peoples R China.; Cai, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, North Rui Jin Hosp, Dept Neurosurg, Shanghai 201800, Peoples R China.	caiyu10746@sina.com; wuzhebao@aliyun.com; ruijinsjwk@qq.com	Wu, Zhe Bao/AAH-8078-2020	Wu, Zhe Bao/0000-0002-1611-8228	Natural Science Fund from Science and Technology Commission of Shanghai Municipality [14ZR1426000, 16ZR14212000]	This research was supported by the Natural Science Fund (No. 14ZR1426000; 16ZR14212000) from the Science and Technology Commission of Shanghai Municipality.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718; Bauernfeind F, 2011, CELL MOL LIFE SCI, V68, P765, DOI 10.1007/s00018-010-0567-4; Cai ZL, 2013, EUR J PHARMACOL, V714, P249, DOI 10.1016/j.ejphar.2013.05.049; Cao GS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091418; Cha JY, 2013, FOOD CHEM TOXICOL, V60, P52, DOI 10.1016/j.fct.2013.07.033; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Chang W, 2008, EUR J PHARMACOL, V597, P64, DOI 10.1016/j.ejphar.2008.08.030; Chen LS, 2008, BRIT J HAEMATOL, V140, P682, DOI 10.1111/j.1365-2141.2007.06955.x; Cheng ZY, 2011, EUR J PHARMACOL, V664, P20, DOI 10.1016/j.ejphar.2011.04.052; Chiu GS, 2012, J NEUROSCI, V32, P13945, DOI 10.1523/JNEUROSCI.0704-12.2012; Choi YH, 2014, DRUG DES DEV THER, V8, P1941, DOI 10.2147/DDDT.S71957; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Duan XC, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1203285; Ellis A, 2016, BRAIN BEHAV IMMUN, V58, P348, DOI 10.1016/j.bbi.2016.08.004; Fann DYW, 2013, AGEING RES REV, V12, P941, DOI 10.1016/j.arr.2013.09.004; Feng L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0409-2; Geldhoff M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-358; GLAZER RI, 1978, CANCER RES, V38, P2233; Hwang IK, 2008, PLANTA MED, V74, P114, DOI 10.1055/s-2008-1034277; Jiang W, 2016, J SURG RES, V203, P331, DOI 10.1016/j.jss.2016.02.041; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Krafft PR, 2014, BEHAV BRAIN RES, V264, P151, DOI 10.1016/j.bbr.2014.01.052; Lamkanfi M, 2010, J IMMUNOL, V185, P4385, DOI 10.4049/jimmunol.1000803; Lammerding L, 2016, NEUROENDOCRINOLOGY, V103, P460, DOI 10.1159/000439435; Lebeaupin C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.248; Li B, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyv112; Li Y, 2015, PHARMACOL RES, V99, P101, DOI 10.1016/j.phrs.2015.05.012; Liu H, 2013, J NANOMATER, V2013, P3; Ma L, 2015, NUTR RES, V35, P431, DOI 10.1016/j.nutres.2015.04.011; Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070; Meng XF, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0212-5; Nakamura K, 2015, J PHARMACOL SCI, V127, P53, DOI 10.1016/j.jphs.2014.09.001; Nguemeni C, 2015, J NEUROSCI METH, V242, P72, DOI 10.1016/j.jneumeth.2015.01.005; Olatunji OJ, 2016, BIOMED PHARMACOTHER, V81, P7, DOI 10.1016/j.biopha.2016.03.009; Olsen I, 2016, J ALZHEIMERS DIS, V54, P45, DOI 10.3233/JAD-160197; Ribo M, 2006, CURR NEUROL NEUROSCI, V6, P17, DOI 10.1007/s11910-996-0004-0; Rynkowski MA, 2008, NAT PROTOC, V3, P122, DOI 10.1038/nprot.2007.513; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Shao LW, 2016, ONCOL LETT, V12, P995, DOI 10.3892/ol.2016.4706; SHIGEURA HT, 1965, J BIOL CHEM, V240, P806; Shin Seulmee, 2009, Immune Netw, V9, P255, DOI 10.4110/in.2009.9.6.255; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Wali Jibran A, 2013, Cells, V2, P266, DOI 10.3390/cells2020266; Wang BJ, 2005, FOOD CHEM TOXICOL, V43, P543, DOI 10.1016/j.fct.2004.12.008; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Williams A, 2010, CURR OPIN IMMUNOL, V22, P34, DOI 10.1016/j.coi.2010.01.004; Wu HY, 2007, PHYTOMEDICINE, V14, P43, DOI 10.1016/j.phymed.2006.11.005; Xiao L, 2012, FREE RADICAL RES, V46, P174, DOI 10.3109/10715762.2011.647688; Yang XF, 2015, INT IMMUNOPHARMACOL, V26, P401, DOI 10.1016/j.intimp.2015.04.017; Yang Z, 2015, MOL IMMUNOL, V65, P267, DOI 10.1016/j.molimm.2014.12.018; Yuan BQ, 2015, J NEUROIMMUNOL, V287, P71, DOI 10.1016/j.jneuroim.2015.08.002; Yuan J, 2016, BRAIN RES BULL, V127, P171, DOI 10.1016/j.brainresbull.2016.09.010; Yue K, 2013, J PHARM PHARMACOL, V65, P474, DOI 10.1111/j.2042-7158.2012.01601.x; Zhao Y, 2015, J ETHNOPHARMACOL, V169, P210, DOI 10.1016/j.jep.2015.04.030; Zhong ZH, 2013, NEUROSCI LETT, V555, P24, DOI 10.1016/j.neulet.2013.09.023; Zhou Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0094-3; Zhou Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/142458; Zhu XX, 2012, STROKE, V43, P524, DOI 10.1161/STROKEAHA.111.635672; Zhu ZS, 2016, CELL MOL NEUROBIOL, V36, P981, DOI 10.1007/s10571-015-0288-1	61	29	31	1	18	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	AUG	2017	32	4					1133	1145		10.1007/s11011-017-0003-7			13	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	FA3FF	WOS:000405327200023	28401330				2022-02-06	
J	Tucker, R; Raftery, M; Fuller, GW; Hester, B; Kemp, S; Cross, MJ				Tucker, Ross; Raftery, Martin; Fuller, Gordon Ward; Hester, Ben; Kemp, Simon; Cross, Matthew J.			A video analysis of head injuries satisfying the criteria for a head injury assessment in professional Rugby Union: a prospective cohort study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS INJURIES; TACKLE INJURIES; CONCUSSION; EPIDEMIOLOGY; PREVENTION; MANAGEMENT; TIME	Objectives Concussion is the most common match injury in professional Rugby Union, accounting for 25% of match injuries. The primary prevention of head injuries requires that the injury mechanism be known so that interventions can be targeted to specifically overall incidence by focusing on characteristics with the greatest propensity to cause a head injury. Methods 611 head injury assessment (HIA) events in professional Rugby Union over a 3-year period were analysed, with specific reference to match events, position, time and nature of head contact. Results 464 (76%) of HIA events occur during tackles, with the tackler experiencing a significantly greater propensity for an HIA than the ball carrier (1.40 HIAs/1000 tackles for the tackler vs 0.54 HIAs/1000 tackles for the ball carrier, incidence rate ratio (IRR) 2.59). Propensity was significantly greater for backline players than forwards (IRR 1.54, 95% CI 1.28 to 1.84), but did not increase over the course of the match. Head to head contact accounted for the most tackler HIAs, with the greatest propensity. Conclusions By virtue of its high propensity and frequency, the tackle should be the focus for interventions that may include law change and technique education. A specific investigation of the characteristics of the tackle is warranted to refine the approach to preventative strategies.	[Tucker, Ross; Raftery, Martin; Hester, Ben] World Rugby Pty Ltd, Dublin, Ireland; [Fuller, Gordon Ward] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Kemp, Simon; Cross, Matthew J.] Rugby Football Union, London, England; [Cross, Matthew J.] Univ Bath, Dept Hlth, Bath, Avon, England		Tucker, R (corresponding author), World Rugby Pty Ltd, Dublin, Ireland.	Ross.tucker@mweb.co.za		Fuller, Gordon Ward/0000-0001-8532-3500; Kemp, Simon/0000-0002-3250-2713	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish		Bahr R, 2003, BRIT J SPORT MED, V37, P384, DOI 10.1136/bjsm.37.5.384; Batten J, 2016, BRIT J SPORT MED, V50, P1293, DOI 10.1136/bjsports-2015-095949; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Freitag A, 2015, BRIT J SPORT MED, V49, P511, DOI 10.1136/bjsports-2014-093684; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hollis SJ, 2011, BRIT J SPORT MED, V45, P997, DOI 10.1136/bjsm.2010.079707; Kemp S, ENGLAND PROFESSIONAL; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Makdissi M, 2016, J SCI MED SPORT, V19, P958, DOI 10.1016/j.jsams.2016.02.014; Mc Fie S, 2016, CLIN J SPORT MED, V26, P398, DOI 10.1097/JSM.0000000000000276; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Raftery M, 2016, BRIT J SPORT MED, V50, P642, DOI 10.1136/bjsports-2016-095959; Roberts SP, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114562781; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9	22	29	29	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2017	51	15					1147	1151		10.1136/bjsports-2017-097883			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	FA9US	WOS:000405792300011	28663217	Green Accepted			2022-02-06	
J	Teng, ZP; Guo, ZD; Zhong, JJ; Cheng, CJ; Huang, ZJ; Wu, Y; Tang, S; Luo, C; Peng, X; Wu, HT; Sun, XC; Jiang, L				Teng, Zhipeng; Guo, Zongduo; Zhong, Jianjun; Cheng, Chongjie; Huang, Zhijian; Wu, Yue; Tang, Shuang; Luo, Chao; Peng, Xing; Wu, Haitao; Sun, Xiaochuan; Jiang, Li			ApoE Influences the Blood-Brain Barrier Through the NF-kappa B/MMP-9 Pathway After Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							APOLIPOPROTEIN-E; MATRIX METALLOPROTEINASES; SUBARACHNOID HEMORRHAGE; MMP-9; APOPTOSIS; MODEL; IMPAIRMENT; DISRUPTION; ACTIVATION; INTEGRITY	Apolipoprotein E (ApoE), encoded by the ApoE gene (APOE), influences the outcomes of traumatic brain injury (TBI), but the mechanism remains unclear. The present study aimed to investigate the effects of different ApoEs on the outcome of TBI and to explore the possible mechanisms. Controlled cortical impact (CCI) was performed on APOE epsilon 3 (E3) and APOE epsilon 4 (E4) transgenic mice, APOE-KO (KO) mice, and wild type (WT) mice to construct an in vivo TBI model. Neurological deficits, blood brain barrier (BBB) permeability and brain edema were detected at days 1, 3, and 7 after TBI. The results revealed no significant differences among the four groups at day 1 or day 3 after injury, but more severe deficits were found in E4 and KO mice than in E3 and WT mice. Furthermore, a significant loss of tight junction proteins was observed in E4 and KO mice compared with E3 and WT mice at day 7. Additionally, more expression and activation of NF-kappa B and MMP-9 were found in E4 mice compared with E3 mice. Different ApoEs had distinct effects on neuro-function and BBB integrity after TBI. ApoE3, but not E4, might inhibit the NF-kappa B/MMP-9 pathway to alleviate BBB disruption and improve TBI outcomes.	[Guo, Zongduo; Zhong, Jianjun; Cheng, Chongjie; Huang, Zhijian; Wu, Yue; Sun, Xiaochuan; Jiang, Li] Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing, Peoples R China; [Teng, Zhipeng; Luo, Chao; Peng, Xing] Chongqing Tradit Chinese Med Hosp, Dept Neurosurg, Chongqing, Peoples R China; [Wu, Haitao] Zunyi Med Coll, Dept Neurosurg, Affiliated Hosp, Zunyi, Guizhou, Peoples R China; [Tang, Shuang] Suining Cent Hosp, Dept Neurosurg, Suining, Sichuan, Peoples R China		Jiang, L (corresponding author), Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing, Peoples R China.	156313147@qq.com		Huang, Zhijian/0000-0002-8241-0761; sun, xiao chuan/0000-0001-6992-332X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81100865, 81571159]; National Key Clinical Specialty Construction Project of China [2011170]; Chongqing Key Discipline [40010200010008]; Guizhou Science and Technology Department [2332]	This work was supported by grants from the National Natural Science Foundation of China (No. 81100865 and 81571159) and the National Key Clinical Specialty Construction Project of China (No. 2011170), Chongqing Key Discipline (No. 40010200010008) and a grant from the Guizhou Science and Technology Department (2013, 2332).	Batra A, 2010, J CEREBR BLOOD F MET, V30, P1188, DOI 10.1038/jcbfm.2010.1; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Candelario-Jalil E, 2011, STROKE, V42, P1345, DOI 10.1161/STROKEAHA.110.600825; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Chen LG, 2015, EXP CELL RES, V334, P294, DOI 10.1016/j.yexcr.2015.03.004; Chen YJ, 2014, BIOCHEM PHARMACOL, V92, P530, DOI 10.1016/j.bcp.2014.09.026; Cheng CJ, 2015, TRANSL STROKE RES, V6, P446, DOI 10.1007/s12975-015-0426-6; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guo ZD, 2015, NEUROL SCI, V36, P1241, DOI 10.1007/s10072-015-2092-6; Guo ZD, 2010, NEUROL RES, V32, P715, DOI 10.1179/016164109X12478302362491; Guo ZD, 2010, NEUROL SCI, V31, P143, DOI 10.1007/s10072-009-0192-x; Hafezi-Moghadam A, 2007, AM J PHYSIOL-CELL PH, V292, pC1256, DOI 10.1152/ajpcell.00563.2005; Halliday MR, 2016, J CEREBR BLOOD F MET, V36, P216, DOI 10.1038/jcbfm.2015.44; Jha R, 2014, STROKE, V45, P1040, DOI 10.1161/STROKEAHA.113.004627; Jia F, 2014, J NEUROTRAUM, V31, P1225, DOI 10.1089/neu.2013.3230; Jiang L, 2015, NEUROSCIENCE, V301, P375, DOI 10.1016/j.neuroscience.2015.06.005; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Lee CS, 2009, ARTERIOSCL THROM VAS, V29, P472, DOI 10.1161/ATVBAHA.108.176230; Nishitsuji K, 2011, J BIOL CHEM, V286, P17536, DOI 10.1074/jbc.M111.225532; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Zheng MH, 2014, J MOL NEUROSCI, V54, P282, DOI 10.1007/s12031-014-0291-x; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003; Zlokovic BV, 2013, JAMA NEUROL, V70, P440, DOI 10.1001/jamaneurol.2013.2152	28	29	31	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 27	2017	7								6649	10.1038/s41598-017-06932-3			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FB8CH	WOS:000406366000007	28751738	gold, Green Published			2022-02-06	
J	Kawata, K; Rubin, LH; Takahagi, M; Lee, JH; Sim, T; Szwanki, V; Bellamy, A; Tierney, R; Langford, D				Kawata, Keisuke; Rubin, Leah H.; Takahagi, Masahiro; Lee, Jong Hyun; Sim, Thomas; Szwanki, Victor; Bellamy, Al; Tierney, Ryan; Langford, Dianne			Subconcussive Impact-Dependent Increase in Plasma S100 Levels in Collegiate Football Players	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; concussion; head impact kinematics; subconcussive; traumatic brain injury	NEURON-SPECIFIC ENOLASE; BRAIN-INJURY; BLOOD BIOMARKERS; SERUM; S-100B; VULNERABILITY; MARKER; ADULTS; DAMAGE	The current study investigates whether repetitive subconcussive impacts cause changes in plasma S100 levels, and also tests the associations between S100 changes and frequency/magnitude of impacts sustained. This prospective study of 22 Division-I collegiate football players included baseline and pre-season practices (one helmet-only and four full-gear). Blood samples were obtained and assessed for S100 levels at baseline and pre- to post-practices; symptom scores were assessed at each time-point. An accelerometer-embedded mouthguard was employed to measure the number of impacts (hits), peak linear acceleration (PLA), and peak rotational acceleration (PRA). Because we observed a distinct gap in impact exposure (hits, PLA, and PRA), players were clustered into lower (n=7) or higher (n=15) impact groups based on the sum of impact kinematics from all five practices. S100 levels significantly changed across the study duration. Although S100 levels remained stable from baseline to all pre-practice values, statistically significant acute increases in S100 levels were observed in all post-practice measures compared with the respective pre-practice values (range: 133-246% in the overall sample). Greater number of hits, sum of PLA, and sum of PRA were significantly associated with greater acute increases in S100 levels. There were significant differences in head impact kinematics between lower and higher impact groups (hits, 6 vs. 43 [M-lower - M-higher=35, p<0.001]; PLA, 99.4 vs. 1148.5 g [M-lower - M-higher=1049.1, p<0.001]; PRA, 7589 vs. 68,259rad/s(2) [M-lower - M-higher=60,670, p<0.001]). Players in the higher impact group showed consistently greater increases in plasma S100 levels, but not symptom scores, at each post-practice than the lower impact group. Collectively, these data suggest that although players continued to play without noticeable change in symptoms, a brain-enriched serological factor suggests an acute burden from head impacts. Assessing the effects of repetitive subconcussive head impacts on acute changes in S100 levels may be a clinically useful blood biomarker in tracking real-time acute brain damage in collegiate football players.	[Kawata, Keisuke; Lee, Jong Hyun; Langford, Dianne] Temple Univ, Dept Neurosci, Lewis Katz Sch Med, MERB 750,3500 North Broad St, Philadelphia, PA 19122 USA; [Kawata, Keisuke] Indiana Univ, Dept Kinesiol, Bloomington, IN 47405 USA; [Rubin, Leah H.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; [Takahagi, Masahiro; Szwanki, Victor; Bellamy, Al] Temple Univ, Dept Athlet, Philadelphia, PA 19122 USA; [Sim, Thomas; Tierney, Ryan] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA		Langford, D (corresponding author), Temple Univ, Dept Neurosci, Lewis Katz Sch Med, MERB 750,3500 North Broad St, Philadelphia, PA 19122 USA.	tdl@temple.edu			Pennsylvania Athletic Trainers' Society; Marianne Garman Burton Foundation for Caregivers; Temple University Office of the Vice Provost for Research	This work was supported by the Pennsylvania Athletic Trainers' Society research grant (to K. Kawata), generous support from Athole G. Jacobi, MD, and from the Marianne Garman Burton Foundation for Caregivers (to D. Langford), and a seed grant from Temple University Office of the Vice Provost for Research (to D. Langford). Sponsors had no role in the design or execution of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Daley M, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1131-5; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; Effgen GB, 2017, J NEUROTRAUM, V34, P914, DOI 10.1089/neu.2016.4477; Effgen GB, 2016, J NEUROTRAUM, V33, P1901, DOI 10.1089/neu.2015.4327; Esposito G, 2008, J CELL MOL MED, V12, P914, DOI 10.1111/j.1582-4934.2008.00159.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Higgins M, 2007, J ATHL TRAINING, V42, P5; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Kawata K, 2016, NEUROSCI BIOBEHAV R, V68, P460, DOI 10.1016/j.neubiorev.2016.05.009; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Kiechle K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084977; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Tyler CJ, 2010, EUR J APPL PHYSIOL, V110, P1063, DOI 10.1007/s00421-010-1567-7; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Weiner RB, 2013, CIRCULATION, V128, P524, DOI 10.1161/CIRCULATIONAHA.113.003522; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	40	29	29	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2017	34	14					2254	2260		10.1089/neu.2016.4786			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EZ8RQ	WOS:000404995000008	28181857				2022-02-06	
J	Brody, AL; Hubert, R; Enoki, R; Garcia, LY; Mamoun, MS; Okita, K; London, ED; Nurmi, EL; Seaman, LC; Mandelkern, MA				Brody, Arthur L.; Hubert, Robert; Enoki, Ryutaro; Garcia, Lizette Y.; Mamoun, Michael S.; Okita, Kyoji; London, Edythe D.; Nurmi, Erika L.; Seaman, Lauren C.; Mandelkern, Mark A.			Effect of Cigarette Smoking on a Marker for Neuroinflammation: A [C-11]DAA1106 Positron Emission Tomography Study	NEUROPSYCHOPHARMACOLOGY			English	Article							PERIPHERAL BENZODIAZEPINE-RECEPTOR; NICOTINIC ACETYLCHOLINE-RECEPTORS; PROTEIN 18 KDA; TRAUMATIC BRAIN-INJURY; LIGAND DAA1106 BINDS; IN-VIVO BINDING; TRANSLOCATOR PROTEIN; ALZHEIMERS-DISEASE; MICROGLIAL ACTIVATION; DOPAMINE RELEASE	In the brain, microglia continuously scan the surrounding extracellular space in order to respond to damage or infection by becoming activated and participating in neuroinflammation. When activated, microglia increase the expression of translocator protein (TSPO) 18 kDa, thereby making the TSPO expression a marker for neuroinflammation. We used the radiotracer [C-11] DAA1106 (a ligand for TSPO) and positron emission tomography (PET) to determine the effect of smoking on availability of this marker for neuroinflammation. Forty-five participants (30 smokers and 15 non-smokers) completed the study and had usable data. Participants underwent a dynamic PET scanning session with bolus injection of [C-11] DAA1106 (with smokers in the satiated state) and blood draws during PET scanning to determine TSPO affinity genotype and plasma nicotine levels. Whole-brain standardized uptake values (SUVs) were determined, and analysis of variance was performed, with group (smoker vs non-smoker) and genotype as factors, thereby controlling for genotype. Smokers and non-smokers differed in whole-brain SUVs (P = 0.006) owing to smokers having 16.8% lower values than non-smokers. The groups did not differ in injected radiotracer dose or body weight, which were used to calculate SUV. An inverse association was found between whole-brain SUV and reported cigarettes per day (P<0.05), but no significant relationship was found for plasma nicotine. Thus, smokers have less [C-11] DAA1106 binding globally than non-smokers, indicating less microglial activation. Study findings are consistent with much prior research demonstrating that smokers have impaired inflammatory functioning compared with non-smokers and that constituents of tobacco smoke other than nicotine affect inflammatory processes.	[Brody, Arthur L.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Brody, Arthur L.] VA San Diego Healthcare Syst, Dept Psychiat, San Diego, CA USA; [Hubert, Robert; Enoki, Ryutaro; Garcia, Lizette Y.; Mamoun, Michael S.; Okita, Kyoji] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA; [Okita, Kyoji; London, Edythe D.; Nurmi, Erika L.; Seaman, Lauren C.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA; [Mandelkern, Mark A.] VA Greater Los Angeles Healthcare Syst, Dept Radiol, Los Angeles, CA USA		Brody, AL (corresponding author), Univ Calif San Diego, Dept Psychiat, VA San Diego Healthcare Syst, 3350 La Jolla Village Dr,116A, San Diego, CA 92161 USA.	abrody@ucsd.edu	Nurmi, Erika/AAX-1625-2020; Nurmi, Erika L/P-4627-2014	Nurmi, Erika/0000-0003-4893-8957; Nurmi, Erika L/0000-0003-4893-8957	Tobacco-Related Disease Research ProgramUniversity of California System [23XT-0002]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01 DA20872]; Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award) [I01 CX000412]; DOMONKAI fund from the Department of Psychiatry, Graduate School of Medicine, at Chiba University; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 DA024635]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA024635] Funding Source: NIH RePORTER	This study was supported by the Tobacco-Related Disease Research Program (to ALB (23XT-0002)), the National Institute on Drug Abuse (to ALB (R01 DA20872)), and the Department of Veterans Affairs, Office of Research and Development (CSR&D Merit Review Award I01 CX000412 (to ALB)). This research was also supported, in part, by the DOMONKAI fund from the Department of Psychiatry, Graduate School of Medicine, at Chiba University (to KO), endowments from the Thomas P. and Katherine K. Pike Chair in Addiction Studies (to EDL) and Marjorie M. Green Trust (to EDL), and the National Institutes of Health (T32 DA024635 (to LCS)). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The authors declare no conflict of interest.	Abobo CV, 2012, NICOTINE TOB RES, V14, P801, DOI 10.1093/ntr/ntr287; Anthony DC, 2013, MOL CELL NEUROSCI, V53, P1, DOI 10.1016/j.mcn.2012.11.005; Arimilli S, 2015, JOVE-J VIS EXP, DOI 10.3791/52351; Baker RR, 2004, FOOD CHEM TOXICOL, V42, pS53, DOI 10.1016/j.fct.2004.01.001; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483, DOI 10.1038/clpt.1994.169; Brody AL, 2004, AM J PSYCHIAT, V161, P1211, DOI 10.1176/appi.ajp.161.7.1211; Brody AL, 2002, ARCH GEN PSYCHIAT, V59, P1162, DOI 10.1001/archpsyc.59.12.1162; Brody AL, 2006, ARCH GEN PSYCHIAT, V63, P808, DOI 10.1001/archpsyc.63.7.808; Brody AL, 2006, ARCH GEN PSYCHIAT, V63, P907, DOI 10.1001/archpsyc.63.8.907; Brody AL, 2013, INT J NEUROPSYCHOPH, V16, P957, DOI 10.1017/S1461145712001022; Brody AL, 2011, ARCH GEN PSYCHIAT, V68, P953, DOI 10.1001/archgenpsychiatry.2011.51; Brody AL, 2009, INT J NEUROPSYCHOPH, V12, P305, DOI 10.1017/S146114570800922X; Brody AL, 2009, NEUROPSYCHOPHARMACOL, V34, P282, DOI 10.1038/npp.2008.87; Chaki S, 1999, EUR J PHARMACOL, V371, P197, DOI 10.1016/S0014-2999(99)00118-1; Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9; Colasanti A, 2016, BIOL PSYCHIAT, V80, P62, DOI 10.1016/j.biopsych.2015.11.022; Cosgrove KP, 2009, ARCH GEN PSYCHIAT, V66, P666, DOI 10.1001/archgenpsychiatry.2009.41; Coughlin JM, 2014, J NEUROVIROL, V20, P219, DOI 10.1007/s13365-014-0239-5; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; Fan Z, 2015, BRAIN, V138, P3685, DOI 10.1093/brain/awv288; First MB, 1995, STRUCTURED CLIN INTE; Fowles J, 2003, TOB CONTROL, V12, P424, DOI 10.1136/tc.12.4.424; Gandhi KK, 2009, INT J CLIN PRACT, V63, P360, DOI 10.1111/j.1742-1241.2008.01969.x; Gao Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107979; Goncalves RB, 2011, INFLAMM RES, V60, P409, DOI 10.1007/s00011-011-0308-7; Green CR, 1996, RECENT ADV TOBACCO S, V22, P131; Haarman BCM, 2016, BRAIN BEHAV IMMUN, V56, P21, DOI 10.1016/j.bbi.2015.09.004; Hafizi S, 2017, AM J PSYCHIAT, V174, P118, DOI 10.1176/appi.ajp.2016.16020171; Hamelin L, 2016, BRAIN, V139, P1252, DOI 10.1093/brain/aww017; Hannestad J, 2013, BRAIN BEHAV IMMUN, V33, P131, DOI 10.1016/j.bbi.2013.06.010; HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119; Henderson BJ, 2015, NEUROPHARMACOLOGY, V96, P178, DOI 10.1016/j.neuropharm.2015.01.022; Hines CS, 2013, J NUCL MED, V54, P64, DOI 10.2967/jnumed.112.106872; Ikoma Y, 2007, J CEREBR BLOOD F MET, V27, P173, DOI 10.1038/sj.jcbfm.9600325; Kalra R, 2004, CLIN DIAGN LAB IMMUN, V11, P563, DOI 10.1128/CDLI.11.3.563-568.2004; Khanna A, 2013, J NEUROIMMUNOL, V254, P69, DOI 10.1016/j.jneuroim.2012.09.006; Koshimori Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138721; Kreisl WC, 2016, NEUROBIOL AGING, V44, P53, DOI 10.1016/j.neurobiolaging.2016.04.011; Kreisl WC, 2013, BRAIN, V136, P2228, DOI 10.1093/brain/awt145; Lartey FM, 2014, MOL IMAGING BIOL, V16, P109, DOI 10.1007/s11307-013-0664-5; Lyoo CH, 2015, J NUCL MED, V56, P701, DOI 10.2967/jnumed.114.146027; Maeda J, 2004, SYNAPSE, V52, P283, DOI 10.1002/syn.20027; Mizrahi R, 2012, J CEREBR BLOOD F MET, V32, P968, DOI 10.1038/jcbfm.2012.46; Muscat JE, 2009, CANCER EPIDEM BIOMAR, V18, P35, DOI 10.1158/1055-9965.EPI-08-0744; Nair A, 2016, EJNMMI RES, V6, DOI 10.1186/s13550-016-0226-3; Narendran R, 2014, J NEUROSCI, V34, P9945, DOI 10.1523/JNEUROSCI.0928-14.2014; Nayak D, 2014, ANNU REV IMMUNOL, V32, P367, DOI 10.1146/annurev-immunol-032713-120240; Okubo T, 2004, BIOORGAN MED CHEM, V12, P423, DOI 10.1016/j.bmc.2003.10.050; Okuyemi KS, 2007, ADDICTION, V102, P1979, DOI 10.1111/j.1360-0443.2007.02010.x; Ory D, 2015, NUCL MED BIOL, V42, P753, DOI 10.1016/j.nucmedbio.2015.06.010; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Owen DRJ, 2011, J NUCL MED, V52, P24, DOI 10.2967/jnumed.110.079459; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Piao WH, 2009, ACTA PHARMACOL SIN, V30, P715, DOI 10.1038/aps.2009.67; Pletcher MJ, 2006, ARCH INTERN MED, V166, P1915, DOI 10.1001/archinte.166.17.1915; Pluvy I, 2015, ANN CHIR PLAST ESTH, V60, pE3, DOI 10.1016/j.anplas.2014.06.011; Reuther WJ, 2014, BRIT J ORAL MAX SURG, V52, P102, DOI 10.1016/j.bjoms.2013.11.003; Rinker B, 2013, ANN PLAS SURG, V70, P599, DOI 10.1097/SAP.0b013e3182764fcd; Rizzo G, 2014, J CEREBR BLOOD F MET, V34, P1060, DOI 10.1038/jcbfm.2014.55; Sajja RK, 2016, J CEREBR BLOOD F MET, V36, P539, DOI 10.1177/0271678X15616978; SAMHSA, 2009, SUBST AB MENT HLTH S; Sandiego CM, 2015, P NATL ACAD SCI USA, V112, P12468, DOI 10.1073/pnas.1511003112; Setiawan E, 2015, JAMA PSYCHIAT, V72, P268, DOI 10.1001/jamapsychiatry.2014.2427; SHIFFMAN SM, 1976, PSYCHOPHARMACOLOGY, V50, P35, DOI 10.1007/BF00634151; Sorensen LT, 2012, ARCH SURG-CHICAGO, V147, P373, DOI 10.1001/archsurg.2012.5; Spielberger CD, 1989, MANUAL STATE TRAIT A, V2nd; Staley JK, 2006, J NEUROSCI, V26, P8707, DOI 10.1523/JNEUROSCI.0546-06.2006; Surendranathan A, 2015, PARKINSONISM RELAT D, V21, P1398, DOI 10.1016/j.parkreldis.2015.10.009; Suridjan I, 2015, MOL PSYCHIATR, V20, P1579, DOI 10.1038/mp.2015.1; Suridjan I, 2014, NEUROIMAGE, V84, P868, DOI 10.1016/j.neuroimage.2013.09.021; Takano A, 2010, INT J NEUROPSYCHOPH, V13, P943, DOI 10.1017/S1461145710000313; Tilp C, 2016, CLIN EXP ALLERGY, V46, P957, DOI 10.1111/cea.12665; Toth M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125917; Towler J, 2000, J Wound Care, V9, P100; Turkheimer FE, 2015, BIOCHEM SOC T, V43, P586, DOI 10.1042/BST20150058; Varrone A, 2015, EUR J NUCL MED MOL I, V42, P438, DOI 10.1007/s00259-014-2955-8; Venneti S, 2008, J NEUROPATH EXP NEUR, V67, P1001, DOI 10.1097/NEN.0b013e318188b204; Venneti S, 2007, EXP NEUROL, V207, P118, DOI 10.1016/j.expneurol.2007.06.003; Venneti S, 2007, J NEUROCHEM, V102, P2118, DOI 10.1111/j.1471-4159.2007.04690.x; Walberer M, 2014, BRAIN RES, V1581, P80, DOI 10.1016/j.brainres.2014.05.030; Walker MD, 2015, J CEREBR BLOOD F MET, V35, P1331, DOI 10.1038/jcbfm.2015.54; Wang M, 2012, APPL RADIAT ISOTOPES, V70, P965, DOI 10.1016/j.apradiso.2012.03.011; Wang Y, 2014, EUR J NUCL MED MOL I, V41, P1440, DOI 10.1007/s00259-014-2727-5; Williams JM, 2007, NICOTINE TOB RES, V9, P873, DOI 10.1080/14622200701484995; Yasuno F, 2012, PSYCHIAT RES-NEUROIM, V203, P67, DOI 10.1016/j.pscychresns.2011.08.013; Yasuno F, 2008, BIOL PSYCHIAT, V64, P835, DOI 10.1016/j.biopsych.2008.04.021; Yoder KK, 2015, NUCL MED BIOL, V42, P305, DOI 10.1016/j.nucmedbio.2014.11.003; Yoder KK, 2013, J NUCL MED, V54, P1320, DOI 10.2967/jnumed.112.118885; Yu I, 2010, J NEUROTRAUM, V27, P1463, DOI 10.1089/neu.2009.1196; Zhang MR, 2003, NUCL MED BIOL, V30, P513, DOI 10.1016/S0969-8051(03)00016-7; Zurcher NR, 2015, NEUROIMAGE-CLIN, V7, P409, DOI 10.1016/j.nicl.2015.01.009	92	29	30	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JUL	2017	42	8					1630	1639		10.1038/npp.2017.48			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	EX4WL	WOS:000403235600008	28262740	Green Published, Bronze			2022-02-06	
J	Liu, XY; Donnelly, J; Czosnyka, M; Aries, MJH; Brady, K; Cardim, D; Robba, C; Cabeleira, M; Kim, DJ; Haubrich, C; Hutchinson, PJ; Smielewski, P				Liu, Xiuyun; Donnelly, Joseph; Czosnyka, Marek; Aries, Marcel J. H.; Brady, Ken; Cardim, Danilo; Robba, Chiara; Cabeleira, Manuel; Kim, Dong-Joo; Haubrich, Christina; Hutchinson, Peter J.; Smielewski, Peter			Cerebrovascular pressure reactivity monitoring using wavelet analysis in traumatic brain injury patients: A retrospective study	PLOS MEDICINE			English	Article							DYNAMIC CEREBRAL AUTOREGULATION; ARTERIAL-BLOOD-PRESSURE; PERFUSION-PRESSURE; COHERENCE ANALYSIS; INTRACRANIAL-PRESSURE; HEART-RATE; AGE; CIRCULATION; TRANSFORM	Background After traumatic brain injury (TBI), the ability of cerebral vessels to appropriately react to changes in arterial blood pressure (pressure reactivity) is impaired, leaving patients vulnerable to cerebral hypo-or hyperperfusion. Although, the traditional pressure reactivity index (PRx) has demonstrated that impaired pressure reactivity is associated with poor patient outcome, PRx is sometimes erratic and may not be reliable in various clinical circumstances. Here, we introduce a more robust transform-based wavelet pressure reactivity index (wPRx) and compare its performance with the widely used traditional PRx across 3 areas: its stability and reliability in time, its ability to give an optimal cerebral perfusion pressure (CPPopt) recommendation, and its relationship with patient outcome. Methods and findings Five hundred and fifteen patients with TBI admitted in Addenbrooke's Hospital, United Kingdom (March 23rd, 2003 through December 9th, 2014), with continuous monitoring of arterial blood pressure (ABP) and intracranial pressure (ICP), were retrospectively analyzed to calculate the traditional PRx and a novel wavelet transform-based wPRx. wPRx was calculated by taking the cosine of the wavelet transform phase-shift between ABP and ICP. A time trend of CPPopt was calculated using an automated curve-fitting method that determined the cerebral perfusion pressure (CPP) at which the pressure reactivity (PRx or wPRx) was most efficient (CPPopt_PRx and CPPopt_wPRx, respectively). There was a significantly positive relationship between PRx and wPRx (r = 0.73), and wavelet wPRx was more reliable in time (ratio of between-hour variance to total variance, wPRx 0.957 +/- 0.0032 versus PRx and 0.949 +/- 0.047 for PRx, p = 0.002). The 2-hour interval standard deviation of wPRx (0.19 +/- 0.07) was smaller than that of PRx (0.30 +/- 0.13, p < 0.001). wPRx performed better in distinguishing between mortality and survival (the area under the receiver operating characteristic [ROC] curve [AUROC] for wPRx was 0.73 versus 0.66 for PRx, p = 0.003). The mean difference between the patients' CPP and their CPPopt was related to outcome for both calculation methods. There was a good relationship between the 2 CPPopts (r = 0.814, p < 0.001). CPPopt_wPRx was more stable than CPPopt_ PRx (within patient standard deviation 7.05 +/- 3.78 versus 8.45 +/- 2.90; p < 0.001). Key limitations include that this study is a retrospective analysis and only compared wPRx with PRx in the cohort of patients with TBI. Prior prospective validation is required to better assess clinical utility of this approach. Conclusions wPRx offers several advantages to the traditional PRx: it is more stable in time, it yields a more consistent CPPopt recommendation, and, importantly, it has a stronger relationship with patient outcome. The clinical utility of wPRx should be explored in prospective studies of critically injured neurological patients.	[Liu, Xiuyun; Donnelly, Joseph; Czosnyka, Marek; Aries, Marcel J. H.; Cardim, Danilo; Robba, Chiara; Cabeleira, Manuel; Hutchinson, Peter J.; Smielewski, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Aries, Marcel J. H.] Maastricht Univ, Med Ctr, Dept Intens Care, Maastricht, Netherlands; [Brady, Ken] Baylor Coll Med, Houston, TX 77030 USA; [Robba, Chiara] Univ Genoa, Dept Neurosci, Genoa, Italy; [Kim, Dong-Joo] Korea Univ, Dept Brain & Cognit Engn, Seoul, South Korea; [Haubrich, Christina] Univ Aachen, Fac Med, Aachen, Germany		Liu, XY (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge, England.	xl334@cam.ac.uk	Liu, Xiuyun/V-4427-2017; Donnelly, Joseph/E-9235-2018; Robba, Chiara/AAS-7421-2020; Cardim, Danilo Augusto/B-8447-2012; Donnelly, Joseph/N-6803-2019	Liu, Xiuyun/0000-0001-9540-4865; Donnelly, Joseph/0000-0002-6502-8069; Cardim, Danilo Augusto/0000-0002-9261-1321; Donnelly, Joseph/0000-0002-6502-8069; Cabeleira, Manuel/0000-0002-1710-6544; Brady, Ken/0000-0002-3260-0233	Gates Cambridge Scholarship (University of Cambridge)University of Cambridge; Woolf Fisher Scholarship (the Woolf Fisher Trust, NZ); Cambridge Commonwealth, European & International Trust Scholarship (University of Cambridge); National Institute for Health Research (NIHR) ProfessorshipNational Institute for Health Research (NIHR); NIHR Cambridge Bran Repair Centre; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0601025, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G1002277, G0601025] Funding Source: UKRI	XL is a recipient of Gates Cambridge Scholarship (University of Cambridge, https://www.gatescambridge.org/). JD is funded by Woolf Fisher Scholarship (the Woolf Fisher Trust, NZ, http://www.woolffishertrust.co.nz/). DC is supported by a Cambridge Commonwealth, European & International Trust Scholarship (University of Cambridge, https://www.cambridgetrust.org/). PJH is supported by a National Institute for Health Research (NIHR) Professorship and the NIHR Cambridge Bran Repair Centre. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addison P., 2002, BIOMEDICAL INSTRUMEN; Addison P. S., 2002, ILLUSTRATED WAVELET, P353; [Anonymous], 2015, C P IEEE ENG MED BIO, V8, P5960; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Carey BJ, 2003, STROKE, V34, P1871, DOI 10.1161/01.STR.0000081981.99908.F3; Cooper PR, 1993, HEAD INJURY; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; FLEG JL, 1986, AM J CARDIOL, V57, pC33, DOI 10.1016/0002-9149(86)91025-8; GRIBBIN B, 1971, CIRC RES, V29, P424, DOI 10.1161/01.RES.29.4.424; Grinsted A, 2004, NONLINEAR PROC GEOPH, V11, P561, DOI 10.5194/npg-11-561-2004; JENNETT B, 1975, LANCET, V1, P480; KANNEL WB, 1978, B NEW YORK ACAD MED, V54, P573; Keissar K, 2009, PHILOS T R SOC A, V367, P1393, DOI 10.1098/rsta.2008.0273; Kvandal P, 2013, J CLIN MONIT COMPUT, V27, P375, DOI 10.1007/s10877-013-9484-z; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Obuchowski NA, 2003, RADIOLOGY, V229, P3, DOI 10.1148/radiol.2291010898; Panerai RB, 2002, PHYSIOL MEAS, V23, P59, DOI 10.1088/0967-3334/23/1/306; Robin A. X., 2013, PACKAGE PROC, V12, P1, DOI [10.1186/1471-2105-12-77, DOI 10.1186/1471-2105-12-77]; Soul JS, 2007, PEDIATR RES, V61, P467, DOI 10.1203/pdr.0b013e31803237f6; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tian FH, 2016, NEUROIMAGE-CLIN, V11, P124, DOI 10.1016/j.nicl.2016.01.020; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Toledo E, 2003, AM J PHYSIOL-REG I, V284, pR1079, DOI 10.1152/ajpregu.00287.2002; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Wagner M, 2012, AM J NEURORADIOL, V33, P2081, DOI 10.3174/ajnr.A3138; Yam AT, 2005, J CLIN NEUROSCI, V12, P643, DOI 10.1016/j.jocn.2004.08.017	34	29	29	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JUL	2017	14	7							e1002348	10.1371/journal.pmed.1002348			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FC1QA	WOS:000406611200018	28742798	Green Published, gold, Green Submitted			2022-02-06	
J	Zhang, MK; Cui, ZW; Cui, H; Wang, Y; Zhong, CL				Zhang, Mingkun; Cui, Zhenwen; Cui, Hua; Wang, Yong; Zhong, Chunlong			Astaxanthin protects astrocytes against trauma-induced apoptosis through inhibition of NKCC1 expression via the NF-kappa B signaling pathway	BMC NEUROSCIENCE			English	Article						Astaxanthin; Traumatic brain injury; Apoptosis; Astrocyte; Na+-K+-2Cl(-) co-transporter-1; NF-kappa B	INDUCED BRAIN EDEMA; CULTURED ASTROCYTES; CL-COTRANSPORTER; OXIDATIVE STRESS; ACTIVATION; INJURY; NEUROPROTECTION; GENE; NA+; INFLAMMATION	Background: Astaxanthin (ATX) is a carotenoid pigment with pleiotropic pharmacological properties that is seen as a possible drug for treating cerebral ischemic injury and subarachnoid hemorrhage. Na+-K+-2Cl(-) co-transporter-1 (NKCC1), an intrinsic membrane protein expressed by many cell types, is activated by various insults, leading to the formation of cell swelling and brain edema. We previously established that ATX attenuated brain edema and improved neurological outcomes by modulating NKCC1 expression after traumatic brain injury in mice. This paper explored the molecular mechanism of ATX-mediated inhibition of NKCC1 utilizing an in vitro astrocyte stretch injury model. Results: Stretch injury in cultured astrocytes lowered cell viability time-dependently, which was substantially reducing by pretreating with ATX (50 mu mol/L). Stretch injury increased Bax level and cleaved caspase-3 activity, and decreased Bcl-2 level and pro-caspase 3 activity, resulting in the apoptosis of astrocytes. Additionally, stretch injury substantially raised the gene and protein expressions of interleukin (IL)-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha and prompted the expression and nuclear translocation of NF-kappa B. Pretreatment with ATX remarkably prevented the trauma-induced initiation of NF-kappa B, expressions of pro-inflammatory cytokines, and cell apoptosis. Moreover, stretch injury markedly elevated the gene and protein expression of NKCC1, which was partly blocked by co-treatment with ATX (50 mu mol/L) or an NF-kappa B inhibitor (PDTC, 10 mu mol/L). Cleaved caspase-3 activity was partially reduced by PDTC (10 mu mol/L) or an NKCC1 inhibitor (bumetanide, 50 mu mol/L). Conclusions: ATX attenuates apoptosis after stretch injury in cultured astrocytes by inhibiting NKCC1 expression, and it acts by reducing the expression of NF-kappa B-mediated pro-inflammatory factors.	[Zhang, Mingkun; Cui, Hua; Wang, Yong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China; [Zhang, Mingkun; Cui, Zhenwen; Zhong, Chunlong] Tongji Univ, Sch Med, East Hosp, Dept Neurosurg, 150 Jimo Rd, Shanghai 200120, Peoples R China; [Cui, Zhenwen] Qingdao Univ, Dept Neurosurg, Affiliated Hosp, Qingdao 266005, Peoples R China		Wang, Y (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, Shanghai 200127, Peoples R China.; Zhong, CL (corresponding author), Tongji Univ, Sch Med, East Hosp, Dept Neurosurg, 150 Jimo Rd, Shanghai 200120, Peoples R China.	wangyong68@163.com; drchunlongzhong@126.com		Zhong, Chunlong/0000-0002-0605-7273	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571184, 81070990, 30670719, 30500525]; Shanghai Science and Technology CommissionShanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM) [15140902100, 10QH1401700, 09140901300]; Shanghai Municipal Education CommissionShanghai Municipal Education Commission (SHMEC) [09SG20]	We received funds from the National Natural Science Foundation of China (Nos. 81571184, 81070990, 30670719, 30500525) and the Shanghai Science and Technology Commission (Nos. 15140902100, 10QH1401700) in the process of study design, experiment implementation and data collection. Data interpretation and article writing were supported by the grants from the Shanghai Science and Technology Commission (No. 09140901300) and the Shanghai Municipal Education Commission (No. 09SG20).	Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Borsello T, 2007, CURR PHARM DESIGN, V13, P1875; Chan KC, 2009, J FOOD SCI, V74, pH225, DOI 10.1111/j.1750-3841.2009.01274.x; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Conti L, 2011, EPILEPSIA, V52, P1635, DOI 10.1111/j.1528-1167.2011.03111.x; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Cui ZW, 2015, ACTA PHARMACOL SIN, V36, P1426, DOI 10.1038/aps.2015.90; Cuzzocrea S, 2002, BRIT J PHARMACOL, V135, P496, DOI 10.1038/sj.bjp.0704463; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Franceschelli S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088359; Haas BR, 2010, CANCER RES, V70, P5597, DOI 10.1158/0008-5472.CAN-09-4666; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Jayakumar AR, 2010, METAB BRAIN DIS, V25, P31, DOI 10.1007/s11011-010-9180-3; Jensen CJ, 2013, J NEUROIMMUNE PHARM, V8, P824, DOI 10.1007/s11481-013-9480-6; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Khan SK, 2010, THROMB RES, V126, P299, DOI 10.1016/j.thromres.2010.07.003; Kim JA, 2001, BIOCHEM BIOPH RES CO, V281, P511, DOI 10.1006/bbrc.2001.4371; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Lee SJ, 2003, MOL CELLS, V16, P97; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; Marmarou A, 2003, ACT NEUR S, V86, P7; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Sathish V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023662; Sehnert B, 2013, P NATL ACAD SCI USA, V110, P16556, DOI 10.1073/pnas.1218219110; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Sirabella R, 2009, STROKE, V40, P922, DOI 10.1161/STROKEAHA.108.531962; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Speranza L, 2012, MAR DRUGS, V10, P890, DOI 10.3390/md10040890; Valsecchi V, 2013, ADV EXP MED BIOL, V961, P137, DOI 10.1007/978-1-4614-4756-6_12; Wu Q, 2014, MAR DRUGS, V12, P6125, DOI 10.3390/md12126125; Xing B, 2007, J NEUROIMMUNOL, V192, P89, DOI 10.1016/j.jneuroim.2007.09.029; Yan YP, 2001, J CEREBR BLOOD F MET, V21, P711, DOI 10.1097/00004647-200106000-00009; Youdim MBH, 1999, ANN NY ACAD SCI, V890, P7, DOI 10.1111/j.1749-6632.1999.tb07977.x; Yu Y, 2009, CIRCULATION, V119, P2313, DOI 10.1161/CIRCULATIONAHA.108.782458; Zhang MA, 2016, ENERGY STORAGE MATER, V4, P1, DOI 10.1016/j.ensm.2016.02.001; Zhang XS, 2014, J SURG RES, V192, P206, DOI 10.1016/j.jss.2014.05.029; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730	47	29	32	5	16	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	MAY 10	2017	18								42	10.1186/s12868-017-0358-z			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EV4LP	WOS:000401731800001	28490320	gold, Green Published			2022-02-06	
J	Khalili, H; Derakhshan, N; Niakan, A; Ghaffarpasand, F; Salehi, M; Eshraghian, H; Shakibafard, A; Zahabi, B				Khalili, Hosseinali; Derakhshan, Nima; Niakan, Amin; Ghaffarpasand, Fariborz; Salehi, Mohammad; Eshraghian, Hamed; Shakibafard, Alireza; Zahabi, Bita			Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial	WORLD NEUROSURGERY			English	Article						Contusion; Functional outcome; Glibenclamide; Traumatic brain injury	RAT MODEL; UNITED-STATES; EDEMA; NEUROINFLAMMATION; PATHOPHYSIOLOGY; INHIBITION; HEMORRHAGE; GLYBURIDE	OBJECTIVE: This study investigated effects of oral glibenclamide on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries. METHODS: A randomized clinical trial including 66 patients with moderate (Glasgow Coma Scale score 9-12) to severe (Glasgow Coma Scale score 5-8) traumatic brain injury and brain contusions of <30 mL volume was conducted from May 2015 to August 2016 in a Level I trauma center in southern Iran. Patients who required surgical intervention were excluded. Patients were randomly assigned to receive 10 mg oral glibenclamide daily for 10 days (n = 29) or placebo in the same dosage (n = 23). Brain contusion volumetry was performed on days 0, 3, and 7 using spiral thin-cut brain computed tomography scan (1-mm thickness). Outcome measures including modified Rankin Scale, Glasgow Outcome Scale, and Disability Rating Scale were evaluated 3 months after injury. RESULTS: There was no significant difference between the 2 study groups in baseline, day 3, and day 7 contusion volumes. Patients receiving glibenclamide had a significantly lower expansion ratio from first to second volumetry (P < 0.001). Similarly, the first to third expansion ratio was significantly lower in the glibenclamide group compared with placebo (P = 0.003). There was no significant difference between the 2 groups regarding functional outcome measured by Glasgow Outcome Scale, modified Rankin Scale, and Disability Rating Scale. CONCLUSIONS: Oral glibenclamide is associated with decreased contusion expansion rate in patients with moderate and severe traumatic brain injuries sustaining cerebral contusions.	[Khalili, Hosseinali; Niakan, Amin] Shiraz Univ Med Sci, Trauma Res Ctr, Shiraz, Iran; [Derakhshan, Nima; Ghaffarpasand, Fariborz] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran; [Khalili, Hosseinali; Derakhshan, Nima; Niakan, Amin; Ghaffarpasand, Fariborz; Salehi, Mohammad; Eshraghian, Hamed] Shiraz Univ Med Sci, Dept Neurosurg, Shiraz, Iran; [Shakibafard, Alireza; Zahabi, Bita] Shiraz Univ Med Sci, Dept Radiol, Shiraz, Iran; [Zahabi, Bita] Chamran Hosp, Radiol Dept, Shiraz, Iran		Derakhshan, N (corresponding author), Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran.; Derakhshan, N (corresponding author), Shiraz Univ Med Sci, Dept Neurosurg, Shiraz, Iran.	nima_med83@yahoo.com	Khalili, Hosseinali/I-1087-2016; Derakhshan, Nima/Q-2454-2019; niakan, amin/A-6818-2019; Ghaffarpasand, Fariborz/I-4204-2019	Khalili, Hosseinali/0000-0002-3390-4212; Derakhshan, Nima/0000-0001-7142-3404; niakan, amin/0000-0003-2644-8543; Ghaffarpasand, Fariborz/0000-0002-1721-9987			Boggs DH, 2014, EXPERT REV NEUROTHER, V14, P379, DOI 10.1586/14737175.2014.890891; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Ding J, 2013, CLIN NEUROL NEUROSUR, V115, P2166, DOI 10.1016/j.clineuro.2013.08.010; Fiez JA, 2000, HUM BRAIN MAPP, V9, P192, DOI 10.1002/(SICI)1097-0193(200004)9:4<192::AID-HBM2>3.0.CO;2-Y; Gerzanich V, 2009, NAT MED, V15, P185, DOI 10.1038/nm.1899; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Heydari ST, 2013, PUBLIC HEALTH, V127, P704, DOI 10.1016/j.puhe.2013.05.003; Hosier H, 2015, J NEUROTRAUM, V32, P1633, DOI 10.1089/neu.2015.3892; Khalili H, 2017, CLIN NEUROL NEUROSUR, V152, P34, DOI 10.1016/j.clineuro.2016.11.011; Khalili H, 2016, WORLD NEUROSURG, V94, P120, DOI 10.1016/j.wneu.2016.06.122; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kunte H, 2007, STROKE, V38, P2526, DOI 10.1161/STROKEAHA.107.482216; Kunte H, 2012, ANN NEUROL, V72, P799, DOI 10.1002/ana.23680; Kurland DB, 2013, PHARMACEUTICALS, V6, P1287, DOI 10.3390/ph6101287; Lu J, 2005, ACT NEUR S, V95, P281; Mandell JG, 2015, J NEUROSURG-PEDIATR, V15, P133, DOI 10.3171/2014.9.PEDS12428; Michinaga S, 2015, INT J MOL SCI, V16, P9949, DOI 10.3390/ijms16059949; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Rahmanian Abdolkarim, 2014, Bull Emerg Trauma, V2, P151; Rambiritch V, 2016, CLIN PHARMACOL-ADV A, V8, P83, DOI 10.2147/CPAA.S102676; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Sheth KN, 2014, STROKE, V45, P281, DOI 10.1161/STROKEAHA.113.003352; Simard JM, 2013, SPINAL CORD, V51, P823, DOI 10.1038/sc.2013.99; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2013, J SPINE S4; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; Taghipour M, 2006, J RES MED SCI, V11, P248; Thompson EM, 2013, NEOPLASIA, V15, P535, DOI 10.1593/neo.13164; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Welling LC, 2016, WORLD NEUROSURG, V87, P475, DOI 10.1016/j.wneu.2016.01.044; Xu ZM, 2016, J NEUROTRAUMA; Zacko J, 2011, YOUMANS WINN NEUROLO, P3424; Zafardoost P, 2016, TRAUMA MON, V21, DOI 10.5812/traumamon.25113; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	44	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2017	101						130	136		10.1016/j.wneu.2017.01.103			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EV7CR	WOS:000401932500016	28185976				2022-02-06	
J	Santos, VV; Stark, R; Rial, D; Silva, HB; Bayliss, JA; Lemus, MB; Davies, JS; Cunha, RA; Prediger, RD; Andrews, ZB				Santos, V. V.; Stark, R.; Rial, D.; Silva, H. B.; Bayliss, J. A.; Lemus, M. B.; Davies, J. S.; Cunha, R. A.; Prediger, R. D.; Andrews, Z. B.			Acyl ghrelin improves cognition, synaptic plasticity deficits and neuroinflammation following amyloid beta (A beta 1-40) administration in mice	JOURNAL OF NEUROENDOCRINOLOGY			English	Article						Acyl ghrelin; Alzheimer's disease; amyloid beta; Y-maze; novel object recognition; olfactory discrimination; ghrelin knockout	OREXIGENIC HORMONE GHRELIN; DECREASE FOOD-INTAKE; ALZHEIMERS-DISEASE; MOUSE MODEL; HIPPOCAMPAL NEUROGENESIS; PARKINSONS-DISEASE; RECOGNITION MEMORY; OLFACTORY-BULB; ADULT MICE; SPATIAL MEMORY	Ghrelin is a metabolic hormone that has neuroprotective actions in a number of neurological conditions, including Parkinson's disease (PD), stroke and traumatic brain injury. Acyl ghrelin treatment in vivo and in vitro also shows protective capacity in Alzheimer's disease (AD). In the present study, we used ghrelin knockout (KO) and their wild-type littermates to test whether or not endogenous ghrelin is protective in a mouse model of AD, in which human amyloid beta peptide 1-40 (A beta 1-40) was injected into the lateral ventricles i.c.v. Recognition memory, using the novel object recognition task, was significantly impaired in ghrelin KO mice and after i.c.v. A beta 1-40 treatment. These deficits could be prevented by acyl ghrelin injections for 7 days. Spatial orientation, as assessed by the Y-maze task, was also significantly impaired in ghrelin KO mice and after i.c.v. A beta 1-40 treatment. These deficits could be prevented by acyl ghrelin injections for 7 days. Ghrelin KO mice had deficits in olfactory discrimination; however, neither i.c.v. A beta 1-40 treatment, nor acyl ghrelin injections affected olfactory discrimination. We used stereology to show that ghrelin KO and A beta 1-40 increased the total number of glial fibrillary acidic protein expressing astrocytes and ionised calcium-binding adapter expressing microglial in the rostral hippocampus. Finally, A beta 1-40 blocked long-term potentiation induced by high-frequency stimulation and this effect could be acutely blocked with co-administration of acyl ghrelin. Collectively, our studies demonstrate that ghrelin deletion affects memory performance and also that acyl ghrelin treatment may delay the onset of early events of AD. This supports the idea that acyl ghrelin treatment may be therapeutically beneficial with respect to restricting disease progression in AD.	[Santos, V. V.; Stark, R.; Bayliss, J. A.; Lemus, M. B.; Andrews, Z. B.] Monash Univ, Monash Biomed Discovery Inst, Clayton, Vic, Australia; [Santos, V. V.; Stark, R.; Bayliss, J. A.; Lemus, M. B.; Andrews, Z. B.] Monash Univ, Dept Physiol, Clayton, Vic, Australia; [Davies, J. S.] Swansea Univ, Inst Life Sci, Mol Neurobiol, Swansea, W Glam, Wales; [Rial, D.; Prediger, R. D.] Univ Fed Santa Catarina, Ctr Biol Sci, Dept Pharmacol, Florianopolis, SC, Brazil; [Rial, D.; Silva, H. B.; Cunha, R. A.] Univ Coimbra, Ctr Neurosci & Cell Biol, CNC, Coimbra, Portugal; [Cunha, R. A.] Univ Coimbra, Fac Med, Coimbra, Portugal		Andrews, ZB (corresponding author), Monash Univ, Monash Biomed Discovery Inst, Clayton, Vic, Australia.; Andrews, ZB (corresponding author), Monash Univ, Dept Physiol, Clayton, Vic, Australia.	zane.andrews@monash.edu	Santos, Vanessa/AAP-4130-2020; Prediger, Rui Daniel/AAV-3419-2020; Rial, Daniel/D-3219-2009; Cunha, Rodrigo A/E-7475-2015; Prediger, Rui D/C-4036-2013; Davies, Jeffrey S/K-1400-2019; da silva, Henrique Bernardo/AAY-4358-2020; Rial, Daniel/C-3595-2013	Prediger, Rui Daniel/0000-0002-7547-6463; Cunha, Rodrigo A/0000-0003-2550-6422; Prediger, Rui D/0000-0002-7547-6463; Davies, Jeffrey S/0000-0002-4234-0033; da silva, Henrique Bernardo/0000-0002-7234-3411; Stark, Romana/0000-0002-4264-0060; Rial, Daniel/0000-0002-2079-7331; Andrews, Zane B./0000-0002-9097-7944	Conselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [546131, 1084344]; Australian Research CouncilAustralian Research Council [FT100100966]; Santa Casa da Misericordia; QREN; CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; National Health and Medical Research Council, Grant/Award Number: 546131 and 1084344; Australian Research Council, Grant/Award Number: FT100100966; Santa Casa da Misericordia and QREN; Brazilian Funding Agency CNPq	Alonso M, 2006, J NEUROSCI, V26, P10508, DOI 10.1523/JNEUROSCI.2633-06.2006; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Andrews ZB, 2008, NATURE, V454, P846, DOI 10.1038/nature07181; Andrews ZB, 2009, J NEUROSCI, V29, P14057, DOI 10.1523/JNEUROSCI.3890-09.2009; Attems J, 2014, ACTA NEUROPATHOL, V127, P459, DOI 10.1007/s00401-014-1261-7; Bayliss JA, 2016, J NEUROCHEM, V137, P460, DOI 10.1111/jnc.13576; Bayliss JA, 2016, J NEUROSCI, V36, P3049, DOI 10.1523/JNEUROSCI.4373-15.2016; Bayliss JA, 2013, THER ADV ENDOCRINOL, V4, P25, DOI 10.1177/2042018813479645; Beheshti S, 2015, NEUROPEPTIDES, V52, P97, DOI 10.1016/j.npep.2015.05.003; Briggs DI, 2011, NEUROENDOCRINOLOGY, V93, P48, DOI 10.1159/000322589; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Brown MW, 2010, HIPPOCAMPUS, V20, P1228, DOI 10.1002/hipo.20858; Cahill SP, 2014, BEHAV BRAIN RES, V264, P105, DOI 10.1016/j.bbr.2014.02.004; Canas PM, 2014, NEUROPHARMACOLOGY, V76, P51, DOI 10.1016/j.neuropharm.2013.08.026; Canas PM, 2009, J NEUROSCI, V29, P14741, DOI 10.1523/JNEUROSCI.3728-09.2009; Chung H, 2007, ENDOCRINOLOGY, V148, P148, DOI 10.1210/en.2006-0991; Davis JF, 2011, PHYSIOL BEHAV, V103, P39, DOI 10.1016/j.physbeh.2010.10.017; Dhurandhar EJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060437; Diano S, 2006, NAT NEUROSCI, V9, P381, DOI 10.1038/nn1656; Dixit VD, 2004, J CLIN INVEST, V114, P57, DOI 10.1172/JCI200421134; dos Santos VV, 2013, BEHAV BRAIN RES, V244, P107, DOI 10.1016/j.bbr.2013.01.039; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Gomes S, 2014, J NEUROENDOCRINOL, V26, P176, DOI 10.1111/jne.12138; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Harmatz E.S., 2016, BIOL PSYCHIAT; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hornsby AKE, 2016, PSYCHONEUROENDOCRINO, V63, P198, DOI 10.1016/j.psyneuen.2015.09.023; Hsu TM, 2015, ELIFE, V4, DOI 10.7554/eLife.11190; Kang S, 2015, PEPTIDES, V71, P84, DOI 10.1016/j.peptides.2015.07.005; Kanoski SE, 2017, BIOL PSYCHIAT, V81, P748, DOI 10.1016/j.biopsych.2015.09.011; Kaster MP, 2015, P NATL ACAD SCI USA, V112, P7833, DOI 10.1073/pnas.1423088112; Kent BA, 2015, PSYCHONEUROENDOCRINO, V51, P431, DOI 10.1016/j.psyneuen.2014.10.015; Kunath N, 2015, SCI REP-UK, V5, DOI 10.1038/srep11452; Li E, 2014, EXP NEUROL, V252, P75, DOI 10.1016/j.expneurol.2013.11.021; Loch D, 2015, CHEM SENSES, V40, P469, DOI 10.1093/chemse/bjv028; Lutter M, 2008, NAT NEUROSCI, V11, P752, DOI 10.1038/nn.2139; Mani BK, 2014, J COMP NEUROL, V522, P3644, DOI 10.1002/cne.23627; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Martins I, 2013, NEUROSCIENCE, V241, P41, DOI 10.1016/j.neuroscience.2013.02.062; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McFarlane MR, 2014, CELL METAB, V20, P54, DOI 10.1016/j.cmet.2014.04.007; Medeiros R, 2007, J NEUROSCI, V27, P5394, DOI 10.1523/JNEUROSCI.5047-06.2007; Moon M, 2014, J ALZHEIMERS DIS, V41, P233, DOI 10.3233/JAD-132417; Moon M, 2011, J ALZHEIMERS DIS, V23, P147, DOI 10.3233/JAD-2010-101263; Moon M, 2009, ENDOCR J, V56, P525, DOI 10.1507/endocrj.K09E-089; Moreno MM, 2009, P NATL ACAD SCI USA, V106, P17980, DOI 10.1073/pnas.0907063106; Muller TD, 2015, MOL METAB, V4, P437, DOI 10.1016/j.molmet.2015.03.005; Ondrejcak T, 2010, NEUROMOL MED, V12, P13, DOI 10.1007/s12017-009-8091-0; Prediger RDS, 2007, BEHAV BRAIN RES, V177, P205, DOI 10.1016/j.bbr.2006.11.032; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shibata N, 2011, DEMENT GERIATR COGN, V32, P178, DOI 10.1159/000333075; Sultan S, 2010, FASEB J, V24, P2355, DOI 10.1096/fj.09-151456; Takeda S, 2009, BRAIN RES, V1280, P137, DOI 10.1016/j.brainres.2009.05.035; Theodoropoulou A, 2012, J NUTR HEALTH AGING, V16, P472, DOI 10.1007/s12603-012-0058-4; Tong J, 2011, J NEUROSCI, V31, P5841, DOI 10.1523/JNEUROSCI.5680-10.2011; Van Dam D, 2011, NEUROMETHODS, V48, P35, DOI 10.1007/978-1-60761-898-0_3; Vann SD, 2011, CURR OPIN NEUROBIOL, V21, P440, DOI 10.1016/j.conb.2011.02.002; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wortley KE, 2005, J CLIN INVEST, V115, P3573, DOI 10.1172/JCI26003; Yi JH, 2016, BEHAV BRAIN RES, V297, P141, DOI 10.1016/j.bbr.2015.10.018; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao TJ, 2010, P NATL ACAD SCI USA, V107, P7467, DOI 10.1073/pnas.1002271107; Zigman JM, 2016, TRENDS ENDOCRIN MET, V27, P348, DOI 10.1016/j.tem.2016.02.007; Zigman JM, 2006, J COMP NEUROL, V494, P528, DOI 10.1002/cne.20823	66	29	30	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-8194	1365-2826		J NEUROENDOCRINOL	J. Neuroendocrinol.	MAY	2017	29	5								10.1111/jne.12476			11	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	EX1LY	WOS:000402986000008	28380673	Green Published, Bronze			2022-02-06	
J	Berkowitz, CD				Berkowitz, Carol D.			Physical Abuse of Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SHAKEN BABY SYNDROME; HEAD TRAUMA; YOUNG-CHILDREN; INFANTS; FRACTURES; RISK; LESS-THAN-1; PATTERNS; TODDLERS	A 4-month-old male infant is brought to the emergency department by paramedics. His mother had dialed 911 because the infant appeared to be limp when she lifted him from his crib after she returned from work; she had left him with her boyfriend while she was at work. On arrival in the emergency department, the infant's temperature is 37 degrees C, heart rate 114 beats per minute, blood pressure 90/68 mm Hg, and respiratory rate 28 breaths per minute. The physical examination is normal except for decreased muscle tone, and there is a 1-cm bruise on his left cheek. How should this case be evaluated and managed?	[Berkowitz, Carol D.] Univ Calif Los Angeles, David Geffen Sch Med, Harbor UCLA Med Ctr, Torrance, CA USA		Berkowitz, CD (corresponding author), Harbor UCLA Med Ctr, Dept Pediat, 1000 W Carson St, Torrance, CA 90509 USA.	cberkowitz52@gmail.com					Adamsbaum C, 2010, PEDIATRICS, V126, P546, DOI 10.1542/peds.2009-3647; Administration for Children and Families Administration on Children Youth and Families Children's Bureau, 2017, YOUTH FAM CHILDR BUR; Barr RG, 2012, P NATL ACAD SCI USA, V109, P17294, DOI 10.1073/pnas.1121267109; Barsness KA, 2003, J TRAUMA, V54, P1107, DOI 10.1097/01.TA.0000068992.01030.A8; Bell E, 2011, CHILD ABUSE NEGLECT, V35, P74, DOI 10.1016/j.chiabu.2010.11.001; Chadwick DL, 2008, PEDIATRICS, V121, P1213, DOI 10.1542/peds.2007-2281; Cheung MS, 2008, REV ENDOCR METAB DIS, V9, P153, DOI 10.1007/s11154-008-9074-4; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; Dias MS, 2017, JAMA PEDIATR, V171, P223, DOI 10.1001/jamapediatrics.2016.4218; Duffy SO, 2011, PEDIATRICS, V127, pE47, DOI 10.1542/peds.2010-0298; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Gaines BA, 2004, J PEDIATR SURG, V39, P600, DOI 10.1016/j.jpedsurg.2003.12.010; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Greiner MV, 2013, J PEDIATR-US, V163, P527, DOI 10.1016/j.jpeds.2013.01.063; Hymel KP, 2013, PEDIATR CRIT CARE ME, V14, P210, DOI 10.1097/PCC.0b013e3182712b09; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C, 2007, PEDIATRICS, V119, P1232, DOI 10.1542/peds.2007-0883; Jenny C, 2006, PEDIATRICS, V118, P1299, DOI 10.1542/peds.2006-1795; Jones R, 2008, PEDIATRICS, V122, P259, DOI 10.1542/peds.2007-2312; Kairys SW, 2001, PEDIATRICS, V108, P206; Kemp AM, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1518; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; Kleinman PK, 2008, PEDIATR RADIOL, V38, pS388, DOI 10.1007/s00247-008-0845-6; Lane WG, 2009, PEDIATRICS, V124, P1595, DOI 10.1542/peds.2009-0904; Leaman LA, 2016, J CHILD ORTHOP, V10, P467, DOI 10.1007/s11832-016-0764-2; Levey EJ, 2017, CHILD ABUSE NEGLECT, V65, P48, DOI 10.1016/j.chiabu.2017.01.004; Levin AV, 2010, PEDIATRICS, V126, P376, DOI 10.1542/peds.2010-1397; Lindberg DM, 2013, PEDIATRICS, V131, P268, DOI 10.1542/peds.2012-1952; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Maguire S, 2005, ARCH DIS CHILD, V90, P182, DOI 10.1136/adc.2003.044065; Maguire S, 2005, ARCH DIS CHILD, V90, P187, DOI 10.1136/adc.2003.044073; Maguire S, 2007, ARCH DIS CHILD, V92, P1113, DOI 10.1136/adc.2006.113001; Maguire SA, 2011, PEDIATRICS, V128, pE550, DOI 10.1542/peds.2010-2949; Matschke J, 2009, PEDIATRICS, V124, P1587, DOI 10.1542/peds.2008-3734; Matshes EW, 2011, ACAD FOR PATHOL, V1, P82; Mehta H, 2016, AM J NEURORADIOL, V37, P11, DOI 10.3174/ajnr.A4464; Perez-Rossello JM, 2012, RADIOLOGY, V262, P234, DOI 10.1148/radiol.11110358; Prange MT, 2003, J NEUROSURG, V99, P143, DOI 10.3171/jns.2003.99.1.0143; Schilling S, 2011, PEDIATRICS, V127, P835, DOI 10.1542/peds.2010-0533; Sheets LK, 2013, PEDIATRICS, V131, P701, DOI 10.1542/peds.2012-2780; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Spies EL, 2016, MMWR-MORBID MORTAL W, V65, P505, DOI 10.15585/mmwr.mm6520a1; Sugar NF, 1999, ARCH PEDIAT ADOL MED, V153, P399, DOI 10.1001/archpedi.153.4.399; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469; Trokel M, 2006, PEDIATR EMERG CARE, V22, P700, DOI 10.1097/01.pec.0000238734.76413.d0; van Rijn RR, 2011, MAGN RESON IMAGING C, V19, P791, DOI 10.1016/j.mric.2011.08.006	48	29	29	3	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 27	2017	376	17					1659	1666		10.1056/NEJMcp1701446			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ET2AY	WOS:000400071900009	28445667				2022-02-06	
J	Xu, SX; Zhong, AQ; Ma, HN; Li, D; Hu, Y; Xu, YZ; Zhang, JP				Xu, Shixin; Zhong, Aiqin; Ma, Huining; Li, Dan; Hu, Yue; Xu, Yingzhi; Zhang, Junping			Neuroprotective effect of salvianolic acid B against cerebral ischemic injury in rats via the CD40/NF-kappa B pathway associated with suppression of platelets activation and neuroinflammation	BRAIN RESEARCH			English	Article						Cerebral ischemia/reperfusion injury; Platelets activation; Inflammation; Salvianolic acid B	NF-KAPPA-B; INFLAMMATORY GENE-EXPRESSION; TRAUMATIC BRAIN-INJURY; ARTERY OCCLUSION; MICROCIRCULATORY DISTURBANCE; ANTIPLATELET THERAPY; REPERFUSION INJURY; STROKE; ADHESION; INFARCT	Neuroinflammation plays a critical role in the pathogenesis of ischemia/reperfusion (I/R) injury. Activated platelets are increasingly regarded as initiators and/or amplifiers of inflammatory processes in cerebral I/R injury. Salvianolic acid B (SAB) is the most abundant bioactive compound of Salviae miltiorrhizae, a well-known Chinese herb used to promote blood circulation and eliminating blood stasis. S. miltiorrhizae has been used clinically in Asia for the treatment of ischemic cerebrovascular diseases. In the present study, a rat model of transient middle cerebral artery occlusion (tMCAO) was established to investigate the neuroprotective effects and mechanisms of SAB treatment against focal cerebral I/R insult. The results showed that SAB treatment (3 mg/kg, 6 mg/kg and 12 mg/kg, i.p.) dose-dependently decreased I/R-induced neurological deficits at 24, 48, and 72 h after reperfusion and decreased plasma-soluble P-selectin and soluble CD40 ligand as early as 6 h after onset of I/12 insult. At 24 h after reperfusion, SAB treatment significantly reduced neuronal and DNA damage in the hippocampal CA1 region and decreased neural cell loss in the ischemic core. The I/R-induced pro-inflammatory mediator mRNA and protein overexpression in the penumbra cortex, including ICAM-1, IL-1 beta, IL-6, IL-8, and MCP-1, were significantly inhibited by SAB in a dose-dependent manner. Further studies suggested SAB treatment attenuated CD40 expression and NF-kappa B activation, which involved NF-kappa B/p65 phosphorylation and h kappa B alpha phosphorylation and degradation. In conclusion, our findings indicated that the neuroprotective effects of SAB post cerebral I/R injury are associated with the inhibition of both platelets activation and production of pro-inflammatory mediators and the downregulation of the CD40/NF-kappa B pathway. (C) 2017 Elsevier B.V. All rights reserved.	[Xu, Shixin; Li, Dan] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Med Expt Ctr, 314 An Shan Xi Rd, Tianjin 300193, Peoples R China; [Zhong, Aiqin; Xu, Yingzhi; Zhang, Junping] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Geriatr, 314 An Shan Xi Rd, Tianjin 300193, Peoples R China; [Ma, Huining; Hu, Yue] Tianjin Univ Tradit Chinese Med, 312 An Shan Xi Rd, Tianjin 300193, Peoples R China		Xu, SX (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Med Expt Ctr, 314 An Shan Xi Rd, Tianjin 300193, Peoples R China.; Zhang, JP (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Geriatr, 314 An Shan Xi Rd, Tianjin 300193, Peoples R China.	shixinxu1973@outlook.com; tjzhtcm@163.com		Xu, Shixin/0000-0003-2270-2911	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81373850]; Tianjin Natural Science FoundationNatural Science Foundation of Tianjin [13JCZDJC31500]	This work was supported by the National Natural Science Foundation of China (No. 81373850) and Tianjin Natural Science Foundation (No. 13JCZDJC31500).	Adams HP, 2008, STROKE, V39, P87, DOI 10.1161/STROKEAHA.106.476648; Andre P, 2002, CIRCULATION, V106, P896, DOI 10.1161/01.CIR.0000028962.04520.01; Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Berger C, 2004, BRAIN RES, V998, P237, DOI 10.1016/j.brainres.2003.11.049; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Chen KQ, 2006, CELL MOL IMMUNOL, V3, P163; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chen YH, 2000, ACTA PHARMACOL SIN, V21, P463; Cheng TO, 2007, INT J CARDIOL, V121, P9, DOI 10.1016/j.ijcard.2007.01.004; Davidson DC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-144; De Meyer Simon F, 2011, Exp Transl Stroke Med, V3, P9, DOI 10.1186/2040-7378-3-9; del Zoppo GJ, 1998, NEUROLOGY, V51, pS9, DOI 10.1212/WNL.51.3_Suppl_3.S9; Garcia-Bonilla L, 2011, BRAIN RES, V1373, P211, DOI 10.1016/j.brainres.2010.12.005; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Han JY, 2008, PHARMACOL THERAPEUT, V117, P280, DOI 10.1016/j.pharmthera.2007.09.008; Harari OA, 2010, ANN NY ACAD SCI, V1207, P32, DOI 10.1111/j.1749-6632.2010.05735.x; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hong KS, 2014, J CLIN NEUROL, V10, P189, DOI 10.3988/jcn.2014.10.3.189; Hu P, 2005, CHEM PHARM BULL, V53, P677, DOI 10.1248/cpb.53.677; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Ishikawa M, 2005, CIRCULATION, V111, P1690, DOI 10.1161/01.CIR.0000160349.42665.0C; Ishikawa M, 2004, J CEREBR BLOOD F MET, V24, P907, DOI 10.1097/01.WCB.0000132690.96836.7F; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Ji XY, 2000, ACTA PHARMACOL SIN, V21, P1089; Jiang Y.F., 2014, CHIN J INTEGR MED; Jin R, 2013, J CARDIOVASC TRANSL, V6, P834, DOI 10.1007/s12265-013-9508-6; Kim DY, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-25; Kitagawa K, 1998, J CEREBR BLOOD F MET, V18, P1336, DOI 10.1097/00004647-199812000-00008; Kleinig TJ, 2009, CURR OPIN NEUROL, V22, P294, DOI 10.1097/WCO.0b013e32832b4db3; Kleinschnitz C, 2007, CIRCULATION, V115, P2323, DOI 10.1161/CIRCULATIONAHA.107.691279; Lee JH, 2007, BRAIN RES, V1152, P182, DOI 10.1016/j.brainres.2007.03.035; Lindsberg PJ, 1996, CIRCULATION, V94, P939, DOI 10.1161/01.CIR.94.5.939; Liu L, 2014, THROMB RES, V134, P866, DOI 10.1016/j.thromres.2014.07.019; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Ma C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014692; Matsumoto T, 1997, LAB INVEST, V77, P119; Nagai N, 2015, INT J MOL SCI, V16, P29329, DOI 10.3390/ijms161226166; Nagy B, 2012, CURR MED CHEM, V19, P518, DOI 10.2174/092986712798918770; Nieswandt B, 2011, J THROMB HAEMOST, V9, P92, DOI 10.1111/j.1538-7836.2011.04361.x; Nieswandt B, 2011, J PHYSIOL-LONDON, V589, P4115, DOI 10.1113/jphysiol.2011.212886; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Ramirez SH, 2010, J NEUROSCI, V30, P9454, DOI 10.1523/JNEUROSCI.5796-09.2010; Ruehl ML, 2002, NEUROL RES, V24, P226, DOI 10.1179/016164102101199738; Sandercock PAG, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000029.pub3; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schwaninger M, 2006, BIOCHEM SOC T, V34, P1291, DOI 10.1042/BST0341291; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Steinhubl SR, 2007, HEMATOL ONCOL CLIN N, V21, P115, DOI 10.1016/j.hoc.2006.11.015; Steinhubl SR, 2007, VASC MED, V12, P113, DOI 10.1177/1358863X07077462; Stoll G, 2008, BLOOD, V112, P3555, DOI 10.1182/blood-2008-04-144758; Stoll G, 2010, ANN NY ACAD SCI, V1207, P149, DOI 10.1111/j.1749-6632.2010.05730.x; Tang MK, 2006, BEHAV PHARMACOL, V17, P493, DOI 10.1097/00008877-200609000-00015; Tian JW, 2009, BRAIN RES, V1263, P114, DOI 10.1016/j.brainres.2009.01.034; Tomizawa A, 2015, THROMB RES, V136, P1224, DOI 10.1016/j.thromres.2015.09.013; Tuttolomondo A, 2010, ATHEROSCLEROSIS, V208, P290, DOI 10.1016/j.atherosclerosis.2009.07.032; Vemuganti R, 2004, STROKE, V35, P179, DOI 10.1161/01.STR.0000106479.53235.3E; Wang Y, 2010, CHINESE MED J-PEKING, V123, P3612, DOI 10.3760/cma.j.issn.0366-6999.2010.24.020; Whitehead SN, 2007, STROKE, V38, P381, DOI 10.1161/01.STR.0000254464.05561.72; Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018; Wu B, 2007, STROKE, V38, P1973, DOI 10.1161/STROKEAHA.106.473165; Wu YP, 2008, THROMB RES, V123, P298, DOI 10.1016/j.thromres.2008.05.020; Xu SX, 2015, THROMB RES, V135, P137, DOI 10.1016/j.thromres.2014.10.034; Yang LJ, 2015, THROMB RES, V136, P1310, DOI 10.1016/j.thromres.2015.10.039; Zhang JX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102506; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630; Zhu HB, 2013, EUR J PHARMACOL, V714, P23, DOI 10.1016/j.ejphar.2013.05.043	70	29	35	2	30	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	2017	1661						37	48		10.1016/j.brainres.2017.02.011			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ER2TP	WOS:000398647000004	28214521				2022-02-06	
J	Bachstetter, AD; Ighodaro, ET; Hassoun, Y; Aldeiri, D; Neltner, JH; Patel, E; Abner, EL; Nelson, PT				Bachstetter, Adam D.; Ighodaro, Eseosa T.; Hassoun, Yasmin; Aldeiri, Danah; Neltner, Janna H.; Patel, Ela; Abner, Erin L.; Nelson, Peter T.			Rod-shaped microglia morphology is associated with aging in 2 human autopsy series	NEUROBIOLOGY OF AGING			English	Article						Aging; Microglia activation; Neurodegeneration; Neuroinflammation; Neuropathology; Hippocampus; Alzheimer's disease; Traumatic brain injury	FRACTALKINE RECEPTOR; ALZHEIMERS-DISEASE; BRAIN-INJURY; IMPAIRMENT; PATHOLOGY; DEMENTIA; NEURONS; RISK; MICE	A subtype of microglia is defined by the morphological appearance of the cells as rod shaped. Little is known about this intriguing cell type, as there are only a few case reports describing rod-shaped microglia in the neuropathological literature. Rod-shaped microglia were shown recently to account for a substantial proportion of the microglia cells in the hippocampus of both demented and cognitively intact aged individuals. We hypothesized that aging could be a defining feature in the occurrence of rodshaped microglia. To test this hypothesis, 2 independent series of autopsy cases (total n 168 cases), which covered the adult lifespan from 20 to 100_ years old, were included in the study. The presence or absence of rod-shaped microglia was scored on IBA1 immunohistochemically stained slides for the hippocampus and cortex. We found that age was one of the strongest determinants for the presence of rod-shaped microglia in the hippocampus and the cortex. We found no association with the presence of rod-shaped microglia and a self-reported history of a TBI. Alzheimer's diseaseerelated pathology was found to influence the presence of rod-shaped microglia, but only in the parietal cortex and not in the hippocampus or temporal cortex. Future studies are warranted to determine the functional relevance of rod-shaped microglia in supporting the health of neurons in the aged brain, and the signaling processes that regulate the formation of rod-shaped microglia. (C) 2017 Elsevier Inc. All rights reserved.	[Bachstetter, Adam D.; Ighodaro, Eseosa T.; Hassoun, Yasmin; Aldeiri, Danah] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; [Bachstetter, Adam D.] Univ Kentucky, Dept Neurosci, Lexington, KY USA; [Ighodaro, Eseosa T.; Neltner, Janna H.; Patel, Ela; Abner, Erin L.; Nelson, Peter T.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Neltner, Janna H.; Nelson, Peter T.] Univ Kentucky, Dept Pathol & Lab Med, Div Neuropathol, Lexington, KY USA; [Abner, Erin L.] Univ Kentucky, Dept Epidemiol, Lexington, KY USA		Bachstetter, AD (corresponding author), Univ Kentucky, Dept Neurosci, Spinal Cord & Brain Injury Res Ctr, B459 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	adam.bachstetter@uky.edu		Bachstetter, Adam/0000-0003-4646-6757	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG028383, R00 AG044445]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS090714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R00AG044445, P30AG028383] Funding Source: NIH RePORTER	The authors are profoundly grateful to all of the study participants who made this research possible. The corresponding author, Adam Bachstetter, PhD, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Research reported in this publication was supported by National Institutes of Health under award numbers P30 AG028383, R00 AG044445. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health.	Abner EL, 2016, ALZHEIMERS DEMENT, V12, P882, DOI 10.1016/j.jalz.2015.12.006; Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Ackman JB, 2006, J NEUROSCI, V26, P11413, DOI 10.1523/JNEUROSCI.3340-06.2006; Bachstetter AD, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0209-z; Bachstetter AD, 2011, NEUROBIOL AGING, V32, P2030, DOI 10.1016/j.neurobiolaging.2009.11.022; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Hayakawa K, 2016, NATURE, V535, P551, DOI 10.1038/nature18928; Ighodaro ET, 2017, J CEREBR BLOOD F MET, V37, P201, DOI 10.1177/0271678X15621574; Lyons A, 2009, J NEUROCHEM, V110, P1547, DOI 10.1111/j.1471-4159.2009.06253.x; Morfini GA, 2009, J NEUROSCI, V29, P12776, DOI 10.1523/JNEUROSCI.3463-09.2009; Nelson PT, 2010, J NEUROL, V257, P1875, DOI 10.1007/s00415-010-5630-4; Rogers JT, 2011, J NEUROSCI, V31, P16241, DOI 10.1523/JNEUROSCI.3667-11.2011; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sanders DW, 2014, NEURON, V82, P1271, DOI 10.1016/j.neuron.2014.04.047; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Streit WJ, 2006, TRENDS NEUROSCI, V29, P506, DOI 10.1016/j.tins.2006.07.001; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Yuan TF, 2015, SCI REP-UK, V5, DOI 10.1038/srep10788; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	25	29	29	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	APR	2017	52						98	105		10.1016/j.neurobiolaging.2016.12.028			8	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	EP1UE	WOS:000397169000011	28131016	Green Published, Green Accepted			2022-02-06	
J	Loris, ZB; Pieper, AA; Dietrich, WD				Loris, Zachary B.; Pieper, Andrew A.; Dietrich, W. Dalton			The neuroprotective compound P7C3-A20 promotes neurogenesis and improves cognitive function after ischemic stroke	EXPERIMENTAL NEUROLOGY			English	Article						Aminopropyl carbazole; Ischemic stroke; Neuroprotection; Neurogenesis; P7C3-A20; NAD	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ADULT NEUROGENESIS; HIPPOCAMPAL ATROPHY; SPATIAL MEMORY; RAT; NAMPT; POLY(ADP-RIBOSE)	Ischemic stroke is a devastating condition with few therapeutic interventions available. The neuroprotective compound P7C3-A20 inhibits mature neuronal cell death while also increasing the net magnitude of postnatal neurogenesis in models of neurodegeneration and acute injury. P7C3 compounds enhance flux of nicotinamide adenine dinucleotide (NAD) in mammalian cells, a proposed therapeutic approach to treating cerebral ischemia. The effectiveness of P7C3-A20 treatment on chronic histopathological and behavioral outcomes and neurogenesis after ischemic stroke has not previously been established. Here, a transient middle cerebral artery occlusion in rats was followed by twice daily injection of P7C3-A20 or vehicle for 7 days. P7C3-A20-treated rats performed significantly better than vehicle-treated controls in sensorimotor cylinder and grid-walk tasks, and in a chronic test of spatial learning and memory. These behavioral improvements with P7C3-A20 treatment were correlated with significantly decreased cortical and hippocampal atrophy, and associated with increased neurogenesis in the subventricular zone and hippocampal dentate gyrus subgranular zone. Furthermore, cerebral ischemia significantly reduced NAD in the cortex but P7C3-A20 treatment restored NAD to sham levels. Thus, P7C3-A20 treatment mitigates neurodegeneration and augments repair in the brain after focal ischemia, which translates into chronic behavioral improvement. This suggests a new therapeutic approach of using P7C3 compounds to safely augment NAD and thereby promote two independent processes critical to protecting the brain from ischemic stroke: mature neuron survival and postnatal neurogenesis throughout the post-ischemic brain. Published by Elsevier Inc.	[Loris, Zachary B.; Pieper, Andrew A.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Neurosci Program, Dept Neurol Surg, Miami, FL 33136 USA; [Loris, Zachary B.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Neurol, Iowa City, IA USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Free Radical, Iowa City, IA USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Radiat Biol Program, Oncol Comprehens Canc Ctr,Radiat Dept,Dept Vet Af, Iowa City, IA USA; [Pieper, Andrew A.] Univ Iowa, Pappajohn Biomed Inst, Iowa City, IA USA		Pieper, AA; Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Neurosci Program, Dept Neurol Surg, Miami, FL 33136 USA.	andrew-pieper@uiowa.edu; ddietrich@miami.edu	Pieper, Andrew A/R-5552-2016	Pieper, Andrew/0000-0001-6299-6577	American Heart Association GrantAmerican Heart Association [16PRE27050003]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS089443]; University of Iowa; Department of Veterans AffairsUS Department of Veterans Affairs; Titan Neurologic Research fund	The authors would like to thank Dr. Melissa Carballosa-Gautam, Dr. Kristien Van Vlasselaer, Julie Freund, and Enmanuel Perez for their technical contributions to this study. We would also like to acknowledge Ofelia Furones-Alonso for training on the tMCAO model and Dr. Grace Zhai for helping with the NAD assessments. Finally, we would like to thank Dr. Coleen Atkins for her critical review of the manuscript. This work was funded with the support of the American Heart Association Grant # 16PRE27050003 and NINDS RO1NS089443. A.A.P. was supported for this work by funds from an anonymous donor to the Mary Alice Smith Fund for Neuropsychiatry Research, the Titan Neurologic Research fund, and institutional funds from the University of Iowa and the Department of Veterans Affairs.	Amtul Z, 2014, NEUROBIOL AGING, V35, P1605, DOI 10.1016/j.neurobiolaging.2014.01.005; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Bingham D, 2012, J CEREBR BLOOD F MET, V32, P989, DOI 10.1038/jcbfm.2012.16; Blaya MO, 2015, EXP NEUROL, V264, P67, DOI 10.1016/j.expneurol.2014.11.014; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Blokland A, 2004, BEHAV BRAIN RES, V154, P71, DOI 10.1016/j.bbr.2004.01.022; Burkle A, 2005, FEBS J, V272, P4576, DOI 10.1111/j.1742-4658.2005.04864.x; Carmichael S Thomas, 2005, NeuroRx, V2, P396; CHEN CJ, 2016, NEUROLOGY, V86, P2316; De Jesus-Cortes H, 2016, NEUROGENESIS; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; De Jesus-Cortest H, 2015, NPJ PARKINSON DIS, V1, DOI 10.1038/npjparkd.2015.10; Dibajnia P, 2013, ACTA PHARMACOL SIN, V34, P78, DOI 10.1038/aps.2012.107; Dirnagl U, 2016, STROKE, V47, P2148, DOI 10.1161/STROKEAHA.116.013244; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gil-Bea FJ, 2012, NEUROBIOL DIS, V48, P439, DOI 10.1016/j.nbd.2012.06.020; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Ito H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128445; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jing Z, 2014, J CEREBR BLOOD F MET, V34, P1613, DOI 10.1038/jcbfm.2014.119; Kemp SWP, 2015, NEUROSCIENCE, V284, P202, DOI 10.1016/j.neuroscience.2014.10.005; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Krueger H, 2015, STROKE, V46, P2226, DOI 10.1161/STROKEAHA.115.009616; Lee A. S., 2016, ENEURO, P3; Li Y, 2009, CURR TOP DEV BIOL, V87, P149, DOI 10.1016/S0070-2153(09)01205-8; Lichtenwalner RJ, 2006, J CEREBR BLOOD F MET, V26, P1, DOI 10.1038/sj.jcbfm.9600170; Lindau NT, 2014, BRAIN, V137, P739, DOI 10.1093/brain/awt336; Liu YP, 2009, ACTA NEUROPATHOL, V117, P469, DOI 10.1007/s00401-009-0516-1; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Miller DJ, 2011, NEUROHOSPITALIST, V1, P138, DOI 10.1177/1941875211408731; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mokin M, 2016, NAT REV NEUROL, V12, P86, DOI 10.1038/nrneurol.2015.240; Morris-Blanco KC, 2014, J CEREBR BLOOD F MET, V34, P1024, DOI 10.1038/jcbfm.2014.51; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Naidoo J, 2013, TETRAHEDRON LETT, V54, P4429, DOI 10.1016/j.tetlet.2013.06.024; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; O'Collins VE, 2006, ANN NEUROL, V59, P467, DOI 10.1002/ana.20741; Ohab JJ, 2008, NEUROSCIENTIST, V14, P369, DOI 10.1177/1073858407309545; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Pieper AA, 2014, CHEM SOC REV, V43, P6716, DOI 10.1039/c3cs60448a; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Pierot L, 2015, STROKE, V46, P1440, DOI 10.1161/STROKEAHA.115.008416; Ramos-Cabrer P, 2011, STROKE, V42, pS7, DOI 10.1161/STROKEAHA.110.596684; Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Stein LR, 2014, EMBO J, V33, P1321, DOI 10.1002/embj.201386917; Sutherland BA, 2012, INT J STROKE, V7, P407, DOI 10.1111/j.1747-4949.2012.00770.x; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Thored P, 2007, STROKE, V38, P3032, DOI 10.1161/STROKEAHA.107.488445; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Walker AK, 2015, MOL PSYCHIATR, V20, P500, DOI 10.1038/mp.2014.34; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wang P, 2015, TRENDS PHARMACOL SCI, V36, P891, DOI 10.1016/j.tips.2015.08.012; Wang P, 2011, ANN NEUROL, V69, P360, DOI 10.1002/ana.22236; Wang SN, 2016, CNS NEUROSCI THER, V22, P431, DOI 10.1111/cns.12539; Xing CH, 2012, INT J STROKE, V7, P378, DOI 10.1111/j.1747-4949.2012.00839.x; Yang J, 2015, BRAIN RES, V1629, P231, DOI 10.1016/j.brainres.2015.10.032; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; Yonemori F, 1996, J CEREBR BLOOD F MET, V16, P973, DOI 10.1097/00004647-199609000-00022; Zerna C, 2016, CIRC RES, V118, P1425, DOI 10.1161/CIRCRESAHA.116.307005; Zhao SS, 2013, STROKE, V44, P1698, DOI 10.1161/STROKEAHA.111.000361; Zhao Y, 2015, STROKE, V46, P1966, DOI 10.1161/STROKEAHA.115.009216	76	29	29	2	27	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	APR	2017	290						63	73		10.1016/j.expneurol.2017.01.006			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EM5QR	WOS:000395368000006	28077334				2022-02-06	
J	Shively, SB; Edgerton, SL; Iacono, D; Purohit, DP; Qu, BX; Haroutunian, V; Davis, KL; Diaz-Arrastia, R; Perl, DP				Shively, Sharon B.; Edgerton, Sarah L.; Iacono, Diego; Purohit, Dushyant P.; Qu, Bao-Xi; Haroutunian, Vahram; Davis, Kenneth L.; Diaz-Arrastia, Ramon; Perl, Daniel P.			Localized cortical chronic traumatic encephalopathy pathology after single, severe axonal injury in human brain	ACTA NEUROPATHOLOGICA			English	Article						Traumatic brain injury; Chronic traumatic encephalopathy; Axonal injury; Tau; Neurofibrillary tangle; beta-Amyloid plaque	AMYLOID PROTEIN DEPOSITION; APOLIPOPROTEIN-E EPSILON-4; HEAD-INJURY; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; BETA-PROTEIN; WHITE-MATTER; RISK; DEGENERATION; ASSOCIATION	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with repetitive mild impact traumatic brain injury from contact sports. Recently, a consensus panel defined the pathognomonic lesion for CTE as accumulations of abnormally hyperphosphorylated tau (p-tau) in neurons (neurofibrillary tangles), astrocytes and cell processes distributed around small blood vessels at sulcal depths in irregular patterns within the cortex. The pathophysiological mechanism for this lesion is unknown. Moreover, a subset of CTE cases harbors cortical beta-amyloid plaques. In this study, we analyzed postmortem brain tissues from five institutionalized patients with schizophrenia and history of surgical leucotomy with subsequent survival of at least another 40 years. Because leucotomy involves severing axons bilaterally in prefrontal cortex, this surgical procedure represents a human model of single traumatic brain injury with severe axonal damage and no external impact. We examined cortical tissues at the leucotomy site and at both prefrontal cortex rostral and frontal cortex caudal to the leucotomy site. For comparison, we analyzed brain tissues at equivalent neuroanatomical sites from non-leucotomized patients with schizophrenia, matched in age and gender. All five leucotomy cases revealed severe white matter damage with dense astrogliosis at the axotomy site and also neurofibrillary tangles and p-tau immunoreactive neurites in the overlying gray matter. Four cases displayed p-tau immunoreactivity in neurons, astrocytes and cell processes encompassing blood vessels at cortical sulcal depths in irregular patterns, similar to CTE. The three cases with apolipoprotein E epsilon 4 haplotype showed scattered beta-amyloid plaques in the overlying gray matter, but not the two cases with apolipoprotein E epsilon 3/3 genotype. Brain tissue samples from prefrontal cortex rostral and frontal cortex caudal to the leucotomy site, and all cortical samples from the non-leucotomized patients, showed minimal p-tau and beta-amyloid pathology. These findings suggest that chronic axonal damage contributes to the unique pathology of CTE over time.	[Shively, Sharon B.; Iacono, Diego; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Shively, Sharon B.; Edgerton, Sarah L.; Iacono, Diego; Qu, Bao-Xi; Diaz-Arrastia, Ramon; Perl, Daniel P.] Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Shively, Sharon B.; Edgerton, Sarah L.; Iacono, Diego] Henry M Jackson Fdn Adv Mil Med, 6720 Rockledge Dr, Bethesda, MD 20817 USA; [Purohit, Dushyant P.] Icahn Sch Med Mt Sinai, Dept Pathol, 1468 Madison Ave, New York, NY 10029 USA; [Qu, Bao-Xi; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Haroutunian, Vahram; Davis, Kenneth L.] Icahn Sch Med Mt Sinai, Dept Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Haroutunian, Vahram] Icahn Sch Med Mt Sinai, Dept Neurosci, 1 Gustave L Levy Pl, New York, NY 10029 USA; [Haroutunian, Vahram] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA; [Davis, Kenneth L.] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, 1 Gustave L Levy Pl, New York, NY 10029 USA		Perl, DP (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Perl, DP (corresponding author), Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	daniel.perl@usuhs.edu	Iacono, Diego/K-8203-2016	Iacono, Diego/0000-0001-5511-0950; Diaz-Arrastia, Ramon/0000-0001-6051-3594	Defense Health Program of the United States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH45212, MH064673]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH064673] Funding Source: NIH RePORTER	This study was funded by the Defense Health Program of the United States Department of Defense and the National Institutes of Health (grants MH45212, MH064673). This study utilized neuropathology core facilities of Center for Neuroscience and Regenerative Medicine and Uniformed Services University of the Health Sciences within the United States Department of Defense. The authors wish to thank Dr. Peter Davies for the generous gift of CP13 and PHF1 antibodies. We also thank Drs. Charles Rice, Arthur Kellermann, Yvonne Maadox and Regina Armstrong for their continuous encouragement and support, and Patricia Lee for her technical expertise. The cases were obtained from tissue archives of the Pilgrim Psychiatric Center Brain Bank in West Brentwood, NY. The opinions expressed herein are those of the authors and are not necessarily representative of those of the Uniformed Services University of the Health Sciences, the Department of Defense; or, the United States Army, Navy or Air Force.	Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Calero O, 2009, J NEUROSCI METH, V183, P238, DOI 10.1016/j.jneumeth.2009.06.033; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HIRANO A, 1962, ARCH NEUROL-CHICAGO, V6, P114, DOI 10.1001/archneur.1962.00450200028003; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iliff JJ, 2015, LANCET NEUROL, V14, P977, DOI 10.1016/S1474-4422(15)00221-5; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Leclercq PD, 2005, J NEUROL NEUROSUR PS, V76, P229, DOI 10.1136/jnnp.2003.025528; Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Purohit DP, 1998, ARCH GEN PSYCHIAT, V55, P205, DOI 10.1001/archpsyc.55.3.205; Rapp MA, 2010, SCHIZOPHR RES, V116, P90, DOI 10.1016/j.schres.2009.10.013; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Watts JW, 1950, PSYCHOSURGERY TREATM; Zhao Z, 2015, NAT NEUROSCI, V18, P978, DOI 10.1038/nn.4025; Zlokovic BV, 2010, J NEUROCHEM, V115, P1077, DOI 10.1111/j.1471-4159.2010.07002.x	50	29	29	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2017	133	3					353	366		10.1007/s00401-016-1649-7			14	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	EL9ST	WOS:000394961100002	27885490	hybrid, Green Published			2022-02-06	
J	Takizawa, T; Shibata, M; Kayama, Y; Shimizu, T; Toriumi, H; Ebine, T; Unekawa, M; Koh, A; Yoshimura, A; Suzuki, N				Takizawa, Tsubasa; Shibata, Mamoru; Kayama, Yohei; Shimizu, Toshihiko; Toriumi, Haruki; Ebine, Taeko; Unekawa, Miyuki; Koh, Anri; Yoshimura, Akihiko; Suzuki, Norihiro			High-mobility group box I is an important mediator of microglial activation induced by cortical spreading depression	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cortical spreading depression; microglia; high-mobility group box I; Toll-like receptors; cathepsin D	PROLONGED MIGRAINE AURA; TRAUMATIC BRAIN-INJURY; RECEPTOR 4; NEUROVASCULAR CHANGES; DEPOLARIZATIONS; HMGB1; APOPTOSIS; ISCHEMIA; LOCALIZATION; HEMORRHAGE	Single episodes of cortical spreading depression (CSD) are believed to cause typical migraine aura, whereas clusters of spreading depolarizations have been observed in cerebral ischemia and subarachnoid hemorrhage. We recently demonstrated that the release of high-mobility group box I (HMGBI) from cortical neurons after CSD in a rodent model is dependent on the number of CSD episodes, such that only multiple CSD episodes can induce significant HMGBI release. Here, we report that only multiple CSD inductions caused microglial hypertrophy (activation) accompanied by a greater impact on the transcription activity of the HMGBI receptor genes, TLR2 and TLR4, while the total number of cortical microglia was not affected. Both an HMGBI-neurtalizing antibody and the HMGBI inhibitor glycyrrhizin abrogated multiple CSD-induced microglial hypertrophy. Moreover, multiple CSD inductions failed to induce microglial hypertrophy in TLR2/4 double knockout mice. These results strongly implicate the HMGBI-TLR2/4 axis in the activation of microglia following multiple CSD inductions. Increased expression of the lysosomal acid hydrolase cathepsin D was detected in activated microglia by immunostaining, suggesting that lysosomal phagocytic activity may be enhanced in multiple CSD-activated microglia.	[Takizawa, Tsubasa; Shibata, Mamoru; Kayama, Yohei; Shimizu, Toshihiko; Toriumi, Haruki; Ebine, Taeko; Unekawa, Miyuki; Koh, Anri; Suzuki, Norihiro] Keio Univ, Sch Med, Dept Neurol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan; [Yoshimura, Akihiko] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo, Japan		Shibata, M (corresponding author), Keio Univ, Sch Med, Dept Neurol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	mshibata@a7.keio.jp	Yoshimura, Akihiko/K-5515-2013; Suzuki, Norihiro/J-5125-2013; Unekawa, Miyuki/M-2415-2013; Shibata, Mamoru/L-8537-2013; Shimizu, Toshihiko/M-4870-2013	Suzuki, Norihiro/0000-0002-0399-6590; Shibata, Mamoru/0000-0002-2416-4259; 	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26460706, 22390132]; Takeda Science FoundationTakeda Science Foundation (TSF); Pfizer Inc.Pfizer [WS1878886]; Keio University Doctorate Student	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by JSPS KAKENHI (grant numbers 26460706 to MS and 22390132 to NS), a grant from the Takeda Science Foundation to MS, a research grant from Pfizer Inc. to NS (WS1878886), and Keio University Doctorate Student Grant- in- Aid Program to TT.	Andersson A, 2008, J LEUKOCYTE BIOL, V84, P1248, DOI 10.1189/jlb.1207844; Ayata C, 2006, ANN NEUROL, V59, P652, DOI 10.1002/ana.20778; Ayata C, 2015, PHYSIOL REV, V95, P953, DOI 10.1152/physrev.00027.2014; Casano AM, 2015, DEV CELL, V32, P469, DOI 10.1016/j.devcel.2015.01.018; Casula M, 2011, NEUROSCIENCE, V179, P233, DOI 10.1016/j.neuroscience.2011.02.001; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Eichler FS, 2008, ANN NEUROL, V63, P729, DOI 10.1002/ana.21391; Eikermann-Haerter K, 2015, ANN NEUROL, V78, P193, DOI 10.1002/ana.24449; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; GEHRMANN J, 1993, BRAIN PATHOL, V3, P11, DOI 10.1111/j.1750-3639.1993.tb00720.x; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089450; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222; Iizuka T, 2015, J NEUROL NEUROSUR PS, V86, P344, DOI 10.1136/jnnp-2014-307731; Iizuka T, 2012, J NEUROL NEUROSUR PS, V83, P205, DOI 10.1136/jnnp-2011-300843; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Kim JB, 2008, J NEUROSCI RES, V86, P1125, DOI 10.1002/jnr.21555; Kim SW, 2012, NEUROBIOL DIS, V46, P147, DOI 10.1016/j.nbd.2011.12.056; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.00216.x; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Luo XG, 2012, TRANSL NEURODEGENER, V1, DOI 10.1186/2047-9158-1-9; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; Pietrobon D, 2014, NAT REV NEUROSCI, V15, P379, DOI 10.1038/nrn3770; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Rajbhandari L, 2014, GLIA, V62, P1982, DOI 10.1002/glia.22719; Sato H, 2013, NEUROSCIENCE, V248, P345, DOI 10.1016/j.neuroscience.2013.06.010; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Takizawa T, 2016, CEPHALALGIA, V36, P44, DOI 10.1177/0333102415580100; Trotta T, 2014, J NEUROIMMUNOL, V268, P1, DOI 10.1016/j.jneuroim.2014.01.014; Unekawa M, 2015, J CEREBR BLOOD F MET, V35, P689, DOI 10.1038/jcbfm.2014.250; VERHAEGEN M, 1992, BRAIN RES, V581, P153, DOI 10.1016/0006-8993(92)90355-D; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; White CA, 1998, INT IMMUNOL, V10, P935, DOI 10.1093/intimm/10.7.935; Yang QW, 2011, J CEREBR BLOOD F MET, V31, P593, DOI 10.1038/jcbfm.2010.129; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334	43	29	30	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2017	37	3					890	901		10.1177/0271678X16647398			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	EL5KQ	WOS:000394660400013	27142867	Green Published, Bronze			2022-02-06	
J	Cen, LP; Liang, JJ; Chen, JH; Harvey, AR; Ng, TK; Zhang, MZ; Pang, CP; Cui, Q; Fan, YM				Cen, Ling-Ping; Liang, Jia-Jian; Chen, Jian-Huan; Harvey, Alan R.; Ng, Tsz Kin; Zhang, Mingzhi; Pang, Chi Pui; Cui, Qi; Fan, You-Ming			AAV-MEDIATED TRANSFER OF RhoA shRNA AND CNTF PROMOTES RETINAL GANGLION CELL SURVIVAL AND AXON REGENERATION	NEUROSCIENCE			English	Article						CNTF; retina; ganglion cell; RhoA; RNAi; nerve; regeneration	CILIARY NEUROTROPHIC FACTOR; OPTIC-NERVE REGENERATION; MYELIN-ASSOCIATED GLYCOPROTEIN; ADENOASSOCIATED VIRAL VECTORS; ADULT-RATS; IN-VIVO; NEURITE GROWTH; NOGO RECEPTOR; GENE-THERAPY; CYCLIC-AMP	The aim of the present study was to determine whether adeno-associated viral vector (AAV) mediated transfer of ciliary neurotrophic factor (CNTF) and RhoA shRNA has additive effects on promoting the survival and axon regeneration of retinal ganglion cells (RGCs) after optic nerve crush (ONC). Silencing effects of AAV-RhoA shRNA were confirmed by examining neurite outgrowth in PC12 cells, and by quantifying RhoA expression levels with western blotting. Young adult Fischer rats received an intravitreal injection of (i) saline, (ii) AAV green fluorescent protein (GFP), (iii) AAV-CNTF, (iv) AAV-RhoA shRNA, or (v) a combination of both AAV-CNTF and AAV-RhoA shRNA. Two weeks later, the ON was completely crushed. Three weeks after ONC, RGC survival was estimated by counting beta III-tubulin-positive neurons in retinal whole mounts. Axon regeneration was evaluated by counting GAP-43-positive axons in the crushed ON. It was found that AAV-RhoA shRNA decreased RhoA expression levels and promoted neurite outgrowth in vitro. In the ONC model, AAV-RhoA shRNA by itself had only weak beneficial effects on RGC axon regeneration. However, when combined with AAV-CNTF, AAV-RhoA shRNA significantly improved the therapeutic effect of AAV-CNTF on axon regeneration by nearly two fold, even though there was no significant change in RGC viability. In sum, this combination of vectors increases the regenerative response and can lead to more successful therapeutic outcomes following neurotrauma. (C) 2016 IBRO. Published by Elsevier Ltd. All rights reserved.	[Cen, Ling-Ping; Liang, Jia-Jian; Chen, Jian-Huan; Zhang, Mingzhi; Pang, Chi Pui; Cui, Qi; Fan, You-Ming] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China; [Cen, Ling-Ping; Liang, Jia-Jian; Chen, Jian-Huan; Zhang, Mingzhi; Pang, Chi Pui; Cui, Qi; Fan, You-Ming] Chinese Univ Hong Kong, Shantou, Peoples R China; [Ng, Tsz Kin; Pang, Chi Pui; Cui, Qi] Chinese Univ Hong Kong, Fac Med, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China; [Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA, Australia; [Fan, You-Ming] Hubei Univ Nationalities, Dept Neurol, Affiliated Hosp, Enshi, Peoples R China		Cen, LP (corresponding author), Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.; Cen, LP (corresponding author), Chinese Univ Hong Kong, Shantou, Peoples R China.	cenlp@hotmail.com; youmingf@aliyun.com	Chen, Jian-Huan/ABB-9660-2021; Cen Ling-Ping, Cen Lingping/O-4216-2015; Ng, Tsz Kin/I-8061-2014	Chen, Jian-Huan/0000-0001-8714-2543; Cen Ling-Ping, Cen Lingping/0000-0003-3876-0606; Ng, Tsz Kin/0000-0001-7863-7229; , Alan/0000-0002-2590-831X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81570849, 30672038]; Research Fund for Doctoral Program of Higher Education of ChinaResearch Fund for the Doctoral Program of Higher Education of China (RFDP) [20114402120007]; Natural Science Foundation of Guangdong Province, ChinaNational Natural Science Foundation of Guangdong Province [2015A030313446]; Joint Shantou International Eye Center of The Shantou University; Chinese University of Hong KongChinese University of Hong Kong [09-017]	This work is supported by the National Natural Science Foundation of China (81570849, 30672038), Research Fund for Doctoral Program of Higher Education of China (20114402120007), Natural Science Foundation of Guangdong Province, China (2015A030313446), and an internal grant from the Joint Shantou International Eye Center of The Shantou University and The Chinese University of Hong Kong (09-017).	Asher R A, 2001, Prog Brain Res, V132, P611; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bertrand J, 2005, J NEUROSCI, V25, P1113, DOI 10.1523/JNEUROSCI.3931-04.2005; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760; Cui Qi, 2004, Anatomical Science International, V79, P209, DOI 10.1111/j.1447-073x.2004.00089.x; de Lima S, 2012, INT REV NEUROBIOL, V106, P153, DOI 10.1016/B978-0-12-407178-0.00007-7; Dergham P, 2002, J NEUROSCI, V22, P6570; Drummond ES, 2014, RESTOR NEUROL NEUROS, V32, P391, DOI 10.3233/RNN-130360; Fan YM, 2008, NEUROSCI LETT, V440, P170, DOI 10.1016/j.neulet.2008.05.045; Fischer D, 2000, INVEST OPHTH VIS SCI, V41, P3943; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fischer D, 2001, EXP NEUROL, V172, P257, DOI 10.1006/exnr.2001.7822; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Fujita Y, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.85; Fujita Y, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00338; Fujita Y, 2011, EMBO J, V30, P1389, DOI 10.1038/emboj.2011.55; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Guo X, 2016, ELIFE, V5; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Harvey AR, 2012, INT REV NEUROBIOL, V106, P1, DOI 10.1016/B978-0-12-407178-0.00002-8; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Hellstrom M, 2011, MOL CELL NEUROSCI, V46, P507, DOI 10.1016/j.mcn.2010.12.003; Hellstrom M, 2014, INT J BIOCHEM CELL B, V56, P66, DOI 10.1016/j.biocel.2014.04.018; Hellstrom M, 2011, J NEUROTRAUM, V28, P2475, DOI 10.1089/neu.2011.1928; Hellstrom M, 2011, CURR GENE THER, V11, P116, DOI 10.2174/156652311794940746; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Heskamp A, 2013, NEUROBIOL DIS, V55, P76, DOI 10.1016/j.nbd.2013.04.001; Hoffmann A, 2008, GLIA, V56, P1162, DOI 10.1002/glia.20687; Hu Y, 2005, MOL THER, V11, P906, DOI 10.1016/j.ymthe.2005.01.016; Hu Y, 2007, MOL CELL NEUROSCI, V34, P88, DOI 10.1016/j.mcn.2006.10.005; Israelsson C, 2014, RESTOR NEUROL NEUROS, V32, P717, DOI 10.3233/RNN-140419; Just I, 2011, N-S ARCH PHARMACOL, V383, P247, DOI 10.1007/s00210-010-0589-3; Koch JC, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00273; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Leaver SG, 2006, EUR J NEUROSCI, V24, P3323, DOI 10.1111/j.1460-9568.2006.05230.x; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Lingor P, 2008, BRAIN, V131, P250, DOI 10.1093/brain/awm284; Loucks FA, 2006, J NEUROCHEM, V97, P957, DOI 10.1111/j.1471-4159.2006.03802.x; MALORNI W, 1991, TOXICON, V29, P417, DOI 10.1016/0041-0101(91)90016-K; Martin KRG, 2002, METHODS, V28, P267, DOI 10.1016/S1046-2023(02)00232-3; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Muller A, 2009, MOL CELL NEUROSCI, V41, P233, DOI 10.1016/j.mcn.2009.03.002; Niederost B, 2002, J NEUROSCI, V22, P10368; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Park KK, 2009, MOL CELL NEUROSCI, V41, P313, DOI 10.1016/j.mcn.2009.04.002; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Sharma A, 2012, INVEST OPHTH VIS SCI, V53, P8367, DOI 10.1167/iovs.12-10799; Sharma B, 2014, INT OPHTHALMOL, V34, P893, DOI 10.1007/s10792-014-9898-8; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Xu R, 2001, GENE THER, V8, P1323, DOI 10.1038/sj.gt.3301529; Yavas GF, 2007, EUR J OPHTHALMOL, V17, P812, DOI 10.1177/112067210701700520; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; You SW, 2016, EXP NEUROL, V279, P197, DOI 10.1016/j.expneurol.2016.03.006; Yungher BJ, 2015, GENE THER, V22, P811, DOI 10.1038/gt.2015.51; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	66	29	31	2	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 20	2017	343						472	482		10.1016/j.neuroscience.2016.12.027			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EJ5PB	WOS:000393269100044	28017835				2022-02-06	
J	Jokar, A; Ahmadi, K; Salehi, T; Sharif-Alhoseini, M; Rahimi-Movaghar, V				Jokar, Abolfazl; Ahmadi, Koorosh; Salehi, Tayyebeh; Sharif-Alhoseini, Mahdi; Rahimi-Movaghar, Vafa			The effect of tranexamic acid in traumatic brain injury: A randomized controlled trial	CHINESE JOURNAL OF TRAUMATOLOGY			English	Article						Traumatic brain injuries; Intracranial hemorrhage; Traumatic; Tranexamic acid	HEMORRHAGE; CRASH-2	Purpose: Traumatic brain injury (TBI) is a leading cause of death and disability. Intracranial hemorrhage (ICH) secondary to TBI is associated with a high risk of coagulopathy which leads to increasing risk of hemorrhage growth and higher mortality rate. Therefore, antifibrinolytic agents such as tranexamic acid (TA) might reduce traumatic ICH. The aim of the present study was to investigate the extent of ICH growth after TA administration in TBI patients. Methods: This single-blind randomized controlled trial was conducted on patients with traumatic ICH (with less than 30 ml) referring to the emergency department of Vali-Asr Hospital, Arak, Iran in 2014. Patients, based on the inclusion and exclusion criteria, were divided into intervention and control groups (40 patients each). All patients received a conservative treatment for ICH, as well as either intravenous TA or placebo. The extent of ICH growth as the primary outcome was measured by brain CT scan after 48 h. Results: Although brain CT scan showed a significant increase in hemorrhage volume in both groups after 48 h, it was significantly less in the TA group than in the control group (p = 0.04). The mean total hemorrhage expansion was (1.7 +/- 9.7) ml and (4.3 +/- 12.9) ml in TA and placebo groups, respectively (p < 0.001). Conclusion: It has been established that TA, as an effective hospital-based treatment for acute TBI, could reduce ICH growth. Larger studies are needed to compare the effectiveness of different doses. (c) 2017 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Production and hosting by Elsevier B.V.	[Jokar, Abolfazl; Salehi, Tayyebeh] Arak Univ Med Sci, Dept Emergency Med, Arak, Iran; [Ahmadi, Koorosh] Alborz Univ Med Sci, Dept Emergency Med, Karaj, Iran; [Sharif-Alhoseini, Mahdi; Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, Iran; [Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Shariati Hosp, Dept Neurosurg, Tehran, Iran		Rahimi-Movaghar, V (corresponding author), Sina Hosp, Sina Trauma & Surg Res Ctr, Hassan Abad Sq,Imam Khomeini Ave, Tehran, Iran.	v_rahimi@sina.tums.ac.ir	Ahmadi, Koorosh/AAF-7559-2020; Rahimi-Movaghar, Vafa/L-6339-2019; Rahimi-Movaghar, Vafa/T-7816-2017	Rahimi-Movaghar, Vafa/0000-0001-7347-8767	Arak University of Medical Sciences [806]	This study was supported by Arak University of Medical Sciences (Grant No. 806).	[Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Epstein DS, 2015, BRIT J NEUROSURG, V29, P118, DOI 10.3109/02688697.2014.950632; French KF, 2012, NEUROCRIT CARE, V17, P107, DOI 10.1007/s12028-012-9681-5; Gruen RL, 2011, LANCET, V377, P1052, DOI 10.1016/S0140-6736(11)60396-6; Harvey V, 2014, ANN EMERG MED, V63, P460, DOI 10.1016/j.annemergmed.2013.08.028; Lipsky AM, 2014, INJURY, V45, P66, DOI 10.1016/j.injury.2013.08.025; Liu Lin-tao, 2006, Chin J Traumatol, V9, P249; Meretoja A, 2014, INT J STROKE, V9, P519, DOI 10.1111/ijs.12132; Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039; Perel P, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16130; Rahimi-Movaghar V, 2011, AM SURGEON, V77, pE112; Roberts I, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5839; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Specogna AV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096743; Valle EJ, 2014, J TRAUMA ACUTE CARE, V76, P1373, DOI 10.1097/TA.0000000000000242; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zehtabchi S, 2015, AM J EMERG MED, V33, P458, DOI 10.1016/j.ajem.2014.11.009; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023	20	29	30	0	2	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	1008-1275			CHIN J TRAUMATOL	Chin. J. Traumatol.	FEB	2017	20	1					49	51		10.1016/j.cjtee.2016.02.005			3	Orthopedics	Emerging Sources Citation Index (ESCI)	Orthopedics	GQ9PH	WOS:000442113000011	28209450	Green Published, gold			2022-02-06	
J	Liu, ZY; Pouli, D; Sood, D; Sundarakrishnan, A; Mingalone, CKH; Arendt, LM; Alonzo, C; Quinn, KP; Kuperwasser, C; Zeng, L; Schnelldorfer, T; Kaplan, DL; Georgakoudi, I				Liu, Zhiyi; Pouli, Dimitra; Sood, Disha; Sundarakrishnan, Aswin; Mingalone, Carrie K. Hui; Arendt, Lisa M.; Alonzo, Carlo; Quinn, Kyle P.; Kuperwasser, Charlotte; Zeng, Li; Schnelldorfer, Thomas; Kaplan, David L.; Georgakoudi, Irene			Automated quantification of three-dimensional organization of fiber-like structures in biological tissues	BIOMATERIALS			English	Article						Three-dimensional organization; Collagen fiber; Neuronal axon; Cancer; Traumatic brain injury; Multi-photon microscopy	VIVO MULTIPHOTON MICROSCOPY; TRAUMATIC BRAIN-INJURY; 2ND-HARMONIC GENERATION; EXTRACELLULAR-MATRIX; IMAGING MICROSCOPY; PANCREATIC-CANCER; STEM-CELLS; COLLAGEN; PROGRESSION; FIBROBLASTS	Fiber-like structures are prevalent in biological tissues, yet quantitative approaches to assess their three-dimensional (3D) organization are lacking. We develop 3D directional variance, as a quantitative biomarker of truly 3D fibrillar organization by extending the directional statistics formalism developed for describing circular data distributions (i.e. when 0 degrees and 360 degrees are equivalent) to axial ones (i.e. when 0 degrees and 180 degrees are equivalent). Significant advantages of this analysis include its time efficiency, sensitivity and ability to provide quantitative readouts of organization over different size scales of a given data set. We establish a broad range of applications for this method by characterizing collagen fibers, neuronal axons and fibroblasts in the context of cancer diagnostics, traumatic brain injury and cell-matrix interactions in developing engineered tissues. This method opens possibilities for unraveling in a sensitive, and quantitative manner the organization of essential fiber-like structures in tissues and ultimately its impact on tissue function. (C) 2016 Elsevier Ltd. All rights reserved.	[Liu, Zhiyi; Pouli, Dimitra; Sood, Disha; Sundarakrishnan, Aswin; Alonzo, Carlo; Quinn, Kyle P.; Kaplan, David L.; Georgakoudi, Irene] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Mingalone, Carrie K. Hui; Arendt, Lisa M.; Kuperwasser, Charlotte; Zeng, Li] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA; [Schnelldorfer, Thomas] Lahey Hosp & Med Ctr, Burlington, MA 01805 USA; [Quinn, Kyle P.] Univ Arkansas, Dept Biomed Engn, Fayetteville, AR 72701 USA			Irene.Georgakoudi@tufts.edu		Sundarakrishnan, Aswin/0000-0002-2672-7780; Arendt, Lisa/0000-0002-7954-3635	American Cancer SocietyAmerican Cancer Society [RSG-09-174-01-CCE]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH/NIBIB P41EB002520, NIH R01NS092847, NIH/NIBIB R00EB017723, NIH/NCI CA170851, NIH F31AR067638-01A1]; Tufts University; Raymond & Beverly Sackler Convergence Lab; Breast Cancer Research Foundation; Alexander S. Onassis Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA170851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [F31AR067638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R00EB017723, P41EB002520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092847] Funding Source: NIH RePORTER	This study was supported by the American Cancer Society (RSG-09-174-01-CCE to I.G.), the National Institutes of Health (NIH/NIBIB P41EB002520 to D.L.K., NIH R01NS092847 to D.L.K., NIH/NIBIB R00EB017723 to K.P.Q., NIH/NCI CA170851 to C.K. and NIH F31AR067638-01A1 to C.K.H.M.), Tufts University (Tufts Collaborates awards to T.S., L.Z. and I.G.), Raymond & Beverly Sackler Convergence Lab, the Breast Cancer Research Foundation and the Alexander S. Onassis Foundation. We acknowledge valuable help and support from Dr. Michael Whalen from the Massachusetts General Hospital in establishing the in vitro brain TBI model.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Altendorf H, 2012, J MICROSC-OXFORD, V247, P161, DOI 10.1111/j.1365-2818.2012.03629.x; Ambekar R, 2012, BIOMED OPT EXPRESS, V3, P2021, DOI 10.1364/BOE.3.002021; Balu M, 2015, JAMA DERMATOL, V151, P1068, DOI 10.1001/jamadermatol.2015.0453; Balu M, 2014, CANCER RES, V74, P2688, DOI 10.1158/0008-5472.CAN-13-2582; Barnes C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093325; Bayan C, 2009, J APPL PHYS, V105, DOI 10.1063/1.3116626; Birk JW, 2014, DIGEST DIS SCI, V59, P1529, DOI 10.1007/s10620-014-3121-7; Brown E, 2003, NAT MED, V9, P796, DOI 10.1038/nm879; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Campagnola PJ, 2003, NAT BIOTECHNOL, V21, P1356, DOI 10.1038/nbt894; Choi SH, 2014, NATURE, V515, P274, DOI 10.1038/nature13800; Chwalek K, 2015, NAT PROTOC, V10, P1362, DOI 10.1038/nprot.2015.091; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233; Dapul HR, 2013, J NEUROTRAUM, V30, P382, DOI 10.1089/neu.2012.2536; Dedinaite A, 2012, SOFT MATTER, V8, P273, DOI 10.1039/c1sm06335a; Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Hanley CJ, 2016, ONCOTARGET, V7, P6159, DOI 10.18632/oncotarget.6740; Hirokawa N, 2010, NEURON, V68, P610, DOI 10.1016/j.neuron.2010.09.039; HOLBROOK KA, 1982, J INVEST DERMATOL, V79, pS7, DOI 10.1111/1523-1747.ep12544609; Hughes L C, 2005, Eur Cell Mater, V9, P68; Ingber DE, 2006, INT J DEV BIOL, V50, P255, DOI 10.1387/ijdb.052044di; Ingber DE, 2008, SEMIN CANCER BIOL, V18, P356, DOI 10.1016/j.semcancer.2008.03.016; Lau TY, 2012, OPT EXPRESS, V20, P21821, DOI 10.1364/OE.20.021821; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li MY, 2005, BIOMATERIALS, V26, P5999, DOI 10.1016/j.biomaterials.2005.03.030; Liu ZY, 2015, BIOMED OPT EXPRESS, V6, P2294, DOI 10.1364/BOE.6.002294; Mardia KV., 2000, DIRECTIONAL STAT; Nadiarnykh O, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-94; Napadow VJ, 2001, BIOPHYS J, V80, P2968, DOI 10.1016/S0006-3495(01)76262-5; Nieminen MT, 2001, MAGN RESON MED, V46, P487, DOI 10.1002/mrm.1218; Paszek MJ, 2004, J MAMMARY GLAND BIOL, V9, P325, DOI 10.1007/s10911-004-1404-x; Perentes JY, 2009, NAT METHODS, V6, P143, DOI [10.1038/NMETH.1295, 10.1038/nmeth.1295]; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Provenzano PP, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-11; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Quinn KP, 2015, EXP DERMATOL, V24, P78, DOI 10.1111/exd.12553; Quinn KP, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.4.046003; Robertson C, 2013, BIOMATERIALS, V34, P6127, DOI 10.1016/j.biomaterials.2013.04.019; Roy P, 2002, NAT CELL BIOL, V4, pE91, DOI 10.1038/ncb0402-e91; Schnelldorfer T, 2008, ANN SURG, V247, P456, DOI 10.1097/SLA.0b013e3181613142; Schriefl AJ, 2012, J R SOC INTERFACE, V9, P1275, DOI 10.1098/rsif.2011.0727; Tang-Schomer MD, 2014, P NATL ACAD SCI USA, V111, P13811, DOI 10.1073/pnas.1324214111; TINGSTROM A, 1992, J CELL SCI, V102, P315; Whatcott CJ, 2015, CLIN CANCER RES, V21, P3561, DOI 10.1158/1078-0432.CCR-14-1051; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zemel A, 2010, NAT PHYS, V6, P468, DOI 10.1038/NPHYS1613; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	54	29	31	0	21	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	FEB	2017	116						34	47		10.1016/j.biomaterials.2016.11.041			14	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	EI7MC	WOS:000392681100004	27914265	Green Accepted			2022-02-06	
J	Liu, ZK; Ng, CF; Shiu, HT; Wong, HL; Wong, CW; Li, KK; Zhang, JF; Lam, PK; Poon, WS; Lau, CBS; Leung, PC; Ko, CH				Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Wong, Chun-Wai; Li, Kai-Kai; Zhang, Jin-Fang; Lam, Ping-Kuen; Poon, Wai-Sang; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay			A traditional Chinese formula composed of Chuanxiong Rhizoma and Gastrodiae Rhizoma (Da Chuanxiong Formula) suppresses inflammatory response in LPS -induced RAW 264.7 cells through inhibition of NF-kappa B pathway	JOURNAL OF ETHNOPHARMACOLOGY			English	Article						Chuanxiong Rhizoma; Gastrodiae Rhizoma; Da Chuanxiong Formula; Anti-inflammation; NF-kappa B	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NITRIC-OXIDE; CLUSTER HEADACHE; MEMORY DEFICITS; RATS; TETRAMETHYLPYRAZINE; CYCLOOXYGENASE-2; EXPRESSION; CYTOKINES	Ethnopharmacological relevance: Da Chuanxiong Formula (DCXF) which origins from Jin Dynasty is a famous classical 2-herb Chinese medicinal prescription. It is composed of dried rhizomes of Ligusticum chuanxiong (Chuanxiong Rhizoma, CR) and Gastrodia elata (Gastrodiae Rhizoma, GR) at the ratio of 4:1 (w/w). It has been used to treat headache which is caused by wind pathogen and blood stasis for thousands of years in China. Aim of study: The present study was performed to investigate the anti-inflammatory effect of DCXF and elucidate its underlying molecular mechanisms using LPS-stimulated RAW 264.7 cells. Materials and methods: The anti-inflammatory effect of DCXF was evaluated using LPS-stimulated RAW 264.7 cells. Generation of nitric oxide (NO) and prostaglandin E-2 (PGE(2)) were measured by the Griess colorimetric method and enzyme-linked immunosorbent assay (ELISA), respectively. The gene expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were detected by reverse transcription-polymerase chain reaction (RT-PCR). Furthermore, the effect of DCXF on NF-kappa B activation was measured by western blot assay. Results: Treatment with DCXF significantly suppressed the productions of NO and PGE(2) through inhibitions of iNOS and COX-2 expressions in LPS-stimulated RAW 264.7 cells. DCXF significantly decreased I kappa B alpha phosphorylation, inhibited p65 expression and reduced p-p65 level. These results suggested the anti-inflammatory effect of DCXF was associated with the reduction of inflammatory mediators through inhibition of NF-kappa B pathway. Conclusions: These results indicated that DCXF inhibited inflammation in LPS-stimulated RAW 264.7 cells through inactivation of NF-kappa B pathway.	[Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Wong, Chun-Wai; Li, Kai-Kai; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, Inst Chinese Med, Sci Ctr East Block, Shatin, Hong Kong, Peoples R China; [Liu, Zhi-Ke; Ng, Chun-Fai; Shiu, Hoi-Ting; Wong, Hing-Lok; Wong, Chun-Wai; Li, Kai-Kai; Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, State Key Lab Phytochem & Plant Resources West Ch, Shatin, Hong Kong, Peoples R China; [Lau, Clara Bik-San; Leung, Ping-Chung; Ko, Chun-Hay] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen 518057, Peoples R China; [Zhang, Jin-Fang] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Orthopaed & Traumatol, Shatin, Hong Kong, Peoples R China; [Lam, Ping-Kuen; Poon, Wai-Sang] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China		Leung, PC; Ko, CH (corresponding author), Chinese Univ Hong Kong, Inst Chinese Med, Sci Ctr East Block, Shatin, Hong Kong, Peoples R China.	liuzhikebee@163.com; ncf0000@hotmail.com; hoitingshiu@gmail.com; vhlwong@yahoo.com; cwwong_eric@cuhk.edu.hk; likaicuhk@gmail.com; zhangjf06@cuhk.edu.hk; lampingkuen@yahoo.com.hk; wpoon@surgery.cuhk.edu.hk; claralau@cuhk.edu.hk; pingcleung@cuhk.edu.hk; gohey@yahoo.com	Poon, Wai Sang/F-1558-2011; Lau, Clara Bik-San/AAF-3989-2020	Lau, Clara Bik-San/0000-0002-7409-1270	Food and Health Bureau, Hong Kong, Special Administration Region, Health and Medical Research Fund [12134111]	The research was financially supported by the Food and Health Bureau, Hong Kong, Special Administration Region, Health and Medical Research Fund (no. 12134111).	Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Antonova M, 2013, CURR OPIN NEUROL, V26, P269, DOI 10.1097/WCO.0b013e328360864b; Blatteis CM, 2005, PROSTAG OTH LIPID M, V76, P1, DOI 10.1016/j.prostaglandins.2005.01.001; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; Brietzke E, 2012, MED HYPOTHESES, V78, P601, DOI 10.1016/j.mehy.2012.01.036; Chavarria A, 2004, AUTOIMMUN REV, V3, P251, DOI 10.1016/j.autrev.2003.09.006; Chinese Pharmacopoeia Commission, 2010, PHARMACOPOEIA PEOPLE; Cimino PJ, 2008, CURR MED CHEM, V15, P1863, DOI 10.2174/092986708785132915; Dai JN, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021891, 10.1371/journal.pone.0028903]; Ferreiro DU, 2010, BIOCHEMISTRY-US, V49, P1560, DOI 10.1021/bi901948j; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fung A, 2012, BRAIN RES, V1446, P144, DOI 10.1016/j.brainres.2012.01.061; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Guo JM, 2013, J ETHNOPHARMACOL, V150, P649, DOI 10.1016/j.jep.2013.09.020; Guo JM, 2011, FITOTERAPIA, V82, P441, DOI 10.1016/j.fitote.2010.12.002; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He Li, 2004, Sichuan Da Xue Xue Bao Yi Xue Ban, V35, P821; Hu YK, 2014, NEUROPATHOLOGY, V34, P370, DOI 10.1111/neup.12115; John S, 2014, HEADACHE, V54, P572, DOI 10.1111/head.12306; Kao TK, 2013, EXP NEUROL, V247, P188, DOI 10.1016/j.expneurol.2013.04.010; Kim YM, 1997, BIOCHEM BIOPH RES CO, V236, P655, DOI 10.1006/bbrc.1997.7031; Koh PO, 2013, SYNAPSE, V67, P390, DOI 10.1002/syn.21649; Korhonen Riku, 2005, Current Drug Targets - Inflammation and Allergy, V4, P471, DOI 10.2174/1568010054526359; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Legler DF, 2010, INT J BIOCHEM CELL B, V42, P198, DOI 10.1016/j.biocel.2009.09.015; Li Y., 2015, J ETHNOPHARMACOL; Lin LC, 2007, ANAL CHIM ACTA, V590, P173, DOI 10.1016/j.aca.2007.03.035; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Nagy G, 2007, IMMUNOL LETT, V111, P1, DOI 10.1016/j.imlet.2007.04.013; Ng CF, 2016, J ETHNOPHARMACOL, V185, P87, DOI 10.1016/j.jep.2016.03.018; Niu J. X., 2011, J EMERGENCY TRADITIO, V20, P833; Olesen J, 2010, NEUROTHERAPEUTICS, V7, P183, DOI 10.1016/j.nurt.2010.03.006; Olesen J, 2008, PHARMACOL THERAPEUT, V120, P157, DOI 10.1016/j.pharmthera.2008.08.003; Peng Z, 2013, PHYSIOL RES, V62, P537, DOI 10.33549/physiolres.932507; Peng ZW, 2015, NEUROCHEM RES, V40, P661, DOI 10.1007/s11064-015-1513-5; Predonzani Andrea, 2015, World J Exp Med, V5, P64, DOI 10.5493/wjem.v5.i2.64; Pu QH, 2015, LIFE SCI, V121, P46, DOI 10.1016/j.lfs.2014.11.016; Steinberg A, 2012, CURR PAIN HEADACHE R, V16, P185, DOI 10.1007/s11916-012-0250-6; Sun SC, 2008, TRENDS IMMUNOL, V29, P469, DOI 10.1016/j.it.2008.07.003; Tsai TH, 2001, INT J PHARMACEUT, V216, P61, DOI 10.1016/S0378-5173(01)00572-5; Waeber C, 2005, NEUROLOGY, V64, pS9, DOI 10.1212/WNL.64.10_suppl_2.S9; Wang HN, 2014, BEHAV BRAIN RES, V266, P153, DOI 10.1016/j.bbr.2014.02.046; Wang L., 2013, SCI WORLD J, V2013, P1, DOI DOI 10.1002/AS12.454.WILEY0NLINELIBRARY.C0M; Wang XN, 2014, NEUROCHEM RES, V39, P1458, DOI 10.1007/s11064-014-1335-x; Wienecke T, 2009, CEPHALALGIA, V29, P509, DOI 10.1111/j.1468-2982.2008.01748.x; Wu K, 2014, J ETHNOPHARMACOL, V151, P1133, DOI 10.1016/j.jep.2013.12.027; Yang HW, 2008, CURR PHARM DESIGN, V14, P1443, DOI 10.2174/138161208784480144; [姚干 Yao Gan], 2004, [中成药, Chinese Traditional Patent Medicine], V26, P314; Yeo SJ, 2003, J BIOL CHEM, V278, P40590, DOI 10.1074/jbc.M306280200; Yuste JE, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00322; Zhao Y., 2008, INFORM TRADITIONAL C, V25, P67; Zhou Y., 2003, HENAN TRADIT CHIN ME, V23, P22; Zhu MD, 2014, BRAIN RES BULL, V109, P54, DOI 10.1016/j.brainresbull.2014.10.002; 周明眉, 2008, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V24, P6; 周明眉, 2009, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V25, P9	57	29	34	2	46	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-8741			J ETHNOPHARMACOL	J. Ethnopharmacol.	JAN 20	2017	196						20	28		10.1016/j.jep.2016.12.014			9	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	EJ9ER	WOS:000393529900003	27965052				2022-02-06	
J	Vergara, VM; Mayer, AR; Damaraju, E; Hutchison, K; Calhoun, VD				Vergara, Victor M.; Mayer, Andrew R.; Damaraju, Eswar; Hutchison, Kent; Calhoun, Vince D.			The effect of preprocessing pipelines in subject classification and detection of abnormal resting state functional network connectivity using group ICA	NEUROIMAGE			English	Article							TRAUMATIC BRAIN-INJURY; DEFAULT-MODE NETWORK; CEREBRAL-CORTEX; SMOKING CUES; HEAD MOTION; TIME-SERIES; FMRI DATA; BOLD; IDENTIFICATION; ACTIVATION	Resting state functional network connectivity (rsFNC) derived from functional magnetic resonance (fMRI) imaging is emerging as a possible biomarker to identify several brain disorders. Recently it has been pointed out that methods used to preprocess head motion variance might not fully remove all unwanted effects in the data. Proposed processing pipelines locate the treatment of head motion effects either close to the beginning or as one of the final steps. In this work, we assess several preprocessing pipelines applied in group independent component analysis (gICA) methods to study the rsFNC of the brain. The evaluation method utilizes patient/control classification performance based on linear support vector machines and leave-one-out cross validation. In addition, we explored group tests and correlation with severity measures in the patient population. We also tested the effect of removing high frequencies via filtering. Two real data cohorts were used: one consisting of 48 mTBI and one composed of 21 smokers, both with their corresponding matched controls. A simulation procedure was designed to test the classification power of each pipeline. Results show that data preprocessing can change the classification performance. In real data, regressing motion variance before gICA produced clearer group differences and stronger correlation with nicotine dependence. (C) 2016 Elsevier Inc. All rights reserved.	[Vergara, Victor M.; Mayer, Andrew R.; Calhoun, Vince D.] Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA; [Damaraju, Eswar; Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87106 USA; [Hutchison, Kent] Univ Colorado, Dept Psychol, Boulder, CO 80302 USA; [Hutchison, Kent] Univ Colorado, Dept Neurosci, Boulder, CO 80302 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA		Vergara, VM (corresponding author), Mind Res Network, 1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	vvergara@mrn.org			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD050836/R21NS064464/R21NS064464, P20GM103472/R01EB006841/R01EB020407]; NSFNational Science Foundation (NSF) [1539067]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB020407, R01EB006841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA040487] Funding Source: NIH RePORTER; Office of Integrative ActivitiesNational Science Foundation (NSF)NSF - Office of the Director (OD) [1539067] Funding Source: National Science Foundation	The authors thank Joseph Ling, Jill Fries, Vikram Rao, Prashanth Nyalakanti, and Sandeep Panta for help with preprocessing the data. We also appreciate the advice provided by Professor Eric Erhart to improve our statistical analysis. This work was funded by NIH grants R24HD050836/R21NS064464/R21NS064464 (to A.M.), and P20GM103472/R01EB006841/R01EB020407 and NSF grant 1539067 (to V.D.C.).	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Boubela RN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00168; Calhoun V. D., 2011, FRONT PSYCHOL, V2; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Calhoun Vince D, 1800, IEEE Rev Biomed Eng, V5, P60, DOI 10.1109/RBME.2012.2211076; Chai XQJ, 2011, NEUROPSYCHOPHARMACOL, V36, P2009, DOI 10.1038/npp.2011.88; Chanraud S, 2011, CEREB CORTEX, V21, P2272, DOI 10.1093/cercor/bhq297; Chen JYE, 2015, NEUROIMAGE, V107, P207, DOI 10.1016/j.neuroimage.2014.12.012; Claus ED, 2013, NEUROPSYCHOPHARMACOL, V38, P2363, DOI 10.1038/npp.2013.134; Cordes D, 2001, AM J NEURORADIOL, V22, P1326; Damaraju E., 2014, 4 BIENN C REST STAT; Das P, 2014, NEUROIMAGE, V98, P73, DOI 10.1016/j.neuroimage.2014.04.062; Due DL, 2002, AM J PSYCHIAT, V159, P954, DOI 10.1176/appi.ajp.159.6.954; Ely AV, 2015, APPETITE, V95, P126, DOI 10.1016/j.appet.2015.06.022; Erhardt EB, 2011, HUM BRAIN MAPP, V32, P2075, DOI 10.1002/hbm.21170; FAGERSTROM K O, 1990, Ear Nose and Throat Journal, V69, P763; First M., 1995, STRUCTURED CLIN INTE, V9, P92; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Garrity A. G., 2007, ABERRANT DEFAULT MOD; Grouiller F, 2011, BRAIN, V134, P2867, DOI 10.1093/brain/awr156; Himberg J, 2004, NEUROIMAGE, V22, P1214, DOI 10.1016/j.neuroimage.2004.03.027; K/tter, 2003, NEUROSCIENCE DATABAS, P237, DOI [10.1007/978-1-4615-1079-6_16, DOI 10.1007/978-1-4615-1079-6{\_}16]; Konova AB, 2015, BRAIN RES, V1628, P147, DOI 10.1016/j.brainres.2015.02.002; Kundu P, 2012, NEUROIMAGE, V60, P1759, DOI 10.1016/j.neuroimage.2011.12.028; Lee HL, 2013, NEUROIMAGE, V65, P216, DOI 10.1016/j.neuroimage.2012.10.015; Lee MH, 2013, AM J NEURORADIOL, V34, P1866, DOI 10.3174/ajnr.A3263; Liu F, 2015, BRAIN STRUCT FUNCT, V220, P101, DOI 10.1007/s00429-013-0641-4; Ma S, 2011, IEEE T BIO-MED ENG, V58, P3406, DOI 10.1109/TBME.2011.2167149; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McClernon FJ, 2009, PSYCHOPHARMACOLOGY, V204, P25, DOI 10.1007/s00213-008-1436-9; Mowinckel AM, 2012, NEUROIMAGE, V63, P1364, DOI 10.1016/j.neuroimage.2012.08.004; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Niazy RK, 2011, PROG BRAIN RES, V193, P259, DOI 10.1016/B978-0-444-53839-0.00017-X; Olsen A, 2015, CEREB CORTEX, V25, P2170, DOI 10.1093/cercor/bhu023; Pariyadath V, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00425; Power JD, 2014, NEUROIMAGE, V84, P320, DOI 10.1016/j.neuroimage.2013.08.048; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Rachakonda S., 2011, ALTERED TOPOLOGICAL; Rocca MA, 2013, NEUROTHERAPEUTICS, V10, P511, DOI 10.1007/s13311-013-0189-2; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schmidt A, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.28; Sheline YI, 2013, BIOL PSYCHIAT, V74, P340, DOI 10.1016/j.biopsych.2012.11.028; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; Vakhtin AA, 2013, BRAIN INJURY, V27, P1304, DOI 10.3109/02699052.2013.823561; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Yaesoubi M, 2015, NEUROIMAGE, V120, P133, DOI 10.1016/j.neuroimage.2015.07.002; Yuan K, 2016, BRAIN STRUCT FUNCT, V221, P1427, DOI 10.1007/s00429-014-0982-7; Zeng LL, 2014, HUM BRAIN MAPP, V35, P1630, DOI 10.1002/hbm.22278	56	29	31	1	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 15	2017	145		B		SI		365	376		10.1016/j.neuroimage.2016.03.038			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EG3WU	WOS:000390976200020	27033684	Green Accepted			2022-02-06	
J	Capo-Aponte, JE; Jorgensen-Wagers, KL; Sosa, JA; Walsh, DV; Goodrich, GL; Temme, LA; Riggs, DW				Capo-Aponte, Jose E.; Jorgensen-Wagers, Kendra L.; Sosa, Josue A.; Walsh, David V.; Goodrich, Gregory L.; Temme, Leonard A.; Riggs, Daniel W.			Visual Dysfunctions at Different Stages after Blast and Non-blast Mild Traumatic Brain Injury	OPTOMETRY AND VISION SCIENCE			English	Article						visual dysfunction; mild traumatic brain injury; mTBI; military; blast	POSTCONCUSSIVE SYMPTOMS; SUBACUTE STAGE; MODERATE; PROGRESSION; POPULATION; IMPAIRMENT; MECHANISMS; MILITARY; VETERANS; PROTOCOL	Purpose. To assess the prevalence of visual dysfunctions and associated symptoms in war fighters at different stages after nonYblast- or blast-induced mild traumatic brain injury (mTBI). Methods. A comprehensive retrospective review of the electronic health records of 500 U.S. military personnel with a diagnosis of deployment-related mTBI who received eye care at the Landstuhl Regional Medical Center. For analysis, the data were grouped by mechanism of injury, and each group was further divided in three subgroups based on the number of days between injury and initial eye examination. Results. The data showed a high frequency of visual symptoms and visual dysfunctions. However, the prevalence of visual symptoms and visual dysfunctions did not differ significantly between mechanism of injury and postinjury stage, except for eye pain and diplopia. Among visual symptoms, binocular dysfunctions were more common, including higher near vertical phoria, reduced negative fusional vergence break at near, receded near point of convergence, decreased stereoacuity, and reduced positive relative accommodation. Conclusions. The lack of difference in terms of visual sequelae between subgroups (blast vs. nonblast) suggests that research addressing the assessment and management of mTBI visual sequelae resulting from civilian nonblast events is relevant to military personnel where combat injury results primarily from a blast event.	[Capo-Aponte, Jose E.; Sosa, Josue A.; Walsh, David V.; Temme, Leonard A.; Riggs, Daniel W.] US Army, Visual Sci Branch, Sensory Res Div, Aeromed Res Lab, Ft Rucker, AL USA; [Capo-Aponte, Jose E.] Womack Army Med Ctr, Dept Optometry, 2817 Reilly Rd Stop A, Ft Bragg, NC 28310 USA; [Jorgensen-Wagers, Kendra L.] Landstuhl Reg Med Ctr, Traumat Brain Injury Clin, APO, Landstuhl, Germany; [Goodrich, Gregory L.] Veteran Affairs Palo Alto Hlth Care Syst, Psychol Serv, Menlo Pk, CA USA; [Goodrich, Gregory L.] Veteran Affairs Palo Alto Hlth Care Syst, Western Blind Rehabil Ctr, Menlo Pk, CA USA		Capo-Aponte, JE (corresponding author), Womack Army Med Ctr, Dept Optometry, 2817 Reilly Rd Stop A, Ft Bragg, NC 28310 USA.	jose.e.capoaponte.mil@mail.mil	Goodrich, Gregory L./AAF-7184-2019	Riggs, Daniel/0000-0002-3503-0600	Postgraduate Research Participation Program at the U.S. Army Aeromedical Research Laboratory; U.S. Department of EnergyUnited States Department of Energy (DOE); U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Sponsored in part by the appointment to the Postgraduate Research Participation Program at the U.S. Army Aeromedical Research Laboratory administered by the Oak Ridge Institute of Science and Education through an interagency agreement, the U.S. Department of Energy and the U.S. Army Medical Research and Materiel Command.	Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Capo-Aponte JE, 2012, J REHABIL RES DEV, V49, P1377, DOI 10.1682/JRRD.2011.07.0128; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Carlson NB, 2004, CLIN PROCEDURES OCUL, P28; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda KJ, 2011, OPTOMETRY, V82, P61, DOI 10.1016/j.optm.2010.11.011; Ciuffreda KJ, 2007, JBO, V18, P72; Ciuffreda KJ, 2001, VISUAL VESTIBULAR CO, P77; Cockerham GC, 2013, OCUL SURF, V11, P25, DOI 10.1016/j.jtos.2012.09.004; Doble JE, 2010, PM&R, V2, P244, DOI 10.1016/j.pmrj.2010.01.011; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, J REHABIL RES DEV, V50, P757, DOI 10.1682/JRRD.2012.10.0184; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Goss DA, 1991, CLIN PROCEDURES OPTO, P716; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Magone MT, 2014, J REHABIL RES DEV, V51, P71, DOI 10.1682/JRRD.2013.01.0008; Maples W C, 1988, J Am Optom Assoc, V59, P549; Matheron E, 2007, NEUROSCI LETT, V423, P236, DOI 10.1016/j.neulet.2007.07.016; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Sutter P., 1995, TRAUMATIC BRAIN INJU, P187; U. S. Department of Defense (DoD), DEP DEF NUMB TRAUM B; U. S. Department of Defense (DoD), 2015, DEP DEF NUMB TRAUM B	36	29	29	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JAN	2017	94	1					7	15		10.1097/OPX.0000000000000825			9	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Ophthalmology	EM5ZZ	WOS:000395393900003	26889821				2022-02-06	
J	Chrisman, SPD; Whitlock, KB; Somers, E; Burton, MS; Herring, SA; Rowhani-Rahbar, A; Rivara, FP				Chrisman, Sara P. D.; Whitlock, Kathryn B.; Somers, Elissa; Burton, Monique S.; Herring, Stanley A.; Rowhani-Rahbar, Ali; Rivara, Frederick P.			Pilot study of the Sub-Symptom Threshold Exercise Program (SSTEP) for persistent concussion symptoms in youth	NEUROREHABILITATION			English	Article						Brain concussion; sport; child; adolescent; traumatic brain injury; exercise; treatment; prolonged concussion syndrome	TRAUMATIC BRAIN-INJURY; POSTCONCUSSIVE SYMPTOMS; VOLUNTARY EXERCISE; CHILDREN; RECOVERY; PREDICTORS; REST; REHABILITATION; TRIAL	BACKGROUND: Prior studies suggest potential benefit using monitored aerobic exercise to treat youth with persistent concussion symptoms, but these studies have been small. OBJECTIVES: To explore the safety and potential benefits of a rehabilitative exercise intervention, the Sub-symptom Threshold Exercise Program (SSTEP), for treating youth with persistent concussion symptoms >1 month. METHODS: We conducted a retrospective cohort study of 83 youth who participated inSSTEP, completing trajectory analysis of concussion symptoms using the symptom subscale of the Sport Concussion Assessment Tool, version 2 (SCAT-2). RESULTS: The average age of patients was 14.9+/-2.3 years and 54% were female. Most concussions (76%) were due to sports, the majority from football and girls' soccer, and 55% had a previous concussion. Comorbidity was not uncommon: 14% had history of ADHD and 16% history of depression and/or anxiety. Most patients improved following the intervention, and none reported worsening. Symptoms decreased exponentially following initiation of SSTEP, and trajectory did not differ by duration of symptoms at presentation (< 6 weeks, 6-12 weeks, >12 weeks). CONCLUSIONS: Monitored exercise programs appear to be safe and potentially beneficial for youth with persistent concussive symptoms. Large-scale controlled studies are needed to examine efficacy, ideal timing and duration.	[Chrisman, Sara P. D.; Whitlock, Kathryn B.; Rivara, Frederick P.] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Chrisman, Sara P. D.] Univ Washington, Adolescent Med, Seattle, WA 98195 USA; [Chrisman, Sara P. D.; Rivara, Frederick P.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Somers, Elissa] Seattle Childrens Hosp, Dept Phys Therapy Seattle, Seattle, WA USA; [Burton, Monique S.] Seattle Childrens Hosp, Dept Orthoped & Sports Med, Dept Pediat, Seattle, WA USA; [Herring, Stanley A.] Univ Washington, Sports Spine & Orthoped Hlth, Seattle, WA 98195 USA; [Rowhani-Rahbar, Ali] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA		Chrisman, SPD (corresponding author), POB 5371,Mailstop CW8-6, Seattle, WA 98145 USA.	sara.chrisman@seattlechildrens.org		Chrisman, Sara/0000-0001-5373-7223; Rowhani-Rahbar, Ali/0000-0002-2705-4485	Satterberg Foundation, Seattle Pediatric Concussion Research Collaborative	This study was funded by the Satterberg Foundation, Seattle Pediatric Concussion Research Collaborative. Dr. Stan Herring has multiple affiliations within in the Sports Medicine arena, including acting as Chair of the Medical Advisory Committee for USA Football and participating as a member of the Board of Directors USA Football, the Pop Warner Medical Advisory Board and the NCAA Concussion Task Force, as well as a former member of the NFL Head, Neck and Spine Committee. The authors have no financial interests to disclose.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2015, PEDIATR NEUROL, V53, P491, DOI 10.1016/j.pediatrneurol.2015.04.011; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Crane AT, 2012, RESTOR NEUROL NEUROS, V30, P325, DOI 10.3233/RNN-2012-120232; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giza CC, 2011, SPORTS HEALTH, V3, P46, DOI 10.1177/1941738110391732; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Snyder AR, 2014, CLIN NEUROPSYCHOL, V28, P1091, DOI 10.1080/13854046.2014.952667; Steiner Emanuel, 2016, J Trauma Manag Outcomes, V10, P5, DOI 10.1186/s13032-016-0035-8; Szabo Z, 2010, BRAIN RES, V1341, P25, DOI 10.1016/j.brainres.2009.01.035; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Winkelman C, 2009, AACN ADV CRIT CARE, V20, P254, DOI 10.1097/NCI.0b013e3181ac838d; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	35	29	29	5	19	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2017	40	4					493	499		10.3233/NRE-161436			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EX7SC	WOS:000403447500004	28222566				2022-02-06	
J	Dobney, DM; Grilli, L; Kocilowicz, H; Beaulieu, C; Straub, M; Friedman, D; Gagnon, I				Dobney, Danielle M.; Grilli, Lisa; Kocilowicz, Helen; Beaulieu, Christine; Straub, Meghan; Friedman, Debbie; Gagnon, Isabelle			Evaluation of an active rehabilitation program for concussion management in children and adolescents	BRAIN INJURY			English	Article						Brain concussion; mild traumatic brain injury; exercise therapy	TRAUMATIC-BRAIN-INJURY; SPORTS-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; POSTCONCUSSION SYNDROME; AGREEMENT STATEMENT; SEX-DIFFERENCES; BASE-LINE; SYMPTOMS; CONSENSUS; RECOVERY	Objective: To estimate the extent to which post-concussion symptoms were influenced by participation In an Active Rehabilitation (AR) program (aerobic exercise, coordination drills, visualization and education) for children and adolescents who are slow to recover from concussion. A secondary exploratory objective included examining the influence of sex on symptom evolution.& para;& para;Methods: Analysis of prospectively collected data was performed on 277 youth who Initiated an AR program, between three and four weeks post-injury at a Concussion Clinic in a tertiary care paediatric teaching hospital.& para;& para;Main outcome measure. Post-concussion symptom scale (PCSS) from Sport Concussion Assessment Tool- 3 (SCAT 3).& para;& para;Results: Children and adolescents participating in an active rehabilitation program displayed Improved post- concussion symptom severity at follow-up (median = 9.5) compared to pre-intervention (median = 18) (p < .05). Patients demonstrated Improved physical, cognitive, emotional and sleep-related post-concussion symptoms (p < .05). Female sex was associated with an increased post-concussion symptom severity at follow-up.& para;& para;Conclusions: Youth experiencing persisting symptoms three to four weeks post-concussion demonstrated Improved post-concussion symptoms scores (physical, cognitive, emotional and sleep related) with participation in an active rehabilitation program.	[Dobney, Danielle M.] McGill Univ, Fac Med, Sch Phys & Occupat Therapy, 3654 Prom Sir William Osler, Montreal, PQ H3G 1Y5, Canada; [Grilli, Lisa; Kocilowicz, Helen; Beaulieu, Christine; Straub, Meghan; Friedman, Debbie] McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Trauma Ctr, Montreal, PQ, Canada; [Friedman, Debbie] McGill Univ, Fac Med, Dept Pediat, Canadian Hosp Injury Reporting & Prevent Program, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Montreal Univ Hlth Ctr, Montreal Childrens Hosp, Sch Phys & Occupat Therapy, Montreal, PQ, Canada		Dobney, DM (corresponding author), McGill Univ, Fac Med, Sch Phys & Occupat Therapy, 3654 Prom Sir William Osler, Montreal, PQ H3G 1Y5, Canada.	danielle.dobney@mail.mcgill.ca		Gagnon, Isabelle/0000-0003-2043-1644	Fonds de recherche du Quebec - Sante (FRQS)Fonds de la Recherche en Sante du Quebec; Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	The authors acknowledge funding from Fonds de recherche du Quebec - Sante (FRQS) and Canadian Institutes of Health Research (CIHR).	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; DiFazio M, 2015, CLIN PEDIATR; Echemendia RJ, 2015, BRAIN INJURY, V29, P185, DOI 10.3109/02699052.2014.965212; Gagnon I, 2015, SCANDINAVIAN J MED S; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2015, BRAIN INJURY, V29, P195, DOI 10.3109/02699052.2014.965210; Hugentobler JA, 2015, INT J SPORTS PHYS TH, V10, P676; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2012, MILD TRAUMATIC BRAIN, P281; Kurowski BG, 2016, J HEAD TRAUMA REHABI; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, S AFRICAN J SPORTS M, V21; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; Pardini D., 2004, BR J SPORTS MED, V38, P661; Roemmich JN, 2006, MED SCI SPORT EXER, V38, P1014, DOI 10.1249/01.mss.0000218123.81079.49; Schneider KJ, 2013, BRIT J SPORT MED, V47, P1; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Terwilliger VK, 2016, J NEUROTRAUM, V33, P761, DOI 10.1089/neu.2015.4082; Verschuren O, 2011, DEV MED CHILD NEUROL, V53, P861, DOI 10.1111/j.1469-8749.2011.03989.x; Hunt AW, 2016, J ATHL TRAINING, V51, P749, DOI 10.4085/1062-6050-51.11.12; Winkler R, 2015, J HEAD TRAUMA REHABI; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	35	29	29	1	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	13-14					1753	1759		10.1080/02699052.2017.1346294			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FO2MD	WOS:000416612500007	29058559				2022-02-06	
J	Erdodi, LA; Rai, JK				Erdodi, Laszlo A.; Rai, Jaspreet K.			A single error is one too many: Examining alternative cutoffs on Trial 2 of the TOMM	BRAIN INJURY			English	Article						Test of Memory Malingering; performance validity assessment; alternative cutoffs	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; COMPLEX FIGURE TEST; CARD SORTING TEST; MALINGERED NEUROCOGNITIVE DYSFUNCTION; WORD MEMORY TEST; CLASSIFICATION ACCURACY; PERFORMANCE VALIDITY; RESPONSE BIAS; CROSS-VALIDATION	Objective: This study investigated the potential of alternative, more liberal cutoffs on Trial 2 of the Test of Memory Malingering (TOMM) to improve classification accuracy relative to the standard cutoffs (44). Method: The sample consisted of 152 patients (49.3% male) with psychiatric conditions (PSY) and traumatic brain injury (TBI) referred for neuropsychological assessment in a medico-legal setting (M-Age = 44.4, M-Education = 11.9 years). Classification accuracy for various TOMM Trial 2 cutoffs was computed against three criterion measures.Results: Patients with TBI failed TOMM Trial 2 cutoffs at higher rates than patients with PSY. Trial 2 49 achieved acceptable combinations of sensitivity (0.38-0.67) and specificity (0.89-0.96) in all but one comparison group. Trial 2 48 improved specificity (0.94-0.98) with minimal loss in sensitivity. The standard cutoff (44) disproportionally traded sensitivity (0.15-0.50) for specificity (0.96-1.00).Conclusions: One error on TOMM Trial 2 constitutes sufficient evidence to question the credibility of a response set. However, the confidence in classifying a score as invalid continues to increase with each additional error. Even at the most liberal conceivable cutoff (49), the TOMM detected only about half of the patients who failed other criterion measures. Therefore, it should never be used in isolation to determine performance validity.	[Erdodi, Laszlo A.; Rai, Jaspreet K.] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada		Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com					Armistead-Jehle P, 2015, APPL NEUROPSYCH-ADUL, V22, P415, DOI 10.1080/23279095.2014.953678; Armistead-Jehle P, 2011, APPL NEUROPSYCHOL, V18, P284, DOI 10.1080/09084282.2011.595455; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bigler ED, BRAIN INJ, V28, P1623; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone, 2007, ASSESSMENT FEIGNED C, P152; Boone K.B., 2013, CLIN PRACTICE FORENS; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Cappa KA, 2011, HEALTH PSYCHOL, V30, P542, DOI 10.1037/a0025220; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Considine CM, 2011, ARCH CLIN NEUROPSYCH, V26, P445, DOI 10.1093/arclin/acr041; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Erdodi LA, 2016, PSYCHOL ASSESSM, DOI 10.1037/pas0000319; Erdodi LA, 2016, J CLIN EXP NEUROPSYC, DOI [10.1080/13803395.2016. 1230181, DOI 10.1080/13803395.2016]; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P327, DOI 10.1080/23279095.2017.1298600; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Green P., 2003, GREENS WORD MEMORY T; Green P., 2008, GREENS NONVERBAL MED; Green P, 2004, GREENS MED SYMPTOM V; Green P, 2011, APPL NEUROPSYCHOL, V18, P18, DOI 10.1080/09084282.2010.523365; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P1250, DOI 10.1080/13854040902828272; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Larrabee G.L., 2012, FORENSIC NEUROPSYCHO, V2nd ed, P116; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lichtenstein JD, 2016, CHILD NEUROPSYCHOL, DOI [10.1080/09297049.2015. 1135422, DOI 10.1080/09297049.2015]; Love CM, 2014, ASSESSMENT, V21, P618, DOI 10.1177/1073191114528028; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Schroeder RW, 2013, ARCH CLIN NEUROPSYCH, V28, P21, DOI 10.1093/arclin/acs094; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Slick D., 1997, VSVT VICTORIA SYMPTO; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Sugarman MA, 2016, APPL NEUROPSYCH-ADUL, V23, P105, DOI 10.1080/23279095.2015.1014557; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2013, BEHAV SCI LAW, V31, P756, DOI 10.1002/bsl.2088; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697, DOI DOI 10.1080/01688639408402671	68	29	29	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	10					1362	1368		10.1080/02699052.2017.1332386			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	FN4GH	WOS:000415961800014	28657355				2022-02-06	
J	Karhade, AV; Cote, DJ; Larsen, AMG; Smith, TR				Karhade, Aditya V.; Cote, David J.; Larsen, Alexandra M. G.; Smith, Timothy R.			Neurosurgical Infection Rates and Risk Factors: A National Surgical Quality Improvement Program Analysis of 132,000 Patients, 2006e-2014	WORLD NEUROSURGERY			English	Article						Complications; Infection; Neurosurgery; NSQIP; Quality improvement; Organ space infections; Surgical site infections; Urinary tract infections	TRAUMATIC BRAIN-INJURY; SITE INFECTIONS; AMERICAN-COLLEGE; SURGERY; CRANIOTOMY; PREDICTORS; CARE; REOPERATION; READMISSION; MORTALITY	BACKGROUND: The existing body of literature on postoperative neurosurgical infections lacks large multi-center reports on postoperative neurosurgical infections. This is the largest study to date of postoperative neurosurgical infections rates, time to event, and risk factors. METHODS: Demographics, medical history, and post-operative infections were assessed for all adult patients in the large, randomized, multicenter American College of Surgeonse-National Surgical Quality Improvement Program (ACS-NSQIP) database undergoing an operation with a surgeon whose primary specialty was neurological surgery from 2006 to 2014. RESULTS: Of 3,723,797 cases from 517 institutions in the NSQIP from 2006 to 2014, 132,063 neurosurgery cases were identified. Within these patients, the 30-day rate of postoperative infections was 5.3%. Postoperatively, 1.8% of patients developed surgical site infections (SSI), and 3.9% developed other infections including pneumonia and urinary tract infections. Superficial SSI had a cumulative incidence of 0.8% at a median of 16 (interquartile range [IQR], 11-22) days. Pneumonia had a cumulative incidence of 1.4% at a median of 5 days (IQR, 2-10 days). Systemic inflammatory response syndrome had a cumulative incidence of 1.6% at a median of 3 days (IQR, 8-16 days). Predictors of post-operative infections on multivariable analysis included female sex, older age, obesity, functionally dependent status before surgery, ventilator dependence, preoperative steroid use, bleeding disorders, hyponatremia, lymphocytosis, anemia, thrombocytosis, emergent case status, wound class II-IV, American Society of Anesthesiologists class 3-5, and longer operative times. CONCLUSION: The overall ACS- NSQIP reported rate of postoperative infections was 5.3% from 2006 to 2014. Multivariable analysis demonstrated several predictive factors for postoperative infections.	[Smith, Timothy R.] Brigham & Womens Hosp, Cushing Neurosurg Outcomes Ctr, Harvard Med Sch, Dept Neurosurg, Boston, MA 02115 USA		Smith, TR (corresponding author), Brigham & Womens Hosp, Cushing Neurosurg Outcomes Ctr, Harvard Med Sch, Dept Neurosurg, Boston, MA 02115 USA.	trsmith@partners.org	Cote, David James/ABG-6013-2021; Smith, Timothy R/N-2481-2014	Smith, Timothy R/0000-0003-1976-0766; Giantini Larsen, Alexandra/0000-0002-9545-8502			Abu Hamdeh S, 2014, BRIT J NEUROSURG, V28, P270, DOI 10.3109/02688697.2013.835376; Algattas H, 2016, WORLD NEUROSURG, V87, P531, DOI 10.1016/j.wneu.2015.09.020; Algattas H, 2015, WORLD NEUROSURG, V84, P1372, DOI 10.1016/j.wneu.2015.06.033; ARUNODAYA GR, 2001, NEUROL INDIA S1, V49, P51; Beiner JM, 2003, NEUROSURG FOCUS, V15, P1, DOI [DOI 10.3171/F0C.2003.15.3.14, http://dx.doi.org/10.3171/foc.2003.153.14]; Birkmeyer JD, 2008, J AM COLL SURGEONS, V207, P777, DOI 10.1016/j.jamcollsurg.2008.07.018; BLOMSTEDT GC, 1985, ACTA NEUROCHIR, V78, P81, DOI 10.1007/BF01808684; Braxton EE, 2005, NEUROSURG REV, V28, P249, DOI 10.1007/s10143-005-0403-8; Cassir N, 2015, AM J INFECT CONTROL, V43, P1288, DOI 10.1016/j.ajic.2015.07.005; Chaichana KL, 2015, NEUROL RES, V37, P717, DOI 10.1179/1743132815Y.0000000042; Chiang HY, 2014, J NEUROSURG, V120, P509, DOI 10.3171/2013.9.JNS13843; Dasenbrock HH, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.10.FOCUS15386; Dettenkofer M, 1999, ACTA NEUROCHIR, V141, P1303, DOI 10.1007/s007010050434; Erman T, 2005, SURG NEUROL, V63, P107, DOI 10.1016/j.surneu.2004.04.024; Gupta H, 2013, CHEST, V143, P1599, DOI 10.1378/chest.12-1499; Hover AR, 2014, AM J MED QUAL, V29, P517, DOI 10.1177/1062860613505680; Karhade AV, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16168; Khuri SF, 1997, J AM COLL SURGEONS, V185, P315, DOI 10.1016/S1072-7515(01)00938-3; Khuri SF, 2008, ANN SURG, V248, P329, DOI 10.1097/SLA.0b013e3181823485; Kimmell KT, 2015, J NEUROSURG, V122, P1004, DOI 10.3171/2014.10.JNS14632; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Kourbeti IS, 2011, BRIT J NEUROSURG, V25, P9, DOI 10.3109/02688697.2010.500411; Lieber B, 2016, WORLD NEUROSURG, V89, P517, DOI 10.1016/j.wneu.2015.12.085; Lieber BA, 2016, J NEUROSURG, V125, P187, DOI 10.3171/2015.4.JNS142719; Longo WE, 2005, AM J SURG, V190, P662, DOI 10.1016/j.amjsurg.2005.07.001; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721; McClelland S, 2008, AM J INFECT CONTROL, V36, P570, DOI 10.1016/j.ajic.2007.07.015; Oz BS, 2013, CARDIOVASC J AFR, V24, P184, DOI 10.5830/CVJA-2013-034; PATIR R, 1992, ACTA NEUROCHIR, V119, P80, DOI 10.1007/BF01541786; Raval MV, 2011, J AM COLL SURGEONS, V212, P1, DOI 10.1016/j.jamcollsurg.2010.08.013; Rolston JD, 2014, J NEUROSURG, V120, P736, DOI 10.3171/2013.10.JNS122419; Seicean A, 2015, J NEUROSURG, V123, P91, DOI 10.3171/2014.10.JNS14551; Sherrod BA, 2016, J NEUROSURG-PEDIATR, V18, P350, DOI 10.3171/2016.2.PEDS15604; Shiloach M, 2010, J AM COLL SURGEONS, V210, P6, DOI 10.1016/j.jamcollsurg.2009.09.031; Valentini LG, 2008, NEUROSURGERY, V62, P88, DOI 10.1227/01.NEU.0000311065.95496.C5; 김영희, 2014, [The Journal of Fundamentals of Nursing, 기본간호학회지], V21, P151, DOI 10.7739/jkafn.2014.21.2.151; Zhan R, 2014, EUR J CLIN MICROBIOL, V33, P861, DOI 10.1007/s10096-013-2026-2	40	29	36	3	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JAN	2017	97						205	212		10.1016/j.wneu.2016.09.056			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EO1HO	WOS:000396449400027	27671880				2022-02-06	
J	Shen, L; Wang, Z; Su, ZZ; Qiu, S; Xu, J; Zhou, Y; Yan, A; Yin, R; Lu, B; Nie, XH; Zhao, SF; Yan, RF				Shen, Liang; Wang, Zhuo; Su, Zhongzhou; Qiu, Sheng; Xu, Jie; Zhou, Yue; Yan, Ai; Yin, Rui; Lu, Bin; Nie, Xiaohu; Zhao, Shufa; Yan, Renfu			Effects of Intracranial Pressure Monitoring on Mortality in Patients with Severe Traumatic Brain Injury: A Meta-Analysis	PLOS ONE			English	Article							CEREBRAL PERFUSION-PRESSURE; INTENSIVE-CARE; MANAGEMENT; CHILDREN; REACTIVITY; MODERATE; IMPACT; TRIAL	Background The Brain Trauma Foundation (BTF) guidelines published in 2007 suggest some indications for intracranial pressure (ICP) monitoring in severe traumatic brain injury (TBI). However, some studies had not shown clinical benefit in patients with severe TBI; several studies had even reported that ICP monitoring was associated with an increased mortality rate. The effect of ICP monitoring has remained controversial, regardless of the ICP monitoring guidelines. Here we performed a meta-analysis of published studies to assess the effects of ICP monitoring in patients with severe TBI. Methods We searched three comprehensive databases, the Cochrane Library, PUBMED, and EMBASE, for studies without limitations published up to September 2015. Mortality, ICU LOS, and hospital LOS were analyzed with Review Manager software according to data from the included studies. Results Eighteen eligible studies involving 25229 patients with severe TBI were included in our meta-analysis. The results indicated no significant reduction in the ICP monitored group in mortality (hospitalized before 2007), hospital mortality (hospitalized before 2007), mortality in randomized controlled trials. However, overall mortality, mortality (hospitalized after 2007), hospital mortality (hospitalized after 2007), mortality in observational studies (hospitalized after 2007), 2-week mortality, 6-month mortality, were reduced in ICP monitored group. Patients with an increased ICP were more likely to require ICP monitoring. Conclusion Superior survival was observed in severe TBI patients with ICP monitoring since the third edition of "Guidelines for the Management of Severe Traumatic Brain Injury," which included "Indications for intracranial pressure monitoring," was published in 2007.	[Shen, Liang; Su, Zhongzhou; Qiu, Sheng; Xu, Jie; Zhou, Yue; Yan, Ai; Yin, Rui; Lu, Bin; Nie, Xiaohu; Zhao, Shufa; Yan, Renfu] Huzhou Cent Hosp, Dept Neurosurg, Huzhou, Zhejiang, Peoples R China; [Wang, Zhuo] Huzhou Univ, Coll Nursing, Dept Med Coll, Huzhou, Zhejiang, Peoples R China		Yan, RF (corresponding author), Huzhou Cent Hosp, Dept Neurosurg, Huzhou, Zhejiang, Peoples R China.	20125232086@suda.edu.cn					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Agrawal D, 2015, J NEUROTRAUMA; Alali AS, 2015, J NEUROSURG-PEDIATR, V16, P523, DOI 10.3171/2015.3.PEDS14507; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Alkhoury F, 2014, JAMA SURG, V149, P544, DOI 10.1001/jamasurg.2013.4329; Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bratton SI, GUIDELINES MANAGEMEN, VVIII; Carney N, 2016, NEUROSURGERY; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dawes AJ, 2015, J TRAUMA ACUTE CARE, V78, P492, DOI 10.1097/TA.0000000000000559; Dings J, 1996, ZBL NEUROCHIR, V57, P177; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Gao L, 2013, WORLD NEUROSURG, V80, P879, DOI 10.1016/j.wneu.2013.01.020; Griesdale DEG, 2010, CAN J NEUROL SCI, V37, P43, DOI 10.1017/S031716710000963X; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Haddad S, 2011, ANAESTH INTENS CARE, V39, P1043, DOI 10.1177/0310057X1103900610; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Kim DR, 2014, J KOREAN NEUROSURG S, V55, P26, DOI 10.3340/jkns.2014.55.1.26; Korley FK, 2015, J HEAD TRAUMA REHABI; Koskinen LOD, 2014, NEUROSCIENCE, V283, P245, DOI 10.1016/j.neuroscience.2014.06.039; Kostic Aleksandar, 2011, Med Pregl, V64, P461; Kukreti V, 2014, J PEDIATR NEUROSCI, V9, P207, DOI 10.4103/1817-1745.147572; Lang EW, 2016, ACTA NEUROCHIR SUPPL, V122, P221, DOI 10.1007/978-3-319-22533-3_44; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Soeken KL, 2003, NURS RES, V52, P57, DOI 10.1097/00006199-200301000-00009; Su SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087432; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Tang A, 2015, J SURG RES, V194, P565, DOI 10.1016/j.jss.2014.11.017; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Wells G., NEWCASTLE OTTAWA SCA; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965; Yuan Q, 2015, J NEUROSURG, V122, P574, DOI 10.3171/2014.10.JNS1460; Zhou ZR, 2013, J CANCER RES CLIN, V139, P783, DOI 10.1007/s00432-013-1383-7; Zintzaras E, 2005, GENET EPIDEMIOL, V28, P123, DOI 10.1002/gepi.20048	48	29	31	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 28	2016	11	12							e0168901	10.1371/journal.pone.0168901			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	EG7JB	WOS:000391222000083	28030638	Green Submitted, gold, Green Published			2022-02-06	
J	Hirai, K; Ishii, H; Shimoshikiryo, T; Shimomura, T; Tsuji, D; Inoue, K; Kadoiri, T; Itoh, K				Hirai, Keita; Ishii, Hidetoshi; Shimoshikiryo, Takayuki; Shimomura, Tatsuki; Tsuji, Daiki; Inoue, Kazuyuki; Kadoiri, Toshihiko; Itoh, Kunihiko			Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin	THERAPEUTIC DRUG MONITORING			English	Article						augmented renal clearance; vancomycin; febrile neutropenia	CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; CREATININE CLEARANCE; PHARMACODYNAMICS; INFECTIONS; GUIDELINES; OUTCOMES	Background: Augmented renal clearance (ARC) has frequently been observed in critically ill patients. The risk factors for ARC in patients, including those in the general ward, and their influences on vancomycin (VCM) treatment remain unclear. The aims of this study were to investigate the risk factors for ARC and to evaluate the influence of ARC on the pharmacokinetic parameters of VCM. Methods: This study included a total of 292 patients with VCM treatment who had normal serum creatinine concentrations. ARC was defined by an estimated creatinine clearance >= 130 mL.min(-1).1.73 m(-2). The risk factors for ARC were determined with stepwise logistic regression analysis. The pharmacokinetic parameters of VCM were estimated through the Bayesian method using a 2-compartment model. Results: ARC was observed in 48 patients (16.4%). Age <= 65 years [odds ratio (OR): 5.77; 95% CI: 2.89-11.97; P < 0.0001], brain injury (OR: 5.11; 95% CI: 1.49-17.57; P = 0.0086), febrile neutropenia (OR: 2.76; 95% CI: 1.11-6.67; P = 0.0254), and a mean volume of infusion fluid >= 1500 mL/d (OR: 2.53; 95% CI: 1.27-5.16; P = 0.0091) were independent risk factors for the occurrence of ARC. The patients with ARC exhibited higher VCM clearance values than the non-ARC patients. The median trough serum concentrations of VCM were 7.4 (interquartile range: 5.2-11.6) mcg/mL in the ARC patients and 12.2 (8.9-16.3) mcg/mL in the non-ARC patients (P < 0.0001). Subtherapeutic trough concentrations of VCM (<10.0 mcg/mL) were found in 68.8% of the ARC patients and in 32.8% of the non-ARC patients (P < 0.0001). Conclusions: This observational study investigated the influence of febrile neutropenia on the emergency of ARC for the first time. ARC was strongly associated with VCM pharmacokinetics, and twothirds of the ARC patients had subtherapeutic VCM concentrations. In patients with ARC, individualized dosing regimens are required to achieve the target trough concentration.	[Hirai, Keita; Ishii, Hidetoshi; Shimoshikiryo, Takayuki; Shimomura, Tatsuki; Tsuji, Daiki; Inoue, Kazuyuki; Itoh, Kunihiko] Univ Shizuoka, Sch Pharmaceut Sci, Dept Clin Pharmacol & Genet, Shizuoka, Japan; [Hirai, Keita; Tsuji, Daiki; Inoue, Kazuyuki; Itoh, Kunihiko] Shizuoka Prefectural Gen Hosp, Lab Clin Pharmacogen, Shizuoka, Japan; [Ishii, Hidetoshi; Kadoiri, Toshihiko] Shizuoka Prefectural Gen Hosp, Dept Pharm, Shizuoka, Japan		Itoh, K (corresponding author), Univ Shizuoka, Dept Clin Pharmacol & Genet, Sch Pharmaceut Sci, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	itohk@u-shizuoka-ken.ac.jp	Hirai, Keita/K-6290-2014	Hirai, Keita/0000-0001-8027-3508			Baptista JP, 2012, INT J ANTIMICROB AG, V39, P420, DOI 10.1016/j.ijantimicag.2011.12.011; Baptista JP, 2011, CRIT CARE, V15, DOI 10.1186/cc10262; BROWN R, 1980, CRIT CARE MED, V8, P68, DOI 10.1097/00003246-198002000-00004; Carlier M, 2013, CRIT CARE, V17, DOI 10.1186/cc12705; Conil JM, 2007, BRIT J CLIN PHARMACO, V63, P583, DOI 10.1111/j.1365-2125.2006.02807.x; Cook AM, 2013, NEUROCRIT CARE, V19, P210, DOI 10.1007/s12028-013-9837-y; Fuster-Lluch O, 2008, ANAESTH INTENS CARE, V36, P674, DOI 10.1177/0310057X0803600507; Grootaert V, 2012, ANN PHARMACOTHER, V46, P952, DOI 10.1345/aph.1Q708; Haeseker MB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112008; Hirai K, 2016, THER DRUG MONIT, V38, P393, DOI 10.1097/FTD.0000000000000270; Hobbs ALV, 2015, PHARMACOTHERAPY, V35, P1063, DOI 10.1002/phar.1653; Huttner A, 2015, INT J ANTIMICROB AG, V45, P385, DOI 10.1016/j.ijantimicag.2014.12.017; Kullar R, 2011, CLIN INFECT DIS, V52, P975, DOI 10.1093/cid/cir124; Lortholary O, 2008, LANCET INFECT DIS, V8, P612, DOI 10.1016/S1473-3099(08)70228-7; Martin JH, 2011, INTERN MED J, V41, P537, DOI 10.1111/j.1445-5994.2009.02160.x; Matsumoto K, 2013, J INFECT CHEMOTHER, V19, P365, DOI 10.1007/s10156-013-0599-4; May CC, 2015, NEUROCRIT CARE, V23, P374, DOI 10.1007/s12028-015-0127-8; Minkute R, 2013, J CLIN PHARM THER, V38, P462, DOI 10.1111/jcpt.12088; Minville V, 2011, CRIT CARE, V15, DOI 10.1186/cc10013; Moise-Broder PA, 2004, CLIN PHARMACOKINET, V43, P925, DOI 10.2165/00003088-200443130-00005; Ruiz S, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0090-8; Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI 10.2146/ajhp080434; Shimamoto Y, 2013, INTENS CARE MED, V39, P1247, DOI 10.1007/s00134-013-2909-9; Udy A, 2010, ANESTH ANALG, V111, P1505, DOI 10.1213/ANE.0b013e3181f7107d; Udy AA, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0750-y; Udy AA, 2015, INT J ANTIMICROB AG, V45, P331, DOI 10.1016/j.ijantimicag.2014.12.020; Udy AA, 2013, CRIT CARE, V17, DOI 10.1186/cc12544; Udy AA, 2012, CHEST, V142, P30, DOI 10.1378/chest.11-1671; Udy AA, 2010, INT J ANTIMICROB AG, V35, P606, DOI 10.1016/j.ijantimicag.2010.02.013; Udy AA, 2010, CLIN PHARMACOKINET, V49, P1, DOI 10.2165/11318140-000000000-00000; Yamamoto M, 2009, J CLIN PHARM THER, V34, P473, DOI 10.1111/j.1365-2710.2008.01016.x	31	29	32	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0163-4356	1536-3694		THER DRUG MONIT	Ther. Drug Monit.	DEC	2016	38	6					706	710		10.1097/FTD.0000000000000346			5	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	ED5LY	WOS:000388894900009	27681114				2022-02-06	
J	Seiger, R; Hahn, A; Hummer, A; Kranz, GS; Ganger, S; Woletz, M; Kraus, C; Sladky, R; Kautzky, A; Kasper, S; Windischberger, C; Lanzenberger, R				Seiger, Rene; Hahn, Andreas; Hummer, Allan; Kranz, Georg S.; Ganger, Sebastian; Woletz, Michael; Kraus, Christoph; Sladky, Ronald; Kautzky, Alexander; Kasper, Siegfried; Windischberger, Christian; Lanzenberger, Rupert			Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration	PSYCHONEUROENDOCRINOLOGY			English	Article						Hormone therapy; Transgender; Transsexuals; Hormones; Gray matter volume	ESTROGEN-RECEPTOR-ALPHA; TRAUMATIC BRAIN-INJURY; MESSENGER-RNA EXPRESSION; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; HIPPOCAMPAL NEUROGENESIS; PROGESTERONE TREATMENT; ANDROGEN RECEPTORS; HUMAN HYPOTHALAMUS; PREFRONTAL CORTEX	Sex-steroid hormones are primarily involved in sexual differentiation and development and are thought to underlie processes related to cognition and emotion. However, divergent results have been reported concerning the effects of hormone administration on brain structure including side effects like brain atrophy and dementia. Cross-sex hormone therapy in transgender subjects offers a unique model for studying the effects of sex hormones on the living human brain. In this study, 25 Female-to-Male (FtM) and 14 Male-to-Female (MtF) subjects underwent MRI examinations at baseline and after a period of at least 4-months of continuous cross-sex hormone administration. While MtFs received estradiol and anti-androgens, FtM subjects underwent high-dose testosterone treatment. The longitudinal processing stream of the FreeSurfer software suite was used for the automated assessment and delineation of brain volumes to assess the structural changes over the treatment period of cross-sex hormone administration. Most prominent results were found for MtFs receiving estradiol and anti-androgens in the form of significant decreases in the hippocampal region. Further analysis revealed that these decreases were reflected by increases in the ventricles. Additionally, changes in progesterone levels correlated with changes in gray matter structures in MtF subjects. In line with prior studies, our results indicate hormonal influences on subcortical structures related to memory and emotional processing. Additionally, this study adds valuable knowledge that progesterone may play an important role in this process. (C) 2016 Elsevier Ltd. All rights reserved.	[Seiger, Rene; Hahn, Andreas; Kranz, Georg S.; Ganger, Sebastian; Kraus, Christoph; Kautzky, Alexander; Kasper, Siegfried; Lanzenberger, Rupert] Med Univ Vienna, Dept Psychiat & Psychotherapy, A-1090 Vienna, Austria; [Hummer, Allan; Woletz, Michael; Sladky, Ronald; Windischberger, Christian] Med Univ Vienna, MR Ctr Excellence, Ctr Med Phys & Biomed Engn, A-1090 Vienna, Austria		Lanzenberger, R (corresponding author), Med Univ Vienna, NEUROIMAGING LABs NIL, PET & MRI & EEG & Chem Lab, Dept Psychiat & Psychotherapy, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rupert.lanzenberger@meduniwien.ac.at	Lanzenberger, Rupert/I-5438-2019; Sladky, Ronald/ABD-5222-2021; Kranz, Georg S./T-8981-2019	Lanzenberger, Rupert/0000-0003-4641-9539; Kranz, Georg/0000-0002-3892-1804; Seiger, Rene/0000-0003-1556-4346; Hahn, Andreas/0000-0001-9727-7580; Kasper, Siegfried/0000-0001-8278-191X; Hummer, Allan/0000-0002-9819-0433; Kautzky, Alexander/0000-0001-9251-8285; Woletz, Michael/0000-0002-9200-4468; Windischberger, Christian/0000-0002-9944-0190; Kraus, Christoph/0000-0002-7144-2282; Sladky, Ronald/0000-0002-5986-1572			Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Bao AM, 2011, FRONT NEUROENDOCRIN, V32, P214, DOI 10.1016/j.yfrne.2011.02.007; BAULIEU EE, 1990, J STEROID BIOCHEM, V37, P395, DOI 10.1016/0960-0760(90)90490-C; Beyenburg S, 2000, NEUROSCI LETT, V294, P25, DOI 10.1016/S0304-3940(00)01542-1; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; BROWN TJ, 1995, STEROIDS, V60, P726, DOI 10.1016/0039-128X(95)00107-2; Buckwalter JG, 1999, PSYCHONEUROENDOCRINO, V24, P69; Cooke B, 1998, FRONT NEUROENDOCRIN, V19, P323, DOI 10.1006/frne.1998.0171; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; Derntl B., 2008, PSYCHONEUROENDOCRINO; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fernandez-Guasti A, 2000, J COMP NEUROL, V425, P422, DOI 10.1002/1096-9861(20000925)425:3<422::AID-CNE7>3.0.CO;2-H; Finley SK, 1999, J NEUROBIOL, V40, P446; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Follesa P, 2000, MOL PHARMACOL, V57, P1262; Galea LAM, 2006, HIPPOCAMPUS, V16, P225, DOI 10.1002/hipo.20154; Gonzalez M, 2007, J COMP NEUROL, V503, P790, DOI 10.1002/cne.21419; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; GOULD E, 1990, J NEUROSCI, V10, P1286; Griksiene R., 2011, PSYCHONEUROENDOCRINO; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hahn A, 2015, CEREB CORTEX, V25, P3527, DOI 10.1093/cercor/bhu194; Hazell GGJ, 2009, J ENDOCRINOL, V202, P223, DOI 10.1677/JOE-09-0066; Hofer P, 2013, EUR NEUROPSYCHOPHARM, V23, P79, DOI 10.1016/j.euroneuro.2012.04.013; Pol HEH, 2006, EUR J ENDOCRINOL, V155, pS107, DOI 10.1530/eje.1.02248; KATO J, 1994, HORM BEHAV, V28, P454, DOI 10.1006/hbeh.1994.1043; Kranz GS, 2014, J NEUROSCI, V34, P15466, DOI 10.1523/JNEUROSCI.2488-14.2014; Kruijver FPM, 2000, J CLIN ENDOCR METAB, V85, P2034, DOI 10.1210/jc.85.5.2034; Kruijver FPM, 2002, J COMP NEUROL, V454, P115, DOI 10.1002/cne.10416; Leranth C, 2003, J NEUROSCI, V23, P1588; MacLusky NJ, 2006, NEUROSCIENCE, V138, P957, DOI 10.1016/j.neuroscience.2005.12.054; Montague D, 2008, J NEUROENDOCRINOL, V20, P893, DOI 10.1111/j.1365-2826.2008.01743.x; Neufang S, 2009, CEREB CORTEX, V19, P464, DOI 10.1093/cercor/bhn100; Osterlund MK, 2000, NEUROSCIENCE, V95, P333; Osterlund MK, 2000, J CLIN ENDOCR METAB, V85, P3840, DOI 10.1210/jc.85.10.3840; Paus T, 2010, HORM BEHAV, V57, P63, DOI 10.1016/j.yhbeh.2009.08.004; Peper JS, 2009, PSYCHONEUROENDOCRINO, V34, P332, DOI 10.1016/j.psyneuen.2008.09.012; PUY L, 1995, J STEROID BIOCHEM, V55, P197, DOI 10.1016/0960-0760(95)00165-V; Rametti G, 2012, PSYCHONEUROENDOCRINO, V37, P1261, DOI 10.1016/j.psyneuen.2011.12.019; Resnick SM, 2009, NEUROLOGY, V72, P135, DOI 10.1212/01.wnl.0000339037.76336.cf; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2011, NEUROIMAGE, V57, P19, DOI 10.1016/j.neuroimage.2011.02.076; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Rupprecht R, 1999, TRENDS NEUROSCI, V22, P410, DOI 10.1016/S0166-2236(99)01399-5; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schulz KM, 2009, HORM BEHAV, V55, P597, DOI 10.1016/j.yhbeh.2009.03.010; Schumacher M, 1996, DEV NEUROSCI-BASEL, V18, P6, DOI 10.1159/000111391; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; Sisk CL, 2005, FRONT NEUROENDOCRIN, V26, P163, DOI 10.1016/j.yfrne.2005.10.003; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Steiner M, 2003, J AFFECT DISORDERS, V74, P67, DOI 10.1016/S0165-0327(02)00432-9; Talairach J., 1988, COPLANAR STEREOTAXIC; Toffoletto S, 2014, PSYCHONEUROENDOCRINO, V50, P28, DOI 10.1016/j.psyneuen.2014.07.025; van Wingen GA, 2009, NEUROPSYCHOPHARMACOL, V34, P539, DOI [10.1038/sj.npp.2008.2, 10.1038/npp.2008.2]; Wharton W, 2012, CURR PSYCHIATRY REV, V8, P247, DOI 10.2174/157340012800792957; Witte AV, 2010, NEUROIMAGE, V49, P1205, DOI 10.1016/j.neuroimage.2009.09.046; WOOLLEY CS, 1992, J NEUROSCI, V12, P2549; Yankova M, 2001, P NATL ACAD SCI USA, V98, P3525, DOI 10.1073/pnas.051624598; ZHOU JN, 1995, NATURE, V378, P68, DOI 10.1038/378068a0; Zubiaurre-Elorza L, 2014, J SEX MED, V11, P1248, DOI 10.1111/jsm.12491	67	29	29	1	40	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	DEC	2016	74						371	379		10.1016/j.psyneuen.2016.09.028			9	Endocrinology & Metabolism; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	EB6VW	WOS:000387524700043	27744092				2022-02-06	
J	Gioia, GA; Glang, AE; Hooper, SR; Brown, BE				Gioia, Gerard A.; Glang, Ann E.; Hooper, Stephen R.; Brown, Brenda Eagan			Building Statewide Infrastructure for the Academic Support of Students With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						academic outcomes; intervention strategies; mild TBI; school management; statewide infrastructure	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; KNOWLEDGE; EDUCATION; SYMPTOMS; CHILDREN; PATHOPHYSIOLOGY; STATEMENT; RECOVERY; REST	Objectives: To focus attention on building statewide capacity to support students with mild traumatic brain injury (mTBI)/concussion. Method: Consensus-building process with a multidisciplinary group of clinicians, researchers, policy makers, and state Department of Education personnel. Results: The white paper presents the group's consensus on the essential components of a statewide educational infrastructure to support the management of students with mTBI. The nature and recovery process of mTBI are briefly described specifically with respect to its effects on school learning and performance. State and local policy considerations are then emphasized to promote implementation of a consistent process. Five key components to building a statewide infrastructure for students with mTBI are described including (1) definition and training of the interdisciplinary school team, (2) professional development of the school and medical communities, (3) identification, assessment, and progress monitoring protocols, (4) a flexible set of intervention strategies to accommodate students' recovery needs, and (5) systematized protocols for active communication among medical, school, and family team members. The need for a research to guide effective program implementation is stressed. Conclusion: This guiding framework strives to assist the development of support structures for recovering students with mTBI to optimize academic outcomes. Until more evidence is available on academic accommodations and other school-based supports, educational systems should follow current best practice guidelines.	[Gioia, Gerard A.] Childrens Natl Med Ctr, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Ste 350, Rockville, MD 20850 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Pediat & Psychiat & Behav Sci, Washington, DC USA; [Glang, Ann E.] Univ Oregon, Ctr Brain Injury Res & Training, Eugene, OR 97403 USA; [Glang, Ann E.] ORCAS, Eugene, OR USA; [Hooper, Stephen R.] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Chapel Hill, NC USA; [Brown, Brenda Eagan] Brain Injury Assoc Penn, BrainSTEPS State Program, Carlisle, PA USA		Gioia, GA (corresponding author), Childrens Natl Med Ctr, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Ste 350, Rockville, MD 20850 USA.	ggioia@cnmc.org	Hooper, Stephen/X-8171-2019				Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Becker MH, 1974, HLTH ED MONOGR, V2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Centers for Disease Control and Prevention, HEADS SCH KNOW YOUR; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Cusimano MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061865; Davies SC, 2013, CONCUSSION AWARENESS; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Dettmer J, 2014, J HEAD TRAUMA REHAB, V29, P224, DOI 10.1097/HTR.0b013e3182a1cd68; Diaz AL, 2012, CONCUSSIONS ROLE SCH; Eagan Brown B, 2013, BRAINSTEPS CONCUSSIO; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Evans K, 2009, CONT ISSUES COMMUN S, V36, P166; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Faul M, 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2016, J CHILD NEUROL, V31, P93, DOI 10.1177/0883073814555604; Gioia GA, 2015, BRAIN INJURY, V29, P195, DOI 10.3109/02699052.2014.965210; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Glang A, 2008, NEUROREHABILITATION, V23, P477; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henehan M, 2003, CLIN J SPORT MED, V13, P285, DOI 10.1097/00042752-200309000-00003; Heyer GL, 2015, J PEDIATR-US, V166, P594, DOI 10.1016/j.jpeds.2014.09.038; Hooper S., 2006, EXCEPTIONALITY, V14, P171, DOI [DOI 10.1207/S15327035EX1403_5, DOI 10.1207/s15327035ex1403_5]; Hux K, 2006, BRAIN INJURY, V20, P547, DOI 10.1080/02699050600676784; Institute of Medicine and National Research Council, 2013, SPORTS REL CONC YOUT; Institute of Medicine's Committee on Sports-Related Concussions in Youth, 2013, SPORTS RELATED CONCU; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly JP, 1997, NEUROLOGY, V48, P581; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Lin AC, 2015, SPORTS HEALTH, V7, P124, DOI 10.1177/1941738115571570; Lincoln AE, 2011, AM J SPORTS MED; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Mazmanian PE, 2009, CHEST, V135, p49S, DOI 10.1378/chest.08-2518; McAvoy K, 2009, REAP BENEFITS GOOD C; McAvoy K, 2012, BRAIN INJ PROF, V9, P26; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Nygren-de Boussard Catharina, 2014, Arch Phys Med Rehabil, V95, pS257, DOI 10.1016/j.apmr.2013.10.009; O'Brien LM, 2009, CHILD ADOL PSYCH CL, V18, P813, DOI 10.1016/j.chc.2009.04.008; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Popoli DM, 2014, CLIN PEDIATR, V53, P217, DOI 10.1177/0009922813499070; PREMI J, 1994, ACAD MED, V69, P800, DOI 10.1097/00001888-199410000-00002; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Signoretti S, 2011, PM&R, V3, pS359, DOI 10.1016/j.pmrj.2011.07.018; Smits PBA, 2002, BMJ-BRIT MED J, V324, P153, DOI 10.1136/bmj.324.7330.153; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Zemek R, 2014, GUIDELINES DIAGNOSIN; Zirkel PA, 2015, J SCH NURS, V31, P99, DOI 10.1177/1059840514521465; Zonfrillo MR, 2014, J NEUROTRAUM, V31, P722, DOI 10.1089/neu.2013.3088; Zuckerbraun NS, 2014, PEDIATRICS, V133, P635, DOI 10.1542/peds.2013-2600	86	29	29	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2016	31	6					397	406		10.1097/HTR.0000000000000205			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	EC0IW	WOS:000387784800011	26709582				2022-02-06	
J	Li, ZM; Xiao, YL; Zhu, JX; Geng, FY; Guo, CJ; Chong, ZL; Wang, LX				Li, Zhong-min; Xiao, Yi-lei; Zhu, Jian-xin; Geng, Feng-yang; Guo, Chuan-jun; Chong, Zong-lei; Wang, Le-xin			Recombinant human erythropoietin improves functional recovery in patients with severe traumatic brain injury: A randomized, double blind and controlled clinical trial	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Erythropoietin; Severe traumatic brain injury; Neurological function; Thromboembolic events; Neuron specific enolase	PROGNOSTIC VALUE; NEUROPROTECTION; SAFETY	Objective: To investigate the short-term effect of recombinant human erythropoietin (EPO) on patients with severe traumatic brain injury. Methods: One hundred and fifty-nine patients with severe traumatic brain injury were randomly divided into EPO (n=79) and control group (n=80). EPO group was treated with subcutaneous injection of EPO (100 units/kg) on day 1, 3, 6, 9 and 12 following the brain injury. Glasgow outcome scores (GOS) were used to evaluate the outcomes three months after the treatment. Serum neuron specific enolase (NSE) and S-100 beta protein were measured within the first three months after treatment. Results: In the end, 146 patients (75 of the EPO group and 71 of the control group) completed the trial. Three months after the treatment, Good recovery was found in 33.3% of the EPO and 12.6% of the control group patients (p < 0.05). Serum NSE and S-100 beta protein were decreased gradually in both groups after treatment, but their levels in the EPO group were lower than that of control group (p < 0.05). There was no statistically significant difference in blood pressure, hemoglobin levels, pneumonia, sepsis or thromboembolic events between the two groups three months after the treatment (p >0.05). Conclusion: Treatment with five doses of recombinant human erythropoietin is associated with an improved functional recovery in patients with severe traumatic brain injury. This treatment does not seem to increase the risk of thromboembolic events or severe infections. (C) 2016 Elsevier B.V. All rights reserved.	[Li, Zhong-min; Xiao, Yi-lei; Zhu, Jian-xin; Geng, Feng-yang; Guo, Chuan-jun; Chong, Zong-lei] Taishan Med Univ, Dept Neurosurg, Liaocheng Peoples Hosp, Liaocheng 252000, Shandong, Peoples R China; [Wang, Le-xin] Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2678, Australia		Wang, LX (corresponding author), Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW 2678, Australia.	lwang@csu.edu.au		Wang, Lexin/0000-0002-9760-7436			Bohlius J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003407.pub4; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Fauchere JC, 2015, J PEDIATR-US, V167, P52, DOI 10.1016/j.jpeds.2015.02.052; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Juul S, 2012, J MATERN-FETAL NEO M, V25, P105, DOI 10.3109/14767058.2012.715025; Kumral A, 2011, BRAIN DEV-JPN, V33, P632, DOI 10.1016/j.braindev.2010.10.014; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Ponce Lucido L, 2013, Pathophysiology, V20, P31, DOI 10.1016/j.pathophys.2012.02.005; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Talving P, 2010, ANN SURG, V251, P1, DOI 10.1097/SLA.0b013e3181b844fa; Tonia T, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003407.pub5; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2015, TRANSL STROKE RES, V6, P50, DOI 10.1007/s12975-014-0362-x; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844	21	29	31	2	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	NOV	2016	150						80	83		10.1016/j.clineuro.2016.09.001			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EA5EN	WOS:000386642300014	27611985				2022-02-06	
J	Mathew, MJ; Deepika, A; Shukla, D; Devi, BI; Ramesh, VJ				Mathew, Manish Joseph; Deepika, Akhil; Shukla, Dhaval; Devi, Bhagavatula Indira; Ramesh, Venkatapura J.			Paroxysmal sympathetic hyperactivity in severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Paroxysmal sympathetic hyperactivity; Dysautonomia; Disability	INTENSIVE-CARE-UNIT; AUTONOMIC INSTABILITY; DIAGNOSTIC-CRITERIA; DYSAUTONOMIA; DYSTONIA; SEIZURES	Paroxysmal sympathetic hyperactivity (PSH) is a less-known complication of traumatic brain injury (TBI). This study was done to assess the clinical features and outcome of patients who develop PSH following severe TBI. A prospective observational study was done on patients, admitted in the intensive care unit, for treatment of severe TBI. The clinical characteristics and outcome of patients, with and without PSH, was compared. At the time of discharge, patients were assessed with the Disability Rating Scale (DRS), and at 6 months with the Glasgow Outcome Score Extended (GOSE). The incidence of PSH was 8 % (29/343). Tachycardia, hypertension, and sweating were seen in all of the patients. Tachypnea was seen in 24 (82.8 %), hyperthermia in 28 (96.6 %), and posturing in 13 (44.8 %) patients. Thirteen (44.8 %) patients had all six symptoms of PSH. Follow-up data were available for 23 (79.3 %) patients. At the end of 6 months, 14 (60.9 %) patients had died, seven (30.4 %) were severely disabled, and two (8.7 %) were moderately disabled. There was a significant correlation of GOSE with the number of symptoms of PSH (Spearman's rho = 0.502, p = 0.015). The patients with PSH had significantly higher DRS scores at discharge, 25.3 vs. 19.9, p < 0.001; higher mortality at 6 months 60.9 vs. 30.4 %, p < 0.001; and higher proportions with unfavorable outcome. Presence of PSH in patients with severe TBI was associated with prolonged hospital stay, poorer DRS at discharge, more deaths, and unfavorable outcome. The number of symptoms of PSH had a significant effect on outcome at 6 months.	[Mathew, Manish Joseph; Shukla, Dhaval; Devi, Bhagavatula Indira] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India; [Deepika, Akhil] Natl Inst Mental Hlth & Neurosci, Clin Neurosci, Bangalore, Karnataka, India; [Ramesh, Venkatapura J.] Natl Inst Mental Hlth & Neurosci, Neuroanesthesiol & Neuroctit Care, Bangalore, Karnataka, India		Shukla, D (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India.	neurodhaval@rediffmail.com	Ramesh, Venkatapura J/H-1147-2013	MATHEW, MANISH JOSEPH/0000-0002-8566-5954; Shukla, Dhaval/0000-0001-7613-1929			Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Deepika A, 2015, AUTON NEUROSCI-BASIC, V193, P149, DOI 10.1016/j.autneu.2015.08.003; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Fernandez-Ortega JF, 2004, REV NEUROLOGIA, V39, P715, DOI 10.33588/rn.3908.2004034; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Goddeau RP, 2007, NEUROCRIT CARE, V7, P217, DOI 10.1007/s12028-007-0066-0; Hinson HE, 2012, CURR OPIN CRIT CARE, V18, P139, DOI 10.1097/MCC.0b013e3283513290; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Pozzi M, 2015, J HEAD TRAUMA REHAB, V30, P357, DOI 10.1097/HTR.0000000000000084; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Sander A., 2002, EXTENDED GLASGOW OUT; Srinivasan S, 2007, CLIN AUTON RES, V17, P378, DOI 10.1007/s10286-007-0428-x; Wright J, 2000, DISABILITY RATING SC	18	29	34	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2016	158	11					2047	2052		10.1007/s00701-016-2934-x			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	EA1OR	WOS:000386362200003	27581717				2022-02-06	
J	Reynolds, BB; Patrie, J; Henry, EJ; Goodkin, HP; Broshek, DK; Wintermark, M; Druzgal, TJ				Reynolds, Bryson B.; Patrie, James; Henry, Erich J.; Goodkin, Howard P.; Broshek, Donna K.; Wintermark, Max; Druzgal, T. Jason			Quantifying Head Impacts in Collegiate Lacrosse	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injuries/concussion; female sports; lacrosse; biomechanics; subconcussion	INJURY SURVEILLANCE SYSTEM; VIDEO INCIDENT ANALYSIS; HIGH-SCHOOL FOOTBALL; STATES HIGH-SCHOOL; UNITED-STATES; DESCRIPTIVE EPIDEMIOLOGY; IN-VIVO; CONCUSSION; SPORTS; EXPOSURE	Background: Concussion and repetitive head impact in sports has increased interest and concern for clinicians, scientists, and athletes. Lacrosse is the fastest growing sport in the United States, but the burden of head impact in lacrosse is unknown. Purpose: The goal of this pilot study was to quantify head impact associated with practicing and playing collegiate lacrosse while subjects were fitted with wearable accelerometers. Study Design: Descriptive epidemiology study. Methods: In a single year, a collegiate cohort of 14 women's and 15 men's lacrosse players wore mastoid-patch accelerometers to measure the frequency and severity of head impacts during official practices and games. Average impact severity, mean number of impacts, and cumulative acceleration were evaluated, stratified by sport and event type. Results: Men's and women's collegiate lacrosse players did not significantly differ in the number of head impacts received during games (11.5 for men vs 9.2 for women) or practices (3.1 vs 3.1). Men's lacrosse players had significantly higher average head acceleration per impact during games compared with women (21.1g vs 14.7g) but not during practices (21.3g vs 18.1g). For both men and women, more impacts occurred during games than during practices (men, 11.5 vs 3.1; women, 9.2 vs 3.1), but impact severity did not significantly differ between events for either sport (men, 21.1g vs 21.3g; women, 14.7g vs 18.1g). Conclusion: The study data suggest a higher impact burden during games compared with practices, but this effect is driven by the quantity rather than severity of impacts. In contrast, sex-based effects in impact burden are driven by average impact severity rather than quantity. Data collected from larger multisite trials and/or different age groups could be used to inform ongoing debates, including headgear and practice regulations, that might appreciably affect the burden of head impacts in lacrosse. Clinical Relevance: While most head impacts do not result in a clinical diagnosis of concussion, evidence indicates that subconcussive head impacts may increase susceptibility to concussion and contribute to long-term neurodegeneration.	[Reynolds, Bryson B.; Patrie, James; Henry, Erich J.; Goodkin, Howard P.; Broshek, Donna K.; Wintermark, Max; Druzgal, T. Jason] Univ Virginia, POB 800170, Charlottesville, VA 22908 USA; [Wintermark, Max] Stanford Univ, Palo Alto, CA 94304 USA		Druzgal, TJ (corresponding author), Univ Virginia, POB 800170, Charlottesville, VA 22908 USA.	tjd4m@virginia.edu	Broshek, Donna/ABA-4208-2021	Broshek, Donna/0000-0002-7175-7815; Goodkin, Howard/0000-0003-0528-4949; Druzgal, Jason/0000-0001-7240-9487; Reynolds, Bryson/0000-0001-9196-1461	University of Virginia Health System Research Award; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2 T32 GM 8328-21]; University of Virginia Department of Radiology and Medical Imaging; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008328] Funding Source: NIH RePORTER	One or more of the authors has declared the following potential conflict of interest or source of funding: Financial support was provided by a University of Virginia Health System Research Award, NIH 2 T32 GM 8328-21, and the University of Virginia Department of Radiology and Medical Imaging. Access to the xPatch impact sensors was obtained through a research agreement with X2 Biosystems. M.W. is a member of the advisory board of the GA NFL project.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Caswell SV, 2012, AM J SPORT MED, V40, P756, DOI 10.1177/0363546512436647; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Crisco JJ, 2015, J APPL BIOMECH, V31, P122, DOI [10.1123/jab.2014-0102, 10.1123/JAB.2014-0102]; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P255; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Huber P., 1967, P 5 BERK S MATH STAT; Johnson B.D., 2014, CONCUSSIONS ATHLETIC, P331, DOI [10.1007/978-1-4939-0295-8_19, DOI 10.1007/978-1-4939-0295-8_19]; King D, 2016, SPORTS MED, V46, P151, DOI 10.1007/s40279-015-0423-7; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Reynolds BB, 2016, J NEUROSURG, V124, P501, DOI 10.3171/2015.5.JNS15573; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Swartz EE, 2015, J ATHL TRAINING, V50, P1219, DOI 10.4085/1062-6050-51.1.06; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3; Yard EE, 2006, J ATHL TRAINING, V41, P441	49	29	29	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2016	44	11					2947	2956		10.1177/0363546516648442			10	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	EB4RE	WOS:000387359900006	27281278	Green Accepted			2022-02-06	
J	Zhao, W; Ford, JC; Flashman, LA; McAllister, TW; Ji, SB				Zhao, Wei; Ford, James C.; Flashman, Laura A.; McAllister, Thomas W.; Ji, Songbai			White Matter Injury Susceptibility via Fiber Strain Evaluation Using Whole-Brain Tractography	JOURNAL OF NEUROTRAUMA			English	Article						Dartmouth Head Injury Model; fiber strain; neural pathway; tractography; traumatic brain injury; white matter injury	MAXIMUM PRINCIPAL STRAIN; IN-VITRO MODELS; HEAD IMPACT; AXONAL DAMAGE; RESPONSES; KINEMATICS; FOOTBALL; SPORTS; ATLAS; ACCELERATIONS	Microscale brain injury studies suggest axonal elongation as a potential mechanism for diffuse axonal injury (DAI). Recent studies have begun to incorporate white matter (WM) structural anisotropy in injury analysis, with initial evidence suggesting improved injury prediction performance. In this study, we further develop a tractography-based approach to analyze fiber strains along the entire lengths of fibers from voxel- or anatomically constrained whole-brain tractography. This technique potentially extends previous element- or voxel-based methods that instead utilize WM fiber orientations averaged from typically coarse elements or voxels. Perhaps more importantly, incorporating tractography-based axonal structural information enables assessment of the overall injury risks to functionally important neural pathways and the anatomical regions they connect, which is not possible with previous methods. A DAI susceptibility index was also established to quantify voxel-wise WM local structural integrity and tract-wise damage of individual neural pathways. This graded injury susceptibility potentially extends the commonly employed treatment of injury as a simple binary condition. As an illustration, we evaluate the DAI susceptibilities of WM voxels and transcallosal fiber tracts in three idealized head impacts. Findings suggest the potential importance of the tractography-based approach for injury prediction. These efforts may enable future studies to correlate WM mechanical responses with neuroimaging, cognitive alteration, and concussion, and to reveal the relative vulnerabilities of neural pathways and identify the most vulnerable ones in real-world head impacts.	[Zhao, Wei; Ji, Songbai] Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Lebanon, NH 03766 USA; [Ford, James C.; Flashman, Laura A.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Ji, Songbai] Geisel Sch Med Dartmouth, Dept Surg & Orthopaed Surg, Lebanon, NH USA		Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Lebanon, NH 03766 USA.	Songbai.Ji@Dartmouth.edu	Ford, James/AAF-7039-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078607, R21NS088781, R01NS092853] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS092853, R21 NS078607, R21 NS088781] Funding Source: Medline		Abaqus, 2012, ABAQUS, V6, P12; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Carlsen RW, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00028; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Debanne D, 2011, PHYSIOL REV, V91, P555, DOI 10.1152/physrev.00048.2009; Domont A., 1992, P 36 STAPP CAR CRASH, DOI [10.4271/922527, DOI 10.4271/922527]; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Feigl GC, 2014, WORLD NEUROSURG, V81, P144, DOI 10.1016/j.wneu.2013.01.004; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Gennarelli TA, 1987, DIRECTIONAL DEPENDEN; Giordano C, 2014, J BIOMECH, V47, P1052, DOI 10.1016/j.jbiomech.2013.12.036; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Giordano C, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2013.0914; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Holbourn AHS, 1943, LANCET, V2, P438; Ji SB, 2015, ANN BIOMED ENG, V43, P1877, DOI 10.1007/s10439-014-1193-3; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Kimpara H, 2012, ANN BIOMED ENG, V40, P114, DOI 10.1007/s10439-011-0414-2; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leemans A., 2009, P INT SOC MAG RESON; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Morrison B, 2011, STUD MECHANOBIOL TIS, V3, P247, DOI 10.1007/8415_2011_79; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Nahum A, 1977, 770922 SAE; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J A, 2000, Stapp Car Crash J, V44, P215; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Prasad G, 2014, NEUROIMAGE, V97, P284, DOI 10.1016/j.neuroimage.2014.04.033; Roossien DH, 2014, J CELL SCI, V127, P3593, DOI 10.1242/jcs.152611; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts Erik G, 2003, Stapp Car Crash J, V47, P107; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; The CDC NI H DoD and VA Leadership Panel, 2013, REP C TRAUM BRAIN IN; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Versace J., 1971, REV SEVERITY INDEX; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049; Zhao W, 2015, IRCOBI C LYON FRANC, P208; Zhao W, 2016, INTERFACE FOCUS, V6, DOI 10.1098/rsfs.2015.0091; Zhao W, 2015, BIOMECH MODEL MECHAN, V14, P753, DOI 10.1007/s10237-014-0634-0	76	29	29	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2016	33	20					1834	1847		10.1089/neu.2015.4239			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	EA6YO	WOS:000386775300004	26782139	Green Published			2022-02-06	
J	Dunning, DL; Westgate, B; Adlam, ALR				Dunning, Darren L.; Westgate, Briony; Adlam, Anna-Lynne R.			A Meta-Analysis of Working Memory Impairments in Survivors of Moderate-to-Severe Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						TBI; traumatic brain injury; working memory; cognition	HEAD-INJURY; EXECUTIVE FUNCTION; SUSTAINED-ATTENTION; DIVIDED ATTENTION; TASK-PERFORMANCE; SEVERE TBI; SHORT-TERM; CHILDREN; DEFICITS; OUTCOMES	Objectives: To establish the magnitude of deficits in working memory (WM) and short-term memory (STM) in those with moderate-to-severe traumatic brain injury (TBI) relative to age-matched, healthy controls and to explore the moderating effects of time since injury and age at injury on these impairments. Method: Twenty-one studies that compared the WM and/or STM abilities of individuals with at least a moderate TBI relative to healthy controls were included in a random effects meta-analysis. Measures used to examine memory performance were categorized by modality (visuospatial, verbal) and memory system (WM, STM). Results: Individuals with TBI had significant deficits in verbal STM (Cohen's d =.41), visuospatial WM (Cohen's d =.69), and verbal WM (Cohen's d =.37) relative to controls. Greater decrements in verbal STM and verbal WM skills were associated with longer time postinjury. Larger deficits were observed in verbal WM abilities in individuals with older age at injury. Conclusion: Evidence for WM impairments following TBI is consistent with previous research. Larger verbal STM and verbal WM deficits were related to a longer time postinjury, suggesting that these aspects of memory do not "recover" over time and instead, individuals might show increased rates of cognitive decline. Age at injury was associated with the severity of verbal WM impairments, with larger deficits evident for injuries that occurred later in life. Further research needs to chart the long-term effects of TBI on WM and to compare the effects of injury on verbal relative to visuospatial memory.	[Dunning, Darren L.; Westgate, Briony; Adlam, Anna-Lynne R.] Univ East Anglia, Sch Med, Norwich, Norfolk, England; [Adlam, Anna-Lynne R.] Univ Exeter, Ctr Clin Neuropsychol Res, Exeter EX4 4QJ, Devon, England		Dunning, DL (corresponding author), Cognit & Brain Sci Unit, Chaucer Rd, Cambridge CB2 7EF, England.	darren.dunning@mrc-cbu.cam.ac.uk		Adlam, Anna/0000-0001-7212-4051	Henry Smith Charity; Action Medical Research; Action Medical Research [1833] Funding Source: researchfish	This project was supported by generous grants from the Henry Smith Charity and Action Medical Research.	Alloway TP, 2006, CHILD DEV, V77, P1698, DOI 10.1111/j.1467-8624.2006.00968.x; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley AD, 2011, NEUROPSYCHOLOGIA, V49, P1393, DOI 10.1016/j.neuropsychologia.2010.12.042; Beddeley AD., 1974, PSYCHOL LEARN MOTIV, V8, P47, DOI [DOI 10.1016/S0079-7421(08)60452-1, 10.1016/S0079-7421(08)60452-1]; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Burgess GC, 2011, J EXP PSYCHOL GEN, V140, P674, DOI 10.1037/a0024695; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chapman S.B., 2006, BRAIN INJ PROF, V3, P10; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen J., 2013, STAT POWER ANAL BEHA; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Curtis CE, 2006, HDB FUNCTIONAL NEURO, P269; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Faul M, 2010, TRAUMATIC BRAIN INJU; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Gathercole S. E., 2014, PERSPECTIVES LANGUAG, V40, P36; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; Gorman S, 2012, J INT NEUROPSYCH SOC, V18, P29, DOI 10.1017/S1355617711001251; Hanten G, 2003, BRAIN INJURY, V17, P871, DOI 10.1080/02699050210147220; Health and Social Care Information Centre, 2010, HES TRAUM BRAIN INJ; Hellgren L., 2015, OPEN J THERAPY REHAB, V3, P46, DOI [DOI 10.4236/OJTR.2015.32007, 10.4236/ojtr.2015.32007]; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Higgins, 2005, COMPREHENSIVE META A; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kolb B., 2013, BRAIN PLASTICITY BEH; Kraus JF, 2005, TXB TRAUMATIC BRAIN, P3; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Lehto JH, 1996, Q J EXP PSYCHOL-A, V49, P29, DOI 10.1080/027249896392793; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lezak M., 1995, NEUROPSYCHOLOGICAL T; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McDonald S., 2015, APHASIOLOGY, V29, P1; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McHugh SB, 2008, BEHAV BRAIN RES, V186, P41, DOI 10.1016/j.bbr.2007.07.021; McVay JC, 2012, J EXP PSYCHOL GEN, V141, P302, DOI 10.1037/a0025250; Merzagora ACR, 2014, BRAIN IMAGING BEHAV, V8, P446, DOI 10.1007/s11682-013-9258-8; Moran C, 2004, BRAIN INJURY, V18, P273, DOI 10.1080/02699050310001617415; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Nobre Alexandre de Pontes, 2013, Psychol. Neurosci., V6, P331, DOI 10.3922/j.psns.2013.3.10; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Phillips N. L., 2015, CHILD NEUROPSYCHOLOG; Raghubar KP, 2013, J INT NEUROPSYCH SOC, V19, P254, DOI 10.1017/S1355617712001312; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rosenberg MS, 2005, EVOLUTION, V59, P464, DOI 10.1111/j.0014-3820.2005.tb01004.x; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Savage RC, 2005, PREV SCH FAIL, V49, P43, DOI 10.3200/PSFL.49.4.43-52; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Teichner G, 2000, AGGRESS VIOLENT BEH, V5, P509, DOI 10.1016/S1359-1789(98)00035-4; Valentine JC, 2010, J EDUC BEHAV STAT, V35, P215, DOI 10.3102/1076998609346961; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Vallat-Azouvi C, 2012, NEUROPSYCHOL REHABIL, V22, P634, DOI 10.1080/09602011.2012.681110; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wilhelm O, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00433; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; World Health Organization, 2008, WORLD HLTH STAT 2008	95	29	29	1	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2016	30	7					811	819		10.1037/neu0000285			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	DY9FX	WOS:000385440400004	27182710				2022-02-06	
J	Wang, Y; Zhang, CH; Peng, WJ; Xia, ZA; Gan, PP; Huang, W; Shi, YF; Fan, R				Wang, Yang; Zhang, Chunhu; Peng, Weijun; Xia, Zian; Gan, Pingping; Huang, Wei; Shi, Yafei; Fan, Rong			Hydroxysafflor yellow A exerts antioxidant effects in a rat model of traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						hydroxysafflor yellow A; traumatic brain injury; oxidative stress; neuroprotective effect; ultra performance liquid chromatography-tandem mass spectrometry	OXIDATIVE STRESS; ISCHEMIA; MICE; NEURODEGENERATION; NEUROPROTECTION; OVEREXPRESSION; EPIDEMIOLOGY; PEROXIDATION; PERMEABILITY; CONTRIBUTES	Free radical-induced oxidative damage occurs rapidly and is of primary importance during the secondary pathophysiological cascades of traumatic brain injury (TBI). Hydroxysafflor yellow A (HSYA) is a constituent of the flower petals of Carthamus tinctorius (safflower) and may represent a potential therapeutic strategy to improve outcomes following TBI. The present study aimed to identify HSYA in the brain tissues of rats exposed to TBI to determine its absorption and to investigate the underlying effects of HSYA on antioxidant enzymes in the brain tissues of TBI rats. To determine the absorption of HSYA for the investigation of the underlying antioxidant effects of HSYA in TBI, the presence of HSYA in the brain tissues of the TBI rats was identified using an ultra performance liquid chromatography-tandem mass spectrometry method. Subsequently, the state of oxidative stress in the TBI rat model following the administration of HSYA was investigated by determining the levels of antioxidant enzymes, including superoxide dismutase (SOD), malondialdehyde (MDA) and catalase (CAT), and the ratio of glutathione (GSH)/glutathione disulfide (GSSG). The data obtained demonstrated that HSYA was absorbed in the brain tissues of the TBI rats. HSYA increased the activities of SOD and CAT, the level of GSH and the GSH/GSSG ratio. However, HSYA concomitantly decreased the levels of MDA and GSSG. These preliminary data suggest that HSYA has the potential to be utilized as a neuroprotective drug in cases of TBI.	[Wang, Yang; Zhang, Chunhu; Peng, Weijun; Xia, Zian; Gan, Pingping; Huang, Wei; Fan, Rong] Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Shi, Yafei] Guangzhou Univ Tradit Chinese Med, Coll Basic Med, Guangzhou 510006, Guangdong, Peoples R China		Fan, R (corresponding author), Cent S Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.	fanrong819@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81303074, 81403259, 81202781, 81303098]; Administration of Traditional Chinese Medicine of Hunan Province, China [201455]	This study was supported by the National Natural Science Foundation of China (grant nos. 81303074, 81403259, 81202781 and 81303098) and the Administration of Traditional Chinese Medicine of Hunan Province, China (grant no. 201455).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Alexi T, 2000, PROG NEUROBIOL, V60, P409, DOI 10.1016/S0301-0082(99)00032-5; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bar-Or D, 2015, REDOX BIOL, V4, P340, DOI 10.1016/j.redox.2015.01.006; Bie XD, 2010, J ASIAN NAT PROD RES, V12, P239, DOI 10.1080/10286020903510636; Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Ehsaei M, 2015, ACTA NEUROL BELG, V115, P69, DOI 10.1007/s13760-014-0300-4; Fan LH, 2011, CELL MOL NEUROBIOL, V31, P1187, DOI 10.1007/s10571-011-9720-3; Freire MAM, 2012, W INDIAN MED J, V61, P751; Gan L, 2015, BIOMED ENVIRON SCI, V28, P148, DOI 10.3967/bes2015.019; Gracy RW, 1999, MUTAT RES-FUND MOL M, V428, P17, DOI 10.1016/S1383-5742(99)00027-7; Guo Y, 2014, BIOMED CHROMATOGR, V28, P1090, DOI 10.1002/bmc.3124; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kim JY, 2013, J NEUROTRAUM, V30, P1170, DOI 10.1089/neu.2012.2691; Kou K, 2014, WORLD J EMERG MED, V5, P245, DOI 10.5847/wjem.j.issn.1920-8642.2014.04.001; Lau WKW, 2012, NEUROTOX RES, V22, P170, DOI 10.1007/s12640-011-9301-8; Lei J, 2013, J NEUROTRAUM, V30, P529, DOI 10.1089/neu.2012.2548; Li J, 2013, BIOMED REP, V1, P925, DOI 10.3892/br.2013.162; Li J, 2013, NEUROSCI LETT, V535, P51, DOI 10.1016/j.neulet.2012.12.056; Lv LZ, 2013, INT J NANOMED, V8, P2709, DOI 10.2147/IJN.S47400; Mojtahedzadeh M, 2014, J RES MED SCI, V19, P867; Pharmacopoeia Commission of PRC, 2010, PHARMACOPOEIA PEOPLE, P141; Qi JP, 2011, INT J NANOMED, V6, P985, DOI 10.2147/IJN.S18821; Qi ZF, 2014, TRANSL STROKE RES, V5, P501, DOI 10.1007/s12975-014-0346-x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Schoch KM, 2012, EXP NEUROL, V236, P371, DOI 10.1016/j.expneurol.2012.04.022; SHARMA SK, 1980, J BIOCHEM BIOPH METH, V2, P247, DOI 10.1016/0165-022X(80)90039-1; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sun L, 2012, BRAIN RES, V1473, P227, DOI 10.1016/j.brainres.2012.07.047; Tuominen R, 2012, BRAIN INJURY, V26, P1697, DOI 10.3109/02699052.2012.722256; Wang CY, 2013, PHYTOMEDICINE, V20, P592, DOI 10.1016/j.phymed.2013.02.001; Wang D, 2012, MOLECULES, V17, P9803, DOI 10.3390/molecules17089803; Wang Y, 2012, CHIN J INTEGR MED, V18, P690, DOI 10.1007/s11655-012-1053-7; Wei XB, 2005, NEUROSCI LETT, V386, P58, DOI 10.1016/j.neulet.2005.05.069; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xie ZY, 2012, BRAIN RES, V1472, P113, DOI 10.1016/j.brainres.2012.06.053; Xue T, 2012, TOXICOL APPL PHARM, V261, P280, DOI 10.1016/j.taap.2012.04.010; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhao H, 2009, HIGH ALT MED BIOL, V10, P283, DOI 10.1089/ham.2008.1087; Zhu HB, 2003, PLANTA MED, V69, P429, DOI 10.1055/s-2003-39714	46	29	31	2	18	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	OCT	2016	14	4					3690	3696		10.3892/mmr.2016.5720			7	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	DZ1ED	WOS:000385580800106	27599591	hybrid, Green Published, Green Submitted			2022-02-06	
J	Lopiz, Y; Gonzalez, A; Garcia-Fernandez, C; Garcia-Coiradas, J; Marco, F				Lopiz, Yaiza; Gonzalez, Ana; Garcia-Fernandez, Carlos; Garcia-Coiradas, Javier; Marco, Fernando			Comminuted fractures of the radial head: resection or prosthesis?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Radial head fracture; Metal prosthesis; Radial head resection; Elbow instability	TERM-FOLLOW-UP; LONG-TERM; INTERNAL-FIXATION; CLOSED FRACTURE; DEFICIENT ELBOW; III FRACTURES; EXCISION; ARTHROPLASTY; REPLACEMENT; NECK	Introduction: At present, surgical treatment of comminuted radial head fractures without associated instability continues to be controversial. When anatomical reconstruction is not possible, radial head excision is performed. However, the appearance of long-term complications with this technique, along with the development of new radial head implants situates arthroplasty as a promising surgical alternative. The purpose of the present study was to compare the mid-term functional outcomes of both techniques. Materials and Methods: A retrospective study was performed between 2002 and 2011 on 25 Mason type-III fractures, 11 patients treated with primary radial head resection and 14 who received treatment of the fracture with metal prosthesis. At the end of follow-up, patients were contacted and outcomes evaluated according to: Mayo Elbow Performance Score (MEPS), the Disabilities of the Arm, Shoulder and Hand score (DASH) and strength measurement. Radiographic assessment (proximal migration of the radius, osteoarthritic changes, and signs of prosthesis loosening) was also performed. Results: The average age of the sample was 53.7 years in the resection group, and 54.4 years in the replacement group, with a mean follow-up of 60.3 and 42 months respectively. According to the MEPS scale, there were 6 excellent cases, 3 good and 2 acceptable in the resection group, and 6 excellent cases, 3 good, 3 acceptable, and 2 poor in the prosthesis group. The mean DASH score were 13.5, and 24.8 for the resection and the replacement group respectively. We found one postoperative complication in the resection group (stiffness and valgus instability) and 6 in the replacement group: 3 of joint stiffness, 1 case of prosthesis breakage, and 2 neurological injuries. Conclusions: Although this is a retrospective study, the high complication rate occurring after radial head replacement in comparison with radial head resection, as well as good functional results obtained with this last technique, leads us to recommend it for comminuted radial head fractures without associated instability. (C) 2016 Elsevier Ltd. All rights reserved.	[Lopiz, Yaiza; Gonzalez, Ana; Garcia-Fernandez, Carlos; Garcia-Coiradas, Javier; Marco, Fernando] Univ Complutense Madrid, Clin San Carlos Hosp, Dept Orthopaed Surg, Shoulder & Elbow Unit, Madrid, Spain		Lopiz, Y (corresponding author), Hosp Clin San Carlos, Serv Traumatol & Cirugia Ortoped, Plaza Cristo Rey S-N, Madrid 28040, Spain.	yaizalopiz@gmail.com		/0000-0002-0678-5086			Antuna SA, 2000, REV ORTOP TRAUMATOL, V44, P67; Antuna SA, 2010, J BONE JOINT SURG AM, V92A, P558, DOI 10.2106/JBJS.I.00332; Ashwood N, 2004, J BONE JOINT SURG AM, V86A, P274, DOI 10.2106/00004623-200402000-00009; Bain G I, 2005, J Bone Joint Surg Am, V87 Suppl 1, P136, DOI 10.2106/JBJS.D.02710; BAKALIM G, 1970, ACTA ORTHOP SCAND, V41, P320, DOI 10.3109/17453677008991518; Beingessner DM, 2004, J BONE JOINT SURG AM, V86A, P1730, DOI 10.2106/00004623-200408000-00018; BERGER M, 1991, ANN RADIOL, V34, P330; BROBERG MA, 1986, J BONE JOINT SURG AM, V68A, P669, DOI 10.2106/00004623-198668050-00005; Charalambous CP, 2006, INJURY, V37, P849, DOI 10.1016/j.injury.2006.04.125; Chen X, 2011, INT ORTHOP, V35, P1071, DOI 10.1007/s00264-010-1107-4; Cheung EV, 2009, J AM ACAD ORTHOP SUR, V17, P325, DOI 10.5435/00124635-200905000-00007; Faldini C, 2012, J ORTHOP TRAUMA, V26, P236, DOI 10.1097/BOT.0b013e318220af4f; Giannicola G, 2014, INJURY, V45, P428, DOI 10.1016/j.injury.2013.09.019; GOLDBERG I, 1986, J BONE JOINT SURG AM, V68A, P675, DOI 10.2106/00004623-198668050-00006; GORDON M, 1982, J BONE JOINT SURG AM, V64, P574, DOI 10.2106/00004623-198264040-00013; Harrington IJ, 2001, J TRAUMA, V50, P46, DOI 10.1097/00005373-200101000-00009; HASTINGS H, 1994, HAND CLIN, V10, P417; Herbertsson P, 2004, J BONE JOINT SURG AM, V86A, P1925, DOI 10.2106/00004623-200409000-00010; Herbertsson P, 2004, J BONE JOINT SURG AM, V86A, P569, DOI 10.2106/00004623-200403000-00016; Hotchkiss RN, 1998, AAOS INSTR COURS LEC, V47, P173; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Iftimie PP, 2011, J SHOULDER ELB SURG, V20, P45, DOI 10.1016/j.jse.2010.09.005; Ikeda M, 2005, J BONE JOINT SURG AM, V87A, P76, DOI 10.2106/JBJS.C.01323; Ikeda Masayoshi, 2006, J Bone Joint Surg Am, V88 Suppl 1 Pt 1, P11; Janssen RPA, 1998, J BONE JOINT SURG BR, V80B, P231, DOI 10.1302/0301-620X.80B2.8255; Jensen SL, 1999, J SHOULDER ELB SURG, V8, P238, DOI 10.1016/S1058-2746(99)90135-0; Kachooei AR, 2016, INJURY, V47, P1253, DOI 10.1016/j.injury.2016.02.023; Liu Bifeng, 2010, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V24, P900; MANN FA, 1992, RADIOLOGY, V184, P15, DOI 10.1148/radiology.184.1.1609073; Martin-Fuentes A M, 2013, Rev Esp Cir Ortop Traumatol, V57, P217, DOI 10.1016/j.recot.2013.02.005; MASON ML, 1954, BRIT J SURG, V42, P123, DOI 10.1002/bjs.18004217203; MAYHALL WST, 1981, J BONE JOINT SURG AM, V63, P459, DOI 10.2106/00004623-198163030-00022; Maynou C, 1996, Acta Orthop Belg, V62 Suppl 1, P105; Moro JK, 2001, J BONE JOINT SURG AM, V83A, P1201, DOI 10.2106/00004623-200108000-00010; MORREY BF, 1991, CLIN ORTHOP RELAT R, P187; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P454, DOI 10.2106/00004623-198163030-00021; MORREY BF, 1979, J BONE JOINT SURG AM, V61, P63, DOI 10.2106/00004623-197961010-00012; Morrey BF, 1985, ELBOW ITS DISORDERS, P62; Obert L, 2005, Chir Main, V24, P17, DOI 10.1016/j.main.2004.11.009; Pavic R, 2015, INJURY, V46, pS119, DOI 10.1016/j.injury.2015.10.050; Pilato G, 2004, Chir Organi Mov, V89, P213; Popovic N, 2000, J ORTHOP TRAUMA, V14, P171, DOI 10.1097/00005131-200003000-00004; Sanchez Gomez P, 2010, REV ESP CIR ORTOP TR, V54, P280; Sanchez-Sotelo J, 2000, J ORTHOP TRAUMA, V14, P354, DOI 10.1097/00005131-200006000-00009; Saus Milan N, 2012, REV ESPANOLA CIRUGIA, V47, P151; Schnetzke M, 2014, INT ORTHOP, V38, P2295, DOI 10.1007/s00264-014-2478-8; Shepard MF, 2001, J BONE JOINT SURG AM, V83A, P92, DOI 10.2106/00004623-200101000-00013; Shin R, 2007, J BONE JOINT SURG AM, V89A, P1108, DOI 10.2106/JBJS.F.00594; Smets S, 2000, Acta Orthop Belg, V66, P353; Smits AJ, 2014, INJURY, V45, P1564, DOI 10.1016/j.injury.2014.05.034; SOWA DT, 1995, CLIN ORTHOP RELAT R, P106; STEPHEN IBM, 1981, ACTA ORTHOP SCAND, V52, P409, DOI 10.3109/17453678109050121; Stoffelen D V, 1994, Acta Orthop Belg, V60, P402; TROUSDALE RT, 1992, J BONE JOINT SURG AM, V74A, P1486, DOI 10.2106/00004623-199274100-00007; Van Glabbeek F, 2005, MED ENG PHYS, V27, P336, DOI 10.1016/j.medengphy.2004.04.011; Van Glabbeek F, 2004, J BONE JOINT SURG AM, V86A, P2629, DOI 10.2106/00004623-200412000-00007; Yalcinkaya M, 2013, ORTHOPEDICS, V36, pE1358, DOI 10.3928/01477447-20131021-15; Zarattini G, 2012, J ORTHOP TRAUMA, V26, P229, DOI 10.1097/BOT.0b013e318220a227; Zhao JJ, 2007, J HUAZHONG U SCI-MED, V27, P681, DOI 10.1007/s11596-007-0616-x; Zwingmann J, 2013, INJURY, V44, P1540, DOI 10.1016/j.injury.2013.04.003	60	29	31	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2016	47			3			S29	S34		10.1016/S0020-1383(16)30603-9			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	EF7VW	WOS:000390538400006	27692103				2022-02-06	
J	Radulovic, M; Yoon, H; Wu, JM; Mustafa, K; Scarisbrick, IA				Radulovic, Maja; Yoon, Hyesook; Wu, Jianmin; Mustafa, Karim; Scarisbrick, Isobel A.			Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic spinal cord injury; Astrogliosis; Inflammation; Cytokine; GPCR; Serine protease; Astrocyte; Microglia; Interleukin 6	PROTEASE-ACTIVATED RECEPTOR-1; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIBRILLARY ACIDIC PROTEIN; INDUCED MICROGLIAL ACTIVATION; PROTHROMBIN-MESSENGER-RNA; MODEL MOTOR-NEURONS; BLOOD-BRAIN-BARRIER; REACTIVE ASTROCYTES; NERVOUS-SYSTEM; FUNCTIONAL RECOVERY	The deregulation of serine protease activity is a common feature of neurological injury, but little is known regarding their mechanisms of action or whether they can be targeted to facilitate repair. In this study we demonstrate that the thrombin receptor (Protease Activated Receptor 1, (PAR1)) serves as a critical translator of the spinal cord injury (SCI) proteolytic microenvironment into a cascade of pro-inflammatory events that contribute to astrogliosis and functional decline. PAR1 knockout mice displayed improved locomotor recovery after SCI and reduced signatures of inflammation and astrogliosis, including expression of glial fibrillary acidic protein (GFAP), vimentin, and STAT3 signaling. SCI-associated elevations in pro-inflammatory cytokines such as IL-1 beta and IL-6 were also reduced in PAR1-/- mice and co-ordinate improvements in tissue sparing and preservation of NeuN-positive ventral horn neurons, and PKC gamma corticospinal axons, were observed. PAR1 and its agonist's thrombin and neurosin were expressed by perilesional astrocytes and each agonist increased the production of IL-6 and STAT3 signaling in primary astrocyte cultures in a PAR1-dependent manner. In turn, IL-6-stimulated astrocytes increased expression of PAR1, thrombin, and neurosin, pointing to a model in which PAR1 activation contributes to increased astrogliosis by feedforward- and feedback-signaling dynamics. Collectively, these findings identify the thrombin receptor as a key mediator of inflammation and astrogliosis in the aftermath of SCI that can be targeted to reduce neurodegeneration and improve neurobehavioral recovery. (C) 2016 Elsevier Inc. All rights reserved.	[Radulovic, Maja; Mustafa, Karim; Scarisbrick, Isobel A.] Mayo Med & Grad Sch, Rehabil Med Res Ctr, Neurobiol Dis Program, Rochester, MN 55905 USA; [Yoon, Hyesook; Wu, Jianmin; Scarisbrick, Isobel A.] Mayo Med & Grad Sch, Rehabil Med Res Ctr, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Yoon, Hyesook; Scarisbrick, Isobel A.] Mayo Med & Grad Sch, Rehabil Med Res Ctr, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA		Scarisbrick, IA (corresponding author), Mayo Clin Rochester, Neurobiol Dis Program, 642B Guggenheim Bldg,200 First St SW, Rochester, MN 55905 USA.	Scarisbrick.Isobel@mayo.edu		Mustafa, Karim/0000-0003-2567-635X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS052741]; Pilot Project [PP2009, RG4958]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [CA1060A11]; Mayo Clinic Center for Regenerative Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052741] Funding Source: NIH RePORTER	Studies were supported by the National Institutes of Health 5R01NS052741, Pilot Project PP2009, RG4958 and a Collaborative MS Research Center Award CA1060A11 from the National Multiple Sclerosis Society, and an Accelerated Regenerative Medicine Award from the Mayo Clinic Center for Regenerative Medicine. The authors declare no competing financial interests.	Acharjee S, 2011, BRAIN, V134, P3209, DOI 10.1093/brain/awr242; Adams MN, 2011, PHARMACOL THERAPEUT, V130, P248, DOI 10.1016/j.pharmthera.2011.01.003; Arai T, 2006, J NEUROPATH EXP NEUR, V65, P19, DOI 10.1097/01.jnen.0000196133.74087.cb; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Blaber SI, 2004, FASEB J, V18, P920, DOI 10.1096/fj.03-1212fje; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Burda JE, 2013, GLIA, V61, P1456, DOI 10.1002/glia.22534; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chen B, 2012, J NEUROSCI, V32, P7622, DOI 10.1523/JNEUROSCI.0369-12.2012; Chen B, 2010, STROKE, V41, P2348, DOI 10.1161/STROKEAHA.110.584920; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Citron BA, 2000, J NEUROTRAUM, V17, P1191, DOI 10.1089/neu.2000.17.1191; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; Dibaj P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043963; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; Dominguez E, 2010, J NEUROSCI, V30, P5754, DOI 10.1523/JNEUROSCI.5007-09.2010; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Drucker KL, 2013, NEURO-ONCOLOGY, V15, P305, DOI 10.1093/neuonc/nos313; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Festoff BM, 2000, MOL MED, V6, P410, DOI 10.1007/BF03401784; Festoff BW, 2004, J NEUROTRAUM, V21, P907, DOI 10.1089/0897715041526168; French SL, 2015, BLOOD REV, V29, P179, DOI 10.1016/j.blre.2014.10.006; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Hamill Cecily E, 2005, Clin Neurosurg, V52, P29; Hamill CE, 2009, EXP NEUROL, V217, P136, DOI 10.1016/j.expneurol.2009.01.023; Han KS, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-32; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Itsekson-Hayosh Z, 2015, J NEUROTRAUMA; Joshi M, 2002, J NEUROTRAUM, V19, P191, DOI 10.1089/08977150252806956; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Kim HN, 2015, J NEUROCHEM, V135, P577, DOI 10.1111/jnc.13285; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Kraft AW, 2013, FASEB J, V27, P187, DOI 10.1096/fj.12-208660; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lepekhin EA, 2001, J NEUROCHEM, V79, P617, DOI 10.1046/j.1471-4159.2001.00595.x; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Liedtke W, 1998, AM J PATHOL, V152, P251; Lieu A, 2013, J NEUROIMMUNOL, V256, P43, DOI 10.1016/j.jneuroim.2013.01.003; Liu DZ, 2010, ANN NEUROL, V67, P526, DOI 10.1002/ana.21924; Liu ZW, 2014, GLIA, V62, P2022, DOI 10.1002/glia.22723; Lyden P, 2014, STROKE, V45, P896, DOI 10.1161/STROKEAHA.113.004488; Macauley SL, 2011, J NEUROSCI, V31, P15575, DOI 10.1523/JNEUROSCI.3579-11.2011; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; MORI M, 1990, J COMP NEUROL, V299, P167, DOI 10.1002/cne.902990204; NICLOU S, 1994, CELL MOL BIOL, V40, P421; Niclou SP, 1998, EUR J NEUROSCI, V10, P1590, DOI 10.1046/j.1460-9568.1998.00183.x; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Okada S, 2004, J NEUROSCI RES, V76, P265, DOI 10.1002/jnr.20044; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Olson EE, 2004, J CEREBR BLOOD F MET, V24, P964, DOI 10.1097/01.WCB.0000128266.87474.BF; Panos M, 2014, BIOL CHEM, V395, P1063, DOI 10.1515/hsz-2014-0141; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Radulovic M, 2015, NEUROBIOL DIS, V83, P75, DOI 10.1016/j.nbd.2015.08.021; Radulovic Maja, 2013, J Neuropathol Exp Neurol, V72, P1072, DOI 10.1097/NEN.0000000000000007; Rajput PS, 2014, NEUROSCIENCE, V281, P229, DOI 10.1016/j.neuroscience.2014.09.038; Rawlings N.D., 2012, HDB PROTEOLYTIC ENZY, P2780; Riek-Burchardt M, 2002, NEUROSCI LETT, V329, P181, DOI 10.1016/S0304-3940(02)00645-6; Scarisbrick IA, 2008, CURR TOP MICROBIOL, V318, P133; Scarisbrick IA, 2006, EUR J NEUROSCI, V24, P1457, DOI 10.1111/j.1460-9568.2006.05021.x; Scarisbrick IA, 1999, J NEUROSCI, V19, P7757; Scarisbrick IA, 2002, BRAIN, V125, P1283, DOI 10.1093/brain/awf142; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Scarisbrick IA, 2012, BRAIN PATHOL, V22, P709, DOI 10.1111/j.1750-3639.2012.00577.x; Scarisbrick IA, 2012, BIOL CHEM, V393, P355, DOI 10.1515/hsz-2011-0241; Scarisbrick IA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018376; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shao W, 2013, NATURE, V494, P90, DOI 10.1038/nature11748; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smirnova IV, 1998, J NEUROBIOL, V36, P64, DOI 10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.3.CO;2-4; Smirnova IV, 2001, J NEUROBIOL, V48, P87, DOI 10.1002/neu.1044; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Suo ZM, 2003, J BIOL CHEM, V278, P37681, DOI 10.1074/jbc.M301406200; Suo ZM, 2003, J BIOL CHEM, V278, P31177, DOI 10.1074/jbc.M302137200; Suo ZM, 2002, J NEUROCHEM, V80, P655, DOI 10.1046/j.0022-3042.2001.00745.x; Taoka Y, 2000, THROMB HAEMOSTASIS, V83, P462, DOI 10.1055/s-0037-1613837; Toft-Hansen H, 2011, GLIA, V59, P166, DOI 10.1002/glia.21088; Turgeon VL, 1998, J NEUROSCI, V18, P6882; Vandell AG, 2008, J NEUROCHEM, V107, P855, DOI 10.1111/j.1471-4159.2008.05658.x; Voskuhl RR, 2009, J NEUROSCI, V29, P11511, DOI 10.1523/JNEUROSCI.1514-09.2009; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wang H, 2002, GLIA, V37, P53, DOI 10.1002/glia.10012; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Xue MZ, 2001, STROKE, V32, P2164, DOI 10.1161/hs0901.095408; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Yoon H, 2015, GLIA, V63, P846, DOI 10.1002/glia.22788; Yoon H, 2013, J NEUROCHEM, V127, P283, DOI 10.1111/jnc.12293; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang J, 2012, J NEUROL SCI, V320, P6, DOI 10.1016/j.jns.2012.05.040	101	29	30	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2016	93						226	242		10.1016/j.nbd.2016.04.010			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DQ8IE	WOS:000379452600021	27145117	Green Accepted			2022-02-06	
J	Simon-O'Brien, E; Gauthier, D; Riban, V; Verleye, M				Simon-O'Brien, Emmanuelle; Gauthier, Delphine; Riban, Veronique; Verleye, Marc			Etifoxine improves sensorimotor deficits and reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Etifoxine; Neuroinflammation; TSPO; Neurosteroids; Functional recovery; Cytokines; Astrogliosis; Neuronal degeneration; Microglia	PERIPHERAL BENZODIAZEPINE-RECEPTOR; CONTROLLED CORTICAL IMPACT; TUMOR-NECROSIS-FACTOR; PROTEIN 18 KDA; CELL-DEATH; INFLAMMATORY RESPONSE; ANXIOLYTIC ETIFOXINE; GABA(A) RECEPTORS; TEMPORAL PROFILE; NERVOUS-SYSTEM	Background: Traumatic brain injury (TBI) results in important neurological impairments which occur through a cascade of deleterious physiological events over time. There are currently no effective treatments to prevent these consequences. TBI is followed not only by an inflammatory response but also by a profound reorganization of the GABAergic system and a dysregulation of translocator protein 18 kDa (TSPO). Etifoxine is an anxiolytic compound that belongs to the benzoxazine family. It potentiates GABAergic neurotransmission, either through a positive allosteric effect or indirectly, involving the activation of TSPO that leads to an increase in neurosteroids synthesis. In several models of peripheral nerve injury, etifoxine has been demonstrated to display potent regenerative and anti-inflammatory properties and to promote functional recovery. Prior study also showed etifoxine efficacy in reducing brain edema in rats. In light of these positive results, we used a rat model of TBI to explore etifoxine treatment effects in a central nervous system injury, from functional outcomes to the underlying mechanisms. Methods: Male Sprague-Dawley rats received contusion (n = 18) or sham (n = 19) injuries centered laterally to bregma over the left sensorimotor cortex. They were treated with etifoxine (50 mg/kg, i.p.) or its vehicle 30 min following injury and every day during 7 days. Rats underwent behavioral testing to assess sensorimotor function. In another experiment, injured rats (n = 10) or sham rats (n = 10) received etifoxine (EFX) (50 mg/kg, i.p.) or its vehicle 30 min post-surgery. Brains were then dissected for analysis of neuroinflammation markers, glial activation, and neuronal degeneration. Results: Brain-injured rats exhibited significant sensorimotor function deficits compared to sham-injured rats in the bilateral tactile adhesive removal test, the beam walking test, and the limb-use asymmetry test. After 2 days of etifoxine treatment, behavioral impairments were significantly reduced. Etifoxine treatment reduced pro-inflammatory cytokines levels without affecting anti-inflammatory cytokines levels in injured rats, reduced macrophages and glial activation, and reduced neuronal degeneration. Conclusions: Our results showed that post-injury treatment with etifoxine improved functional recovery and reduced neuroinflammation in a rat model of TBI. These findings suggest that etifoxine may have a therapeutic potential in the treatment of TBI.	[Simon-O'Brien, Emmanuelle; Gauthier, Delphine; Riban, Veronique; Verleye, Marc] Biocodex, Dept Pharmacol, Chemin Armancourt, F-60200 Compiegne, France		Simon-O'Brien, E (corresponding author), Biocodex, Dept Pharmacol, Chemin Armancourt, F-60200 Compiegne, France.	e.simonobrien@biocodex.fr					Akk G, 2007, PHARMACOL THERAPEUT, V116, P35, DOI 10.1016/j.pharmthera.2007.03.004; Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Anderson GD, 2011, J NEUROTRAUM, V28, P1827, DOI 10.1089/neu.2011.1911; Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; Baratz R, 2015, J NEUROINFLAMM, V7, P12; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Chauveau F, 2011, EUR J NUCL MED MOL I, V38, P509, DOI 10.1007/s00259-010-1628-5; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; Daugherty DJ, 2013, EMBO MOL MED, V5, P891, DOI 10.1002/emmm.201202124; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; do Rego JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120473; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Ferzaz B, 2002, J PHARMACOL EXP THER, V301, P1067, DOI 10.1124/jpet.301.3.1067; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Freret T, 2006, EUR J NEUROSCI, V23, P1757, DOI 10.1111/j.1460-9568.2006.04699.x; Galani R, 2001, RESTOR NEUROL NEUROS, V18, P161; Girard C, 2012, J NEUROENDOCRINOL, V24, P71, DOI 10.1111/j.1365-2826.2011.02215.x; Girard C, 2008, P NATL ACAD SCI USA, V105, P20505, DOI 10.1073/pnas.0811201106; Girard P, 2009, CLIN EXP PHARMACOL P, V36, P655, DOI 10.1111/j.1440-1681.2008.05127.x; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hamon A, 2003, NEUROPHARMACOLOGY, V45, P293, DOI 10.1016/S0028-3908(03)00187-4; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kaufman NA, 2010, BEHAV BRAIN RES, V214, P395, DOI 10.1016/j.bbr.2010.06.017; Khateb A, 1998, NEUROSCIENCE, V86, P937, DOI 10.1016/S0306-4522(98)00094-3; Kim DH, 2010, PHYSIOL BEHAV, V101, P660, DOI 10.1016/j.physbeh.2010.09.021; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mukherjee S, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00021; Nguyen N, 2006, HUM PSYCHOPHARM CLIN, V21, P139, DOI 10.1002/hup.757; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Papadopoulos V, 2006, NEUROSCIENCE, V138, P749, DOI 10.1016/j.neuroscience.2005.05.063; Papadopoulos V, 2009, EXP NEUROL, V219, P53, DOI 10.1016/j.expneurol.2009.04.016; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; Perego C, 2013, JOVE-J VIS EXP, DOI 10.3791/50605; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pu BF, 2015, MOL MED REP, V12, P3704, DOI 10.3892/mmr.2015.3830; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; Ravikumar B, 2016, NEUROPHARMACOLOGY, V108, P229, DOI 10.1016/j.neuropharm.2016.03.053; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Romanides AJ, 1999, NEUROSCIENCE, V92, P97, DOI 10.1016/S0306-4522(98)00747-7; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Ryu JK, 2005, NEUROBIOL DIS, V20, P550, DOI 10.1016/j.nbd.2005.04.010; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHALLERT T, 1983, PHARMACOL BIOCHEM BE, V18, P753, DOI 10.1016/0091-3057(83)90019-9; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; Schlichter R, 2000, NEUROPHARMACOLOGY, V39, P1523, DOI 10.1016/S0028-3908(99)00253-1; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Servant D, 1998, ENCEPHALE, V24, P569; Shafer RA, 1997, GLIA, V21, P370, DOI 10.1002/(SICI)1098-1136(199712)21:4<370::AID-GLIA4>3.0.CO;2-7; Stein DJ, 2015, ADV THER, V32, P57, DOI 10.1007/s12325-015-0176-6; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; TANAKA M, 1994, J NEUROCHEM, V63, P266; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Torres SR, 2000, EUR J PHARMACOL, V408, P199, DOI 10.1016/S0014-2999(00)00760-3; Toth M, 2016, BRAIN STRUCT FUNCT, V221, P1279, DOI 10.1007/s00429-014-0970-y; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Veiga S, 2005, J NEUROSCI RES, V80, P129, DOI 10.1002/jnr.20430; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Verleye M, 2005, PHARMACOL BIOCHEM BE, V82, P712, DOI 10.1016/j.pbb.2005.11.013; Verleye M, 2004, PHYSIOL BEHAV, V82, P891, DOI 10.1016/j.physbeh.2004.07.010; Verleye M, 2002, NEUROSCI RES, V44, P167, DOI 10.1016/S0168-0102(02)00121-9; Verleye M, 1999, NEUROREPORT, V10, P3207, DOI 10.1097/00001756-199910190-00015; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang Y, 2014, EUR J NUCL MED MOL I, V41, P1440, DOI 10.1007/s00259-014-2727-5; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6; Wolf L, 2015, PHARMACOPSYCHIATRY, V48, P72, DOI 10.1055/s-0034-1398507; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Woodlee MT, 2005, EXP NEUROL, V191, P310, DOI 10.1016/j.expneurol.2004.09.005; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	106	29	29	3	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 26	2016	13								203	10.1186/s12974-016-0687-3			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	DV4EN	WOS:000382878200006	27565146	Green Published, gold			2022-02-06	
J	Borgialli, DA; Mahajan, P; Hoyle, JD; Powell, EC; Nadel, FM; Tunik, MG; Foerster, A; Dong, L; Miskin, M; Dayan, PS; Holmes, JF; Kuppermann, N				Borgialli, Dominic A.; Mahajan, Prashant; Hoyle, John D., Jr.; Powell, Elizabeth C.; Nadel, Frances M.; Tunik, Michael G.; Foerster, Adele; Dong, Lydia; Miskin, Michelle; Dayan, Peter S.; Holmes, James F.; Kuppermann, Nathan		Pediat Emergency Care Appl Res Net	Performance of the Pediatric Glasgow Coma Scale Score in the Evaluation of Children With Blunt Head Trauma	ACADEMIC EMERGENCY MEDICINE			English	Article							YOUNG-CHILDREN; INJURY; CONSCIOUSNESS; INFANTS; LEVEL	Objective: The objective was to compare the accuracy of the pediatric Glasgow Coma Scale (GCS) score in preverbal children to the standard GCS score in older children for identifying those with traumatic brain injuries (TBIs) after blunt head trauma. Methods: This was a planned secondary analysis of a large prospective observational multicenter cohort study of children with blunt head trauma. Clinical data were recorded onto case report forms before computed tomography (CT) results or clinical outcomes were known. The total and component GCS scores were assigned by the physician at initial emergency department evaluation. The pediatric GCS was used for children <2 years old and the standard GCS for those >= 2 years old. Outcomes were TBI visible on CT and clinically important TBI (ciTBI), defined as death from TBI, neurosurgery, intubation for more than 24 hours for the head injury, or hospitalization for 2 or more nights for the head injury in association with TBI on CT. We compared the areas under the receiver operating characteristic (ROC) curves between age cohorts for the association of GCS and the TBI outcomes. Results: We enrolled 42,041 patients, of whom 10,499 (25.0%) were <2 years old. Among patients <2 years, 313/3,329 (9.4%, 95% confidence interval [CI] = 8.4% to 10.4%) of those imaged had TBIs on CT and 146/10,499 (1.4%, 95% CI = 1.2% to 1.6%) had ciTBIs. In patients >= 2 years, 773/11,977 (6.5%, 95% CI = 6.0% to 6.9%) of those imaged had TBIs on CT and 572/31,542 (1.8%, 95% CI = 1.7% to 2.0%) had ciTBIs. For the pediatric GCS in children <2 years old, the area under the ROC curve was 0.61 (95% CI = 0.59 to 0.64) for TBI on CT and 0.77 (95% CI = 0.73 to 0.81) for ciTBI. For the standard GCS in older children, the area under the ROC curve was 0.71 (95% CI = 0.70 to 0.73) for TBI on CT scan and 0.81 (95% CI = 0.79 to 0.83) for ciTBI. Conclusions: The pediatric GCS for preverbal children was somewhat less accurate than the standard GCS for older children in identifying those with TBI on CT. However, the pediatric GCS for preverbal children and the standard GCS for older children were equally accurate for identifying ciTBI. (C) 2016 by the Society for Academic Emergency Medicine	[Borgialli, Dominic A.] Hurley Med Ctr, Dept Emergency Med, Flint, MI USA; [Borgialli, Dominic A.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA; [Mahajan, Prashant] Wayne State Univ, Sch Med, Dept Pediat, Div Pediat Emergency Med, Detroit, MI 48201 USA; [Hoyle, John D., Jr.] Helen DeVos Childrens Hosp, Div Emergency Med, E Lansing, MI USA; [Hoyle, John D., Jr.] Michigan State Univ, Dept Emergency Med, E Lansing, MI 48824 USA; [Hoyle, John D., Jr.] Western Michigan Univ, Sch Med, Dept Emergency Med, Kalamazoo, MI 49008 USA; [Hoyle, John D., Jr.] Western Michigan Univ, Sch Med, Dept Pediat, Kalamazoo, MI 49008 USA; [Powell, Elizabeth C.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Div Pediat Emergency Med, Chicago, IL 60611 USA; [Nadel, Frances M.] Univ Penn, Sch Med, Dept Pediat, Div Pediat Emergency Med, Philadelphia, PA 19104 USA; [Tunik, Michael G.] NYU, Dept Pediat, Sch Med, New York, NY 10016 USA; [Tunik, Michael G.] NYU, Sch Med, Dept Emergency Med, New York, NY USA; [Foerster, Adele] Holy Cross Hosp, Silver Spring Emergency Phys, Silver Spring, MD USA; [Dong, Lydia; Miskin, Michelle] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Dong, Lydia; Miskin, Michelle] PECARN Data Coordinating Ctr, Salt Lake City, UT USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Morgan Stanley Childrens Hosp, Div Pediat Emergency Med, 630 W 168th St, New York, NY 10032 USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA		Kuppermann, N (corresponding author), Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA.; Kuppermann, N (corresponding author), Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA.	nkuppermann@ucdavis.edu	; Holmes, Jain/K-2125-2016	Tunik, Michael/0000-0002-2368-5933; Holmes, Jain/0000-0003-2465-102X; Powell, Elizabeth/0000-0003-3147-9889	Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Education, and TrainingUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Emergency Medical Services of Children (EMSC) Program [R40MC02461]; HRSAUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); MCHB; EMSC Network Development Demonstration Program [U03MC00008, U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC22684, U03MC22685]	This work was supported by a grant from the Health Resources and Services Administration/Maternal and Child Health Bureau (HRSA/MCHB), Division of Research, Education, and Training, and the Emergency Medical Services of Children (EMSC) Program (R40MC02461). This project was also supported in part by HRSA, MCHB, and the EMSC Network Development Demonstration Program under cooperative agreements U03MC00008, U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC22684, and U03MC22685. The information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government.	Acker SN, 2014, J TRAUMA ACUTE CARE, V77, P304, DOI 10.1097/TA.0000000000000300; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Force Joint Task, 1993, APLS PEDIAT EMERGENC; Fortune PM, 2010, PEDIATR CRIT CARE ME, V11, P339, DOI 10.1097/PCC.0b013e3181c014ab; Gedeit R, 2001, Pediatr Rev, V22, P118, DOI 10.1542/pir.22-4-118; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; JAMES HE, 1986, PEDIATR ANN, V15, P16, DOI 10.3928/0090-4481-19860101-05; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Marcin JP, 2002, CRIT CARE MED, V30, pS457, DOI 10.1097/00003246-200211001-00011; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Riechers RG, 2005, J NEUROTRAUM, V22, P1327, DOI 10.1089/neu.2005.22.1327; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; TEASDALE G, 1974, LANCET, V2, P81; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019	21	29	30	1	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2016	23	8					878	884		10.1111/acem.13014			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	DW1BQ	WOS:000383378200005	27197686	Green Published, Bronze			2022-02-06	
J	Sirajuddin, S; Valdez, C; DePalma, L; Maluso, P; Singhal, R; Schroeder, M; Sarani, B				Sirajuddin, Sarah; Valdez, Carrie; DePalma, Louis; Maluso, Patrick; Singhal, Rishi; Schroeder, Mary; Sarani, Babak			Inhibition of platelet function is common following even minor injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Thrombocytopathy; platelet dysfunction; coagulopathy; trauma; platelet inhibition	TRAUMA PATIENTS; COAGULOPATHY; DYSFUNCTION; THROMBOELASTOGRAPHY; EPIDEMIOLOGY; TRANSFUSION; COAGULATION; PLASMA; IMPACT	BACKGROUND: Hemorrhage remains the leading cause of preventable death following injury. Whereas significant attention has been paid to the coagulation cascade, there are fewer studies evaluating platelet dysfunction following injury. Thrombelastogram platelet mapping (TEG-PM) allows for the measurement of maximal potential clot strength and clot strength selectively caused by arachidonic acid and adenosine disphosphate receptors on the platelet. The purpose of this study was to determine the incidence and magnitude of receptor-specific platelet dysfunction following injury in patients who are not otherwise pharmacologically anticoagulated. METHODS: A retrospective study of adult trauma patients evaluated at a Level I trauma center from August 2013 to September 2014 was conducted. Platelet function was assessed using TEG-PM. Patients on any anticoagulant or antiplatelet medication were excluded. Patients were divided into those with and without radiographically evident traumatic brain injury (TBI). Demographic variables, Injury Severity Score (ISS), injury pattern, laboratory test results, and mortality were abstracted. Statistical comparisons were made using the Student's t test or Mann-Whitney U-test. RESULTS: The study includes 459 patients, 92% following blunt injury. Median ISS was 5. Patients with TBI (n = 102) were significantly older (median age, 54 years vs. 35 years), weremore severely injured (median ISS, 10 vs. 4), had a longer stay and higher mortality (9% vs. 0.3%). Maximal potential clot strength was normal in all cohorts, but the arachidonic acid and adenosine diphosphate pathways were significantly inhibited (30% +/- 26% and 58% +/- 27%, respectively). There was no correlation between TEG-PM values and ISS, length of stay, or mortality. There was no difference in the TBI cohort. There were no significant differences in TEG-PM parameters in those with an ISS greater than 14. There was no significant change in TEG-PM following platelet transfusion. CONCLUSION: Marked platelet inhibition is common following minor injury. Whereas the clinical significance of this finding remains unknown, the results of this study should be factored in the overall resuscitative strategy. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.	[Sirajuddin, Sarah; Valdez, Carrie; Maluso, Patrick; Singhal, Rishi; Schroeder, Mary; Sarani, Babak] George Washington Univ, Ctr Trauma & Crit Care, Washington, DC USA; [DePalma, Louis] George Washington Univ, Dept Surg, Washington, DC USA; [DePalma, Louis] George Washington Univ, Dept Pathol, Washington, DC USA		Sarani, B (corresponding author), 2150 Penn Ave NW,Suite 6B, Washington, DC 20037 USA.	bsarani@mfa.gwu.edu					Basila D, 2005, THROMB RES, V117, P49, DOI 10.1016/j.thromres.2005.04.017; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Castellino FJ, 2014, J TRAUMA ACUTE CARE, V76, P1169, DOI 10.1097/TA.0000000000000216; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Gonzalez E, 2010, J SURG RES, V163, P96, DOI 10.1016/j.jss.2010.03.058; Harrison P, 2005, BLOOD REV, V19, P111, DOI 10.1016/j.blre.2004.05.002; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Inaba K, 2010, J AM COLL SURGEONS, V211, P573, DOI 10.1016/j.jamcollsurg.2010.06.392; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Lindemann S, 2001, J CELL BIOL, V154, P485, DOI 10.1083/jcb.200105058; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Swallow RA, 2006, PLATELETS, V17, P385, DOI 10.1080/09537100600757521; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Zink KA, 2009, AM J SURG, V197, P70; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	21	29	29	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2016	81	2					328	332		10.1097/TA.0000000000001057			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	DS5CE	WOS:000380797300017	27027558				2022-02-06	
J	Liu, LY; Song, HF; Duan, HJ; Chai, JK; Yang, J; Li, X; Yu, YH; Zhang, XL; Hu, XH; Xiao, MJ; Feng, R; Yin, HN; Hu, Q; Yang, LL; Du, JD; Li, TR				Liu, Lingying; Song, Huifeng; Duan, Hongjie; Chai, Jiake; Yang, Jing; Li, Xiao; Yu, Yonghui; Zhang, Xulong; Hu, Xiaohong; Xiao, Mengjing; Feng, Rui; Yin, Huinan; Hu, Quan; Yang, Longlong; Du, Jundong; Li, Tianran			TSG-6 secreted by human umbilical cord-MSCs attenuates severe burn-induced excessive inflammation via inhibiting activations of P38 and JNK signaling	SCIENTIFIC REPORTS			English	Article							MESENCHYMAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; ANTIINFLAMMATORY PROTEIN TSG-6; COLLAGEN-INDUCED ARTHRITIS; BV2 MICROGLIAL CELLS; OXIDATIVE STRESS; IN-VIVO; SYSTEMIC INFLAMMATION; IMMUNE-RESPONSES; DBA/1J MICE	The hMSCs have become a promising approach for inflammation treatment in acute phase. Our previous study has demonstrated that human umbilical cord-MSCs could alleviate the inflammatory reaction of severely burned wound. In this study, we further investigated the potential role and mechanism of the MSCs on severe burn-induced excessive inflammation. Wistar rats were randomly divided into following groups: Sham, Burn, Burn+ MSCs, Burn+ MAPKs inhibitors, and Burn, Burn+ MSCs, Burn+ Vehicle, Burn+ siTSG-6, Burn+ rhTSG-6 in the both experiments. It was found that MSCs could only down-regulate P38 and JNK signaling, but had no effect on ERK in peritoneal macrophages of severe burn rats. Furthermore, suppression of P38 and JNK activations significantly reduced the excessive inflammation induced by severe burn. TSG-6 was secreted by MSCs using different inflammatory mediators. TSG-6 from MSCs and recombinant human (rh) TSG-6 all significantly reduced activations of P38 and JNK signaling induced by severe burn and then attenuated excessive inflammations. On the contrary, knockdown TSG-6 in the cells significantly increased phosphorylation of P38 and JNK signaling and reduced therapeutic effect of the MSCs on excessive inflammation. Taken together, this study suggested TSG-6 from MSCs attenuated severe burn-induced excessive inflammation via inhibiting activation of P38 and JNK signaling.	[Liu, Lingying; Song, Huifeng; Duan, Hongjie; Chai, Jiake; Yang, Jing; Li, Xiao; Yu, Yonghui; Zhang, Xulong; Hu, Xiaohong; Xiao, Mengjing; Feng, Rui; Yin, Huinan; Hu, Quan; Yang, Longlong; Du, Jundong; Li, Tianran] Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Burn & Plast Surg, Beijing, Peoples R China		Chai, JK (corresponding author), Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Dept Burn & Plast Surg, Beijing, Peoples R China.	cjk304@126.com	Yu, Yonghui/AAZ-4093-2021		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81372052, 81501694, 81471873]; Nursery Fund of PLA General Hospital [14KMM22]	This work was supported by four research projects of National Natural Science Foundation of China (81372052), (81501694), (81471873) and the Nursery Fund of PLA General Hospital (14KMM22).	Arno A, 2011, PHARMACEUTICALS, V4, P1355, DOI 10.3390/ph4101355; Bardos T, 2001, AM J PATHOL, V159, P1711, DOI 10.1016/S0002-9440(10)63018-0; Beltran SR, 2015, J PERIODONTOL, V86, P62, DOI 10.1902/jop.2014.140187; Bettaieb A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113019; Chen Xinguang, 2012, J Biom Biostat, VSuppl 1; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Chu Wan-li, 2012, Zhonghua Yi Xue Za Zhi, V92, P853; Chu WH, 2013, J TRAUMA ACUTE CARE, V74, P1446, DOI 10.1097/TA.0b013e31829246ad; Costantini TW, 2009, J SURG RES, V156, P64, DOI 10.1016/j.jss.2009.03.066; Dahiya P, 2009, FRONT BIOSCI, V14, P4962, DOI 10.2741/3580; Eynott PR, 2004, IMMUNOLOGY, V112, P446, DOI 10.1111/j.1365-2567.2004.01887.x; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Gu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep08733; Guo SX, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0548-3; Hatakeyama N, 2014, CURR PHARM DESIGN, V20, P5766, DOI 10.2174/138161282036140912122809; Hocking AM, 2010, EXP CELL RES, V316, P2213, DOI 10.1016/j.yexcr.2010.05.009; Ipaktchi K, 2006, J IMMUNOL, V177, P8065, DOI 10.4049/jimmunol.177.11.8065; Kim DS, 2015, AM J CHINESE MED, V43, P731, DOI 10.1142/S0192415X15500457; Kott M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112323; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee MJ, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-40; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Li BS, 2015, NAT MED, V21, P563, DOI 10.1038/nm.3840; Liu LY, 2013, J TRAUMA ACUTE CARE, V75, P789, DOI 10.1097/TA.0b013e3182a6862b; Liu LY, 2015, INT J CLIN EXP PATHO, V8, P6367; Liu LY, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0088348, 10.1371/journal.pone.0104748]; Liu Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-135; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Milner CM, 2006, BIOCHEM SOC T, V34, P446, DOI 10.1042/BST0340446; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mindrescu C, 2000, ARTHRITIS RHEUM, V43, P2668, DOI 10.1002/1529-0131(200012)43:12<2668::AID-ANR6>3.0.CO;2-E; Nemoto W, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-38; Noone C, 2013, STEM CELLS DEV, V22, P3003, DOI 10.1089/scd.2013.0028; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Qiu JL, 2015, NEUROCHEM INT, V85-86, P46, DOI 10.1016/j.neuint.2015.04.007; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Sheikh AM, 2011, NEUROBIOL DIS, V41, P717, DOI 10.1016/j.nbd.2010.12.009; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Sun T, 2015, AM J TRANSL RES, V7, P891; Sun X, 2015, J ETHNOPHARMACOL, V170, P81, DOI 10.1016/j.jep.2015.05.001; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Wang N, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt142; Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043768; Wang S, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0019-z; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Wisniewski HG, 2004, CYTOKINE GROWTH F R, V15, P129, DOI 10.1016/j.cytogfr.2004.01.005; Xu Jiajun, 2014, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V26, P405, DOI 10.3760/cma.j.issn.2095-4352.2014.06.008; Xue LA, 2013, INT J CLIN EXP PATHO, V6, P1327; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	50	29	30	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 22	2016	6								30121	10.1038/srep30121			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DR6OQ	WOS:000380021600001	27444207	Green Published, gold			2022-02-06	
J	Aligholi, H; Rezayat, SM; Azari, H; Mehr, SE; Akbari, M; Mousavi, SMM; Attari, F; Alipour, F; Hassanzadeh, G; Gorji, A				Aligholi, Hadi; Rezayat, Seyed Mandi; Azari, Hassan; Mehr, Shahram Ejtemaei; Akbari, Mohammad; Mousavi, Seyed Mostafa Modarres; Attari, Fatemeh; Alipour, Fatemeh; Hassanzadeh, Gholamreza; Gorji, Ali			Preparing neural stem/progenitor cells in PuraMatrix hydrogel for transplantation after brain injury in rats: A comparative methodological study	BRAIN RESEARCH			English	Article						Brain injury; Traumatic brain lesion; Autologous transplantation; Nanoscaffold; Neural tissue engineering	SELF-COMPLEMENTARY OLIGOPEPTIDE; PEPTIDE HYDROGEL; STEM-CELLS; SCAFFOLDS; DIFFERENTIATION; DESIGN; MICROENVIRONMENTS; BIOMATERIALS; PH	Cultivation of neural stem/progenitor cells (NS/PCs) in PuraMatrix (PM) hydrogel is an option for stem cell transplantation. The efficacy of a novel method for placing adult rat NS/PCs in PM (injection method) was compared to encapsulation and surface plating approaches. In addition, the efficacy of injection method for transplantation of autologous NS/PCs was studied in a rat model of brain injury. NS/PCs were obtained from the subventricular zone (SVZ) and cultivated without (control) or with scaffold (three-dimensional cultures; 3D). The effect of different approaches on survival, proliferation, and differentiation of NS/PCs were investigated. In in vivo study, brain injury was induced 45 days after NS/PCs were harvested from the SVZ and phosphate buffered saline, PM, NS/PCs, or PM+NS/PCs were injected into the brain lesion. There was an increase in cell viability and proliferation after injection and surface plating of NS/PCs compared to encapsulation and neural differentiation markers were expressed seven days after culturing the cells. Using injection method, transplantation of NS/PCs cultured in PM resulted in significant reduction of lesion volume, improvement of neurological deficits, and enhancement of surviving cells. In addition, the transplanted cells could differentiate in to neurons, astrocytes, or oligodendrocytes. Our results indicate that the injection and surface plating methods enhanced cell survival and proliferation of NS/PCs and suggest the injection method as a promising approach for transplantation of NS/PCs in brain injury. (C) 2016 Elsevier B.V. All rights reserved.	[Aligholi, Hadi; Mousavi, Seyed Mostafa Modarres; Attari, Fatemeh; Alipour, Fatemeh; Gorji, Ali] Khatam al Anbia Hosp, Shefa Neurosci Res Ctr, Tehran, Iran; [Aligholi, Hadi; Attari, Fatemeh] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Neurosci, Tehran, Iran; [Aligholi, Hadi] Shiraz Univ Med Sci, Sch Adv Med Sci & Technol, Dept Neurosci, Shiraz, Iran; [Rezayat, Seyed Mandi; Mehr, Shahram Ejtemaei] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran; [Azari, Hassan] Sch Med, Dept Anat Sci, Neural Stem Cell & Regenerat Neurosci Lab, Shiraz, Iran; [Azari, Hassan] Shiraz Univ Med Sci, Shiraz Stem Cell Inst, Shiraz, Iran; [Akbari, Mohammad; Hassanzadeh, Gholamreza] Univ Tehran Med Sci, Sch Med, Dept Anat, Tehran, Iran; [Gorji, Ali] Mashhad Univ Med Sci, Dept Neurosci, Mashhad, Iran; [Gorji, Ali] Univ Munster, Epilepsy Res Ctr, Dept Neurosurg, D-48149 Munster, Germany; [Gorji, Ali] Univ Munster, Dept Neurol, D-48149 Munster, Germany		Hassanzadeh, G (corresponding author), Univ Tehran Med Sci, Sch Med, Dept Anat, Tehran, Iran.; Gorji, A (corresponding author), Univ Munster, Epilepsy Res Ctr, D-48149 Munster, Germany.	hassanzadeh@tums.ac.ir; gorjial@uni-muenster.de	Azari, Hassan/V-6092-2017; aligholi, hadi/A-1054-2018	Azari, Hassan/0000-0002-8021-3166; aligholi, hadi/0000-0002-2241-5296	Tehran University of Medical Sciences and Health ServicesTehran University of Medical Sciences [11696-87-01-90]; Shefa Neuroscience Research Center [28102]; Iran National Science Foundation (INSF)Iran National Science Foundation (INSF)	We thank Dr. Stjepana Kovac for her critical review of the manuscript. The present study was supported by Tehran University of Medical Sciences and Health Services (Grant no. 11696-87-01-90), Shefa Neuroscience Research Center (Dr. Thesis 28102) and Iran National Science Foundation (INSF).	Aligholi H, 2014, J NEUROSCI METH, V225, P81, DOI 10.1016/j.jneumeth.2013.12.008; Azari Hassan, 2010, J Vis Exp, DOI 10.3791/2393; Azari H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020941; Burdick JA, 2009, TISSUE ENG PT A, V15, P205, DOI 10.1089/ten.tea.2008.0131; Cavalcanti BN, 2013, DENT MATER, V29, P97, DOI 10.1016/j.dental.2012.08.002; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; FREED LE, 1994, BIO-TECHNOL, V12, P689, DOI 10.1038/nbt0794-689; FROEHLICH JE, 1974, J CELL PHYSIOL, V84, P253, DOI 10.1002/jcp.1040840211; Ghadiri T, 2014, J NEUROSCI METH, V233, P18, DOI 10.1016/j.jneumeth.2014.05.035; Guo JS, 2009, NANOMED-NANOTECHNOL, V5, P345, DOI 10.1016/j.nano.2008.12.001; Hauser CAE, 2010, CHEM SOC REV, V39, P2780, DOI 10.1039/b921448h; Langnaese K, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-53; Liedmann A, 2012, BIORESEARCH OPEN ACC, V1, P16, DOI 10.1089/biores.2012.0209; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Moradi F, 2012, J NEUROSCI RES, V90, P2335, DOI 10.1002/jnr.23120; Nava MM, 2012, BIOMED RES INT, V2012; Ortinau S, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-70; Paxinos G, 2006, RAT BRAIN STEREOTAXI; Peinnequin Andre, 2004, BMC Immunology, V5, P1, DOI 10.1186/1471-2172-5-3; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Shivachar AC, 2008, TOPICS TISSUE ENG, V4; Shrode LD, 1997, J BIOENERG BIOMEMBR, V29, P393, DOI 10.1023/A:1022407116339; Takei J., 2006, AATEX, V11, P170, DOI DOI 10.11232/aatex.11.170; Thonhoff JR, 2008, BRAIN RES, V1187, P42, DOI 10.1016/j.brainres.2007.10.046; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang SF, 2001, TISSUE ENG, V7, P679, DOI 10.1089/107632701753337645; Yang SF, 2002, TISSUE ENG, V8, P1, DOI 10.1089/107632702753503009; Zhang S., 2005, SCAFFOLDING TISSUE E, P217; Zhang SG, 2005, SEMIN CANCER BIOL, V15, P413, DOI 10.1016/j.semcancer.2005.05.007; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y	32	29	29	4	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 1	2016	1642						197	208		10.1016/j.brainres.2016.03.043			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DP7EI	WOS:000378661600023	27038753	Bronze			2022-02-06	
J	Murray, CE; Lundgren, K; Olson, LN; Hunnicutt, G				Murray, Christine E.; Lundgren, Kristine; Olson, Loreen N.; Hunnicutt, Gwen			Practice Update: What Professionals Who Are Not Brain Injury Specialists Need to Know About Intimate Partner Violence-Related Traumatic Brain Injury	TRAUMA VIOLENCE & ABUSE			English	Article						traumatic brain injury; intimate partner violence; domestic violence; battering; victimization	BATTERED WOMEN; HEAD-INJURY; HELP-SEEKING; RECOVERY; REHABILITATION; PERFORMANCE; CONCUSSION; OUTCOMES; MODEL; SCALE	There is growing recognition of the risk for traumatic brain injury (TBI) among victims and survivors of intimate partner violence (IPV). A wide range of physically abusive behaviors may lead to injuries to the head or neck and place an individual at risk for a TBI. The purpose of this article is to consolidate current research and present practical guidelines for professionals, who are not brain injury specialists, but work with clients who may have sustained a TBI in the context of IPV. Recommendations are provided for TBI risk screening, making appropriate referrals, and providing services in light of a potential TBI.	[Murray, Christine E.] Univ N Carolina, Dept Counseling & Educ Dev, Greensboro, NC 27412 USA; [Lundgren, Kristine] Univ N Carolina, Dept Commun Sci & Disorders, Greensboro, NC 27412 USA; [Olson, Loreen N.] Univ N Carolina, Dept Commun Studies, Greensboro, NC 27412 USA; [Hunnicutt, Gwen] Univ N Carolina, Sociol & Womens & Gender Studies, Greensboro, NC 27412 USA		Murray, CE (corresponding author), Univ N Carolina, 224A Curry Bldg, Greensboro, NC 27412 USA.	cemurray@uncg.edu	Hunnicutt, Gwen/AAS-1272-2020				Almeida RV, 1999, J MARITAL FAM THER, V25, P313, DOI 10.1111/j.1752-0606.1999.tb00250.x; Arosarena OA, 2009, ARCH FACIAL PLAST S, V11, P48, DOI 10.1001/archfacial.2008.507; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brain Injury Association of America, 2014, AB BRAIN INJ; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Centers for disease control and prevention, 2014, INJ PREV CONTR TRAUM; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Crowe A, 2015, PARTN ABUSE, V6, P157, DOI 10.1891/1946-6560.6.2.157; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Faul M, 2010, EMERGENCY DEP VISITS; Giza CC, 2001, J ATHL TRAINING, V36, P228; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; GRONWALL D, 1975, LANCET, V2, P995; Hoofien D, 2001, BRAIN INJURY, V15, P189; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P434; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Mayo Clinic, 2014, DIS COND TRAUM BRAIN; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mechanic MB, 2008, VIOLENCE AGAINST WOM, V14, P1148, DOI 10.1177/1077801208323792; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Murray CE, 2013, RESPONDING TO FAMILY VIOLENCE: A COMPREHENSIVE, RESEARCH-BASED GUIDE FOR THERAPISTS, P1; Murray CE, 2015, J FAM VIOLENCE, V30, P381, DOI 10.1007/s10896-015-9674-1; Novack TA, 2000, BRAIN INJURY, V14, P987; Overstreet NM, 2013, BASIC APPL SOC PSYCH, V35, P109, DOI 10.1080/01973533.2012.746599; Picard M., 1991, HELPS; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Roberts AR, 2005, J SOC SERV RES, V32, P33, DOI 10.1300/J079v32n01_03; Ruff RM, 1999, BRAIN INJURY, V13, P943; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Tanielian T., 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Tinius TP, 2003, ARCH CLIN NEUROPSYCH, V18, P439, DOI 10.1016/S0887-6177(02)00144-0; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wenner K., 2012, NY TIMES; Wong JYH, 2014, TRAUMA VIOLENCE ABUS, V15, P22, DOI 10.1177/1524838013496333	51	29	30	1	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1524-8380	1552-8324		TRAUMA VIOLENCE ABUS	Trauma Violence Abus.	JUL	2016	17	3					298	305		10.1177/1524838015584364			8	Criminology & Penology; Family Studies; Social Work	Social Science Citation Index (SSCI)	Criminology & Penology; Family Studies; Social Work	DN5HP	WOS:000377097500005	25951838				2022-02-06	
J	Sawyer, TW; Wang, YS; Ritzel, DV; Josey, T; Villanueva, M; Shei, YM; Nelson, P; Hennes, G; Weiss, T; Vair, C; Fan, CY; Barnes, J				Sawyer, Thomas W.; Wang, Yushan; Ritzel, David V.; Josey, Tyson; Villanueva, Mercy; Shei, Yimin; Nelson, Peggy; Hennes, Grant; Weiss, Tracy; Vair, Cory; Fan, Changyang; Barnes, Julia			High-Fidelity Simulation of Primary Blast: Direct Effects on the Head	JOURNAL OF NEUROTRAUMA			English	Article						blast; glial fibrillary acidic protein (GFAP); primary blast-induced traumatic brain injury (PbTBI); shockwaves; traumatic brain injury (TBI)	TRAUMATIC BRAIN-INJURY; TIME-DEPENDENT CHANGES; BIOMARKER LEVELS; MOUSE MODEL; EXPOSURE; RAT; OVERPRESSURE; MECHANISM; PATHOLOGY; PROTEIN	The role of primary blast in blast-induced traumatic brain injury (bTBI) is controversial in part due to the technical difficulties of generating free-field blast conditions in the laboratory. The use of traditional shock tubes often results in artifacts, particularly of dynamic pressure, whereas the forces affecting the head are dependent on where the animal is placed relative to the tube, whether the exposure is whole-body or head-only, and on how the head is actually exposed to the insult (restrained or not). An advanced blast simulator (ABS) has been developed that enables high-fidelity simulation of free-field blastwaves, including sharply defined static and dynamic overpressure rise times, underpressures, and secondary shockwaves. Rats were exposed in head-only fashion to single-pulse blastwaves of 15 to 30 psi static overpressure. Head restraints were configured so as to eliminate concussive and minimize whiplash forces exerted on the head, as shown by kinematic analysis. No overt signs of trauma were present in the animals post-exposure. However, significant changes in brain 2',3'-cyclic nucleotide 3'-phosphohydrolase (CNPase) and neurofilament heavy chain levels were evident by 7 days. In contrast to most studies of primary blast-induced TBI (PbTBI), no elevation of glial fibrillary acidic protein (GFAP) levels was noted when head movement was minimized The ABS described in this article enables the generation of shockwaves highly representative of free-field blast. The use of this technology, in concert with head-only exposure, minimized head movement, and the kinematic analysis of the forces exerted on the head provide convincing evidence that primary blast directly causes changes in brain function and that GFAP may not be an appropriate biomarker of PbTBI.	[Sawyer, Thomas W.; Wang, Yushan; Josey, Tyson; Villanueva, Mercy; Shei, Yimin; Nelson, Peggy; Hennes, Grant; Weiss, Tracy; Vair, Cory] Def Res & Dev Canada, Medicine Hat, AB T1A 8K6, Canada; [Ritzel, David V.] Dyn Fx Consulting Ltd, Amherstburg, ON, Canada; [Fan, Changyang; Barnes, Julia] Canada West Biosci, Calgary, AB, Canada		Sawyer, TW (corresponding author), Def Res & Dev Canada, Suffield Res Ctr, Box 4000, Medicine Hat, AB T1A 8K6, Canada.	Thomas.sawyer@drdc-rddc.gc.ca					Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Appelboom G, 2012, ACTA NEUROCHIR, V154, P131, DOI 10.1007/s00701-011-1210-3; Argyros GJ, 1997, TOXICOLOGY, V121, P105, DOI 10.1016/S0300-483X(97)03659-7; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Bass R. C., 2006, P PERS ARM SYST S, P233; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Bowen I., 1968, ESTIMATE TOLERANCE D; Cernak I, 2010, MED DATA REV, V2, P297; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chandra N, 2012, SHOCK WAVES, V22, P403, DOI 10.1007/s00193-012-0399-2; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen Y, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00117; CLEMEDSON CJ, 1956, ACTA PHYSIOL SCAND, V37, P202; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Courtney MW, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3518970; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; DREILING CE, 1980, ANAL BIOCHEM, V102, P304, DOI 10.1016/0003-2697(80)90157-8; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guy R J, 2000, J R Nav Med Serv, V86, P27; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mott FW, 1916, LANCET, V1, P331; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Ritzel D. V., 2011, 207 NATO HFM; Romba J., 1961, PROPAGATION AIR SHOC, P17; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Shridharani Jay K, 2012, Front Neurol, V3, P70, DOI 10.3389/fneur.2012.00070; Simard JM, 2014, J NEUROTRAUM, V31, P1292, DOI 10.1089/neu.2013.3016; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Yuan AD, 2012, J CELL SCI, V125, P3257, DOI 10.1242/jcs.104729	66	29	29	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1181	1193		10.1089/neu.2015.3914			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200384	26582146				2022-02-06	
J	Baum, J; Entezami, P; Shah, K; Medhkour, A				Baum, Justin; Entezami, Pouya; Shah, Kavit; Medhkour, Azedine			Predictors of Outcomes in Traumatic Brain Injury	WORLD NEUROSURGERY			English	Article						Outcomes; Traumatic brain injury	ACUTE LUNG INJURY; MULTIPLE-ORGAN FAILURE; RESPIRATORY-DISTRESS-SYNDROME; GLASGOW COMA SCALE; CONCOMITANT INJURIES; HEAD-INJURY; EXTRACRANIAL INJURIES; MAJOR CAUSE; MORTALITY; IMPACT	INTRODUCTION: The purpose of this study was to retrospectively evaluate patients treated for traumatic brain injuries (TBI) to determine how multiple organ trauma (MOT) and lung injuries sustained at the time of initial injury affect outcome. METHODS: A single institution retrospective review of all patients diagnosed with TBI at a level I trauma center from 2000 to 2014 was conducted. Clinical outcome was based on Glasgow Outcome Scale at hospital discharge. Lung injury was defined as the presence of pulmonary contusions, pneumothorax, hemothorax, rib fractures, or diaphragmatic rupture proven by x-ray or computed tomography scan. MOT was defined as trauma to one body region with an Abbreviated Injury Scale (AIS) score >= 3 plus trauma to 2 additional body regions with AIS scores > 1. Regression analysis was conducted with SPSS 21. RESULTS: There were 409 patients reviewed. The majority of patients were male (73%), average age was 46 years (range, 16-94 years), average Glasgow Coma Scale (GCS) score was 7, and 71% had a severe TBI (GCS <= 8). Thirty percent of patients had poor outcome (Glasgow Outcome Scale = 1-2) Regression analysis indicated age (odds ratio [OR] 1.03, P < 0.001), initial GCS (OR 0.88, P < 0.001), Injury Severity Score (OR 1.03, P = 0.021), and head AIS >= 5 (OR 0.55, P = 0.019) were significant independent predictors of poor outcome. Sex, MOT, lung injury, and lung injury severity were not significant predictors of outcome. CONCLUSIONS: Age, GCS, Injury Severity Score, and critical head injuries (AIS >= 5) were significant tools in predicting outcome in this patient cohort. MOT and traumatic lung injury may cause significant damage to a patient suffering from a severe TBI, but these injuries do not predict mortality in this patient population.	[Baum, Justin; Entezami, Pouya; Shah, Kavit; Medhkour, Azedine] Univ Toledo, Med Ctr, Div Neurosurg, 2801 W Bancroft St, Toledo, OH 43606 USA		Medhkour, A (corresponding author), Univ Toledo, Med Ctr, Div Neurosurg, 2801 W Bancroft St, Toledo, OH 43606 USA.	Azedine.Medhkour@utoledo.edu	Shah, Kavit/ABC-6493-2020	Shah, Kavit/0000-0001-8378-8224			Andruszkow H, 2013, CLIN ORTHOP RELAT R, V471, P2899, DOI 10.1007/s11999-013-3031-6; Arbabi S, 2014, J TRAUMA ACUTE CARE, V76, P927; Asilioglu N, 2011, J PEDIAT-BRAZIL, V87, P325, DOI [10.1590/S0021-75572011000400009, 10.2223/JPED.2097]; Baker CC, 2001, J TRAUMA, V51, P841; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Brazinova A, 2010, J NEUROTRAUM, V27, P1549, DOI 10.1089/neu.2010.1315; Faul M, 2010, TRAUMATIC BRAIN INJU; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Frohlich M, 2014, J TRAUMA ACUTE CARE, V76, P921, DOI 10.1097/TA.0000000000000199; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Johnson ER, 2010, J AEROSOL MED PULM D, V23, P243, DOI 10.1089/jamp.2009.0775; Kemp CD, 2008, AM SURGEON, V74, P866; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Leitgeb J, 2013, ARCH ORTHOP TRAUM SU, V133, P659, DOI 10.1007/s00402-013-1710-0; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Leong BK, 2013, DISABIL REHABIL, V35, P1546, DOI 10.3109/09638288.2012.748832; Li N, 2011, NEUROCRIT CARE, V14, P377, DOI 10.1007/s12028-011-9511-1; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Matthay MA, 2005, AM J RESP CELL MOL, V33, P319, DOI 10.1165/rcmb.F305; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Nast-Kolb D, 2001, J TRAUMA, V51, P835, DOI 10.1097/00005373-200111000-00003; Nayak NV, 2013, J TRAUMA ACUTE CARE, V75, P273, DOI 10.1097/TA.0b013e3182905eb4; Oddo M, 2010, NEUROSURGERY, V67, P338, DOI 10.1227/01.NEU.0000371979.48809.D9; Oliveira RARA, 2012, ARQ NEURO-PSIQUIAT, V70, P604, DOI 10.1590/S0004-282X2012000800009; Orliaguet C, 2000, ANN FR ANESTH, V19, P164; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perl M, 2011, EXPERT REV RESP MED, V5, P115, DOI 10.1586/ERS.10.92; Raj R, 2014, CRIT CARE, V18, DOI 10.1186/cc13814; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Sharma S, 2013, J TRAUMA ACUTE CARE, V74, P890, DOI 10.1097/TA.0b013e3182827253; Stewart TC, 2013, J TRAUMA ACUTE CARE, V75, P836, DOI 10.1097/TA.0b013e3182a685b0; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; TEASDALE G, 1974, LANCET, V2, P81; Valle EJ, 2014, J TRAUMA ACUTE CARE, V77, P243, DOI 10.1097/TA.0000000000000307; Vavilala MS, 2014, CRIT CARE MED, V42, P2258, DOI 10.1097/CCM.0000000000000507; Ward PA, 1999, ARCH SURG-CHICAGO, V134, P666, DOI 10.1001/archsurg.134.6.666; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007	47	29	29	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2016	90						525	529		10.1016/j.wneu.2015.12.012			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DS1MS	WOS:000380360500066	26721615				2022-02-06	
J	Delbary-Gossart, S; Lee, S; Baroni, M; Lamarche, I; Arnone, M; Canolle, B; Lin, A; Sacramento, J; Salegio, EA; Castel, MN; Delesque-Touchard, N; Alam, A; Laboudie, P; Ferzaz, B; Savi, P; Herbert, JM; Manley, GT; Ferguson, AR; Bresnahan, JC; Bono, F; Beattie, MS				Delbary-Gossart, Sandrine; Lee, Sangmi; Baroni, Marco; Lamarche, Isabelle; Arnone, Michele; Canolle, Benoit; Lin, Amity; Sacramento, Jeffrey; Salegio, Ernesto A.; Castel, Marie-Noelle; Delesque-Touchard, Nathalie; Alam, Antoine; Laboudie, Patricia; Ferzaz, Badia; Savi, Pierre; Herbert, Jean-Marc; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Bono, Francoise; Beattie, Michael S.			A novel inhibitor of p75-neurotrophin receptor improves functional outcomes in two models of traumatic brain injury	BRAIN			English	Article						p75NTR; TBI; EVT901; neuron; oligodendrocyte	P75 NEUROTROPHIN RECEPTOR; SPINAL-CORD-INJURY; CELL-DEATH; IN-VITRO; P75(NTR); LIGAND; APOPTOSIS; DOMAIN; OLIGODENDROCYTES; RECOVERY	The p75 neurotrophin receptor (p75NTR) is a member of the TNF-receptor superfamily. Delbary-Gossart, Lee et al. describe the neuroprotective effects of a novel piperizine derivative that blocks p75NTR. In two rodent models of traumatic brain injury, EVT901 protects neurons and glia, reduces inflammation and seizure susceptibility, and improves neurological outcomes.The p75 neurotrophin receptor (p75NTR) is a member of the TNF-receptor superfamily. Delbary-Gossart, Lee et al. describe the neuroprotective effects of a novel piperizine derivative that blocks p75NTR. In two rodent models of traumatic brain injury, EVT901 protects neurons and glia, reduces inflammation and seizure susceptibility, and improves neurological outcomes.The p75 neurotrophin receptor is important in multiple physiological actions including neuronal survival and neurite outgrowth during development, and after central nervous system injury. We have discovered a novel piperazine-derived compound, EVT901, which interferes with p75 neurotrophin receptor oligomerization through direct interaction with the first cysteine-rich domain of the extracellular region. Using ligand binding assays with cysteine-rich domains-fused p75 neurotrophin receptor, we confirmed that EVT901 interferes with oligomerization of full-length p75 neurotrophin receptor in a dose-dependent manner. Here we report that EVT901 reduces binding of pro-nerve growth factor to p75 neurotrophin receptor, blocks pro-nerve growth factor induced apoptosis in cells expressing p75 neurotrophin receptor, and enhances neurite outgrowth in vitro. Furthermore, we demonstrate that EVT901 abrogates p75 neurotrophin receptor signalling by other ligands, such as prion peptide and amyloid-beta. To test the efficacy of EVT901 in vivo, we evaluated the outcome in two models of traumatic brain injury. We generated controlled cortical impacts in adult rats. Using unbiased stereological analysis, we found that EVT901 delivered intravenously daily for 1 week after injury, reduced lesion size, protected cortical neurons and oligodendrocytes, and had a positive effect on neurological function. After lateral fluid percussion injury in adult rats, oral treatment with EVT901 reduced neuronal death in the hippocampus and thalamus, reduced long-term cognitive deficits, and reduced the occurrence of post-traumatic seizure activity. Together, these studies provide a new reagent for altering p75 neurotrophin receptor actions after injury and suggest that EVT901 may be useful in treatment of central nervous system trauma and other neurological disorders where p75 neurotrophin receptor signalling is affected.	[Delbary-Gossart, Sandrine; Bono, Francoise] Evotec, 195 Route Espagne, F-31036 Toulouse, France; [Lee, Sangmi; Lin, Amity; Sacramento, Jeffrey; Salegio, Ernesto A.; Manley, Geoffrey T.; Ferguson, Adam R.; Bresnahan, Jacqueline C.; Beattie, Michael S.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, 1001 Potrero Ave, San Francisco, CA 94110 USA; [Baroni, Marco] Sanofi Rech, Exploratory Unit, Via Gaetano Sbodio 2, I-20134 Milan, Italy; [Lamarche, Isabelle; Arnone, Michele; Canolle, Benoit; Castel, Marie-Noelle; Delesque-Touchard, Nathalie; Alam, Antoine; Laboudie, Patricia; Ferzaz, Badia; Savi, Pierre; Herbert, Jean-Marc] Sanofi Rech, 195 Route Espagne, F-31036 Toulouse, France		Beattie, MS (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, Box 0899,1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94143 USA.	Michael.Beattie@ucsf.edu	Beattie, Michael S/A-8953-2009	Ferguson, Adam/0000-0001-7102-1608	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038079]; UCSF/BASIC; Sanofi R and D; UCSF; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067092, R01NS038079] Funding Source: NIH RePORTER	This work was supported by NIH NS038079, with statistical support from NIH NS067092, UCSF/BASIC pilot funds, and a sponsored research agreement (SRA) between Sanofi R and D and UCSF.	Anastasia A, 2015, J NEUROSCI, V35, P11911, DOI 10.1523/JNEUROSCI.0591-15.2015; BALDWIN AN, 1995, J BIOL CHEM, V270, P4594, DOI 10.1074/jbc.270.9.4594; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bunone G, 1997, ONCOGENE, V14, P1463, DOI 10.1038/sj.onc.1200972; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chan FKM, 2007, CYTOKINE, V37, P101, DOI 10.1016/j.cyto.2007.03.005; Covolan L, 2000, EPILEPSY RES, V39, P133, DOI 10.1016/S0920-1211(99)00119-9; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Deinhardt K, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002060; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Deng GM, 2005, NAT MED, V11, P1066, DOI 10.1038/nm1304; Diarra Adama, 2009, Biochem Biophys Res Commun, V390, P352, DOI 10.1016/j.bbrc.2009.09.116; Domeniconi M, 2007, MOL CELL NEUROSCI, V34, P271, DOI 10.1016/j.mcn.2006.11.005; Gentry JJ, 2004, PROG BRAIN RES, V146, P25, DOI 10.1016/S0079-6123(03)46002-0; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Inoue T, 2013, EXP NEUROL, V248, P136, DOI 10.1016/j.expneurol.2013.06.006; Langevin C, 2002, J BIOL CHEM, V277, P37655, DOI 10.1074/jbc.M201374200; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Miller BA, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-28; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Nykjaer A, 2005, CURR OPIN NEUROBIOL, V15, P49, DOI 10.1016/j.conb.2005.01.004; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Routbort MJ, 1999, NEUROSCIENCE, V94, P755, DOI 10.1016/S0306-4522(99)00358-9; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; Schor NF, 2005, PROG NEUROBIOL, V77, P201, DOI 10.1016/j.pneurobio.2005.10.006; Sebastiani A, 2015, J NEUROTRAUM, V32, P1599, DOI 10.1089/neu.2014.3751; Shi J, 2013, STEM CELLS, V31, P2561, DOI 10.1002/stem.1516; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Sun F, 2010, GLIA, V58, P1304, DOI 10.1002/glia.21009; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Turner BJ, 2004, J NEUROSCI RES, V78, P193, DOI 10.1002/jnr.20256; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Veiga S, 2011, NEUROSCI LETT, V503, P10, DOI 10.1016/j.neulet.2011.07.053; Vilar M, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001918; Vilar M, 2009, NEURON, V62, P72, DOI 10.1016/j.neuron.2009.02.020; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; Wang JJL, 2000, J NEUROSCI RES, V60, P587, DOI 10.1002/(SICI)1097-4547(20000601)60:5<587::AID-JNR3>3.0.CO;2-1; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yang JM, 2014, CELL REP, V7, P796, DOI 10.1016/j.celrep.2014.03.040; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Zhang HQ, 2011, J NEUROSCI, V31, P15894, DOI 10.1523/JNEUROSCI.3943-11.2011; Zhao YY, 2011, ACTA NEUROBIOL EXP, V71, P322	45	29	32	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUN	2016	139		6				1762	1782		10.1093/brain/aww074			21	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DN9WA	WOS:000377430200023	27084575	hybrid, Green Published			2022-02-06	
J	Williams, JA; Bartoshuk, LM; Fillingim, RB; Dotson, CD				Williams, Johnny A.; Bartoshuk, Linda M.; Fillingim, Roger B.; Dotson, Cedrick D.			Exploring Ethnic Differences in Taste Perception	CHEMICAL SENSES			English	Article						epidemiology; gustation; methods; psychophysics; sex differences; spatial testing	TRAUMATIC BRAIN-INJURY; CHORDA TYMPANI NERVE; BITTER-TASTE; FOOD PREFERENCES; 6-N-PROPYLTHIOURACIL PROP; INTENSITY PERCEPTION; GENETIC SENSITIVITY; GUSTATORY FUNCTION; NUTRITIONAL-STATUS; INSULIN-RELEASE	It is well known that nutritional intake can vary substantially as a function of demographic variables such as ethnicity and/or sex. Although a variety of factors are known to underlie the relationship between these demographic variables and nutritional intake, it is interesting to speculate that variation in food intake associated with ethnicity or sex may result, in part, from differences in the perceived taste of foods in these different populations. Thus, we initiated a study to evaluate taste responsiveness in different ethnic groups. Moreover, because of the known differences in taste responsiveness between males and females, analyses were stratified by sex. The ethnic groups tested differed significantly from one another in reported perceived taste intensity. Our results showed that Hispanics and African Americans rated taste sensations higher than non-Hispanic Whites and that these differences were more pronounced in males. Understanding the nature of these differences in taste perception is important, because taste perception may contribute to dietary health risk. When attempting to modify diet, individuals of different ethnicities may require personalized interventions that take into account the different sensory experience that these individuals may have when consuming foods.	[Williams, Johnny A.] Univ Florida, Coll Dent, Gainesville, FL 32610 USA; [Bartoshuk, Linda M.] Univ Florida, Inst Food & Agr Sci, Dept Food Sci & Human Nutr, Gainesville, FL 32610 USA; [Bartoshuk, Linda M.; Dotson, Cedrick D.] Univ Florida, Ctr Smell & Taste, Gainesville, FL 32611 USA; [Fillingim, Roger B.] Univ Florida, Coll Dent, Dept Community Dent & Behav Sci, Gainesville, FL 32610 USA; [Dotson, Cedrick D.] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32611 USA; [Dotson, Cedrick D.] Univ Florida, Coll Med, Dept Psychiat, Div Addict Med, Gainesville, FL 32611 USA		Dotson, CD (corresponding author), Univ Florida, Dept Neurosci, McKnight Brain Inst, 1149 Newell Dr,Box 100244, Gainesville, FL 32611 USA.	c.dotson@mbi.ufl.edu	Fillingim, Roger/K-3569-2019	Dotson, Cedrick/0000-0003-0992-1191; Fillingim, Roger/0000-0002-7699-8183	National Institute of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DC283, P30DC010763, R01NS042754]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000283, P30DC010763] Funding Source: NIH RePORTER	This work was supported by National Institute of Health (NIH) [R01DC283, P30DC010763 and R01NS042754].	Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Ahne G, 2000, LARYNGOSCOPE, V110, P1396, DOI 10.1097/00005537-200008000-00033; Bartoshuk LM, 2006, PHILOS T R SOC B, V361, P1137, DOI 10.1098/rstb.2006.1853; Bartoshuk LM, 2012, PHYSIOL BEHAV, V107, P516, DOI 10.1016/j.physbeh.2012.06.013; BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1; Bartoshuk LM, 2005, CHEM SENSES, V30, pI218, DOI 10.1093/chemse/bjh192; Bartoshuk LM, 2005, CURR DIR PSYCHOL SCI, V14, P122, DOI 10.1111/j.0963-7214.2005.00346.x; Bartoshuk LM, 2004, PHYSIOL BEHAV, V82, P109, DOI 10.1016/j.physbeh.2004.02.033; BERNSTEIN IL, 1980, PHYSIOL BEHAV, V24, P529, DOI 10.1016/0031-9384(80)90247-4; BERTHOUD HR, 1980, AM J PHYSIOL, V238, pE336, DOI 10.1152/ajpendo.1980.238.4.E336; Bertoli S, 2014, WORLD J DIABETES, V5, P717, DOI 10.4239/wjd.v5.i5.717; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Choi SE, 2014, J ACAD NUTR DIET, V114, P938, DOI 10.1016/j.jand.2013.11.015; Coldwell SE, 2013, NEUROLOGY, V80, pS20, DOI 10.1212/WNL.0b013e3182872e38; Coronado VG, 2012, BRAIN INJURY MED PRI, P91; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daradkeh Ghazi, 2014, Pak J Biol Sci, V17, P1089, DOI 10.3923/pjbs.2014.1089.1097; Dinehart ME, 2006, PHYSIOL BEHAV, V87, P304, DOI 10.1016/j.physbeh.2005.10.018; Drewnowski A, 1997, AM J CLIN NUTR, V66, P391, DOI 10.1093/ajcn/66.2.391; Drewnowski A, 1998, ANN NY ACAD SCI, V855, P797, DOI 10.1111/j.1749-6632.1998.tb10661.x; DREWNOWSKI A, 1985, PHYSIOL BEHAV, V35, P617, DOI 10.1016/0031-9384(85)90150-7; Drewnowski A, 2000, J AM DIET ASSOC, V100, P191, DOI 10.1016/S0002-8223(00)00061-4; Drewnowski A, 2007, J AM DIET ASSOC, V107, P1340, DOI 10.1016/j.jada.2007.05.013; Drewnowski A, 1999, PUBLIC HEALTH NUTR, V2, P513, DOI 10.1017/S1368980099000695; Duffy VB, 2004, APPETITE, V43, P5, DOI 10.1016/j.appet.2004.02.007; Finsterer J, 2015, J NEUROSCI RURAL PRA, V6, P377, DOI 10.4103/0976-3147.158768; Fischer ME, 2014, J ACAD NUTR DIET, V114, P1195, DOI 10.1016/j.jand.2014.04.013; FISCHER R, 1961, NATURE, V191, P1328, DOI 10.1038/1911328a0; Fox AL, 1932, P NATL ACAD SCI USA, V18, P115, DOI 10.1073/pnas.18.1.115; FRIJTERS JER, 1982, J GEN PSYCHOL, V107, P233, DOI 10.1080/00221309.1982.9709931; Gemousakakis T, 2011, J INTEGR NEUROSCI, V10, P537, DOI 10.1142/S0219635211002828; GLANVILL.EV, 1965, NATURE, V205, P851, DOI 10.1038/205851a0; Goldstein GL, 2005, OBES RES, V13, P1017, DOI 10.1038/oby.2005.119; GREEN BG, 1993, CHEM SENSES, V18, P683, DOI 10.1093/chemse/18.6.683; GRINKER J, 1978, AM J CLIN NUTR, V31, P1078, DOI 10.1093/ajcn/31.6.1078; Gudziol H, 2007, ACTA OTO-LARYNGOL, V127, P658, DOI 10.1080/00016480600951491; Haase L, 2011, APPETITE, V57, P421, DOI 10.1016/j.appet.2011.06.009; Habib SS, 2015, JCPSP-J COLL PHYSICI, V25, pS132, DOI 10.2015/JCPSP.S132133; JERZSALATTA M, 1990, APPETITE, V15, P127, DOI 10.1016/0195-6663(90)90045-A; Kalva JJ, 2014, J FOOD SCI, V79, pS238, DOI [10.1111/1750-3841.1, 10.1111/1750-3841.12342]; Kaminski LC, 2000, PHYSIOL BEHAV, V68, P691, DOI 10.1016/S0031-9384(99)00240-1; Keast RSJ, 2014, APPETITE, V80, P1, DOI 10.1016/j.appet.2014.04.022; Kim UK, 2003, SCIENCE, V299, P1221, DOI 10.1126/science.1080190; Kokrashvili Z, 2009, CHEM SENSES, V34, pA77; Kumanyika SK, 2008, PHYSIOL BEHAV, V94, P61, DOI 10.1016/j.physbeh.2007.11.019; Landis BN, 2006, ADV OTO-RHINO-LARYNG, V63, P242, DOI 10.1159/000093763; Landis BN, 2009, J NEUROL, V256, P242, DOI 10.1007/s00415-009-0088-y; LEHMAN CD, 1995, PHYSIOL BEHAV, V57, P943, DOI 10.1016/0031-9384(95)91121-R; Marks LE, 2012, PHYSIOL BEHAV, V105, P443, DOI 10.1016/j.physbeh.2011.08.039; MATTES R, 1989, J AM DIET ASSOC, V89, P692; Mennella JA, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-60; Meyerhof W, 2010, CHEM SENSES, V35, P157, DOI 10.1093/chemse/bjp092; Moser RP, 2005, J NUTR EDUC BEHAV, V37, P306, DOI 10.1016/S1499-4046(06)60161-9; Nahab F, 2011, NEUROLOGY, V76, P154, DOI 10.1212/WNL.0b013e3182061afb; NIEWIND A, 1988, NUTR RES, V8, P13, DOI 10.1016/S0271-5317(88)80083-6; Penniston KL, 2008, J ENDOUROL, V22, P567, DOI 10.1089/end.2007.0304; Pingel J, 2010, EUR ARCH OTO-RHINO-L, V267, P1911, DOI 10.1007/s00405-010-1276-1; Rankin KM, 2000, CHEM SENSES, V25, P747, DOI 10.1093/chemse/25.6.747; RANKIN KM, 1992, PERCEPT PSYCHOPHYS, V52, P479, DOI 10.3758/BF03206709; Reifsnider E, 2008, J SPEC PEDIATR NURS, V13, P154, DOI 10.1111/j.1744-6155.2008.00150.x; Reineccius G, 1994, SOURCE BOOK FLAVORS, P626; Salbe AD, 2004, AM J CLIN NUTR, V79, P372; Skrandies W, 2015, PHYSIOL BEHAV, V142, P1, DOI 10.1016/j.physbeh.2015.01.024; Teff KL, 2010, PHYSIOL BEHAV, V99, P317, DOI 10.1016/j.physbeh.2009.11.009; TEFF KL, 1995, PHYSIOL BEHAV, V57, P1089, DOI 10.1016/0031-9384(94)00373-D; Tepper BJ, 2008, OBESITY, V16, P2289, DOI 10.1038/oby.2008.357; Tepper BJ, 2009, INT J FOOD SCI NUTR, V60, P35, DOI 10.1080/09637480802304499; Tepper BJ, 2002, PHYSIOL BEHAV, V75, P305, DOI 10.1016/S0031-9384(01)00664-3; Tepper BJ, 1999, APPETITE, V32, P422, DOI 10.1006/appe.1999.0240; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tonkin AM, 2010, CIRCULATION, V122, P850, DOI 10.1161/CIRCULATIONAHA.110.960112; Wang JC, 2007, ALCOHOL CLIN EXP RES, V31, P209, DOI 10.1111/j.1530-0277.2006.00297.x; WOODS SC, 1980, PHYSIOL BEHAV, V24, P485, DOI 10.1016/0031-9384(80)90241-3; Yackinous CA, 2002, APPETITE, V38, P201, DOI 10.1006/appe.2001.0481; Yanagisawa K, 1998, PHYSIOL BEHAV, V63, P329, DOI 10.1016/S0031-9384(97)00423-X	75	29	29	4	27	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0379-864X	1464-3553		CHEM SENSES	Chem. Senses	JUN	2016	41	5					449	456		10.1093/chemse/bjw021			8	Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology	DR2MU	WOS:000379739400008	26994473	Bronze, Green Published			2022-02-06	
J	Hilz, MJ; Liu, M; Koehn, J; Wang, RH; Ammon, F; Flanagan, SR; Hosl, KM				Hilz, Max J.; Liu, Mao; Koehn, Julia; Wang, Ruihao; Ammon, Fabian; Flanagan, Steven R.; Hoesl, Katharina M.			Valsalva maneuver unveils central baroreflex dysfunction with altered blood pressure control in persons with a history of mild traumatic brain injury	BMC NEUROLOGY			English	Article						Mild traumatic brain injury; Central autonomic network; Valsalva maneuver; Blood pressure overshoot; Sympathetic dysregulation; Baroreflex dysfunction	HEART-RATE-VARIABILITY; REGRESSIVE SPECTRAL-ANALYSIS; BARORECEPTOR SENSITIVITY; AUTONOMIC DYSFUNCTION; HYPERTENSIVE PATIENTS; FREQUENCY-DOMAIN; PROGNOSTIC VALUE; MORTALITY; DEATH; ADULTS	Background: Patients with a history of mild TBI (post-mTBI-patients) have an unexplained increase in long-term mortality which might be related to central autonomic dysregulation (CAD). We investigated whether standardized baroreflex-loading, induced by a Valsalva maneuver (VM), unveils CAD in otherwise healthy post-mTBI-patients. Methods: In 29 healthy persons (31.3 +/- 12.2 years; 9 women) and 25 post-mTBI-patients (35.0 +/- 13.2 years, 7 women, 4-98 months post-injury), we monitored respiration (RESP), RR-intervals (RRI) and systolic blood pressure (BP) at rest and during three VMs. At rest, we calculated parameters of total autonomic modulation [RRI-coefficient-of-variation (CV), RRI-standard-deviation (RRI-SD), RRI-total-powers], of sympathetic [RRI-low-frequency-powers (LF), BP-LF-powers] and parasympathetic modulation [square-root-of-mean-squared-differences-of-successive-RRIs (RMSSD), RRI-high-frequency-powers (HF)], the index of sympatho-vagal balance (RRI LF/HF-ratios), and baroreflex sensitivity (BRS). We calculated Valsalva-ratios (VR) and times from lowest to highest RRIs after strain (VR-time) as indices of parasympathetic activation, intervals from highest systolic BP-values after strain-release to the time when systolic BP had fallen by 90 % of the differences between peak-phase-IV-BP and baseline-BP (90 %-BP-normalization-times), and velocities of BP-normalization (90 %-BP-normalization-velocities) as indices of sympathetic withdrawal. We compared patient-and control-parameters before and during VM (Mann-Whitney-U-tests or t-tests; significance: P < 0.05). Results: At rest, RRI-CVs, RRI-SDs, RRI-total-powers, RRI-LF-powers, BP-LF-powers, RRI-RMSSDs, RRI-HF-powers, and BRS were lower in patients than controls. During VMs, 90 %-BP-normalization-times were longer, and 90 %-BP-normalization-velocities were lower in patients than controls (P < 0.05). Conclusions: Reduced autonomic modulation at rest and delayed BP-decrease after VM-induced baroreflex-loading indicate subtle CAD with altered baroreflex adjustment to challenge. More severe autonomic challenge might trigger more prominent cardiovascular dysregulation and thus contribute to increased mortality risk in post-mTBI-patients.	[Hilz, Max J.; Liu, Mao; Koehn, Julia; Wang, Ruihao; Ammon, Fabian] Univ Erlangen Nurnberg, Dept Neurol, Schwabachanlage 6, D-91054 Erlangen, Germany; [Flanagan, Steven R.] NYU, Dept Rehabil Med, Sch Med, 240 East 38th St, New York, NY 10016 USA; [Hoesl, Katharina M.] Paracelsus Med Univ Nuremberg, Dept Psychiat & Psychotherapy, Prof Ernst Nathan Str 1, D-90419 Nurnberg, Germany		Hilz, MJ (corresponding author), Univ Erlangen Nurnberg, Dept Neurol, Schwabachanlage 6, D-91054 Erlangen, Germany.	max.hilz@uk-erlangen.de	Liu, Mao/AAI-1391-2019	Liu, Mao/0000-0002-1948-0337; Flanagan, Steven/0000-0001-9005-5897; Wang, Ruihao/0000-0003-4792-5572	International Brain Research Foundation, IBRF, Flanders, NJ, USA	The study was partially funded by the International Brain Research Foundation, IBRF, Flanders, NJ, USA.	Aminoff, 2002, NEUROMUSCULAR FUNCTI, P1899; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Benarroch EE, 1993, CLIN AUTONOMIC DISOR, P209; Benarroch EE, 1997, CENTRAL AUTONOMIC NE; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Black M, 2002, J CLIN PATHOL, V55, P44, DOI 10.1136/jcp.55.1.44; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Buccelletti F, 2009, EUR REV MED PHARMACO, V13, P299; Camm AJ, 1996, EUR HEART J, V17, P354; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Cencetti S, 1999, HEART, V82, P365, DOI 10.1136/hrt.82.3.365; Cerutti S, 2001, AUTON NEUROSCI-BASIC, V90, P3, DOI 10.1016/S1566-0702(01)00261-2; Chida K, 1994, Funct Neurol, V9, P65; Christou DD, 2003, HYPERTENSION, V41, P1219, DOI 10.1161/01.HYP.0000072011.17095.AE; Colivicchi F, 2005, STROKE, V36, P1710, DOI 10.1161/01.STR.0000173400.19346.bd; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dauphinot V, 2013, INT J CARDIOL, V168, P4010, DOI 10.1016/j.ijcard.2013.06.080; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Drawz PE, 2013, AM J NEPHROL, V38, P517, DOI 10.1159/000357200; EWING DJ, 1980, Q J MED, V49, P95; EWING DJ, 1993, CLIN AUTONOMIC DISOR, P297; Ewing DJ, 1992, AUTONOMIC FAILURE TX, P312; Ferrettia G, 2009, J HYPERTENS, V27, P551, DOI 10.1097/HJH.0b013e328322ca2f; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gulli G, 2005, CLIN AUTON RES, V15, P207, DOI 10.1007/s10286-005-0273-8; Hallman DM, 2015, INT J ENV RES PUB HE, V12, P14811, DOI 10.3390/ijerph121114811; Hassett LM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006123.pub2; Hilz MJ, 2008, STROKE, V39, P2421, DOI 10.1161/STROKEAHA.108.518613; Hilz MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132139; Hilz MJ, 2014, AUTON NEUROSCI-BASIC, V183, P83, DOI 10.1016/j.autneu.2014.02.004; Hilz MJ, 2011, J HYPERTENS, V29, P2387, DOI 10.1097/HJH.0b013e32834c31db; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Hilz MJ, 2010, J HYPERTENS, V28, P1438, DOI 10.1097/HJH.0b013e328336a077; Hilz MJ, 2011, STROKE, V42, P1528, DOI 10.1161/STROKEAHA.110.607721; Hilz MJ, 2001, ANN NEUROL, V49, P575, DOI 10.1002/ana.1006; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Huikuri HV, 1996, CIRCULATION, V94, P122, DOI 10.1161/01.CIR.94.2.122; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Johansson M, 2007, J HYPERTENS, V25, P163, DOI 10.1097/01.hjh.0000254377.18983.eb; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Katarzynska-Szymanska A, 2013, BRIT J CLIN PHARMACO, V75, P1516, DOI 10.1111/bcp.12027; Kiviniemi AM, 2014, AM J CARDIOL, V114, P571, DOI 10.1016/j.amjcard.2014.05.032; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Krause M, 2009, PEDIATR DIABETES, V10, P255, DOI 10.1111/j.1399-5448.2008.00447.x; La Rovere MT, 1998, LANCET, V351, P478; Lanfranchi PA, 2002, AM J PHYSIOL-REG I, V283, pR815, DOI 10.1152/ajpregu.00051.2002; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Low PA, 1997, CLIN AUTONOMIC DISOR, V2, P287; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malliani Alberto, 2005, Eur J Intern Med, V16, P12, DOI 10.1016/j.ejim.2004.06.016; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2014, J NEUROL NEUROSUR PS, V85, P1214, DOI 10.1136/jnnp-2013-307279; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mirizzi G, 2013, INT J CARDIOL, V169, pE9, DOI 10.1016/j.ijcard.2013.08.120; Montano N, 2009, NEUROSCI BIOBEHAV R, V33, P71, DOI 10.1016/j.neubiorev.2008.07.006; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; OPPENHEIMER SM, 1991, BRAIN RES, V550, P115, DOI 10.1016/0006-8993(91)90412-O; Ormezzano O, 2008, J HYPERTENS, V26, P1373, DOI 10.1097/HJH.0b013e3283015e5a; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; Palma Jose-Alberto, 2014, Neurology, V83, P261, DOI 10.1212/WNL.0000000000000605; Parati G, 2001, ANN NY ACAD SCI, V940, P469; Ponikowski P, 1997, AM J CARDIOL, V79, P1645, DOI 10.1016/S0002-9149(97)00215-4; Reimann M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012187; Robinson TG, 2003, STROKE, V34, P705, DOI 10.1161/01.STR.0000058493.94875.9F; Rosengard-Barlund M, 2009, DIABETOLOGIA, V52, P1164, DOI 10.1007/s00125-009-1340-9; Rudiger H, 1999, COMPUT METH PROG BIO, V58, P1; Rudiger H, 2001, AUTON NEUROSCI-BASIC, V93, P71, DOI 10.1016/S1566-0702(01)00326-5; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sapoznikov D, 2011, MED BIOL ENG COMPUT, V49, P1045, DOI 10.1007/s11517-011-0806-3; Scholten AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110905; Sleight P, 1992, HUMAN BAROREFLEXES H; Soares-Miranda L, 2014, CIRCULATION, V129, P2100, DOI 10.1161/CIRCULATIONAHA.113.005361; Spallone V, 2011, DIABETES-METAB RES, V27, P639, DOI 10.1002/dmrr.1239; Sung CW, 2016, PSYCHOPHYSIOLOGY, V53, P455, DOI 10.1111/psyp.12575; Sung CW, 2016, CLIN NEUROPHYSIOL, V127, P1629, DOI 10.1016/j.clinph.2015.08.006; Sykora M, 2008, CRIT CARE MED, V36, P3074, DOI 10.1097/CCM.0b013e31818b306d; Sykora M, 2012, STROKE, V43, P714, DOI 10.1161/STROKEAHA.111.632778; Sykora M, 2009, STROKE, V40, pE678, DOI 10.1161/STROKEAHA.109.565838; Sykora M, 2009, STROKE, V40, P737, DOI 10.1161/STROKEAHA.108.519967; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Tang SC, 2015, J NEUROL NEUROSUR PS, V86, P95, DOI 10.1136/jnnp-2014-308389; Toschi-Dias E, 2013, AM J PHYSIOL-HEART C, V304, pH1038, DOI 10.1152/ajpheart.00848.2012; Vinik AI, 2003, DIABETES CARE, V26, P1553, DOI 10.2337/diacare.26.5.1553; Vogel ER, 2005, NEUROLOGY, V65, P1533, DOI 10.1212/01.wnl.0000184504.13173.ef; Voss A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118308; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Yperzeele L, 2015, INT J STROKE, V10, P796, DOI 10.1111/ijs.12573; Ziemssen T, 2013, J NEURAL TRANSM, V120, pS27, DOI 10.1007/s00702-013-1054-5	99	29	30	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	MAY 4	2016	16								61	10.1186/s12883-016-0584-5			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DL6RX	WOS:000375767500004	27146718	Green Published, gold			2022-02-06	
J	Koutsoudaki, PN; Papastefanaki, F; Stamatakis, A; Kouroupi, G; Xingi, E; Stylianopoulou, F; Matsas, R				Koutsoudaki, Paraskevi N.; Papastefanaki, Florentia; Stamatakis, Antonios; Kouroupi, Georgia; Xingi, Evangelia; Stylianopoulou, Fotini; Matsas, Rebecca			Neural stem/progenitor cells differentiate into oligodendrocytes, reduce inflammation, and ameliorate learning deficits after transplantation in a mouse model of traumatic brain injury	GLIA			English	Article						insulin-like growth factor-I (IGF-I); mechanical brain trauma; hippocampus; astrogliosis; Morris Water Maze	GROWTH-FACTOR-I; SPINAL-CORD-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; PROMOTE FUNCTIONAL RECOVERY; CENTRAL-NERVOUS-SYSTEM; TEMPORAL-LOBE EPILEPSY; WHITE-MATTER INJURY; STEM-CELLS; PROGENITOR CELLS; MULTIPLE-SCLEROSIS	The central nervous system has limited capacity for regeneration after traumatic injury. Transplantation of neural stem/progenitor cells (NPCs) has been proposed as a potential therapeutic approach while insulin-like growth factor I (IGF-I) has neuroprotective properties following various experimental insults to the nervous system. We have previously shown that NPCs transduced with a lentiviral vector for IGF-I overexpression have an enhanced ability to give rise to neurons in vitro but also in vivo, upon transplantation in a mouse model of temporal lobe epilepsy. Here we studied the regenerative potential of NPCs, IGF-I-transduced or not, in a mouse model of hippocampal mechanical injury. NPC transplantation, with or without IGF-I transduction, rescued the injury-induced spatial learning deficits as revealed in the Morris Water Maze. Moreover, it had beneficial effects on the host tissue by reducing astroglial activation and microglial/macrophage accumulation while enhancing generation of endogenous oligodendrocyte precursor cells. One or two months after transplantation the grafted NPCs had migrated towards the lesion site and in the neighboring myelin-rich regions. Transplanted cells differentiated toward the oligodendroglial, but not the neuronal or astrocytic lineages, expressing the early and late oligodendrocyte markers NG2, Olig2, and CNPase. The newly generated oligodendrocytes reached maturity and formed myelin internodes. Our current and previous observations illustrate the high plasticity of transplanted NPCs which can acquire injury-dependent phenotypes within the host CNS, supporting the fact that reciprocal interactions between transplanted cells and the host tissue are an important factor to be considered when designing prospective cell-based therapies for CNS degenerative conditions. GLIA 2016;64:763-779	[Koutsoudaki, Paraskevi N.; Papastefanaki, Florentia; Kouroupi, Georgia; Matsas, Rebecca] Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, 127 Vas Sofias Ave, Athens 11521, Greece; [Stamatakis, Antonios; Stylianopoulou, Fotini] Univ Athens, Fac Nursing, Dept Basic Sci, Biol Biochem Lab, Athens 11527, Greece; [Xingi, Evangelia] Hellenic Pasteur Inst, Light Microscopy Unit, Athens 11521, Greece		Matsas, R (corresponding author), Hellenic Pasteur Inst, Lab Cellular & Mol Neurobiol, 127 Vas Sofias Ave, Athens 11521, Greece.	rmatsa@pasteur.gr	Xingi, Evangelia/AAA-4882-2020; Stamatakis, A./J-5294-2019; STYLIANOPOULOU, FOTINI/B-1403-2008	Stamatakis, A./0000-0003-2480-5578; Koutsoudaki, Paraskevi N./0000-0003-4765-3730	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7 REGPOT Neurosign 264083]; Greek Ministry of Education, Research and Religious Affairs [09SYN-21-969, Excellence I-2272, KRIPIS MIS450598]; Empeirikion Foundation; Theodore-Theochari Cozzika Foundation	Grant sponsor: European Commission; Grant number: FP7 REGPOT Neurosign 264083; Grant sponsor: Greek Ministry of Education, Research and Religious Affairs; Grant number: 09SYN-21-969, Excellence I-2272, KRIPIS MIS450598; Grant sponsor: Empeirikion Foundation.; F. Papastefanaki was recipient of a fellowship from the Theodore-Theochari Cozzika Foundation. The authors have no conflict of interest to declare.	Aberg ND, 2003, J NEUROSCI RES, V74, P12, DOI 10.1002/jnr.10734; Altemus KL, 1997, HIPPOCAMPUS, V7, P403, DOI 10.1002/(SICI)1098-1063(1997)7:4<403::AID-HIPO6>3.0.CO;2-J; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Barkas LJ, 2010, BEHAV BRAIN RES, V208, P535, DOI 10.1016/j.bbr.2009.12.035; Ben-Ari Y, 2000, TRENDS NEUROSCI, V23, P580, DOI 10.1016/S0166-2236(00)01659-3; Blaya MO, 2015, EXP NEUROL, V264, P67, DOI 10.1016/j.expneurol.2014.11.014; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; Cendes F, 2014, ACTA NEUROPATHOL, V128, P21, DOI 10.1007/s00401-014-1292-0; Chesik D, 2007, INT REV NEUROBIOL, V79, P203, DOI 10.1016/S0074-7742(07)79009-8; Cossetti C, 2014, MOL CELL, V56, P193, DOI 10.1016/j.molcel.2014.08.020; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI 10.1529/biophysi.103.038422; Crocker SJ, 2011, NEUROPATH APPL NEURO, V37, P643, DOI 10.1111/j.1365-2990.2011.01165.x; Curt A, 2012, EXPERT OPIN BIOL TH, V12, P271, DOI 10.1517/14712598.2012.655722; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; Drago D, 2013, BIOCHIMIE, V95, P2271, DOI 10.1016/j.biochi.2013.06.020; Ebert AD, 2008, EXP NEUROL, V209, P213, DOI 10.1016/j.expneurol.2007.09.022; Einstein O, 2009, J NEUROSCI, V29, P15694, DOI 10.1523/JNEUROSCI.3364-09.2009; Enomoto M, 2003, EUR J NEUROSCI, V17, P1223, DOI 10.1046/j.1460-9568.2003.02555.x; Fernandez AM, 2012, NAT REV NEUROSCI, V13, P225, DOI 10.1038/nrn3209; Franklin KBJ, 2001, MOUSE BRAIN STEREOTA; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gerlai RT, 2002, BRAIN RES BULL, V57, P3, DOI 10.1016/S0361-9230(01)00630-X; Gold AE, 2005, HIPPOCAMPUS, V15, P808, DOI 10.1002/hipo.20103; Groticke I, 2007, EXP NEUROL, V207, P329, DOI 10.1016/j.expneurol.2007.06.021; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Hwang DH, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-117; Kalladka D, 2014, STEM CELLS CLONING, V7, P31, DOI 10.2147/SCCAA.S38003; Kaspar BK, 2003, SCIENCE, V301, P839, DOI 10.1126/science.1086137; Katsimpardi L, 2008, STEM CELLS, V26, P1796, DOI 10.1634/stemcells.2007-0921; Kazanis I, 2004, EXP NEUROL, V186, P221, DOI 10.1016/j.expneurol.2003.12.004; Kazanis I, 2003, BRAIN RES, V991, P34, DOI 10.1016/S0006-8993(03)03525-X; Kesner RP, 2004, REV NEUROSCIENCE, V15, P333; Kim DS, 2010, STEM CELLS, V28, P2099, DOI 10.1002/stem.526; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kouroupi G, 2010, J NEUROCHEM, V115, P460, DOI 10.1111/j.1471-4159.2010.06939.x; Koutsoudaki PN, 2009, NEUROSCI LETT, V451, P83, DOI 10.1016/j.neulet.2008.11.058; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Laterza C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3597; Levine JB, 1999, GLIA, V28, P215; Li MF, 2013, CELL PHYSIOL BIOCHEM, V32, P1776, DOI 10.1159/000356611; Liu X, 1995, Mult Scler, V1, P2; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Makri G, 2010, STEM CELLS, V28, P127, DOI 10.1002/stem.258; Mallucci G, 2015, PROG NEUROBIOL, V127, P1, DOI 10.1016/j.pneurobio.2015.02.003; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Miltiadous P, 2013, STEM CELL TRANSL MED, V2, P185, DOI 10.5966/sctm.2012-0074; Miltiadous P, 2011, EXP NEUROL, V231, P223, DOI 10.1016/j.expneurol.2011.06.014; Miltiadous P, 2010, CELL MOL NEUROBIOL, V30, P347, DOI 10.1007/s10571-009-9457-4; Mitome M, 2001, BRAIN, V124, P2147, DOI 10.1093/brain/124.11.2147; Muller CJ, 2009, EXP NEUROL, V219, P284, DOI 10.1016/j.expneurol.2009.05.035; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Nudi ET, 2015, J NEUROTRAUM, V32, P1117, DOI 10.1089/neu.2014.3618; Papastefanaki F, 2007, BRAIN, V130, P2159, DOI 10.1093/brain/awm155; Papastefanaki F, 2015, GLIA, V63, P1101, DOI 10.1002/glia.22809; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Plemel JR, 2011, GLIA, V59, P1891, DOI 10.1002/glia.21232; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Pluchino S, 2013, GLIA, V61, P1379, DOI 10.1002/glia.22500; Politi LS, 2007, STEM CELLS, V25, P2583, DOI 10.1634/stemcells.2007-0037; Poltavtseva RA, 2012, B EXP BIOL MED+, V153, P586, DOI 10.1007/s10517-012-1772-y; Porambo M, 2015, GLIA, V63, P452, DOI 10.1002/glia.22764; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sakowski SA, 2009, AMYOTROPH LATERAL SC, V10, P63, DOI 10.1080/17482960802160370; Salewski RP, 2015, STEM CELL TRANSL MED, V4, P743, DOI 10.5966/sctm.2014-0236; Samanta J, 2015, NATURE, V526, P448, DOI 10.1038/nature14957; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Skardelly M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00318; Sun Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057534; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Toft A, 2013, GLIA, V61, P513, DOI 10.1002/glia.22452; Torres-Aleman I, 2007, EXPERT OPIN THER TAR, V11, P1535, DOI 10.1517/14728222.11.12.1535; van der Staay FJ, 2000, PHYSIOL BEHAV, V68, P599, DOI 10.1016/S0031-9384(99)00236-X; van Praag H, 1998, BEHAV BRAIN RES, V92, P21, DOI 10.1016/S0166-4328(97)00117-4; Vargas MR, 2010, NEUROTHERAPEUTICS, V7, P471, DOI 10.1016/j.nurt.2010.05.012; Vicario-Abejon C, 2003, J NEUROSCI, V23, P895; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Wallenquist U, 2009, RESTOR NEUROL NEUROS, V27, P323, DOI 10.3233/RNN-2009-0481; Wang JY, 2013, CNS NEUROL DISORD-DR, V12, P413, DOI 10.2174/1871527311312030014; Whitman LM, 2012, EXP NEUROL, V235, P380, DOI 10.1016/j.expneurol.2012.03.003; Yan J, 2007, PLOS MED, V4, P318, DOI 10.1371/journal.pmed.0040039; Yasuda A, 2011, STEM CELLS, V29, P1983, DOI 10.1002/stem.767; Ye P, 2004, J NEUROSCI RES, V78, P472, DOI 10.1002/jnr.20288; Yokota K, 2015, STEM CELL REP, V5, P264, DOI 10.1016/j.stemcr.2015.06.004; Zawadzka M, 2010, CELL STEM CELL, V6, P578, DOI 10.1016/j.stem.2010.04.002	90	29	30	1	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAY	2016	64	5					763	779		10.1002/glia.22959			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI0OR	WOS:000373197000007	26712314				2022-02-06	
J	Orr, CA; Albaugh, MD; Watts, R; Garavan, H; Andrews, T; Nickerson, JP; Gonyea, J; Hipko, S; Zweber, C; Logan, K; Hudziak, JJ				Orr, Catherine A.; Albaugh, Matthew D.; Watts, Richard; Garavan, Hugh; Andrews, Trevor; Nickerson, Joshua P.; Gonyea, Jay; Hipko, Scott; Zweber, Cole; Logan, Katherine; Hudziak, James J.			Neuroimaging Biomarkers of a History of Concussion Observed in Asymptomatic Young Athletes	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; head trauma; MRI; neuroplasticity	TRAUMATIC BRAIN-INJURY; WHITE-MATTER INTEGRITY; INDEPENDENT COMPONENT ANALYSIS; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; DIFFUSION KURTOSIS; DEFAULT NETWORK; SPORT; ENCEPHALOPATHY; CONNECTIVITY	Participation in contact sports places athletes at elevated risk for repeated head injuries and is associated with negative mental health outcomes later in life. The current study identified changes observable on neuroimaging that persisted beyond the apparent resolution of acute symptoms of concussion. Sixteen young adult ice hockey players with a remote history of concussion but no subjective complaints were compared against 13 of their teammates with no history of concussion. Participants completed a detailed phenotypic assessment and a neuroimaging battery including diffusion kurtosis imaging and resting-state functional magnetic resonance imaging. Athletes with a history of concussion performed no differently from those without on phenotypic assessment, but showed significantly elevated fractional anisotropy (FA) in the left genu and anterior corona radiata relative to those without. Post hoc analyses revealed that elevated FA was associated with increased microstructural complexity perpendicular to the primary axon (radial kurtosis). Athletes with concussion history also showed significant differences in the organization of the default mode network (DMN) characterized by stronger temporal coherence in posterior DMN, decreased temporal coherence in anterior DMN, and increased functional connectivity outside the DMN. In the absence of deficits on detailed phenotypic assessment, athletes with a history of concussion displayed changes to the microstructural architecture of the cerebral white matter and to the functional connectivity of the brain at rest. Some of these changes are consistent with those previously associated with persisting deficits and complaints, but we also report novel, complementary changes that possibly represent compensatory mechanisms.	[Orr, Catherine A.; Albaugh, Matthew D.; Zweber, Cole; Logan, Katherine; Hudziak, James J.] Univ Vermont, Vermont Ctr Children Youth & Families, Burlington, VT USA; [Watts, Richard; Andrews, Trevor; Nickerson, Joshua P.] Univ Vermont, Dept Radiol, Burlington, VT USA; [Garavan, Hugh] Univ Vermont, Dept Psychiat, Burlington, VT USA; [Garavan, Hugh] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA; [Watts, Richard; Andrews, Trevor; Nickerson, Joshua P.; Gonyea, Jay; Hipko, Scott] Univ Vermont, MRI Ctr Biomed Imaging, Burlington, VT USA; [Andrews, Trevor] Philips Healthcare, Cleveland, OH USA; [Hudziak, James J.] Erasmus Univ, Sophia Childrens Hosp, Rotterdam, Netherlands; [Hudziak, James J.] Washington Univ, Dept Child Psychiat, St Louis, MO USA		Hudziak, JJ (corresponding author), Univ Vermont, Coll Med, Vermont Ctr Children Youth & Families, Univ Hlth Ctr Campus,1 South Prospect St, Burlington, VT 05401 USA.	james.hudziak@uvm.edu	Meijer, Anna/K-5118-2016; Albaugh, Matthew D/R-4349-2016; Albaugh, Matthew/ABB-5839-2020	Albaugh, Matthew/0000-0002-5971-6658; Andrews, Trevor/0000-0003-0331-1798			Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Achenbach TM, 2003, RATINGS RELATIONS DS; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Calhoun VD, 2004, MAGN RESON IMAGING, V22, P1181, DOI 10.1016/j.mri.2004.09.004; Calhoun VD, 2006, HUM BRAIN MAPP, V27, P47, DOI 10.1002/hbm.20166; Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Di Martino A, 2014, MOL PSYCHIATR, V19, P659, DOI 10.1038/mp.2013.78; Ducharme S, 2011, BIOL PSYCHIAT, V70, P283, DOI 10.1016/j.biopsych.2011.03.015; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Groves AR, 2011, NEUROIMAGE, V54, P2198, DOI 10.1016/j.neuroimage.2010.09.073; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hammeke TA, 2013, J INT NEUROPSYCH SOC, V19, P863, DOI 10.1017/S1355617713000702; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; Korngold C, 2013, J AM ACAD PSYCHIATRY, V41, P430; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li X., 2012, ENG MED BIOL SOC EMB; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lovell M, 2000, IMPACT IMMEDIATE POS; Luo L, 2012, BRAIN CONNECT, V2, P33, DOI 10.1089/brain.2011.0026; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Parmet Sharon, 2003, JAMA, V290, P2628, DOI 10.1001/jama.290.19.2628; Patel DR, 2013, ADOLESCENCE SPORTS; Qin SZ, 2014, BIOL PSYCHIAT, V75, P892, DOI 10.1016/j.biopsych.2013.10.006; Rabinowitz AR, 2014, ANNU REV PSYCHOL, V65, P301, DOI 10.1146/annurev-psych-010213-115103; Rivara FP, 2014, JAMA-J AM MED ASSOC, V311, P239, DOI 10.1001/jama.2013.282985; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Smith S., 2007, TR07JA2 FMRIB U OXF; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tabesh A, 2011, MAGN RESON MED, V65, P823, DOI 10.1002/mrm.22655; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Yan CG, 2013, NEUROIMAGE, V76, P183, DOI 10.1016/j.neuroimage.2013.03.004; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748; Zhuo J., 2012, ORG HUM BRAIN MAPP A; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	67	29	29	1	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2016	33	9					803	810		10.1089/neu.2014.3721			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	DK7SA	WOS:000375124800001	26413910				2022-02-06	
J	Seli, P				Seli, Paul			The Attention-Lapse and Motor Decoupling accounts of SART performance are not mutually exclusive	CONSCIOUSNESS AND COGNITION			English	Article						The Sustained Attention to Response Task; SART; Mind wandering; Motor decoupling; Inattention; Attention lapses	DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; SUSTAINED-ATTENTION; RESPONSE-TASK; FAILURES; ADHD	There is an ongoing debate about the mechanisms purported to underlie performance in the Sustained-Attention-to-Response Task (SART). Whereas the Attention-Lapse account posits that SART errors result from attentional disengagement, the Motor Decoupling account proposes that SART errors result from failures to inhibit a fast, prepotent motor response, despite adequate attention to the task. That SART performance might be fully accounted for by motor decoupling is problematic for a Attention-Lapse account, and for the use of the SART as an index of attention lapses. To test whether SART performance is in fact fully accounted for by motor decoupling, I examined the relation between SART performance and attention lapses while controlling for motor decoupling. The results were clear: The SART was associated with attention lapses independently of motor decoupling. Thus, the present study suggests that both accounts are correct and that the SART is a valid measure of attention lapses. (C) 2016 Elsevier Inc. All rights reserved.	[Seli, Paul] Harvard Univ, Dept Psychol, William James Hall,33 Kirkland St, Cambridge, MA 02138 USA		Seli, P (corresponding author), Harvard Univ, Dept Psychol, William James Hall,33 Kirkland St, Cambridge, MA 02138 USA.	paulseli@fas.harvard.edu			Natural Sciences and Engineering Research Council of Canada (NSERC) Post-Doctoral FellowshipNatural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) Post-Doctoral Fellowship to Paul Seli.	Bellgrove MA, 2006, CORTEX, V42, P838, DOI 10.1016/S0010-9452(08)70426-X; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chan RCK, 2009, COGN BEHAV NEUROL, V22, P180, DOI 10.1097/WNN.0b013e3181b7ef84; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Head J, 2014, EXP BRAIN RES, V232, P565, DOI 10.1007/s00221-013-3765-0; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Jonker TR, 2013, CONSCIOUS COGN, V22, P1468, DOI 10.1016/j.concog.2013.10.005; Kline R. B., 2016, PRINCIPLES PRACTICE, VFourth; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Marquez CMS, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00333; Molenberghs P, 2009, NEUROPSYCHOLOGIA, V47, P2866, DOI 10.1016/j.neuropsychologia.2009.06.012; Peebles D, 2004, PROCEEDINGS OF THE SIXTH INTERNATIONAL CONFERENCE ON COGNITIVE MODELING, P231; Robertson I.H., 2000, CLIN NEUROPSYCHOL, V3, P167; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Seli P., 2014, PSYCHOL RES; Seli P., PSYCHONOMIC IN PRESS, DOI 10.3758/s13423-015-0979-0; Seli P., 2013, FRONTIERS PSYCHOL; Seli P, 2013, BEHAV RES METHODS, V45, P355, DOI 10.3758/s13428-012-0266-1; Seli P, 2012, CAN J EXP PSYCHOL, V66, P44, DOI 10.1037/a0025111; Seli P, 2012, CONSCIOUS COGN, V21, P277, DOI 10.1016/j.concog.2011.09.017; Smallwood J, 2004, CONSCIOUS COGN, V13, P789, DOI 10.1016/j.concog.2004.07.004; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Smilek D, 2010, NEUROPSYCHOLOGIA, V48, P2564, DOI 10.1016/j.neuropsychologia.2010.05.002; Van der Linden D, 2005, WORK STRESS, V19, P23, DOI 10.1080/02678370500065275; Wilson KM, 2015, CONSCIOUS COGN, V33, P406, DOI 10.1016/j.concog.2015.02.014	28	29	29	2	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100	1090-2376		CONSCIOUS COGN	Conscious. Cogn.	APR	2016	41						189	198		10.1016/j.concog.2016.02.017			10	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	DI7BF	WOS:000373653400019	26946296				2022-02-06	
J	Winkler, EA; Yue, JK; Burke, JF; Chan, AK; Dhall, SS; Berger, MS; Manley, GT; Tarapore, PE				Winkler, Ethan A.; Yue, John K.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Berger, Mitchel S.; Manley, Geoffrey T.; Tarapore, Phiroz E.			Adult sports-related traumatic brain injury in United States trauma centers	NEUROSURGICAL FOCUS			English	Article						concussion; mortality; outcome; sports; traumatic brain injury	HIGH-SCHOOL; EXTERNAL VALIDATION; RISK-FACTORS; EPIDEMIOLOGY; CONCUSSIONS; MORBIDITY; SEVERITY; MODERATE; IMPACT; PROGNOSIS	OBJECTIVE Sports-related traumatic brain injury (TBI) is an important public health concern estimated to affect 300,000 to 3.8 million people annually in the United States. Although injuries to professional athletes dominate the media, this group represents only a small proportion of the overall population. Here, the authors characterize the demographics of sports-related TBI in adults from a community-based trauma population and identify predictors of prolonged hospitalization and increased morbidity and mortality rates. METHODS Utilizing the National Sample Program of the National Trauma Data Bank (NTDB), the authors retrospectively analyzed sports-related TBI data from adults (age >= 18 years) across 5 sporting categories-fall or interpersonal contact (FIC), roller sports, skiing/snowboarding, equestrian sports, and aquatic sports. Multivariable regression analysis was used to identify predictors of prolonged hospital length of stay (LOS), medical complications, inpatient mortality rates, and hospital discharge disposition. Statistical significance was assessed at alpha < 0.05, and the Bonferroni correction for multiple comparisons was applied for each outcome analysis. RESULTS From 2003 to 2012, in total, 4788 adult sports-related TBIs were documented in the NTDB, which represented 18,310 incidents nationally. Equestrian sports were the greatest contributors to sports-related TBI (45.2%). Mild TBI represented nearly 86% of injuries overall. Mean (+/- SEM) LOSs in the hospital or intensive care unit (ICU) were 4.25 +/- 0.09 days and 1.60 +/- 0.06 days, respectively. The mortality rate was 3.0% across all patients, but was statistically higher in TBI from roller sports (4.1%) and aquatic sports (7.7%). Age, hypotension on admission to the emergency department (ED), and the severity of head and extracranial injuries were statistically significant predictors of prolonged hospital and ICU LOSs, medical complications, failure to discharge to home, and death. Traumatic brain injury during aquatic sports was similarly associated with prolonged ICU and hospital LOSs, medical complications, and failure to be discharged to home. CONCLUSIONS Age, hypotension on ED admission, severity of head and extracranial injuries, and sports mechanism of injury are important prognostic variables in adult sports-related TBI. Increasing TBI awareness and helmet use-particularly in equestrian and roller sports-are critical elements for decreasing sports-related TBI events in adults.	[Winkler, Ethan A.; Yue, John K.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Berger, Mitchel S.; Manley, Geoffrey T.; Tarapore, Phiroz E.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Winkler, Ethan A.; Yue, John K.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Manley, Geoffrey T.; Tarapore, Phiroz E.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA		Tarapore, PE (corresponding author), San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94110 USA.	taraporep@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Burke, John/0000-0002-6190-5116			American College of Surgeons, 2013, NAT TRAUM DAT BANK N; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baschera D, 2015, J NEUROTRAUM, V32, P557, DOI 10.1089/neu.2014.3604; Bekelis K, 2015, ANN SURG, V261, P579, DOI 10.1097/SLA.0000000000000672; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chang SKY, 2006, J TRAUMA, V60, P1041, DOI 10.1097/01.ta.0000218256.39295.8f; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Faul M, 2010, TRAUMATIC BRAIN INJU; Fenerty L, 2013, J TRAUMA ACUTE CARE, V74, P895, DOI 10.1097/TA.0b013e31827e19ca; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Haring RS, 2015, BRAIN INJURY, V29, P989, DOI 10.3109/02699052.2015.1033014; Ibsen LM, 2002, CRIT CARE MED, V30, pS402, DOI 10.1097/00003246-200211001-00004; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lustenberger T, 2010, J TRAUMA, V69, P924, DOI 10.1097/TA.0b013e3181b9a05a; Majidi S, 2013, AM J EMERG MED, V31, P1215, DOI 10.1016/j.ajem.2013.05.026; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Norwood S, 2000, J TRAUMA, V48, P740, DOI 10.1097/00005373-200004000-00025; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Saigal Rajiv, 2014, Neurosurgery, V75 Suppl 4, pS149, DOI 10.1227/NEU.0000000000000497; Schoenfeld AJ, 2013, SPINE J, V13, P1766, DOI 10.1016/j.spinee.2013.03.024; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Sorli J M, 2000, Inj Prev, V6, P59, DOI 10.1136/ip.6.1.59; SOSIN DM, 1991, BRAIN INJURY, V10, P47, DOI DOI 10.1080/026990596124719; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tominaga GT, 2015, BRAIN INJURY, V29, P1044, DOI 10.3109/02699052.2014.989404; Underwood E, 2013, SCIENCE, V339, P1367, DOI 10.1126/science.339.6126.1367; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Winkler EA, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15270; Yue JK, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15612; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634; Zuckerman SL, 2015, WORLD NEUROSURG, V83, P1098, DOI 10.1016/j.wneu.2014.12.030	49	29	30	0	14	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E4	10.3171/2016.1.FOCUS15613			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500009	27032921	gold			2022-02-06	
J	Yue, JK; Winkler, EA; Burke, JF; Chan, AK; Dhall, SS; Berger, MS; Manley, GT; Tarapore, PE				Yue, John K.; Winkler, Ethan A.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Berger, Mitchel S.; Manley, Geoffrey T.; Tarapore, Phiroz E.			Pediatric sports-related traumatic brain injury in United States trauma centers	NEUROSURGICAL FOCUS			English	Article						concussion; mortality; pediatric; sports; outcome; traumatic brain injury	HIGH-SCHOOL; HEAD-INJURY; DATA-BANK; FOOTBALL PLAYERS; CONCUSSION; CHILDREN; EPIDEMIOLOGY; POPULATION; PREDICTORS; MANAGEMENT	OBJECTIVE Traumatic brain injury (TBI) in children is a significant public health concern estimated to result in over 500,000 emergency department (ED) visits and more than 60,000 hospitalizations in the United States annually. Sports activities are one important mechanism leading to pediatric TBI. In this study, the authors characterize the demographics of sports-related TBI in the pediatric population and identify predictors of prolonged hospitalization and of increased morbidity and mortality rates. METHODS Utilizing the National Sample Program of the National Trauma Data Bank (NTDB), the authors retrospectively analyzed sports-related TBI data from children (age 0-17 years) across 5 sports categories: fall or interpersonal contact (FIC), roller sports, skiing/snowboarding, equestrian sports, and aquatic sports. Multivariable regression analysis was used to identify predictors of prolonged length of stay (LOS) in the hospital or intensive care unit (ICU), medical complications, inpatient mortality rates, and hospital discharge disposition. Statistical significance was assessed at alpha < 0.05, and the Bonferroni correction (set at significance threshold p = 0.01) for multiple comparisons was applied in each outcome analysis. RESULTS From 2003 to 2012, in total 3046 pediatric sports-related TBIs were recorded in the NTDB, and these injuries represented 11,614 incidents nationally after sample weighting. Fall or interpersonal contact events were the greatest contributors to sports-related TBI (47.4%). Mild TBI represented 87.1% of the injuries overall. Mean (+/- SEM) LOSs in the hospital and ICU were 2.68 +/- 0.07 days and 2.73 +/- 0.12 days, respectively. The overall mortality rate was 0.8%, and the prevalence of medical complications was 2.1% across all patients. Severities of head and extracranial injuries were significant predictors of prolonged hospital and ICU LOSs, medical complications, failure to discharge to home, and death. Hypotension on admission to the ED was a significant predictor of failure to discharge to home (OR 0.05, 95% CI 0.03-0.07, p < 0.001). Traumatic brain injury incurred during roller sports was independently associated with prolonged hospital LOS compared with FIC events (mean increase 0.54 +/- 0.15 days, p < 0.001). CONCLUSIONS In pediatric sports-related TBI, the severities of head and extracranial traumas are important predictors of patients developing acute medical complications, prolonged hospital and ICU LOSs, in-hospital mortality rates, and failure to discharge to home. Acute hypotension after a TBI event decreases the probability of successful discharge to home. Increasing TBI awareness and use of head-protective gear, particularly in high-velocity sports in older age groups, is necessary to prevent pediatric sports-related TBI or to improve outcomes after a TBI.	[Yue, John K.; Winkler, Ethan A.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Berger, Mitchel S.; Manley, Geoffrey T.; Tarapore, Phiroz E.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yue, John K.; Winkler, Ethan A.; Burke, John F.; Chan, Andrew K.; Dhall, Sanjay S.; Manley, Geoffrey T.; Tarapore, Phiroz E.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA		Tarapore, PE (corresponding author), San Francisco Gen Hosp, 1001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94110 USA.	taraporep@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Burke, John/0000-0002-6190-5116			Agran PF, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.3.e45; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; American College of Surgeons, 2013, NAT TRAUM DAT BANK N; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bekelis K, 2015, ANN SURG, V261, P579, DOI 10.1097/SLA.0000000000000672; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Buller DB, 2003, J TRAUMA, V55, P939, DOI 10.1097/01.TA.0000078694.53320.CA; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Coronado VG, 2015, J HEAD TRAUMA REHAB, V30, P185, DOI 10.1097/HTR.0000000000000156; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Eisenberg MA, 2014, PEDIATRICS, V133, P999, DOI 10.1542/peds.2014-0158; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gassner R, 2004, J ORAL MAXIL SURG, V62, P399, DOI 10.1016/j.joms.2003.05.013; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilliam Jerene M, 2007, J Agromedicine, V12, P11; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Glass T, 2015, AM J EMERG MED, V33, P1458, DOI 10.1016/j.ajem.2015.06.069; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Haring RS, 2015, BRAIN INJURY, V29, P989, DOI 10.3109/02699052.2015.1033014; Hendricks K J, 2001, Inj Prev, V7, P307, DOI 10.1136/ip.7.4.307; Hendricks KJ, 2005, J SAFETY RES, V36, P149, DOI 10.1016/j.jsr.2005.01.002; Hubler Crystal L, 2002, J Emerg Nurs, V28, P284, DOI 10.1067/men.2002.124797; Kannan Nithya, 2014, Int J Crit Illn Inj Sci, V4, P131, DOI 10.4103/2229-5151.134152; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Lam WH, 1999, PAEDIATR ANAESTH, V9, P377; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Majidi S, 2013, AM J EMERG MED, V31, P1215, DOI 10.1016/j.ajem.2013.05.026; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Rose SC, 2015, PEDIATR NEUROL, V53, P108, DOI 10.1016/j.pediatrneurol.2015.04.003; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schoenfeld AJ, 2013, SPINE J, V13, P1766, DOI 10.1016/j.spinee.2013.03.024; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Smith GA, 2004, CLIN PEDIATR, V43, P335, DOI 10.1177/000992280404300404; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stocchetti N, 2010, MINERVA ANESTESIOL, V76, P1052; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; U. S. Consumer Product Safety Commission: NationalBike Helmet Use Survey, NAT BIK HELM USE SUR; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Winkler EA, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15613; Winkler EA, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15270	56	29	30	0	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E3	10.3171/2016.1.FOCUS15612			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500008	27032920	gold			2022-02-06	
J	Jaramillo, CA; Eapen, BC; McGeary, CA; McGeary, DD; Robinson, J; Amuan, M; Pugh, MJ				Jaramillo, Carlos A.; Eapen, Blessen C.; McGeary, Cindy A.; McGeary, Donald D.; Robinson, Jedediah; Amuan, Megan; Pugh, Mary Jo			A cohort study examining headaches among veterans of Iraq and Afghanistan wars: Associations with traumatic brain injury, PTSD, and depression	HEADACHE			English	Article						headache; traumatic brain injury; posttraumatic stress disorder; postconcussive symptoms; persistence; veterans	POSTTRAUMATIC-STRESS-DISORDER; HEAD; MILITARY; SOLDIERS; PREVALENCE; CONCUSSION; SEVERITY; MIGRAINE; BLAST; PAIN	ObjectivesTo describe the prevalence and persistence of headache and associated conditions in an inception cohort of U.S. veterans of Iraq and Afghanistan wars. BackgroundIraq and Afghanistan war veterans (IAV) suffer from persistent and difficult-to-treat headaches that have been found to co-occur with traumatic brain injury (TBI) and other deployment related comorbidities. MethodsThis longitudinal retrospective cohort study used data from the national Veterans Health Administration (VA) data repository for IAV who first received VA care in 2008 (baseline) and also received care each year in 2009, 2010, and 2011. We used ICD-9-CM codes, to identify those treated for headache each year (2008-2011). Individuals with headache diagnosed each year were classified as having persistent headache. We also identified comorbidities that may be associated with baseline headache using algorithms validated for use with ICD-9-CM codes. Comorbidities included TBI, posttraumatic stress disorder (PTSD), depression, and conditions associated with these diagnoses (anxiety, memory/attention/cognition, neck pain, tinnitus/hyperacusis, photosensitivity/photo blurring, insomnia, malaise/fatigue, and vertigo/dizziness). Multivariable logistic regression analysis was used to determine characteristics associated with baseline headache as well as those associated with persistent headache. ResultsAmong all IAV, 38,426 received their first year of VA care in 2008 and had care each year 2009-2011: 13.7% of these were diagnosed with headache in 2008. Veterans diagnosed with headache in 2008 were more likely than those without a headache diagnosis to also have a diagnosis of TBI alone (adjusted odds ratios [AOR] 6.75; 95% CI 5.79-7.86), TBI+depression (AOR 7.09; 95% CI 5.23-9.66), TBI+PTSD (AOR 10.16; 95% CI 8.96-11.53), TBI+PTSD+depression (AOR 9.40; 95% CI 8.12-10.09), and neck pain (AOR 2.44; 95% CI 2.14-2.77). Among those with headache diagnosis in 2008, 24.3% had a headache diagnosis each of the subsequent years of care (persistent headache). While diagnoses of TBI, PTSD, and/or depression at baseline were not associated with headache persistence, persistence was more likely for individuals with baseline tinnitus/hyperacusis (AOR 1.21; 95% CI 1.02-1.45), insomnia (AOR 1.19; 95% CI 1.02-1.39), and vertigo/dizziness (AOR 1.83; 95% CI 1.30-2.57). ConclusionsOur results indicate that TBI alone is a strong predictor of headache in the first year of VA care among IAV and that comorbid psychiatric comorbidities increase the likelihood of headache among individuals with TBI. However, among those with baseline headache, only tinnitus, insomnia, and vertigo were baseline clinical predictors of headache persistence. These results suggest that attention to other symptoms and conditions early in the diagnosis and treatment of headaches may be important for understanding prognosis. These comorbidities offer potential targets for intervention strategies that may help address postdeployment headaches.	[Jaramillo, Carlos A.; Eapen, Blessen C.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA; [Jaramillo, Carlos A.; Eapen, Blessen C.; Robinson, Jedediah] Univ Texas Hlth Sci Ctr San Antonio, Dept Rehabil Med, San Antonio, TX 78229 USA; [McGeary, Cindy A.; McGeary, Donald D.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Amuan, Megan] Edith Nourse Rogers Mem Hosp, CHQOER, Bedford, MA USA; [Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA; [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA		Jaramillo, CA (corresponding author), South Texas Vet Healthcare Syst ALMD, Polytrauma Rehabil Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	jaramilloc3@uthscsa.edu	Pugh, Mary Jo/K-5336-2019	Pugh, Mary Jo/0000-0003-4196-7763	VA Health Services Research and DevelopmentUS Department of Veterans Affairs [DHI 09-237]	The study was funded by VA Health Services Research and Development (DHI 09-237).	Antonaci F, 2011, J HEADACHE PAIN, V12, P115, DOI 10.1007/s10194-010-0282-4; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Breslau N, 2003, NEUROLOGY, V60, P1308, DOI 10.1212/01.WNL.0000058907.41080.54; Bryan CJ, 2011, HEADACHE, V51, P945, DOI 10.1111/j.1526-4610.2011.01887.x; Burch RC, 2015, HEADACHE, V55, P21, DOI 10.1111/head.12482; Carlson KF, 2013, HEADACHE, V53, P1573, DOI 10.1111/head.12216; CHIBNALL JT, 1994, HEADACHE, V34, P357, DOI 10.1111/j.1526-4610.1994.hed3406357.x; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Cohen SP, 2012, CEPHALALGIA, V32, P94, DOI 10.1177/0333102411422382; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; Martins HAD, 2009, ARQ NEURO-PSIQUIAT, V67, P43; Defrin R, 2015, J NEUROTRAUM, V32, P28, DOI 10.1089/neu.2014.3359; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; DoD, 2015, WORLDW NUMB TBI DVBI; Dodick DW, 2003, HEADACHE, V43, P282, DOI 10.1046/j.1526-4610.2003.03055.x; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Hebert P L, 1999, Am J Med Qual, V14, P270, DOI 10.1177/106286069901400607; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaramillo CA, 2015, BRAIN IMAGING BEHAV, V9, P445, DOI 10.1007/s11682-015-9402-8; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Knol MJ, 2011, EUR J EPIDEMIOL, V26, P253, DOI 10.1007/s10654-011-9563-8; Landy PJB, 1998, INJURY, V29, P199, DOI 10.1016/S0020-1383(97)00178-2; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Norman RS, 2013, BRAIN INJURY, V27, P1623, DOI 10.3109/02699052.2013.834380; Odegard SS, 2011, HEADACHE, V51, P570, DOI 10.1111/j.1526-4610.2011.01859.x; Patil VK, 2011, HEADACHE, V51, P1112, DOI 10.1111/j.1526-4610.2011.01946.x; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Seidler GH, 2006, PSYCHOL MED, V36, P1515, DOI 10.1017/S0033291706007963; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; So CWL, 2009, J VESTIBUL RES-EQUIL, V19, P49, DOI 10.3233/VES-2009-0340; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Theeler BJ, 2010, HEADACHE, V50, P790, DOI 10.1111/j.1526-4610.2009.01571.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Volcy M, 2005, HEADACHE, V45, P1083, DOI 10.1111/j.1526-4610.2005.05193_2.x; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Walter KH, 2012, REHABIL PSYCHOL, V57, P13, DOI 10.1037/a0026254; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WICKENS T. D., 1989, MULTIWAY CONTINGENCY; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	54	29	29	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAR	2016	56	3					528	539		10.1111/head.12726			12	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DH6HG	WOS:000372891000009	26688427				2022-02-06	
J	Kumar, RG; Rubin, JE; Berger, RP; Kochanek, PM; Wagner, AK				Kumar, Raj G.; Rubin, Jonathan E.; Berger, Rachel P.; Kochanek, Patrick M.; Wagner, Amy K.			Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						TBI; Inflammation; Principal component analysis; Cluster analysis; Interleukins; Cytokines; Soluble cell surface markers; Outcome; Prognosis; Rehabilomics	CEREBROSPINAL-FLUID; HORMONE-LEVELS; MARKERS; REHABILITATION; NEUTRALIZATION; ASSOCIATIONS; PROGNOSIS; BIOMARKER; CYTOKINE; IMPACT	Studies have characterized absolute levels of multiple inflammatory markers as significant risk factors for poor outcomes after traumatic brain injury (TBI). However, inflammatory marker concentrations are highly inter-related, and production of one may result in the production or regulation of another. Therefore, a more comprehensive characterization of the inflammatory response post-TBI should consider relative levels of markers in the inflammatory pathway. We used principal component analysis (PCA) as a dimension-reduction technique to characterize the sets of markers that contribute independently to variability in cerebrospinal (CSF) inflammatory profiles after TBI. Using PCA results, we defined groups (or clusters) of individuals (n = 111) with similar patterns of acute CSF inflammation that were then evaluated in the context of outcome and other relevant CSF and serum biomarkers collected days 0-3 and 4-5 post-injury. We identified four significant principal components (PC1-PC4) for CSF inflammation from days 0-3, and PC1 accounted for the greatest (31%) percentage of variance. PC1 was characterized by relatively higher CSF sICAM-1, sFAS, IL-10, IL-6, sVCAM-1, IL-5, and IL-8 levels. Cluster analysis then defined two distinct clusters, such that individuals in cluster 1 had highly positive PC1 scores and relatively higher levels of CSF cortisol, progesterone, estradiol, testosterone, brain derived neurotrophic factor (BDNF), and S100b; this group also had higher serum cortisol and lower serum BDNF. Multinomial logistic regression analyses showed that individuals in cluster I had a 10.9 times increased likelihood of GOS scores of 2/3 vs. 4/5 at 6 months compared to cluster 2, after controlling for covariates. Cluster group did not discriminate between mortality compared to GOS scores of 4/5 after controlling for age and other covariates. Cluster groupings also did not discriminate mortality or 12 month outcomes in multivariate models. PCA and cluster analysis establish that a subset of CSF inflammatory markers measured in days 0-3 post-TBI may distinguish individuals with poor 6-month outcome, and future studies should prospectively validate these findings. PCA of inflammatory mediators after TBI could aid in prognostication and in identifying patient subgroups for therapeutic interventions. (C) 2015 Elsevier Inc. All rights reserved.	[Kumar, Raj G.; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15260 USA; [Rubin, Jonathan E.] Univ Pittsburgh, Dept Math, 301 Thackeray Hall, Pittsburgh, PA 15260 USA; [Berger, Rachel P.; Kochanek, Patrick M.; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Berger, Rachel P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15260 USA.; Rubin, JE (corresponding author), Univ Pittsburgh, Dept Math, 301 Thackeray Hall, Pittsburgh, PA 15260 USA.	jonrubin@pitt.edu; wagnerak@upmc.edu	RUBIN, JONATHAN/AAD-9071-2019	Rubin, Jonathan/0000-0002-1513-1551	CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR 323155]; DODUnited States Department of Defense [W81XWH-071-0701]; NIDILRRUnited States Department of Health & Human Services [90DP0041-02-01]; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMOUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U48DP000041] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE323155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	The authors wish to thank the UPMC Trauma Registry for providing some elements of data collection. The authors also wish to thank the University of Pittsburgh Cancer Institute for Luminex services. This work was supported in part by: CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDILRR 90DP0041-02-01.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bryant Fred B, 1995, PRINCIPAL COMPONENTS; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CDC, NAT VIT STAT SYST MO; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Crownover J, 2012, CURR GERIATR REP, V1, P149, DOI 10.1007/s13670-012-0021-6; Daun S, 2008, J CRIT CARE, V23, P585, DOI 10.1016/j.jcrc.2008.02.003; De Guise E., 2015, BRAIN INJURY, P1; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Failla M.D., 2015, NEUROREHABIL NEURAL; Friedland-Leuner K, 2014, PROG MOL BIOL TRANSL, V127, P183, DOI 10.1016/B978-0-12-394625-6.00007-6; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; GERMANN T, 1993, EUR J IMMUNOL, V23, P1762, DOI 10.1002/eji.1830230805; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Grimm L.G., 1995, READING UNDERSTANDIN; HALLENBECK JM, 1977, NEUROLOGY, V27, P3, DOI 10.1212/WNL.27.1.3; HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; JENNETT B, 1975, LANCET, V1, P480; Jeong Hey-Kyeong, 2013, Exp Neurobiol, V22, P59, DOI 10.5607/en.2013.22.2.59; Juengst S.B., 2014, J HEAD TRAUMA REHABI; Kaiser H.F., 1960, ED PSYCHOL MEAS; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Kumar R., 2014, J HEAD TRAUMA REHABI; Lourbopoulos A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00054; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Machado RF, 2005, AM J RESP CRIT CARE, V171, P1286, DOI 10.1164/rccm.200409-1184OC; MacQueen J, 1967, P 5 BERKELEY S MATH; Mocchegiani E, 2014, AGEING RES REV, V14, P81, DOI 10.1016/j.arr.2014.01.001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nettleton JA, 2007, AM J CLIN NUTR, V85, P1615, DOI 10.1093/ajcn/85.6.1615; Norden D., 2014, NEUROPHARMACOLOGY; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roe C, 2013, J REHABIL MED, V45, P734, DOI 10.2340/16501977-1198; Salminen LE, 2014, REV NEUROSCIENCE, V25, P805, DOI 10.1515/revneuro-2014-0046; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Suhr DD, 2005, PSAS US GROUP INT C, P203, DOI DOI 10.1177/096228029200100105; Tadevosyan-Leyfer O, 2003, J AM ACAD CHILD PSY, V42, P864, DOI 10.1097/01.CHI.0000046870.56865.90; WAGNER A, 2015, J NEUROTRAUM, V32, pA92, DOI DOI 10.1089/NEU.2015.29000.ABSTRACTS; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu K, 2008, ADV EXP MED BIOL, V614, P379, DOI 10.1007/978-0-387-74911-2_42	51	29	31	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAR	2016	53						183	193		10.1016/j.bbi.2015.12.008			11	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	DG9BJ	WOS:000372377500019	26705843	Bronze, Green Accepted			2022-02-06	
J	Soltani, Z; Khaksari, M; Shahrokhi, N; Mohammadi, G; Mofid, B; Vaziri, A; Amiresmaili, S				Soltani, Zahra; Khaksari, Mohammad; Shahrokhi, Nader; Mohammadi, Gholamabbas; Mofid, Behshad; Vaziri, Ali; Amiresmaili, Sedigheh			Effect of estrogen and/or progesterone administration on traumatic brain injury-caused brain edema: the changes of aquaporin-4 and interleukin-6	JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Interleukin-6; Aquaporin-4; Traumatic brain injury; Estrogen; Progesterone	SEX STEROID-HORMONES; REACTIVE ASTROCYTES; BARRIER DISRUPTION; ISCHEMIC BRAIN; MESSENGER-RNA; RAT-BRAIN; EXPRESSION; STROKE; TNF; MATRIX-METALLOPROTEINASE-9	The role of aquaporin-4 (AQP4) and interleukin-6 (IL-6) in the development of brain edema post-traumatic brain injury (TBI) has been indicated. The present study was designed to investigate the effect(s) of administration of progesterone (P) and/or estrogen (E) on brain water content, AQP4 expression, and IL-6 levels post-TBI. The ovariectomized rats were divided into 11 groups: sham, one vehicle, two vehicles, E1, E2, P1, P2, E1 + P1, E1 + P2, E2 + P1, and E2 + P2. The brain AQP4 expression, IL-6 levels, and water content were evaluated 24 h after TBI induced by Marmarou's method. The low (E1 and P1) and high (E2 and P2) doses of estrogen and progesterone were administered 30 min post-TBI. The results showed that brain water content and AQP4 expression decreased in the E1, E2, P1, and P2-treated groups. The administration of E1 decreased IL-6 levels. Addition of progesterone decreased the inhibitory effect of E1 and E2 on the accumulation of water in the brain. Administration of E1 + P1 and E1 + P2 decreased the inhibitory effect of E1 on the IL-6 levels and AQP4 protein expression. Our findings suggest that estrogen or progesterone by itself has more effective roles in decrease of brain edema than combination of both. Possible mechanism may be mediated by the alteration of AQP4 and IL-6 expression. However, further studies are required to verify the exact mechanism.	[Soltani, Zahra; Shahrokhi, Nader] Kerman Univ Med Sci, Physiol Res Ctr, Inst Neuropharmacol, Kerman, Iran; [Khaksari, Mohammad] Kerman Univ Med Sci, Ctr Res Neurosci, Inst Neuropharmacol, Kerman, Iran; [Mohammadi, Gholamabbas; Vaziri, Ali] Kerman Univ Med Sci, Med Sch Afzalipour, Dept Biochem, Kerman, Iran; [Mofid, Behshad] Shahid Bahonar Hosp Kerman, Dept Neurosurg, Kerman, Iran; [Amiresmaili, Sedigheh] Bam Univ Med Sci, Kerman, Iran		Khaksari, M (corresponding author), Kerman Univ Med Sci, Ctr Res Neurosci, Inst Neuropharmacol, Kerman, Iran.	mkhaksari@kmu.ac.ir	Shahrokhi, Nader/AAV-3747-2020; Haddad, Mohammad Khaksari/AAB-9025-2019; Soltani, Zahra/AAC-1350-2019	Shahrokhi, Nader/0000-0002-0149-7819; Haddad, Mohammad Khaksari/0000-0003-0770-4281; Soltani, Zahra/0000-0002-8423-6189; Mohammadi, Gholamabbas/0000-0002-2621-0810	neuroscience research center of Kerman University of Medical Sciences; physiology research center of Kerman University of Medical Sciences	The present study was supported by neuroscience and physiology research centers of Kerman University of Medical Sciences.	Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Ding ZY, 2013, CELL BIOCHEM BIOPHYS, V67, P615, DOI 10.1007/s12013-013-9549-0; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Jain SK, 2004, CYTOKINE, V26, P102, DOI 10.1016/j.cyto.2004.01.002; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; Kleindienst A, 2013, ACTA NEUROCHIR, V155, P151, DOI 10.1007/s00701-012-1558-z; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leonardo CC, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-13; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P981, DOI 10.1016/0002-9378(95)90246-5; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181, DOI 10.1097/01.WCB.0000037990.07114.07; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Shi WZ, 2012, NEUROSCI LETT, V520, P121, DOI 10.1016/j.neulet.2012.05.052; Shi WZ, 2012, NEUROSCI BULL, V28, P61, DOI 10.1007/s12264-012-1063-7; Shin JA, 2011, BBA-MOL BASIS DIS, V1812, P1154, DOI 10.1016/j.bbadis.2011.05.004; Simpkins J. W., 1997, AM J MED, V103, P19, DOI 10.1016/s0002-9343(97)00260-x; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Suzuki S, 2009, FRONT NEUROENDOCRIN, V30, P201, DOI 10.1016/j.yfrne.2009.04.007; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Teede HJ, 2003, BEST PRACT RES CL EN, V17, P73, DOI 10.1016/S1521-690X(02)00083-0; Tomas-Camardiel M, 2005, J NEUROSCI RES, V80, P235, DOI 10.1002/jnr.20443; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang XY, 2013, EXP THER MED, V6, P263, DOI 10.3892/etm.2013.1116; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207	42	29	30	0	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1138-7548	1877-8755		J PHYSIOL BIOCHEM	J. Physiol. Biochem.	MAR	2016	72	1					33	44		10.1007/s13105-015-0453-5			12	Biochemistry & Molecular Biology; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Physiology	DF5PG	WOS:000371403500004	26638215	Green Accepted			2022-02-06	
J	Mohamed, RA; Agha, AM; Abdel-Rahman, AA; Nassar, NN				Mohamed, R. A.; Agha, A. M.; Abdel-Rahman, A. A.; Nassar, N. N.			ROLE OF ADENOSINE A(2A) RECEPTOR IN CEREBRAL ISCHEMIA REPERFUSION INJURY: SIGNALING TO PHOSPHORYLATED EXTRACELLULAR SIGNAL-REGULATED PROTEIN KINASE (pERK1/2)	NEUROSCIENCE			English	Article						A(2A); ischemia reperfusion; pERK1/2; microglia; apoptosis; oxidative stress	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; C-FOS; FOREBRAIN ISCHEMIA; MICROGLIAL CELLS; FACTOR-ALPHA; ACTIVATION; RATS; EXPRESSION	Following brain ischemia reperfusion (IR), the dramatic increase in adenosine activates A(2A)R to induce further neuronal damage. Noteworthy, A(2A) antagonists have proven efficacious in halting IR injury, however, the detailed downstream signaling remains elusive. To this end, the present study aimed to investigate the possible involvement of phospho-extracellular signal-regulated kinase (pERK1/2) pathway in mediating protection afforded by the central A(2A) blockade. Male Wistar rats (250-270 g) subjected to bilateral carotid occlusion for 45 min followed by a 24-h reperfusion period showed increased infarct size corroborating histopathological damage, memory impairment and motor incoordination as well as increased locomotor activity. Those events were mitigated by the unilateral intrahippocampal administration of the selective A(2A) antagonist SCH58261 via a decrease in pERK1/2 downstream from diacyl glycerol (DAG) signaling. Consequent to pERK1/2 inhibition, reduced hippocampal microglial activation, glial tumor necrosis factor-alpha (TNF-alpha) and brain-derived neurotropic factor (BDNF) expression, glutamate (Glu), inducible nitric oxide synthase (iNOS) and thiobarbituric acid reactive substances (TBARS) were evident in animals receiving SCH58261. Additionally, the anti-inflammatory cytokine interleukin-10 (IL-10) increased following nuclear factor (erythroid-derived 2)-like 2 (Nrf-2). Taken all together, these events suppressed apoptotic pathways via a reduction in cytochrome c (Cyt.c) as well as caspase-3 supporting a crucial role for pERK1/2 inhibition in consequent reduction of inflammatory and excitotoxic cascades as well as correction of the redox imbalance. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.	[Mohamed, R. A.; Agha, A. M.; Nassar, N. N.] Cairo Univ, Fac Pharm, Dept Pharmacol & Toxicol, Cairo 11562, Egypt; [Abdel-Rahman, A. A.] E Carolina Univ, Brody Sch Med, Dept Pharmacol & Toxicol, Greenville, NC 27858 USA		Nassar, NN (corresponding author), Cairo Univ, Fac Pharm, Dept Pharmacol & Toxicol, Kasr El Aini St, Cairo 11562, Egypt.	reham.atef@pharma.cu.edu.eg; azzaagha@yahoo.com; abdelrahmana@ecu.edu; noha.nassar@pharma.cu.edu.eg	Abdel-Rahman, Abdel/AAJ-6753-2020	Abdel-Rahman, Abdel/0000-0002-3461-2190			Abdallah DM, 2011, BRAIN RES, V1385, P257, DOI 10.1016/j.brainres.2011.02.007; Alonso D, 2002, J COMP NEUROL, V443, P183, DOI 10.1002/cne.10111; Alvarez-Diaz A, 2007, NEONATOLOGY, V92, P227, DOI 10.1159/000103741; Baldanzi G, 2010, CELL DEATH DIFFER, V17, P1059, DOI 10.1038/cdd.2009.210; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bender TS, 2009, ALCOHOL CLIN EXP RES, V33, P408, DOI 10.1111/j.1530-0277.2008.00860.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005; Cheng HC, 2002, J BIOL CHEM, V277, P33930, DOI 10.1074/jbc.M201206200; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Edling Y, 2007, GLIA, V55, P328, DOI 10.1002/glia.20464; ELNASR MS, 1992, J PHARMACOL TOXICOL, V27, P23, DOI 10.1016/1056-8719(92)90016-T; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Fischer AJ, 2009, GLIA, V57, P166, DOI 10.1002/glia.20743; Fredholm BB, 2007, PROG NEUROBIOL, V83, P263, DOI 10.1016/j.pneurobio.2007.07.005; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Galvao RIM, 2005, NEUROCHEM RES, V30, P39, DOI 10.1007/s11064-004-9684-5; Gao C, 2010, HIPPOCAMPUS, V20, P1072, DOI 10.1002/hipo.20705; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gomes C, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-16; Gui L, 2009, BRAIN RES, V1297, P185, DOI 10.1016/j.brainres.2009.08.050; Gupta S., 2001, Current Molecular Medicine (Hilversum), V1, P317, DOI 10.2174/1566524013363780; Harukuni I, 2006, NEUROL CLIN, V24, P1, DOI 10.1016/j.ncl.2005.10.004; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; Institute for Laboratory Animal Research (ILAR), 1996, GUIDE CARE USE LAB A; Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Jeltsch H, 2001, NEUROBIOL LEARN MEM, V76, P81, DOI 10.1006/nlme.2000.3986; Jones PA, 1998, BRAIN RES, V800, P328, DOI 10.1016/S0006-8993(98)00540-X; Karnam HB, 2009, EPILEPSY RES, V85, P221, DOI 10.1016/j.eplepsyres.2009.03.008; Kim YH, 2010, INT IMMUNOPHARMACOL, V10, P1560, DOI 10.1016/j.intimp.2010.09.007; KURINO M, 1995, J NEUROCHEM, V65, P1282; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Macaya A, 1996, Rev Neurol, V24, P1356; Maddahi A, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-107; Malik ZA, 2011, J ETHNOPHARMACOL, V133, P729, DOI 10.1016/j.jep.2010.10.061; Mao LM, 2007, BRAIN RES BULL, V72, P302, DOI 10.1016/j.brainresbull.2007.01.009; McManus MJ, 2014, MOL CELL NEUROSCI, V63, P13, DOI 10.1016/j.mcn.2014.09.002; Medeiros R, 2007, J NEUROSCI, V27, P5394, DOI 10.1523/JNEUROSCI.5047-06.2007; Melani A, 2009, BRAIN, V132, P1480, DOI 10.1093/brain/awp076; Milot MR, 2009, BEHAV BRAIN RES, V200, P173, DOI 10.1016/j.bbr.2009.01.009; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Mohamed RA, 2012, NEUROCHEM RES, V37, P538, DOI 10.1007/s11064-011-0640-x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Okada S, 2003, INT IMMUNOL, V15, P1275, DOI 10.1093/intimm/dxg126; Olajide OA, 2013, J ETHNOPHARMACOL, V145, P42, DOI 10.1016/j.jep.2012.10.031; OSSENKOPP KP, 1990, PHARMACOL BIOCHEM BE, V36, P875, DOI 10.1016/0091-3057(90)90093-W; Park GH, 2010, NITRIC OXIDE-BIOL CH, V22, P18, DOI 10.1016/j.niox.2009.10.008; Park JS, 2007, J PHARMACOL EXP THER, V320, P1237, DOI 10.1124/jpet.106.114322; Paterniti I, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-31; Pedata F, 2007, PURINERG SIGNAL, V3, P299, DOI 10.1007/s11302-007-9085-8; Pedata F, 2001, ANN NY ACAD SCI, V939, P74; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; Quiroz C, 2006, J NEUROSCI, V26, P10808, DOI 10.1523/JNEUROSCI.1661-06.2006; Rebola N, 2011, J NEUROCHEM, V117, P100, DOI 10.1111/j.1471-4159.2011.07178.x; Rehni AK, 2008, FUND CLIN PHARMACOL, V22, P179, DOI 10.1111/j.1472-8206.2008.00567.x; Rehni AK, 2008, PHARMACOL REP, V60, P904; Sairanen TR, 2001, J NEUROL SCI, V186, P87, DOI 10.1016/S0022-510X(01)00508-1; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Sebastiao AM, 2009, BRIT J PHARMACOL, V158, P15, DOI 10.1111/j.1476-5381.2009.00157.x; Sharifzadeh M, 2005, J NEUROCHEM, V95, P1078, DOI 10.1111/j.1471-4159.2005.03454.x; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tian HP, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-139; Ulrich PT, 1998, STROKE, V29, P2412, DOI 10.1161/01.STR.29.11.2412; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Vitkovic L, 2000, MOL PSYCHIATR, V5, P604, DOI 10.1038/sj.mp.4000813; Wang Wei-Bin, 2005, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V21, P278; Wang XK, 2003, J PHARMACOL EXP THER, V304, P172, DOI 10.1124/jpet.102.040246; Yang YL, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-55; Zhang H, 2014, J HUAZHONG U SCI-MED, V34, P354, DOI 10.1007/s11596-014-1282-4; Zhang YS, 2004, MOL CANCER THER, V3, P885; Zhou MA, 2013, BRAIN RES, V1506, P105, DOI 10.1016/j.brainres.2013.02.010; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367	83	29	33	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 9	2016	314						145	159		10.1016/j.neuroscience.2015.11.059			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CZ9CE	WOS:000367394600013	26642806				2022-02-06	
J	Kontos, AP; Elbin, RJ; Sufrinko, A; Dakan, S; Bookwalter, K; Price, A; Meehan, WP; Collins, MW				Kontos, Anthony P.; Elbin, R. J.; Sufrinko, Alicia; Dakan, Scott; Bookwalter, Kylie; Price, Ali; Meehan, William P., III; Collins, Michael W.			Incidence of Concussion in Youth Ice Hockey Players	PEDIATRICS			English	Article							STATES HIGH-SCHOOL; INJURY; EPIDEMIOLOGY; SPORTS; RATES; RISK	BACKGROUND: Ice hockey is a fast-paced collision sport that entails both intentional (ie, body checking) and incidental contact that may involve the head. The objective of this study was to determine the incidence of concussions in relation to games/practices and age among competition-level youth ice hockey players (ages 12-18 years). METHODS: Participants included 397 youth ice hockey players from Western Pennsylvania; Boston, Massachusetts; and Birmingham, Alabama, during the 2012-2013 and 2013-2014 youth ice hockey seasons. Incidence rates (IRs) and incidence rate ratios (IRRs) of concussion were calculated for games/practices and age groups. RESULTS: A total of 23 369 (12 784 practice/10 585 game) athletic exposures (AEs) involving 37 medically diagnosed concussions occurred. More than 40% of concussions involved illegal contact. The combined IR for games and practices was 1.58 concussions per 1000 AEs. The IRR was 2.86 times (95% confidence interval 0.68-4.42) higher during games (2.49 per 1000 AEs) than practices (1.04 per 1000 AEs). CONCLUSIONS: The overall IR for concussion in youth ice hockey was comparable to those reported in other youth collision sports. The game-to-practice IRR was lower than previously reported in ice hockey and other youth sports, although more concussions per exposure occurred in games compared with practices. Younger players had a higher rate of concussions than older players.	[Kontos, Anthony P.; Sufrinko, Alicia; Dakan, Scott; Bookwalter, Kylie; Price, Ali; Collins, Michael W.] Univ Pittsburgh, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Elbin, R. J.] Univ Arkansas, Dept Hlth Human Performance & Recreat, Off Sport Concuss Res, Fayetteville, AR 72701 USA; [Dakan, Scott] Lake Erie Coll Osteopath Med, Coll Med, Erie, PA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA		Kontos, AP (corresponding author), UPMC Ctr Sports Med, 3200 South Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1K01DC012332-01A1]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; University of PittsburghUniversity of Pittsburgh; Bauer Performance Sports, Ltd.; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	Supported in part by a grant to the University of Pittsburgh through the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1) to Dr Kontos, and through a research contract between the University of Pittsburgh and Bauer Performance Sports, Ltd. with Dr Kontos and Dr Collins. Funded by the National Institutes of Health (NIH).	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Blake Tracy, 2012, Clin J Sport Med, V22, P377, DOI 10.1097/JSM.0b013e31826038e0; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Brenner JS, 2014, PEDIATRICS, V133, P1151, DOI 10.1542/peds.2014-0692; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2011, BRIT J SPORT MED, V45, P1289, DOI 10.1136/bjsports-2011-090538; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gwin J. T., 2009, J ASTM INT, V6, P1; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Katzmarzyk PT, 2004, PEDIATRICS, V114, P198; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Council of Youth Sports, REP TRENDS PART ORG; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091	21	29	29	0	16	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2016	137	2							e20151633	10.1542/peds.2015-1633			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	DF5LA	WOS:000371392000014	26746405	Green Published			2022-02-06	
J	Leung, A; Shukla, S; Fallah, A; Song, D; Lin, LS; Golshan, S; Tsai, A; Jak, A; Polston, G; Lee, R				Leung, Albert; Shukla, Shivshil; Fallah, Amir; Song, David; Lin, Lisa; Golshan, Shahrokh; Tsai, Alice; Jak, Amy; Polston, Greg; Lee, Roland			Repetitive Transcranial Magnetic Stimulation in Managing Mild Traumatic Brain Injury-Related Headaches	NEUROMODULATION			English	Article						Chronic posttraumatic headaches; mild traumatic brain injury-related headache; MTBI-HA; pain; repetitive transcranial magnetic stimulation; rTMS; traumatic brain injury	MAJOR DEPRESSION; PREFRONTAL CORTEX; YOUNG-PATIENTS; RTMS TREATMENT; PREVALENCE; VETERANS; MIGRAINE; SAFETY; PAIN	ObjectiveHeadache is one of the most common debilitating chronic pain conditions in either active or retired military personnel with mild traumatic brain injury (MTBI). This study assessed the effect of repetitive transcranial magnetic stimulation (rTMS) in alleviating MTBI-related headache (MTBI-HA). Materials and MethodVeterans with MTBI-HA were randomized to receive either real rTMS (REAL group) at 10 hz for a total of 2000 pulses divided into 20 trains with one-sec inter-train interval or sham rTMS (SHAM group) at the left motor cortex (LMC) with brain magnetic resonance imaging neuronavigation guidance. Pretreatment, posttreatment one-week and four-week headache and neuropsychological assessments were conducted. ResultThirty veterans were screened and twenty four (21 men and 3 women with average year-old SD at 14.3 +/- 12.6) subjects' data were analyzed. A two-factor (visit x treatment) repeated measures analysis of variance (RM-ANOVA) indicated a close to significant (p = 0.06) trend of interaction between pretreatment and posttreatment one-week assessment with the intensity of the persistent daily headache decreasing from 5.7 +/- 1.9 to 2.2 +/- 2.7 and 4.6 +/- 1.3 to 3.5 +/- 2.0 for the REAL and SHAM groups, respectively. Subsequent analyses indicated REAL group demonstrated a significantly (p = 0.041) higher % of reduction in persistent headache intensity than the SHAM group (56.3 +/- 48.2% vs.15.4 +/- 43.6%) at the posttreatment one-week assessment and the trend continued to the four-week assessment. Overall, a significantly (p = 0.035) higher percentage of the subjects in the REAL group (58.3%) demonstrated at least a 50% headache intensity reduction at posttreatment one-week assessment compared with the SHAM group (16.6%). The overall composite score of functionally debilitating headache exacerbation is significantly (p = 0.017) reduced in REAL group at the posttreatment four-week assessment in comparison with the SHAM group. No major sustained change in neuropsychological assessments was noted. ConclusionThe studied rTMS protocol appears to be a clinically feasible and effective treatment option in managing MTBI-HA.	[Leung, Albert; Shukla, Shivshil; Fallah, Amir; Song, David; Lin, Lisa; Golshan, Shahrokh; Tsai, Alice; Jak, Amy; Polston, Greg; Lee, Roland] Vet Adm San Diego Healthcare Syst, La Jolla, CA USA; [Golshan, Shahrokh] Vet Med Res Fdn, Biostat Core, San Diego, CA USA		Leung, A (corresponding author), Univ Calif San Diego, Dept Anesthesiol, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.; Leung, A (corresponding author), Vet Adm San Diego Healthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	ayleung@ucsd.edu	Brighina, Filippo/K-9864-2016	Brighina, Filippo/0000-0001-5875-3126	VA Rehabilitation and Research Development Award	VA Rehabilitation and Research Development Award	Bakker N, 2015, BRAIN STIMUL, V8, P208, DOI 10.1016/j.brs.2014.11.002; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brighina F, 2004, J NEUROL SCI, V227, P67, DOI 10.1016/j.jns.2004.08.008; Brunelin J, 2007, ENCEPHALE, V33, P126; Caeyenberghs K, 2015, BRAIN CONNECT, V5, P423, DOI 10.1089/brain.2014.0293; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Defrin R, 2014, J MAN MANIP THER, V22, P36, DOI 10.1179/2042618613Y.0000000053; DiTommaso C, 2014, HEADACHE, V54, P511, DOI 10.1111/head.12254; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; Joubert Jacques, 2005, Aust Fam Physician, V34, P621; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Leung A, 2014, HEADACHE, V54, P57; Leung A, 2009, J PAIN, V10, P1205, DOI 10.1016/j.jpain.2009.03.010; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton RB, 2010, NEUROTHERAPEUTICS, V7, P204, DOI 10.1016/j.nurt.2010.03.002; Ljubisavljevic M, 1996, ELECTROMYOGR MOTOR C, V101, P281, DOI 10.1016/0924-980X(96)95627-1; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Misra UK, 2013, J NEUROL, V260, P2793, DOI 10.1007/s00415-013-7072-2; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Ohn SH, 2012, NEUROREHAB NEURAL RE, V26, P344, DOI 10.1177/1545968311423110; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pal D, 2012, CLIN NEUROL NEUROSUR, V114, P564, DOI 10.1016/j.clineuro.2011.12.002; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Patil VK, 2011, HEADACHE, V51, P1112, DOI 10.1111/j.1526-4610.2011.01946.x; Peng HJ, 2012, J AFFECT DISORDERS, V136, P249, DOI 10.1016/j.jad.2011.12.006; PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wu E, 2015, J HEAD TRAUMA REHABI	35	29	30	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	FEB	2016	19	2					133	141		10.1111/ner.12364			9	Medicine, Research & Experimental; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Neurosciences & Neurology	DF1KF	WOS:000371097600002	26555886				2022-02-06	
J	Nichols, JN; Deshane, AS; Niedzielko, TL; Smith, CD; Floyd, CL				Nichols, Jessica N.; Deshane, Alok S.; Niedzielko, Tracy L.; Smith, Cory D.; Floyd, Candace L.			Greater neurobehavioral deficits occur in adult mice after repeated, as compared to single, mild traumatic brain injury (mTBI)	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Mild; Repetitive; Behavior; Learning and memory; Sleep	PROFESSIONAL FOOTBALL PLAYERS; MORRIS WATER MAZE; SLEEP DISTURBANCE; RECURRENT CONCUSSION; MOUSE MODEL; LONG-TERM; UPTAKE INHIBITORS; FLUID PERCUSSION; GENE-EXPRESSION; SPATIAL MEMORY	Mild traumatic brain injury (mTBI) accounts for the majority of all brain injuries and affected individuals typically experience some extent of cognitive and/or neuropsychiatric deficits. Given that repeated mTBIs often result in worsened prognosis, the cumulative effect of repeated mTBIs is an area of clinical concern and on-going pre-clinical research. Animal models are critical in elucidating the underlying mechanisms of single and repeated mTBI-associated deficits, but the neurobehavioral sequelae produced by these models have not been well characterized. Thus, we sought to evaluate the behavioral changes incurred after single and repeated mTBIs in mice utilizing a modified impact-acceleration model. Mice in the mTBI group received 1 impact while the repeated mTBI group received 3 impacts with an inter-injury interval of 24 h. Classic behavior evaluations included the Morris water maze (MWM) to assess learning and memory, elevated plus maze (EPM) for anxiety, and forced swim test (FST) for depression/helplessness. Additionally, species-typical behaviors were evaluated with the marble-burying and nestlet shredding tests to determine motivation and apathy. Non-invasive vibration platforms were used to examine sleep patterns post-mTBI. We found that the repeated mTBI mice demonstrated deficits in MWM testing and poorer performance on species-typical behaviors. While neither single nor repeated mTBI affected behavior in the EPM or FST, sleep disturbances were observed after both single and repeated mTBI. Here, we conclude that behavioral alterations shown after repeated mTBI resemble several of the deficits or disturbances reported by patients, thus demonstrating the relevance of this murine model to study repeated mTBIs. (C) 2015 Elsevier B.V. All rights reserved.	[Nichols, Jessica N.; Deshane, Alok S.; Niedzielko, Tracy L.; Floyd, Candace L.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA; [Smith, Cory D.] Univ Alabama Birmingham, Sch Med, Birmingham, AL 35294 USA		Floyd, CL (corresponding author), Univ Alabama Birmingham, Dept Phys Med & Rehabil, Spain Rehabil Ctr 529C, 1717 6th Ave South, Birmingham, AL 35249 USA.	jnic@uab.edu; adeshane@uab.edu; tracyniedzielko@uabmc.edu; cdsmith2@uab.edu; candacefloyd@uabmc.edu			National Institutes of Health, NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075162]; NFL Charities Medical Research Grant; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS075162] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health, NINDS grant # R01NS075162 (to CLF) and NFL Charities Medical Research Grant.	Angoa-Perez M, 2013, JOVE-J VIS EXP, DOI 10.3791/50978; Aubert A, 1999, NEUROSCI BIOBEHAV R, V23, P1029, DOI 10.1016/S0149-7634(99)00034-2; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; BROEKKAMP CL, 1986, EUR J PHARMACOL, V126, P223, DOI 10.1016/0014-2999(86)90051-8; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Centers for Disease Control and Prevention, 2014, REP C TRAUM BRAIN IN; Cheng JS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115765; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Committee on Sports-Related Concussions in Youth, 2014, SPORTS REL CONC YOUT; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Deacon RMJ, 2005, BEHAV BRAIN RES, V156, P241, DOI 10.1016/j.bbr.2004.05.027; Deacon R, 2012, JOVE-J VIS EXP, DOI 10.3791/2607; Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Faul M, 2010, TRAUMATIC BRAIN INJU; Feldman LA, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-35; Florian C, 2006, LEARN MEMORY, V13, P465, DOI 10.1101/lm.249306; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Jirkof P, 2014, J NEUROSCI METH, V234, P139, DOI 10.1016/j.jneumeth.2014.02.001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li X, 2006, LIFE SCI, V78, P1933, DOI 10.1016/j.lfs.2005.08.002; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moojen VKM, 2012, BRAIN RES, V1466, P82, DOI 10.1016/j.brainres.2012.05.041; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nicolas LB, 2006, EUR J PHARMACOL, V547, P106, DOI 10.1016/j.ejphar.2006.07.015; NJUNGE K, 1991, BRIT J PHARMACOL, V104, P105, DOI 10.1111/j.1476-5381.1991.tb12392.x; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Porsolt R.D., 2001, RODENT MODELS OR DEP; Riggio S, 2011, NEUROL CLIN, V29, P35, DOI 10.1016/j.ncl.2010.10.008; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rowe RK, 2014, BRAIN INJURY, V28, P504, DOI 10.3109/02699052.2014.888768; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Starkstein SE, 2014, PSYCHIAT CLIN N AM, V37, P103, DOI 10.1016/j.psc.2013.10.002; Sullivan KA, 2015, J NEUROTRAUM, V32, P474, DOI 10.1089/neu.2013.3284; Thomas A, 2009, PSYCHOPHARMACOLOGY, V204, P361, DOI 10.1007/s00213-009-1466-y; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Van de Weerd HA, 2001, BEHAV PROCESS, V53, P11, DOI 10.1016/S0376-6357(00)00135-2; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu L, 2014, EXP NEUROL; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	71	29	30	1	34	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 1	2016	298		B				111	124		10.1016/j.bbr.2015.10.052			14	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	CZ9JM	WOS:000367413900013	26542813				2022-02-06	
J	Saverino, C; Swaine, B; Jaglal, S; Lewko, J; Vernich, L; Voth, J; Calzavara, A; Colantonio, A				Saverino, Cristina; Swaine, Bonnie; Jaglal, Susan; Lewko, John; Vernich, Lee; Voth, Jennifer; Calzavara, Andrew; Colantonio, Angela			Rehospitalization After Traumatic Brain Injury: A Population-Based Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Patient readmission, hospital readmission; Rehabiliation; Risk factors	UNPLANNED HOSPITAL READMISSION; RISK; RATES; CARE; SYSTEM	Objective: To examine, from a Canadian population-based perspective, the incidence and etiology of long-term hospital utilization among persons living with traumatic brain injury (TBI) by age and sex. Design: Retrospective cohort study. Setting: Acute care hospitals. Participants: Index cases of TBI (N=29,269) were identified from the Discharge Abstract Database for fiscal years 2002/2003 through 2009/ 2010 and were followed-up until 36 months after injury. Interventions: Not applicable. Main Outcome Measures: Rehospitalization was defined as admission to an acute care facility that occurred up to 36 months after index injury. Diagnoses associated with subsequent rehospitalization were examined by age and sex. Results: Of the patients with TBI, 35.5% (n=10,390) were subsequently hospitalized during the 3-year follow-up period. Multivariable logistic regression (controlling for index admission hospital) identified men, older age, mechanism of injury being a fall, greater injury severity, rural residence, greater comorbidity, and psychiatric comorbidity to be significant predictors of rehospitalization in a 3-year period postinjury. The most common causes for rehospitalization differed by age and sex. Conclusions: Rehospitalization after TBI is common. Factors associated with rehospitalization can inform long-term postdischarge planning. Findings also support examining causes for rehospitalization by age and sex. (C) 2016 by the American Congress of Rehabilitation Medicine	[Saverino, Cristina] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Saverino, Cristina] Baycrest, Rotman Res Inst, Toronto, ON, Canada; [Saverino, Cristina; Jaglal, Susan; Voth, Jennifer; Colantonio, Angela] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada; [Swaine, Bonnie] Univ Montreal, Fac Med, Sch Rehabil, Montreal, PQ H3C 3J7, Canada; [Jaglal, Susan] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; [Lewko, John] Laurentian Univ, Ctr Res Human Dev, Sudbury, ON P3E 2C6, Canada; [Vernich, Lee] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Calzavara, Andrew; Colantonio, Angela] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada		Colantonio, A (corresponding author), 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765; Jaglal, Susan/0000-0002-2930-1443	Ontario Neurotrauma Foundation [2006-ABI-RTBI-432]; Ontario Neurotrauma Foundation-Reseau provincial de recherche en adaptation-readaptation [ONF-2011-ONF-REPAR2-883]; Toronto Rehabilitation InstituteUniversity of Toronto; Institute for Clinical Evaluative Sciences, Ontario Ministry of Health and Long-Term Care; Canadian Institutes of Health Research Research Chair in Gender, Work and Health from the Institute of Gender and HealthCanadian Institutes of Health Research (CIHR) [CGW-126580]	Supported by the Ontario Neurotrauma Foundation (grant no. 2006-ABI-RTBI-432); Ontario Neurotrauma Foundation-Reseau provincial de recherche en adaptation-readaptation (grant no. ONF-2011-ONF-REPAR2-883); the Toronto Rehabilitation Institute, the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care; and a Canadian Institutes of Health Research Research Chair in Gender, Work and Health (grant no. CGW-126580) from the Institute of Gender and Health.	Association for the Advancement of Automotive Medicine, 2008, ABBR INJ SCAL 2005 U; Boutin A., 2013, CRIT CARE, V17, pP331; Cakir B, 2010, SOUTH MED J, V103, P1079, DOI 10.1097/SMJ.0b013e3181f20a0f; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Canadian Institute for Health Information, 2012, ALL CAUS READM AC CA; Canadian Institute for Health Information, 2004, DAT QUAL DOC DISCH A; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; Colantonio A, 2005, ARCH PHYS MED REHAB, V86, pE21; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; CORRIGAN JM, 1992, HEALTH SERV RES, V27, P81; Dai YT, 2002, J FORMOS MED ASSOC, V101, P779; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Jaglal SB, 2009, SPINAL CORD, V47, P604, DOI 10.1038/sc.2009.9; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Johns Hopkins University, 2013, J HOPK ACG SYST; Kim H, 2006, CAN J NEUROL SCI, V33, P48, DOI 10.1017/S0317167100004686; Kim H, 2006, NEUROREHABILITATION, V21, P269; Kralj B, 2000, ONTARIO MED REV, P37; Madi Nawaf, 2007, Healthc Q, V10, P30; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; McCrone P, 2006, SOC PSYCH PSYCH EPID, V41, P656, DOI 10.1007/s00127-006-0075-x; Moore L, 2014, J TRAUMA ACUTE CARE, V76, P1310, DOI 10.1097/TA.0000000000000202; Moore L, 2014, ANN SURG, V259, P374, DOI 10.1097/SLA.0b013e31828b0fae; Morris DS, 2014, INJURY, V45, P56, DOI 10.1016/j.injury.2013.04.029; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P1884, DOI 10.1016/j.apmr.2012.11.054; Reid RJ, 2001, MED CARE, V39, P86, DOI 10.1097/00005650-200101000-00010; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shipton S, 1996, Home Care Provid, V1, P83, DOI 10.1016/S1084-628X(96)90234-8; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Van Rensbergen G, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-46; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; Weissman JS, 1999, MED CARE, V37, P490, DOI 10.1097/00005650-199905000-00008; Westert GP, 2002, HEALTH POLICY, V61, P269, DOI 10.1016/S0168-8510(01)00236-6; Williams JI, 1996, PATTERNS HLTH CARE O; Worrell SS, 2006, J TRAUMA, V60, P379, DOI 10.1097/01.ta.0000203549.15373.7b	37	29	29	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2016	97	2		1			S19	S25		10.1016/j.apmr.2015.04.016			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	DC4RI	WOS:000369207600003	25944501	Bronze			2022-02-06	
J	Taylor, KM; Saint-Hilaire, MH; Sudarsky, L; Simon, DK; Hersh, B; Sparrow, D; Hu, H; Weisskopf, MG				Taylor, Kathryn M.; Saint-Hilaire, Marie-Helene; Sudarsky, Lewis; Simon, David K.; Hersh, Bonnie; Sparrow, David; Hu, Howard; Weisskopf, Marc G.			Head injury at early ages is associated with risk of Parkinson's disease	PARKINSONISM & RELATED DISORDERS			English	Article						Head injury; Parkinson's disease; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; MICROGLIAL ACTIVATION; INFLAMMATION; EXPOSURE	Introduction: The literature on the effect of head injuries on the risk of PD is inconclusive. Some researchers have hypothesized that studies that have seen an effect are simply capturing injury related to pre-clinical PD. However in animal models brain inflammation, which can be initiated by head trauma, has been shown to produce PD-like effects. Furthermore, animal studies have found that early life inflammation in particular is of relevance for PD pathology. Methods: We conducted an unmatched case control study of 379 neurologist confirmed PD patients and 230 controls from the greater Boston, Massachusetts area with questionnaire data on history of head injury and other covariates. We used multivariable logistic regression to estimate adjusted odds ratios (OR) and their corresponding 95% confidence intervals (CI) for PD. Results: When we excluded injuries that occurred less than 10 years prior to the diagnosis of PD (in order to avoid reverse causation), we found an increased risk of PD associated with a head injury that resulted in a loss of consciousness, but it did not reach statistical significance (OR = 1.57; 95% CI = 0.89-2.80). We found a significant (p = 0.04) effect of age at first head injury. For every 5 year earlier age at first head injury with loss of consciousness the OR for PD was 1.37 (95% CI: 1.01-1.86). Conclusion: Our results suggest that head injury in early life increases the risk of PD. (C) 2015 Published by Elsevier Ltd.	[Taylor, Kathryn M.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 401 Pk Dr,Landmark Bldg,3rd Floor, Boston, MA 02215 USA; [Saint-Hilaire, Marie-Helene] Boston Univ, Dept Neurol, Med Ctr, 72 East Concord St,C3, Boston, MA 02118 USA; [Sudarsky, Lewis] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA; [Simon, David K.] Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA; [Simon, David K.] Harvard Univ, Sch Med, Dept Neurol, 330 Brookline Ave, Boston, MA 02215 USA; [Hersh, Bonnie] Harvard Vanguard Med Associates, 133 Brookline Ave, Boston, MA 02215 USA; [Sparrow, David] VA Boston Healthcare Syst, 150 South Huntington Ave, Boston, MA 02130 USA; [Sparrow, David] Boston Univ, Sch Publ Hlth, 715 Albany St, Boston, MA 02118 USA; [Sparrow, David] Boston Univ, Sch Med, 715 Albany St, Boston, MA 02118 USA; [Hu, Howard] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Epidemiol, 6th Floor,155 Coll St, Toronto, ON, Canada; [Hu, Howard] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Global Hlth, 6th Floor,155 Coll St, Toronto, ON, Canada; [Hu, Howard] Univ Toronto, Dalla Lana Sch Publ Hlth, Dept Environm Hlth, 6th Floor,155 Coll St, Toronto, ON, Canada; [Weisskopf, Marc G.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol & Environm Hlth, 677 Huntington Ave, Boston, MA 02115 USA		Taylor, KM (corresponding author), Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, 401 Pk Dr,Landmark Bldg,3rd Floor, Boston, MA 02215 USA.	kmt691@mail.harvard.edu; neuromsh@bu.edu; lsudarsky@partners.com; dsimon1@bidmc.harvard.edu; bonnie_hersh@vmed.org; david.sparrow@va.gov; howard.hu@utoronto.ca; mweissko@hsph.harvard.edu	Hu, Howard/AAV-5360-2021	Hu, Howard/0000-0002-3676-2707	National Institute of Health, National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01-ES010798, P01-ES000002]; National Institute of Health: IMSD Academic Training grant [R25 GM055353]; National Institute for Occupational Safety and Health: ERC training grant [T42 OH008416]; VA Research Career Scientist award; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [T42OH008416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES000002, R01ES010798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R25GM055353] Funding Source: NIH RePORTER	This work was supported by the National Institute of Health, National Institute of Environmental Health Sciences (R01-ES010798 and P01-ES000002 (M W.)), National Institute of Health: IMSD Academic Training grant (R25 GM055353 (K.T.)), the National Institute for Occupational Safety and Health: ERC training grant (T42 OH008416 (K T.)) and VA Research Career Scientist award (D.S.)	Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Cai ZW, 2013, DEV NEUROSCI-BASEL, V35, P155, DOI 10.1159/000346156; Cory-Slechta DA, 2005, BIRTH DEFECTS RES A, V73, P136, DOI 10.1002/bdra.20118; Ezcurra ALD, 2010, NEUROBIOL DIS, V37, P630, DOI 10.1016/j.nbd.2009.11.018; Fang F, 2012, MOVEMENT DISORD, V27, P1632, DOI 10.1002/mds.25143; Faul M, 2010, TRAUMATIC BRAIN INJU; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gao JJ, 2015, PARKINSONISM RELAT D, V21, P292, DOI 10.1016/j.parkreldis.2014.12.033; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; Harris MA, 2013, OCCUP ENVIRON MED, V70, P839, DOI 10.1136/oemed-2013-101444; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lees AJ, 2009, LANCET, V373, P2055, DOI 10.1016/S0140-6736(09)60492-X; Ling ZD, 2006, EXP NEUROL, V199, P499, DOI 10.1016/j.expneurol.2006.01.010; Liu B, 2003, ENVIRON HEALTH PERSP, V111, P1065, DOI 10.1289/ehp.6361; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; McGeer PL, 2004, PARKINSONISM RELAT D, V10, pS3, DOI 10.1016/j.parkreldis.2004.01.005; R C Team, 2013, R LANG ENV STAT COMP; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; S.I. Inc, 2012, SAS ONL DOC; Tanner CM, 2003, ADV NEUROL, V91, P133	26	29	29	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1353-8020	1873-5126		PARKINSONISM RELAT D	Parkinsonism Relat. Disord.	FEB	2016	23						57	61		10.1016/j.parkreldis.2015.12.005			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DE8KW	WOS:000370885900009	26725141	Green Accepted			2022-02-06	
J	Namjoshi, DR; Cheng, WH; Carr, M; Martens, KM; Zareyan, S; Wilkinson, A; McInnes, KA; Cripton, PA; Wellington, CL				Namjoshi, Dhananjay R.; Cheng, Wai Hang; Carr, Michael; Martens, Kris M.; Zareyan, Shahab; Wilkinson, Anna; McInnes, Kurt A.; Cripton, Peter A.; Wellington, Cheryl L.			Chronic Exposure to Androgenic-Anabolic Steroids Exacerbates Axonal Injury and Microgliosis in the CHIMERA Mouse Model of Repetitive Concussion	PLOS ONE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; RECEPTOR MESSENGER-RNA; NATIONAL-FOOTBALL-LEAGUE; BRAIN-INJURY; HEAD-INJURY; POSTCONCUSSION SYNDROME; PROTEIN-TAU; MALE-MICE; SEROTONIN; IMPACT	Concussion is a serious health concern. Concussion in athletes is of particular interest with respect to the relationship of concussion exposure to risk of chronic traumatic encephalopathy (CTE), a neurodegenerative condition associated with altered cognitive and psychiatric functions and profound tauopathy. However, much remains to be learned about factors other than cumulative exposure that could influence concussion pathogenesis. Approximately 20% of CTE cases report a history of substance use including androgenic-anabolic steroids (AAS). How acute, chronic, or historical AAS use may affect the vulnerability of the brain to concussion is unknown. We therefore tested whether antecedent AAS exposure in young, male C57BI/6 mice affects acute behavioral and neuropathological responses to mild traumatic brain injury (TBI) induced with the CHIMERA (Closed Head Impact Model of Engineered Rotational Acceleration) platform. Male C57Bl/6 mice received either vehicle or a cocktail of three AAS (testosterone, nandrolone and 17 alpha-methyltestosterone) from 8-16 weeks of age. At the end of the 7th week of treatment, mice underwent two closed-head TBI or sham procedures spaced 24 h apart using CHIMERA. Post-repetitive TBI (rTBI) behavior was assessed for 7 d followed by tissue collection. AAS treatment induced the expected physiological changes including increased body weight, testicular atrophy, aggression and downregulation of brain 5-HT1B receptor expression. rTBI induced behavioral deficits, widespread axonal injury and white matter microgliosis. While AAS treatment did not worsen post-rTBI behavioral changes, AAS-treated mice exhibited significantly exacerbated axonal injury and microgliosis, indicating that AAS exposure can alter neuronal and innate immune responses to concussive TBI.	[Namjoshi, Dhananjay R.; Cheng, Wai Hang; Carr, Michael; Martens, Kris M.; Zareyan, Shahab; Wilkinson, Anna; Wellington, Cheryl L.] Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [McInnes, Kurt A.; Cripton, Peter A.] Univ British Columbia, Dept Biomech Engn, Vancouver, BC V5Z 1M9, Canada; [Cripton, Peter A.; Wellington, Cheryl L.] Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC V5Z 1M9, Canada		Wellington, CL (corresponding author), Univ British Columbia, Djavad Mowafaghian Ctr Brain Hlth, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada.; Wellington, CL (corresponding author), Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC V5Z 1M9, Canada.	wcheryl@mail.ubc.ca	Cripton, Peter Alec/AAC-8268-2020; Meijer, Anna/K-5118-2016	Cripton, Peter Alec/0000-0002-5067-0833; Cheng, Wai Hang/0000-0002-3408-9184; McInnes, Kurt/0000-0001-5931-2963	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP 123461]; Alzheimer Society Research Program Doctoral award; Comissao Technica de Atribuicao de Bolsas para Estudos Pos-Graduados Macao	This work was supported by operating funding from the Canadian Institutes of Health Research (MOP 123461) to CLW (http://www.cihrirsc.gc.ca/e/193.htm). WHC is supported by Alzheimer Society Research Program Doctoral award (http://www.alzheimer.ca/en/Research/Alzheimer-Society-Research-Program) and Comissao Technica de Atribuicao de Bolsas para Estudos Pos-Graduados Macao. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambar G, 2009, GENES BRAIN BEHAV, V8, P161, DOI 10.1111/j.1601-183X.2008.00458.x; ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bonaventure P, 1998, NEUROSCIENCE, V82, P469; Bressan S, 2016, J PAEDIATR CHILD H, V52, P151, DOI 10.1111/jpc.12967; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cernich AN, 2012, J HEAD TRAUMA REHAB, V27, P253, DOI 10.1097/HTR.0b013e3182585cd5; Clark AS, 2003, NEUROSCI BIOBEHAV R, V27, P413, DOI 10.1016/S0149-7634(03)00064-2; Coccaro EF, 2015, CNS SPECTRUMS, V20, P295, DOI 10.1017/S1092852915000310; Covassin T, 2013, TRANSL STROKE RES, V4, P420, DOI 10.1007/s12975-012-0228-z; Cunningham RL, 2013, HORM BEHAV, V64, P350, DOI 10.1016/j.yhbeh.2012.12.009; de Boer SF, 2005, EUR J PHARMACOL, V526, P125, DOI 10.1016/j.ejphar.2005.09.065; Duke AA, 2013, PSYCHOL BULL, V139, P1148, DOI 10.1037/a0031544; Evans NA, 2004, AM J SPORT MED, V32, P534, DOI 10.1177/0363546503262202; Faul M, 2010, TRAUMATIC BRAIN INJU; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gerberding JL, 2003, THE REPORT TO CONGRE; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grimes JM, 2002, PHARMACOL BIOCHEM BE, V73, P713, DOI 10.1016/S0091-3057(02)00880-8; Hartgens F, 2004, SPORTS MED, V34, P513, DOI 10.2165/00007256-200434080-00003; Hoffman JR, 2006, J SPORT SCI MED, V5, P182; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Iverson GL, 2015, JAMA PEDIATR, V169, P1132, DOI 10.1001/jamapediatrics.2015.2374; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Kindlundh AMS, 2003, NEUROSCIENCE, V119, P113, DOI 10.1016/S0306-4522(03)00120-9; Kubala KH, 2008, BRAIN RES, V1232, P21, DOI 10.1016/j.brainres.2008.07.065; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Levin B, 2014, NEUROCRIT CARE, V20, P334, DOI 10.1007/s12028-013-9931-1; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Marshall-Gradisnik S, 2009, CENT EUR J BIOL, V4, P19, DOI 10.2478/s11535-008-0058-x; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McMillan P, 2008, J COMP NEUROL, V511, P788, DOI 10.1002/cne.21867; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mills JD, 2012, NEUROSURGERY, V70, P205, DOI 10.1227/NEU.0b013e3182250918; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Namjoshi DR, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-55; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Nelson RJ, 2001, TRENDS NEUROSCI, V24, P713, DOI 10.1016/S0166-2236(00)01996-2; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Penatti CAA, 2009, J NEUROSCI, V29, P12484, DOI 10.1523/JNEUROSCI.3108-09.2009; Popova N K, 2008, Neurosci Behav Physiol, V38, P471, DOI 10.1007/s11055-008-9004-7; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Reilly P, 2007, PROG BRAIN RES, V161, P3, DOI 10.1016/S0079-6123(06)61001-7; Robinson S, 2012, HORM BEHAV, V61, P67, DOI 10.1016/j.yhbeh.2011.10.004; Sagoe D, 2014, ANN EPIDEMIOL, V24, P383, DOI 10.1016/j.annepidem.2014.01.009; SANCHEZ C, 1993, PSYCHOPHARMACOLOGY, V110, P53, DOI 10.1007/BF02246950; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Turillazzi E, 2011, MINI-REV MED CHEM, V11, P374, DOI 10.2174/138955711795445925; van Amsterdam J, 2010, REGUL TOXICOL PHARM, V57, P117, DOI 10.1016/j.yrtph.2010.02.001; Varnas K, 2005, SYNAPSE, V56, P21, DOI 10.1002/syn.20128; VIRKKUNEN M, 1995, J PSYCHIATR NEUROSCI, V20, P271	66	29	30	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 19	2016	11	1							e0146540	10.1371/journal.pone.0146540			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DB5BP	WOS:000368528400046	26784694	Green Submitted, Green Published, gold			2022-02-06	
J	Cotton, RT; Pearce, CW; Young, PG; Kota, N; Leung, AC; Bagchi, A; Qidwai, SM				Cotton, R. T.; Pearce, C. W.; Young, P. G.; Kota, N.; Leung, A. C.; Bagchi, A.; Qidwai, S. M.			Development of a geometrically accurate and adaptable finite element head model for impact simulation: the Naval Research Laboratory-Simpleware Head Model	COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING			English	Article						head impact; blast; traumatic brain injury; simulation; finite element; meshing	CORTICAL BONE; BRAIN MOTION; INJURY; MECHANISMS	This study demonstrates a novel model generation methodology that addresses several limitations of conventional finite element head models (FEHM). By operating chiefly in image space, new structures can be incorporated or merged, and the mesh either decimated or refined both locally and globally. This methodology is employed in the development of a highly bio-fidelic FEHM from high-resolution scan data. The model is adaptable and presented here in a form optimised for impact and blast simulations. The accuracy and feasibility of the model are successfully demonstrated against a widely used experimental benchmark in impact loading and through the investigation of potential brain injury under blast overpressure loading.	[Cotton, R. T.; Pearce, C. W.] Simpleware Ltd, Exeter EX4 3PL, Devon, England; [Young, P. G.] Univ Exeter, Coll Engn Math & Phys Sci, Exeter, Devon, England; [Kota, N.] Leidos Corp, MCET Dept, Arlington, VA USA; [Leung, A. C.; Bagchi, A.; Qidwai, S. M.] US Naval Res Lab, Multifunct Mat Branch, Washington, DC USA		Cotton, RT (corresponding author), Simpleware Ltd, Bradninch Hall,Castle St, Exeter EX4 3PL, Devon, England.	r.cotton@simpleware.com			Office of Naval Research (ONR) through US Naval Research Laboratory's Basic Research Program; Department of Defense (DoD) High Performance Computing Modernization Program (HPCMP); Air Force Research Laboratory (AFRL)United States Department of DefenseUS Air Force Research Laboratory; Major Shared Resource Center (MSRC) [416, 231]	This work was supported by the Office of Naval Research (ONR) through the US Naval Research Laboratory's Basic Research Program, and the Department of Defense (DoD) High Performance Computing Modernization Program (HPCMP) using the Air Force Research Laboratory (AFRL) Major Shared Resource Center (MSRC) under project 416, subproject 231.	ABAQUS, 2012, ABAQUS DOC; Alves JM, 1996, IEEE T BIO-MED ENG, V43, P249, DOI 10.1109/10.486282; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Dewey JM., 2010, 21 INT S MIL ASP BLA; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Johnson TPM, 2010, ACTA BIOMATER, V6, P4073, DOI 10.1016/j.actbio.2010.04.017; Kang HS, 1997, SAE T, V106, P3849; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kota N, 2014, J BIOMECH; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Li YA, 2010, J APPL BIOMATER BIOM, V8, P191, DOI 10.5301/JABB.2010.6095; Lim J, 2011, INT J IMPACT ENG, V38, P130, DOI 10.1016/j.ijimpeng.2010.09.003; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Mehta BV, 1997, J DIGIT IMAGING, V10, P203, DOI 10.1007/BF03168701; Mercer C, 2006, ACTA BIOMATER, V2, P59, DOI 10.1016/j.actbio.2005.08.004; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Nahum A., 1977, 21 STAPP CAR CRASH C, DOI DOI 10.4271/770922; NASA, 1995, ANTHR BIOM MAN SYST, V1; Nie X, 2011, J APPL MECH-T ASME, V78, DOI 10.1115/1.4002580; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; Peterson J, 2002, ANAT REC, V268, P7, DOI 10.1002/ar.10131; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwartz-Dabney CL, 2002, J DENT RES, V81, P613, DOI 10.1177/154405910208100907; Sigal IA, 2004, INVEST OPHTH VIS SCI, V45, P4378, DOI 10.1167/iovs.04-0133; Sigal IA, 2009, BIOMECH MODEL MECHAN, V8, P85, DOI 10.1007/s10237-008-0120-7; Simpleware Ltd, 2013, REF GUID SCANIP SOFT; Song B, 2007, J BIOMECH, V40, P2999, DOI 10.1016/j.jbiomech.2007.02.001; Takhounts EG, 2008, STAPP CAR C, V52, P1; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; TROTTER M, 1960, J BONE JOINT SURG AM, V42, P50, DOI 10.2106/00004623-196042010-00005; US Centers for Disease Control and Prevention, 2010, GET STATS TRAUM BRAI; US Department of Veterans Affairs, TRAUM BRAIN INJ GUID; Ward SR, 2005, J BIOMECH, V38, P2317, DOI 10.1016/j.jbiomech.2004.10.001; Young PG, 2008, PHILOS T R SOC A, V366, P3155, DOI 10.1098/rsta.2008.0090; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	41	29	29	1	29	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-5842	1476-8259		COMPUT METHOD BIOMEC	Comput. Methods Biomech. Biomed. Eng.	JAN 2	2016	19	1					101	113		10.1080/10255842.2014.994118			13	Computer Science, Interdisciplinary Applications; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering	CV0FF	WOS:000363923600002	25563692				2022-02-06	
J	Iraji, A; Chen, HB; Wiseman, N; Welch, RD; O'Neil, BJ; Haacke, EM; Liu, TM; Kou, ZF				Iraji, Armin; Chen, Hanbo; Wiseman, Natalie; Welch, Robert D.; O'Neil, Brian J.; Haacke, E. Mark; Liu, Tianming; Kou, Zhifeng			Compensation through Functional Hyperconnectivity: A Longitudinal Connectome Assessment of Mild Traumatic Brain Injury	NEURAL PLASTICITY			English	Article							WORKING-MEMORY; NETWORK TOPOLOGY; IMAGING FINDINGS; AXONAL INJURY; CONNECTIVITY; PLASTICITY; ACTIVATION; MRI; PERFORMANCE; DYSFUNCTION	Mild traumatic brain injury (mTBI) is a major public health concern. Functional MRI has reported alterations in several brain networks following mTBI. However, the connectome-scale brain network changes are still unknown. In this study, sixteen mTBI patients were prospectively recruited from an emergency department and followed up at 4-6weeks after injury. Twenty-four healthy controls were also scanned twice with the same time interval. Three hundred fifty-eight brain landmarks that preserve structural and functional correspondence of brain networks across individuals were used to investigate longitudinal brain connectivity. Network-based statistic (NBS) analysis did not find significant difference in the group-by-time interaction and time effects. However, 258 functional pairs show group differences in which mTBI patients have higher functional connectivity. Meta-analysis showed that "Action" and "Cognition" are the most affected functional domains. Categorization of connectomic signatures using multiview group-wise cluster analysis identified two patterns of functional hyperconnectivity among mTBI patients: (I) between the posterior cingulate cortex and the association areas of the brain and (II) between the occipital and the frontal lobes of the brain. Our results demonstrate that brain concussion renders connectome-scale brain network connectivity changes, and the brain tends to be hyperactivated to compensate the pathophysiological disturbances.	[Iraji, Armin; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI USA; [Chen, Hanbo; Liu, Tianming] Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA; [Wiseman, Natalie] Wayne State Univ, Dept Psychiat & Behav Neurosci, Detroit, MI 48207 USA; [Welch, Robert D.; O'Neil, Brian J.] Wayne State Univ, Dept Emergency Med, Detroit, MI USA; [Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Radiol, Detroit, MI USA		Liu, TM (corresponding author), Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA.	tianming.liu@gmail.com; zhifeng_kou@wayne.edu	Liu, Tianming/AAA-4602-2022	Iraji, Armin/0000-0002-0605-593X	Department of DefenseUnited States Department of Defense [W81XWH-11-1-0493]; International Society for Magnetic Resonance in Medicine (ISMRM) Seed Grant Award	This study is supported by the Department of Defense (Award no. W81XWH-11-1-0493) and International Society for Magnetic Resonance in Medicine (ISMRM) Seed Grant Award. The first author (Armin Iraji) would also like to sincerely acknowledge Drs. Anthony and Joyce Danielski Kales Endowed Scholars Award which significantly helped to accomplish this work.	Barbey AK, 2015, CURR OPIN BEHAV SCI, V4, P92, DOI 10.1016/j.cobeha.2015.04.002; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bergman K, 2010, J EMERG NURS, V36, P221, DOI 10.1016/j.jen.2009.07.001; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Buckner RL, 2007, NEUROIMAGE, V37, P1091, DOI 10.1016/j.neuroimage.2007.01.010; Carter AR, 2012, NEUROIMAGE, V62, P2271, DOI 10.1016/j.neuroimage.2012.02.070; Carter AR, 2010, ANN NEUROL, V67, P365, DOI 10.1002/ana.21905; CDC, 2003, REP C MILD TRAUM BRA; Chen HB, 2013, IEEE T MED IMAGING, V32, P1576, DOI [10.1109/TMI.2013.2259248, 10.1007/978-3-642-33454-2_37]; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Finn ES, 2014, BIOL PSYCHIAT, V76, P397, DOI 10.1016/j.biopsych.2013.08.031; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Gillebert CR, 2013, NEUROSCIENTIST, V19, P509, DOI 10.1177/1073858412463168; Guerra-Carrillo B, 2014, NEUROSCIENTIST, V20, P522, DOI 10.1177/1073858414524442; Harrington DL, 2015, BRAIN, V138, P2332, DOI 10.1093/brain/awv145; Hebb D.O, 2005, ORG BEHAV NEUROPSYCH; Hillary FG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104021; Hillary FG, 2011, BRAIN, V134, P1555, DOI 10.1093/brain/awr043; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Iraji A, 2011, IEEE ENG MED BIO, P2796, DOI 10.1109/IEMBS.2011.6090765; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Kelly C, 2014, NEUROPSYCHOL REV, V24, P63, DOI 10.1007/s11065-014-9252-y; Korgaonkar MS, 2014, BIOL PSYCHIAT, V76, P567, DOI 10.1016/j.biopsych.2014.02.018; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kou ZF, 2014, NEURAL REGEN RES, V9, P693, DOI 10.4103/1673-5374.131568; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Krienen FM, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0526; Laird Angela R, 2009, Front Neuroinform, V3, P23, DOI 10.3389/neuro.11.023.2009; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Li K., 2010, ADV NEURAL INFORM PR, P1369; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lv JL, 2015, IEEE T BIO-MED ENG, V62, P1120, DOI 10.1109/TBME.2014.2369495; Mackey AP, 2013, J NEUROSCI, V33, P4796, DOI 10.1523/JNEUROSCI.4141-12.2013; Mackey AP, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00032; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McEwen BS, 2013, NEURON, V79, P16, DOI 10.1016/j.neuron.2013.06.028; Merzenich MM, 2013, PROG BRAIN RES, V207, P1; Messe A, 2015, NEUROIMAGE, V111, P65, DOI 10.1016/j.neuroimage.2015.02.001; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Passingham RE, 2002, NAT REV NEUROSCI, V3, P606, DOI 10.1038/nrn893; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Taubert M, 2011, NEUROIMAGE, V57, P1492, DOI 10.1016/j.neuroimage.2011.05.078; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Voss HU, 2009, PROG BRAIN RES, V175, P483, DOI 10.1016/S0079-6123(09)17532-5; Wan CY, 2010, NEUROSCIENTIST, V16, P566, DOI 10.1177/1073858410377805; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Yuan YX, 2013, NEUROINFORMATICS, V11, P47, DOI 10.1007/s12021-012-9165-y; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041; Zhou IY, 2014, NEUROIMAGE, V84, P1, DOI 10.1016/j.neuroimage.2013.08.037; Zhu DJ, 2014, HUM BRAIN MAPP, V35, P2911, DOI 10.1002/hbm.22373; Zhu DJ, 2013, CEREB CORTEX, V23, P786, DOI 10.1093/cercor/bhs072	70	29	29	1	11	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-5904	1687-5443		NEURAL PLAST	Neural. Plast.		2016	2016								4072402	10.1155/2016/4072402			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DB3FR	WOS:000368396200001	26819765	Green Submitted, Green Published, gold			2022-02-06	
J	Nikolakopoulou, AM; Koeppen, J; Garcia, M; Leish, J; Obenaus, A; Ethell, IM				Nikolakopoulou, Angeliki M.; Koeppen, Jordan; Garcia, Michael; Leish, Joshua; Obenaus, Andre; Ethell, Iryna M.			Astrocytic Ephrin-B1 Regulates Synapse Remodeling Following Traumatic Brain Injury	ASN NEURO			English	Article						astrocytes; hippocampus; ephrinB1; STAT3; synapse; traumatic brain injury	DENDRITIC SPINE MORPHOGENESIS; RECEPTOR TYROSINE KINASES; CENTRAL-NERVOUS-SYSTEM; EPHB RECEPTORS; REACTIVE ASTROCYTES; CORD-INJURY; GLUTAMATE TRANSPORT; BINDING-PROTEIN; PLASTICITY; HIPPOCAMPUS	Traumatic brain injury (TBI) can result in tissue alterations distant from the site of the initial injury, which can trigger pathological changes within hippocampal circuits and are thought to contribute to long-term cognitive and neuropsychological impairments. However, our understanding of secondary injury mechanisms is limited. Astrocytes play an important role in brain repair after injury and astrocyte-mediated mechanisms that are implicated in synapse development are likely important in injury-induced synapse remodeling. Our studies suggest a new role of ephrin-B1, which is known to regulate synapse development in neurons, in astrocyte-mediated synapse remodeling following TBI. Indeed, we observed a transient upregulation of ephrin-B1 immunoreactivity in hippocampal astrocytes following moderate controlled cortical impact model of TBI. The upregulation of ephrin-B1 levels in hippocampal astrocytes coincided with a decline in the number of vGlut1-positive glutamatergic input to CA1 neurons at 3 days post injury even in the absence of hippocampal neuron loss. In contrast, tamoxifen-induced ablation of ephrin-B1 from adult astrocytes in ephrin-B1(loxP/y)ERT2-Cre(GFAP) mice accelerated the recovery of vGlut1-positive glutamatergic input to CA1 neurons after TBI. Finally, our studies suggest that astrocytic ephrin-B1 may play an active role in injury-induced synapse remodeling through the activation of STAT3-mediated signaling in astrocytes. TBI-induced upregulation of STAT3 phosphorylation within the hippocampus was suppressed by astrocyte-specific ablation of ephrin-B1 in vivo, whereas the activation of ephrin-B1 in astrocytes triggered an increase in STAT3 phosphorylation in vitro. Thus, regulation of ephrin-B1 signaling in astrocytes may provide new therapeutic opportunities to aid functional recovery after TBI.	[Nikolakopoulou, Angeliki M.; Koeppen, Jordan; Garcia, Michael; Leish, Joshua; Ethell, Iryna M.] Univ Calif Riverside, Sch Med, Div Biomed Sci, 900 Univ Ave, Riverside, CA 92521 USA; [Koeppen, Jordan; Ethell, Iryna M.] Univ Calif Riverside, Cell Mol & Dev Biol Grad Program, Riverside, CA 92521 USA; [Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA		Ethell, IM (corresponding author), Univ Calif Riverside, Sch Med, Div Biomed Sci, 900 Univ Ave, Riverside, CA 92521 USA.	iryna.ethell@ucr.edu		Nikolakopoulou, Angeliki/0000-0002-1621-4965; Koeppen, Jordan/0000-0002-8618-5792	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH67121]; NMSSNational Multiple Sclerosis Society [PP1903]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH067121] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was supported by MH67121 grant from NIMH (to I. M. E.) and PP1903 grant from NMSS (to A. M. N.).	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Atkins CM, 2011, TRANSL STROKE RES, V2, P546, DOI 10.1007/s12975-011-0123-z; Badaut J, 2011, CEREBROVASC DIS, V31, P521, DOI 10.1159/000324328; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Barker AJ, 2008, J NEUROSCI, V28, P8150, DOI 10.1523/JNEUROSCI.1744-08.2008; Barthet G, 2013, NEUROBIOL AGING, V34, P499, DOI 10.1016/j.neurobiolaging.2012.02.024; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Bong YS, 2007, P NATL ACAD SCI USA, V104, P17305, DOI 10.1073/pnas.0702337104; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Brown CE, 2008, NEUROSCIENTIST, V14, P139, DOI 10.1177/1073858407309854; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Carmona MA, 2009, P NATL ACAD SCI USA, V106, P12524, DOI 10.1073/pnas.0903328106; Catchpole T, 2011, J NEUROSCI, V31, P11472, DOI 10.1523/JNEUROSCI.6349-10.2011; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Cibert-Goton V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053673; Cisse M, 2011, NATURE, V469, P47, DOI 10.1038/nature09635; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Contractor A, 2002, SCIENCE, V296, P1864, DOI 10.1126/science.1069081; Coulthard MG, 2012, AM J PATHOL, V181, P1493, DOI 10.1016/j.ajpath.2012.06.043; Dalva MB, 2000, CELL, V103, P945, DOI 10.1016/S0092-8674(00)00197-5; Du J, 2007, CURR PHARM DESIGN, V13, P2507; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Ethell IM, 2001, NEURON, V31, P1001, DOI 10.1016/S0896-6273(01)00440-8; Filosa A, 2009, NAT NEUROSCI, V12, P1285, DOI 10.1038/nn.2394; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Georgakopoulos A, 2011, FASEB J, V25, P3594, DOI 10.1096/fj.11-187856; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldshmit Y, 2006, BRAIN RES REV, V52, P327, DOI 10.1016/j.brainresrev.2006.04.006; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Grunwald IC, 2004, NAT NEUROSCI, V7, P33, DOI 10.1038/nn1164; Grunwald IC, 2001, NEURON, V32, P1027, DOI 10.1016/S0896-6273(01)00550-5; Henderson JT, 2001, NEURON, V32, P1041, DOI 10.1016/S0896-6273(01)00553-0; Henkemeyer M, 2003, J CELL BIOL, V163, P1313, DOI 10.1083/jcb.200306033; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hoogenraad CC, 2005, NAT NEUROSCI, V8, P906, DOI 10.1038/nn1487; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; INNOCENTI GM, 1995, NEUROPSYCHOLOGIA, V33, P961, DOI 10.1016/0028-3932(95)00033-Y; Ito U, 2006, STROKE, V37, P2134, DOI 10.1161/01.STR.0000231875.96714.b1; Kayser MS, 2006, J NEUROSCI, V26, P12152, DOI 10.1523/JNEUROSCI.3072-06.2006; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lauterbach J, 2006, J NEUROSCI, V26, P11575, DOI 10.1523/JNEUROSCI.2697-06.2006; Li SL, 2006, NEUROBIOL DIS, V23, P362, DOI 10.1016/j.nbd.2006.03.011; Lin KT, 2008, J BIOL CHEM, V283, P28969, DOI 10.1074/jbc.M804401200; Liu X, 2006, J NEUROSCI, V26, P3087, DOI 10.1523/JNEUROSCI.4797-05.2006; Luria V, 2008, NEURON, V60, P1039, DOI 10.1016/j.neuron.2008.11.011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marston DJ, 2003, NAT CELL BIOL, V5, P879, DOI 10.1038/ncb1044; Mendes SW, 2006, J NEUROSCI, V26, P882, DOI 10.1523/JNEUROSCI.3162-05.2006; Moeller ML, 2006, J BIOL CHEM, V281, P1587, DOI 10.1074/jbc.M511756200; Mostany R, 2010, J NEUROSCI, V30, P14116, DOI 10.1523/JNEUROSCI.3908-10.2010; Murai KK, 2011, GLIA, V59, P1567, DOI 10.1002/glia.21226; Murai KK, 2003, NAT NEUROSCI, V6, P153, DOI 10.1038/nn994; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nolt MJ, 2011, J NEUROSCI, V31, P5353, DOI 10.1523/JNEUROSCI.0282-11.2011; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; O'Callaghan JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102003; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Overman JJ, 2012, P NATL ACAD SCI USA, V109, pE2230, DOI 10.1073/pnas.1204386109; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Parker M, 2004, BIOCHEM BIOPH RES CO, V323, P17, DOI 10.1016/j.bbrc.2004.07.209; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Petros TJ, 2009, J NEUROSCI, V29, P3463, DOI 10.1523/JNEUROSCI.5655-08.2009; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Ren Z, 2013, NEUROSCIENCE, V241, P89, DOI 10.1016/j.neuroscience.2013.03.010; Sanders SJ, 2012, NATURE, V485, P237, DOI 10.1038/nature10945; Schafer DP, 2012, NEURON, V74, P691, DOI 10.1016/j.neuron.2012.03.026; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Segura I, 2007, NAT NEUROSCI, V10, P301, DOI 10.1038/nn1858; Shen XF, 2013, INT J MOL SCI, V14, P21598, DOI 10.3390/ijms141121598; Shields J, 2011, TRANSL STROKE RES, V2, P633, DOI 10.1007/s12975-011-0129-6; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Srivastava N, 2013, MOL CELL NEUROSCI, V52, P106, DOI 10.1016/j.mcn.2012.11.003; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tremblay ME, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000527; Tyzack GE, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5294; Van Hoecke A, 2012, NAT MED, V18, P1418, DOI 10.1038/nm.2901; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wang Y, 2005, EUR J NEUROSCI, V21, P2336, DOI 10.1111/j.1460-9568.2005.04093.x; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Xu NJ, 2012, SEMIN CELL DEV BIOL, V23, P58, DOI 10.1016/j.semcdb.2011.10.024; Xu NJ, 2009, NAT NEUROSCI, V12, P268, DOI 10.1038/nn.2254; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	92	29	29	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro	JAN-FEB	2016	8	1							1759091416630220	10.1177/1759091416630220			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DF8VR	WOS:000371639000001	26928051	gold, Green Published			2022-02-06	
J	Thompson, WH; Thelin, EP; Lilja, A; Bellander, BM; Fransson, P				Thompson, William Hedley; Thelin, Eric Peter; Lilja, Anders; Bellander, Bo-Michael; Fransson, Peter			Functional resting-state fMRI connectivity correlates with serum levels of the S100B protein in the acute phase of traumatic brain injury	NEUROIMAGE-CLINICAL			English	Article						Traumatic brain injury; Resting-state; Brain connectivity; fMRI; S100B	DEFAULT-MODE NETWORK; PROPOFOL-INDUCED LOSS; GLASGOW COMA SCALE; PROGNOSTIC VALUE; S-100B PROTEIN; AXONAL INJURY; HEAD-INJURY; CONNECTOMICS; BIOMARKERS; COMPONENT	The S100B protein is an intra-cellular calcium-binding protein that mainly resides in astrocytes in the central nervous system. The serum level of S100B is used as biomarker for the severity of brain damage in traumatic brain injury (TBI) patients. In this study we investigated the relationship between intrinsic resting-state brain connectivity, measured 1-22 days (mean 8 days) after trauma, and serum levels of S100B in a patient cohort with mild-to-severe TBI in need of neuro-intensive care in the acute phase. In line with previous investigations, our results show that the peak level of S100B acquired during the acute phase of TBI was negatively correlated with behavioral measures (Glasgow Outcome Score, GOS) of functional outcome assessed 6 to 12 months post injury. Using a multi-variate pattern analysis-informed seed-based correlation analysis, we show that the strength of resting-state brain connectivity in multiple resting-state networks was negatively correlated with the peak of serum levels of S100B. A negative correspondence between S100B peak levels recorded 12-36 h after trauma and intrinsic connectivity was found for brain regions located in the default mode, fronto-parietal, visual and motor resting-state networks. Our results suggest that resting-state brain connectivity measures acquired during the acute phase of TBI is concordant with results obtained from molecular biomarkers and that it may hold a capacity to predict long-term cognitive outcome in TBI patients. (C) 2016 The Authors. Published by Elsevier Inc.	[Thompson, William Hedley; Thelin, Eric Peter; Bellander, Bo-Michael; Fransson, Peter] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Bellander, Bo-Michael] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Lilja, Anders] Karolinska Inst, Dept Clin Neurosci, Neuroradiol Sect, Stockholm, Sweden		Fransson, P (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.	Peter.Fransson@ki.se	Thompson, William Hedley/I-1347-2019; Thelin, Eric Peter/K-2144-2012; Fransson, Peter/M-5679-2014	Thompson, William Hedley/0000-0002-0533-6035; Thelin, Eric Peter/0000-0002-2338-4364; Bellander, Bo-Michael/0000-0002-0648-2501; Fransson, Peter/0000-0002-1305-9875	Swedish Research Agency (Vetenskapstradet) [621-202-4911]	Peter Fransson was funded by the Swedish Research Agency (Vetenskapstradet), 621-202-4911.	Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; ACS, 2012, ADV TRAUM LIF SUPP P; Astrand Ramona, 2013, Methods Mol Biol, V963, P373, DOI 10.1007/978-1-62703-230-8_23; Beaty RE, 2015, SCI REP-UK, V5, DOI 10.1038/srep10964; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Boveroux P, 2010, ANESTHESIOLOGY, V113, P1038, DOI 10.1097/ALN.0b013e3181f697f5; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; COOK S, 1989, Journal of Drug Development, V2, P65; DIKMEN S, 1978, EPILEPSIA, V19, P177, DOI 10.1111/j.1528-1157.1978.tb05028.x; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Fornito A, 2015, NAT REV NEUROSCI, V16, P159, DOI 10.1038/nrn3901; Fox MD, 2010, FRONT SYST NEUROSCI, V4, DOI [10.3389/fnsys.2010.00019, 10.3389/fnsys.2010.0001]; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Greenacre M., 1983, THEORY APPL CORRES A; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Greicius MD, 2008, HUM BRAIN MAPP, V29, P839, DOI 10.1002/hbm.20537; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Lorenzo-Seva U, 2009, J STAT SOFTW, V31, P1; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Mayer AR, 2015, J NEUROTRAUM, V32, P1046, DOI 10.1089/neu.2014.3542; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schrouff J, 2011, NEUROIMAGE, V57, P198, DOI 10.1016/j.neuroimage.2011.04.020; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Tate RL, 2013, NEUROREHABILITATION, V32, P729, DOI 10.3233/NRE-130898; Teasdale G., 1976, LANCET, V13, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Thelin E. P., 2015, EUR J TRAUMA EMERG S; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Whitfield-Gabrieli S., 2015, MOL PSYCHIATR, DOI DOI 10.1038/MP.2015.109; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Wintermark Max, 2015, J Am Coll Radiol, V12, pe1, DOI 10.1016/j.jacr.2014.10.014; Yarkoni T, 2011, NAT METHODS, V8, P665, DOI [10.1038/NMETH.1635, 10.1038/nmeth.1635]; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127	78	29	29	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2016	12						1004	1012		10.1016/j.nicl.2016.05.005			9	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EF3AI	WOS:000390196400113	27995066	gold, Green Published			2022-02-06	
J	Jayaram, H; Cepurna, WO; Johnson, EC; Morrison, JC				Jayaram, Hari; Cepurna, William O.; Johnson, Elaine C.; Morrison, John C.			MicroRNA Expression in the Glaucomatous Retina	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						microRNA; glaucoma model; retina	NEURONAL CELL-DEATH; ELEVATED INTRAOCULAR-PRESSURE; OPTIC-NERVE DAMAGE; LARGE GENE LISTS; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA LEVELS; OPEN-ANGLE GLAUCOMA; SPINAL-CORD-INJURY; GANGLION-CELL	PURPOSE. MicroRNAs are small, endogenous noncoding RNAs that modulate posttranscriptional gene expression. Although the contribution of microRNAs to the pathogenesis of glaucomatous damage is unknown, supporting evidence from central nervous system (CNS) research suggests they may play a role. It was therefore hypothesized that microRNAs known to be altered in CNS injury are also altered in experimental glaucoma. METHODS. Intraocular pressure (IOP) was elevated in rats by unilateral injection of hypertonic saline and IOP monitored for 5 weeks. After rats were killed, retrobulbar optic nerve sections were graded for damage. MicroRNA was extracted from whole retinae of eyes with advanced nerve damage (n = 8) and from normal, noninjected control eyes (n = 8). Quantitative PCRs were performed using a panel of 17 microRNAs, reported from CNS research to be implicated in mechanisms also linked to glaucomatous damage. Computationally and experimentally derived gene targets were identified for the differentially expressed microRNAs. These were then integrated with existing gene array data. Functional interpretation was performed using the Molecular Signatures Database and DAVID Functional Annotation Clustering. RESULTS. Eight microRNAs were significantly downregulated in glaucomatous retinae compared with controls (miR-181c, miR-497, miR-204, let-7a, miR-29b, miR-16, miR106b, and miR-25); miR-27a was significantly upregulated. Enrichment of targets associated with extracellular matrix/cell proliferation, immune system, and regulation of apoptosis were observed. Cholesterol homeostasis and mTORC-1 pathways showed reduced expression. CONCLUSIONS. MicroRNAs are differentially expressed in retinae of eyes with advanced glaucomatous damage compared with normal controls. Integrating microRNA with gene expression data may improve understanding of the complex biological responses produced by chronically elevated IOP.	[Jayaram, Hari; Cepurna, William O.; Johnson, Elaine C.; Morrison, John C.] Oregon Hlth & Sci Univ, Casey Eye Inst, Kenneth C Swan Ocular Neurobiol Lab, Portland, OR 97239 USA		Morrison, JC (corresponding author), Oregon Hlth & Sci Univ, Casey Eye Inst, Kenneth C Swan Ocular Neurobiol Lab, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.	morrisoj@ohsu.edu		Jayaram, Hari/0000-0003-1998-0670	US-UK Fulbright Commission; Fight for Sight; Special Trustees of Moorfields Eye Hospital; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EY010145, P30EY010572]; Research to Prevent Blindness, Inc (RPB)Research to Prevent Blindness (RPB); NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY010572, R01EY010145] Funding Source: NIH RePORTER	Supported by the US-UK Fulbright Commission in conjunction with Fight for Sight, The Special Trustees of Moorfields Eye Hospital (HJ), National Institutes of Health Grants R01EY010145 (JCM) and P30EY010572 (OHSU Core Grant), and an unrestricted grant from Research to Prevent Blindness, Inc (RPB). JCM is an RPB Senior Investigator.	Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P1247, DOI 10.1167/iovs.03-1123; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Buckingham BP, 2008, J NEUROSCI, V28, P2735, DOI 10.1523/JNEUROSCI.4443-07.2008; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Burgos KL, 2013, RNA, V19, P712, DOI 10.1261/rna.036863.112; Chang CY, 2014, ARCH TOXICOL, DOI [10.1007/s00204-014-1364-x, DOI 10.1007/S00204-014-1364-X]; Cheng HYM, 2007, CELL CYCLE, V6, P3034, DOI 10.4161/cc.6.24.5106; Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111; De Santis G, 2010, J NEUROIMMUNOL, V226, P165, DOI 10.1016/j.jneuroim.2010.06.009; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Guo L, 2005, INVEST OPHTH VIS SCI, V46, P175, DOI 10.1167/iovs.04-0832; Guo Y, 2011, INVEST OPHTH VIS SCI, V52, P1460, DOI 10.1167/iovs.10-5930; Guo Y, 2010, INVEST OPHTH VIS SCI, V51, P3003, DOI 10.1167/iovs.09-4663; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hanninen VA, 2002, CURR EYE RES, V25, P389; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Hong PW, 2014, GLIA, V62, P2044, DOI 10.1002/glia.22725; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Howell GR, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-429; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hutchison ER, 2013, GLIA, V61, P1018, DOI 10.1002/glia.22483; Jadhav SP, 2014, J NEUROCHEM, V130, P388, DOI 10.1111/jnc.12731; Jakobs TC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a020636; Jia LJ, 2000, INVEST OPHTH VIS SCI, V41, P1380; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson EC, 2000, INVEST OPHTH VIS SCI, V41, P431; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Jovicic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054222; Khanna S, 2013, J CEREBR BLOOD F MET, V33, P1197, DOI 10.1038/jcbfm.2013.68; Kinoshita C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4823; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Lehmann SM, 2012, NAT NEUROSCI, V15, P827, DOI 10.1038/nn.3113; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liu G, 2010, EXP NEUROL, V226, P200, DOI 10.1016/j.expneurol.2010.08.032; Lozano DC, 2015, CHRONOBIOL INT, V32, P513, DOI 10.3109/07420528.2015.1008135; McMahon DG, 2014, PROG RETIN EYE RES, V39, P58, DOI 10.1016/j.preteyeres.2013.12.001; Meza-Sosa KF, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00175; Miyahara T, 2003, INVEST OPHTH VIS SCI, V44, P4347, DOI 10.1167/iovs.02-1032; Moon JM, 2013, J CEREBR BLOOD F MET, V33, P1976, DOI 10.1038/jcbfm.2013.157; Moon LDF, 2001, EUR J NEUROSCI, V14, P1667, DOI 10.1046/j.0953-816x.2001.01795.x; Morrison JC, 2005, PROG RETIN EYE RES, V24, P217, DOI 10.1016/j.preteyeres.2004.08.003; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; Murray AR, 2013, INVEST OPHTH VIS SCI, V54, P1689, DOI 10.1167/iovs.12-10921; Nickells RW, 2007, CAN J OPHTHALMOL, V42, P278, DOI 10.3129/canjophthalmol.i07-036; Ouyang YB, 2013, GLIA, V61, P1784, DOI 10.1002/glia.22556; Ouyang YB, 2012, NEUROBIOL DIS, V45, P555, DOI 10.1016/j.nbd.2011.09.012; Peng ZF, 2013, J NEUROSCI RES, V91, P1349, DOI 10.1002/jnr.23255; Quigley HA, 1999, PROG RETIN EYE RES, V18, P39, DOI 10.1016/S1350-9462(98)00014-7; QUIGLEY HA, 1983, AM J OPHTHALMOL, V95, P673, DOI 10.1016/0002-9394(83)90389-6; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009; Rehmsmeier M, 2004, RNA, V10, P1507, DOI 10.1261/rna.5248604; Reichstein D, 2007, EXP EYE RES, V84, P13, DOI 10.1016/j.exer.2006.08.009; Roshan R, 2014, RNA, V20, P1287, DOI 10.1261/rna.044008.113; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; Sarkar S, 2008, MOL BIOSYST, V4, P895, DOI 10.1039/b804606a; Selles-Navarro I, 2001, EXP NEUROL, V167, P282, DOI 10.1006/exnr.2000.7573; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shi GD, 2012, EXP BRAIN RES, V216, P225, DOI 10.1007/s00221-011-2925-3; Shibata Chikako, 2013, Mol Cell Ther, V1, P5, DOI 10.1186/2052-8426-1-5; Soto I, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017269; Steele MR, 2006, INVEST OPHTH VIS SCI, V47, P977, DOI 10.1167/iovs.05-0865; Stein JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123682; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787; Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X; Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013; Wang CY, 2015, GLIA, V63, P194, DOI 10.1002/glia.22743; Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856; Wang HL, 2010, BRAIN RES, V1357, P166, DOI 10.1016/j.brainres.2010.08.023; Wang Q, 2014, INVEST OPHTH VIS SCI, V55, P3986, DOI 10.1167/iovs.13-13076; Wang Y, 2015, BRAIN RES BULL, V117, P1, DOI 10.1016/j.brainresbull.2015.06.001; Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0; Yang ZY, 2007, INVEST OPHTH VIS SCI, V48, P5539, DOI 10.1167/iovs.07-0542; Ye EA, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0265-0; Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021; Zhang L, 2015, J NEUROCHEM, V132, P713, DOI 10.1111/jnc.13021; Zhang L, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-211; Zhang L, 2012, GLIA, V60, P1888, DOI 10.1002/glia.22404; Zhang Y, 2010, J INTEGR BIOINFORMAT, V7, DOI 10.2390/biecoll-jib-2010-127; Zhao HP, 2013, STROKE, V44, P1706, DOI 10.1161/STROKEAHA.111.000504	93	29	31	1	8	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404	1552-5783		INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	DEC	2015	56	13					7971	7982		10.1167/iovs.15-18088			12	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	DB1BU	WOS:000368243800044	26720444	Green Published			2022-02-06	
J	Kabadi, SV; Stoica, BA; Zimmer, DB; Afanador, L; Duffy, KB; Loane, DJ; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Zimmer, Danna B.; Afanador, Lauriaselle; Duffy, Kara B.; Loane, David J.; Faden, Alan I.			S100B inhibition reduces behavioral and pathologic changes in experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						AGER; behavior (rodent); brain trauma; microglia; neurodegeneration; neuroprotection; S100B	FLUID-PERCUSSION INJURY; GLYCATION END-PRODUCTS; NEURONAL SURVIVAL; TRANSGENIC MICE; PROTEIN S100B; RAGE; RECEPTOR; ACTIVATION; S100-BETA; EXPRESSION	Neuroinflammation following traumatic brain injury (TBI) is increasingly recognized to contribute to chronic tissue loss and neurologic dysfunction. Circulating levels of S100B increase after TBI and have been used as a biomarker. S100B is produced by activated astrocytes and can promote microglial activation; signaling by S100B through interaction with the multiligand advanced glycation end product-specific receptor (AGER) has been implicated in brain injury and microglial activation during chronic neurodegeneration. We examined the effects of S100B inhibition in a controlled cortical impact model, using S100B knockout mice or administration of neutralizing S100B antibody. Both interventions significantly reduced TBI-induced lesion volume, improved retention memory function, and attenuated microglial activation. The neutralizing antibody also significantly reduced sensorimotor deficits and improved neuronal survival in the cortex. However, S100B did not alter microglial activation in BV2 cells or primary microglial cultures stimulated by lipopolysaccharide or interferon gamma. Further, proximity ligation assays did not support direct interaction in the brain between S100B and AGER following TBI. Future studies are needed to elucidate specific pathways underlying S100B-mediated neuroinflammatory actions after TBI. Our results strongly implicate S100B in TBI-induced neuroinflammation, cell loss, and neurologic dysfunction, thereby indicating that it is a potential therapeutic target for TBI.	[Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Zimmer, Danna B.; Afanador, Lauriaselle; Duffy, Kara B.] Univ Maryland, Sch Med, Ctr Biomol Therapeut, Baltimore, MD 21201 USA; [Zimmer, Danna B.; Afanador, Lauriaselle; Duffy, Kara B.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA		Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, HSFII, S247 20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434; Faden, Alan I./0000-0003-0128-2348	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS052568, R01NS037313]; Center for Biomolecular Therapeutics (University of Maryland School of Medicine); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS052568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	These studies were supported by grants from the National Institutes of Health (R01NS052568 and R01NS037313) to Dr Alan I Faden and by the Center for Biomolecular Therapeutics (University of Maryland School of Medicine).	Adami C, 2004, BBA-MOL CELL RES, V1742, P169, DOI 10.1016/j.bbamcr.2004.09.008; Adami C, 2001, GLIA, V33, P131, DOI 10.1002/1098-1136(200102)33:2<131::AID-GLIA1012>3.0.CO;2-D; Afanador L, 2014, CELL CALCIUM, V56, P68, DOI 10.1016/j.ceca.2014.05.002; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bianchi R, 2007, J LEUKOCYTE BIOL, V81, P108, DOI 10.1189/jlb.0306198; Bianchi R, 2010, NEUROBIOL AGING, V31, P665, DOI 10.1016/j.neurobiolaging.2008.05.017; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Bouvier D, 2012, CLIN CHEM, V58, P1116, DOI 10.1373/clinchem.2011.180828; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Donato R, 2009, BBA-MOL CELL RES, V1793, P1008, DOI 10.1016/j.bbamcr.2008.11.009; Gazzolo D, 2010, CARDIOVASC PSYCHIAT, V2010, P1; GERLAI R, 1995, LEARN MEMORY, V2, P26, DOI 10.1101/lm.2.1.26; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kabadi SV, 2012, J NEUROTRAUM, V29, P813, DOI 10.1089/neu.2011.1980; Kleindienst A, 2005, J NEUROSURG, V102, P1115, DOI 10.3171/jns.2005.102.6.1115; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Roltsch E, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-78; Schmidt A, 2007, J NEURAL TRANSM, V114, P1413, DOI 10.1007/s00702-007-0770-0; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; Tsoporis JN, 2010, CIRC RES, V106, P93, DOI 10.1161/CIRCRESAHA.109.195834; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Villarreal A, 2014, J NEUROCHEM, V131, P190, DOI 10.1111/jnc.12790; Villarreal A, 2011, J NEUROCHEM, V117, P321, DOI 10.1111/j.1471-4159.2011.07207.x; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Winocur G, 2001, NEUROBIOL LEARN MEM, V75, P230, DOI 10.1006/nlme.2000.3961; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	40	29	32	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2015	35	12					2010	2020		10.1038/jcbfm.2015.165			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CX7OI	WOS:000365891300013	26154869	Green Published, Bronze			2022-02-06	
J	Honan, CA; McDonald, S; Gowland, A; Fisher, A; Randall, RK				Honan, Cynthia A.; McDonald, Skye; Gowland, Alison; Fisher, Alana; Randall, Rebekah K.			Deficits in comprehension of speech acts after TBI: The role of theory of mind and executive function	BRAIN AND LANGUAGE			English	Article						Traumatic brain injury; Executive function; Theory of mind; Social cognition; Pragmatic language	TRAUMATIC BRAIN-INJURY; ASSESSING SOCIAL-PERCEPTION; DIFFUSE AXONAL INJURY; EMOTION RECOGNITION; FRONTAL LOBES; EYES TEST; IMPAIRMENTS; COGNITION; ADULTS; PERFORMANCE	Theory of mind (TOM) is critical to effective communication following traumatic brain injury (TBI) however, whether impairments are specific to social cognition, or reflective of executive demands is unclear. This study examined whether ToM impairments are predicted by executive function difficulties using everyday conversation tasks. Twenty-five individuals with severe-TBI were compared to 25 healthy controls on low- and high-ToM tasks across four conditions: (1) low cognitive load, (2) high flexibility, (3) high working memory (WM) and (4) high inhibition. TBI individuals were impaired on high-ToM tasks in the WM condition. When the WM demands of the task were controlled, the impairments were no longer apparent. TBI individuals were not impaired on high-TOM tasks in the inhibition and flexibility conditions, suggesting these tasks may not have been sufficiently demanding of ToM abilities. The results suggest that ToM impairments in everyday communication may arise due to WM demands, in individuals with TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Honan, Cynthia A.; McDonald, Skye; Gowland, Alison] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Honan, Cynthia A.; McDonald, Skye] Moving Ahead Ctr Res Excellence Brain Recovery, Sydney, NSW, Australia; [Fisher, Alana] Univ Sydney, Ctr Med Psychol & Evidence Based Decis Making CeM, Sch Psychol, Sydney, NSW 2006, Australia; [Randall, Rebekah K.] Univ Melbourne, Sch Psychol Sci, Melbourne, Vic, Australia		Honan, CA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	c.honan@unsw.edu.au; s.mcdonald@unsw.edu.au; Alison.gowland@gmail.com; a.fisher@sydney.edu.au; Rebekah.k.randall@gmail.com	Fisher, Alana/T-1869-2019; Honan, Cynthia/O-6332-2017	Honan, Cynthia/0000-0001-5735-4270; Fisher, Alana/0000-0002-6027-659X; Gowland, Alison/0000-0002-6578-4112	Australian Research CouncilAustralian Research Council [DP09886689]	This research was supported by the Australian Research Council with an ARC Discovery Project Grant [number DP09886689]. We are grateful to the Royal Ryde Rehabilitation Centre who assisted with recruitment. We are particularly grateful to the people with traumatic brain injuries and our control participants who gave willingly of their time to assist this research.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Benton AL, 1994, MULTILINGUAL APHASIA; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Brownell H, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P309; Bull R, 2008, COGNITION, V107, P663, DOI 10.1016/j.cognition.2007.07.015; Burgess P.W., 1997, HAYLING BRIXTON TEST; Byom LJ, 2012, INT J LANG COMM DIS, V47, P310, DOI 10.1111/j.1460-6984.2011.00102.x; Carlson SM, 2002, INFANT CHILD DEV, V11, P73, DOI 10.1002/icd.298; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Channon S, 2010, NEUROPSYCHOL REHABIL, V20, P739, DOI 10.1080/09602011003794583; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Courville C. B., 1945, PATHOLOGY NERVOUS SY; D'Argembeau A, 2007, J COGNITIVE NEUROSCI, V19, P935, DOI 10.1162/jocn.2007.19.6.935; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Dress ML, 2008, J LANG SOC PSYCHOL, V27, P71, DOI 10.1177/0261927X07309512; Martin-Rodriguez JF, 2010, NEUROPSYCHOLOGIA, V48, P1181, DOI 10.1016/j.neuropsychologia.2010.02.009; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HADLEY DM, 1988, CLIN RADIOL, V39, P131; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hughes C, 1998, BRIT J DEV PSYCHOL, V16, P233, DOI 10.1111/j.2044-835X.1998.tb00921.x; Johnco C, 2013, J ANXIETY DISORD, V27, P576, DOI 10.1016/j.janxdis.2012.10.004; Johnston L, 2008, AUST J PSYCHOL, V60, P135, DOI 10.1080/00049530701449521; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; LEUKEL F, 1972, INTRO PHYSL PSYCHOL; Levy N. K., 2014, CHILD NEUROPSYCHOLOG; Linacre J.M., 2006, USERS GUIDE WINSTEPS; Lough S, 2006, NEUROPSYCHOLOGIA, V44, P950, DOI 10.1016/j.neuropsychologia.2005.08.009; LOVIBOND PF, 1995, MANUAL DEPRESSION AN; Maehara Y, 2011, ACTA PSYCHOL, V138, P367, DOI 10.1016/j.actpsy.2011.09.009; Marcovitch S, 2015, COGNITIVE DEV, V33, P40, DOI 10.1016/j.cogdev.2014.07.001; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S., 2011, AWARENESS SOCIAL INF; McDonald S, 2014, NEUROPSYCHOLOGY, V28, P801, DOI 10.1037/neu0000089; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McDonald S, 2012, AUST PSYCHOL, V47, P39, DOI 10.1111/j.1742-9544.2011.00054.x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Ochsner KN, 2001, AM PSYCHOL, V56, P717, DOI 10.1037//0003-066X.56.9.717; Perner J, 1999, TRENDS COGN SCI, V3, P337, DOI 10.1016/S1364-6613(99)01362-5; Pickup GJ, 2008, PSYCHOPATHOLOGY, V41, P206, DOI 10.1159/000125554; Powell J., 2000, COGNITIVE NEUROPSYCH, V5, P175, DOI [DOI 10.1080/13546800050083520, 10.1080/13546800050083520]; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Reitan RM, 1992, TRAIL MAKING TEST; Ruby P, 2004, J COGNITIVE NEUROSCI, V16, P988, DOI 10.1162/0898929041502661; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spreen O., 1983, CONTRIBUTION NEUROPS; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; The Psychological Corporation, 2001, WECHSLER TEST ADULT; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062	80	29	31	2	41	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	NOV	2015	150						69	79		10.1016/j.bandl.2015.08.007			11	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	CY1EG	WOS:000366148900008	26335998				2022-02-06	
J	Labombarda, F; Jure, I; Gonzalez, S; Lima, A; Roig, P; Guennoun, R; Schumacher, M; De Nicola, AF				Labombarda, Florencia; Jure, Ignacio; Gonzalez, Susana; Lima, Analia; Roig, Paulina; Guennoun, Rachida; Schumacher, Michael; De Nicola, Alejandro F.			A functional progesterone receptor is required for immunomodulation, reduction of reactive gliosis and survival of oligodendrocyte precursors in the injured spinal cord	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Astrocytes; Knockout mice; Microglia; Neuroinflammation; Progesterone receptor; Spinal cord injury	TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE; SECONDARY DAMAGE; STEROID-HORMONES; NERVOUS-SYSTEM; WHITE-MATTER; CELL-DEATH; RAT MODEL; EXPRESSION	The anti-inflammatory effects of progesterone have been increasingly recognized in several neuropathological models, including spinal cord inflammation. In the present investigation, we explored the regulation of proinflammatory factors and enzymes by progesterone at several time points after spinal cord injury (SCI) in male rats. We also demonstrated the role of the progesterone receptor (PR) in inhibiting inflammation and reactive gliosis, and in enhancing the survival of oligodendrocyte progenitors cells (OPC) in injured PR knockout (PRKO) mice receiving progesterone. First, after SCI in rats, progesterone greatly attenuated the injury-induced hyperexpression of the mRNAs of interleukin 1 beta (IL1 beta), IL6, tumor necrosis factor alpha (TNF alpha), inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2), all involved in oligodendrocyte damage. Second, the role of the PR was investigated in PRKO mice after SCI, in which progesterone failed to reduce the high expression of IL1 beta, IL6, TNF alpha and I kappa B-alpha mRNAs, the latter being considered an index of reduced NF-kappa B transactivation. These effects occurred in a time framework coincident with a reduction in the astrocyte and microglial responses. In contrast to wild-type mice, progesterone did not increase the density of OPC and did not prevent apoptotic death of these cells in PRKO mice. Our results support a role of PR in: (a) the anti-inflammatory effects of progesterone; (b) the modulation of astrocyte and microglial responses and (c) the prevention of OPC apoptosis, a mechanism that would enhance the commitment of progenitors to the remyelination pathway in the injured spinal cord. (C) 2015 Elsevier Ltd. All rights reserved.	[Labombarda, Florencia; Jure, Ignacio; Lima, Analia; Roig, Paulina; De Nicola, Alejandro F.] Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [Labombarda, Florencia; Gonzalez, Susana; De Nicola, Alejandro F.] Univ Buenos Aires, Fac Med, Dept Human Biochem, Buenos Aires, DF, Argentina; [Guennoun, Rachida; Schumacher, Michael] INSERM, U1195, F-94276 Le Kremlin Bicetre, France; [Guennoun, Rachida; Schumacher, Michael] Univ Paris Sud, F-94276 Le Kremlin Bicetre, France; [Gonzalez, Susana] Inst Biol & Med Expt, Lab Nocicept & Neuropath Pain, RA-1428 Buenos Aires, DF, Argentina		De Nicola, AF (corresponding author), Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	alejandrodenicola@gmail.com	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300	Ministry of Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [PICT 2012-0009]; National Research Council of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 112 20120100016]; University of Buenos AiresUniversity of Buenos Aires [Ubacyt 20020100100089]; Roemmers Fundation	This work was supported by grants from the Ministry of Science and Technology (PICT 2012-0009), the National Research Council of Argentina (PIP 112 20120100016), the University of Buenos Aires (Ubacyt 20020100100089) and Roemmers Fundation. These funding sources did not have a role in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The authors report no conflict of interests.	Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Arnold S, 2008, J MOL ENDOCRINOL, V41, P289, DOI 10.1677/JME-08-0085; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Boato F, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-6; Bottero Virginie, 2003, Mol Diagn, V7, P187, DOI 10.2165/00066982-200307030-00008; Bracchi-Ricard V, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-92; Bracken MB, 2002, J NEUROSURG, V96, P259, DOI 10.3171/spi.2002.96.3.0259; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Coronel MF, 2014, EUR J PAIN, V18, P348, DOI 10.1002/j.1532-2149.2013.00376.x; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; De Nicola AF, 2013, CNS NEUROL DISORD-DR, V12, P1205; Deng YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087420; El-Etr M, 2015, GLIA, V63, P104, DOI 10.1002/glia.22736; Erta M, 2012, INT J BIOL SCI, V8, P1254, DOI 10.7150/ijbs.4679; Forstermann U, 1995, Adv Pharmacol, V34, P171; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; Garay LI, 2012, NEUROSCIENCE, V226, P40, DOI 10.1016/j.neuroscience.2012.09.032; Garcia-Ovejero D, 2014, J NEUROTRAUM, V31, P857, DOI 10.1089/neu.2013.3162; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Goddard LM, 2013, VASC PHARMACOL, V59, P36, DOI 10.1016/j.vph.2013.06.001; Deniselle MCG, 2012, J NEUROCHEM, V122, P185, DOI 10.1111/j.1471-4159.2012.07753.x; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Hanada M, 2012, ANAL BIOANAL CHEM, V403, P1873, DOI 10.1007/s00216-012-5900-3; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Jurewicz A, 2005, BRAIN, V128, P2675, DOI 10.1093/brain/awh627; Kaplin AI, 2005, J CLIN INVEST, V115, P2731, DOI 10.1172/JCI25141; Kim S, 2011, J NEUROCHEM, V116, P53, DOI 10.1111/j.1471-4159.2010.07084.x; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2013, NEUROPHARMACOLOGY, V71, P46, DOI 10.1016/j.neuropharm.2013.03.010; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Lech M, 2013, BBA-MOL BASIS DIS, V1832, P989, DOI 10.1016/j.bbadis.2012.12.001; Lei BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103969; Liu DX, 2001, J NEUROCHEM, V77, P1036, DOI 10.1046/j.1471-4159.2001.00306.x; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; Meffre D, 2013, NEUROSCIENCE, V231, P111, DOI 10.1016/j.neuroscience.2012.11.039; Menzies FM, 2011, IMMUNOLOGY, V134, P281, DOI 10.1111/j.1365-2567.2011.03488.x; Miller BA, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-28; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Pang YF, 2013, ENDOCRINOLOGY, V154, P283, DOI 10.1210/en.2012-1772; Pascual G, 2006, TRENDS ENDOCRIN MET, V17, P321, DOI 10.1016/j.tem.2006.08.005; Patte-Mensah C, 2006, J MOL NEUROSCI, V28, P17, DOI 10.1385/JMN:28:1:17; Pereira JE, 2009, EXP NEUROL, V220, P71, DOI 10.1016/j.expneurol.2009.07.030; Perrier S, 2006, FEBS LETT, V580, P6289, DOI 10.1016/j.febslet.2006.10.061; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schroeder GD, 2014, SPINE, V39, P971, DOI 10.1097/BRS.0000000000000297; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Su ZD, 2011, J NEUROTRAUM, V28, P1089, DOI 10.1089/neu.2010.1597; Subramaniam S, 2004, DEV COMP IMMUNOL, V28, P415, DOI 10.1016/j.dci.2003.09.016; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Watzlawik J, 2010, EXPERT REV NEUROTHER, V10, P441, DOI 10.1586/ERN.10.13; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Ye JN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054590; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; Zhou X, 2014, NEURAL REGEN RES, V9, P1787, DOI 10.4103/1673-5374.143423	73	29	29	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	NOV	2015	154						274	284		10.1016/j.jsbmb.2015.09.011			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CV4QI	WOS:000364251200031	26369614				2022-02-06	
J	Severini, C; Lattanzi, R; Maftei, D; Marconi, V; Ciotti, MT; Passeri, PP; Florenzano, F; Del Duca, E; Caioli, S; Zona, C; Balboni, G; Salvadori, S; Nistico, R; Negri, L				Severini, Cinzia; Lattanzi, Roberta; Maftei, Daniela; Marconi, Veronica; Ciotti, Maria Teresa; Passeri, Pamela Petrocchi; Florenzano, Fulvio; Del Duca, Ester; Caioli, Silvia; Zona, Cristina; Balboni, Gianfranco; Salvadori, Severo; Nistico, Robert; Negri, Lucia			Bv8/prokineticin 2 is involved in A beta-induced neurotoxicity	SCIENTIFIC REPORTS			English	Article							ALZHEIMERS-DISEASE; PROTEIN; CHEMOKINE; BV8; INFLAMMATION; CYTOKINES; RECEPTORS; OLIGOMERS; NEUROINFLAMMATION; NEURODEGENERATION	Bv8/Prokineticin 2 (PROK2) is a bioactive peptide initially discovered as a regulator of gastrointestinal motility. Among multiple biological roles demonstrated for PROK2, it was recently established that PROK2 is an insult-inducible endangering mediator for cerebral damage. Aim of the present study was to evaluate the PROK2 and its receptors' potential involvement in amyloid beta (A beta) neurotoxicity, a hallmark of Alzheimer's disease (AD) and various forms of traumatic brain injury (TBI). Analyzing primary cortical cultures (CNs) and cortex and hippocampus from A beta treated rats, we found that PROK2 and its receptors PKR1 and PKR2 mRNA are up-regulated by A beta, suggesting their potential involvement in AD. Hence we evaluated if impairing the prokineticin system activation might have protective effect against neuronal death induced by A beta. We found that a PKR antagonist concentration-dependently protects CNs against A beta 1-42-induced neurotoxicity, by reducing the A beta-induced PROK2 neuronal up-regulation. Moreover, the antagonist completely rescued LTP impairment in hippocampal slices from 6 month-old Tg2576 AD mice without affecting basal synaptic transmission and paired pulse-facilitation paradigms. These results indicate that PROK2 plays a role in cerebral amyloidosis and that PROK2 antagonists may represent a new approach for ameliorating the defining pathology of AD.	[Severini, Cinzia; Ciotti, Maria Teresa; Passeri, Pamela Petrocchi] CNR, Inst Cell Biol & Neurobiol, I-00143 Rome, Italy; [Severini, Cinzia; Florenzano, Fulvio; Del Duca, Ester; Nistico, Robert] European Brain Res Inst, I-00143 Rome, Italy; [Lattanzi, Roberta; Maftei, Daniela; Marconi, Veronica; Negri, Lucia] Univ Roma La Sapienza, Dept Human Physiol & Pharmacol Vittorio Erspamer, I-00185 Rome, Italy; [Caioli, Silvia; Zona, Cristina; Nistico, Robert] Univ Roma Tor Vergata, I-00133 Rome, Italy; [Caioli, Silvia; Zona, Cristina] IRCCS Fdn Santa Lucia, I-00142 Rome, Italy; [Balboni, Gianfranco] Univ Cagliari, Dept Life & Environm Sci, I-09124 Cagliari, Italy; [Salvadori, Severo] Univ Ferrara, Dept Pharmaceut Sci, I-44100 Ferrara, Italy		Severini, C (corresponding author), CNR, Inst Cell Biol & Neurobiol, Via Fosso Fiorano 64, I-00143 Rome, Italy.	cinzia.severini@cnr.it	Maftei, Daniela/AAY-1133-2021; Del Duca, Ester/AAC-2711-2022; Gianfranco, Balboni/K-1503-2019; Severini, Cinzia/AAX-3569-2020; Caioli, Silvia/I-9106-2014; Zona, Cristina/K-5079-2014	Maftei, Daniela/0000-0002-8679-2840; Severini, Cinzia/0000-0002-6932-704X; Caioli, Silvia/0000-0002-7888-0664; LATTANZI, Roberta/0000-0002-6377-9256	Italian Ministry of University and Scientific ResearchMinistry of Education, Universities and Research (MIUR) [20099F3XPM-003]; PNR-CNR Aging Program	This work was supported by a grant from the Italian Ministry of University and Scientific Research (20099F3XPM-003 to LR) and by PNR-CNR Aging Program 2012-2014.	Abou-Hamdan M, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000095; Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Balboni G, 2008, J MED CHEM, V51, P7635, DOI 10.1021/jm800854e; Balducci C, 2011, J ALZHEIMERS DIS, V24, P799, DOI 10.3233/JAD-2011-101839; Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308; Campolongo P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078036; Cheng MY, 2006, J COMP NEUROL, V498, P796, DOI 10.1002/cne.21087; Cheng MY, 2012, P NATL ACAD SCI USA, V109, P5475, DOI 10.1073/pnas.1113363109; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Congiu C, 2014, EUR J MED CHEM, V81, P334, DOI 10.1016/j.ejmech.2014.05.030; Cooper NR, 2000, IMMUNOL RES, V21, P159, DOI 10.1385/IR:21:2-3:159; Crews L, 2010, HUM MOL GENET, V19, pR12, DOI 10.1093/hmg/ddq160; Dorsch M, 2005, J LEUKOCYTE BIOL, V78, P426, DOI 10.1189/jlb.0205061; Farfara D, 2008, J CELL MOL MED, V12, P762, DOI 10.1111/j.1582-4934.2008.00314.x; Finch CE, 2007, CURR ALZHEIMER RES, V4, P185, DOI 10.2174/156720507780362254; Frozza RL, 2013, MOL NEUROBIOL, V47, P1066, DOI 10.1007/s12035-013-8401-2; Giannini E, 2009, P NATL ACAD SCI USA, V106, P14646, DOI 10.1073/pnas.0903720106; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Heneka MT, 2007, J NEUROIMMUNOL, V184, P69, DOI 10.1016/j.jneuroim.2006.11.017; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Ingves MV, 2010, AM J PHYSIOL-REG I, V298, pR617, DOI 10.1152/ajpregu.00620.2009; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; Johnstone M, 1999, J NEUROIMMUNOL, V93, P182, DOI 10.1016/S0165-5728(98)00226-4; Kaser A, 2003, EMBO REP, V4, P469, DOI 10.1038/sj.embor.embor830; Klein WL, 2013, ADV ALZH DIS, V3, P49, DOI 10.3233/978-1-61499-154-0-49; Lattanzi R, 2014, INT J PHARM SCI RES, V5, P5066, DOI 10.13040/IJPSR.0975-8232.5(11).5066-74; Lattanzi R., 2014, BIOMED RES IN PRESS, DOI [10.1155/2014/301292, DOI 10.1155/2014/301292]; LeCouter J, 2004, P NATL ACAD SCI USA, V101, P16813, DOI 10.1073/pnas.0407697101; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Maftei D, 2014, BRIT J PHARMACOL, V171, P4850, DOI 10.1111/bph.12793; Meda L, 2001, NEUROBIOL AGING, V22, P885, DOI 10.1016/S0197-4580(01)00307-4; Melchiorri D, 2001, EUR J NEUROSCI, V13, P1694, DOI 10.1046/j.1460-9568.2001.01549.x; Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357; Mines M, 2007, CURR MED CHEM, V14, P2456, DOI 10.2174/092986707782023686; Mollay C, 1999, EUR J PHARMACOL, V374, P189, DOI 10.1016/S0014-2999(99)00229-0; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Negri L, 2005, BRIT J PHARMACOL, V146, P625, DOI 10.1038/sj.bjp.0706376; Negri L, 2002, BRIT J PHARMACOL, V137, P1147, DOI 10.1038/sj.bjp.0704995; Negri L, 2007, LIFE SCI, V81, P1103, DOI 10.1016/j.lfs.2007.08.011; Negri L, 2006, CURR NEUROPHARMACOL, V4, P207, DOI 10.2174/157015906778019518; Negri L, 2011, CURR PHARM BIOTECHNO, V12, P1720, DOI 10.2174/138920111798357410; Nistico R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054666; Nistico R, 2012, MOL NEUROBIOL, V46, P572, DOI 10.1007/s12035-012-8324-3; Pieri M, 2010, NEUROPHARMACOLOGY, V58, P268, DOI 10.1016/j.neuropharm.2009.06.029; Ren P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020263; Selkoe Dennis J., 1994, Current Opinion in Neurobiology, V4, P708, DOI 10.1016/0959-4388(94)90014-0; Severini C, 2014, J ALZHEIMERS DIS, V38, P281, DOI 10.3233/JAD-131070; Smits HA, 2002, J NEUROIMMUNOL, V127, P160, DOI 10.1016/S0165-5728(02)00112-1; Soga T, 2002, BBA-GENE STRUCT EXPR, V1579, P173, DOI 10.1016/S0167-4781(02)00546-8; Sudduth TL, 2013, NEUROBIOL AGING, V34, P1051, DOI 10.1016/j.neurobiolaging.2012.09.012; Urayama K, 2008, ARTERIOSCL THROM VAS, V28, P841, DOI 10.1161/ATVBAHA.108.162404; Wu J, 2013, NEUROBIOL AGING, V34, P2843, DOI 10.1016/j.neurobiolaging.2013.06.003; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xiong YC, 2010, NEUROPHARMACOLOGY, V59, P589, DOI 10.1016/j.neuropharm.2010.08.014	58	29	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	OCT 19	2015	5								15301	10.1038/srep15301			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CT7GC	WOS:000362981700001	26477583	Green Submitted, Green Published, gold			2022-02-06	
J	Chaudhary, N; Pandey, AS; Gemmete, JJ; Hua, Y; Huang, YN; Gu, YX; Xi, GH				Chaudhary, Neeraj; Pandey, Aditya S.; Gemmete, Joseph J.; Hua, Ya; Huang, Yining; Gu, Yuxiang; Xi, Guohua			Diffusion tensor imaging in hemorrhagic stroke	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	3rd Pangu Stroke Conference	OCT 10-12, 2014	Beijing, PEOPLES R CHINA			Cerebral hemorrhage; Diffusion tensor imaging; Subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; INTRACEREBRAL HEMORRHAGE; CORTICOSPINAL TRACT; WALLERIAN DEGENERATION; INTRAVENTRICULAR HEMORRHAGE; FRACTIONAL ANISOTROPY; SUBARACHNOID HEMORRHAGE; DECREASED DIFFUSION; AXONAL-TRANSPORT	Diffusion tensor imaging (DTI) has evolved considerably over the last decade to now be knocking on the doors of wider clinical applications. There have been several efforts over the last decade to seek valuable and reliable application of DTI in different neurological disorders. The role of DTI in predicting outcomes in patients with brain tumors has been extensively studied and has become a fairly established clinical tool in this scenario. More recently DTI has been applied in mild traumatic brain injury to predict clinical outcomes based on DTI of the white matter tracts. The resolution of white matter fiber tractography based on DTI has improved over the years with increased magnet strength and better tractography post-processing. The role of DTI in hemorrhagic stroke has been studied preliminarily in the scientific literature. There is some evidence that DTI may be efficacious in predicting outcomes of motor function in animal models of intracranial hemorrhage. Only a handful of studies of DTI have been performed in subarachnoid hemorrhage or intraventricular hemorrhage scenarios. In this manuscript we will review the evolution of DTI, the existing evidence for its role in hemorrhagic stroke and discuss possible application of this non-invasive evaluation technique of human cerebral white matter tracts in the future. (C) 2015 Elsevier Inc. All rights reserved.	[Chaudhary, Neeraj; Pandey, Aditya S.; Gemmete, Joseph J.] Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; [Chaudhary, Neeraj; Pandey, Aditya S.; Gemmete, Joseph J.; Hua, Ya; Xi, Guohua] Univ Michigan, Dept Neurosurg, Ann Arbor, MI 48109 USA; [Huang, Yining] Peking Univ, Dept Neurol, Affiliated Hosp 1, Beijing 100871, Peoples R China; [Gu, Yuxiang] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China		Chaudhary, N (corresponding author), Univ Michigan Hlth Syst, Dept Radiol, B1D330A,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	guohuaxi@umich.edu	Gemmete, JJ/N-1604-2019; Gemmete, Joseph J./H-5508-2019	Gemmete, Joseph J./0000-0003-2760-3613	UMHS-PUHSC Joint Institute; 973 ProgramNational Basic Research Program of China [2014CB541600];  [NS-073595];  [NS-079157];  [NS-084049];  [NS-091545];  [NS-090925]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079157, R21NS084049, R21NS091545, R01NS090925, R01NS073595] Funding Source: NIH RePORTER	Supported by grants NS-073595, NS-079157, NS-084049, NS-091545, NS-090925, 973 Program-2014CB541600 and an UMHS-PUHSC Joint Institute grant.	Arboix A, 2002, ACTA NEUROL SCAND, V105, P282, DOI 10.1034/j.1600-0404.2002.1o170.x; Arboix A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-32; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Bucci M, 2013, NEUROIMAGE-CLIN, V3, P361, DOI 10.1016/j.nicl.2013.08.008; Buffon F, 2005, J CEREBR BLOOD F MET, V25, P641, DOI 10.1038/sj.jcbfm.9600054; Chen S, 2014, PROG NEUROBIOL, V115, P64, DOI 10.1016/j.pneurobio.2013.09.002; Cho SH, 2007, NEUROSCI LETT, V421, P142, DOI 10.1016/j.neulet.2007.04.052; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Chua CO, 2009, STROKE, V40, P3369, DOI 10.1161/STROKEAHA.109.549212; Chua TC, 2008, CURR OPIN NEUROL, V21, P83, DOI 10.1097/WCO.0b013e3282f4594b; Condette-Auliac S, 2001, STROKE, V32, P1818, DOI 10.1161/01.STR.32.8.1818; DELAMONTE SM, 1990, J CHILD NEUROL, V5, P101, DOI 10.1177/088307389000500206; Delsing BJP, 2001, PEDIATR NEUROL, V24, P283, DOI 10.1016/S0887-8994(01)00245-4; DeVetten G, 2010, STROKE, V41, P751, DOI 10.1161/STROKEAHA.109.573287; Diehl B, 2008, EPILEPSIA, V49, P1409, DOI 10.1111/j.1528-1167.2008.01596.x; Domi T, 2009, STROKE, V40, P780, DOI 10.1161/STROKEAHA.108.529958; Egashira Y, 2014, STROKE, V45, P2141, DOI 10.1161/STROKEAHA.114.005307; Fan SJ, 2013, NMR BIOMED, V26, P1089, DOI 10.1002/nbm.2922; FERRANTE L, 1992, SURG NEUROL, V38, P43, DOI 10.1016/0090-3019(92)90210-E; Feys H, 2000, ACTA NEUROL SCAND, V102, P371, DOI 10.1034/j.1600-0404.2000.102006371.x; Filler A, 2009, NEUROSURGERY, V65, pA29, DOI 10.1227/01.NEU.0000351279.78110.00; Filler AG, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-8; FILLER AG, 1994, J MAGN RESON IMAGING, V4, P259, DOI 10.1002/jmri.1880040308; Fujiwara S, 2014, NEUROIMAGE, V102, P789, DOI 10.1016/j.neuroimage.2014.08.049; Garg RK, 2012, STROKE, V43, P67, DOI 10.1161/STROKEAHA.111.629493; GREENE KA, 1995, NEUROLOGY, V45, P45, DOI 10.1212/WNL.45.1.45; Gu YX, 2009, STROKE, V40, P2241, DOI 10.1161/STROKEAHA.108.539536; Hatakeyama T, 2013, TRANSL STROKE RES, V4, P546, DOI 10.1007/s12975-013-0270-5; Hsieh CT, 2008, SURG NEUROL, V70, P75, DOI 10.1016/j.surneu.2007.04.004; Hsieh CT, 2008, SURG NEUROL, V69, P633, DOI 10.1016/j.surneu.2007.03.045; INOUE Y, 1990, AM J NEURORADIOL, V11, P897; Jones DK, 2005, MAGNET RESON MED, V53, P1143, DOI 10.1002/mrm.20466; Kakuda W, 2008, J CEREBR BLOOD F MET, V28, P887, DOI 10.1038/sj.jcbfm.9600604; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Kiphuth IC, 2011, CEREBROVASC DIS, V32, P420, DOI 10.1159/000330652; Koyama T, 2013, NEUROREHABILITATION, V32, P87, DOI 10.3233/NRE-130825; Koyama T, 2012, J STROKE CEREBROVASC, V21, P704, DOI 10.1016/j.jstrokecerebrovasdis.2011.03.004; Kusano Y, 2009, AM J NEURORADIOL, V30, P1561, DOI 10.3174/ajnr.A1639; Kuzu Y, 2012, CEREBROVASC DIS, V33, P566, DOI 10.1159/000338904; Kwak SY, 2010, EUR NEUROL, V63, P149, DOI 10.1159/000281108; Lansberg MG, 2001, AM J NEURORADIOL, V22, P637; Larroque B, 2003, J PEDIATR-US, V143, P477, DOI 10.1067/S0022-3476(03)00417-7; Lazar M, 2003, NEUROIMAGE, V20, P1140, DOI 10.1016/S1053-8119(03)00277-5; Le Bihan D, 1991, Magn Reson Q, V7, P1; Leak RK, 2014, PROG NEUROBIOL, V115, P1, DOI 10.1016/j.pneurobio.2013.12.003; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Liu X, 2012, EUR J RADIOL, V81, P292, DOI 10.1016/j.ejrad.2010.12.053; Ma CC, 2014, J CLIN NEUROSCI, V21, P1388, DOI 10.1016/j.jocn.2013.11.032; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mukherjee P, 2005, NEUROIMAG CLIN N AM, V15, P655, DOI 10.1016/j.nic.2005.08.010; Pandey AS, 2014, TRANSL STROKE RES, V5, P313, DOI 10.1007/s12975-014-0344-z; PANG D, 1986, NEUROSURGERY, V19, P547, DOI 10.1227/00006123-198610000-00009; Parker GJM, 2003, J MAGN RESON IMAGING, V18, P242, DOI 10.1002/jmri.10350; Pendlebury ST, 2007, INT J STROKE, V2, P80, DOI 10.1111/j.1747-4949.2007.00126.x; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Presseau C, 2015, NEUROIMAGE, V109, P73, DOI 10.1016/j.neuroimage.2014.12.058; Puig J, 2011, AM J NEURORADIOL, V32, P857, DOI 10.3174/ajnr.A2400; Qiu TM, 2008, ACTA NEUROCHIR SUPPL, V105, P165; Qureshi AI, 2012, STROKE, V43, P6, DOI 10.1161/STROKEAHA.111.639278; Sawlani V, 1997, J NEUROL SCI, V146, P103, DOI 10.1016/S0022-510X(96)00299-7; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; TAKASHIMA S, 1989, BRAIN DEV-JPN, V11, P121, DOI 10.1016/S0387-7604(89)80080-4; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; TSO MK, 2014, STROKE RES, V5, DOI DOI 10.1007/S12975-014-0323-4; VANGIJN J, 1985, NEUROLOGY, V35, P493, DOI 10.1212/WNL.35.4.493; Wagner KR, 2007, STROKE, V38, P753, DOI 10.1161/01.STR.0000255033.02904.db; Wang DM, 2012, CEREBROVASC DIS, V34, P199, DOI 10.1159/000341857; Wasserman JK, 2008, EXP NEUROL, V214, P266, DOI 10.1016/j.expneurol.2008.08.010; Werring DJ, 2000, J NEUROL NEUROSUR PS, V69, P269, DOI 10.1136/jnnp.69.2.269; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wu GF, 2013, J STROKE CEREBROVASC, V22, P232, DOI 10.1016/j.jstrokecerebrovasdis.2011.08.005; Wu GF, 2011, NEUROL RES, V33, P300, DOI 10.1179/016164110X12759951866993; Wu JS, 2007, NEUROSURGERY, V61, P935, DOI 10.1227/01.neu.0000303189.80049.ab; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xi GH, 2014, PROG NEUROBIOL, V115, P45, DOI 10.1016/j.pneurobio.2013.09.007; Yeo SS, 2012, STROKE, V43, P2239, DOI 10.1161/STROKEAHA.112.661116; Yeo SS, 2011, EUR NEUROL, V66, P235, DOI 10.1159/000330942; Yokoyama K, 2008, AM J NEURORADIOL, V29, P1159, DOI 10.3174/ajnr.A1001; Yoshioka H, 2008, NEUROSURGERY, V62, P97, DOI 10.1227/01.NEU.0000311066.03121.B8; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang JH, 2014, TRANSL STROKE RES, V5, P423, DOI 10.1007/s12975-014-0355-9; Zhao XR, 2014, TRANSL STROKE RES, V5, P554, DOI 10.1007/s12975-014-0341-2; Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003	89	29	31	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2015	272				SI		88	96		10.1016/j.expneurol.2015.05.011			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	CV6AS	WOS:000364353700011	26015333	Green Accepted			2022-02-06	
J	Dorminy, M; Hoogeveen, A; Tierney, RT; Higgins, M; McDevitt, JK; Kretzschmar, J				Dorminy, Millie; Hoogeveen, Ashley; Tierney, Ryan T.; Higgins, Michael; McDevitt, Jane K.; Kretzschmar, Jan			Effect of soccer heading ball speed on S100B, sideline concussion assessments and head impact kinematics	BRAIN INJURY			English	Article						Brain injury; brain injury biomarker; head impact acceleration; subconcussion; sub-concussive head impacts	NEURON-SPECIFIC ENOLASE; SERUM S-100B PROTEIN; BIOCHEMICAL MARKERS; POSTURAL CONTROL; BRAIN-INJURY; POSITION STATEMENT; DAMAGE S-100B; PLAYERS; ACCELERATION; SYMPTOMS	Objective: To examine the effect of soccer heading ball speed on S-100B serum concentration, concussion sideline assessments and linear head impact acceleration. Methods: Sixteen division I soccer players participated in this pre-test post-test design study. Athletes performed five standing headers over a 10 minute period at 30 (n=5), 40 (n=5) or 50 (n=6) miles per hour (mph) (randomized). S-100B serum concentration (ng mL(-1)) and sideline concussion assessments were measured prior to and post-heading. Peak resultant linear head acceleration (gravitational units; g) was measured during soccer heading. Results: No statistically significant interaction effects were identified between ball velocity groups over time on S100B (effect sizes ranged from 0.03-0.23) or concussion assessments tests. There was a non-significant increase (p=0.06) in head impact acceleration from the 30 (30.6; SD = 6.2 g) to 50 mph (50.7; SD = 7.7 g) ball speed. Conclusions: In this controlled setting, an acute bout of soccer heading across various ball velocities did not affect S100B or concussion assessment test scores. These findings are preliminary, as the small sample size in each group may have played a role in the lack of significant findings.	[Dorminy, Millie; Hoogeveen, Ashley; Tierney, Ryan T.; McDevitt, Jane K.; Kretzschmar, Jan] Temple Univ, Dept Kinesiol, Philadelphia, PA 19122 USA; [Higgins, Michael] Towson Univ, Dept Kinesiol, Towson, MD USA		Tierney, RT (corresponding author), 259 Pearson Hall,1800 North Broad St, Philadelphia, PA 19122 USA.	rtierney@temple.edu			Mid-Atlantic Athletic Trainers' Association	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This research was funded in part with a grant from the Mid-Atlantic Athletic Trainers' Association.	Biberthaler P, 2002, EUR J MED RES, V7, P164; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Higgins MJ, 2009, P I MECH ENG P-J SPO, V223, P117, DOI 10.1243/17543371JSET15; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Korfias S, 2009, MINI-REV MED CHEM, V9, P227, DOI 10.2174/138955709787315994; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; Matek J, 2012, Rozhl Chir, V91, P545; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mussack T, 2003, EUR J MED RES, V8, P457; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Straume-Naesheim TM, 2008, NEUROSURGERY, V62, P1297, DOI 10.1227/01.neu.0000333301.34189.3d; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Watkins MP., 2015, FDN CLIN RES APPL PR, V3rd; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	44	29	29	1	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2015	29	10					1158	1164		10.3109/02699052.2015.1035324			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CR3UK	WOS:000361258400003	26004753				2022-02-06	
J	Hu, T; Zhou, FJ; Chang, YF; Li, YS; Liu, GC; Hong, Y; Chen, HL; Xiyang, YB; Bao, TH				Hu, Tao; Zhou, Feng-Jie; Chang, Ye-Fei; Li, Ya-Shan; Liu, Guang-Cai; Hong, Ying; Chen, Hong-Lan; Xiyang, Yan-Bin; Bao, Tian-Hao			miR21 is Associated with the Cognitive Improvement Following Voluntary Running Wheel Exercise in TBI Mice	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						miR21; Voluntary running wheel; Traumatic brain injury; Learning and memory	TRAUMATIC BRAIN-INJURY; TREADMILL EXERCISE; EXPRESSION; HIPPOCAMPUS; TARGETS; MEMORY; RATS; RNAS	Recent evidences revealed that the alteration of microRNAs (miRNAs) might be associated with neuroplasticity induced by voluntary running wheel (RW) exercise in mice suffered from traumatic brain injury (TBI). In the present study, we explored the possible role of miR21 involved in the cognitive improvement following voluntary RW in TBI mice. Firstly, in situ hybridization and quantitative real-time PCR (qRT-PCR) were employed to determine the hippocampal expression and location of miR21 in TBI mice with or without spontaneous RW. Either miR21-mimics/plenti-miR21 or miR21-agomir/miR21-sponge was employed to regulate the miR21 expression in vivo and in vitro. Acquisition of spatial learning and memory retention was assessed by Morris Water Maze (MWM) test. Golgi stain was also performed to evaluate the alteration of hippocampal dendrite. Our finding confirmed that the elevated miR21 level in hippocampal post-TBI was significantly reduced by spontaneous RW. Overexpression of miR21 in TBI mice with spontaneous RW induced deteriorations in spatial learning and memory retention by significant decreases in the somata size and branch points of the hippocampus neurons. In vitro transduction with miR21 also reduced the neurite extension and the area of cultured hippocampal neuron. However, miR21 down-regulation reversed these effects. The present data strongly suggest that miR21 is an important molecule that has been involved in neuroprotection induced by voluntary RW exercise post-TBI.	[Hu, Tao; Chang, Ye-Fei; Li, Ya-Shan; Liu, Guang-Cai; Hong, Ying; Chen, Hong-Lan] Third Peoples Hosp Yunnan Prov, Dept Lab Med, Kunming, Yunnan Province, Peoples R China; [Zhou, Feng-Jie] First Peoples Hosp XianTao, XianTao, Hubei Province, Peoples R China; [Xiyang, Yan-Bin] Kunming Med Univ, Inst Neurosci, Kunming 650500, Yunnan Province, Peoples R China; [Bao, Tian-Hao] Kunming Med Univ, Affiliated Hosp 2, Dept Neurol, Kunming 650500, Yunnan Province, Peoples R China		Xiyang, YB (corresponding author), Kunming Med Univ, Inst Neurosci, 1168 West Chunrong Rd,Yuhua Ave, Kunming 650500, Yunnan Province, Peoples R China.	xiyang_neuro@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81100911]; Special Fund of the Applied Basic Research Programs of Yunnan Province; Kunming Medical University in China [2013FB116]	We thank Dr. Kevin J. Wells for his valuable comments during the preparation of this manuscript. This work is supported by National Natural Science Foundation of China (Grant NO.81100911, http://isisn.nsfc.gov.cn/egrantweb/), the Special Fund of the Applied Basic Research Programs of Yunnan Province associated with Kunming Medical University in China (Grant NO.2013FB116, http://61.166.241.213/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baek SS, 2012, BRAIN DEV-JPN, V34, P45, DOI 10.1016/j.braindev.2011.01.011; Bao TH, 2014, J MOL NEUROSCI, V54, P622, DOI 10.1007/s12031-014-0344-1; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Gu YL, 2014, NEUROSCI LETT, V570, P86, DOI 10.1016/j.neulet.2014.04.004; Heo YM, 2014, INT NEUROUROL J, V18, P16, DOI 10.5213/inj.2014.18.1.16; Hoffman AN, 2011, EUR J NEUROSCI, V34, P1023, DOI 10.1111/j.1460-9568.2011.07820.x; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; JASLOVE SW, 1992, NEUROSCIENCE, V47, P495, DOI 10.1016/0306-4522(92)90161-T; Kim SE, 2013, MOL MED REP, V7, P31, DOI 10.3892/mmr.2012.1160; Kim SE, 2010, EXP GERONTOL, V45, P357, DOI 10.1016/j.exger.2010.02.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Long JM, 2011, CURR MED CHEM, V18, P3314, DOI 10.2174/092986711796504592; Ntanasis-Stathopoulos J, 2013, J MUSCULOSKEL NEURON, V13, P133; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Rosi S, 2012, HIPPOCAMPUS, V22, P544, DOI 10.1002/hipo.20920; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; VanLeeuwen JE, 2010, J NEUROSCI RES, V88, P650, DOI 10.1002/jnr.22216; Wibrand K, 2010, EUR J NEUROSCI, V31, P636, DOI 10.1111/j.1460-9568.2010.07112.x	22	29	30	3	13	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	SEP	2015	57	1					114	122		10.1007/s12031-015-0584-8			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	CP7MW	WOS:000360073300013	26018937				2022-02-06	
J	Albayrak, S; Atci, IB; Kalayci, M; Yilmaz, M; Kuloglu, T; Aydin, S; Kom, M; Ayden, O; Aydin, S				Albayrak, Serdal; Atci, Ibrahim Burak; Kalayci, Mehmet; Yilmaz, Musa; Kuloglu, Tuncay; Aydin, Suna; Kom, Mustafa; Ayden, Omer; Aydin, Suleyman			Effect of carnosine, methylprednisolone and their combined application on irisin levels in the plasma and brain of rats with acute spinal cord injury	NEUROPEPTIDES			English	Article						Carnosine; Methylprednisolone; Irisin; Spinal cord injury	METABOLIC SYNDROME; MOTOR FUNCTION; COMPRESSION; EXPRESSION; RECOVERY; IMPROVES; TISSUES; ISCHEMIA; GHRELIN; ALPHA	Spinal cord injury (SCI) might occur to anybody at any time and any age. In its treatment, methylprednisolone (MP) is a first choice worldwide, but there is still no significant breakthrough in truly beneficial treatment due to SCI's complex pathophysiology. We investigated the effect of camosine, methylprednisolone (MP) and its combination on irisin levels in the plasma, brain and medulla spinalis tissues in SCI using a rat model. The rats were divided into 6 groups: I (Control, saline); II (sham animals with laminectomy without cross-clamping); III (SCI); IV (SCI treated with 150 mg/kg carnosine); V (SCI treated with 30 mg/kg methylprednisolone); and VI (SCI treated with a combination of carnosine and MP). The animals were given traumatic SCI after laminectomy, using 70-g closing force aneurysm clips (Yasargil FE 721). Irisin concentration was measured by ELISA. The distribution of irisin in brain and spinal cord tissues was examined by immunochemistry. Irisin was mainly expressed in the astrocytes and microglia of brain tissues, and multipolar neurones of the anterior horn of spinal cord tissue in rats of all groups, indicating that irisin is physiologically indispensable. MP and camosine and the combination of the two, significantly increased irisin in plasma and were accompanied by a significant rise in irisin immunoreactivity of brain and spinal cord tissues of the injured rats compared with control and sham. This finding raises the possibility that methylprednisolone and camosine regulate the brain and spinal cord tissues in SCI by inducing irisin expression, and may therefore offer a better neurological prognosis. (C) 2015 Elsevier Ltd. All rights reserved.	[Albayrak, Serdal; Atci, Ibrahim Burak; Ayden, Omer] Elazig Educ & Res Hosp, Dept Neurosurg, TR-23100 Elazig, Turkey; [Kalayci, Mehmet] Elazig Educ & Res Hosp, Med Biochem Lab, TR-23100 Elazig, Turkey; [Yilmaz, Musa; Aydin, Suleyman] Firat Univ, Sch Med, Dept Med Biochem, First Hormones Res Grp, TR-23119 Elazig, Turkey; [Kuloglu, Tuncay] Firat Univ, Sch Med, Dept Histol & Embryol, TR-23119 Elazig, Turkey; [Aydin, Suna] Elazig Educ & Res Hosp, Cardiovasc Surg Anat, TR-23100 Elazig, Turkey; [Kom, Mustafa] Firat Univ, Vet Med, Dept Surg, TR-23119 Elazig, Turkey		Aydin, S (corresponding author), Firat Univ, Sch Med, Dept Med Biochem, First Hormones Res Grp, TR-23119 Elazig, Turkey.	saydinl@hotmail.com	kuloglu, tuncay/W-2310-2018	KALAYCI, Mehmet/0000-0001-9122-9289			Aydin S, 2014, BIOTECH HISTOCHEM, V89, P98, DOI 10.3109/10520295.2013.821167; Aydin S., 2014, BIOTECH HISTOCHEM, P1; Aydin S, 2007, J BIOCHEM MOL BIOL, V40, P29; Aydin S, 2014, PEPTIDES, V61, P130, DOI 10.1016/j.peptides.2014.09.014; Aydin S, 2014, PEPTIDES, V56, P94, DOI 10.1016/j.peptides.2014.03.021; Aydin S, 2015, PEPTIDES, V64, P14, DOI 10.1016/j.peptides.2014.11.008; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; Boldyrev AA, 2012, BIOCHEMISTRY-MOSCOW+, V77, P313, DOI 10.1134/S0006297912040013; Boldyrev AA, 2013, PHYSIOL REV, V93, P1803, DOI 10.1152/physrev.00039.2012; Bostrom P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777; Cassano M, 2009, J MUSCLE RES CELL M, V30, P243, DOI 10.1007/s10974-010-9204-y; Catak Z, 2014, NEUROPEPTIDES, V48, P167, DOI 10.1016/j.npep.2014.04.002; Coban Jale, 2013, Curr Aging Sci, V6, P199; Di Paola R, 2011, BIOCHEM PHARMACOL, V82, P1478, DOI 10.1016/j.bcp.2011.07.074; Dun SL, 2013, NEUROSCIENCE, V240, P155, DOI 10.1016/j.neuroscience.2013.02.050; Farooque M, 1996, J NEUROCHEM, V66, P1125; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; Gravholt CH, 2002, OBES RES, V10, P774, DOI 10.1038/oby.2002.105; Holmes FE, 2005, NEUROPEPTIDES, V39, P191, DOI 10.1016/j.npep.2005.01.001; HOLTZ A, 1990, ACTA NEUROL SCAND, V82, P68; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Jing YH, 2012, ACTA NEUROBIOL EXP, V72, P240; Kumamaru H, 2012, J CELL PHYSIOL, V227, P1335, DOI 10.1002/jcp.22845; Li XL, 2007, NEUROPEPTIDES, V41, P135, DOI 10.1016/j.npep.2007.02.001; Meng B, 2011, J INT MED RES, V39, P805, DOI 10.1177/147323001103900313; Mu XJ, 2000, J NEUROTRAUM, V17, P773, DOI 10.1089/neu.2000.17.773; Nasirinezhad F, 2015, MOL PAIN, V11, DOI 10.1186/1744-8069-11-2; Pereira RMR, 2011, JOINT BONE SPINE, V78, P41, DOI 10.1016/j.jbspin.2010.02.025; Shaw PJ, 1997, J NEUROL SCI, V147, P115, DOI 10.1016/S0022-510X(96)05316-6; Shi E, 2005, J THORAC CARDIOV SUR, V129, P364, DOI 10.1016/j.jtcvs.2004.05.006; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P271, DOI 10.1001/archneurpsyc.1954.02320390001001; Taylor JA, 2011, PM&R, V3, P817, DOI 10.1016/j.pmrj.2011.03.020; Vaquero J, 2006, HISTOL HISTOPATHOL, V21, P1091, DOI 10.14670/HH-21.1091; Xu J, 2001, J NEUROSCI, V21, P92, DOI 10.1523/JNEUROSCI.21-01-00092.2001; XU J, 1992, J NEUROTRAUM, V9, P245, DOI 10.1089/neu.1992.9.245; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9	36	29	32	1	16	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4179	1532-2785		NEUROPEPTIDES	Neuropeptides	AUG	2015	52						47	54		10.1016/j.npep.2015.06.004			8	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	CQ2FT	WOS:000360416100005	26142757				2022-02-06	
J	Cui, CM; Gao, JL; Cui, Y; Sun, LQ; Wang, YC; Wang, KJ; Li, R; Tian, YX; Cui, JZ				Cui, Chang-Meng; Gao, Jun-Ling; Cui, Ying; Sun, Li-Qian; Wang, Yong-Chao; Wang, Kai-Jie; Li, Ran; Tian, Yan-Xia; Cui, Jian-Zhong			Chloroquine exerts neuroprotection following traumatic brain injury via suppression of inflammation and neuronal autophagic death	MOLECULAR MEDICINE REPORTS			English	Article						chloroquine; autophagy; neuroprotection; traumatic brain injury; rats	CLOSED-HEAD INJURY; DOUBLE-EDGED-SWORD; CELL-DEATH; ISCHEMIA; MICE; MECHANISMS; RAPAMYCIN; THERAPY; HEALTH; TARGET	The antimalarial drug, chloroquine (CQ), has been reported as an autophagy inhibitor in a variety of disorders, including Alzheimer's disease and brain ischemia. To the best of our knowledge, no studies to date have examined the potential for CQ to provide neuroprotection in animal models of traumatic brain injury (TBI). The aim of this study was to investigate the neuroprotective actions of CQ in TBI and to determine the mechanisms underlying this effect. Rats were immediately subjected to a diffuse cortical impact injury caused by a modified weight-drop device and divided randomly into three groups: sham-operated, CQ treatment and vehicle. The CQ treatment group was administered CQ (intra-peritoneally, 3 mg/kg body weight) immediately following the induction of injury. The co-localization of neuron-specific nuclear protein (NeuN) and microtubule-associated protein 1 light chain 3 (LC3), was followed by immunofluorescent staining. The expression of LC3 and inflammatory cytokines was identified by western blot analysis. Wet-dry weight method was utilized to evaluate TBI-induced brain edema. Motor function was evaluated using the Neurological Severity Score (NSS) scale and the Morris water maze was employed to assess spatial learning ability. This study demonstrated that the administration of CQ attenuates TBI-induced cerebral edema, and the associated motor and cognitive functional deficits that occur post-injury. Following the induction of cerebral trauma, CQ treatment significantly suppressed neuronal autophagy and reduced expression levels of the inflammatory cytokines, interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), in the rat hippocampus. Our results have provided in vivo evidence that CQ may exert neuroprotective effects following TBI, in attenuating brain edema and improving neurological functioning, by reducing the damaging consequences of neuronal autophagy and cerebral inflammation.	[Cui, Chang-Meng; Cui, Jian-Zhong] Hebei Med Univ, Dept Surg, Shijiazhuang 050017, Hebei, Peoples R China; [Gao, Jun-Ling; Wang, Yong-Chao; Li, Ran; Tian, Yan-Xia] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei, Peoples R China; [Cui, Ying; Sun, Li-Qian; Wang, Kai-Jie; Cui, Jian-Zhong] Tangshan Workers Hosp, Dept Neurosurg, Tangshan 063000, Hebei, Peoples R China		Cui, JZ (corresponding author), Hebei Med Univ, Dept Surg, 361 East Zhongshan Rd, Shijiazhuang 050017, Hebei, Peoples R China.	jzhcuidr2001@163.com			Natural Science Foundation of Hebei, ChinaNatural Science Foundation of Hebei Province [H2012401071, H2014105079]	This study was supported by the grant from the Natural Science Foundation of Hebei, China (grant nos. H2012401071 and H2014105079).	Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0; Jang CH, 2006, RHEUMATOLOGY, V45, P703, DOI 10.1093/rheumatology/kei282; Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liu CL, 2010, J NEUROCHEM, V115, P68, DOI 10.1111/j.1471-4159.2010.06905.x; Liu HG, 2010, SLEEP MED, V11, P205, DOI 10.1016/j.sleep.2009.05.015; Lopez G, 2011, AUTOPHAGY, V7, P440, DOI 10.4161/auto.7.4.14680; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Tang JP, 2004, J CEREBR BLOOD F MET, V24, P1133, DOI 10.1097/01.WCB.0000135593.05952.DE; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang JY, 2009, J ALZHEIMERS DIS, V16, P39, DOI 10.3233/JAD-2009-0908; [No title captured], DOI DOI 10.1038/NRCLINONC.2011.71	33	29	35	0	22	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	AUG	2015	12	2					2323	2328		10.3892/mmr.2015.3611			6	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	CN8GR	WOS:000358678600099	25872478	Bronze			2022-02-06	
J	Wei, WT; Wang, HD; Wu, Y; Ding, K; Li, T; Cong, ZX; Xu, JG; Zhou, ML; Huang, LT; Ding, H; Wu, HM				Wei, Wuting; Wang, Handong; Wu, Yong; Ding, Ke; Li, Tao; Cong, Zixiang; Xu, Jianguo; Zhou, Mengliang; Huang, Litian; Ding, Hui; Wu, Heming			Alpha lipoic acid inhibits neural apoptosis via a mitochondrial pathway in rats following traumatic brain injury	NEUROCHEMISTRY INTERNATIONAL			English	Article						Alpha lipoic acid; Apoptosis; Traumatic brain injury; Mitochondria	EXPERIMENTAL SUBARACHNOID HEMORRHAGE; REDUCING OXIDATIVE STRESS; CELL-DEATH; NRF2-ARE PATHWAY; CYTOCHROME-C; SYNAPTIC PROTEINS; NEUROPROTECTION; PROTECTS; ACTIVATION; DYSFUNCTION	Alpha lipoic acid (ALA) is a powerful antioxidant that has proven protective effects against brain damage following a traumatic brain injury (TBI) in rats. However, the molecular mechanisms underlying these effects are not well understood. This study investigated the effect of ALA on neural apoptosis and the potential mechanism of these effects in the weight-drop model of TBI in male Sprague-Dawley rats that were treated with ALA (20 or 100 mg/kg) or vehicle via intragastric administration 30 min after TBI. Brain samples were collected 48 h later for analysis. ALA treatment resulted in a downregulation of caspase-3 expression, reduced the number of positive cells in the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay and improved neuronal survival. Furthermore, the level of malondialdehyde and glutathione peroxidase activity were restored, while Bcl-2-associated X protein translocation to mitochondria and cytochrome c release into the cytosol were reduced by ALA treatment. These results demonstrate that ALA improves neurological outcome in rats by protecting neural cell against apoptosis via a mechanism that involves the mitochondria following TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Wei, Wuting; Wang, Handong; Huang, Litian; Ding, Hui] Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Wu, Yong; Ding, Ke; Li, Tao; Cong, Zixiang; Xu, Jianguo; Zhou, Mengliang; Wu, Heming] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81301180]; Jiangsu Planned Projects for Postdoctoral Research Funds [1401002A]	This work was supported by grants from the National Natural Science Foundation of China (nos. 81371357, 81301180) and Jiangsu Planned Projects for Postdoctoral Research Funds (1401002A).	Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Cahill J, 2007, NEUROSURGERY, V60, P531, DOI 10.1227/01.NEU.0000249287.99878.9B; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Feeney D. M., 1981, BRAIN RES, V211, P66; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gloryy A, 2014, INT J HYPERTHER, V30, P502, DOI 10.3109/02656736.2014.968641; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Paradies G, 2014, WORLD J GASTROENTERO, V20, P14205, DOI 10.3748/wjg.v20.i39.14205; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Reed LJ, 1998, PROTEIN SCI, V7, P220, DOI 10.1002/pro.5560070125; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Simpkins JW, 2010, BBA-GEN SUBJECTS, V1800, P1113, DOI 10.1016/j.bbagen.2009.11.013; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Smith AR, 2004, CURR MED CHEM, V11, P1135, DOI 10.2174/0929867043365387; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Tirosh O, 2003, BIOFACTORS, V17, P297, DOI 10.1002/biof.5520170129; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xie F, 2014, INT J CLIN EXP MED, V7, P2009; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, BRAIN INJURY, V22, P802, DOI 10.1080/02699050802372174; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zhang D, 2013, NEUROSCIENCE, V238, P209, DOI 10.1016/j.neuroscience.2013.02.022; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47	39	29	29	1	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	AUG	2015	87						85	91		10.1016/j.neuint.2015.06.003			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	CO7HO	WOS:000359330400009	26055972				2022-02-06	
J	Khan, M; Dhammu, TS; Matsuda, F; Singh, AK; Singh, I				Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Singh, Avtar K.; Singh, Inderjit			Blocking a vicious cycle nNOS/peroxynitrite/AMPK by S-nitrosoglutathione: implication for stroke therapy	BMC NEUROSCIENCE			English	Article						AMP-activated protein kinase; Neuronal nitric oxide synthase; Neuroprotection; Peroxynitrite; S-nitrosoglutathione; Stroke; Cerebral ischemia reperfusion	NITRIC-OXIDE SYNTHASE; ACTIVATED PROTEIN-KINASE; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; RAT MODEL; NEUROPROTECTIVE EFFICACY; PEROXYNITRITE FORMATION; NEUROVASCULAR UNIT; BLOOD-FLOW; LIFE-SPAN	Background: Stroke immediately sets into motion sustained excitotoxicity and calcium dysregulation, causing aberrant activity in neuronal nitric oxide synthase (nNOS) and an imbalance in the levels of nitric oxide (NO). Drugs targeting nNOS-originated toxicity may therefore reduce stroke-induced damage. Recently, we observed that a redox-modulating agent of the NO metabolome, S-nitrosoglutathione (GSNO), confers neurovascular protection by reducing the levels of peroxynitrite, a product of aberrant NOS activity. We therefore investigated whether GSNO-mediated neuroprotection and improved neurological functions depend on blocking nNOS/peroxynitrite-associated injurious mechanisms using a rat model of cerebral ischemia reperfusion (IR). Results: IR increased the activity of nNOS, the levels of neuronal peroxynitrite and phosphorylation at Ser(1412) of nNOS. GSNO treatment of IR animals decreased IR-activated nNOS activity and neuronal peroxynitrite levels by reducing nNOS phosphorylation at Ser(1412). The Ser(1412) phosphorylation is associated with increased nNOS activity. Supporting the notion that nNOS activity and peroxynitrite are deleterious following IR, inhibition of nNOS by its inhibitor 7-nitroindazole or reducing peroxynitrite by its scavenger FeTPPS decreased IR injury. GSNO also decreased the activation of AMP Kinase (AMPK) and its upstream kinase LKB1, both of which were activated in IR brain. AMPK has been implicated in nNOS activation via Ser(1412) phosphorylation. To determine whether AMPK activation is deleterious in the acute phase of IR, we treated animals after IR with AICAR (an AMPK activator) and compound c (an AMPK inhibitor). While AICAR potentiated, compound c reduced the IR injury. Conclusions: Taken together, these results indicate an injurious nNOS/peroxynitrite/AMPK cycle following stroke, and GSNO treatment of IR inhibits this vicious cycle, resulting in neuroprotection and improved neurological function. GSNO is a natural component of the human body, and its exogenous administration to humans is not associated with any known side effects. Currently, the FDA-approved thrombolytic therapy suffers from a lack of neuronal protective activity. Because GSNO provides neuroprotection by ameliorating stroke's initial and causative injuries, it is a candidate of translational value for stroke therapy.	[Khan, Mushfiquddin; Dhammu, Tajinder S.; Matsuda, Fumiyo; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Matsuda, Fumiyo] Kagoshima Univ, Sch Hlth Sci, Kagoshima 890, Japan; [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA		Khan, M (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	khanm@musc.edu; singhi@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-72511]; VA merit awardUS Department of Veterans Affairs [BX001062, BX002829]; NIH, National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455, C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072511] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002829, I01BX001062] Funding Source: NIH RePORTER	This work was supported by grants from NIH (NS-72511) and VA merit award (BX001062 and BX002829). This work was also supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. We thank Ms. Joyce Bryan and Ms. Terry Hope for their technical help and secretarial assistance. We are grateful to Drs. Harutoshi Sakakima and Yoshihiro Yoshida for their scientific input and to Ms. Danielle Lowe (MD/PhD student at the MUSC) for statistical analysis. We also acknowledge Dr. Tom Smith from the MUSC Writing Center for his valuable editing of the manuscript.	Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Broniowska KA, 2013, BBA-GEN SUBJECTS, V1830, P3173, DOI 10.1016/j.bbagen.2013.02.004; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; Chiueh CC, 1999, FREE RADICAL RES, V31, P641, DOI 10.1080/10715769900301211; Coert BA, 2003, AM J PHYSIOL-HEART C, V284, pH151, DOI 10.1152/ajpheart.00580.2002; Colagiovanni DB, 2011, INT J TOXICOL, V30, P466, DOI 10.1177/1091581811412084; Cramer SC, 2008, ANN NEUROL, V63, P549, DOI 10.1002/ana.21412; Cramer SC, 2008, ANN NEUROL, V63, P272, DOI 10.1002/ana.21393; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; Douglas PM, 2010, J CELL BIOL, V190, P719, DOI 10.1083/jcb.201005144; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Garcia-Bonilla L, 2014, J IMMUNOL, V193, P2531, DOI 10.4049/jimmunol.1400918; Gingerich S, 2008, NEUROPHARMACOLOGY, V55, P878, DOI 10.1016/j.neuropharm.2008.06.058; GINSBERG MD, 1989, STROKE, V20, P1627, DOI 10.1161/01.STR.20.12.1627; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Gursoy-Ozdemir Y, 2012, J NEUROCHEM, V123, P2, DOI 10.1111/j.1471-4159.2012.07938.x; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Hurt KJ, 2012, P NATL ACAD SCI USA, V109, P16624, DOI 10.1073/pnas.1213790109; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Jatana M, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-12; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2012, J NEUROCHEM, V123, P86, DOI 10.1111/j.1471-4159.2012.07947.x; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Komeima K, 2000, J BIOL CHEM, V275, P28139; Komeima K, 2001, FEBS LETT, V497, P65, DOI 10.1016/S0014-5793(01)02389-4; Li J, 2010, J CEREBR BLOOD F MET, V30, P480, DOI 10.1038/jcbfm.2009.255; Lo EH, 2004, NAT MED, V10, P1295, DOI 10.1038/nm1204-1295; Ma T, 2014, J NEUROSCI, V34, P12230, DOI 10.1523/JNEUROSCI.1694-14.2014; Mair W, 2011, NATURE, V470, P404, DOI 10.1038/nature09706; Manwani B, 2013, J NEUROSCI RES, V91, P1018, DOI 10.1002/jnr.23207; Matsuda F, 2011, ACTA PHYSIOL, V201, P275, DOI [10.1111/j.1748-1716.2010.02174.x, 10.1111/j.1748-1708.2010.02174.x]; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Murphy BA, 2009, AM J PHYSIOL-CELL PH, V297, pC750, DOI 10.1152/ajpcell.00127.2009; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Qu ZW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052788; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Rameau GA, 2003, NEUROBIOL AGING, V24, P1123, DOI 10.1016/j.neurobiolaging.2003.07.002; Rameau GA, 2007, J NEUROSCI, V27, P3445, DOI 10.1523/JNEUROSCI.4799-06.2007; Sakakima H, 2012, RESTOR NEUROL NEUROS, V30, P383, DOI 10.3233/RNN-2012-110209; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Schrammel A, 2003, FREE RADICAL BIO MED, V34, P1078, DOI 10.1016/S0891-5849(03)00038-8; Selim M, 2007, NEW ENGL J MED, V356, P706, DOI 10.1056/NEJMra062668; Sun J, 2008, ARCH BIOCHEM BIOPHYS, V471, P126, DOI 10.1016/j.abb.2008.01.003; Sun M, 2009, NEUROCHEM INT, V54, P339, DOI 10.1016/j.neuint.2008.12.017; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thiyagarajan M, 2004, BRIT J PHARMACOL, V142, P899, DOI 10.1038/sj.bjp.0705811; WANG Q, 1995, J CEREBR BLOOD F MET, V15, P774, DOI 10.1038/jcbfm.1995.97; Wei G, 1999, BBA-MOL BASIS DIS, V1455, P23, DOI 10.1016/S0925-4439(99)00051-4; Weisova P, 2011, ANTIOXID REDOX SIGN, V14, P1863, DOI 10.1089/ars.2010.3544; Willmot M, 2005, FREE RADICAL BIO MED, V39, P412, DOI 10.1016/j.freeradbiomed.2005.03.028; Won JS, 2013, J ALZHEIMERS DIS, V34, P621, DOI 10.3233/JAD-121786; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	62	29	30	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JUL 15	2015	16								42	10.1186/s12868-015-0179-x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CM7CM	WOS:000357848000001	26174015	gold, Green Published			2022-02-06	
J	Biscotti, M; Gannon, WD; Abrams, D; Agerstrand, C; Claassen, J; Brodie, D; Bacchetta, M				Biscotti, M.; Gannon, W. D.; Abrams, D.; Agerstrand, C.; Claassen, J.; Brodie, D.; Bacchetta, M.			Extracorporeal membrane oxygenation use in patients with traumatic brain injury	PERFUSION-UK			English	Article						Extracorporeal membrane oxygenation; ECMO; traumatic brain injury; TBI; acute respiratory distress syndrome; ARDS		Venovenous extracorporeal membrane oxygenation (ECMO) is used for patients with severe, potentially reversible, respiratory failure unresponsive to conventional management. It is relatively contraindicated in patients with traumatic brain injury (TBI) due to bleeding complications and use of anticoagulation. We report two cases of TBI patients treated with ECMO.	[Biscotti, M.] Columbia Univ, Med Ctr, Dept Gen Surg, New York, NY 10032 USA; [Gannon, W. D.; Abrams, D.; Agerstrand, C.; Brodie, D.] Columbia Univ, Med Ctr, Dept Pulm Allergy & Crit Care Med, New York, NY 10032 USA; [Claassen, J.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA; [Bacchetta, M.] Columbia Univ, Med Ctr, Dept Cardiothorac Surg, New York, NY 10032 USA		Bacchetta, M (corresponding author), Columbia Univ, Med Ctr, Surg, Herbert Irving Pavil, 3rd Floor 161 Ft Washington Ave, New York, NY 10032 USA.	mb781@columbia.edu	Claassen, Jan/AAA-5451-2020				Arlt M, 2010, RESUSCITATION, V81, P804, DOI 10.1016/j.resuscitation.2010.02.020; Brodie D, 2011, NEW ENGL J MED, V365, P1905, DOI 10.1056/NEJMct1103720; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hwang GJ, 2013, J KOREAN MED SCI, V28, P962, DOI 10.3346/jkms.2013.28.6.962; Messing JA, 2014, ASAIO J, V60, P597, DOI 10.1097/MAT.0000000000000103; Yen TS, 2008, CLIN NEUROL NEUROSUR, V110, P295, DOI 10.1016/j.clineuro.2007.10.017	6	29	30	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0267-6591	1477-111X		PERFUSION-UK	Perfusion-UK	JUL	2015	30	5					407	409		10.1177/0267659114554327			3	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	CK2AJ	WOS:000356011400009	25313096				2022-02-06	
J	Pape, TLB; Rosenow, JM; Steiner, M; Parrish, T; Guernon, A; Harton, B; Patil, V; Bhaumik, DK; McNamee, S; Walker, M; Froehlich, K; Burress, C; Odle, C; Wang, X; Herrold, AA; Zhao, WH; Reda, D; Mallinson, T; Conneely, M; Nemeth, AJ				Pape, Theresa Louise-Bender; Rosenow, Joshua M.; Steiner, Monica; Parrish, Todd; Guernon, Ann; Harton, Brett; Patil, Vijaya; Bhaumik, Dulal K.; McNamee, Shane; Walker, Matthew; Froehlich, Kathleen; Burress, Catherine; Odle, Cheryl; Wang, Xue; Herrold, Amy A.; Zhao, Weihan; Reda, Domenic; Mallinson, Trudy; Conneely, Mark; Nemeth, Alexander J.			Placebo-Controlled Trial of Familiar Auditory Sensory Training for Acute Severe Traumatic Brain Injury: A Preliminary Report	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; neurorehabilitation; sensory stimulation; disordered consciousness; treatment; auditory plasticity	MINIMALLY CONSCIOUS STATE; VEGETATIVE STATE; DISORDERS; COMA; STIMULATION; REHABILITATION; SCALES	Background. Sensory stimulation is often provided to persons incurring severe traumatic brain injury (TBI), but therapeutic effects are unclear. Objective. This preliminary study investigated neurobehavioral and neurophysiological effects related to sensory stimulation on global neurobehavioral functioning, arousal, and awareness. Methods. A double-blind randomized placebo-controlled trial where 15 participants in states of disordered consciousness (DOC), an average of 70 days after TBI, were provided either the Familiar Auditory Sensory Training (FAST) or Placebo of silence. Global neurobehavioral functioning was measured with the Disorders of Consciousness Scale (DOCS). Arousal and awareness were measured with the Coma-Near-Coma (CNC) scale. Neurophysiological effect was measured using functional magnetic resonance imaging (fMRI). Results. FAST (n = 8) and Placebo (n = 7) groups each showed neurobehavioral improvement. Mean DOCS change (FAST = 13.5, SD = 8.2; Placebo = 18.9, SD = 15.6) was not different, but FAST patients had significantly (P = .049; 95% confidence interval [CI] = -1.51, -.005) more CNC gains (FAST = 1.01, SD = 0.60; Placebo = 0.25, SD = 0.70). Mixed-effects models confirm CNC findings (P = .002). Treatment effect, based on CNC, is large (d = 1.88, 95% CI = 0.77, 3.00). Number needed to treat is 2. FAST patients had more fMRI activation in language regions and whole brain (P values <.05) resembling healthy controls' activation. Conclusions. For persons with DOC 29 to 170 days after TBI, FAST resulted in CNC gains and increased neural responsivity to vocal stimuli in language regions. Clinicians should consider providing the FAST to support patient engagement in neurorehabilitation.	[Pape, Theresa Louise-Bender; Steiner, Monica; Guernon, Ann; Harton, Brett; Patil, Vijaya; Bhaumik, Dulal K.; Odle, Cheryl; Herrold, Amy A.; Reda, Domenic] Edward Hines Jr VA Hosp, Hines, IL 60141 USA; [Pape, Theresa Louise-Bender; Rosenow, Joshua M.; Parrish, Todd; Wang, Xue; Nemeth, Alexander J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Rosenow, Joshua M.] Northwestern Mem Hosp, Chicago, IL USA; [Steiner, Monica; Patil, Vijaya] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA; [Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA; [Bhaumik, Dulal K.; Zhao, Weihan] Univ Illinois, Chicago, IL USA; [McNamee, Shane] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA; [Walker, Matthew] Northshore Univ Hlth Syst, Evanston, IL USA; [Froehlich, Kathleen; Burress, Catherine] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Mallinson, Trudy] George Washington Univ, Washington, DC USA; [Conneely, Mark] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA		Pape, TLB (corresponding author), Edward Hines Jr VA Hosp, Ctr Innovat Complex Chron Healthcare & Res Serv, Dept Vet Affairs VA, PO 5000 S 5th Ave,Bldg 1 M-C 151H, Hines, IL 60141 USA.	Theresa.Pape@va.gov	Nemeth, Alexander J./AAI-2481-2020; Mallinson, Trudy/S-7381-2019	Nemeth, Alexander J./0000-0003-0579-3866; Mallinson, Trudy/0000-0002-4888-5579; Parrish, Todd/0000-0002-1184-1572; Bender Pape, Theresa/0000-0001-7738-5963; , Domenic/0000-0003-1831-4270	Department of Veterans Affairs, Office of Research and DevelopmentUS Department of Veterans Affairs; Rehabilitation Research and Development Merit Grant [B4591R]; career development transition award [B4949N]; National Center for Research Resources, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025741]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025741] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Department of Veterans Affairs, Office of Research and Development, Rehabilitation Research and Development Merit Grant # B4591R and career development transition award # B4949N. Northwestern University's Clinical and Translation Sciences Institute, which is supported by the National Center for Research Resources, National Institutes of Health (Grant UL1RR025741). The Nick Kot Charity for traumatic brain injury (www.nkc4tbi.com).	Adamovich B. B., 1992, SCALES COGNITIVE ABI; American Academy of Neurology, 1995, PRACT PAR ASS MAN PA; ANSELL BJ, 1991, J SPEECH HEAR RES, V34, P1017, DOI 10.1044/jshr.3405.1017; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Chleboun S, 2009, BRAIN INJURY, V23, P101, DOI 10.1080/02699050802649639; Citrome L, 2013, INT J CLIN PRACT, V67, P407, DOI 10.1111/ijcp.12142; Cohen J., 2013, STAT POWER ANAL BEHA; Di Stefano C, 2012, BRAIN INJURY, V26, P1250, DOI 10.3109/02699052.2012.667588; Eton DT, 2004, J CLIN EPIDEMIOL, V57, P898, DOI 10.1016/j.jclinepi.2004.01.012; Ganesh S, 2013, ARCH PHYS MED REHAB, V94, P1899, DOI 10.1016/j.apmr.2012.12.026; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Giacino JT, 1996, NEUROREHABILITATION, V6, P69, DOI 10.3233/NRE-1996-6108; Gibbons R, 2009, STAT METHODS GROUND, V2; GIBBONS RD, 2000, SANKHYA SERIES B, V62, P70; Gruner ML, 2000, BRAIN INJURY, V14, P585; Hedeker D., 2006, LONGITUDINAL DATA AN; Imaizumi S, 1997, NEUROREPORT, V8, P2809, DOI 10.1097/00001756-199708180-00031; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; KURTZ D, 1977, REV EEG NEUROPHYSIOL, V7, P62, DOI 10.1016/S0370-4475(77)80036-1; Lancioni GE, 2010, RES DEV DISABIL, V31, P1121, DOI 10.1016/j.ridd.2010.06.019; Laureys S, 2006, CURR OPIN NEUROL, V19, P520, DOI 10.1097/WCO.0b013e3280106ba9; Linacre M., 1994, MANY FACETS RASCH ME; Lombardi F, 2002, CLIN REHABIL, V16, P464, DOI 10.1191/0269215502cr519oa; Megha M, 2013, BRAIN INJURY, V27, P570, DOI 10.3109/02699052.2013.767937; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; Meyer MJ, 2010, BRAIN INJURY, V24, P722, DOI 10.3109/02699051003692134; MORAY N, 1959, Q J EXP PSYCHOL, V11, P56, DOI 10.1080/17470215908416289; Moritz CH, 2001, MAGN RESON IMAGING, V19, P1129, DOI 10.1016/S0730-725X(01)00432-5; Pape TLB, 2014, ARCH PHYS MED REHAB, V95, P1672, DOI 10.1016/j.apmr.2014.04.015; Pape TLB, 2013, REHABIL PSYCHOL, V58, P253, DOI 10.1037/a0032610; Pape TLB, 2012, J REHABIL RES DEV, V49, P1137, DOI 10.1682/JRRD.2011.08.0154; Pape TLB, 2009, PM&R, V1, P152, DOI 10.1016/j.pmrj.2008.11.002; Pape TLB, 2005, J REHABIL RES DEV, V42, P1, DOI 10.1682/JRRD.2004.03.0032; Perrin F, 2006, ARCH NEUROL-CHICAGO, V63, P562, DOI 10.1001/archneur.63.4.562; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; Proverbio AM, 2001, NEUROPSYCHOLOGIA, V39, P815, DOI 10.1016/S0028-3932(01)00003-3; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1981, CLIN ELECTROENCEPHAL, V12, P154, DOI 10.1177/155005948101200402; Rappaport M, 1996, MED REHABILITATION T, P271; RAPPAPORT M, 1986, J HEAD TRAUMA REHABI, P00015, DOI DOI 10.1097/00001199-198603000-00005; Rasch Georg, 1980, PROBABILISTIC MODELS; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; SIGNORINO M, 1995, LANCET, V345, P255, DOI 10.1016/S0140-6736(95)90252-X; Tempini MLG, 1998, BRAIN, V121, P2103, DOI 10.1093/brain/121.11.2103; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Whyte J, 2003, AM J PHYS MED REHAB, V82, pS16, DOI 10.1097/01.PHM.0000086992.95121.C2; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Yasuda K, 2000, APHASIOLOGY, V14, P1067, DOI 10.1080/02687030050174638	53	29	31	2	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL	2015	29	6					537	547		10.1177/1545968314554626			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CN3GM	WOS:000358313600005	25613986				2022-02-06	
J	Woods, DL; Wyma, JM; Herron, TJ; Yund, EW				Woods, David L.; Wyma, John M.; Herron, Timothy J.; Yund, E. William			The Effects of Aging, Malingering, and Traumatic Brain Injury on Computerized Trail-Making Test Performance	PLOS ONE			English	Article							REGRESSION-BASED NORMS; D-KEFS TRAIL; NORMATIVE DATA; COGNITIVE IMPAIRMENT; OLDER-ADULTS; TEST-A; TEST-B; AGE; SAMPLE; EDUCATION	The trail making test (TMT) is widely used to assess speed of processing and executive function. However, normative data sets gathered at different sites show significant inconsistencies. Here, we describe a computerized version of the TMT (C-TMT) that increases the precision and replicability of the TMT by permitting a segment-by-segment analysis of performance and separate analyses of dwell-time, move-time, and error time. Experiment 1 examined 165 subjects of various ages and found that completion times on both the C-TMT-A (where subjects connect successively numbered circles) and the C-TMT-B (where subjects connect circles containing alternating letters and numbers) were strongly influenced by age. Experiment 2 examined 50 subjects who underwent three test sessions. The results of the first test session were well fit by the normative data gathered in Experiment 1. Sessions 2 and 3 demonstrated significant learning effects, particularly on the C-TMT-B, and showed good test-retest reliability. Experiment 3 examined performance in subjects instructed to feign symptoms of traumatic brain injury: 44% of subjects produced abnormal completion times on the C-TMT-A, and 18% on the C-TMT-B. Malingering subjects could be distinguished from abnormally slow controls based on (1) disproportionate increases in dwell-time on the C-TMT-A, and (2) greater deficits on the C-TMT-A than on the C-TMT-B. Experiment 4 examined the performance of 28 patients with traumatic brain injury: C-TMT-B completion times were slowed, and TBI patients showed reduced movement velocities on both tests. The C-TMT improves the reliability and sensitivity of the trail making test of processing speed and executive function.	[Woods, David L.; Wyma, John M.; Herron, Timothy J.; Yund, E. William] Vet Affairs Northern Calif Heath Care Syst, Human Cognit Neurophysiol Lab, Martinez, CA 95553 USA; [Woods, David L.] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA; [Woods, David L.] Univ Calif Davis, Ctr Neurosci, Davis, CA 95616 USA; [Woods, David L.] Univ Calif Davis, Ctr Mind & Brain, Davis, CA 95616 USA		Woods, DL (corresponding author), Vet Affairs Northern Calif Heath Care Syst, Human Cognit Neurophysiol Lab, 150 Muir Rd, Martinez, CA 95553 USA.	dlwoods@ucdavis.edu		Herron, Timothy/0000-0002-4297-014X; Woods, David/0000-0002-8804-3587; Yund, E./0000-0002-6833-0052	VA Research Service Grants [CX000583, CX001000]; Veterans AffairsUS Department of Veterans Affairs [I01CX001000] Funding Source: NIH RePORTER	This research was supported by a VA Research Service Grants CX000583 and CX001000 to DLW. The content is solely the responsibility of the authors and does not necessarily represent the official views of Department of Veterans Affairs or the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amodio P, 2002, AGING CLIN EXP RES, V14, P117, DOI 10.1007/BF03324425; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Ashendorf L, 2008, ARCH CLIN NEUROPSYCH, V23, P129, DOI 10.1016/j.acn.2007.11.005; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bezdicek O, 2012, ARCH CLIN NEUROPSYCH, V27, P906, DOI 10.1093/arclin/acs084; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Buck KK, 2008, J CLIN EXP NEUROPSYC, V30, P312, DOI 10.1080/13803390701390483; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Cangoz B, 2009, J NEUROL SCI, V283, P73, DOI 10.1016/j.jns.2009.02.313; Cavaco S, 2013, ARCH CLIN NEUROPSYCH, V28, P189, DOI 10.1093/arclin/acs115; de Frias CM, 2007, NEUROPSYCHOLOGIA, V45, P2499, DOI 10.1016/j.neuropsychologia.2007.03.022; Delis DC., 2001, DELIS KAPLAN EXECUTI; Demery JA, 2010, CLIN NEUROPSYCHOL, V24, P1292, DOI 10.1080/13854046.2010.528452; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Egeland J, 2007, APPL NEUROPSYCHOL, V14, P113, DOI 10.1080/09084280701319953; Era P, 2011, AGING CLIN EXP RES, V23, P135, DOI 10.1007/BF03351077; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P906, DOI 10.1076/jcen.20.6.906.1104; Fernandez AL, 2008, SCAND J PSYCHOL, V49, P239, DOI 10.1111/j.1467-9450.2008.00637.x; Fine EM, 2011, CLIN NEUROPSYCHOL, V25, P1331, DOI 10.1080/13854046.2011.609838; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Haines ME, 2001, CLIN NEUROPSYCHOL, V15, P171, DOI 10.1076/clin.15.2.171.1891; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Heaton RK, 1999, J CLIN EXP NEUROPSYC, V21, P571, DOI 10.1076/jcen.21.4.572.882; Heled E, 2012, J CLIN EXP NEUROPSYC, V34, P151, DOI 10.1080/13803395.2011.625351; Hubel KA, 2013, J CLIN EXP NEUROPSYC, V35, P745, DOI 10.1080/13803395.2013.824070; Ising M, 2014, GENES BRAIN BEHAV, V13, P501, DOI 10.1111/gbb.12132; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; KENNEDY KJ, 1981, PERCEPT MOTOR SKILL, V52, P671, DOI 10.2466/pms.1981.52.2.671; KLUSMAN LE, 1989, PERCEPT MOTOR SKILL, V68, P1199, DOI 10.2466/pms.1989.68.3c.1199; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Levine AJ, 2007, J CLIN EXP NEUROPSYC, V29, P669, DOI 10.1080/13803390600920471; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Li G, 2014, JAMA NEUROL, V71, P742, DOI 10.1001/jamaneurol.2014.445; Lovell MR, 2011, APPL NEUROPSYCHOL, V18, P197, DOI 10.1080/09084282.2011.595446; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; Onoda K, 2013, CLIN INTERV AGING, V8, P353, DOI 10.2147/CIA.S42342; Ozen LJ, 2010, J INT NEUROPSYCH SOC, V16, P556, DOI 10.1017/S1355617710000202; Pe~na-Casanova J., 2009, ARCH CLIN NEUROPSYCH; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Plotek W, 2014, MED SCI MONITOR, V20, P173, DOI 10.12659/MSM.889776; Poreh A., 2012, ARCH ASSESSMENT PSYC, V2, P57; Powell MR, 2011, CLIN NEUROPSYCHOL, V25, P108, DOI 10.1080/13854046.2010.532912; Rabin LA, 2007, CLIN NEUROPSYCHOL, V21, P727, DOI 10.1080/13854040600888776; Reitan R, 1985, HALSTEAD REITAN NEUR; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Schneider ALC, 2015, ALZ DIS ASSOC DIS, V29, P32, DOI 10.1097/WAD.0000000000000042; Soukup V M, 1998, Appl Neuropsychol, V5, P65, DOI 10.1207/s15324826an0502_2; Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Then FS, 2014, J OCCUP MED TOXICOL, V9, DOI 10.1186/1745-6673-9-23; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Wagner S, 2011, ARCH CLIN NEUROPSYCH, V26, P314, DOI 10.1093/arclin/acr024; Wecker NS, 2000, NEUROPSYCHOLOGY, V14, P409, DOI 10.1037//0894-4105.14.3.409; Woods DL, 2011, J CLIN EXP NEUROPSYC, V33, P101, DOI 10.1080/13803395.2010.493149; Woods DL, 2015, J COGNITIVE EXPT NEU; Woods DL, 2015, ARCH CLIN NEUROPSYCH; Yochim B, 2007, J INT NEUROPSYCH SOC, V13, P704, DOI 10.1017/S1355617707070907; Zalonis I, 2008, CLIN NEUROPSYCHOL, V22, P842, DOI 10.1080/13854040701629301	66	29	29	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2015	10	6							e0124345	10.1371/journal.pone.0124345			30	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	CK1PO	WOS:000355979500006	26060999	Green Published, gold, Green Submitted			2022-02-06	
J	Sashindranath, M; Daglas, M; Medcalf, RL				Sashindranath, M.; Daglas, M.; Medcalf, R. L.			Evaluation of gait impairment in mice subjected to craniotomy and traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Treadmill gait analysis; Traumatic brain injury; Craniotomy; Controlled cortical impact	PLASMINOGEN-ACTIVATOR; DEFICITS; IMPACT	Traumatic brain injury (TBI) represents a significant global health burden and causes long-lasting neuromotor deficits, particularly in individuals who sustain severe TBI. A better understanding of gait impairment after experimental TBI will provide valuable information for the recovery and rehabilitation of TBI survivors. Here we utilised the DigiGait system to perform kinematic gait analysis in mice subjected to brain injury induced by the controlled cortical impact (CCI) TBI model. Naive mice, non-craniotomised and craniotomised mice were included as controls. The temporal and spatial profile of gait was mapped from 3 h to 1-week post-TBI. Remarkably, there was a noticeable alteration in some aspects of gait in craniotomised sham mice from their pre-surgery baseline at various time-points over the testing period. This was not observed in naive mice or non-craniotomised sham controls over the same time period. This finding indicates that the craniotomy procedure alone effects gait. When craniotomised mice were subjected to TBI, additional deleterious effects on gait function were observed, including forelimb stance and swing duration as well as left hindlimb swing and stride duration and frequency. Hence, mice subjected to CCI-induced TBI develop clear alterations in gait but part of this is attributable to the effect of craniotomy alone. This study also highlights the need to include both non-craniotomised and craniotomised sham mice as controls when undertaking the CCI-induced model of TBI, particularly when early time points are being evaluated. (C) 2015 Elsevier B.V. All rights reserved.	[Sashindranath, M.; Daglas, M.; Medcalf, R. L.] Monash Univ, Australian Ctr Blood Dis, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Sashindranath, M.; Daglas, M.; Medcalf, R. L.] Monash Univ, Mol Neurotrauma & Haemostasis, Cent Clin Sch, Melbourne, Vic 3004, Australia		Sashindranath, M (corresponding author), Monash Univ, Australian Ctr Blood Dis, Cent Clin Sch, Level 2,Amrep Bldg, Melbourne, Vic 3004, Australia.	maithili.sashindranath@monash.edu; maria.daglas@monash.edu; robert.medcalf@monash.edu	Medcalf, Robert L/E-9632-2011; Sashindranath, Maithili/AAI-7408-2021	Sashindranath, Maithili/0000-0002-9712-4784; Daglas, Maria/0000-0002-9356-4061	NHMRCNational Health and Medical Research Council of Australia [606660, 1045755]	This study was supported by NHMRC grants 606660 and 1045755 awarded to RLM.	Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beare JE, 2009, J NEUROTRAUM, V26, P2045, DOI 10.1089/neu.2009.0914; Brooks SP, 2009, NAT REV NEUROSCI, V10, P519, DOI 10.1038/nrn2652; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cops EJ, 2013, EXP NEUROL, V249, P8, DOI 10.1016/j.expneurol.2013.08.001; Crack PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-37; Ek CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012021; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hamers FPT, 2006, J NEUROTRAUM, V23, P537, DOI 10.1089/neu.2006.23.537; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Lagraoui Mouna, 2012, Front Neurol, V3, P155, DOI 10.3389/fneur.2012.00155; NAVARI RM, 1978, MICROVASC RES, V16, P304, DOI 10.1016/0026-2862(78)90064-X; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Niechwiej-Szwedo E, 2007, GAIT POSTURE, V25, P70, DOI 10.1016/j.gaitpost.2006.01.002; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; Williams G, 2010, J HEAD TRAUMA REHAB, V25, P366, DOI 10.1097/HTR.0b013e3181cd3600; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013	20	29	29	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 1	2015	286						33	38		10.1016/j.bbr.2015.02.038			6	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	CG8XS	WOS:000353599600006	25721743				2022-02-06	
J	Zuckerman, SL; Morgan, CD; Burks, S; Forbes, JA; Chambless, LB; Solomon, GS; Sills, AK				Zuckerman, Scott L.; Morgan, Clinton D.; Burks, Stephen; Forbes, Jonathan A.; Chambless, Lola B.; Solomon, Gary S.; Sills, Allen K.			Functional and Structural Traumatic Brain Injury in Equestrian Sports: A Review of the Literature	WORLD NEUROSURGERY			English	Article						Brain concussion; Head protective devices; Intracranial epidural hematoma; Recreation; Sports; Subdural hematoma; TBI (traumatic brain injury)	HORSE-RELATED INJURIES; STATES HIGH-SCHOOL; UNITED-STATES; PROFESSIONAL JOCKEYS; CONCUSSIONS; HEAD; PATTERNS; ACCIDENTS; SEVERITY; CHILDREN	OBJECTIVE: Sports-related concussions and traumatic brain injury (TBI) represent a growing public health concern. We reviewed the literature regarding equestrian-related brain injury, ranging from concussion to severe TBI. METHODS: A literature review was performed to address the epidemiology of sports-related concussion and TBI in equestrian-related sports. MEDLINE and PUBMED databases were searched to identify all studies pertaining to brain injury in equestrian-related sports. We included two broad types of brain injury using a distinction established in the literature: 1) TBI with functional impairment, including concussion, or mild TBI, with negative imaging findings; and 2) TBI with structural impairment, with positive imaging and at least one of the following pathologies identified: subdural hemorrhage, epidural hemorrhage, subarachnoid hemorrhage, intraparenchymal hemorrhage, cerebral contusions, and skull fractures. RESULTS: Our literature search yielded 199 results. We found 26 studies describing functional TBI and 25 mentioning structural TBI, and 8 including both. Of all modern sporting activities, equestrian sports were found to cause some of the highest rates of total bodily injury, severe brain injury, and mortality. Concussions comprise 9.7%-15% of all equestrian-related injuries brought to hospitals for evaluation. Structural TBI was rare, and documentation of these injuries was poor. Although demographic risk factors like age and sex are minimally discussed in the literature, two studies identified a protective effect of increasing rider experience on all forms of bodily injury. However, it remains unclear whether increasing rider experience protects specifically against head injury. Finally, rates of helmet use in horseback riding remain dismally low-ranging from 9%-25%, depending on the activity. These low rates have persisted over time, despite evidence in this literature that helmets lead to an absolute risk reduction for head injury of 40%-50% in equestrian sports. CONCLUSIONS: Equestrian-related functional and structural TBI represent a significant public health burden. Rider and horse characteristics make the sport uniquely dangerous, as the athlete has limited control over an animal weighing a thousand pounds. Helmet use rates remain very low despite clear evidence of risk reduction. Health care providers are strongly urged to lobby professional and governmental organizations for mandatory helmet use in all equestrian sports.	[Zuckerman, Scott L.; Morgan, Clinton D.; Chambless, Lola B.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37235 USA; [Burks, Stephen] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Forbes, Jonathan A.] Travis Air Force Base, David Grant Med Ctr, Dept Neurol Surg, Fairfield, CA USA		Zuckerman, SL (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37235 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019	Morgan, Clinton/0000-0002-7511-0488			Abu-Kishk Ibrahim, 2013, Isr Med Assoc J, V15, P169; Abu-Zidan FM, 2003, INJURY, V34, P897, DOI 10.1016/S0020-1383(03)00054-8; Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; ARONSON H, 1993, AM J FOREN MED PATH, V14, P28, DOI 10.1097/00000433-199303000-00006; ASTM, 2013, STAND SPEC PROT HEAD; Balendra G, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.038950; Ball CG, 2007, AM J SURG, V193, P636, DOI 10.1016/j.amjsurg.2007.01.016; Ball J.E., 2009, J TRAUMA MANAG OUTCO, V3, P2; BARONE GW, 1989, J TRAUMA, V29, P245, DOI 10.1097/00005373-198902000-00019; Bixby-Hammett Doris M, 2006, N C Med J, V67, P161; Bleetman D, 2012, INJURY, V43, P2023, DOI 10.1016/j.injury.2011.09.026; BOND GR, 1995, PEDIATRICS, V95, P487; British Standards Institution, 2005, SPEC HELM EQ ACT; BUCKLEY SM, 1993, AUST J PUBLIC HEALTH, V17, P269; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P209; Chitnavis JP, 1996, INJURY, V27, P103, DOI 10.1016/0020-1383(95)00176-X; CHRISTEY GL, 1994, J FAM PRACTICE, V39, P148; Costa-Paz M, 1999, BRIT J SPORT MED, V33, P329, DOI 10.1136/bjsm.33.5.329; Cripps RA, 2000, AUSTR INJURY PREV B, V24; Crowe LM, 2010, EMERG MED AUSTRALAS, V22, P56, DOI 10.1111/j.1742-6723.2009.01249.x; Cuenca AG, 2009, J PEDIATR SURG, V44, P148, DOI 10.1016/j.jpedsurg.2008.10.025; Deignan Patrick J, 2012, MD Advis, V5, P41; Dohman T, 2005, J EMERG NURS, V31, P456, DOI 10.1016/j.jen.2005.08.008; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Dunn IF, 2009, NEUROSURGERY, V65, P383, DOI 10.1227/01.NEU.0000347474.69080.A1; Eckert V, 2011, CLIN J SPORT MED, V21, P353, DOI 10.1097/JSM.0b013e318221840f; Edmiston J, 2012, TRAUMATIC BRAIN INJU, V25, P70; Edmiston Julie, 2012, JAAPA, V25, P67; Faul M, 2010, TRAUMATIC BRAIN INJU; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Fleming PRI, 2001, CLIN EXP OPHTHALMOL, V29, P208, DOI 10.1046/j.1442-9071.2001.00430.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Ghosh A, 2000, J PEDIATR SURG, V35, P1766, DOI 10.1053/jpsu.2000.19247; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Griffen M, 2002, SOUTHERN MED J, V95, P441, DOI 10.1097/00007611-200204000-00013; Guyton K, 2013, AM SURGEON, V79, P76; Harrison TI MN, 1996, JOCKEYS INJURIES SKU; Hasler Rebecca M, 2011, J Trauma Manag Outcomes, V5, P4, DOI 10.1186/1752-2897-5-4; Hendricks K J, 2001, Inj Prev, V7, P307, DOI 10.1136/ip.7.4.307; Jagodzinski Tanya, 2005, WMJ, V104, P50; Johns E, 2004, INJURY, V35, P1234, DOI 10.1016/j.injury.2003.11.003; Kriss TC, 1997, J TRAUMA, V43, P97, DOI 10.1097/00005373-199707000-00022; Lim J, 2003, ANZ J SURG, V73, P567, DOI 10.1046/j.1445-2197.2003.02707.x; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Loder RT, 2008, J TRAUMA, V65, P447, DOI 10.1097/TA.0b013e31817dac43; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Mayberry JC, 2007, J TRAUMA, V62, P735, DOI 10.1097/ta.0b013e318031b5d4; McAbee GN, 1996, PEDIATR NEUROL, V15, P235, DOI 10.1016/S0887-8994(96)00162-2; McCrory P, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2003.006338; McCrory P, 2005, MED SPORT SCI, V48, P8, DOI 10.1159/000084280; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Moss PS, 2002, EMERG MED J, V19, P412, DOI 10.1136/emj.19.5.412; Fontan MM, 2009, AN PEDIATR, V70, P434, DOI 10.1016/j.anpedi.2008.12.005; Nanda Anil, 2012, J La State Med Soc, V164, P246; National Electronic Injury Surveillance System, 2002, NAT EL INJ SURV SYST; Newton AM, 2005, J EMERG NURS, V31, P442, DOI 10.1016/j.jen.2005.08.009; Norwood S, 2000, J TRAUMA, V48, P740, DOI 10.1097/00005373-200004000-00025; OGAWA Y, 1994, NEUROSURG REV, V17, P217, DOI 10.1007/BF00418437; Paix BR, 1999, BRIT J SPORT MED, V33, P46, DOI 10.1136/bjsm.33.1.46; Petridou E, 2004, J TRAUMA, V56, P643, DOI 10.1097/01.TA.0000053470.38129.F4; PRESS JM, 1995, CLIN J SPORT MED, V5, P236, DOI 10.1097/00042752-199510000-00005; Ross DS, 2010, CURR SPORT MED REP, V9, P342, DOI 10.1249/JSR.0b013e3181fc7357; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Rueda MAF, 2010, INJURY, V41, P533, DOI 10.1016/j.injury.2009.05.009; Saigal R, 2014, WORLD NEUROSURG, V82, P485, DOI 10.1016/j.wneu.2014.06.043; Sorli J M, 2000, Inj Prev, V6, P59, DOI 10.1136/ip.6.1.59; Temes RT, 1997, J TRAUMA, V43, P492, DOI 10.1097/00005373-199709000-00017; Thomas KE, 2006, BRIT J SPORT MED, V40, P619, DOI 10.1136/bjsm.2006.025858; Thompson JM, 1996, CAN FAM PHYSICIAN, V42, P1103; Trojian Thomas H, 2012, Conn Med, V76, P495; Turner M, 2008, BRIT J SPORT MED, V42, P763, DOI 10.1136/bjsm.2007.040337; Turner M, 2002, BRIT J SPORT MED, V36, P403, DOI 10.1136/bjsm.36.6.403; Worley GH, 2009, J EMERG NURS, V35, P230, DOI 10.1016/j.jen.2008.08.012; Yim VWT, 2007, INJURY, V38, P98, DOI 10.1016/j.injury.2006.08.026; Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12257	77	29	29	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	JUN	2015	83	6					1098	1113		10.1016/j.wneu.2014.12.030			16	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CK3TN	WOS:000356138800048	25535066				2022-02-06	
J	Roguski, M; Morel, B; Sweeney, M; Talan, J; Rideout, L; Riesenburger, RI; Madan, N; Hwang, S				Roguski, Marie; Morel, Brent; Sweeney, Megan; Talan, Jordan; Rideout, Leslie; Riesenburger, Ron I.; Madan, Neel; Hwang, Steven			Magnetic resonance imaging as an alternative to computed tomography in select patients with traumatic brain injury: a retrospective comparison	Journal of Neurosurgery-Pediatrics			English	Article						pediatric; head injury; MRI; CT; trauma	HEAD-INJURY; EMERGENCY-DEPARTMENT; RADIATION-EXPOSURE; UNITED-STATES; CT; CANCER; RISK; PREDICTION; CHILDREN; RULE	OBJECT Traumatic head injury (THI) is a highly prevalent condition in the United States, and concern regarding excess radiation-related cancer mortality has placed focus on limiting the use of CT in the evaluation of pediatric patients with THI. Given the success of rapid-acquisition MRI in the evaluation of ventriculoperitoneal shunt malfunction in pediatric patient populations, this study sought to evaluate the sensitivity of MRI in the setting of acute THI. METHODS Medical records of 574 pediatric admissions for THI to a Level 1 trauma center over a 10-year period were retrospectively reviewed to identify patients who underwent both CT and MRI examinations of the head within a 5-day period. Thirty-five patients were found, and diagnostic images were available for 30 patients. De-identified images were reviewed by a neuroradiologist for presence of any injury, intracranial hemorrhage, diffuse axonal injury (DAD, and skull fracture. Radiology reports were used to calculate interrater reliability scores. Baseline demographics and concordance analysis was performed with Stata version 13. RESULTS The mean age of the 30-patient cohort was 8.5 +/- 6.7 years, and 63.3% were male. The mean Injury Severity Score was 13.7 +/- 9.2, and the mean Glasgow Coma Scale score was 9 +/- 5.7. Radiology reports noted 150 abnormal findings. CT scanning missed findings in 12 patients; the missed findings included DAI (n = 5), subarachnoid hemorrhage (n = 6), small subdural hematomas (n = 6), cerebral contusions (n = 3), and an encephalocele. The CT scan was negative in 3 patients whose subsequent MRI revealed findings. MRI missed findings in 13 patients; missed findings included skull fracture (n = 5), small subdural hematomas (n = 4), cerebral contusions (n = 3), subarachnoid hemorrhage (n = 3), and DAI (n = 1). MRI was negative in 1 patient whose preceding CT scan was read as positive for injury. Although MRI more frequently reported intracranial findings than CT scanning, there was no statistically significant difference between CT and MRI in the detection of any intracranial injury (p = 0.63), DAI (p = 0.22), or intracranial hemorrhage (p = 0.25). CT scanning tended to more frequently identify skull fractures than MRI (p = 0.06). CONCLUSIONS MRI may be as sensitive as CT scanning in the detection of THI, DAI, and intracranial hemorrhage, but missed skull fractures in 5 of 13 patients. MRI may be a useful alternative to CT scanning in select stable patients with mild THI who warrant neuroimaging by clinical decision rules.	[Roguski, Marie; Morel, Brent; Talan, Jordan; Riesenburger, Ron I.; Hwang, Steven] Tufts Med Ctr, Dept Neurosurg, Boston, MA 02111 USA; [Sweeney, Megan; Rideout, Leslie] Tufts Med Ctr, Dept Gen Surg, Boston, MA 02111 USA; [Madan, Neel] Tufts Med Ctr, Dept Radiol, Boston, MA 02111 USA; [Morel, Brent; Talan, Jordan] Tufts Univ, Sch Med, Boston, MA 02111 USA		Hwang, S (corresponding author), Tufts Med Ctr, Dept Neurosurg, Proger 7,800 Washington St, Boston, MA 02111 USA.	shwang@tuftsmedicalcenter.org					Atabaki SM, 2008, ARCH PEDIAT ADOL MED, V162, P439, DOI 10.1001/archpedi.162.5.439; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Berdahl CT, 2013, ANN EMERG MED, V62, P486, DOI 10.1016/j.annemergmed.2013.02.018; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Faul M, 2010, TRAUMATIC BRAIN INJU; Hennelly KE, 2013, J PEDIATR-US, V162, P392, DOI 10.1016/j.jpeds.2012.07.018; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Larson DB, 2011, RADIOLOGY, V259, P793, DOI 10.1148/radiol.11101939; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; O'Neill BR, 2013, WORLD NEUROSURG, V80, pE307, DOI 10.1016/j.wneu.2012.10.066; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Schachar JL, 2011, PEDIATR RADIOL, V41, P971, DOI 10.1007/s00247-011-2032-4; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	19	29	29	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	MAY	2015	15	5					529	534		10.3171/2014.10.PEDS14128			6	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CG5XM	WOS:000353369200016	25700122	Bronze			2022-02-06	
J	Schiraldi, M; Patil, CG; Mukherjee, D; Ugiliweneza, B; Nuno, M; Lad, SP; Boakye, M				Schiraldi, Michael; Patil, Chirag G.; Mukherjee, Debraj; Ugiliweneza, Beatrice; Nuno, Miriam; Lad, Shivanand P.; Boakye, Maxwell			Effect of Insurance and Racial Disparities on Outcomes in Traumatic Brain Injury	JOURNAL OF NEUROLOGICAL SURGERY PART A-CENTRAL EUROPEAN NEUROSURGERY			English	Article						traumatic brain Injury (TBI); disparities; length of stay (LOS); discharge disposition; resource utilization	ETHNIC DISPARITIES; SOCIOECONOMIC DISPARITIES; RACE; MORTALITY; DISEASES; MODERATE; IMPACT; RISK; CARE	Introduction We evaluated outcome and resource utilization disparities between commercially insured, Medicaid, and Medicare patients. We further analyzed racial disparities in a subset cohort. Methods We reviewed the MarketScan database (2000-2009) for adult traumatic brain injury (TBI) patients. Analyses were performed to evaluate outcome differences by insurance type and race. Outpatient service utilization disparities by insurance and race were also evaluated. Results Our study included 92,159 TBI patients, 44,108 (47.9%) of whom utilized commercial insurance, 19,743 (21.4%) utilized Medicaid, and 28,308 (30.7%) utilized Medicare. In-hospital mortality was lowest for commercially insured (5.0%) versus 7.6% and 8.5% for Medicaid and Medicare patients, respectively (p < 0.0001). Medicaid patients had a longer hospitalization than commercially insured (12 days versus 6 days; p < 0.0001). Medicaid patients were 1.29 and 1.78 times more likely to die and experience complications than the commercially insured. Females had a lower mortality risk (odds ratio [OR]: 0.80, p < 0.0001) and less complications (OR: 0.67; p < 0.0001) than males. Higher comorbidities increased mortality risk (OR: 2.71; p < 0.0001) and complications (OR: 2.96, p < 0.0001). Mild injury patients had lower mortality (OR: 0.01; p < 0.0001) and less complications (OR: 0.07; p < 0.0001). Medicare (OR: 1.33; p < 0.0001) and higher comorbidity (OR: 1.26; p < 0.0001) patients utilized outpatient rehabilitation services more frequently. Medicare patients had twice the emergency department visits as the commercially insured (p < 0.0001). Medicare (16.6%) patients utilized more rehabilitation than commercially insured (13.4%) and Medicaid (9.1%) patients. Racial disparities were analyzed in a subset of 12,847 white and 4,780 African American (AA) patients. Multivariate analysis showed that AAs were more likely to experience a complication than white patients (OR: 1.13; p = 0.0024) and less likely to utilize outpatient rehabilitation services (OR: 0.83; p = 0.0025) than whites. Conclusions Insurance and racial disparities continue to exist for TBI patients. Insurance status appears to have an impact on short-and long-term outcomes to a greater degree than patient race.	[Schiraldi, Michael; Patil, Chirag G.; Mukherjee, Debraj; Nuno, Miriam] Cedars Sinai Med Ctr, Dept Neurosurg, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; [Ugiliweneza, Beatrice; Boakye, Maxwell] Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA; [Lad, Shivanand P.] Duke Univ, Med Ctr, Dept Surg, Div Neurosurg, Durham, NC 27710 USA		Patil, CG (corresponding author), Cedars Sinai Med Ctr, Dept Neurosurg, Ctr Neurosurg Outcomes Res, 127 South San Vicente Blvd,Suite A6600, Los Angeles, CA 90048 USA.	chiragpatil@gmail.com					Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Augenstein JS, 1997, J TRAUMA, V43, P256; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cryer C, 2005, INJURY PREV, V11, P53, DOI 10.1136/ip.2003.004143; Curry WT, 2010, NEUROSURGERY, V66, P427, DOI 10.1227/01.NEU.0000365265.10141.8E; Curry WT, 2009, J NEURO-ONCOL, V93, P25, DOI 10.1007/s11060-009-9840-5; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Downing SR, 2011, J TRAUMA, V70, P130, DOI 10.1097/TA.0b013e3182032b34; Eden SV, 2008, NEUROCRIT CARE, V9, P55, DOI 10.1007/s12028-007-9039-6; Falcone RA, 2008, J PEDIATR SURG, V43, P1858, DOI 10.1016/j.jpedsurg.2008.01.058; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Greene WR, 2010, AM J SURG, V199, P554, DOI 10.1016/j.amjsurg.2009.11.005; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hakmeh W, 2010, ACAD EMERG MED, V17, P809, DOI 10.1111/j.1553-2712.2010.00819.x; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; Langley John, 2003, Traffic Inj Prev, V4, P291, DOI 10.1080/714040487; Maybury RS, 2010, SURGERY, V148, P202, DOI 10.1016/j.surg.2010.05.010; Mukherjee D, 2010, ARCH SURG-CHICAGO, V145, P247, DOI 10.1001/archsurg.2009.288; Mukherjee D, 2010, CHILD NERV SYST, V26, P305, DOI 10.1007/s00381-009-1014-4; Nirula R, 2009, J TRAUMA, V66, P255, DOI 10.1097/TA.0b013e31815ede46; Osler TM, 1997, J TRAUMA, V43, P253, DOI 10.1097/00005373-199708000-00008; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Shermer CR, 2007, J TRAUMA, V63, P1268; Stallion A, 2007, J TRAUMA, V62, P1262; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979	37	29	29	0	8	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	2193-6315	2193-6323		J NEUROL SURG PART A	J. Neurol. Surg. Part A	MAY	2015	76	3					224	232		10.1055/s-0034-1543958			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	CI0GQ	WOS:000354415500007	25798799				2022-02-06	
J	Taylor, CA; Greenspan, AI; Xu, LK; Kresnow, MJ				Taylor, Christopher A.; Greenspan, Arlene I.; Xu, Likang; Kresnow, Marcie-jo			Comparability of National Estimates for Traumatic Brain Injury-Related Medical Encounters	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						emergency department visits; epidemiology; hospitalizations; traumatic brain injury		Objective: To describe similarities and differences in the number of civilian traumatic brain injury (TBI)-related hospitalizations and emergency department visits between national databases that capture US hospital data. Participants: TBI-related hospitalizations included in the National Hospital Discharge Survey (NHDS) and Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP-NIS) and emergency department visits in the National Hospital Ambulatory Medical Care Survey (NHAMCS) and HCUP Nationwide Emergency Department Sample (HCUP-NEDS) for 2006-2010. Design: Cross-sectional design. Main Measures: Nationwide counts of TBI-related medical encounters. Results: Overall, the frequency of TBI is comparable when comparing NHDS with HCUP-NIS and NHAMCS with HCUP-NEDS. However, annual counts in both NHDS and NHAMCS are consistently unstable when examined in smaller subgroups, such as by age group and injury mechanism. Injury mechanism is consistently missing from many more records in NHDS compared with HCUP-NIS. Conclusion: Given the large sample size of HCUP-NIS and HCUP-NEDS, these data can offer a valuable resource for examining TBI-related hospitalization and emergency department visits, especially by subgroup. These data hold promise for future examinations of annual TBI counts, but ongoing comparisons with national probability samples will be necessary to ensure that HCUP continues to track with estimates from these data.	[Taylor, Christopher A.; Greenspan, Arlene I.; Xu, Likang; Kresnow, Marcie-jo] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA		Taylor, CA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy,MS F-62, Atlanta, GA 30341 USA.	CATaylor1@cdc.gov	Taylor, Christopher A/D-2067-2013	Taylor, Christopher A/0000-0002-0937-5461	Intramural CDC HHS [CC999999] Funding Source: Medline		Agency for Healthcare Research and Quality, 2012, INTR 2010 HCUP NAT I; Agency for Healthcare Research and Quality, 2012, INTR 2010 HCUP NAT E; Barrett M, 2014, 201401 HCUP; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control and Prevention, 2010, PUBL US DAT FIL DOC; Centers for Disease Control and Prevention, HOSP CAR SURV; Centers for Disease Control and Prevention, EST PROC; Centers for Medicare & Medicaid Services Statistics NCfH, 2011, STAT NCFH ICD 9 CM O; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dennison C, 2000, Vital Health Stat 1, P1; Faul M, 2010, TRAUMATIC BRAIN INJU; Johnson R. L., 2010, STATE INJURY INDICAT; Kish L., 1965, SURVEY SAMPLING, P182; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levit K., 2007, HCUP FACTS FIGURES S; Marr A., 2004, CENTRAL NERVOUS SYST; Pfuntner A, 2012, OVERVIEW HOSP STAYS	17	29	29	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					150	159		10.1097/HTR.0000000000000105			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100128	25955702	Green Accepted			2022-02-06	
J	Joseph, B; Pandit, V; Zangbar, B; Kulvatunyou, N; Khalil, M; Tang, A; O'Keeffe, T; Gries, L; Vercruysse, G; Friese, RS; Rhee, P				Joseph, Bellal; Pandit, Viraj; Zangbar, Bardiya; Kulvatunyou, Narong; Khalil, Mazhar; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Vercruysse, Gary; Friese, Randall S.; Rhee, Peter			Secondary brain injury in trauma patients: The effects of remote ischemic conditioning	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	73rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 09-13, 2014	Philadelphia, PA	Amer Assoc Surg Trauma		Remote ischemic conditioning; traumatic brain injury; S-100B; neuron-specific enolase	NEURON-SPECIFIC ENOLASE; CHANNEL-DEPENDENT MECHANISM; ACUTE MYOCARDIAL-INFARCTION; REPERFUSION INJURY; INTRACRANIAL HYPERTENSION; POSTCONDITIONING PROTECTS; GENE-EXPRESSION; HUMANS; HEART; SERUM	BACKGROUND: Management of traumatic brain injury (TBI) is focused on preventing secondary brain injury. Remote ischemic conditioning (RIC) is an established treatment modality that has been shown to improve patient outcomes secondary to inflammatory insults. The aim of our study was to assess whether RIC in trauma patients with severe TBI could reduce secondary brain injury. METHODS: This prospective consented interventional trial included all TBI patients admitted to our Level 1 trauma center with an intracranial hemorrhage and a Glasgow Coma Scale (GCS) score of 8 or lower on admission. In each patient, four cycles of RIC were performed within 1 hour of admission. Each cycle consisted of 5 minutes of controlled upper limb (arm) ischemia followed by 5 minutes of reperfusion using a blood pressure cuff. Serum biomarkers of acute brain injury, S-100B, and neuron-specific enolase (NSE) were measured at 0, 6, and 24 hours. Outcome measure was reduction in the level of serum biomarkers after RIC. RESULTS: A total of 40 patients (RIC, 20; control, 20) were enrolled. The mean (SD) age was 46.15 (18.64) years, the median GCS score was 8 (interquartile range, 3-8), and the median head Abbreviated Injury Scale (AIS) score was 3 (interquartile range, 3-5), and there was no difference between the RIC and control groups in any of the baseline demographics or injury characteristics including the type and size of intracranial bleed or skull fracture patterns. There was no difference in the 0-hour S-100B (p = 0.9) and NSE (p = 0.72) level between the RIC and the control group. There was a significant reduction in the mean levels of S-100B (p = 0.01) and NSE (p = 0.04) at 6 hours and 24 hours in comparison with the 0-hour level in the RIC group. CONCLUSION: This study showed that RIC significantly decreased the standard biomarkers of acute brain injury in patients with severe TBI. Our study highlights the novel therapeutic role of RIC for preventing secondary brain insults in TBI patients. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.	[Joseph, Bellal; Pandit, Viraj; Zangbar, Bardiya; Kulvatunyou, Narong; Khalil, Mazhar; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Vercruysse, Gary; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, Med Ctr, Tucson, AZ 85724 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu	Zangbar, Bardiya/K-7147-2014	Zangbar, Bardiya/0000-0003-1215-1693			Ali ZA, 2007, CIRCULATION, V116, pI98, DOI 10.1161/circulationaha.106.679167; Andreka G, 2007, HEART, V93, P749, DOI 10.1136/hrt.2006.114504; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Botker HE, 2010, LANCET, V375, P727, DOI 10.1016/S0140-6736(09)62001-8; Candilio L, 2013, J CARDIOVASC MED, V14, P193, DOI 10.2459/JCM.0b013e328359dd7b; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Darnous LL, 2008, TRANSPL P, V40, P861, DOI 10.1016/j.transproceed.2008.02.065; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Farahvar A, 2011, J NEUROSURG, V114, P1471, DOI 10.3171/2010.11.JNS101116; Hausenloy DJ, 2011, NAT REV CARDIOL, V8, P619, DOI 10.1038/nrcardio.2011.85; Hu S, 2010, J NEUROSURG ANESTH, V22, P46, DOI 10.1097/ANA.0b013e3181c572bd; Kanoria S, 2007, TRANSPLANTATION, V84, P445, DOI 10.1097/01.tp.0000228235.55419.e8; Kharbanda RK, 2006, HEART, V92, P1506, DOI 10.1136/hrt.2004.042366; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Konstantinov IE, 2005, J THORAC CARDIOV SUR, V130, P1326, DOI 10.1016/j.jtcvs.2005.03.050; Konstantinov IE, 2005, TRANSPLANTATION, V79, P1691, DOI 10.1097/01.TP.0000159137.76400.5D; Konstantinov IE, 2004, PHYSIOL GENOMICS, V19, P143, DOI 10.1152/physiolgenomics.00046.2004; Kuntscher MV, 2003, ANN PLAS SURG, V51, P84; Lim SY, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00027; Loukogeorgakis SP, 2005, J AM COLL CARDIOL, V46, P450, DOI 10.1016/j.jacc.2005.04.044; Loukogeorgakis SP, 2007, CIRCULATION, V116, P1386, DOI 10.1161/CIRCULATIONAHA.106.653782; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; McKeating EG, 1998, ACT NEUR S, V71, P117; Munk K, 2010, CIRC-CARDIOVASC IMAG, V3, P656, DOI 10.1161/CIRCIMAGING.110.957340; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Sahebally SM, 2014, INT J SURG, V12, P16, DOI 10.1016/j.ijsu.2013.11.004; Saxena P, 2010, J CARDIAC SURG, V25, P127, DOI 10.1111/j.1540-8191.2009.00820.x; Steiger HJ, 2007, ACTA NEUROCHIR, V149, P1, DOI 10.1007/s00701-006-1057-1; Stein DM, 2012, J NEUROTRAUM, V29, P1140, DOI 10.1089/neu.2011.2149; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Wei M, 2011, CIRC RES, V108, P1220, DOI 10.1161/CIRCRESAHA.110.236190; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	38	29	34	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2015	78	4					698	703		10.1097/TA.0000000000000584			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	CE8EJ	WOS:000352074000005	25742251				2022-02-06	
J	Weber, ML; Welch, CE; Parsons, JT; McLeod, TCV				Weber, Michelle L.; Welch, Cailee E.; Parsons, John T.; McLeod, Tamara C. Valovich			School Nurses' Familiarity and Perceptions of Academic Accommodations for Student-Athletes Following Sport-Related Concussion	JOURNAL OF SCHOOL NURSING			English	Article						concussion management; IEPs; 504 plans	STATES HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; EPIDEMIOLOGY; MANAGEMENT; CHILDREN; ZURICH	The purpose of this study was to evaluate school nurses' familiarity and perceptions regarding academic accommodations for student-athletes following sport-related concussion. School nurses (N = 1,246) accessed the survey School Nurses' Beliefs, Attitudes and Knowledge of Pediatric Athletes with Concussions (BAKPAC-SN). The BAKPAC-SN contained several questions pertaining to concussion management and academic accommodations. There were significant differences regarding personal experience as well as familiarity of academic accommodations (p < .001) between school nurses who work at a school that employs an athletic trainer and school nurses who work at a school that does not employ an athletic trainer. There were significant weak positive relationships between years of experience and familiarity with academic accommodations (r = .210, p < .001), 504 plans (r = .243, p < .001), and individualized education plans (r = .205, p < .001). School nurses employed at a single school were significantly more familiar with academic accommodations (p = .027) and 504 plans (p = .001) than school nurses employed at multiple schools. Health care professionals should collaborate to effectively manage a concussed patient and should consider academic accommodations to ensure whole-person health care.	[Weber, Michelle L.] AT Still Univ, Postprofess Athlet Training Program, Mesa, AZ 85206 USA; [Welch, Cailee E.] AT Still Univ, Dept Interdisciplinary Hlth Sci, Athlet Training, Mesa, AZ 85206 USA; [McLeod, Tamara C. Valovich] AT Still Univ, Postprofess Athlet Training Program, Dept Interdisciplinary Hlth Sci, Mesa, AZ 85206 USA; [Parsons, John T.] Natl Collegiate Athlet Assoc, Sports Sci Inst, Indianapolis, IN USA		Welch, CE (corresponding author), AT Still Univ, Dept Interdisciplinary Hlth Sci, 5850 E Still Circle, Mesa, AZ 85206 USA.	cwmccarty@atsu.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722	National Association of School Nurses (NASN)	The authors acknowledge the National Association of School Nurses (NASN) for their support and cooperation in obtaining the mailing lists for this study.	[Anonymous], 2013, PROTECTING STUDENTS; [Anonymous], 2010, ALL ABOUT THE IEP; [Anonymous], 2013, DEFINING ATHLETIC TR; [Anonymous], 2006, INDIVIDUALIZED ED PR; Board C., 2011, ROLE SCH NURSE POSIT; Borich M., 2013, J NEUROL PHYS THER, V37, P7; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Diaz Anne L, 2013, NASN Sch Nurse, V28, P110; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Kay M. C., 2014, MES INT RES COMM RES; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee Michael A, 2009, Conn Med, V73, P171; Lowe R, 2009, MANDATING ATHLETIC T; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall Cameron M, 2012, J Can Chiropr Assoc, V56, P299; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Mayfield R., J ATHLETIC IN PRESS; Mayfield R., SPORTS HLTH IN PRESS; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGrath N., 2010, J ATHL TRAINING, V45, P8; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; Piebes SK, 2009, J SCH NURS, V25, P270, DOI 10.1177/1059840509339782; Rains C., 2010, NASN SCH NURSE, V25, P5, DOI DOI 10.1177/1942602X10376672; Saffary R., 2012, AM J LIFESTYLE MED, V2, P8	31	29	30	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1059-8405	1546-8364		J SCH NURS	J. Sch. Nurs.	APR	2015	31	2					146	154		10.1177/1059840514540939			9	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	CE0CZ	WOS:000351473300009	25015367				2022-02-06	
J	Jaja, BNR; Lingsma, H; Schweizer, TA; Thorpe, KE; Steyerberg, EW; Macdonald, RL				Jaja, Blessing N. R.; Lingsma, Hester; Schweizer, Tom A.; Thorpe, Kevin E.; Steyerberg, Ewout W.; Macdonald, R. Loch		SAHIT Collaboration	Prognostic value of premorbid hypertension and neurological status in aneurysmal subarachnoid hemorrhage: pooled analyses of individual patient data in the SAHIT repository	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; prognostic factors; hypertension; neurological status; meta-analysis; outcomes; vascular disorders	TRAUMATIC BRAIN-INJURY; INTRACRANIAL ANEURYSMS; RISK-FACTORS; CEREBRAL INFARCTION; GRADING SCALES; CASE-FATALITY; PREDICTION; IMPACT; MANAGEMENT; SURVIVAL	OBJECT The literature has conflicting reports about the prognostic value of premorbid hypertension and neurological status in aneurysmal subarachnoid hemorrhage (SAH). The aim of this study was to investigate the prognostic value of premorbid hypertension and neurological status in the SAH International Trialists repository. METHODS Patient-level meta-analyses were conducted to investigate univariate associations between premorbid hypertension (6 studies; n = 7249), admission neurological status measured on the World Federation of Neurosurgical Societies (WFNS) scale (10 studies; n = 10,869), and 3-month Glasgow Outcome Scale (GOS) score. Multivariable analyses were performed to sequentially adjust for the effects of age, CT clot burden, aneurysm location, aneurysm size, and modality of aneurysm repair. Prognostic associations were estimated across the ordered categories of the GOS using proportional odds models. Nagelkerke's R-2 statistic was used to quantify the added prognostic value of hypertension and neurological status beyond those of the adjustment factors. RESULTS Premorbid hypertension was independently associated with poor outcome, with an unadjusted pooled odds ratio (OR) of 1.73 (95% confidence interval [Cl] 1.50-2.00) and an adjusted OR of 1.38 (95% 01 1.25-1.53). Patients with a premorbid history of hypertension had higher rates of cardiovascular and renal comorbidities, poorer neurological status (p <= 0.001), and higher odds of neurological complications including cerebral infarctions, hydrocephalus, rebleeding, and delayed ischemic neurological deficits. Worsening neurological status was strongly independently associated with poor outcome, including WFNS Grades II (OR 1.85, 95% 01 1.68-2.03), III (OR 3.85, 95% Cl 3.32-4.47), IV (OR 5.58, 95% Cl 4.91-6.35), and V (OR 14.18, 95% CI 12.20-16.49). Neurological status had substantial added predictive value greater than the combined value of other prognostic factors (R-2 increase > 10%), while the added predictive value of hypertension was marginal (R-2 increase < 0.5%). CONCLUSIONS This study confirmed the strong prognostic effect of neurological status as measured on the WFNS scale and the independent but weak prognostic effect of premorbid hypertension. The effect of premorbid hypertension could involve multifactorial mechanisms, including an increase in the severity of initial bleeding, the fate of comorbid events, and neurological complications.	[Jaja, Blessing N. R.; Schweizer, Tom A.; Macdonald, R. Loch] St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada; [Jaja, Blessing N. R.; Schweizer, Tom A.; Thorpe, Kevin E.; Macdonald, R. Loch] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Jaja, Blessing N. R.; Schweizer, Tom A.; Macdonald, R. Loch] Univ Toronto, Inst Med Sci, Toronto, ON M5B 1W8, Canada; [Thorpe, Kevin E.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5B 1W8, Canada; [Lingsma, Hester; Steyerberg, Ewout W.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands		Macdonald, RL (corresponding author), Univ Toronto, Dept Surg, 30 Bond St, Toronto, ON M5B 1W8, Canada.	macdonaldlo@smh.ca		Noble, Adam/0000-0002-8070-4352; Thorpe, Kevin/0000-0002-7586-3893; Singh, Jeffrey/0000-0003-3499-574X; hasan, david/0000-0002-8335-5442	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Ontario Ministry of Research and InnovationMinistry of Research and Innovation, Ontario; Physicians Services Incorporated Foundation; Brain Aneurysm Foundation; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This work was supported by a grant from the Canadian Institutes for Health Research, a Personnel Award from the Heart and Stroke Foundation of Canada, and an Early Researcher Award from the Ontario Ministry of Research and Innovation to Dr. Schweizer. Dr. Macdonald receives grant support from the Physicians Services Incorporated Foundation, Brain Aneurysm Foundation, Canadian Institutes of Health Research, and the Heart and Stroke Foundation of Canada; and is Chief Scientific Officer of Edge Therapeutics, Inc., for which he has direct stock ownership. The remaining authors have no conflicts of interest to declare.	Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Baraldi AN, 2010, J SCHOOL PSYCHOL, V48, P5, DOI 10.1016/j.jsp.2009.10.001; Caranci F, 2013, EUR J RADIOL, V82, P1598, DOI 10.1016/j.ejrad.2012.12.026; Chiang VLS, 2000, NEUROSURGERY, V46, P28, DOI 10.1093/neurosurgery/46.1.28; Clarke M, 2008, NEURORADIOLOGY, V50, P653, DOI 10.1007/s00234-008-0411-9; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; De Marchis GM, 2014, J NEUROL NEUROSUR PS, V85, P56, DOI 10.1136/jnnp-2013-305051; Degen LAR, 2011, STROKE, V42, P1546, DOI 10.1161/STROKEAHA.110.601211; Eskesen V, 1987, Br J Neurosurg, V1, P455, DOI 10.3109/02688698708999636; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Germanson TP, 1998, SURG NEUROL, V49, P155, DOI 10.1016/S0090-3019(97)00337-6; Giraldo EA, 2012, J NEUROSURG, V117, P15, DOI 10.3171/2012.3.JNS11706; Heinze G, 2003, COMPUT METH PROG BIO, V71, P155, DOI 10.1016/S0169-2607(02)00077-9; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; Jaja BNR, 2014, NEUROCRIT CARE, V21, P551, DOI 10.1007/s12028-014-9990-y; Jaja BNR, 2013, NEUROCRIT CARE, V18, P143, DOI 10.1007/s12028-012-9792-z; Julien JS, 2008, NEUROSURGERY, V63, P204, DOI 10.1227/01.NEU.0000316857.80632.9A; Juvela S, 2005, J NEUROSURG, V102, P998, DOI 10.3171/jns.2005.102.6.0998; Juvela S, 2003, STROKE, V34, P1852, DOI 10.1161/01.STR.0000080380.56799.DD; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KELLER AZ, 1970, AM J EPIDEMIOL, V91, P139, DOI 10.1093/oxfordjournals.aje.a121121; LeRoux PD, 1996, J NEUROSURG, V85, P39, DOI 10.3171/jns.1996.85.1.0039; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mitchell P, 2006, SURG NEUROL, V66, P574, DOI 10.1016/j.surneu.2006.06.063; Mocco J, 2006, NEUROSURGERY, V59, P529, DOI 10.1227/01.NEU.0000228680.22550.A2; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nieuwkamp DJ, 2009, LANCET NEUROL, V8, P635, DOI 10.1016/S1474-4422(09)70126-7; Pobereskin LH, 2001, J NEUROSURG, V95, P555, DOI 10.3171/jns.2001.95.4.0555; Pobereskin LH, 2001, J NEUROL NEUROSUR PS, V70, P340, DOI 10.1136/jnnp.70.3.340; Rosen DS, 2005, NEUROCRIT CARE, V2, P110, DOI 10.1385/NCC:2:2:110; Rosen DS, 2004, NEUROSURGERY, V54, P566, DOI 10.1227/01.NEU.0000108862.32404.A5; Rosengart AJ, 2007, STROKE, V38, P2315, DOI 10.1161/STROKEAHA.107.484360; Sadasivan C, 2013, ANN BIOMED ENG, V41, P1347, DOI 10.1007/s10439-013-0800-z; Schemper M, 2003, STAT MED, V22, P2299, DOI 10.1002/sim.1486; Starke RM, 2009, J CLIN NEUROSCI, V16, P894, DOI 10.1016/j.jocn.2008.10.010; Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; TAYLOR CL, 1995, J NEUROSURG, V83, P812, DOI 10.3171/jns.1995.83.5.0812; Toftdahl D B, 1997, Ugeskr Laeger, V159, P1434; van den Bergh WM, 2006, ACTA NEUROCHIR, V148, P1065, DOI 10.1007/s00701-006-0863-9; van Heuven AW, 2008, STROKE, V39, P1347, DOI 10.1161/STROKEAHA.107.498345; Wostrack M, 2013, ACTA NEUROCHIR, V155, P579, DOI 10.1007/s00701-013-1634-z	43	29	30	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2015	122	3					644	652		10.3171/2014.10.JNS132694			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CC3RJ	WOS:000350266600023	25554825	Bronze			2022-02-06	
J	Lin, AC; Salzman, GA; Bachman, SL; Burke, RV; Zaslow, T; Piasek, CZ; Edison, BR; Hamilton, A; Upperman, JS				Lin, Ann C.; Salzman, Garrett A.; Bachman, Shelby L.; Burke, Rita V.; Zaslow, Tracy; Piasek, Carolina Z.; Edison, Bianca R.; Hamilton, Anita; Upperman, Jeffrey S.			Assessment of Parental Knowledge and Attitudes Toward Pediatric Sports-Related Concussions	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						brain concussion; knowledge; parents; pediatric sports injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; LEGISLATION; EDUCATION; PLAYERS; COACHES	Background: Parents of young athletes play a major role in the identification and management of sports-related concussions. However, they are often unaware of the consequences of concussions and recommended management techniques. Hypothesis: This study quantitatively assessed parental understanding of concussions to identify specific populations in need of additional education. We predicted that parents with increased education and prior sports- and concussion-related experience would have more knowledge and safer attitudes toward concussions. Study Design: Cross-sectional survey. Methods: Participants were parents of children brought to a pediatric hospital and 4 satellite clinics for evaluation of orthopaedic injuries. Participants completed a validated questionnaire that assessed knowledge of concussion symptoms, attitudes regarding diagnosis and return-to-play guidelines, and previous sports-and concussion-related experience. Results: Over 8 months, 214 parents completed surveys. Participants scored an average of 18.4 (possible, 0-25) on the Concussion Knowledge Index and 63.1 (possible, 15-75) on the Concussion Attitude Index. Attitudes were safest among white women, and knowledge increased with income and education levels. Previous sports experience did not affect knowledge or attitudes, but parents who reported experiencing an undiagnosed concussion had significantly better concussion knowledge than those who did not. Conclusion: Parents with low income and education levels may benefit from additional concussion-related education.	[Lin, Ann C.; Salzman, Garrett A.; Bachman, Shelby L.; Burke, Rita V.; Zaslow, Tracy; Upperman, Jeffrey S.] Childrens Hosp Los Angeles, Div Pediat Surg, 4650 Sunset Blvd,Mailstop 100, Los Angeles, CA 90027 USA; [Lin, Ann C.; Burke, Rita V.; Zaslow, Tracy; Edison, Bianca R.; Hamilton, Anita; Upperman, Jeffrey S.] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Zaslow, Tracy; Piasek, Carolina Z.; Edison, Bianca R.; Hamilton, Anita] Childrens Hosp Los Angeles, Childrens Orthoped Ctr Sports Med & Concuss Progr, Los Angeles, CA 90027 USA; [Zaslow, Tracy; Piasek, Carolina Z.; Edison, Bianca R.; Hamilton, Anita] Childrens Hosp Los Angeles, Concuss Program, Los Angeles, CA 90027 USA		Upperman, JS (corresponding author), Childrens Hosp Los Angeles, Div Pediat Surg, 4650 Sunset Blvd,Mailstop 100, Los Angeles, CA 90027 USA.	jupperman@chla.usc.edu		Bachman, Shelby/0000-0002-4460-4661; Edison, Bianca/0000-0003-3181-5758			Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Centers for Disease Control and Prevention, HEADS CONC; Chrisman SP, 2014, AM J SPORT MED, V42, P1190, DOI 10.1177/0363546513519073; Coghlin Craig J, 2009, J Can Chiropr Assoc, V53, P233; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gordon KE, 2010, PEDIATR NEUROL, V43, P253, DOI 10.1016/j.pediatrneurol.2010.05.012; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Upshaw JE, 2012, PEDIATR EMERG CARE, V28, P926, DOI 10.1097/PEC.0b013e318267f674	20	29	29	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	MAR-APR	2015	7	2					124	129		10.1177/1941738115571570			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	V20HU	WOS:000214878500004	25984257	Green Published			2022-02-06	
J	Troyanskaya, M; Pastorek, NJ; Scheibel, RS; Petersen, NJ; McCulloch, K; Wilde, EA; Henson, HK; Levin, HS				Troyanskaya, Maya; Pastorek, Nicholas J.; Scheibel, Randall S.; Petersen, Nancy J.; McCulloch, Katie; Wilde, Elisabeth A.; Henson, Helene K.; Levin, Harvey S.			Combat Exposure, PTSD Symptoms, and Cognition Following Blast-Related Traumatic Brain Injury in OEF/OIF/OND Service Members and Veterans	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SELECTIVE REMINDING TEST; ENDURING FREEDOM; TEST-PERFORMANCE; VALIDITY TEST; IRAQ WAR; DEPLOYMENT; SOLDIERS; PERSONNEL	Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are frequently documented among the Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans. This study will investigate both combat exposure and PTSD as factors that may influence objective cognitive outcomes following blast-related mild TBI (mTBI). Participants included 54 OEF/OIF/OND veterans who had been exposed to blast and reported symptoms consistent with mTBI and 43 combat-deployed control participants who had no history of blast exposure or TBI. Raw scores from the Controlled Oral Word Association Test, Trail Making Test, Color-Word Interference Test, and Verbal Selective Reminding Test were used to measure cognitive functioning. All participants demonstrated adequate effort on the Word Memory Test. Demographics, injury characteristics, overall intellectual functioning, and total scores from the PTSD Checklist-Civilian Version (PCL-C) and Combat Exposure Scale (CES) were used as the predictors for each cognitive measure. History of mTBI was significantly associated with higher PCL-C and CES scores. Multivariable linear regression, however, showed no significant differences in cognitive performance between groups. The absence of effect of mTBI, PTSD, and combat exposure on cognitive functioning noted in this study may be partially explained by the inclusion of only those participants who passed performance validity testing.	[Troyanskaya, Maya; Pastorek, Nicholas J.; Scheibel, Randall S.; Petersen, Nancy J.; McCulloch, Katie; Wilde, Elisabeth A.; Henson, Helene K.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Troyanskaya, Maya; Pastorek, Nicholas J.; Scheibel, Randall S.; Wilde, Elisabeth A.; Henson, Helene K.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Petersen, Nancy J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [McCulloch, Katie] Univ Houston, Dept Psychol, Houston, TX 77204 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA		Troyanskaya, M (corresponding author), Michael E DeBakey VA Med Ctr, 2002 Holcombe Blvd, Houston, TX 77030 USA.			Pastorek, Nicholas/0000-0002-9290-380X; McCulloch, Katie/0000-0003-0385-6536	Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs [B6812C]; Veterans AffairsUS Department of Veterans Affairs [I01RX001062, I01RX001320] Funding Source: NIH RePORTER	This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, B6812C (PI-Levin HS) VA RR&D "Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks"; O1062I (PIs-Scheibel RS and Wilde EA) VA RR&D "A Longitudinal Study of Chronic TBI in OEF/OIF/OND Veterans and Service Members"; B7241R (PIs-Levin HS and Scheibel RS) "An FMRI Study of TBI Associated with Blast Injury"; and CIN 13-413 (PI-Petersen LA) VA HSR&D Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, TX.	*AM PSYCH ASS, 2000, DIAGN STAT MAN MENT, P00424; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Benton A., 1978, MULTILINGUAL APHASIA; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bliese P.D., 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; Brown L., 2010, TEST NONVERBAL INTEL; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Delis DC., 2001, DELIS KAPLAN EXECUTI; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2005, WORD MEMORY TEST WIN; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Nelson NW, 2010, ARCH CLIN NEUROPSYCH, V25, P713, DOI 10.1093/arclin/acq075; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020	31	29	29	0	11	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	MAR	2015	180	3					285	289		10.7205/MILMED-D-14-00256			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	CD3OI	WOS:000350987700013	25735018	Bronze			2022-02-06	
J	Williams, RM; Welch, CE; Parsons, JT; McLeod, TCV				Williams, Richelle M.; Welch, Cailee E.; Parsons, John T.; McLeod, Tamara C. Valovich			Athletic Trainers' Familiarity With and Perceptions of Academic Accommodations in Secondary School Athletes After Sport-Related Concussion	JOURNAL OF ATHLETIC TRAINING			English	Article						adolescent sport-related concussions; concussion management; 504 plans; Individualized Education Programs	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; HEAD-INJURY; MANAGEMENT; SYMPTOMS; ZURICH	Context: Sport-related concussion can affect athletes' sport participation and academic success. With the recent emphasis on cognitive rest, student-athletes may benefit from academic accommodations (AA) in the classroom; however, athletic trainers' (ATs') perceived familiarity with, and use of, AA is unknown. Objective: To assess secondary school ATs' perceived familiarity with, attitudes and beliefs about, and incorporation of AA for student-athletes after sport-related concussion. A secondary purpose was to determine whether employment status altered familiarity and use of AA. Design: Cross-sectional study. Setting: Online survey. Patients or Other Participants: Of 3286 possible respondents, 851 secondary school ATs accessed the survey (response rate = 25.9%; 308 men [36.2%], 376 women [44.2%], 167 respondents [19.6%] with sex information missing; age = 37.3 +/- 10.1 years). Main Outcome Measure(s): Participants were solicited via e-mail to complete the Beliefs, Attitudes and Knowledge Following Pediatric Athlete Concussion among Athletic Trainers employed in the secondary school setting (BAKPAC-AT) survey. The BAKPAC-AT assessed ATs' perceived familiarity, perceptions, and roles regarding 504 plans, Individualized Education Programs (IEPs), and returning student-athletes to the class-room. Independent variables were employment status (full time versus part time), employment model (direct versus outreach), years certified, and years of experience in the secondary school setting. The dependent variables were participants' responses to the AA questions. Spearman rank-correlation coefficients were used to assess relationships and Mann-Whitney U and chi(2) tests (P < .05) were used to identify differences. Results: Respondents reported that approximately 41% of the student-athletes whose sport-related concussions they managed received AA. Respondents employed directly by the school were more familiar with 504 plans (P < .001) and IEPs (P < .001) and had a greater belief that ATs should have a role in AA. Both the number of years certified and the years of experience at the secondary school were significantly correlated with perceived familiarity regarding 504 plans and IEPs. Conclusions: The ATs employed directly by secondary schools and those with more experience as secondary school ATs were more familiar with AA. Understanding AA is important for all ATs because cognitive rest and "return to learn" are becoming more widely recommended in concussion management.	[Williams, Richelle M.] Univ Michigan, Ann Arbor, MI 48109 USA; [Welch, Cailee E.; McLeod, Tamara C. Valovich] AT Still Univ, Mesa, AZ 85206 USA; [Parsons, John T.] Natl Collegiate Athlet Assoc, Indianapolis, IN USA		McLeod, TCV (corresponding author), AT Still Univ, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	Valovich McLeod, Tamara/AAU-9435-2020	Valovich McLeod, Tamara/0000-0001-9082-8722; Williams, Richelle/0000-0003-4728-7443			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Bey T, 2009, WEST J EMERG MED, V10, P6; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cochrane LJ, 2007, J CONTIN EDUC HEALTH, V27, P94, DOI 10.1002/chp.106; Commission on Accreditation of Athletic Training Education, 2012, STAND ACCR PROF ATHL; Cunningham J, 2011, J EMERG MED, V40, P262, DOI 10.1016/j.jemermed.2008.08.017; Disabilities Rights Center Web site, IND ED PROGR IEP 504; Duggan PS, 2006, PATIENT EDUC COUNS, V62, P271, DOI 10.1016/j.pec.2005.08.001; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Kaloir L., WHATS A 504 PLAN; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mazerolle SM, 2010, J ATHL TRAINING, V45, P170, DOI 10.4085/1062-6050-45.2.170; McCrea M, 2004, SPORTS MED UPDATE, V38, P369, DOI DOI 10.1001/JAMA.290.19.2556.[; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McLeod TCV, 2013, J ATHL TRAINING, V48, P483, DOI 10.4085/1062-6050-48.4.04; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Mensch J, 2005, J ATHL TRAINING, V40, P333; Moser Rosemarie Scolaro, 2012, Front Neurol, V3, P171, DOI 10.3389/fneur.2012.00171; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; National Athletic Trainers' Association, 2011, ATHL TRAIN ED COMP; National Center for Learning Disabilities, WHAT IS AN IEP; Piebes SK, 2009, J SCH NURS, V25, P270, DOI 10.1177/1059840509339782; Portney L.G., 2009, FDN CLIN RES APPL PR, V3rd ed.; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Sady M, 2001, PHYS MED REH CLIN N, V22, P701	31	29	29	0	9	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2015	50	3					262	269		10.4085/1062-6050-49.3.81			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	CQ8AM	WOS:000360828300005	25562456	Green Published			2022-02-06	
J	Nauman, EA; Breedlove, KM; Breedlove, EL; Talavage, TM; Robinson, ME; Leverenz, LJ				Nauman, Eric A.; Breedlove, Katherine M.; Breedlove, Evan L.; Talavage, Thomas M.; Robinson, Meghan E.; Leverenz, Larry J.			Post-Season Neurophysiological Deficits Assessed by ImPACT and fMRI in Athletes Competing in American Football	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	2nd Annual Meeting of the CIC/Big Ten/Ivy League Traumatic Brain Injury Summit	JUL 16-17, 2014	Philadelphia, PA				HEAD IMPACTS; CONCUSSION; PLAYERS; INJURY; MRI	Neurocognitive assessment, functional magnetic resonance imaging, and head impact monitoring were used to evaluate neurological changes in high school football players throughout competitive seasons. A substantial number of asymptomatic athletes exhibited neurophysiological changes that persisted post-season, with abnormal measures significantly more common in athletes receiving 50 or more hits per week during the season.	[Nauman, Eric A.] Purdue Univ, Sch Mech Engn, Weldon Sch Biomed Engn, Dept Basic Med Sci, W Lafayette, IN 47907 USA; [Breedlove, Katherine M.; Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Breedlove, Evan L.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Robinson, Meghan E.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA		Nauman, EA (corresponding author), Purdue Univ, 585 Purdue Mall, W Lafayette, IN 47907 USA.	enauman@purdue.edu		Talavage, Thomas/0000-0003-4977-6398	Indiana State Department of Health Spinal Cord and Brain Injury Research Fund; National Defense Science and Engineering Graduate Fellowship; National Science Foundation Graduate Fellowship ProgramNational Science Foundation (NSF); General Electric HealthcareGeneral ElectricGE Healthcare	Indiana State Department of Health Spinal Cord and Brain Injury Research Fund; National Defense Science and Engineering Graduate Fellowship; National Science Foundation Graduate Fellowship Program; General Electric Healthcare.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHL TRAIN SPORTS HL, V6, P1; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Davis TL, 1998, P NATL ACAD SCI USA, V95, P1834, DOI 10.1073/pnas.95.4.1834; Evans AC, 2006, NEUROIMAGE, V30, P184, DOI 10.1016/j.neuroimage.2005.09.068; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512	16	29	29	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	FEB 17	2015	40	2			SI		85	91		10.1080/87565641.2015.1016161			7	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology	CH6UW	WOS:000354172800007	25961591				2022-02-06	
J	Johnen, VM; Neubert, FX; Buch, ER; Verhagen, LM; O'Reilly, J; Mars, RB; Rushworth, MFS				Johnen, Vanessa M.; Neubert, Franz-Xaver; Buch, Ethan R.; Verhagen, Lennart M.; O'Reilly, Jill; Mars, Rogier B.; Rushworth, Matthew F. S.			Causal manipulation of functional connectivity in a specific neural pathway during behaviour and at rest	ELIFE			English	Article						Resting-state connectivity; functional connectivity; premotor cortex; fMRI; TMS; plasticity	VENTRAL PREMOTOR CORTEX; PRIMARY MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; TRACTOGRAPHY-BASED PARCELLATION; PAIRED ASSOCIATIVE STIMULATION; TRAUMATIC BRAIN-INJURY; HUMAN PARIETAL CORTEX; MACAQUE MONKEY; FRONTAL-CORTEX; MR-IMAGES	Correlations in brain activity between two areas (functional connectivity) have been shown to relate to their underlying structural connections. We examine the possibility that functional connectivity also reflects short-term changes in synaptic efficacy. We demonstrate that paired transcranial magnetic stimulation (TMS) near ventral premotor cortex (PMv) and primary motor cortex (M1) with a short 8ms inter-pulse interval evoking synchronous pre- and post-synaptic activity and which strengthens interregional connectivity between the two areas in a pattern consistent with Hebbian plasticity, leads to increased functional connectivity between PMv and M1 as measured with functional magnetic resonance imaging (fMRI). Moreover, we show that strengthening connectivity between these nodes has effects on a wider network of areas, such as decreasing coupling in a parallel motor programming stream. A control experiment revealed that identical TMS pulses at identical frequencies caused no change in fMRI-measured functional connectivity when the inter-pulse-interval was too long for Hebbian-like plasticity.	[Johnen, Vanessa M.; Neubert, Franz-Xaver; Verhagen, Lennart M.; Mars, Rogier B.; Rushworth, Matthew F. S.] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England; [Buch, Ethan R.] NINDS, Human Cort Physiol & Neurorehabilitat Sect, NIH, Bethesda, MD 20814 USA; [Buch, Ethan R.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Verhagen, Lennart M.; Mars, Rogier B.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Ctr Cognit Neuroimaging, NL-6500 HB Nijmegen, Netherlands; [O'Reilly, Jill; Mars, Rogier B.; Rushworth, Matthew F. S.] Univ Oxford, Funct Magnet Resonance Imaging Brain FMRIB Ctr, John Radcliffe Hosp, Oxford OX3 9DU, England		Johnen, VM (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.	vanessa.johnen@psy.ox.ac.uk	Verhagen, Lennart/D-1070-2013; Buch, Ethan/AAB-4549-2021; Mars, Rogier B./G-2312-2018	Verhagen, Lennart/0000-0003-3207-7929; Mars, Rogier B./0000-0001-6302-8631; O'Reilly, Jill/0000-0002-6998-455X; Rushworth, Matthew/0000-0002-5578-9884	Wellcome TrustWellcome TrustEuropean Commission; Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Christopher Welch Scholarship; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0700399, G0400593] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0700399, G0400593] Funding Source: researchfish	Wellcome Trust Matthew FS Rushworth; Medical Research Council (MRC) Matthew FS Rushworth; Christopher Welch Scholarship Franz-Xaver Neubert	Arai N, 2011, J NEUROSCI, V31, P15376, DOI 10.1523/JNEUROSCI.2271-11.2011; Baumer T, 2009, CLIN NEUROPHYSIOL, V120, P1724, DOI 10.1016/j.clinph.2009.07.035; Bassett DS, 2008, J NEUROSCI, V28, P9239, DOI 10.1523/JNEUROSCI.1929-08.2008; Beckmann CF, 2005, NEUROIMAGE, V25, P294, DOI 10.1016/j.neuroimage.2004.10.043; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Brochier T, 2007, CURR OPIN NEUROBIOL, V17, P637, DOI 10.1016/j.conb.2007.12.002; Buch ER, 2011, J NEUROSCI, V31, P17669, DOI 10.1523/JNEUROSCI.1513-11.2011; Buch ER, 2010, J NEUROSCI, V30, P1395, DOI 10.1523/JNEUROSCI.4882-09.2010; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Chawla D, 2000, NEURAL COMPUT, V12, P2805, DOI 10.1162/089976600300014737; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Davare M, 2008, J PHYSIOL-LONDON, V586, P2735, DOI 10.1113/jphysiol.2008.152603; Davare M, 2010, CURR BIOL, V20, P176, DOI 10.1016/j.cub.2009.11.063; Davare M, 2009, CORTEX, V45, P1050, DOI 10.1016/j.cortex.2009.02.011; Dayan E, 2011, NEURON, V72, P443, DOI 10.1016/j.neuron.2011.10.008; Dum RP, 2005, J NEUROSCI, V25, P1375, DOI 10.1523/JNEUROSCI.3902-04.2005; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Fair DA, 2008, P NATL ACAD SCI USA, V105, P4028, DOI 10.1073/pnas.0800376105; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Friston KJ, 1995, HUM BRAIN MAPP, V3, P56, DOI 10.1002/hbm.460030106; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Galletti C, 2003, EXP BRAIN RES, V153, P158, DOI 10.1007/s00221-003-1589-z; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Geyer S, 2000, ANAT EMBRYOL, V202, P443, DOI 10.1007/s004290000127; GODSCHALK M, 1984, EXP BRAIN RES, V56, P410; Grafton ST, 2010, EXP BRAIN RES, V204, P475, DOI 10.1007/s00221-010-2315-2; Grefkes C, 2010, NEUROIMAGE, V50, P233, DOI 10.1016/j.neuroimage.2009.12.029; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Grol MJ, 2007, J NEUROSCI, V27, P11877, DOI 10.1523/JNEUROSCI.3923-07.2007; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Hampson M, 2002, HUM BRAIN MAPP, V15, P247, DOI 10.1002/hbm.10022; Hartwigsen G, 2012, J NEUROSCI, V32, P16162, DOI 10.1523/JNEUROSCI.1010-12.2012; Jackson A, 2006, NATURE, V444, P56, DOI 10.1038/nature05226; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnson PB, 1997, PARIETAL LOBE CONTRI, P222; Koch G, 2013, J NEUROSCI, V33, P9725, DOI 10.1523/JNEUROSCI.4988-12.2013; Lee L, 2003, J NEUROSCI, V23, P5308; Lotze M, 2006, J NEUROSCI, V26, P6096, DOI 10.1523/JNEUROSCI.4564-05.2006; Luppino G, 1999, EXP BRAIN RES, V128, P181, DOI 10.1007/s002210050833; Majdandzic J, 2007, NEUROIMAGE, V37, P589, DOI 10.1016/j.neuroimage.2007.04.071; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mars RB, 2011, J NEUROSCI, V31, P4087, DOI 10.1523/JNEUROSCI.5102-10.2011; MATELLI M, 1986, J COMP NEUROL, V251, P281, DOI 10.1002/cne.902510302; Matelli M, 1998, J COMP NEUROL, V402, P327; Mayka MA, 2006, NEUROIMAGE, V31, P1453, DOI 10.1016/j.neuroimage.2006.02.004; Munchau A, 2002, J NEUROSCI, V22, P554, DOI 10.1523/JNEUROSCI.22-02-00554.2002; Neubert FX, 2014, NEURON, V81, P700, DOI 10.1016/j.neuron.2013.11.012; Neubert FX, 2010, P NATL ACAD SCI USA, V107, P13240, DOI 10.1073/pnas.1000674107; Neubert FX, 2014, NEURON; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; O'Reilly JX, 2013, P NATL ACAD SCI USA, V110, P13982, DOI 10.1073/pnas.1305062110; O'Reilly JX, 2012, SOC COGN AFFECT NEUR, V7, P604, DOI 10.1093/scan/nss055; O'Reilly JX, 2010, CEREB CORTEX, V20, P953, DOI 10.1093/cercor/bhp157; O'Shea J, 2007, NEURON, V54, P479, DOI 10.1016/j.neuron.2007.04.021; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Prabhu G, 2009, J PHYSIOL-LONDON, V587, P1057, DOI 10.1113/jphysiol.2008.165571; Rizzo V, 2009, CEREB CORTEX, V19, P907, DOI 10.1093/cercor/bhn144; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Rushworth MFS, 2006, CEREB CORTEX, V16, P1418, DOI 10.1093/cercor/bhj079; Sallet J, 2013, J NEUROSCI, V33, P12255, DOI 10.1523/JNEUROSCI.5108-12.2013; Seeley WW, 2009, NEURON, V62, P42, DOI 10.1016/j.neuron.2009.03.024; Shimazu H, 2004, J NEUROSCI, V24, P1200, DOI 10.1523/JNEUROSCI.4731-03.2004; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Sussillo D, 2009, NEURON, V63, P544, DOI 10.1016/j.neuron.2009.07.018; Tanne-Gariepy J, 2002, EXP BRAIN RES, V145, P91, DOI 10.1007/s00221-002-1078-9; Tokuno H, 2000, CEREB CORTEX, V10, P58, DOI 10.1093/cercor/10.1.58; Tomassini V, 2007, J NEUROSCI, V27, P10259, DOI 10.1523/JNEUROSCI.2144-07.2007; Turella L, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00686; VALLSSOLE J, 1992, ELECTROEN CLIN NEURO, V85, P355, DOI 10.1016/0168-5597(92)90048-G; Verhagen L, 2008, J NEUROSCI, V28, P4726, DOI 10.1523/JNEUROSCI.0057-08.2008; Vogels TP, 2011, SCIENCE, V334, P1569, DOI 10.1126/science.1211095; Wang L, 2010, BRAIN, V133, P1224, DOI 10.1093/brain/awq043; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	81	29	29	2	17	ELIFE SCIENCES PUBLICATIONS LTD	CAMBRIDGE	SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND	2050-084X			ELIFE	eLife	FEB 9	2015	4								e04585	10.7554/eLife.04585			50	Biology	Science Citation Index Expanded (SCI-EXPANDED)	Life Sciences & Biomedicine - Other Topics	CB2MD	WOS:000349460700002	25664941	gold, Green Submitted, Green Published			2022-02-06	
J	Hanell, A; Greer, JE; McGinn, MJ; Povlishock, JT				Hanell, Anders; Greer, John E.; McGinn, Melissa J.; Povlishock, John T.			Traumatic brain injury-induced axonal phenotypes react differently to treatment	ACTA NEUROPATHOLOGICA			English	Article						Traumatic brain injury; Axonal injury; Mitochondrial permeability transition pore; Cyclophilin D; Wallerian degeneration; Mouse	MITOCHONDRIAL PERMEABILITY TRANSITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CYCLOSPORINE-A; ATP SYNTHASE; WALLERIAN DEGENERATION; C-SUBUNIT; PORE; DISCONNECTION; TRANSPORT; PATHOLOGY	Injured axons with distinct morphologies have been found following mild traumatic brain injury (mTBI), although it is currently unclear whether they reflect varied responses to the injury or represent different stages of progressing pathology. This complicates evaluation of therapeutic interventions targeting axonal injury. To address this issue, we assessed axonal injury over time within a well-defined axonal population, while also evaluating mitochondrial permeability transition as a therapeutic target. We utilized mice expressing yellow fluorescent protein (YFP) in cortical neurons which were crossed with mice which lacked Cyclophilin D (CypD), a positive regulator of mitochondrial permeability transition pore opening. Their offspring were subjected to mTBI and the ensuing axonal injury was assessed using YFP expression and amyloid precursor protein (APP) immunohistochemistry, visualized by confocal and electron microscopy. YFP+ axons initially developed a single, APP(+), focal swelling (proximal bulb) which progressed to axotomy. Disconnected axonal segments developed either a single bulb (distal bulb) or multiple bulbs (varicosities), which were APP(-) and whose ultrastructure was consistent with ongoing Wallerian degeneration. CypD knock-out failed to reduce proximal bulb formation but decreased the number of distal bulbs and varicosities, as well as a population of small, APP(+), callosal bulbs not associated with YFP+ axons. The observation that YFP+ axons contain several pathological morphologies points to the complexity of traumatic axonal injury. The fact that CypD knock-out reduced some, but not all, subtypes highlights the need to appropriately characterize injured axons when evaluating potential neuroprotective strategies.	[Hanell, Anders; Greer, John E.; McGinn, Melissa J.; Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu	Hanell, Anders/E-4776-2011	Hanell, Anders/0000-0001-9369-3886	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS077675, NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS077675] Funding Source: NIH RePORTER	The authors thank Carol Davis, Susan Walker and Jesse Sims for invaluable technical assistance, Scott Henderson and Frances White for sharing their expertise in confocal microscopy, Audrey Lafrenaye, Vishal Patel and Michal Vascak for scientific discussions and comments on this manuscript as well as Michael Forte and Paolo Bernardi for generating and providing the CypD KO mice. This work was funded by NIH grants NS077675 and NS047463.	Alavian KN, 2014, P NATL ACAD SCI USA, V111, P10580, DOI 10.1073/pnas.1401591111; Avery MA, 2012, CURR BIOL, V22, P596, DOI 10.1016/j.cub.2012.02.043; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Beirowski B, 2010, J NEUROPATH EXP NEUR, V69, P455, DOI 10.1097/NEN.0b013e3181da84db; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bernardi P, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00095; Bonora M, 2013, CELL CYCLE, V12, P674, DOI 10.4161/cc.23599; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cesarovic N, 2010, LAB ANIM-UK, V44, P329, DOI 10.1258/la.2010.009085; Conforti L, 2014, NAT REV NEUROSCI, V15, P394, DOI 10.1038/nrn3680; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Dziedzic T, 2010, BRAIN PATHOL, V20, P976, DOI 10.1111/j.1750-3639.2010.00401.x; English AW, 2005, EUR J NEUROSCI, V21, P2624, DOI 10.1111/j.1460-9568.2005.04124.x; Ewald AJ, 2011, COLD SPRING HARB PRO; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Forte M, 2007, P NATL ACAD SCI USA, V104, P7558, DOI 10.1073/pnas.0702228104; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hayat MJ, 2014, J NURS EDUC, V53, P208, DOI 10.3928/01484834-20140325-04; Haynes RL, 2008, PEDIATR RES, V63, P656, DOI 10.1203/PDR.0b013e31816c825c; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Luvisetto S, 2008, NEUROSCIENCE, V155, P585, DOI 10.1016/j.neuroscience.2008.06.030; Marx M, 2012, NAT PROTOC, V7, P394, DOI 10.1038/nprot.2011.449; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Palma E, 2009, HUM MOL GENET, V18, P2024, DOI 10.1093/hmg/ddp126; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Readnower RD, 2011, J NEUROTRAUM, V28, P1845, DOI 10.1089/neu.2011.1755; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844	43	29	29	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	FEB	2015	129	2					317	332		10.1007/s00401-014-1376-x			16	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	AZ7ZS	WOS:000348435100010	25528329				2022-02-06	
J	Gautam, A; Arpa, PD; Donohue, DE; Muhie, S; Chakraborty, N; Luke, BT; Grapov, D; Carroll, EE; Meyerhoff, JL; Hammamleh, R; Jett, M				Gautam, Aartl; Arpa, Peter D'; Donohue, Duncan E.; Muhie, Seid; Chakraborty, Nabarun; Luke, Brian T.; Grapov, Dmitry; Carroll, Erica E.; Meyerhoff, James L.; Hammamleh, Rasha; Jett, Marti			Acute and Chronic Plasma Metabolomic and Liver Transcriptomic Stress Effects in a Mouse Model with Features of Post-Traumatic Stress Disorder	PLOS ONE			English	Article							GUT MICROBIOTA; PSYCHOSOCIAL STRESS; ACID-METABOLISM; INJURY; PHASE; PTSD; MATRIX-METALLOPROTEINASE-9; MYELOPEROXIDASE; COMORBIDITY; COMPLEMENT	Acute responses to intense stressors can give rise to post-traumatic stress disorder (PTSD). PTSD diagnostic criteria include trauma exposure history and self-reported symptoms. Individuals who meet PTSD diagnostic criteria often meet criteria for additional psychiatric diagnoses. Biomarkers promise to contribute to reliable phenotypes of PTSD and comorbidities by linking biological system alterations to behavioral symptoms. Here we have analyzed unbiased plasma metabolomics and other stress effects in a mouse model with behavioral features of PTSD. In this model, C57BL/6 mice are repeatedly exposed to a trained aggressor mouse (albino SJL) using a modified, resident-intruder, social defeat paradigm. Our recent studies using this model found that aggressor-exposed mice exhibited acute stress effects including changed behaviors, body weight gain, increased body temperature, as well as inflammatory and fibrotic histopathologies and transcriptomic changes of heart tissue. Some of these acute stress effects persisted, reminiscent of PTSD. Here we report elevated proteins in plasma that function in inflammation and responses to oxidative stress and damaged tissue at 24 hrs post-stressor. Additionally at this acute time point, transcriptomic analysis indicated liver inflammation. The unbiased metabolomics analysis showed altered metabolites in plasma at 24 hrs that only partially normalized toward control levels after stress-withdrawal for 1.5 or 4 wks. In particular, gut-derived metabolites were altered at 24 hrs post-stressor and remained altered up to 4 wks after stress-withdrawal. Also at the 4 wk time point, hyperlipidemia and suppressed metabolites of amino acids and carbohydrates in plasma coincided with transcriptomic indicators of altered liver metabolism (activated xenobiotic and lipid metabolism). Collectively, these system-wide sequelae to repeated intense stress suggest that the simultaneous perturbed functioning of multiple organ systems (e.g., brain, heart, intestine and liver) can interact to produce injuries that lead to chronic metabolic changes and disorders that have been associated with PTSD.	[Gautam, Aartl; Arpa, Peter D'; Donohue, Duncan E.; Chakraborty, Nabarun; Meyerhoff, James L.; Hammamleh, Rasha; Jett, Marti] US Army Ctr Environm Hlth Res, Ft Detrick, MD 21702 USA; [Gautam, Aartl; Arpa, Peter D'; Donohue, Duncan E.; Chakraborty, Nabarun; Meyerhoff, James L.] Geneva Fdn, Tacoma, WA 98402 USA; [Muhie, Seid; Luke, Brian T.] Adv Biomed Comp Ctr, Frederick Natl Lab Canc Res, Frederick, MD USA; [Grapov, Dmitry] Univ Calif Davis, NIH, West Coast Metabol Ctr, Davis, CA USA; [Carroll, Erica E.] Army Inst Publ Hlth, Aberdeen Proving Ground, MD 21010 USA		Jett, M (corresponding author), US Army Ctr Environm Hlth Res, Ft Detrick, Ft Detrick, MD 21702 USA.	marti.jett-tilton.civ@mail.mil		Grapov, Dmitry/0000-0002-7204-3128; Donohue, Duncan/0000-0002-3137-8773; D'Arpa, Peter/0000-0002-0562-0263	Office of the Assistant Secretary of Defense for Health Affairs; Military Operational Medicine Research Program (MOMRP); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 U24 DK097154];  [09284002]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U24DK097154] Funding Source: NIH RePORTER	This project is supported by the Office of the Assistant Secretary of Defense for Health Affairs and the Military Operational Medicine Research Program (MOMRP), and the support of grant #USAMRMC NO: 09284002 is highly acknowledged. DG was supported by NIH 1 U24 DK097154. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055766; ARAGOZZINI F, 1979, APPL ENVIRON MICROB, V38, P544, DOI 10.1128/AEM.38.3.544-546.1979; Association AP, 2013, DIAGN STAT MAN MENT, DOI [10.1016/j.amsu.2013.12.001, DOI 10.1016/J.AMSU.2013.12.001]; Atkinson C, 2005, EXP BIOL MED, V230, P155, DOI 10.1177/153537020523000302; Bailey MT, 2011, BRAIN BEHAV IMMUN, V25, P397, DOI 10.1016/j.bbi.2010.10.023; Bailey MT, 2006, J NEUROIMMUNOL, V171, P29, DOI 10.1016/j.jneuroim.2005.09.008; Balmer ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008618; Bartoli F, 2013, METAB SYNDR RELAT D, V11, P301, DOI 10.1089/met.2013.0010; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger JA, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-194; Bessede A, 2014, NATURE; Blankenberg S, 2003, CIRCULATION, V107, P1579, DOI 10.1161/01.CIR.0000058700.41738.12; Calabrese JR, 2011, J CLIN PSYCHIAT, V72, P1072, DOI 10.4088/JCP.11m06956; Camprecios G, 2009, GROWTH FACTORS, V27, P300, DOI 10.1080/08977190903137736; Cho JH, 2014, P NATL ACAD SCI USA, V111, P3188, DOI 10.1073/pnas.1400113111; Choudhary SP, 2011, CURR MED CHEM, V18, P4557; Chuang JC, 2010, J LIPID RES, V51, P1344, DOI 10.1194/jlr.M002196; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Conover W, 1971, PRACTICAL NONPARAMET, DOI 10.1002/bimj.19730150311; Coughlin SS, 2011, OPEN CARDIOVASC MED, V5, P164, DOI 10.2174/1874192401105010164; CRISPENS CG, 1973, LAB ANIM SCI, V23, P408; Czech B, 2013, INT J CLIN EXP PATHO, V6, P1585; de Jong JTVM, 2001, JAMA-J AM MED ASSOC, V286, P555, DOI 10.1001/jama.286.5.555; Eckel-Mahan KL, 2012, P NATL ACAD SCI USA, V109, P5541, DOI 10.1073/pnas.1118726109; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Freidman MJ, 2007, PTSD HIST OVERVIEW, DOI [10.1093/jxb/erm028, DOI 10.1093/JXB/ERM028]; Fury Wen, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P5531; Gall WE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010883; Galley JD, 2014, GUT MICROBES, V5, DOI [10.4161/19490976.2014.973349, DOI 10.4161/19490976.2014.973349]; Gareau MG, 2008, CURR MOL MED, V8, P274, DOI 10.2174/156652408784533760; Garvin P, 2009, PSYCHOSOM MED, V71, P292, DOI 10.1097/PSY.0b013e3181960e7f; GOODWIN BL, 1994, BIOCHEM PHARMACOL, V47, P2294, DOI 10.1016/0006-2952(94)90268-2; Green BT, 2012, FOOD CHEM TOXICOL, V50, P2049, DOI 10.1016/j.fct.2012.03.049; Gupta MA, 2013, INT REV PSYCHIATR, V25, P86, DOI 10.3109/09540261.2012.736367; Hall JE, 2011, GUYTON HALL TXB MED, DOI [10.3390/jpm1010005, DOI 10.3390/JPM1010005]; Hammamieh R, 2012, BEHAV BRAIN RES, V235, P55, DOI 10.1016/j.bbr.2012.07.022; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hansson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016185; Health NIoM, 2008, NAT I MENT HLTH STRA; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; Heslop CL, 2010, J AM COLL CARDIOL, V55, P1102, DOI 10.1016/j.jacc.2009.11.050; HOLLANDER M, 1973, NONPARAMETRIC STAT M, P15; Jennewein C, 2011, MOL MED, V17, P568, DOI 10.2119/molmed.2010.00146; Jensen KJ, 2013, COMPR PHYSIOL, V3, P655, DOI 10.1002/cphy.c120018; JOYCE PR, 1992, BIOL PSYCHIAT, V32, P1035, DOI 10.1016/0006-3223(92)90065-8; KEANE TM, 1987, J CLIN PSYCHOL, V43, P32, DOI 10.1002/1097-4679(198701)43:1<32::AID-JCLP2270430106>3.0.CO;2-X; Keeney A, 2006, J NEUROENDOCRINOL, V18, P330, DOI 10.1111/j.1365-2826.2006.01422.x; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kramer A, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-253; Lee CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076817; Li X, 2009, ANAL CHIM ACTA, V633, P257, DOI 10.1016/j.aca.2008.11.058; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lord RS, 2008, ALTERN MED REV, V13, P292; Lu K, 2012, J PROTEOME RES, V11, P4916, DOI 10.1021/pr300429x; Lyte M, 2011, CELL TISSUE RES, V343, P23, DOI 10.1007/s00441-010-1050-0; Ma BW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047416; Macfarlane G.T., 1991, LARGE INTESTINE PHYS, P51; Marcobal A, 2013, ISME J, V7, P1933, DOI 10.1038/ismej.2013.89; McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Murray LA, 2011, INT J BIOCHEM CELL B, V43, P154, DOI 10.1016/j.biocel.2010.10.013; Nakamura MT, 2014, PROG LIPID RES, V53, P124, DOI 10.1016/j.plipres.2013.12.001; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Pacella ML, 2013, J ANXIETY DISORD, V27, P33, DOI 10.1016/j.janxdis.2012.08.004; Peckett AJ, 2011, METABOLISM, V60, P1500, DOI 10.1016/j.metabol.2011.06.012; Phipson B, 2010, STAT APPL GENET MOL, V9, DOI 10.2202/1544-6115.1585; R Development Core Team, 2018, R LANG ENV STAT COMP, DOI 10.1007/978-3-540-74686-7; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Sanchez O, 2002, CELL STRESS CHAPERON, V7, P36, DOI 10.1379/1466-1268(2002)007<0036:ASITII>2.0.CO;2; Sanchez O, 2007, AM J PHYSIOL-REG I, V293, pR1908, DOI 10.1152/ajpregu.00113.2007; Sanghez V, 2013, PSYCHONEUROENDOCRINO, V38, P2933, DOI 10.1016/j.psyneuen.2013.07.022; Saura-Calixto F, 2010, MOL NUTR FOOD RES, V54, P939, DOI 10.1002/mnfr.200900276; Savignac HM, 2011, BEHAV BRAIN RES, V216, P576, DOI 10.1016/j.bbr.2010.08.049; Sayin SI, 2013, CELL METAB, V17, P225, DOI 10.1016/j.cmet.2013.01.003; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Smith EA, 1997, ANAEROBE, V3, P327, DOI 10.1006/anae.1997.0121; SONG C, 1994, J AFFECT DISORDERS, V30, P283, DOI 10.1016/0165-0327(94)90135-X; Stengel A, 2009, ANNU REV PHYSIOL, V71, P219, DOI 10.1146/annurev.physiol.010908.163221; Sundstrom J, 2006, CURR OPIN LIPIDOL, V17, P45, DOI 10.1097/01.mol.0000203891.34890.b5; Uschold-Schmidt N, 2013, J ENDOCRINOL, V218, P193, DOI 10.1530/JOE-13-0027; Vijay-Kumar M, 2010, SCIENCE, V328, P228, DOI 10.1126/science.1179721; Wikoff WR, 2009, P NATL ACAD SCI USA, V106, P3698, DOI 10.1073/pnas.0812874106; Wilson EB, J AM STAT ASS, V22, P209; Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065; Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040; Zhao Y, 2013, J PROTEOME RES, V12, P2987, DOI 10.1021/pr400263n	88	29	29	2	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2015	10	1							e0117092	10.1371/journal.pone.0117092			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA2IM	WOS:000348732100063	25629821	Green Submitted, gold, Green Published			2022-02-06	
J	Gioia, GA				Gioia, Gerard A.			Multimodal evaluation and management of children with concussion: Using our heads and available evidence	BRAIN INJURY			English	Article						Assessment; concussion; children; mild traumatic brain injury; rehabilitation	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; COMPUTER-BASED ASSESSMENT; HIGH-SCHOOL; AGE SUBGROUPS; RECOMMENDATIONS; RECOVERY; SPECIFICITY; VALIDATION	Background: Significant attention has been focused on concussions in children, but a dearth of research evidence exists supporting clinical evaluation and management. Aim: The primary objective of this review paper is to describe a multimodal, developmentally adapted, standardized concussion assessment and active rehabilitation approach for children as young as 5 years old. Methods: This study reviews the CDC-funded research programme, including the development of tools for post-concussion symptom assessment involving the child and parent, measurement of specific neurocognitive functions and assessment of dynamic cognitive exertional effects. Results: A clinical approach to active, individualized, moderated concussion rehabilitation management is presented, including a 10-step guide to symptom management, with a specific focus on the school challenges faced by the recovering student. Conclusion: To better inform concussion practice across the developmental age spectrum, a significant need exists for further research evidence to refine clinical assessment methods and develop effective treatment approaches.	[Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat, Div Pediat Neuropsychol Childrens Natl Hlth Syst, Rockville, MD 20852 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Psychiat & Behav Med, Rockville, MD USA		Gioia, GA (corresponding author), George Washington Univ, Sch Med, Dept Pediat, Div Pediat Neuropsychol Childrens Natl Hlth Syst, Rockville, MD 20852 USA.	ggioia@childrensnational.org	Meijer, Anna/K-5118-2016		CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5-MOI-RR-020359-02]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER	I declare that I am a co-author of the Acute Concussion Evaluation (ACE), Post-Concussion Symptom Inventories (PCSI), Multimodal Assessment of Cognition & Symptoms for Children (MACS), and Exertion Effects Rating Scale (EERS). The work reported in this paper was supported in part by grants from CDC no. U17/CCU323352-01 and NIH no. 5-MOI-RR-020359-02. I have received no financial remuneration for the development of the above tools.	Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; (CDC). National Center for Injury Prevention and Control, 2007, HEADS BRAIN INJ YOUR; (CDC). National Center for Injury Prevention and Control, 2007, HEADS SCH KNOW YOUR; Chelune GJ, 2010, CLIN NEUROPSYCHOL, V24, P454, DOI 10.1080/13854040802360574; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; Echemendia RJ, 2011, CLIN NEUROPSYCHOL, V25, P1289, DOI 10.1080/13854046.2011.618466; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fritz GK, 1996, J PEDIATR PSYCHOL, V21, P153, DOI 10.1093/jpepsy/21.2.153; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Gioia G, 2011, J INT NEUROPSYCH SOC, V17, P134; Gioia G, 2006, J INT NEUROPSYCHO S1, V12, P39; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2012, PEDIATR ANN, V41, P198, DOI 10.3928/00904481-20120426-10; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Institute of Medicine's Committee on Sports-Related Concussions in Youth, 2013, SPORTS REL CONC YOUT; Iverson GL, 2012, MILD TRAUMATIC BRAIN, P281; Iverson GL, 2012, HDB SPORT NEUROPSYCH, P131; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; Newman JB, 2013, CLIN NEUROPSYCHOL, V27, P779, DOI 10.1080/13854046.2013.789552; Ransom D, ACAD EFFECTS C UNPUB; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Riccio CA, 2001, ANN NY ACAD SCI, V931, P113; Riccio CA, 2001, J NEUROPSYCH CLIN N, V13, P326, DOI 10.1176/appi.neuropsych.13.3.326; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sady MD, 2013, J INT NEUROPSYCH SOC, V19, P194, DOI DOI 10.1017/S1355617713000362; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2006, APPL NEUROPSYCHOL, V13, P151, DOI 10.1207/s15324826an1303_2; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-1; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Wodka EL, 2008, CLIN NEUROPSYCHOL, V22, P826, DOI 10.1080/13854040701563583; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Youngwirth SD, 2007, CHILD NEUROPSYCHOL, V13, P422, DOI 10.1080/13825580601025890	57	29	29	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	2					195	206		10.3109/02699052.2014.965210			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AZ4OI	WOS:000348201500009	25356518	Green Accepted			2022-02-06	
J	Holubkov, R; Clark, AE; Moler, FW; Slomine, BS; Christensen, JR; Silverstein, FS; Meert, KL; Pollack, MM; Dean, JM				Holubkov, Richard; Clark, Amy E.; Moler, Frank W.; Slomine, Beth S.; Christensen, James R.; Silverstein, Faye S.; Meert, Kathleen L.; Pollack, Murray M.; Dean, J. Michael			Efficacy Outcome Selection in the Therapeutic Hypothermia After Pediatric Cardiac Arrest Trials	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cardiac arrest; clinical trials; hypothermia; randomized; simulations	TRAUMATIC BRAIN-INJURY; ENCEPHALOPATHY	Objectives: The Therapeutic Hypothermia After Pediatric Cardiac Arrest trials will determine whether therapeutic hypothermia improves survival with good neurobehavioral outcome, as assessed by the Vineland Adaptive Behavior Scales Second Edition, in children resuscitated after cardiac arrest in the in-hospital and out-of-hospital settings. We describe the innovative efficacy outcome selection process during Therapeutic Hypothermia After Pediatric Cardiac Arrest protocol development. Design/Setting: Consensus assessment of potential outcomes and evaluation timepoints. Interventions: None. Measurements and Main Results: We evaluated practical and technical advantages of several follow-up timepoints and continuous/categorical outcome variants. Simulations estimated power assuming varying hypothermia benefit on mortality and on neurobehavioral function among survivors. Twelve months after arrest was selected as the optimal assessment timepoint for pragmatic and clinical reasons. Change in Vineland Adaptive Behavior Scales Second Edition from prearrest level, measured as quasicontinuous with death and vegetative status being worst-possible levels, yielded optimal statistical power. However, clinicians preferred simpler multicategorical or binary outcomes because of easier interpretability and favored outcomes based solely on postarrest status because of concerns about accurate parental assessment of prearrest status and differing clinical impact of a given Vineland Adaptive Behavior Scales Second Edition change depending on prearrest status. Simulations found only modest power loss from categorizing or dichotomizing quasicontinuous outcomes because of high expected mortality. The primary outcome selected was survival with 12-month Vineland Adaptive Behavior Scales Second Edition no less than two SD below a reference population mean (70 points), necessarily evaluated only among children with prearrest Vineland Adaptive Behavior Scales Second Edition greater than or equal to 70. Two secondary efficacy outcomes, 12-month survival and quasicontinuous Vineland Adaptive Behavior Scales Second Edition change from prearrest level, will be evaluated among all randomized children, including those with compromised function prearrest. Conclusions: Extensive discussion of optimal efficacy assessment timing, and of the advantages versus drawbacks of incorporating prearrest status and using quasicontinuous versus simpler outcomes, was highly beneficial to the final Therapeutic Hypothermia After Pediatric Cardiac Arrest design. A relatively simple, binary primary outcome evaluated at 12 months was selected, with two secondary outcomes that address the potential disadvantages of primary outcome.	[Holubkov, Richard; Clark, Amy E.; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Moler, Frank W.; Silverstein, Faye S.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Christensen, James R.] Kennedy Krieger Inst, Dept Pediat Rehabil Med, Baltimore, MD USA; [Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Christensen, James R.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Meert, Kathleen L.] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Pollack, Murray M.] Childrens Natl Med Ctr, Dept Crit Care Med, Washington, DC 20010 USA; [Pollack, Murray M.] George Washington Univ, Dept Pediat, Sch Hlth Sci, Washington, DC 20052 USA		Holubkov, R (corresponding author), Intermt Injury Control Res Ctr, 295 Chipeta Way,Suite 2E600, Salt Lake City, UT 84158 USA.	rich.holubkov@hsc.utah.edu		Holubkov, Richard/0000-0003-0431-3381	Pediatric Emergency Care Applied Research Network (PECARN) from the Emergency Medical Services for Children program of the Maternal and Child Health Bureau of the Health Resources and Services Administration [UO3MC00001, UO3MC00003, UO3MC00006, UO3MC00007, UO3MC00008]; National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network (CPCCRN) [U10HD500009, U1OHD050096, U10HD049981, U10HD049945, U10HD049983, U1OHD050012, UO1HD049934]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Heart, Lung, and Blood Institute (NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI); Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD]United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD044955, R34 HD 050531]; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01 HL094339, U01 HL094345, HL094345]; NHLBI, NICHD;  [HD073692]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD049981, UG1HD050096, R21HD073692, UG1HD049981, U10HD050096, U10HD049983, UG1HD049983, U10HD050012, U01HD049934] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD044955, U10HD050009, R34HD050531, U10HD049945] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094339, U01HL094345] Funding Source: NIH RePORTER	Supported, in part, by the Pediatric Emergency Care Applied Research Network (PECARN) under cooperative agreements UO3MC00001, UO3MC00003, UO3MC00006, UO3MC00007, and UO3MC00008 from the Emergency Medical Services for Children program of the Maternal and Child Health Bureau of the Health Resources and Services Administration, and from the National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network (CPCCRN) under cooperative agreements U10HD500009, U1OHD050096, U10HD049981, U10HD049945, U10HD049983, U1OHD050012, and UO1HD049934.; Dr. Holubkov served as board member for Pfizer and the American Burn Association (Data and Safety Monitoring Board [DSMB] memberships), consulted for St. Jude Medical and the Physicians Committee for Responsible Medicine (Biostatistical consultancies) and received support for article research from the National Institutes of Health (NIH). Dr. Holubkov and his institution received grant support from the National Heart, Lung, and Blood Institute (NHLBI; chief biostatistician for Therapeutic Hypothermia After Pediatric Cardiac Arrest [THAPCA]). His institution received support for travel from the NHLBI (THAPCA planning meeting). Ms. Clark received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Moler received support for article research from the NIH. His institution received grant support, support for travel, and support for participation in review activities (R21 HD044955 and R34 HD 050531 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD], and by U01 HL094339 [Dr. Dean] and U01 HL094345 [Dr. Moler] from the NHLBI). Dr. Slomine received support for writing/reviewing the article from the NHLBI (U01HL094345/co-investigator), received support from the NHLBI (grant pays for administrative support and overhead), served as board member for the American Board of Clinical Neuropsychology (travel expenses as oral examiner), consulted for the University of Michigan (Executive Committee for Planning Grant) and University of California, Davis (DSMB Member), is employed by Kennedy Krieger Institute, provided expert testimony for private practice, lectured for St. Joseph's Hospital (presentation at Grand Rounds), and received support for article research from the NIH. Dr. Slomine and her institution received support for travel from the NHLBI (U01HL094345/co-investigator). Her institution received grant support from the NHLBI (U01HL094345/co-investigator). Dr. Christensen is employed by Kennedy Krieger Institute and received support for article research from the NIH. His institution received grant support, support for travel, and support for writing/reviewing the article from the NHLBI (U01HL094345/co-investigator) and received support from the NHLBI (grant pays for administrative support and overhead). Dr. Silverstein received support for travel from the March of Dimes (scientific advisory board) and received support for article research from the NIH. Her institution received grant support from the NHLBI (funding for role as co-investigator on grant U01 HL094345) and from the NICHD (effort funded on an unrelated project HD073692) and received support for travel from the NHLBI (investigator meeting HL094345). Dr. Meert received support for article research from the NIH. Her institution received grant support from the NIH. Dr. Pollack received support for article research from the NIH. His institution received grant support Dr. Dean's institution received grant support from the NHLBI, NICHD, and NIH.	Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hill, 1996, SCALES INDEPENDENT B; HOLM S, 1979, SCAND J STAT, V6, P65; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hothorn T, 2014, EXACTRANKTESTS EXACT; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Jennison C., 2000, GROUP SEQUENTIAL MET; Lachenbruch PA, 2001, STAT MED, V20, P1215, DOI 10.1002/sim.790; Limperopoulos Catherine, 2006, Phys Occup Ther Pediatr, V26, P115, DOI 10.1300/J006v26n01_08; Moler FW, 2013, PEDIATR CRIT CARE ME, V14, pE304, DOI 10.1097/PCC.0b013e31828a863a; Moler FW, 2009, CRIT CARE MED, V37, P2259, DOI 10.1097/CCM.0b013e3181a00a6a; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; R Development Core Team, R LANG ENV STAT COMP; Sauve M J, 1996, Am J Crit Care, V5, P127; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sparrow S.S., 2005, VINELAND ADAPTIVE BE	20	29	29	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	JAN	2015	16	1					1	10		10.1097/PCC.0000000000000272			10	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	AZ1DW	WOS:000347981400002	25268768	Green Accepted			2022-02-06	
J	Martini, R; Rios, J; Polatajko, H; Wolf, T; McEwen, S				Martini, Rose; Rios, Jorge; Polatajko, Helene; Wolf, Timothy; McEwen, Sara			The performance quality rating scale (PQRS): reliability, convergent validity, and internal responsiveness for two scoring systems	DISABILITY AND REHABILITATION			English	Article						Development coordination disorder; outcome measures; performance quality rating scale; PQRS; psychometric properties; stroke	DEVELOPMENTAL COORDINATION DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE ORIENTATION; CHRONIC STROKE; CHILDREN; REPRODUCIBILITY; REHABILITATION; ADULTS; TRIAL	Purpose: The performance quality rating scale (PQRS) is an observational measure of performance quality of client-selected, personally meaningful activities. It has been used inconsistently with different scoring systems, and there have been no formal publications on its psychometric properties. The purpose of this study was to test and compare the psychometric properties of two PQRS scoring systems in two populations. Methods: A secondary analysis of video recorded participant-selected activities from previous studies involving either adults living with stroke or children diagnosed with developmental coordination disorder (DCD) was conducted. Three pairs of raters scored the video recorded performances with PQRS operational definitions (PQRS-OD) and a generic rating system (PQRS-G). Results: For inter-rater reliability, PQRS-OD ICCs were substantial, ranging from 0.83 to 0.93; while the PQRS-G ICCs were moderate, ranging from 0.71 to 0.77. Test-retest reliability was substantial, >0.80 (ICC), for both rating systems across all rater pairs. Internal responsiveness was high for both rating systems. Convergent validity with the Canadian Occupational Performance Measure (COPM) was inconsistent, with scores ranging from low to moderate. Conclusion: Both scoring systems have demonstrated they are reliable and have good internal responsiveness. The PQRS-OD demonstrated greater consistency across raters and is more sensitive to clinically important change than the PQRS-G and should be used when greater accuracy is required. Further exploration of validity with actual rather than perceived performance measures is required.	[Martini, Rose] Univ Ottawa, Sch Rehabil Sci, Ottawa, ON, Canada; [Rios, Jorge; McEwen, Sara] Sunnybrook Res Inst, St Johns Rehab Res Program, Toronto, ON M2M 2G1, Canada; [Polatajko, Helene] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Wolf, Timothy] Washington Univ, Sch Med, Program Occupat Therapy, St Louis, MO USA; [McEwen, Sara] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada		McEwen, S (corresponding author), Sunnybrook Res Inst, St Johns Rehab Res Program, 285 Cummer Ave, Toronto, ON M2M 2G1, Canada.	sara.mcewen@utoronto.ca	Martini, Rose/AAB-1195-2019	Wolf, Timothy/0000-0003-3607-9454; McEwen, Sara/0000-0002-8529-7717	Canadian Institutes of Health Research (FRN)Canadian Institutes of Health Research (CIHR) [111200]	This study was partially funded by the Canadian Institutes of Health Research (FRN #111200). The authors report no conflict of interest.	Beckerman H, 2001, QUAL LIFE RES, V10, P571, DOI 10.1023/A:1013138911638; Bragante KC, 2012, REV BRAS FISIOTER, V16, P141, DOI 10.1590/S1413-35552012005000021; Chan CC., 1997, OCCUP THER INT, V4, P231; Cup EHC, 2003, CLIN REHABIL, V17, P402, DOI 10.1191/0269215503cr635oa; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; Eyssen ICJM, 2005, CLIN REHABIL, V19, P888, DOI 10.1191/0269215505cr883oa; Forbes D A, 1998, J Gerontol Nurs, V24, P34; Gowland C, 1995, CHEDOKE MCMASTER STR; Henderson S.E., 2007, MOVEMENT ASSESSMENT, V2nd ed.; Husted JA, 2000, J CLIN EPIDEMIOL, V53, P459, DOI 10.1016/S0895-4356(99)00206-1; Jones G., 2009, J DATA SCI, V7, P179; Kenny D. A., 2006, DYADIC DATA ANALYSIS; Law M, 1990, Can J Occup Ther, V57, P82; Law Mary, 2007, BMC Pediatr, V7, P31, DOI 10.1186/1471-2431-7-31; Lemmens RJM, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-21; Lexell JE, 2005, AM J PHYS MED REHAB, V84, P719, DOI 10.1097/01.phm.0000176452.17771.20; Lu WS, 2008, J REHABIL MED, V40, P615, DOI 10.2340/16501977-0230; Martini R, 1998, OCCUP THER J RES, V18, P157, DOI 10.1177/153944929801800403; Martini R, 2014, BRIT J OCCUP THER, V77, P214, DOI 10.4276/030802214X13968769798917; McEwen SE, 2010, NEUROPSYCHOL REHABIL, V20, P541, DOI 10.1080/09602011003638194; McEwen SE, 2009, BRAIN INJURY, V23, P1041, DOI 10.3109/02699050903421107; Meek GE, 2007, J MOD APPL STAT METH, V6, P91, DOI 10.22237/jmasm/1177992540; Middel B, 2002, INT J INTEGR CARE, V2, P2; Miller LT, 2001, HUM MOVEMENT SCI, V20, P183, DOI 10.1016/S0167-9457(01)00034-3; Norman G. R., 2007, BIOSTATISTICS THE BA; Phelan S, 2009, CAN J OCCUP THER, V76, P23, DOI 10.1177/000841740907600107; Phipps S, 2007, AM J OCCUP THER, V61, P328, DOI 10.5014/ajot.61.3.328; Polatajko HJ, 2012, AM J OCCUP THER, V66, P104, DOI 10.5014/ajot.2012.001784; Pollock N, 1998, CANADIAN OCCUPATIONA; Shrout P E, 1998, Stat Methods Med Res, V7, P301, DOI 10.1191/096228098672090967; Uswatte G, 2009, REHABIL PSYCHOL, V54, P398, DOI 10.1037/a0017501; Vun M., 2008, BR J OCCUP THER, V71, P23, DOI [https://doi.org/10.1177/030802260807100105, DOI 10.1177/030802260807100105, DOI 10.1177/030802260807100]; WANG C, 2009, ASIAN J GERONTOL GER, V4, P8	33	29	29	0	13	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2015	37	3					231	238		10.3109/09638288.2014.913702			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	CA3EP	WOS:000348789500006	24766150				2022-02-06	
J	Merritt, VC; Lange, RT; French, LM				Merritt, Victoria C.; Lange, Rael T.; French, Louis M.			Resilience and symptom reporting following mild traumatic brain injury in military service members	BRAIN INJURY			English	Article						Mild traumatic brain injury; military service members; post-concussion symptoms; post-traumatic stress disorder; resilience	PERSISTENT POSTCONCUSSIVE SYMPTOMS; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; QUALITY-OF-LIFE; PTSD CHECKLIST; PSYCHOMETRIC PROPERTIES; PSYCHOLOGICAL RESILIENCE; SOCIAL SUPPORT; RISK; VETERANS	Primary objective: The purpose of this study was to examine the relationship between resilience and symptom reporting following mild traumatic brain injury (mTBI). It was hypothesized that, as resilience increases, self-reported symptoms would decrease. Research design: Cross-sectional design. Methods and procedures: Participants were 142 US military service members who sustained a mTBI, divided into three resilience groups based on participants' responses on the Response to Stressful Experiences Scale: Moderate (n = 42); High (n = 51); and Very High (n = 49). Participants completed the Neurobehavioral Symptom Inventory (NSI) and PTSD Checklist-Civilian Version (PCL-C) within 12 months following injury. Main outcomes and results: There were significant main effects for the NSI total score, cognitive cluster and affective cluster, as well as for the PCL-C total score, avoidance cluster and hyperarousal cluster. Pairwise comparisons revealed that there was a negative relationship between resilience and self-reported symptoms overall. Specifically, participants with higher resilience reported fewer post-concussion and PTSD-related symptoms than participants with lower levels of resilience. Conclusions: These findings underscore the important role that resilience plays in symptom expression in military service members with mTBI and suggest that research on targeted interventions to increase resilience in the acute phase following injury is indicated.	[Merritt, Victoria C.] Penn State Univ, University Pk, PA 16802 USA; [Lange, Rael T.; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Lange, Rael T.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Merritt, Victoria/0000-0001-5683-4168			Adler AB, 2009, MIL MED, V174, P21, DOI 10.7205/MILMED-D-00-2208; Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; Agaibi CE, 2005, TRAUMA VIOLENCE ABUS, V6, P195, DOI 10.1177/1524838005277438; American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; Bensimon M, 2012, PERS INDIV DIFFER, V52, P782, DOI 10.1016/j.paid.2012.01.011; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Block J, 1996, J PERS SOC PSYCHOL, V70, P349, DOI 10.1037/0022-3514.70.2.349; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Burke HS, 2009, J REHABIL, V75, P5; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Department of Defense, 2014, DOD NUMB TRAUM BRAIN; Dolan CA, 2006, MIL MED, V171, P93, DOI 10.7205/MILMED.171.2.93; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Franke LM, 2015, J HEAD TRAUMA REHAB, V30, pE34, DOI 10.1097/HTR.0000000000000042; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Hoge EA, 2007, DEPRESS ANXIETY, V24, P139, DOI 10.1002/da.20175; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P697, DOI 10.1007/978-0-387-76978-3_22; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P745, DOI 10.1007/978-0-387-76978-3_24; Johnsen BH, 2002, SCAND J PSYCHOL, V43, P181, DOI 10.1111/1467-9450.00285; Johnson DC, 2014, AM J PSYCHIAT, V171, P844, DOI 10.1176/appi.ajp.2014.13040502; Johnson DC, 2011, MIL MED, V176, P161, DOI 10.7205/MILMED-D-10-00258; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; KOBASA SC, 1979, J PERS SOC PSYCHOL, V37, P1, DOI 10.1037/0022-3514.37.1.1; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Lang AJ, 2003, J TRAUMA STRESS, V16, P257, DOI 10.1023/A:1023796007788; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, PSYCHOMETRIC PROPERT; Leners C, 2014, ISSUES MENT HEALTH N, V35, P497, DOI 10.3109/01612840.2014.887164; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Pietrzak RH, 2011, J AFFECT DISORDERS, V133, P560, DOI 10.1016/j.jad.2011.04.028; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P745, DOI 10.1002/da.20558; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Regehr C, 2000, J NERV MENT DIS, V188, P333, DOI 10.1097/00005053-200006000-00003; Rizzo Albert, 2013, MILITARY BEHAV HLTH, V1, P52, DOI DOI 10.1080/21635781.2012.721064; Roy A, 2007, ARCH SUICIDE RES, V11, P211, DOI 10.1080/13811110701250150; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schok ML, 2010, AGING MENT HEALTH, V14, P328, DOI 10.1080/13607860903228812; Sharkansky EJ, 2000, J ABNORM PSYCHOL, V109, P188, DOI 10.1037/0021-843X.109.2.188; Shively SB, 2012, J HEAD TRAUMA REHAB, V27, P234, DOI 10.1097/HTR.0b013e318250e9dd; Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Tugade M., 2007, J HAPPINESS STUD, V8, P311, DOI DOI 10.1007/S10902-006-9015-4; Ursano RJ, 2014, PSYCHIATRY, V77, P107, DOI 10.1521/psyc.2014.77.2.107; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Yeh PH, 2014, HUM BRAIN MAPP, V35, P2652, DOI 10.1002/hbm.22358; Yehuda R, 2007, J TRAUMA STRESS, V20, P435, DOI 10.1002/jts.20260; Ying LH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089401	69	29	30	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	11					1325	1336		10.3109/02699052.2015.1043948			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CR4MF	WOS:000361306100007	26204318				2022-02-06	
J	Mychasiuk, R; Hehar, H; van Waes, L; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; van Waes, Linda; Esser, Michael J.			Diet, age, and prior injury status differentially alter behavioral outcomes following concussion in rats	NEUROBIOLOGY OF DISEASE			English	Article						Brain injury; Development; High fat diet; Repetitive TBI; Telomeres	TRAUMATIC BRAIN-INJURY; BODY-MASS INDEX; MOTOR CORTEX LESIONS; MILD HEAD-INJURY; SEX-DIFFERENCES; ALZHEIMERS-DISEASE; CALORIC-INTAKE; MOUSE MODEL; OBESITY; DYSFUNCTION	Mild traumatic brain injury (mTBI) or concussion affects a large portion of the population and although many of these individuals recover completely, a small subset of people experience lingering symptomology and poor outcomes. Little is known about the factors that affect individual susceptibility or resilience to poor outcomes after mTBI and there are currently no biomarkers to delineate mTBI diagnosis or prognosis. Based upon the growing literature associated with caloric intake and altered neurological aging and the ambiguous link between repetitive mTBI and progressive neurodegeneration, the current study was designed to examine the effect of a high fat diet (HFD), developmental age, and repetitive mTBI on behavioral outcomes following a mTBI. In addition, telomere length was examined before and after experimental mTBI. Sprague Dawley rats were maintained on a HFD or standard rat chow throughout life (including the prenatal period) and then experienced an mTBI/concussion at P30, P30 and P60, or only at P60. Behavioral outcomes were examined using a test battery that was administered between P61-P80 and included; beam-walking, open field, elevated plus maze, novel context mismatch, Morris water task, and forced swim task. Animals with a P30 mTBI often demonstrated lingering symptomology that was still present during testing at P80. Injuries at P30 and P60 rarely produced cumulative effects, and in some tests (i.e. beam walking), the first injury may have protected the brain from the second injury. Exposure to the high fat diet exacerbated many of the behavioral deficits associated with concussion. Finally, telomere length was shortened following mTBI and was influenced by the animal's dietary intake. Diet, age at the time of injury, and the number of prior concussion incidents differentially contribute to behavioral deficits and may help explain individual variations in susceptibility and resilience to poor outcomes following an mTBI. (C) 2015 Elsevier Inc. All rights reserved.	[Mychasiuk, Richelle; Hehar, Harleen; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 1N4, Canada; [van Waes, Linda] Univ British Columbia, Fac Med, Vancouver, BC V5Z 1M9, Canada		Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp Res Inst, Heritage Med Res Bldg,Room 274,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.			Mychasiuk, Richelle/0000-0001-5291-5083	Canadian Institute for Military and Veteran Health Research (CIMVHR) program [Rt - 10007008]; Alberta Children's Hospital Foundation (ACHF) [Rt - 10003014]; Alberta Children's Hospital Research Institute (ACHRI) [Rt - 10003877]	The authors would like to thank the Canadian Institute for Military and Veteran Health Research (CIMVHR) (Rt - 10007008) program, the Alberta Children's Hospital Foundation (ACHF) (Rt - 10003014) and the Alberta Children's Hospital Research Institute (ACHRI) (Rt - 10003877) for funding the research conducted in this study. The authors would also like to thank Dr. Yushan Wang and Dr. Thomas Sawyer for their ideological input as well as, Irene Ma, Rose Tobias, and Dr. Jong Rho for their technical and organizational assistance.	Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CVR, 2006, J TRAUMA, V61, P572, DOI 10.1097/01.ta.0000200842.19740.38; Carroll L., 2004, J REHABIL MED S, V43, P84; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; de la Monte SM, 2014, BIOCHEM PHARMACOL, V88, P548, DOI 10.1016/j.bcp.2013.12.012; Demerath EW, 2004, HUM BIOL, V76, P127, DOI 10.1353/hub.2004.0018; Elias MF, 2003, INT J OBESITY, V27, P260, DOI 10.1038/sj.ijo.802225; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Garrido P, 2011, AGING DIS, V2, P80; Gilley D, 2008, MECH AGEING DEV, V129, P27, DOI 10.1016/j.mad.2007.10.010; Gunstad J, 2008, INT J NEUROSCI, V118, P1582, DOI 10.1080/00207450701392282; Gunstad J, 2007, COMPR PSYCHIAT, V48, P57, DOI 10.1016/j.comppsych.2006.05.001; Hood MY, 2000, INT J OBESITY, V24, P1319, DOI 10.1038/sj.ijo.0801396; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kalichman L, 2007, AM J PHYS MED REHAB, V86, P650, DOI 10.1097/PHM.0b013e318115f41b; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; Kolb B, 2000, RESTOR NEUROL NEUROS, V17, P61; Kolb B, 2000, BRAIN RES, V882, P62, DOI 10.1016/S0006-8993(00)02828-6; Kolb B., 2008, FUNDAMENTALS HUMAN N; Kolb B, 2007, DEV PSYCHOBIOL, V49, P107, DOI 10.1002/dev.20199; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lindqvist A, 2006, EUR J NEUROL, V13, P1385, DOI 10.1111/j.1468-1331.2006.01500.x; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh TK, 1996, LAB INVEST, V74, P315; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Molteni R, 2001, BRAIN RES REV, V37, P249, DOI 10.1016/S0165-0173(01)00128-X; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Panossian LA, 2003, NEUROBIOL AGING, V24, P77, DOI 10.1016/S0197-4580(02)00043-X; Paul L, 2011, J NUTR BIOCHEM, V22, P895, DOI 10.1016/j.jnutbio.2010.12.001; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Savage JS, 2007, J LAW MED ETHICS, V35, P22, DOI 10.1111/j.1748-720X.2007.00111.x; Schallert T., 2002, PHARM CEREB ISCHEMIA, V2002, P201; SENA A, 1985, J NEUROL SCI, V68, P233, DOI 10.1016/0022-510X(85)90104-2; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Suk SH, 2003, STROKE, V34, P1586, DOI 10.1161/01.STR.0000075294.98582.2F; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Walther K, 2010, HUM BRAIN MAPP, V31, P1052, DOI 10.1002/hbm.20916; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0	67	29	29	1	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JAN	2015	73						1	11		10.1016/j.nbd.2014.09.003			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AW5QB	WOS:000346328100001	25270295				2022-02-06	
J	Nishijima, DK; Yang, Z; Urbich, M; Holmes, JF; Zwienenberg-Lee, M; Melnikow, J; Kuppermann, N				Nishijima, Daniel K.; Yang, Zhuo; Urbich, Michael; Holmes, James F.; Zwienenberg-Lee, Marike; Melnikow, Joy; Kuppermann, Nathan			Cost-effectiveness of the PECARN Rules in Children With Minor Head Trauma	ANNALS OF EMERGENCY MEDICINE			English	Article							CLINICAL DECISION RULES; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; EMERGENCY-DEPARTMENTS; UNITED-STATES; BRAIN-TUMORS; CT SCANS; INJURY; STRATEGIES; PREDICTION	Study objective: To improve the efficiency and appropriateness of computed tomography (CT) use in children with minor head trauma, clinical prediction rules were derived and validated by the Pediatric Emergency Care Applied Research Network (PECARN). The objective of this study was to conduct a cost-effectiveness analysis comparing the PECARN traumatic brain injury prediction rules to usual care for selective CT use. Methods: We used decision analytic modeling to project the outcomes, costs, and cost-effectiveness of applying the PECARN rules compared with usual care in a hypothetical cohort of 1,000 children with minor blunt head trauma. Clinical management was directed by level of risk as specified by the presence or absence of variables in the PECARN traumatic brain injury prediction rules. Immediate costs of care (diagnostic testing, treatment [not including clinician time], and hospital stay) were derived on single-center data. Quality-adjusted life-year losses related to the sequelae of clinically important traumatic brain injuries and to radiation-induced cancers, number of CT scans, number of radiation-induced cancers, number of missed clinically important traumatic brain injury, and total costs were evaluated. Results: Compared with the usual care strategy, the PECARN strategy was projected to miss slightly more children with clinically important traumatic brain injuries (0.26 versus 0.02 per 1,000 children) but used fewer cranial CT scans (274 versus 353), resulted in fewer radiation-induced cancers (0.34 versus 0.45), cost less ($904,940 versus $954,420), and had lower net quality-adjusted life-year loss (-4.64 versus -5.79). Because the PECARN strategy was more effective (less quality-adjusted life-year loss) and less costly, it dominated the usual care strategy. Results were robust under sensitivity analyses. Conclusion: Application of the PECARN traumatic brain injury prediction rules for children with minor head trauma would lead to beneficial outcomes and more cost-effective care.	[Nishijima, Daniel K.; Holmes, James F.; Kuppermann, Nathan] UC Davis Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Yang, Zhuo; Melnikow, Joy] UC Davis Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA USA; [Zwienenberg-Lee, Marike] UC Davis Sch Med, Dept Neurol Surg, Sacramento, CA USA; [Urbich, Michael] Univ York, Dept Econ & Related Studies, York YO10 5DD, N Yorkshire, England		Nishijima, DK (corresponding author), UC Davis Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA.	daniel.nishijima@ucdmc.ucdavis.edu	yang, zhuo/D-7378-2018	yang, zhuo/0000-0003-1998-1104; Yang, Zhuo/0000-0002-8158-3003	Mentored Clinical Research Training Program [KL2]; National Center for Advancing Translational Sciences [NCATS], a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 RR024146]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Health Resources Services Administration (HRSA)/Maternal Child Health Bureau (MCHB)/Emergency Medical Services for Children (EMSC); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024146] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist and provided the following details: Dr. Nishijima was supported through a Mentored Clinical Research Training Program Award (KL2), grant UL1 RR024146 from the National Center for Research Resources (now National Center for Advancing Translational Sciences [NCATS]), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The PECARN was funded by the Health Resources Services Administration (HRSA)/Maternal Child Health Bureau (MCHB)/Emergency Medical Services for Children (EMSC).	American Academy of Pediatrics, 2013, 5 THINGS PHYS PAT SH; Arias E., 2007, NATL VITAL STAT REPO; Beers SR, 2012, J NEUROTRAUM, V29, P1126, DOI 10.1089/neu.2011.2272; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Bobinac A, 2013, HEALTH ECON, V22, P1272, DOI 10.1002/hec.2879; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Faul M, 2010, TRAUMATIC BRAIN INJU; Garber AM, 1997, J HEALTH ECON, V16, P1, DOI 10.1016/S0167-6296(96)00506-1; Gausche-Hill M, 2007, PEDIATRICS, V120, P1229, DOI 10.1542/peds.2006-3780; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Holmes MW, 2012, INJURY, V43, P1423, DOI 10.1016/j.injury.2011.07.017; Kirkdale R, 2010, QJM-INT J MED, V103, P715, DOI 10.1093/qjmed/hcq081; Kosty J, 2012, J NEUROTRAUM, V29, P1322, DOI 10.1089/neu.2011.2222; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutikova L, 2007, J NEURO-ONCOL, V81, P61, DOI 10.1007/s11060-006-9197-y; Lyttle MD, 2012, EMERG MED J, V29, P785, DOI 10.1136/emermed-2011-200225; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Prieto Luis, 2003, Health Qual Life Outcomes, V1, P80, DOI 10.1186/1477-7525-1-80; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stein SC, 2008, PEDIATR NEUROSURG, V44, P448, DOI 10.1159/000172967; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Weinstein MC, 2003, VALUE HEALTH, V6, P9, DOI 10.1046/j.1524-4733.2003.00234.x	29	29	30	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JAN	2015	65	1					72	80		10.1016/j.annemergmed.2014.08.019			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	AY6GC	WOS:000347664200017	25443992	Green Accepted			2022-02-06	
J	Tal, S; Hadanny, A; Berkovitz, N; Sasson, E; Ben-Jacob, E; Efrati, S				Tal, Sigal; Hadanny, Amir; Berkovitz, Nadav; Sasson, Efrat; Ben-Jacob, Eshel; Efrati, Shai			Hyperbaric oxygen may induce angiogenesis in patients suffering from prolonged post-concussion syndrome due to traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Hyperbaric oxygen; angiogenesis; MRI; perfusion; cognitive; TBI; post concussion	HIGH-RESOLUTION MEASUREMENT; TRACER BOLUS PASSAGES; MINOR HEAD-INJURY; STROKE; DAMAGE; RATS; NETWORKS; LANGUAGE; THERAPY; TRIAL	Purpose: Recent clinical studies present convincing evidence that hyperbaric oxygen therapy (HBOT) may be the coveted neurotherapeutic method for brain repair. One of the most interesting ways in which HBOT can induce neuroplasticity is angiogenesis. The objective in this study was to assess the neurotherapeutic effect of HBOT in post TBI patients using brain perfusion imaging and clinical cognitive functions. Methods: Retrospective analysis of patients suffering from chronic neuro-cognitive impairment from TBI treated with HBOT. The HBOT protocol included 60 daily HBOT sessions, 5 days per week. All patients had pre and post HBOT objective computerized cognitive tests (NeuroTrax) and brain perfusion MRI. Results: Ten post-TBI patients were treated with HBOT with mean of 10.3 +/- 3.2 years after their injury. After HBOT, whole-brain perfusion analysis showed significantly increased cerebral blood flow and cerebral blood volume. Clinically, HBOT induced significant improvement in the global cognitive scores (p = 0.007). The most prominent improvements were seen in information processing speed, visual spatial processing and motor skills indices. Conclusion: HBOT may induce cerebral angiogenesis, which improves perfusion to the chronic damage brain tissue even months to years after the injury.	[Hadanny, Amir; Efrati, Shai] Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, IL-7030 Zerifin, Israel; [Tal, Sigal; Hadanny, Amir; Berkovitz, Nadav; Efrati, Shai] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Tal, Sigal; Berkovitz, Nadav] Assaf Harofeh Med Ctr, Dept Radiol, IL-7030 Zerifin, Israel; [Sasson, Efrat] WiseImage, Hod Hasharon, Israel; [Ben-Jacob, Eshel; Efrati, Shai] Assaf Harofeh Med Ctr, Res & Dev Unit, IL-7030 Zerifin, Israel; [Ben-Jacob, Eshel; Efrati, Shai] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Ben-Jacob, Eshel] Tel Aviv Univ, Sch Phys & Astron, Raymond & Beverly Sackler Fac Exact Sci, IL-69978 Tel Aviv, Israel		Efrati, S (corresponding author), Assaf Harofeh Med Ctr, Sagol Ctr Hyperbar Med & Res, IL-7030 Zerifin, Israel.	efratishai@013.net					Achiron A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071058; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Boussi-Gross R, 2015, NEUROPSYCHOLOGY, V29, P610, DOI 10.1037/neu0000149; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen ZQ, 2010, J MAGN RESON IMAGING, V31, P1054, DOI 10.1002/jmri.22142; Doniger GM, 2014, GUIDE NORMATIVE DATA; Duan SS, 2015, INT J NEUROSCI, V125, P625, DOI 10.3109/00207454.2014.956101; Dwolatzky Tzvi, 2003, BMC Geriatr, V3, P4, DOI 10.1186/1471-2318-3-4; Efrati S, 2014, UNDERSEA HYPERBAR M, V41, P71; Efrati S, 2014, EXPERT REV NEUROTHER, V14, P233, DOI 10.1586/14737175.2014.884928; Efrati S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053716; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hadanny A. G. H., 2015, RESTORATIVE IN PRESS; Huang L, 2011, MED GAS RES, V1, DOI 10.1186/2045-9912-1-21; Jiang Q, 2005, NEUROIMAGE, V28, P698, DOI 10.1016/j.neuroimage.2005.06.063; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kim JS, 2005, NEUROLOGY, V64, P1438, DOI 10.1212/01.WNL.0000158656.09335.E7; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Kochanek PM, 2007, BRAIN INJURY MED PRI, P81; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lin KC, 2012, J TRAUMA ACUTE CARE, V72, P650, DOI 10.1097/TA.0b013e31823c575f; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Melton J.L., 2005, PSYCHOMETRIC EVALUAT; Neubauer RA, 1998, NEUROL RES, V20, pS33; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ostergaard L, 1996, MAGNET RESON MED, V36, P726, DOI 10.1002/mrm.1910360511; Ostergaard L, 1996, MAGN RESON MED, V36, P715, DOI 10.1002/mrm.1910360510; Ostergaard L, 2014, J CEREBR BLOOD F MET, V34, P1585, DOI 10.1038/jcbfm.2014.131; PARENT A, 1995, BRAIN RES REV, V20, P91, DOI 10.1016/0165-0173(94)00007-C; Peleg RK, 2013, DIVING HYPERB MED, V43, P218; Peng ZR, 2014, J NEUROL SCI, V342, P114, DOI 10.1016/j.jns.2014.04.037; Purves D, 2012, NEUROSCIENCE; Simon ES., 2003, ACTA NEUROPSYCHOLOGI, V1, P407, DOI DOI 10.5604/17307503/9168; Simon O, 2004, NEUROIMAGE, V23, P1192, DOI 10.1016/j.neuroimage.2004.09.023; Simon O, 2002, NEURON, V33, P475, DOI 10.1016/S0896-6273(02)00575-5; Sohlberg M., 2001, COGNITIVE REHABILITA; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Thaler A, 2012, NEUROLOGY, V79, P1027, DOI 10.1212/WNL.0b013e3182684646; Timmann D, 2010, CORTEX, V46, P845, DOI 10.1016/j.cortex.2009.06.009; Urbanski M, 2008, J NEUROL NEUROSUR PS, V79, P598, DOI 10.1136/jnnp.2007.126276; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wolf EG, 2012, UNDERSEA HYPERBAR M, V39, P1075; Zhang John H, 2005, Pathophysiology, V12, P63, DOI 10.1016/j.pathophys.2005.01.003; Zur D, 2015, J NEURO-OPHTHALMOL, V35, P26, DOI 10.1097/WNO.0000000000000199	50	29	31	1	10	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2015	33	6					943	951		10.3233/RNN-150585			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DA1MU	WOS:000367560700012	26484702				2022-02-06	
J	Baker, CS; Cinelli, ME				Baker, Carmen S.; Cinelli, Michael E.			Visuomotor deficits during locomotion in previously concussed athletes 30 or more days following return to play	PHYSIOLOGICAL REPORTS			English	Article						Collision avoidance; concussion; human locomotion; perception action integration		Current protocols for returning athletes to play (RTP) center around resolution of physical symptoms of concussion. However, recent research has identified that balance and cognitive deficits persist beyond physical symptom recovery. Protocols that involve testing dynamic balance and visuomotor integration have been recommended as potential tools for better understanding of length of impairment following concussion. A dynamic, visuomotor paradigm was undertaken in the current study to assess decision making in athletes who had sustained a concussion >30 days before study participation and had been cleared to RTP (N = 10). Two obstacles created a gap that varied between 0.6 and 1.89 participants' individual shoulder width in open space. Participants made decisions to navigate through or deviate around the gap created by the two obstacles. The results revealed that previously concussed athletes were highly variable in their decision making and demonstrated variable Medial-Lateral (ML) center of mass (COM) control when approaching the obstacles, when compared with nonconcussed, age-matched controls. As such, they showed poor visuomotor control and decision making, as well as poor dynamic stability compared to controls. Visuomotor deficits were persistent in the sample of previously concussed individuals, well beyond deficits identified by current RTP standards. This study suggests that dynamic, visuomotor integration tasks may be of benefit to increase safety of athletes returning to sport.	[Baker, Carmen S.; Cinelli, Michael E.] Wilfrid Laurier Univ, Dept Kinesiol & Phys Ed, 75 Univ Ave W, Waterloo, ON N2L 3C5, Canada		Cinelli, ME (corresponding author), Wilfrid Laurier Univ, Dept Kinesiol & Phys Ed, 75 Univ Ave W, Waterloo, ON N2L 3C5, Canada.	mcinelli@wlu.ca	Cinelli, Michael/ABE-7625-2020	Cinelli, Michael/0000-0002-5802-2590			Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Dessy A. M., 2014, NEUROSURG QUART, DOI [10.1097/WNQ.0000000000000085, DOI 10.1097/WNQ.0000000000000085]; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fajen BR, 2009, INT J SPORT PSYCHOL, V40, P79; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; FITTS PM, 1964, J EXP PSYCHOL, V67, P103, DOI 10.1037/h0045689; Gerin-Lajoie M, 2007, GAIT POSTURE, V26, P539, DOI 10.1016/j.gaitpost.2006.11.209; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hackney AL, 2015, GAIT POSTURE, V41, P323, DOI 10.1016/j.gaitpost.2014.09.018; Hackney AL, 2013, Q J EXP PSYCHOL, V66, P1104, DOI 10.1080/17470218.2012.730532; Hackney AL, 2013, GAIT POSTURE, V37, P93, DOI 10.1016/j.gaitpost.2012.06.020; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Higuchi T., 2011, HUM MOVEMENT SCI, V30, P543; Hollis SJ, 2012, BRIT J SPORT MED, V46, P735, DOI 10.1136/bjsm.2011.085332; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Lee D.N., 1975, J HUM MOVEMENT STUD, V1, P87; Locklin J, 2010, SPORTS MED, V40, P183, DOI 10.2165/11319440-000000000-00000; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moy S., 2014, OSTEOPATH FAM PHYS, V2, P8; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Patla AE, 1997, GAIT POSTURE, V5, P54, DOI 10.1016/S0966-6362(96)01109-5; Sandel M. R., 2012, APPL NEUROPSYCH-CHIL, V2, P64; SCAT2, BR J SPORTS MED S, V43, pi85; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022	30	29	29	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2051-817X			PHYSIOL REP	PHYSIOL. REP.	DEC	2014	2	12							e12252	10.14814/phy2.12252			7	Physiology	Emerging Sources Citation Index (ESCI)	Physiology	V17WZ	WOS:000214715200002	25539832	Green Published, gold			2022-02-06	
J	Lu, HZ; Liu, PY; Yezhuvath, U; Cheng, YM; Marshall, O; Ge, YL				Lu, Hanzhang; Liu, Peiying; Yezhuvath, Uma; Cheng, Yamei; Marshall, Olga; Ge, Yulin			MRI Mapping of Cerebrovascular Reactivity via Gas Inhalation Challenges	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Medicine; Issue 94; Cerebrovascular reactivity; cerebrovascular diseases; MRI-compatible gas delivery systems; hypercapnia; hyperoxia; CO2; O-2	CEREBRAL-BLOOD-FLOW; LEVEL-DEPENDENT MRI; CARBON-DIOXIDE; OXYGEN; HYPERCAPNIA; RESPONSES; DISEASE; CO2	The brain is a spatially heterogeneous and temporally dynamic organ, with different regions requiring different amount of blood supply at different time. Therefore, the ability of the blood vessels to dilate or constrict, known as Cerebral-Vascular-Reactivity (CVR), represents an important domain of vascular function. An imaging marker representing this dynamic property will provide new information of cerebral vessels under normal and diseased conditions such as stroke, dementia, atherosclerosis, small vessel diseases, brain tumor, traumatic brain injury, and multiple sclerosis. In order to perform this type of measurement in humans, it is necessary to deliver a vasoactive stimulus such as CO2 and/or O-2 gas mixture while quantitative brain magnetic resonance images (MRI) are being collected. In this work, we presented a MR compatible gas-delivery system and the associated protocol that allow the delivery of special gas mixtures (e.g., O-2, CO2, N-2, and their combinations) while the subject is lying inside the MRI scanner. This system is relatively simple, economical, and easy to use, and the experimental protocol allows accurate mapping of CVR in both healthy volunteers and patients with neurological disorders. This approach has the potential to be used in broad clinical applications and in better understanding of brain vascular pathophysiology. In the video, we demonstrate how to set up the system inside an MRI suite and how to perform a complete experiment on a human participant.	[Lu, Hanzhang; Liu, Peiying; Yezhuvath, Uma; Cheng, Yamei] Univ Texas Southwestern Med Ctr, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Marshall, Olga; Ge, Yulin] NYU, Sch Med, Ctr Biomed Imaging, Dept Radiol, New York, NY 10003 USA		Lu, HZ (corresponding author), Univ Texas Southwestern Med Ctr, Adv Imaging Res Ctr, Dallas, TX 75390 USA.	hanzhang.lu@utsouthwestern.edu	Ge, Yulin/D-9060-2019; Liu, Peiying/D-7512-2017; Ge, Yulin/L-7052-2019	Ge, Yulin/0000-0002-2320-6031; Liu, Peiying/0000-0003-0830-5960; 	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH084021, R01 NS067015, R01 AG042753, NS076588, NS029029-20S1, R21 NS078656]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [RG4707A2]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH084021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS029029, R01NS076588, R01NS029029, R01NS067015, R21NS078656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG042753] Funding Source: NIH RePORTER	This work was partly supported by grants from the National Institutes of Health (NIH), under grant numbers R01 MH084021, R01 NS067015, R01 AG042753, NS076588, NS029029-20S1, R21 NS078656; and from National Multiple Sclerosis Society, under grant number of RG4707A2.	Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Bright MG, 2011, J CEREBR BLOOD F MET, V31, P426, DOI 10.1038/jcbfm.2010.187; ELLINGSEN I, 1987, ACTA PHYSIOL SCAND, V129, P157, DOI 10.1111/j.1748-1716.1987.tb08054.x; GREENBERG SM, 2006, NEW ENGL J MED, V354, P1451, DOI DOI 10.1056/NEJMP068043; Han JS, 2008, NAT CLIN PRACT NEURO, V4, P628, DOI 10.1038/ncpneuro0918; Hsu YY, 2004, J MAGN RESON IMAGING, V19, P160, DOI 10.1002/jmri.10447; Ide Kojiro, 2003, Journal of Applied Physiology, V95, P129; Kastrup A, 2001, MAGN RESON IMAGING, V19, P13, DOI 10.1016/S0730-725X(01)00227-2; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Krainik A, 2005, STROKE, V36, P1146, DOI 10.1161/01.STR.0000166178.40973.a7; Liu PY, 2013, HUM BRAIN MAPP, V34, P2078, DOI 10.1002/hbm.22053; Liu PY, 2013, NEUROIMAGE, V78, P415, DOI 10.1016/j.neuroimage.2013.04.053; Lu H, 2003, MAGNET RESON MED, V50, P263, DOI 10.1002/mrm.10519; Lu HZ, 2011, CEREB CORTEX, V21, P1426, DOI 10.1093/cercor/bhq224; Mandell DM, 2008, STROKE, V39, P2021, DOI 10.1161/STROKEAHA.107.506709; Marshall O., 2014, JAMA NEUROL IN PRESS; Mikulis DJ, 2005, J NEUROSURG, V103, P347, DOI 10.3171/jns.2005.103.2.0347; Rostrup E, 2000, NEUROIMAGE, V11, P87, DOI 10.1006/nimg.1999.0526; Slessarev M, 2007, J PHYSIOL-LONDON, V581, P1207, DOI 10.1113/jphysiol.2007.129395; Thesen T, 2012, HUM BRAIN MAPP, V33, P715, DOI 10.1002/hbm.21242; Thomas BP, 2013, J MAGN RESON IMAGING, V38, P1177, DOI 10.1002/jmri.24090; van der Zande FHR, 2005, NEURORADIOLOGY, V47, P114, DOI 10.1007/s00234-004-1274-3; Wise RG, 2007, J CEREBR BLOOD F MET, V27, P1521, DOI 10.1038/sj.jcbfm.9600465; Xie AL, 2005, AM J RESP CRIT CARE, V172, P371, DOI 10.1164/rccm.200406-807OC; Xu F, 2011, J CEREBR BLOOD F MET, V31, P58, DOI 10.1038/jcbfm.2010.153; Yezhuvath US, 2012, NEUROBIOL AGING, V33, P75, DOI 10.1016/j.neurobiolaging.2010.02.005; Yezhuvath US, 2009, NMR BIOMED, V22, P779, DOI 10.1002/nbm.1392; Zappe AC, 2008, CEREB CORTEX, V18, P2666, DOI 10.1093/cercor/bhn023	28	29	29	1	5	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	DEC	2014		94							e52306	10.3791/52306			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CB1AE	WOS:000349358000064	25549106	Green Submitted, Bronze, Green Published			2022-02-06	
J	Monaco, CM; Gebhardt, KM; Chlebowski, SM; Shaw, KE; Cheng, JP; Henchir, JJ; Zupa, MF; Kline, AE				Monaco, Christina M.; Gebhardt, Kory M.; Chlebowski, Sarah M.; Shaw, Kaitlyn E.; Cheng, Jeffrey P.; Henchir, Jeremy J.; Zupa, Margaret F.; Kline, Anthony E.			A Combined Therapeutic Regimen of Buspirone and Environmental Enrichment Is More Efficacious than Either Alone in Enhancing Spatial Learning in Brain-Injured Pediatric Rats	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; controlled cortical impact (CCI); functional recovery; learning and memory; behavior; Morris water maze; 5-HT1A receptor agonist, beam-walking; traumatic brain injury	RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; MEDIATED FUNCTIONAL IMPROVEMENT; COGNITIVE DEFICITS; NEUROBEHAVIORAL BENEFIT; YOUNG-CHILDREN; UNITED-STATES; HEAD-INJURY; 5-HT1A; RECOVERY; 8-OH-DPAT	Buspirone, a 5-HT1A receptor agonist, and environmental enrichment (EE) enhance cognition and reduce histopathology after traumatic brain injury (TBI) in adult rats, but have not been fully evaluated after pediatric TBI, which is the leading cause of death in children. Hence, the aims of this study were to assess the efficacy of buspirone alone (Experiment 1) and in combination with EE (Experiment 2) in TBI postnatal day-17 male rats. The hypothesis was that both therapies would confer cognitive and histological benefits when provided singly, but their combination would be more efficacious. Anesthetized rats received a cortical impact or sham injury and then were randomly assigned to receive intraperitoneal injections of buspirone (0.08 mg/kg, 0.1 mg/kg, and 0.3 mg/kg) or saline vehicle (1.0 mL/kg) 24 h after surgery and once daily for 16 days (Experiment 1). Spatial learning and memory were assessed using the Morris water maze (MWM) on post-operative days 11-16, and cortical lesion volume was quantified on day 17. Sham controls for each condition were significantly better than all TBI groups. In the TBI groups, buspirone (0.1 mg/kg) enhanced MWM performance versus vehicle and buspirone (0.08 mg/kg and 0.3 mg/kg) (p<0.05) and reduced lesion volume relative to vehicle (p=0.038). In Experiment 2, buspirone (0.1 mg/kg) or vehicle was combined with EE after TBI, and the data were compared to the standard (STD)-housed groups from Experiment 1. EE lead to a significant enhancement of spatial learning and a reduction in lesion size versus STD. Moreover, the combined treatment group (buspirone+EE) performed markedly better than the buspirone+STD and vehicle+EE groups, which suggests an additive effect and supports the hypothesis. The data replicate previous studies assessing these therapies in adult rats. These novel findings may have important rehabilitation-relevant implications for clinical pediatric TBI.	[Monaco, Christina M.; Gebhardt, Kory M.; Chlebowski, Sarah M.; Shaw, Kaitlyn E.; Cheng, Jeffrey P.; Kline, Anthony E.] Univ Pittsburgh, Pittsburgh, PA 15213 USA; [Monaco, Christina M.; Gebhardt, Kory M.; Chlebowski, Sarah M.; Shaw, Kaitlyn E.; Cheng, Jeffrey P.; Henchir, Jeremy J.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA; [Zupa, Margaret F.] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA		Kline, AE (corresponding author), Univ Pittsburgh, 3471 Fifth Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Cheng, Jeffrey/0000-0001-8285-3207	NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005, HD069620]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	Supported, in part, by NIH grants HD046700, NS060005, and HD069620 (AEK).	Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; Bondi CO, 2014, J NEUROTRAUM, V31, P873, DOI 10.1089/neu.2014.3328; Briones TL, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-57; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Cheng JP, 2007, NEUROSCI LETT, V416, P165, DOI 10.1016/j.neulet.2007.02.006; Cheng JP, 2012, J NEUROTRAUM, V29, P2684, DOI 10.1089/neu.2012.2560; de Witt BW, 2011, NEUROREHAB NEURAL RE, V25, P343, DOI 10.1177/1545968310390520; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Harkany T, 2001, NEUROSCIENCE, V108, P629, DOI 10.1016/S0306-4522(01)00444-4; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Herlenius E, 2004, EXP NEUROL, V190, pS8, DOI 10.1016/j.expneurol.2004.03.027; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; Lippert-Gruener M, 2007, EXP NEUROL, V203, P82, DOI 10.1016/j.expneurol.2006.07.025; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; Matter AM, 2011, NEUROREHAB NEURAL RE, V25, P558, DOI 10.1177/1545968310397206; Meneses A, 1999, NEUROSCI BIOBEHAV R, V23, P1111, DOI 10.1016/S0149-7634(99)00067-6; Meneses A, 2007, NEUROSCI BIOBEHAV R, V31, P705, DOI 10.1016/j.neubiorev.2007.02.001; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olsen AS, 2012, J NEUROTRAUM, V29, P1898, DOI 10.1089/neu.2012.2358; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Sakaue M, 2000, BRIT J PHARMACOL, V129, P1028, DOI 10.1038/sj.bjp.0703139; Garcia AS, 2011, J INVEST ALLERG CLIN, V21, P1; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; TEYLER TJ, 1989, NEUROPSYCHOLOGIA, V27, P31, DOI 10.1016/0028-3932(89)90088-2; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wheaton P, 2009, J CLIN PSYCHOPHARM, V29, P468, DOI 10.1097/JCP.0b013e3181b66f04; Xu L., 2010, TRAUMATIC BRAIN INJU; Yelleswarapu NK, 2012, NEUROSCI LETT, V515, P153, DOI 10.1016/j.neulet.2012.03.033	57	29	29	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1934	1941		10.1089/neu.2014.3541			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500006	25050595	Green Published			2022-02-06	
J	Shimada, SL; Brandt, CA; Feng, H; McInnes, DK; Rao, SR; Rothendler, JA; Haggstrom, DA; Abel, EA; Cioffari, LS; Houston, TK				Shimada, Stephanie Leah; Brandt, Cynthia A.; Feng, Hua; McInnes, D. Keith; Rao, Sowmya R.; Rothendler, James A.; Haggstrom, David A.; Abel, Erica A.; Cioffari, Lisa S.; Houston, Thomas K.			Personal Health Record Reach in the Veterans Health Administration: A Cross-Sectional Analysis	JOURNAL OF MEDICAL INTERNET RESEARCH			English	Article						personal health records; patient characteristics; medical conditions; veterans	POSTTRAUMATIC-STRESS-DISORDER; PRIMARY-CARE CLINICS; MENTAL-HEALTH; RANDOMIZED-TRIAL; AFGHANISTAN VETERANS; PHYSICIAN REMINDERS; SELF-MANAGEMENT; PATIENT ACCESS; SERVICE USE; PREVALENCE	Background: My HealtheVet (MHV) is the personal health record and patient portal developed by the United States Veterans Health Administration (VA). While millions of American veterans have registered for MHV, little is known about how a patient's health status may affect adoption and use of the personal health record. Objective: Our aim was to characterize the reach of the VA personal health record by clinical condition. Methods: This was a cross-sectional analysis of all veterans nationwide with at least one inpatient admission or two outpatient visits between April 2010 and March 2012. We compared adoption (registration, authentication, opt-in to use secure messaging) and use (prescription refill and secure messaging) of MHV in April 2012 across 18 specific clinical conditions prevalent in and of high priority to the VA. We calculated predicted probabilities of adoption by condition using multivariable logistic regression models adjusting for sociodemographics, comorbidities, and clustering of patients within facilities. Results: Among 6,012,875 veterans, 6.20% were women, 61.45% were Caucasian, and 26.31% resided in rural areas. The mean age was 63.3 years. Nationwide, 18.64% had registered for MHV, 11.06% refilled prescriptions via MHV, and 1.91% used secure messaging with their clinical providers. Results from the multivariable regression suggest that patients with HIV, hyperlipidemia, and spinal cord injury had the highest predicted probabilities of adoption, whereas those with schizophrenia/schizoaffective disorder, alcohol or drug abuse, and stroke had the lowest. Variation was observed across diagnoses in actual (unadjusted) adoption and use, with registration rates ranging from 29.19% of patients with traumatic brain injury to 14.18% of those with schizophrenia/schizoaffective disorder. Some of the variation in actual reach can be explained by facility-level differences in MHV adoption and by differences in patients' sociodemographic characteristics (eg, age, race, income) by diagnosis. Conclusions: In this phase of early adoption, opportunities are being missed for those with specific medical conditions that require intensive treatment and self-management, which could be greatly supported by functions of a tethered personal health record.	[Shimada, Stephanie Leah; Feng, Hua; McInnes, D. Keith; Rao, Sowmya R.; Rothendler, James A.; Cioffari, Lisa S.; Houston, Thomas K.] Edith Nourse Rogers Mem VA Med Ctr, eHlth Qual Enhancement Res Initiat, Ctr Healthcare Org & Implementat Res, Bedford, MA 01730 USA; [Shimada, Stephanie Leah; McInnes, D. Keith; Rothendler, James A.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Shimada, Stephanie Leah; Feng, Hua; Cioffari, Lisa S.; Houston, Thomas K.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Div Hlth Informat & Implementat Sci, Worcester, MA USA; [Brandt, Cynthia A.; Abel, Erica A.] VA Connecticut Healthcare Syst, Pain Res Informat Multi Morbid & Educ Ctr, West Haven, CT USA; [Brandt, Cynthia A.; Abel, Erica A.] Yale Univ, Sch Med, Yale Ctr Med Informat, New Haven, CT USA; [Brandt, Cynthia A.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA; [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Div Biostat, Worcester, MA USA; [Rao, Sowmya R.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Hlth Serv Res, Worcester, MA USA; [Haggstrom, David A.] Richard L Roudebush Vet Adm Med Ctr, Ctr Hlth Informat & Commun, Indianapolis, IN 46202 USA; [Haggstrom, David A.] Indiana Univ Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN 46202 USA		Shimada, SL (corresponding author), Edith Nourse Rogers Mem VA Med Ctr, eHlth Qual Enhancement Res Initiat, Ctr Healthcare Org & Implementat Res, 200 Springs Rd 152, Bedford, MA 01730 USA.	stephanie.shimada@va.gov			Department of Veterans Affairs (VA) Health Services Research and Development Service, Quality Enhancement Research Initiative [RRP 11-404]; VA Health Services Research and Development Career Development Award (CDA) [10-210]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000142] Funding Source: NIH RePORTER	( The research reported here was supported by the Department of Veterans Affairs (VA) Health Services Research and Development Service, Quality Enhancement Research Initiative (RRP 11-404). In addition, Dr Shimada was supported by a VA Health Services Research and Development Career Development Award (CDA# 10-210). The views expressed in this paper are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.	Ahern DK, 2011, AM J PREV MED, V40, pS162, DOI 10.1016/j.amepre.2011.01.005; Amante DJ, 2014, DIABETES TECHNOL THE, V16, P784, DOI 10.1089/dia.2014.0078; Ansseau M, 2004, J AFFECT DISORDERS, V78, P49, DOI 10.1016/S0165-0327(02)00219-7; Archer N, 2011, J AM MED INFORM ASSN, V18, P515, DOI 10.1136/amiajnl-2011-000105; Ayanian JZ, 2008, J GEN INTERN MED, V23, P762, DOI 10.1007/s11606-008-0576-2; Bali RK, 2010, STUD HEALTH TECHNOL, V156, P138, DOI 10.3233/978-1-60750-565-5-138; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Chumbler NR, 2011, MED CARE, V49, pS36, DOI 10.1097/MLR.0b013e3181d558f9; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW, P164; Davison KP, 2000, AM PSYCHOL, V55, P205, DOI 10.1037/0003-066X.55.2.205; Department of Veterans Affairs, 2013, MY HEALTHEVET ACC TY; Detmer D, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-45; Druss BG, 2014, AM J PSYCHIAT, V171, P360, DOI 10.1176/appi.ajp.2013.13070913; Frueh BC, 2007, AM J GERIAT PSYCHIAT, V15, P660, DOI 10.1097/JGP.0b013e3180487cc2; Glasgow RE, 1999, AM J PUBLIC HEALTH, V89, P1322, DOI 10.2105/AJPH.89.9.1322; Golub A, 2013, MIL MED, V178, P107, DOI 10.7205/MILMED-D-12-00131; Goulet JL, 2007, CLIN INFECT DIS, V45, P1593, DOI 10.1086/523577; Grubaugh AL, 2006, WOMEN HEALTH, V43, P41, DOI 10.1300/J013v43n03_03; Hall AK, 2015, HEALTH EDUC BEHAV, V42, P202, DOI 10.1177/1090198114547815; Jonas BS, 2003, SOC PSYCH PSYCH EPID, V38, P618, DOI 10.1007/s00127-003-0682-8; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lorig KR, 2008, ARTHRIT RHEUM-ARTHR, V59, P1009, DOI 10.1002/art.23817; Lorig KR, 2006, MED CARE, V44, P964, DOI 10.1097/01.mlr.0000233678.80203.c1; Lorig KR, 2008, CHRONIC ILLN, V4, P247, DOI 10.1177/1742395308098886; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; Magruder KM, 2005, GEN HOSP PSYCHIAT, V27, P169, DOI 10.1016/j.genhosppsych.2004.11.001; Mattocks KM, 2010, J WOMENS HEALTH, V19, P2159, DOI 10.1089/jwh.2009.1892; Miller Holly, 2007, J Healthc Inf Manag, V21, P44; Nazi KM, 2013, MED CARE, V51, pS52, DOI 10.1097/MLR.0b013e31827808db; Nazi KM, 2010, J GEN INTERN MED, V25, P62, DOI 10.1007/s11606-009-1114-6; Palen TE, 2012, JAMA-J AM MED ASSOC, V308, P2012, DOI 10.1001/jama.2012.14126; Riolo SA, 2005, AM J PUBLIC HEALTH, V95, P998, DOI 10.2105/AJPH.2004.047225; Roblin DW, 2009, J AM MED INFORM ASSN, V16, P683, DOI 10.1197/jamia.M3169; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI 10.1002/jts.20493; Sequist TD, 2009, ARCH INTERN MED, V169, P364, DOI 10.1001/archinternmed.2008.564; Shimada SL, 2013, MED CARE, V51, pS21, DOI 10.1097/MLR.0b013e3182780917; Song H, 2015, AM J MENS HEALTH, V9, P235, DOI 10.1177/1557988314539502; Stone EG, 2002, ANN INTERN MED, V136, P641, DOI 10.7326/0003-4819-136-9-200205070-00006; Tang PC, 2006, J AM MED INFORM ASSN, V13, P121, DOI 10.1197/jamia.M2025; Tsai J, 2012, J AM MED INFORM ASSN, V19, P1089, DOI 10.1136/amiajnl-2012-000971; US Department of Health and Human Services. The National Infrastructure Workgroup of the National Committee on Vital Statistics (NICVHS), 2006, NAT INFR WORKGR NAT; Veterans Health Administration Office of Health Information Product Effectiveness, 2009, MY HEALTHEVET SHEP S; Walkup JT, 2004, MED CARE, V42, P756, DOI 10.1097/01.mlr.0000132749.20897.46; Weingart SN, 2008, INT J MED INFORM, V77, P161, DOI 10.1016/j.ijmedinf.2007.04.007; Weingart SN, 2006, J AM MED INFORM ASSN, V13, P91, DOI 10.1197/jamia.M1833; Woods SS, 2013, J MED INTERNET RES, V15, P182, DOI 10.2196/jmir.2356; Yamin CK, 2011, ARCH INTERN MED, V171, P568, DOI 10.1001/archinternmed.2011.34; Yoon J, 2014, MED CARE, V52, pS31, DOI 10.1097/MLR.0000000000000061	49	29	29	0	27	JMIR PUBLICATIONS, INC	TORONTO	59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA	1438-8871			J MED INTERNET RES	J. Med. Internet Res.	DEC	2014	16	12					165	177		10.2196/jmir.3751			13	Health Care Sciences & Services; Medical Informatics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Medical Informatics	AW2TH	WOS:000346141400014	25498515	gold, Green Published, Green Submitted			2022-02-06	
J	Shogren, KA; Kennedy, W; Dowsett, C; Little, TD				Shogren, Karrie A.; Kennedy, William; Dowsett, Chantelle; Little, Todd D.			Autonomy, Psychological Empowerment, and Self-Realization: Exploring Data on Self-Determination From NLTS2	EXCEPTIONAL CHILDREN			English	Article							QUALITY-OF-LIFE; STUDENT PARTICIPATION; HIGH-SCHOOL; DETERMINATION INTERVENTIONS; LEARNING-DISABILITIES; ADULT OUTCOMES; DIRECTED-IEP; TRANSITION; PROMOTE; PREDICTORS	The authors used data from the National Longitudinal Transition Study-2 (NLTS2; SRI International, 2000) to examine the aspects of self-determination assessed in NLTS2 and measurement equivalence and latent differences across the 12 disability categories recognized in the Individuals With Disabilities Education Act (IDEA; 2004). NLTS2 included a direct assessment with items representing 3 of the 4 essential characteristics of self-determination-autonomy, self-realization, and psychological empowerment. The authors established measurement equivalence, but significant latent differences occurred across specific disability groups. Students with high-incidence disabilities (learning disabilities, emotional disturbances, speech or language impairments, and other health impairments) showed similar latent means and variances, as did students with sensory disabilities (visual and hearing impairments) and cognitive disabilities (autism, multiple disabilities, and deaf-blindness). Students with intellectual disability, traumatic brain injury, and orthopedic impairments could not be collapsed with any other group. Across the 6 collapsed disability groups, significant differences existed in the latent variances and limited mean level differences.	[Shogren, Karrie A.] Univ Illinois, Urbana, IL USA; [Kennedy, William; Dowsett, Chantelle; Little, Todd D.] Univ Kansas, Ctr Res Methods & Data Anal, Lawrence, KS 66045 USA		Shogren, KA (corresponding author), Univ Illinois, Dept Special Educ, 1310 S 6th St, Champaign, IL 61820 USA.	kshogren@illinois.edu	Stroilova, Nataly/E-6440-2014	Shogren, Karrie/0000-0001-7925-1299			Agran M, 2007, J VISUAL IMPAIR BLIN, V101, P453, DOI 10.1177/0145482X0710100802; Algozzine B, 2001, REV EDUC RES, V71, P219, DOI 10.3102/00346543071002219; Arndt SA, 2006, REM SPEC EDUC, V27, P194, DOI 10.1177/07419325060270040101; Bandalos DL, 2002, STRUCT EQU MODELING, V9, P78, DOI 10.1207/S15328007SEM0901_5; Brown TA., 2015, CONFIRMATORY FACTOR, V2; Calkins C, 2011, EXCEPTIONALITY, V19, P2, DOI 10.1080/09362835.2011.537219; Carter EW, 2010, J EMOT BEHAV DISORD, V18, P67, DOI 10.1177/1063426609332605; CHADSEYRUSCH J, 1991, REM SPEC EDUC, V12, P23; Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5; Cobb B, 2009, CAREER DEV TRANSIT E, V32, P108, DOI 10.1177/0885728809336654; HASAZI SB, 1985, EXCEPT CHILDREN, V51, P455, DOI 10.1177/001440298505100601; Hill, 1996, SCALES INDEPENDENT B; Hughes C, 1997, EDUC TRAIN MENT RET, V32, P201; Javitz H., 2005, ANAL POTENTIAL BIAS; Konrad M, 2007, LEARN DISABILITY Q, V30, P89, DOI 10.2307/30035545; Lane KL, 2006, J EMOT BEHAV DISORD, V14, P108, DOI 10.1177/10634266060140020101; Lee Y, 2012, REM SPEC EDUC, V33, P150, DOI 10.1177/0741932510392053; Lee Y, 2011, J SPEC EDUC, V45, P104, DOI 10.1177/0022466909358916; Little T. D., PSYCHOL MET IN PRESS; Little T. D., 2013, LONGITUDINAL STRUCTU; Little TD, 1997, MULTIVAR BEHAV RES, V32, P53, DOI 10.1207/s15327906mbr3201_3; Little TD, 2002, STRUCT EQU MODELING, V9, P151, DOI 10.1207/S15328007SEM0902_1; Martin JE, 2006, EXCEPT CHILDREN, V72, P299, DOI 10.1177/001440290607200303; McDougall J, 2010, REM SPEC EDUC, V31, P252, DOI 10.1177/0741932509355989; MITHAUG DE, 1985, EXCEPT CHILDREN, V51, P397, DOI 10.1177/001440298505100505; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; National Research Council, 2001, ED CHILDR AUT; Nota L, 2007, J INTELL DISABIL RES, V51, P850, DOI 10.1111/j.1365-2788.2006.00939.x; Orelove F., 2004, ED CHILDREN MULTIPLE; Palmer SB, 2004, EXCEPT CHILDREN, V70, P427, DOI 10.1177/001440290407000403; Sabornie EJ, 2006, REM SPEC EDUC, V27, P95, DOI 10.1177/07419325060270020701; Sabornie EJ, 2005, EXCEPT CHILDREN, V72, P47, DOI 10.1177/001440290507200103; Shogren KA, 2007, EXCEPT CHILDREN, V73, P488, DOI 10.1177/001440290707300406; Shogren KA, 2012, REM SPEC EDUC, V33, P320, DOI 10.1177/0741932511410072; Shogren KA, 2010, RES PRACT PERS SEV D, V35, P80, DOI 10.2511/rpsd.35.3-4.80; Shogren KA, 2008, ASSES EFF INTERV, V33, P94, DOI 10.1177/1534508407311395; SITLINGTON PL, 1990, LEARN DISABILITY Q, V13, P97, DOI 10.2307/1510654; SRI International, 2000, NAT LONG TRANS STUD; Stancliffe RJ, 2001, MENT RETARD DEV D R, V7, P91, DOI 10.1002/mrdd.1013; Stancliffe RJ, 1997, MENT RETARD, V35, P1, DOI 10.1352/0047-6765(1997)035<0001:CLSSPA>2.0.CO;2; Test D. W., 2004, J BEHAV EDUC, V13, P135; Thoma CA, 2002, REM SPEC EDUC, V23, P82, DOI 10.1177/074193250202300204; Van Reusen A. K., 1994, SELF ADVOCACY STRATE; VANREUSEN AK, 1994, EXCEPT CHILDREN, V60, P466, DOI 10.1177/001440299406000510; Wagner M., 2006, ACAD ACHIEVEMENT FUN; Walker HM, 2011, EXCEPTIONALITY, V19, P6, DOI 10.1080/09362835.2011.537220; Wehman P., 2006, LIFE CLASSROOM TRANS; Wehmeyer M, 1997, EXCEPT CHILDREN, V63, P245, DOI 10.1177/001440299706300207; Wehmeyer M. L., 2011, ADOLESCENT SELF DETE; Wehmeyer M. L., 2004, WHOSE FUTURE IS IT A, V2nd; Wehmeyer M. L., 2008, ED CHILDREN YOUTH AU, P433; Wehmeyer ML, 2011, EXCEPTIONALITY, V19, P19, DOI 10.1080/09362835.2011.537225; Wehmeyer ML, 2010, EDUC TRAIN AUTISM DE, V45, P475; Wehmeyer ML, 1996, EDUC TRAIN MENT RET, V31, P282; Wehmeyer ML, 2003, J APPL RES INTELLECT, V16, P255, DOI 10.1046/j.1468-3148.2003.00161.x; Wehmeyer ML, 2003, EDUC TRAIN MENT RET, V38, P131; Wehmeyer ML., 1995, ARCS SELF DETERMINAT; Williams-Diehm K., 2008, J DEV DISABILITIES, V14, P27; Wood WM, 2005, RES PRACT PERS SEV D, V30, P121, DOI 10.2511/rpsd.30.3.121; Ysseldyke J., 2006, TEACHING STUDENTS SE	60	29	30	0	205	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0014-4029	2163-5560		EXCEPT CHILDREN	Except. Child.	WIN	2014	80	2					221	235		10.1177/001440291408000206			15	Education, Special; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Rehabilitation	287GY	WOS:000329531200007					2022-02-06	
J	Lu, P; Kamboj, A; Gibson, SB; Anderson, CM				Lu, Ping; Kamboj, Amit; Gibson, Spencer B.; Anderson, Christopher M.			Poly(ADP-Ribose) Polymerase-1 Causes Mitochondrial Damage and Neuron Death Mediated by Bnip3	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis-inducing factor; Bnip3; ischemia; mitochondrial permeability; PARP; sirtuin	TRAUMATIC BRAIN INJURY; CELL-DEATH; NAD(+) DEPLETION; TRANSCRIPTION FACTOR; DNA DAMAGE; APOPTOSIS; INHIBITION; METABOLISM; SIRT1; PARP	Excessive pathophysiological activity of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP1) causes neuron death in brain hypoxia/ischemia by inducing mitochondrial permeability transition and nuclear translocation of apoptosis-inducing factor (AIF). Bcl-2/adenovirus E1B 19 kDa-interacting protein (Bnip3) is a prodeath BH3-only Bcl-2 protein family member that is induced in hypoxia, and has effects on mitochondrial permeability and neuronal survival similar to those caused by PARP1 activation. We hypothesized that Bnip3 is a critical mediator of PARP1-induced mitochondrial dysfunction and neuron death. Hypoxic death of mouse cortical neuron cultures was mitigated by deletion of either PARP1 or Bnip3, indicating that both factors are involved. Direct normoxic PARP1 activation by a DNA alkylating agent enhanced Bnip3 expression, and caused Bnip3-dependent mitochondrial membrane permeability, AIF translocation, and neuron death. Hypoxia produced PARP1-dependent depletion of nicotinamide adenine dinucleotide (NAD(+)) and inhibition of the NAD(+)-dependent class III histone deactelyase (HDAC) sirtuin-1 (SIRT1). This, in turn, led to hyperacetylation and nuclear localization of the forkhead box (Fox) protein FoxO3a, followed by enhanced association of FoxO3a with the Bnip3 upstream promoter region, increased levels of Bnip3 transcript, and elevated mitochondrial Bnip3 immunoreactivity. Finally, FoxO3a silencing using a lentiviral short hairpin RNA approach significantly reduced hypoxic Bnip3 expression, mitochondrial damage, and neuron death. Together, these data illustrate a direct PARP1-mediated hypoxic signaling pathway involving NAD(+) depletion, SIRT1 inhibition, FoxO3a-driven Bnip3 generation, and mitochondrial AIF release.	[Lu, Ping; Kamboj, Amit; Anderson, Christopher M.] Univ Manitoba, Winnipeg Hlth Sci Ctr, Kleysen Inst Adv Med, Neurosci Res Program, Winnipeg, MB R3E 0Z3, Canada; [Lu, Ping; Kamboj, Amit; Anderson, Christopher M.] Univ Manitoba, Coll Med, Winnipeg, MB R3E 0Z3, Canada; [Lu, Ping; Kamboj, Amit; Anderson, Christopher M.] Univ Manitoba, Coll Med, Dept Pharmacol & Therapeut, Winnipeg, MB R3E 0T6, Canada; [Gibson, Spencer B.] Manitoba Inst Cell Biol, Winnipeg, MB R3E 0T3, Canada		Anderson, CM (corresponding author), Kleysen Inst Adv Med, Hlth Sci Ctr, Neurosci Res Program, 710 William Ave,SR452, Winnipeg, MB R3E 0Z3, Canada.	chris.anderson@med.umanitoba.ca		Anderson, Christopher/0000-0003-0678-3002; Gibson, Spencer/0000-0003-0119-732X	Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada; Research Manitoba	This work was supported by the Heart and Stroke Foundation of Canada. P.L. and A.K. were supported by postdoctoral fellowships from Research Manitoba. C.M.A. holds a Manitoba Research Chair from Research Manitoba. We thank Dr. Gerald Dorn for providing bnip3<SUP>-/-</SUP> mice, and Dr. Jiming Kong for providing the Bnip3 antibody.	Akhter R, 2014, J BIOL CHEM, V289, P10812, DOI 10.1074/jbc.M113.519355; Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; Almeida A, 1998, BRAIN RES PROTOC, V2, P209, DOI 10.1016/S1385-299X(97)00044-5; Althaus J, 2006, NEUROCHEM INT, V48, P687, DOI 10.1016/j.neuint.2005.12.008; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Andrabi SA, 2014, P NATL ACAD SCI USA, V111, P10209, DOI 10.1073/pnas.1405158111; Bai P, 2011, CELL METAB, V13, P461, DOI 10.1016/j.cmet.2011.03.004; Baxter P, 2014, TRANSL STROKE RES, V5, P136, DOI 10.1007/s12975-013-0283-0; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Chen Y, 2010, P NATL ACAD SCI USA, V107, P9035, DOI 10.1073/pnas.0914013107; Chinnadurai G, 2008, ONCOGENE, V27, pS114, DOI 10.1038/onc.2009.49; COHEN A, 1987, ARCH BIOCHEM BIOPHYS, V258, P498, DOI 10.1016/0003-9861(87)90371-7; Cosi C, 1999, ANN NY ACAD SCI, V890, P227, DOI 10.1111/j.1749-6632.1999.tb07998.x; Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416; Ghosh AP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039586; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Hagenbuchner J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00147; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Hunt WT, 2010, J NEUROCHEM, V115, P123, DOI 10.1111/j.1471-4159.2010.06908.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Pillai JB, 2005, J BIOL CHEM, V280, P43121, DOI 10.1074/jbc.M506162200; Qi YM, 2012, J CELL BIOL, V198, P103, DOI 10.1083/jcb.201111063; Regula KM, 2002, CIRC RES, V91, P226, DOI 10.1161/01.RES.0000029232.42227.16; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Tang KS, 2010, GLIA, V58, P446, DOI 10.1002/glia.20936; Thompson JW, 2012, LIFE SCI, V91, P223, DOI 10.1016/j.lfs.2012.03.034; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wang F, 2013, STEM CELL RES, V11, P657, DOI 10.1016/j.scr.2013.04.005; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Won SJ, 2012, J NEUROTRAUM, V29, P1401, DOI 10.1089/neu.2011.2228; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang ZF, 2007, STROKE, V38, P1606, DOI 10.1161/STROKEAHA.106.475129; Zhang ZF, 2011, FEBS J, V278, P134, DOI 10.1111/j.1742-4658.2010.07939.x	47	29	33	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 26	2014	34	48					15975	15987		10.1523/JNEUROSCI.2499-14.2014			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU9OJ	WOS:000345923600015	25429139	Bronze, Green Published			2022-02-06	
J	Majdan, M; Lingsma, HF; Nieboer, D; Mauritz, W; Rusnak, M; Steyerberg, EW				Majdan, Marek; Lingsma, Hester F.; Nieboer, Daan; Mauritz, Walter; Rusnak, Martin; Steyerberg, Ewout W.			Performance of IMPACT, CRASH and Nijmegen models in predicting six month outcome of patients with severe or moderate TBI: an external validation study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Prognostic model; External validation; Traumatic brain injury; Outcome prediction	TRAUMATIC BRAIN-INJURY; PROGNOSTIC MODELS; INTERNATIONAL MISSION; EPIDEMIOLOGY; PROGRESS	Background: External validation on different TBI populations is important in order to assess the generalizability of prognostic models to different settings. We aimed to externally validate recently developed models for prediction of six month unfavourable outcome and six month mortality. Methods: The International Neurotrauma Research Organization - Prehospital dataset (INRO-PH) was collected within an observational study between 2009-2012 in Austria and includes 778 patients with TBI of GCS < = 12. Three sets of prognostic models were externally validated: the IMPACT core and extended models, CRASH basic models and the Nijmegen models developed by Jacobs et al - all for prediction of six month unfavourable outcome and six month mortality. The external validity of the models was assessed by discrimination (Area Under the receiver operating characteristic Curve, AUC) and calibration (calibration statistics and plots). Results: Median age in the validation cohort was 50 years and 44% had an admission GSC motor score of 1-3. Six-month mortality was 27%. Mortality could better be predicted (AUCs around 0.85) than unfavourable outcome (AUCs around 0.80). Calibration plots showed that the observed outcomes were systematically better than was predicted for all models considered. The best performance was noted for the original Nijmegen model, but refitting led to similar performance for the IMPACT Extended, CRASH Basic, and Nijmegen models. Conclusions: In conclusion, all the prognostic models we validated in this study possess good discriminative ability for prediction of six month outcome in patients with moderate or severe TBI but outcomes were systemically better than predicted. After adjustment for this under prediction in locally adapted models, these may well be used for recent TBI patients.	[Majdan, Marek; Rusnak, Martin] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava 91701, Slovakia; [Majdan, Marek; Mauritz, Walter; Rusnak, Martin] INRO, A-1080 Vienna, Austria; [Lingsma, Hester F.; Nieboer, Daan; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, NL-3015 CE Rotterdam, Netherlands		Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia.	mmajdan@igeh.org	Rusnak, Martin/K-9349-2016; Majdan, Marek/K-5017-2012	Rusnak, Martin/0000-0003-3321-1042; Majdan, Marek/0000-0001-8037-742X	Austrian Ministry of Health; Austrian Worker's Compensation Board (AUVA) [FK 11/2008, FK 11/2010]; AUVA [FK 09/13]; Trnava University [12/TU/13]; European Union Seventh Framework Programme (FP7) [602150]	The project was funded jointly by the Austrian Ministry of Health (Contract Oct. 15, 2008) and by the Austrian Worker's Compensation Board (AUVA; FK 11/2008 and FK 11/2010). Data analysis was supported by a grant from AUVA (FK 09/13). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by small donations from various sources. The work of Marek Majdan on this paper was supported by an institutional grant from the Trnava University, No. 12/TU/13. The validation study and the preparation of this paper has been partly done within the CENTER-TBI project that has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no 602150.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; Franschman G, 2012, INJURY, V43, P1838, DOI 10.1016/j.injury.2012.05.020; Jacobs B, 2013, NEUROCRIT CARE, V19, P79, DOI 10.1007/s12028-012-9795-9; LINGSMA H, 2013, TRAUMA ACUTE CARE SU, V74, P639; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg, 2019, CLIN PREDICTION MODE; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165	19	29	29	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	NOV 19	2014	22								68	10.1186/s13049-014-0068-9			10	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	AX3YF	WOS:000346870900001	25406964	Green Published, gold			2022-02-06	
J	Arbour, C; Choiniere, M; Topolovec-Vranic, J; Loiselle, CG; Puntillo, K; Gelinas, C				Arbour, Caroline; Choiniere, Manon; Topolovec-Vranic, Jane; Loiselle, Carmen G.; Puntillo, Kathleen; Gelinas, Celine			Detecting Pain in Traumatic Brain-injured Patients With Different Levels of Consciousness During Common Procedures in the ICU Typical or Atypical Behaviors?	CLINICAL JOURNAL OF PAIN			English	Article						traumatic brain injury; pain; behaviors; pain assessment; intensive care unit	INTENSIVE-CARE-UNIT; CRITICALLY-ILL; OBSERVATION TOOL; RELIABILITY; SCALE; VALIDATION; ADULT; PREVALENCE; SEVERITY; VALIDITY	Purpose: Pain behaviors such as grimacing and muscle rigidity are recommended for pain assessment in nonverbal populations. However, these behaviors may not be appropriate for critically ill patients with a traumatic brain injury (TBI) depending on their level of consciousness (LOC). This study aimed to validate the use of behaviors for assessing pain of critically ill TBI adults with different LOC. Methods: Using a repeated measure within subject design, participants (N = 45) were observed for 1 minute before (baseline), during, and 15 minutes after 2 procedures: (1) noninvasive blood pressure: NIBP (non-nociceptive); and (2) turning (nociceptive). A behavioral checklist combining 50 items from existing pain assessment tools and video recording were used to describe participants' behaviors. Intrarater and interrater agreements of observed behaviors were also examined. Results: Overall, pain behaviors were observed more frequently during turning (median = 4; T = -5.336; P <= 0.001) than at baseline (median = 1), or during noninvasive blood pressure (median = 0). TBI patients' pain behaviors were mostly "atypical" and included uncommon responses such as flushing, sudden eye opening, eye weeping, and flexion of limbs. These behaviors were observed in >= 25.0% of TBI participants during turning independent of their LOC, and in 22.2% to 66.7% of conscious participants who reported the presence of pain. Agreements were > 92% among and between the 2 raters. Conclusions: This study support previous findings that critically ill TBI patients could exhibit atypical behaviors when exposed to nociceptive procedures. As such, use of current recommended pain behaviors as part of standardized scales may not be optimal for assessing the analgesic needs of this vulnerable group.	[Arbour, Caroline; Loiselle, Carmen G.; Gelinas, Celine] McGill Univ, Ingram Sch Nursing, Montreal, PQ H3A 2A7, Canada; [Arbour, Caroline; Loiselle, Carmen G.; Gelinas, Celine] McGill Univ, Jewish Gen Hosp, Centre Nursing Res, Montreal, PQ H3T 1E2, Canada; [Arbour, Caroline; Loiselle, Carmen G.; Gelinas, Celine] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; [Arbour, Caroline; Loiselle, Carmen G.; Gelinas, Celine] Quebec Nursing Intervent Res Network RRISIQ, Montreal, PQ, Canada; [Arbour, Caroline; Gelinas, Celine] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ H3A 2A7, Canada; [Choiniere, Manon] Univ Montreal, CRCHUM, Montreal, PQ, Canada; [Topolovec-Vranic, Jane] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Trauma & Neurosurg Program, Toronto, ON M5B 1W8, Canada; [Puntillo, Kathleen] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA		Gelinas, C (corresponding author), McGill Univ, Ingram Sch Nursing, 3506 Univ St, Montreal, PQ H3A 2A7, Canada.	celine.gelinas@mcgill.ca	Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212; Loiselle, Carmen/0000-0002-1981-2645	Louise and Alan Edwards Foundation; Canadian Institutes of Health Research (CIHR), CanadaCanadian Institutes of Health Research (CIHR) [258 867]; Fonds de la Recherche du Quebec-Sante (FRQ-S), Montreal, Qc, Canada [25094]; Quebec Nursing Intervention Research Network (RRISIQ), Montreal, Qc, Canada; Louise and Alan Edwards; FRQ-S; Quebec Ministry of Education (FRESIQ-MELS program)	This study was initially funded by a pilot research grant from the Louise and Alan Edwards Foundation, and is part of a larger research program funded by the Canadian Institutes of Health Research (CIHR #258 867), Canada; and the Fonds de la Recherche du Quebec-Sante (FRQ-S #25094), Montreal, Qc, Canada; held by the principal investigator (C. G.). Part of this study was also funded by a research grant from the Quebec Nursing Intervention Research Network (RRISIQ), Montreal, Qc, Canada; and 3 PhD studentship awards (C. A.) from the Louise and Alan Edwards, the FRQ-S, and by the Quebec Ministry of Education (FRESIQ-MELS program). The authors declare no conflict of interest.	Ahlers SJGM, 2010, ANESTH ANALG, V110, P127, DOI 10.1213/ANE.0b013e3181c3119e; Aissaoui Y, 2005, ANESTH ANALG, V101, P1470, DOI 10.1213/01.ANE.0000182331.68722.FF; American Pain Society, 2003, PRINC AN US TREATM A; Arbour C, 2013, RECH SOINS INFIRM, P46, DOI 10.3917/rsi.112.0046; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Benditt JO, 2006, RESPIR CARE, V51, P829; Berben SAA, 2008, INJURY, V39, P578, DOI 10.1016/j.injury.2007.04.013; Chahine LM, 2006, EPILEPSY BEHAV, V8, P610, DOI 10.1016/j.yebeh.2006.01.017; Dunwoody Colleen J, 2008, J Perianesth Nurs, V23, pS15, DOI 10.1016/j.jopan.2007.11.007; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Gelinas C, 2008, PAIN MANAG NURS, V9, P120, DOI 10.1016/j.pmn.2007.12.001; Gelinas Celine, 2007, Perspect Infirm, V4, P12; Gelinas C, 2007, CLIN J PAIN, V23, P497, DOI 10.1097/ajp.0b013e31806a23fb; Gelinas C, 2006, AM J CRIT CARE, V15, P420; Gelinas C, 2013, SEMIN RESP CRIT CARE, V34, P153, DOI 10.1055/s-0033-1342970; Gelinas C, 2011, INT J NURS STUD, V48, P1495, DOI 10.1016/j.ijnurstu.2011.03.012; Gelinas C, 2009, J CRIT CARE, V24, DOI 10.1016/j.jcrc.2009.01.013; GOODWIN LD, 1981, RES NURS HEALTH, V4, P323, DOI 10.1002/nur.4770040308; Haidet KK, 2009, RES NURS HEALTH, V32, P465, DOI 10.1002/nur.20334; Herr K, 2011, PAIN MANAG NURS, V12, P230, DOI 10.1016/j.pmn.2011.10.002; Kastrup M, 2009, J INT MED RES, V37, P1267, DOI 10.1177/147323000903700502; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kreipke CW, 2009, J CELL MOL MED, V13, P262, DOI 10.1111/j.1582-4934.2008.00508.x; Le Q, 2013, PAIN MANAG NURS, V14, pE251, DOI 10.1016/j.pmn.2012.02.005; Marmo L, 2010, PAIN MANAG NURS, V11, P134, DOI 10.1016/j.pmn.2009.05.007; McHugh ML, 2011, BIOCHEM MEDICA, V21, P203; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Puntillo K A, 2001, Am J Crit Care, V10, P238; Puntillo KA, 2004, CRIT CARE MED, V32, P421, DOI 10.1097/01.CCM.0000108875.35298.D2; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Samuel M. L., 2012, STAT LIFE SCI; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Stanik-Hutt J A, 2001, Am J Crit Care, V10, P252; Streiner DL., 2008, HLTH MEASUREMENT SCA; TEASDALE G, 1974, LANCET, V2, P81	38	29	30	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	NOV	2014	30	11					960	969		10.1097/AJP.0000000000000061			10	Anesthesiology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Anesthesiology; Neurosciences & Neurology	AR0GG	WOS:000343247000005	24480910				2022-02-06	
J	Murray, KN; Girard, S; Holmes, WM; Parkes, LM; Williams, SR; Parry-Jones, AR; Allan, SM				Murray, Katie N.; Girard, Sylvie; Holmes, William M.; Parkes, Laura M.; Williams, Stephen R.; Parry-Jones, Adrian R.; Allan, Stuart M.			Systemic Inflammation Impairs Tissue Reperfusion Through Endothelin-Dependent Mechanisms in Cerebral Ischemia	STROKE			English	Article						brain ischemia; endothelin-1; inflammation; interleukin-1; magnetic resonance imaging; reperfusion	TRAUMATIC BRAIN-INJURY; EXPERIMENTAL STROKE; MAGNETIC-RESONANCE; DIABETIC-RATS; BLOOD-FLOW; THROMBOLYSIS; RECEPTOR; MICE; HYPOPERFUSION; INTERLEUKIN-1	Background and Purpose Systemic inflammation contributes to diverse acute and chronic brain pathologies, and extensive evidence implicates inflammation in stroke susceptibility and poor outcome. Here we investigate whether systemic inflammation alters cerebral blood flow during reperfusion after experimental cerebral ischemia. Methods Serial diffusion and perfusion-weighted MRI was performed after reperfusion in Wistar rats given systemic (intraperitoneal) interleukin-1 or vehicle before 60-minute transient middle cerebral artery occlusion. The expression and location of endothelin-1 was assessed by polymerase chain reaction, ELISA, and immunofluorescence. Results Systemic interleukin-1 caused a severe reduction in cerebral blood flow and increase in infarct volume compared with vehicle. Restriction in cerebral blood flow was observed alongside activation of the cerebral vasculature and upregulation of the vasoconstricting peptide endothelin-1 in the ischemic penumbra. A microthrombotic profile was also observed in the vasculature of rats receiving interleukin-1. Blockade of endothelin-1 receptors reversed this hypoperfusion, reduced tissue damage, and improved functional outcome. Conclusions These data suggest patients with a raised inflammatory profile may have persistent deficits in perfusion after reopening of an occluded vessel. Future therapeutic strategies to interrupt the mechanism identified could lead to enhanced recovery of penumbra in patients with a heightened inflammatory burden and a better outcome after stroke.	[Murray, Katie N.; Allan, Stuart M.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Parkes, Laura M.; Williams, Stephen R.] Univ Manchester, Ctr Imaging Sci, Manchester, Lancs, England; [Girard, Sylvie] Univ Montreal, St Justine Hosp Res Ctr, Montreal, PQ H3C 3J7, Canada; [Holmes, William M.] Univ Glasgow, Glasgow Expt MRI Ctr, Glasgow, Lanark, Scotland; [Parry-Jones, Adrian R.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford M6 8DH, Lancs, England		Parry-Jones, AR (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal NHS Fdn Trust, Stott Lane, Salford M6 8DH, Lancs, England.	adrian.parry-jones@manchester.ac.uk	holmes, william/AAP-3417-2021; Williams, Steve R/C-8945-2011; Parry-Jones, Adrian/ABE-2418-2021; Williams, Steve C/D-6979-2011; Allan, Stuart/AAL-1245-2020	Williams, Steve R/0000-0001-5940-1675; Parry-Jones, Adrian/0000-0002-4462-3846; Williams, Steve C/0000-0003-4299-1941; Allan, Stuart/0000-0001-9646-4456; Parkes, Laura/0000-0001-6488-507X	Neuroscience Research Institute; Biomedical Imaging Institute; Medical Research Council, United KingdomUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/F011350]; Natalie Kate Moss Trust; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/F011350/1] Funding Source: UKRI; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0802001] Funding Source: UKRI; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/F011350/1] Funding Source: researchfish; British Heart FoundationBritish Heart Foundation [PG/13/8/29989] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1259754, G0802001] Funding Source: researchfish	This work was supported by the Neuroscience Research Institute, Biomedical Imaging Institute, and Medical Research Council, United Kingdom. This work was made possible by an equipment grant from the Biotechnology and Biological Sciences Research Council (BB/F011350), which funded the imaging console used in this study. K.N. Murray was funded by the Natalie Kate Moss Trust.	ADNER M, 1993, NEUROREPORT, V4, P441, DOI 10.1097/00001756-199304000-00026; Baskerville TA, 2012, J CEREBR BLOOD F MET, V32, P973, DOI 10.1038/jcbfm.2012.19; BEASLEY D, 1989, J CLIN INVEST, V83, P331, DOI 10.1172/JCI113879; Blamire AM, 2000, J NEUROSCI, V20, P8153; Briyal S, 2010, EUR J PHARMACOL, V644, P73, DOI 10.1016/j.ejphar.2010.06.071; D'haeseleer M, 2013, P NATL ACAD SCI USA, V110, P5654, DOI 10.1073/pnas.1222560110; De Silva DA, 2009, STROKE, V40, P2872, DOI 10.1161/STROKEAHA.108.543595; Denes A, 2014, ANN NEUROL, V75, P670, DOI 10.1002/ana.24146; Denes A, 2012, J AM HEART ASSOC, V1, DOI 10.1161/JAHA.112.002006; Denes A, 2010, J NEUROSCI, V30, P10086, DOI 10.1523/JNEUROSCI.1227-10.2010; Dorrance AM, 2007, VASC PHARMACOL, V47, P160, DOI 10.1016/j.vph.2007.05.007; Drake C, 2011, BRAIN BEHAV IMMUN, V25, P1113, DOI 10.1016/j.bbi.2011.02.008; Endeman H, 2011, EUR RESPIR J, V37, P1431, DOI 10.1183/09031936.00074410; Fan X, 2013, STROKE, V44, P745, DOI 10.1161/STROKEAHA.111.000309; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; Gan Y, 2014, P NATL ACAD SCI USA, V111, P2704, DOI 10.1073/pnas.1315943111; Glynn RJ, 2009, NEW ENGL J MED, V360, P1851, DOI 10.1056/NEJMoa0900241; Griebe M, 2013, CEREBROVASC DIS, V35, P554, DOI 10.1159/000351146; Grotta J, 2012, ANN NY ACAD SCI, V1268, P141, DOI 10.1111/j.1749-6632.2012.06690.x; Guo X, 1996, Hypertens Res, V19, P23, DOI 10.1291/hypres.19.23; Herz J, 2014, NEUROBIOL DIS, V62, P456, DOI 10.1016/j.nbd.2013.10.022; Kallakuri S, 2010, NEUROSCIENCE, V168, P820, DOI 10.1016/j.neuroscience.2010.01.018; Kammersgaard L P, 2001, J Stroke Cerebrovasc Dis, V10, P217, DOI 10.1053/jscd.2001.30366; Kaundal RK, 2012, DRUG DISCOV TODAY, V17, P793, DOI 10.1016/j.drudis.2012.02.017; Kreipke CW, 2010, NEUROL RES, V32, P209, DOI 10.1179/174313209X414515; Le Heron CJ, 2014, J CEREBR BLOOD F MET, V34, P964, DOI 10.1038/jcbfm.2014.40; Lenzlinger PM, 2004, RESTOR NEUROL NEUROS, V22, P73; Li WG, 2013, AM J PHYSIOL-REG I, V304, pR1001, DOI 10.1152/ajpregu.00523.2012; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lopez-Castejon G, 2011, CELL MOL LIFE SCI, V68, P3095, DOI 10.1007/s00018-010-0609-y; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; Maher CO, 2003, J NEUROSURG, V99, P907, DOI 10.3171/jns.2003.99.5.0907; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; Meng XJ, 2004, ANN NEUROL, V55, P207, DOI 10.1002/ana.10803; Moffat BA, 2005, J MAGN RESON IMAGING, V21, P290, DOI 10.1002/jmri.20268; Nam J, 2015, INT J STROKE, V10, P13, DOI 10.1111/j.1747-4949.2012.00914.x; Palomares SM, 2012, J CEREBR BLOOD F MET, V32, P1035, DOI 10.1038/jcbfm.2012.14; Pradillo JM, 2012, J CEREBR BLOOD F MET, V32, P1810, DOI 10.1038/jcbfm.2012.101; Rewell SSJ, 2010, J CEREBR BLOOD F MET, V30, P729, DOI 10.1038/jcbfm.2009.273; Rupp J, 2003, EUR RESPIR J, V22, P274, DOI 10.1183/09031936.03.00007303; Selvarajah JR, 2011, INT J STROKE, V6, P187, DOI 10.1111/j.1747-4949.2010.00561.x; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Soares BP, 2010, STROKE, V41, pE34, DOI 10.1161/STROKEAHA.109.568766; Thornton P, 2010, BLOOD, V115, P3632, DOI 10.1182/blood-2009-11-252643; Tiainen M, 2013, INT J STROKE, V8, P632, DOI 10.1111/ijs.12039; Zhang X, 2013, NEUROBIOL LEARN MEM, V101, P46, DOI 10.1016/j.nlm.2013.01.002	48	29	35	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499	1524-4628		STROKE	Stroke	NOV	2014	45	11					3412	3419		10.1161/STROKEAHA.114.006613			8	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	AS6CD	WOS:000344351500054	25228257	Green Accepted			2022-02-06	
J	Robinson, KE; Fountain-Zaragoza, S; Dennis, M; Taylor, HG; Bigler, ED; Rubin, K; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Robinson, Kristen E.; Fountain-Zaragoza, Stephanie; Dennis, Maureen; Taylor, H. Gerry; Bigler, Erin D.; Rubin, Kenneth; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Executive Functions and Theory of Mind as Predictors of Social Adjustment in Childhood Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						executive function; pediatric; social adjustment; traumatic brain injury	INHIBITORY CONTROL; HEAD-INJURY; CHILDREN; PATTERNS; OUTCOMES; NEUROSCIENCE	This study examined whether executive function and theory of mind mediate the effects of pediatric traumatic brain injury (TBI) on social adjustment, relative to children with orthopedic injury (OI). Participants included 19 children with severe TBI, 41 children with complicated mild/moderate TBI, and 57 children with OI. They completed measures of executive function, as well as cognitive, affective, and conative theory of mind. Parents provided ratings of children's social adjustment. Children with severe TBI performed more poorly than children with OI on executive function and theory of mind tasks and were rated by parents as having more behavioral symptoms and worse communication and social skills. Executive function and theory of mind were positively correlated with social skills and communication skills, and negatively correlated with behavioral symptoms. In multiple mediator models, theory of mind and executive function were not significant direct predictors of any measure of social adjustment, but mediated the association between injury and adjustment for children with severe TBI. Theory of mind was a significant independent mediator when predicting social skills, but executive function was not. TBI in children, particularly severe injury, is associated with poor social adjustment. The impact of TBI on children's social adjustment is likely mediated by its effects on executive function and theory of mind.	[Robinson, Kristen E.; Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA; [Robinson, Kristen E.; Fountain-Zaragoza, Stephanie; Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Dennis, Maureen] Hosp Sick Children, Dept Psychol, Toronto, ON M5G 1X8, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Magnet Resonance Imaging MRI Res Facil, Provo, UT 84602 USA; [Rubin, Kenneth] Univ Maryland, Dept Human Dev & Quantitat Methodol, College Pk, MD 20742 USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA		Robinson, KE (corresponding author), Ohio State Univ, Dept Pediat, Res Inst, Nationwide Childrens Hosp, 700 Childrens Dr, Columbus, OH 43205 USA.	Kristen.robinson@nationwidechildrens.org	Rubin, Kenneth H/M-5276-2018; Fountain-Zaragoza, Stephanie/AAC-4512-2021; Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019; Hoskinson, Kristen/AAL-9162-2020	Rubin, Kenneth H/0000-0002-2608-2484; Fountain-Zaragoza, Stephanie/0000-0002-9365-4884; Hoskinson, Kristen/0000-0003-4044-9753; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 R01 HD048946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	The preparation of this article was supported in part by grant 5 R01 HD048946 from the National Institute of Child Health and Human Development to Keith Yeates.	Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Carlson SM, 2004, J EXP CHILD PSYCHOL, V87, P299, DOI 10.1016/j.jecp.2004.01.002; Crowe LM, 2013, CHILD NEUROPSYCHOL, V19, P113, DOI 10.1080/09297049.2011.651079; De Los Reyes A, 2005, PSYCHOL BULL, V131, P483, DOI 10.1037/0033-2909.131.4.483; DEEGAN J, 1978, EDUC PSYCHOL MEAS, V38, P873, DOI 10.1177/001316447803800404; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P338, DOI 10.1017/S1355617712001440; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Dodge KA, 2002, PSYCHOL ASSESSMENT, V14, P60, DOI 10.1037//1040-3590.14.1.60; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; DROTAR D, 1995, J CLIN CHILD PSYCHOL, V24, P184, DOI 10.1207/s15374424jccp2402_6; Gordon ACL, 1998, J EXP CHILD PSYCHOL, V68, P70, DOI 10.1006/jecp.1997.2423; Hanten G, 2011, NEUROPSYCHOLOGIA, V49, P486, DOI 10.1016/j.neuropsychologia.2010.12.007; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; Heaton SC, 2001, CHILD NEUROPSYCHOL, V7, P251, DOI 10.1076/chin.7.4.251.8736; Howard I, 2005, ETHNIC DIS, V15, pS51; Johnson MH, 2005, DEV PSYCHOPATHOL, V17, P599, DOI 10.1017/S0954579405050297; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Manly T, 1999, TEA CH TEST EVERYDAY; Moses LJ, 2001, CHILD DEV, V72, P688, DOI 10.1111/1467-8624.00306; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Reynolds C. R., 2004, BEHAV ASSESSMENT SYS, V2nd; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2014, CLIN PSYCHOL SCI, V2, P97, DOI 10.1177/2167702613499734; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	40	29	29	2	34	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1835	1842		10.1089/neu.2014.3422			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400003	25003478	Green Published			2022-02-06	
J	Phelan, HA; Richter, AA; Scott, WW; Pruitt, JH; Madden, CJ; Rickert, KL; Wolf, SE				Phelan, Herb A.; Richter, Adam A.; Scott, William W.; Pruitt, Jeffrey H.; Madden, Christopher J.; Rickert, Kim L.; Wolf, Steven E.			Does Isolated Traumatic Subarachnoid Hemorrhage Merit a Lower Intensity Level of Observation Than Other Traumatic Brain Injury?	JOURNAL OF NEUROTRAUMA			English	Article						isolated; progression; sequelae; subarachnoid; traumatic	RISK	Evidence is emerging that isolated traumatic subarachnoid hemorrhage (ITSAH) may be a milder form of traumatic brain injury (TBI). If true, ITSAH may not benefit from intensive care unit (ICU) admission, which would, in turn, decrease resource utilization. We conducted a retrospective review of all TBI admissions to our institution between February 2010 and November 2012 to compare the presentation and clinical course of subjects with ITSAH to all other TBI. We then performed descriptive statistics on the subset of ITSAH subjects presenting with a Glasgow Coma Score (GCS) of 13-15. Of 698 subjects, 102 had ITSAH and 596 had any other intracranial hemorrhage pattern. Compared to all other TBI, ITSAH had significantly lower injury severity scores (p < 0.0001), lower head abbreviated injury scores (p < 0.0001), higher emergency department GCS (p < 0.0001), shorter ICU stays (p = 0.007), higher discharge GCS (p = 0.005), lower mortality (p = 0.003), and significantly fewer head computed tomography scans (p < 0.0001). Of those ITSAH subjects presenting with a GCS of 13-15 (n = 77), none underwent placement of an intracranial monitor or craniotomy. One subject (1.3%) demonstrated a change in exam (worsened headache and dizziness) concomitant with a progression of his intracranial injury. His symptoms resolved with readmission to the ICU and continued observation. Our results suggest that ITSAH are less-severe brain injuries than other TBI. ITSAH patients with GCS scores of 13-15 demonstrate low rates of clinical progression, and when progression occurs, it resolves without further intervention. This subset of TBI patients does not appear to benefit from ICU admission.	[Phelan, Herb A.; Wolf, Steven E.] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burns Trauma Crit Care, Parkland Mem Hosp, Dallas, TX 75390 USA; [Richter, Adam A.] Vanderbilt Univ Sch Med, Dept Surg, Div Vasc Surg, Nashville, TN USA; [Scott, William W.; Madden, Christopher J.; Rickert, Kim L.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Parkland Mem Hosp, Dallas, TX 75390 USA; [Pruitt, Jeffrey H.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Parkland Mem Hosp, Dallas, TX 75390 USA		Phelan, HA (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burns Trauma Crit Care, Parkland Mem Hosp, 5323 Harry Hines Blvd,E5-508A, Dallas, TX 75390 USA.	herb.phelan@utsouthwestern.edu		Wolf, Steven/0000-0003-2972-3440	UT Southwestern Clinical Translational Science Initiative - NIH [1 KL2 RR024983-01]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001103] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024983] Funding Source: NIH RePORTER	This work was supported by a pilot grant awarded by the UT Southwestern Clinical Translational Science Initiative, which is itself funded by NIH grant no. 1 KL2 RR024983-01 titled, "North and Central Texas Clinical and Translational Science Initiative" (Robert Toto MD, PI). This work was presented as a poster at the October 2013 Annual Meeting of the Neurocritical Care Society in Philadelphia, Pennsylvania.	AbdelFattah KR, 2012, J TRAUMA ACUTE CARE, V73, P685, DOI 10.1097/TA.0b013e318265ccd9; Borczuk P, 2013, J TRAUMA ACUTE CARE, V74, P1504, DOI 10.1097/TA.0b013e31829215cf; Levy AS, 2011, J TRAUMA, V71, P1199, DOI 10.1097/TA.0b013e31822067fc; Lin TK, 2012, J TRAUMA ACUTE CARE, V73, P131, DOI 10.1097/TA.0b013e31824aff74; Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, pS122, DOI 10.1097/TA.0b013e3182606327; Quigley MR, 2013, J TRAUMA ACUTE CARE, V74, P581, DOI 10.1097/TA.0b013e31827d6088; Sander S., 1993, J NEUROL SCI, V119, P1	7	29	30	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2014	31	20					1733	1736		10.1089/neu.2014.3377			4	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AP8BF	WOS:000342302200006	24926612	Green Published			2022-02-06	
J	Costanzo, ME; Chou, YY; Leaman, S; Pham, DL; Keyser, D; Nathan, DE; Coughlin, M; Rapp, P; Roy, MJ				Costanzo, Michelle E.; Chou, Yi-Yu; Leaman, Suzanne; Pham, Dzung L.; Keyser, David; Nathan, Dominic E.; Coughlin, Mary; Rapp, Paul; Roy, Michael J.			Connecting combat-related mild traumatic brain injury with posttraumatic stress disorder symptoms through brain imaging	NEUROSCIENCE LETTERS			English	Article						Combat-related posttraumatic stress; Mild traumatic brain injury; Diffusion tensor imaging; Functional magnetic resonance imaging; Default mode network	DEFAULT MODE NETWORK; WHITE-MATTER TRACTS; ENDURING FREEDOM; PTSD; SEGMENTATION; VALIDATION; INTEGRITY; VETERANS; SYSTEM; CORTEX	Mild traumatic brain injury (mTBI) and posttraumatic stress disorder (PTSD) may share common symptom and neuropsychological profiles in military service members (SMs) following deployment; while a connection between the two conditions is plausible, the relationship between them has been difficult to discern. The intent of this report is to enhance our understanding of the relationship between findings on structural and functional brain imaging and symptoms of PTSD. Within a cohort of SMs who did not meet criteria for PTSD but were willing to complete a comprehensive assessment within 2 months of their return from combat deployment, we conducted a nested case-control analysis comparing those with combat-related mTBI to age/gender-matched controls with diffusion tensor imaging, resting state functional magnetic resonance imaging and a range of psychological measures. We report degraded white matter integrity in those with a history of combat mTBI, and a positive correlation between the white matter microstructure and default mode network (DMN) connectivity. Higher clinician-administered and self-reported subthreshold PTSD symptoms were reported in those with combat mTBI. Our findings offer a potential mechanism through which mTBI may alter brain function, and in turn, Contribute to PTSD symptoms. Published by Elsevier Ireland Ltd.	[Costanzo, Michelle E.; Leaman, Suzanne; Coughlin, Mary; Roy, Michael J.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA; [Costanzo, Michelle E.; Nathan, Dominic E.] Henry M Jackson Fdn, Bethesda, MD USA; [Chou, Yi-Yu; Pham, Dzung L.] Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, Image Proc Core, Bethesda, MD USA; [Keyser, David; Nathan, Dominic E.; Rapp, Paul] Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Traumat Injury Res Program, Bethesda, MD 20814 USA		Roy, MJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	michael.roy@usuhs.edu	Pham, Dzung/AAR-8263-2020		Department of Defense the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300601 8.01 60855510005]	This work was funded by the Department of Defense the Center for Neuroscience and Regenerative Medicine 300601 8.01 60855510005. Any opinions or assertions expressed are solely those of the authors and do not necessarily represent those of Uniformed Services University, the US Army, US Navy, Department of Defense, or the US Government. Thank you to Mariam Masheeb, Julie McEntee, Rochelle Ndiongue, Carol Roos, Patricia Taylor and Joanna Vivalda for their administrative and facilitative contributions.	Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazin PL, 2011, NEUROIMAGE, V58, P458, DOI 10.1016/j.neuroimage.2011.06.020; Bennett CM, 2009, SOC COGN AFFECT NEUR, V4, P417, DOI 10.1093/scan/nsp053; Betthauser LM, 2012, NEUROPSYCHOL REV, V22, P35, DOI 10.1007/s11065-012-9191-4; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Capehart B, 2012, J REHABIL RES DEV, V49, P789, DOI 10.1682/JRRD.2011.10.0185; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI 10.1002/da.22044; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; DVBIC, 2007, MIL AC CONC EV; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Germain A, 2005, J ANXIETY DISORD, V19, P233, DOI 10.1016/j.janxdis.2004.02.001; Geuze E, 2007, PROG BRAIN RES, V167, P293, DOI 10.1016/S0079-6123(07)67026-5; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Landman BA, 2013, NEUROINFORMATICS, V11, P91, DOI 10.1007/s12021-012-9159-9; Lanius RA, 2010, ACTA PSYCHIAT SCAND, V121, P33, DOI 10.1111/j.1600-0447.2009.01391.x; Lawes INC, 2008, NEUROIMAGE, V39, P62, DOI 10.1016/j.neuroimage.2007.06.041; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smid GE, 2009, J CLIN PSYCHIAT, V70, P1572, DOI 10.4088/JCP.08r04484; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Sours C, 2013, BRAIN RES, V1537, P201, DOI 10.1016/j.brainres.2013.08.034; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Yan CG, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00013; Yan XD, 2013, NEUROSCI LETT, V547, P1, DOI 10.1016/j.neulet.2013.04.032; Zhou Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046833	38	29	29	1	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 8	2014	577						11	15		10.1016/j.neulet.2014.05.054			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN0XY	WOS:000340308500003	24907686				2022-02-06	
J	Acker, SN; Ross, JT; Partrick, DA; Nadlonek, NA; Bronsert, M; Bensard, DD				Acker, Shannon N.; Ross, James T.; Partrick, David A.; Nadlonek, Nicole A.; Bronsert, Michael; Bensard, Denis D.			Glasgow motor scale alone is equivalent to Glasgow Coma Scale at identifying children at risk for serious traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; children; Glasgow Coma Scale; Glasgow Coma Scale motor score	SCORE; RELIABILITY	BACKGROUND: Glasgow Coma Scale (GCS) is a validated assessment of neurologic state. Assessment of the eye and verbal components is difficult to reliably obtain in children. We hypothesized that an abnormal Glasgow motor scale (GMS) score alone will reliably identify children with serious traumatic brain injury (TBI). METHODS: We reviewed all children with a diagnosis of TBI from 2002 to 2011 at two urban Level I pediatric trauma centers. We used logistic regression to model GCS, GMS, Glasgow verbal scale (GVS), and Glasgow eye scale (GES) for seven outcomes: need for craniotomy, intracranial pressure monitoring, admission to the intensive care unit, hospital stay of 5 days or longer, discharge to rehabilitation, dependence on caretakers at follow-up, and survival to hospital discharge. We then used three measures of fit analysis to determine which scale offered the best fit for each of the outcomes. RESULTS: A total of 2,341 patients (mean [SD] age, 6.9 [5.8] years; 64.7% male) with TBI and GCS data available were identified. The median GCS on presentation was 15 (interquartile range [IQR], 8-15); the median GMS on presentation was 6 (IQR, 4-6). The median GVS was 5 (IQR, 1-5), and the median GES was 4 (IQR, 2-4). GCS as a whole offered the best fit for the data in predicting need for intensive care unit admission, need for intracranial pressure monitoring, prolonged hospital length of stay, and discharge to rehabilitation but was equivalent to GMS in predicting need for craniotomy, survival to hospital discharge, or dependence on a caretaker at follow-up. Further analysis revealed that GMS was more predictive of these outcomes than GVS + GES, indicating that GMS provides the greatest contribution to the predictive ability of the GCS. CONCLUSION: GMS score alone and GCS do not differ in identifying children with serious TBI. Eliminating the eye and verbal components of GCS does not adversely affect the accuracy of this tool to identify children at risk for serious TBI. Copyright (C) 2014 by Lippincott Williams & Wilkins	[Acker, Shannon N.; Ross, James T.; Partrick, David A.; Nadlonek, Nicole A.; Bensard, Denis D.] Univ Colorado, Sch Med, Dept Pediat Surg, Childrens Hosp Colorado, Aurora, CO 80045 USA; [Bronsert, Michael] Univ Colorado, Sch Med, Dept Surg, Aurora, CO 80045 USA; [Bensard, Denis D.] Denver Hlth & Hosp Author, Dept Surg, Denver, CO USA		Acker, SN (corresponding author), Univ Colorado, Sch Med, Dept Pediat Surg, Childrens Hosp Colorado, 12631 E 17th Ave,C302, Aurora, CO 80045 USA.	shannon.acker@ucdenver.edu					Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Browne G J, 2001, Emerg Med (Fremantle), V13, P418, DOI 10.1046/j.1035-6851.2001.00255.x; Caterino JM, 2012, EMERG MED J, V29, P492, DOI 10.1136/emj.2010.110437; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fortune PM, 2010, PEDIATR CRIT CARE ME, V11, P339, DOI 10.1097/PCC.0b013e3181c014ab; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Kornbluth J, 2011, NEUROCRIT CARE, V14, P134, DOI 10.1007/s12028-010-9409-3; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SIMPSON D, 1982, LANCET, V2, P450; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563, DOI 10.1089/neu.2000.17.563; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007	22	29	29	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	AUG	2014	77	2					304	309		10.1097/TA.0000000000000300			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AN0EJ	WOS:000340255700020	25058258				2022-02-06	
J	Mei, C; Reilly, S; Reddihough, D; Mensah, F; Morgan, A				Mei, Cristina; Reilly, Sheena; Reddihough, Dinah; Mensah, Fiona; Morgan, Angela			Motor speech impairment, activity, and participation in children with cerebral palsy	INTERNATIONAL JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						Cerebral palsy; motor speech disorders; activity and participation	COMPLEX COMMUNICATION NEEDS; TRAUMATIC BRAIN-INJURY; CLASSIFICATION-SYSTEM; DYSARTHRIA; INTELLIGIBILITY; DISABILITIES; INDIVIDUALS; RELIABILITY; PERSPECTIVE; ENVIRONMENT	The present study used a population-based sample of children with cerebral palsy (CP) to estimate the prevalence of motor speech impairment and its association with activity and participation. A sample of 79 Victorian children aged 4 years 11 months to 6 years 5 months was recruited through the Victorian CP Register. The presence of motor speech impairment was recorded using the Viking Speech Scale (VSS). Activity and participation outcomes included speech intelligibility (the National Technical Institute for the Deaf rating scale, NTID), the Functional Communication Classification System (FCCS) and Communication Function Classification System (CFCS). A parent completed rating scale was used to examine the association between motor speech impairment and participation. Ninety per cent (71/79) of children demonstrated a motor speech impairment. Strong associations were found between the VSS and NTID (<.001), CFCS (<.001), and FCCS levels (<.001). VSS levels III-IV were significantly associated with restrictions in home, school, and community-based participation as perceived by parents. Although some diversity in activity and participation outcomes was observed within specific VSS levels, the results of this study suggested that children with mild motor speech impairments are more likely to demonstrate superior activity and participation outcomes compared to children with moderate or severe deficits.	[Mei, Cristina; Reilly, Sheena; Reddihough, Dinah; Mensah, Fiona; Morgan, Angela] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Mei, Cristina; Reilly, Sheena; Reddihough, Dinah; Mensah, Fiona; Morgan, Angela] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Reilly, Sheena; Reddihough, Dinah; Mensah, Fiona; Morgan, Angela] Royal Childrens Hosp, Melbourne, Vic, Australia		Mei, C (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	cristina.mei@mcri.edu.au	Reilly, Sheena/A-7035-2016; Mensah, Fiona K/G-3382-2018; Morgan, Angela/J-5235-2017	Reilly, Sheena/0000-0001-6506-4767; Mensah, Fiona K/0000-0002-6951-9949; Mei, Cristina/0000-0002-6765-8064; Morgan, Angela/0000-0003-1147-7405	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [607448]; Speech Pathology Australia; NHMRCNational Health and Medical Research Council of Australia [607315, 1041892, 436914, 1037449]; Victorian Government	We are grateful to all the families who participated in this study. We kindly thank Sue Reid (Manager of the VCPR) and the following departments at the Royal Children's Hospital, Melbourne, for their generous assistance in recruiting families: Developmental Medicine, Orthopaedics, and the Victorian Paediatric Rehabilitation Service. This project was funded by a National Health and Medical Research Council (NHMRC) Postgraduate Scholarship (#607448) and a Speech Pathology Australia Nadia Verrall Research Grant. The following authors were funded by NHMRC: AM (Career Development Award #607315); SR (Practitioner Fellowship #1041892); and FM (Population Health Capacity Building Grant #436914 and Early Career Fellowship #1037449). Support was also received from the Victorian Government's Operational Infrastructure Support Program.	Andersen G, 2010, PERSPECTIVES AUGMENT, V19, P12, DOI DOI 10.1044/AAC19.1.12; Barty E, 2009, 3 INT CER PALS C SYD; Clarke MT, 2011, RES DEV DISABIL, V32, P774, DOI 10.1016/j.ridd.2010.11.002; Clarke M, 2012, AUGMENT ALTERN COMM, V28, P44, DOI 10.3109/07434618.2011.653605; Cockerill H, 2014, CHILD CARE HLTH DEV, V40, P149, DOI 10.1111/cch.12066; Colver A, 2012, ARCH PHYS MED REHAB, V93, P2154, DOI 10.1016/j.apmr.2012.07.011; Dickinson HO, 2007, LANCET, V369, P2171, DOI 10.1016/S0140-6736(07)61013-7; Eadie TL, 2006, AM J SPEECH-LANG PAT, V15, P307, DOI 10.1044/1058-0360(2006/030); Eliasson AC, 2006, DEV MED CHILD NEUROL, V48, P549, DOI 10.1017/S0012162206001162; FLIPSEN P, 1995, J COMMUN DISORD, V28, P3, DOI 10.1016/0021-9924(94)00015-R; Forsyth R, 2007, DEV MED CHILD NEUROL, V49, P345, DOI 10.1111/j.1469-8749.2007.00345.x; Hammal D, 2004, DEV MED CHILD NEUROL, V46, P292, DOI 10.1017/S0012162204000489; Hartelius L, 2008, FOLIA PHONIATR LOGO, V60, P11, DOI 10.1159/000111799; Hidecker MJC, 2011, DEV MED CHILD NEUROL, V53, P704, DOI 10.1111/j.1469-8749.2011.03996.x; Johnson, 1975, J ACADEMY REHABILITA, V8, P17; Kent RD., 1994, AM J SPEECH-LANG PAT, V3, P81, DOI DOI 10.1044/1058-0360.0302.81; Lawlor K, 2006, DEV NEUROREHABIL, V9, P219; Liegeois F, 2010, BRAIN LANG, V114, P126, DOI 10.1016/j.bandl.2009.12.004; Liegeois FJ, 2013, BRAIN LANG, V127, P388, DOI 10.1016/j.bandl.2013.05.003; McAuliffe MJ, 2010, BRAIN INJURY, V24, P1408, DOI 10.3109/02699052.2010.511590; McFadd E, 2013, DEV NEUROREHABIL, V16, P102, DOI 10.3109/17518423.2012.723762; Mei C., 2012, DEV MED CHILD NEU S5, V54, P84; Michelsen SI, 2013, DEV MED CHILD NEUROL, V55, P684, DOI 10.1111/dmcn.12186; Nordberg A, 2013, ACTA PAEDIATR, V102, P161, DOI 10.1111/apa.12076; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Parkes J, 2010, DEV MED CHILD NEUROL, V52, P1113, DOI 10.1111/j.1469-8749.2010.03765.x; Pennington L, 2001, DEV MED CHILD NEUROL, V43, P83, DOI 10.1017/S0012162201000147; Pennington L, 2013, RES DEV DISABIL, V34, P3202, DOI 10.1016/j.ridd.2013.06.035; Pennington L, 2013, DEV MED CHILD NEUROL, V55, P464, DOI 10.1111/dmcn.12098; Raghavendra P, 2011, DEV NEUROREHABIL, V14, P145, DOI 10.3109/17518423.2011.568994; Reid SM, 2011, RES DEV DISABIL, V32, P2909, DOI 10.1016/j.ridd.2011.05.012; Thirumanickam A, 2011, AUGMENT ALTERN COMM, V27, P195, DOI 10.3109/07434618.2011.610818; Virella D., 2012, 4 INT CER PALS C PIS; World Health Organization, 2007, INT CLASS FUNCT DIS; Yorkston KM, 2001, AM J SPEECH-LANG PAT, V10, P126, DOI 10.1044/1058-0360(2001/013); Zimmerman I. L., 2002, PRESCHOOL LANGUAGE S	36	29	31	0	21	INFORMA HEALTHCARE	NEW YORK	52 VANDERBILT AVE, NEW YORK, NY 10017 USA	1754-9507	1754-9515		INT J SPEECH-LANG PA	Int. J. Speech-Lang. Pathol.	AUG	2014	16	4					427	435		10.3109/17549507.2014.917439			9	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	AM4DT	WOS:000339803700010	24910254				2022-02-06	
J	Ratcliff, JJ; Adeoye, O; Lindsell, CJ; Hart, KW; Pancioli, A; McMullan, JT; Yue, JK; Nishijima, DK; Gordon, WA; Valadka, AB; Okonkwo, DO; Lingsma, HF; Maas, AIR; Manley, GT				Ratcliff, Jonathan J.; Adeoye, Opeolu; Lindsell, Christopher J.; Hart, Kimberly W.; Pancioli, Arthur; McMullan, Jason T.; Yue, John K.; Nishijima, Daniel K.; Gordon, Wayne A.; Valadka, Alex B.; Okonkwo, David O.; Lingsma, Hester F.; Maas, Andrew I. R.; Manley, Geoffrey T.		TRACK-TBI Investigators	ED disposition of the Glasgow Coma Scale 13 to 15 traumatic brain injury patient: analysis of the Transforming Research and Clinical Knowledge in TBI study	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							INTRACRANIAL HEMORRHAGE; ADULT PATIENTS; HEAD-INJURY; CT; SATISFACTION; RELIABILITY; RULE	Objective: Mild traumatic brain injury (mTBI) patients are frequently admitted to high levels of care despite limited evidence suggesting benefit. Such decisions may contribute to the significant cost of caring for mTBI patients. Understanding the factors that drive disposition decision making and how disposition is associated with outcomes is necessary for developing an evidence-base supporting disposition decisions. We evaluated factors associated with emergency department triage of mTBI patients to 1 of 3 levels of care: home, inpatient floor, or intensive care unit (ICU). Methods: This multicenter, prospective, cohort study included patients with isolated head trauma, a cranial computed tomography as part of routine care, and a Glasgow Coma Scale (GCS) score of 13 to 15. Data analysis was performed using multinomial logistic regression. Results: Of the 304 patients included, 167 (55%) were discharged home, 76 (25%) were admitted to the inpatient floor, and 61 (20%) were admitted to the ICU. In the multivariable model, admission to the ICU, compared with floor admission, varied by study site, odds ratio (OR) 0.18 (95% confidence interval [CI], 0.06-0.57); antiplatelet/anticoagulation therapy, OR 7.46 (95% CI, 1.79-31.13); skull fracture, OR 7.60 (95% CI, 2.44-23.73); and lower GCS, OR 2.36 (95% CI, 1.05-5.30). No difference in outcome was observed between the 3 levels of care. Conclusion: Clinical characteristics and local practice patterns contribute to mTBI disposition decisions. Level of care was not associated with outcomes. Intracranial hemorrhage, GCS 13 to 14, skull fracture, and current antiplatelet/anticoagulant therapy influenced disposition decisions. (C) 2014 Elsevier Inc. All rights reserved.	[Ratcliff, Jonathan J.; Adeoye, Opeolu; Lindsell, Christopher J.; Hart, Kimberly W.; Pancioli, Arthur; McMullan, Jason T.] Univ Cincinnati, Cincinnati, OH 45267 USA; [Yue, John K.] Univ Calif San Francisco, San Francisco, CA 94110 USA; [Nishijima, Daniel K.; Manley, Geoffrey T.] Univ Calif Davis, Sacramento, CA 95817 USA; [Gordon, Wayne A.] Mt Sinai Sch Med, New York, NY 10029 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; [Lingsma, Hester F.] Erasmus MC, NL-3000 CA Rotterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp, Univ Antwerp Hosp, B-102650 Edegem, Belgium		Ratcliff, JJ (corresponding author), Univ Cincinnati, 231 Albert Sabin Way,POB 670769, Cincinnati, OH 45267 USA.	ratclijn@uc.edu; adeoyeo@uc.edu; lindsecj@ucmail.uc.edu; hartkb@ucmail.uc.edu; arthur.pancioli@uc.edu; jason.mcmullan@uc.edu; yuej@neurosurg.ucsf.edu; daniel.nishijima@ucdmc.ucdavis.edu; wayne.gordon@mssm.edu; avaladka@gmail.com; okonkwodo@upmc.edu; h.lingsma@erasmusmc.nl; andrew.maas@uza.be; manleyg@neurosurg.ucsf.edu	McMullan, Jason/ABB-9691-2020; Yue, John K/P-1348-2015	McMullan, Jason/0000-0002-7656-7447; Yue, John K/0000-0001-9694-7722	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, T32NS047996] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR001425] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2 NS069409, T32 NS047996] Funding Source: Medline		AAAM, 2008, ABBR INJ SCAL 2005 R; af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M., 2010, TRAUMATIC BRAIN US E; Franschman G, 2012, J NEUROTRAUM, V29, P128, DOI 10.1089/neu.2011.2044; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Homnick A, 2012, INJURY, V43, P2122, DOI 10.1016/j.injury.2012.04.013; Jagoda AS, 2010, PSYCHIAT CLIN N AM, V33, P797, DOI 10.1016/j.psc.2010.09.004; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Nishijima DK, 2013, ANN EMERG MED, V61, P509, DOI 10.1016/j.annemergmed.2012.08.024; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; THURMAN D, 2001, HEAD TRAUMA BASIC PR; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	31	29	29	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	AUG	2014	32	8					844	850		10.1016/j.ajem.2014.04.003			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	AR1AK	WOS:000343311000004	24857248	Green Accepted			2022-02-06	
J	Sun, TY; Chen, XR; Liu, ZL; Zhao, LL; Jiang, YX; Qu, GQ; Wang, RS; Huang, SZ; Liu, L				Sun, Ting-yi; Chen, Xiao-rui; Liu, Zi-long; Zhao, Li-li; Jiang, Yong-xiang; Qu, Guo-qiang; Wang, Rong-shuai; Huang, Si-zhe; Liu, Liang			Expression profiling of MicroRNAs in hippocampus of rats following traumatic brain injury	JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES			English	Article						forensic clinical medicine; traumatic brain injury; microRNA; microarray technique; hippocampus	CELL PROLIFERATION; MIR-222; MIR-142-3P; CARCINOMA; GENES	The changes of microRNA expression in rat hippocampus after traumatic brain injury (TBI) were explored. Adult SD rats received a single controlled cortical impact injury, and the ipsilateral hippocampus was harvested for the subsequent microarray assay at three time points after TBI: 1st day, 3rd day and 5th day, respectively. We characterized the microRNA expression profile in rat hippocampus using the microRNA microarray analysis, and further verified microarray results of miR-142-3p and miR-221 using quantitative real-time PCR. Totally 205 microRNAs were identified and up-/down-regulated more than 1.5 times. There were significant changes in 17 microRNAs at all three time points post-TBI. The quantitative real-time PCR results of miR-142-3p and miR-221 indicated good consistency with the results of the microarray method. MicroRNAs altered at different time points post-TBI. MiR-142-3p and miR-221 may be used as potentially biological markers for TBI assessment in forensic practice.	[Sun, Ting-yi; Chen, Xiao-rui; Liu, Zi-long; Zhao, Li-li; Qu, Guo-qiang; Wang, Rong-shuai; Huang, Si-zhe; Liu, Liang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430030, Peoples R China; [Jiang, Yong-xiang] Xiling Dist Publ Secur Bur, Forens Expertise Ctr, Yichang 443001, Peoples R China		Liu, ZL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430030, Peoples R China.	sty-j211@sohu.com; chenxiaorui@mails.tjmu.edu.cn; lzlongfy@gmail.com; liuliang@mails.tjmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81102304]; Doctoral Fund of Ministry of Education of ChinaMinistry of Education, China [20090142120054]; Foundation of Huazhong University of Science and Technology [20100573]	This project was supported by grants from the National Natural Science Foundation of China (No. 81102304), Doctoral Fund of Ministry of Education of China (No. 20090142120054), and Foundation of Huazhong University of Science and Technology (No. 20100573).	Almog N, 2013, TRANSCR-AUSTIN, V4, P177, DOI 10.4161/trns.25558; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Beezhold K, 2011, TOXICOL SCI, V123, P411, DOI 10.1093/toxsci/kfr188; Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Castagnino P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056140; Chen Y, 2010, MOL CELL BIOL, V30, P3902, DOI 10.1128/MCB.01237-09; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Huang B, 2009, EMBO REP, V10, P180, DOI 10.1038/embor.2008.224; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Kaduthanam S, 2013, LUNG CANCER, V80, P223, DOI 10.1016/j.lungcan.2013.01.013; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Krichevsky Anna M, 2007, ScientificWorldJournal, V7, P155; le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu XJ, 2009, CIRC RES, V104, P476, DOI 10.1161/CIRCRESAHA.108.185363; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Smith B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011109; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Wang F, 2012, MOL BIOL REP, V39, P2713, DOI 10.1007/s11033-011-1026-5; Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840	29	29	29	2	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1672-0733	1993-1352		J HUAZHONG U SCI-MED	J. Huazhong Univ. Sci. Tech.-Med.	AUG	2014	34	4					548	553		10.1007/s11596-014-1313-1			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	AN5DT	WOS:000340610700013	25135725				2022-02-06	
J	Umschweif, G; Shabashov, D; Alexandrovich, AG; Trembovler, V; Horowitz, M; Shohami, E				Umschweif, Gali; Shabashov, Dalia; Alexandrovich, Alexander G.; Trembovler, Victoria; Horowitz, Michal; Shohami, Esther			Neuroprotection after traumatic brain injury in heat-acclimated mice involves induced neurogenesis and activation of angiotensin receptor type 2 signaling	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						angiotensin receptor type 2; heat acclimation; neurogenesis; neuroprotection; PD123319; traumatic brain injury	NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; FUNCTIONAL RECOVERY; AT(2) RECEPTOR; STROKE; MECHANISMS; APOPTOSIS; SEVERITY; ISCHEMIA; CELLS	Long-term exposure of mice to mild heat (34 degrees C +/- 1 degrees C) confers neuroprotection against traumatic brain injury (TBI); however, the underling mechanisms are not fully understood. Heat acclimation (HA) increases hypothalamic angiotensin II receptor type 2 (AT(2)) expression and hypothalamic neurogenesis. Accumulating data suggest that activation of the brain AT(2) receptor confers protection against several types of brain pathologies, including ischemia, a hallmark of the secondary injury occurring following TBI. As AT(2) activates the same pro-survival pathways involved in HA-mediated neuroprotection (e.g., Akt phosphorylation, hypoxia-inducible factor 1 alpha (HIF-1 alpha), and brain-derived neurotrophic factor (BDNF)), we examined the role of AT(2) in HA-mediated neuroprotection after TBI. Using an AT(2)-specific antagonist PD123319, we found that the improvements in motor and cognitive recovery as well as reduced lesion volume and neurogenesis seen in HA mice were all diminished by AT(2) inhibition, whereas no significant alternations were observed in control mice. We also found that nerve growth factor/tropomyosin-related kinase receptor A (TrkA), BDNF/TrkB, and HIF-1a pathways are upregulated by HA and inhibited on PD123319 administration, suggesting that these pathways play a role in AT(2) signaling in HA mice. In conclusion, AT(2) is involved in HA-mediated neuroprotection, and AT(2) activation may be protective and should be considered a novel drug target in the treatment of TBI patients.	[Umschweif, Gali; Shabashov, Dalia; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Sch Pharm, Inst Drug Res, Dept Pharmacol, Jerusalem, Israel; [Umschweif, Gali; Horowitz, Michal] Hebrew Univ Jerusalem, Lab Environm Physiol, IL-91120 Jerusalem, Israel		Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Lab Environm Physiol, POB 12272, IL-91120 Jerusalem, Israel.	m.horowitz@mail.huji.ac.il; esty.shohami@mail.huji.ac.il			Brettler Foundation at the School of Pharmacy; Dr Miriam and Sheldon G Adelson Medical Research Foundation (AMRF)	This study was partially supported by grants from Brettler Foundation at the School of Pharmacy, and by the Dr Miriam and Sheldon G Adelson Medical Research Foundation (AMRF).	Chao J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063488; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Cunningham LA, 2012, BEHAV BRAIN RES, V227, P410, DOI 10.1016/j.bbr.2011.08.002; Day RT, 2010, CELL SIGNAL, V22, P1849, DOI 10.1016/j.cellsig.2010.07.012; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dumont EC, 1999, NEUROSCIENCE, V93, P877, DOI 10.1016/S0306-4522(99)00206-7; Ferrer I, 2001, ACTA NEUROPATHOL, V101, P229; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Guimond MO, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/351758; Guimond Marie-Odile, 2012, Front Endocrinol (Lausanne), V3, P164, DOI 10.3389/fendo.2012.00164; Hafko R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069234; Hagg T, 2009, NEUROSCIENTIST, V15, P20, DOI 10.1177/1073858408324789; Horowitz M, 2014, COMPR PHYSIOL, V4, P199, DOI 10.1002/cphy.c130025; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kan I, 2011, STEM CELL REV REP, V7, P404, DOI 10.1007/s12015-010-9190-x; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; Lu B, 2013, NAT REV NEUROSCI, V14, P401, DOI 10.1038/nrn3505; Lu J, 2013, P NATL ACAD SCI USA, V110, P10747, DOI 10.1073/pnas.1308950110; Macova M, 2009, BRAIN RES, V1250, P130, DOI 10.1016/j.brainres.2008.11.006; Matsuzaki K, 2009, PFLUG ARCH EUR J PHY, V458, P661, DOI 10.1007/s00424-009-0654-2; McCarthy CA, 2012, HYPERTENSION, V60, P1531, DOI 10.1161/HYPERTENSIONAHA.112.199646; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mogi M, 2013, GERIATR GERONTOL INT, V13, P13, DOI 10.1111/j.1447-0594.2012.00900.x; Muller HD, 2008, STROKE, V39, P1012, DOI 10.1161/STROKEAHA.107.495069; Namsolleck P, 2013, NEUROBIOL DIS, V51, P177, DOI 10.1016/j.nbd.2012.11.008; Naruse M, 2002, HYPERTENSION, V40, P28, DOI 10.1161/01.HYP.0000022606.52221.2F; Reinecke K, 2003, FASEB J, V17, P2094, DOI 10.1096/fj.02-1193fje; Saavedra JM, 2006, CELL MOL NEUROBIOL, V26, P1099, DOI 10.1007/s10571-006-9009-0; Schwimmer H, 2004, MOL BRAIN RES, V130, P95, DOI 10.1016/j.molbrainres.2004.07.011; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tota S, 2012, PSYCHOPHARMACOLOGY, V222, P185, DOI 10.1007/s00213-012-2639-7; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Umschweif G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076129; Umschweif G, 2013, J CEREBR BLOOD F MET, V33, P524, DOI 10.1038/jcbfm.2012.193; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; VARON S, 1994, J NEUROTRAUM, V11, P473, DOI 10.1089/neu.1994.11.473; Wolf G, 2004, AM J NEPHROL, V24, P415, DOI 10.1159/000080086; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang P, 2012, NEUROSCIENCE, V201, P297, DOI 10.1016/j.neuroscience.2011.11.005; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	44	29	30	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2014	34	8					1381	1390		10.1038/jcbfm.2014.93			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AM4ZG	WOS:000339864100015	24849663	Bronze, Green Published			2022-02-06	
J	Haegerich, TM; Dahlberg, LL; Simon, TR; Baldwin, GT; Sleet, DA; Greenspan, AI; Degutis, LC				Haegerich, Tamara M.; Dahlberg, Linda L.; Simon, Thomas R.; Baldwin, Grant T.; Sleet, David A.; Greenspan, Arlene I.; Degutis, Linda C.			Prevention of injury and violence in the USA	LANCET			English	Article							ADVERSE CHILDHOOD EXPERIENCES; TRAUMATIC BRAIN-INJURY; PEDIATRIC PRIMARY-CARE; UNITED-STATES; PUBLIC-HEALTH; OLDER-ADULTS; EMERGENCY-DEPARTMENT; INTERVENTIONS; RISK; DEATHS	In the first three decades of life, more individuals in the USA die from injuries and violence than from any other cause. Millions more people survive and are left with physical, emotional, and financial problems. Injuries and violence are not accidents; they are preventable. Prevention has a strong scientific foundation, yet efforts are not fully implemented or integrated into clinical and community settings. In this Series paper, we review the burden of injuries and violence in the USA, note effective interventions, and discuss methods to bring interventions into practice. Alliances between the public health community and medical care organisations, health-care providers, states, and communities can reduce injuries and violence. We encourage partnerships between medical and public health communities to consistently frame injuries and violence as preventable, identify evidence-based interventions, provide scientific information to decision makers, and strengthen the capacity of an integrated health system to prevent injuries and violence.	[Haegerich, Tamara M.; Dahlberg, Linda L.; Simon, Thomas R.; Baldwin, Grant T.; Sleet, David A.; Greenspan, Arlene I.; Degutis, Linda C.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; [Haegerich, Tamara M.; Dahlberg, Linda L.; Simon, Thomas R.; Baldwin, Grant T.; Sleet, David A.; Greenspan, Arlene I.; Degutis, Linda C.] US Dept HHS, Atlanta, GA USA		Haegerich, TM (corresponding author), Ctr Dis Control & Prevent, Div Unint Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA.	thaegerich@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline		ACIP, 2012, SOC DET INJ; Adams WG, 2003, PEDIATRICS, V111, P626, DOI 10.1542/peds.111.3.626; Bilukha O, 2005, AM J PREV MED, V28, P11, DOI 10.1016/j.amepre.2004.10.004; Black M C., 2011, NATL INTIMATE PARTNE; Brownson RC, 2012, DISSEMINATION IMPLEM, P2022; Carande-Kulis VG, 2010, INJURY PREV, V16, pA249, DOI 10.1136/ip.2010.029215.886; Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Chorpita Bruce F, 2005, Ment Health Serv Res, V7, P5, DOI 10.1007/s11020-005-1962-6; Cook PJ, 2011, ECON J, V121, P445, DOI 10.1111/j.1468-0297.2011.02419.x; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Crosby Alex E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; Cubbin C, 2002, ANNU REV PUBL HEALTH, V23, P349, DOI 10.1146/annurev.publhealth.23.100901.140548; D'Onofrio G, 2008, ANN EMERG MED, V51, P742, DOI 10.1016/j.annemergmed.2007.11.028; D'Onofrio G, 2010, ACAD EMERG MED, V17, P903, DOI 10.1111/j.1553-2712.2010.00824.x; Dahlberg L. L., 2006, PREVENTING VIOLENCE, P97, DOI DOI 10.1037/11385-004; Danese A, 2009, ARCH PEDIAT ADOL MED, V163, P1135, DOI 10.1001/archpediatrics.2009.214; Dellinger AM, 2009, FAM COMMUNITY HEALTH, V32, P115, DOI 10.1097/FCH.0b013e31819946e7; Dinh-Zarr TB, 2001, AM J PREV MED, V21, P48, DOI 10.1016/S0749-3797(01)00378-6; Doll L.S., 2007, HDB INJURY VIOLENCE; Dubowitz H, 2009, PEDIATRICS, V123, P858, DOI 10.1542/peds.2008-1376; Fang XM, 2012, CHILD ABUSE NEGLECT, V36, P156, DOI 10.1016/j.chiabu.2011.10.006; Faul M, 2010, TRAUMATIC BRAIN INJU; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Finkelhor D, 2005, CHILD MALTREATMENT, V10, P5, DOI 10.1177/1077559504271287; Finkelhor D, 2009, PEDIATRICS, V124, P1411, DOI 10.1542/peds.2009-0467; Florence C, 2014, INJURY PREV, V20, P108, DOI 10.1136/injuryprev-2012-040622; Florence C, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3313; Frieden TR, 2010, AM J PUBLIC HEALTH, V100, P590, DOI 10.2105/AJPH.2009.185652; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gielen AC, 2002, ARCH PEDIAT ADOL MED, V156, P33, DOI 10.1001/archpedi.156.1.33; Gilchrist Julie, 2012, Morbidity and Mortality Weekly Report, V61, P270; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Girasek DC, 2001, ACCIDENT ANAL PREV, V33, P455, DOI 10.1016/S0001-4575(00)00059-2; Haegerich TM, 2011, AM J LIFESTYLE MED, V5, P392, DOI 10.1177/1559827611409127; Hahn RA, 2005, AM J PREV MED, V28, P72, DOI 10.1016/j.amepre.2004.10.007; Hahn R, 2007, AM J PREV MED, V33, pS114, DOI 10.1016/j.amepre.2007.04.012; Hall JE, 2012, AM J PREV MED, V43, pS60, DOI 10.1016/j.amepre.2012.04.019; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Health Resources & Services Administration, MAT INF EARL CHILDH; Ikeda RM, 2010, AM J LIFESTYLE MED, V4, P5, DOI 10.1177/1559827609348459; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P619; Lee S, 2012, 12041201 WASH STAT I; Lyons RA, 2010, INT J INJ CONTROL SA, V17, P145, DOI 10.1080/17457300903453104; MacDonald J, 2010, INJURY PREV, V16, P327, DOI 10.1136/ip.2009.024943; McClure R, 2004, SCI BASIS INJURY PRE; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller TR, 2006, INJURY PREVENTION CH; *NAT CTR INJ PREV, 2009, CDC INJ RES AG 2009; Neumann T, 2006, J TRAUMA, V61, P805, DOI 10.1097/01.ta.0000196399.29893.52; Owen N, 2012, DISSEMINATION IMPLEM, P114, DOI DOI 10.1093/ACPROF.OSO/9780199751877.003.0006; Owusu-Edusei K, 2013, SEX TRANSM DIS, V40, P197, DOI 10.1097/OLQ.0b013e318285c6d2; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Pollack KM, 2012, EPIDEMIOL REV, V34, P73, DOI 10.1093/epirev/mxr019; Rubenstein LZ, 2002, CLIN GERIATR MED, V18, P141, DOI 10.1016/S0749-0690(02)00002-2; Sachs-Ericsson N, 2009, J TRAUMA DISSOCIATIO, V10, P170, DOI 10.1080/15299730802624585; SCHEIER MF, 1992, COGNITIVE THER RES, V16, P201, DOI 10.1007/BF01173489; Scutchfield FD, 2012, AM J PREV MED, V42, pS1, DOI 10.1016/j.amepre.2012.01.027; Shakur H, 2012, LANCET, V380, P2062, DOI 10.1016/S0140-6736(12)62037-6; Shiffman J, 2007, LANCET, V370, P1370, DOI 10.1016/S0140-6736(07)61579-7; Shonkoff JP, 2012, PEDIATRICS, V129, pE232, DOI 10.1542/peds.2011-2663; Shults RA, 2001, AM J PREV MED, V21, P66, DOI 10.1016/S0749-3797(01)00381-6; Sleet DA, 2012, J SAFETY RES, V43, P233, DOI 10.1016/j.jsr.2012.09.002; Sleet David A, 2011, MMWR Suppl, V60, P78; Sleet DA, 2009, FAM COMMUNITY HEALTH, V32, P88, DOI 10.1097/01.FCH.0000347985.67681.9d; Sleet David A., 2009, P439, DOI 10.1007/978-3-7643-9923-8_27; Sogolow E. D., 2007, Handbook of injury and violence prevention, P493, DOI 10.1007/978-0-387-29457-5_28; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; Stevens JA, 2013, HEALTH PROMOT PRACT, V14, P706, DOI 10.1177/1524839912463576; TENO J, 1990, J AM GERIATR SOC, V38, P1321, DOI 10.1111/j.1532-5415.1990.tb03455.x; The American Geriatrics Society and British Geriatric Society, 2010, AGS ABS CLIN PRACT G; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; TORELL U, 1995, J SAFETY RES, V26, P63, DOI 10.1016/0022-4375(95)00007-D; US Department of Health and Human Services Administration on Children and Families, 2011, DROP; Wandersman A, 2008, AM J COMMUN PSYCHOL, V41, P171, DOI 10.1007/s10464-008-9174-z; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635; Zaza S, 2001, AM J PREV MED, V21, P31, DOI 10.1016/S0749-3797(01)00377-4; ZAZA S, 2005, GUIDE COMMUNITY PREV	81	29	29	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 5	2014	384	9937					64	74		10.1016/S0140-6736(14)60074-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AL1XL	WOS:000338919600027	24996591	Green Accepted			2022-02-06	
J	Beltran, E; Platt, SR; McConnell, JF; Dennis, R; Keys, DA; De Risio, L				Beltran, E.; Platt, S. R.; McConnell, J. F.; Dennis, R.; Keys, D. A.; De Risio, L.			Prognostic Value of Early Magnetic Resonance Imaging in Dogs after Traumatic Brain Injury: 50 Cases	JOURNAL OF VETERINARY INTERNAL MEDICINE			English	Article						Dogs; MRI; Prognostic; Traumatic brain injury	LATE POSTTRAUMATIC SEIZURES; GLASGOW COMA SCALE; SEVERE HEAD-INJURY; RISK-FACTORS; EPILEPSY; STEM; MRI; LEVETIRACETAM; PREVALENCE; PREDICTION	Background: The prognostic value of early magnetic resonance imaging (MRI) in dogs after traumatic brain injury (TBI) remains unclear. Objectives: Determine whether MRI findings are associated with prognosis after TBI in dogs. Animals: Fifty client-owned dogs. Methods: Retrospective study of dogs with TBI that underwent 1.5T MRI within 14 days after head trauma. MRI evaluators were blinded to the clinical presentation, and all images were scored based on an MRI grading system (Grade I [normal brain parenchyma] to Grade VI [bilateral lesions affecting the brainstem with or without any lesions of lesser grade]). Skull fractures, percentage of intraparenchymal lesions, degree of midline shift, and type of brain herniation were evaluated. MGCS was assessed at presentation. The presence of seizures was recorded. Outcome was assessed at 48 h (alive or dead) and at 3, 6, 12, and 24 months after TBI. Results: Sixty-six percent of the dogs had abnormal MRI findings. MRI grade was negatively correlated (P <.001) with MGCS. A significant negative correlation of MRI grade, degree of midline shift, and percentage of intraparenchymal lesions with follow-up scores was identified. The MGCS was lower in dogs with brain herniation (P =.0191). Follow-up scores were significantly lower in dogs that had brain herniation or skull fractures. The possibility of having seizures was associated with higher percentage of intraparenchymal lesions (P = 0.0054) and 10% developed PTE. Conclusions and Clinical Importance: Significant associations exist between MRI findings and prognosis in dogs with TBI. MRI can help to predict prognosis in dogs with TBI.	[Beltran, E.; Dennis, R.; De Risio, L.] Anim Hlth Trust, Ctr Small Anim Studies, Newmarket CB8 7UU, Suffolk, England; [Platt, S. R.] Univ Georgia, Coll Vet Med, Athens, GA 30602 USA; [McConnell, J. F.] Univ Liverpool, Sch Vet Sci, Liverpool L69 3BX, Merseyside, England		Beltran, E (corresponding author), Anim Hlth Trust, Ctr Small Anim Studies, Lanwades Pk, Newmarket CB8 7UU, Suffolk, England.	elsa.beltran@aht.org.uk	De Risio, Luisa/ABB-3561-2020	De Risio, Luisa/0000-0001-9005-4165; BELTRAN, ELSA/0000-0002-0807-7817; mcconnell, james fraser/0000-0001-7097-786X; Platt, Simon/0000-0002-7818-1011			Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; BYRNE JV, 1989, NEURORADIOLOGY, V31, P129, DOI 10.1007/BF00698839; Chew BG, 2012, J NEUROSURG, V117, P722, DOI 10.3171/2012.6.JNS111736; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Friedenberg SG, 2012, JAVMA-J AM VET MED A, V241, P1479, DOI 10.2460/javma.241.11.1479; Hicks JA, 2013, JAVMA-J AM VET MED A, V243, P1310, DOI 10.2460/javma.243.9.1310; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Kearsley-Fleet L, 2013, VET REC, V172, DOI 10.1136/vr.101133; Klein P, 2012, ARCH NEUROL-CHICAGO, V69, P1290, DOI 10.1001/archneurol.2012.445; KORNEGAY JN, 1983, J AM VET MED ASSOC, V182, P1111; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; Lee SY, 2012, J CLIN NEUROL, V8, P224, DOI 10.3988/jcn.2012.8.3.224; LOSCHER W, 1985, ARZNEIMITTEL-FORSCH, V35, P82; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pearl PL, 2013, EPILEPSIA, V54, pe135, DOI 10.1111/epi.12326; Platt SR, 2001, J VET INTERN MED, V15, P581, DOI 10.1892/0891-6640(2001)015&lt;0581:TPVOTM&gt;2.3.CO;2; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; SCHWARTZ-PORSCHE D., 1986, P ACVIM, P161; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shores A., 1983, CURRENT VET THERAPY, P847; Simpson SA, 2009, J VET EMERG CRIT CAR, V19, P588, DOI 10.1111/j.1476-4431.2009.00468.x; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Steinmetz S, 2013, EPILEPSIA, V54, P580, DOI 10.1111/epi.12071; Tanoue K, 2012, ACTA PAEDIATR, V101, P614, DOI 10.1111/j.1651-2227.2012.02635.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wendt-Hornickle EL, 2011, JAVMA-J AM VET MED A, V239, P194, DOI 10.2460/javma.239.2.194; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	39	29	31	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0891-6640	1939-1676		J VET INTERN MED	J. Vet. Intern. Med.	JUL-AUG	2014	28	4					1256	1262		10.1111/jvim.12368			7	Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Veterinary Sciences	AN4YT	WOS:000340596600015	24814522	Green Published, Bronze, Green Accepted			2022-02-06	
J	Brooks, BL; Mrazik, M; Barlow, KM; McKay, CD; Meeuwisse, WH; Emery, CA				Brooks, Brian L.; Mrazik, Martin; Barlow, Karen M.; McKay, Carly D.; Meeuwisse, Willem H.; Emery, Carolyn A.			Absence of Differences Between Male and Female Adolescents With Prior Sport Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; cumulative; lingering; mild traumatic brain injury; pediatric; gender	TRAUMATIC BRAIN-INJURY; BASE-LINE; SEX-DIFFERENCES; NEUROCOGNITIVE PERFORMANCE; HIGH-SCHOOL; NEUROPSYCHOLOGICAL FUNCTION; SOCCER PLAYERS; SYMPTOMS; OUTCOMES; HISTORY	Objective: Sex differences following concussion are poorly understood. The purpose of this study was to examine whether male and female adolescent athletes with prior concussions differ regarding neurocognitive function and symptom reporting. Setting: Community-based hockey teams. Participants: Participants included 615 elite hockey players 13 to 17 years old (mean = 15.5, 95% confidence interval [CI] = 15.4-15.6). There were 517 males and 98 females. Players with English as a second language, attention or learning problems, a concussion within 6 months of baseline, or suspected invalid test profiles were excluded from these analyses. Design: Cross-sectional. Main Measure: Domain scores and symptom ratings from the ImPACT computerized battery. Results: There were no significant neurocognitive differences between males and females with (F-5,F-227 = 1.40, P = .227) or without (F-5,F-376 = 1.33, P = 0.252) a prior history of concussion. Male and female athletes with a history of concussion reported higher raw symptom scores than those without a prior concussion; however, sex differences disappear when symptom scores are adjusted for known sex differences in controls (total score, F-2,F-230 = 0.77, P = .46; Cohen d = 0.01 or domain scores (F-4,F-227 = 1.52, P = .197; Cohen d = 0.07-0.18). Conclusions: Although those with prior concussions report more symptoms (but do not differ on neurocognition), this study does not support sex differences with cognition or symptoms in adolescent athletes with prior concussions.	[Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Neurosci Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Brain Injury Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Rehabil Program, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.] Univ Calgary, Fac Med, Dept Paediat, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Calgary, AB, Canada; [Mrazik, Martin] Univ Alberta, Dept Educ Psychol, Edmonton, AB T6G 2E1, Canada; [Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Fac Med,Neurosci Program, Calgary, AB, Canada; [Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Fac Med,Brain Injury Program, Calgary, AB, Canada; [Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Fac Med,Rehabil Program, Calgary, AB, Canada; [McKay, Carly D.; Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Emery, Carolyn A.] Univ Calgary, Alberta Childrens Hosp, Res Inst Child & Maternal Hlth, Sport Injury Prevent Res Ctr,Fac Kinesiol, Calgary, AB, Canada		Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Barlow, Karen/C-1323-2014; Meijer, Anna/K-5118-2016; Emery, Carolyn/AAI-2761-2020; Barlow, Karen/I-6492-2019	Barlow, Karen/0000-0003-2612-8507; Barlow, Karen/0000-0003-2612-8507; McKay, Carly/0000-0001-7664-3211	Psychological Assessment Resources, Inc; McCarthy Tetrault award; International Olympic Committee; Alberta Innovates Health Solutions (AIHS); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute for Child & Maternal Health (ACHRI)	None of the authors have a financial interest in the ImPACT battery. B.L.B. receives funding from a test publisher (Psychological Assessment Resources, Inc), book royalties from Oxford University Press, and in-kind test credits for research from another computerized test publisher (CNS Vital Signs). In-kind support from ImPACT was provided to M. M. for the assessments conducted in Edmonton.; Computerized cognitive testing in this study was funded in Calgary by the McCarthy Tetrault award (administered by the Alberta Children's Hospital Research Institute for Child & Maternal Health on behalf of the Alberta Children's Hospital Foundation) to B.L.B. for a computerized neurocognitive laboratory (computers, test credits) and in Edmonton by funding provided to M. M. and in-kind support by ImPACT to M. M. The Sport Injury Prevention Research Centre is one of the International Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee. W. H. M. and C. A. E. acknowledge funding from Alberta Innovates Health Solutions (AIHS), Canadian Institutes of Health Research (CIHR), and the Alberta Children's Hospital Research Institute for Child & Maternal Health (ACHRI; Professorship in pediatric rehabilitation for C.A.E.). None of the funding sources were involved in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.	[Anonymous], 1999, JAMA, V282, P974; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Blake T.A., 2012, CLIN J SPORT MED, V22, P307; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dougan BK, J INT NEURO IN PRESS; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Elbin RJ, 2012, BRAIN INJURY, V26, P1217, DOI 10.3109/02699052.2012.672788; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McKay C, 2012, CLIN J SPORT MED, V22, P307; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schneider K.J., 2012, CLIN J SPORT MED, V22, P307; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	43	29	29	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2014	29	3					257	264		10.1097/HTR.0000000000000016			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AG9SE	WOS:000335759100014	24413074	Green Submitted			2022-02-06	
J	Almeida-Suhett, CP; Li, Z; Marini, AM; Braga, MFM; Eiden, LE				Almeida-Suhett, Camila P.; Li, Zheng; Marini, Ann M.; Braga, Maria F. M.; Eiden, Lee E.			Temporal Course of Changes in Gene Expression Suggests a Cytokine-Related Mechanism for Long-Term Hippocampal Alteration after Controlled Cortical Impact	JOURNAL OF NEUROTRAUMA			English	Article						Ccl2; Lcn2; mild traumatic brain injury (mTBI); controlled cortical injury (CCI); Ccl7	TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; MOUSE MODEL; HEAD-INJURY; CHEMOKINES; MODULATION; INHIBITOR; RECEPTORS; INDUCTION; IMMUNE	Mild traumatic brain injury (mTBI) often has long-term effects on cognitive function and social behavior. Altered gene expression may be predictive of long-term psychological effects of mTBI, even when acute clinical effects are minimal or transient. Controlled cortical impact (CCI), which causes concussive, but nonpenetrant, trauma to underlying (non-cortical) brain, resulting in persistent changes in hippocampal synaptic function, was used as a model of mTBI. The hippocampal transcriptomes of sham-operated or injured male rats at 1, 7, and 30 days postinjury were examined using microarrays comprising a comprehensive set of expressed genes, subsequently confirmed by quantitative reverse-transcriptase polymerase chain reaction. Transcripts encoding the chemokines, chemokine (C-C motif) ligand (Ccl)2 and Ccl7, inflammatory mediators lipocalin-2 (Lcn2) and tissue inhibitor of metalloproteinase 1 (Timp1), immunocyte activators C-C chemokine receptor type 5 (Ccr5) and Fc fragment of IgG, low affinity IIb, receptor (CD32) (Fcgr2b), the major histocompatibility complex II immune response-related genes, Cd74 and RT1 class II, locus Da (RT1-Da), the complement component, C3, and the transcription factor, Kruppel-like factor 4 (Klf4), were identified as early (Ccl2, Ccl7, Lcn2, and Timp1), intermediate (Ccr5, Fcgr2b, Cd74, RT1-Da, and C3), and late (Klf4) markers for bilateral hippocampal response to CCI. Ccl2 and Ccl7 transcripts were up-regulated within 24 h after CCI, and their elevation subsided within 1 week of injury. Other transcriptional changes occurred later and were more stable, some persisting for at least 1 month, suggesting that short-term inflammatory responses trigger longer-term alteration in the expression of genes previously associated with injury, aging, and neuronal function in the brain. These transcriptional responses to mTBI may underlie long-term changes in excitatory and inhibitory neuronal imbalance in hippocampus, leading to long-term behavioral consequences of mTBI.	[Almeida-Suhett, Camila P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Program Neurosci, Bethesda, MD 20814 USA; [Li, Zheng] Natl Inst Mental Hlth, Unit Synapse Dev & Plast, Bethesda, MD 20892 USA; [Marini, Ann M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Physiol, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Genet, Bethesda, MD 20814 USA; [Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Psychiat, Bethesda, MD 20814 USA; [Eiden, Lee E.] Natl Inst Mental Hlth, Sect Mol Neurosci, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA		Eiden, LE (corresponding author), Natl Inst Mental Hlth, Sect Mol Neurosci, Lab Cellular & Mol Regulat, 9000 Rockville Pike Bldg 49,Room 5A-38, Bethesda, MD 20892 USA.	eidenl@mail.nih.gov	Li, Zheng/I-8016-2014; Almeida-Suhett, Camila/I-8045-2016	Li, Zheng/0000-0002-2978-2531; Eiden, Lee/0000-0001-7524-944X; Almeida-Suhett, Camila/0000-0002-7588-9487	NIMH Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); Department of DefenseUnited States Department of Defense; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002881, ZIAMH002386] Funding Source: NIH RePORTER	The authors thank Charisse Winston (NIMH-IRP Technical IRTA) and Dr. Babru Samal (NIMH Bioinformatics Core Specialist), for contributions to early phases of this work, and Dr. Abdel Eklahloun (Core Manager, NIHGRI-NIMH-NINCDS Microarray Core Facility) for invaluable assistance and consultation throughout the duration of these experiments. Work reported here was funded, in part, by the NIMH Intramural Research Program and by a grant from the Department of Defense administered through the Center for Neuroscience and Regenerative Medicine. The contributions of Djida Ait-Ali, who participated in the project as a Henry M. Jackson Foundation Research Fellow, are acknowledged here in lieu of co-authorship for which her written permission could not be obtained.	Almeida C. P., 2011, SOC NEUR 2011 2011 N; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bugno M, 1999, FEBS LETT, V448, P9, DOI 10.1016/S0014-5793(99)00323-3; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Figueiredo TH, 2011, BRIT J PHARMACOL, V164, P1495, DOI 10.1111/j.1476-5381.2011.01427.x; Figueiredo TH, 2011, J PHARMACOL EXP THER, V336, P303, DOI 10.1124/jpet.110.171835; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gardner J, 2003, J NEUROSCI RES, V74, P801, DOI 10.1002/jnr.10835; Griffin WST, 2013, NEW ENGL J MED, V368, P770, DOI 10.1056/NEJMcibr1214546; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HAYASHI M, 1995, J NEUROIMMUNOL, V60, P143, DOI 10.1016/0165-5728(95)00064-9; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Khandaker GM, 2011, JAMA-J AM MED ASSOC, V305, P673, DOI 10.1001/jama.2011.142; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Naude PJW, 2012, FASEB J, V26, P2811, DOI 10.1096/fj.11-202457; Renner NA, 2011, J NEUROVIROL, V17, P146, DOI 10.1007/s13365-010-0017-y; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Schmitz C, 2000, J CHEM NEUROANAT, V20, P93, DOI 10.1016/S0891-0618(00)00066-1; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson WL, 2009, BRAIN RES, V1287, P47, DOI 10.1016/j.brainres.2009.06.081; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; VanGuilder HD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-138; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wang XK, 1999, MOL BRAIN RES, V71, P304, DOI 10.1016/S0169-328X(99)00203-X; Xu BJ, 2000, J NEUROSCI, V20, P6888, DOI 10.1523/JNEUROSCI.20-18-06888.2000; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang N, 2005, J LEUKOCYTE BIOL, V78, P1210, DOI 10.1189/jlb.0405224; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	29	29	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2014	31	7					683	690		10.1089/neu.2013.3029			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AD7PB	WOS:000333455000010	24344922	Green Published			2022-02-06	
J	Dhandapani, M; Dhandapani, S; Agarwal, M; Mahapatra, AK				Dhandapani, Manju; Dhandapani, Sivashanmugam; Agarwal, Meena; Mahapatra, Ashok K.			Pressure ulcer in patients with severe traumatic brain injury: significant factors and association with neurological outcome	JOURNAL OF CLINICAL NURSING			English	Article						albumin; haemoglobin; outcome; pressure ulcer; traumatic brain injury	RISK-FACTORS; HOSPITALIZED-PATIENTS; PRACTICAL SCALE; CLINICAL-TRIAL; SORE	Aims and objectives. To assess the factors associated with development of pressure ulcer in patients with severe traumatic brain injury (TBI) and study its prognostic significance with respect to neurological outcome at three months. Background. Patients with severe TBI are prone to develop pressure ulcer due to various factors, which have never been studied in detail. Design. Prospective longitudinal study. Methods. Eighty-nine patients of TBI in age group 20-60 years admitted with Glasgow Coma Scale (GCS) 4-8 without serious systemic disorder were enrolled for the study. Patient characteristics, haemoglobin, serum albumin levels at admission and their weekly changes till 21 days were noted along with daily assessment for presence of pressure ulcer. Mortality was assessed at 21 days and neurological outcome at three months through telephonic interview. Results. Of 89 patients studied, pressure ulcer was observed in 6 (7%) and 14 (16%) at the end of two and three weeks, respectively. Pressure ulcer in univariate analysis was significantly associated with poorer GCS (p = 0.05), delayed enteral feeding (p = 0.005) and fall in haemoglobin at two weeks (p = 0.005). Only the latter two were found significant in multivariate analysis. Age, gender, surgical intervention, tracheostomy, prolonged fever and change in albumin had no significant association with pressure ulcer development. Presence of pressure ulcer was significantly associated with mortality at 21 days (p = 0.006) and unfavourable neurological outcome at three months (p = 0.01). Conclusions. The significant factors influencing pressure ulcer development in patients with TBI were delayed enteral feeding and fall in haemoglobin. Pressure ulcer had significant association with mortality at 21 days and recovery status at three months. Relevance to clinical practice. Early nutritional supplementation and monitoring of haemoglobin should be an important part of nursing care interventions for patients at increased risk of developing pressure ulcer.	[Dhandapani, Manju] PGIMER, Natl Inst Nursing Educ, Chandigarh 160012, India; [Dhandapani, Sivashanmugam] PGIMER, Dept Neurosurg, Chandigarh 160012, India; [Agarwal, Meena] AIIMS, Coll Nursing, New Delhi, India; [Mahapatra, Ashok K.] AIIMS, Dept Neurosurg, New Delhi, India		Dhandapani, S (corresponding author), PGIMER, Dept Neurosurg, Chandigarh 160012, India.	ssdhandapani.neurosurg@gmail.com	Dhandapani, Sivashanmugam/I-2395-2013	Dhandapani, Sivashanmugam/0000-0002-3497-4255; Dhandapani, Manju/0000-0003-3351-3841			ALLMAN RM, 1995, JAMA-J AM MED ASSOC, V273, P865, DOI 10.1001/jama.273.11.865; BERGSTROM N, 1987, NURS CLIN N AM, V22, P417; Chauhan V S, 2005, J Wound Care, V14, P36; de Laat E H E W, 2006, J Wound Care, V15, P269; Dhandapani SS, 2010, INDIAN J NEUROTRAUM, V7, P23, DOI 10.1016/S0973-0508(10)80007-3; DHANDAPANI SS, 2009, PAN ARAB J NEUROSURG, V13, P60; Feuchtinger J, 2005, HEART LUNG, V34, P375, DOI 10.1016/j.hrtlng.2005.04.004; Gengenbacher M, 2002, AGING CLIN EXP RES, V14, P420; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hartgrink HH, 1998, CLIN NUTR, V17, P287, DOI 10.1016/S0261-5614(98)80321-X; Jaul E, 2001, Harefuah, V140, P903; Jay R, 1995, Ostomy Wound Manage, V41, P36; JENNETT B, 1975, LANCET, V1, P480; KANE R, 1989, ESSENTIALS CLIN GERI; Keast David H, 2004, Ostomy Wound Manage, V50, P64; Lindgren M, 2004, SCAND J CARING SCI, V18, P57, DOI 10.1046/j.0283-9318.2003.00250.x; MAKLEBUST J, 1987, NURS CLIN N AM, V22, P359; Mustoe TA, 2006, PLAST RECONSTR SURG, V117, p35S, DOI 10.1097/01.prs.0000225431.63010.1b; Norton D., 1962, INVESTIGATION GERIAT; Pender Lauren R, 2005, Intensive Crit Care Nurs, V21, P29, DOI 10.1016/j.iccn.2004.07.005; Reed RL, 2003, GERONTOLOGY, V49, P255, DOI 10.1159/000070407; REULER JB, 1981, ANN INTERN MED, V94, P661, DOI 10.7326/0003-4819-94-5-661; Reynolds TM, 2006, J CLIN PATHOL, V59, P308, DOI 10.1136/jcp.2005.029405; STOTTS NA, 1988, HEART LUNG, V17, P641; TEASDALE G, 1974, LANCET, V2, P81; United States Department of Health and Human Services, 1992, PUB AG HLTH CAR POL; van Marum RJ, 2001, ANGIOLOGY, V52, P409, DOI 10.1177/000331970105200606	27	29	31	11	22	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	APR	2014	23	7-8					1114	1119		10.1111/jocn.12396			6	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	AC4BT	WOS:000332466300011	24112115				2022-02-06	
J	Monea, AG; Baeck, K; Verbeken, E; Verpoest, I; Sloten, JV; Goffin, J; Depreitere, B				Monea, Aida Georgeta; Baeck, Katrien; Verbeken, Eric; Verpoest, Ignaas; Vander Sloten, Jos; Goffin, Jan; Depreitere, Bart			The biomechanical behaviour of the bridging vein-superior sagittal sinus complex with implications for the mechanopathology of acute subdural haematoma	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Acute subdural haematoma; Parasagittal bridging veins; Superior sagittal sinus; Strain rate; Uniaxial tensile test; Longitudinal stretch	CEREBRAL BLOOD-VESSELS; MECHANICAL-PROPERTIES; STRAIN TOLERANCE; MORTALITY; CADAVERS; RUPTURE; FRESH; TESTS; AGE	Background: Traumatic brain injury is expected to become the major cause of death and disability for children and young adults by the year 2020. One of the most frequent and most morbid pathologies resulted from a head trauma is acute subdural haematoma (ASDH). For nearly one third of the ASDH cases the etiopathology directly relates to a bridging vein (BV) rupture. Methods: In the current study the bridging vein-superior sagittal sinus (BV-SSS) units were axially stretched until failure for strain rates ranging from 2.66 s(-1) to 185.61 s(-1), in order to investigate any strain rate dependency in their mechanical behaviour. Findings: Results showed that up to 200 s(-1), the effect of the strain rate on veins' mechanical behaviour is outweighed by the large morphological intra- and inter-individual variations. Gender had a strong influence on the BVs geometrical description, but exerted no direct influence on the BV biomechanical parameters. Veins' dimensions had the strongest influence on the BV mechanical behaviour and on the failure mechanism. Interpretation: The present study brings important contribution to the ASDH research, emphasising the importance of considering the BV-SSS complex as a whole when trying to describe the ASDH mechanopathology. (c) 2013 Elsevier Ltd. All rights reserved.	[Monea, Aida Georgeta] Katholieke Univ Leuven, Div Expt Neurosurg & Neuroanat, B-3000 Louvain, Belgium; [Monea, Aida Georgeta; Baeck, Katrien; Vander Sloten, Jos] Katholieke Univ Leuven, Biomech Sect, B-3001 Heverlee, Belgium; [Verbeken, Eric] Katholieke Univ Leuven, Translat Cell & Tissue Res, B-3000 Louvain, Belgium; [Verpoest, Ignaas] Katholieke Univ Leuven, Dept Met & Mat Engn MTM, B-3001 Heverlee, Belgium		Monea, AG (corresponding author), Biomech Sect, Celestijnenlaan 300 Box 2419, B-3001 Heverlee, Belgium.	moneaaida@yahoo.com; katrien.baeck@mech.kuleuven.be; erik.verbeken@med.kuleuven.be; ignaas.verpoest@mtm.kuleuven.be; jos.vandersloten@mech.kuleuven.be; jan.goffin@med.kuleuven.be; bart.depreitere@med.kuleuven.be	Depreitere, Bart/AAA-9846-2020	Depreitere, Bart/0000-0002-7458-0648			BOUISSOU H, 1991, RETURN CIRCULATION AND NOREPINEPHRINE : AN UPDATE, P139; Brossollet LJ, 1997, J BIOMECH ENG-T ASME, V119, P1, DOI 10.1115/1.2796059; BROSSOLLET LJ, 1995, J BIOMECH, V28, P679, DOI 10.1016/0021-9290(94)00119-O; Delye Hans, 2006, Stapp Car Crash J, V50, P625; Depreitere B, 2006, J NEUROSURG, V104, P950, DOI 10.3171/jns.2006.104.6.950; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Depreitere B., 2004, THESIS KU LEUVEN BEL; FRUIN AH, 1984, J NEUROSURG, V60, P1300, DOI 10.3171/jns.1984.60.6.1300; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Gentner JM, 1998, CELL MOL BIOL, V44, P251; Graham D.I., 1996, NEUROTRAUMA, P43; Greaney JL, 2011, J APPL PHYSIOL, V110, P11, DOI 10.1152/japplphysiol.01273.2010; GUR RC, 1991, P NATL ACAD SCI USA, V88, P2845, DOI 10.1073/pnas.88.7.2845; Han H., 2008, J NEURORADIOLOGY, V49, P169; Han H, 2007, NEURORADIOLOGY, V49, P169, DOI 10.1007/s00234-006-0175-z; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; LOWENHIELM P, 1978, J BIOENG, V2, P509; LOWENHIELM P, 1974, Z RECHTSMED, V75, P131, DOI 10.1007/BF02114709; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; Maxeiner H, 1997, FORENSIC SCI INT, V89, P103, DOI 10.1016/S0379-0738(97)00124-2; Meaney DF, 1991, THESIS U PENNSYLVANI; Monea AG, 2012, J NEUROTRAUM, V29, P2305, DOI 10.1089/neu.2011.2271; Monson K. L., 2001, THESIS U CALIFORNIA; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; OKA K, 1985, NEUROSURGERY, V17, P711, DOI 10.1227/00006123-198511000-00003; OLSON CL, 1974, J AM STAT ASSOC, V69, P894, DOI 10.2307/2286159; Pang Q, 2001, J VASC RES, V38, P83, DOI 10.1159/000051033; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Stemper BD, 2007, J BIOMECH, V40, P1806, DOI 10.1016/j.jbiomech.2006.07.005; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WILLIAMS PL, 1995, GRAYS ANATOMY, P1580; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Young RJ, 2002, NEUROIMAG CLIN N AM, V12, P189, DOI 10.1016/S1052-5149(02)00003-5	34	29	30	1	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	APR	2014	32						155	165		10.1016/j.jmbbm.2013.12.007			11	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	AD8AG	WOS:000333488300016	24463477				2022-02-06	
J	Coronel, MF; Labombarda, F; De Nicola, AF; Gonzalez, SL				Coronel, M. F.; Labombarda, F.; De Nicola, A. F.; Gonzalez, S. L.			Progesterone reduces the expression of spinal cyclooxygenase-2 and inducible nitric oxide synthase and prevents allodynia in a rat model of central neuropathic pain	EUROPEAN JOURNAL OF PAIN			English	Article							TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; GLUCOCORTICOID-MEDIATED REPRESSION; RANDOMIZED CLINICAL-TRIAL; CORD-INJURY; NERVE INJURY; GLIAL-CELLS; ACTIVATION; RECEPTOR; INFLAMMATION	BackgroundSpinal cord injury (SCI) results in the development of chronic pain that is refractory to conventional treatment. Progesterone, a neuroprotective steroid, may offer a promising perspective in pain modulation after central injury. Here, we explore the impact of progesterone administration on the post-injury inflammatory cascade involving the enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) at the spinal cord level. We also analyse pain behaviours, the profile of glial cell activation, and IB- mRNA levels, as an index of NF-B transactivation. MethodsWe used biochemical, immunohistochemical and molecular techniques, as well as behavioural studies, to investigate the effects of progesterone in a well-characterized model of central neuropathic pain. ResultsInjured animals receiving progesterone presented reduced mRNA levels of the proinflammatory enzymes, as well as decreased COX-2 activity and nitrite levels, as compared to vehicle-treated injured rats. Further, animals receiving the steroid exhibited lower levels of IB- mRNA, suggesting decreased NF-B transactivation. Progesterone administration also attenuated the injury-induced increase in the number of glial fibrillary acidic protein and OX-42 positive cells both at early and late time points after injury, and prevented the development of mechanical and thermal allodynia. Further, when injured rats received early progesterone administration for a critical period of time after injury, they did not display allodynic behaviours even after the treatment had stopped. ConclusionsOur results suggest that progesterone, by modulating early neuroinflammatory events triggered after SCI, may represent a useful strategy to prevent the development of central chronic pain.	[Coronel, M. F.; Gonzalez, S. L.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Nocicepc & Dolor Neuropt, RA-1033 Buenos Aires, DF, Argentina; [Labombarda, F.; De Nicola, A. F.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Bioquim Neuroendocrina, RA-1033 Buenos Aires, DF, Argentina; [Labombarda, F.; De Nicola, A. F.; Gonzalez, S. L.] Univ Buenos Aires, Fac Med, Dept Bioquim Humana, RA-1053 Buenos Aires, DF, Argentina		Gonzalez, SL (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Nocicepc & Dolor Neuropt, RA-1033 Buenos Aires, DF, Argentina.	sugnzlz@gmail.com	Labombarda, Fabien/AAE-7747-2020		Universidad de Buenos AiresUniversity of Buenos Aires [20020090200126]; CONICETConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 201-101-00576]; Fundacion Alberto J. Roemmers	This work was supported by Universidad de Buenos Aires (Grant no. 20020090200126), CONICET (PIP 201-101-00576) and Fundacion Alberto J. Roemmers.	APPLEBY SB, 1994, BIOCH J, V302; Bottero Virginie, 2003, Mol Diagn, V7, P187, DOI 10.2165/00066982-200307030-00008; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Cady RJ, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-94; Christensen MD, 1996, PAIN, V68, P97, DOI 10.1016/S0304-3959(96)03224-1; Coronel MF, 2011, J PAIN, V12, P71, DOI 10.1016/j.jpain.2010.04.013; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dableh Liliane J, 2011, J Pain Res, V4, P91, DOI 10.2147/JPR.S17009; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Finnerup NB, 2012, CURR PAIN HEADACHE R, V16, P207, DOI 10.1007/s11916-012-0259-x; Coronel MF, 2011, PAIN MED, V12, P1249, DOI 10.1111/j.1526-4637.2011.01178.x; Fu ES, 2010, PAIN, V148, P509, DOI 10.1016/j.pain.2010.01.001; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garcia-Segura LM, 2006, GLIA, V54, P485, DOI 10.1002/glia.20404; Gwak YS, 2012, EXP NEUROL, V234, P362, DOI 10.1016/j.expneurol.2011.10.010; Hardy DB, 2006, MOL ENDOCRINOL, V20, P2724, DOI 10.1210/me.2006-0112; Hervera A, 2010, J PHARMACOL EXP THER, V334, P887, DOI 10.1124/jpet.110.167585; Hewett SJ, 2006, PHARMACOL THERAPEUT, V112, P335, DOI 10.1016/j.pharmthera.2005.04.011; Jiang C, 2011, INT IMMUNOPHARMACOL, V11, P1925, DOI 10.1016/j.intimp.2011.08.001; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kim MJ, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-16; Kuboyama K, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-50; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2010, NEUROSCIENCE, V166, P94, DOI 10.1016/j.neuroscience.2009.12.012; Labombarda F, 2000, NEUROSCI LETT, V288, P29, DOI 10.1016/S0304-3940(00)01191-5; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Labombarda F, 2008, NEUROSCI LETT, V447, P115, DOI 10.1016/j.neulet.2008.09.062; Leonelli E, 2007, NEUROSCIENCE, V144, P1293, DOI 10.1016/j.neuroscience.2006.11.014; Little JW, 2012, AMINO ACIDS, V42, P75, DOI 10.1007/s00726-010-0633-0; Luongo L, 2010, NEUROBIOL DIS, V37, P177, DOI 10.1016/j.nbd.2009.09.021; Ma WY, 2012, EXPERT OPIN THER TAR, V16, P527, DOI 10.1517/14728222.2012.680955; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; Mensah-Nyagan AG, 2009, PSYCHONEUROENDOCRINO, V34, pS169, DOI [10.1016/j.psyneuen.2009.06.004, DOI 10.1016/j.psyneuen.2009.06.004, 10.1016/j.psyneue n.2009.06.004, DOI 10.1016/J.PSYNEUEN.2009.06.004]; Menzies FM, 2011, IMMUNOLOGY, V134, P281, DOI 10.1111/j.1365-2567.2011.03488.x; Milani P, 2010, J BRACHIAL PLEX PERI, V5, DOI 10.1186/1749-7221-5-11; Molander Carl, 1995, P39; Pautz A, 2010, NITRIC OXIDE-BIOL CH, V23, P75, DOI 10.1016/j.niox.2010.04.007; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rafati DS, 2008, J NEUROSCI RES, V86, P566, DOI 10.1002/jnr.21508; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; Roh DH, 2010, EXP NEUROL, V224, P123, DOI 10.1016/j.expneurol.2010.03.002; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Schmidtko A, 2009, TRENDS NEUROSCI, V32, P339, DOI 10.1016/j.tins.2009.01.010; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Seybold V S, 2009, Handb Exp Pharmacol, P451, DOI 10.1007/978-3-540-79090-7_13; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Tamura I, 2011, J CLIN ENDOCR METAB, V96, pE1073, DOI 10.1210/jc.2010-2489; Tan AM, 2009, J REHABIL RES DEV, V46, P123, DOI 10.1682/JRRD.2008.03.0048; Tenorio G, 2013, PAIN, V154, P71, DOI 10.1016/j.pain.2012.09.008; Vaisanen-Tommiska M, 2006, HUM REPROD, V21, P2180, DOI 10.1093/humrep/del141; Vanegas HN, 2001, PROG NEUROBIOL, V64, P327, DOI 10.1016/S0301-0082(00)00063-0; Wang Z, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/848309; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yezierski RP, 2009, J REHABIL RES DEV, V46, P95, DOI 10.1682/JRRD.2008.06.0074; Zhang G., 2011, PLOS ONE, V6; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007	67	29	33	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAR	2014	18	3					348	359		10.1002/j.1532-2149.2013.00376.x			12	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	304JZ	WOS:000330744200006	23929706				2022-02-06	
J	Hasan, KM; Wilde, EA; Miller, ER; Patel, VK; Staewen, TD; Frisby, ML; Garza, HM; McCarthy, JJ; Hunter, JV; Levin, HS; Robertson, CS; Narayana, PA				Hasan, Khader M.; Wilde, Elisabeth A.; Miller, Emmy R.; Patel, Vipul Kumar; Staewen, Terrell D.; Frisby, Melisa L.; Garza, Hector M.; McCarthy, James J.; Hunter, Jill V.; Levin, Harvey S.; Robertson, Claudia S.; Narayana, Ponnada A.			Serial Atlas-Based Diffusion Tensor Imaging Study of Uncomplicated Mild Traumatic Brain Injury in Adults	JOURNAL OF NEUROTRAUMA			English	Article						atlas-based; corona radiate; corpus callosum; CSF; diffusion tensor imaging; hippocampus; lateral ventricles; mild traumatic brain injury; scanner stability; water phantom	HYPERTONIC SALINE RESUSCITATION; INFLAMMATORY RESPONSE SYNDROME; LENGTH-OF-STAY; NOSOCOMIAL INFECTIONS; HEMORRHAGIC-SHOCK; ACQUIRED INFECTIONS; INHIBITS NEUTROPHIL; HEAD-INJURY; IN-VIVO; COMPLICATIONS	In this report, we applied diffusion tensor imaging (DTI) methods in 36 patients with uncomplicated mild traumatic brain injury (mTBI) and a comparison group of 37 participants with orthopedic injury. Our aim was to characterize regional and global macro- and microstructural attributes of white matter (WM), gray matter (GM), in addition to volume and diffusivity of cerebrospinal fluid (CSF) to identify and differentiate patterns of acute and short-term recovery. Given that previous DTI reports on mTBI in adults using a region-of-interest approach implicated the corona radiata (CR), corpus callosum, and hippocampus, we analyzed and quantified DTI metrics of these regions using atlas-based methods. The normalized volume percentages of global CSF, GM, and WM were not different between the mTBI and orthopedic comparison (OC) groups at either the baseline or follow-up time points or between the baseline and follow-up time points within the OC group (p>0.17; uncorrected for multiple comparisons). The DTI metrics did not differ between groups at either occasion. However, an increase was noted on follow-up in the OC group in the global mean diffusivity of GM (uncorrected p=0.003) and WM (uncorrected p=0.02), indicating a decrease in diffusivity at the 3-month postinjury, as compared to the baseline scan. An analysis of the DTI data collected longitudinally in the CR show insignificant changes in the OC group (p>0.08; N=37). CR radial diffusivity was found to be elevated in the between-group comparison at baseline (mTBI1 vs. OC1), but did not differ in the within-group comparison (mTBI1 vs. mTBI2; N=19), suggesting the possible resolution of edema. Our analysis of the cross-sectional and follow-up data, which is uncorrected for multiple comparisons, demonstrates dissociation between volumetric (macrostructural) and tissue integrity (microstructural) attributes and shows the potential utility of DTI to capture transient edema in the CR.	[Hasan, Khader M.; Patel, Vipul Kumar; Staewen, Terrell D.; Narayana, Ponnada A.] Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, Houston, TX 77030 USA; [McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Frisby, Melisa L.; Garza, Hector M.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Miller, Emmy R.; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA		Hasan, KM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Diagnost & Intervent Imaging, 6431 Fannin St,MSB 2-100, Houston, TX 77030 USA.	Khader.M.Hasan@uth.tmc.edu	Hasan, Khader M./ABB-5767-2020		Dunn Research Fund; Congressionally Directed Medical Research Program of the Department of Defense [W81XWH-08-2-0133, W81XWH-08-2-0135, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0142, W81XWH-08-2-0140, W81XWH-08-2-0131]	This study was funded by the Dunn Research Fund (to K. M. H) and awards from the Congressionally Directed Medical Research Program of the Department of Defense (W81XWH-08-2-0133, W81XWH-08-2-0135, W81XWH-08-2-0138, W81XWH-08-2-0132, W81XWH-08-2-0149, W81XWH-08-2-0142, W81XWH-08-2-0140, and W81XWH-08-2-0131).	Alharfi IM, 2013, J NEUROTRAUM, V30, P361, DOI 10.1089/neu.2012.2410; Alharfi IM, 2013, PEDIATR CRIT CARE ME, V14, P203, DOI 10.1097/PCC.0b013e31827127b5; Allison KR, 2011, NATURE, V473, P216, DOI 10.1038/nature10069; Berrouane Y, 1998, J HOSP INFECT, V40, P275, DOI 10.1016/S0195-6701(98)90303-6; Bochicchio GV, 2001, J TRAUMA, V50, P817, DOI 10.1097/00005373-200105000-00007; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; Brook I, 1998, J ACCID EMERG MED, V15, P162; Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001; Centers for Disease Control and Prevention, 2010, HEALTHC ASS INF HAIS; Ciesla DJ, 2000, SHOCK, V14, P265, DOI 10.1097/00024382-200014030-00004; Ciesla DJ, 2001, SURGERY, V129, P567, DOI 10.1067/msy.2001.113286; CorreaSales C, 1997, INT J IMMUNOPHARMACO, V19, P117, DOI 10.1016/S0192-0561(97)00003-9; Croce MA, 2001, AM SURGEON, V67, P105; Dziedzic T, 2004, CRIT CARE, V8, P266, DOI 10.1186/cc2828; El-Rashdi AS, 2006, ARCH DIS CHILD, V91, P351, DOI 10.1136/adc.2005.088831; Fabregas N, 2002, Minerva Anestesiol, V68, P285; Fink Matthew E, 2012, Continuum (Minneap Minn), V18, P640, DOI 10.1212/01.CON.0000415432.84147.1e; Galley HF, 2000, INTENS CARE MED, V26, P267, DOI 10.1007/s001340051149; Glance LG, 2011, ARCH SURG-CHICAGO, V146, P794, DOI 10.1001/archsurg.2011.41; Grohskopf LA, 2002, J PEDIATR-US, V140, P432, DOI 10.1067/mpd.2002.122499; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; Hoover L, 2006, J TRAUMA, V61, P310, DOI 10.1097/01.ta.0000229052.75460.c2; Hosmer D, 1989, APPL LOGISTIC REGRES; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Junger WG, 2012, SHOCK, V38, P341, DOI 10.1097/SHK.0b013e3182635aca; Khan R, 2011, SHOCK, V36, P440, DOI 10.1097/SHK.0b013e3182336bda; Kim JY, 2012, J SURG RES, V178, P401, DOI 10.1016/j.jss.2012.01.055; Kimura F, 2010, SURG TODAY, V40, P793, DOI 10.1007/s00595-010-4323-z; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Nadal P, 1995, Eur J Emerg Med, V2, P14, DOI 10.1097/00063110-199503000-00004; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; Pascual JL, 2003, J TRAUMA, V54, P121, DOI 10.1097/00005373-200301000-00015; Pascual JL, 2002, ANN SURG, V236, P634, DOI 10.1097/00000658-200211000-00014; Patel JC, 2000, J PEDIATR SURG, V35, P1174, DOI 10.1053/jpsu.2000.8722; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Ploppa A, 2008, INFECTION, V36, P220, DOI 10.1007/s15010-007-7240-3; Raymond J, 2000, INFECT CONT HOSP EP, V21, P260, DOI 10.1086/501755; Richards MJ, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.4.e39; Schneemilch CE, 2005, EUR J ANAESTH, V22, P616, DOI 10.1017/S0265021505001031; Stewart TC, 2013, J TRAUMA ACUTE CARE, V75, P836, DOI 10.1097/TA.0b013e3182a685b0; Suz P, 2006, J NEUROSURG ANESTH, V18, P5, DOI 10.1097/01.ana.0000189079.26212.37; Taira BR, 2009, PEDIATR CRIT CARE ME, V10, P491, DOI 10.1097/PCC.0b013e3181a3108d; Urrea M, 2005, J PEDIATR ORTHOP B, V14, P371, DOI 10.1097/01202412-200509000-00011	47	29	31	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					466	475		10.1089/NEU.2013.3085			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600245	24224684				2022-02-06	
J	Shimada, R; Abe, K; Furutani, R; Kibayashi, K				Shimada, Ryo; Abe, Keiichi; Furutani, Rui; Kibayashi, Kazuhiko			Changes in dopamine transporter expression in the midbrain following traumatic brain injury: an immunohistochemical and in situ hybridization study in a mouse model	NEUROLOGICAL RESEARCH			English	Article						Head trauma; Dopamine transporter; Retrorubral field; In situ hybridization	VENTRAL TEGMENTAL AREA; STRIATAL DOPAMINE; RETRORUBRAL FIELD; HIPPOCAMPAL-FORMATION; SUBSTANTIA-NIGRA; RAT; INNERVATION; PROJECTIONS; PROBES; RNA	Objectives: An association has been suggested between trauma and neurological degenerative diseases. Magnetic resonance imaging has revealed that traumatic brain injury (TBI) can cause primary lesions in the midbrain including the substantia nigra (SN). Dopamine transporter (DAT) is mainly expressed in the SN, ventral tegmental area (VTA), and retrorubral field (RRF) of the ventral midbrain. Previous western blot studies have examined DAT levels in the rat frontal cortex and striatum after a controlled cortical impact (CCI); however, no study has comprehensively examined DAT expression in the midbrain following TBI in an animal model. Methods: We used immunohistochemistry and in situ hybridization to examine the time-dependent changes in the expression of DAT in the midbrain during the first 14 days after TBI in a mouse CCI model. Results: The expression of DAT protein in the RRF on the side ipsilateral to the site of injury decreased in 14 days after injury. Dopamine transporter mRNA expression in the RRF on the ipsilateral side decreased in 1, 7, and 14 days and increased in 4 days after injury. Discussion: These findings indicated that TBI induced changes in DAT expression in the RRF. Because the DAT pumps dopamine (DA) out of the synapse back into the cytosol and maintains DA homeostasis, the decreased expression of DAT after TBI may result in decreased DA neurotransmission in the brain.	[Shimada, Ryo; Furutani, Rui; Kibayashi, Kazuhiko] Tokyo Womens Med Univ, Sch Med, Dept Legal Med, Tokyo 1628666, Japan; [Abe, Keiichi] Tokyo Womens Med Univ, Sch Med, Dept Neurosurg, Tokyo 1628666, Japan		Shimada, R (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Legal Med, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	shimada@research.twmu.ac.jp	Kazuhiko, Kibayashi/F-5173-2013	Kazuhiko, Kibayashi/0000-0001-6510-5215			Backman CM, 2006, GENESIS, V44, P383, DOI 10.1002/dvg.20228; Bisaglia M, 2013, FASEB J, V27, P2101, DOI 10.1096/fj.12-226852; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; Dahlstroem A., 1964, ACTA PHYSIOL SCAND S, V232, P1; Desvignes C, 1999, NEUROSCI LETT, V261, P175, DOI 10.1016/S0304-3940(99)00026-9; Fazeli G, 2011, BRAIN PATHOL, V21, P237, DOI 10.1111/j.1750-3639.2010.00440.x; Fu YH, 2012, BRAIN STRUCT FUNCT, V217, P591, DOI 10.1007/s00429-011-0349-2; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Gasbarri A, 1997, PROG NEURO-PSYCHOPH, V21, P1, DOI 10.1016/S0278-5846(96)00157-1; Gasbarri A, 1996, EXP BRAIN RES, V112, P244; Hasue RH, 2002, J COMP NEUROL, V454, P15, DOI 10.1002/cne.10420; Hu ZL, 2004, J COMP NEUROL, V476, P301, DOI 10.1002/cne.20230; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Kerner JA, 1998, BRAIN RES PROTOC, V3, P22, DOI 10.1016/S1385-299X(98)00017-8; KOLLER WC, 1989, MOVEMENT DISORD, V4, P20, DOI 10.1002/mds.870040106; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Mejias-Aponte CA, 2009, J NEUROSCI, V29, P3613, DOI 10.1523/JNEUROSCI.4632-08.2009; MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507; Nakao K, 2010, J NEUROTRAUM, V27, P1925, DOI 10.1089/neu.2010.1379; Patel J, 2003, J NEUROCHEM, V85, P898, DOI 10.1046/j.1471-4159.2003.01732.x; Sato H, 1994, PROG COMPUT IMAGING, V16, P187; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Shimada R, 2012, J CLIN NEUROSCI, V19, P447, DOI 10.1016/j.jocn.2011.06.033; Tanizaki Y, 2006, PATHOL INT, V56, P510, DOI 10.1111/j.1440-1827.2006.01999.x; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Vikman P, 2007, J NEUROSURG, V107, P1015, DOI 10.3171/JNS-07/11/1015; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013	34	29	32	1	11	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	MAR	2014	36	3					239	246		10.1179/1743132813Y.0000000289			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AI7VL	WOS:000337108800007	24512017				2022-02-06	
J	Donahue, DL; Beck, J; Fritz, B; Davis, P; Sandoval-Cooper, MJ; Thomas, SG; Yount, RA; Walsh, M; Ploplis, VA; Castellino, FJ				Donahue, Deborah L.; Beck, Julia; Fritz, Braxton; Davis, Patrick; Sandoval-Cooper, Mayra J.; Thomas, Scott G.; Yount, Robert A.; Walsh, Mark; Ploplis, Victoria A.; Castellino, Francis J.			Early Platelet Dysfunction in a Rodent Model of Blunt Traumatic Brain Injury Reflects the Acute Traumatic Coagulopathy Found in Humans	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; coagulopathy; platelets; thromboelastography; trauma	ACTIVATION	Acute coagulopathy is a serious complication of traumatic brain injury (TBI) and is of uncertain etiology because of the complex nature of TBI. However, recent work has shown a correlation between mortality and abnormal hemostasis resulting from early platelet dysfunction. The aim of the current study was to develop and characterize a rodent model of TBI that mimics the human coagulopathic condition so that mechanisms of the early acute coagulopathy in TBI can be more readily assessed. Studies utilizing a highly reproducible constrained blunt-force brain injury in rats demonstrate a strong correlation with important postinjury pathological changes that are observed in human TBI patients, namely, diminished platelet responses to agonists, especially adenosine diphosphate (ADP), and subarachnoid bleeding. Additionally, administration of a direct thrombin inhibitor, preinjury, recovers platelet functionality to ADP stimulation, indicating a direct role for excess thrombin production in TBI-induced early platelet dysfunction.	[Donahue, Deborah L.; Beck, Julia; Davis, Patrick; Sandoval-Cooper, Mayra J.; Ploplis, Victoria A.; Castellino, Francis J.] Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; [Beck, Julia; Ploplis, Victoria A.; Castellino, Francis J.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Fritz, Braxton; Thomas, Scott G.; Yount, Robert A.; Walsh, Mark] Mem Hosp South Bend, South Bend, IN USA		Castellino, FJ (corresponding author), Univ Notre Dame, WM Keck Ctr Transgene Res, 230 Raclin Carmichael Hall, Notre Dame, IN 46556 USA.	fcastell@nd.edu		Walsh, Mark/0000-0002-5795-1144	Haemonetics (Braintree, MA); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL019982]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL019982] Funding Source: NIH RePORTER	This study was funded, in part, by an equipment grant from Haemonetics (Braintree, MA) and the National Institutes of Health (HL019982; to F.J.C.).	Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Frith D, 2012, THROMB RES, V129, P551, DOI 10.1016/j.thromres.2011.11.053; Gryglewski RJ, 2008, PHARMACOL REP, V60, P3; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jennings LK, 2009, THROMB HAEMOSTASIS, V102, P248, DOI 10.1160/TH09-03-0192; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Kunio NR, 2012, AM J SURG, V203, P584, DOI 10.1016/j.amjsurg.2011.12.011; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; LAPETINA EG, 1979, P NATL ACAD SCI USA, V76, P121, DOI 10.1073/pnas.76.1.121; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Medzon R, 2010, J EMERG MED, V39, P399, DOI 10.1016/j.jemermed.2007.11.059; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; Pathak A, 2005, Neurol India, V53, P178; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Utter GH, 2002, J TRAUMA, V52, P1071, DOI 10.1097/00005373-200206000-00008; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Woulfe D, 2001, J CLIN INVEST, V107, P1503, DOI 10.1172/JCI13361	26	29	31	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2014	31	4					404	410		10.1089/neu.2013.3089			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AA7PY	WOS:000331290600013	24040968	Green Published			2022-02-06	
J	Ferreira, MC; Batista, AM; Ferreira, FD; Ramos-Jorge, ML; Marques, LS				Ferreira, Meire Coelho; Batista, Anne Margareth; Ferreira, Fernanda de Oliveira; Ramos-Jorge, Maria Leticia; Marques, Leandro Silva			Pattern of oral-maxillofacial trauma stemming from interpersonal physical violence and determinant factors	DENTAL TRAUMATOLOGY			English	Article						maxillofacial injuries; soft tissues injuries; tooth injuries; violence; risk factors	INTIMATE PARTNER VIOLENCE; DOMESTIC VIOLENCE; FACIAL INJURIES; RISK-FACTORS; FRACTURES; PREVALENCE; VICTIMS; ASSAULT; MARKERS; WOMEN	Background/Aim: Facial trauma is among the most common types of injury. The aim of the present study was to assess the prevalence and pattern of oral-maxillofacial trauma stemming from interpersonal physical violence (IPV) and determine whether IPV is factor associated with oral-maxillofacial trauma. Materials and methods: A retrospective analysis was conducted of 790 complete patient charts for data on the type of IPV for the gender, area of residence (urban or rural), age and type of trauma. Statistical analysis involved the chi-squared test (P < 0.05), univariate/multivariate Poisson, and logistic regression (P < 0.20). Type of oral-maxillofacial trauma was the dependent variable. Socio-demographic status and type of IPV were the independent variables. Results: One hundred forty (17.7%) individuals had oral-maxillofacial injuries stemming from IPV [80 (10.1%) due to urban violence (UV) and 42 (5.3%) due to domestic violence (DV)]. DV was more prevalent among females (69%), and UV was more prevalent among males (67.5%). The most common types of trauma were facial contusion and laceration, dental concussion, and mandibular fracture. Age and UV were explanatory factors for mandibular fracture. Females from rural areas and who suffered DV were more likely to exhibit facial contusion and dental concussion. Conclusions: Interpersonal physical violence was identified as a factor associated with oral-maxillofacial trauma, specifically mandibular fracture, facial contusion, and dental concussion.	[Ferreira, Meire Coelho; Batista, Anne Margareth; Ramos-Jorge, Maria Leticia; Marques, Leandro Silva] Univ Fed Vales Jequitinhonha & Mucuri, Dept Dent, Sch Biol & Hlth Sci, Diamantina, Brazil; [Ferreira, Fernanda de Oliveira] Fed Univ Jequitinhonha & Mucuri Valleys, Dept Basic Sci, Diamantina, Brazil		Ferreira, MC (corresponding author), R Doze 648, BR-35020690 Governador Valadares, MG, Brazil.	meirecofe@hotmail.com	Marques, Leandro S/J-4053-2014	Marques, Leandro S/0000-0002-7089-8739	Brazilian Coordination of Higher Education (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Ministry of Education; National Council for Scientific and Technological Development (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Ministry of Science and Technology; State of Minas Gerais Research Foundation (FAPEMIG), BrazilFundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)	This study was supported by the Brazilian Coordination of Higher Education (CAPES), Ministry of Education, the National Council for Scientific and Technological Development (CNPq), Ministry of Science and Technology, and the State of Minas Gerais Research Foundation (FAPEMIG), Brazil.	Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; BERRIOS DC, 1991, WESTERN J MED, V155, P133; CHEZ RA, 1988, AM J OBSTET GYNECOL, V158, P1; Chrcanovic BR, 2012, ORAL MAXILLOFAC SURG, V16, P3, DOI 10.1007/s10006-011-0280-y; De Sousa A, 2008, BRIT J ORAL MAX SURG, V46, P661, DOI 10.1016/j.bjoms.2008.07.192; Desai J, 2010, S AFR J SURG, V48, P122; Dicker RA, 2009, J TRAUMA, V67, P1169, DOI 10.1097/TA.0b013e3181bdb78a; Eggensperger N, 2007, J CRANIO MAXILL SURG, V35, P161, DOI 10.1016/j.jcms.2007.01.002; Brasileiro BF, 2006, ORAL SURG ORAL MED O, V102, P28, DOI 10.1016/j.tripleo.2005.07.023; Furniss K, 2007, MCN-AM J MATERN-CHIL, V32, P238, DOI 10.1097/01.NMC.0000281964.45905.89; Gandhi S, 2011, DENT TRAUMATOL, V27, P257, DOI 10.1111/j.1600-9657.2011.00996.x; Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8; Hashemi HM, 2011, DENT TRAUMATOL, V27, P385, DOI 10.1111/j.1600-9657.2011.01016.x; Hegarty K, 2000, MED J AUSTRALIA, V173, P363, DOI 10.5694/j.1326-5377.2000.tb125688.x; Landenburger K M, 1998, J Obstet Gynecol Neonatal Nurs, V27, P700, DOI 10.1111/j.1552-6909.1998.tb02641.x; Laverick S, 2008, BRIT J ORAL MAX SURG, V46, P542, DOI 10.1016/j.bjoms.2008.01.021; Le BT, 2001, J ORAL MAXIL SURG, V59, P1277, DOI 10.1053/joms.2001.27490; LE BT, 2001, J ORAL MAXILLOFAC SU, V59, P1283; Leporace Antonio Augusto Ferreirinha, 2009, Rev. Col. Bras. Cir., V36, P472; Macedo JLS, 2007, REV SOC BRAS CIR PLA, V22, P209; Maliska Maximiana Cristina de Souza, 2009, Braz. oral res., V23, P268, DOI 10.1590/S1806-83242009000300008; O'Meara C, 2012, BRIT J ORAL MAX SURG, V50, P36, DOI 10.1016/j.bjoms.2010.11.003; Ochs HA, 1996, J AM DENT ASSOC, V127, P757, DOI 10.14219/jada.archive.1996.0311; Othman S, 2008, ASIA PAC FAM MED, V7, P1187; Perciaccante VJ, 1999, J ORAL MAXIL SURG, V57, P760, DOI 10.1016/S0278-2391(99)90808-X; Leles JLR, 2010, J APPL ORAL SCI, V18, P23, DOI 10.1590/S1678-77572010000100006; Saddki N, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-268; SHEPHERD JP, 1990, J ROY SOC MED, V83, P75, DOI 10.1177/014107689008300206; Sheridan DJ, 2007, TRAUMA VIOLENCE ABUS, V8, P281, DOI 10.1177/1524838007303504; Silva Joaquim José de Lima, 2011, Rev. Bras. Cir. Plást., V26, P37, DOI 10.1590/S1983-51752011000100009; Waters H, 2004, EC DIMENSIONS INTERP; World Health Organization, 1997, WHOFRHWHD978; World Health Organization, 2002, WORLD REPORT VIOLENC; World Health Organization (WHO), 1996, VIOL PUBL HLTH PRIOR	34	29	32	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	FEB	2014	30	1					15	21		10.1111/edt.12047			7	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	AH6SE	WOS:000336260200002	23675634				2022-02-06	
J	Naim-Feil, J; Fitzgerald, PB; Bradshaw, JL; Lubman, DI; Sheppard, D				Naim-Feil, Jodie; Fitzgerald, Paul B.; Bradshaw, John L.; Lubman, Dan I.; Sheppard, Dianne			Neurocognitive Deficits, Craving, and Abstinence among Alcohol-Dependent Individuals Following Detoxification	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Neurocognitive deficits; Alcohol dependence; Frontostriatal dysfunction; Attentional control; Craving; Cognitive recovery	RANDOM-NUMBER-GENERATION; DORSOLATERAL PREFRONTAL CORTEX; COMPULSIVE DRINKING SCALE; HIGH-FUNCTIONING AUTISM; TRAUMATIC BRAIN-INJURY; STOP SIGNAL INHIBITION; SUSTAINED-ATTENTION; EXECUTIVE FUNCTIONS; PARKINSONS-DISEASE; RESPONSE-TASK	Alcohol dependence, a chronic relapsing disorder, is characterized by an impaired ability to regulate compulsive urges to consume alcohol. Very few empirical studies have examined the presence of these executive deficits, how they relate to craving, and the enduring nature of these deficits during abstinence. As such, the current study aimed to characterize these cognitive deficits within a sample of 24 alcohol-dependent participants post-detoxification and 23 non-alcohol-dependent participants. Participants were administered the Sustained Attention to Response Task to measure response inhibition and sustained attention and the Random Number Generation Task to examine executive deficits. Correlations between cognitive performance and clinical measures of alcohol dependence were examined. As predicted, the alcohol-dependent group exhibited poorer performance across the domains of response inhibition, executive function, and attentional control. Cognitive performance was related to clinical measures of craving and years of alcohol consumption, whereas the duration of abstinence was not associated with improved cognitive performance. These findings highlight the need for therapeutic strategies to target these enduring neurocognitive deficits in improving the treatment of alcohol dependence.	[Naim-Feil, Jodie; Fitzgerald, Paul B.] Alfred & Monash Univ, Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Prahran, Vic 3004, Australia; [Naim-Feil, Jodie; Bradshaw, John L.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic, Australia; [Lubman, Dan I.] Eastern Hlth, Turning Point Alcohol & Drug Ctr, Box Hill, Vic, Australia; [Lubman, Dan I.] Monash Univ, Clayton, Vic 3800, Australia; [Sheppard, Dianne] Monash Univ, Monash Injury Res Inst, Clayton, Vic, Australia		Naim-Feil, J (corresponding author), Alfred & Monash Univ, Cent Clin Sch, Monash Alfred Psychiat Res Ctr, Prahran, Vic 3004, Australia.	jodie@naimfeil.org	Fitzgerald, Paul B/A-1225-2008	Fitzgerald, Paul B/0000-0003-4217-8096; Feil, Jodie/0000-0001-7895-4021; Lubman, Dan/0000-0002-6747-1937; Sheppard, Dianne/0000-0002-9928-1740	Graduate Women Victoria scholarship; NHMRC Practitioner FellowshipNational Health and Medical Research Council of Australia	J.N.-F. is a recipient of the Graduate Women Victoria scholarship, which supported the development of this study. P.B.F. has received equipment for research from Medtronic Ltd, MagVenture A/S, and Brainsway Ltd. He has undertaken research with funding and equipment from Cervel Neurotech. He is supported by a NHMRC Practitioner Fellowship.	Alfonso-Loeches S, 2011, CRIT REV CL LAB SCI, V48, P19, DOI 10.3109/10408363.2011.580567; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anton RF, 1996, ARCH GEN PSYCHIAT, V53, P225; Anton RF, 2000, ADDICTION, V95, pS211; BADDELEY AD, 1966, Q J EXP PSYCHOL, V18, P119, DOI 10.1080/14640746608400019; Baicy K, 2007, ADDICTION, V102, P5, DOI 10.1111/j.1360-0443.2006.01777.x; Bates ME, 2002, EXP CLIN PSYCHOPHARM, V10, P193, DOI 10.1037//1064-1297.10.3.193; Beck A.T., 1987, MANUAL BECK DEPRESSI; Bonnefond A, 2010, BEHAV BRAIN RES, V211, P185, DOI 10.1016/j.bbr.2010.03.030; Bottlender M, 2004, ALCOHOL ALCOHOLISM, V39, P357, DOI 10.1093/alcalc/agh073; Bowden-Jones H, 2005, J NEUROPSYCH CLIN N, V17, P417, DOI 10.1176/appi.neuropsych.17.3.417; Braet W, 2009, NEUROPSYCHOLOGIA, V47, P3143, DOI 10.1016/j.neuropsychologia.2009.07.018; BRANDT J, 1983, ARCH GEN PSYCHIAT, V40, P435; Braver TS, 2003, NEURON, V39, P713, DOI 10.1016/S0896-6273(03)00466-5; Brown RG, 1998, NEUROPSYCHOLOGIA, V36, P1355, DOI 10.1016/S0028-3932(98)00015-3; Brugger P, 1997, PERCEPT MOTOR SKILL, V84, P627, DOI 10.2466/pms.1997.84.2.627; Carriere JSA, 2010, PSYCHOL AGING, V25, P569, DOI 10.1037/a0019363; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Chan KKS, 2011, PERCEPT MOTOR SKILL, V112, P91, DOI 10.2466/02.15.19.22.PMS.112.1.91-103; Chan RCK, 2009, COGN BEHAV NEUROL, V22, P180, DOI 10.1097/WNN.0b013e3181b7ef84; Chan RCK, 2004, CLIN NEUROPSYCHOL, V18, P114, DOI 10.1080/13854040490507208; Chanraud S, 2007, NEUROPSYCHOPHARMACOL, V32, P429, DOI 10.1038/sj.npp.1301219; Cohen HL, 1997, ALCOHOL CLIN EXP RES, V21, P1398; Cox WM, 2002, DRUG ALCOHOL DEPEN, V68, P237, DOI 10.1016/S0376-8716(02)00219-3; Crews FT, 2005, ALCOHOL CLIN EXP RES, V29, P1504, DOI 10.1097/01.alc.0000175013.50644.61; Davies SJC, 2005, ALCOHOL ALCOHOLISM, V40, P498, DOI 10.1093/alcalc/agh203; De Wilde B, 2007, ALCOHOL CLIN EXP RES, V31, P1820, DOI 10.1111/j.1530-0277.2007.00484.x; Dirnberger G, 2005, NEUROIMAGE, V25, P588, DOI 10.1016/j.neuroimage.2004.11.023; Dirnberger G, 2010, EXP BRAIN RES, V201, P535, DOI 10.1007/s00221-009-2068-y; Dockree PM, 2005, NEUROIMAGE, V27, P587, DOI 10.1016/j.neuroimage.2005.05.044; Durazzo TC, 2008, ALCOHOL ALCOHOLISM, V43, P683, DOI 10.1093/alcalc/agn078; Evren C, 2012, DRUG ALCOHOL REV, V31, P81, DOI 10.1111/j.1465-3362.2011.00303.x; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Feil J, 2010, NEUROSCI BIOBEHAV R, V35, P248, DOI 10.1016/j.neubiorev.2010.03.001; Fein G, 2006, ALCOHOL CLIN EXP RES, V30, P1538, DOI 10.1111/j.1530-0277.2006.00185.x; Fernandez-Serrano MJ, 2011, NEUROSCI BIOBEHAV R, V35, P377, DOI 10.1016/j.neubiorev.2010.04.008; Ginsburg N, 1995, PERCEPT MOTOR SKILL, V81, P1183, DOI 10.2466/pms.1995.81.3f.1183; Gordon SM, 2006, AM J ADDICTION, V15, P242, DOI 10.1080/10550490600626556; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Hermens DF, 2013, CORTEX, V49, P3, DOI 10.1016/j.cortex.2012.05.021; Hester R, 2004, CEREB CORTEX, V14, P986, DOI 10.1093/cercor/bhh059; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Ihara H, 2000, J NEUROL NEUROSUR PS, V68, P731, DOI 10.1136/jnnp.68.6.731; Jahanshahi M, 2000, NEUROIMAGE, V12, P713, DOI 10.1006/nimg.2000.0647; Jahanshahi M, 1998, BRAIN, V121, P1533, DOI 10.1093/brain/121.8.1533; Jahanshahi M, 1999, NEUROPSYCHOLOGIA, V37, P181; Jahanshahi M, 2006, NEUROPSYCHOLOGY, V20, P391, DOI 10.1037/0894-4105.20.4.391; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Joppich G, 2004, NEUROSCI RES, V49, P157, DOI 10.1016/j.neures.2004.02.003; Kamarajan C, 2005, BIOL PSYCHOL, V69, P353, DOI 10.1016/j.biopsycho.2004.08.004; Kamarajan C, 2004, INT J PSYCHOPHYSIOL, V51, P155, DOI 10.1016/j.ijpsycho.2003.09.004; Keppel G., 2004, DESIGN ANAL RES HDB, V4th ed.; Knoch D, 2005, CEREB CORTEX, V15, P885, DOI 10.1093/cercor/bhh196; Kranzler HR, 1999, ALCOHOL CLIN EXP RES, V23, P108, DOI 10.1111/j.1530-0277.1999.tb04030.x; Lawrence AJ, 2009, PSYCHOPHARMACOLOGY, V207, P163, DOI 10.1007/s00213-009-1645-x; Li CSR, 2008, NEUROPSYCHOPHARMACOL, V33, P1798, DOI 10.1038/sj.npp.1301568; Li CSR, 2006, DRUG ALCOHOL DEPEN, V85, P205, DOI 10.1016/j.drugalcdep.2006.04.008; Li CSR, 2009, ALCOHOL CLIN EXP RES, V33, P740, DOI 10.1111/j.1530-0277.2008.00891.x; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manning V, 2008, EUR ADDICT RES, V14, P226, DOI 10.1159/000156479; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Molenberghs P, 2009, NEUROPSYCHOLOGIA, V47, P2866, DOI 10.1016/j.neuropsychologia.2009.06.012; Monterosso JR, 2005, DRUG ALCOHOL DEPEN, V79, P273, DOI 10.1016/j.drugalcdep.2005.02.002; Morrison F, 2011, INT J MENT HEALTH AD, V9, P151, DOI 10.1007/s11469-009-9261-x; Noel X, 2002, ALCOHOL ALCOHOLISM, V37, P347, DOI 10.1093/alcalc/37.4.347; Noel X, 2001, ARCH GEN PSYCHIAT, V58, P1152, DOI 10.1001/archpsyc.58.12.1152; Noel X, 2001, ALCOHOL ALCOHOLISM, V36, P556, DOI 10.1093/alcalc/36.6.556; Noel X, 2007, PSYCHOPHARMACOLOGY, V192, P291, DOI 10.1007/s00213-006-0695-6; Noel X, 2010, J PSYCHOPHYSIOL, V24, P240, DOI 10.1027/0269-8803/a000037; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; O'Connell RG, 2006, NEUROPSYCHOL REHABIL, V16, P653, DOI 10.1080/09602010500200250; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Connor C, 2004, BRAIN COGNITION, V54, P133, DOI 10.1016/S0278-2626(03)00268-9; Oscar-Berman M, 2007, NEUROPSYCHOL REV, V17, P239, DOI 10.1007/s11065-007-9038-6; Peters M, 2007, J INT NEUROPSYCH SOC, V13, P626, DOI 10.1017/S1355617707070786; Potvin S., 2012, ADDICTION BIOL; Ratti MT, 2002, ACTA NEUROL SCAND, V105, P276, DOI 10.1034/j.1600-0404.2002.0o315.x; Rinehart NJ, 2006, AUTISM, V10, P70, DOI 10.1177/1362361306062011; Roberts JS, 1999, ALCOHOL CLIN EXP RES, V23, P1484, DOI 10.1097/00000374-199909000-00010; Robertson C, 1996, NEUROPSYCHOLOGIA, V34, P1069, DOI 10.1016/0028-3932(96)00031-0; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rogers BP, 2012, ALCOHOL CLIN EXP RES, V36, P294, DOI 10.1111/j.1530-0277.2011.01614.x; Rubia K, 2003, NEUROIMAGE, V20, P351, DOI 10.1016/S1053-8119(03)00275-1; Rubio G, 2008, ALCOHOL CLIN EXP RES, V32, P1681, DOI 10.1111/j.1530-0277.2008.00746.x; Salame P, 2007, J INT NEUROPSYCH SOC, V13, P277, DOI 10.1017/S1355617707070300; Schmidt P, 2011, SUBST ABUSE TREAT PR, V6, DOI 10.1186/1747-597X-6-14; Sorg SF, 2012, BIOL PSYCHIAT, V71, P262, DOI 10.1016/j.biopsych.2011.09.022; STOCKWELL T, 1994, ADDICTION, V89, P167, DOI 10.1111/j.1360-0443.1994.tb00875.x; STOCKWELL T, 1979, BRIT J ADDICT, V74, P79; Sullivan EV, 2000, NEUROPSYCHOLOGY, V14, P178, DOI 10.1037//0894-4105.14.2.178; Tapert SF, 2007, PSYCHOPHARMACOLOGY, V194, P173, DOI 10.1007/s00213-007-0823-y; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Towse JN, 1997, EUR J COGN PSYCHOL, V9, P381, DOI 10.1080/713752566; Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777, DOI 10.1016/j.neubiorev.2007.11.003; Verdejo-Garcia A, 2012, PSYCHOPHARMACOLOGY, V219, P519, DOI 10.1007/s00213-011-2512-0; Verdejo-Garcia AJ, 2007, ADDICT BEHAV, V32, P950, DOI 10.1016/j.addbeh.2006.06.032; VIVIAN TN, 1973, PERCEPT MOTOR SKILL, V36, P136, DOI 10.2466/pms.1973.36.1.136; WechslerD, 2001, WECHSLER TEST ADULT; Weinstein A, 2006, J PSYCHOPHARMACOL, V20, P850, DOI 10.1177/0269881106061116; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Williams MA, 2002, J AUTISM DEV DISORD, V32, P43, DOI 10.1023/A:1017904207328; Yucel M, 2007, MOL PSYCHIATR, V12, P691, DOI 10.1038/sj.mp.4001955; Zinn S, 2004, ALCOHOL CLIN EXP RES, V28, P1338, DOI 10.1097/01.ALC.0000139814.81811.62	106	29	35	0	21	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2014	29	1					26	37		10.1093/arclin/act090			12	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	AA1CA	WOS:000330832700004	24334264	Bronze			2022-02-06	
J	Di Saverio, S; Gambale, G; Coccolini, F; Catena, F; Giorgini, E; Ansaloni, L; Amadori, N; Coniglio, C; Giugni, A; Biscardi, A; Magnone, S; Filicori, F; Cavallo, P; Villani, S; Cinquantini, F; Annicchiarico, M; Gordini, G; Tugnoli, G				Di Saverio, Salomone; Gambale, Giorgio; Coccolini, Federico; Catena, Fausto; Giorgini, Eleonora; Ansaloni, Luca; Amadori, Niki; Coniglio, Carlo; Giugni, Aimone; Biscardi, Andrea; Magnone, Stefano; Filicori, Filippo; Cavallo, Piergiorgio; Villani, Silvia; Cinquantini, Francesco; Annicchiarico, Massimo; Gordini, Giovanni; Tugnoli, Gregorio			Changes in the outcomes of severe trauma patients from 15-year experience in a Western European trauma ICU of Emilia Romagna region (1996-2010). A population cross-sectional survey study	LANGENBECKS ARCHIVES OF SURGERY			English	Article						Trauma; Trauma outcomes; Epidemiology; Trauma ICU; Morbidity; Mortality; Prognostic factors; Damage control surgery; Trauma center; Safety regulations; Prevention; Traumatic brain injury; Hemorrhage; MOF	DAMAGE CONTROL; MORTALITY; INJURY; CARE; LEVEL; TRANSFUSION; SURVIVAL; CENTERS; SURGERY	Our experience in trauma center management increased over time and improved with development of better logistics, optimization of structural and technical resources. In addition recent Government policy in safety regulations for road traffic accident (RTA) prevention, such compulsory helmet use (2000) and seatbelt restraint (2003) were issued with aim of decreasing mortality rate for trauma. The evaluation of their influence on mortality during the last 15 years can lead to further improvements. In our level I trauma center, 60,247 trauma admissions have been recorded between 1996 and 2010, with 2183 deaths (overall mortality 3.6 %). A total of 2,935 trauma patients with ISS > 16 have been admitted to Trauma ICU and recorded in a prospectively collected database (1996-2010). Blunt trauma occurred in 97.1 % of the cases, whilst only 2.5 % were penetrating. A retrospective review of the outcomes was carried out, including mortality, cause of death, morbidity and length of stay (LOS) in the intensive care unit (ICU), with stratification of the outcome changes through the years. Age, sex, mechanism, glasgow coma scale (GCS), systolic blood pressure (SBP), respiratory rate (RR), revised trauma score (RTS), injury severity score (ISS), pH, base excess (BE), as well as therapeutic interventions (i.e., angioembolization and number of blood units transfused in the first 24 h), were included in univariate and multivariate analyses by logistic regression of mortality predictive value. Overall mortality through the whole period was 17.2 %, and major respiratory morbidity in the ICU was 23.3 %. A significant increase of trauma admissions has been observed (before and after 2001, p < 0.01). Mean GCS (10.2) increased during the period (test trend p < 0.05). Mean age, ISS (24.83) and mechanism did not change significantly, whereas mortality rate decreased showing two marked drops, from 25.8 % in 1996, to 18.3 % in 2000 and again down to 10.3 % in 2004 (test trend p < 0.01). Traumatic brain injury (TBI) accounted for 58.4 % of the causes of death; hemorrhagic shock was the death cause in 28.4 % and multiple organ failure (MOF)/sepsis in 13.2 % of the patients. However, the distribution of causes of death changed during the period showing a reduction of TBI-related and increase of MOF/sepsis (CTR test trend p < 0.05). Significant predictors of mortality in the whole group were year of admission (p < 0.05), age, hemorrhagic shock and SBP at admission, ISS and GCS, pH and BE (all p < 0.01). In the subgroup of patients that underwent emergency surgery, the same factors confirmed their prognostic value and remained significant as well as the adjunctive parameter of total amount of blood units transfused (p < 0.05). Surgical time (mean 71 min) showed a significant trend towards reduction but did not show significant association with mortality (p = 0.06). Mortality of severe trauma decreased significantly during the last 15 years as well as mean GCS improved whereas mean ISS remained stable. The new safety regulations positively influenced incidence and severity of TBI and seemed to improve the outcomes. ISS seems to be a better predictor of outcome than RTS.	[Di Saverio, Salomone; Giorgini, Eleonora; Amadori, Niki; Biscardi, Andrea; Villani, Silvia; Tugnoli, Gregorio] AUSL Bologna Local Hlth Dist, Maggiore Hosp Trauma Ctr, Dept Emergency, Trauma Surg Unit, Bologna, Italy; [Gambale, Giorgio; Coniglio, Carlo; Giugni, Aimone; Cavallo, Piergiorgio; Gordini, Giovanni] Maggiore Hosp, Dept Emergency, Ctr Trauma, Trauma ICU, Bologna, Italy; [Coccolini, Federico; Ansaloni, Luca; Magnone, Stefano] Osped Riuniti Bergamo, Unit 1, I-24100 Bergamo, Italy; [Catena, Fausto] S Orsola Malpighi Univ Hosp, Dept Gen & Transplant Surg, Emergency Surg Unit, Bologna, Italy; [Filicori, Filippo] New York Presbyterian Hosp, Dept Surg, Weill Cornell Med Coll, New York, NY USA; [Cinquantini, Francesco] Maggiore Hosp, Dept Radiol, Intervent Radiol Unit, Bologna, Italy; [Annicchiarico, Massimo] AUSL Bologna, Bologna, Italy		Di Saverio, S (corresponding author), AUSL Bologna Local Hlth Dist, Maggiore Hosp Trauma Ctr, Dept Emergency, Trauma Surg Unit, Bologna, Italy.	salo75@inwind.it	Gordini, Giovanni/AAB-8170-2022; Magnone, Stefano/N-4905-2019; Di Saverio, Salomone/G-1437-2012; Ansaloni, Luca/AAP-9134-2020; Coccolini, Federico/AAJ-6507-2020; Magnone, Stefano/R-6719-2016; Coniglio, Carlo/AAB-7128-2022	Gordini, Giovanni/0000-0003-4518-0204; Magnone, Stefano/0000-0002-8001-3754; Di Saverio, Salomone/0000-0001-5685-5022; Ansaloni, Luca/0000-0001-6427-0307; Coccolini, Federico/0000-0001-6364-4186; Magnone, Stefano/0000-0002-8001-3754; Coniglio, Carlo/0000-0002-8207-0525			[Anonymous], 2000, DAMAGE CONTROL SURG, V5, P6; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Baldoni F, 2011, AM J SURG, V201, pE5, DOI 10.1016/j.amjsurg.2010.05.015; Casali M, 2008, ANN ITAL CHIR, V79, P399; Christensen MC, 2010, J TRAUMA, V69, P344, DOI 10.1097/TA.0b013e3181e74c69; Christensen MC, 2008, CRIT CARE, V12, DOI 10.1186/cc6797; Cudnik MT, 2009, J TRAUMA, V66, P1321, DOI 10.1097/TA.0b013e3181929e2b; Davenport RA, 2010, BRIT J SURG, V97, P109, DOI 10.1002/bjs.6806; Di Saverio S, MINERVA ANE IN PRESS; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Edwards A, 2007, RESUSCITATION, V75, P286, DOI 10.1016/j.resuscitation.2007.06.023; Filicori F, 2010, WORLD J SURG, V34, P2064, DOI 10.1007/s00268-010-0667-1; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; Hackford SR, 1986, J TRAUMA, V26, P812; Haddon W Jr, 1999, Inj Prev, V5, P231; Hammond J, 2008, SURGERY, VTwo, P403, DOI [10.1007/978-0-387-68113-9_21, DOI 10.1007/978-0-387-68113-9_21]; HIRSHBERG A, 1995, ANN SURG, V222, P3, DOI 10.1097/00000658-199507000-00002; Hosmer D.W., 2000, LEMESHOW S APPL LOGI; Ikegami Keiichi, 2002, Nihon Geka Gakkai Zasshi, V103, P507; Liu B, 2005, COCHRANE DATABASE SY; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Moore EE, 1996, AM J SURG, V172, P405, DOI 10.1016/S0002-9610(96)00216-4; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Napolitano LM, 2010, J TRAUMA, V69, P1619, DOI 10.1097/TA.0b013e3182011089; Newgard CD, 2007, J TRAUMA, V63, P965, DOI 10.1097/TA.0b013e31803c5665; Organization W.H, 2008, GLOBAL BURDEN DIS 20; Peden M, 2004, WORLD REPORT ROAD TR, P12; Poortman P, 2000, Ned Tijdschr Geneeskd, V144, P1337; Racioppi F., 2004, PREVENTING ROAD TRAF; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Rotondo MF, 1997, SURG CLIN N AM, V77, P761, DOI 10.1016/S0039-6109(05)70582-X; Servadei F, 2003, INJURY PREV, V9, P257, DOI 10.1136/ip.9.3.257; Shafi S, 2010, J TRAUMA, V69, P1367, DOI 10.1097/TA.0b013e3181fb785d; Spiritus E, 2000, AM J MANAG CARE, V6, pS1216; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Teixeira PGR, 2007, J TRAUMA, V63, P1338, DOI 10.1097/TA.0b013e31815078ae; Tien H, 2007, CAN J SURG, V50, P202; Tugnoli G, 2007, ANN ITAL CHIR, V78, P81	38	29	29	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1435-2443	1435-2451		LANGENBECK ARCH SURG	Langenbecks Arch. Surg.	JAN	2014	399	1					109	126		10.1007/s00423-013-1143-9			18	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	291MW	WOS:000329833800013	24292078				2022-02-06	
J	Mauritz, W; Brazinova, A; Majdan, M; Leitgeb, J				Mauritz, Walter; Brazinova, Alexandra; Majdan, Marek; Leitgeb, Johannes			Epidemiology of traumatic brain injury in Austria	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						Traumatic brain injury; Epidemiology; Outcome; Severity; Age; Sex; Geographical factors	HEAD-INJURY; UNITED-STATES; NEW-ZEALAND; POPULATION; TRENDS; IMPACT; SEVERITY; GERMANY	Traumatic brain injury (TBI) is an important cause of preventable deaths. The goal of this study was to provide data on epidemiology of TBI in Austria. Data on all hospital discharges, outpatients, and extra- as well as in-hospital deaths due to TBI were collected from various sources for the years 2009-2011. Population data (number of male/female people per age-group, population of Austrian cities, towns, and villages) for 2009-2011 were collected from the national statistical office. Incidence, case fatality rate(s) (CFR), and mortality rate(s) (MR) were calculated for the whole population and for age groups. Incidence (303/100,000/year), CFR (3.6 %), and MR (11/100,000/year) of TBI in Austria are comparable with those from other European countries. We found a high rate of geriatric TBI. The ratio between male and female cases was 1.4:1 for all cases, and was 2.2:1 for fatal cases. The most common mechanism was falls; traffic accidents accounted for only 7 % of the cases. Males died more frequently from traffic accidents and suicides, and females died more frequently from falls. CFRs and MRs increased with increasing age. CFRs were higher in patients from less populated areas, and MRs were lower in cases who lived closer to hospitals that admitted TBI. The high rate of geriatric TBI warrants better prevention of falls in this age group.	[Mauritz, Walter] Trauma Hosp Lorenz Boehler, A-1200 Vienna, Austria; [Brazinova, Alexandra; Majdan, Marek] Trnava Univ, Dept Publ Hlth, Fac Hlth & Social Serv, Vienna, Austria; [Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, Vienna, Austria		Mauritz, W (corresponding author), Trauma Hosp Lorenz Boehler, Donaueschingestr 13, A-1200 Vienna, Austria.	walter.mauritz@auva.at; abrazinova@igeh.org; mmajdan@igeh.org; johannes.leitgeb@meduniwien.ac.at	Brazinova, Alexandra/C-4265-2016; Majdan, Marek/K-5017-2012	Brazinova, Alexandra/0000-0003-0625-256X; Majdan, Marek/0000-0001-8037-742X; Mauritz, Walter/0000-0001-9043-3712	Austrian Worker's Compensation Board (AUVA) [FK 09/13]; Mrs. Ala Auersperg-Isham and Mr. Ralph Isham	This work was supported by a grant from the Austrian Worker's Compensation Board (AUVA; FK 09/13). The International Neurotrauma Research Organization (INRO) is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by small donations from various sources.	Adekoya N, 2004, PUBLIC HEALTH REP, V119, P486, DOI 10.1016/j.phr.2004.07.006; Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Coburn K, 1992, AACN Clin Issues Crit Care Nurs, V3, P9; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Rosso A, 2007, WIEN KLIN WOCHENSCHR, V119, P29, DOI 10.1007/s00508-006-0761-4; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	22	29	30	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	JAN	2014	126	1-2					42	52		10.1007/s00508-013-0456-6			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	304JR	WOS:000330743400008	24249325	Bronze, Green Published			2022-02-06	
J	Sinclair, E; Radford, K; Grant, M; Terry, J				Sinclair, Emma; Radford, Kathryn; Grant, Mary; Terry, Jane			Developing stroke-specific vocational rehabilitation: a soft systems analysis of current service provision	DISABILITY AND REHABILITATION			English	Article						Mapping; soft systems analysis; stroke; vocational rehabilitation	TRAUMATIC BRAIN-INJURY; WORK; RETURN	Purpose: This study aimed to clarify the existing service provision of stroke-specific vocational rehabilitation (VR) in one English county, in order to facilitate future service development. Method: Using soft systems methodology, services in Health, Social Care, Department of Work and Pensions, the voluntary and private sectors, which were identified as supporting return to work after stroke, were mapped using a mixed-methodology approach. Results: A lack of a sanctioned VR pathway meant access to support relied on brokered provision and tacit knowledge. The timing of an intervention was complex and there was a substantial degree of unmet need for mild stroke patients. VR was seen as "non-essential" due to competing commissioning priorities. Service providers from all sectors lacked training and cross-sector partnerships were tenuous and provider roles unclear. Conclusions: Stroke-specific VR should be delivered by an integrated, cross-sector multi-disciplinary team and integrated commissioning between health and other sectors is necessary. Although early intervention is important, support later on in the recovery process is also necessary. Service providers need adequate training to meet the needs of stroke survivors wishing to return to work and better awareness of best practice guidelines. Business cases which demonstrate the efficacy and cost-effectiveness of VR are vital.	[Sinclair, Emma; Radford, Kathryn; Grant, Mary] Univ Nottingham, Div Rehabil & Ageing, Nottingham NG7 2RD, England; [Terry, Jane] Nottingham CityCare Partnership, Community Stroke Team, Nottingham, England		Radford, K (corresponding author), Queens Med Ctr, Med Sch B102, Div Rehabil & Ageing, Nottingham NG7 2UH, England.	kate.radford@nottingham.ac.uk	Radford, Kate A/F-8571-2013	Radford, Kate A/0000-0001-6246-3180	National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care for Nottinghamshire, Derbyshire and Lincolnshire (NIHR CLAHRC NDL)	This research was funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care for Nottinghamshire, Derbyshire and Lincolnshire (NIHR CLAHRC NDL). The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Barker G, 2006, GETTING BACK WORK ST; Bedekar Y., 2009, INT J STROKE, V4, P1; Black C., 2008, WORKING HLTH TOMORRO; British Society of Rehabilitation Medicine, 2008, NEUR REH BRIEF PAP C; British Society of Rehabilitation Medicine, 2009, BSRM STAND REH SERV; Burton A.K., 2006, IS WORK GOOD YOUR HL; Care Quality Commission, 2011, SUPP LIF STROK REV S; Checkland P., 1999, SOFT SYSTEMS METHODO; Daniel K, 2009, STROKE, V40, pE431, DOI [10.1161/STROKEAHA.108.534487, 10.1161/STROKEAHA.108.535088]; Department of Health, 2007, NAT STROK STRAT; Department of Health, 2005, NAT SERV FRAM LONG T; Department of Health, 2010, EQ EXC LIB NHS; Department of Health, 2010, NHS OUTC FRAM 2011 1; Frost D., 2011, HLTH WORK INDEPENDEN; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Lock S, 2005, DISABIL SOC, V20, P33, DOI 10.1080/0968759042000283629; National Audit Office, 2005, RED BRAIN DAM FAST A; Playford ED, 2011, MAPPING VOCATIONAL R; Radford KA, 2012, BRAIN INJURY, V26, P600; Radford KA, HLTH SERV R IN PRESS; SAEKI S, 1995, STROKE, V26, P399, DOI 10.1161/01.STR.26.3.399; Saeki S, 2010, J REHABIL MED, V42, P254, DOI 10.2340/16501977-0503; Saka O, 2009, AGE AGEING, V38, P27, DOI 10.1093/ageing/afn281; Scottish Intercollegiate Guidelines Network, 2010, MAN PAT STROK REH PR; The Royal College of Physicians Intercollegiate Stroke Working Party, 2008, NAT CLIN GUID STROK; Turner-Stokes L, 2001, CLIN REHABIL, V15, P611, DOI 10.1191/0269215501cr455oa; Tyerman A, 2004, VOCATIONAL ASSESSMEN; van Eeden M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-122; Vestling M, 2003, J REHABIL MED, V35, P127, DOI 10.1080/16501970310010475	29	29	31	0	23	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2014	36	5					409	417		10.3109/09638288.2013.793410			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	AC4HF	WOS:000332481100009		Green Published, Green Accepted			2022-02-06	
J	Sun, D; McGinn, M; Hankins, JE; Mays, KM; Rolfe, A; Colello, RJ				Sun, Dong; McGinn, Melissa; Hankins, Jeanette E.; Mays, Katherine M.; Rolfe, Andrew; Colello, Raymond J.			Aging-and injury-related differential apoptotic response in the dentate gyrus of the hippocampus in rats following brain trauma	FRONTIERS IN AGING NEUROSCIENCE			English	Article						aging; apoptosis; dentate gyrus; neurogenesis; proteomics; traumatic brain injury	PROGRAMMED CELL-DEATH; NEURONAL DIFFERENTIATION; GRANULE CELLS; HUMAN HSP27; ADULT RATS; HIPPOCALCIN; EXPRESSION; NEUROGENESIS; CALCIUM; PROLIFERATION	The elderly are among the most vulnerable to traumatic brain injury (TBI) with poor functional outcomes and impaired cognitive recovery. Of the pathological changes that occur following TBI, apoptosis is an important contributor to the secondary insults and subsequent morbidity associated with TBI. The current study investigated age-related differences in the apoptotic response to injury, which may represent a mechanistic underpinning of the heightened vulnerability of the aged brain to TBI. This study compared the degree of TBI-induced apoptotic response and changes of several apoptosis-related proteins in the hippocampal dentate gyrus (DG) of juvenile and aged animals following injury. Juvenile (p28) and aged rats (24 months) were subjected to a moderate fluid percussive injury or sham injury and sacrificed at 2 days post-injury. One group of rats in both ages was sacrificed and brain sections were processed for TUNEL and immunofluorescent labeling to assess the level of apoptosis and to identify cell types which undergo apoptosis. Another group of animals was subjected to proteomic analysis, whereby proteins from the ipsilateral DG were extracted and subjected to 2D-gel electrophoresis and mass spectrometry analysis. Histological studies revealed age- and injury-related differences in the number of TUNEL labeled cells in the DG. In sham animals, juveniles displayed a higher number of TUNEL+ apoptotic cells located primarily in the subgranular zone of the DG as compared to the aged brain. These apoptotic cells expressed the early neuronal marker PSA-NCAM, suggestive of newly generated immature neurons. In contrast, aged rats had a significantly higher number of TUNEL+ cells following TBI than injured juveniles, which were NeuN-positive mature neurons located predominantly in the granule cell layer. Fluorescent triple labeling revealed that microglial cells were closely associated to the apoptotic cells. In concert with these cellular changes, proteomic studies revealed both age-associated and injury-induced changes in the expression levels of three apoptotic-related proteins: hippocalcin, leucine-rich acidic nuclear protein and heat shock protein 27. Taken together, this study revealed distinct apoptotic responses following TBI in the juvenile and aged brain which may contribute to the differential cognitive recovery observed.	[Sun, Dong; Rolfe, Andrew] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [McGinn, Melissa; Hankins, Jeanette E.; Mays, Katherine M.; Colello, Raymond J.] Virginia Commonwealth Univ, Dept Anat, Richmond, VA 23298 USA; [McGinn, Melissa; Hankins, Jeanette E.; Mays, Katherine M.; Colello, Raymond J.] Virginia Commonwealth Univ, Dept Neurobiol, Richmond, VA 23298 USA		Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Med Coll Virginia Campus,POB 980631, Richmond, VA 23298 USA.	dsun@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055086, NS048377]; NIH-NINDS centerUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]	This study was funded by the National Institutes of Health Grant No. NS055086 (Sun) and NS048377 (Colello). Microscopy work was performed at the VCU-Department of Anatomy and Neurobiology Microscopy Facility, supported, in part, with funding from NIH-NINDS center core grant 5P30NS047463. We thank Andrew Ottens for his assistance with proteomic data analysis.	Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clelland CD, 2009, SCIENCE, V325, P210, DOI 10.1126/science.1173215; Colello RJ, 2002, ELECTROPHORESIS, V23, P144, DOI 10.1002/1522-2683(200201)23:1<144::AID-ELPS144>3.0.CO;2-P; Conti AC, 1998, J NEUROSCI, V18, P5663; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Deng W, 2009, J NEUROSCI, V29, P13532, DOI 10.1523/JNEUROSCI.3362-09.2009; Dickstein DL, 2007, AGING CELL, V6, P275, DOI 10.1111/j.1474-9726.2007.00289.x; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Furuta Y, 1999, NEUROCHEM RES, V24, P651, DOI 10.1023/A:1021000425070; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Guay J, 1997, J CELL SCI, V110, P357; Habrukowich C, 2010, J BIOL CHEM, V285, P26825, DOI 10.1074/jbc.M110.147058; Havasi A, 2008, J BIOL CHEM, V283, P12305, DOI 10.1074/jbc.M801291200; Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Kim WR, 2009, EUR J NEUROSCI, V29, P1408, DOI 10.1111/j.1460-9568.2009.06693.x; Kobayashi M, 2005, NEUROSCIENCE, V133, P471, DOI 10.1016/j.neuroscience.2005.02.034; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Korhonen L, 2005, MOL CELL NEUROSCI, V28, P85, DOI 10.1016/j.mcn.2004.08.015; Kuhn HG, 2005, EUR J NEUROSCI, V22, P1907, DOI 10.1111/j.1460-9568.2005.04377.x; Kular RK, 2009, J BIOL CHEM, V284, P7783, DOI 10.1074/jbc.M806150200; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Masuo Y, 2007, NEUROSCIENCE, V145, P495, DOI 10.1016/j.neuroscience.2006.12.011; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mercer EA, 2000, EMBO J, V19, P3597, DOI 10.1093/emboj/19.14.3597; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Olariu A, 2007, J COMP NEUROL, V501, P659, DOI 10.1002/cne.21268; Palmer CL, 2005, NEURON, V47, P487, DOI 10.1016/j.neuron.2005.06.014; Pan W, 2009, J BIOL CHEM, V284, P6946, DOI 10.1074/jbc.M805801200; Pavlopoulos E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006373; PAXINOS G, 1986, RRAT BRAIN STEREOTAX; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramirez-Amaya V, 2006, J NEUROSCI, V26, P12237, DOI 10.1523/JNEUROSCI.2195-06.2006; Rao MS, 2006, AGING CELL, V5, P545, DOI 10.1111/j.1474-9726.2006.00243.x; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; SHAPIRA Y, 1989, Neurological Research, V11, P169; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Small SA, 2011, NAT REV NEUROSCI, V12, P585, DOI 10.1038/nrn3085; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun W, 2004, J NEUROSCI, V24, P11205, DOI 10.1523/JNEUROSCI.1436-04.2004; Timaru-Kast R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043829; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vidyasagar A, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-7; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Walter J, 2011, NEUROBIOL AGING, V32, P1906, DOI 10.1016/j.neurobiolaging.2009.11.011; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	59	29	31	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	DEC 18	2013	5								95	10.3389/fnagi.2013.00095			13	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	275CQ	WOS:000328653700001	24385964	gold, Green Published			2022-02-06	
J	Honeybul, S; Janzen, C; Kruger, K; Ho, KM				Honeybul, Stephen; Janzen, Courtney; Kruger, Kate; Ho, Kwok M.			Decompressive craniectomy for severe traumatic brain injury: is life worth living? Clinical article	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; traumatic brain injury; outcome; retrospective consent	MIDDLE CEREBRAL-ARTERY; MINIMALLY CONSCIOUS STATE; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; SUBARACHNOID HEMORRHAGE; FOLLOW-UP; HEMICRANIECTOMY; INFARCTION; RECOVERY; SURGERY	Object. The object of this study was to assess the long-term outcome and quality of life of patients who have survived with severe disability following decompressive craniectomy for severe traumatic brain injury (TBI). Methods. The authors assessed outcome beyond 3 years among a cohort of 39 patients who had been adjudged either severely disabled or in vegetative state 18 months after decompressive craniectomy for TBI. Assessments performed included the Extended Glasgow Outcome Scale, modified Barthel Index (mBI), Zarit Burden Interview, and 36-Item Short-Form Health Survey (SF-36). The issue of retrospective consent for surgery was also assessed. Results. Of the 39 eligible patients, 7 died, 12 were lost to follow-up, and 20 patients or their next of kin consented to participate in the study. Among those 20 patients, 5 in a vegetative state at 18 months remained so beyond 3 years, and the other 15 patients remained severely disabled after a median follow-up of 5 years. The patients' average daily activity per the mBI (Pearson correlation coefficient [r] = -0.661, p = 0.01) and SF-36 physical score (r = -0.543, p = 0.037) were inversely correlated with the severity of TBI. However, the SF-36 mental scores of the patients were reasonably high (median 46, interquartile range 37-52). The majority of patients and their next of kin believed that they would have provided consent for surgical decompression even if they had known the eventual outcome. Conclusions. Substantial physical recovery beyond 18 months after decompressive craniectomy for severe TBI was not observed; however, many patients appeared to have recalibrated their expectations regarding what they believed to be an acceptable quality of life.	[Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6009, Australia; [Honeybul, Stephen] Royal Perth Hosp, Perth, WA 6001, Australia; [Janzen, Courtney; Kruger, Kate] Sir Charles Gairdner Hosp, Dept Occupat Therapy, Perth, WA 6009, Australia; [Ho, Kwok M.] Royal Perth Hosp, Dept Intens Care Med, Perth, WA 6001, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Ho, Kwok M./E-3546-2010	Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agrawal D, 2005, EUR J CLIN MICROBIOL, V24, P772, DOI 10.1007/s10096-005-0017-7; Ahmed AI, 2010, NEUROCRIT CARE, V13, P393, DOI 10.1007/s12028-010-9420-8; Baussart B, 2006, ACTA ANAESTH SCAND, V50, P762, DOI 10.1111/j.1399-6576.2006.01038.x; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper P R, 1976, Surg Neurol, V5, P25; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; DELASHAW JB, 1990, STROKE, V21, P874, DOI 10.1161/01.STR.21.6.874; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Ferro JM, 2011, STROKE, V42, P2825, DOI 10.1161/STROKEAHA.111.615393; Fins JJ, 2009, ANN NY ACAD SCI, V1157, P131, DOI 10.1111/j.1749-6632.2009.04473.x; Foerch C, 2004, J NEUROSURG, V101, P248, DOI 10.3171/jns.2004.101.2.0248; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2011, CRIT CARE MED, V39, P2495, DOI 10.1097/CCM.0b013e318225764e; Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226; Honeybul S, 2012, J MED ETHICS, V38, P657, DOI 10.1136/medethics-2012-100672; Honeybul S, 2012, MED J AUSTRALIA, V196, P531, DOI 10.5694/mja11.11485; Honeybul S, 2011, J NEUROTRAUM, V28, P2199, DOI 10.1089/neu.2011.1907; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Honeybul S, 2011, J NEUROTRAUM, V28, P13, DOI 10.1089/neu.2010.1584; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Kiphuth IC, 2010, NEUROCRIT CARE, V13, P380, DOI 10.1007/s12028-010-9449-8; Kobylarz E, 2004, ARCH NEUROL-CHICAGO, V61, P1357, DOI 10.1001/archneur.61.9.1357; Lanterna LA, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0910; Leonhardt G, 2002, J NEUROL, V249, P1433, DOI 10.1007/s00415-002-0875-1; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Puetz V, 2007, LANCET NEUROL, V6, P580, DOI 10.1016/S1474-4422(07)70160-6; Rahme R, 2012, J NEUROSURG, V117, P749, DOI 10.3171/2012.6.JNS111140; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schneider GH, 2002, ACT NEUR S, V81, P77; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Timmons SD, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; ZARIT SH, 1986, GERONTOLOGIST, V26, P260, DOI 10.1093/geront/26.3.260	53	29	29	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2013	119	6					1566	1575		10.3171/2013.8.JNS13857			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	257EU	WOS:000327367200030	24116729				2022-02-06	
J	Lemke, S; Cockerham, GC; Glynn-Milley, C; Cockerham, KP				Lemke, Sonne; Cockerham, Glenn C.; Glynn-Milley, Catherine; Cockerham, Kimberly P.			Visual Quality of Life in Veterans With Blast-Induced Traumatic Brain Injury	JAMA OPHTHALMOLOGY			English	Article							FUNCTION QUESTIONNAIRE; MULTIPLE-SCLEROSIS; EYE; VISION; DYSFUNCTION; PEOPLE; NEI-VFQ-25; TYPE-1; VFQ-25	IMPORTANCE Traumatic brain injury (TBI) is an important cause of morbidity worldwide, with increasing awareness of the role of blast exposure in military and civilian casualties. Visual problems have been reported in TBI and may affect functioning and quality of life. OBJECTIVE To evaluate the 25-item National Eye Institute Visual Functioning Questionnaire and Neuro-Ophthalmic Supplement for utility in assessing the effect of blast exposure on perceived visual functioning among veterans with TBI. DESIGN, SETTING, AND PARTICIPANTS Observational cohort study from a tertiary care Veterans Health Administration hospital. Reported visual quality of life was compared with existing norms, and relationships between perceived visual quality and ocular injury, diplopia, visual performance, and blast exposure characteristics were examined. Participants included inpatients with blast-induced TBI who underwent baseline examination between December 7, 2006, and January 11, 2012, at a multiple-trauma rehabilitation center and who had at least 1 intact eye and were able to undergo psychometric testing and ocular examination. Among 64 sequentially eligible patients, 60 completed visual quality testing,1 declined study participation, and 3 were evaluated prior to inclusion of visual quality testing in the protocol. Thirty-nine patients returned for outpatient follow-up, with a median test-retest interval of 11 months. EXPOSURE Combat blast exposure with documented TBI. MAIN OUTCOMES AND MEASURES Composite and subscale scores on the 25-item National Eye Institute Visual Functioning Questionnaire and Neuro-Ophthalmic Supplement. RESULTS Both tests had high test-retest reliability. Blast-exposed veterans reported significantly poorer visual quality compared with healthy samples and some patient samples with known eye disease. Scores tended to be worse for participants with identified visual performance deficits (poorer visual acuity or spatial contrast sensitivity, visual field depression or defects). Scores were not related to the extent of ocular injury or to blast exposure characteristics such as use of protective eyewear or TBI severity level. CONCLUSIONS AND RELEVANCE Individuals with blast-induced TBI reliably completed both tests and reported significant decrements in their subjective visual experiences. Measures of subjective visual quality may be useful to identify patients needing additional visual or neurologic evaluation and to monitor the effect of visual rehabilitation on patients with blast-related visual disabilities.	[Lemke, Sonne] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA; [Cockerham, Glenn C.] Stanford Univ, Sch Med, Dept Pathol, Palo Alto, CA 94304 USA; [Cockerham, Glenn C.; Glynn-Milley, Catherine; Cockerham, Kimberly P.] VA Palo Alto Hlth Care Syst, Ophthalmol Serv, Palo Alto, CA 94304 USA; [Cockerham, Glenn C.; Cockerham, Kimberly P.] Stanford Univ, Sch Med, Dept Ophthalmol, Palo Alto, CA 94304 USA		Cockerham, GC (corresponding author), VA Palo Alto Hlth Care Syst, Ophthalmol Serv, 112-B1,3801 Miranda Ave, Palo Alto, CA 94304 USA.	glenn.cockerham@va.gov	Cockerham, Kimberly/AAR-5917-2021		Veterans AdministrationUS Department of Veterans Affairs [C5O18R]	This work was supported by Merit Review Award C5O18R from the Veterans Administration.	Bradley EA, 2006, OPHTHALMOLOGY, V113, P1450, DOI 10.1016/j.ophtha.2006.02.060; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Clemons TE, 2008, INVEST OPHTH VIS SCI, V49, P4340, DOI 10.1167/iovs.08-1749; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Cusick M, 2005, AM J OPHTHALMOL, V139, P1042, DOI 10.1016/j.ajo.2005.01.008; Defense and Veterans Brain Injury Center, DOD WORLDWIDE NUMBER; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Faul M, 2010, TRAUMATIC BRAIN INJU; Gal RL, 2008, OPHTHALMOLOGY, V115, P1079, DOI 10.1016/j.ophtha.2007.08.004; Gall C, 2009, INVEST OPHTH VIS SCI, V50, P2765, DOI 10.1167/iovs.08-2519; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Holmes JM, 2005, OPHTHALMOLOGY, V112, P2035, DOI 10.1016/j.ophtha.2005.06.013; Hyman LG, 2005, OPHTHALMOLOGY, V112, P1505, DOI 10.1016/j.ophtha.2005.03.028; Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P733, DOI 10.1001/archopht.119.5.733; Kymes SM, 2008, AM J OPHTHALMOL, V145, P611, DOI 10.1016/j.ajo.2007.11.017; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Ma SL, 2002, AM J OPHTHALMOL, V133, P686, DOI 10.1016/S0002-9394(02)01337-5; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maguire M, 2004, OPHTHALMOLOGY, V111, P1307; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Murray CJL, 1996, GLOBAL HEALTH STATIS; Noble J, 2006, AM J OPHTHALMOL, V142, P464, DOI 10.1016/j.ajo.2006.04.051; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Optic Neuritis Study Group, 2008, OPHTHALMOLOGY, V115, pe5; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Papageorgiou E, 2007, GRAEF ARCH CLIN EXP, V245, P1749, DOI 10.1007/s00417-007-0644-z; Pieramici DJ, 1997, AM J OPHTHALMOL, V123, P820, DOI 10.1016/S0002-9394(14)71132-8; Pineles SL, 2011, AM J OPHTHALMOL, V152, P133, DOI 10.1016/j.ajo.2011.01.023; Raphael BA, 2006, AM J OPHTHALMOL, V142, P1026, DOI 10.1016/j.ajo.2006.06.060; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schimiti RB, 2002, OPHTHALMOLOGY, V109, P2084, DOI 10.1016/S0161-6420(02)01253-8; Shao X, 2011, J CLIN EXP OPHTHALMO, V2, DOI [10.4172/2155-9570.1000117, DOI 10.4172/2155-9570.1000117]; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; VectorVision, CONTRAST SENSITIVITY; Veterans Health Administration, 2008, PERFORMANCE OF TRAUM; Vitale Susan, 2004, Health Qual Life Outcomes, V2, P44, DOI 10.1186/1477-7525-2-44; Vitale Susan, 2003, International Ophthalmology Clinics, V43, P17; Walline JJ, 2000, OPTOMETRY VISION SCI, V77, P648, DOI 10.1097/00006324-200012000-00011; Walter SD, 2012, OPHTHALMOLOGY, V119, P1250, DOI 10.1016/j.ophtha.2011.11.032; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071	47	29	29	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6165	2168-6173		JAMA OPHTHALMOL	JAMA Ophthalmol.	DEC	2013	131	12					1602	1609		10.1001/jamaophthalmol.2013.5028			8	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Ophthalmology	291SU	WOS:000329850600017	24136237	Bronze			2022-02-06	
J	Pathak, NN; Balaganur, V; Lingaraju, MC; More, AS; Kant, V; Kumar, D; Kumar, D; Tandan, SK				Pathak, Nitya N.; Balaganur, Venkanna; Lingaraju, Madhu C.; More, Amar S.; Kant, Vinay; Kumar, Dhirendra; Kumar, Dinesh; Tandan, Surendra Kumar			Antihyperalgesic and Anti-inflammatory Effects of Atorvastatin in Chronic Constriction Injury-Induced Neuropathic Pain in Rats	INFLAMMATION			English	Article						CCI; neuropathic pain; proinflammatory cytokines; MMP-2; NGF; atorvastatin	NERVE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; ROOT GANGLION NEURONS; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; KAPPA-B PATHWAY; SCIATIC-NERVE; INDUCED HYPERALGESIA; SIGNALING PATHWAYS; MODEL	Atorvastatin is a 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor used in treatment of hypercholesterolemia and prevention of coronary heart disease. The aim of this study is to investigate the antihyperalgesic and anti-inflammatory effects of atorvastatin (3, 10, and 30 mg/kg by oral gavages for 14 days) in chronic constriction injury (CCI) model of neuropathic pain in rats. CCI caused significant increase in tumor necrosis factor-alpha, interleukin 1 beta, prostaglandin E2, along with matrix metalloproteases (MMP-2) and nerve growth factor (NGF) levels in sciatic nerve and spinal cord concomitant with mechanical and thermal hyperalgesia, which were significantly reduced by oral administration of atorvastatin for 14 days as compared to CCI rats. Our study demonstrated that atorvastatin attenuates neuropathic pain through inhibition of cytokines, MMP-2, and NGF in sciatic nerve and spinal cord suggesting that atorvastatin could be an additional therapeutic strategy in management of neuropathic pain.	[Pathak, Nitya N.; Balaganur, Venkanna; Lingaraju, Madhu C.; More, Amar S.; Kant, Vinay; Kumar, Dhirendra; Kumar, Dinesh; Tandan, Surendra Kumar] Indian Vet Res Inst, Div Pharmacol & Toxicol, Bareilly 243122, Uttar Pradesh, India		Tandan, SK (corresponding author), Indian Vet Res Inst, Div Pharmacol & Toxicol, Bareilly 243122, Uttar Pradesh, India.	sktandan@ivri.res.in	Kant, Vinay/C-2897-2016	Kant, Vinay/0000-0001-9600-4417			Agrawal SM, 2008, SEMIN CELL DEV BIOL, V19, P42, DOI 10.1016/j.semcdb.2007.06.003; Ali S, 2004, CELL BIOCHEM FUNCT, V22, P67, DOI 10.1002/cbf.1082; Amarenco P, 2006, NEW ENGL J MED, V355, P549; Barsante MM, 2005, EUR J PHARMACOL, V516, P282, DOI 10.1016/j.ejphar.2005.05.005; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bonnington JK, 2003, J PHYSIOL-LONDON, V551, P433, DOI 10.1113/jphysiol.2003.039990; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Cain JH, 2007, ANN NEUROSCI, V14, P96, DOI 10.5214/ans.0972.7531.2007.140403; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen YW, 2012, ANESTH ANALG, V114, P1330, DOI 10.1213/ANE.0b013e31824c4ed4; Chu LW, 2012, INT J IMMUNOPATH PH, V25, P219, DOI 10.1177/039463201202500124; Clarke R, 2007, SIGHT SOUND, V17, P52; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dray A, 2008, BRIT J ANAESTH, V101, P48, DOI 10.1093/bja/aen107; Durrenberger PF, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-1; Etminan M, 2010, NEUROLOGY, V75, P1496, DOI 10.1212/WNL.0b013e3181f96253; Folgueras AR, 2009, P NATL ACAD SCI USA, V106, P16451, DOI 10.1073/pnas.0908507106; Fukuoka T, 2001, J NEUROSCI, V21, P4891, DOI 10.1523/JNEUROSCI.21-13-04891.2001; Gandhi R, 2004, J NEUROSCI, V24, P9405, DOI 10.1523/JNEUROSCI.0899-04.2004; Gholami MR, 2008, EUR J PHARMACOL, V590, P111, DOI 10.1016/j.ejphar.2008.05.050; Gwak YS, 2003, NEUROSCI LETT, V336, P117, DOI 10.1016/S0304-3940(02)01251-X; Hao JX, 2000, NEUROSCI LETT, V286, P208, DOI 10.1016/S0304-3940(00)01107-1; Hao SL, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-6; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Herzberg U, 1997, NEUROREPORT, V8, P1613, DOI 10.1097/00001756-199705060-00012; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Ji RR, 2009, TRENDS PHARMACOL SCI, V30, P336, DOI 10.1016/j.tips.2009.04.002; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Laufs U, 2000, STROKE, V31, P2442, DOI 10.1161/01.STR.31.10.2442; Lee HL, 2004, NEUROREPORT, V15, P2807; LEWIN GR, 1993, J NEUROSCI, V13, P2136; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Massaro M, 2010, CARDIOVASC RES, V86, P311, DOI 10.1093/cvr/cvp375; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001; Mika J, 2009, EUR J PHARMACOL, V623, P65, DOI 10.1016/j.ejphar.2009.09.030; Moolwaney AS, 2005, MOL BRAIN RES, V137, P202, DOI 10.1016/j.molbrainres.2005.03.010; Muja N, 2004, GLIA, V46, P116, DOI 10.1002/glia.10349; Muthuraman A, 2012, J ETHNOPHARMACOL, V142, P723, DOI 10.1016/j.jep.2012.05.049; Naval NS, 2009, NEUROL RES, V31, P425, DOI 10.1179/174313208X353686; Pan HC, 2010, NEUROSURGERY, V67, P376, DOI 10.1227/01.NEU.0000371729.47895.A0; Paul S, 2009, NAT REV DRUG DISCOV, V8, P14, DOI 10.1038/nrd2800; PETTY BG, 1994, ANN NEUROL, V36, P244, DOI 10.1002/ana.410360221; Planavila A, 2005, BBA-MOL CELL BIOL L, V1687, P76, DOI 10.1016/j.bbalip.2004.11.004; Prasad R, 2005, J NEUROCHEM, V94, P204, DOI 10.1111/j.1471-4159.2005.03182.x; Ramer MS, 1998, NEUROSCI LETT, V251, P53, DOI 10.1016/S0304-3940(98)00493-5; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Ryschich E., 2009, GUT, V23, P243; Sacerdote P, 2013, J NEUROIMMUNE PHARM, V8, P202, DOI 10.1007/s11481-012-9428-2; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Santodomingo-Garzon T, 2006, BRIT J PHARMACOL, V149, P14, DOI 10.1038/sj.bjp.0706836; Schafers Maria, 2007, Expert Rev Neurother, V7, P1613, DOI 10.1586/14737175.7.11.1613; Schonbeck U, 2004, CIRCULATION, V109, P18, DOI 10.1161/01.CIR.0000129505.34151.23; Shamash S, 2002, J NEUROSCI, V22, P3052, DOI 10.1523/JNEUROSCI.22-08-03052.2002; Shi XQ, 2011, PAIN, V152, P1033, DOI 10.1016/j.pain.2011.01.006; Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179; Smaldone Costantino, 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry, V7, P279; Sommer C, 2004, NEUROSCI LETT, V361, P184, DOI 10.1016/j.neulet.2003.12.007; SOMMER C, 1993, J NEUROPATH EXP NEUR, V52, P223, DOI 10.1097/00005072-199305000-00006; Sommer C, 1997, NEUROSCI LETT, V237, P45, DOI 10.1016/S0304-3940(97)00813-6; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; Stepien K, 2005, PHARMACOL REP, V57, P561; Takahashi M, 2004, NEUROSCI LETT, V363, P203, DOI 10.1016/j.neulet.2004.03.040; Tartakover-Matalon S, 2007, HUM REPROD, V22, P1161, DOI 10.1093/humrep/del464; Uceyler N, 2008, NEUROSCI LETT, V437, P194, DOI 10.1016/j.neulet.2008.03.050; van der Most PJ, 2009, PROG NEUROBIOL, V88, P64, DOI 10.1016/j.pneurobio.2009.02.002; Wagner R, 1996, NEUROREPORT, V7, P2897, DOI 10.1097/00001756-199611250-00018; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang Y, 2007, CURR NEUROVASC RES, V4, P176; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; Wu KK, 2005, PROSTAG LEUKOTR ESS, V72, P89, DOI 10.1016/j.plefa.2004.11.001; Yaksh TL, 2001, J NEUROSCI, V21, P5847, DOI 10.1523/JNEUROSCI.21-16-05847.2001; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Yang Dongmei, 2012, World J Neurosci, V2, P74; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zelenka M, 2005, PAIN, V116, P257, DOI 10.1016/j.pain.2005.04.018; ZHANG J, 2009, FUNCTIONAL PAIN SYND, P319	83	29	29	0	6	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	DEC	2013	36	6					1468	1478		10.1007/s10753-013-9688-x			11	Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Immunology	248IM	WOS:000326692200034	23872719				2022-02-06	
J	Ross, DE; Ochs, AL; Seabaugh, JM; Shrader, CR				Ross, David E.; Ochs, Alfred L.; Seabaugh, Jan M.; Shrader, Carole R.		Alzheimer's Dis Neuroimaging	Man Versus Machine: Comparison of Radiologists' Interpretations and NeuroQuant (R) Volumetric Analyses of Brain MRIs in Patients With Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							NEUROIMAGING INITIATIVE ADNI	NeuroQuant (R) is a recently developed, FDA-approved software program for measuring brain MRI volume in clinical settings. The purpose of this study was to compare NeuroQuant with the radiologist's traditional approach, based on visual inspection, in 20 outpatients with mild or moderate traumatic brain injury (TBI). Each MRI was analyzed with NeuroQuant, and the resulting volumetric analyses were compared with the attending radiologist's interpretation. The radiologist's traditional approach found atrophy in 10.0% of patients; NeuroQuant found atrophy in 50.0% of patients. NeuroQuant was more sensitive for detecting brain atrophy than the traditional radiologist's approach. (The Journal of Neuropsychiatry and Clinical Neurosciences 2013; 25:32-39)	[Ross, David E.] Virginia Inst Neuropsychiat, Midlothian, VA USA; Virginia Commonwealth Univ, Richmond, VA USA		Ross, DE (corresponding author), Virginia Inst Neuropsychiat, Midlothian, VA USA.	DRoss@VaNeuropsychiatry.org	Levey, Allan/F-2104-2011; Preda, Adrian/K-8889-2013; Hsiung, Robin/AAT-1661-2021; Saykin, Andrew/A-1318-2007	Levey, Allan/0000-0002-3153-502X; Preda, Adrian/0000-0003-3373-2438; Hsiung, Robin/0000-0002-8017-0856; Saykin, Andrew/0000-0002-1376-8532; Ochs, Alfred/0000-0003-3932-876X	Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG010129, K01 AG030514]; Dana Foundation; Northern California Institute for Research and Education; Virginia Institute of Neuropsychiatry; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010129, U01AG032438, K01AG030514, U01AG024904] Funding Source: NIH RePORTER	Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U. S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129, K01 AG030514, and the Dana Foundation.; The authors had no conflicts of interest. This project was funded internally by the Virginia Institute of Neuropsychiatry.	Bigler ED, 2011, STRUCTURAL IMAGING, P73; Bigler ED, 2005, STRUCTURAL IMAGING, P79; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.1155/2009/616581, 10.3233/BEN-2009-0226]; Brewer JB, 2009, AM J NEURORADIOL, V30, P578, DOI 10.3174/ajnr.A1402; Huppertz HJ, 2010, NEUROIMAGE, V49, P2216, DOI 10.1016/j.neuroimage.2009.10.066; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Kovacevic S, 2009, ALZ DIS ASSOC DIS, V23, P139, DOI 10.1097/WAD.0b013e318192e745; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miyahira Yoshinao, 2004, Seishin Shinkeigaku Zasshi, V106, P138; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Raz N, 2007, ANN NY ACAD SCI, V1097, P84, DOI 10.1196/annals.1379.018; Raz N, 2010, NEUROIMAGE, V51, P501, DOI 10.1016/j.neuroimage.2010.03.020; Ross DE, 2012, J NEUROPSYCH CLIN N, V24, pE33, DOI 10.1176/appi.neuropsych.11020044; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Talairach J., 1988, COPLANAR STEREOTAXIC; VICTOROFF J, 1994, NEUROLOGY, V44, P2267, DOI 10.1212/WNL.44.12.2267; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007	18	29	29	0	62	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2013	25	1					32	39		10.1176/appi.neuropsych.11120377			8	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	123SK	WOS:000317410800046	23487191	Green Accepted			2022-02-06	
J	Svider, PF; Pashkova, AA; Folbe, AJ; Eloy, JD; Setzen, M; Baredes, S; Eloy, JA				Svider, Peter F.; Pashkova, Anna A.; Folbe, Adam J.; Eloy, Jean Daniel; Setzen, Michael; Baredes, Soly; Eloy, Jean Anderson			Obstructive Sleep Apnea: Strategies for Minimizing Liability and Enhancing Patient Safety	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article						obstructive sleep apnea; medical malpractice; litigation; physician liability; informed consent; OSA; OSA liability; otolaryngology litigation; sleep apnea malpractice; otolaryngology malpractice	ENDOSCOPIC SINUS SURGERY; READABILITY ASSESSMENT; EDUCATION MATERIALS; MEDICAL MALPRACTICE; OTOLARYNGOLOGY-HEAD; AMERICAN ACADEMY; INFORMED-CONSENT; UNITED-STATES; LITIGATION; INJURY	Objective To characterize malpractice litigation regarding obstructive sleep apnea (OSA) and educate physicians on frequently cited factors. Study Design and Setting Analysis of the Westlaw legal database Methods Jury verdict and settlement reports were examined for outcome, awards, patient demographic factors, defendant specialty, and alleged causes of malpractice Results Out of 54 identified cases, 33 (61.1%) cases were resolved in favor of defendants, 12 (22.2%) via settlement, and 9 (16.7%) through jury award. Median settlement and jury awards did not significantly differ ($750,000 vs $550,000, P > .50). Age and gender did not affect outcome. Otolaryngologists and anesthesiologists were the most frequently named defendants. Forty-seven cases (87.1%) stemmed from OSA patients who underwent procedures with resultant perioperative adverse events. Common alleged factors included death (48.1%), permanent deficits (42.6%), intraoperative complications (35.2%), requiring additional surgery (25.9%), anoxic brain injury (24.1%), inadequate informed consent (24.1%), inappropriate medication administration (22.2%), and inadequate monitoring (20.4%). Conclusion Litigation related to OSA is frequently associated with perioperative complications more than nonoperative issues such as a failure to diagnose this disorder. Nonetheless, OSA is considerably underdiagnosed, and special attention should be paid to at-risk patients, including close monitoring of their clinical status and the medications they receive. For patients with diagnosed or suspected OSA with planned operative intervention, whether for OSA or an unrelated issue, a comprehensive informed consent process detailing the factors outlined in this analysis is an effective strategy to increase communication and improve the physician-patient relationship, minimize liability, and ultimately improve patient safety.	[Svider, Peter F.; Baredes, Soly; Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, Newark, NJ 07103 USA; [Svider, Peter F.; Folbe, Adam J.] Wayne State Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Detroit, MI USA; [Pashkova, Anna A.] Rutgers Robert Wood Johnson Med Sch, New Brunswick, NJ USA; [Eloy, Jean Daniel] Rutgers New Jersey Med Sch, Dept Anesthesiol, Newark, NJ 07103 USA; [Setzen, Michael] N Shore Univ Hosp, Rhinol Sect, Manhasset, NY USA; [Setzen, Michael] NYU, Sch Med, Dept Otolaryngol, New York, NY USA; [Baredes, Soly; Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Ctr Skull Base & Pituitary Surg, Newark, NJ 07103 USA; [Eloy, Jean Anderson] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA		Eloy, JA (corresponding author), Rutgers New Jersey Med Sch, Dept Otolaryngol Head & Neck Surg, 90 Bergen St,Suite 8100, Newark, NJ 07103 USA.	jean.anderson.eloy@gmail.com		Eloy, Jean/0000-0002-3555-9432			Anderson GF, 2005, HEALTH AFFAIR, V24, P903, DOI 10.1377/hlthaff.24.4.903; Annas GJ, 2012, NEW ENGL J MED, V367, P445, DOI 10.1056/NEJMra1108646; Blaivas M, 2012, AM J EMERG MED, V30, P338, DOI 10.1016/j.ajem.2010.12.016; Blake DM, OTOLARYNGOL HEAD NEC, DOI 10.1177/0194599813498696; Brooks RG, 2004, ARCH INTERN MED, V164, P2217, DOI 10.1001/archinte.164.20.2217; Cherla DV, 2012, LARYNGOSCOPE, V122, P1649, DOI 10.1002/lary.23309; Choudhry AJ, J GASTROINTEST SURG, DOI 10.1007/s11605-013-2248-8; Chung SA, 2008, ANESTH ANALG, V107, P1543, DOI 10.1213/ane.0b013e318187c83a; Colaco M, 2013, J UROLOGY, V189, P1048, DOI 10.1016/j.juro.2012.08.255; de Serres LM, 2000, ARCH OTOLARYNGOL, V126, P1423, DOI 10.1001/archotol.126.12.1423; Eloy JA, J NEUROSURG IN PRESS; Eloy JA, INT FORUM ALLERGY RH, DOI 10.1177/0194599813498696; Eloy JA, OTO HEAD NE IN PRESS; Eloy JA, 2013, OTOLARYNG HEAD NECK, V148, P764, DOI 10.1177/0194599813481943; Eloy JA, 2012, OTOLARYNG HEAD NECK, V147, P848, DOI 10.1177/0194599812456152; Erichsen D, 2012, CLIN PEDIATR, V51, P1125, DOI 10.1177/0009922812464548; Fink AS, 2010, ANN SURG, V252, P27, DOI 10.1097/SLA.0b013e3181e3ec61; Finkel KJ, 2009, SLEEP MED, V10, P753, DOI 10.1016/j.sleep.2008.08.007; Frank-Stromborg Marilyn, 2002, Semin Oncol Nurs, V18, P128, DOI 10.1053/sonu.2002.32510; General Accounting Office, 1995, MED LIAB IMP HOSP PH; Hansberry DR, LARYNGOSCOPE, DOI 10.1002/lary.24261; Hong SS, 2013, OTOLARYNG HEAD NECK, V148, P589, DOI 10.1177/0194599813475566; Kasabwala K, 2013, INT FORUM ALLERGY RH, V3, P325, DOI 10.1002/alr.21097; Kasabwala K, 2012, OTOLARYNG HEAD NECK, V147, P466, DOI 10.1177/0194599812442783; Kezirian EJ, 2010, OTOLARYNG HEAD NECK, V143, P441, DOI 10.1016/j.otohns.2010.05.009; Kovalerchik O, INT FORUM ALLERGY RH, DOI 10.1002/alr.21169; Lekovic GP, 2007, NEUROSURGERY, V60, P516, DOI 10.1227/01.NEU.0000255337.80285.39; Lydiatt DD, 2003, ARCH OTOLARYNGOL, V129, P50, DOI 10.1001/archotol.129.1.50; Lynn-Macrae AG, 2004, LARYNGOSCOPE, V114, P1492, DOI 10.1097/00005537-200408000-00032; Mehlman MJ, 2006, J LEGAL MED, V27, P17, DOI 10.1080/01947640500533218; Mello MM, 2011, SYNTH PROJ RES SY S1, V21, P72097; Misra P, 2013, LARYNGOSCOPE, V123, P90, DOI 10.1002/lary.23574; MITNICK JS, 1995, J AM COLL SURGEONS, V181, P315; Moffett P, 2011, WEST J EMERG MED, V12, P109; Morris LGT, 2008, ARCH OTOLARYNGOL, V134, P102, DOI 10.1001/archotol.134.1.102; Nash JJ, 2011, OTOLARYNG HEAD NECK, V144, P10, DOI 10.1177/0194599810390470; Paik AM, AESTHET SUR IN PRESS; Patel CR, HEAD NECK, DOI 10.1002/hed.23157; Reilly BK, 2013, LARYNGOSCOPE, V123, P112, DOI 10.1002/lary.23608; Sanghvi S, 2012, LARYNGOSCOPE, V122, P1943, DOI 10.1002/lary.23424; Seabury SA, 2013, HEALTH AFFAIR, V32, P111, DOI 10.1377/hlthaff.2012.0967; Sohn H, 2003, OTOLARYNG HEAD NECK, V128, P344, DOI 10.1067/mhn.2003.4; Studdert DM, 2006, NEW ENGL J MED, V354, P2024, DOI 10.1056/NEJMsa054479; Studdert DM, 2004, NEW ENGL J MED, V350, P283, DOI 10.1056/NEJMhpr035470; Svider PF, 2013, LARYNGOSCOPE, V123, P2099, DOI 10.1002/lary.24000; Svider PF, 2013, LARYNGOSCOPE, V123, P1849, DOI 10.1002/lary.23905; Svider PF, 2013, LARYNGOSCOPE, V123, P1754, DOI 10.1002/lary.23997; Svider PF, 2013, LARYNGOSCOPE, V123, P1156, DOI 10.1002/lary.23995; Svider PF, 2013, AM J OTOLARYNG, V34, P31, DOI 10.1016/j.amjoto.2012.08.001; Svider PF, J GASTROINTEST SURG, DOI 10.1007/s11605-013-2261-y; Svider PF, OPHTHAL PLA IN PRESS; Svider PF, AM J OTOLAR IN PRESS; Wegman B, 2012, CLIN ORTHOP RELAT R, V470, P1379, DOI 10.1007/s11999-012-2244-4; Wolf JS, 2002, LARYNGOSCOPE, V112, P774, DOI 10.1097/00005537-200205000-00002	54	29	30	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0194-5998	1097-6817		OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	DEC	2013	149	6					947	953		10.1177/0194599813504074			7	Otorhinolaryngology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Otorhinolaryngology; Surgery	255ND	WOS:000327245700023	24025916				2022-02-06	
J	Wang, XM; Ji, JH; Fen, L; Wang, AZ				Wang, Xuemin; Ji, Junhui; Fen, Liang; Wang, Aizhong			Effects of dexmedetomidine on cerebral blood flow in critically ill patients with or without traumatic brain injury: A prospective controlled trial	BRAIN INJURY			English	Article						Cerebral blood flow; cerebral metabolic rate; patient; traumatic brain injury	ALPHA(2)-AGONIST DEXMEDETOMIDINE; ALPHA(2A)-ADRENOCEPTOR SUBTYPE; OXYGEN-CONSUMPTION; RATS; ISCHEMIA; SEDATION; ULTRASOUND; VOLUME; DOGS; AUTOREGULATION	Study objective: To examine the effect of dexmedetomidine on CBF in critical ill patients with or without TBI. Research design: Prospective controlled trial (ISRCTN57998533). Methods: Fifteen patients without TBI and 20 patients with TBI with a Glasgow Coma Scale score of 4-14 were assigned to CON or TBI groups, respectively. All patients received 1 mu g kg(-1) dexmedetomidine infused over 10 minutes, followed by a 0.4 mu g kg(-1) h(-1) continuous infusion for 60 minutes. Blood pressure was maintained at the pre-sedation level with dopamine for all patients. The CBF and cerebral metabolic rate equivalent (CMRe) were measured before sedation and 70 minutes after dexmedetomidine administration. Results: Dexmedetomidine administration significantly decreased CBF in patients of the CON group (difference = 3.3 ml s(-1), 95% confidence interval [CI] = 0.92-5.7 ml s(-1), p = 0.008), without altering the CMRe and CMRe/CBF ratio. The dexmedetomidine-induced change of CBF, CMRe and CMRe/CBF was not significant in the TBI group. The percentage of CBF reduction was greater in the CON group than in the TBI group (difference = 13.9%, 95% CI = 5.5-22.2%, p = 0.002). Conclusions: Dexmedetomidine may be used in patients with TBI without risk of affecting brain oxygenation.	[Wang, Xuemin; Wang, Aizhong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Intens Care Unit, Coll Med, Shanghai 200233, Peoples R China; [Ji, Junhui] Soochow Univ, Affiliated Hosp 1, Dept Anesthesiol, Suzhou, Jiangsu, Peoples R China; [Fen, Liang] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Ultrasound Med, Coll Med, Shanghai 200233, Peoples R China		Wang, AZ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Intens Care Unit, Coll Med, 600 Yishan Rd, Shanghai 200233, Peoples R China.	think.free@hotmail.com		Wang, Xuemin/0000-0002-7241-868X	Suzhou University	The authors report no conflicts of interest. This work was supported by an Educational Medical Doctor Research Grant from Suzhou University.	Albayrak R, 2006, RESP MED, V100, P1826, DOI 10.1016/j.rmed.2006.01.015; Aryan HE, 2006, BRAIN INJURY, V20, P791, DOI 10.1080/02699050600789447; But AK, 2006, ACTA ANAESTH SCAND, V50, P1207, DOI 10.1111/j.1399-6576.2006.01136.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi OZ, 2011, ANESTH ANALG, V113, P349, DOI 10.1213/ANE.0b013e31822071db; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Drummond JC, 2008, ANESTHESIOLOGY, V108, P225, DOI 10.1097/01.anes.0000299576.00302.4c; Elvan EG, 2008, EUR J ANAESTH, V25, P357, DOI 10.1017/S0265021507003110; Engelhard K, 2002, ANESTHESIOLOGY, V96, P450, DOI 10.1097/00000542-200202000-00034; Engelhard K, 2003, ANESTH ANALG, V96, P524, DOI 10.1097/00000539-200302000-00041; Farag E, 2010, DISCOV MED, V9, P42; GILL RW, 1985, ULTRASOUND MED BIOL, V11, P625, DOI 10.1016/0301-5629(85)90035-3; Grof TM, 2010, NEUROCRIT CARE, V12, P356, DOI 10.1007/s12028-008-9156-x; Ho SSY, 2002, AM J ROENTGENOL, V178, P551, DOI 10.2214/ajr.178.3.1780551; Huang R, 2000, J CEREBR BLOOD F MET, V20, P895, DOI 10.1097/00004647-200006000-00001; Iida H, 1999, ANESTHESIOLOGY, V91, P479, DOI 10.1097/00000542-199908000-00023; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Jolkkonen J, 1999, EUR J PHARMACOL, V372, P31, DOI 10.1016/S0014-2999(99)00186-7; KARLSSON BR, 1990, ANESTH ANALG, V71, P125; Ma DQ, 2004, EUR J PHARMACOL, V502, P87, DOI 10.1016/j.ejphar.2004.08.044; McPherson RW, 1997, ANESTH ANALG, V84, P139, DOI 10.1097/00000539-199701000-00026; Mirski MA, 2010, INTENS CARE MED, V36, P1505, DOI 10.1007/s00134-010-1874-9; Nakano T, 2009, J ANESTH, V23, P378, DOI 10.1007/s00540-009-0777-9; Ogawa Y, 2008, ANESTHESIOLOGY, V109, P642, DOI 10.1097/ALN.0b013e3181862a33; Paris A, 2006, ANESTH ANALG, V102, P456, DOI 10.1213/01.ane.0000194301.79118.e9; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; REIVICH M, 1964, AM J PHYSIOL, V206, P25, DOI 10.1152/ajplegacy.1964.206.1.25; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Sanders RD, 2009, ANESTHESIOLOGY, V110, P1077, DOI 10.1097/ALN.0b013e31819daedd; Schebesch KM, 2007, NEUROL RES, V29, P210, DOI 10.1179/016164107X181761; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Talke P, 1997, ANESTH ANALG, V85, P1136, DOI 10.1097/00000539-199711000-00033; Tang JF, 2011, NEUROCRIT CARE, V15, P175, DOI 10.1007/s12028-009-9315-8	33	29	34	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2013	27	13-14					1617	1622		10.3109/02699052.2013.831130			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	259BW	WOS:000327503400017	24102571				2022-02-06	
